amod||infection-9/NN||occult-1/JJ	conj_or||occult-1/JJ||latent-3/JJ	amod||infection-9/NN||latent-3/JJ	amod||infection-9/NN||hepatitisb-4/JJ	nn||infection-9/NN||virus-5/NN	appos||infection-9/NN||hbv-7/NN	nsubjpass||defined-11/VBN||infection-9/NN	auxpass||defined-11/VBN||is-10/VBZ	root||ROOT-0/null||defined-11/VBN	prep_as||defined-11/VBN||infection-13/NN	amod||dna-17/NN||detectable-15/JJ	nn||dna-17/NN||hbv-16/NN	prep_with||defined-11/VBN||dna-17/NN	amod||antigen-21/NN||undetectable-19/JJ	nn||antigen-21/NN||surface-20/NN	prep_with||defined-11/VBN||antigen-21/NN	conj_and||dna-17/NN||antigen-21/NN	appos||dna-17/NN||hbsag-23/NN	poss||blood-28/NN||patients-26/NNS	prep_in||dna-17/NN||blood-28/NN	hbv-16||hbsag-23||yes||occult or latent hepatitisb virus (hbv) infection is defined as infection with detectable hbv dna and undetectable surface antigen (hbsag) in patients' blood.
nsubjpass||recovered-6/VBN||epstein-barrvirus-1/NNS	appos||epstein-barrvirus-1/NNS||ebv-3/NN	auxpass||recovered-6/VBN||was-5/VBD	root||ROOT-0/null||recovered-6/VBN	amod||cells-9/NNS||cerebrospinal-8/JJ	prep_from||recovered-6/VBN||cells-9/NNS	cc||not-12/RB||but-11/CC	dep||cells-9/NNS||not-12/RB	amod||fluid-15/NN||cell-free-14/JJ	prep_from||not-12/RB||fluid-15/NN	det||patient-19/NN||a-18/DT	prep_of||cells-9/NNS||patient-19/NN	amod||infectiousmononucleosis-23/NNS||meningoencephalitis-21/JJ	amod||infectiousmononucleosis-23/NNS||complicating-22/VBG	prep_with||recovered-6/VBN||infectiousmononucleosis-23/NNS	infectiousmononucleosis-23||epstein-barrvirus-1||no||epstein-barrvirus (ebv) was recovered from cerebrospinal cells (but not from cell-free fluid) of a patient with meningoencephalitis complicating infectiousmononucleosis.
det||system-5/NN||a-1/DT	amod||system-5/NN||continuous-2/JJ	nn||system-5/NN||glucose-3/NN	nn||system-5/NN||monitoring-4/NN	nsubj||have-7/VB||system-5/NN	aux||have-7/VB||may-6/MD	root||ROOT-0/null||have-7/VB	dobj||have-7/VB||utility-8/NN	amod||women-11/NNS||pregnant-10/JJ	prep_in||utility-8/NN||women-11/NNS	amod||diabetes-14/NN||insulin-treated-13/JJ	prep_with||have-7/VB||diabetes-14/NN	advmod||for-17/IN||especially-16/RB	dep||have-7/VB||for-17/IN	det||women-19/NNS||those-18/DT	pobj||for-17/IN||women-19/NNS	nsubj||difficult-25/JJ||women-19/NNS	nsubj||control-27/VB||women-19/NNS	nn||sugars-22/NNS||blood-21/NN	prep_with||women-19/NNS||sugars-22/NNS	cop||difficult-25/JJ||are-24/VBP	rcmod||women-19/NNS||difficult-25/JJ	aux||control-27/VB||to-26/TO	xcomp||difficult-25/JJ||control-27/VB	nsubj||experience-30/VBP||who-29/WP	dep||have-7/VB||experience-30/VBP	conj_or||for-17/IN||experience-30/VBP	amod||hypoglycemia-32/NN||nocturnal-31/JJ	dobj||experience-30/VBP||hypoglycemia-32/NN	advmod||need-40/VBP||however-34/RB	amod||systems-39/NNS||continuous-36/JJ	nn||systems-39/NNS||glucose-37/NN	nn||systems-39/NNS||monitoring-38/NN	nsubj||need-40/VBP||systems-39/NNS	parataxis||have-7/VB||need-40/VBP	amod||study-42/NN||additional-41/JJ	dobj||need-40/VBP||study-42/NN	prep_as||need-40/VBP||part-44/NN	amod||trials-49/NNS||larger-46/JJR	amod||trials-49/NNS||randomized-48/JJ	prep_of||part-44/NN||trials-49/NNS	insulin--1||hypoglycemia-32||no_rel||a continuous glucose monitoring system may have utility in pregnant women with insulin-treated diabetes, especially for those women with blood sugars that are difficult to control or who experience nocturnal hypoglycemia; however, continuous glucose monitoring systems need additional study as part of larger, randomized trials.
det||decade-4/NN||the-2/DT	amod||decade-4/NN||past-3/JJ	prep_during||contributed-17/VBN||decade-4/NN	nsubj||contributed-17/VBN||progress-6/NN	amod||therapy-9/NN||endocrine-8/JJ	prep_in||progress-6/NN||therapy-9/NN	det||use-12/NN||the-11/DT	conj_and||progress-6/NN||use-12/NN	nsubj||contributed-17/VBN||use-12/NN	prep_of||use-12/NN||trastuzumab-14/NN	aux||contributed-17/VBN||has-15/VBZ	advmod||contributed-17/VBN||significantly-16/RB	root||ROOT-0/null||contributed-17/VBN	det||decline-20/NN||the-19/DT	prep_to||contributed-17/VBN||decline-20/NN	nn||mortality-24/NN||breast-22/NN	nn||mortality-24/NN||cancer-23/NN	prep_in||decline-20/NN||mortality-24/NN	nn||receptor-positive-27/NN||hormone-26/NN	prep_for||mortality-24/NN||receptor-positive-27/NN	amod||her2-31/NNS||erbb2-29/JJ	prep_in||decline-20/NN||her2-31/NNS	conj_and||mortality-24/NN||her2-31/NNS	amod||cases-35/NNS||positive-34/JJ	prep_in||decline-20/NN||cases-35/NNS	conj_and||mortality-24/NN||cases-35/NNS	prep_in||decline-20/NN||respectively-37/RB	amod||mortality-24/NN||respectively-37/RB	conj_and||mortality-24/NN||respectively-37/RB	cancer-23||trastuzumab-14||no_rel||during the past decade, progress in endocrine therapy and the use of trastuzumab has significantly contributed to the decline in breast cancer mortality for hormone receptor-positive and erbb2 (her2)-positive cases, respectively.
nn||albumin-2/NN||serum-1/NN	nsubj||predictor-19/NN||albumin-2/NN	det||reactant-7/NN||a-4/DT	amod||reactant-7/NN||negative-5/JJ	amod||reactant-7/NN||acute-phase-6/JJ	appos||albumin-2/NN||reactant-7/NN	appos||albumin-2/NN||marker-9/NN	conj_and||reactant-7/NN||marker-9/NN	amod||malnutrition-14/NN||underlying-11/JJ	nn||malnutrition-14/NN||inflammation-12/NN	nn||malnutrition-14/NN||and/or-13/NN	prep_for||marker-9/NN||malnutrition-14/NN	cop||predictor-19/NN||is-16/VBZ	det||predictor-19/NN||an-17/DT	amod||predictor-19/NN||independent-18/JJ	root||ROOT-0/null||predictor-19/NN	prep_of||predictor-19/NN||cvd-21/NN	prep_of||predictor-19/NN||mortality-23/NN	conj_and||cvd-21/NN||mortality-23/NN	nn||patients-27/NNS||ckd-25/NN	nn||patients-27/NNS||vi-26/NN	prep_in||predictor-19/NN||patients-27/NNS	cvd-21||albumin-2||no_rel||serum albumin, a negative acute-phase reactant and marker for underlying inflammation and/or malnutrition, is an independent predictor of cvd and mortality in ckd vi patients.
nsubjpass||assessed-3/VBN||pain-1/NN	auxpass||assessed-3/VBN||was-2/VBD	root||ROOT-0/null||assessed-3/VBN	xcomp||assessed-3/VBN||using-4/VBG	xcomp||assessed-3/VBN||using-4/VBG	conj_and||using-4/VBG||using-4/VBG	det||scale-8/NN||a-5/DT	amod||scale-8/NN||visual-6/JJ	amod||scale-8/NN||analog-7/JJ	dobj||using-4/VBG||scale-8/NN	num||=-11/NNS||0-10/CD	dep||scale-8/NN||=-11/NNS	neg||pain-13/NN||no-12/DT	dep||=-11/NNS||pain-13/NN	dep||pain-13/NN||100-15/CD	dep||pain-20/NN||=-16/SYM	det||pain-20/NN||the-17/DT	amod||pain-20/NN||worst-18/JJS	amod||pain-20/NN||possible-19/JJ	rcmod||100-15/CD||pain-20/NN	prep_at||using-4/VBG||0-23/NNP	num||0-23/NNP||5-25/CD	num||0-23/NNP||10-27/CD	num||minutes-31/NNS||30-30/CD	npadvmod||using-4/VBG||minutes-31/NNS	prepc_after||using-4/VBG||stopping-33/VBG	det||infusion-36/NN||the-34/DT	amod||infusion-36/NN||remifentanil-35/JJ	dobj||stopping-33/VBG||infusion-36/NN	pain-20||remifentanil-35||yes||pain was assessed using a visual analog scale (0 = no pain; 100 = the worst possible pain) at 0, 5, 10, and 30 minutes after stopping the remifentanil infusion.
det||study-3/NN||a-1/DT	nn||study-3/NN||retrospective-2/NN	nsubjpass||performed-5/VBN||study-3/NN	auxpass||performed-5/VBN||was-4/VBD	root||ROOT-0/null||performed-5/VBN	num||patients-8/NNS||213-7/CD	prep_in||performed-5/VBN||patients-8/NNS	prep_with||patients-8/NNS||type2diabetesmellitus-10/CD	det||administration-13/NN||the-12/DT	prep_under||performed-5/VBN||administration-13/NN	prep_of||administration-13/NN||metformin-15/NN	mwe||than-18/IN||more-17/JJR	quantmod||one-19/CD||than-18/IN	prep_for||metformin-15/NN||one-19/CD	tmod||performed-5/VBN||year-20/NN	type2diabetesmellitus-10||metformin-15||yes||a retrospective study was performed in 213 patients with type2diabetesmellitus under the administration of metformin for more than one year.
amod||attachments-5/NNS||multipoint-1/JJ	conj_and||multipoint-1/JJ||multisubunit-3/JJ	amod||attachments-5/NNS||multisubunit-3/JJ	nn||attachments-5/NNS||covalent-4/NN	nsubj||provide-14/VBP||attachments-5/NNS	prep_of||attachments-5/NNS||enzymes-7/NNS	advmod||functionalized-10/JJ||appropriately-9/RB	amod||supports-11/NNS||functionalized-10/JJ	prep_on||enzymes-7/NNS||supports-11/NNS	prep_via||supports-11/NNS||linkers-13/NNS	root||ROOT-0/null||provide-14/VBP	acomp||provide-14/VBP||rigidity-15/JJ	det||structure-20/NN||the-17/DT	amod||structure-20/NN||immobilized-18/JJ	nn||structure-20/NN||enzyme-19/NN	prep_to||rigidity-15/JJ||structure-20/NN	advmod||resulting-23/VBG||ultimately-22/RB	xcomp||provide-14/VBP||resulting-23/VBG	amod||stability-27/NN||improved-25/VBN	nn||stability-27/NN||enzyme-26/NN	prep_in||resulting-23/VBG||stability-27/NN	enzyme-26||rigidity-15||no_rel||multipoint and multisubunit covalent attachments of enzymes on appropriately functionalized supports via linkers provide rigidity to the immobilized enzyme structure, ultimately resulting in improved enzyme stability.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||elucidate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||elucidate-8/VB||to-7/TO	xcomp||was-6/VBD||elucidate-8/VB	det||pathophysiology-10/NN||the-9/DT	dobj||elucidate-8/VB||pathophysiology-10/NN	amod||osteoporosis-13/NNS||as-related-12/JJ	prep_of||pathophysiology-10/NN||osteoporosis-13/NNS	prepc_by||elucidate-8/VB||investigating-15/VBG	det||relation-17/NN||the-16/DT	dobj||investigating-15/VBG||relation-17/NN	nn||density-21/NN||bone-19/NN	nn||density-21/NN||mineral-20/NN	prep_between||relation-17/NN||density-21/NN	dep||density-21/NN||bmd-23/VBN	prep_between||relation-17/NN||btm-26/NN	conj_and||density-21/NN||btm-26/NN	vmod||btm-26/NN||vitamind-28/VBN	amod||assessments-32/NNS||clinical-31/JJ	prep_between||relation-17/NN||assessments-32/NNS	conj_and||density-21/NN||assessments-32/NNS	nn||activity-35/NN||disease-34/NN	prep_of||assessments-32/NNS||activity-35/NN	amod||function-38/NN||physical-37/JJ	prep_of||assessments-32/NNS||function-38/NN	conj_and||activity-35/NN||function-38/NN	aux||identify-44/VB||to-43/TO	prep_between||relation-17/NN||identify-44/VB	conj_and||density-21/NN||identify-44/VB	vmod||density-21/NN||identify-44/VB	dobj||identify-44/VB||parameters-45/NNS	nsubjpass||related-48/VBN||parameters-45/NNS	auxpass||related-48/VBN||are-47/VBP	rcmod||parameters-45/NNS||related-48/VBN	amod||bmd-51/NN||low-50/JJ	prep_to||related-48/VBN||bmd-51/NN	appos||bmd-51/NN||osteopenia-53/NN	appos||bmd-51/NN||osteoporosis-55/NNS	conj_or||osteopenia-53/NN||osteoporosis-55/NNS	dep||related-48/VBN||in-57/IN	prep_as||related-48/VBN||patients-59/NNS	amod||disease-62/NN||active-61/JJ	prep_with||patients-59/NNS||disease-62/NN	osteoporosis-55||vitamind-28||yes||the aim of this study was to elucidate the pathophysiology of as-related osteoporosis by investigating the relation between bone mineral density (bmd), btm, vitamind, and clinical assessments of disease activity and physical function, as well as to identify parameters that are related to low bmd (osteopenia or osteoporosis) in as patients with active disease.
det||injection-3/NN||an-2/DT	prep_after||enhanced-22/VBN||injection-3/NN	prep_of||injection-3/NN||cocaine-5/NN	amod||mg/kg-10/NN||15â-7/JJ	amod||mg/kg-10/NN||$-8/$	dep||$-8/$||‰-9/JJ	dep||cocaine-5/NN||mg/kg-10/NN	appos||mg/kg-10/NN||ip-12/NN	det||hyperactivity-17/NN||both-15/DT	amod||hyperactivity-17/NN||horizontal-16/JJ	nsubjpass||enhanced-22/VBN||hyperactivity-17/NN	conj_and||hyperactivity-17/NN||rearing-19/NN	nsubjpass||enhanced-22/VBN||rearing-19/NN	auxpass||enhanced-22/VBN||were-20/VBD	advmod||enhanced-22/VBN||significantly-21/RB	root||ROOT-0/null||enhanced-22/VBN	amod||rats-25/NNS||virus-treated-24/JJ	prep_in||enhanced-22/VBN||rats-25/NNS	nn||â-28/NN||p-27/NN	dep||rats-25/NNS||â-28/NN	num||â-32/NN||$-29/$	number||<-31/CD||‰-30/CD	num||$-29/$||<-31/CD	dep||â-28/NN||â-32/NN	dep||â-32/NN||$-33/$	num||$-33/$||‰-34/CD	num||$-33/$||0.05-35/CD	virus--1||cocaine-5||no_rel||after an injection of cocaine (15â€‰mg/kg, ip), both horizontal hyperactivity and rearing were significantly enhanced in virus-treated rats ( p â€‰<â€‰0.05).
nn||samples-2/NNS||plasma-1/NN	nsubjpass||tested-21/VBN||samples-2/NNS	amod||patients-6/NNS||hiv-4/JJ	amod||patients-6/NNS||infected-5/JJ	prep_from||samples-2/NNS||patients-6/NNS	num||individuals-9/NNS||190-8/CD	dep||samples-2/NNS||individuals-9/NNS	prep_with||individuals-9/NNS||clinically-11/NNP	vmod||individuals-9/NNS||defined-12/VBN	dobj||defined-12/VBN||aids-13/NNS	nn||individuals-16/NNS||382-15/NN	dobj||defined-12/VBN||individuals-16/NNS	conj_and||aids-13/NNS||individuals-16/NNS	prep_without||defined-12/VBN||aids-18/NNS	auxpass||tested-21/VBN||were-20/VBD	root||ROOT-0/null||tested-21/VBN	advmod||tested-21/VBN||retrospectively-22/RB	det||presence-25/NN||the-24/DT	prep_for||tested-21/VBN||presence-25/NN	nn||sero-markers-28/NNS||hbv-27/NN	prep_of||presence-25/NN||sero-markers-28/NNS	nn||dna-33/NN||serum-31/NN	nn||dna-33/NN||hbv-32/NN	prep_for||tested-21/VBN||dna-33/NN	conj_and||presence-25/NN||dna-33/NN	vmod||dna-33/NN||screened-35/VBN	nn||infection-38/NN||hcv-37/NN	prep_for||screened-35/VBN||infection-38/NN	agent||screened-35/VBN||testing-40/VBG	amod||antibody-43/NN||anti-hcv-42/JJ	prep_for||testing-40/VBG||antibody-43/NN	nn||rna-46/NN||hcv-45/NN	prep_for||testing-40/VBG||rna-46/NN	conj_and||antibody-43/NN||rna-46/NN	aids-18||hiv-4||no||plasma samples from hiv infected patients (190 individuals with clinically defined aids and 382 individuals without aids) were tested retrospectively for the presence of hbv sero-markers and for serum hbv dna, screened for hcv infection by testing for anti-hcv antibody and hcv rna.
aux||characterize-3/VB||to-1/TO	advmod||characterize-3/VB||better-2/RBR	dep||tested-14/VBD||characterize-3/VB	dobj||characterize-3/VB||mutations-4/NNS	amod||oncogenes-8/NNP||established-6/VBN	amod||oncogenes-8/NNP||known-7/VBN	prep_in||mutations-4/NNS||oncogenes-8/NNP	nn||genes-12/NNS||tumor-10/NN	nn||genes-12/NNS||suppressor-11/NN	prep_in||mutations-4/NNS||genes-12/NNS	conj_and||oncogenes-8/NNP||genes-12/NNS	nsubj||tested-14/VBD||we-13/PRP	root||ROOT-0/null||tested-14/VBD	det||spectrometric-17/NN||a-15/DT	amod||spectrometric-17/NN||mass-16/JJ	dobj||tested-14/VBD||spectrometric-17/NN	vmod||spectrometric-17/NN||based-18/VBN	dobj||based-18/VBN||platform-19/NN	aux||interrogate-21/VB||to-20/TO	vmod||based-18/VBN||interrogate-21/VB	amod||cancer-23/NN||common-22/JJ	dobj||interrogate-21/VB||cancer-23/NN	vmod||cancer-23/NN||associated-24/VBN	dobj||associated-24/VBN||mutations-25/NNS	det||panel-28/NN||a-27/DT	prep_across||associated-24/VBN||panel-28/NN	num||paraffin-33/NNS||77-30/CD	nn||paraffin-33/NNS||formalin-31/NN	amod||paraffin-33/NNS||fixed-32/VBN	prep_of||panel-28/NN||paraffin-33/NNS	vmod||paraffin-33/NNS||embedded-34/VBN	amod||cases-37/NNS||archived-35/JJ	nn||cases-37/NNS||btc-36/NN	dobj||embedded-34/VBN||cases-37/NNS	formalin-31||cancer-23||no_rel||to better characterize mutations in established known oncogenes and tumor suppressor genes we tested a mass spectrometric based platform to interrogate common cancer associated mutations across a panel of 77 formalin fixed paraffin embedded archived btc cases.
nsubj||effective-61/JJ||analysis-1/NN	amod||terbinafine-58/NN||total-3/JJ	num||trials-5/NNS||eight-4/CD	nsubj||state-9/NN||trials-5/NNS	num||patients-8/NNS||1181-7/CD	prep_including||trials-5/NNS||patients-8/NNS	ccomp||total-3/JJ||state-9/NN	mark||likely-17/JJ||that-10/IN	nsubj||likely-17/JJ||treatment-11/NN	nsubj||produce-19/VB||treatment-11/NN	amod||terbinafine-14/NN||continuous-13/JJ	prep_with||treatment-11/NN||terbinafine-14/NN	cop||likely-17/JJ||is-15/VBZ	advmod||likely-17/JJ||more-16/RBR	ccomp||state-9/NN||likely-17/JJ	aux||produce-19/VB||to-18/TO	xcomp||likely-17/JJ||produce-19/VB	amod||cure-23/NN||mycological-20/JJ	conj_and||mycological-20/JJ||clinical-22/JJ	amod||cure-23/NN||clinical-22/JJ	dobj||produce-19/VB||cure-23/NN	prepc_compared_to||produce-19/VB||to-25/TO	amod||itraconazole-27/NN||intermittent-26/JJ	pobj||produce-19/VB||itraconazole-27/NN	nn||2.3-31/NNS||odds-29/NNS	nn||2.3-31/NNS||ratio-30/NN	prep_with||itraconazole-27/NN||2.3-31/NNS	number||%-34/NN||95-33/CD	amod||ci-35/NN||%-34/NN	dep||likely-17/JJ||ci-35/NN	amod||ci-35/NN||1.7-37/CD	num||p-40/NNS||3.0-39/CD	prep_to||ci-35/NN||p-40/NNS	number||0.0001-42/CD||<-41/CD	num||p-40/NNS||0.0001-42/CD	mark||tolerated-51/JJ||though-44/IN	preconj||itraconazole-46/NN||both-45/DT	nsubj||tolerated-51/JJ||itraconazole-46/NN	conj_and||itraconazole-46/NN||terbinafine-48/NN	nsubj||tolerated-51/JJ||terbinafine-48/NN	cop||tolerated-51/JJ||are-49/VBP	advmod||tolerated-51/JJ||well-50/RB	ccomp||likely-17/JJ||tolerated-51/JJ	advmod||effective-54/JJ||highly-53/RB	conj_and||total-3/JJ||effective-54/JJ	amod||terbinafine-58/NN||effective-54/JJ	nn||terbinafine-58/NN||drugs-55/NNS	amod||terbinafine-58/NN||continuous-57/JJ	prep_of||analysis-1/NN||terbinafine-58/NN	cop||effective-61/JJ||is-59/VBZ	advmod||effective-61/JJ||more-60/RBR	root||ROOT-0/null||effective-61/JJ	amod||itraconazole-64/NN||intermittent-63/JJ	prep_than||effective-61/JJ||itraconazole-64/NN	prepc_at||effective-61/JJ||achieving-66/VBG	amod||cure-68/NN||mycological-67/JJ	dobj||achieving-66/VBG||cure-68/NN	amod||onychomycosis-71/NNS||toenail-70/JJ	prep_of||cure-68/NN||onychomycosis-71/NNS	onychomycosis-71||itraconazole-64||yes||analysis of total eight trials including 1181 patients state that treatment with continuous terbinafine is more likely to produce mycological and clinical cure compared to intermittent itraconazole with odds ratio 2.3(95% ci, 1.7 to 3.0 p <0.0001) though both itraconazole and terbinafine are well tolerated and highly effective drugs, continuous terbinafine is more effective than intermittent itraconazole at achieving mycological cure of toenail onychomycosis
amod||protocol-3/NN||post-transplant-1/JJ	nn||protocol-3/NN||prophylaxis-2/NNS	nsubjpass||based-8/VBN||protocol-3/NN	nsubj||keep-28/VB||protocol-3/NN	nn||recurrence-6/NN||hbv-5/NN	prep_against||protocol-3/NN||recurrence-6/NN	auxpass||based-8/VBN||was-7/VBD	root||ROOT-0/null||based-8/VBN	det||milligrams-12/NNS||a-10/DT	num||milligrams-12/NNS||hundred-11/CD	prep_on||based-8/VBN||milligrams-12/NNS	prep_of||milligrams-12/NNS||lamivudine-14/NN	amod||lamivudine-14/NN||daily-15/JJ	amod||lamivudine-14/NN||plus-16/IN	nn||injections-18/NNS||intramuscular-17/NN	dep||lamivudine-14/NN||injections-18/NNS	prep_of||injections-18/NNS||hepatitisbimmuneglobulin-20/NN	appos||injections-18/NNS||hbig-22/NN	amod||dosage-26/NN||appropriate-25/JJ	prep_with||based-8/VBN||dosage-26/NN	aux||keep-28/VB||to-27/TO	xcomp||based-8/VBN||keep-28/VB	amod||titer-31/NN||anti-hbs-29/JJ	nn||titer-31/NN||antibody-30/NN	dobj||keep-28/VB||titer-31/NN	num||iu/l-34/NN||300-33/CD	prep_above||titer-31/NN||iu/l-34/NN	num||iu/l-37/NN||100-36/CD	prep_above||titer-31/NN||iu/l-37/NN	conj_and||iu/l-34/NN||iu/l-37/NN	prep||keep-28/VB||in-38/IN	det||months-42/NNS||the-39/DT	amod||months-42/NNS||first-40/JJ	num||months-42/NNS||six-41/CD	pobj||in-38/IN||months-42/NNS	prep||keep-28/VB||afterwards-44/RB	conj_and||in-38/IN||afterwards-44/RB	prep||keep-28/VB||respectively-46/RB	conj_and||in-38/IN||respectively-46/RB	hbv-5||lamivudine-14||yes||post-transplant prophylaxis protocol against hbv recurrence was based on a hundred milligrams of lamivudine daily plus intramuscular injections of hepatitisbimmuneglobulin (hbig) with appropriate dosage to keep anti-hbs antibody titer above 300 iu/l and 100 iu/l in the first six months and afterwards, respectively.
num||patients-2/NNS||97-1/CD	nsubjpass||recruited-7/VBN||patients-2/NNS	nsubjpass||treated-14/VBN||patients-2/NNS	amod||falciparummalaria-5/NN||uncomplicated-4/JJ	prep_with||patients-2/NNS||falciparummalaria-5/NN	auxpass||recruited-7/VBN||were-6/VBD	root||ROOT-0/null||recruited-7/VBN	prep_from||recruited-7/VBN||april-9/NNP	prep_to||recruited-7/VBN||june-11/NNP	num||june-11/NNP||2006-12/CD	conj_and||recruited-7/VBN||treated-14/VBN	det||al-17/NNP||either-16/DT	prep_with||treated-14/VBN||al-17/NNP	amod||q-21/NN||quinine-19/JJ	prep_with||treated-14/VBN||q-21/NN	conj_or||al-17/NNP||q-21/NN	amod||ap-26/NN||atovaquone/proguanil-24/JJ	prep_with||treated-14/VBN||ap-26/NN	conj_or||al-17/NNP||ap-26/NN	nn||hospital-31/NN||jimma-29/NN	nn||hospital-31/NN||university-30/NN	prep_in||treated-14/VBN||hospital-31/NN	appos||hospital-31/NN||ethiopia-33/NN	falciparummalaria-5||proguanil--1||yes||97 patients with uncomplicated falciparummalaria were recruited from april to june 2006 and treated with either al, quinine (q) or atovaquone/proguanil (ap) in jimma university hospital, ethiopia.
nsubj||included-2/VBD||these-1/DT	root||ROOT-0/null||included-2/VBD	det||role-4/NN||the-3/DT	dobj||included-2/VBD||role-4/NN	prep_of||role-4/NN||statins-6/NNS	det||agent-10/NN||an-8/DT	amod||agent-10/NN||anti-lipid-9/JJ	appos||statins-6/NNS||agent-10/NN	prepc_in||included-2/VBD||reducing-13/VBG	amod||morbidity-15/NN||post-stroke-14/JJ	dobj||reducing-13/VBG||morbidity-15/NN	dobj||reducing-13/VBG||mortality-17/NN	conj_and||morbidity-15/NN||mortality-17/NN	prepc_in||included-2/VBD||decreasing-20/VBG	conj_and||reducing-13/VBG||decreasing-20/VBG	det||plaque-24/NN||the-21/DT	amod||plaque-24/NN||carotid-22/JJ	amod||plaque-24/NN||atherosclerotic-23/JJ	dobj||decreasing-20/VBG||plaque-24/NN	prep_in||plaque-24/NN||middle-26/NN	vmod||middle-26/NN||aged-27/VBN	dobj||aged-27/VBN||patients-28/NNS	amod||risk-31/NN||increased-30/VBN	prep_at||aged-27/VBN||risk-31/NN	prep_of||risk-31/NN||cardiovasculardisease-33/NN	amod||infusion-36/NN||glucose-potassium-insulin-35/JJ	dobj||decreasing-20/VBG||infusion-36/NN	conj_and||plaque-24/NN||infusion-36/NN	amod||acute-39/JJ||hyperglyceamic-38/JJ	amod||patients-41/NNS||acute-39/JJ	nn||patients-41/NNS||stroke-40/NN	prep_in||infusion-36/NN||patients-41/NNS	dep||infusion-36/NN||pioglitazone-43/VB	det||medication-47/NN||an-45/DT	amod||medication-47/NN||anti-diabetic-46/JJ	dobj||pioglitazone-43/VB||medication-47/NN	nsubj||reduce-50/VB||medication-47/NN	aux||reduce-50/VB||to-49/TO	xcomp||pioglitazone-43/VB||reduce-50/VB	dobj||reduce-50/VB||recurrence-51/NN	prep_of||recurrence-51/NN||stroke-53/NN	nn||patients-58/NNS||type-55/NN	num||patients-58/NNS||2-56/CD	nn||patients-58/NNS||diabetic-57/NN	prep_in||reduce-50/VB||patients-58/NNS	parataxis||pioglitazone-43/VB||administration-60/NN	amod||urokinase-63/NN||intra-arterial-62/JJ	prep_of||administration-60/NN||urokinase-63/NN	det||agent-67/NN||a-65/DT	amod||agent-67/NN||thrombolytic-66/JJ	appos||urokinase-63/NN||agent-67/NN	det||role-71/NN||the-70/DT	prep_of||administration-60/NN||role-71/NN	conj_and||urokinase-63/NN||role-71/NN	nn||therapy-74/NN||laser-73/NN	prep_of||role-71/NN||therapy-74/NN	amod||dissolution-77/NN||clot-76/JJ	prep_in||therapy-74/NN||dissolution-77/NN	dep||administration-60/NN||given-78/VBN	mark||is-83/VBZ||that-79/IN	prep_at||is-83/VBZ||present-81/JJ	expl||is-83/VBZ||there-82/EX	pcomp||given-78/VBN||is-83/VBZ	advmod||fda-86/NN||only-84/RB	num||fda-86/NN||one-85/CD	nsubj||is-83/VBZ||fda-86/NN	vmod||fda-86/NN||approved-87/VBN	amod||agent-89/NN||thrombolytic-88/JJ	dobj||approved-87/VBN||agent-89/NN	nn||tpa-92/NN||r-91/NN	dep||administration-60/NN||tpa-92/NN	parataxis||pioglitazone-43/VB||benefit-95/VB	prep_of||benefit-95/VB||warfarin-97/NN	det||anticoagulant-100/NN||an-99/DT	appos||warfarin-97/NN||anticoagulant-100/NN	amod||patients-104/NNS||elderly-103/JJ	prep_in||warfarin-97/NN||patients-104/NNS	prep_with||benefit-95/VB||atrialfibrillation-106/NN	det||community-109/NN||the-108/DT	prep_in||atrialfibrillation-106/NN||community-109/NN	parataxis||pioglitazone-43/VB||nxy-111/VB	det||agent-117/NN||a-113/DT	amod||radical-115/JJ||free-114/JJ	amod||agent-117/NN||radical-115/JJ	amod||agent-117/NN||trapping-116/JJ	dep||nxy-111/VB||agent-117/NN	parataxis||pioglitazone-43/VB||minocycline-120/VB	conj_and||nxy-111/VB||minocycline-120/VB	det||tested-122/NN||both-121/DT	dobj||nxy-111/VB||tested-122/NN	prep_as||nxy-111/VB||neuroprotectants-124/NNS	dobj||decreasing-20/VBG||zoledronate-127/NN	conj_and||plaque-24/NN||zoledronate-127/NN	det||bisphosphonate-131/NN||an-129/DT	amod||bisphosphonate-131/NN||intravenous-130/JJ	appos||zoledronate-127/NN||bisphosphonate-131/NN	aux||prevent-134/VB||to-133/TO	vmod||zoledronate-127/NN||prevent-134/VB	dobj||prevent-134/VB||loss-135/NN	nn||density-139/NN||bone-137/NN	nn||density-139/NN||mineral-138/NN	prep_of||loss-135/NN||density-139/NN	det||extremity-143/NN||the-141/DT	amod||extremity-143/NN||affected-142/VBN	prep_of||density-139/NN||extremity-143/NN	advmod||role-148/NN||finally-146/RB	det||role-148/NN||the-147/DT	prep_of||density-139/NN||role-148/NN	conj_and||extremity-143/NN||role-148/NN	prep_of||role-148/NN||nicardipine-150/NN	det||blocker-155/NN||a-152/DT	nn||blocker-155/NN||calcium-153/NN	nn||blocker-155/NN||channel-154/NN	dep||nicardipine-150/NN||blocker-155/NN	det||prevention-159/NN||the-158/DT	prep_in||nicardipine-150/NN||prevention-159/NN	prep_of||prevention-159/NN||vasospasm-161/NN	vmod||zoledronate-127/NN||hydrocortisone-164/VB	conj_and||prevent-134/VB||hydrocortisone-164/VB	aux||prevent-166/VB||to-165/TO	xcomp||hydrocortisone-164/VB||prevent-166/VB	dobj||prevent-166/VB||hyponatraemia-167/NN	amod||hemorrhage-170/NN||sub-arachnoid-169/JJ	prep_after||prevent-166/VB||hemorrhage-170/NN	stroke-53||warfarin-97||yes||these included the role of statins (an anti-lipid agent) in reducing post-stroke morbidity and mortality, and decreasing the carotid atherosclerotic plaque in middle aged patients at increased risk of cardiovasculardisease; glucose-potassium-insulin infusion in hyperglyceamic acute stroke patients; pioglitazone (an anti-diabetic medication) to reduce recurrence of stroke in type 2 diabetic patients; administration of intra-arterial urokinase (a thrombolytic agent) and the role of laser therapy in clot dissolution given that at present there is only one fda approved thrombolytic agent (r tpa); benefit of warfarin (an anticoagulant) in elderly patients with atrialfibrillation in the community; nxy (a free radical trapping agent) and minocycline both tested as neuroprotectants; and zoledronate (an intravenous bisphosphonate) to prevent loss of bone mineral density of the affected extremity, and finally the role of nicardipine (a calcium channel blocker) in the prevention of vasospasm, and hydrocortisone to prevent hyponatraemia after sub-arachnoid hemorrhage.
num||rickettsiae-2/NN||seven-1/CD	nsubjpass||identified-8/VBN||rickettsiae-2/NN	det||group-6/NN||the-4/DT	nn||group-6/NN||spottedfever-5/NN	prep_of||rickettsiae-2/NN||group-6/NN	auxpass||identified-8/VBN||were-7/VBD	root||ROOT-0/null||identified-8/VBN	num||pathogens-12/NNS||4-11/CD	prep_including||identified-8/VBN||pathogens-12/NNS	dep||pathogens-12/NNS||r-13/SYM	spottedfever-5||rickettsiae-2||no||seven rickettsiae of the spottedfever group were identified, including 4 pathogens r .
det||diagnosis-2/NN||a-1/DT	nsubjpass||suspected-6/VBN||diagnosis-2/NN	prep_of||diagnosis-2/NN||vasculitis-4/NNS	auxpass||suspected-6/VBN||was-5/VBD	root||ROOT-0/null||suspected-6/VBN	det||basis-9/NN||the-8/DT	prep_on||suspected-6/VBN||basis-9/NN	det||course-15/NN||the-11/DT	amod||course-15/NN||clinical-12/JJ	conj_and||clinical-12/JJ||biological-14/JJ	amod||course-15/NN||biological-14/JJ	prep_of||basis-9/NN||course-15/NN	nn||lesions-18/NNS||skin-17/NN	dep||course-15/NN||lesions-18/NNS	appos||lesions-18/NNS||arthralgias-20/NNS	amod||c3-26/NNS||proteinuria-22/JJ	amod||c3-26/NNS||low-24/JJ	nn||c3-26/NNS||complement-25/NN	appos||lesions-18/NNS||c3-26/NNS	nn||fractions-29/NNS||c4-28/NN	appos||lesions-18/NNS||fractions-29/NNS	conj_and||c3-26/NNS||fractions-29/NNS	dep||lesions-18/NNS||etc.-31/FW	nsubj||steroid-35/VBD||pulse-34/NN	conj_and||suspected-6/VBN||steroid-35/VBD	nsubjpass||prescribed-38/VBN||therapy-36/NN	auxpass||prescribed-38/VBN||was-37/VBD	ccomp||steroid-35/VBD||prescribed-38/VBN	vasculitis-4||steroid-35||no_rel||a diagnosis of vasculitis was suspected on the basis of the clinical and biological course (skin lesions, arthralgias, proteinuria, low complement c3 and c4 fractions, etc.) and pulse steroid therapy was prescribed.
det||need-6/NN||an-3/DT	amod||need-6/NN||unmet-4/JJ	amod||need-6/NN||clinical-5/JJ	prep_due_to||moved-19/VBD||need-6/NN	prep_for||need-6/NN||treatment-8/NN	det||inhibitor-15/NN||the-10/DT	amod||inhibitor-15/NN||first-11/JJ	nn||proteasome-14/NN||class-13/NN	prep_in||first-11/JJ||proteasome-14/NN	nsubj||moved-19/VBD||inhibitor-15/NN	nsubj||fda-24/VB||inhibitor-15/NN	appos||inhibitor-15/NN||bortezomib-17/NN	root||ROOT-0/null||moved-19/VBD	nn||discovery-22/NN||drug-21/NN	prep_from||moved-19/VBD||discovery-22/NN	aux||fda-24/VB||to-23/TO	xcomp||moved-19/VBD||fda-24/VB	dobj||fda-24/VB||approval-25/NN	prep_in||fda-24/VB||multiplemyeloma-27/NN	det||years-32/NNS||an-29/DT	amod||years-32/NNS||unprecedented-30/JJ	num||years-32/NNS||eight-31/CD	prep_in||multiplemyeloma-27/NN||years-32/NNS	multiplemyeloma-27||bortezomib-17||yes||due to an unmet clinical need for treatment, the first in class proteasome inhibitor, bortezomib, moved from drug discovery to fda approval in multiplemyeloma in an unprecedented eight years.
det||correlation-3/NN||a-1/DT	amod||correlation-3/NN||similar-2/JJ	nsubjpass||reported-15/VBN||correlation-3/NN	amod||responses-7/NNS||certain-5/JJ	amod||responses-7/NNS||allergic-6/JJ	prep_between||correlation-3/NN||responses-7/NNS	amod||expression-12/NN||increased-9/VBN	amod||expression-12/NN||ifn-î-10/JJ	nn||expression-12/NN||³-11/NN	prep_between||correlation-3/NN||expression-12/NN	conj_and||responses-7/NNS||expression-12/NN	aux||reported-15/VBN||has-13/VBZ	auxpass||reported-15/VBN||been-14/VBN	root||ROOT-0/null||reported-15/VBN	amod||studies-19/NNS||human-17/JJ	amod||studies-19/NNS||clinical-18/JJ	prep_in||reported-15/VBN||studies-19/NNS	prep_of||studies-19/NNS||allergy-21/NN	det||model-25/NN||this-23/DT	nn||model-25/NN||pig-24/NN	nsubj||indicative-30/JJ||model-25/NN	prep_of||model-25/NN||allergy-27/NN	aux||indicative-30/JJ||may-28/MD	cop||indicative-30/JJ||be-29/VB	parataxis||reported-15/VBN||indicative-30/JJ	amod||modulation-34/NN||potential-32/JJ	amod||modulation-34/NN||probiotic-33/JJ	prep_of||indicative-30/JJ||modulation-34/NN	amod||lungdisease-37/NN||allergic-36/JJ	prep_of||modulation-34/NN||lungdisease-37/NN	prep_in||indicative-30/JJ||humans-39/NNS	ifn--1||allergy-27||no_rel||a similar correlation between certain allergic responses and increased ifn-î³ expression has been reported in human clinical studies of allergy; this pig model of allergy may be indicative of potential probiotic modulation of allergic lungdisease in humans.
nn||heterozygous-2/NNS||patients-1/NNS	nsubj||constitute-10/VBP||heterozygous-2/NNS	prep_for||heterozygous-2/NNS||hbs-4/NN	prep_for||heterozygous-2/NNS||hbc-6/NN	conj_and||hbs-4/NN||hbc-6/NN	dep||heterozygous-2/NNS||hbsc-8/JJ	root||ROOT-0/null||constitute-10/VBP	quantmod||third-13/JJ||about-11/RB	quantmod||third-13/JJ||a-12/DT	dobj||constitute-10/VBP||third-13/JJ	nn||cases-16/NNS||scd-15/NN	prep_of||third-13/JJ||cases-16/NNS	vmod||constitute-10/VBP||making-18/VBG	nsubj||form-24/NN||this-19/DT	det||form-24/NN||the-20/DT	amod||form-24/NN||second-21/JJ	advmod||common-23/JJ||most-22/RBS	amod||form-24/NN||common-23/JJ	xcomp||making-18/VBG||form-24/NN	prep_of||form-24/NN||scd-26/NN	quantmod||80,000-30/CD||approximately-29/RB	num||births-31/NNS||80,000-30/CD	prep_with||making-18/VBG||births-31/NNS	nn||worldwide-34/NNS||year-33/NN	prep_per||births-31/NNS||worldwide-34/NNS	scd-26||hbs-4||no||patients heterozygous for hbs and hbc (hbsc) constitute about a third of scd cases, making this the second most common form of scd, with approximately 80,000 births per year worldwide.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	neg||difference-5/NN||no-3/DT	amod||difference-5/NN||significant-4/JJ	nsubj||was-2/VBD||difference-5/NN	det||groups-9/NNS||the-7/DT	num||groups-9/NNS||two-8/CD	prep_between||difference-5/NN||groups-9/NNS	prep_with||was-2/VBD||regard-11/NN	det||incidence-14/NN||the-13/DT	prep_to||was-2/VBD||incidence-14/NN	prep_of||incidence-14/NN||complications-16/NNS	det||incidence-21/NN||an-19/DT	amod||incidence-21/NN||increased-20/VBN	prep_except_for||was-2/VBD||incidence-21/NN	nsubj||necessitated-28/VBD||incidence-21/NN	nn||pain-24/NN||breakthrough-23/NN	prep_of||incidence-21/NN||pain-24/NN	prep_of||incidence-21/NN||discomfort-26/NN	conj_and||pain-24/NN||discomfort-26/NN	rcmod||incidence-21/NN||necessitated-28/VBD	det||use-30/NN||the-29/DT	dobj||necessitated-28/VBD||use-30/NN	prep_of||use-30/NN||fentanyl-32/NN	mark||p-41/VBP||as-33/IN	det||treatment-36/NN||a-34/DT	nn||treatment-36/NN||rescue-35/NN	nsubj||p-41/VBP||treatment-36/NN	det||group-40/NN||the-38/DT	amod||group-40/NN||propofol-39/JJ	prep_in||treatment-36/NN||group-40/NN	advcl||necessitated-28/VBD||p-41/VBP	number||0.001-43/CD||<-42/CD	dobj||p-41/VBP||0.001-43/CD	pain-24||propofol-39||yes||there was no significant difference between the two groups with regard to the incidence of complications except for an increased incidence of breakthrough pain and discomfort which necessitated the use of fentanyl as a rescue treatment in the propofol group p <0.001.
num||hundred-2/CD||one-1/CD	nsubjpass||randomized-10/VBN||hundred-2/CD	num||patients-5/NNS||twenty-4/CD	conj_and||hundred-2/CD||patients-5/NNS	nsubjpass||randomized-10/VBN||patients-5/NNS	amod||hypertension-8/NN||essential-7/JJ	prep_with||hundred-2/CD||hypertension-8/NN	auxpass||randomized-10/VBN||were-9/VBD	root||ROOT-0/null||randomized-10/VBN	num||groups-13/NNS||four-12/CD	prep_into||randomized-10/VBN||groups-13/NNS	vmod||groups-13/NNS||receiving-14/VBG	acomp||receiving-14/VBG||enalapril-15/JJ	acomp||receiving-14/VBG||lisinopril-17/JJ	conj_and||enalapril-15/JJ||lisinopril-17/JJ	acomp||receiving-14/VBG||ramipril-19/JJ	conj_and||enalapril-15/JJ||ramipril-19/JJ	acomp||receiving-14/VBG||fosinopril-22/JJ	conj_and||enalapril-15/JJ||fosinopril-22/JJ	hypertension-8||ramipril-19||yes||one hundred and twenty patients with essential hypertension were randomized into four groups receiving enalapril, lisinopril, ramipril, and fosinopril.
advmod||investigate-4/VB||here-1/RB	nsubj||investigate-4/VB||we-3/PRP	root||ROOT-0/null||investigate-4/VB	mark||determinant-39/NN||whether-5/IN	nn||variation-8/NN||copy-6/NN	nn||variation-8/NN||number-7/NN	nsubj||determinant-39/NN||variation-8/NN	appos||variation-8/NN||cnv-10/NN	prep_at||variation-8/NN||ccl3-13/CD	prep_like||variation-8/NN||genes-16/NNS	appos||genes-16/NNS||ccl3l-18/NNP	det||factor-25/NN||a-21/DT	amod||factor-25/NN||key-22/JJ	amod||factor-25/NN||genetic-23/JJ	nn||factor-25/NN||host-24/NN	appos||genes-16/NNS||factor-25/NN	amod||susceptibility-28/NN||hiv/aids-27/JJ	prep_for||factor-25/NN||susceptibility-28/NN	amod||response-32/NN||cell-mediated-30/JJ	amod||response-32/NN||immune-31/JJ	prep_like||variation-8/NN||response-32/NN	conj_and||genes-16/NNS||response-32/NN	prep_in||response-32/NN||humans-34/NNS	cop||determinant-39/NN||is-36/VBZ	advmod||determinant-39/NN||also-37/RB	det||determinant-39/NN||a-38/DT	ccomp||investigate-4/VB||determinant-39/NN	prep_of||determinant-39/NN||time-41/NN	prep_until||determinant-39/NN||onset-43/NN	prep_of||onset-43/NN||simian-aids-45/NNS	amod||macaques-48/NNS||rhesus-47/JJ	prep_in||simian-aids-45/NNS||macaques-48/NNS	aids--1||hiv--1||no||here, we investigate whether copy number variation (cnv) at ccl3 -like genes ( ccl3l ), a key genetic host factor for hiv/aids susceptibility and cell-mediated immune response in humans, is also a determinant of time until onset of simian-aids in rhesus macaques.
aux||identify-2/VB||to-1/TO	advcl||undertaken-29/VBN||identify-2/VB	det||variations-5/NNS||the-3/DT	amod||variations-5/NNS||genetic-4/JJ	dobj||identify-2/VB||variations-5/NNS	vmod||variations-5/NNS||associated-6/VBN	nn||intolerance-9/NN||aspirin-8/NN	prep_with||associated-6/VBN||intolerance-9/NN	prep_in||intolerance-9/NN||asthmatics-11/NNS	det||stage-15/NN||the-13/DT	amod||stage-15/NN||first-14/JJ	nsubjpass||undertaken-29/VBN||stage-15/NN	amod||study-19/NN||genome-wide-17/JJ	nn||study-19/NN||association-18/NN	prep_of||stage-15/NN||study-19/NN	num||polymorphisms-24/NNS||109,365-21/CD	amod||polymorphisms-24/NNS||single-22/JJ	nn||polymorphisms-24/NNS||nucleotide-23/NN	prep_with||study-19/NN||polymorphisms-24/NNS	appos||polymorphisms-24/NNS||snps-26/NNS	auxpass||undertaken-29/VBN||was-28/VBD	root||ROOT-0/null||undertaken-29/VBN	det||cohort-43/NN||a-31/DT	amod||cohort-43/NN||korean-32/JJ	amod||cohort-43/NN||aia-33/JJ	dep||cohort-43/NN||nâ-35/NN	num||â-39/NN||$-36/$	number||=-38/CD||š-37/CD	num||$-36/$||=-38/CD	dep||nâ-35/NN||â-39/NN	dep||â-39/NN||$-40/$	num||$-40/$||š80-41/CD	prep_in||undertaken-29/VBN||cohort-43/NN	nn||subjects-58/NNS||aspirin-tolerant-45/NN	nn||subjects-58/NNS||asthma-46/NN	dep||subjects-58/NNS||ata-48/NN	appos||ata-48/NN||nâ-50/NN	num||â-54/NN||$-51/$	number||=-53/CD||š-52/CD	num||$-51/$||=-53/CD	dep||nâ-50/NN||â-54/NN	dep||ata-48/NN||$-55/$	num||$-55/$||š100-56/CD	prep_in||undertaken-29/VBN||subjects-58/NNS	conj_and||cohort-43/NN||subjects-58/NNS	prep_as||cohort-43/NN||controls-60/NNS	asthma-46||aspirin-8||no||to identify the genetic variations associated with aspirin intolerance in asthmatics, the first stage of genome-wide association study with 109,365 single nucleotide polymorphisms (snps) was undertaken in a korean aia (nâ€š=â€š80) cohort and aspirin-tolerant asthma (ata, nâ€š=â€š100) subjects as controls.
prep_in||shown-24/VBN||patients-2/NNS	amod||asthma-5/NN||persistent-4/JJ	prep_with||patients-2/NNS||asthma-5/NN	advmod||treated-7/VBN||previously-6/RB	vmod||asthma-5/NN||treated-7/VBN	preconj||treated-7/VBN||either-8/CC	amod||beta-agonists-11/NNS||short-acting-10/JJ	prep_with||treated-7/VBN||beta-agonists-11/NNS	advmod||treated-7/VBN||alone-12/RB	amod||therapy-16/NN||twice-daily-14/JJ	nn||therapy-16/NN||maintenance-15/NN	npadvmod||treated-7/VBN||therapy-16/NN	prep_with||treated-7/VBN||ics-18/NN	conj_or||beta-agonists-11/NNS||ics-18/NN	amod||mf-21/NN||once-daily-20/JJ	nsubjpass||shown-24/VBN||mf-21/NN	nsubj||superior-27/JJ||mf-21/NN	nsubj||placebo-29/VB||mf-21/NN	nsubjpass||shown-45/VBN||mf-21/NN	aux||shown-24/VBN||has-22/VBZ	auxpass||shown-24/VBN||been-23/VBN	root||ROOT-0/null||shown-24/VBN	aux||superior-27/JJ||to-25/TO	cop||superior-27/JJ||be-26/VB	xcomp||shown-24/VBN||superior-27/JJ	aux||placebo-29/VB||to-28/TO	xcomp||superior-27/JJ||placebo-29/VB	prepc_in||placebo-29/VB||improving-31/VBG	nn||function-33/NN||lung-32/NN	dobj||improving-31/VBG||function-33/NN	nn||control-36/NN||symptom-35/NN	dobj||improving-31/VBG||control-36/NN	conj_and||function-33/NN||control-36/NN	dobj||improving-31/VBG||quality-39/NN	conj_and||function-33/NN||quality-39/NN	prep_of||quality-39/NN||life-41/NN	aux||shown-45/VBN||has-44/VBZ	conj_and||shown-24/VBN||shown-45/VBN	amod||efficacy-47/NN||comparable-46/JJ	dobj||shown-45/VBN||efficacy-47/NN	prepc_compared_with||shown-45/VBN||with-49/IN	pobj||shown-45/VBN||budesonide-50/JJ	pobj||shown-45/VBN||beclomethasone-52/JJ	conj_and||budesonide-50/JJ||beclomethasone-52/JJ	pobj||shown-45/VBN||fluticasone-55/JJ	conj_and||budesonide-50/JJ||fluticasone-55/JJ	asthma-5||beclomethasone-52||yes||in patients with persistent asthma previously treated either with short-acting beta-agonists alone or twice-daily maintenance therapy with ics, once-daily mf has been shown to be superior to placebo in improving lung function, symptom control, and quality of life; and has shown comparable efficacy compared with budesonide, beclomethasone, and fluticasone.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||show-7/VBP||study-4/NN	nsubj||show-7/VBP||we-6/PRP	root||ROOT-0/null||show-7/VBP	mark||ny-eso-1â-14/VBD||that-8/IN	det||fraction-10/NN||a-9/DT	nsubj||ny-eso-1â-14/VBD||fraction-10/NN	amod||+-13/NNS||pd-1-12/JJ	prep_of||fraction-10/NN||+-13/NNS	ccomp||show-7/VBP||ny-eso-1â-14/VBD	dep||ny-eso-1â-14/VBD||$-15/$	advmod||cd8-18/RB||specific-17/RB	dep||+-19/CD||cd8-18/RB	num||$-15/$||+-19/CD	nn||cells-21/NNS||t-20/NN	dobj||ny-eso-1â-14/VBD||cells-21/NNS	iobj||ny-eso-1â-14/VBD||cells-21/NNS	prep_in||cells-21/NNS||patients-23/NNS	amod||up-regulates-27/NNS||advanced-25/VBN	nn||up-regulates-27/NNS||melanoma-26/NN	prep_with||patients-23/NNS||up-regulates-27/NNS	amod||expression-29/NN||tim-3-28/JJ	dep||cells-21/NNS||expression-29/NN	mark||ny-eso-1â-36/VBZ||that-31/IN	amod||+-35/NNS||tim-3-32/JJ	amod||+-35/NNS||+-33/JJ	amod||+-35/NNS||pd-1-34/JJ	nsubj||ny-eso-1â-36/VBZ||+-35/NNS	ccomp||show-7/VBP||ny-eso-1â-36/VBZ	conj_and||ny-eso-1â-14/VBD||ny-eso-1â-36/VBZ	dobj||ny-eso-1â-36/VBZ||$-37/$	advmod||cd8-40/RB||specific-39/RB	dep||+-41/CD||cd8-40/RB	num||$-37/$||+-41/CD	nn||cells-43/NNS||t-42/NN	nsubj||dysfunctional-46/JJ||cells-43/NNS	cop||dysfunctional-46/JJ||are-44/VBP	advmod||dysfunctional-46/JJ||more-45/RBR	rcmod||$-37/$||dysfunctional-46/JJ	poss||ny-eso-1â-57/NNS||tim-3âˆ-48/NN	amod||ny-eso-1â-57/NNS||pd-1-50/JJ	dep||pd-1âˆ-55/JJ||+-51/JJ	conj_and||pd-1âˆ-55/JJ||tim-3âˆ-53/JJ	amod||ny-eso-1â-57/NNS||tim-3âˆ-53/JJ	amod||ny-eso-1â-57/NNS||pd-1âˆ-55/JJ	prep_than||dysfunctional-46/JJ||ny-eso-1â-57/NNS	dep||$-37/$||$-58/$	advmod||cd8-61/RB||specific-60/RB	dep||+-62/CD||cd8-61/RB	num||$-58/$||+-62/CD	nn||cells-64/NNS||t-63/NN	dep||$-37/$||cells-64/NNS	vmod||cells-64/NNS||producing-66/VBG	amod||³-69/NNS||less-67/JJR	amod||³-69/NNS||ifn-î-68/JJ	dobj||producing-66/VBG||³-69/NNS	amod||$-37/$||tnf-71/JJ	amod||$-37/$||il-2-74/JJ	conj_and||tnf-71/JJ||il-2-74/JJ	melanoma-26||ifn--1||yes||in the present study, we show that a fraction of pd-1+ ny-eso-1â€“specific cd8+ t cells in patients with advanced melanoma up-regulates tim-3 expression and that tim-3+pd-1+ ny-eso-1â€“specific cd8+ t cells are more dysfunctional than tim-3âˆ’pd-1+ and tim-3âˆ’pd-1âˆ’ ny-eso-1â€“specific cd8+ t cells, producing less ifn-î³, tnf, and il-2.
advmod||seem-5/VB||hence-1/RB	nsubj||seem-5/VB||it-3/PRP	aux||seem-5/VB||would-4/MD	root||ROOT-0/null||seem-5/VB	xcomp||seem-5/VB||logic-6/NN	aux||postulate-8/VB||to-7/TO	vmod||seem-5/VB||postulate-8/VB	mark||effective-18/JJ||that-9/IN	csubj||effective-18/JJ||rinsing-10/VBG	prep_with||rinsing-10/VBG||chlorhexidine-12/NN	amod||sex-15/NN||oral-14/JJ	prep_before||rinsing-10/VBG||sex-15/NN	aux||effective-18/JJ||will-16/MD	cop||effective-18/JJ||be-17/VB	ccomp||postulate-8/VB||effective-18/JJ	prep_for||effective-18/JJ||prevention-20/NN	amod||entry-23/NN||retrograde-22/JJ	prep_of||prevention-20/NN||entry-23/NN	prep_of||entry-23/NN||bacteria-25/NNS	amod||cavity-28/NN||oral-27/JJ	prep_from||bacteria-25/NNS||cavity-28/NN	det||urethra-31/NN||the-30/DT	prep_into||effective-18/JJ||urethra-31/NN	cavity-28||bacteria-25||no||hence, it would seem logic to postulate that rinsing with chlorhexidine before oral sex will be effective for prevention of retrograde entry of bacteria from oral cavity into the urethra.
det||study-3/NN||this-1/DT	amod||study-3/NN||observational-2/JJ	nsubjpass||comprised-5/VBN||study-3/NN	auxpass||comprised-5/VBN||was-4/VBD	ccomp||referred-17/VBD||comprised-5/VBN	num||males-8/NNS||11-7/CD	prep_of||comprised-5/VBN||males-8/NNS	num||females-11/NNS||11-10/CD	prep_of||comprised-5/VBN||females-11/NNS	conj_and||males-8/NNS||females-11/NNS	amod||patients-16/NNS||physician-assessed-13/JJ	amod||patients-16/NNS||hivseropositive-15/JJ	nsubj||referred-17/VBD||patients-16/NNS	nsubj||exercise-19/VB||patients-16/NNS	root||ROOT-0/null||referred-17/VBD	aux||exercise-19/VB||to-18/TO	xcomp||referred-17/VBD||exercise-19/VB	dobj||exercise-19/VB||programmes-20/NNS	det||service-26/NN||a-22/DT	amod||service-26/NN||tertiary-23/JJ	amod||service-26/NN||multi-disciplinary-24/JJ	nn||service-26/NN||outpatient-25/NN	prep_in||programmes-20/NNS||service-26/NN	nn||patients-29/NNS||hiv-28/NN	prep_for||service-26/NN||patients-29/NNS	det||hospital-34/NN||an-31/DT	amod||hospital-34/NN||urban-32/JJ	nn||hospital-34/NN||teaching-33/NN	prep_at||exercise-19/VB||hospital-34/NN	prep_in||hospital-34/NN||london-36/NN	appos||london-36/NN||uk-38/NN	hivseropositive-15||hiv-28||no||this observational study was comprised of 11 males and 11 females, physician-assessed, hivseropositive patients referred to exercise programmes in a tertiary multi-disciplinary outpatient service for hiv patients at an urban teaching hospital in london (uk).
nn||patients-2/NNS||tuberculosis-1/NNP	nsubjpass||described-9/VBN||patients-2/NNS	amod||strains-5/NNS||identical-4/JJ	prep_with||patients-2/NNS||strains-5/NNS	prep_of||strains-5/NNS||mycobacteriumtuberculosis-7/NNS	auxpass||described-9/VBN||are-8/VBP	root||ROOT-0/null||described-9/VBN	prep_as||described-9/VBN||clustered-11/NNP	tuberculosis-1||mycobacteriumtuberculosis-7||no||tuberculosis patients with identical strains of mycobacteriumtuberculosis are described as clustered.
det||use-2/NN||the-1/DT	nsubjpass||associated-11/VBN||use-2/NN	prep_of||use-2/NN||warfarin-4/NN	advmod||associated-11/VBN||up-5/RB	num||days-8/NNS||90-7/CD	prep_to||up-5/RB||days-8/NNS	auxpass||associated-11/VBN||was-9/VBD	neg||associated-11/VBN||not-10/RB	root||ROOT-0/null||associated-11/VBN	nn||protection-14/NN||stroke-13/NN	prep_with||associated-11/VBN||protection-14/NN	nn||mi-17/NN||anterior-16/NN	prep_after||associated-11/VBN||mi-17/NN	nn||-RSB--23/NNP||hazard-19/NN	nn||-RSB--23/NNP||ratio-20/NN	nn||-RSB--23/NNP||-LSB--21/NNP	nn||-RSB--23/NNP||hr-22/FW	dep||mi-17/NN||-RSB--23/NNP	amod||-RSB--23/NNP||0.68-25/CD	number||%-28/NN||95-27/CD	amod||interval-30/NN||%-28/NN	nn||interval-30/NN||confidence-29/NN	dep||-RSB--23/NNP||interval-30/NN	nn||â-36/FW||-LSB--31/FW	nn||â-36/FW||ci-32/FW	nn||â-36/FW||-RSB--33/FW	dep||â-36/FW||0.37-35/FW	dep||interval-30/NN||â-36/FW	dep||-RSB--23/NNP||$-37/$	num||$-37/$||1.26-39/CD	stroke-13||warfarin-4||yes||the use of warfarin up to 90 days was not associated with stroke protection after anterior mi (hazard ratio [hr], 0.68; 95% confidence interval [ci], 0.37â€“1.26).
det||paper-2/NN||this-1/DT	nsubj||describes-3/VBZ||paper-2/NN	root||ROOT-0/null||describes-3/VBZ	det||findings-6/NNS||the-4/DT	amod||findings-6/NNS||main-5/JJ	dobj||describes-3/VBZ||findings-6/NNS	det||exercises-10/NNS||the-8/DT	num||exercises-10/NNS||two-9/CD	prep_from||describes-3/VBZ||exercises-10/NNS	prep_in||exercises-10/NNS||relation-12/NN	aux||contraception-14/VB||to-13/TO	vmod||describes-3/VBZ||contraception-14/VB	prep_for||contraception-14/VB||women-16/NNS	vmod||women-16/NNS||living-17/VBG	prep_with||living-17/VBG||hiv-19/NN	prep_with||living-17/VBG||aids-21/NNS	conj_or||hiv-19/NN||aids-21/NNS	amod||care-24/NN||abortion-related-23/JJ	prep_for||contraception-14/VB||care-24/NN	conj_and||women-16/NNS||care-24/NN	amod||adoption-27/NN||legal-26/JJ	prep_for||contraception-14/VB||adoption-27/NN	conj_and||women-16/NNS||adoption-27/NN	amod||parents-30/NNS||hiv-positive-29/JJ	prep_by||adoption-27/NN||parents-30/NNS	amod||rights-34/NNS||reproductive-33/JJ	prep_for||contraception-14/VB||rights-34/NNS	conj_and||women-16/NNS||rights-34/NNS	aids-21||hiv-19||no||this paper describes the main findings from the two exercises in relation to contraception for women living with hiv or aids, abortion-related care, legal adoption by hiv-positive parents, and reproductive rights.
mark||were-3/VBD||although-1/IN	expl||were-3/VBD||there-2/EX	advcl||decreased-26/VBN||were-3/VBD	neg||differences-6/NNS||no-4/DT	amod||differences-6/NNS||significant-5/JJ	nsubj||were-3/VBD||differences-6/NNS	det||-rrb--14/NN||the-8/DT	amod||-rrb--14/NN||vibriocidal-9/JJ	conj_or||vibriocidal-9/JJ||lipopolysaccharide-11/JJ	amod||-rrb--14/NN||lipopolysaccharide-11/JJ	amod||-rrb--14/NN||-lrb--12/JJ	nn||-rrb--14/NN||lps-13/NN	prep_in||differences-6/NNS||-rrb--14/NN	amod||responses-18/NNS||specific-16/JJ	amod||responses-18/NNS||immune-17/JJ	dep||-rrb--14/NN||responses-18/NNS	prep_to||responses-18/NNS||v.cholerae-20/NN	amod||patients-24/NNS||helminth-infected-22/JJ	nn||patients-24/NNS||cholera-23/NN	nsubj||decreased-26/VBN||patients-24/NNS	aux||decreased-26/VBN||had-25/VBD	root||ROOT-0/null||decreased-26/VBN	amod||responses-32/NNS||fecal-27/JJ	conj_and||fecal-27/JJ||serum-29/JJ	amod||responses-32/NNS||serum-29/JJ	amod||responses-32/NNS||iga-30/JJ	amod||responses-32/NNS||immune-31/JJ	dobj||decreased-26/VBN||responses-32/NNS	det||subunit-36/NN||the-34/DT	amod||subunit-36/NN||b-35/JJ	prep_to||responses-32/NNS||subunit-36/NN	nn||-rrb--42/NNP||cholera-38/NN	nn||-rrb--42/NNP||toxin-39/NN	nn||-rrb--42/NNP||-lrb--40/NNP	nn||-rrb--42/NNP||ctb-41/NNP	prep_of||subunit-36/NN||-rrb--42/NNP	det||decrease-49/NN||a-46/DT	advmod||modest-48/JJ||more-47/RBR	amod||decrease-49/NN||modest-48/JJ	dobj||decreased-26/VBN||decrease-49/NN	conj_and||responses-32/NNS||decrease-49/NN	nn||response-53/NN||serum-51/NN	nn||response-53/NN||igg-52/NN	prep_in||decrease-49/NN||response-53/NN	prep_to||decreased-26/VBN||ctb-55/NN	cholera-38||v.cholerae-20||no||although there were no significant differences in the vibriocidal or lipopolysaccharide -lrb- lps -rrb- - specific immune responses to v.cholerae , helminth-infected cholera patients had decreased fecal and serum iga immune responses to the b subunit of cholera toxin -lrb- ctb -rrb- as well as a more modest decrease in serum igg response to ctb .
amod||centers-3/NNS||many-1/JJ	amod||centers-3/NNS||medical-2/JJ	nsubj||culture-5/VBD||centers-3/NNS	advmod||culture-5/VBD||routinely-4/RB	root||ROOT-0/null||culture-5/VBD	amod||samples-7/NNS||bronchoscopy-6/JJ	dobj||culture-5/VBD||samples-7/NNS	prep_for||culture-5/VBD||mycobacteriumtuberculosis-9/NNS	advmod||suspected-17/VBN||even-11/RB	advmod||suspected-17/VBN||when-12/WRB	nsubjpass||suspected-17/VBN||tuberculosis-13/NNP	auxpass||suspected-17/VBN||is-14/VBZ	neg||suspected-17/VBN||not-15/RB	advmod||suspected-17/VBN||strongly-16/RB	advcl||culture-5/VBD||suspected-17/VBN	tuberculosis-13||mycobacteriumtuberculosis-9||no||many medical centers routinely culture bronchoscopy samples for mycobacteriumtuberculosis , even when tuberculosis is not strongly suspected.
poss||results-2/NNS||our-1/PRP$	nsubj||indicate-3/VBP||results-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||share-8/VB||that-4/IN	nsubj||share-8/VB||lrua-5/NN	conj_and||lrua-5/NN||lrub-7/NN	nsubj||share-8/VB||lrub-7/NN	ccomp||indicate-3/VBP||share-8/VB	amod||epitopes-10/NNS||immuno-relevant-9/JJ	dobj||share-8/VB||epitopes-10/NNS	nn||proteins-13/NNS||eye-12/NN	prep_with||share-8/VB||proteins-13/NNS	vmod||share-8/VB||suggesting-15/VBG	mark||contribute-24/VB||that-16/IN	amod||interactions-19/NNS||cross-reactive-17/JJ	nn||interactions-19/NNS||antibody-18/NN	nsubj||contribute-24/VB||interactions-19/NNS	nn||antigens-22/NNS||eye-21/NN	prep_with||interactions-19/NNS||antigens-22/NNS	aux||contribute-24/VB||may-23/MD	ccomp||suggesting-15/VBG||contribute-24/VB	prep_to||contribute-24/VB||immunopathogenesis-26/NNS	prep_of||immunopathogenesis-26/NNS||leptospira-28/NN	dep||share-8/VB||associated-30/JJ	amod||uveitis-32/NNS||recurrent-31/JJ	dobj||associated-30/JJ||uveitis-32/NNS	uveitis-32||antibody-18||no_rel||our results indicate that lrua and lrub share immuno-relevant epitopes with eye proteins, suggesting that cross-reactive antibody interactions with eye antigens may contribute to immunopathogenesis of leptospira -associated recurrent uveitis.
advmod||have-12/VBP||however-1/RB	prepc_compared_with||have-12/VBP||with-4/IN	pobj||have-12/VBP||youth-5/NN	prep_with||youth-5/NN||ngt-7/NN	nsubj||have-12/VBP||youth-9/NN	prep_with||youth-9/NN||igt-11/NN	root||ROOT-0/null||have-12/VBP	advmod||lower-14/JJR||significantly-13/RB	amod||insulin-16/NN||lower-14/JJR	amod||insulin-16/NN||first-phase-15/JJ	dobj||have-12/VBP||insulin-16/NN	amod||levels-19/NNS||c-peptide-18/JJ	dobj||have-12/VBP||levels-19/NNS	conj_and||insulin-16/NN||levels-19/NNS	conj_and||insulin-16/NN||gdi-21/NN	conj_and||levels-19/NNS||gdi-21/NN	dep||levels-19/NNS||p-23/VBN	dep||0.012-25/CD||=-24/SYM	ccomp||p-23/VBN||0.012-25/CD	mark||have-32/VBP||whereas-28/IN	nsubj||have-32/VBP||youth-29/NN	prep_with||youth-29/NN||type2diabetes-31/CD	advcl||have-12/VBP||have-32/VBP	det||defect-35/NN||an-33/DT	amod||defect-35/NN||additional-34/JJ	dobj||have-32/VBP||defect-35/NN	amod||insulin-38/NN||second-phase-37/JJ	prep_in||defect-35/NN||insulin-38/NN	type2diabetes-31||insulin-38||yes||however, compared with youth with ngt, youth with igt have significantly lower first-phase insulin and c-peptide levels and gdi ( p = 0.012), whereas youth with type2diabetes have an additional defect in second-phase insulin.
det||sequence-4/NN||the-1/DT	amod||sequence-4/NN||complete-2/JJ	nn||sequence-4/NN||genome-3/NN	nsubjpass||presented-27/VBN||sequence-4/NN	amod||ll195-7/NNS||listeriamonocytogenes-6/JJ	prep_of||sequence-4/NN||ll195-7/NNS	det||strain-13/NN||a-9/DT	amod||strain-13/NN||serotype-10/JJ	amod||strain-13/NN||4b-11/JJ	amod||strain-13/NN||clinical-12/JJ	appos||sequence-4/NN||strain-13/NN	vmod||strain-13/NN||isolated-14/VBN	det||1983â-17/NNS||the-16/DT	prep_during||isolated-14/VBN||1983â-17/NNS	dep||isolated-14/VBN||$-18/$	num||listeriosis-21/NN||1987-20/CD	npadvmod||in-23/RB||listeriosis-21/NN	advmod||listeriosis-21/NN||epidemic-22/RB	dep||switzerland-24/CD||in-23/RB	num||$-18/$||switzerland-24/CD	auxpass||presented-27/VBN||is-26/VBZ	root||ROOT-0/null||presented-27/VBN	listeriosis-21||listeriamonocytogenes-6||no||the complete genome sequence of listeriamonocytogenes ll195, a serotype 4b clinical strain isolated during the 1983â€“1987 listeriosis epidemic in switzerland, is presented.
neg||differences-3/NNS||no-1/DT	amod||differences-3/NNS||significant-2/JJ	nsubjpass||found-5/VBN||differences-3/NNS	auxpass||found-5/VBN||were-4/VBD	root||ROOT-0/null||found-5/VBN	nn||subjects-10/NNS||smoking-7/NN	conj_and||smoking-7/NN||non-smoking-9/NN	nn||subjects-10/NNS||non-smoking-9/NN	prep_between||found-5/VBN||subjects-10/NNS	amod||asthma-13/NN||mild-12/JJ	prep_with||subjects-10/NNS||asthma-13/NN	prep_in||asthma-13/NN||regard-15/NN	amod||changes-18/NNS||clinical-17/JJ	prep_to||found-5/VBN||changes-18/NNS	nn||control-21/NN||asthma-20/NN	prep_in||changes-18/NNS||control-21/NN	amod||function-24/NN||pulmonary-23/JJ	appos||control-21/NN||function-24/NN	nn||inflammation-27/NN||airway-26/NN	appos||control-21/NN||inflammation-27/NN	conj_and||function-24/NN||inflammation-27/NN	det||period-32/NN||a-29/DT	amod||period-32/NN||2-month-30/JJ	nn||period-32/NN||treatment-31/NN	prep_following||function-24/NN||period-32/NN	prep_with||period-32/NN||budesonide-34/NN	det||association-37/NN||the-36/DT	prep_following||function-24/NN||association-37/NN	conj_or||period-32/NN||association-37/NN	prep_of||association-37/NN||budesonide-39/NN	prep_of||association-37/NN||formoterol-41/NN	conj_and||budesonide-39/NN||formoterol-41/NN	det||period-44/NN||a-43/DT	prep_for||association-37/NN||period-44/NN	num||months-47/NNS||2-46/CD	prep_of||period-44/NN||months-47/NNS	asthma-20||budesonide-39||no||no significant differences were found between smoking and non-smoking subjects with mild asthma in regard to clinical changes in asthma control, pulmonary function and airway inflammation following a 2-month treatment period with budesonide or the association of budesonide and formoterol for a period of 2 months.
nsubj||remains-5/VBZ||quinine-1/NN	appos||quinine-1/NN||qn-3/NN	root||ROOT-0/null||remains-5/VBZ	det||drug-10/NN||the-6/DT	amod||drug-10/NN||first-7/JJ	nn||drug-10/NN||line-8/NN	nn||drug-10/NN||anti-malarial-9/NN	xcomp||remains-5/VBZ||drug-10/NN	det||treatment-13/NN||the-12/DT	prep_for||drug-10/NN||treatment-13/NN	amod||malaria-16/NN||complicated-15/JJ	prep_of||treatment-13/NN||malaria-16/NN	prep_in||malaria-16/NN||europe-18/NN	prep_in||malaria-16/NN||africa-20/NN	conj_and||europe-18/NN||africa-20/NN	malaria-16||quinine-1||yes||quinine (qn) remains the first line anti-malarial drug for the treatment of complicated malaria in europe and africa.
nn||women-2/NNS||conclusion-1/NN	nsubj||reduced-17/VBN||women-2/NNS	amod||intracranialhypertension-5/NN||idiopathic-4/JJ	prep_with||women-2/NNS||intracranialhypertension-5/NN	nsubj||followed-7/VBD||intracranialhypertension-5/NN	rcmod||intracranialhypertension-5/NN||followed-7/VBD	det||diet-11/NN||a-8/DT	amod||diet-11/NN||low-9/JJ	nn||diet-11/NN||energy-10/NN	dobj||followed-7/VBD||diet-11/NN	num||months-14/NNS||three-13/CD	prep_for||followed-7/VBD||months-14/NNS	aux||reduced-17/VBN||had-15/VBD	advmod||reduced-17/VBN||significantly-16/RB	root||ROOT-0/null||reduced-17/VBN	amod||pressure-19/NN||intracranial-18/JJ	dobj||reduced-17/VBN||pressure-19/NN	prepc_compared_with||reduced-17/VBN||with-21/IN	pobj||reduced-17/VBN||pressure-22/NN	vmod||pressure-22/NN||measured-23/VBN	det||months-27/NNS||the-25/DT	num||months-27/NNS||three-26/CD	prep_in||measured-23/VBN||months-27/NNS	det||diet-30/NN||the-29/DT	prep_before||measured-23/VBN||diet-30/NN	amod||symptoms-36/NNS||improved-35/VBN	pobj||reduced-17/VBN||symptoms-36/NNS	conj_and||pressure-22/NN||symptoms-36/NNS	amod||papilloedema-39/NN||reduced-38/VBN	conj_and||pressure-22/NN||papilloedema-39/NN	conj_and||symptoms-36/NNS||papilloedema-39/NN	papilloedema-39||intracranialhypertension-5||no||conclusion women with idiopathic intracranialhypertension who followed a low energy diet for three months had significantly reduced intracranial pressure compared with pressure measured in the three months before the diet, as well as improved symptoms and reduced papilloedema.
nsubj||were-10/VBD||background-1/NN	det||systems-9/NNS||the-3/DT	amod||systems-9/NNS||past-4/JJ	amod||systems-9/NNS||many-6/JJ	nn||systems-9/NNS||data-7/NN	nn||systems-9/NNS||collection-8/NN	prep_in||background-1/NN||systems-9/NNS	root||ROOT-0/null||were-10/VBD	prep_in||were-10/VBD||operation-12/NN	amod||projects-16/NNS||different-14/JJ	nn||projects-16/NNS||hiv/aids-15/NNS	prep_for||operation-12/NN||projects-16/NNS	prep_in||projects-16/NNS||china-18/NN	aids--1||hiv--1||no||background in the past, many data collection systems were in operation for different hiv/aids projects in china.
amod||infection-5/NNS||humantcelllymphotropicvirustype1-1/JJ	dep||infection-5/NNS||htlv-1-3/JJ	nsubj||lead-7/VB||infection-5/NNS	aux||lead-7/VB||can-6/MD	root||ROOT-0/null||lead-7/VB	prep_to||lead-7/VB||development-9/NN	amod||leukemia/lymphoma-14/NN||adult-11/JJ	nn||leukemia/lymphoma-14/NN||t-12/NN	nn||leukemia/lymphoma-14/NN||cell-13/NN	prep_of||development-9/NN||leukemia/lymphoma-14/NN	appos||leukemia/lymphoma-14/NN||atl-16/NN	amod||tropicalspasticparaparesis-21/NNS||htlv-1-associatedmyelopathy-19/JJ	amod||tropicalspasticparaparesis-21/NNS||/-20/JJ	prep_of||development-9/NN||tropicalspasticparaparesis-21/NNS	conj_or||leukemia/lymphoma-14/NN||tropicalspasticparaparesis-21/NNS	appos||leukemia/lymphoma-14/NN||ham/tsp-23/NN	det||subset-27/NN||a-26/DT	prep_in||lead-7/VB||subset-27/NN	amod||subjects-30/NNS||infected-29/JJ	prep_of||subset-27/NN||subjects-30/NNS	ham--1||humantcelllymphotropicvirustype1-1||no||humantcelllymphotropicvirustype1 (htlv-1) infection can lead to development of adult t cell leukemia/lymphoma (atl) or htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp) in a subset of infected subjects.
amod||treatment-3/NN||adjuvant-2/JJ	prep_after||developed-6/VBD||treatment-3/NN	num||patients-5/NNS||15-4/CD	nsubj||developed-6/VBD||patients-5/NNS	root||ROOT-0/null||developed-6/VBD	dobj||developed-6/VBD||recurrentdisease-7/NN	prep_of||10-9/CD||recurrentdisease-7/NN	nsubj||had-12/VBD||10-9/CD	rcmod||recurrentdisease-7/NN||had-12/VBD	amod||metastases-14/NNS||distant-13/JJ	dobj||had-12/VBD||metastases-14/NNS	adjuvant-2||recurrentdisease-7||no_rel||after adjuvant treatment 15 patients developed recurrentdisease, 10 of whom had distant metastases.
det||challenge-2/NN||a-1/DT	nsubj||is-9/VBZ||challenge-2/NN	nsubj||develop-11/VB||challenge-2/NN	nn||research-8/NN||tuberculosis-4/NNP	appos||research-8/NN||tb-6/NN	prep_in||challenge-2/NN||research-8/NN	root||ROOT-0/null||is-9/VBZ	aux||develop-11/VB||to-10/TO	xcomp||is-9/VBZ||develop-11/VB	det||test-15/NN||a-12/DT	amod||test-15/NN||new-13/JJ	amod||test-15/NN||immunological-14/JJ	dobj||develop-11/VB||test-15/NN	nsubj||help-18/VB||test-15/NN	aux||help-18/VB||can-17/MD	rcmod||test-15/NN||help-18/VB	ccomp||help-18/VB||distinguish-19/VB	prep_among||distinguish-19/VB||subjects-22/NNS	amod||subjects-22/NNS||responsive-23/JJ	nn||gold-27/NN||quantiferon-25/NN	nn||gold-27/NN||tb-26/NN	prep_to||responsive-23/JJ||gold-27/NN	prep_in||gold-27/NN||tube-29/NN	appos||subjects-22/NNS||qft-it-31/NN	dobj||distinguish-19/VB||those-34/DT	nsubj||able-37/JJ||those-34/DT	nsubj||control-39/VB||those-34/DT	cop||able-37/JJ||are-36/VBP	rcmod||those-34/DT||able-37/JJ	aux||control-39/VB||to-38/TO	xcomp||able-37/JJ||control-39/VB	nn||replication-41/NN||mtb-40/NN	dobj||control-39/VB||replication-41/NN	amod||ltbi-44/NNS||remote-43/JJ	dep||replication-41/NN||ltbi-44/NNS	amod||infection-47/NN||recent-46/JJ	dep||replication-41/NN||infection-47/NN	conj_and||ltbi-44/NNS||infection-47/NN	amod||tb-50/NN||past-49/JJ	dep||replication-41/NN||tb-50/NN	conj_and||ltbi-44/NNS||tb-50/NN	prep_from||control-39/VB||those-53/DT	nsubj||can-55/MD||those-53/DT	rcmod||those-53/DT||can-55/MD	neg||can-55/MD||not-56/RB	amod||disease-60/NN||active-58/JJ	nn||disease-60/NN||tb-59/NN	appos||those-53/DT||disease-60/NN	tb-59||mtb-40||no||a challenge in tuberculosis (tb) research is to develop a new immunological test that can help distinguish, among subjects responsive to quantiferon tb gold in tube (qft-it), those who are able to control mtb replication (remote ltbi, recent infection and past tb) from those who cannot (active tb disease).
poss||depressiveepisode-6/NN||his-2/PRP$	advmod||recent-4/JJ||most-3/RBS	amod||depressiveepisode-6/NN||recent-4/JJ	amod||depressiveepisode-6/NN||severe-5/JJ	prep_during||taking-10/VBG||depressiveepisode-6/NN	nsubj||taking-10/VBG||he-8/PRP	aux||taking-10/VBG||was-9/VBD	root||ROOT-0/null||taking-10/VBG	prt||taking-10/VBG||up-11/RP	num||mg-14/NN||1,500-13/CD	prep_to||taking-10/VBG||mg-14/NN	prep_of||mg-14/NN||venlafaxine-16/NN	advmod||taking-10/VBG||daily-17/RB	depressiveepisode-6||venlafaxine-16||yes||during his most recent severe depressiveepisode, he was taking up to 1,500 mg of venlafaxine daily.
nsubj||vlmâ-2/VBZ||abbreviations-1/NNS	root||ROOT-0/null||vlmâ-2/VBZ	ccomp||vlmâ-2/VBZ||$-3/VBG	amod||migrans-7/NNS||visceral-5/JJ	nn||migrans-7/NNS||larva-6/NN	dobj||$-3/VBG||migrans-7/NNS	dep||$-3/VBG||olmâ-9/VBG	dobj||olmâ-9/VBG||$-10/NN	nn||$-10/NN||ocular-12/FW	nn||$-10/NN||larva-13/FW	dep||$-10/NN||migrans-14/FW	amod||rate-21/NN||esrâ-16/JJ	amod||rate-21/NN||$-17/$	nn||rate-21/NN||erythrocyte-19/NN	nn||rate-21/NN||sedimentation-20/NN	appos||$-10/NN||rate-21/NN	dep||$-3/VBG||hbvâ-23/VBG	amod||hepatitisbvirus-26/NNS||$-24/$	dobj||hbvâ-23/VBG||hepatitisbvirus-26/NNS	dep||$-3/VBG||hcvâ-28/VBG	dep||virus-33/NN||$-29/$	nn||virus-33/NN||hepatits-31/NN	nn||virus-33/NN||c-32/NN	dobj||hcvâ-28/VBG||virus-33/NN	dep||$-3/VBG||ebvâ-35/VBG	dobj||ebvâ-35/VBG||$-36/$	num||$-36/$||epsteinâ-38/CD	vmod||ebvâ-35/VBG||$-39/VBG	amod||virus-42/NN||barr-41/JJR	dobj||$-39/VBG||virus-42/NN	dep||$-3/VBG||cmvâ-44/VBG	dobj||cmvâ-44/VBG||$-45/$	dep||$-45/$||cytomegalovirusinfection-47/NN	dep||$-3/VBG||hivâ-49/VBG	amod||tomography-58/NN||$-50/JJ	dep||tomography-58/NN||humanimmunodeficiencyvirus-52/NNS	amod||tomography-58/NN||ctâ-54/JJ	amod||tomography-58/NN||$-55/$	amod||tomography-58/NN||computed-57/JJ	dobj||hivâ-49/VBG||tomography-58/NN	dep||$-3/VBG||elisaâ-60/VBG	num||$-64/NNS||$-61/$	num||$-61/$||enzymeâ-63/CD	dobj||elisaâ-60/VBG||$-64/NNS	amod||assay-68/NN||linked-66/VBN	nn||assay-68/NN||immunosorbent-67/NN	dep||elisaâ-60/VBG||assay-68/NN	dep||$-3/VBG||cbcâ-70/VBG	dobj||cbcâ-70/VBG||$-71/$	amod||count-75/NN||complete-73/JJ	nn||count-75/NN||blood-74/NN	dobj||$-3/VBG||count-75/NN	hbv--1||hepatitisbvirus-26||no||abbreviations vlmâ€“visceral larva migrans, olmâ€“ocular larva migrans, esrâ€“erythrocyte sedimentation rate, hbvâ€“ hepatitisbvirus, hcvâ€“hepatits c virus, ebvâ€“epsteinâ€“barr virus, cmvâ€“ cytomegalovirusinfection, hivâ€“humanimmunodeficiencyvirus, ctâ€“ computed tomography, elisaâ€“enzymeâ€“linked immunosorbent assay, cbcâ€“complete blood count.
nsubjpass||complicated-14/VBN||treatment-1/NN	nn||patients-4/NNS||cancer-3/NN	prep_of||treatment-1/NN||patients-4/NNS	amod||doxorubicin-8/NN||anthracycline-6/JJ	amod||doxorubicin-8/NN||antibiotic-7/JJ	prep_with||patients-4/NNS||doxorubicin-8/NN	appos||treatment-1/NN||dox-10/NN	aux||complicated-14/VBN||may-12/MD	auxpass||complicated-14/VBN||be-13/VB	root||ROOT-0/null||complicated-14/VBN	agent||complicated-14/VBN||development-16/NN	amod||congestiveheartfailure-21/NN||acute-18/JJ	conj_and||acute-18/JJ||chronic-20/JJ	amod||congestiveheartfailure-21/NN||chronic-20/JJ	prep_of||development-16/NN||congestiveheartfailure-21/NN	appos||congestiveheartfailure-21/NN||chf-23/NN	amod||arrhythmias-27/NNS||malignant-26/JJ	prep_of||development-16/NN||arrhythmias-27/NNS	conj_and||congestiveheartfailure-21/NN||arrhythmias-27/NNS	prep_of||development-16/NN||death-29/NN	conj_and||congestiveheartfailure-21/NN||death-29/NN	congestiveheartfailure-21||dox-10||no||treatment of cancer patients with anthracycline antibiotic doxorubicin (dox) may be complicated by development of acute and chronic congestiveheartfailure (chf), malignant arrhythmias and death.
det||number-2/NN||the-1/DT	nsubjpass||caused-11/VBN||number-2/NN	nsubj||increasing-20/VBG||number-2/NN	prep_of||number-2/NN||individuals-4/NNS	vmod||individuals-4/NNS||diagnosed-5/VBN	prep_with||diagnosed-5/VBN||type2diabetesmellitus-7/CD	auxpass||caused-11/VBN||is-10/VBZ	rcmod||number-2/NN||caused-11/VBN	amod||secretion-17/NN||insulinresistance-13/JJ	nn||secretion-17/NN||and/or-14/NNP	amod||secretion-17/NN||abnormal-15/JJ	nn||secretion-17/NN||insulin-16/NN	agent||caused-11/VBN||secretion-17/NN	aux||increasing-20/VBG||is-19/VBZ	root||ROOT-0/null||increasing-20/VBG	advmod||increasing-20/VBG||worldwide-21/RB	vmod||increasing-20/VBG||creating-23/VBG	det||demand-26/NN||a-24/DT	amod||demand-26/NN||strong-25/JJ	dobj||creating-23/VBG||demand-26/NN	det||development-29/NN||the-28/DT	prep_for||creating-23/VBG||development-29/NN	advmod||effective-32/JJ||more-31/RBR	amod||drugs-34/NNS||effective-32/JJ	amod||drugs-34/NNS||anti-diabetic-33/JJ	prep_of||development-29/NN||drugs-34/NNS	type2diabetesmellitus-7||insulin-16||yes||the number of individuals diagnosed with type2diabetesmellitus, which is caused by insulinresistance and/or abnormal insulin secretion, is increasing worldwide, creating a strong demand for the development of more effective anti-diabetic drugs.
amod||research-2/NN||further-1/JJ	nsubj||critical-23/JJ||research-2/NN	det||prevalence-5/NN||the-4/DT	prep_on||research-2/NN||prevalence-5/NN	amod||acceptance-8/NN||hiv-related-7/JJ	prep_of||prevalence-5/NN||acceptance-8/NN	prep_of||prevalence-5/NN||stigma-10/NN	conj_and||acceptance-8/NN||stigma-10/NN	prep_among||prevalence-5/NN||caregivers-12/NNS	prep_among||prevalence-5/NN||implications-14/NNS	conj_and||caregivers-12/NNS||implications-14/NNS	amod||stigma-17/NN||such-16/JJ	prep_of||caregivers-12/NNS||stigma-17/NN	nn||development-20/NN||child-19/NN	prep_for||stigma-17/NN||development-20/NN	aux||critical-23/JJ||will-21/MD	cop||critical-23/JJ||be-22/VB	root||ROOT-0/null||critical-23/JJ	mark||responds-28/VBZ||as-24/IN	det||community-27/NN||the-25/DT	nn||community-27/NN||policy-26/NN	nsubj||responds-28/VBZ||community-27/NN	advcl||critical-23/JJ||responds-28/VBZ	det||crisis-34/NN||the-30/DT	amod||crisis-34/NN||global-31/JJ	amod||crisis-34/NN||hiv/aids-32/JJ	amod||crisis-34/NN||orphan-33/JJ	prep_to||responds-28/VBZ||crisis-34/NN	aids--1||hiv--1||no||further research on the prevalence of hiv-related acceptance and stigma among caregivers and implications of such stigma for child development will be critical as the policy community responds to the global hiv/aids orphan crisis.
det||estimates-4/NNS||these-1/DT	amod||estimates-4/NNS||absolute-2/JJ	nn||estimates-4/NNS||risk-3/NN	nsubj||inform-6/VB||estimates-4/NNS	nsubj||help-18/VB||estimates-4/NNS	aux||inform-6/VB||may-5/MD	root||ROOT-0/null||inform-6/VB	nn||policy-8/NN||health-7/NN	dobj||inform-6/VB||policy-8/NN	nn||planning-11/NN||resource-10/NN	dobj||inform-6/VB||planning-11/NN	conj_and||policy-8/NN||planning-11/NN	amod||populations-14/NNS||diverse-13/JJ	prep_across||policy-8/NN||populations-14/NNS	aux||help-18/VB||can-17/MD	conj_and||inform-6/VB||help-18/VB	nsubj||weigh-22/VB||patients-19/NNS	conj_and||patients-19/NNS||physicians-21/NNS	nsubj||weigh-22/VB||physicians-21/NNS	ccomp||help-18/VB||weigh-22/VB	det||probabilities-24/NNS||the-23/DT	dobj||weigh-22/VB||probabilities-24/NNS	prepc_of||probabilities-24/NNS||developing-26/VBG	amod||subtypes-30/NNS||specific-27/JJ	nn||subtypes-30/NNS||breast-28/NN	nn||subtypes-30/NNS||cancer-29/NN	dobj||developing-26/VBG||subtypes-30/NNS	amod||risks-34/NNS||competing-32/VBG	nn||risks-34/NNS||health-33/NN	prep_against||subtypes-30/NNS||risks-34/NNS	cancer-29||inform-6||no_rel||these absolute risk estimates may inform health policy and resource planning across diverse populations, and can help patients and physicians weigh the probabilities of developing specific breast cancer subtypes against competing health risks.
advmod||describe-3/VBP||here-1/RB	nsubj||describe-3/VBP||we-2/PRP	root||ROOT-0/null||describe-3/VBP	det||inhibitor-5/NN||an-4/DT	dobj||describe-3/VBP||inhibitor-5/NN	prep_of||inhibitor-5/NN||nf-îºb-7/NN	prep_from||describe-3/VBP||vacciniavirus-9/NNS	nsubj||has-11/VBZ||vacciniavirus-9/NNS	rcmod||vacciniavirus-9/NNS||has-11/VBZ	det||counterpart-15/NN||a-12/DT	advmod||related-14/VBN||closely-13/RB	amod||counterpart-15/NN||related-14/VBN	dobj||has-11/VBZ||counterpart-15/NN	prep_in||counterpart-15/NN||variolavirus-17/NNS	det||cause-20/NN||the-19/DT	dobj||has-11/VBZ||cause-20/NN	conj_and||counterpart-15/NN||cause-20/NN	prep_of||cause-20/NN||smallpox-22/NN	amod||similarity-26/NN||mechanistic-25/JJ	dobj||has-11/VBZ||similarity-26/NN	conj_and||counterpart-15/NN||similarity-26/NN	det||vpu-31/NN||the-28/DT	nn||vpu-31/NN||hiv-29/NN	nn||vpu-31/NN||protein-30/NN	prep_with||similarity-26/NN||vpu-31/NN	smallpox-22||variolavirus-17||no||here we describe an inhibitor of nf-îºb from vacciniavirus that has a closely related counterpart in variolavirus, the cause of smallpox, and mechanistic similarity with the hiv protein vpu.
advmod||uncovered-4/VBD||however-1/RB	nsubj||uncovered-4/VBD||we-3/PRP	root||ROOT-0/null||uncovered-4/VBD	det||signal-7/NN||a-5/DT	nn||signal-7/NN||safety-6/NN	dobj||uncovered-4/VBD||signal-7/NN	xcomp||uncovered-4/VBD||identifying-8/VBG	det||calciumphosphateproduct-11/NN||an-9/DT	amod||calciumphosphateproduct-11/NN||elevated-10/JJ	dobj||identifying-8/VBG||calciumphosphateproduct-11/NN	det||trend-14/NN||a-13/DT	dobj||identifying-8/VBG||trend-14/NN	conj_and||calciumphosphateproduct-11/NN||trend-14/NN	det||development-17/NN||the-16/DT	prep_towards||identifying-8/VBG||development-17/NN	prep_of||development-17/NN||hypercalcemia-19/NN	hypercalcemia-19||calciumphosphateproduct-11||no||however, we uncovered a safety signal identifying an elevated calciumphosphateproduct and a trend towards the development of hypercalcemia.
amod||acid-2/NN||arachidonic-1/JJ	nsubj||stimulated-8/VBN||acid-2/NN	poss||metabolites-5/NNS||its-4/PRP$	conj_and||acid-2/NN||metabolites-5/NNS	nsubj||stimulated-8/VBN||metabolites-5/NNS	aux||stimulated-8/VBN||have-6/VBP	advmod||stimulated-8/VBN||recently-7/RB	root||ROOT-0/null||stimulated-8/VBN	amod||interest-10/NN||great-9/JJ	dobj||stimulated-8/VBN||interest-10/NN	nn||biology-13/NN||cancer-12/NN	prep_in||stimulated-8/VBN||biology-13/NN	prep_unlike||received-30/VBN||prostaglandins-18/NNS	conj_and||prostaglandins-18/NNS||leukotrienes-20/NNS	prep_unlike||received-30/VBN||leukotrienes-20/NNS	det||link-22/NN||the-21/DT	nsubj||received-30/VBN||link-22/NN	amod||metabolites-26/NNS||cytochome-24/JJ	amod||metabolites-26/NNS||p450-25/JJ	prep_between||link-22/NN||metabolites-26/NNS	prep_between||link-22/NN||cancer-28/NN	conj_and||metabolites-26/NNS||cancer-28/NN	aux||received-30/VBN||has-29/VBZ	conj_but||stimulated-8/VBN||received-30/VBN	amod||attention-32/NN||little-31/JJ	dobj||received-30/VBN||attention-32/NN	cancer-28||prostaglandins-18||no_rel||arachidonic acid and its metabolites have recently stimulated great interest in cancer biology; but, unlike prostaglandins and leukotrienes the link between cytochome p450 metabolites and cancer has received little attention.
nn||length-2/NN||stride-1/NN	nsubj||improved-3/VBD||length-2/NN	root||ROOT-0/null||improved-3/VBD	dep||improved-3/VBD||73-5/CD	number||%-8/NN||95-7/CD	amod||14â-10/NNS||%-8/NN	nn||14â-10/NNS||ci-9/NN	dep||73-5/CD||14â-10/NNS	npadvmod||14â-10/NNS||$-11/$	nn||mm/year-15/NN||131-13/NNP	npadvmod||in-21/RB||mm/year-15/NN	dep||=-18/NNP||p-17/RB	dep||mm/year-15/NN||=-18/NNP	num||=-18/NNP||.01-19/CD	dep||favor-22/CD||in-21/RB	num||$-11/$||favor-22/CD	prep_of||14â-10/NNS||â-24/NN	npadvmod||active-29/JJ||$-25/$	num||$-25/$||œsuccessfulâ-26/CD	amod||$-25/$||$-27/$	dep||$-27/$||blinded-28/JJ	amod||â-24/NN||active-29/JJ	prep_over||â-24/NN||placebo-31/NN	amod||medication-36/NN||anti-parkinsonian-35/JJ	prep_irrespective_of||73-5/CD||medication-36/NN	dep||improved-3/VBD||despite-39/IN	conj_and||73-5/CD||despite-39/IN	amod||limb-42/NN||worsening-40/JJ	amod||limb-42/NN||upper-41/JJ	pobj||despite-39/IN||limb-42/NN	nn||rigidity-44/NN||flexor-43/NN	dep||73-5/CD||rigidity-44/NN	nn||57â-48/NNP||237-46/NNP	dep||rigidity-44/NN||57â-48/NNP	dep||57â-48/NNP||$-49/$	nn||ã-54/NN||416-51/NN	amod||ã-54/NN||nm-53/JJ	npadvmod||=-61/RB||ã-54/NN	amod||3/year-58/NNS||10âˆ-56/JJ	dep||ã-54/NN||3/year-58/NNS	appos||3/year-58/NNS||p-60/NN	dep||.01-62/CD||=-61/RB	num||$-49/$||.01-62/CD	rigidity-44||nm-53||no_rel||stride length improved (73 (95% ci 14â€“131) mm/year, p = .01) in favor of â€œsuccessfulâ€? blinded active over placebo, irrespective of anti-parkinsonian medication, and despite worsening upper limb flexor rigidity (237 (57â€“416) nm ã— 10âˆ’3/year, p = .01).
num||characteristics-4/NNS||six-1/CD	nn||characteristics-4/NNS||baseline-2/NN	nn||characteristics-4/NNS||participant-3/NN	nsubjpass||designated-6/VBN||characteristics-4/NNS	nsubj||participantsâ-60/VBZ||characteristics-4/NNS	auxpass||designated-6/VBN||were-5/VBD	root||ROOT-0/null||designated-6/VBN	amod||predictors-9/NNS||putative-8/JJ	prep_as||designated-6/VBN||predictors-9/NNS	nn||response-12/NN||treatment-11/NN	prep_of||predictors-9/NNS||response-12/NN	appos||response-12/NN||1-14/CD	dep||response-12/NN||gender-16/NN	appos||gender-16/NN||2-19/CD	dep||gender-16/NN||education-21/NN	dep||use-27/NN||3-24/LS	amod||use-27/NN||internet-26/VBN	appos||education-21/NN||use-27/NN	amod||sociodemographics-30/NNS||competence-28/JJ	dep||use-27/NN||sociodemographics-30/NNS	appos||sociodemographics-30/NNS||4-34/CD	amod||consumption-39/NN||mean-36/JJ	amod||consumption-39/NN||weekly-37/JJ	nn||consumption-39/NN||alcohol-38/NN	dep||sociodemographics-30/NNS||consumption-39/NN	appos||consumption-39/NN||5-42/CD	amod||help-46/NN||prior-44/JJ	amod||help-46/NN||professional-45/JJ	dep||consumption-39/NN||help-46/NN	nn||problems-49/NNS||alcohol-48/NN	prep_for||help-46/NN||problems-49/NNS	dep||problems-49/NNS||level-51/NN	prep_of||level-51/NN||problemdrinking-53/VBG	dep||participantsâ-60/VBZ||6-58/CD	conj_and||designated-6/VBN||participantsâ-60/VBZ	dep||expectancies-63/NNS||$-61/$	num||expectancies-63/NNS||™-62/CD	dobj||participantsâ-60/VBZ||expectancies-63/NNS	amod||interventions-66/NNS||web-based-65/JJ	prep_of||expectancies-63/NNS||interventions-66/NNS	prep_for||interventions-66/NNS||problemdrinking-68/VBG	problemdrinking-68||alcohol-48||no||six baseline participant characteristics were designated as putative predictors of treatment response (1) gender, (2) education, (3) internet use competence (sociodemographics), (4) mean weekly alcohol consumption, (5) prior professional help for alcohol problems (level of problemdrinking), and (6) participantsâ€™ expectancies of web-based interventions for problemdrinking.
amod||dependent-2/JJ||vitamind-1/JJ	amod||i-5/NNS||dependent-2/JJ	amod||i-5/NNS||rickets-3/JJ	nn||i-5/NNS||type-4/NN	nsubj||disorder-29/NN||i-5/NNS	appos||i-5/NNS||vddr-i-7/NNP	advmod||referred-11/VBN||also-10/RB	vmod||i-5/NNS||referred-11/VBN	advmod||vitamind-14/JJ||as-13/RB	amod||±-16/NNS||vitamind-14/JJ	amod||±-16/NNS||1î-15/JJ	prep_to||referred-11/VBN||±-16/NNS	amod||deficiency-19/NN||hydroxylase-18/JJ	dep||±-16/NNS||deficiency-19/NN	amod||rickets-23/NNS||pseudovitamind-21/JJ	nn||rickets-23/NNS||deficiency-22/NN	dep||±-16/NNS||rickets-23/NNS	conj_or||deficiency-19/NN||rickets-23/NNS	cop||disorder-29/NN||is-25/VBZ	det||disorder-29/NN||an-26/DT	amod||disorder-29/NN||autosomal-27/JJ	nn||disorder-29/NN||recessive-28/NN	root||ROOT-0/null||disorder-29/NN	vmod||disorder-29/NN||characterized-30/VBN	dep||characterized-30/VBN||clinically-31/RB	prep_by||clinically-31/RB||hypotonia-33/NN	conj_and||disorder-29/NN||muscleweakness-35/NNS	nn||failure-38/NN||growth-37/NN	appos||muscleweakness-35/NNS||failure-38/NN	amod||seizures-41/NNS||hypocalcemic-40/JJ	conj_and||disorder-29/NN||seizures-41/NNS	amod||infancy-44/NN||early-43/JJ	prep_in||seizures-41/NNS||infancy-44/NN	amod||findings-48/NNS||radiographic-47/JJ	conj_and||disorder-29/NN||findings-48/NNS	prep_of||findings-48/NNS||rickets-50/NNS	rickets-50||vitamind-14||yes||vitamind dependent rickets type i (vddr-i), also referred to as vitamind 1î±-hydroxylase deficiency or pseudovitamind deficiency rickets, is an autosomal recessive disorder characterized clinically by hypotonia, muscleweakness, growth failure, hypocalcemic seizures in early infancy, and radiographic findings of rickets.
det||network-2/NN||the-1/DT	nsubjpass||induced-19/VBN||network-2/NN	prep_including||network-2/NN||calnexin-4/NN	amod||protein-9/NN||endoplasmic-6/JJ	nn||protein-9/NN||reticulum-7/NN	nn||protein-9/NN||stress-8/NN	prep_including||network-2/NN||protein-9/NN	conj_and||calnexin-4/NN||protein-9/NN	nn||proteins-13/NNS||heat-11/NN	nn||proteins-13/NNS||shock-12/NN	prep_including||network-2/NN||proteins-13/NNS	conj_and||calnexin-4/NN||proteins-13/NNS	amod||genes-17/NNS||proteasome-16/JJ	prep_including||network-2/NN||genes-17/NNS	conj_and||calnexin-4/NN||genes-17/NNS	auxpass||induced-19/VBN||was-18/VBD	root||ROOT-0/null||induced-19/VBN	amod||treatment-22/NN||pioglitazone-21/JJ	agent||induced-19/VBN||treatment-22/NN	shock-12||pioglitazone-21||no_rel||the network including calnexin, endoplasmic reticulum stress protein, heat shock proteins, and proteasome genes was induced by pioglitazone treatment.
nsubjpass||used-4/VBN||mesalamine-1/NN	aux||used-4/VBN||has-2/VBZ	auxpass||used-4/VBN||been-3/VBN	root||ROOT-0/null||used-4/VBN	det||medication-8/NN||the-6/DT	amod||medication-8/NN||first-line-7/JJ	prep_as||used-4/VBN||medication-8/NN	det||treatment-11/NN||the-10/DT	prep_for||medication-8/NN||treatment-11/NN	prep_of||treatment-11/NN||ulcerativecolitis-13/NNS	appos||ulcerativecolitis-13/NNS||uc-15/NN	uc-15||mesalamine-1||yes||mesalamine has been used as the first-line medication for the treatment of ulcerativecolitis (uc).
advmod||remain-10/VBP||thus-1/RB	det||number-5/NN||a-3/DT	amod||number-5/NN||considerable-4/JJ	nsubj||remain-10/VBP||number-5/NN	amod||donors-9/NNS||hbv-7/JJ	amod||donors-9/NNS||infected-8/JJ	prep_of||number-5/NN||donors-9/NNS	root||ROOT-0/null||remain-10/VBP	acomp||remain-10/VBP||undiagnosed-11/JJ	mark||used-17/VBN||if-13/IN	advmod||hbsag-15/NN||only-14/RB	nsubjpass||used-17/VBN||hbsag-15/NN	auxpass||used-17/VBN||is-16/VBZ	advcl||remain-10/VBP||used-17/VBN	prep_for||used-17/VBN||screening-19/NN	hbv-7||hbsag-15||yes||thus, a considerable number of hbv infected donors remain undiagnosed, if only hbsag is used for screening.
amod||exposure-2/NN||maternal-1/JJ	nsubj||results-10/VBZ||exposure-2/NN	advmod||low-5/JJ||even-4/RB	amod||doses-6/NNS||low-5/JJ	prep_to||exposure-2/NN||doses-6/NNS	amod||compounds-9/NNS||cannabinoid-8/JJ	prep_of||doses-6/NNS||compounds-9/NNS	root||ROOT-0/null||results-10/VBZ	amod||activity-14/NN||atypical-12/JJ	nn||activity-14/NN||locomotor-13/NN	prep_in||results-10/VBZ||activity-14/NN	prep_in||results-10/VBZ||cognitiveimpairments-16/NNS	conj_and||activity-14/NN||cognitiveimpairments-16/NNS	amod||behavior-20/NN||altered-18/JJ	amod||behavior-20/NN||emotional-19/JJ	prep_in||results-10/VBZ||behavior-20/NN	conj_and||activity-14/NN||behavior-20/NN	amod||sensitivity-24/NN||enhanced-23/JJ	prep_in||results-10/VBZ||sensitivity-24/NN	conj_and||activity-14/NN||sensitivity-24/NN	prep_to||results-10/VBZ||drugs-26/NNS	prep_of||drugs-26/NNS||abuse-28/NN	det||offspring-33/NN||the-30/DT	amod||offspring-33/NN||adult-31/JJ	nn||offspring-33/NN||rodent-32/NN	prep_in||abuse-28/NN||offspring-33/NN	cognitiveimpairments-16||cannabinoid-8||no_rel||maternal exposure to even low doses of cannabinoid compounds results in atypical locomotor activity, cognitiveimpairments, altered emotional behavior, and enhanced sensitivity to drugs of abuse in the adult rodent offspring.
det||cells-2/NNS||these-1/DT	nsubjpass||exposed-4/VBN||cells-2/NNS	auxpass||exposed-4/VBN||were-3/VBD	root||ROOT-0/null||exposed-4/VBN	amod||gonococci-7/NNS||whole-6/JJ	prep_to||exposed-4/VBN||gonococci-7/NNS	amod||cytokines-18/NNS||supernatants-9/JJ	amod||pbmcs-12/NNS||gonococcal-infected-11/JJ	prep_from||supernatants-9/JJ||pbmcs-12/NNS	conj_or||supernatants-9/JJ||n.gonorrhoeae-15/JJ	amod||cytokines-18/NNS||n.gonorrhoeae-15/JJ	amod||cytokines-18/NNS||induced-17/JJ	appos||gonococci-7/NNS||cytokines-18/NNS	amod||levels-21/NNS||varying-20/VBG	prep_at||cytokines-18/NNS||levels-21/NNS	gonococcal--1||n.gonorrhoeae-15||no||these cells were exposed to whole gonococci , supernatants from gonococcal-infected pbmcs , or n.gonorrhoeae - induced cytokines at varying levels .
det||d1-4/NN||the-1/DT	amod||d1-4/NN||mean-2/JJ	nn||d1-4/NN||cyclin-3/NN	nsubj||<-13/VBD||d1-4/NN	amod||scores-7/NNS||d3-6/JJ	conj_and||d1-4/NN||scores-7/NNS	nsubj||<-13/VBD||scores-7/NNS	prep_of||scores-7/NNS||melanomas-9/NNS	nn||thickness-12/NN||breslow-11/NN	prep_with||melanomas-9/NNS||thickness-12/NN	root||ROOT-0/null||<-13/VBD	amod||mm-15/NN||1â-14/JJ	nsubj||different-23/JJ||mm-15/NN	amod||mm-19/NN||>-17/JJ	amod||mm-19/NN||1â-18/JJ	conj_and||mm-15/NN||mm-19/NN	nsubj||different-23/JJ||mm-19/NN	cop||different-23/JJ||were-20/VBD	neg||different-23/JJ||not-21/RB	advmod||different-23/JJ||significantly-22/RB	ccomp||<-13/VBD||different-23/JJ	melanomas-9||d3-6||no_rel||the mean cyclin d1 and d3 scores of melanomas with breslow thickness <1â mm and >1â mm were not significantly different.
vmod||produced-10/VBD||resultsâ-1/VBG	dobj||resultsâ-1/VBG||$-2/$	prep_with||resultsâ-1/VBG||hyperinsulinemia-5/FW	prep_with||resultsâ-1/VBG||hyperglycemia-7/FW	conj_and||hyperinsulinemia-5/FW||hyperglycemia-7/FW	nsubj||produced-10/VBD||exenatide-9/NN	root||ROOT-0/null||produced-10/VBD	det||increase-13/NN||a-11/DT	amod||increase-13/NN||significant-12/JJ	dobj||produced-10/VBD||increase-13/NN	amod||turnover-17/NN||total-15/JJ	nn||turnover-17/NN||glucose-16/NN	prep_in||produced-10/VBD||turnover-17/NN	quantmod||30-21/CD||âˆ-19/RB	number||30-21/CD||1/4-20/CD	num||%-22/NN||30-21/CD	prep_by||produced-10/VBD||%-22/NN	mark||indicated-25/VBD||as-24/IN	advcl||produced-10/VBD||indicated-25/VBD	amod||infusion-29/NN||portal-27/JJ	nn||infusion-29/NN||glucose-28/NN	prep_by||indicated-25/VBD||infusion-29/NN	dobj||indicated-25/VBD||rate-30/NN	nn||rate-30/NN||-lrb--31/FW	nn||rate-30/NN||saline-32/FW	nn||rate-30/NN||15.9-33/FW	nn||rate-30/NN||â-34/FW	nn||rate-30/NN||±-35/FW	nn||rate-30/NN||1.6-36/FW	nn||rate-30/NN||vs.-37/FW	nn||rate-30/NN||exenatide-38/FW	nn||rate-30/NN||20.4-39/FW	nn||rate-30/NN||â-40/FW	nn||rate-30/NN||±-41/FW	nn||rate-30/NN||2.1-42/FW	nn||rate-30/NN||mg-43/FW	nn||rate-30/NN||â-44/FW	nn||rate-30/NN||·-45/FW	nn||rate-30/NN||kgâˆ-46/FW	nn||rate-30/NN||1-48/FW	nn||rate-30/NN||â-49/FW	nn||rate-30/NN||·-50/FW	dep||rate-30/NN||minâˆ-51/FW	nsubj||âˆ-70/VBP||1-53/CD	nsubj||increased-76/VBD||1-53/CD	vmod||1-53/CD||p-55/VBN	dep||-rrb--58/NNS||<-56/SYM	num||-rrb--58/NNS||0.001-57/CD	ccomp||p-55/VBN||-rrb--58/NNS	xcomp||p-55/VBN||resulting-60/VBG	amod||d-68/NNP||increased-62/VBN	amod||d-68/NNP||whole-body-63/JJ	nn||d-68/NNP||glucose-64/NN	nn||d-68/NNP||disposal-65/NN	nn||d-68/NNP||-lrb--66/NN	nn||d-68/NNP||r-67/NNP	prep_from||resulting-60/VBG||d-68/NNP	rcmod||rate-30/NN||âˆ-70/VBP	number||20-72/CD||1/4-71/CD	num||%-73/NN||20-72/CD	nsubj||-rrb--74/NN||%-73/NN	xcomp||âˆ-70/VBP||-rrb--74/NN	rcmod||rate-30/NN||increased-76/VBD	conj_and||âˆ-70/VBP||increased-76/VBD	amod||uptake-79/NN||net-77/JJ	amod||uptake-79/NN||hepatic-78/JJ	nsubj||-rrb--88/NN||uptake-79/NN	nn||âˆ-84/FW||exogenous-81/FW	nn||âˆ-84/FW||glucose-82/FW	nn||âˆ-84/FW||-lrb--83/FW	prep_of||uptake-79/NN||âˆ-84/FW	number||%-87/NN||1/4-85/CD	number||%-87/NN||80-86/CD	amod||âˆ-84/FW||%-87/NN	xcomp||increased-76/VBD||-rrb--88/NN	hyperglycemia-7||glucose-82||no||resultsâ $ '' with hyperinsulinemia and hyperglycemia , exenatide produced a significant increase in total glucose turnover by âˆ 1/4 30 % , as indicated by portal glucose infusion rate -lrb- saline 15.9 â ± 1.6 vs. exenatide 20.4 â ± 2.1 mg â · kgâˆ ' 1 â · minâˆ ' 1 , p < 0.001 -rrb- , resulting from increased whole-body glucose disposal -lrb- r d , âˆ 1/4 20 % -rrb- and increased net hepatic uptake of exogenous glucose -lrb- âˆ 1/4 80 % -rrb- .
amod||outcome-2/NN||main-1/JJ	nsubj||measures-3/VBZ||outcome-2/NN	root||ROOT-0/null||measures-3/VBZ	det||index-6/NN||a-4/DT	nn||index-6/NN||price-5/NN	nsubjpass||used-20/VBN||index-6/NN	nsubj||estimate-22/VB||index-6/NN	amod||therapy-11/NN||first-8/JJ	nn||therapy-11/NN||line-9/NN	nn||therapy-11/NN||antiretroviral-10/NN	prep_of||index-6/NN||therapy-11/NN	prep_with||therapy-11/NN||data-13/NNS	amod||assistance-16/NN||foreign-15/JJ	prep_on||data-13/NNS||assistance-16/NN	prep_for||assistance-16/NN||hiv-18/NN	auxpass||used-20/VBN||was-19/VBD	ccomp||measures-3/VBZ||used-20/VBN	aux||estimate-22/VB||to-21/TO	xcomp||used-20/VBN||estimate-22/VB	det||associations-24/NNS||the-23/DT	dobj||estimate-22/VB||associations-24/NNS	prep_of||associations-24/NNS||prices-26/NNS	amod||assistance-29/NN||foreign-28/JJ	dobj||estimate-22/VB||assistance-29/NN	conj_and||associations-24/NNS||assistance-29/NN	amod||coverage-32/NN||antiretroviral-31/JJ	prep_with||assistance-29/NN||coverage-32/NN	dep||associations-24/NNS||percentage-34/NN	prep_of||percentage-34/NN||people-36/NNS	amod||hivinfection-39/NN||advanced-38/JJ	prep_with||people-36/NNS||hivinfection-39/NN	vmod||hivinfection-39/NN||receiving-40/VBG	amod||therapy-42/NN||antiretroviral-41/JJ	dobj||receiving-40/VBG||therapy-42/NN	dobj||estimate-22/VB||controlling-45/VBG	conj_and||associations-24/NNS||controlling-45/VBG	amod||spending-50/NN||national-47/JJ	amod||spending-50/NN||public-48/JJ	nn||spending-50/NN||health-49/NN	prep_for||controlling-45/VBG||spending-50/NN	nn||prevalence-53/NN||hiv-52/NN	prep_for||controlling-45/VBG||prevalence-53/NN	conj_and||spending-50/NN||prevalence-53/NN	prep_for||controlling-45/VBG||governance-55/NN	conj_and||spending-50/NN||governance-55/NN	amod||effects-59/NNS||fixed-58/JJ	prep_for||controlling-45/VBG||effects-59/NNS	conj_and||spending-50/NN||effects-59/NNS	prep_for||controlling-45/VBG||countries-61/NNS	prep_for||controlling-45/VBG||years-63/NNS	conj_and||countries-61/NNS||years-63/NNS	hivinfection-39||hiv-52||no||main outcome measures a price index of first line antiretroviral therapy with data on foreign assistance for hiv was used to estimate the associations of prices and foreign assistance with antiretroviral coverage (percentage of people with advanced hivinfection receiving antiretroviral therapy), controlling for national public health spending, hiv prevalence, governance, and fixed effects for countries and years.
nn||volume-2/NN||infarct-1/NN	nsubj||greater-4/JJR||volume-2/NN	cop||greater-4/JJR||was-3/VBD	root||ROOT-0/null||greater-4/JJR	nn||±-7/NNP||tnfî-6/NNP	prep_in||greater-4/JJR||±-7/NNP	nn||rats-10/NNS||tg-9/NN	dep||±-7/NNP||rats-10/NNS	dep||greater-4/JJR||than-11/IN	amod||controls-14/NNS||non-tg-13/JJ	prep_in||greater-4/JJR||controls-14/NNS	num||hours-17/NNS||24-16/CD	prep_at||controls-14/NNS||hours-17/NNS	nn||‰-21/NNS||p-19/NN	nn||‰-21/NNS||â-20/NN	dep||hours-17/NNS||‰-21/NNS	dep||‰-21/NNS||$-22/$	num||$-22/$||0.05-23/CD	num||days-27/NNS||7-26/CD	prep_at||controls-14/NNS||days-27/NNS	conj_and||hours-17/NNS||days-27/NNS	nn||‰-31/NNS||p-29/NN	nn||‰-31/NNS||â-30/NN	dep||days-27/NNS||‰-31/NNS	dep||‰-31/NNS||$-32/$	num||$-32/$||0.01-33/CD	tg-9||infarct-1||no_rel||infarct volume was greater in tnfî±-tg rats than in non-tg controls at 24 hours (p â‰¤ 0.05) and 7 days (p â‰¤ 0.01).
prep_in||isolates-14/VBZ||177-2/CD	num||%-5/NN||4-4/CD	appos||177-2/CD||%-5/NN	num||cases-11/NNS||4,557-8/CD	amod||cases-11/NNS||culture-positive-9/JJ	nn||cases-11/NNS||tb-10/NN	prep_of||177-2/CD||cases-11/NNS	nsubj||isolates-14/VBZ||mycobacteriumtuberculosis-13/NNS	root||ROOT-0/null||isolates-14/VBZ	auxpass||identified-16/VBN||were-15/VBD	ccomp||isolates-14/VBZ||identified-16/VBN	nn||tb-19/NN||mdr-18/NN	prep_as||identified-16/VBN||tb-19/NN	det||7-23/CD||an-21/DT	amod||7-23/CD||additional-22/JJ	nsubj||met-28/VBD||7-23/CD	num||%-26/NN||0.15-25/CD	appos||7-23/CD||%-26/NN	parataxis||isolates-14/VBZ||met-28/VBD	dobj||met-28/VBD||criteria-29/NNS	nn||tb-32/NN||xdr-31/NN	prep_for||met-28/VBD||tb-32/NN	tb-32||mycobacteriumtuberculosis-13||no||in 177 (4%) of 4,557 culture-positive tb cases, mycobacteriumtuberculosis isolates were identified as mdr tb; an additional 7 (0.15%) met criteria for xdr tb.
nn||options-2/NNS||treatment-1/NN	nsubj||include-11/VBP||options-2/NNS	amod||pd-9/NN||advanced-4/JJ	nn||pd-9/NN||parkinson-5/NN	amod||pd-9/NN||sdisease-7/JJ	prep_in||options-2/NNS||pd-9/NN	root||ROOT-0/null||include-11/VBP	nsubj||nucleus-18/VBG||subcutaneous-12/NNS	dep||nucleus-18/VBG||apomorphine-13/JJ	conj_or||apomorphine-13/JJ||pallidal-15/JJ	dep||nucleus-18/VBG||pallidal-15/JJ	conj_or||apomorphine-13/JJ||subthalamic-17/JJ	dep||nucleus-18/VBG||subthalamic-17/JJ	xcomp||include-11/VBP||nucleus-18/VBG	amod||stimulation-21/NN||deep-19/JJ	nn||stimulation-21/NN||brain-20/NN	dobj||nucleus-18/VBG||stimulation-21/NN	appos||stimulation-21/NN||dbs-23/NN	amod||gel-29/NN||levodopa/carbidopa-27/JJ	amod||gel-29/NN||intestinal-28/JJ	dobj||nucleus-18/VBG||gel-29/NN	conj_or||stimulation-21/NN||gel-29/NN	appos||gel-29/NN||lcig/duodopa-31/NNP	parkinson'sdisease--1||levodopa--1||yes||treatment options in advanced parkinson'sdisease (pd) include subcutaneous apomorphine, pallidal or subthalamic nucleus deep brain stimulation (dbs), or levodopa/carbidopa intestinal gel (lcig/duodopa).
prep_in||abolished-16/VBN||contrast-2/NN	csubjpass||abolished-16/VBN||reducing-4/VBG	dobj||reducing-4/VBG||hyperinsulinemia-5/NN	amod||levels-8/NNS||basal-7/JJ	prep_to||reducing-4/VBG||levels-8/NNS	amod||turnover-13/NN||exenatide-increased-10/JJ	amod||turnover-13/NN||total-11/JJ	nn||turnover-13/NN||glucose-12/NN	appos||levels-8/NNS||turnover-13/NN	auxpass||abolished-16/VBN||was-14/VBD	advmod||abolished-16/VBN||completely-15/RB	dep||kgâˆ-34/VBD||abolished-16/VBN	nn||±-23/NN||hyperglycemia-18/NN	nn||±-23/NN||-lrb--19/NN	nn||±-23/NN||saline-20/NN	num||±-23/NN||2.9-21/CD	amod||±-23/NN||â-22/JJ	prep_despite||abolished-16/VBN||±-23/NN	num||±-23/NN||0.6-24/CD	amod||·-33/NNS||exenatide-26/JJ	dep||exenatide-26/JJ||2.3-27/CD	amod||·-33/NNS||â-28/JJ	amod||·-33/NNS||±-29/JJ	num||·-33/NNS||0.3-30/CD	nn||·-33/NNS||mg-31/NN	nn||·-33/NNS||â-32/NN	prep_vs.||±-23/NN||·-33/NNS	root||ROOT-0/null||kgâˆ-34/VBD	num||minâˆ-39/NNS||1-36/CD	nn||minâˆ-39/NNS||â-37/NN	nn||minâˆ-39/NNS||·-38/NN	dobj||kgâˆ-34/VBD||minâˆ-39/NNS	nsubj||kgâˆ-34/VBD||1-41/CD	appos||1-41/CD||p-43/NN	dep||-rrb--46/NNS||=-44/SYM	num||-rrb--46/NNS||0.29-45/CD	rcmod||p-43/NN||-rrb--46/NNS	hyperglycemia-18||glucose-12||no||in contrast , reducing hyperinsulinemia to basal levels , exenatide-increased total glucose turnover was completely abolished despite hyperglycemia -lrb- saline 2.9 â ± 0.6 vs. exenatide 2.3 â ± 0.3 mg â · kgâˆ ' 1 â · minâˆ ' 1 , p = 0.29 -rrb- .
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	neg||association-4/NN||no-3/DT	nsubj||was-2/VBD||association-4/NN	amod||alleles-10/NNS||functional-6/JJ	dep||functional-6/JJ||cyp2c19-7/CD	dep||functional-6/JJ||cyp2d6-9/CD	conj_and||cyp2c19-7/CD||cyp2d6-9/CD	prep_between||association-4/NN||alleles-10/NNS	nn||outcome-13/NN||treatment-12/NN	nsubj||was-2/VBD||outcome-13/NN	conj_and||association-4/NN||outcome-13/NN	nn||patients-16/NNS||multiplemyeloma-15/NN	prep_in||outcome-13/NN||patients-16/NNS	vmod||patients-16/NNS||treated-17/VBN	prep_with||treated-17/VBN||cyclophosphamide-19/NN	prep_with||treated-17/VBN||thalidomide-21/NN	conj_or||cyclophosphamide-19/NN||thalidomide-21/NN	prep_with||treated-17/VBN||bortezomib-23/NN	conj_or||cyclophosphamide-19/NN||bortezomib-23/NN	multiplemyeloma-15||bortezomib-23||yes||there was no association between functional cyp2c19 and cyp2d6 alleles and treatment outcome in multiplemyeloma patients treated with cyclophosphamide, thalidomide or bortezomib.
advmod||assessing-2/VBG||when-1/WRB	advcl||predominated-17/VBD||assessing-2/VBG	amod||profiles-4/NNS||cytokine-3/JJ	dobj||assessing-2/VBG||profiles-4/NNS	amod||cells-10/NNS||ppd-6/JJ	amod||cells-10/NNS||specific-7/JJ	amod||cells-10/NNS||cd4-8/JJ	nn||cells-10/NNS||t-9/NN	nsubj||predominated-17/VBD||cells-10/NNS	vmod||cells-10/NNS||secreting-11/VBG	preconj||³-14/JJ||both-12/DT	amod||³-14/JJ||ifn-î-13/JJ	dobj||secreting-11/VBG||³-14/JJ	dobj||secreting-11/VBG||il-2-16/JJ	conj_and||³-14/JJ||il-2-16/JJ	root||ROOT-0/null||predominated-17/VBD	prepc_in||predominated-17/VBD||treated-19/VBN	dobj||treated-19/VBN||tb-20/NN	nn||infection-23/NN||latent-22/NN	dobj||treated-19/VBN||infection-23/NN	conj_and||tb-20/NN||infection-23/NN	dobj||treated-19/VBN||bcg-vaccination-25/NN	conj_and||tb-20/NN||bcg-vaccination-25/NN	mark||shifted-35/VBN||whilst-27/IN	amod||tb-30/NN||active-29/JJ	prep_in||shifted-35/VBN||tb-30/NN	det||profile-33/NN||the-31/DT	amod||profile-33/NN||cytokine-32/JJ	nsubjpass||shifted-35/VBN||profile-33/NN	auxpass||shifted-35/VBN||was-34/VBD	dep||treated-19/VBN||shifted-35/VBN	prep_towards||shifted-35/VBN||cells-37/NNS	xcomp||shifted-35/VBN||secreting-38/VBG	amod||³-40/NNS||ifn-î-39/JJ	dobj||secreting-38/VBG||³-40/NNS	advmod||secreting-38/VBG||only-41/RB	dep||secreting-38/VBG||p-43/NNP	number||0.0001-45/CD||<-44/CD	num||p-43/NNP||0.0001-45/CD	tb-30||bcg--1||no||when assessing cytokine profiles, ppd specific cd4 t cells secreting both ifn-î³ and il-2 predominated in treated tb, latent infection and bcg-vaccination, whilst in active tb the cytokine profile was shifted towards cells secreting ifn-î³ only (p<0.0001).
amod||concentrations-3/NNS||increased-1/VBN	nn||concentrations-3/NNS||hepcidin-2/NN	nsubj||lead-4/VBP||concentrations-3/NNS	nsubj||iron-6/VB||concentrations-3/NNS	root||ROOT-0/null||lead-4/VBP	aux||iron-6/VB||to-5/TO	xcomp||lead-4/VBP||iron-6/VB	dobj||iron-6/VB||sequestration-7/NN	prep_in||sequestration-7/NN||macrophages-9/NNS	vmod||sequestration-7/NN||contributing-11/VBG	det||pathogenesis-14/NNS||the-13/DT	prep_to||contributing-11/VBG||pathogenesis-14/NNS	prep_of||pathogenesis-14/NNS||anaemia-16/NN	amod||disease-19/NN||chronic-18/JJ	prep_of||anaemia-16/NN||disease-19/NN	mark||observed-24/VBN||whereas-20/IN	amod||hepcidin-22/NN||decreased-21/VBN	nsubjpass||observed-24/VBN||hepcidin-22/NN	auxpass||observed-24/VBN||is-23/VBZ	advcl||contributing-11/VBG||observed-24/VBN	amod||ironoverloaddiseases-29/NNS||irondeficiency-26/JJ	conj_and||irondeficiency-26/JJ||primary-28/JJ	amod||ironoverloaddiseases-29/NNS||primary-28/JJ	prep_in||observed-24/VBN||ironoverloaddiseases-29/NNS	prep_such_as||ironoverloaddiseases-29/NNS||hereditaryhemochromatosis-32/NNS	hereditaryhemochromatosis-32||iron-6||no||increased hepcidin concentrations lead to iron sequestration in macrophages, contributing to the pathogenesis of anaemia of chronic disease whereas decreased hepcidin is observed in irondeficiency and primary ironoverloaddiseases such as hereditaryhemochromatosis.
det||safety-2/NN||the-1/DT	nsubj||+-9/VBD||safety-2/NN	amod||cd-8/NN||chlorproguanil-dapsone-4/JJ	nn||cd-8/NN||+-5/NNP	amod||cd-8/NN||artesunate-6/JJ	amod||cd-8/NN||-lrb--7/JJ	prep_of||safety-2/NN||cd-8/NN	root||ROOT-0/null||+-9/VBD	det||-rrb--20/NN||a-10/DT	amod||-rrb--20/NN||-rrb--11/JJ	conj_and||-rrb--11/JJ||amodiaquine-13/JJ	amod||-rrb--20/NN||amodiaquine-13/JJ	nn||-rrb--20/NN||+-14/NNP	amod||-rrb--20/NN||sulphadoxine-pyrimethamine-15/JJ	nn||-rrb--20/NN||-lrb--16/NN	nn||-rrb--20/NN||aq-17/NN	amod||-rrb--20/NN||+-18/JJ	nn||-rrb--20/NN||sp-19/NN	nsubjpass||evaluated-29/VBN||-rrb--20/NN	det||treatment-23/NN||the-22/DT	prep_for||-rrb--20/NN||treatment-23/NN	amod||falciparummalaria-27/NN||uncomplicated-25/JJ	nn||falciparummalaria-27/NN||p.-26/NN	prep_of||treatment-23/NN||falciparummalaria-27/NN	auxpass||evaluated-29/VBN||was-28/VBD	ccomp||+-9/VBD||evaluated-29/VBN	prepc_according_to||evaluated-29/VBN||to-31/TO	amod||deficiency-33/NN||g6pd-32/JJ	pobj||evaluated-29/VBN||deficiency-33/NN	det||analysis-37/NN||a-35/DT	amod||analysis-37/NN||secondary-36/JJ	prep_in||deficiency-33/NN||analysis-37/NN	det||trial-44/NN||an-39/DT	amod||trial-44/NN||open-label-40/JJ	amod||trial-44/NN||randomized-42/JJ	amod||trial-44/NN||clinical-43/JJ	prep_of||analysis-37/NN||trial-44/NN	vmod||trial-44/NN||-lsb--45/VBG	number||-rsb--47/CD||1-46/CD	dobj||-lsb--45/VBG||-rsb--47/CD	falciparummalaria-27||sulphadoxine--1||yes||the safety of chlorproguanil-dapsone + artesunate -lrb- cd+a -rrb- and amodiaquine + sulphadoxine-pyrimethamine -lrb- aq+sp -rrb- for the treatment of uncomplicated p. falciparummalaria was evaluated according to g6pd deficiency in a secondary analysis of an open-label , randomized clinical trial -lsb- 1 -rsb- .
det||effect-2/NN||the-1/DT	nsubjpass||evaluated-27/VBN||effect-2/NN	det||extract-6/NN||the-4/DT	nn||extract-6/NN||ethanol-5/NN	prep_of||effect-2/NN||extract-6/NN	det||motility-9/NN||the-8/DT	prep_on||extract-6/NN||motility-9/NN	det||git-12/NN||the-11/DT	prep_of||motility-9/NN||git-12/NN	prep_in||git-12/NN||mice-14/NNS	vmod||mice-14/NNS||using-15/VBG	det||method-19/NN||the-16/DT	nn||method-19/NN||charcoal-17/NN	nn||method-19/NN||plug-18/NN	dobj||using-15/VBG||method-19/NN	amod||diarrhoea-23/NN||castoroil-21/JJ	nn||diarrhoea-23/NN||induced-22/NN	dobj||using-15/VBG||diarrhoea-23/NN	conj_and||method-19/NN||diarrhoea-23/NN	prep_in||method-19/NN||rats-25/NNS	auxpass||evaluated-27/VBN||was-26/VBD	root||ROOT-0/null||evaluated-27/VBN	diarrhoea-23||charcoal-17||yes||the effect of the ethanol extract on the motility of the git in mice using the charcoal plug method and castoroil induced diarrhoea in rats was evaluated.
nn||design-2/NN||research-1/NN	nsubjpass||studied-25/VBN||design-2/NN	poss||consequences-8/NNS||methods-4/NNS	amod||consequences-8/NNS||$-6/JJ	conj_and||design-2/NN||consequences-8/NNS	nsubjpass||studied-25/VBN||consequences-8/NNS	amod||changes-14/NNS||euglycemia-10/NN	conj_and||euglycemia-10/NN||hyperglycemia-induced-13/JJ	amod||changes-14/NNS||hyperglycemia-induced-13/JJ	prep_of||consequences-8/NNS||changes-14/NNS	amod||emptying-17/NN||gastric-16/JJ	prep_in||changes-14/NNS||emptying-17/NN	amod||fluxes-21/NNS||postprandial-19/JJ	nn||fluxes-21/NNS||glucose-20/NN	prep_on||emptying-17/NN||fluxes-21/NNS	prep_on||emptying-17/NN||excursions-23/NNS	conj_and||fluxes-21/NNS||excursions-23/NNS	auxpass||studied-25/VBN||were-24/VBD	root||ROOT-0/null||studied-25/VBN	num||subjects-29/NNS||10-27/CD	amod||subjects-29/NNS||healthy-28/JJ	prep_in||studied-25/VBN||subjects-29/NNS	num||type-32/NN||15-31/CD	prep_in||studied-25/VBN||type-32/NN	conj_and||subjects-29/NNS||type-32/NN	num||subjects-35/NNS||1-33/CD	amod||subjects-35/NNS||diabetic-34/JJ	dep||type-32/NN||subjects-35/NNS	prep_after||studied-25/VBN||ingestion-37/NN	det||meal-41/NN||a-39/DT	amod||meal-41/NN||mixed-40/JJ	prep_of||ingestion-37/NN||meal-41/NN	vmod||meal-41/NN||using-42/VBG	det||approach-46/NN||the-43/DT	amod||approach-46/NN||double-44/JJ	nn||approach-46/NN||isotope-45/NN	dobj||using-42/VBG||approach-46/NN	amod||-RSB--50/NNS||-LSB--48/JJ	amod||-RSB--50/NNS||6,6-2h2-49/JJ	dep||approach-46/NN||-RSB--50/NNS	amod||glucose-55/NN||-LSB--52/JJ	amod||glucose-55/NN||1-13c-53/JJ	nn||glucose-55/NN||-RSB--54/NN	dep||approach-46/NN||glucose-55/NN	conj_and||-RSB--50/NNS||glucose-55/NN	amod||measurements-59/NNS||scintigraphic-58/JJ	dobj||using-42/VBG||measurements-59/NNS	conj_and||approach-46/NN||measurements-59/NNS	amod||emptying-62/NN||gastric-61/JJ	prep_of||measurements-59/NNS||emptying-62/NN	hyperglycemia--1||glucose-55||no||research design and methods â€”consequences of euglycemia- and hyperglycemia-induced changes in gastric emptying on postprandial glucose fluxes and excursions were studied in 10 healthy subjects and 15 type 1 diabetic subjects after ingestion of a mixed meal using the double isotope approach ([6,6-2h2] and [1-13c]glucose) and scintigraphic measurements of gastric emptying.
nsubj||represents-14/VBZ||development-1/NN	amod||-lrb--5/NNS||recombinant-3/JJ	nn||-lrb--5/NNS||bcg-4/NN	prep_of||development-1/NN||-lrb--5/NNS	vmod||-lrb--5/NNS||rbcg-6/VBG	amod||antigens-11/NNS||-rrb--7/JJ	amod||antigens-11/NNS||over-expressing-8/JJ	amod||antigens-11/NNS||promising-9/JJ	nn||antigens-11/NNS||immunodominant-10/NN	dobj||rbcg-6/VBG||antigens-11/NNS	prep_of||antigens-11/NNS||m.tuberculosis-13/NNS	root||ROOT-0/null||represents-14/VBZ	dobj||represents-14/VBZ||one-15/CD	det||approaches-19/NNS||the-17/DT	amod||approaches-19/NNS||potential-18/JJ	prep_of||one-15/CD||approaches-19/NNS	det||development-22/NN||the-21/DT	prep_for||approaches-19/NNS||development-22/NN	prep_of||development-22/NN||vaccines-24/NNS	prep_against||vaccines-24/NNS||tb-26/NN	tb-26||m.tuberculosis-13||no||development of recombinant bcg -lrb- rbcg -rrb- over-expressing promising immunodominant antigens of m.tuberculosis represents one of the potential approaches for the development of vaccines against tb .
amod||virus-2/NN||hepatitisc-1/JJ	nsubj||agent-9/NN||virus-2/NN	appos||virus-2/NN||hcv-4/NN	cop||agent-9/NN||is-6/VBZ	det||agent-9/NN||the-7/DT	amod||agent-9/NN||etiological-8/JJ	root||ROOT-0/null||agent-9/NN	det||majority-12/NN||the-11/DT	prep_for||agent-9/NN||majority-12/NN	prep_of||majority-12/NN||cases-14/NNS	prep_of||cases-14/NNS||non-a-16/NN	appos||non-a-16/NN||non-bhepatitis-18/NNS	non-a-16||non-bhepatitis-18||no||hepatitisc virus (hcv) is the etiological agent for the majority of cases of non-a, non-bhepatitis.
nsubj||medication-6/NN||ranolazine-1/NN	nsubjpass||considered-16/VBN||ranolazine-1/NN	cop||medication-6/NN||is-2/VBZ	det||medication-6/NN||a-3/DT	amod||medication-6/NN||proven-4/JJ	amod||medication-6/NN||antianginal-5/JJ	root||ROOT-0/null||medication-6/NN	prep_in||medication-6/NN||patients-8/NNS	amod||coronaryheartdisease-11/NN||symptomatic-10/JJ	prep_with||patients-8/NNS||coronaryheartdisease-11/NN	aux||considered-16/VBN||should-14/MD	auxpass||considered-16/VBN||be-15/VB	conj_and||medication-6/NN||considered-16/VBN	det||agent-21/NN||an-18/DT	amod||agent-21/NN||initial-19/JJ	amod||agent-21/NN||antianginal-20/JJ	prep_as||considered-16/VBN||agent-21/NN	prep_for||agent-21/NN||those-23/DT	prep_with||those-23/DT||hypotension-25/NN	prep_with||those-23/DT||bradycardia-27/NN	conj_or||hypotension-25/NN||bradycardia-27/NN	antianginal-20||coronaryheartdisease-11||no_rel||ranolazine is a proven antianginal medication in patients with symptomatic coronaryheartdisease, and should be considered as an initial antianginal agent for those with hypotension or bradycardia.
nsubj||undertook-2/VBD||we-1/PRP	root||ROOT-0/null||undertook-2/VBD	det||analysis-5/NN||a-3/DT	nn||analysis-5/NN||retrospective-4/NN	dobj||undertook-2/VBD||analysis-5/NN	det||prevalence-8/NN||the-7/DT	prep_of||analysis-5/NN||prevalence-8/NN	prep_of||prevalence-8/NN||mdr-tb-10/NN	prep_in||undertook-2/VBD||children-12/NNS	prep_with||children-12/NNS||mycobacteriumtuberculosis-14/NNS	appos||mycobacteriumtuberculosis-14/NNS||mtb-16/NN	num||hospitals-20/NNS||two-19/CD	prep_at||undertook-2/VBD||hospitals-20/NNS	amod||africa-25/NN||johannesburg-22/JJ	amod||africa-25/NN||south-24/JJ	prep_in||hospitals-20/NNS||africa-25/NN	tb--1||mtb-16||no||we undertook a retrospective analysis of the prevalence of mdr-tb in children with mycobacteriumtuberculosis (mtb) at two hospitals in johannesburg, south africa.
amod||studies-2/NNS||recent-1/JJ	nsubj||suggest-3/VBP||studies-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||plays-10/VBZ||that-4/IN	det||induction-6/NN||the-5/DT	nsubj||plays-10/VBZ||induction-6/NN	amod||expression-9/NN||ho-1-8/JJ	prep_of||induction-6/NN||expression-9/NN	ccomp||suggest-3/VBP||plays-10/VBZ	det||role-14/NN||a-11/DT	amod||role-14/NN||critical-12/JJ	amod||role-14/NN||protective-13/JJ	dobj||plays-10/VBZ||role-14/NN	amod||models-18/NNS||intestinal-16/JJ	nn||models-18/NNS||damage-17/NN	prep_in||plays-10/VBZ||models-18/NNS	vmod||models-18/NNS||induced-19/VBN	agent||induced-19/VBN||ischemia-reperfusion-21/NN	agent||induced-19/VBN||indomethacin-23/NN	conj_and||ischemia-reperfusion-21/NN||indomethacin-23/NN	amod||sepsis-26/NN||lipopolysaccharide-associated-25/JJ	agent||induced-19/VBN||sepsis-26/NN	conj_and||ischemia-reperfusion-21/NN||sepsis-26/NN	amod||acid-30/NN||trinitrobenzene-28/JJ	amod||acid-30/NN||sulfonic-29/JJ	agent||induced-19/VBN||acid-30/NN	conj_and||ischemia-reperfusion-21/NN||acid-30/NN	nn||sodium-35/NN||dextran-33/NN	nn||sodium-35/NN||sulfate-34/NN	agent||induced-19/VBN||sodium-35/NN	conj_and||ischemia-reperfusion-21/NN||sodium-35/NN	vmod||plays-10/VBZ||indicating-37/VBG	mark||act-43/VB||that-38/IN	nsubj||act-43/VB||activation-39/NN	nsubj||reduce-50/VB||activation-39/NN	prep_of||activation-39/NN||ho-1-41/CD	aux||act-43/VB||may-42/MD	ccomp||indicating-37/VBG||act-43/VB	det||mechanism-48/NN||an-45/DT	amod||mechanism-48/NN||endogenous-46/JJ	amod||mechanism-48/NN||defensive-47/JJ	prep_as||act-43/VB||mechanism-48/NN	aux||reduce-50/VB||to-49/TO	xcomp||act-43/VB||reduce-50/VB	nn||injury-54/NN||inflammation-51/NN	conj_and||inflammation-51/NN||tissue-53/NN	nn||injury-54/NN||tissue-53/NN	dobj||reduce-50/VB||injury-54/NN	det||tract-58/NN||the-56/DT	amod||tract-58/NN||gastrointestinal-57/JJ	prep_in||reduce-50/VB||tract-58/NN	sepsis-26||indomethacin-23||no_rel||recent studies suggest that the induction of ho-1 expression plays a critical protective role in intestinal damage models induced by ischemia-reperfusion, indomethacin, lipopolysaccharide-associated sepsis, trinitrobenzene sulfonic acid, and dextran sulfate sodium, indicating that activation of ho-1 may act as an endogenous defensive mechanism to reduce inflammation and tissue injury in the gastrointestinal tract.
det||baseline-3/NN||the-1/DT	amod||baseline-3/NN||lower-2/JJR	nsubj||predicted-6/VBD||baseline-3/NN	vmod||baseline-3/NN||hbsag-4/VBG	dobj||hbsag-4/VBG||level-5/NN	root||ROOT-0/null||predicted-6/VBD	det||decline-9/NN||the-7/DT	amod||decline-9/NN||hbsag-8/VBG	dobj||predicted-6/VBD||decline-9/NN	amod||loss-12/NN||hbsag-11/VBG	dobj||predicted-6/VBD||loss-12/NN	conj_and||decline-9/NN||loss-12/NN	mark||predicted-19/VBD||whereas-14/IN	det||hbv-dna-18/NN||the-15/DT	amod||hbv-dna-18/NN||higher-16/JJR	nn||hbv-dna-18/NN||baseline-17/NN	nsubj||predicted-19/VBD||hbv-dna-18/NN	advcl||predicted-6/VBD||predicted-19/VBD	det||flare-22/NN||the-20/DT	nn||flare-22/NN||hepatitis-21/NN	dobj||predicted-19/VBD||flare-22/NN	hbv--1||hbsag-11||yes||the lower baseline hbsag level predicted the hbsag decline and hbsag loss, whereas the higher baseline hbv-dna predicted the hepatitis flare.
amod||syndrome-3/NN||immune-1/JJ	nn||syndrome-3/NN||reconstitution-2/NN	nsubj||common-8/JJ||syndrome-3/NN	amod||therapy-6/NN||antiretroviral-5/JJ	prep_following||syndrome-3/NN||therapy-6/NN	cop||common-8/JJ||is-7/VBZ	root||ROOT-0/null||common-8/JJ	amod||patients-11/NNS||hiv/aids-10/JJ	prep_in||common-8/JJ||patients-11/NNS	prepc_due_to||patients-11/NNS||boosting-14/VBG	prep_of||boosting-14/VBG||immunity-16/NN	aids--1||hiv--1||no||immune reconstitution syndrome following antiretroviral therapy is common in hiv/aids patients due to boosting of immunity.
det||fact-3/NN||the-2/DT	prep_despite||apparent-18/JJ||fact-3/NN	mark||suffer-10/VBP||that-4/IN	nsubj||suffer-10/VBP||men-5/NNS	conj_and||men-5/NNS||women-7/NNS	nsubj||suffer-10/VBP||women-7/NNS	prep_with||men-5/NNS||hiv/aids-9/NNS	dep||fact-3/NN||suffer-10/VBP	det||illness-13/NN||the-11/DT	amod||illness-13/NN||same-12/JJ	dobj||suffer-10/VBP||illness-13/NN	amod||disparities-16/NNS||clear-15/JJ	nsubj||apparent-18/JJ||disparities-16/NNS	cop||apparent-18/JJ||are-17/VBP	root||ROOT-0/null||apparent-18/JJ	det||women-23/NNS||the-20/DT	amod||women-23/NNS||negative-21/JJ	nn||women-23/NNS||reaction-22/NN	prep_in||apparent-18/JJ||women-23/NNS	nn||living-26/NN||men-25/NNS	prep_in||apparent-18/JJ||living-26/NN	conj_and||women-23/NNS||living-26/NN	amod||experience-29/NN||hiv/aids-28/JJ	prep_with||apparent-18/JJ||experience-29/NN	prep_in||experience-29/NN||society-31/NN	aids--1||hiv--1||no||despite the fact that men and women with hiv/aids suffer the same illness, clear disparities are apparent in the negative reaction women and men living with hiv/aids experience in society.
nsubj||constructed-3/VBN||we-1/PRP	aux||constructed-3/VBN||have-2/VBP	dep||take-52/VB||constructed-3/VBN	det||model-5/NN||a-4/DT	dobj||constructed-3/VBN||model-5/NN	prep_of||model-5/NN||hivinfection-7/NN	mark||types-13/VBZ||that-8/IN	nsubj||types-13/VBZ||differentiates-9/NNS	nsubj||used-17/VBN||differentiates-9/NNS	det||hla-12/NN||these-11/DT	prep_between||differentiates-9/NNS||hla-12/NN	ccomp||constructed-3/VBN||types-13/VBZ	aux||used-17/VBN||have-16/VBP	ccomp||constructed-3/VBN||used-17/VBN	conj_and||types-13/VBZ||used-17/VBN	amod||estimates-19/NNS||reported-18/VBN	dobj||used-17/VBN||estimates-19/NNS	det||number-22/NN||the-21/DT	prep_of||estimates-19/NNS||number-22/NN	prep_of||number-22/NN||people-24/NNS	vmod||people-24/NNS||infected-25/VBN	prep_with||infected-25/VBN||hiv-27/NN	det||rates-31/NNS||the-29/DT	amod||rates-31/NNS||different-30/JJ	prep_with||infected-25/VBN||rates-31/NNS	conj_and||hiv-27/NN||rates-31/NNS	prep_of||rates-31/NNS||progression-33/NN	aux||acquiredimmunodeficiencysyndrome-35/VB||to-34/TO	xcomp||infected-25/VBN||acquiredimmunodeficiencysyndrome-35/VB	dobj||acquiredimmunodeficiencysyndrome-35/VB||aids-37/NNS	nsubj||provide-40/VB||aids-37/NNS	aux||provide-40/VB||to-39/TO	xcomp||acquiredimmunodeficiencysyndrome-35/VB||provide-40/VB	det||estimate-44/NN||a-41/DT	dep||bound-43/VBN||lower-42/JJR	amod||estimate-44/NN||bound-43/VBN	dobj||provide-40/VB||estimate-44/NN	det||length-47/NN||the-46/DT	prep_on||provide-40/VB||length-47/NN	prep_of||length-47/NN||time-49/NN	nsubj||take-52/VB||it-50/PRP	nsubj||impose-56/VB||it-50/PRP	aux||take-52/VB||would-51/MD	root||ROOT-0/null||take-52/VB	prep_for||take-52/VB||hiv-54/NN	aux||impose-56/VB||to-55/TO	xcomp||take-52/VB||impose-56/VB	amod||change-59/NN||major-57/JJ	amod||change-59/NN||genetic-58/JJ	dobj||impose-56/VB||change-59/NN	prep_in||impose-56/VB||humans-61/NNS	hivinfection-7||hiv-54||no||we have constructed a model of hivinfection that differentiates between these hla types, and have used reported estimates of the number of people infected with hiv and the different rates of progression to acquiredimmunodeficiencysyndrome (aids) to provide a lower bound estimate on the length of time it would take for hiv to impose major genetic change in humans.
num||rct-3/NN||one-2/CD	prep_in||responded-19/VBD||rct-3/NN	dep||rct-3/NN||shankland-5/NN	num||shankland-5/NN||2002-6/CD	amod||score-9/NN||jadad-8/JJ	appos||shankland-5/NN||score-9/NN	num||score-9/NN||1-10/CD	nsubj||responded-19/VBD||patients-13/NNS	amod||headache-16/NN||tension-type-15/JJ	prep_with||patients-13/NNS||headache-16/NN	prep_with||patients-13/NNS||migraine-18/NN	conj_or||headache-16/NN||migraine-18/NN	root||ROOT-0/null||responded-19/VBD	advmod||favorably-21/RB||more-20/RBR	advmod||responded-19/VBD||favorably-21/RB	det||splint-25/NN||the-23/DT	amod||splint-25/NN||nti-tss-24/JJ	prep_to||favorably-21/RB||splint-25/NN	prep||responded-19/VBD||than-26/IN	pcomp||than-26/IN||to-27/TO	det||tray-30/NN||a-28/DT	amod||tray-30/NN||bleaching-29/JJ	pobj||to-27/TO||tray-30/NN	tss--1||bleaching-29||no_rel||in one rct (shankland 2002, jadad score 1), patients with tension-type headache or migraine responded more favorably to the nti-tss splint than to a bleaching tray.
det||data-2/NNS||these-1/DT	nsubj||differentiate-3/VB||data-2/NNS	root||ROOT-0/null||differentiate-3/VB	det||mechanism-5/NN||the-4/DT	dobj||differentiate-3/VB||mechanism-5/NN	amod||effects-9/NNS||primary-7/JJ	amod||effects-9/NNS||anti-tumor-8/JJ	prep_for||mechanism-5/NN||effects-9/NNS	amod||±-14/NNS||il-2-11/JJ	amod||±-14/NNS||/-12/JJ	nn||±-14/NNS||î-13/NN	prep_of||effects-9/NNS||±-14/NNS	amod||immunotherapy-17/NN||cd40-16/JJ	dep||mechanism-5/NN||immunotherapy-17/NN	nsubj||independent-21/JJ||immunotherapy-17/NN	cop||independent-21/JJ||are-20/VBP	rcmod||immunotherapy-17/NN||independent-21/JJ	advmod||independent-21/JJ||of-22/IN	dep||of-22/IN||no-23/DT	det||inhibition-28/NN||the-26/DT	amod||inhibition-28/NN||no-dependent-27/JJ	prep_from||independent-21/JJ||inhibition-28/NN	prep_of||inhibition-28/NN||metastases-30/NNS	il-2-11||metastases-30||no_rel||these data differentiate the mechanism for primary anti-tumor effects of il-2/î±-cd40 immunotherapy, which are independent of no, from the no-dependent inhibition of metastases.
det||manuscript-2/NN||this-1/DT	nsubj||reviews-3/VBZ||manuscript-2/NN	root||ROOT-0/null||reviews-3/VBZ	det||evidence-6/NN||the-4/DT	amod||evidence-6/NN||available-5/JJ	dobj||reviews-3/VBZ||evidence-6/NN	nn||searches-11/NNS||medline-8/NN	conj_and||medline-8/NN||embase-10/NN	nn||searches-11/NNS||embase-10/NN	prep_including||evidence-6/NN||searches-11/NNS	prep_including||evidence-6/NN||abstracts-13/NNS	conj_and||searches-11/NNS||abstracts-13/NNS	amod||meetings-17/NNS||international-15/JJ	nn||meetings-17/NNS||allergy-16/NN	prep_of||abstracts-13/NNS||meetings-17/NNS	nn||papers-20/NNS||position-19/NN	prep_including||evidence-6/NN||papers-20/NNS	conj_and||searches-11/NNS||papers-20/NNS	det||literature-25/NN||the-22/DT	nn||literature-25/NN||world-23/NN	nn||literature-25/NN||allergy-24/NN	prep_from||papers-20/NNS||literature-25/NN	allergy-24||allergy-24||no||this manuscript reviews the available evidence including medline and embase searches, abstracts of international allergy meetings and position papers from the world allergy literature.
det||method-2/NN||the-1/DT	nsubjpass||optimized-5/VBN||method-2/NN	auxpass||optimized-5/VBN||was-3/VBD	advmod||optimized-5/VBN||first-4/RB	root||ROOT-0/null||optimized-5/VBN	xcomp||optimized-5/VBN||utilizing-6/VBG	amod||strains-9/NNS||borrelia-7/JJ	nn||strains-9/NNS||laboratory-8/NN	dobj||utilizing-6/VBG||strains-9/NNS	advmod||followed-25/VBD||later-12/RB	prepc_by||later-12/RB||demonstrating-14/VBG	dobj||demonstrating-14/VBG||growth-15/NN	prep_of||growth-15/NN||borrelia-17/NN	prep_from||demonstrating-14/VBG||sera-19/NN	amod||seropositive-22/NN||fifty-21/JJ	prep_from||demonstrating-14/VBG||seropositive-22/NN	amod||patients-24/NNS||lymedisease-23/JJ	nsubj||followed-25/VBD||patients-24/NNS	conj_and||optimized-5/VBN||followed-25/VBD	det||cohort-28/NN||another-27/DT	prep_by||followed-25/VBD||cohort-28/NN	num||patients-32/NNS||72-30/CD	amod||patients-32/NNS||lymedisease-31/JJ	prep_of||cohort-28/NN||patients-32/NNS	pobj||of-35/IN||patients-32/NNS	dep||of-35/IN||all-34/DT	nsubj||satisfied-37/VBD||of-35/IN	rcmod||patients-32/NNS||satisfied-37/VBD	det||definition-43/NN||the-38/DT	amod||definition-43/NN||strict-39/JJ	nn||definition-43/NN||cdc-40/NN	nn||definition-43/NN||surveillance-41/NN	nn||definition-43/NN||case-42/NN	dobj||satisfied-37/VBD||definition-43/NN	prep_for||satisfied-37/VBD||lymedisease-45/NN	lymedisease-45||borrelia-17||no||the method was first optimized utilizing borrelia laboratory strains, and later by demonstrating growth of borrelia from sera from fifty seropositive lymedisease patients followed by another cohort of 72 lymedisease patients, all of whom satisfied the strict cdc surveillance case definition for lymedisease.
nn||parahaemolyticus-2/NNS||vibrio-1/NN	nsubj||bacterium-7/NN||parahaemolyticus-2/NNS	cop||bacterium-7/NN||is-3/VBZ	det||bacterium-7/NN||a-4/DT	amod||bacterium-7/NN||common-5/JJ	amod||bacterium-7/NN||marine-6/JJ	root||ROOT-0/null||bacterium-7/NN	det||cause-11/NN||a-9/DT	amod||cause-11/NN||leading-10/VBG	conj_and||bacterium-7/NN||cause-11/NN	amod||bacterialgastroenteritis-14/NNS||seafood-borne-13/JJ	prep_of||cause-11/NN||bacterialgastroenteritis-14/NNS	advmod||bacterialgastroenteritis-14/NNS||worldwide-15/RB	bacterialgastroenteritis-14||bacterium-7||no||vibrio parahaemolyticus is a common marine bacterium and a leading cause of seafood-borne bacterialgastroenteritis worldwide.
nn||terms-2/NNS||search-1/NN	nsubj||included-3/VBD||terms-2/NNS	root||ROOT-0/null||included-3/VBD	dobj||included-3/VBD||dyslipidemia-4/NN	dobj||included-3/VBD||obesity-6/NN	conj_and||dyslipidemia-4/NN||obesity-6/NN	dobj||included-3/VBD||tobacco-8/NN	conj_and||dyslipidemia-4/NN||tobacco-8/NN	dobj||included-3/VBD||hypertension-10/NN	conj_and||dyslipidemia-4/NN||hypertension-10/NN	dobj||included-3/VBD||diabetesmellitus-13/NNS	conj_and||dyslipidemia-4/NN||diabetesmellitus-13/NNS	tobacco-8||diabetesmellitus-13||no_rel||search terms included dyslipidemia, obesity, tobacco, hypertension, and diabetesmellitus.
nsubj||collected-2/VBD||we-1/PRP	root||ROOT-0/null||collected-2/VBD	amod||records-4/NNS||medical-3/JJ	dobj||collected-2/VBD||records-4/NNS	num||men-8/NNS||170-6/CD	amod||men-8/NNS||adult-7/JJ	prep_of||records-4/NNS||men-8/NNS	dep||men-8/NNS||diagnosed-9/VBN	prep_with||diagnosed-9/VBN||chronichepatitisc-11/NN	nsubj||started-13/VBD||chronichepatitisc-11/NN	rcmod||chronichepatitisc-11/NN||started-13/VBD	dobj||started-13/VBD||treatment-14/NN	det||combination-17/NN||a-16/DT	prep_with||started-13/VBD||combination-17/NN	amod||interferon-alpha-20/NN||pegylated-19/JJ	prep_of||combination-17/NN||interferon-alpha-20/NN	prep_with||started-13/VBD||ribavirin-22/NNP	conj_and||combination-17/NN||ribavirin-22/NNP	prep_between||ribavirin-22/NNP||january-24/NNP	num||january-24/NNP||2003-25/CD	dep||men-8/NNS||june-27/NNP	conj_and||diagnosed-9/VBN||june-27/NNP	num||june-27/NNP||2009-28/CD	det||centre-33/NN||the-30/DT	amod||centre-33/NN||croatian-31/JJ	nn||centre-33/NN||reference-32/NN	prep_at||june-27/NNP||centre-33/NN	prep_for||centre-33/NN||viralhepatitis-35/NNS	interferon--1||viralhepatitis-35||no_rel||we collected medical records of 170 adult men diagnosed with chronichepatitisc who started treatment with a combination of pegylated interferon-alpha and ribavirin between january 2003 and june 2009 at the croatian reference centre for viralhepatitis.
dep||vitro-2/NN||in-1/IN	amod||exposure-3/NN||vitro-2/NN	nsubj||revealed-15/VBD||exposure-3/NN	amod||samples-6/NNS||patient-5/JJ	prep_of||exposure-3/NN||samples-6/NNS	aux||etoposide-8/VB||to-7/TO	vmod||exposure-3/NN||etoposide-8/VB	det||agent-13/NN||a-10/DT	advmod||damaging-12/VBG||dna-11/RB	amod||agent-13/NN||damaging-12/VBG	appos||exposure-3/NN||agent-13/NN	root||ROOT-0/null||revealed-15/VBD	num||â-18/NN||three-16/CD	amod||â-18/NN||distinct-17/JJ	dobj||revealed-15/VBD||â-18/NN	amod||response-22/NN||$-19/$	dep||$-19/$||œdna-20/JJ	nn||response-22/NN||damage-21/NN	prep||â-18/NN||response-22/NN	appos||response-22/NN||ddr-24/NN	punct||$-28/$||/-26/:	dep||$-28/$||apoptosisâ-27/RB	dep||response-22/NN||$-28/$	number||1-30/CD||profiles-29/CD	num||$-28/$||1-30/CD	nn||blasts-33/NNS||aml-32/NN	dep||response-22/NN||blasts-33/NNS	det||ddr-37/NN||a-35/DT	amod||ddr-37/NN||defective-36/JJ	prep_with||blasts-33/NNS||ddr-37/NN	prep_with||blasts-33/NNS||failure-39/NN	conj_and||ddr-37/NN||failure-39/NN	aux||undergo-41/VB||to-40/TO	vmod||blasts-33/NNS||undergo-41/VB	dobj||undergo-41/VB||apoptosis-42/NNS	dep||blasts-47/NNS||2-44/LS	nn||blasts-47/NNS||aml-46/NN	dep||response-22/NN||blasts-47/NNS	conj_and||blasts-33/NNS||blasts-47/NNS	amod||ddr-50/NN||proficient-49/JJ	prep_with||blasts-47/NNS||ddr-50/NN	prep_with||blasts-47/NNS||failure-52/NN	conj_and||ddr-50/NN||failure-52/NN	aux||undergo-54/VB||to-53/TO	vmod||failure-52/NN||undergo-54/VB	dobj||undergo-54/VB||apoptosis-55/NNS	dep||blasts-60/NNS||3-57/LS	nn||blasts-60/NNS||aml-59/NN	dep||response-22/NN||blasts-60/NNS	conj_and||blasts-33/NNS||blasts-60/NNS	prep_with||blasts-60/NNS||proficiency-62/NN	det||ddr-65/NN||both-64/DT	prep_in||proficiency-62/NN||ddr-65/NN	amod||pathways-68/NNS||apoptosis-67/JJ	dep||response-22/NN||pathways-68/NNS	conj_and||blasts-33/NNS||pathways-68/NNS	aml-59||etoposide-8||yes||in vitro exposure of patient samples to etoposide, a dna damaging agent, revealed three distinct â€œdna damage response (ddr)/apoptosisâ€? profiles 1) aml blasts with a defective ddr and failure to undergo apoptosis; 2) aml blasts with proficient ddr and failure to undergo apoptosis; 3) aml blasts with proficiency in both ddr and apoptosis pathways.
det||study-2/NN||this-1/DT	nsubj||defined-3/VBD||study-2/NN	root||ROOT-0/null||defined-3/VBD	det||dose-6/NN||a-4/DT	amod||dose-6/NN||tolerable-5/JJ	dobj||defined-3/VBD||dose-6/NN	prep_of||dose-6/NN||olaparib-8/NN	prep_in||defined-3/VBD||combination-10/NN	prep_with||defined-3/VBD||dacarbazine-12/NN	expl||were-16/VBD||there-15/EX	conj_but||defined-3/VBD||were-16/VBD	neg||responses-18/NNS||no-17/DT	nsubj||were-16/VBD||responses-18/NNS	amod||patients-22/NNS||chemonaive-20/JJ	nn||patients-22/NNS||melanoma-21/NN	prep_in||responses-18/NNS||patients-22/NNS	vmod||responses-18/NNS||demonstrating-24/VBG	neg||advantage-27/NN||no-25/DT	amod||advantage-27/NN||clinical-26/JJ	dobj||demonstrating-24/VBG||advantage-27/NN	amod||dacarbazine-30/NN||single-agent-29/JJ	prep_over||advantage-27/NN||dacarbazine-30/NN	det||doses-33/NNS||these-32/DT	prep_at||demonstrating-24/VBG||doses-33/NNS	melanoma-21||dacarbazine-30||yes||this study defined a tolerable dose of olaparib in combination with dacarbazine, but there were no responses in chemonaive melanoma patients, demonstrating no clinical advantage over single-agent dacarbazine at these doses.
det||study-3/NN||this-1/DT	amod||study-3/NN||prospective-2/JJ	nsubj||assessed-4/VBD||study-3/NN	root||ROOT-0/null||assessed-4/VBD	det||effects-6/NNS||the-5/DT	dobj||assessed-4/VBD||effects-6/NNS	amod||function-9/NN||auditory-8/JJ	prep_on||assessed-4/VBD||function-9/NN	det||dose-15/NN||a-11/DT	amod||dose-15/NN||standard-12/JJ	amod||dose-15/NN||3-day-13/JJ	amod||dose-15/NN||oral-14/JJ	prep_of||function-9/NN||dose-15/NN	prep_of||dose-15/NN||artesunate-17/NN	num||mg/kg/day-20/NN||4-19/CD	appos||artesunate-17/NN||mg/kg/day-20/NN	prep||assessed-4/VBD||combined-22/VBN	pcomp||combined-22/VBN||with-23/IN	pobj||with-23/IN||mefloquine-24/NN	num||mg/kg-27/NN||25-26/CD	appos||mefloquine-24/NN||mg/kg-27/NN	prep_in||mefloquine-24/NN||patients-30/NNS	amod||falciparummalaria-34/NN||acute-32/JJ	amod||falciparummalaria-34/NN||uncomplicated-33/JJ	prep_with||patients-30/NNS||falciparummalaria-34/NN	vmod||falciparummalaria-34/NN||treated-35/VBN	det||unit-41/NN||the-37/DT	amod||unit-41/NN||shoklo-38/JJ	nn||unit-41/NN||malaria-39/NN	nn||unit-41/NN||research-40/NN	prep_at||treated-35/VBN||unit-41/NN	det||border-46/NN||the-44/DT	amod||border-46/NN||thai-burmese-45/JJ	prep_on||treated-35/VBN||border-46/NN	falciparummalaria-34||mefloquine-24||yes||this prospective study assessed the effects on auditory function of a standard 3-day oral dose of artesunate (4 mg/kg/day) combined with mefloquine (25 mg/kg) in patients with acute uncomplicated falciparummalaria treated at the shoklo malaria research unit, on the thai-burmese border.
prep_in||up-regulated-15/JJ||autoimmunehaemolyticanaemia-2/NN	appos||autoimmunehaemolyticanaemia-2/NN||aiha-4/NNP	amod||antibodies-8/NNS||autoreactive-7/JJ	nsubj||up-regulated-15/JJ||antibodies-8/NNS	vmod||antibodies-8/NNS||directed-9/VBN	amod||cells-13/NNS||red-11/JJ	nn||cells-13/NNS||blood-12/NN	prep_against||directed-9/VBN||cells-13/NNS	cop||up-regulated-15/JJ||are-14/VBP	root||ROOT-0/null||up-regulated-15/JJ	xcomp||up-regulated-15/JJ||leading-17/VBG	aux||erythrocyte-19/VB||to-18/TO	xcomp||leading-17/VBG||erythrocyte-19/VB	dobj||erythrocyte-19/VB||death-20/NN	autoimmunehaemolyticanaemia-2||antibodies-8||no||in autoimmunehaemolyticanaemia (aiha), autoreactive antibodies directed against red blood cells are up-regulated, leading to erythrocyte death.
nsubj||completed-29/VBD||subjects-1/NNS	det||biomarkers-7/NNS||the-3/DT	amod||biomarkers-7/NNS||australian-4/JJ	nn||biomarkers-7/NNS||imaging-5/NN	prep_in||subjects-1/NNS||biomarkers-7/NNS	nn||study-10/NN||lifestyle-9/NN	prep_in||subjects-1/NNS||study-10/NN	conj_and||biomarkers-7/NNS||study-10/NN	amod||cohort-13/NN||ageing-12/VBG	prep_of||biomarkers-7/NNS||cohort-13/NN	num||controls-17/NNS||723-15/CD	amod||controls-17/NNS||healthy-16/JJ	dep||cohort-13/NN||controls-17/NNS	appos||controls-17/NNS||hc-19/NN	num||mci-23/NN||98-22/CD	appos||controls-17/NNS||mci-23/NN	num||participants-27/NNS||149-25/CD	nn||participants-27/NNS||ad-26/NN	appos||controls-17/NNS||participants-27/NNS	conj_and||mci-23/NN||participants-27/NNS	root||ROOT-0/null||completed-29/VBD	det||council-32/NN||the-30/DT	nn||council-32/NN||cancer-31/NN	dobj||completed-29/VBD||council-32/NN	amod||questionnaire-37/NN||victoria-34/JJ	nn||questionnaire-37/NN||food-35/NN	nn||questionnaire-37/NN||frequency-36/NN	prep_of||council-32/NN||questionnaire-37/NN	cancer-31||hc-19||no_rel||subjects in the australian imaging, biomarkers and lifestyle study of ageing cohort (723 healthy controls (hc), 98 mci and 149 ad participants) completed the cancer council of victoria food frequency questionnaire.
poss||series-4/NN||our-1/PRP$	advmod||large-3/JJ||relatively-2/RB	amod||series-4/NN||large-3/JJ	nsubj||suggested-5/VBD||series-4/NN	nsubj||responsive-79/JJ||series-4/NN	nsubj||pyridoxine-81/VB||series-4/NN	root||ROOT-0/null||suggested-5/VBD	mark||challenging-15/JJ||that-6/IN	amod||diagnosis-8/NN||clinical-7/JJ	nsubj||challenging-15/JJ||diagnosis-8/NN	amod||dependent-11/JJ||pyridoxine-10/JJ	amod||epilepsy-12/NN||dependent-11/JJ	prep_of||diagnosis-8/NN||epilepsy-12/NN	aux||challenging-15/JJ||can-13/MD	cop||challenging-15/JJ||be-14/VB	ccomp||suggested-5/VBD||challenging-15/JJ	mark||response-24/NN||because-16/IN	dep||response-24/NN||i-18/NNP	expl||response-24/NN||there-20/EX	aux||response-24/NN||may-21/MD	cop||response-24/NN||be-22/VB	det||response-24/NN||some-23/DT	ccomp||challenging-15/JJ||response-24/NN	amod||drugs-27/NNS||antiepileptic-26/JJ	prep_to||response-24/NN||drugs-27/NNS	nsubj||instant-45/JJ||ii-30/NN	nsubj||obvious-47/JJ||ii-30/NN	prep_in||ii-30/NN||infants-33/NNS	nn||pathology-36/NN||multisystem-35/NN	prep_with||infants-33/NNS||pathology-36/NN	det||response-39/NN||the-38/DT	appos||pathology-36/NN||response-39/NN	aux||pyridoxine-41/VB||to-40/TO	vmod||response-39/NN||pyridoxine-41/VB	aux||instant-45/JJ||may-42/MD	neg||instant-45/JJ||not-43/RB	cop||instant-45/JJ||be-44/VB	parataxis||response-24/NN||instant-45/JJ	parataxis||response-24/NN||obvious-47/JJ	conj_and||instant-45/JJ||obvious-47/JJ	dep||challenging-15/JJ||iii-51/NN	amod||abnormalities-55/NNS||structural-53/JJ	nn||abnormalities-55/NNS||brain-54/NN	nsubj||co-exist-57/VB||abnormalities-55/NNS	nsubjpass||considered-60/VBN||abnormalities-55/NNS	aux||co-exist-57/VB||may-56/MD	ccomp||suggested-5/VBD||co-exist-57/VB	conj_and||challenging-15/JJ||co-exist-57/VB	auxpass||considered-60/VBN||be-59/VB	conj_and||challenging-15/JJ||considered-60/VBN	conj_and||co-exist-57/VB||considered-60/VBN	amod||cause-62/NN||sufficient-61/JJ	dobj||considered-60/VBN||cause-62/NN	prep_of||cause-62/NN||epilepsy-64/NN	mark||consequence-72/NN||whereas-66/IN	det||fits-68/NNS||the-67/DT	nsubj||consequence-72/NN||fits-68/NNS	aux||consequence-72/NN||may-69/MD	cop||consequence-72/NN||be-70/VB	det||consequence-72/NN||a-71/DT	advcl||considered-60/VBN||consequence-72/NN	nn||deficiency-75/NN||antiquitin-74/NN	prep_of||consequence-72/NN||deficiency-75/NN	cop||responsive-79/JJ||are-77/VBP	advmod||responsive-79/JJ||then-78/RB	conj_and||suggested-5/VBD||responsive-79/JJ	aux||pyridoxine-81/VB||to-80/TO	xcomp||responsive-79/JJ||pyridoxine-81/VB	fits-68||pyridoxine-81||yes||our relatively large series suggested that clinical diagnosis of pyridoxine dependent epilepsy can be challenging because (i) there may be some response to antiepileptic drugs; (ii) in infants with multisystem pathology, the response to pyridoxine may not be instant and obvious; and (iii) structural brain abnormalities may co-exist and be considered sufficient cause of epilepsy, whereas the fits may be a consequence of antiquitin deficiency and are then responsive to pyridoxine.
det||patients-2/NNS||all-1/DT	nsubjpass||treated-4/VBN||patients-2/NNS	auxpass||treated-4/VBN||were-3/VBD	root||ROOT-0/null||treated-4/VBN	amod||debridement-7/NN||surgical-6/JJ	agent||treated-4/VBN||debridement-7/NN	vmod||debridement-7/NN||followed-8/VBN	det||combination-11/NN||a-10/DT	agent||followed-8/VBN||combination-11/NN	prep_of||combination-11/NN||antibiotics-13/NNS	dep||combination-11/NN||ceftazidime-16/NN	amod||acid-19/NN||amoxy-clavulanic-18/JJ	dep||ceftazidime-16/NN||acid-19/NN	dep||ceftazidime-16/NN||co-trimoxazole-21/JJ	dep||ceftazidime-16/NN||doxycycline-23/JJ	conj_and||co-trimoxazole-21/JJ||doxycycline-23/JJ	num||months-27/NNS||six-26/CD	prep_for||combination-11/NN||months-27/NNS	prep_except_for||followed-8/VBN||one-30/CD	nsubj||died-32/VBD||one-30/CD	rcmod||one-30/CD||died-32/VBD	acomp||died-32/VBD||due-33/JJ	aux||fulminant-35/VB||to-34/TO	xcomp||due-33/JJ||fulminant-35/VB	dobj||fulminant-35/VB||septicemia-36/NN	septicemia-36||co-trimoxazole-21||no_rel||all patients were treated by surgical debridement followed by a combination of antibiotics; (ceftazidime, amoxy-clavulanic acid, co-trimoxazole and doxycycline) for six months except for one who died due to fulminant septicemia.
nn||treatment-3/NN||gancyclovir-2/NN	prep_following||went-11/VBD||treatment-3/NN	amod||viremia-7/NN||subsequent-5/JJ	nn||viremia-7/NN||cytomegalovirus-6/NNS	prep_of||treatment-3/NN||viremia-7/NN	det||patient-10/NN||the-9/DT	nsubj||went-11/VBD||patient-10/NN	nsubj||receive-14/VB||patient-10/NN	root||ROOT-0/null||went-11/VBD	prt||went-11/VBD||on-12/RP	aux||receive-14/VB||to-13/TO	xcomp||went-11/VBD||receive-14/VB	det||course-16/NN||a-15/DT	dobj||receive-14/VB||course-16/NN	prep_of||course-16/NN||epoch-18/NN	advmod||mg/m2/day-52/NN||etoposide-20/RB	num||mg/m2/day-22/NNS||50-21/CD	pobj||etoposide-20/RB||mg/m2/day-22/NNS	prep_on||etoposide-20/RB||days-24/NNS	amod||mg/m2/day-52/NN||1â-25/JJ	amod||mg/m2/day-52/NN||$-26/$	num||$-26/$||4-28/CD	amod||mg/m2/day-52/NN||vincristine-30/JJ	num||mg/m2/day-32/NNS||0.4-31/CD	dep||vincristine-30/JJ||mg/m2/day-32/NNS	prep_on||mg/m2/day-32/NNS||days-34/NNS	amod||mg/m2/day-52/NN||1â-35/JJ	amod||mg/m2/day-52/NN||$-36/$	num||$-36/$||4-38/CD	amod||mg/m2/day-52/NN||doxorubicin-40/JJ	num||mg/m2/day-42/NNS||10-41/CD	dep||doxorubicin-40/JJ||mg/m2/day-42/NNS	prep_on||mg/m2/day-42/NNS||days-44/NNS	amod||mg/m2/day-52/NN||1â-45/JJ	amod||mg/m2/day-52/NN||$-46/$	num||$-46/$||4-48/CD	amod||mg/m2/day-52/NN||cyclophosphamide-50/JJ	number||cyclophosphamide-50/JJ||750-51/CD	dep||epoch-18/NN||mg/m2/day-52/NN	prep_on||mg/m2/day-52/NN||day-54/NN	num||day-54/NN||6-55/CD	advmod||1â-63/JJ||prednisolone-58/RB	num||mg/m2/day-60/NNS||60-59/CD	pobj||prednisolone-58/RB||mg/m2/day-60/NNS	prep_on||prednisolone-58/RB||days-62/NNS	prep_on||mg/m2/day-52/NN||1â-63/JJ	conj_and||day-54/NN||1â-63/JJ	dep||1â-63/JJ||$-64/$	num||$-64/$||6-66/CD	doxorubicin-40||cytomegalovirus-6||no_rel||following gancyclovir treatment of subsequent cytomegalovirus viremia, the patient went on to receive a course of epoch (etoposide 50 mg/m2/day on days 1â€“4, vincristine 0.4 mg/m2/day on days 1â€“4, doxorubicin 10 mg/m2/day on days 1â€“4, cyclophosphamide 750 mg/m2/day on day 6, and prednisolone 60 mg/m2/day on days 1â€“6).
nsubj||anthracycline-8/VBP||all-1/DT	dep||all-1/DT||transretinoicacid-3/VBN	dep||transretinoicacid-3/VBN||atra-5/NNP	punct||transretinoicacid-3/VBN||/-7/:	root||ROOT-0/null||anthracycline-8/VBP	nsubj||beneficial-11/JJ||chemotherapy-9/NN	cop||beneficial-11/JJ||is-10/VBZ	ccomp||anthracycline-8/VBP||beneficial-11/JJ	advmod||diagnosed-14/JJ||newly-13/RB	amod||acutepromyelocyticleukemia-15/NN||diagnosed-14/JJ	prep_in||beneficial-11/JJ||acutepromyelocyticleukemia-15/NN	appos||acutepromyelocyticleukemia-15/NN||apl-17/NN	advmod||important-24/JJ||however-20/RB	nsubj||important-24/JJ||it-22/PRP	nsubj||identify-26/VB||it-22/PRP	cop||important-24/JJ||is-23/VBZ	parataxis||anthracycline-8/VBP||important-24/JJ	aux||identify-26/VB||to-25/TO	xcomp||important-24/JJ||identify-26/VB	dobj||identify-26/VB||patients-27/NNS	amod||disease-30/NN||high-risk-29/JJ	prep_with||patients-27/NNS||disease-30/NN	aux||increase-32/VB||to-31/TO	vmod||identify-26/VB||increase-32/VB	det||rate-35/NN||the-33/DT	nn||rate-35/NN||cure-34/NN	dobj||increase-32/VB||rate-35/NN	acutepromyelocyticleukemia-15||transretinoicacid-3||yes||all- transretinoicacid (atra)/anthracycline chemotherapy is beneficial in newly diagnosed acutepromyelocyticleukemia (apl); however, it is important to identify patients with high-risk disease to increase the cure rate.
det||understanding-2/NN||an-1/DT	nsubj||evolving-24/VBG||understanding-2/NN	nsubj||become-55/VBN||understanding-2/NN	det||risks-5/NNS||the-4/DT	prep_of||understanding-2/NN||risks-5/NNS	prep_of||understanding-2/NN||benefits-7/NNS	conj_and||risks-5/NNS||benefits-7/NNS	amod||value-11/NN||relative-10/JJ	prep_of||understanding-2/NN||value-11/NN	conj_and||risks-5/NNS||value-11/NN	prep_of||value-11/NN||glatirameracetate-13/NN	appos||glatirameracetate-13/NN||ga-15/NN	prep_in||glatirameracetate-13/NN||multiplesclerosis-18/NNS	appos||multiplesclerosis-18/NNS||ms-20/NN	aux||evolving-24/VBG||has-22/VBZ	aux||evolving-24/VBG||been-23/VBN	root||ROOT-0/null||evolving-24/VBG	prepc_based_on||evolving-24/VBG||on-26/IN	advmod||completed-28/VBN||recently-27/RB	amod||studies-30/NNS||completed-28/VBN	amod||studies-30/NNS||head-to-head-29/JJ	pobj||evolving-24/VBG||studies-30/NNS	dep||studies-30/NNS||regard-31/VBP	parataxis||regard-31/VBP||rebif-33/VB	nn||glatirameracetate-35/NN||vs-34/NN	dobj||rebif-33/VB||glatirameracetate-35/NN	prepc_in||rebif-33/VB||relapsing-37/VBG	nn||disease-39/NN||ms-38/NN	dobj||relapsing-37/VBG||disease-39/NN	prep||evolving-24/VBG||beyond-42/IN	amod||outcomes-47/NNS||betaseron-44/JJ	advmod||yielding-46/JJ||efficacy-45/RB	amod||outcomes-47/NNS||yielding-46/JJ	dep||evolving-24/VBG||outcomes-47/NNS	det||dose-51/NN||a-49/DT	amod||dose-51/NN||new-50/JJ	prep_of||outcomes-47/NNS||dose-51/NN	conj_and||evolving-24/VBG||become-55/VBN	nn||copaxone-59/NN||betaseron-57/NN	nn||copaxone-59/NN||vs-58/NN	dep||become-55/VBN||copaxone-59/NN	prep_in||copaxone-59/NN||multiplesclerosis-61/NNS	amod||gadolinium-64/NN||triple-dose-63/JJ	prep_with||multiplesclerosis-61/NNS||gadolinium-64/NN	amod||endpoints-68/NNS||3-tesla-66/JJ	nn||endpoints-68/NNS||mri-67/NN	prep_with||multiplesclerosis-61/NNS||endpoints-68/NNS	conj_and||gadolinium-64/NN||endpoints-68/NNS	glatirameracetate-35||multiplesclerosis-61||no_rel||an understanding of the risks, benefits, and relative value of glatirameracetate (ga) in multiplesclerosis (ms) has been evolving based on recently completed head-to-head studies regard (rebif vs glatirameracetate in relapsing ms disease); beyond (betaseron efficacy yielding outcomes of a new dose); and become (betaseron vs copaxone in multiplesclerosis with triple-dose gadolinium and 3-tesla mri endpoints).
nsubjpass||characterized-6/VBN||type1diabetes-1/NNS	appos||type1diabetes-1/NNS||t1d-3/NNP	auxpass||characterized-6/VBN||is-5/VBZ	root||ROOT-0/null||characterized-6/VBN	amod||depletion-9/NN||autoimmune-8/JJ	agent||characterized-6/VBN||depletion-9/NN	amod||cells-14/NNS||insulin-producing-11/JJ	amod||cells-14/NNS||pancreatic-12/JJ	nn||cells-14/NNS||beta-13/NN	prep_of||depletion-9/NN||cells-14/NNS	type1diabetes-1||insulin--1||yes||type1diabetes (t1d) is characterized by autoimmune depletion of insulin-producing pancreatic beta cells.
nsubjpass||analyzed-30/VBN||frequency-1/NN	conj_and||frequency-1/NN||intensity-3/NN	nsubjpass||analyzed-30/VBN||intensity-3/NN	amod||production-7/NN||intrathecal-5/JJ	nn||production-7/NN||antibody-6/NN	prep_of||frequency-1/NN||production-7/NN	prep_against||production-7/NN||ebv-9/NN	advmod||ebv-9/NN||as-10/RB	prepc_compared_to||ebv-9/NN||to-12/TO	nn||zoster-18/NN||measles-13/NN	dep||zoster-18/NN||rubella-15/NN	amod||zoster-18/NN||varicella-17/JJ	pobj||ebv-9/NN||zoster-18/NN	appos||zoster-18/NN||vzv-20/NN	amod||virus-25/NN||herpes-23/JJ	nn||virus-25/NN||simplex-24/NN	pobj||ebv-9/NN||virus-25/NN	conj_and||zoster-18/NN||virus-25/NN	appos||zoster-18/NN||hsv-27/NN	auxpass||analyzed-30/VBN||were-29/VBD	root||ROOT-0/null||analyzed-30/VBN	agent||analyzed-30/VBN||determination-32/NN	amod||indices-37/NNS||virus-specific-34/JJ	amod||indices-37/NNS||csf-to-serum-35/JJ	nn||indices-37/NNS||antibody-36/NN	prep_of||determination-32/NN||indices-37/NNS	appos||indices-37/NNS||ai-39/NNP	varicella-17||vzv-20||no||frequency and intensity of intrathecal antibody production against ebv as compared to measles, rubella, varicella zoster (vzv) and herpes simplex virus (hsv) were analyzed by determination of virus-specific csf-to-serum antibody indices (ai).
nsubj||causes-2/VBZ||chlamydiatrachomatis-1/NNS	root||ROOT-0/null||causes-2/VBZ	dobj||causes-2/VBZ||diseases-3/NNS	prep_such_as||diseases-3/NNS||trachoma-6/NN	amod||infection-9/NN||urogenital-8/JJ	prep_such_as||diseases-3/NNS||infection-9/NN	conj_and||trachoma-6/NN||infection-9/NN	prep_such_as||diseases-3/NNS||lymphogranulomavenereum-11/NN	conj_and||trachoma-6/NN||lymphogranulomavenereum-11/NN	amod||morbidity-14/NN||severe-13/JJ	prep_with||causes-2/VBZ||morbidity-14/NN	lymphogranulomavenereum-11||chlamydiatrachomatis-1||no||chlamydiatrachomatis causes diseases such as trachoma, urogenital infection and lymphogranulomavenereum with severe morbidity.
advmod||conduct-5/VB||therefore-1/RB	nsubj||conduct-5/VB||we-3/PRP	aux||conduct-5/VB||will-4/MD	root||ROOT-0/null||conduct-5/VB	det||trial-11/NN||a-6/DT	nn||trial-11/NN||multicenter-7/NN	amod||trial-11/NN||randomized-8/JJ	nn||trial-11/NN||phase-9/NN	nn||trial-11/NN||ii-10/NN	dobj||conduct-5/VB||trial-11/NN	nsubj||compare-13/VB||trial-11/NN	aux||compare-13/VB||to-12/TO	xcomp||conduct-5/VB||compare-13/VB	amod||cycles-17/NNS||six-week-14/JJ	conj_and||six-week-14/JJ||three-week-16/JJ	amod||cycles-17/NNS||three-week-16/JJ	dobj||compare-13/VB||cycles-17/NNS	aux||establish-19/VB||to-18/TO	vmod||compare-13/VB||establish-19/VB	det||schedule-22/NN||the-20/DT	amod||schedule-22/NN||optimal-21/JJ	dobj||establish-19/VB||schedule-22/NN	amod||therapy-26/NN||s-1-24/JJ	nn||therapy-26/NN||adjuvant-25/NN	prep_of||schedule-22/NN||therapy-26/NN	prep_for||therapy-26/NN||patients-28/NNS	nn||cancer-33/NN||stage-30/NN	nn||cancer-33/NN||iii-31/NN	nn||cancer-33/NN||colon-32/NN	prep_with||patients-28/NNS||cancer-33/NN	amod||resection-36/NN||curative-35/JJ	prep_after||establish-19/VB||resection-36/NN	cancer-33||adjuvant-25||no_rel||therefore, we will conduct a multicenter randomized phase ii trial to compare six-week and three-week cycles to establish the optimal schedule of s-1 adjuvant therapy for patients with stage iii colon cancer after curative resection.
det||phase-4/NN||the-2/DT	amod||phase-4/NN||first-3/JJ	prep_in||conduct-10/VB||phase-4/NN	det||study-7/NN||this-6/DT	prep_of||phase-4/NN||study-7/NN	nsubj||conduct-10/VB||we-8/PRP	aux||conduct-10/VB||will-9/MD	root||ROOT-0/null||conduct-10/VB	amod||interviews-12/NNS||structured-11/JJ	dobj||conduct-10/VB||interviews-12/NNS	aux||determine-14/VB||to-13/TO	vmod||conduct-10/VB||determine-14/VB	poss||preferences-17/NNS||their-15/PRP$	nn||preferences-17/NNS||treatment-16/NN	dobj||determine-14/VB||preferences-17/NNS	prep_for||determine-14/VB||warfarin-19/NN	prep_vs.||warfarin-19/NN||aspirin-21/NN	aux||prevent-23/VB||to-22/TO	vmod||determine-14/VB||prevent-23/VB	dobj||prevent-23/VB||strokes-24/NNS	vmod||strokes-24/NNS||associated-25/VBN	prep_with||associated-25/VBN||atrialfibrillation-27/NN	xcomp||associated-25/VBN||using-28/VBG	det||technique-32/NN||the-29/DT	nn||technique-32/NN||probability-30/NN	nn||technique-32/NN||trade-off-31/NN	dobj||using-28/VBG||technique-32/NN	strokes-24||warfarin-19||yes||in the first phase of this study we will conduct structured interviews to determine their treatment preferences for warfarin vs. aspirin to prevent strokes associated with atrialfibrillation using the probability trade-off technique .
amod||forms-4/NNS||attractive-1/JJ	conj_and||attractive-1/JJ||novel-3/JJ	amod||forms-4/NNS||novel-3/JJ	nsubj||include-7/VBP||forms-4/NNS	prep_of||forms-4/NNS||therapy-6/NN	root||ROOT-0/null||include-7/VBP	dobj||include-7/VBP||strategies-8/NNS	aux||eliminate-10/VB||to-9/TO	vmod||strategies-8/NNS||eliminate-10/VB	amod||peptides-13/NNS||detrimental-11/JJ	nn||peptides-13/NNS||gluten-12/NN	dobj||eliminate-10/VB||peptides-13/NNS	det||diet-17/NN||the-15/DT	amod||diet-17/NN||celiac-16/JJ	prep_from||eliminate-10/VB||diet-17/NN	advmod||neutralized-29/VBN||so-18/RB	mark||neutralized-29/VBN||that-19/IN	det||effect-22/NN||the-20/DT	amod||effect-22/NN||immunogenic-21/JJ	nsubjpass||neutralized-29/VBN||effect-22/NN	det||epitopes-26/NNS||the-24/DT	nn||epitopes-26/NNS||gluten-25/NN	prep_of||effect-22/NN||epitopes-26/NNS	aux||neutralized-29/VBN||can-27/MD	auxpass||neutralized-29/VBN||be-28/VB	advcl||eliminate-10/VB||neutralized-29/VBN	dobj||include-7/VBP||strategies-34/NNS	conj_and||strategies-8/NNS||strategies-34/NNS	aux||block-36/VB||to-35/TO	vmod||strategies-34/NNS||block-36/VB	det||response-40/NN||the-37/DT	amod||response-40/NN||gluten-induced-38/JJ	amod||response-40/NN||inflammatory-39/JJ	dobj||block-36/VB||response-40/NN	gluten-25||celiac-16||no_rel||attractive and novel forms of therapy include strategies to eliminate detrimental gluten peptides from the celiac diet so that the immunogenic effect of the gluten epitopes can be neutralized, as well as strategies to block the gluten-induced inflammatory response.
dep||is-3/VBZ||fludarabine-1/JJ	root||ROOT-0/null||is-3/VBZ	nsubj||is-3/VBZ||one-4/CD	det||agents-10/NNS||the-6/DT	advmod||active-8/JJ||most-7/RBS	amod||agents-10/NNS||active-8/JJ	amod||agents-10/NNS||single-9/JJ	prep_of||one-4/CD||agents-10/NNS	det||treatment-13/NN||the-12/DT	prep_in||agents-10/NNS||treatment-13/NN	prep_of||treatment-13/NN||chroniclymphocyticleukemia-15/NN	appos||chroniclymphocyticleukemia-15/NN||cll-17/NN	cll-17||fludarabine-1||yes||fludarabine, is one of the most active single agents in the treatment of chroniclymphocyticleukemia (cll).
amod||level-2/NN||pd-1-1/JJ	nsubj||correlated-10/JJ||level-2/NN	amod||tem/temra-7/NN||peripheral-4/JJ	amod||tem/temra-7/NN||cd8-5/JJ	amod||tem/temra-7/NN||+-6/JJ	prep_on||level-2/NN||tem/temra-7/NN	cop||correlated-10/JJ||was-8/VBD	advmod||correlated-10/JJ||highly-9/RB	root||ROOT-0/null||correlated-10/JJ	nn||load-14/NN||hcv-12/NN	amod||load-14/NN||viral-13/JJ	prep_with||correlated-10/JJ||load-14/NN	amod||patients-18/NNS||chronic-16/JJ	amod||patients-18/NNS||hcv-infected-17/JJ	prep_in||load-14/NN||patients-18/NNS	nsubj||made-21/VBD||patients-18/NNS	rcmod||patients-18/NNS||made-21/VBD	amod||indicator-25/NN||pd-1-22/JJ	det||indicator-25/NN||a-23/DT	nn||indicator-25/NN||novel-24/NN	dobj||made-21/VBD||indicator-25/NN	aux||evaluate-27/VB||to-26/TO	vmod||made-21/VBD||evaluate-27/VB	nn||replication-29/NN||hcv-28/NN	dobj||evaluate-27/VB||replication-29/NN	nn||progression-32/NN||disease-31/NN	dobj||evaluate-27/VB||progression-32/NN	conj_and||replication-29/NN||progression-32/NN	amod||patients-35/NNS||chronichepatitisc-34/JJ	prep_in||replication-29/NN||patients-35/NNS	chronichepatitisc-34||hcv-28||no||pd-1 level on peripheral cd8+ tem/temra was highly correlated with hcv viral load in chronic hcv-infected patients, which made pd-1 a novel indicator to evaluate hcv replication and disease progression in chronichepatitisc patients.
nsubj||endocrinedisease-6/NN||endogenous-1/NNS	vmod||endogenous-1/NNS||cushing-2/VBG	dobj||cushing-2/VBG||syndrome-3/NN	cop||endocrinedisease-6/NN||is-4/VBZ	det||endocrinedisease-6/NN||an-5/DT	root||ROOT-0/null||endocrinedisease-6/NN	vmod||endocrinedisease-6/NN||caused-7/VBN	amod||secretion-10/NN||excessive-9/JJ	agent||caused-7/VBN||secretion-10/NN	nn||hormone-13/NN||adrenocorticotropin-12/NN	prep_of||secretion-10/NN||hormone-13/NN	quantmod||80-16/CD||approximately-15/RB	num||%-17/NN||80-16/CD	prep_in||caused-7/VBN||%-17/NN	prep_of||%-17/NN||cases-19/NNS	advmod||caused-7/VBN||usually-21/RB	det||adenoma-26/NN||a-23/DT	advmod||corticotroph-25/JJ||pituitary-24/RB	amod||adenoma-26/NN||corticotroph-25/JJ	agent||caused-7/VBN||adenoma-26/NN	amod||-RSB--31/NNP||cushingdisease-28/JJ	nn||-RSB--31/NNP||-LSB--29/NNP	nn||-RSB--31/NNP||cd-30/NN	appos||adenoma-26/NN||-RSB--31/NNP	pituitary-24||hormone-13||no_rel||endogenous cushing syndrome is an endocrinedisease caused by excessive secretion of adrenocorticotropin hormone in approximately 80% of cases, usually by a pituitary corticotroph adenoma (cushingdisease [cd]).
nsubj||treatment-9/NN||intravenousimmunoglobulin-1/NN	appos||intravenousimmunoglobulin-1/NN||ivig-3/NN	cop||treatment-9/NN||is-5/VBZ	det||treatment-9/NN||a-6/DT	amod||treatment-9/NN||proven-7/VBN	amod||treatment-9/NN||effective-8/JJ	root||ROOT-0/null||treatment-9/NN	prep_for||treatment-9/NN||gbs-11/NN	dep||gbs-11/NN||class-13/NN	num||evidence-15/NN||1-14/CD	dep||class-13/NN||evidence-15/NN	gbs-11||intravenousimmunoglobulin-1||yes||intravenousimmunoglobulin (ivig) is a proven effective treatment for gbs (class 1 evidence).
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||outcome-12/NN||the-9/DT	amod||outcome-12/NN||long-term-10/JJ	nn||outcome-12/NN||treatment-11/NN	dobj||investigate-8/VB||outcome-12/NN	prep_of||outcome-12/NN||lamivudine-14/NN	prepc_in||investigate-8/VB||preventing-16/VBG	nn||reactivation-18/NN||hbv-17/NN	dobj||preventing-16/VBG||reactivation-18/NN	poss||morbidity-22/NN||its-20/PRP$	amod||morbidity-22/NN||associated-21/JJ	dobj||preventing-16/VBG||morbidity-22/NN	conj_and||reactivation-18/NN||morbidity-22/NN	prepc_according_to||preventing-16/VBG||to-24/TO	amod||status-26/NN||hbeag-25/JJ	pobj||preventing-16/VBG||status-26/NN	hbv-17||lamivudine-14||yes||the aim of this study was to investigate the long-term treatment outcome of lamivudine in preventing hbv reactivation and its associated morbidity according to hbeag status.
poss||hospitalization-3/NN||his-2/PRP$	prep_during||presented-5/VBD||hospitalization-3/NN	nsubj||presented-5/VBD||he-4/PRP	root||ROOT-0/null||presented-5/VBD	det||episode-7/NN||an-6/DT	dobj||presented-5/VBD||episode-7/NN	nsubjpass||treated-18/VBN||episode-7/NN	amod||peritonitis-11/NNS||spontaneous-9/JJ	amod||peritonitis-11/NNS||bacterial-10/JJ	prep_of||episode-7/NN||peritonitis-11/NNS	prep_of||episode-7/NN||hepaticencephalopathy-13/NN	conj_and||peritonitis-11/NNS||hepaticencephalopathy-13/NN	auxpass||treated-18/VBN||were-16/VBD	advmod||treated-18/VBN||successfully-17/RB	rcmod||episode-7/NN||treated-18/VBN	amod||clysmas-21/NNS||lactulose-20/JJ	prep_with||treated-18/VBN||clysmas-21/NNS	prep_with||treated-18/VBN||ciprofloxacine-23/NN	conj_and||clysmas-21/NNS||ciprofloxacine-23/NN	hepaticencephalopathy-13||lactulose-20||yes||during his hospitalization he presented an episode of spontaneous bacterial peritonitis and hepaticencephalopathy, which were successfully treated with lactulose clysmas and ciprofloxacine.
amod||patients-2/NNS||sixty-1/JJ	nsubjpass||divided-12/VBN||patients-2/NNS	prep_with||patients-2/NNS||psychoticdisorder-4/NN	nsubjpass||assigned-7/VBN||psychoticdisorder-4/NN	auxpass||assigned-7/VBN||were-6/VBD	rcmod||psychoticdisorder-4/NN||assigned-7/VBN	amod||treatment-10/NN||6-month-9/JJ	prep_to||assigned-7/VBN||treatment-10/NN	auxpass||divided-12/VBN||were-11/VBD	root||ROOT-0/null||divided-12/VBN	num||groups-15/NNS||two-14/CD	prep_in||divided-12/VBN||groups-15/NNS	num||haloperidol-18/NN||30-16/CD	amod||haloperidol-18/NN||received-17/VBN	dobj||divided-12/VBN||haloperidol-18/NN	amod||antipsychotic-22/NN||first-20/JJ	nn||antipsychotic-22/NN||generation-21/NN	appos||haloperidol-18/NN||antipsychotic-22/NN	num||olanzapine-27/NN||30-25/CD	amod||olanzapine-27/NN||received-26/VBN	dobj||divided-12/VBN||olanzapine-27/NN	conj_and||haloperidol-18/NN||olanzapine-27/NN	amod||antipsychotic-31/NN||second-29/JJ	nn||antipsychotic-31/NN||generation-30/NN	appos||olanzapine-27/NN||antipsychotic-31/NN	psychoticdisorder-4||antipsychotic-31||no_rel||sixty patients with psychoticdisorder who were assigned to 6-month treatment were divided in two groups 30 received haloperidol (first generation antipsychotic) and 30 received olanzapine (second generation antipsychotic).
mark||correlate-16/VBP||although-1/IN	amod||levels-3/NNS||increased-2/VBN	nsubj||correlate-16/VBP||levels-3/NNS	amod||interferon-8/NN||systemic-5/JJ	nn||interferon-8/NN||type-6/NN	nn||interferon-8/NN||i-7/NN	prep_of||levels-3/NNS||interferon-8/NN	amod||±-11/NN||ifnî-10/JJ	dep||interferon-8/NN||±-11/NN	nn||²-14/NN||î-13/NN	dep||interferon-8/NN||²-14/NN	conj_and||±-11/NN||²-14/NN	advcl||demonstrated-36/VBN||correlate-16/VBP	amod||resolution-19/NN||accelerated-18/VBN	prep_with||correlate-16/VBP||resolution-19/NN	prep_of||resolution-19/NN||rotavirusdisease-21/NN	amod||strains-25/NNS||multiple-23/JJ	nn||strains-25/NNS||rotavirus-24/NNS	nsubjpass||demonstrated-36/VBN||strains-25/NNS	nsubj||antagonize-38/VB||strains-25/NNS	amod||rotavirus-29/NNS||rhesus-28/JJ	prep_including||strains-25/NNS||rotavirus-29/NNS	appos||rotavirus-29/NNS||rrv-31/NN	aux||demonstrated-36/VBN||have-34/VBP	auxpass||demonstrated-36/VBN||been-35/VBN	root||ROOT-0/null||demonstrated-36/VBN	aux||antagonize-38/VB||to-37/TO	xcomp||demonstrated-36/VBN||antagonize-38/VB	nn||production-42/NN||type-39/FW	nn||production-42/NN||i-40/FW	nn||production-42/NN||ifn-41/NN	dobj||antagonize-38/VB||production-42/NN	det||variety-45/NN||a-44/DT	prep_in||production-42/NN||variety-45/NN	amod||types-51/NNS||epithelial-47/JJ	conj_and||epithelial-47/JJ||fibroblast-49/JJ	amod||types-51/NNS||fibroblast-49/JJ	nn||types-51/NNS||cell-50/NN	prep_of||variety-45/NN||types-51/NNS	amod||mechanisms-54/NNS||several-53/JJ	prep_through||antagonize-38/VB||mechanisms-54/NNS	prep_including||antagonize-38/VB||degradation-57/NN	amod||factors-62/NNS||multiple-59/JJ	amod||factors-62/NNS||interferon-60/JJ	amod||factors-62/NNS||regulatory-61/JJ	prep_of||degradation-57/NN||factors-62/NNS	det||protein-67/NN||a-64/DT	amod||protein-67/NN||viral-65/JJ	amod||protein-67/NN||nonstructural-66/JJ	prep_by||factors-62/NNS||protein-67/NN	rotavirusdisease-21||rotavirus-29||yes||although increased levels of systemic type i interferon (ifnî± and î²) correlate with accelerated resolution of rotavirusdisease, multiple rotavirus strains, including rhesus rotavirus (rrv), have been demonstrated to antagonize type i ifn production in a variety of epithelial and fibroblast cell types through several mechanisms, including degradation of multiple interferon regulatory factors by a viral nonstructural protein.
advmod||le-3/JJ||significantly-1/RB	advmod||le-3/JJ||more-2/RBR	amod||patients-5/NNS||le-3/JJ	amod||patients-5/NNS||ointment-treated-4/JJ	nsubj||had-9/VBD||patients-5/NNS	amod||patients-8/NNS||vehicle-treated-7/JJ	prep_than||patients-5/NNS||patients-8/NNS	root||ROOT-0/null||had-9/VBD	amod||resolution-11/NN||complete-10/JJ	dobj||had-9/VBD||resolution-11/NN	prep_of||resolution-11/NN||aci-13/NN	num||%-16/NN||27.7-15/CD	dep||aci-13/NN||%-16/NN	num||%-19/NN||12.5-18/CD	dep||aci-13/NN||%-19/NN	conj_versus||%-16/NN||%-19/NN	neg||pain-23/NN||no-22/DT	prep_of||resolution-11/NN||pain-23/NN	conj_and||aci-13/NN||pain-23/NN	num||%-26/NN||75.5-25/CD	dep||aci-13/NN||%-26/NN	num||%-29/NN||43.1-28/CD	dep||aci-13/NN||%-29/NN	conj_versus||%-26/NN||%-29/NN	prep_at||had-9/VBD||day-32/NN	num||day-32/NN||8-33/CD	dep||day-32/NN||p-35/VBN	number||0.0001-37/CD||<-36/CD	dobj||p-35/VBN||0.0001-37/CD	prep_for||0.0001-37/CD||both-39/DT	vehicle--1||pain-23||no_rel||significantly more le ointment-treated patients than vehicle-treated patients had complete resolution of aci (27.7% versus 12.5%) and no pain (75.5% versus 43.1%) at day 8 ( p < 0.0001 for both).
nsubj||lorazepam-4/VBP||treatment-1/NN	nsubj||prevent-11/VB||treatment-1/NN	prep_with||treatment-1/NN||intravenous-3/NNP	root||ROOT-0/null||lorazepam-4/VBP	amod||vomiting-6/NN||aborted-5/JJ	dobj||lorazepam-4/VBP||vomiting-6/NN	aux||prevent-11/VB||could-9/MD	neg||prevent-11/VB||not-10/RB	conj_but||lorazepam-4/VBP||prevent-11/VB	dobj||prevent-11/VB||recurrences-12/NNS	nn||pain-17/NN||vomiting-14/NN	conj_and||vomiting-14/NN||epigastric-16/JJ	nn||pain-17/NN||epigastric-16/JJ	prep_of||recurrences-12/NNS||pain-17/NN	vomiting-14||lorazepam-4||yes||treatment with intravenous lorazepam aborted vomiting, but could not prevent recurrences of vomiting and epigastric pain.
det||efficacy-3/NN||the-1/DT	amod||efficacy-3/NN||uncertain-2/JJ	nsubj||motivated-20/VBN||efficacy-3/NN	prep_of||efficacy-3/NN||ondansetron-5/NN	amod||patients-9/NNS||pediatric-7/JJ	amod||patients-9/NNS||neurosurgical-8/JJ	prep_for||ondansetron-5/NN||patients-9/NNS	det||effect-14/NN||the-11/DT	amod||effect-14/NN||possible-12/JJ	amod||effect-14/NN||antiemetic-13/JJ	prep_of||efficacy-3/NN||effect-14/NN	conj_or||ondansetron-5/NN||effect-14/NN	amod||dose-17/NN||small-16/JJ	prep_of||effect-14/NN||dose-17/NN	prep_of||dose-17/NN||propofol-19/NN	root||ROOT-0/null||motivated-20/VBN	dobj||motivated-20/VBN||us-21/PRP	nsubj||evaluate-23/VB||us-21/PRP	aux||evaluate-23/VB||to-22/TO	xcomp||motivated-20/VBN||evaluate-23/VB	det||effect-26/NN||the-24/DT	amod||effect-26/NN||preventive-25/JJ	dobj||evaluate-23/VB||effect-26/NN	det||dose-30/NN||a-28/DT	amod||dose-30/NN||subhypnotic-29/JJ	prep_of||effect-26/NN||dose-30/NN	prep_of||dose-30/NN||propofol-32/NN	prep||evaluate-23/VB||combined-33/VBN	pcomp||combined-33/VBN||with-34/IN	pobj||with-34/IN||dexamethasone-35/NN	amod||vomiting-38/NN||postoperative-37/JJ	prep_on||motivated-20/VBN||vomiting-38/NN	appos||vomiting-38/NN||pov-40/NN	advmod||motivated-20/VBN||especially-43/RB	amod||periods-47/NNS||immediate-45/JJ	nn||periods-47/NNS||postoperative-46/NN	prep_during||especially-43/RB||periods-47/NNS	vomiting-38||dexamethasone-35||yes||the uncertain efficacy of ondansetron for pediatric neurosurgical patients or the possible antiemetic effect of small dose of propofol motivated us to evaluate the preventive effect of a subhypnotic dose of propofol combined with dexamethasone on postoperative vomiting (pov), especially during immediate postoperative periods.
det||estimate-4/NN||a-1/DT	amod||estimate-4/NN||population-based-2/JJ	nn||estimate-4/NN||incidence-3/NN	nsubjpass||calculated-6/VBN||estimate-4/NN	auxpass||calculated-6/VBN||is-5/VBZ	root||ROOT-0/null||calculated-6/VBN	ccomp||calculated-6/VBN||using-7/VBG	nn||data-10/NNS||hiv-8/NN	nn||data-10/NNS||testing-9/NN	dobj||using-7/VBG||data-10/NNS	advmod||diagnosed-13/JJ||newly-12/RB	amod||cases-14/NNS||diagnosed-13/JJ	prep_from||using-7/VBG||cases-14/NNS	ccomp||calculated-6/VBN||imputing-16/VBG	conj_and||using-7/VBG||imputing-16/VBG	prep_for||imputing-16/VBG||persons-18/NNS	amod||persons-18/NNS||unaware-19/JJ	poss||hivinfection-22/NN||their-21/PRP$	prep_of||persons-18/NNS||hivinfection-22/NN	hivinfection-22||hiv-8||no||a population-based incidence estimate is calculated using hiv testing data from newly diagnosed cases and imputing for persons unaware of their hivinfection.
nsubj||analyzed-2/VBD||we-1/PRP	root||ROOT-0/null||analyzed-2/VBD	advmod||analyzed-2/VBD||retrospectively-3/RB	num||cases-5/NNS||11-4/CD	dobj||analyzed-2/VBD||cases-5/NNS	prep_of||cases-5/NNS||radiochemotherapy-7/NN	amod||ifosfamide-10/NN||single-agent-9/JJ	prep_with||analyzed-2/VBD||ifosfamide-10/NN	prep_in||analyzed-2/VBD||patients-12/NNS	amod||sarcomas-16/NNS||macroscopic-14/JJ	amod||sarcomas-16/NNS||soft-tissue-15/JJ	prep_with||patients-12/NNS||sarcomas-16/NNS	sarcomas-16||ifosfamide-10||yes||we analyzed retrospectively 11 cases of radiochemotherapy with single-agent ifosfamide in patients with macroscopic soft-tissue sarcomas.
det||study-3/NN||this-2/DT	prep_in||employed-6/VBN||study-3/NN	nsubj||employed-6/VBN||we-5/PRP	nsubj||demonstrated-34/VBN||we-5/PRP	root||ROOT-0/null||employed-6/VBN	npadvmod||microbial-9/JJ||vitro-8/NN	amod||floras-10/NNS||microbial-9/JJ	prep_in||employed-6/VBN||floras-10/NNS	xcomp||employed-6/VBN||representing-11/VBG	dobj||representing-11/VBG||microorganisms-12/NNS	nsubj||inhabit-14/VBP||microorganisms-12/NNS	rcmod||microorganisms-12/NNS||inhabit-14/VBP	det||tract-20/NN||the-15/DT	amod||tract-20/NN||oral-16/JJ	amod||tract-20/NN||cavities-17/JJ	conj_and||cavities-17/JJ||intestinal-19/JJ	amod||tract-20/NN||intestinal-19/JJ	dobj||inhabit-14/VBP||tract-20/NN	prep_of||tract-20/NN||mice-22/NNS	prep_in||mice-22/NNS||combination-24/NN	nn||coli-27/NNS||escherichia-26/NN	prep_with||inhabit-14/VBP||coli-27/NNS	det||bacterium-32/NN||a-29/DT	nn||bacterium-32/NN||model-30/NN	nn||bacterium-32/NN||intestinal-31/NN	prep_as||coli-27/NNS||bacterium-32/NN	conj_and||employed-6/VBN||demonstrated-34/VBN	mark||displays-38/VBZ||that-35/IN	nn||coli-37/NNS||e.-36/NN	nsubj||displays-38/VBZ||coli-37/NNS	ccomp||demonstrated-34/VBN||displays-38/VBZ	det||preference-42/NN||a-39/DT	amod||preference-42/NN||striking-40/JJ	nn||preference-42/NN||community-41/NN	dobj||displays-38/VBZ||preference-42/NN	cavities-17||bacterium-32||no||in this study , we employed in vitro microbial floras representing microorganisms that inhabit the oral cavities and intestinal tract of mice in combination with escherichia coli as a model intestinal bacterium and demonstrated that e. coli displays a striking community preference .
det||gattii-5/NN||the-1/DT	amod||gattii-5/NN||pathogenic-2/JJ	nn||gattii-5/NN||yeast-3/NN	nn||gattii-5/NN||cryptococcus-4/NN	nsubj||causing-9/VBG||gattii-5/NN	nsubj||causes-21/VBZ||gattii-5/NN	aux||causing-9/VBG||is-8/VBZ	rcmod||gattii-5/NN||causing-9/VBG	det||outbreak-11/NN||an-10/DT	dobj||causing-9/VBG||outbreak-11/NN	det||region-16/NN||the-13/DT	amod||region-16/NN||pacific-14/JJ	amod||region-16/NN||northwest-15/JJ	prep_in||outbreak-11/NN||region-16/NN	nn||america-19/NN||north-18/NN	prep_of||region-16/NN||america-19/NN	root||ROOT-0/null||causes-21/VBZ	acomp||causes-21/VBZ||life-threatening-22/JJ	amod||infections-24/NNS||pulmonary-23/JJ	dep||life-threatening-22/JJ||infections-24/NNS	dep||life-threatening-22/JJ||meningoencephalitis-26/NNS	conj_and||infections-24/NNS||meningoencephalitis-26/NNS	amod||individuals-29/NNS||healthy-28/JJ	prep_in||infections-24/NNS||individuals-29/NNS	prep_unlike||causes-21/VBZ||cryptococcusneoformans-32/NNS	nsubj||infects-36/VBZ||cryptococcusneoformans-32/NNS	advmod||infects-36/VBZ||commonly-35/RB	rcmod||cryptococcusneoformans-32/NNS||infects-36/VBZ	amod||patients-38/NNS||immunocompromised-37/JJ	dobj||infects-36/VBZ||patients-38/NNS	cryptococcusneoformans-32||cryptococcus-4||no||the pathogenic yeast cryptococcus gattii , which is causing an outbreak in the pacific northwest region of north america, causes life-threatening pulmonary infections and meningoencephalitis in healthy individuals, unlike cryptococcusneoformans , which commonly infects immunocompromised patients.
nsubj||physically-5/VB||stat3-1/NNS	conj_and||stat3-1/NNS||c-jun-3/NN	nsubj||physically-5/VB||c-jun-3/NN	aux||physically-5/VB||could-4/MD	root||ROOT-0/null||physically-5/VB	dobj||physically-5/VB||interact-6/NN	dobj||physically-5/VB||bind-8/NN	conj_and||interact-6/NN||bind-8/NN	det||site-12/NN||the-10/DT	amod||site-12/NN||ap-1-11/JJ	prep_to||physically-5/VB||site-12/NN	vmod||physically-5/VB||implicating-14/VBG	mark||responsible-27/JJ||that-15/IN	det||interplay-17/NN||the-16/DT	nsubj||responsible-27/JJ||interplay-17/NN	det||factors-21/NNS||both-19/DT	amod||factors-21/NNS||transcriptional-20/JJ	prep_of||interplay-17/NN||factors-21/NNS	det||site-25/NN||the-23/DT	amod||site-25/NN||ap-1-24/JJ	prep_on||factors-21/NNS||site-25/NN	cop||responsible-27/JJ||is-26/VBZ	ccomp||implicating-14/VBG||responsible-27/JJ	amod||expression-31/NN||isoproterenol-stimulated-29/JJ	amod||expression-31/NN||mmp-7-30/JJ	prep_for||responsible-27/JJ||expression-31/NN	amod||cells-35/NNS||gastric-33/JJ	nn||cells-35/NNS||cancer-34/NN	prep_in||expression-31/NN||cells-35/NNS	cancer-34||isoproterenol--1||no_rel||stat3 and c-jun could physically interact and bind to the ap-1 site, implicating that the interplay of both transcriptional factors on the ap-1 site is responsible for isoproterenol-stimulated mmp-7 expression in gastric cancer cells.
nsubj||live-3/VB||plha-1/NN	nsubjpass||associated-165/VBN||plha-1/NN	rcmod||plha-1/NN||live-3/VB	poss||-LSB--7/NN||their-5/PRP$	nn||-LSB--7/NN||families-6/NNS	prep_with||live-3/VB||-LSB--7/NN	prep_with||live-3/VB||=-9/NNP	conj_or||-LSB--7/NN||=-9/NNP	num||=-9/NNP||3.29-10/CD	num||%-13/NN||95-12/CD	dobj||live-3/VB||%-13/NN	vmod||%-13/NN||ci-14/VBN	num||-RSB--18/NNS||1.28-8-15/CD	nn||-RSB--18/NNS||.45-16/CD	dobj||ci-14/VBN||-RSB--18/NNS	dobj||ci-14/VBN||lived-20/VBN	conj_or||-RSB--18/NNS||lived-20/VBN	vmod||-RSB--18/NNS||lived-20/VBN	det||-LSB--25/NN||a-22/DT	amod||-LSB--25/NN||rented-23/VBN	nn||-LSB--25/NN||house-24/NN	prep_in||lived-20/VBN||-LSB--25/NN	number||2.52-28/CD||=-27/CD	num||-RSB--35/NN||2.52-28/CD	number||%-31/NN||95-30/CD	amod||-RSB--35/NN||%-31/NN	amod||-RSB--35/NN||ci-32/JJ	nn||-RSB--35/NN||1.09-5-33/NN	num||-RSB--35/NN||.79-34/CD	prep_in||lived-20/VBN||-RSB--35/NN	conj_or||-LSB--25/NN||-RSB--35/NN	dobj||have-54/VBP||-RSB--35/NN	amod||women-38/NNS||non-pregnant-37/JJ	appos||-RSB--35/NN||women-38/NNS	num||women-38/NNS||-LSB--39/CD	num||9.3-42/CD||=-41/CD	num||women-38/NNS||9.3-42/CD	conj_or||-LSB--39/CD||9.3-42/CD	number||%-45/NN||95-44/CD	amod||ci-46/NN||%-45/NN	appos||-RSB--35/NN||ci-46/NN	num||-RSB--49/NNS||1.93-44-47/CD	num||-RSB--49/NNS||.82-48/CD	dep||ci-46/NN||-RSB--49/NNS	amod||art-53/NN||perceived-52/VBN	nsubj||have-54/VBP||art-53/NN	rcmod||-RSB--35/NN||have-54/VBP	amod||effects-57/NNS||many-55/JJ	nn||effects-57/NNS||side-56/NN	dobj||have-54/VBP||effects-57/NNS	vmod||effects-57/NNS||-LSB--58/VBN	dep||6.23-61/CD||=-60/SYM	dobj||have-54/VBP||6.23-61/CD	conj_or||effects-57/NNS||6.23-61/CD	num||%-64/NN||95-63/CD	prep_in||lived-20/VBN||%-64/NN	conj_or||-LSB--25/NN||%-64/NN	num||-RSB--68/NNS||ci1-65/CD	nn||-RSB--68/NNS||.63,23.82-66/CD	dep||%-64/NN||-RSB--68/NNS	nsubj||perceived-71/VBD||who-70/WP	prep_in||lived-20/VBN||perceived-71/VBD	conj_or||-LSB--25/NN||perceived-71/VBD	amod||-LSB--92/NNS||hiv-72/JJ	prepc_as||hiv-72/JJ||stigmatizing-74/VBG	nn||-LSB--76/NNS||disease-75/NN	iobj||stigmatizing-74/VBG||-LSB--76/NNS	number||3.1-79/CD||=-78/CD	num||ci-83/NN||3.1-79/CD	number||%-82/NN||95-81/CD	amod||ci-83/NN||%-82/NN	iobj||stigmatizing-74/VBG||ci-83/NN	conj_or||-LSB--76/NNS||ci-83/NN	num||-RSB--86/NNS||1.09-8-84/CD	num||-RSB--86/NNS||.76-85/CD	dobj||stigmatizing-74/VBG||-RSB--86/NNS	nsubj||tested-89/VBN||-RSB--86/NNS	rcmod||-RSB--86/NNS||tested-89/VBN	prep_with||tested-89/VBN||sickness/symptoms-91/NNS	dobj||perceived-71/VBD||-LSB--92/NNS	dep||2.62-95/CD||=-94/SYM	dobj||perceived-71/VBD||2.62-95/CD	conj_or||-LSB--92/NNS||2.62-95/CD	number||%-98/NN||95-97/CD	amod||-RSB--102/NNS||%-98/NN	nn||-RSB--102/NNS||ci-99/NN	amod||-RSB--102/NNS||1.26-5-100/JJ	num||-RSB--102/NNS||.44-101/CD	dobj||ci-14/VBN||-RSB--102/NNS	conj_or||-RSB--18/NNS||-RSB--102/NNS	nsubj||disclose-107/VB||-RSB--102/NNS	aux||disclose-107/VB||did-105/VBD	neg||disclose-107/VB||not-106/RB	rcmod||-RSB--102/NNS||disclose-107/VB	poss||status-110/NN||their-108/PRP$	nn||status-110/NN||hiv-109/NN	dobj||disclose-107/VB||status-110/NN	poss||-LSB--114/NN||their-112/PRP$	nn||-LSB--114/NN||partner-113/NN	prep_for||disclose-107/VB||-LSB--114/NN	number||2.78-117/CD||=-116/CD	num||ci-121/NN||2.78-117/CD	number||%-120/NN||95-119/CD	amod||ci-121/NN||%-120/NN	dobj||ci-14/VBN||ci-121/NN	conj_or||-RSB--18/NNS||ci-121/NN	num||-LSB--129/NNS||1.02-7-122/CD	num||-LSB--129/NNS||.56-123/CD	nn||-LSB--129/NNS||-RSB--124/NNP	amod||-LSB--129/NNS||frequent-126/JJ	nn||-LSB--129/NNS||alcohol-127/NN	nn||-LSB--129/NNS||users-128/NNS	dep||ci-121/NN||-LSB--129/NNS	dep||3.55-132/CD||=-131/SYM	dobj||live-3/VB||3.55-132/CD	conj_or||%-13/NN||3.55-132/CD	number||%-135/NN||95-134/CD	amod||-LSB--152/NN||%-135/NN	amod||-LSB--152/NN||ci-136/JJ	amod||-LSB--152/NN||1.63-7-137/JJ	num||-RSB--139/NNS||.71-138/CD	nn||-LSB--152/NN||-RSB--139/NNS	nsubj||spent-142/VBD||who-141/WP	conj_and||-RSB--139/NNS||spent-142/VBD	nn||-LSB--152/NN||spent-142/VBD	mwe||than-144/IN||more-143/JJR	quantmod||120-145/CD||than-144/IN	num||months-146/NNS||120-145/CD	tmod||spent-142/VBD||months-146/NNS	prep_with||spent-142/VBD||partner-148/NN	nn||diagnosis-151/NN||hiv-150/NN	prep_at||spent-142/VBD||diagnosis-151/NN	dobj||live-3/VB||-LSB--152/NN	dep||5.86-155/CD||=-154/SYM	dobj||live-3/VB||5.86-155/CD	conj_or||-LSB--152/NN||5.86-155/CD	number||%-158/NN||95-157/CD	amod||-RSB--162/NNS||%-158/NN	amod||-RSB--162/NNS||ci-159/JJ	number||.41-161/CD||1.35-25-160/CD	num||-RSB--162/NNS||.41-161/CD	dobj||live-3/VB||-RSB--162/NNS	auxpass||associated-165/VBN||were-163/VBD	advmod||associated-165/VBN||significantly-164/RB	root||ROOT-0/null||associated-165/VBN	amod||presentation-168/NN||late-167/JJ	prep_with||associated-165/VBN||presentation-168/NN	amod||care-171/NN||hiv/aids-170/JJ	prep_to||associated-165/VBN||care-171/NN	aids--1||hiv-150||no||plha who live with their families [or = 3.29, 95%ci 1.28-8.45)], lived in a rented house [or = 2.52, 95%ci 1.09-5.79], non-pregnant women [or = 9.3, 95% ci 1.93-44.82], who perceived art have many side effects [or = 6.23, 95%ci1.63,23.82)], who perceived hiv as stigmatizing disease [or = 3.1, 95% ci 1.09-8.76], who tested with sickness/symptoms [or = 2.62, 95% ci 1.26-5.44], who did not disclose their hiv status for their partner [or = 2.78, 95% ci 1.02-7.56], frequent alcohol users [or = 3.55, 95% ci 1.63-7.71] and who spent more than 120 months with partner at hiv diagnosis[or = 5.86, 95% ci 1.35-25.41] were significantly associated with late presentation to hiv/aids care.
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-8/VBD||aim-3/NN	nsubj||observe-10/VB||aim-3/NN	nsubj||compare-12/VB||aim-3/NN	det||study-7/NN||the-5/DT	amod||study-7/NN||present-6/JJ	prep_of||aim-3/NN||study-7/NN	root||ROOT-0/null||was-8/VBD	aux||observe-10/VB||to-9/TO	xcomp||was-8/VBD||observe-10/VB	xcomp||was-8/VBD||compare-12/VB	conj_and||observe-10/VB||compare-12/VB	det||effects-14/NNS||the-13/DT	dobj||compare-12/VB||effects-14/NNS	amod||crl183-18/NNS||enterococcus-16/JJ	nn||crl183-18/NNS||faecium-17/NN	prep_of||effects-14/NNS||crl183-18/NNS	amod||microorganism-21/NN||probiotic-20/JJ	appos||effects-14/NNS||microorganism-21/NN	det||mixture-26/NN||an-24/DT	amod||mixture-26/NN||isoflavones-25/JJ	dobj||compare-12/VB||mixture-26/NN	conj_and||effects-14/NNS||mixture-26/NN	dobj||compare-12/VB||simvastatin-28/NN	conj_and||effects-14/NNS||simvastatin-28/NN	dep||effects-14/NNS||drug-30/NN	vmod||drug-30/NN||used-31/VBN	aux||treat-33/VB||to-32/TO	xcomp||used-31/VBN||treat-33/VB	dobj||treat-33/VB||hypercholesterolemia-34/NN	nn||parameters-38/NNS||lipid-37/NN	prep_on||compare-12/VB||parameters-38/NNS	prep_on||compare-12/VB||atherosclerosis-40/NNS	conj_and||parameters-38/NNS||atherosclerosis-40/NNS	dobj||observe-10/VB||development-41/NN	prep_in||observe-10/VB||rabbits-43/NNS	amod||hypercholesterolemia-46/NN||induced-45/JJ	prep_with||rabbits-43/NNS||hypercholesterolemia-46/NN	hypercholesterolemia-46||simvastatin-28||yes||objective the aim of the present study was to observe and compare the effects of enterococcus faecium crl183 (probiotic microorganism), an isoflavones mixture and simvastatin (drug used to treat hypercholesterolemia) on lipid parameters and atherosclerosis development in rabbits with induced hypercholesterolemia.
amod||tax-specific-2/NN||htlv-1-1/JJ	root||ROOT-0/null||tax-specific-2/NN	vmod||tax-specific-2/NN||hla-a-4/VBN	dep||cells-11/NNS||*-5/SYM	num||cells-11/NNS||02-6/CD	amod||cells-11/NNS||restricted-7/VBN	amod||cells-11/NNS||cd8-8/JJ	amod||cells-11/NNS||+-9/JJ	nn||cells-11/NNS||t-10/NN	dep||hla-a-4/VBN||cells-11/NNS	nn||individuals-14/NNS||ham/tsp-13/NN	prep_among||cells-11/NNS||individuals-14/NNS	vmod||individuals-14/NNS||expressed-15/VBN	advmod||lower-17/JJR||markedly-16/RB	amod||levels-18/NNS||lower-17/JJR	dobj||expressed-15/VBN||levels-18/NNS	prep_of||levels-18/NNS||tim-3-20/CD	ham--1||htlv-1-1||no||htlv-1 tax-specific, hla-a*02 restricted cd8+ t cells among ham/tsp individuals expressed markedly lower levels of tim-3.
det||review-3/NN||a-1/DT	nn||review-3/NN||retrospective-2/NN	nsubj||included-15/VBD||review-3/NN	prep_of||review-3/NN||costs-5/NNS	nn||programmes-9/NNS||vector-7/NN	nn||programmes-9/NNS||control-8/NN	prep_for||costs-5/NNS||programmes-9/NNS	vmod||programmes-9/NNS||carried-10/VBN	prt||carried-10/VBN||out-11/RP	amod||areas-14/NNS||rural-13/JJ	prep_in||carried-10/VBN||areas-14/NNS	root||ROOT-0/null||included-15/VBD	num||houses-17/NNS||3,084-16/CD	dobj||included-15/VBD||houses-17/NNS	vmod||houses-17/NNS||surveyed-18/VBN	prep_for||surveyed-18/VBN||infestation-20/NN	amod||bugs-23/NNS||triatomine-22/JJ	prep_with||surveyed-18/VBN||bugs-23/NNS	num||houses-26/NNS||3,305-25/CD	dobj||included-15/VBD||houses-26/NNS	conj_and||houses-17/NNS||houses-26/NNS	vmod||houses-26/NNS||sprayed-27/VBN	prep_with||sprayed-27/VBN||insecticide-29/NN	insecticide-29||infestation-20||no_rel||a retrospective review of costs for vector control programmes carried out in rural areas included 3,084 houses surveyed for infestation with triatomine bugs and 3,305 houses sprayed with insecticide.
advmod||proposed-16/VBN||however-1/RB	nsubj||progressed-7/VBN||knowledge-3/NN	conj_and||knowledge-3/NN||technology-5/NN	nsubj||progressed-7/VBN||technology-5/NN	aux||progressed-7/VBN||have-6/VBP	parataxis||proposed-16/VBN||progressed-7/VBN	advmod||vaccines-13/NNS||hence-9/RB	amod||vaccines-13/NNS||new-10/JJ	amod||vaccines-13/NNS||plant-derived-11/JJ	amod||vaccines-13/NNS||anti-hbv-12/JJ	nsubjpass||proposed-16/VBN||vaccines-13/NNS	aux||proposed-16/VBN||can-14/MD	auxpass||proposed-16/VBN||be-15/VB	root||ROOT-0/null||proposed-16/VBN	tmod||proposed-16/VBN||today-17/NN	hbv--1||vaccines-13||no_rel||however, knowledge and technology have progressed, hence new plant-derived anti-hbv vaccines can be proposed today.
det||result-3/NN||a-2/DT	prep_as||inhibits-6/VBZ||result-3/NN	nsubj||inhibits-6/VBZ||fad-5/NN	root||ROOT-0/null||inhibits-6/VBZ	amod||transport-9/NN||insulin-stimulated-7/JJ	amod||transport-9/NN||aminoacid-8/JJ	dobj||inhibits-6/VBZ||transport-9/NN	nsubj||have-13/VB||transport-9/NN	aux||have-13/VB||may-12/MD	rcmod||transport-9/NN||have-13/VB	amod||implications-15/NNS||important-14/JJ	dobj||have-13/VB||implications-15/NNS	amod||transport-19/NN||placental-17/JJ	nn||transport-19/NN||nutrient-18/NN	prep_for||implications-15/NNS||transport-19/NN	amod||growth-22/NN||fetal-21/JJ	prep_for||implications-15/NNS||growth-22/NN	conj_and||transport-19/NN||growth-22/NN	prep_in||transport-19/NN||pregnancycomplications-24/NNS	vmod||pregnancycomplications-24/NNS||associated-25/VBN	amod||levels-30/NNS||altered-27/JJ	amod||levels-30/NNS||maternal-28/JJ	nn||levels-30/NNS||adiponectin-29/NN	prep_with||associated-25/VBN||levels-30/NNS	aminoacid-8||pregnancycomplications-24||no_rel||as a result, fad inhibits insulin-stimulated aminoacid transport, which may have important implications for placental nutrient transport and fetal growth in pregnancycomplications associated with altered maternal adiponectin levels.
nn||analysis-2/NN||meta-1/NN	nsubj||showed-3/VBD||analysis-2/NN	root||ROOT-0/null||showed-3/VBD	mark||higher-59/JJR||that-4/IN	det||rate-6/NN||the-5/DT	nsubj||higher-59/JJR||rate-6/NN	amod||dna-11/NN||undetected-8/JJ	nn||dna-11/NN||serum-9/NN	nn||dna-11/NN||hbv-10/NN	prep_of||rate-6/NN||dna-11/NN	amod||risk-14/NN||relative-13/JJ	dep||dna-11/NN||risk-14/NN	amod||risk-14/NN||1.73-16/CD	number||%-19/NN||95-18/CD	amod||interval-21/NN||%-19/NN	nn||interval-21/NN||confidence-20/NN	dep||risk-14/NN||interval-21/NN	num||.17-24/CD||1.38-2-23/CD	dep||risk-14/NN||.17-24/CD	conj_and||interval-21/NN||.17-24/CD	dep||0.00001-28/CD||p-26/RB	number||0.00001-28/CD||<-27/CD	dep||.17-24/CD||0.00001-28/CD	dep||risk-14/NN||that-31/DT	conj_and||interval-21/NN||that-31/DT	nn||normalization-35/NN||serum-33/NN	nn||normalization-35/NN||alt-34/NN	prep_of||that-31/DT||normalization-35/NN	amod||risk-38/NN||relative-37/JJ	dep||normalization-35/NN||risk-38/NN	dep||risk-38/NN||1.25-40/CD	number||%-43/NN||95-42/CD	amod||interval-45/NN||%-43/NN	nn||interval-45/NN||confidence-44/NN	dep||risk-14/NN||interval-45/NN	num||.49-48/CD||1.06-1-47/CD	appos||interval-45/NN||.49-48/CD	dep||risk-14/NN||p-50/NN	dep||0.009-52/CD||=-51/SYM	rcmod||p-50/NN||0.009-52/CD	det||group-57/NN||the-55/DT	nn||group-57/NN||entecavir-56/NN	prep_in||dna-11/NN||group-57/NN	cop||higher-59/JJR||were-58/VBD	ccomp||showed-3/VBD||higher-59/JJR	prep_than||higher-59/JJR||those-61/DT	det||group-65/NN||the-63/DT	nn||group-65/NN||adefovir-64/NN	prep_in||those-61/DT||group-65/NN	hbv-10||adefovir-64||yes||meta analysis showed that the rate of undetected serum hbv dna (relative risk, 1.73; 95% confidence interval, 1.38-2.17; p < 0.00001) and that of serum alt normalization (relative risk, 1.25; 95% confidence interval, 1.06-1.49; p = 0.009) in the entecavir group were higher than those in the adefovir group.
amod||advances-2/NNS||newer-1/JJR	nsubj||include-3/VBP||advances-2/NNS	ccomp||revolutionized-63/VBD||include-3/VBP	dobj||include-3/VBP||introduction-4/NN	amod||techniques-7/NNS||newer-6/JJR	prep_of||introduction-4/NN||techniques-7/NNS	amod||epidurals-11/NNS||combined-9/VBN	amod||epidurals-11/NNS||spinal-10/JJ	prep_like||techniques-7/NNS||epidurals-11/NNS	amod||epidurals-14/NNS||low-dose-13/JJ	dobj||include-3/VBP||epidurals-14/NNS	conj_and||introduction-4/NN||epidurals-14/NNS	vmod||epidurals-14/NNS||facilitating-15/VBG	dobj||facilitating-15/VBG||ambulation-16/NN	amod||advances-19/NNS||pharmacological-18/JJ	dobj||include-3/VBP||advances-19/NNS	conj_and||introduction-4/NN||advances-19/NNS	prep_like||advances-19/NNS||introduction-21/NN	prep_of||introduction-21/NN||remifentanil-23/NN	amod||analgesia-27/NN||patient-controlled-25/JJ	amod||analgesia-27/NN||intravenous-26/JJ	prep_for||remifentanil-23/NN||analgesia-27/NN	dobj||include-3/VBP||introduction-29/NN	conj_and||introduction-4/NN||introduction-29/NN	amod||anaesthetics-33/NNS||newer-31/JJR	amod||anaesthetics-33/NNS||local-32/JJ	prep_of||introduction-29/NN||anaesthetics-33/NNS	dobj||include-3/VBP||adjuvants-35/NNS	conj_and||introduction-4/NN||adjuvants-35/NNS	prep_like||adjuvants-35/NNS||ropivacaine-37/JJ	prep_like||adjuvants-35/NNS||levobupivacaine-39/JJ	conj_and||ropivacaine-37/JJ||levobupivacaine-39/JJ	prep_like||adjuvants-35/NNS||sufentanil-41/JJ	conj_and||ropivacaine-37/JJ||sufentanil-41/JJ	prep_like||adjuvants-35/NNS||clonidine-43/JJ	conj_and||ropivacaine-37/JJ||clonidine-43/JJ	prep_like||adjuvants-35/NNS||neostigmine-45/JJ	conj_and||ropivacaine-37/JJ||neostigmine-45/JJ	appos||introduction-4/NN||use-47/NN	amod||agents-50/NNS||inhalational-49/JJ	prep_of||use-47/NN||agents-50/NNS	prep_like||agents-50/NNS||sevoflourane-52/NN	amod||analgesia-56/NN||patient-controlled-54/JJ	amod||analgesia-56/NN||inhalational-55/JJ	prep_for||sevoflourane-52/NN||analgesia-56/NN	vmod||analgesia-56/NN||using-57/VBG	amod||vaporizers-59/NNS||special-58/JJ	dobj||using-57/VBG||vaporizers-59/NNS	nsubj||revolutionized-63/VBD||all-61/DT	aux||revolutionized-63/VBD||have-62/VBP	root||ROOT-0/null||revolutionized-63/VBD	det||practice-65/NN||the-64/DT	dobj||revolutionized-63/VBD||practice-65/NN	nn||management-68/NN||pain-67/NN	prep_of||practice-65/NN||management-68/NN	prepc_in||revolutionized-63/VBD||labouring-70/VBG	dobj||labouring-70/VBG||parturients-71/NNS	pain-67||levobupivacaine-39||yes||newer advances include introduction of newer techniques like combined spinal epidurals, low-dose epidurals facilitating ambulation, pharmacological advances like introduction of remifentanil for patient-controlled intravenous analgesia, introduction of newer local anaesthetics and adjuvants like ropivacaine, levobupivacaine, sufentanil, clonidine and neostigmine, use of inhalational agents like sevoflourane for patient-controlled inhalational analgesia using special vaporizers, all have revolutionized the practice of pain management in labouring parturients.
det||report-3/NN||this-2/DT	prep_in||describe-6/VBP||report-3/NN	nsubj||describe-6/VBP||we-5/PRP	root||ROOT-0/null||describe-6/VBP	det||rapid-8/JJ||a-7/DT	dobj||describe-6/VBP||rapid-8/JJ	amod||nanoparticle-12/NN||simple-10/JJ	nn||nanoparticle-12/NN||gold-11/NN	dobj||describe-6/VBP||nanoparticle-12/NN	conj_and||rapid-8/JJ||nanoparticle-12/NN	appos||rapid-8/JJ||np-14/NN	prep||rapid-8/JJ||based-17/VBN	amod||assay-20/NN||genomic-18/JJ	nn||assay-20/NN||microarray-19/NN	npadvmod||from-30/IN||assay-20/NN	amod||identification-23/NN||specific-22/JJ	prep_for||assay-20/NN||identification-23/NN	amod||h5n1-26/NNS||avianinfluenzavirus-25/JJ	prep_of||identification-23/NN||h5n1-26/NNS	poss||discrimination-29/NN||its-28/PRP$	prep_of||identification-23/NN||discrimination-29/NN	conj_and||h5n1-26/NNS||discrimination-29/NN	pcomp||based-17/VBN||from-30/IN	amod||influenza-33/NN||other-31/JJ	amod||influenza-33/NN||major-32/JJ	pobj||from-30/IN||influenza-33/NN	det||strains-36/NNS||a-34/DT	nn||strains-36/NNS||virus-35/NN	dep||influenza-33/NN||strains-36/NNS	dep||influenza-33/NN||h1n1-38/NNS	appos||h1n1-38/NNS||h3n2-40/NNS	gold-11||h5n1-26||no_rel||in this report, we describe a rapid and simple gold nanoparticle (np)-based genomic microarray assay for specific identification of avianinfluenzavirus h5n1 and its discrimination from other major influenza a virus strains (h1n1, h3n2).
num||2005-4/CD||2002-2/CD	dep||2005-4/CD||to-3/TO	prep_from||identified-9/VBD||2005-4/CD	num||reviews-8/NNS||two-6/CD	nn||reviews-8/NNS||literature-7/NN	appos||2005-4/CD||reviews-8/NNS	root||ROOT-0/null||identified-9/VBD	det||number-11/NN||a-10/DT	dobj||identified-9/VBD||number-11/NN	nsubj||appeared-16/VBD||number-11/NN	nsubj||neglected-20/JJ||number-11/NN	amod||issues-14/NNS||reproductive-health-13/JJ	prep_of||number-11/NN||issues-14/NNS	rcmod||number-11/NN||appeared-16/VBD	aux||neglected-20/JJ||to-17/TO	cop||neglected-20/JJ||be-18/VB	advmod||neglected-20/JJ||relatively-19/RB	xcomp||appeared-16/VBD||neglected-20/JJ	prep_in||neglected-20/JJ||relation-22/NN	amod||information-26/NN||hiv/aids-24/JJ	amod||information-26/NN||contraceptive-25/JJ	prep_to||neglected-20/JJ||information-26/NN	vmod||information-26/NN||tailored-27/VBN	det||needs-30/NNS||the-29/DT	prep_to||tailored-27/VBN||needs-30/NNS	amod||people-33/NNS||hiv-positive-32/JJ	prep_of||needs-30/NNS||people-33/NNS	amod||hiv-36/NN||voluntary-35/JJ	dobj||identified-9/VBD||hiv-36/NN	conj_and||number-11/NN||hiv-36/NN	nsubj||appeared-16/VBD||hiv-36/NN	nsubj||neglected-20/JJ||hiv-36/NN	vmod||hiv-36/NN||counselling-37/VBG	vmod||hiv-36/NN||testing-39/VBG	conj_and||counselling-37/VBG||testing-39/VBG	amod||care-42/NN||antenatal-41/JJ	prep_during||counselling-37/VBG||care-42/NN	prep_during||counselling-37/VBG||labour-44/NN	conj_and||care-42/NN||labour-44/NN	prep_during||counselling-37/VBG||delivery-47/NN	conj_and||care-42/NN||delivery-47/NN	nn||options-50/NNS||parenting-49/NN	dobj||identified-9/VBD||options-50/NNS	conj_and||number-11/NN||options-50/NNS	nsubj||appeared-16/VBD||options-50/NNS	nsubj||neglected-20/JJ||options-50/NNS	amod||people-53/NNS||hiv-positive-52/JJ	prep_for||options-50/NNS||people-53/NNS	dep||conception-62/NN||pregnancy-55/NNP	amod||-lrb--59/NNS||unprotected-57/JJ	nn||-lrb--59/NNS||intercourse-58/NN	prep_through||pregnancy-55/NNP||-lrb--59/NNS	advmod||assisted-61/VBN||i.e.-60/RB	amod||conception-62/NN||assisted-61/VBN	prep_besides||people-53/NNS||conception-62/NN	amod||adoption-65/NN||legal-64/JJ	dobj||identified-9/VBD||adoption-65/NN	conj_and||number-11/NN||adoption-65/NN	nsubj||appeared-16/VBD||adoption-65/NN	nsubj||neglected-20/JJ||adoption-65/NN	amod||care-68/NN||foster-67/JJ	conj_and||number-11/NN||care-68/NN	conj_or||adoption-65/NN||care-68/NN	nsubj||identified-9/VBD||-rrb--69/NNP	amod||pregnancy-72/NN||unwanted-71/JJ	nsubj||identified-9/VBD||pregnancy-72/NN	conj_and||-rrb--69/NNP||pregnancy-72/NN	amod||care-76/NN||abortion-related-75/JJ	nsubj||identified-9/VBD||care-76/NN	conj_and||-rrb--69/NNP||care-76/NN	aids--1||hiv-36||no||from 2002 to 2005 , two literature reviews identified a number of reproductive-health issues that appeared to be relatively neglected in relation to hiv/aids contraceptive information tailored to the needs of hiv-positive people ; voluntary hiv counselling and testing during antenatal care , labour , and delivery ; parenting options for hiv-positive people besides pregnancy through unprotected intercourse -lrb- i.e. assisted conception and legal adoption or foster care -rrb- ; unwanted pregnancy ; and abortion-related care .
dep||duration-3/NN||neither-1/CC	det||duration-3/NN||the-2/DT	nsubj||showed-13/VBD||duration-3/NN	nn||instillation-10/NN||ventriculostomy-5/NN	prep_of||duration-3/NN||revision-7/NN	conj_or||instillation-10/NN||revision-7/NN	prep_of||duration-3/NN||urokinase-9/JJ	amod||instillation-10/NN||urokinase-9/JJ	conj_or||instillation-10/NN||urokinase-9/JJ	prep_of||duration-3/NN||instillation-10/NN	prep_of||duration-3/NN||haemorrhage-12/NN	conj_or||instillation-10/NN||haemorrhage-12/NN	root||ROOT-0/null||showed-13/VBD	dobj||showed-13/VBD||significance-14/NN	det||rate-17/NN||the-16/DT	prep_in||showed-13/VBD||rate-17/NN	amod||infection-20/NN||ventriculostomy-related-19/JJ	prep_of||rate-17/NN||infection-20/NN	haemorrhage-12||urokinase-9||no||neither the duration of ventriculostomy, revision, urokinase instillation or haemorrhage showed significance in the rate of ventriculostomy-related infection.
det||study-3/NN||this-2/DT	prep_in||sought-6/VBD||study-3/NN	nsubj||sought-6/VBD||we-5/PRP	nsubj||examine-8/VB||we-5/PRP	root||ROOT-0/null||sought-6/VBD	aux||examine-8/VB||to-7/TO	xcomp||sought-6/VBD||examine-8/VB	dobj||examine-8/VB||associations-9/NNS	auxpass||designated-12/VBN||being-11/VBG	prepc_between||associations-9/NNS||designated-12/VBN	det||country-17/NN||a-14/DT	nn||country-17/NN||pepfar-15/NN	nn||country-17/NN||focus-16/NN	prep_as||designated-12/VBN||country-17/NN	cc||receiving-20/VBG||and-19/CC	dep||examine-8/VB||receiving-20/VBG	amod||funding-23/NN||increased-21/JJ	nn||funding-23/NN||pepfar-22/NN	dobj||receiving-20/VBG||funding-23/NN	amod||outcomes-28/NNS||non-hiv-specific-26/JJ	nn||outcomes-28/NNS||health-27/NN	xcomp||sought-6/VBD||outcomes-28/NNS	conj_and||examine-8/VB||outcomes-28/NNS	det||region-38/NN||the-30/DT	nn||organization-33/NN||world-31/NN	nn||organization-33/NN||health-32/NN	nn||region-38/NN||organization-33/NN	dep||organization-33/NN||who-35/WP	nn||region-38/NN||africa-37/NN	prep_in||outcomes-28/NNS||region-38/NN	det||area-41/NN||the-40/DT	appos||region-38/NN||area-41/NN	advmod||affected-43/VBN||most-42/RBS	vmod||area-41/NN||affected-43/VBN	det||epidemic-47/NN||the-45/DT	amod||epidemic-47/NN||hiv/aids-46/JJ	agent||affected-43/VBN||epidemic-47/NN	aids--1||hiv--1||no||in this study, we sought to examine associations between being designated as a pepfar focus country (and receiving increased pepfar funding) and non-hiv-specific health outcomes in the world health organization (who) africa region, the area most affected by the hiv/aids epidemic.
advmod||studied-144/VBN||therefore-1/RB	mark||gain-6/VB||in-3/IN	dep||gain-6/VB||order-4/NN	aux||gain-6/VB||to-5/TO	advcl||studied-144/VBN||gain-6/VB	amod||knowledge-8/NN||further-7/JJ	dobj||gain-6/VB||knowledge-8/NN	nn||development-12/NN||fish-10/NN	amod||development-12/NN||larval-11/JJ	prep_of||knowledge-8/NN||development-12/NN	poss||disruption-15/NN||its-14/PRP$	prep_of||knowledge-8/NN||disruption-15/NN	conj_and||development-12/NN||disruption-15/NN	amod||imbalance-19/NN||nutritional-17/JJ	nn||imbalance-19/NN||va-18/NN	prep_by||gain-6/VB||imbalance-19/NN	det||expression-23/NN||the-21/DT	amod||expression-23/NN||relative-22/JJ	nsubjpass||studied-144/VBN||expression-23/NN	det||rars-26/NNS||some-25/DT	prep_of||expression-23/NN||rars-26/NNS	prep_of||expression-23/NN||rxrs-28/NNS	conj_and||rars-26/NNS||rxrs-28/NNS	amod||genes-34/NNS||several-33/JJ	prep_of||expression-23/NN||genes-34/NNS	conj_and||rars-26/NNS||genes-34/NNS	vmod||genes-34/NNS||involved-35/VBN	prep_in||involved-35/VBN||morpho-37/NN	conj_and||rars-26/NNS||skeletogenesis-40/NNS	conj_and||genes-34/NNS||skeletogenesis-40/NNS	amod||receptors-45/NNS||peroxisome-43/JJ	amod||receptors-45/NNS||proliferator-activated-44/JJ	prep_such_as||skeletogenesis-40/NNS||receptors-45/NNS	dep||receptors-45/NNS||ppara-47/NN	appos||ppara-47/NN||pparb-49/NN	appos||ppara-47/NN||pparg-51/NN	conj_and||pparb-49/NN||pparg-51/NN	amod||protein-55/NN||retinol-binding-54/JJ	dep||skeletogenesis-40/NNS||protein-55/NN	appos||protein-55/NN||rbp-57/NN	amod||factors-62/NNS||insulin-like-60/JJ	nn||factors-62/NNS||growth-61/NN	dep||skeletogenesis-40/NNS||factors-62/NNS	dep||factors-62/NNS||i-63/NN	dep||factors-62/NNS||ii-65/NN	conj_and||i-63/NN||ii-65/NN	dep||i-63/NN||igf1-67/NNS	dep||i-63/NN||igf2-69/NNS	conj_and||igf1-67/NNS||igf2-69/NNS	advmod||igf1-67/NNS||respectively-71/RB	nn||protein-76/NN||bone-74/NN	amod||protein-76/NN||morphogenetic-75/JJ	dep||skeletogenesis-40/NNS||protein-76/NN	dep||protein-76/NN||2-77/CD	appos||2-77/CD||bmp2-79/NNP	amod||²-86/NNS||transforming-82/JJ	nn||²-86/NNS||growth-83/NN	nn||²-86/NNS||factor-84/NN	nn||²-86/NNS||î-85/NN	dep||skeletogenesis-40/NNS||²-86/NNS	dep||²-86/NNS||-1-87/CD	appos||-1-87/CD||tgfb1-89/NNP	conj_and||rars-26/NNS||genes-93/NNS	conj_and||genes-34/NNS||genes-93/NNS	vmod||genes-93/NNS||encoding-94/VBG	amod||proteins-101/NNS||different-95/JJ	nn||proteins-101/NNS||extracellular-96/NN	nn||proteins-101/NNS||matrix-97/NN	appos||proteins-101/NNS||ecm-99/NN	dobj||encoding-94/VBG||proteins-101/NNS	nn||protein-106/NN||matrix-104/NN	nn||protein-106/NN||gla-105/NN	prep_such_as||proteins-101/NNS||protein-106/NN	appos||protein-106/NN||mgp-108/NN	prep_such_as||proteins-101/NNS||osteocalcin-111/NN	conj_and||protein-106/NN||osteocalcin-111/NN	appos||osteocalcin-111/NN||bglap-113/NN	prep_such_as||proteins-101/NNS||osteopontin-116/NN	conj_and||protein-106/NN||osteopontin-116/NN	appos||osteopontin-116/NN||spp1-118/NNP	amod||acidic-123/NNS||secreted-121/JJ	nn||acidic-123/NNS||protein-122/NN	prep_such_as||proteins-101/NNS||acidic-123/NNS	conj_and||protein-106/NN||acidic-123/NNS	amod||chain-138/NN||rich-125/JJ	prep_in||rich-125/JJ||cysteine-127/NN	dep||cysteine-127/NN||sparc-129/JJ	nn||î-135/NN||type-132/FW	nn||î-135/NN||i-133/FW	nn||î-135/NN||collagen-134/NN	prep_in||rich-125/JJ||î-135/NN	conj_and||cysteine-127/NN||î-135/NN	number||1-137/CD||±-136/CD	dep||î-135/NN||1-137/CD	prep_such_as||proteins-101/NNS||chain-138/NN	conj_and||protein-106/NN||chain-138/NN	appos||chain-138/NN||col1a1-140/NNP	aux||studied-144/VBN||have-142/VBP	auxpass||studied-144/VBN||been-143/VBN	root||ROOT-0/null||studied-144/VBN	amod||bream-148/NN||gilthead-146/JJ	nn||bream-148/NN||sea-147/NN	prep_in||studied-144/VBN||bream-148/NN	collagen-134||gla-105||no_rel||therefore, in order to gain further knowledge of fish larval development and its disruption by nutritional va imbalance, the relative expression of some rars and rxrs , as well as several genes involved in morpho- and skeletogenesis such as peroxisome proliferator-activated receptors ( ppara , pparb and pparg ); retinol-binding protein ( rbp ); insulin-like growth factors i and ii ( igf1 and igf2 , respectively); bone morphogenetic protein 2 ( bmp2 ); transforming growth factor î²-1 ( tgfb1 ); and genes encoding different extracellular matrix (ecm) proteins such as matrix gla protein ( mgp ), osteocalcin ( bglap ), osteopontin ( spp1 ), secreted protein acidic and rich in cysteine ( sparc ) and type i collagen î±1 chain ( col1a1 ) have been studied in gilthead sea bream.
amod||analyses-5/NNS||case-control-2/JJ	conj_and||case-control-2/JJ||case-series-4/JJ	amod||analyses-5/NNS||case-series-4/JJ	prep_in||examined-8/VBD||analyses-5/NNS	nsubj||examined-8/VBD||we-7/PRP	root||ROOT-0/null||examined-8/VBD	nn||concentrations-10/NNS||serum-9/NN	dobj||examined-8/VBD||concentrations-10/NNS	amod||25ohd-14/NNS||25-hydroxyvitamind-12/JJ	prep_of||concentrations-10/NNS||25ohd-14/NNS	prep_in||25ohd-14/NNS||relation-17/NN	nn||characteristics-22/NNS||breast-19/NN	nn||characteristics-22/NNS||cancer-20/NN	amod||characteristics-22/NNS||prognostic-21/JJ	prep_to||examined-8/VBD||characteristics-22/NNS	amod||grade-26/NN||histologic-25/JJ	prep_including||examined-8/VBD||grade-26/NN	nn||receptor-29/NN||estrogen-28/NN	appos||grade-26/NN||receptor-29/NN	appos||receptor-29/NN||er-31/NN	amod||subtypes-36/NNS||molecular-35/JJ	nsubj||enrolled-67/VBD||subtypes-36/NNS	vmod||subtypes-36/NNS||defined-37/VBN	agent||defined-37/VBN||er-39/NN	amod||pr-44/NN||progesterone-41/JJ	nn||pr-44/NN||receptor-42/NN	agent||defined-37/VBN||pr-44/NN	conj_and||er-39/NN||pr-44/NN	agent||defined-37/VBN||her2-47/NNS	conj_and||er-39/NN||her2-47/NNS	num||women-51/NNS||579-50/CD	prep_among||defined-37/VBN||women-51/NNS	nn||cancer-55/NN||incident-53/NN	nn||cancer-55/NN||breast-54/NN	prep_with||women-51/NNS||cancer-55/NN	num||controls-58/NNS||574-57/CD	prep_among||defined-37/VBN||controls-58/NNS	conj_and||women-51/NNS||controls-58/NNS	vmod||controls-58/NNS||matched-59/VBN	prep_on||matched-59/VBN||age-61/NN	prep_on||matched-59/VBN||time-63/NN	conj_and||age-61/NN||time-63/NN	nn||draw-66/NN||blood-65/NN	prep_of||age-61/NN||draw-66/NN	conj_and||examined-8/VBD||enrolled-67/VBD	det||institute-73/NN||the-69/DT	amod||institute-73/NN||roswell-70/JJ	nn||institute-73/NN||park-71/NN	nn||institute-73/NN||cancer-72/NN	prep_in||enrolled-67/VBD||institute-73/NN	num||2008-77/CD||2003-75/CD	dep||2008-77/CD||to-76/TO	prep_from||enrolled-67/VBD||2008-77/CD	cancer-72||estrogen-28||no_rel||in case-control and case-series analyses, we examined serum concentrations of 25-hydroxyvitamind (25ohd) in relation to breast cancer prognostic characteristics, including histologic grade, estrogen receptor (er), and molecular subtypes defined by er, progesterone receptor (pr) and her2, among 579 women with incident breast cancer and 574 controls matched on age and time of blood draw enrolled in the roswell park cancer institute from 2003 to 2008.
root||ROOT-0/null||asbestos-1/NN	conj_or||asbestos-1/NN||asbestos-1/NN	amod||diseases-3/NNS||related-2/JJ	nsubj||include-4/VBP||diseases-3/NNS	rcmod||asbestos-1/NN||include-4/VBP	det||number-6/NN||a-5/DT	dobj||include-4/VBP||number-6/NN	prep_of||number-6/NN||conditions-8/NNS	prep_due_to||asbestos-1/NN||inhalation-11/NN	prep_of||inhalation-11/NN||asbestosfibres-13/NNS	prep_at||asbestosfibres-13/NNS||work-15/NN	prep_at||asbestos-1/NN||home-18/NN	det||environment-22/NN||the-21/DT	prep_in||asbestos-1/NN||environment-22/NN	amod||mesothelioma-27/NN||pleural-26/JJ	prep_such_as||asbestos-1/NN||mesothelioma-27/NN	prep_such_as||asbestos-1/NN||asbestosis-29/NNS	conj_and||mesothelioma-27/NN||asbestosis-29/NNS	amod||plaques-33/NNS||calcified-31/JJ	amod||plaques-33/NNS||pleural-32/JJ	prep_such_as||asbestos-1/NN||plaques-33/NNS	conj_and||mesothelioma-27/NN||plaques-33/NNS	asbestosis-29||asbestosfibres-13||no||asbestos related diseases include a number of conditions due to inhalation of asbestosfibres at work, at home or in the environment, such as pleural mesothelioma, asbestosis and calcified pleural plaques.
amod||deficits-3/NNS||declarative-1/JJ	nn||deficits-3/NNS||memory-2/NN	nsubj||common-5/JJ||deficits-3/NNS	cop||common-5/JJ||are-4/VBP	root||ROOT-0/null||common-5/JJ	amod||adults-8/NNS||untreated-7/JJ	prep_in||common-5/JJ||adults-8/NNS	prep_with||adults-8/NNS||attention-deficithyperactivitydisorder-10/NN	dep||adults-8/NNS||adhd-12/VBN	amod||evidence-17/NN||limited-16/JJ	nsubj||exists-18/VBZ||evidence-17/NN	nsubj||support-20/VB||evidence-17/NN	conj_but||common-5/JJ||exists-18/VBZ	aux||support-20/VB||to-19/TO	xcomp||exists-18/VBZ||support-20/VB	dobj||support-20/VB||improvement-21/NN	prep_after||support-20/VB||treatment-23/NN	prep_with||treatment-23/NN||methylphenidate-25/NN	attention-deficithyperactivitydisorder-10||methylphenidate-25||yes||declarative memory deficits are common in untreated adults with attention-deficithyperactivitydisorder (adhd), but limited evidence exists to support improvement after treatment with methylphenidate.
det||effect-4/NN||the-1/DT	amod||effect-4/NN||main-2/JJ	amod||effect-4/NN||biological-3/JJ	nsubj||is-8/VBZ||effect-4/NN	det||substitutions-7/NNS||these-6/DT	prep_of||effect-4/NN||substitutions-7/NNS	root||ROOT-0/null||is-8/VBZ	aux||attenuate-10/VB||to-9/TO	ccomp||is-8/VBZ||attenuate-10/VB	det||consequences-12/NNS||the-11/DT	dobj||attenuate-10/VB||consequences-12/NNS	det||activity-16/NN||the-14/DT	amod||activity-16/NN||mutagenic-15/JJ	prep_of||consequences-12/NNS||activity-16/NN	nn||$-20/NNP||ribavirin-18/NNP	nn||$-20/NNP||â-19/FW	prep_of||activity-16/NN||$-20/NNP	prepc_by||attenuate-10/VB||avoiding-23/VBG	det||repertoire-26/NN||the-24/DT	amod||repertoire-26/NN||biased-25/JJ	dobj||avoiding-23/VBG||repertoire-26/NN	nn||mutations-29/NNS||transition-28/NN	prep_of||repertoire-26/NN||mutations-29/NNS	vmod||mutations-29/NNS||produced-30/VBN	det||$-35/NN||this-32/DT	amod||$-35/NN||purine-33/JJ	amod||$-35/NN||analogueâ-34/JJ	agent||produced-30/VBN||$-35/NN	aux||maintain-39/VB||to-38/TO	ccomp||is-8/VBZ||maintain-39/VB	conj_and||attenuate-10/VB||maintain-39/VB	det||fitness-42/NN||the-40/DT	amod||fitness-42/NN||replicative-41/JJ	dobj||maintain-39/VB||fitness-42/NN	det||virus-45/NN||the-44/DT	prep_of||fitness-42/NN||virus-45/NN	nsubj||able-48/JJ||virus-45/NN	nsubj||escape-50/VB||virus-45/NN	cop||able-48/JJ||is-47/VBZ	rcmod||virus-45/NN||able-48/JJ	aux||escape-50/VB||to-49/TO	xcomp||able-48/JJ||escape-50/VB	dobj||escape-50/VB||extinction-51/NN	prep_by||escape-50/VB||ribavirin-53/NNP	virus-45||ribavirin-53||yes||the main biological effect of these substitutions is to attenuate the consequences of the mutagenic activity of ribavirin â€”by avoiding the biased repertoire of transition mutations produced by this purine analogueâ€”and to maintain the replicative fitness of the virus which is able to escape extinction by ribavirin.
nn||loads-3/NNS||ebv-1/NN	nn||loads-3/NNS||dna-2/NN	nsubj||ã-8/NN||loads-3/NNS	cop||ã-8/NN||were-4/VBD	amod||ã-8/NN||detectable-5/JJ	prep_from||detectable-5/JJ||8.0-7/CD	root||ROOT-0/null||ã-8/NN	number||1.3-12/CD||102-10/CD	dep||1.3-12/CD||to-11/TO	num||ã-13/NN||1.3-12/CD	dep||ã-8/NN||ã-13/NN	num||copies/ml-16/NN||108-15/CD	conj_and||ã-8/NN||copies/ml-16/NN	amod||disease-20/NN||post-transplant-18/JJ	nn||disease-20/NN||lymphoproliferative-19/NN	prep_in||copies/ml-16/NN||disease-20/NN	dep||ã-8/NN||n-22/VBN	dep||5-24/CD||=-23/SYM	ccomp||n-22/VBN||5-24/CD	num||ã-28/NN||1.5-27/CD	conj_and||ã-8/NN||ã-28/NN	number||2.0-32/CD||103-30/CD	dep||2.0-32/CD||to-31/TO	num||ã-33/NN||2.0-32/CD	dep||ã-28/NN||ã-33/NN	num||copies/ml-36/NN||105-35/CD	conj_and||ã-8/NN||copies/ml-36/NN	prep_in||copies/ml-36/NN||infectiousmononucleosis-38/NNS	dep||ã-8/NN||n-40/VBN	dep||7-42/CD||=-41/SYM	ccomp||n-40/VBN||7-42/CD	num||ã-46/NN||7.5-45/CD	conj_and||ã-8/NN||ã-46/NN	number||1.1-50/CD||104-48/CD	dep||1.1-50/CD||to-49/TO	num||ã-51/NN||1.1-50/CD	dep||ã-46/NN||ã-51/NN	num||copies/ml-54/NN||105-53/CD	conj_and||ã-8/NN||copies/ml-54/NN	amod||syndrome-58/NN||ebv-associated-56/JJ	amod||syndrome-58/NN||haemophagocytic-57/JJ	prep_in||copies/ml-54/NN||syndrome-58/NN	dep||ã-8/NN||n-60/VBN	dep||1-62/CD||=-61/SYM	ccomp||n-60/VBN||1-62/CD	number||ã-66/CD||2.0-65/CD	conj_and||ã-8/NN||ã-66/CD	number||5.6-70/CD||102-68/CD	dep||5.6-70/CD||to-69/TO	dep||ã-66/CD||5.6-70/CD	dep||5.6-70/CD||ã-71/NN	num||copies/ml-74/NN||103-73/CD	conj_and||ã-8/NN||copies/ml-74/NN	amod||patients-77/NNS||hiv-infected-76/JJ	prep_in||copies/ml-74/NN||patients-77/NNS	dep||ã-8/NN||n-79/VBN	dep||12-81/CD||=-80/SYM	ccomp||n-79/VBN||12-81/CD	number||ã-86/CD||2.0-85/CD	conj_and||ã-8/NN||ã-86/CD	number||9.1-90/CD||102-88/CD	dep||9.1-90/CD||to-89/TO	num||ã-91/NNS||9.1-90/CD	dep||ã-86/CD||ã-91/NNS	number||copies/ml-94/JJ||104-93/CD	amod||ã-86/CD||copies/ml-94/JJ	det||sample-98/NN||the-96/DT	nn||sample-98/NN||population-97/NN	prep_in||ã-86/CD||sample-98/NN	dep||ã-86/CD||n-100/VBN	dep||218-102/CD||=-101/SYM	ccomp||n-100/VBN||218-102/CD	infectiousmononucleosis-38||ebv-1||no||ebv dna loads were detectable from 8.0 ã— 102 to 1.3 ã— 108 copies/ml in post-transplant lymphoproliferative disease (n = 5), 1.5 ã— 103 to 2.0 ã— 105 copies/ml in infectiousmononucleosis (n = 7), 7.5 ã— 104 to 1.1 ã— 105 copies/ml in ebv-associated haemophagocytic syndrome (n = 1), 2.0 ã— 102 to 5.6 ã— 103 copies/ml in hiv-infected patients (n = 12), and 2.0 ã— 102 to 9.1 ã— 104 copies/ml in the population sample (n = 218).
amod||pertussis-2/NN||diphtheria-tetanus-whole-cell-1/JJ	root||ROOT-0/null||pertussis-2/NN	appos||pertussis-2/NN||dtpw-4/NN	vmod||pertussis-2/NN||based-7/VBN	nn||vaccines-9/NNS||combination-8/NN	nsubj||option-13/NN||vaccines-9/NNS	cop||option-13/NN||are-10/VBP	det||option-13/NN||an-11/DT	amod||option-13/NN||attractive-12/JJ	ccomp||based-7/VBN||option-13/NN	aux||achieve-16/VB||to-14/TO	advmod||achieve-16/VB||rapidly-15/RB	vmod||option-13/NN||achieve-16/VB	amod||coverage-18/NN||high-17/JJ	dobj||achieve-16/VB||coverage-18/NN	dobj||achieve-16/VB||protection-20/NN	conj_and||coverage-18/NN||protection-20/NN	amod||pathogens-24/NNS||other-22/JJ	amod||pathogens-24/NNS||important-23/JJ	prep_against||achieve-16/VB||pathogens-24/NNS	prep_such_as||pertussis-2/NN||hepatitisbvirus-28/NNS	appos||hepatitisbvirus-28/NNS||hbv-30/NN	amod||type-35/NN||haemophilus-33/JJ	nn||type-35/NN||influenzae-34/NN	prep_such_as||pertussis-2/NN||type-35/NN	conj_and||hepatitisbvirus-28/NNS||type-35/NN	dep||type-35/NN||b-36/SYM	appos||b-36/SYM||hib-38/NN	hbv-30||hepatitisbvirus-28||no||diphtheria-tetanus-whole-cell pertussis (dtpw)-based combination vaccines are an attractive option to rapidly achieve high coverage and protection against other important pathogens, such as hepatitisbvirus (hbv) and haemophilus influenzae type b (hib).
amod||diagnosed-10/NN||anonymized-2/JJ	amod||diagnosed-10/NN||linkage-3/JJ	det||survey-6/NN||the-5/DT	prep_with||linkage-3/JJ||survey-6/NN	amod||hivinfections-9/NNS||prevalent-8/JJ	prep_of||survey-6/NN||hivinfections-9/NNS	prep_through||categorized-35/VBN||diagnosed-10/NN	nn||scotland-14/NN||health-12/NN	nn||scotland-14/NN||protection-13/NN	conj_and||diagnosed-10/NN||scotland-14/NN	prep_through||categorized-35/VBN||scotland-14/NN	amod||databases-17/NNS||national-16/JJ	appos||diagnosed-10/NN||databases-17/NNS	det||patients-21/NNS||all-19/DT	nn||patients-21/NNS||hiv-20/NN	prep_of||databases-17/NNS||patients-21/NNS	prep_in||patients-21/NNS||care-23/NN	det||uk-26/NN||the-25/DT	prep_in||care-23/NN||uk-26/NN	advmod||uk-26/NN||up-27/RB	prep_to||up-27/RB||december-29/NNP	num||december-29/NNP||2006-30/CD	amod||patients-33/NNS||loss-to-follow-up-32/JJ	nsubjpass||categorized-35/VBN||patients-33/NNS	auxpass||categorized-35/VBN||were-34/VBD	root||ROOT-0/null||categorized-35/VBN	prep_as||categorized-35/VBN||transfers-37/NNS	advmod||received-40/VBN||subsequently-39/RB	dep||transfers-37/NNS||received-40/VBN	dobj||received-40/VBN||care-41/NN	det||clinic-46/NN||another-43/DT	nn||clinic-46/NN||uk-44/NN	nn||clinic-46/NN||hiv-45/NN	prep_at||received-40/VBN||clinic-46/NN	prep_as||categorized-35/VBN||uklfu-49/VBG	conj_or||transfers-37/NNS||uklfu-49/VBG	neg||record-52/NN||no-51/DT	dep||uklfu-49/VBG||record-52/NN	amod||attendance-55/NN||subsequent-54/JJ	prep_of||record-52/NN||attendance-55/NN	det||clinic-59/NN||any-57/DT	nn||clinic-59/NN||hiv-58/NN	prep_at||attendance-55/NN||clinic-59/NN	det||uk-62/NN||the-61/DT	prep_in||clinic-59/NN||uk-62/NN	hivinfections-9||hiv-58||no||through anonymized linkage with the survey of prevalent hivinfections diagnosed and health protection scotland, national databases of all hiv patients in care in the uk up to december 2006, loss-to-follow-up patients were categorized as transfers (subsequently received care at another uk hiv clinic) or uklfu (no record of subsequent attendance at any hiv clinic in the uk).
nn||scores-2/NNS||pain-1/NN	nsubjpass||collected-14/VBN||scores-2/NNS	nsubjpass||collected-14/VBN||scores-2/NNS	det||esas-5/NNS||the-4/DT	prep_from||scores-2/NNS||esas-5/NNS	prep_from||scores-2/NNS||bpi-7/NN	conj_and||esas-5/NNS||bpi-7/NN	prep_from||scores-2/NNS||data-9/NNS	conj_and||esas-5/NNS||data-9/NNS	amod||consumption-12/NN||analgesic-11/JJ	prep_on||scores-2/NNS||consumption-12/NN	auxpass||collected-14/VBN||were-13/VBD	root||ROOT-0/null||collected-14/VBN	conj_and||collected-14/VBN||collected-14/VBN	prep_at||collected-14/VBN||baseline-16/NN	nn||follow-up-20/NN||telephone-19/NN	agent||collected-14/VBN||follow-up-20/NN	prep_at||collected-14/VBN||4-22/CD	prep_at||collected-14/VBN||8-24/CD	conj_and||4-22/CD||8-24/CD	num||weeks-28/NNS||12-27/CD	prep_at||collected-14/VBN||weeks-28/NNS	conj_and||4-22/CD||weeks-28/NNS	prep_after||collected-14/VBN||rt-30/NN	det||patients-33/NNS||all-32/DT	prep_for||rt-30/NN||patients-33/NNS	pain-1||analgesic-11||no_rel||pain scores from the esas and bpi and data on analgesic consumption were collected at baseline and by telephone follow-up at 4, 8, and 12 weeks after rt for all patients.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	dobj||evaluate-2/VB||barriers-3/NNS	vmod||barriers-3/NNS||preventing-4/VBG	amod||women-6/NNS||pregnant-5/JJ	dobj||preventing-4/VBG||women-6/NNS	prepc_from||preventing-4/VBG||using-8/VBG	amod||nets-10/NNS||insecticide-treated-9/JJ	dobj||using-8/VBG||nets-10/NNS	appos||nets-10/NNS||itn-12/NN	amod||treatment-17/NN||intermittent-15/JJ	nn||treatment-17/NN||presumptive-16/NN	nsubj||promoting-36/VBG||treatment-17/NN	appos||treatment-17/NN||ipt-19/NN	amod||sp-24/NN||sulphadoxine-pyrimethamine-22/JJ	prep_with||treatment-17/NN||sp-24/NN	num||years-27/NNS||5-26/CD	dep||sp-24/NN||years-27/NNS	det||launch-30/NN||the-29/DT	prep_after||sp-24/NN||launch-30/NN	det||strategy-35/NN||the-32/DT	amod||strategy-35/NN||national-33/JJ	nn||strategy-35/NN||malaria-34/NN	prep_of||launch-30/NN||strategy-35/NN	conj_and||evaluate-2/VB||promoting-36/VBG	det||measures-38/NNS||these-37/DT	dobj||promoting-36/VBG||measures-38/NNS	prep_in||promoting-36/VBG||kenya-40/NN	malaria-34||pyrimethamine--1||yes||to evaluate barriers preventing pregnant women from using insecticide-treated nets (itn) and intermittent presumptive treatment (ipt) with sulphadoxine-pyrimethamine (sp) 5 years after the launch of the national malaria strategy promoting these measures in kenya.
prep_on||was-5/VBD||examination-2/NN	expl||was-5/VBD||there-4/EX	root||ROOT-0/null||was-5/VBD	amod||papilledema-7/NN||bilateral-6/JJ	nsubj||was-5/VBD||papilledema-7/NN	amod||intracranialhypertension-10/NN||mild-9/JJ	prep_with||papilledema-7/NN||intracranialhypertension-10/NN	neg||deficits-15/NNS||no-13/DT	amod||deficits-15/NNS||neurological-14/JJ	prep_with||papilledema-7/NN||deficits-15/NNS	conj_but||intracranialhypertension-10/NN||deficits-15/NNS	papilledema-7||intracranialhypertension-10||no||on examination, there was bilateral papilledema with mild intracranialhypertension but with no neurological deficits.
nsubjpass||infected-3/VBN||chickens-1/NNS	auxpass||infected-3/VBN||were-2/VBD	root||ROOT-0/null||infected-3/VBN	prep_with||infected-3/VBN||viruses-5/NNS	vmod||viruses-5/NNS||reconstituted-6/VBN	det||clones-10/NNS||the-8/DT	amod||clones-10/NNS||pc12/130-9/JJ	prep_from||reconstituted-6/VBN||clones-10/NNS	det||virus-15/NN||the-13/DT	amod||virus-15/NN||wild-type-14/JJ	prep_along_with||clones-10/NNS||virus-15/NN	det||comparison-18/NN||the-17/DT	prep_for||virus-15/NN||comparison-18/NN	det||properties-22/NNS||the-20/DT	amod||properties-22/NNS||pathogenic-21/JJ	prep_of||comparison-18/NN||properties-22/NNS	virus-15||viruses-5||no||chickens were infected with viruses reconstituted from the pc12/130 clones along with the wild-type virus for the comparison of the pathogenic properties.
aux||test-2/VB||to-1/TO	csubj||defined-15/VBN||test-2/VB	mark||uniform-12/JJ||whether-3/IN	det||effect-5/NN||the-4/DT	nsubj||uniform-12/JJ||effect-5/NN	prep_of||effect-5/NN||vitamine-7/NN	nn||risk-10/NN||pneumonia-9/NN	prep_on||vitamine-7/NN||risk-10/NN	cop||uniform-12/JJ||is-11/VBZ	ccomp||test-2/VB||uniform-12/JJ	prep_over||uniform-12/JJ||subgroups-14/NNS	root||ROOT-0/null||defined-15/VBN	prep_by||defined-15/VBN||smoking-17/NN	prep_by||defined-15/VBN||exercise-19/NN	conj_and||smoking-17/NN||exercise-19/NN	pneumonia-9||vitamine-7||no_rel||to test whether the effect of vitamine on pneumonia risk is uniform over subgroups defined by smoking and exercise.
amod||prevalence-2/NN||increasing-1/VBG	nsubj||worsening-17/VBG||prevalence-2/NN	nn||resistance-5/NN||inh-4/NN	prep_of||prevalence-2/NN||resistance-5/NN	advmod||resistance-5/NN||especially-7/RB	amod||tb-12/NN||high-9/JJ	nn||tb-12/NN||tuberculosis-10/NNP	nn||tb-12/NN||-lrb--11/NNP	prep_in||especially-7/RB||tb-12/NN	advmod||prevalent-14/JJ||-rrb--13/RB	amod||countries-15/NNS||prevalent-14/JJ	dep||resistance-5/NN||countries-15/NNS	aux||worsening-17/VBG||is-16/VBZ	root||ROOT-0/null||worsening-17/VBG	det||burden-19/NN||the-18/DT	dobj||worsening-17/VBG||burden-19/NN	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||burden-19/NN||programs-23/NNS	mark||noted-30/VBN||since-25/IN	amod||rates-28/NNS||similar-26/JJ	nn||rates-28/NNS||transmission-27/NN	nsubjpass||noted-30/VBN||rates-28/NNS	auxpass||noted-30/VBN||are-29/VBP	advcl||worsening-17/VBG||noted-30/VBN	nn||strains-37/NNS||inh-32/NN	amod||strains-37/NNS||susceptible-33/JJ	conj_and||susceptible-33/JJ||resistant-35/JJ	amod||strains-37/NNS||resistant-35/JJ	nn||strains-37/NNS||m.tuberculosis-36/NN	prep_for||noted-30/VBN||strains-37/NNS	tuberculosis-10||inh-32||yes||increasing prevalence of inh resistance , especially in high tuberculosis -lrb- tb -rrb- prevalent countries is worsening the burden of tb control programs , since similar transmission rates are noted for inh susceptible and resistant m.tuberculosis strains .
amod||factors-2/NNS||protective-1/JJ	nsubj||knowledge-5/NN||factors-2/NNS	cop||knowledge-5/NN||are-3/VBP	amod||knowledge-5/NN||good-4/JJ	root||ROOT-0/null||knowledge-5/NN	prep_about||knowledge-5/NN||risks-7/NNS	prep_about||knowledge-5/NN||protection-9/NN	conj_and||risks-7/NNS||protection-9/NN	conj_and||knowledge-5/NN||opportunities-12/NNS	aux||talk-14/VB||to-13/TO	vmod||opportunities-12/NNS||talk-14/VB	vmod||opportunities-12/NNS||gather-16/VB	conj_and||talk-14/VB||gather-16/VB	dobj||talk-14/VB||information-17/NN	prep_about||information-17/NN||sexuality-19/NN	prep_about||information-17/NN||hiv/aids-21/NNS	conj_and||sexuality-19/NN||hiv/aids-21/NNS	aids--1||hiv--1||no||protective factors are good knowledge about risks and protection, and opportunities to talk and gather information about sexuality and hiv/aids.
det||ulcer-2/NN||the-1/DT	nsubj||improved-3/VBD||ulcer-2/NN	root||ROOT-0/null||improved-3/VBD	advmod||slightly-5/RB||only-4/RB	dobj||improved-3/VBD||slightly-5/RB	num||months-8/NNS||2-7/CD	prep_after||improved-3/VBD||months-8/NNS	amod||ointment-12/NN||povidone-iodine-10/JJ	nn||ointment-12/NN||sugar-11/NN	prep_with||improved-3/VBD||ointment-12/NN	amod||nausea-16/NN||severe-15/JJ	prep_because_of||ointment-12/NN||nausea-16/NN	prep_because_of||ointment-12/NN||anorexia-18/NN	conj_and||nausea-16/NN||anorexia-18/NN	ulcer-2||povidone-iodine-10||no_rel||the ulcer improved only slightly after 2 months with povidone-iodine sugar ointment because of severe nausea and anorexia.
amod||responses-4/NNS||effective-1/JJ	amod||responses-4/NNS||humoral-2/JJ	amod||responses-4/NNS||immune-3/JJ	nsubjpass||linked-7/VBN||responses-4/NNS	auxpass||linked-7/VBN||are-5/VBP	advmod||linked-7/VBN||intimately-6/RB	root||ROOT-0/null||linked-7/VBN	amod||immunity-10/NN||innate-9/JJ	prep_with||linked-7/VBN||immunity-10/NN	det||interplay-13/NN||the-12/DT	nsubj||area-23/NN||interplay-13/NN	prep_between||interplay-13/NN||retroviruses-15/NNS	nn||immunity-18/NN||innate-17/NN	prep_between||interplay-13/NN||immunity-18/NN	conj_and||retroviruses-15/NNS||immunity-18/NN	cop||area-23/NN||is-19/VBZ	det||area-23/NN||a-20/DT	advmod||expanding-22/JJ||rapidly-21/RB	amod||area-23/NN||expanding-22/JJ	conj_and||linked-7/VBN||area-23/NN	nsubjpass||advanced-29/VBN||area-23/NN	prep_of||area-23/NN||research-25/NN	aux||advanced-29/VBN||has-27/VBZ	auxpass||advanced-29/VBN||been-28/VBN	rcmod||area-23/NN||advanced-29/VBN	advmod||advanced-29/VBN||considerably-30/RB	det||identification-33/NN||the-32/DT	agent||advanced-29/VBN||identification-33/NN	nsubj||provide-39/VBP||identification-33/NN	amod||factors-37/NNS||cellular-35/JJ	nn||factors-37/NNS||restriction-36/NN	prep_of||identification-33/NN||factors-37/NNS	rcmod||identification-33/NN||provide-39/VBP	dobj||provide-39/VBP||barriers-40/NNS	prep_to||provide-39/VBP||retroviralinfection-42/NN	retroviralinfection-42||retroviruses-15||no||effective humoral immune responses are intimately linked with innate immunity and the interplay between retroviruses and innate immunity is a rapidly expanding area of research that has been advanced considerably by the identification of cellular restriction factors that provide barriers to retroviralinfection.
det||report-2/NN||this-1/DT	nsubj||examines-3/VBZ||report-2/NN	nsubj||summarizes-17/VBZ||report-2/NN	root||ROOT-0/null||examines-3/VBZ	det||evidence-5/NN||the-4/DT	dobj||examines-3/VBZ||evidence-5/NN	amod||recommendations-8/NNS||current-7/JJ	prep_behind||evidence-5/NN||recommendations-8/NNS	det||use-11/NN||the-10/DT	prep_for||examines-3/VBZ||use-11/NN	prep_of||use-11/NN||doxycycline-13/NN	prep_for||doxycycline-13/NN||malaria-15/NN	conj_and||examines-3/VBZ||summarizes-17/VBZ	det||literature-20/NN||the-18/DT	amod||literature-20/NN||available-19/JJ	dobj||summarizes-17/VBZ||literature-20/NN	poss||safety-23/NN||its-22/PRP$	prep_on||summarizes-17/VBZ||safety-23/NN	prep_on||summarizes-17/VBZ||tolerability-25/NN	conj_and||safety-23/NN||tolerability-25/NN	malaria-15||doxycycline-13||yes||this report examines the evidence behind current recommendations for the use of doxycycline for malaria and summarizes the available literature on its safety and tolerability.
nsubj||is-9/VBZ||epratuzumab-1/NN	det||antibody-7/NN||a-3/DT	amod||antibody-7/NN||humanized-4/JJ	amod||antibody-7/NN||anti-cd22-5/JJ	nn||antibody-7/NN||monoclonal-6/NN	appos||epratuzumab-1/NN||antibody-7/NN	root||ROOT-0/null||is-9/VBZ	prep_under||is-9/VBZ||investigation-11/NN	det||antibody-15/NN||a-13/DT	amod||antibody-15/NN||therapeutic-14/JJ	prep_as||investigation-11/NN||antibody-15/NN	amod||slymphoma-19/NN||non-hodgkin-17/JJ	prep_in||antibody-15/NN||slymphoma-19/NN	amod||lupuserythematosus-22/NNS||systemic-21/JJ	prep_in||antibody-15/NN||lupuserythematosus-22/NNS	conj_and||slymphoma-19/NN||lupuserythematosus-22/NNS	appos||slymphoma-19/NN||sle-24/NN	poss||mechanism-29/NN||its-28/PRP$	nsubj||remains-34/VBZ||mechanism-29/NN	prep_of||mechanism-29/NN||action-31/NN	prep_on||action-31/NN||b-cells-33/NNS	conj_but||is-9/VBZ||remains-34/VBZ	acomp||remains-34/VBZ||elusive-35/JJ	non-hodgkin'slymphoma--1||antibody-15||no_rel||epratuzumab, a humanized anti-cd22 monoclonal antibody, is under investigation as a therapeutic antibody in non-hodgkin'slymphoma and systemic lupuserythematosus (sle), but its mechanism of action on b-cells remains elusive.
det||course-3/NN||the-1/DT	amod||course-3/NN||clinical-2/JJ	nsubj||unknown-19/JJ||course-3/NN	prep_of||course-3/NN||humanpapillomavirus-5/NNS	appos||humanpapillomavirus-5/NNS||hpv-7/NN	vmod||humanpapillomavirus-5/NNS||associated-9/VBN	prep_with||associated-9/VBN||bowenoidpapulosis-11/NNS	prep_with||associated-9/VBN||condylomaacuminatum-13/NN	conj_and||bowenoidpapulosis-11/NNS||condylomaacuminatum-13/NN	amod||tumors-16/NNS||anogenital-15/JJ	prep_of||bowenoidpapulosis-11/NNS||tumors-16/NNS	cop||unknown-19/JJ||are-17/VBP	advmod||unknown-19/JJ||still-18/RB	root||ROOT-0/null||unknown-19/JJ	condylomaacuminatum-13||humanpapillomavirus-5||no||the clinical course of humanpapillomavirus (hpv) associated with bowenoidpapulosis and condylomaacuminatum of anogenital tumors are still unknown.
advmod||necrosis-11/VBZ||furthermore-1/RB	amod||²-4/NNS||interleukin-1î-3/JJ	nsubj||necrosis-11/VBZ||²-4/NNS	amod||²-7/NN||il-1î-6/JJ	appos||²-4/NNS||²-7/NN	conj_and||²-4/NNS||tumor-10/NN	nsubj||necrosis-11/VBZ||tumor-10/NN	root||ROOT-0/null||necrosis-11/VBZ	advmod||±-13/JJ||factor-î-12/RB	amod||release-27/NN||±-13/JJ	number||±-16/CD||tnf-î-15/CD	dep||±-13/JJ||±-16/CD	neg||interleukin-6-21/JJ||not-20/RB	conj_but||±-13/JJ||interleukin-6-21/JJ	amod||release-27/NN||interleukin-6-21/JJ	conj_but||±-13/JJ||interferon-î-23/JJ	conj_or||interleukin-6-21/JJ||interferon-î-23/JJ	amod||release-27/NN||³-24/JJ	nn||release-27/NN||increase-25/NN	nn||release-27/NN||sepcr-26/NN	dobj||necrosis-11/VBZ||release-27/NN	interferon--1||tumor-10||no_rel||furthermore, interleukin-1î² (il-1î²) and tumor necrosis factor-î± (tnf-î±), but not interleukin-6 or interferon-î³ increase sepcr release.
amod||providers-3/NNS||primary-1/JJ	nn||providers-3/NNS||care-2/NN	nsubj||aware-6/JJ||providers-3/NNS	aux||aware-6/JJ||should-4/MD	cop||aware-6/JJ||be-5/VB	root||ROOT-0/null||aware-6/JJ	num||developments-10/NNS||two-8/CD	amod||developments-10/NNS||new-9/JJ	prep_of||aware-6/JJ||developments-10/NNS	nn||cessation-15/NN||nicotineaddiction-12/NN	conj_and||nicotineaddiction-12/NN||smoking-14/NN	nn||cessation-15/NN||smoking-14/NN	prep_in||developments-10/NNS||cessation-15/NN	dep||emergence-19/NN||1-16/LS	det||emergence-19/NN||the-18/DT	dep||cessation-15/NN||emergence-19/NN	det||system-25/NN||a-21/DT	amod||system-25/NN||novel-22/JJ	nn||system-25/NN||nicotine-23/NN	nn||system-25/NN||delivery-24/NN	prep_of||emergence-19/NN||system-25/NN	vmod||system-25/NN||known-26/VBN	det||cigarette-34/NN||the-28/DT	amod||cigarette-34/NN||electronic-29/JJ	dep||cigarette-34/NN||e-31/JJ	prep_as||known-26/VBN||cigarette-34/NN	dep||reports-40/NNS||2-37/LS	amod||reports-40/NNS||new-39/JJ	dep||cessation-15/NN||reports-40/NNS	conj_and||emergence-19/NN||reports-40/NNS	amod||nicotine-44/NN||residual-42/JJ	amod||nicotine-44/NN||environmental-43/JJ	prep_of||reports-40/NNS||nicotine-44/NN	amod||toxicants-48/NNS||other-46/JJ	nn||toxicants-48/NNS||biopersistent-47/NN	prep_of||reports-40/NNS||toxicants-48/NNS	conj_and||nicotine-44/NN||toxicants-48/NNS	vmod||nicotine-44/NN||found-49/VBN	nn||smoke-52/NN||cigarette-51/NN	prep_in||found-49/VBN||smoke-52/NN	advmod||described-55/VBN||recently-54/RB	vmod||cessation-15/NN||described-55/VBN	nn||$-61/NNS||â-57/NN	amod||$-61/NNS||$-58/$	dep||$-58/$||œthirdhand-59/JJ	nn||$-61/NNS||smokeâ-60/NN	prep_as||described-55/VBN||$-61/NNS	nicotineaddiction-12||nicotine-44||no||primary care providers should be aware of two new developments in nicotineaddiction and smoking cessation 1) the emergence of a novel nicotine delivery system known as the electronic (e-) cigarette; and 2) new reports of residual environmental nicotine and other biopersistent toxicants found in cigarette smoke, recently described as â€œthirdhand smokeâ€?.
advmod||was-3/VBD||also-1/RB	dep||was-3/VBD||notable-2/JJ	root||ROOT-0/null||was-3/VBD	det||role-5/NN||the-4/DT	nsubj||was-3/VBD||role-5/NN	amod||behaviours-8/NNS||risky-7/JJ	prep_of||role-5/NN||behaviours-8/NNS	prep_such_as||behaviours-8/NNS||lack-11/NN	nn||use-14/NN||condom-13/NN	prep_of||lack-11/NN||use-14/NN	det||plwha-17/NN||that-16/DT	prep_of||role-5/NN||plwha-17/NN	conj_and||behaviours-8/NNS||plwha-17/NN	vmod||plwha-17/NN||considered-18/VBN	poss||status-21/NN||their-19/PRP$	nn||status-21/NN||hiv/aids-20/NNS	dobj||considered-18/VBN||status-21/NN	prep_as||considered-18/VBN||secondary-23/JJ	amod||stressors-27/NNS||daily-25/JJ	nn||stressors-27/NNS||life-26/NN	prep_to||secondary-23/JJ||stressors-27/NNS	prep_like||considered-18/VBN||poverty-29/NN	prep_like||considered-18/VBN||unemployment-31/NN	conj_and||poverty-29/NN||unemployment-31/NN	amod||violence-35/NN||gender-based-34/JJ	prep_like||considered-18/VBN||violence-35/NN	conj_and||poverty-29/NN||violence-35/NN	aids--1||hiv--1||no||also notable was the role of risky behaviours such as lack of condom use and that plwha considered their hiv/aids status as secondary to daily life stressors like poverty, unemployment, and gender-based violence.
mark||symptomatic-5/JJ||because-1/IN	nn||chlorosis-3/NNS||foliar-2/NN	nsubj||symptomatic-5/JJ||chlorosis-3/NNS	cop||symptomatic-5/JJ||was-4/VBD	advcl||began-13/VBD||symptomatic-5/JJ	prep_of||symptomatic-5/JJ||irondeficiency-7/NN	num||days-11/NNS||130-10/CD	prep_after||symptomatic-5/JJ||days-11/NNS	nsubj||began-13/VBD||we-12/PRP	nsubj||fertilize-15/VB||we-12/PRP	root||ROOT-0/null||began-13/VBD	aux||fertilize-15/VB||to-14/TO	xcomp||began-13/VBD||fertilize-15/VB	predet||seedlings-20/NNS||half-16/PDT	det||seedlings-20/NNS||the-17/DT	amod||seedlings-20/NNS||e.-18/JJ	nn||seedlings-20/NNS||tetrodonta-19/NN	dobj||fertilize-15/VB||seedlings-20/NNS	amod||soil-23/NN||ambient-22/JJ	prep_in||fertilize-15/VB||soil-23/NN	det||solution-27/NN||an-25/DT	nn||solution-27/NN||iron-26/NN	prep_with||soil-23/NN||solution-27/NN	irondeficiency-7||iron-26||yes||because foliar chlorosis was symptomatic of irondeficiency , after 130 days we began to fertilize half the e. tetrodonta seedlings in ambient soil with an iron solution .
amod||doses-2/NNS||pharmacological-1/JJ	nsubj||improve-5/VB||doses-2/NNS	nsubj||lower-9/VB||doses-2/NNS	nsubj||lead-15/VB||doses-2/NNS	nsubj||weight-17/VB||doses-2/NNS	prep_of||doses-2/NNS||fgf21-4/CD	root||ROOT-0/null||improve-5/VB	nn||tolerance-7/NN||glucose-6/NN	dobj||improve-5/VB||tolerance-7/NN	conj_and||improve-5/VB||lower-9/VB	amod||fattyacids-12/NNS||serum-10/JJ	amod||fattyacids-12/NNS||free-11/JJ	dobj||lower-9/VB||fattyacids-12/NNS	conj_and||improve-5/VB||lead-15/VB	aux||weight-17/VB||to-16/TO	xcomp||lead-15/VB||weight-17/VB	dobj||weight-17/VB||loss-18/NN	amod||mice-21/NNS||obese-20/JJ	prep_in||weight-17/VB||mice-21/NNS	glucose-6||obese-20||no_rel||pharmacological doses of fgf21 improve glucose tolerance, lower serum free fattyacids, and lead to weight loss in obese mice.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||a-3/DT	dobj||report-2/VBP||case-4/NN	amod||male-7/NN||47-yr-old-6/JJ	prep_of||case-4/NN||male-7/NN	vmod||male-7/NN||presented-9/VBN	amod||cancer-13/NN||sigmoid-11/JJ	nn||cancer-13/NN||colon-12/NN	prep_with||presented-9/VBN||cancer-13/NN	amod||liver-16/NN||multiple-15/JJ	prep_with||presented-9/VBN||liver-16/NN	prep_in||was-24/VBD||liver-16/NN	amod||metastases-19/NNS||peritoneal-18/JJ	prep_with||presented-9/VBN||metastases-19/NNS	conj_and||liver-16/NN||metastases-19/NNS	prep_in||was-24/VBD||metastases-19/NNS	expl||was-24/VBD||there-23/EX	rcmod||liver-16/NN||was-24/VBD	det||response-27/NN||a-25/DT	amod||response-27/NN||complete-26/JJ	nsubj||was-24/VBD||response-27/NN	det||cancer-32/NN||the-29/DT	amod||cancer-32/NN||primary-30/JJ	nn||cancer-32/NN||colon-31/NN	prep_for||response-27/NN||cancer-32/NN	prep_after||was-24/VBD||administration-34/NN	amod||chemotherapy-37/NN||preoperative-36/JJ	prep_of||administration-34/NN||chemotherapy-37/NN	vmod||chemotherapy-37/NN||selected-38/VBN	agent||selected-38/VBN||atp-cra-40/NN	atp--1||metastases-19||no_rel||we report a case of 47-yr-old male, presented with sigmoid colon cancer with multiple liver and peritoneal metastases, in which there was a complete response for the primary colon cancer after administration of preoperative chemotherapy selected by atp-cra.
nsubj||caused-10/VBN||yersiniapestis-1/NNS	nsubj||remains-16/VBZ||yersiniapestis-1/NNS	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	appos||yersiniapestis-1/NNS||agent-5/NN	prep_of||agent-5/NN||plague-7/NNP	aux||caused-10/VBN||has-9/VBZ	root||ROOT-0/null||caused-10/VBN	amod||pandemics-12/NNS||several-11/JJ	dobj||caused-10/VBN||pandemics-12/NNS	prep_throughout||caused-10/VBN||history-14/NN	conj_and||caused-10/VBN||remains-16/VBZ	acomp||remains-16/VBZ||endemic-17/JJ	det||populations-21/NNS||the-19/DT	amod||populations-21/NNS||rodent-20/JJ	prep_in||endemic-17/JJ||populations-21/NNS	det||states-26/NNS||the-23/DT	amod||states-26/NNS||western-24/JJ	amod||states-26/NNS||united-25/VBN	prep_of||populations-21/NNS||states-26/NNS	plague-7||yersiniapestis-1||no||yersiniapestis , the causative agent of plague, has caused several pandemics throughout history and remains endemic in the rodent populations of the western united states.
advmod||considered-5/VBN||however-1/RB	nsubjpass||considered-5/VBN||nsaids-3/NNS	nsubj||effective-9/JJ||nsaids-3/NNS	auxpass||considered-5/VBN||are-4/VBP	root||ROOT-0/null||considered-5/VBN	aux||effective-9/JJ||to-6/TO	cop||effective-9/JJ||be-7/VB	advmod||effective-9/JJ||more-8/RBR	xcomp||considered-5/VBN||effective-9/JJ	prep_than||effective-9/JJ||acetaminophen-11/NN	prep_for||effective-9/JJ||relief-13/NN	prep_of||relief-13/NN||pain-15/NN	pain-15||acetaminophen-11||yes||however, nsaids are considered to be more effective than acetaminophen for relief of pain.
num||subjects-4/NNS||one-1/CD	num||subjects-4/NNS||hundred-2/CD	amod||subjects-4/NNS||fifty-one-3/JJ	nsubj||received-8/VBD||subjects-4/NNS	amod||falciparummalaria-7/NN||uncomplicated-6/JJ	prep_with||subjects-4/NNS||falciparummalaria-7/NN	root||ROOT-0/null||received-8/VBD	advmod||observed-10/JJ||directly-9/RB	amod||therapy-11/NN||observed-10/JJ	dobj||received-8/VBD||therapy-11/NN	num||artesunate-15/NN||12-13/CD	amod||artesunate-15/NN||mg/kg-14/VBG	prep_with||received-8/VBD||artesunate-15/NN	num||days-19/NNS||three-18/CD	prep_over||artesunate-15/NN||days-19/NNS	number||mg/kg-23/JJ||25-22/CD	amod||mefloquine-37/NN||mg/kg-23/JJ	amod||mefloquine-37/NN||mefloquine-24/JJ	amod||mefloquine-37/NN||up-26/IN	det||dose-30/NN||a-28/DT	amod||dose-30/NN||maximum-29/JJ	prep_to||up-26/IN||dose-30/NN	num||mg-33/NN||600-32/CD	prep_of||dose-30/NN||mg-33/NN	amod||mefloquine-37/NN||artesunate/1-34/JJ	num||mefloquine-37/NN||,000-35/CD	nn||mefloquine-37/NN||mg-36/NN	prep_with||received-8/VBD||mefloquine-37/NN	conj_and||artesunate-15/NN||mefloquine-37/NN	falciparummalaria-7||mefloquine-37||yes||one hundred fifty-one subjects with uncomplicated falciparummalaria received directly observed therapy with 12 mg/kg artesunate (over three days) and 25 mg/kg mefloquine, up to a maximum dose of 600 mg artesunate/1,000 mg mefloquine.
prep_in||mandated-8/VBD||2006-2/CD	det||agency-7/NN||the-4/DT	nn||agency-7/NN||norwegian-5/NN	nn||agency-7/NN||medicines-6/NNS	nsubj||mandated-8/VBD||agency-7/NN	root||ROOT-0/null||mandated-8/VBD	det||switch-10/NN||a-9/DT	dobj||mandated-8/VBD||switch-10/NN	prep_from||mandated-8/VBD||desloratadine-12/NN	prep_from||mandated-8/VBD||ebastine-14/NN	conj_or||desloratadine-12/NN||ebastine-14/NN	prep_from||mandated-8/VBD||fexofenadine-17/NN	conj_or||desloratadine-12/NN||fexofenadine-17/NN	prep_to||desloratadine-12/NN||cetirizine-19/NN	prep_to||desloratadine-12/NN||loratadine-21/NN	conj_or||cetirizine-19/NN||loratadine-21/NN	prep_in||mandated-8/VBD||patients-23/NNS	amod||rhinitis-26/NNS||allergic-25/JJ	prep_with||patients-23/NNS||rhinitis-26/NNS	appos||rhinitis-26/NNS||ar-28/NN	amod||urticaria-32/NN||chronic-31/JJ	prep_with||patients-23/NNS||urticaria-32/NN	conj_or||rhinitis-26/NNS||urticaria-32/NN	appos||rhinitis-26/NNS||cu-34/NN	urticaria-32||loratadine-21||yes||in 2006, the norwegian medicines agency mandated a switch from desloratadine, ebastine, or fexofenadine to cetirizine or loratadine in patients with allergic rhinitis (ar) or chronic urticaria (cu).
amod||analysis-2/NN||phylogenetic-1/JJ	nsubj||shows-9/VBZ||analysis-2/NN	vmod||analysis-2/NN||using-3/VBG	dobj||using-3/VBG||rdrp-4/NN	amod||viruses-8/NNS||selected-6/VBN	amod||viruses-8/NNS||picorna-like-7/JJ	prep_of||rdrp-4/NN||viruses-8/NNS	root||ROOT-0/null||shows-9/VBZ	det||virus-15/NN||that-10/DT	amod||virus-15/NN||csbv/sbv-11/JJ	conj_and||csbv/sbv-11/JJ||deformed-13/VBN	amod||virus-15/NN||deformed-13/VBN	nn||virus-15/NN||wing-14/NN	nsubj||tend-19/VBP||virus-15/NN	appos||virus-15/NN||dwv-17/NN	ccomp||shows-9/VBZ||tend-19/VBP	prep_to||tend-19/VBP||group-21/NN	advmod||tend-19/VBP||together-22/RB	nsubj||possesses-25/VBZ||which-24/WDT	ccomp||tend-19/VBP||possesses-25/VBZ	det||rna-27/NN||an-26/DT	dobj||possesses-25/VBZ||rna-27/NN	amod||size-30/NN||similar-29/JJ	prep_of||rna-27/NN||size-30/NN	nn||order-33/NN||gene-32/NN	prep_of||rna-27/NN||order-33/NN	conj_and||size-30/NN||order-33/NN	virus-15||viruses-8||no||phylogenetic analysis using rdrp of selected picorna-like viruses shows that csbv/sbv and deformed wing virus (dwv) tend to group together, which possesses an rna of similar size and gene order.
nsubj||has-3/VBZ||enoxaparin-1/NN	nsubjpass||used-23/VBN||enoxaparin-1/NN	advmod||has-3/VBZ||also-2/RB	root||ROOT-0/null||has-3/VBZ	det||body-6/NN||the-4/DT	amod||body-6/NN||largest-5/JJS	dobj||has-3/VBZ||body-6/NN	amod||evidence-9/NN||clinical-8/JJ	prep_of||body-6/NN||evidence-9/NN	vmod||evidence-9/NN||supporting-10/VBG	poss||use-12/NN||its-11/PRP$	dobj||supporting-10/VBG||use-12/NN	det||spectrum-15/NN||the-14/DT	prep_across||supporting-10/VBG||spectrum-15/NN	amod||management-19/NN||venous-17/JJ	nn||management-19/NN||thromboembolism-18/NN	prep_of||spectrum-15/NN||management-19/NN	aux||used-23/VBN||has-21/VBZ	auxpass||used-23/VBN||been-22/VBN	conj_and||has-3/VBZ||used-23/VBN	det||anticoagulant-29/NN||the-25/DT	nn||anticoagulant-29/NN||reference-26/NN	amod||anticoagulant-29/NN||standard-27/JJ	nn||anticoagulant-29/NN||comparator-28/NN	prep_as||used-23/VBN||anticoagulant-29/NN	prep_in||used-23/VBN||trials-31/NNS	amod||anticoagulants-34/NNS||new-33/JJ	prep_of||trials-31/NNS||anticoagulants-34/NNS	thromboembolism-18||enoxaparin-1||yes||enoxaparin also has the largest body of clinical evidence supporting its use across the spectrum of venous thromboembolism management and has been used as the reference standard comparator anticoagulant in trials of new anticoagulants.
amod||treatment-3/NN||adjuvant-2/JJ	prep_after||developed-6/VBD||treatment-3/NN	num||patients-5/NNS||15-4/CD	nsubj||developed-6/VBD||patients-5/NNS	root||ROOT-0/null||developed-6/VBD	dobj||developed-6/VBD||recurrentdisease-7/NN	prep_of||10-9/CD||recurrentdisease-7/NN	nsubj||had-12/VBD||10-9/CD	rcmod||recurrentdisease-7/NN||had-12/VBD	amod||metastases-14/NNS||distant-13/JJ	dobj||had-12/VBD||metastases-14/NNS	adjuvant-2||metastases-14||no_rel||after adjuvant treatment 15 patients developed recurrentdisease, 10 of whom had distant metastases.
det||services-3/NNS||the-1/DT	amod||services-3/NNS||hiv/aids-2/JJ	nsubj||contributed-12/VBN||services-3/NNS	nsubj||lower-14/VB||services-3/NNS	vmod||services-3/NNS||offered-4/VBN	det||centre-9/NN||the-6/DT	amod||centre-9/NN||local-7/JJ	nn||centre-9/NN||health-8/NN	agent||offered-4/VBN||centre-9/NN	aux||contributed-12/VBN||may-10/MD	aux||contributed-12/VBN||have-11/VB	root||ROOT-0/null||contributed-12/VBN	aux||lower-14/VB||to-13/TO	xcomp||contributed-12/VBN||lower-14/VB	amod||mortality-16/NN||relative-15/JJ	dobj||lower-14/VB||mortality-16/NN	det||location-19/NN||that-18/DT	prep_around||lower-14/VB||location-19/NN	aids--1||hiv--1||no||the hiv/aids services offered by the local health centre may have contributed to lower relative mortality around that location.
nsubjpass||stimulated-17/VBN||ams-1/NN	nsubjpass||stimulated-17/VBN||ams-1/NN	vmod||ams-1/NN||obtained-2/VBN	amod||bronchoscopy-5/NN||fiberoptic-4/JJ	agent||obtained-2/VBN||bronchoscopy-5/NN	num||non-asthmatics-8/NNS||14-7/CD	prep_from||obtained-2/VBN||non-asthmatics-8/NNS	num||non-severe-11/NN||12-10/CD	prep_from||obtained-2/VBN||non-severe-11/NN	conj_and||non-asthmatics-8/NNS||non-severe-11/NN	num||asthmatics-15/NNS||11-13/CD	amod||asthmatics-15/NNS||severe-14/JJ	prep_from||obtained-2/VBN||asthmatics-15/NNS	conj_and||non-asthmatics-8/NNS||asthmatics-15/NNS	auxpass||stimulated-17/VBN||were-16/VBD	root||ROOT-0/null||stimulated-17/VBN	conj_or||stimulated-17/VBN||stimulated-17/VBN	prep_with||stimulated-17/VBN||lipopolysaccharide-19/NN	number||,10-22/CD||lps-21/CD	num||1/4-24/CD||,10-22/CD	number||1/4-24/CD||î-23/CD	npadvmod||g/ml-25/JJ||1/4-24/CD	dep||lipopolysaccharide-19/NN||g/ml-25/JJ	prep_with||stimulated-17/VBN||dexamethasone-30/NN	prep_without||stimulated-17/VBN||dexamethasone-30/NN	dep||dexamethasone-30/NN||10-6m-32/JJ	asthmatics-15||dexamethasone-30||yes||ams obtained by fiberoptic bronchoscopy from 14 non-asthmatics, 12 non-severe and 11 severe asthmatics were stimulated with lipopolysaccharide (lps,10 î¼g/ml) with or without dexamethasone (10-6m).
prep_in||give-25/VB||conclusion-2/NN	nsubj||give-25/VB||administration-4/NN	amod||variants-8/NNS||human-6/JJ	nn||variants-8/NNS||apc-7/NN	nsubj||enhanced-10/VBN||variants-8/NNS	aux||enhanced-10/VBN||having-9/VBG	prepc_of||administration-4/NN||enhanced-10/VBN	dobj||enhanced-10/VBN||anticoagulant-11/NN	advmod||enhanced-10/VBN||efficacy-12/RB	amod||ps-16/NN||human-15/JJ	prep_together_with||enhanced-10/VBN||ps-16/NN	det||model-20/NN||a-18/DT	nn||model-20/NN||rat-19/NN	prep_in||enhanced-10/VBN||model-20/NN	prep_of||model-20/NN||arterialthrombosis-22/NNS	aux||give-25/VB||did-23/VBD	neg||give-25/VB||not-24/RB	root||ROOT-0/null||give-25/VB	det||effect-29/NN||an-26/DT	amod||antithrombotic-28/JJ||efficient-27/JJ	amod||effect-29/NN||antithrombotic-28/JJ	dobj||give-25/VB||effect-29/NN	arterialthrombosis-22||anticoagulant-11||no_rel||in conclusion, administration of human apc variants having enhanced anticoagulant efficacy together with human ps in a rat model of arterialthrombosis did not give an efficient antithrombotic effect.
mark||immunization-3/NN||upon-1/IN	nn||immunization-3/NN||rabbit-2/NN	advcl||elicited-8/VBD||immunization-3/NN	det||proteins-7/NNS||both-5/DT	nn||proteins-7/NNS||ha-6/NN	nsubj||elicited-8/VBD||proteins-7/NNS	root||ROOT-0/null||elicited-8/VBD	amod||antibodies-10/NNS||neutralizing-9/VBG	dobj||elicited-8/VBD||antibodies-10/NNS	det||virus-14/NN||the-12/DT	amod||virus-14/NN||homologous-13/JJ	prep_against||antibodies-10/NNS||virus-14/NN	dep||virus-14/NN||a/vietnam/1203-16/NNP	punct||a/vietnam/1203-16/NNP||/-17/:	dep||a/vietnam/1203-16/NNP||2004-18/CD	appos||2004-18/CD||clade-20/NN	num||clade-20/NN||1-21/CD	amod||antibodies-27/NNS||cross-neutralizing-26/JJ	dobj||elicited-8/VBD||antibodies-27/NNS	conj_and||antibodies-10/NNS||antibodies-27/NNS	amod||h5n1-30/NNS||heterologous-29/JJ	prep_against||antibodies-27/NNS||h5n1-30/NNS	amod||h5n1-30/NNS||clade-31/JJ	num||strains-33/NNS||2-32/CD	dep||clade-31/JJ||strains-33/NNS	amod||/-37/NNP||a/indonesia/5-36/JJ	prep_including||h5n1-30/NNS||/-37/NNP	num||/-37/NNP||2005-38/CD	virus-14||antibodies-27||no_rel||upon rabbit immunization, both ha proteins elicited neutralizing antibodies against the homologous virus (a/vietnam/1203/2004, clade 1) as well as cross-neutralizing antibodies against heterologous h5n1 clade 2 strains, including a/indonesia/5/2005.
det||group-3/NN||the-1/DT	nn||group-3/NN||ds-2/NN	nsubj||had-4/VBD||group-3/NN	nsubj||had-35/VBD||group-3/NN	nsubj||required-67/VBD||group-3/NN	root||ROOT-0/null||had-4/VBD	det||rate-8/NN||a-5/DT	advmod||higher-7/JJR||significantly-6/RB	amod||rate-8/NN||higher-7/JJR	dobj||had-4/VBD||rate-8/NN	amod||remission-11/NN||complete-10/JJ	prep_of||rate-8/NN||remission-11/NN	prep_of||remission-11/NN||ponv-13/NNP	det||groups-19/NNS||the-15/DT	nn||groups-19/NNS||d-16/SYM	conj_and||d-16/SYM||dr-18/JJ	nn||groups-19/NNS||dr-18/JJ	prep_than||had-4/VBD||groups-19/NNS	num||%-22/NN||82.5-21/CD	dep||groups-19/NNS||%-22/NN	number||47.5-24/CD||vs-23/CD	num||%-25/NN||47.5-24/CD	dep||%-22/NN||%-25/NN	num||%-29/NN||50.0-28/CD	dep||groups-19/NNS||%-29/NN	conj_and||%-22/NN||%-29/NN	advmod||%-22/NN||respectively-31/RB	conj_and||had-4/VBD||had-35/VBD	amod||rates-37/NNS||lower-36/JJR	dobj||had-35/VBD||rates-37/NNS	prep_of||rates-37/NNS||nausea-39/NN	num||%-42/NN||17.5-41/CD	dep||rates-37/NNS||%-42/NN	vmod||%-42/NN||vs-43/VBN	num||%-45/NN||55.0-44/CD	dobj||vs-43/VBN||%-45/NN	num||%-49/NN||50.0-48/CD	dobj||vs-43/VBN||%-49/NN	conj_and||%-45/NN||%-49/NN	dobj||had-35/VBD||vomiting-53/VBG	conj_and||rates-37/NNS||vomiting-53/VBG	num||vs-57/NN||10.0-55/CD	nn||vs-57/NN||%-56/NN	dep||vomiting-53/VBG||vs-57/NN	num||%-59/NN||50.0-58/CD	dep||vs-57/NN||%-59/NN	num||%-63/NN||25.0-62/CD	dep||vomiting-53/VBG||%-63/NN	conj_and||vs-57/NN||%-63/NN	conj_and||had-4/VBD||required-67/VBD	amod||antiemetics-69/NNS||less-68/JJR	dobj||required-67/VBD||antiemetics-69/NNS	num||%-72/NN||5.0-71/CD	dep||antiemetics-69/NNS||%-72/NN	num||%-75/NN||vs-73/CD	num||%-75/NN||35.0-74/CD	dep||%-72/NN||%-75/NN	num||%-78/NN||22.5-77/CD	appos||%-75/NN||%-78/NN	nn||d-82/NN||group-81/NN	prep_than||required-67/VBD||d-82/NN	nn||dr-85/NN||group-84/NN	prep_than||required-67/VBD||dr-85/NN	conj_and||d-82/NN||dr-85/NN	det||hours-90/NNS||the-87/DT	amod||hours-90/NNS||first-88/JJ	num||hours-90/NNS||24-89/CD	prep_during||d-82/NN||hours-90/NNS	prep_after||required-67/VBD||surgery-92/NN	vomiting-53||ds-2||no||the ds group had a significantly higher rate of complete remission of ponv than the d and dr groups (82.5% vs 47.5%, and 50.0%, respectively), and had lower rates of nausea (17.5% vs 55.0%, and 50.0%), and vomiting (10.0% vs 50.0%, and 25.0%), and required less antiemetics (5.0% vs 35.0%, 22.5%) than group d and group dr during the first 24 hours after surgery.
nsubj||invasion-8/NN||cutaneoustuberculosis-1/NNS	appos||cutaneoustuberculosis-1/NNS||tb-3/NN	cop||invasion-8/NN||is-5/VBZ	advmod||invasion-8/NN||essentially-6/RB	det||invasion-8/NN||an-7/DT	root||ROOT-0/null||invasion-8/NN	det||skin-11/NN||the-10/DT	prep_of||invasion-8/NN||skin-11/NN	prep_by||skin-11/NN||mycobacteriumtuberculosis-13/NNS	det||bacteria-17/NNS||the-15/DT	amod||bacteria-17/NNS||same-16/JJ	appos||mycobacteriumtuberculosis-13/NNS||bacteria-17/NNS	nsubj||causes-19/VBZ||bacteria-17/NNS	rcmod||bacteria-17/NNS||causes-19/VBZ	dobj||causes-19/VBZ||pulmonarytuberculosis-20/NNS	tb-3||mycobacteriumtuberculosis-13||no||cutaneoustuberculosis (tb) is essentially an invasion of the skin by mycobacteriumtuberculosis , the same bacteria that causes pulmonarytuberculosis.
amod||studies-2/NNS||epidemiological-1/JJ	nsubj||validated-5/VBN||studies-2/NNS	aux||validated-5/VBN||have-3/VBP	advmod||validated-5/VBN||clearly-4/RB	root||ROOT-0/null||validated-5/VBN	det||association-7/NN||the-6/DT	dobj||validated-5/VBN||association-7/NN	iobj||validated-5/VBN||association-7/NN	prep_between||association-7/NN||hepatitisbvirus-9/NNS	dep||association-7/NN||hbv-11/VBN	nn||carcinoma-16/NN||infection-13/NN	conj_and||infection-13/NN||hepatocellular-15/NN	nn||carcinoma-16/NN||hepatocellular-15/NN	dep||association-7/NN||carcinoma-16/NN	appos||carcinoma-16/NN||hcc-18/NN	hbv-11||hepatitisbvirus-9||no||epidemiological studies have clearly validated the association between hepatitisbvirus (hbv) infection and hepatocellular carcinoma (hcc).
nsubj||superior-15/JJ||zotarolimus-1/NNS	vmod||zotarolimus-1/NNS||eluting-2/VBG	dobj||eluting-2/VBG||stents-3/NNS	det||stent-9/NN||the-5/DT	amod||stent-9/NN||2nd-6/JJ	nn||stent-9/NN||generation-7/NN	nn||stent-9/NN||drug-eluting-8/NN	prep_as||eluting-2/VBG||stent-9/NN	appos||stent-9/NN||des-11/NNP	cop||superior-15/JJ||was-13/VBD	neg||superior-15/JJ||not-14/RB	root||ROOT-0/null||superior-15/JJ	det||des-20/NNP||the-17/DT	num||des-20/NNP||1st-18/CD	nn||des-20/NNP||generation-19/NN	prep_to||superior-15/JJ||des-20/NNP	prep_in||superior-15/JJ||contrast-23/NN	det||studies-28/NNS||the-25/DT	amod||studies-28/NNS||western-26/JJ	nn||studies-28/NNS||ami-27/NN	prep_to||superior-15/JJ||studies-28/NNS	ami-27||des-20||no_rel||zotarolimus eluting stents as the 2nd generation drug-eluting stent (des) was not superior to the 1st generation des, in contrast to the western ami studies.
det||profile-5/NN||the-1/DT	nn||profile-5/NN||safety-2/NN	conj_and||safety-2/NN||efficacy-4/NN	nn||profile-5/NN||efficacy-4/NN	nsubj||were-15/VBD||profile-5/NN	prep_of||profile-5/NN||caspofungin-7/NN	prep_of||profile-5/NN||micafungin-9/NN	conj_and||caspofungin-7/NN||micafungin-9/NN	amod||patients-12/NNS||japanese-11/JJ	prep_in||caspofungin-7/NN||patients-12/NNS	prep_with||patients-12/NNS||fungalinfections-14/NNS	root||ROOT-0/null||were-15/VBD	advmod||were-15/VBD||directly-16/RB	prep||were-15/VBD||compared-17/VBN	pcomp||compared-17/VBN||in-18/IN	det||study-25/NN||this-19/DT	amod||study-25/NN||prospective-20/JJ	amod||study-25/NN||randomized-22/JJ	amod||study-25/NN||double-blind-24/JJ	pobj||in-18/IN||study-25/NN	fungalinfections-14||micafungin-9||yes||the safety and efficacy profile of caspofungin and micafungin in japanese patients with fungalinfections were directly compared in this prospective, randomized, double-blind study.
nsubj||controlled-4/VBD||treatment-1/NN	prep_with||treatment-1/NN||hydrochlorothiazide-3/NN	root||ROOT-0/null||controlled-4/VBD	poss||hyperkalemia-6/NN||his-5/PRP$	dobj||controlled-4/VBD||hyperkalemia-6/NN	dobj||controlled-4/VBD||hypertension-8/NN	conj_and||hyperkalemia-6/NN||hypertension-8/NN	hypertension-8||hydrochlorothiazide-3||yes||treatment with hydrochlorothiazide controlled his hyperkalemia and hypertension.
det||prionprotein-2/NN||the-1/DT	nsubj||plays-6/VBZ||prionprotein-2/NN	appos||prionprotein-2/NN||prnp/prp-4/NN	root||ROOT-0/null||plays-6/VBZ	det||role-9/NN||a-7/DT	amod||role-9/NN||crucial-8/JJ	dobj||plays-6/VBZ||role-9/NN	prep_in||role-9/NN||transmissiblespongiformencephalopathies-11/NNS	appos||transmissiblespongiformencephalopathies-11/NNS||tses-13/NNS	amod||cjd-18/NN||creutzfeldt-jakobdisease-16/JJ	prep_like||plays-6/VBZ||cjd-18/NN	amod||cjd-18/NN||scrapie-21/JJ	amod||cjd-18/NN||madcowdisease-23/JJ	conj_and||scrapie-21/JJ||madcowdisease-23/JJ	cjd-18||prionprotein-2||no_rel||the prionprotein (prnp/prp) plays a crucial role in transmissiblespongiformencephalopathies (tses) like creutzfeldt-jakobdisease (cjd), scrapie and madcowdisease.
advmod||randomized-51/VBN||overall-1/RB	num||subjects-6/NNS||28-3/CD	amod||subjects-6/NNS||insulin-naive-4/JJ	amod||subjects-6/NNS||type2diabetes-5/JJ	nsubjpass||randomized-51/VBN||subjects-6/NNS	nsubj||add-53/VB||subjects-6/NNS	amod||age-12/NN||mean-8/JJ	nn||age-12/NN||â-9/NN	nn||age-12/NN||±-10/NN	nn||age-12/NN||sd-11/NN	dep||subjects-6/NNS||age-12/NN	num||â-15/NN||61.5-14/CD	appos||age-12/NN||â-15/NN	number||6.7-17/CD||±-16/CD	num||years-18/NNS||6.7-17/CD	dep||â-15/NN||years-18/NNS	nn||duration-21/NN||diabetes-20/NN	dep||â-15/NN||duration-21/NN	num||â-24/NN||9.8-23/CD	appos||duration-21/NN||â-24/NN	number||6.5-26/CD||±-25/CD	num||years-27/NNS||6.5-26/CD	dep||â-24/NN||years-27/NNS	dep||â-15/NN||hba1c-29/NNS	num||±-33/NNS||7.1-31/CD	nn||±-33/NNS||â-32/NN	appos||hba1c-29/NNS||±-33/NNS	number||%-35/NN||0.5-34/CD	amod||±-33/NNS||%-35/NN	dep||â-15/NN||bmi-37/NN	number||â-40/CD||30.7-39/CD	num||kg/m2-43/NNS||â-40/CD	amod||kg/m2-43/NNS||±-41/JJ	num||kg/m2-43/NNS||4.3-42/CD	appos||bmi-37/NN||kg/m2-43/NNS	vmod||subjects-6/NNS||treated-45/VBN	prep_with||treated-45/VBN||metformin-47/NN	prep_with||treated-45/VBN||sulfonylurea-49/NN	conj_and||metformin-47/NN||sulfonylurea-49/NN	auxpass||randomized-51/VBN||were-50/VBD	root||ROOT-0/null||randomized-51/VBN	aux||add-53/VB||to-52/TO	xcomp||randomized-51/VBN||add-53/VB	amod||gla-55/NN||once-daily-54/JJ	dobj||add-53/VB||gla-55/NN	dobj||add-53/VB||nph-57/NN	conj_or||gla-55/NN||nph-57/NN	prep_at||add-53/VB||bedtime-59/NN	type2diabetes-5||insulin--1||yes||overall, 28 insulin-naive type2diabetes subjects (mean â± sd age, 61.5 â± 6.7 years; diabetes duration, 9.8 â± 6.5 years; hba1c, 7.1 â± 0.5%; bmi, 30.7 â± 4.3 kg/m2) treated with metformin and sulfonylurea were randomized to add once-daily gla or nph at bedtime.
det||impairment-3/NN||the-1/DT	nn||impairment-3/NN||growth-2/NN	nsubj||seems-6/VBZ||impairment-3/NN	nsubj||due-9/JJ||impairment-3/NN	prep_in||impairment-3/NN||ts-5/NN	root||ROOT-0/null||seems-6/VBZ	aux||due-9/JJ||to-7/TO	cop||due-9/JJ||be-8/VB	xcomp||seems-6/VBZ||due-9/JJ	amod||factors-12/NNS||multiple-11/JJ	prep_to||due-9/JJ||factors-12/NNS	det||growthhormone-16/NN||an-14/DT	amod||growthhormone-16/NN||abnormal-15/JJ	prep_including||factors-12/NNS||growthhormone-16/NN	discourse||factors-12/NNS||gh-18/UH	det||â-29/NN||â-20/DT	amod||â-29/NN||$-21/JJ	amod||â-29/NN||insulin-like-23/JJ	nn||â-29/NN||growth-24/NN	nn||â-29/NN||factor-25/NN	discourse||â-29/NN||igf-27/UH	dep||factors-12/NNS||â-29/NN	num||axis-35/NNS||$-30/$	num||$-30/$||igf-32/CD	amod||axis-35/NNS||binding-33/JJ	nn||axis-35/NNS||protein-34/NN	dep||factors-12/NNS||axis-35/NNS	prep_to||due-9/JJ||haploinsufficiency-37/NN	conj_and||factors-12/NNS||haploinsufficiency-37/NN	det||gene-42/NN||the-39/DT	amod||gene-42/NN||shortstature-40/JJ	amod||gene-42/NN||homeobox-containing-41/JJ	prep_of||haploinsufficiency-37/NN||gene-42/NN	shortstature-40||growthhormone-16||yes||the growth impairment in ts seems to be due to multiple factors including an abnormal growthhormone (gh) â€“ insulin-like growth factor (igf) â€“ igf binding protein axis and haploinsufficiency of the shortstature homeobox-containing gene.
det||total-2/NN||a-1/DT	nsubjpass||treated-12/VBN||total-2/NN	num||patients-5/NNS||229-4/CD	prep_of||total-2/NN||patients-5/NNS	nn||nsclc-10/NN||stage-7/NN	nn||nsclc-10/NN||iiib/iv-8/NNP	amod||nsclc-10/NN||non-squamous-9/JJ	prep_with||patients-5/NNS||nsclc-10/NN	auxpass||treated-12/VBN||were-11/VBD	root||ROOT-0/null||treated-12/VBN	num||cycles-15/NNS||two-14/CD	prep_with||treated-12/VBN||cycles-15/NNS	prep_of||cycles-15/NNS||carboplatin-17/NN	dep||carboplatin-17/NN||area-19/NN	det||curve-23/NN||the-21/DT	amod||curve-23/NN||concentration-time-22/JJ	prep_under||area-19/NN||curve-23/NN	amod||area-19/NN||5.5-24/CD	amod||mg/m-29/NN||docetaxel-27/JJ	dep||docetaxel-27/JJ||100-28/CD	prep_of||cycles-15/NNS||mg/m-29/NN	conj_and||carboplatin-17/NN||mg/m-29/NN	npadvmod||as-31/RB||2-30/CD	advmod||carboplatin-17/NN||as-31/RB	advmod||treated-12/VBN||chemotherapy-32/RB	nsclc-10||docetaxel-27||yes||a total of 229 patients with stage iiib/iv non-squamous nsclc were treated with two cycles of carboplatin (area under the concentration-time curve 5.5) and docetaxel 100 mg/m 2 as chemotherapy.
nsubj||leads-3/VBZ||gr-1/NN	nsubj||hypertension-5/VB||gr-1/NN	nsubj||hypertension-5/VB||gr-1/NN	advmod||leads-3/VBZ||haploinsufficiency-2/RB	root||ROOT-0/null||leads-3/VBZ	aux||hypertension-5/VB||to-4/TO	xcomp||leads-3/VBZ||hypertension-5/VB	xcomp||leads-3/VBZ||hypertension-5/VB	conj_negcc||hypertension-5/VB||hypertension-5/VB	acomp||hypertension-5/VB||due-6/JJ	amod||occupation-9/NN||illicit-8/JJ	prep_to||due-6/JJ||occupation-9/NN	amod||receptor-13/NN||renal-11/JJ	amod||receptor-13/NN||mineralocorticoid-12/JJ	prep_of||occupation-9/NN||receptor-13/NN	amod||cortisol-16/NN||elevated-15/JJ	prep_by||hypertension-5/VB||cortisol-16/NN	amod||production-22/NN||increased-20/VBN	amod||production-22/NN||mineralocorticoid-21/JJ	prep_to||hypertension-5/VB||production-22/NN	vmod||production-22/NN||reported-23/VBN	amod||resistance-27/NN||primary-25/JJ	amod||resistance-27/NN||glucocorticoid-26/JJ	prep_in||reported-23/VBN||resistance-27/NN	cortisol-16||hypertension-5||no_rel||gr haploinsufficiency leads to hypertension due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.
amod||â-2/NN||objective-1/JJ	nsubj||$-3/VBD||â-2/NN	nsubj||compare-6/VB||â-2/NN	root||ROOT-0/null||$-3/VBD	aux||compare-6/VB||to-5/TO	xcomp||$-3/VBD||compare-6/VB	det||glucose-8/NN||the-7/DT	dobj||compare-6/VB||glucose-8/NN	advmod||associated-10/VBN||variability-9/RB	vmod||glucose-8/NN||associated-10/VBN	amod||insulin-15/NN||insulinglargine-12/JJ	conj_and||insulinglargine-12/JJ||nph/lente-14/JJ	amod||insulin-15/NN||nph/lente-14/JJ	prep_with||associated-10/VBN||insulin-15/NN	vmod||insulin-15/NN||used-16/VBN	det||component-21/NN||the-18/DT	amod||component-21/NN||basal-19/JJ	nn||component-21/NN||insulin-20/NN	prep_as||used-16/VBN||component-21/NN	det||regimen-30/NN||a-23/DT	amod||regimen-30/NN||multiple-24/JJ	amod||regimen-30/NN||daily-25/JJ	nn||regimen-30/NN||injection-26/NN	discourse||regimen-30/NN||mdi-28/UH	prep_of||component-21/NN||regimen-30/NN	amod||patients-33/NNS||pediatric-32/JJ	prep_in||regimen-30/NN||patients-33/NNS	prep_with||$-3/VBD||type1diabetes-35/CD	type1diabetes-35||insulinglargine-12||yes||objective â€”to compare the glucose variability associated with insulinglargine and nph/lente insulin used as the basal insulin component of a multiple daily injection (mdi) regimen in pediatric patients with type1diabetes.
amod||challenges-2/NNS||current-1/JJ	nsubj||include-10/VBP||challenges-2/NNS	det||eradication-6/NN||the-4/DT	amod||eradication-6/NN||final-5/JJ	prep_to||challenges-2/NNS||eradication-6/NN	amod||poliomyelitis-9/NNP||paralytic-8/JJ	prep_of||eradication-6/NN||poliomyelitis-9/NNP	root||ROOT-0/null||include-10/VBP	det||transmission-13/NN||the-11/DT	amod||transmission-13/NN||continued-12/VBN	dobj||include-10/VBP||transmission-13/NN	amod||polioviruses-16/NNS||wild-15/JJ	prep_of||transmission-13/NN||polioviruses-16/NNS	amod||reservoirs-19/NNS||endemic-18/JJ	prep_in||polioviruses-16/NNS||reservoirs-19/NNS	dobj||include-10/VBP||reinfection-21/NN	conj_and||transmission-13/NN||reinfection-21/NN	amod||areas-24/NNS||polio-free-23/JJ	prep_of||reinfection-21/NN||areas-24/NNS	appos||areas-24/NNS||outbreaks-26/NNS	prepc_due_to||outbreaks-26/NNS||circulating-29/VBG	amod||polioviruses-31/NNS||vaccine-derived-30/JJ	dobj||circulating-29/VBG||polioviruses-31/NNS	amod||excretion-35/NN||persistent-34/JJ	dobj||include-10/VBP||excretion-35/NN	conj_and||transmission-13/NN||excretion-35/NN	amod||poliovirus-38/NNS||vaccine-derived-37/JJ	prep_of||excretion-35/NN||poliovirus-38/NNS	det||vaccinees-42/NNS||a-40/DT	amod||vaccinees-42/NNS||few-41/JJ	prep_by||poliovirus-38/NNS||vaccinees-42/NNS	amod||immunodeficiencies-45/NNS||b-cell-44/JJ	prep_with||vaccinees-42/NNS||immunodeficiencies-45/NNS	poliomyelitis-9||poliovirus-38||no||current challenges to the final eradication of paralytic poliomyelitis include the continued transmission of wild polioviruses in endemic reservoirs, reinfection of polio-free areas, outbreaks due to circulating vaccine-derived polioviruses, and persistent excretion of vaccine-derived poliovirus by a few vaccinees with b-cell immunodeficiencies.
amod||analysis-3/NN||bayesian-1/JJ	amod||analysis-3/NN||phylogenetic-2/JJ	nsubj||demonstrated-13/VBD||analysis-3/NN	vmod||analysis-3/NN||using-4/VBG	amod||sequences-8/NNS||partial-5/JJ	nn||sequences-8/NNS||nucleoprotein-6/NN	nn||sequences-8/NNS||gene-7/NN	dobj||using-4/VBG||sequences-8/NNS	vmod||sequences-8/NNS||derived-9/VBN	det||samples-12/NNS||the-11/DT	prep_from||derived-9/VBN||samples-12/NNS	root||ROOT-0/null||demonstrated-13/VBD	det||viruses-15/NNS||the-14/DT	nsubj||belong-16/VB||viruses-15/NNS	nsubj||share-23/VB||viruses-15/NNS	ccomp||demonstrated-13/VBD||belong-16/VB	det||variant-21/NN||a-18/DT	amod||variant-21/NN||single-19/JJ	nn||variant-21/NN||virus-20/NN	prep_to||belong-16/VB||variant-21/NN	ccomp||demonstrated-13/VBD||share-23/VB	conj_and||belong-16/VB||share-23/VB	det||ancestor-26/NN||a-24/DT	amod||ancestor-26/NN||common-25/JJ	dobj||share-23/VB||ancestor-26/NN	prep_with||share-23/VB||viruses-28/NNS	amod||countries-31/NNS||neighbouring-30/JJ	prep_from||share-23/VB||countries-31/NNS	amod||countries-31/NNS||22-33/CD	num||%-36/NN||95-35/CD	dep||countries-31/NNS||%-36/NN	vmod||%-36/NN||hpd-37/VBN	amod||$-39/$||14â-38/VBD	dobj||hpd-37/VBN||$-39/$	num||$-39/$||32-41/CD	npadvmod||ago-44/RB||years-43/NNS	advmod||countries-31/NNS||ago-44/RB	virus-20||viruses-28||no||bayesian phylogenetic analysis using partial nucleoprotein gene sequences derived from the samples demonstrated the viruses belong to a single virus variant and share a common ancestor with viruses from neighbouring countries, 22 (95% hpd 14â€“32) years ago.
det||subset-2/NN||a-1/DT	nsubjpass||dysregulated-7/VBN||subset-2/NN	amod||genes-5/NNS||cellular-4/JJ	prep_of||subset-2/NN||genes-5/NNS	auxpass||dysregulated-7/VBN||was-6/VBD	root||ROOT-0/null||dysregulated-7/VBN	advmod||dysregulated-7/VBN||only-8/RB	prep_in||dysregulated-7/VBN||cells-10/NNS	vmod||cells-10/NNS||infected-11/VBN	amod||virus-14/NN||rta-overexpressing-13/JJ	prep_with||infected-11/VBN||virus-14/NN	advmod||dysregulated-7/VBN||never-17/RB	prep_in||dysregulated-7/VBN||those-19/DT	conj_and||cells-10/NNS||those-19/DT	vmod||those-19/DT||infected-20/VBN	amod||viruses-23/NNS||non-overexpressing-22/JJ	prep_with||infected-20/VBN||viruses-23/NNS	virus-14||viruses-23||no||a subset of cellular genes was dysregulated only in cells infected with rta-overexpressing virus, and never in those infected with non-overexpressing viruses.
mark||drug-11/NN||although-1/IN	nsubj||drug-11/NN||warfarin-2/NN	cop||drug-11/NN||is-3/VBZ	det||drug-11/NN||an-4/DT	amod||drug-11/NN||effective-5/JJ	amod||drug-11/NN||oral-6/JJ	nn||drug-11/NN||anticoagulation-7/NN	appos||drug-11/NN||oac-9/NN	advcl||scarce-32/JJ||drug-11/NN	aux||reduce-13/VB||to-12/TO	vmod||drug-11/NN||reduce-13/VB	det||risk-15/NN||the-14/DT	dobj||reduce-13/VB||risk-15/NN	prep_of||risk-15/NN||thromboembolism-17/NN	prep_in||reduce-13/VB||patients-19/NNS	amod||atrialfibrillation-22/NN||non-valvular-21/JJ	prep_with||patients-19/NNS||atrialfibrillation-22/NN	appos||atrialfibrillation-22/NN||nvaf-24/NN	amod||data-30/NNS||long-27/JJ	nn||data-30/NNS||term-28/NN	nn||data-30/NNS||follow-up-29/NN	nsubj||scarce-32/JJ||data-30/NNS	nsubj||certain-35/JJ||data-30/NNS	cop||scarce-32/JJ||are-31/VBP	root||ROOT-0/null||scarce-32/JJ	aux||certain-35/JJ||to-33/TO	cop||certain-35/JJ||be-34/VB	xcomp||scarce-32/JJ||certain-35/JJ	mark||maintained-42/VBN||whether-36/IN	det||level-40/NN||the-37/DT	nn||level-40/NN||target-38/NN	nn||level-40/NN||inr-39/NN	nsubjpass||maintained-42/VBN||level-40/NN	auxpass||maintained-42/VBN||is-41/VBZ	ccomp||certain-35/JJ||maintained-42/VBN	amod||patients-45/NNS||warfarin-treated-44/JJ	prep_in||maintained-42/VBN||patients-45/NNS	prep_in||patients-45/NNS||korea-47/NN	thromboembolism-17||warfarin-2||yes||although warfarin is an effective oral anticoagulation (oac) drug to reduce the risk of thromboembolism in patients with non-valvular atrialfibrillation (nvaf), long term follow-up data are scarce to be certain whether the target inr level is maintained in warfarin-treated patients in korea.
nsubj||raises-3/VBZ||it-1/PRP	advmod||raises-3/VBZ||also-2/RB	root||ROOT-0/null||raises-3/VBZ	det||possibility-6/NN||an-4/DT	amod||possibility-6/NN||exciting-5/JJ	dobj||raises-3/VBZ||possibility-6/NN	aux||prevent-8/VB||to-7/TO	vmod||possibility-6/NN||prevent-8/VB	amod||cancers-10/NNS||virus-associated-9/JJ	dobj||prevent-8/VB||cancers-10/NNS	advmod||patients-14/NNS||chronically-12/RB	amod||patients-14/NNS||infected-13/JJ	prep_in||cancers-10/NNS||patients-14/NNS	prepc_by||prevent-8/VB||eliminating-16/VBG	dobj||eliminating-16/VBG||cells-17/NNS	vmod||cells-17/NNS||infected-18/VBN	amod||viruses-21/NNS||oncogenic-20/JJ	prep_with||infected-18/VBN||viruses-21/NNS	mark||transform-24/VB||before-22/IN	nsubj||transform-24/VB||they-23/PRP	advcl||infected-18/VBN||transform-24/VB	prep_into||transform-24/VB||cancer-26/NN	virus--1||viruses-21||no||it also raises an exciting possibility to prevent virus-associated cancers in chronically infected patients by eliminating cells infected with oncogenic viruses before they transform into cancer.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	amod||3-13/CD||whether-9/IN	det||3-13/CD||the-10/DT	amod||3-13/CD||vkorc1-11/JJ	number||3-13/CD||*-12/CD	dobj||investigate-8/VB||3-13/CD	nsubj||gâ-16/VBP||rs7294/9041-15/NNS	dep||3-13/CD||gâ-16/VBP	num||â-20/NN||$-17/$	number||>-19/CD||‰-18/CD	num||$-17/$||>-19/CD	dobj||gâ-16/VBP||â-20/NN	dep||â-20/NN||$-21/$	num||$-21/$||‰-22/CD	dep||â-20/NN||a-23/SYM	num||*-27/NNP||vkorc1-26/CD	dobj||investigate-8/VB||*-27/NNP	conj_and||3-13/CD||*-27/NNP	num||*-27/NNP||4-28/CD	amod||câ-31/NN||rs17708472/6009-30/JJ	dep||*-27/NNP||câ-31/NN	dep||â-35/NN||$-32/$	num||â-35/NN||‰-33/CD	amod||â-35/NN||>-34/JJ	dep||câ-31/NN||â-35/NN	dep||â-35/NN||$-36/$	number||t-38/CD||‰-37/CD	num||$-36/$||t-38/CD	dobj||investigate-8/VB||cyp4f2-42/NNS	conj_and||3-13/CD||cyp4f2-42/NNS	amod||câ-45/NN||rs2108622/1347-44/JJ	dep||cyp4f2-42/NNS||câ-45/NN	dep||â-49/NN||$-46/$	num||â-49/NN||‰-47/CD	amod||â-49/NN||>-48/JJ	dep||câ-45/NN||â-49/NN	dep||â-49/NN||$-50/$	number||t-52/CD||‰-51/CD	num||$-50/$||t-52/CD	nsubjpass||associated-56/VBN||polymorphisms-54/NNS	auxpass||associated-56/VBN||were-55/VBD	rcmod||cyp4f2-42/NNS||associated-56/VBN	amod||requirements-62/NNS||elevated-58/JJ	nn||requirements-62/NNS||warfarin-59/NN	nn||requirements-62/NNS||maintenance-60/NN	nn||requirements-62/NNS||dose-61/NN	prep_with||associated-56/VBN||requirements-62/NNS	prep_in||requirements-62/NNS||patients-64/NNS	prep_with||patients-64/NNS||myocardialinfarction-66/NN	dep||3-13/CD||n-68/VBN	dep||105-70/CD||=-69/SYM	ccomp||n-68/VBN||105-70/CD	det||study-77/NN||the-73/DT	amod||study-77/NN||warfarin-74/JJ	nn||study-77/NN||aspirin-75/NN	nn||study-77/NN||reinfarction-76/NN	prep_from||investigate-8/VB||study-77/NN	appos||study-77/NN||waris-ii-79/NNP	myocardialinfarction-66||warfarin-74||yes||the aim of this study was to investigate whether the vkorc1*3 (rs7294/9041 gâ€‰>â€‰a), vkorc1*4 (rs17708472/6009 câ€‰>â€‰t), and cyp4f2 (rs2108622/1347 câ€‰>â€‰t) polymorphisms were associated with elevated warfarin maintenance dose requirements in patients with myocardialinfarction ( n = 105) from the warfarin aspirin reinfarction study (waris-ii).
nsubj||have-9/VBP||adults-1/NNS	amod||living-5/NN||african-caribbean-3/JJ	nn||living-5/NN||origin-4/NN	prep_of||adults-1/NNS||living-5/NN	det||uk-8/NN||the-7/DT	prep_in||living-5/NN||uk-8/NN	root||ROOT-0/null||have-9/VBP	amod||increases-11/NNS||smaller-10/JJR	dobj||have-9/VBP||increases-11/NNS	amod||risk-14/NN||type2diabetes-13/JJ	prep_in||increases-11/NNS||risk-14/NN	vmod||increases-11/NNS||raised-16/VBN	xcomp||raised-16/VBN||circulating-17/VBG	dobj||circulating-17/VBG||insulin-18/NN	dobj||circulating-17/VBG||hdl-cholesterol-20/NN	conj_and||insulin-18/NN||hdl-cholesterol-20/NN	amod||triglyceride-24/NN||low-23/JJ	dobj||have-9/VBP||triglyceride-24/NN	conj_and||increases-11/NNS||triglyceride-24/NN	amod||concentrations-28/NNS||c-reactive-26/JJ	nn||concentrations-28/NNS||protein-27/NN	conj_and||increases-11/NNS||concentrations-28/NNS	conj_and||triglyceride-24/NN||concentrations-28/NNS	type2diabetes-13||triglyceride-24||no_rel||adults of african-caribbean origin living in the uk have smaller increases in type2diabetes risk, raised circulating insulin and hdl-cholesterol, and low triglyceride and c-reactive protein concentrations.
mark||understand-4/VB||in-1/IN	dep||understand-4/VB||order-2/NN	aux||understand-4/VB||to-3/TO	advcl||analysed-27/VBD||understand-4/VB	mark||serve-9/VB||whether-5/IN	det||snp-7/NN||this-6/DT	nsubj||serve-9/VB||snp-7/NN	nsubj||evaluate-11/VB||snp-7/NN	aux||serve-9/VB||may-8/MD	ccomp||understand-4/VB||serve-9/VB	aux||evaluate-11/VB||to-10/TO	xcomp||serve-9/VB||evaluate-11/VB	det||contribution-13/NN||the-12/DT	dobj||evaluate-11/VB||contribution-13/NN	det||gene-17/NN||the-15/DT	amod||gene-17/NN||ccl2-16/JJ	prep_of||contribution-13/NN||gene-17/NN	det||expression-20/NN||the-19/DT	prep_to||evaluate-11/VB||expression-20/NN	nn||disease-23/NN||tb-22/NN	prep_of||expression-20/NN||disease-23/NN	nsubj||analysed-27/VBD||we-25/PRP	advmod||analysed-27/VBD||further-26/RB	root||ROOT-0/null||analysed-27/VBD	dobj||analysed-27/VBD||distribution-28/NN	poss||alleles-31/NNS||its-30/PRP$	prep_of||distribution-28/NN||alleles-31/NNS	prep_of||distribution-28/NN||genotypes-33/NNS	conj_and||alleles-31/NNS||genotypes-33/NNS	num||cases-37/NNS||301-35/CD	nn||cases-37/NNS||tb-36/NN	prep_in||analysed-27/VBD||cases-37/NNS	num||controls-41/NNS||338-39/CD	amod||controls-41/NNS||non-infected-40/JJ	prep_versus||cases-37/NNS||controls-41/NNS	det||bcg-44/NN||all-43/DT	dep||controls-41/NNS||bcg-44/NN	vmod||bcg-44/NN||vaccinated-45/VBN	vmod||controls-41/NNS||representing-47/VBG	det||population-51/NN||a-48/DT	amod||population-51/NN||high-risk-49/JJ	amod||population-51/NN||pediatric-50/JJ	dobj||representing-47/VBG||population-51/NN	nn||china-54/NN||north-53/NN	prep_of||population-51/NN||china-54/NN	tb-36||bcg-44||no||in order to understand whether this snp may serve to evaluate the contribution of the ccl2 gene to the expression of tb disease, we further analysed distribution of its alleles and genotypes in 301 tb cases versus 338 non-infected controls (all bcg vaccinated) representing a high-risk pediatric population of north china.
nsubj||inform-4/VB||it-1/PRP	nsubj||describe-14/VB||it-1/PRP	aux||inform-4/VB||will-2/MD	advmod||inform-4/VB||further-3/RBR	root||ROOT-0/null||inform-4/VB	det||debate-6/NN||the-5/DT	dobj||inform-4/VB||debate-6/NN	det||effectiveness-9/NN||the-8/DT	prep_about||inform-4/VB||effectiveness-9/NN	nn||screening-12/NN||ipv-11/NN	prep_of||effectiveness-9/NN||screening-12/NN	conj_and||inform-4/VB||describe-14/VB	nn||prevalence-16/NN||ipv-15/NN	dobj||describe-14/VB||prevalence-16/NN	det||community-19/NN||a-18/DT	prep_in||describe-14/VB||community-19/NN	vmod||community-19/NN||based-20/VBN	amod||population-25/NN||post-partum-21/JJ	conj_and||post-partum-21/JJ||early-23/JJ	amod||population-25/NN||early-23/JJ	nn||population-25/NN||infant-24/NN	dobj||based-20/VBN||population-25/NN	ipv-15||inform-4||no_rel||it will further inform the debate about the effectiveness of ipv screening and describe ipv prevalence in a community based post-partum and early infant population.
nsubj||pump-22/VBP||objective-1/NN	aux||compare-3/VB||to-2/TO	vmod||objective-1/NN||compare-3/VB	det||safety-5/NN||the-4/DT	dobj||compare-3/VB||safety-5/NN	dobj||compare-3/VB||efficacy-7/NN	conj_and||safety-5/NN||efficacy-7/NN	amod||delivery-12/NN||overnight-9/JJ	amod||delivery-12/NN||closed-10/VBN	nn||delivery-12/NN||loop-11/NN	prep_of||safety-5/NN||delivery-12/NN	prep_of||delivery-12/NN||insulin-14/NN	amod||pancreas-17/NN||artificial-16/JJ	appos||objective-1/NN||pancreas-17/NN	amod||insulin-21/NN||conventional-20/JJ	prep_with||objective-1/NN||insulin-21/NN	root||ROOT-0/null||pump-22/VBP	dobj||pump-22/VBP||therapy-23/NN	prep_in||pump-22/VBP||adults-25/NNS	prep_with||adults-25/NNS||type1diabetes-27/CD	type1diabetes-27||insulin-21||yes||objective to compare the safety and efficacy of overnight closed loop delivery of insulin (artificial pancreas) with conventional insulin pump therapy in adults with type1diabetes.
amod||tumors-3/NNS||giant-1/JJ	nn||tumors-3/NNS||cell-2/NN	nsubj||neoplasms-10/NNS||tumors-3/NNS	appos||tumors-3/NNS||gcts-5/NNS	cop||neoplasms-10/NNS||are-7/VBP	amod||neoplasms-10/NNS||primary-8/JJ	nn||neoplasms-10/NNS||bone-9/NN	root||ROOT-0/null||neoplasms-10/NNS	nsubj||involve-13/VBP||neoplasms-10/NNS	advmod||involve-13/VBP||rarely-12/RB	rcmod||neoplasms-10/NNS||involve-13/VBP	det||base-16/NN||the-14/DT	nn||base-16/NN||skull-15/NN	dobj||involve-13/VBP||base-16/NN	base-16||tumors-3||no_rel||giant cell tumors (gcts) are primary bone neoplasms that rarely involve the skull base.
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	neg||differences-4/NNS||no-3/DT	nsubj||were-2/VBD||differences-4/NNS	amod||mortality-7/NN||in-hospital-6/JJ	prep_in||differences-4/NNS||mortality-7/NN	prep_in||differences-4/NNS||reinfarction-9/NN	conj_or||mortality-7/NN||reinfarction-9/NN	amod||revascularization-14/NN||urgent-11/JJ	nn||revascularization-14/NN||target-12/NN	nn||revascularization-14/NN||vessel-13/NN	prep_in||differences-4/NNS||revascularization-14/NN	conj_or||mortality-7/NN||revascularization-14/NN	prep_in||differences-4/NNS||stroke-16/NN	conj_or||mortality-7/NN||stroke-16/NN	amod||thrombosis-22/NNS||acute-18/JJ	conj_or||acute-18/JJ||subacute-20/JJ	amod||thrombosis-22/NNS||subacute-20/JJ	nn||thrombosis-22/NNS||stent-21/NN	prep_in||differences-4/NNS||thrombosis-22/NNS	conj_or||mortality-7/NN||thrombosis-22/NNS	mark||showed-28/VBD||while-24/IN	nsubj||showed-28/VBD||group-25/NN	num||patients-27/NNS||1-26/CD	dep||group-25/NN||patients-27/NNS	advcl||were-2/VBD||showed-28/VBD	det||incidence-31/NN||a-29/DT	amod||incidence-31/NN||lower-30/JJR	nsubj||-rrb--49/NN||incidence-31/NN	amod||complications-35/NNS||major-33/JJ	amod||complications-35/NNS||bleeding-34/VBG	prep_of||incidence-31/NN||complications-35/NNS	vmod||complications-35/NNS||-lrb--36/VBG	nn||scale-38/NN||acuity-37/NN	dobj||-lrb--36/VBG||scale-38/NN	num||scale-38/NN||1.1-39/CD	prep||-lrb--36/VBG||vs.-40/FW	num||%-42/NN||4.0-41/CD	pobj||vs.-40/FW||%-42/NN	nn||â-45/NN||p-44/NN	appos||%-42/NN||â-45/NN	dep||-rrb--49/NN||=-46/SYM	nn||-rrb--49/NN||â-47/NN	num||-rrb--49/NN||0.035-48/CD	ccomp||showed-28/VBD||-rrb--49/NN	det||length-53/NN||a-51/DT	amod||length-53/NN||shorter-52/JJR	nsubj||stay-56/VBP||length-53/NN	prep_of||length-53/NN||hospital-55/NN	advcl||were-2/VBD||stay-56/VBP	conj_and||showed-28/VBD||stay-56/VBP	number||3.5-58/CD||-lrb--57/CD	num||â-62/NN||3.5-58/CD	nn||â-62/NN||â-59/NN	nn||â-62/NN||â-60/NN	num||â-62/NN||±-61/CD	dobj||stay-56/VBP||â-62/NN	dobj||â-77/NN||1.7-63/CD	prep||1.7-63/CD||vs.-64/FW	amod||â-67/NN||4.0-65/JJ	nn||â-67/NN||â-66/NN	pobj||vs.-64/FW||â-67/NN	amod||â-75/NN||±-68/JJ	nn||â-75/NN||â-69/NN	num||â-75/NN||1.6-70/CD	nn||â-75/NN||â-71/NN	nn||â-75/NN||days-72/NNS	dep||â-75/NN||p-74/NN	nsubj||â-77/NN||â-75/NN	dep||â-77/NN||=-76/SYM	rcmod||â-62/NN||â-77/NN	num||-rrb--79/NNS||0.002-78/CD	npadvmod||as-80/RB||-rrb--79/NNS	advmod||stay-56/VBP||as-80/RB	prepc_compared_with||stay-56/VBP||with-82/IN	pobj||stay-56/VBP||heparin-83/NN	vmod||heparin-83/NN||treated-84/VBN	dobj||treated-84/VBN||patients-85/NNS	heparin-83||bleeding-34||no_rel||there were no differences in in-hospital mortality , reinfarction , urgent target vessel revascularization , stroke or acute or subacute stent thrombosis , while group 1 patients showed a lower incidence of major bleeding complications -lrb- acuity scale 1.1 vs. 4.0 % , p â = â 0.035 -rrb- and a shorter length of hospital stay -lrb- 3.5 â â ± â 1.7 vs. 4.0 â â ± â 1.6 â days , p â = â 0.002 -rrb- as compared with heparin treated patients .
amod||supplementation-2/NN||leucine-1/JJ	nsubjpass||carried-4/VBN||supplementation-2/NN	auxpass||carried-4/VBN||was-3/VBD	root||ROOT-0/null||carried-4/VBN	prt||carried-4/VBN||out-5/RP	prep_in||carried-4/VBN||noncnzo10/ltj-7/NNS	appos||noncnzo10/ltj-7/NNS||rcs10-9/NNP	det||model-14/NN||a-12/DT	amod||model-14/NN||polygenic-13/JJ	prep_in||carried-4/VBN||model-14/NN	conj_and||noncnzo10/ltj-7/NNS||model-14/NN	vmod||model-14/NN||predisposed-15/VBN	amod||failure-19/NN||beta-17/JJ	nn||failure-19/NN||cell-18/NN	prep_to||predisposed-15/VBN||failure-19/NN	prep_in||carried-4/VBN||type2diabetes-21/NNS	conj_and||noncnzo10/ltj-7/NNS||type2diabetes-21/NNS	amod||j-27/NN||b6.cg-ay-25/JJ	amod||j-27/NN||/-26/JJ	prep_in||carried-4/VBN||j-27/NN	conj_and||noncnzo10/ltj-7/NNS||j-27/NN	det||y-30/NN||a-29/DT	appos||j-27/NN||y-30/NN	det||model-35/NN||a-33/DT	amod||model-35/NN||monogenic-34/JJ	conj_and||noncnzo10/ltj-7/NNS||model-35/NN	conj_and||j-27/NN||model-35/NN	amod||receptor-40/NN||impaired-37/VBN	amod||receptor-40/NN||central-38/JJ	nn||receptor-40/NN||melanocortin-39/NN	prep_for||model-35/NN||receptor-40/NN	vmod||receptor-40/NN||signaling-41/VBG	advmod||signaling-41/VBG||obesity-43/RB	amod||insulinresistance-47/NN||severe-46/JJ	conj_and||noncnzo10/ltj-7/NNS||insulinresistance-47/NN	conj_and||j-27/NN||insulinresistance-47/NN	leucine-1||obesity-43||no_rel||leucine supplementation was carried out in noncnzo10/ltj (rcs10) - a polygenic model predisposed to beta cell failure and type2diabetes, and in b6.cg-ay/j ( a y ) - a monogenic model for impaired central melanocortin receptor signaling, obesity, and severe insulinresistance.
amod||studies-2/NNS||recent-1/JJ	nsubj||suggest-3/VBP||studies-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||plays-10/VBZ||that-4/IN	det||induction-6/NN||the-5/DT	nsubj||plays-10/VBZ||induction-6/NN	amod||expression-9/NN||ho-1-8/JJ	prep_of||induction-6/NN||expression-9/NN	ccomp||suggest-3/VBP||plays-10/VBZ	det||role-14/NN||a-11/DT	amod||role-14/NN||critical-12/JJ	amod||role-14/NN||protective-13/JJ	dobj||plays-10/VBZ||role-14/NN	amod||models-18/NNS||intestinal-16/JJ	nn||models-18/NNS||damage-17/NN	prep_in||plays-10/VBZ||models-18/NNS	vmod||models-18/NNS||induced-19/VBN	agent||induced-19/VBN||ischemia-reperfusion-21/NN	agent||induced-19/VBN||indomethacin-23/NN	conj_and||ischemia-reperfusion-21/NN||indomethacin-23/NN	amod||sepsis-26/NN||lipopolysaccharide-associated-25/JJ	agent||induced-19/VBN||sepsis-26/NN	conj_and||ischemia-reperfusion-21/NN||sepsis-26/NN	amod||acid-30/NN||trinitrobenzene-28/JJ	amod||acid-30/NN||sulfonic-29/JJ	agent||induced-19/VBN||acid-30/NN	conj_and||ischemia-reperfusion-21/NN||acid-30/NN	nn||sodium-35/NN||dextran-33/NN	nn||sodium-35/NN||sulfate-34/NN	agent||induced-19/VBN||sodium-35/NN	conj_and||ischemia-reperfusion-21/NN||sodium-35/NN	vmod||plays-10/VBZ||indicating-37/VBG	mark||act-43/VB||that-38/IN	nsubj||act-43/VB||activation-39/NN	nsubj||reduce-50/VB||activation-39/NN	prep_of||activation-39/NN||ho-1-41/CD	aux||act-43/VB||may-42/MD	ccomp||indicating-37/VBG||act-43/VB	det||mechanism-48/NN||an-45/DT	amod||mechanism-48/NN||endogenous-46/JJ	amod||mechanism-48/NN||defensive-47/JJ	prep_as||act-43/VB||mechanism-48/NN	aux||reduce-50/VB||to-49/TO	xcomp||act-43/VB||reduce-50/VB	nn||injury-54/NN||inflammation-51/NN	conj_and||inflammation-51/NN||tissue-53/NN	nn||injury-54/NN||tissue-53/NN	dobj||reduce-50/VB||injury-54/NN	det||tract-58/NN||the-56/DT	amod||tract-58/NN||gastrointestinal-57/JJ	prep_in||reduce-50/VB||tract-58/NN	inflammation-51||dextran-33||no_rel||recent studies suggest that the induction of ho-1 expression plays a critical protective role in intestinal damage models induced by ischemia-reperfusion, indomethacin, lipopolysaccharide-associated sepsis, trinitrobenzene sulfonic acid, and dextran sulfate sodium, indicating that activation of ho-1 may act as an endogenous defensive mechanism to reduce inflammation and tissue injury in the gastrointestinal tract.
nsubj||performed-2/VBD||we-1/PRP	root||ROOT-0/null||performed-2/VBD	det||trial-6/NN||a-3/DT	amod||trial-6/NN||16-week-4/JJ	nn||trial-6/NN||intervention-5/NN	dobj||performed-2/VBD||trial-6/NN	det||diet-12/NN||a-8/DT	amod||diet-12/NN||hypocaloric-9/JJ	amod||diet-12/NN||low-fat-11/JJ	prep_of||trial-6/NN||diet-12/NN	dobj||performed-2/VBD||10-14/CD	conj_plus||trial-6/NN||10-14/CD	advmod||ezetimibe-16/JJ||mg/day-15/RB	amod||10-14/CD||ezetimibe-16/JJ	dep||10-14/CD||n-18/VBN	dep||15-20/CD||=-19/SYM	ccomp||n-18/VBN||15-20/CD	det||diet-27/NN||a-23/DT	amod||diet-27/NN||hypocaloric-24/JJ	amod||diet-27/NN||low-fat-26/JJ	conj_plus||trial-6/NN||diet-27/NN	conj_versus||10-14/CD||diet-27/NN	amod||diet-27/NN||alone-28/RB	dep||trial-6/NN||n-30/VBN	dep||10-32/CD||=-31/SYM	ccomp||n-30/VBN||10-32/CD	amod||triglyceride-36/NN||intrahepatic-35/JJ	prep_on||performed-2/VBD||triglyceride-36/NN	appos||triglyceride-36/NN||ihtg-38/NN	amod||triglyceride-36/NN||content-40/JJ	vmod||triglyceride-36/NN||plasma-42/VBN	amod||subjects-67/NNS||high-43/JJ	dep||$-45/$||sensitivityâ-44/RB	dep||subjects-67/NNS||$-45/$	npadvmod||in-65/RB||c-reactive-47/NN	advmod||c-reactive-47/NN||protein-48/RB	pobj||protein-48/RB||hs-crp-50/NN	appos||hs-crp-50/NN||adipocytokines-53/NNS	amod||concentrations-57/NNS||fetuin-a-56/JJ	pobj||protein-48/RB||concentrations-57/NNS	conj_and||hs-crp-50/NN||concentrations-57/NNS	conj_and||hs-crp-50/NN||apolipoprotein-59/NNS	conj_and||concentrations-57/NNS||apolipoprotein-59/NNS	appos||concentrations-57/NNS||apo-61/NN	amod||kinetics-64/NNS||b-100-63/JJ	dep||concentrations-57/NNS||kinetics-64/NNS	dep||obese-66/CD||in-65/RB	num||$-45/$||obese-66/CD	dobj||plasma-42/VBN||subjects-67/NNS	obese-66||triglyceride-36||no_rel||we performed a 16-week intervention trial of a hypocaloric, low-fat diet plus 10 mg/day ezetimibe ( n = 15) versus a hypocaloric, low-fat diet alone ( n = 10) on intrahepatic triglyceride (ihtg) content, plasma high sensitivityâ€“c-reactive protein (hs-crp), adipocytokines, and fetuin-a concentrations and apolipoprotein (apo)b-100 kinetics in obese subjects.
mark||low-5/JJ||if-1/IN	amod||renin-3/NN||stimulated-2/JJ	nsubj||low-5/JJ||renin-3/NN	cop||low-5/JJ||is-4/VBZ	advcl||aldosteronism-16/NN||low-5/JJ	det||aldosterone-8/NN||the-7/DT	nsubj||high-10/JJ||aldosterone-8/NN	cop||high-10/JJ||is-9/VBZ	conj_and||low-5/JJ||high-10/JJ	advcl||aldosteronism-16/NN||high-10/JJ	det||problem-13/NN||the-12/DT	nsubj||aldosteronism-16/NN||problem-13/NN	cop||aldosteronism-16/NN||is-14/VBZ	amod||aldosteronism-16/NN||primary-15/JJ	root||ROOT-0/null||aldosteronism-16/NN	det||treatment-21/NN||the-19/DT	amod||treatment-21/NN||best-20/JJS	nsubj||antagonists-25/NNS||treatment-21/NN	cop||antagonists-25/NNS||is-22/VBZ	advmod||antagonists-25/NNS||usually-23/RB	amod||antagonists-25/NNS||aldosterone-24/JJ	conj_and||aldosteronism-16/NN||antagonists-25/NNS	dep||antagonists-25/NNS||spironolactone-27/NN	dep||antagonists-25/NNS||eplerenone-29/NN	conj_or||spironolactone-27/NN||eplerenone-29/NN	amod||amiloride-32/JJ||high-dose-31/JJ	amod||spironolactone-27/NN||amiloride-32/JJ	prep_for||spironolactone-27/NN||men-34/NNS	advmod||available-39/JJ||where-35/WRB	nsubj||available-39/JJ||eplerenone-36/NN	cop||available-39/JJ||is-37/VBZ	neg||available-39/JJ||not-38/RB	rcmod||spironolactone-27/NN||available-39/JJ	aldosteronism-16||spironolactone-27||yes||if stimulated renin is low and the aldosterone is high, the problem is primary aldosteronism, and the best treatment is usually aldosterone antagonists (spironolactone or eplerenone; high-dose amiloride for men where eplerenone is not available).
det||findings-3/NNS||some-1/DT	amod||findings-3/NNS||key-2/JJ	nsubjpass||presented-14/VBN||findings-3/NNS	nsubj||show-16/VB||findings-3/NNS	det||trial-8/NN||a-5/DT	advmod||trial-8/NN||recently-6/RB	amod||trial-8/NN||unpublished-7/JJ	prep_of||findings-3/NNS||trial-8/NN	nn||knees-11/NNS||oa-10/NN	prep_in||trial-8/NN||knees-11/NNS	auxpass||presented-14/VBN||are-12/VBP	advmod||presented-14/VBN||also-13/RB	root||ROOT-0/null||presented-14/VBN	aux||show-16/VB||to-15/TO	xcomp||presented-14/VBN||show-16/VB	dobj||show-16/VB||equivalence-17/JJ	amod||medicine-20/NN||ayurvedic-19/JJ	prep_between||equivalence-17/JJ||medicine-20/NN	prep_between||equivalence-17/JJ||celecoxib-22/NN	conj_and||medicine-20/NN||celecoxib-22/NN	prep_between||equivalence-17/JJ||glucosamine-24/NN	conj_and||medicine-20/NN||glucosamine-24/NN	nsubj||speculate-28/VBP||we-27/PRP	conj_and||presented-14/VBN||speculate-28/VBP	mark||way-35/NN||that-29/IN	amod||trials-31/NNS||equivalence-30/JJ	nsubj||way-35/NN||trials-31/NNS	aux||way-35/NN||may-32/MD	cop||way-35/NN||be-33/VB	det||way-35/NN||a-34/DT	ccomp||speculate-28/VBP||way-35/NN	advmod||way-35/NN||forward-36/RB	oa-10||glucosamine-24||yes||some key findings of a recently unpublished trial in oa knees are also presented to show equivalence between ayurvedic medicine and celecoxib and glucosamine, and we speculate that equivalence trials may be a way forward.
advmod||recruited-17/VBN||moreover-1/RB	num||individuals-4/NNS||25-3/CD	nsubjpass||recruited-17/VBN||individuals-4/NNS	prep_with||individuals-4/NNS||immunity-6/NN	amod||immunity-6/NN||consistent-7/JJ	nn||m.tuberculosisinfection-10/NN||latent-9/NN	prep_with||consistent-7/JJ||m.tuberculosisinfection-10/NN	prep_with||consistent-7/JJ||bcg-vaccination-12/NN	conj_and||m.tuberculosisinfection-10/NN||bcg-vaccination-12/NN	advmod||recruited-17/VBN||respectively-14/RB	auxpass||recruited-17/VBN||were-16/VBD	root||ROOT-0/null||recruited-17/VBN	tuberculosisinfection--1||bcg--1||no||moreover , 25 individuals with immunity consistent with latent m.tuberculosisinfection and bcg-vaccination , respectively , were recruited .
nsubj||analysed-2/VBD||we-1/PRP	root||ROOT-0/null||analysed-2/VBD	nn||samples-4/NNS||urine-3/NN	dobj||analysed-2/VBD||samples-4/NNS	amod||patients-7/NNS||consecutive-6/JJ	prep_from||analysed-2/VBD||patients-7/NNS	xcomp||analysed-2/VBD||attending-8/VBG	det||ed-10/NN||the-9/DT	dobj||attending-8/VBG||ed-10/NN	nn||pain-15/NN||trauma-12/NN	conj_or||trauma-12/NN||chest-14/NN	nn||pain-15/NN||chest-14/NN	prep_for||ed-10/NN||pain-15/NN	aux||determine-17/VB||to-16/TO	vmod||attending-8/VBG||determine-17/VB	det||presence-19/NN||the-18/DT	dobj||determine-17/VB||presence-19/NN	prep_of||presence-19/NN||cocaine-21/NN	prep_of||presence-19/NN||cannabis-23/NN	conj_and||cocaine-21/NN||cannabis-23/NN	prep_of||presence-19/NN||amphetamine/metaamphetamine-25/NN	conj_and||cocaine-21/NN||amphetamine/metaamphetamine-25/NN	prep_of||presence-19/NN||opioids-27/NNS	conj_and||cocaine-21/NN||opioids-27/NNS	amod||tests-30/NNS||semiquantative-29/JJ	prep_by||determine-17/VB||tests-30/NNS	amod||immunoassay-34/NN||fluorescence-32/JJ	nn||immunoassay-34/NN||polarization-33/NN	prep_with||determine-17/VB||immunoassay-34/NN	appos||immunoassay-34/NN||fpia-36/NNP	pain-15||cocaine-21||yes||we analysed urine samples from consecutive patients attending the ed for trauma or chest pain to determine the presence of cocaine, cannabis, amphetamine/metaamphetamine and opioids by semiquantative tests with fluorescence polarization immunoassay (fpia).
det||treatments-3/NNS||both-2/DT	prep_under||experienced-9/VBD||treatments-3/NNS	quantmod||many-7/JJ||twice-5/RB	quantmod||many-7/JJ||as-6/RB	num||patients-8/NNS||many-7/JJ	nsubj||experienced-9/VBD||patients-8/NNS	root||ROOT-0/null||experienced-9/VBD	neg||pain-11/NN||no-10/DT	dobj||experienced-9/VBD||pain-11/NN	parataxis||experienced-9/VBD||score-13/VBP	dep||0-15/CD||=-14/SYM	ccomp||score-13/VBP||0-15/CD	det||day-21/NN||the-18/DT	amod||day-21/NN||first-19/JJ	nn||day-21/NN||postoperative-20/NN	prep_on||experienced-9/VBD||day-21/NN	prepc_compared_to||day-21/NN||to-23/TO	det||day-25/NN||the-24/DT	pobj||day-21/NN||day-25/NN	prep_of||day-25/NN||surgery-27/NN	num||%-30/NN||35.9-29/CD	dep||day-25/NN||%-30/NN	number||16.4-32/CD||vs-31/CD	num||%-33/NN||16.4-32/CD	nsubj||vs-39/VBP||%-33/NN	prep_for||%-33/NN||tramadol/paracetamol-35/NN	num||%-38/NN||36.7-37/CD	prep_for||%-33/NN||%-38/NN	conj_and||tramadol/paracetamol-35/NN||%-38/NN	rcmod||%-30/NN||vs-39/VBP	num||%-41/NN||18-40/CD	dobj||vs-39/VBP||%-41/NN	amod||treatment-44/NN||tramadol-43/JJ	prep_for||vs-39/VBP||treatment-44/NN	pain-11||tramadol-43||yes||under both treatments, twice as many patients experienced no pain (score = 0) on the first postoperative day compared to the day of surgery (35.9% vs 16.4% for tramadol/paracetamol and 36.7% vs 18% for tramadol treatment).
vmod||demonstrated-13/VBD||using-1/VBG	amod||administration-3/NN||oral-2/JJ	nsubj||hc-030031-9/JJ||administration-3/NN	det||antagonist-8/NN||the-5/DT	amod||antagonist-8/NN||selective-6/JJ	amod||antagonist-8/NN||trpa1-7/JJ	prep_of||administration-3/NN||antagonist-8/NN	xcomp||using-1/VBG||hc-030031-9/JJ	poss||results-12/NNS||our-11/PRP$	nsubj||demonstrated-13/VBD||results-12/NNS	root||ROOT-0/null||demonstrated-13/VBD	mark||plays-16/VBZ||that-14/IN	nsubj||plays-16/VBZ||trpa1-15/NNS	ccomp||demonstrated-13/VBD||plays-16/VBZ	det||role-19/NN||an-17/DT	amod||role-19/NN||important-18/JJ	dobj||plays-16/VBZ||role-19/NN	det||mechanisms-22/NNS||the-21/DT	prep_in||role-19/NN||mechanisms-22/NNS	amod||role-19/NN||responsible-23/JJ	amod||hypersensitivity-26/NN||mechanical-25/JJ	prep_for||responsible-23/JJ||hypersensitivity-26/NN	vmod||role-19/NN||observed-27/VBN	amod||models-32/NNS||inflammatory-29/JJ	conj_and||inflammatory-29/JJ||neuropathicpain-31/JJ	amod||models-32/NNS||neuropathicpain-31/JJ	prep_in||observed-27/VBN||models-32/NNS	hc--1||neuropathicpain-31||no_rel||using oral administration of the selective trpa1 antagonist hc-030031, our results demonstrated that trpa1 plays an important role in the mechanisms responsible for mechanical hypersensitivity observed in inflammatory and neuropathicpain models.
amod||•-5/NNS||plague-1/JJ	amod||•-5/NNS||diagnostic-2/JJ	amod||•-5/NNS||phages-3/JJ	nn||•-5/NNS||ï-4/NN	nsubjpass||shown-10/VBN||•-5/NNS	nsubj||tools-16/NNS||•-5/NNS	amod||•-5/NNS||a1122-6/JJ	amod||•-5/NNS||l-413c-8/JJ	conj_and||a1122-6/JJ||l-413c-8/JJ	auxpass||shown-10/VBN||were-9/VBD	root||ROOT-0/null||shown-10/VBN	aux||tools-16/NNS||to-11/TO	cop||tools-16/NNS||be-12/VB	advmod||effective-14/JJ||highly-13/RB	amod||tools-16/NNS||effective-14/JJ	amod||tools-16/NNS||diagnostic-15/JJ	xcomp||shown-10/VBN||tools-16/NNS	det||detection-19/NN||the-18/DT	prep_for||tools-16/NNS||detection-19/NN	prep_for||tools-16/NNS||identification-21/NN	conj_and||detection-19/NN||identification-21/NN	prep_of||detection-19/NN||y.pestis-23/NNS	agent||shown-10/VBN||using-25/VBG	dobj||using-25/VBG||qpcr-26/NN	amod||specific-29/NN||primers-28/JJ	prep_with||using-25/VBG||specific-29/NN	amod||dna-32/NN||phage-31/JJ	prep_for||specific-29/NN||dna-32/NN	plague-1||y.pestis-23||no||plague diagnostic phages ï • a1122 and l-413c were shown to be highly effective diagnostic tools for the detection and identification of y.pestis by using qpcr with primers specific for phage dna .
nsubj||herpesvirus-17/NNS||varicella-zostervirus-1/NNS	nsubj||first-24/JJ||varicella-zostervirus-1/NNS	appos||varicella-zostervirus-1/NNS||vzv-3/NN	det||cause-7/NN||the-6/DT	appos||varicella-zostervirus-1/NNS||cause-7/NN	prep_of||cause-7/NN||chickenpox-9/NN	prep_of||cause-7/NN||zoster-11/NN	conj_and||chickenpox-9/NN||zoster-11/NN	cop||herpesvirus-17/NNS||was-13/VBD	det||herpesvirus-17/NNS||the-14/DT	amod||herpesvirus-17/NNS||first-15/JJ	amod||herpesvirus-17/NNS||human-16/JJ	root||ROOT-0/null||herpesvirus-17/NNS	aux||sequenced-20/VBN||to-18/TO	auxpass||sequenced-20/VBN||be-19/VB	vmod||herpesvirus-17/NNS||sequenced-20/VBN	advmod||sequenced-20/VBN||fully-21/RB	det||first-24/JJ||the-23/DT	conj_and||herpesvirus-17/NNS||first-24/JJ	prep_for||licensed-30/VBN||first-24/JJ	nsubjpass||licensed-30/VBN||vaccines-27/NNS	nsubjpass||used-33/VBN||vaccines-27/NNS	aux||licensed-30/VBN||have-28/VBP	auxpass||licensed-30/VBN||been-29/VBN	rcmod||first-24/JJ||licensed-30/VBN	advmod||used-33/VBN||widely-32/RB	rcmod||first-24/JJ||used-33/VBN	conj_and||licensed-30/VBN||used-33/VBN	chickenpox-9||varicella-zostervirus-1||yes||varicella-zostervirus (vzv), the cause of chickenpox and zoster, was the first human herpesvirus to be sequenced fully and the first for which vaccines have been licensed and widely used.
det||study-2/NN||this-1/DT	nsubj||investigated-3/VBD||study-2/NN	root||ROOT-0/null||investigated-3/VBD	det||effects-5/NNS||the-4/DT	dobj||investigated-3/VBD||effects-5/NNS	det||program-11/NN||a-7/DT	amod||program-11/NN||prior-8/JJ	amod||program-11/NN||individualized-9/JJ	nn||program-11/NN||training-10/NN	prep_of||effects-5/NNS||program-11/NN	appos||program-11/NN||tp-13/NN	det||response-17/NN||the-16/DT	prep_on||investigated-3/VBD||response-17/NN	amod||supply-21/NN||acute-19/JJ	nn||supply-21/NN||oxygen-20/NN	prep_to||response-17/NN||supply-21/NN	prep_during||investigated-3/VBD||exercise-23/NN	amod||obstructivepulmonarydisease-26/NN||chronic-25/JJ	prep_in||investigated-3/VBD||obstructivepulmonarydisease-26/NN	dep||obstructivepulmonarydisease-26/NN||copd-28/VBN	dep||obstructivepulmonarydisease-26/NN||patients-30/NNS	vmod||patients-30/NNS||showing-31/VBG	amod||desaturation-33/NN||exercise-induced-32/JJ	dobj||showing-31/VBG||desaturation-33/NN	obstructivepulmonarydisease-26||oxygen-20||yes||this study investigated the effects of a prior individualized training program (tp) on the response to acute oxygen supply during exercise in chronic obstructivepulmonarydisease (copd) patients showing exercise-induced desaturation.
nsubj||disease-10/NN||progressivemultifocalleukoencephalopathy-1/NN	appos||progressivemultifocalleukoencephalopathy-1/NN||pml-3/NN	cop||disease-10/NN||is-5/VBZ	det||disease-10/NN||an-6/DT	advmod||fatal-8/JJ||often-7/RB	amod||disease-10/NN||fatal-8/JJ	nn||disease-10/NN||demyelinating-9/NN	root||ROOT-0/null||disease-10/NN	vmod||disease-10/NN||caused-11/VBN	amod||infection-14/NN||lytic-13/JJ	agent||caused-11/VBN||infection-14/NN	prep_of||infection-14/NN||oligodendrocytes-16/NNS	prep_with||oligodendrocytes-16/NNS||jcvirus-18/NNS	appos||jcvirus-18/NNS||jcv-20/NN	progressivemultifocalleukoencephalopathy-1||jcvirus-18||no||progressivemultifocalleukoencephalopathy (pml) is an often fatal demyelinating disease caused by lytic infection of oligodendrocytes with jcvirus (jcv).
nn||nleinpurpura-3/NNP||henoch-schã-1/NNP	nn||nleinpurpura-3/NNP||¶-2/NNP	nsubj||syndrome-10/NN||nleinpurpura-3/NNP	cop||syndrome-10/NN||is-4/VBZ	det||syndrome-10/NN||a-5/DT	amod||syndrome-10/NN||common-6/JJ	amod||syndrome-10/NN||immunoglobulin-7/JJ	amod||syndrome-10/NN||a-mediated-8/JJ	amod||syndrome-10/NN||vasculitic-9/JJ	root||ROOT-0/null||syndrome-10/NN	prep_in||syndrome-10/NN||children-12/NNS	vmod||children-12/NNS||characterized-14/VBN	amod||rash-17/NN||purpuric-16/JJ	agent||characterized-14/VBN||rash-17/NN	agent||characterized-14/VBN||arthritis-19/NN	conj_and||rash-17/NN||arthritis-19/NN	agent||characterized-14/VBN||abdominalpain-21/NN	conj_and||rash-17/NN||abdominalpain-21/NN	immunoglobulin-7||henoch-schã¶nleinpurpura--1||no_rel||henoch-schã¶nleinpurpura is a common immunoglobulin a-mediated vasculitic syndrome in children, characterized by purpuric rash, arthritis and abdominalpain.
det||essence-2/NN||the-1/DT	nsubj||is-6/VBZ||essence-2/NN	poss||research-5/NN||our-4/PRP$	prep_of||essence-2/NN||research-5/NN	root||ROOT-0/null||is-6/VBZ	mark||characterized-28/VBN||that-7/IN	nsubjpass||characterized-28/VBN||patients-8/NNS	nsubjpass||characterized-28/VBN||patients-8/NNS	prep_with||patients-8/NNS||t1dm-10/NN	prep_with||patients-8/NNS||ht-12/NN	conj_and||t1dm-10/NN||ht-12/NN	prep_with||patients-8/NNS||microalbuminuria-15/NN	conj_and||t1dm-10/NN||microalbuminuria-15/NN	discourse||microalbuminuria-15/NN||ma-17/UH	conj_and||t1dm-10/NN||diabeticretinopathy-20/NN	conj_and||microalbuminuria-15/NN||diabeticretinopathy-20/NN	discourse||microalbuminuria-15/NN||dr-22/UH	appos||patients-8/NNS||ma/dr-25/NN	auxpass||characterized-28/VBN||are-27/VBP	ccomp||is-6/VBZ||characterized-28/VBN	ccomp||is-6/VBZ||characterized-28/VBN	conj_and||characterized-28/VBN||characterized-28/VBN	det||level-33/NN||a-30/DT	advmod||higher-32/JJR||significantly-31/RB	amod||level-33/NN||higher-32/JJR	agent||characterized-28/VBN||level-33/NN	prep_of||level-33/NN||vegf-35/NN	num||â-38/NN||340.23-37/CD	dep||vegf-35/NN||â-38/NN	punct||â-38/NN||±-39/:	npadvmod||â-41/RB||93.22-40/CD	prep||â-38/NN||â-41/RB	pobj||â-41/RB||$-42/$	num||$-42/$||‰-43/CD	advmod||â-41/RB||pgâ-44/RB	num||$-48/$||$-45/$	number||mlâ-47/CD||‰-46/CD	num||$-45/$||mlâ-47/CD	pobj||â-41/RB||$-48/$	num||$-48/$||1-50/CD	nn||serum-54/NN||blood-53/NN	prep_in||characterized-28/VBN||serum-54/NN	prep_in||serum-54/NN||comparison-56/NN	det||group-59/NN||the-58/DT	prep_with||characterized-28/VBN||group-59/NN	amod||patients-62/NNS||t1dm-61/JJ	prep_of||group-59/NN||patients-62/NNS	prep_without||characterized-28/VBN||ht-64/FW	prep_without||characterized-28/VBN||ma/dr-66/FW	conj_and||ht-64/FW||ma/dr-66/FW	num||â-69/NN||183.6-68/CD	dep||characterized-28/VBN||â-69/NN	punct||â-69/NN||±-70/:	num||â-72/NN||96.6-71/CD	dep||â-69/NN||â-72/NN	num||$-76/NNS||$-73/$	number||pgâ-75/CD||‰-74/CD	num||$-73/$||pgâ-75/CD	dep||â-72/NN||$-76/NNS	punct||â-69/NN||‰-77/:	dep||â-69/NN||mlâ-78/VBN	dobj||mlâ-78/VBN||$-79/$	num||$-79/$||1-81/CD	amod||controls-86/NNS||healthy-85/JJ	prep_with||characterized-28/VBN||controls-86/NNS	num||â-89/NN||145.32-88/CD	dep||controls-86/NNS||â-89/NN	punct||â-89/NN||±-90/:	npadvmod||â-92/RB||75.58-91/CD	prep||â-89/NN||â-92/RB	pobj||â-92/RB||$-93/$	num||$-93/$||‰-94/CD	advmod||â-92/RB||pgâ-95/RB	num||$-99/$||$-96/$	number||mlâ-98/CD||‰-97/CD	num||$-96/$||mlâ-98/CD	pobj||â-92/RB||$-99/$	num||$-99/$||1-101/CD	essence-2||diabeticretinopathy-20||no_rel||the essence of our research is that patients with t1dm and ht and with microalbuminuria (ma) and diabeticretinopathy (dr) (ma/dr) are characterized by a significantly higher level of vegf (340.23â±93.22â€‰pgâ€‰mlâ€“1) in blood serum in comparison with the group of t1dm patients without ht and ma/dr (183.6â±96.6â€‰pgâ€‰mlâ€“1) and with healthy controls (145.32â±75.58â€‰pgâ€‰mlâ€“1).
det||prevention-3/NN||the-1/DT	nn||prevention-3/NN||stroke-2/NN	nsubj||reduced-33/VBD||prevention-3/NN	amod||reduction-6/NN||aggressive-5/JJ	prep_by||prevention-3/NN||reduction-6/NN	nn||levels-9/NNS||cholesterol-8/NN	prep_of||reduction-6/NN||levels-9/NNS	dep||levels-9/NNS||sparcl-11/JJ	nsubj||showed-14/VBD||trial-13/NN	rcmod||levels-9/NNS||showed-14/VBD	amod||treatment-16/NN||daily-15/JJ	dobj||showed-14/VBD||treatment-16/NN	num||mg-19/NN||80-18/CD	prep_with||showed-14/VBD||mg-19/NN	prep_of||mg-19/NN||atorvastatin-21/NN	prep_in||showed-14/VBD||patients-23/NNS	det||stroke-27/NN||a-25/DT	amod||stroke-27/NN||recent-26/JJ	prep_with||patients-23/NNS||stroke-27/NN	prep_with||patients-23/NNS||transientischemicattack-29/NN	conj_or||stroke-27/NN||transientischemicattack-29/NN	appos||stroke-27/NN||tia-31/NN	root||ROOT-0/null||reduced-33/VBD	det||incidence-35/NN||the-34/DT	dobj||reduced-33/VBD||incidence-35/NN	amod||stroke-40/NN||fatal-37/JJ	conj_or||fatal-37/JJ||nonfatal-39/JJ	amod||stroke-40/NN||nonfatal-39/JJ	prep_of||incidence-35/NN||stroke-40/NN	num||%-43/NN||16-42/CD	prep_by||reduced-33/VBD||%-43/NN	atorvastatin-21||transientischemicattack-29||no_rel||the stroke prevention by aggressive reduction of cholesterol levels (sparcl) trial showed daily treatment with 80 mg of atorvastatin in patients with a recent stroke or transientischemicattack (tia) reduced the incidence of fatal or nonfatal stroke by 16%.
advmod||exist-6/VBP||however-1/RB	advmod||little-4/JJ||very-3/RB	amod||data-5/NNS||little-4/JJ	nsubj||exist-6/VBP||data-5/NNS	root||ROOT-0/null||exist-6/VBP	xcomp||exist-6/VBP||concerning-7/VBG	det||aspects-9/NNS||these-8/DT	dobj||concerning-7/VBG||aspects-9/NNS	prep_of||aspects-9/NNS||nutrition-11/NN	prep_among||concerning-7/VBG||women-13/NNS	vmod||women-13/NNS||living-14/VBG	prep_with||living-14/VBG||hiv-16/NN	prep_with||living-14/VBG||aids-18/NNS	conj_and||hiv-16/NN||aids-18/NNS	amod||settings-21/NNS||resource-limited-20/JJ	prep_in||hiv-16/NN||settings-21/NNS	prep_such_as||hiv-16/NN||uganda-25/NN	aids-18||hiv-16||no||however, very little data exist concerning these aspects of nutrition among women living with hiv and aids in resource-limited settings, such as uganda.
expl||is-2/VBZ||there-1/EX	dep||polymorphism-21/VBP||is-2/VBZ	amod||evidence-4/NN||conflicting-3/VBG	nsubj||is-2/VBZ||evidence-4/NN	det||contribution-7/NN||the-6/DT	prep_on||evidence-4/NN||contribution-7/NN	det||âˆ-11/NN||the-9/DT	amod||âˆ-11/NN||mcp-1-10/JJ	prep_of||contribution-7/NN||âˆ-11/NN	num||âˆ-11/NN||2518-13/CD	det||g-16/NN||a-14/DT	amod||g-16/NN||>-15/JJ	nsubj||polymorphism-21/VBP||g-16/NN	nsubj||sle-23/VB||g-16/NN	number||1024611-19/CD||rs-18/CD	dep||g-16/NN||1024611-19/CD	root||ROOT-0/null||polymorphism-21/VBP	aux||sle-23/VB||to-22/TO	xcomp||polymorphism-21/VBP||sle-23/VB	nn||manifestations-27/NNS||incidence-24/NN	conj_and||incidence-24/NN||clinical-26/JJ	nn||manifestations-27/NNS||clinical-26/JJ	dobj||sle-23/VB||manifestations-27/NNS	mcp--1||sle-23||no_rel||there is conflicting evidence on the contribution of the mcp-1 âˆ’2518 a>g (rs 1024611) polymorphism to sle incidence and clinical manifestations.
nsubj||invasion-8/NN||cutaneoustuberculosis-1/NNS	appos||cutaneoustuberculosis-1/NNS||tb-3/NN	cop||invasion-8/NN||is-5/VBZ	advmod||invasion-8/NN||essentially-6/RB	det||invasion-8/NN||an-7/DT	root||ROOT-0/null||invasion-8/NN	det||skin-11/NN||the-10/DT	prep_of||invasion-8/NN||skin-11/NN	prep_by||skin-11/NN||mycobacteriumtuberculosis-13/NNS	det||bacteria-17/NNS||the-15/DT	amod||bacteria-17/NNS||same-16/JJ	appos||mycobacteriumtuberculosis-13/NNS||bacteria-17/NNS	nsubj||causes-19/VBZ||bacteria-17/NNS	rcmod||bacteria-17/NNS||causes-19/VBZ	dobj||causes-19/VBZ||pulmonarytuberculosis-20/NNS	cutaneoustuberculosis-1||mycobacteriumtuberculosis-13||no||cutaneoustuberculosis (tb) is essentially an invasion of the skin by mycobacteriumtuberculosis , the same bacteria that causes pulmonarytuberculosis.
nsubj||member-8/NN||missing-in-metastasis-1/NNS	appos||missing-in-metastasis-1/NNS||mim-3/NN	cop||member-8/NN||is-5/VBZ	det||member-8/NN||a-6/DT	amod||member-8/NN||defining-7/VBG	root||ROOT-0/null||member-8/NN	det||subfamily-17/NN||the-10/DT	amod||subfamily-17/NN||inverse-11/JJ	nn||subfamily-17/NN||bin/amphiphysin/rvs-12/NNS	nn||subfamily-17/NN||domain-13/NN	appos||subfamily-17/NN||i-bar-15/NN	prep_of||member-8/NN||subfamily-17/NN	num||regulators-23/NNS||lipid-19/CD	amod||regulators-23/NNS||binding-20/JJ	amod||regulators-23/NNS||cytoskeletal-22/JJ	prep_of||member-8/NN||regulators-23/NNS	dep||altered-27/VBN||whose-24/WP$	nsubjpass||altered-27/VBN||levels-25/NNS	auxpass||altered-27/VBN||are-26/VBP	dep||regulators-23/NNS||altered-27/VBN	det||number-30/NN||a-29/DT	prep_in||altered-27/VBN||number-30/NN	prep_of||number-30/NN||cancers-32/NNS	lipid-19||cancers-32||no_rel||missing-in-metastasis (mim) is a defining member of the inverse bin/amphiphysin/rvs domain (i-bar) subfamily of lipid binding, cytoskeletal regulators whose levels are altered in a number of cancers.
det||chondroitinsulphate-2/NN||the-1/DT	nsubj||one-4/CD||chondroitinsulphate-2/NN	cop||one-4/CD||is-3/VBZ	root||ROOT-0/null||one-4/CD	det||components-8/NNS||the-6/DT	amod||components-8/NNS||major-7/JJ	prep_of||one-4/CD||components-8/NNS	det||matrix-12/NN||the-10/DT	amod||matrix-12/NN||extra-cellular-11/JJ	prep_of||components-8/NNS||matrix-12/NN	det||tissues-17/NNS||the-14/DT	amod||tissues-17/NNS||vertebrate-15/JJ	amod||tissues-17/NNS||connective-16/JJ	prep_of||matrix-12/NN||tissues-17/NNS	det||molecule-22/NN||a-19/DT	amod||molecule-22/NN||high-20/JJ	nn||molecule-22/NN||value-21/NN	prep_of||one-4/CD||molecule-22/NN	conj_and||components-8/NNS||molecule-22/NN	advmod||employed-25/VBN||widely-24/RB	vmod||molecule-22/NN||employed-25/VBN	amod||principle-28/NN||active-27/JJ	prep_as||employed-25/VBN||principle-28/NN	det||treatment-31/NN||the-30/DT	prep_in||principle-28/NN||treatment-31/NN	prep_of||treatment-31/NN||osteoarthritis-33/NNS	osteoarthritis-33||chondroitinsulphate-2||yes||the chondroitinsulphate is one of the major components of the extra-cellular matrix of the vertebrate connective tissues and a high value molecule, widely employed as active principle in the treatment of osteoarthritis.
nsubj||response-11/NN||improvement-1/NN	det||pain-5/NN||the-3/DT	amod||pain-5/NN||back-4/JJ	prep_of||improvement-1/NN||pain-5/NN	aux||response-11/NN||may-6/MD	cop||response-11/NN||be-7/VB	det||response-11/NN||an-8/DT	nn||response-11/NN||association-9/NN	nn||response-11/NN||macrophage-10/NN	root||ROOT-0/null||response-11/NN	det||particle-16/NN||the-14/DT	nn||particle-16/NN||metal-15/NN	conj_negcc||response-11/NN||particle-16/NN	pain-5||metal-15||no_rel||improvement of the back pain may be an association macrophage response rather than the metal particle.
num||±-4/NNS||21-2/CD	nn||±-4/NNS||â-3/NN	prep_after||had-11/VBD||±-4/NNS	num||weeks-6/NNS||9-5/CD	dep||±-4/NNS||weeks-6/NNS	nsubj||had-11/VBD||patients-8/NNS	prep_with||patients-8/NNS||type1diabetes-10/CD	root||ROOT-0/null||had-11/VBD	det||index-17/NN||a-12/DT	advmod||lower-14/JJR||significantly-13/RB	amod||index-17/NN||lower-14/JJR	nn||index-17/NN||body-15/NN	nn||index-17/NN||mass-16/NN	dobj||had-11/VBD||index-17/NN	vmod||index-17/NN||fasting-19/VBG	nn||glucose-21/NN||plasma-20/NN	dobj||fasting-19/VBG||glucose-21/NN	dobj||fasting-19/VBG||fructosamine-23/NN	conj_and||glucose-21/NN||fructosamine-23/NN	dobj||fasting-19/VBG||hba1c-25/NNS	conj_and||glucose-21/NN||hba1c-25/NNS	amod||requirement-30/NN||daily-28/JJ	nn||requirement-30/NN||insulin-29/NN	dobj||fasting-19/VBG||requirement-30/NN	conj_and||glucose-21/NN||requirement-30/NN	type1diabetes-10||insulin-29||yes||after 21 â± 9 weeks, patients with type1diabetes had a significantly lower body mass index, fasting plasma glucose, fructosamine, hba1c, and daily insulin requirement.
det||study-2/NN||this-1/DT	nsubjpass||designed-4/VBN||study-2/NN	nsubj||investigate-6/VB||study-2/NN	auxpass||designed-4/VBN||was-3/VBD	root||ROOT-0/null||designed-4/VBN	aux||investigate-6/VB||to-5/TO	xcomp||designed-4/VBN||investigate-6/VB	det||safety-8/NN||the-7/DT	dobj||investigate-6/VB||safety-8/NN	dobj||investigate-6/VB||efficacy-10/NN	conj_and||safety-8/NN||efficacy-10/NN	num||solution-16/NN||levofloxacin-12/CD	number||%-14/NN||0.5-13/CD	amod||solution-16/NN||%-14/NN	amod||solution-16/NN||ophthalmic-15/JJ	prep_of||safety-8/NN||solution-16/NN	prep_in||solution-16/NN||patients-18/NNS	nsubj||received-20/VBD||patients-18/NNS	rcmod||patients-18/NNS||received-20/VBD	dobj||received-20/VBD||treatment-21/NN	amod||ocularbacterialinfections-24/NNS||external-23/JJ	prep_for||received-20/VBD||ocularbacterialinfections-24/NNS	amod||practice-28/NN||regular-26/JJ	amod||practice-28/NN||clinical-27/JJ	prep_in||received-20/VBD||practice-28/NN	ocularbacterialinfections-24||levofloxacin-12||yes||this study was designed to investigate the safety and efficacy of levofloxacin 0.5% ophthalmic solution in patients who received treatment for external ocularbacterialinfections in regular clinical practice.
det||cancer-2/NN||the-1/DT	nsubj||stem-3/VBP||cancer-2/NN	root||ROOT-0/null||stem-3/VBP	nn||theory-5/NN||cell-4/NN	nsubj||suggests-6/VBZ||theory-5/NN	ccomp||stem-3/VBP||suggests-6/VBZ	nsubj||persist-8/VB||cscs-7/NNS	nsubj||cause-16/VB||cscs-7/NNS	ccomp||suggests-6/VBZ||persist-8/VB	prep_in||persist-8/VB||tumors-10/NNS	det||population-14/NN||a-12/DT	amod||population-14/NN||distinct-13/JJ	prep_as||tumors-10/NNS||population-14/NN	ccomp||suggests-6/VBZ||cause-16/VB	conj_and||persist-8/VB||cause-16/VB	dobj||cause-16/VB||relapse-17/NN	dobj||cause-16/VB||metastasis-19/NNS	conj_and||relapse-17/NN||metastasis-19/NNS	prepc_by||cause-16/VB||giving-21/VBG	dobj||giving-21/VBG||rise-22/NN	amod||tumors-25/NNS||new-24/JJ	prep_to||giving-21/VBG||tumors-25/NNS	rise-22||tumors-25||no_rel||the cancer stem cell theory suggests cscs persist in tumors as a distinct population and cause relapse and metastasis by giving rise to new tumors.
det||therapy-4/NN||the-1/DT	amod||therapy-4/NN||gold-2/JJ	amod||therapy-4/NN||standard-3/JJ	nsubjpass||pegylated-9/VBN||therapy-4/NN	amod||patients-7/NNS||chronichepatitisc-6/JJ	prep_for||therapy-4/NN||patients-7/NNS	auxpass||pegylated-9/VBN||is-8/VBZ	root||ROOT-0/null||pegylated-9/VBN	dobj||pegylated-9/VBN||interferon-10/NN	prep||pegylated-9/VBN||combined-11/VBN	pcomp||combined-11/VBN||with-12/IN	det||drug-15/NN||an-13/DT	amod||drug-15/NN||anti-viral-14/JJ	pobj||with-12/IN||drug-15/NN	appos||drug-15/NN||ribavirin-17/NNP	chronichepatitisc-6||interferon-10||yes||the gold standard therapy for chronichepatitisc patients is pegylated interferon combined with an anti-viral drug (ribavirin).
det||finding-2/NN||the-1/DT	nsubj||has-18/VBZ||finding-2/NN	nsubj||provides-30/VBZ||finding-2/NN	mark||has-6/VBZ||that-3/IN	nn||infection-5/NN||helminth-4/NN	nsubj||has-6/VBZ||infection-5/NN	dep||finding-2/NN||has-6/VBZ	det||association-9/NN||a-7/DT	amod||association-9/NN||profound-8/JJ	dobj||has-6/VBZ||association-9/NN	det||response-15/NN||the-11/DT	amod||response-15/NN||mucosal-12/JJ	amod||response-15/NN||humoral-13/JJ	amod||response-15/NN||immune-14/JJ	prep_with||association-9/NN||response-15/NN	aux||v.cholerae-17/VB||to-16/TO	vmod||response-15/NN||v.cholerae-17/VB	root||ROOT-0/null||has-18/VBZ	dobj||has-18/VBZ||implications-19/NNS	det||development-22/NN||the-21/DT	prep_for||implications-19/NNS||development-22/NN	amod||immunity-25/NN||protective-24/JJ	prep_of||development-22/NN||immunity-25/NN	amod||areas-28/NNS||cholera-endemic-27/JJ	prep_in||immunity-25/NN||areas-28/NNS	conj_and||has-18/VBZ||provides-30/VBZ	det||basis-33/NN||an-31/DT	amod||basis-33/NN||additional-32/JJ	dobj||provides-30/VBZ||basis-33/NN	prepc_for||provides-30/VBZ||deworming-35/VBG	dobj||deworming-35/VBG||programs-36/NNS	amod||areas-39/NNS||cholera-endemic-38/JJ	prep_in||deworming-35/VBG||areas-39/NNS	cholera--1||v.cholerae-17||no||the finding that helminth infection has a profound association with the mucosal humoral immune response to v.cholerae has implications for the development of protective immunity in cholera-endemic areas and provides an additional basis for deworming programs in cholera-endemic areas .
nsubj||undergoing-3/VBG||patients-2/NNS	prepc_among||safe-21/JJ||undergoing-3/VBG	amod||stenting-5/NN||primary-4/JJ	dobj||undergoing-3/VBG||stenting-5/NN	amod||administration-8/NN||abciximab-7/JJ	prep_with||undergoing-3/VBG||administration-8/NN	amod||reversal-12/NN||immediate-10/JJ	nn||reversal-12/NN||post-pci-11/NN	nsubjpass||safe-21/JJ||reversal-12/NN	nsubjpass||associated-23/VBN||reversal-12/NN	vmod||reversal-12/NN||anticoagulation-13/VBN	agent||anticoagulation-13/VBN||protamine-15/NN	amod||infusion-19/NN||associated-17/VBN	nn||infusion-19/NN||heparin-18/NN	prep_without||anticoagulation-13/VBN||infusion-19/NN	auxpass||safe-21/JJ||is-20/VBZ	cop||safe-21/JJ||is-20/VBZ	root||ROOT-0/null||safe-21/JJ	conj_and||safe-21/JJ||associated-23/VBN	det||reduction-27/NN||a-25/DT	amod||reduction-27/NN||significant-26/JJ	prep_with||associated-23/VBN||reduction-27/NN	amod||complications-31/NNS||major-29/JJ	amod||complications-31/NNS||bleeding-30/VBG	prep_in||reduction-27/NN||complications-31/NNS	heparin-18||bleeding-30||no_rel||among patients undergoing primary stenting with abciximab administration, immediate post-pci reversal anticoagulation by protamine without associated heparin infusion is safe and associated with a significant reduction in major bleeding complications.
det||parameters-3/NNS||the-1/DT	amod||parameters-3/NNS||immune-2/JJ	nsubj||undefined-19/JJ||parameters-3/NNS	amod||candidates-7/NNS||hiv/aids-5/JJ	nn||candidates-7/NNS||vaccine-6/NN	prep_of||parameters-3/NNS||candidates-7/NNS	nsubj||relevant-11/JJ||candidates-7/NNS	aux||relevant-11/JJ||might-9/MD	cop||relevant-11/JJ||be-10/VB	rcmod||candidates-7/NNS||relevant-11/JJ	prep_in||relevant-11/JJ||protection-13/NN	amod||infection-16/NN||hiv-1-15/JJ	prep_against||protection-13/NN||infection-16/NN	cop||undefined-19/JJ||are-17/VBP	advmod||undefined-19/JJ||still-18/RB	root||ROOT-0/null||undefined-19/JJ	aids--1||hiv--1||no||the immune parameters of hiv/aids vaccine candidates that might be relevant in protection against hiv-1 infection are still undefined.
poss||laboratory-3/NN||our-2/PRP$	prep_in||address-6/VBP||laboratory-3/NN	nsubj||address-6/VBP||we-5/PRP	root||ROOT-0/null||address-6/VBP	advmod||unsettled-8/VBN||still-7/RB	amod||questions-9/NNS||unsettled-8/VBN	nsubj||ellipticine-47/VBP||questions-9/NNS	nsubj||mechanism-51/NN||questions-9/NNS	prep_of||ellipticine-47/VBP||mechanisms-13/NNS	prep_of||mechanisms-13/NNS||action-15/NN	amod||drugs-18/NNS||dna-damaging-17/JJ	prep_of||action-15/NN||drugs-18/NNS	nsubj||use-21/VBP||both-19/DT	advmod||use-21/VBP||currently-20/RB	rcmod||mechanisms-13/NNS||use-21/VBP	prep_for||use-21/VBP||treatment-23/NN	amod||neuroblastomas-26/NNS||human-25/JJ	prep_of||treatment-23/NN||neuroblastomas-26/NNS	dep||mechanisms-13/NNS||doxorubicin-28/NN	dep||mechanisms-13/NNS||cis-platin-30/NN	conj_and||doxorubicin-28/NN||cis-platin-30/NN	dep||mechanisms-13/NNS||cyclophosphamide-32/NN	conj_and||doxorubicin-28/NN||cyclophosphamide-32/NN	dep||mechanisms-13/NNS||etoposide-34/NN	conj_and||doxorubicin-28/NN||etoposide-34/NN	det||growth-41/NN||another-37/DT	amod||growth-41/NN||anticancer-38/JJ	nn||growth-41/NN||agent-39/NN	amod||growth-41/NN||decreasing-40/VBG	conj_and||mechanisms-13/NNS||growth-41/NN	prep_of||ellipticine-47/VBP||growth-41/NN	prep_of||growth-41/NN||neuroblastomas-43/NNS	prep_in||neuroblastomas-43/NNS||vitro-45/NNP	rcmod||questions-9/NNS||ellipticine-47/VBP	cop||mechanism-51/NN||are-49/VBP	amod||mechanism-51/NN||predominant-50/JJ	ccomp||address-6/VBP||mechanism-51/NN	dep||mechanism-51/NN||s-53/PRP	amod||mechanism-51/NN||responsible-55/JJ	poss||action-59/NN||their-57/PRP$	nn||action-59/NN||antitumor-58/NN	prep_for||responsible-55/JJ||action-59/NN	nn||lines-63/NNS||neuroblastoma-61/NN	nn||lines-63/NNS||cell-62/NN	prep_in||mechanism-51/NN||lines-63/NNS	prep_in||mechanism-51/NN||vitro-65/NN	neuroblastomas-43||cyclophosphamide-32||yes||in our laboratory, we address still unsettled questions, which of mechanisms of action of dna-damaging drugs both currently use for treatment of human neuroblastomas (doxorubicin, cis-platin, cyclophosphamide and etoposide) and another anticancer agent decreasing growth of neuroblastomas in vitro , ellipticine, are predominant mechanism(s) responsible for their antitumor action in neuroblastoma cell lines in vitro .
det||attempt-3/NN||an-2/DT	prep_in||constructed-13/VBN||attempt-3/NN	aux||improve-5/VB||to-4/TO	vmod||attempt-3/NN||improve-5/VB	nn||efficiency-7/NN||expression-6/NN	dobj||improve-5/VB||efficiency-7/NN	det||baculovirus-11/NNS||a-9/DT	amod||baculovirus-11/NNS||recombinant-10/JJ	nsubjpass||constructed-13/VBN||baculovirus-11/NNS	auxpass||constructed-13/VBN||was-12/VBD	root||ROOT-0/null||constructed-13/VBN	xcomp||constructed-13/VBN||expressing-14/VBG	dobj||expressing-14/VBG||hemagglutinin-15/NN	appos||hemagglutinin-15/NN||ha-17/NN	amod||influenzavirus-21/NNS||h5n1-20/JJ	prep_of||hemagglutinin-15/NN||influenzavirus-21/NNS	det||control-24/NN||the-23/DT	prep_under||expressing-14/VBG||control-24/NN	amod||promoter-28/NN||wssv-26/JJ	amod||promoter-28/NN||ie1-27/JJ	prep_of||control-24/NN||promoter-28/NN	h5n1-20||influenzavirus-21||no||in an attempt to improve expression efficiency, a recombinant baculovirus was constructed expressing hemagglutinin (ha) of h5n1 influenzavirus under the control of wssv ie1 promoter.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||the-3/DT	dobj||report-2/VBP||case-4/NN	det||man-8/NN||a-6/DT	amod||man-8/NN||52-year-old-7/JJ	prep_of||case-4/NN||man-8/NN	prep_with||report-2/VBP||hiv-aids-10/NNS	acomp||report-2/VBP||non-complaint-12/JJ	advmod||active-15/JJ||highly-14/RB	amod||therapy-17/NN||active-15/JJ	amod||therapy-17/NN||antiretroviral-16/JJ	prep_with||non-complaint-12/JJ||therapy-17/NN	nsubj||presented-20/VBN||therapy-17/NN	rcmod||therapy-17/NN||presented-20/VBN	amod||dysphagia-23/NN||long-standing-22/JJ	prep_with||presented-20/VBN||dysphagia-23/NN	aids--1||hiv--1||no||we report the case of a 52-year-old man with hiv-aids, non-complaint with highly active antiretroviral therapy, who presented with long-standing dysphagia.
det||vaccines-3/NNS||the-1/DT	num||vaccines-3/NNS||two-2/CD	agent||recommended-32/VBN||vaccines-3/NNS	nsubj||killed-49/VBD||vaccines-3/NNS	advmod||available-5/JJ||currently-4/RB	csubjpass||recommended-32/VBN||available-5/JJ	csubj||consists-38/VBZ||available-5/JJ	advmod||vaccine-15/NN||worldwide-7/RB	cop||vaccine-15/NN||are-8/VBP	dep||vaccine-15/NN||1-10/LS	det||vaccine-15/NN||the-12/DT	amod||vaccine-15/NN||killed-13/JJS	amod||vaccine-15/NN||oral-14/JJ	prepc_in||available-5/JJ||vaccine-15/NN	dep||vaccine-15/NN||dukoral-17/VB	dep||dukoral-17/VB||licensed-19/VBN	number||$-22/CD||sblâ-21/CD	prep_by||licensed-19/VBN||$-22/CD	vmod||$-22/CD||sweden-24/VBN	number||$-27/CD||crucellâ-26/CD	prep_to||sweden-24/VBN||$-27/CD	dep||licensed-19/VBN||holland-29/JJ	auxpass||recommended-32/VBN||is-31/VBZ	rcmod||vaccines-3/NNS||recommended-32/VBN	prep_since||recommended-32/VBN||1999-34/CD	rcmod||vaccines-3/NNS||consists-38/VBZ	conj_and||recommended-32/VBN||consists-38/VBZ	det||mixture-41/NN||a-40/DT	prep_of||vaccines-3/NNS||mixture-41/NN	num||preparations-44/NNS||four-43/CD	prep_of||mixture-41/NN||preparations-44/NNS	prep_of||preparations-44/NNS||heat-46/NN	prep_of||preparations-44/NNS||formalin-48/NN	conj_or||heat-46/NN||formalin-48/NN	root||ROOT-0/null||killed-49/VBD	amod||o1-53/NNS||whole-50/JJ	nn||o1-53/NNS||cell-51/NN	nn||o1-53/NNS||vibriocholera-52/NN	dobj||killed-49/VBD||o1-53/NNS	nsubjpass||added-70/VBN||o1-53/NNS	dep||o1-53/NNS||inaba-55/NN	dep||o1-53/NNS||ogaba-57/NN	conj_and||inaba-55/NN||ogaba-57/NN	dep||inaba-55/NN||serotypes-58/NNS	dep||o1-53/NNS||classical-61/JJ	conj_and||inaba-55/NN||classical-61/JJ	nn||biotypes-65/NNS||el-63/FW	nn||biotypes-65/NNS||tor-64/FW	conj_and||inaba-55/NN||biotypes-65/NNS	conj_and||classical-61/JJ||biotypes-65/NNS	auxpass||added-70/VBN||are-68/VBP	advmod||added-70/VBN||then-69/RB	rcmod||o1-53/NNS||added-70/VBN	prepc_with||added-70/VBN||purified-72/VBG	amod||toxin-75/NN||recombinant-73/JJ	nn||toxin-75/NN||cholera-74/NN	dobj||purified-72/VBG||toxin-75/NN	discourse||toxin-75/NN||ct-77/UH	dep||subunit-80/NN||b-79/SYM	dep||toxin-75/NN||subunit-80/NN	cholera-74||vibriocholera-52||no||the two vaccines currently available in worldwide are (1) the killed oral vaccine (dukoral, licensed by sblâ€“sweden to crucellâ€“holland) is recommended since 1999 by who and consists of a mixture of four preparations of heat or formalin killed whole cell vibriocholera o1 (inaba and ogaba serotypes, and classical and el tor biotypes) that are then added with purified recombinant cholera toxin (ct) b subunit.
amod||dysfunction-2/NN||endothelial-1/JJ	nsubj||present-5/JJ||dysfunction-2/NN	nsubjpass||induced-15/VBN||dysfunction-2/NN	cop||present-5/JJ||is-3/VBZ	advmod||present-5/JJ||frequently-4/RB	root||ROOT-0/null||present-5/JJ	prep_in||present-5/JJ||individuals-7/NNS	prep_with||individuals-7/NNS||insulinresistance-9/NN	prep_with||individuals-7/NNS||type2diabetes-11/NNS	conj_or||insulinresistance-9/NN||type2diabetes-11/NNS	aux||induced-15/VBN||can-13/MD	auxpass||induced-15/VBN||be-14/VB	conj_and||present-5/JJ||induced-15/VBN	amod||meals-20/NNS||high-fat-17/JJ	conj_or||high-fat-17/JJ||high-carbohydrate-19/JJ	amod||meals-20/NNS||high-carbohydrate-19/JJ	agent||induced-15/VBN||meals-20/NNS	carbohydrate--1||type2diabetes-11||no_rel||endothelial dysfunction is frequently present in individuals with insulinresistance or type2diabetes and can be induced by high-fat or high-carbohydrate meals.
det||model-3/NN||a-2/DT	prep_in||examined-8/VBD||model-3/NN	amod||pulmonaryemphysema-6/NN||elastase-induced-5/JJ	prep_of||model-3/NN||pulmonaryemphysema-6/NN	nsubj||examined-8/VBD||we-7/PRP	root||ROOT-0/null||examined-8/VBD	det||response-10/NN||the-9/DT	nsubj||fluid-38/JJ||response-10/NN	amod||mice-13/NNS||il-17a-deficient-12/JJ	prep_of||response-10/NN||mice-13/NNS	nn||inflammation-17/NN||monitoring-15/NN	nn||inflammation-17/NN||airway-16/NN	prep_of||response-10/NN||inflammation-17/NN	conj_and||mice-13/NNS||inflammation-17/NN	amod||compliance-20/NN||static-19/JJ	prep_of||response-10/NN||compliance-20/NN	conj_and||mice-13/NNS||compliance-20/NN	nn||histology-23/NN||lung-22/NN	prep_of||response-10/NN||histology-23/NN	conj_and||mice-13/NNS||histology-23/NN	prep_of||response-10/NN||levels-25/NNS	conj_and||mice-13/NNS||levels-25/NNS	amod||chemokine-28/NN||neutrophil-related-27/JJ	prep_of||response-10/NN||chemokine-28/NN	nn||cytokines-31/NNS||pro-inflammatory-30/NN	prep_of||response-10/NN||cytokines-31/NNS	conj_and||chemokine-28/NN||cytokines-31/NNS	nn||lavage-34/NN||bronchoalveolar-33/NN	prep_in||chemokine-28/NN||lavage-34/NN	appos||response-10/NN||bal-36/NN	xcomp||examined-8/VBD||fluid-38/JJ	pulmonaryemphysema-6||bal-36||no_rel||in a model of elastase-induced pulmonaryemphysema we examined the response of il-17a-deficient mice, monitoring airway inflammation, static compliance, lung histology and levels of neutrophil-related chemokine and pro-inflammatory cytokines in bronchoalveolar lavage (bal) fluid.
amod||effects-2/NNS||direct-1/JJ	nsubjpass||evaluated-9/VBN||effects-2/NNS	prep_of||effects-2/NNS||calcitonin-4/NN	nn||cartilage-7/NN||articular-6/NN	prep_on||calcitonin-4/NN||cartilage-7/NN	auxpass||evaluated-9/VBN||were-8/VBD	root||ROOT-0/null||evaluated-9/VBN	dep||measurement-13/NN||1-11/LS	agent||evaluated-9/VBN||measurement-13/NN	nn||synthesis-16/NN||proteoglycan-15/NN	prep_of||measurement-13/NN||synthesis-16/NN	prep_by||synthesis-16/NN||incorporation-18/NN	prep_of||incorporation-18/NN||radioactive-20/NN	vmod||radioactive-20/NN||labeled-21/VBN	amod||ci-27/NN||35so4-22/JJ	amod||ci-27/NN||-LSB--23/JJ	num||ci-27/NN||5-24/CD	nn||ci-27/NN||î-25/NN	num||ci-27/NN||1/4-26/CD	dobj||labeled-21/VBN||ci-27/NN	xcomp||labeled-21/VBN||-RSB--28/VBG	dep||quantification-31/NN||2-29/LS	dobj||-RSB--28/VBG||quantification-31/NN	nn||formation-34/NN||collagen-type-ii-33/NN	prep_of||quantification-31/NN||formation-34/NN	prep_by||formation-34/NN||pro-peptides-36/NNS	nn||elisa-44/NN||collagen-38/NN	nn||elisa-44/NN||type-39/NN	nn||elisa-44/NN||ii-40/NN	nn||elisa-44/NN||piinp-42/NN	prep_of||pro-peptides-36/NNS||elisa-44/NN	dep||expression-49/NN||3-46/LS	nn||expression-49/NN||qpcr-48/NN	appos||elisa-44/NN||expression-49/NN	det||receptor-53/NN||the-51/DT	nn||receptor-53/NN||calcitonin-52/NN	prep_of||expression-49/NN||receptor-53/NN	nn||chondrocytes-56/NNS||oa-55/NN	prep_in||receptor-53/NN||chondrocytes-56/NNS	vmod||chondrocytes-56/NNS||using-57/VBG	num||pairs-61/NNS||four-58/CD	amod||pairs-61/NNS||individual-59/JJ	nn||pairs-61/NNS||primer-60/NN	dobj||using-57/VBG||pairs-61/NNS	dep||activation-65/NN||4-63/LS	appos||quantification-31/NN||activation-65/NN	det||camp-68/NN||the-67/DT	prep_of||activation-65/NN||camp-68/NN	vmod||camp-68/NN||signaling-69/VBG	advmod||signaling-69/VBG||pathway-70/RB	agent||signaling-69/VBG||eia-72/NN	dep||investigations-77/NNS||5-75/CD	agent||evaluated-9/VBN||investigations-77/NNS	conj_and||measurement-13/NN||investigations-77/NNS	amod||activity-80/NN||metabolic-79/JJ	prep_of||investigations-77/NNS||activity-80/NN	prep_by||activity-80/NN||alamarblue-82/NN	collagen-38||eia-72||no_rel||direct effects of calcitonin on articular cartilage were evaluated by 1) measurement of proteoglycan synthesis by incorporation of radioactive labeled 35so4 [5 î¼ci] 2) quantification of collagen-type-ii formation by pro-peptides of collagen type ii (piinp) elisa, 3) qpcr expression of the calcitonin receptor in oa chondrocytes using four individual primer pairs, 4) activation of the camp signaling pathway by eia and, 5) investigations of metabolic activity by alamarblue.
neg||difference-4/NN||no-1/DT	advmod||significant-3/JJ||statistically-2/RB	amod||difference-4/NN||significant-3/JJ	nsubjpass||found-6/VBN||difference-4/NN	auxpass||found-6/VBN||was-5/VBD	root||ROOT-0/null||found-6/VBN	det||groups-12/NNS||the-8/DT	nn||groups-12/NNS||dexamethasone-9/NN	conj_and||dexamethasone-9/NN||placebo-11/NN	nn||groups-12/NNS||placebo-11/NN	prep_between||found-6/VBN||groups-12/NNS	nn||score-15/NN||pain-14/NN	prep_in||found-6/VBN||score-15/NN	prep_in||found-6/VBN||nausea-17/NN	conj_or||score-15/NN||nausea-17/NN	prep_in||found-6/VBN||vomiting-19/NN	conj_or||score-15/NN||vomiting-19/NN	prep_in||found-6/VBN||irritability-21/NN	conj_or||score-15/NN||irritability-21/NN	amod||postoperatively-26/NN||analgesic-24/JJ	nn||postoperatively-26/NN||requirement-25/NN	prep_in||found-6/VBN||postoperatively-26/NN	conj_or||score-15/NN||postoperatively-26/NN	vomiting-19||dexamethasone-9||yes||no statistically significant difference was found between the dexamethasone and placebo groups in pain score, nausea, vomiting, irritability, or analgesic requirement postoperatively.
aux||compare-2/VB||to-1/TO	csubj||ort-22/VBP||compare-2/VB	det||efficacy-4/NN||the-3/DT	dobj||compare-2/VB||efficacy-4/NN	prep_of||efficacy-4/NN||ondansetron-6/NN	prep_of||efficacy-4/NN||domperidone-8/NN	conj_and||ondansetron-6/NN||domperidone-8/NN	det||treatment-12/NN||the-10/DT	amod||treatment-12/NN||symptomatic-11/JJ	prep_for||compare-2/VB||treatment-12/NN	nsubj||failed-21/VBN||treatment-12/NN	prep_of||treatment-12/NN||vomiting-14/NN	prep_in||vomiting-14/NN||children-16/NNS	prep_with||children-16/NNS||ag-18/NN	aux||failed-21/VBN||have-20/VBP	rcmod||treatment-12/NN||failed-21/VBN	root||ROOT-0/null||ort-22/VBP	vomiting-14||ondansetron-6||yes||to compare the efficacy of ondansetron and domperidone for the symptomatic treatment of vomiting in children with ag who have failed ort.
nsubj||comparable-10/JJ||disability-1/NN	vmod||disability-1/NN||associated-2/VBN	nn||disorder-6/NN||alcohol-4/NN	nn||disorder-6/NN||use-5/NN	prep_with||associated-2/VBN||disorder-6/NN	prep_with||associated-2/VBN||anxiety-8/NN	conj_and||disorder-6/NN||anxiety-8/NN	cop||comparable-10/JJ||is-9/VBZ	root||ROOT-0/null||comparable-10/JJ	prep_to||comparable-10/JJ||disability-12/NN	prep_on_account_of||disability-12/NN||ocd-16/NN	alcohol-4||ocd-16||no_rel||disability associated with alcohol use disorder and anxiety is comparable to disability on account of ocd.
nn||deficiency-2/NN||insulin-1/NN	nsubjpass||induced-6/VBN||deficiency-2/NN	conj_and||deficiency-2/NN||hyperglycemia-4/NN	nsubjpass||induced-6/VBN||hyperglycemia-4/NN	auxpass||induced-6/VBN||were-5/VBD	root||ROOT-0/null||induced-6/VBN	prep_with||induced-6/VBN||streptozotocin-8/NN	appos||streptozotocin-8/NN||stz-10/NN	amod||mice-16/NNS||c57bl/6-13/JJ	nn||mice-16/NNS||fxr-14/NN	nn||mice-16/NNS||ko-15/NN	prep_in||streptozotocin-8/NN||mice-16/NNS	insulin-1||hyperglycemia-4||no_rel||insulin deficiency and hyperglycemia were induced with streptozotocin (stz) in c57bl/6 fxr ko mice.
nsubj||rare-32/JJ||diseases-1/NNS	vmod||diseases-1/NNS||associated-2/VBN	amod||infections-8/NNS||epstein-barrvirus-4/JJ	appos||infections-8/NNS||ebv-6/NN	prep_with||associated-2/VBN||infections-8/NNS	prep_such_as||associated-2/VBN||infectiousmononucleosis-12/NNS	appos||infectiousmononucleosis-12/NNS||im-14/NN	amod||lymphohistiocytosis-19/NNS||ebv-associated-17/JJ	amod||lymphohistiocytosis-19/NNS||hemophagocytic-18/JJ	prep_such_as||associated-2/VBN||lymphohistiocytosis-19/NNS	conj_and||infectiousmononucleosis-12/NNS||lymphohistiocytosis-19/NNS	appos||lymphohistiocytosis-19/NNS||ebv-hlh-21/NN	amod||ebvinfection-26/NN||chronic-24/JJ	amod||ebvinfection-26/NN||active-25/JJ	prep_such_as||associated-2/VBN||ebvinfection-26/NN	conj_and||infectiousmononucleosis-12/NNS||ebvinfection-26/NN	appos||ebvinfection-26/NN||caebv-28/NNP	cop||rare-32/JJ||are-30/VBP	neg||rare-32/JJ||not-31/RB	root||ROOT-0/null||rare-32/JJ	amod||children-35/NNS||chinese-34/JJ	prep_in||rare-32/JJ||children-35/NNS	infectiousmononucleosis-12||ebv-6||no||diseases associated with epstein-barrvirus (ebv) infections, such as infectiousmononucleosis (im), ebv-associated hemophagocytic lymphohistiocytosis (ebv-hlh) and chronic active ebvinfection (caebv) are not rare in chinese children.
nsubj||transpires-2/VBZ||it-1/PRP	root||ROOT-0/null||transpires-2/VBZ	mark||essential-17/JJ||that-3/IN	mark||dispensable-7/JJ||although-4/IN	nsubj||dispensable-7/JJ||rms-5/NN	cop||dispensable-7/JJ||are-6/VBP	advcl||essential-17/JJ||dispensable-7/JJ	prepc_for||dispensable-7/JJ||clearing-9/VBG	dobj||clearing-9/VBG||pmns-10/NNS	amod||inflammation-13/NN||self-limiting-12/JJ	prep_during||clearing-9/VBG||inflammation-13/NN	nsubj||essential-17/JJ||they-15/PRP	cop||essential-17/JJ||are-16/VBP	ccomp||transpires-2/VBZ||essential-17/JJ	prepc_for||essential-17/JJ||signaling-19/VBG	nn||repopulation-22/NN||postresolution-20/NN	nn||repopulation-22/NN||lymphocyte-21/NN	dobj||signaling-19/VBG||repopulation-22/NN	number||2-25/CD||cox-24/CD	num||lipids-26/NNS||2-25/CD	prep_via||repopulation-22/NN||lipids-26/NNS	lipids-26||inflammation-13||no_rel||it transpires that although rms are dispensable for clearing pmns during self-limiting inflammation, they are essential for signaling postresolution lymphocyte repopulation via cox 2 lipids.
det||objectives-3/NNS||the-1/DT	amod||objectives-3/NNS||overall-2/JJ	nsubj||are-7/VBP||objectives-3/NNS	det||paper-6/NN||this-5/DT	prep_of||objectives-3/NNS||paper-6/NN	root||ROOT-0/null||are-7/VBP	dobj||are-7/VBP||1-9/CD	nsubj||provide-12/VB||1-9/CD	aux||provide-12/VB||to-11/TO	xcomp||are-7/VBP||provide-12/VB	det||overview-14/NN||an-13/DT	dobj||provide-12/VB||overview-14/NN	amod||studies-17/NNS||recent-16/JJ	prep_on||provide-12/VB||studies-17/NNS	nsubj||highlight-19/VB||studies-17/NNS	rcmod||studies-17/NNS||highlight-19/VB	det||risk-22/NN||the-20/DT	amod||risk-22/NN||increased-21/VBN	dobj||highlight-19/VB||risk-22/NN	amod||complications-25/NNS||respiratory-24/JJ	prep_for||risk-22/NN||complications-25/NNS	prep_following||complications-25/NNS||sedation-27/NN	prep_following||complications-25/NNS||analgesia-29/NN	conj_and||sedation-27/NN||analgesia-29/NN	prep_in||sedation-27/NN||children-31/NNS	amod||disabilities-34/NNS||developmental-33/JJ	prep_with||children-31/NNS||disabilities-34/NNS	prep_with||children-31/NNS||neurologicdisorders-36/NNS	conj_and||disabilities-34/NNS||neurologicdisorders-36/NNS	appos||disabilities-34/NNS||2-39/CD	aux||provide-42/VB||to-41/TO	vmod||risk-22/NN||provide-42/VB	det||understanding-45/NN||a-43/DT	amod||understanding-45/NN||better-44/JJR	dobj||provide-42/VB||understanding-45/NN	nsubjpass||used-54/VBN||understanding-45/NN	prep_of||understanding-45/NN||sedatives-47/NNS	amod||medications-50/NNS||analgesic-49/JJ	prep_of||understanding-45/NN||medications-50/NNS	conj_and||sedatives-47/NNS||medications-50/NNS	auxpass||used-54/VBN||are-52/VBP	advmod||used-54/VBN||commonly-53/RB	rcmod||understanding-45/NN||used-54/VBN	prep_in||used-54/VBN||children-56/NNS	amod||disabilities-59/NNS||developmental-58/JJ	prep_with||children-56/NNS||disabilities-59/NNS	prep_with||children-56/NNS||neurologicdisorders-61/NNS	conj_and||disabilities-59/NNS||neurologicdisorders-61/NNS	det||system-66/NN||the-63/DT	amod||system-66/NN||central-64/JJ	amod||system-66/NN||nervous-65/JJ	prep_on||used-54/VBN||system-66/NN	neurologicdisorders-61||sedatives-47||no_rel||the overall objectives of this paper are (1) to provide an overview on recent studies that highlight the increased risk for respiratory complications following sedation and analgesia in children with developmental disabilities and neurologicdisorders, (2) to provide a better understanding of sedatives and analgesic medications which are commonly used in children with developmental disabilities and neurologicdisorders on the central nervous system.
nsubj||plays-7/VBZ||glucose-1/NN	vmod||glucose-1/NN||produced-2/VBN	agent||produced-2/VBN||gluconeogenesis-4/NNS	agent||produced-2/VBN||glycogenolysis-6/NNS	conj_and||gluconeogenesis-4/NNS||glycogenolysis-6/NNS	root||ROOT-0/null||plays-7/VBZ	det||role-10/NN||an-8/DT	amod||role-10/NN||important-9/JJ	dobj||plays-7/VBZ||role-10/NN	amod||hyperglycemia-13/NN||aggravating-12/VBG	prep_in||role-10/NN||hyperglycemia-13/NN	prep_in||hyperglycemia-13/NN||diabetes-15/NN	amod||function-20/NN||altered-18/JJ	amod||function-20/NN||mitochondrial-19/JJ	nsubjpass||associated-22/VBN||function-20/NN	auxpass||associated-22/VBN||is-21/VBZ	conj_and||plays-7/VBZ||associated-22/VBN	amod||production-26/NN||impaired-24/VBN	nn||production-26/NN||energy-25/NN	prep_with||associated-22/VBN||production-26/NN	hyperglycemia-13||glucose-1||no||glucose produced by gluconeogenesis and glycogenolysis plays an important role in aggravating hyperglycemia in diabetes, and altered mitochondrial function is associated with impaired energy production.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	cu-63||toxicshocksyndrome-33||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
nsubj||disease-5/NN||anthrax-1/NN	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||a-3/DT	amod||disease-5/NN||fatal-4/JJ	root||ROOT-0/null||disease-5/NN	vmod||disease-5/NN||caused-6/VBN	agent||caused-6/VBN||strains-8/NNS	prep_of||strains-8/NNS||bacillusanthracis-10/NNS	anthrax-1||bacillusanthracis-10||no||anthrax is a fatal disease caused by strains of bacillusanthracis .
amod||t-5/NNS||alefacept-1/JJ	conj_and||alefacept-1/JJ||efalizumab-3/JJ	amod||t-5/NNS||efalizumab-3/JJ	nn||t-5/NNS||target-4/NN	nsubj||lymphocytes-6/VBZ||t-5/NNS	nsubj||effective-9/JJ||t-5/NNS	nsubjpass||approved-19/VBN||t-5/NNS	root||ROOT-0/null||lymphocytes-6/VBZ	cop||effective-9/JJ||are-8/VBP	conj_but||lymphocytes-6/VBZ||effective-9/JJ	det||treatment-12/NN||the-11/DT	prep_in||effective-9/JJ||treatment-12/NN	prep_of||treatment-12/NN||psoriasis-14/NNS	auxpass||approved-19/VBN||are-17/VBP	neg||approved-19/VBN||not-18/RB	conj_but||lymphocytes-6/VBZ||approved-19/VBN	prep_for||approved-19/VBN||psoriaticarthritis-21/NNS	psoriasis-14||alefacept-1||yes||alefacept and efalizumab target t lymphocytes, are effective in the treatment of psoriasis, but are not approved for psoriaticarthritis.
nsubj||tested-2/VBD||we-1/PRP	root||ROOT-0/null||tested-2/VBD	det||hypothesis-4/NNS||the-3/DT	dobj||tested-2/VBD||hypothesis-4/NNS	mark||show-20/VB||that-5/IN	nsubj||show-20/VB||extracts-6/NNS	amod||plants-10/NNS||haudenosaunee-8/JJ	amod||plants-10/NNS||medicinal-9/JJ	prep_from||extracts-6/NNS||plants-10/NNS	vmod||plants-10/NNS||used-11/VBN	aux||treat-13/VB||to-12/TO	xcomp||used-11/VBN||treat-13/VB	dobj||treat-13/VB||symptoms-14/NNS	advmod||caused-16/VBN||often-15/RB	vmod||symptoms-14/NNS||caused-16/VBN	agent||caused-16/VBN||bacterialinfection-18/NN	aux||show-20/VB||would-19/MD	ccomp||tested-2/VBD||show-20/VB	amod||properties-22/NNS||antibacterial-21/JJ	dobj||show-20/VB||properties-22/NNS	nn||assays-25/NNS||laboratory-24/NN	prep_in||show-20/VB||assays-25/NNS	mark||effective-34/JJ||that-28/IN	det||extracts-30/NNS||these-29/DT	nsubj||effective-34/JJ||extracts-30/NNS	aux||effective-34/JJ||would-31/MD	cop||effective-34/JJ||be-32/VB	advmod||effective-34/JJ||more-33/RBR	ccomp||tested-2/VBD||effective-34/JJ	conj_and||show-20/VB||effective-34/JJ	advmod||virulent-37/JJ||moderately-36/RB	amod||bacteria-38/NNS||virulent-37/JJ	prep_against||effective-34/JJ||bacteria-38/NNS	amod||bacteria-42/NNS||less-40/JJR	nn||bacteria-42/NNS||virulent-41/NN	prep_than||effective-34/JJ||bacteria-42/NNS	bacterialinfection-18||bacteria-42||no||we tested the hypothesis that extracts from haudenosaunee medicinal plants used to treat symptoms often caused by bacterialinfection would show antibacterial properties in laboratory assays, and that these extracts would be more effective against moderately virulent bacteria than less virulent bacteria.
det||baseline-3/NN||the-1/DT	amod||baseline-3/NN||lower-2/JJR	nsubj||predicted-6/VBD||baseline-3/NN	vmod||baseline-3/NN||hbsag-4/VBG	dobj||hbsag-4/VBG||level-5/NN	root||ROOT-0/null||predicted-6/VBD	det||decline-9/NN||the-7/DT	amod||decline-9/NN||hbsag-8/VBG	dobj||predicted-6/VBD||decline-9/NN	amod||loss-12/NN||hbsag-11/VBG	dobj||predicted-6/VBD||loss-12/NN	conj_and||decline-9/NN||loss-12/NN	mark||predicted-19/VBD||whereas-14/IN	det||hbv-dna-18/NN||the-15/DT	amod||hbv-dna-18/NN||higher-16/JJR	nn||hbv-dna-18/NN||baseline-17/NN	nsubj||predicted-19/VBD||hbv-dna-18/NN	advcl||predicted-6/VBD||predicted-19/VBD	det||flare-22/NN||the-20/DT	nn||flare-22/NN||hepatitis-21/NN	dobj||predicted-19/VBD||flare-22/NN	hbv--1||hbsag-11||yes||the lower baseline hbsag level predicted the hbsag decline and hbsag loss, whereas the higher baseline hbv-dna predicted the hepatitis flare.
aux||observe-2/VB||to-1/TO	advcl||followed-31/VBN||observe-2/VB	det||prognosis-5/NN||the-3/DT	amod||prognosis-5/NN||long-4/JJ	dobj||observe-2/VB||prognosis-5/NN	amod||patients-11/NNS||chronichepatitisc-7/JJ	appos||patients-11/NNS||chc-9/NN	prep_of||prognosis-5/NN||patients-11/NNS	nn||fibrosis-15/NN||stage-13/NN	num||fibrosis-15/NN||3-14/CD	prep_with||observe-2/VB||fibrosis-15/NN	appos||fibrosis-15/NN||f3-17/NNP	num||patients-22/NNS||55-20/CD	nn||patients-22/NNS||chc-21/NN	nsubjpass||followed-31/VBN||patients-22/NNS	amod||interferon-25/NN||initial-24/JJ	prep_after||patients-22/NNS||interferon-25/NN	dep||patients-22/NNS||ifn-27/VBN	dep||patients-22/NNS||therapy-29/NN	auxpass||followed-31/VBN||were-30/VBD	root||ROOT-0/null||followed-31/VBN	prt||followed-31/VBN||up-32/RP	quantmod||12-36/CD||up-34/IN	dep||12-36/CD||to-35/TO	num||years-37/NNS||12-36/CD	prep_for||followed-31/VBN||years-37/NNS	nn||±-42/NN||average-39/NN	num||±-42/NN||9.8-40/CD	nn||±-42/NN||â-41/NN	dep||years-37/NNS||±-42/NN	num||years-44/NNS||2.3-43/CD	dep||±-42/NN||years-44/NNS	chronichepatitisc-7||interferon-25||yes||to observe the long prognosis of chronichepatitisc (chc) patients with stage 3 fibrosis (f3), 55 chc patients after initial interferon (ifn) therapy were followed up for up to 12 years (average 9.8 â± 2.3 years).
nsubj||are-2/VBP||patients-1/NNS	root||ROOT-0/null||are-2/VBP	amod||immunity-5/NN||dysregulated-4/JJ	prep_with||are-2/VBP||immunity-5/NN	prep_with||are-2/VBP||immunity-5/NN	conj_or||immunity-5/NN||immunity-5/NN	amod||transplantation-9/NN||solid-7/JJ	nn||transplantation-9/NN||organ-8/NN	prep_after||immunity-5/NN||transplantation-9/NN	appos||transplantation-9/NN||hiv/aids-11/NNS	prep_with||immunity-5/NN||psoriasis-15/NNS	prep_after||are-2/VBP||treatment-17/NN	prep_with||treatment-17/NN||etanercept-19/NN	aids--1||hiv--1||no||patients are with dysregulated immunity after solid organ transplantation, hiv/aids, or with psoriasis after treatment with etanercept.
nsubj||attenuate-3/VB||plants-1/NNS	aux||attenuate-3/VB||can-2/MD	root||ROOT-0/null||attenuate-3/VB	det||replication-5/NN||the-4/DT	dobj||attenuate-3/VB||replication-5/NN	nn||viruses-8/NNS||plant-7/NN	prep_of||replication-5/NN||viruses-8/NNS	prep_of||replication-5/NN||viroids-10/NNS	conj_and||viruses-8/NNS||viroids-10/NNS	nn||silencing-13/NN||rna-12/NN	prep_by||attenuate-3/VB||silencing-13/NN	vmod||silencing-13/NN||induced-14/VBN	nn||infection-19/NN||virus-16/NN	conj_and||virus-16/NN||viroid-18/NN	nn||infection-19/NN||viroid-18/NN	agent||induced-14/VBN||infection-19/NN	virus-16||viruses-8||no||plants can attenuate the replication of plant viruses and viroids by rna silencing induced by virus and viroid infection.
prep_in||aggravated-11/VBN||addition-2/NN	amod||injury-6/NN||alcohol-induced-4/JJ	nn||injury-6/NN||liver-5/NN	nsubjpass||aggravated-11/VBN||injury-6/NN	conj_and||injury-6/NN||steatosis-8/NNS	nsubjpass||aggravated-11/VBN||steatosis-8/NNS	auxpass||aggravated-11/VBN||were-9/VBD	advmod||aggravated-11/VBN||profoundly-10/RB	root||ROOT-0/null||aggravated-11/VBN	amod||mice-15/NNS||smad7-13/JJ	nn||mice-15/NNS||deficient-14/NN	prep_in||aggravated-11/VBN||mice-15/NNS	vmod||mice-15/NNS||associated-17/VBN	prep_with||associated-17/VBN||upregulation-19/NN	amod||genes-22/NNS||critical-21/JJ	prep_of||upregulation-19/NN||genes-22/NNS	vmod||genes-22/NNS||involved-23/VBN	prep_in||involved-23/VBN||lipogenesis-25/NNS	prep_in||involved-23/VBN||inflammation-27/NN	conj_and||lipogenesis-25/NNS||inflammation-27/NN	alcohol--1||inflammation-27||no_rel||in addition, alcohol-induced liver injury and steatosis were profoundly aggravated in smad7 deficient mice, associated with upregulation of critical genes involved in lipogenesis and inflammation.
nsubjpass||associated-3/VBN||fecv-1/NNP	auxpass||associated-3/VBN||is-2/VBZ	root||ROOT-0/null||associated-3/VBN	amod||infections-8/NNS||asymptomatic-5/JJ	amod||infections-8/NNS||persistent-6/JJ	amod||infections-8/NNS||enteric-7/JJ	prep_with||associated-3/VBN||infections-8/NNS	mark||causes-12/VBZ||while-10/IN	nsubj||causes-12/VBZ||fipv-11/NNP	dep||infections-8/NNS||causes-12/VBZ	dobj||causes-12/VBZ||felineinfectiousperitonitis-13/NNS	appos||felineinfectiousperitonitis-13/NNS||fip-15/NN	det||disease-22/NN||a-18/DT	advmod||fatal-20/JJ||usually-19/RB	amod||disease-22/NN||fatal-20/JJ	amod||disease-22/NN||systemic-21/JJ	dobj||causes-12/VBZ||disease-22/NN	conj_and||felineinfectiousperitonitis-13/NNS||disease-22/NN	amod||cats-25/NNS||domestic-24/JJ	prep_in||disease-22/NN||cats-25/NNS	det||felidae-29/NN||some-27/DT	amod||felidae-29/NN||wild-28/JJ	dobj||causes-12/VBZ||felidae-29/NN	conj_and||felineinfectiousperitonitis-13/NNS||felidae-29/NN	felineinfectiousperitonitis-13||fipv-11||no||fecv is associated with asymptomatic persistent enteric infections, while fipv causes felineinfectiousperitonitis (fip), a usually fatal systemic disease in domestic cats and some wild felidae.
det||change-3/NN||the-1/DT	amod||change-3/NN||recent-2/JJ	nsubjpass||accompanied-20/VBN||change-3/NN	nn||policy-6/NN||treatment-5/NN	prep_of||change-3/NN||policy-6/NN	amod||malaria-9/NN||uncomplicated-8/JJ	prep_for||policy-6/NN||malaria-9/NN	prep_from||malaria-9/NN||sulfadoxine-pyrime-thamine-11/NN	prep_to||sulfadoxine-pyrime-thamine-11/NN||artemether-lumefantrine-13/NN	appos||artemether-lumefantrine-13/NN||al-15/NNP	prep_in||artemether-lumefantrine-13/NN||kenya-18/NN	auxpass||accompanied-20/VBN||was-19/VBD	root||ROOT-0/null||accompanied-20/VBN	amod||recommendations-25/NNS||revised-22/VBN	nn||recommendations-25/NNS||malaria-23/NN	nn||recommendations-25/NNS||diagnosis-24/NN	nsubj||promoting-26/VBG||recommendations-25/NNS	agent||accompanied-20/VBN||promoting-26/VBG	amod||treatment-29/NN||presumptive-27/JJ	amod||treatment-29/NN||antimalarial-28/JJ	dobj||promoting-26/VBG||treatment-29/NN	amod||children-32/NNS||young-31/JJ	prep_in||treatment-29/NN||children-32/NNS	amod||diagnosis-35/NN||parasitological-34/JJ	dobj||promoting-26/VBG||diagnosis-35/NN	conj_and||treatment-29/NN||diagnosis-35/NN	prep_in||diagnosis-35/NN||patients-37/NNS	num||years-39/NNS||5-38/CD	dep||promoting-26/VBG||years-39/NNS	dep||promoting-26/VBG||older-41/JJR	conj_and||years-39/NNS||older-41/JJR	malaria-23||lumefantrine--1||yes||the recent change of treatment policy for uncomplicated malaria from sulfadoxine-pyrime-thamine to artemether-lumefantrine (al) in kenya was accompanied by revised malaria diagnosis recommendations promoting presumptive antimalarial treatment in young children and parasitological diagnosis in patients 5 years and older.
det||incidence-3/NN||the-1/DT	amod||incidence-3/NN||reported-2/JJ	nsubj||growing-10/VBG||incidence-3/NN	amod||isolates-6/NNS||drug-resistant-5/JJ	prep_of||incidence-3/NN||isolates-6/NNS	prep_of||isolates-6/NNS||m.tuberculosis-8/NNS	aux||growing-10/VBG||is-9/VBZ	root||ROOT-0/null||growing-10/VBG	advmod||growing-10/VBG||steadily-11/RB	advmod||reported-52/VBN||however-13/RB	nsubjpass||reported-52/VBN||data-15/NNS	det||variation-19/NN||the-17/DT	amod||variation-19/NN||genetic-18/JJ	prep_on||data-15/NNS||variation-19/NN	prep_of||variation-19/NN||isolates-21/NNP	prep_of||isolates-21/NNP||m.tuberculosis-23/NNS	vmod||m.tuberculosis-23/NNS||circulating-24/VBG	vmod||m.tuberculosis-23/NNS||circulating-24/VBG	conj_and||circulating-24/VBG||circulating-24/VBG	amod||ukraine-27/NN||northern-26/JJ	prep_in||circulating-24/VBG||ukraine-27/NN	det||spectrum-31/NN||the-30/DT	prep_on||circulating-24/VBG||spectrum-31/NN	prep_on||circulating-24/VBG||frequency-33/NN	conj_and||spectrum-31/NN||frequency-33/NN	prep_of||spectrum-31/NN||occurrence-35/NN	prep_of||occurrence-35/NN||mutations-37/NNS	vmod||mutations-37/NNS||determining-38/VBG	dobj||determining-38/VBG||resistance-39/NN	det||drugs-44/NNS||the-41/DT	amod||drugs-44/NNS||principal-42/JJ	amod||drugs-44/NNS||anti-tuberculosis-43/JJ	prep_to||determining-38/VBG||drugs-44/NNS	amod||drugs-44/NNS||isoniazid-45/JJ	amod||drugs-44/NNS||rifampicin-47/JJ	conj_and||isoniazid-45/JJ||rifampicin-47/JJ	aux||reported-52/VBN||have-48/VBP	neg||reported-52/VBN||not-49/RB	advmod||reported-52/VBN||yet-50/RB	auxpass||reported-52/VBN||been-51/VBN	parataxis||growing-10/VBG||reported-52/VBN	tuberculosis--1||rifampicin-47||yes||the reported incidence of drug-resistant isolates of m.tuberculosis is growing steadily ; however , data on the genetic variation of isolates of m.tuberculosis circulating in northern ukraine and on the spectrum and frequency of occurrence of mutations determining resistance to the principal anti-tuberculosis drugs isoniazid and rifampicin have not yet been reported .
det||patients-4/NNS||the-1/DT	amod||patients-4/NNS||479-2/JJ	amod||patients-4/NNS||evaluable-3/JJ	nsubj||had-11/VBD||patients-4/NNS	prep_with||patients-4/NNS||metastaticcancer-6/NN	amod||sites-10/NNS||other-8/JJ	nn||sites-10/NNS||primarycancer-9/NN	prep_from||metastaticcancer-6/NN||sites-10/NNS	root||ROOT-0/null||had-11/VBD	dobj||had-11/VBD||cr-12/NN	dobj||had-11/VBD||pr-14/NN	conj_and||cr-12/NN||pr-14/NN	amod||rates-20/NNS||cr-17/JJ	amod||rates-20/NNS||+-18/JJ	nn||rates-20/NNS||pr-19/NN	dobj||had-11/VBD||rates-20/NNS	conj_and||cr-12/NN||rates-20/NNS	num||%-23/NN||25-22/CD	prep_of||rates-20/NNS||%-23/NN	num||%-26/NN||27-25/CD	prep_of||rates-20/NNS||%-26/NN	conj_and||%-23/NN||%-26/NN	num||%-30/NN||51-29/CD	prep_of||rates-20/NNS||%-30/NN	conj_and||%-23/NN||%-30/NN	num||weeks-33/NNS||4-32/CD	prep_at||%-30/NN||weeks-33/NNS	num||%-36/NN||26-35/CD	prep_of||rates-20/NNS||%-36/NN	conj_and||%-23/NN||%-36/NN	num||%-39/NN||22-38/CD	prep_of||rates-20/NNS||%-39/NN	conj_and||%-23/NN||%-39/NN	num||%-43/NN||48-42/CD	prep_of||rates-20/NNS||%-43/NN	conj_and||%-23/NN||%-43/NN	num||weeks-46/NNS||8-45/CD	prep_at||%-43/NN||weeks-46/NNS	num||%-50/NN||22-49/CD	prep_of||rates-20/NNS||%-50/NN	conj_and||%-23/NN||%-50/NN	num||%-53/NN||29-52/CD	prep_of||rates-20/NNS||%-53/NN	conj_and||%-23/NN||%-53/NN	num||%-57/NN||51-56/CD	prep_of||rates-20/NNS||%-57/NN	conj_and||%-23/NN||%-57/NN	num||weeks-60/NNS||12-59/CD	prep_at||had-11/VBD||weeks-60/NNS	cr-17||primarycancer-9||no_rel||the 479 evaluable patients with metastaticcancer from other primarycancer sites had cr , pr , and cr + pr rates of 25%, 27%, and 51% at 4 weeks; 26%, 22%, and 48% at 8 weeks; and 22%, 29%, and 51% at 12 weeks.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||cloned-12/VBN||study-4/NN	amod||rv1985c-8/NNS||recombinant-6/JJ	nn||rv1985c-8/NNS||protein-7/NN	nsubjpass||cloned-12/VBN||rv1985c-8/NNS	nsubjpass||expressed-14/VBN||rv1985c-8/NNS	nsubjpass||purified-16/VBN||rv1985c-8/NNS	nsubjpass||characterized-19/VBN||rv1985c-8/NNS	nsubjpass||investigated-21/VBN||rv1985c-8/NNS	prep_from||rv1985c-8/NNS||rd2-10/CD	auxpass||cloned-12/VBN||was-11/VBD	root||ROOT-0/null||cloned-12/VBN	conj_and||cloned-12/VBN||expressed-14/VBN	conj_and||cloned-12/VBN||purified-16/VBN	advmod||characterized-19/VBN||immunologically-18/RB	conj_and||cloned-12/VBN||characterized-19/VBN	conj_and||cloned-12/VBN||investigated-21/VBN	poss||value-26/NN||its-23/PRP$	advmod||diagnostic-25/JJ||potentially-24/RB	amod||value-26/NN||diagnostic-25/JJ	prep_for||investigated-21/VBN||value-26/NN	nn||infection-32/NN||tuberculosis-28/NNP	appos||infection-32/NN||tb-30/NN	prep_for||value-26/NN||infection-32/NN	amod||individuals-35/NNS||bcg-vaccinated-34/JJ	prep_among||investigated-21/VBN||individuals-35/NNS	tuberculosis-28||bcg--1||yes||in the present study, recombinant protein rv1985c from rd2 was cloned, expressed, purified, immunologically characterized and investigated for its potentially diagnostic value for tuberculosis (tb) infection among bcg-vaccinated individuals.
nsubj||mediated-13/JJ||changes-1/NNS	nn||metabolism-4/NN||glucose-3/NN	prep_in||changes-1/NNS||metabolism-4/NN	vmod||metabolism-4/NN||occurring-5/VBG	prep_during||occurring-5/VBG||counterregulation-7/NN	cop||mediated-13/JJ||are-8/VBP	prep_in||mediated-13/JJ||part-11/NN	root||ROOT-0/null||mediated-13/JJ	amod||fattyacids-18/NNS||increased-15/VBN	amod||fattyacids-18/NNS||plasma-16/VBG	amod||fattyacids-18/NNS||free-17/JJ	prep_by||mediated-13/JJ||fattyacids-18/NNS	appos||fattyacids-18/NNS||ffas-20/NNS	det||result-25/NN||a-24/DT	prep_as||mediated-13/JJ||result-25/NN	amod||lipolysis-28/NNS||hypoglycemia-activated-27/JJ	prep_of||result-25/NN||lipolysis-28/NNS	hypoglycemia--1||glucose-3||yes||changes in glucose metabolism occurring during counterregulation are, in part, mediated by increased plasma free fattyacids (ffas), as a result of hypoglycemia-activated lipolysis.
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	amod||cases-4/NNS||295-3/JJ	nsubj||were-2/VBD||cases-4/NNS	prep_of||diagnosed-31/VBN||cases-4/NNS	prep_of||cases-4/NNS||ibd-6/NN	dep||cases-4/NNS||uc-8/VBN	dep||240-10/CD||=-9/SYM	ccomp||uc-8/VBN||240-10/CD	ccomp||uc-8/VBN||cd-12/VB	dep||55-14/CD||=-13/SYM	ccomp||cd-12/VB||55-14/CD	nsubjpass||diagnosed-31/VBN||34-19/CD	dep||34-19/CD||uc-21/VBN	dep||30-23/CD||=-22/SYM	ccomp||uc-21/VBN||30-23/CD	ccomp||uc-21/VBN||cd-25/VB	dep||4-27/CD||=-26/SYM	ccomp||cd-25/VB||4-27/CD	auxpass||diagnosed-31/VBN||were-29/VBD	advmod||diagnosed-31/VBN||newly-30/RB	rcmod||cases-4/NNS||diagnosed-31/VBN	det||year-35/NN||the-33/DT	nn||year-35/NN||study-34/NN	prep_during||diagnosed-31/VBN||year-35/NN	cd-25||ibd-6||no_rel||there were 295 cases of ibd (uc = 240, cd = 55), of which 34 (uc = 30, cd = 4) were newly diagnosed during the study year.
prep_in||antigen-8/NN||conclusion-2/NN	nsubj||antigen-8/NN||rv1985c-4/NNS	cop||antigen-8/NN||is-5/VBZ	det||antigen-8/NN||a-6/DT	nn||antigen-8/NN||novel-7/NN	root||ROOT-0/null||antigen-8/NN	nsubjpass||used-12/VBN||antigen-8/NN	nsubj||diagnose-15/VB||antigen-8/NN	aux||used-12/VBN||can-10/MD	auxpass||used-12/VBN||be-11/VB	rcmod||antigen-8/NN||used-12/VBN	aux||diagnose-15/VB||to-13/TO	advmod||diagnose-15/VB||immunologically-14/RB	xcomp||used-12/VBN||diagnose-15/VB	nn||infection-17/NN||tb-16/NN	dobj||diagnose-15/VB||infection-17/NN	amod||antigens-22/NNS||other-20/JJ	nn||antigens-22/NNS||immunodominant-21/NN	prep_along_with||diagnose-15/VB||antigens-22/NNS	amod||population-25/NN||bcg-vaccinated-24/JJ	prep_among||antigens-22/NNS||population-25/NN	tb-16||bcg--1||no||in conclusion, rv1985c is a novel antigen which can be used to immunologically diagnose tb infection along with other immunodominant antigens among bcg-vaccinated population.
nsubj||reduced-9/VBD||prevention-1/NN	amod||reabsorption-5/NN||renal-3/JJ	nn||reabsorption-5/NN||glucose-4/NN	prep_of||prevention-1/NN||reabsorption-5/NN	amod||deletion-8/NN||sglt2-7/JJ	prep_by||reabsorption-5/NN||deletion-8/NN	root||ROOT-0/null||reduced-9/VBD	dobj||reduced-9/VBD||hfd-10/NN	amod||hyperglycemia-14/NN||obesity-associated-13/JJ	dobj||reduced-9/VBD||hyperglycemia-14/NN	conj_and||hfd-10/NN||hyperglycemia-14/NN	amod||glucoseintolerance-17/NN||improved-16/VBN	conj_and||hfd-10/NN||glucoseintolerance-17/NN	conj_and||hyperglycemia-14/NN||glucoseintolerance-17/NN	amod||secretion-23/NN||increased-20/VBN	amod||secretion-23/NN||glucose-stimulated-21/JJ	nn||secretion-23/NN||insulin-22/NN	conj_and||hfd-10/NN||secretion-23/NN	conj_and||hyperglycemia-14/NN||secretion-23/NN	prep_in||secretion-23/NN||vivo-25/NN	hyperglycemia-14||insulin-22||yes||prevention of renal glucose reabsorption by sglt2 deletion reduced hfd- and obesity-associated hyperglycemia, improved glucoseintolerance, and increased glucose-stimulated insulin secretion in vivo.
det||effects-2/NNS||the-1/DT	nsubj||unknown-20/JJ||effects-2/NNS	amod||treatment-5/NN||alefacept-4/JJ	prep_of||effects-2/NNS||treatment-5/NN	amod||expression-8/NN||il-20-7/JJ	prep_on||treatment-5/NN||expression-8/NN	det||synovium-11/NN||the-10/DT	prep_in||expression-8/NN||synovium-11/NN	prep_of||synovium-11/NN||patients-13/NNS	prep_with||patients-13/NNS||psoriasis-15/NNS	prep_with||patients-13/NNS||psa-17/NN	conj_and||psoriasis-15/NNS||psa-17/NN	cop||unknown-20/JJ||are-18/VBP	advmod||unknown-20/JJ||currently-19/RB	root||ROOT-0/null||unknown-20/JJ	psoriasis-15||alefacept-4||yes||the effects of alefacept treatment on il-20 expression in the synovium of patients with psoriasis and psa are currently unknown.
amod||analysis-2/NN||microarray-1/JJ	nsubj||shows-14/VBZ||analysis-2/NN	det||effects-5/NNS||the-4/DT	prep_of||analysis-2/NN||effects-5/NNS	amod||over-expression-8/NN||ets-1-7/JJ	prep_of||effects-5/NNS||over-expression-8/NN	det||cells-13/NNS||these-10/DT	amod||cells-13/NNS||ovarian-11/JJ	nn||cells-13/NNS||cancer-12/NN	prep_in||over-expression-8/NN||cells-13/NNS	root||ROOT-0/null||shows-14/VBZ	mark||involved-20/VBN||that-15/IN	amod||enzymes-19/NNS||ets-1-16/JJ	amod||enzymes-19/NNS||up-regulates-17/JJ	amod||enzymes-19/NNS||key-18/JJ	nsubj||involved-20/VBN||enzymes-19/NNS	nsubj||associated-24/JJ||enzymes-19/NNS	ccomp||shows-14/VBZ||involved-20/VBN	prep_in||involved-20/VBN||glycolysis-22/NNS	ccomp||shows-14/VBZ||associated-24/JJ	conj_and||involved-20/VBN||associated-24/JJ	nn||pathways-26/NNS||feeder-25/NN	dobj||associated-24/JJ||pathways-26/NNS	amod||metabolism-29/NN||fattyacid-28/JJ	dobj||associated-24/JJ||metabolism-29/NN	conj_and||pathways-26/NNS||metabolism-29/NN	amod||defense-33/NN||antioxidant-32/JJ	dobj||associated-24/JJ||defense-33/NN	conj_and||pathways-26/NNS||defense-33/NN	cancer-12||fattyacid-28||no_rel||microarray analysis of the effects of ets-1 over-expression in these ovarian cancer cells shows that ets-1 up-regulates key enzymes involved in glycolysis and associated feeder pathways, fattyacid metabolism, and antioxidant defense.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||study-5/NN||the-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	prep_of||effect-10/NN||nitrates-12/NNS	prep_on||nitrates-12/NNS||leftventricularhypertrophy-14/NN	appos||leftventricularhypertrophy-14/NN||lvh-16/NN	amod||patients-20/NNS||hypertensive-19/JJ	prep_in||evaluate-8/VB||patients-20/NNS	amod||dialysis-24/NN||chronic-22/JJ	amod||dialysis-24/NN||peritoneal-23/JJ	prep_on||patients-20/NNS||dialysis-24/NN	appos||dialysis-24/NN||pd-26/NN	lvh-16||nitrates-12||no_rel||the aim of the study was to evaluate the effect of nitrates on leftventricularhypertrophy (lvh) in hypertensive patients on chronic peritoneal dialysis (pd).
det||episode-3/NN||the-1/DT	amod||episode-3/NN||bacteremic-2/JJ	nsubjpass||treated-8/VBN||episode-3/NN	prep_of||episode-3/NN||brucellosis-5/NNS	auxpass||treated-8/VBN||was-6/VBD	advmod||treated-8/VBN||successfully-7/RB	root||ROOT-0/null||treated-8/VBN	prep_with||treated-8/VBN||streptomycin-10/NN	prep_with||treated-8/VBN||doxycyclin-12/NN	conj_and||streptomycin-10/NN||doxycyclin-12/NN	prep_with||treated-8/VBN||ciprofloxacin-14/NN	conj_and||streptomycin-10/NN||ciprofloxacin-14/NN	det||clinic-18/NN||the-16/DT	nn||clinic-18/NN||outpatient-17/NN	prep_at||treated-8/VBN||clinic-18/NN	brucellosis-5||streptomycin-10||yes||the bacteremic episode of brucellosis was successfully treated with streptomycin, doxycyclin and ciprofloxacin at the outpatient clinic.
det||study-3/NN||this-2/DT	prep_in||found-6/VBD||study-3/NN	nsubj||found-6/VBD||we-5/PRP	root||ROOT-0/null||found-6/VBD	mark||isolates-11/VBZ||that-7/IN	amod||s.aureus-10/NNS||many-8/JJ	amod||s.aureus-10/NNS||bovine-9/JJ	nsubj||isolates-11/VBZ||s.aureus-10/NNS	ccomp||found-6/VBD||isolates-11/VBZ	dep||isolates-11/VBZ||including-13/VBG	det||strain-16/NN||the-14/DT	amod||strain-16/NN||rf122-15/JJ	pobj||including-13/VBG||strain-16/NN	dep||isolates-11/VBZ||generate-18/VB	amod||amounts-20/NNS||dramatic-19/JJ	dobj||generate-18/VB||amounts-20/NNS	nn||±-23/NNS||î-22/NN	prep_of||amounts-20/NNS||±-23/NNS	dep||amounts-20/NNS||toxin-25/NN	prep_in||toxin-25/NN||vitro-27/NNP	prepc_compared_with||generate-18/VB||with-29/IN	amod||s.aureus-32/NNS||human-30/JJ	amod||s.aureus-32/NNS||clinical-31/JJ	pobj||generate-18/VB||s.aureus-32/NNS	dep||s.aureus-32/NNS||isolates-33/VBZ	nn||wcuh29-37/NNS||mrsa-36/NN	prep_including||s.aureus-32/NNS||wcuh29-37/NNS	nn||usa300-40/NNS||mrsa-39/NN	prep_including||s.aureus-32/NNS||usa300-40/NNS	conj_and||wcuh29-37/NNS||usa300-40/NNS	mrsa-39||s.aureus-32||no||in this study , we found that many bovine s.aureus isolates , including the rf122 strain , generate dramatic amounts of î ± - toxin in vitro compared with human clinical s.aureus isolates , including mrsa wcuh29 and mrsa usa300 .
nsubjpass||shown-12/VBN||reduction-1/NN	amod||layer-6/NN||retinal-3/JJ	nn||layer-6/NN||nerve-4/NN	nn||layer-6/NN||fibre-5/NN	prep_of||reduction-1/NN||layer-6/NN	dep||reduction-1/NN||rnfl-8/JJ	advmod||shown-12/VBN||thickness-10/RB	auxpass||shown-12/VBN||was-11/VBD	root||ROOT-0/null||shown-12/VBN	prep_as||shown-12/VBN||part-14/NN	det||process-18/NN||the-16/DT	amod||process-18/NN||neurodegenerative-17/JJ	prep_of||part-14/NN||process-18/NN	det||range-21/NN||a-20/DT	prep_in||shown-12/VBN||range-21/NN	amod||pathologies-25/NNS||different-23/JJ	nn||pathologies-25/NNS||neurodegenerative-24/NN	prep_of||range-21/NN||pathologies-25/NNS	amod||disease-31/NN||alzheimerâ-27/JJ	dep||alzheimerâ-27/JJ||$-28/$	number||s-30/CD||²-29/CD	num||$-28/$||s-30/CD	prep_including||pathologies-25/NNS||disease-31/NN	appos||disease-31/NN||ad-33/NN	amod||parkinsonâ-37/NNS||idiopathic-36/JJ	prep_including||pathologies-25/NNS||parkinsonâ-37/NNS	conj_and||disease-31/NN||parkinsonâ-37/NNS	num||disease-41/NN||$-38/$	number||s-40/CD||™-39/CD	num||$-38/$||s-40/CD	dep||parkinsonâ-37/NNS||disease-41/NN	appos||disease-41/NN||pd-43/NN	nn||ataxia-47/NN||spinocerebellar-46/NN	prep_including||pathologies-25/NNS||ataxia-47/NN	conj_and||disease-31/NN||ataxia-47/NN	appos||ataxia-47/NN||sca-49/NN	amod||atrophy-54/NN||multiple-52/JJ	nn||atrophy-54/NN||system-53/NN	prep_including||pathologies-25/NNS||atrophy-54/NN	conj_and||disease-31/NN||atrophy-54/NN	appos||atrophy-54/NN||msa-56/NN	sca-49||fibre-5||no_rel||reduction of retinal nerve fibre layer (rnfl) thickness was shown as part of the neurodegenerative process in a range of different neurodegenerative pathologies including alzheimerâ€²s disease (ad), idiopathic parkinsonâ€™s disease (pd), spinocerebellar ataxia (sca) and multiple system atrophy (msa).
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	amod||³-5/JJ||fluorophore-labelled-3/JJ	amod||³-5/JJ||anti-ifn-î-4/NNP	dobj||used-2/VBD||³-5/JJ	amod||antibodies-8/NNS||anti-il-2-7/JJ	dobj||used-2/VBD||antibodies-8/NNS	conj_and||³-5/JJ||antibodies-8/NNS	amod||overlay-11/NN||digital-10/JJ	prep_with||used-2/VBD||overlay-11/NN	amod||images-15/NNS||spatially-mapped-13/JJ	amod||images-15/NNS||colour-filtered-14/JJ	prep_of||overlay-11/NN||images-15/NNS	aux||enumerate-17/VB||to-16/TO	vmod||used-2/VBD||enumerate-17/VB	amod||t-cells-24/NNS||dual-18/JJ	conj_and||dual-18/JJ||single-20/JJ	amod||t-cells-24/NNS||single-20/JJ	amod||t-cells-24/NNS||cytokine-secreting-21/JJ	amod||t-cells-24/NNS||m.tuberculosis-22/JJ	amod||t-cells-24/NNS||antigen-specific-23/JJ	dobj||enumerate-17/VB||t-cells-24/NNS	nn||patients-27/NNS||tuberculosis-26/NNP	prep_in||t-cells-24/NNS||patients-27/NNS	nn||-rrb--34/NNP||latent-30/NN	nn||-rrb--34/NNP||tuberculosisinfection-31/NN	nn||-rrb--34/NNP||-lrb--32/NNP	nn||-rrb--34/NNP||ltbi-33/NNP	prep_in||t-cells-24/NNS||-rrb--34/NNP	conj_and||patients-27/NNS||-rrb--34/NNP	tuberculosis-26||m.tuberculosis-22||no||we used fluorophore-labelled anti-ifn-î ³ and anti-il-2 antibodies with digital overlay of spatially-mapped colour-filtered images to enumerate dual and single cytokine-secreting m.tuberculosis antigen-specific t-cells in tuberculosis patients and in latent tuberculosisinfection -lrb- ltbi -rrb- .
amod||causes-2/NNS||potential-1/JJ	nsubj||include-12/VBP||causes-2/NNS	amod||deterioration-5/NN||clinical-4/JJ	prep_for||causes-2/NNS||deterioration-5/NN	prep_in||deterioration-5/NN||settings-7/NNS	amod||prevalence-11/NN||high-9/JJ	amod||prevalence-11/NN||hiv-1-10/JJ	prep_of||settings-7/NNS||prevalence-11/NN	root||ROOT-0/null||include-12/VBP	npadvmod||resistant-14/JJ||drug-13/NN	amod||mycobacteriumtuberculosis-15/NNS||resistant-14/JJ	dobj||include-12/VBP||mycobacteriumtuberculosis-15/NNS	appos||mycobacteriumtuberculosis-15/NNS||m.tb-17/NN	amod||illnesses-21/NNS||co-morbid-20/JJ	dobj||include-12/VBP||illnesses-21/NNS	conj_and||mycobacteriumtuberculosis-15/NNS||illnesses-21/NNS	amod||adherence-24/NN||poor-23/JJ	dobj||include-12/VBP||adherence-24/NN	conj_and||mycobacteriumtuberculosis-15/NNS||adherence-24/NN	nn||syndrome-32/NN||therapy-26/NN	nn||syndrome-32/NN||tuberculosis-28/NNP	amod||syndrome-32/NN||associated-immune-29/JJ	amod||syndrome-32/NN||reconstitution-30/JJ	amod||syndrome-32/NN||inflammatory-31/JJ	prep_to||adherence-24/NN||syndrome-32/NN	appos||syndrome-32/NN||tb-iris-34/NNS	amod||levels-40/NNS||subtherapeutic-37/JJ	nn||levels-40/NNS||antitubercular-38/NN	nn||levels-40/NNS||drug-39/NN	dobj||include-12/VBP||levels-40/NNS	conj_and||mycobacteriumtuberculosis-15/NNS||levels-40/NNS	tb--1||mycobacteriumtuberculosis-15||no||potential causes for clinical deterioration in settings of high hiv-1 prevalence include drug resistant mycobacteriumtuberculosis (m.tb) , co-morbid illnesses, poor adherence to therapy, tuberculosis associated-immune reconstitution inflammatory syndrome (tb-iris) and subtherapeutic antitubercular drug levels.
advmod||showed-12/VBD||however-1/RB	det||patterns-4/NNS||the-3/DT	nsubj||showed-12/VBD||patterns-4/NNS	prep_of||patterns-4/NNS||mortality-6/NN	advmod||mortality-6/NN||as-7/RB	vmod||mortality-6/NN||determined-8/VBN	det||methods-11/NNS||both-10/DT	agent||determined-8/VBN||methods-11/NNS	root||ROOT-0/null||showed-12/VBD	det||burden-15/NN||a-13/DT	amod||burden-15/NN||high-14/JJ	dobj||showed-12/VBD||burden-15/NN	amod||diseases-18/NNS||infectious-17/JJ	prep_of||burden-15/NN||diseases-18/NNS	nn||tuberculosis-23/NN||hiv/aids-21/NN	prep_including||showed-12/VBD||tuberculosis-23/NN	prep_including||showed-12/VBD||pneumonia-26/NN	conj_and||tuberculosis-23/NN||pneumonia-26/NN	det||population-31/NN||the-29/DT	nn||population-31/NN||study-30/NN	prep_in||tuberculosis-23/NN||population-31/NN	aids--1||hiv--1||no||however, the patterns of mortality as determined by both methods showed a high burden of infectious diseases, including hiv/aids, tuberculosis, and pneumonia, in the study population.
det||seconds-4/NNS||the-2/DT	num||seconds-4/NNS||10-3/CD	prep_during||measured-12/VBN||seconds-4/NNS	amod||injection-7/NN||propofol-6/JJ	prep_after||seconds-4/NNS||injection-7/NN	nn||intensity-10/NN||pain-9/NN	nsubjpass||measured-12/VBN||intensity-10/NN	auxpass||measured-12/VBN||was-11/VBD	root||ROOT-0/null||measured-12/VBN	det||scale-18/NN||an-14/DT	amod||scale-18/NN||11-point-15/JJ	amod||scale-18/NN||numerical-16/JJ	nn||scale-18/NN||rating-17/NN	prep_on||measured-12/VBN||scale-18/NN	dep||scale-18/NN||0-20/CD	dep||pain-23/NN||=-21/SYM	neg||pain-23/NN||no-22/DT	rcmod||0-20/CD||pain-23/NN	num||=-26/NNS||10-25/CD	dep||scale-18/NN||=-26/NNS	conj_and||0-20/CD||=-26/NNS	dep||possible-28/JJ||worst-27/JJS	amod||pain-29/NN||possible-28/JJ	dep||=-26/NNS||pain-29/NN	pain-29||propofol-6||yes||during the 10 seconds after propofol injection, pain intensity was measured on an 11-point numerical rating scale (0 = no pain and 10 = worst possible pain).
aux||examine-2/VB||to-1/TO	advcl||performed-10/VBN||examine-2/VB	det||question-4/NN||this-3/DT	dobj||examine-2/VB||question-4/NN	amod||clamps-8/NNS||euglycemic-6/JJ	nn||clamps-8/NNS||glucose-7/NN	nsubjpass||performed-10/VBN||clamps-8/NNS	auxpass||performed-10/VBN||were-9/VBD	root||ROOT-0/null||performed-10/VBN	advmod||performed-10/VBN||twice-11/RB	amod||order-15/NN||random-14/JJ	prep_in||performed-10/VBN||order-15/NN	num||youth-19/NN||11-18/CD	prep_in||performed-10/VBN||youth-19/NN	prep_with||youth-19/NN||type1diabetes-21/CD	nn||15.1-24/NNS||age-23/NN	nsubj||â-25/VBP||15.1-24/NNS	dep||youth-19/NN||â-25/VBP	number||3-27/CD||±-26/CD	num||years-28/NNS||3-27/CD	tmod||â-25/VBP||years-28/NNS	amod||â-32/NN||a1c-30/JJ	num||â-32/NN||7.6-31/CD	nsubj||±-33/VBG||â-32/NN	vmod||â-25/VBP||±-33/VBG	num||%-35/NN||0.6-34/CD	dobj||±-33/VBG||%-35/NN	num||lispro-40/NN||0.2-38/CD	amod||lispro-40/NN||units/kg-39/VBG	prep_with||youth-19/NN||lispro-40/NN	num||glargine-44/NN||0.4-42/CD	amod||glargine-44/NN||units/kg-43/VBG	prep_with||youth-19/NN||glargine-44/NN	conj_and||lispro-40/NN||glargine-44/NN	vmod||lispro-40/NN||given-46/VBN	preconj||given-46/VBN||either-47/CC	prep_as||given-46/VBN||separate-49/JJ	det||injection-55/NN||a-52/DT	amod||injection-55/NN||single-53/JJ	amod||injection-55/NN||mixed-54/JJ	prep_as||given-46/VBN||injection-55/NN	conj_or||separate-49/JJ||injection-55/NN	type1diabetes-21||lispro-40||yes||to examine this question, euglycemic glucose clamps were performed twice, in random order, in 11 youth with type1diabetes (age 15.1 â± 3 years, a1c 7.6 â± 0.6%) with 0.2 units/kg lispro and 0.4 units/kg glargine, given either as separate or as a single mixed injection.
det||destruction-3/NN||the-1/DT	amod||destruction-3/NN||spontaneous-2/JJ	nsubj||provides-17/VBZ||destruction-3/NN	prep_of||destruction-3/NN||insulin-5/NN	vmod||insulin-5/NN||producing-6/VBG	amod||cells-9/NNS||pancreatic-7/JJ	nn||cells-9/NNS||beta-8/NN	dobj||producing-6/VBG||cells-9/NNS	amod||diabetic-12/JJ||non-obese-11/JJ	amod||mice-16/NNS||diabetic-12/JJ	appos||mice-16/NNS||nod-14/NN	prep_in||producing-6/VBG||mice-16/NNS	root||ROOT-0/null||provides-17/VBZ	det||model-20/NN||a-18/DT	amod||model-20/NN||valuable-19/JJ	dobj||provides-17/VBZ||model-20/NN	prep_of||model-20/NN||type1diabetes-22/CD	type1diabetes-22||insulin-5||yes||the spontaneous destruction of insulin producing pancreatic beta cells in non-obese diabetic (nod) mice provides a valuable model of type1diabetes.
det||attitude-3/NN||the-1/DT	amod||attitude-3/NN||general-2/JJ	nsubj||positive-10/JJ||attitude-3/NN	nsubj||enable-12/VB||attitude-3/NN	prep_of||attitude-3/NN||dentists-5/NNS	prep_toward||dentists-5/NNS||hiv/aids-7/NNS	cop||positive-10/JJ||is-8/VBZ	advmod||positive-10/JJ||sufficiently-9/RB	root||ROOT-0/null||positive-10/JJ	aux||enable-12/VB||to-11/TO	xcomp||positive-10/JJ||enable-12/VB	dobj||enable-12/VB||provision-13/NN	det||treatment-17/NN||the-15/DT	amod||treatment-17/NN||best-16/JJS	prep_of||provision-13/NN||treatment-17/NN	det||patients-20/NNS||the-19/DT	prep_to||enable-12/VB||patients-20/NNS	prep_in||patients-20/NNS||need-22/NN	aids--1||hiv--1||no||the general attitude of dentists toward hiv/aids is sufficiently positive to enable provision of the best treatment to the patients in need.
amod||factors-2/NNS||genetic-1/JJ	nsubj||modulate-4/VB||factors-2/NNS	aux||modulate-4/VB||may-3/MD	root||ROOT-0/null||modulate-4/VB	det||capacity-6/NN||the-5/DT	dobj||modulate-4/VB||capacity-6/NN	det||²-10/NN||the-8/DT	nn||²-10/NN||î-9/NN	prep_of||capacity-6/NN||²-10/NN	dep||capacity-6/NN||cells-12/NNS	aux||secrete-14/VB||to-13/TO	vmod||cells-12/NNS||secrete-14/VB	dobj||secrete-14/VB||insulin-15/NN	advmod||contribute-18/VB||thereby-17/RB	vmod||cells-12/NNS||contribute-18/VB	conj_and||secrete-14/VB||contribute-18/VB	det||risk-21/NN||the-20/DT	prep_to||contribute-18/VB||risk-21/NN	prep_of||risk-21/NN||type2diabetes-23/CD	type2diabetes-23||insulin-15||yes||genetic factors may modulate the capacity of the î²-cells to secrete insulin and thereby contribute to the risk of type2diabetes.
det||profile-4/NN||the-1/DT	amod||profile-4/NN||largest-2/JJS	nn||profile-4/NN||mar-3/NN	nsubj||contained-5/VBD||profile-4/NN	nsubjpass||observed-24/VBN||profile-4/NN	root||ROOT-0/null||contained-5/VBD	num||antibiotics-7/NNS||six-6/CD	dobj||contained-5/VBD||antibiotics-7/NNS	nn||g-10/NN||penicillin-9/NN	dep||antibiotics-7/NNS||g-10/NN	appos||g-10/NN||methicillin-12/NN	appos||g-10/NN||erythromycin-14/NN	conj_and||methicillin-12/NN||erythromycin-14/NN	appos||g-10/NN||ciprofloxacin-16/NN	conj_and||methicillin-12/NN||ciprofloxacin-16/NN	appos||g-10/NN||clindamycin-18/NN	conj_and||methicillin-12/NN||clindamycin-18/NN	appos||g-10/NN||clarithromycin-20/NN	conj_and||methicillin-12/NN||clarithromycin-20/NN	auxpass||observed-24/VBN||was-23/VBD	conj_and||contained-5/VBD||observed-24/VBN	det||isolates-28/NN||the-26/DT	nn||isolates-28/NN||mrsa-27/NN	prep_in||observed-24/VBN||isolates-28/NN	predet||uk-32/NN||both-30/PDT	det||uk-32/NN||the-31/DT	prep_in||isolates-28/NN||uk-32/NN	amod||cohorts-35/NNS||maltese-34/JJ	prep_in||isolates-28/NN||cohorts-35/NNS	conj_and||uk-32/NN||cohorts-35/NNS	ciprofloxacin-16||mrsa-27||no_rel||the largest mar profile contained six antibiotics (penicillin g, methicillin, erythromycin, ciprofloxacin, clindamycin and clarithromycin) and was observed in the mrsa isolates in both the uk and maltese cohorts.
nsubjpass||known-7/VBN||background-1/NN	prep_before||background-1/NN||2003-3/CD	advmod||known-7/VBN||little-5/RB	auxpass||known-7/VBN||was-6/VBD	root||ROOT-0/null||known-7/VBN	det||scale-10/NN||the-9/DT	prep_about||known-7/VBN||scale-10/NN	prepc_of||scale-10/NN||chinaâ-12/VBG	dobj||chinaâ-12/VBG||$-13/$	num||$-13/$||™-14/CD	nsubj||hiv/aids-16/VBZ||s-15/PRP	rcmod||$-13/$||hiv/aids-16/VBZ	dobj||hiv/aids-16/VBZ||epidemic-17/NN	aids--1||hiv--1||no||background before 2003, little was known about the scale of chinaâ€™s hiv/aids epidemic.
amod||cultures-2/NNS||overnight-1/JJ	nsubj||-lrb--24/VBD||cultures-2/NNS	nn||strains-5/NNS||reference-4/NN	prep_of||cultures-2/NNS||strains-5/NNS	nn||albicans-8/NNS||candida-7/NN	prep_of||strains-5/NNS||albicans-8/NNS	nn||coli-11/NNS||escherichia-10/NN	prep_of||strains-5/NNS||coli-11/NNS	conj_and||albicans-8/NNS||coli-11/NNS	amod||aeruginosa-14/NN||pseudomonas-13/JJ	prep_of||strains-5/NNS||aeruginosa-14/NN	conj_and||albicans-8/NNS||aeruginosa-14/NN	prep_of||strains-5/NNS||staphylococcusaureus-17/NNS	conj_and||albicans-8/NNS||staphylococcusaureus-17/NNS	amod||strains-20/NNS||clinical-19/JJ	prep_of||cultures-2/NNS||strains-20/NNS	conj_and||strains-5/NNS||strains-20/NNS	amod||s.aureus-23/NNS||methicillin-resistant-22/JJ	prep_of||strains-20/NNS||s.aureus-23/NNS	root||ROOT-0/null||-lrb--24/VBD	nn||-rrb--26/NNP||mrsa-25/NNP	nsubjpass||used-28/VBN||-rrb--26/NNP	auxpass||used-28/VBN||were-27/VBD	ccomp||-lrb--24/VBD||used-28/VBN	nn||microorganisms-31/NNS||test-30/NN	prep_as||used-28/VBN||microorganisms-31/NNS	mrsa-25||staphylococcusaureus-17||no||overnight cultures of reference strains of candida albicans , escherichia coli , pseudomonas aeruginosa , and staphylococcusaureus and clinical strains of methicillin-resistant s.aureus -lrb- mrsa -rrb- were used as test microorganisms .
mark||identify-4/VB||in-1/IN	dep||identify-4/VB||order-2/NN	aux||identify-4/VB||to-3/TO	advcl||treated-15/VBD||identify-4/VB	dobj||identify-4/VB||genes-5/NNS	nsubjpass||regulated-9/VBN||genes-5/NNS	auxpass||regulated-9/VBN||are-7/VBP	advmod||regulated-9/VBN||epigenetically-8/RB	rcmod||genes-5/NNS||regulated-9/VBN	nn||tumors-12/NNS||neuroblastoma-11/NN	prep_in||regulated-9/VBN||tumors-12/NNS	nsubj||treated-15/VBD||we-14/PRP	root||ROOT-0/null||treated-15/VBD	num||lines-19/NNS||four-16/CD	nn||lines-19/NNS||neuroblastoma-17/NN	nn||lines-19/NNS||cell-18/NN	dobj||treated-15/VBD||lines-19/NNS	det||agent-23/NN||the-21/DT	amod||agent-23/NN||demethylating-22/JJ	prep_with||lines-19/NNS||agent-23/NN	amod||agent-23/NN||5-aza-2-24/JJ	dep||agent-23/NN||deoxycytidine-27/NN	dep||agent-23/NN||5-aza-dc-29/JJ	dep||lines-19/NNS||either-31/DT	dep||either-31/DT||separately-32/RB	dep||lines-19/NNS||in-34/IN	conj_or||either-31/DT||in-34/IN	pobj||in-34/IN||conjunction-35/NN	det||inhibitor-40/NN||the-37/DT	amod||inhibitor-40/NN||histone-38/JJ	nn||inhibitor-40/NN||deacetylase-39/NN	prep_with||conjunction-35/NN||inhibitor-40/NN	vmod||inhibitor-40/NN||trichostatin-41/VBN	det||tsa-44/NN||a-42/DT	dep||trichostatin-41/VBN||tsa-44/NN	neuroblastoma-17||aza--1||no_rel||in order to identify genes that are epigenetically regulated in neuroblastoma tumors, we treated four neuroblastoma cell lines with the demethylating agent 5-aza-2'-deoxycytidine (5-aza-dc) either separately or in conjunction with the histone deacetylase inhibitor trichostatin a (tsa).
mark||indicated-8/VBN||while-1/IN	nn||studies-6/NNS||human-2/NN	conj_and||human-2/NN||animal-4/NN	nn||studies-6/NNS||animal-4/NN	nn||studies-6/NNS||model-5/NN	nsubj||indicated-8/VBN||studies-6/NNS	aux||indicated-8/VBN||have-7/VBP	advcl||shown-29/VBN||indicated-8/VBN	det||role-11/NN||a-9/DT	amod||role-11/NN||protective-10/JJ	dobj||indicated-8/VBN||role-11/NN	prep_for||role-11/NN||estrogen-13/NN	prep_against||indicated-8/VBN||cardiovasculardisease-15/NN	prep_against||indicated-8/VBN||glomerulosclerosis-17/NNS	conj_and||cardiovasculardisease-15/NN||glomerulosclerosis-17/NNS	amod||studies-20/NNS||clinical-19/JJ	nsubj||shown-29/VBN||studies-20/NNS	nn||therapy-24/NN||hormone-22/NN	nn||therapy-24/NN||replacement-23/NN	prep_of||studies-20/NNS||therapy-24/NN	amod||women-27/NNS||postmenopausal-26/JJ	prep_in||therapy-24/NN||women-27/NNS	aux||shown-29/VBN||have-28/VBP	root||ROOT-0/null||shown-29/VBN	amod||results-31/NNS||polar-30/JJ	dobj||shown-29/VBN||results-31/NNS	det||improvement-34/NN||some-33/DT	prep_with||shown-29/VBN||improvement-34/NN	prep_in||improvement-34/NN||hypertension-36/NN	prep_with||shown-29/VBN||worsening-38/VBG	conj_but||improvement-34/NN||worsening-38/VBG	amod||kidneydisease-41/NN||hypertensive-40/JJ	prep_of||worsening-38/VBG||kidneydisease-41/NN	neg||effect-45/NN||no-44/DT	prep_with||shown-29/VBN||effect-45/NN	conj_or||improvement-34/NN||effect-45/NN	prep_at||effect-45/NN||all-47/DT	kidneydisease-41||hormone-22||no_rel||while human and animal model studies have indicated a protective role for estrogen against cardiovasculardisease and glomerulosclerosis, clinical studies of hormone replacement therapy in postmenopausal women have shown polar results with some improvement in hypertension but worsening of hypertensive kidneydisease, or no effect at all.
nsubj||eliminated-12/VBD||suppression-1/NN	amod||expression-4/NN||her4/4icd-3/JJ	prep_of||suppression-1/NN||expression-4/NN	det||line-10/NN||the-6/DT	amod||line-10/NN||mcf-7-7/JJ	nn||line-10/NN||breasttumor-8/NN	nn||line-10/NN||cell-9/NN	prep_in||expression-4/NN||line-10/NN	advmod||eliminated-12/VBD||completely-11/RB	root||ROOT-0/null||eliminated-12/VBD	dobj||eliminated-12/VBD||estrogen-13/NN	vmod||estrogen-13/NN||stimulated-14/VBN	dobj||stimulated-14/VBN||expression-15/NN	prep_of||expression-15/NN||pgr-17/NN	breasttumor-8||estrogen-13||no||suppression of her4/4icd expression in the mcf-7 breasttumor cell line completely eliminated estrogen stimulated expression of pgr.
amod||interviews-2/NNS||in-depth-1/JJ	nsubjpass||conducted-4/VBN||interviews-2/NNS	auxpass||conducted-4/VBN||were-3/VBD	root||ROOT-0/null||conducted-4/VBN	num||persons-7/NNS||nine-6/CD	prep_with||conducted-4/VBN||persons-7/NNS	vmod||persons-7/NNS||living-8/VBG	prep_with||living-8/VBG||hiv/aids-10/NNS	poss||caregivers-16/NNS||their-12/PRP$	num||caregivers-16/NNS||nine-13/CD	amod||caregivers-16/NNS||direct-14/JJ	amod||caregivers-16/NNS||informal-15/JJ	prep_with||living-8/VBG||caregivers-16/NNS	conj_and||hiv/aids-10/NNS||caregivers-16/NNS	aids--1||hiv--1||no||in-depth interviews were conducted with nine persons living with hiv/aids and their nine direct informal caregivers.
amod||therapy-3/NN||dual-1/JJ	nn||therapy-3/NN||antiplatelet-2/NN	nsubjpass||shown-10/VBN||therapy-3/NN	nsubj||increase-12/VB||therapy-3/NN	prep_with||therapy-3/NN||clopidogrel-5/NN	prep_with||therapy-3/NN||aspirin-7/NN	conj_and||clopidogrel-5/NN||aspirin-7/NN	aux||shown-10/VBN||has-8/VBZ	auxpass||shown-10/VBN||been-9/VBN	root||ROOT-0/null||shown-10/VBN	aux||increase-12/VB||to-11/TO	xcomp||shown-10/VBN||increase-12/VB	det||risk-14/NN||the-13/DT	dobj||increase-12/VB||risk-14/NN	prep_of||risk-14/NN||hemorrhage-16/NN	det||effects-20/NNS||the-19/DT	nsubjpass||studied-31/VBN||effects-20/NNS	det||drugs-23/NNS||the-22/DT	prep_of||effects-20/NNS||drugs-23/NNS	nn||parameters-26/NNS||laboratory-25/NN	prep_on||drugs-23/NNS||parameters-26/NNS	aux||studied-31/VBN||have-27/VBP	neg||studied-31/VBN||not-28/RB	auxpass||studied-31/VBN||been-29/VBN	advmod||studied-31/VBN||well-30/RB	conj_but||shown-10/VBN||studied-31/VBN	amod||settings-35/NNS||real-world-33/JJ	amod||settings-35/NNS||clinical-34/JJ	prep_in||studied-31/VBN||settings-35/NNS	hemorrhage-16||clopidogrel-5||no||dual antiplatelet therapy with clopidogrel and aspirin has been shown to increase the risk of hemorrhage, but the effects of the drugs on laboratory parameters have not been well studied in real-world clinical settings.
prepc_based_on||tested-28/VBD||on-2/IN	det||premise-4/NN||the-3/DT	pobj||tested-28/VBD||premise-4/NN	mark||receiving-21/VBG||that-5/IN	amod||patients-7/NNS||postabsorptive-6/JJ	nsubj||receiving-21/VBG||patients-7/NNS	prep_with||patients-7/NNS||type1diabetes-9/NNS	vmod||type1diabetes-9/NNS||receiving-10/VBG	amod||insulin-12/NN||intravenous-11/JJ	dobj||receiving-10/VBG||insulin-12/NN	det||dose-15/NN||a-14/DT	prep_in||receiving-10/VBG||dose-15/NN	nsubj||maintains-17/VBZ||dose-15/NN	rcmod||dose-15/NN||maintains-17/VBZ	amod||euglycemia-19/NN||stable-18/JJ	dobj||maintains-17/VBZ||euglycemia-19/NN	aux||receiving-21/VBG||are-20/VBP	dep||premise-4/NN||receiving-21/VBG	advmod||optimal-23/JJ||biologically-22/RB	amod||replacement-25/NN||optimal-23/JJ	nn||replacement-25/NN||insulin-24/NN	dobj||receiving-21/VBG||replacement-25/NN	nsubj||tested-28/VBD||we-27/PRP	root||ROOT-0/null||tested-28/VBD	det||hypothesis-30/NNS||the-29/DT	dobj||tested-28/VBD||hypothesis-30/NNS	mark||supports-33/VBZ||that-31/IN	nsubj||supports-33/VBZ||glucagon-32/NN	ccomp||tested-28/VBD||supports-33/VBZ	amod||concentrations-37/NNS||postabsorptive-34/JJ	nn||concentrations-37/NNS||plasma-35/NN	nn||concentrations-37/NNS||glucose-36/NN	dobj||supports-33/VBZ||concentrations-37/NNS	prep_in||concentrations-37/NNS||humans-39/NNS	glucagon-32||type1diabetes-9||no_rel||based on the premise that postabsorptive patients with type1diabetes receiving intravenous insulin in a dose that maintains stable euglycemia are receiving biologically optimal insulin replacement, we tested the hypothesis that glucagon supports postabsorptive plasma glucose concentrations in humans.
amod||patients-2/NNS||type2diabetes-high-1/JJ	nsubj||had-3/VBD||patients-2/NNS	root||ROOT-0/null||had-3/VBD	det||bmi-6/NN||the-4/DT	amod||bmi-6/NN||highest-5/JJS	dobj||had-3/VBD||bmi-6/NN	dobj||had-3/VBD||a1c-8/NNS	conj_and||bmi-6/NN||a1c-8/NNS	dobj||had-3/VBD||lowest-10/JJS	conj_and||bmi-6/NN||lowest-10/JJS	amod||sensitivity-13/NN||whole-body-11/JJ	nn||sensitivity-13/NN||insulin-12/NN	dep||lowest-10/JJS||sensitivity-13/NN	dep||sensitivity-13/NN||anova-15/NN	det||<-19/NN||all-17/DT	amod||<-19/NN||p-18/JJ	appos||anova-15/NN||<-19/NN	num||<-19/NN||0.001-20/CD	type2diabetes--1||insulin-12||yes||type2diabetes-high patients had the highest bmi and a1c and lowest whole-body insulin sensitivity (anova, all p < 0.001).
det||nature-6/NN||the-1/DT	amod||nature-6/NN||strong-2/JJ	amod||nature-6/NN||invasive-3/JJ	conj_and||invasive-3/JJ||metastatic-5/JJ	amod||nature-6/NN||metastatic-5/JJ	nsubj||implies-10/VBZ||nature-6/NN	amod||melanoma-9/NN||cutaneous-8/JJ	prep_of||nature-6/NN||melanoma-9/NN	root||ROOT-0/null||implies-10/VBZ	det||interplay-13/NN||a-11/DT	amod||interplay-13/NN||deregulated-12/VBN	dobj||implies-10/VBZ||interplay-13/NN	nn||adhesion-16/NN||intercellular-15/NN	prep_between||interplay-13/NN||adhesion-16/NN	amod||molecules-19/NNS||migration-related-18/JJ	dobj||implies-10/VBZ||molecules-19/NNS	conj_and||interplay-13/NN||molecules-19/NNS	det||study-22/NN||this-21/DT	prep_in||molecules-19/NNS||study-22/NN	nsubj||performed-24/VBD||we-23/PRP	rcmod||study-22/NN||performed-24/VBD	det||analysis-27/NN||a-25/DT	amod||analysis-27/NN||microarray-26/JJ	dobj||performed-24/VBD||analysis-27/NN	aux||compare-29/VB||to-28/TO	vmod||performed-24/VBD||compare-29/VB	det||profile-33/NN||the-30/DT	nn||profile-33/NN||mrna-31/NN	nn||profile-33/NN||expression-32/NN	dobj||compare-29/VB||profile-33/NN	det||line-40/NN||an-35/DT	amod||line-40/NN||invasive-36/JJ	nn||line-40/NN||blm-37/NN	nn||line-40/NN||melanoma-38/NN	nn||line-40/NN||cell-39/NN	prep_of||profile-33/NN||line-40/NN	nn||lie-43/NN||blm-42/NN	appos||line-40/NN||lie-43/NN	det||variant-50/NN||the-46/DT	amod||p-cadherin-48/JJ||non-invasive-47/JJ	amod||variant-50/NN||p-cadherin-48/JJ	amod||variant-50/NN||over-expression-49/JJ	prep_of||profile-33/NN||variant-50/NN	conj_and||line-40/NN||variant-50/NN	nn||p-cad-53/NN||blm-52/NN	appos||variant-50/NN||p-cad-53/NN	melanoma-38||blm-52||yes||the strong invasive and metastatic nature of cutaneous melanoma implies a deregulated interplay between intercellular adhesion and migration-related molecules in this study we performed a microarray analysis to compare the mrna expression profile of an invasive blm melanoma cell line (blm lie) and the non-invasive p-cadherin over-expression variant (blm p-cad).
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	det||benefit-5/NN||the-3/DT	amod||benefit-5/NN||relative-4/JJ	iobj||examined-2/VBD||benefit-5/NN	prepc_of||benefit-5/NN||introducing-7/VBG	amod||maintenance-12/NN||budesonide/formoterol-8/JJ	appos||maintenance-12/NN||bud/form-10/NNP	dobj||introducing-7/VBG||maintenance-12/NN	nn||therapy-15/NN||reliever-14/NN	dobj||introducing-7/VBG||therapy-15/NN	conj_and||maintenance-12/NN||therapy-15/NN	amod||®-21/NNP||symbicort-17/JJ	nn||®-21/NNP||smartâ-18/NNP	nn||®-21/NNP||®-19/NNP	nn||®-21/NNP||turbuhalerâ-20/NNP	appos||therapy-15/NN||®-21/NNP	prep_in||introducing-7/VBG||patients-24/NNS	advmod||prescribed-26/VBN||previously-25/RB	vmod||patients-24/NNS||prescribed-26/VBN	dobj||prescribed-26/VBN||treatments-27/NNS	amod||initiative-30/NN||global-29/JJ	prep_from||prescribed-26/VBN||initiative-30/NN	amod||steps-36/NNS||asthma-32/JJ	appos||steps-36/NNS||gina-34/NNP	prep_for||prescribed-26/VBN||steps-36/NNS	dobj||examined-2/VBD||2-37/CD	num||2-37/CD||3-39/CD	dobj||examined-2/VBD||4-41/CD	conj_or||2-37/CD||4-41/CD	asthma-32||formoterol--1||no||we examined the relative benefit of introducing budesonide/formoterol (bud/form) maintenance and reliever therapy (symbicort smartâ® turbuhalerâ®) in patients previously prescribed treatments from global initiative for asthma (gina) steps 2, 3 or 4.
nsubj||rare-32/JJ||diseases-1/NNS	vmod||diseases-1/NNS||associated-2/VBN	amod||infections-8/NNS||epstein-barrvirus-4/JJ	appos||infections-8/NNS||ebv-6/NN	prep_with||associated-2/VBN||infections-8/NNS	prep_such_as||associated-2/VBN||infectiousmononucleosis-12/NNS	appos||infectiousmononucleosis-12/NNS||im-14/NN	amod||lymphohistiocytosis-19/NNS||ebv-associated-17/JJ	amod||lymphohistiocytosis-19/NNS||hemophagocytic-18/JJ	prep_such_as||associated-2/VBN||lymphohistiocytosis-19/NNS	conj_and||infectiousmononucleosis-12/NNS||lymphohistiocytosis-19/NNS	appos||lymphohistiocytosis-19/NNS||ebv-hlh-21/NN	amod||ebvinfection-26/NN||chronic-24/JJ	amod||ebvinfection-26/NN||active-25/JJ	prep_such_as||associated-2/VBN||ebvinfection-26/NN	conj_and||infectiousmononucleosis-12/NNS||ebvinfection-26/NN	appos||ebvinfection-26/NN||caebv-28/NNP	cop||rare-32/JJ||are-30/VBP	neg||rare-32/JJ||not-31/RB	root||ROOT-0/null||rare-32/JJ	amod||children-35/NNS||chinese-34/JJ	prep_in||rare-32/JJ||children-35/NNS	infectiousmononucleosis-12||ebv-6||no||diseases associated with epstein-barrvirus (ebv) infections, such as infectiousmononucleosis (im), ebv-associated hemophagocytic lymphohistiocytosis (ebv-hlh) and chronic active ebvinfection (caebv) are not rare in chinese children.
amod||rickets-2/NNS||hypophosphatemic-1/JJ	nsubj||represents-3/VBZ||rickets-2/NNS	root||ROOT-0/null||represents-3/VBZ	det||group-5/NN||a-4/DT	dobj||represents-3/VBZ||group-5/NN	amod||disorders-9/NNS||heritable-7/JJ	amod||disorders-9/NNS||renal-8/JJ	prep_of||group-5/NN||disorders-9/NNS	prep_of||disorders-9/NNS||phosphate-11/NN	vmod||phosphate-11/NN||characterized-12/VBN	amod||serum-19/NN||hypophosphatemia-14/JJ	conj_or||hypophosphatemia-14/JJ||normal-16/JJ	amod||serum-19/NN||normal-16/JJ	conj_or||hypophosphatemia-14/JJ||low-18/JJ	amod||serum-19/NN||low-18/JJ	agent||characterized-12/VBN||serum-19/NN	num||serum-19/NN||1,25-20/CD	discourse||serum-19/NN||oh-22/UH	num||vitamind-25/NN||2-24/CD	dep||serum-19/NN||vitamind-25/NN	nn||levels-28/NNS||calcium-27/NN	dep||serum-19/NN||levels-28/NNS	conj_and||vitamind-25/NN||levels-28/NNS	hypophosphatemia-14||vitamind-25||yes||hypophosphatemic rickets represents a group of heritable renal disorders of phosphate characterized by hypophosphatemia, normal or low serum 1,25 (oh)2 vitamind and calcium levels.
det||review-3/NN||this-2/DT	prep_in||summarize-6/VB||review-3/NN	nsubj||summarize-6/VB||we-5/PRP	root||ROOT-0/null||summarize-6/VB	amod||findings-8/NNS||recent-7/JJ	dobj||summarize-6/VB||findings-8/NNS	advmod||restricts-11/VBZ||how-9/WRB	nsubj||restricts-11/VBZ||macroautophagy-10/NN	dep||summarize-6/VB||restricts-11/VBZ	dobj||restricts-11/VBZ||herpesvirusinfections-12/NNS	advmod||restricts-11/VBZ||directly-13/RB	advmod||contribute-21/VBP||how-15/WRB	amod||autophagy-20/NN||macroautophagy-16/JJ	conj_and||macroautophagy-16/JJ||chaperone-18/JJ	amod||autophagy-20/NN||chaperone-18/JJ	amod||autophagy-20/NN||mediated-19/JJ	nsubj||contribute-21/VBP||autophagy-20/NN	nsubj||herpesviral-23/VB||autophagy-20/NN	dep||summarize-6/VB||contribute-21/VBP	conj_and||restricts-11/VBZ||contribute-21/VBP	aux||herpesviral-23/VB||to-22/TO	xcomp||contribute-21/VBP||herpesviral-23/VB	nn||presentation-25/NN||antigen-24/NN	dobj||herpesviral-23/VB||presentation-25/NN	nn||molecules-28/NNS||mhc-27/NN	prep_on||herpesviral-23/VB||molecules-28/NNS	dobj||developed-35/VBN||which-31/WDT	nsubj||interfere-37/VB||which-31/WDT	nn||herpesviruses-33/NNS||mechanisms-32/NNS	nsubj||developed-35/VBN||herpesviruses-33/NNS	aux||developed-35/VBN||have-34/VBP	dep||summarize-6/VB||developed-35/VBN	conj_and||restricts-11/VBZ||developed-35/VBN	aux||interfere-37/VB||to-36/TO	xcomp||developed-35/VBN||interfere-37/VB	det||pathways-40/NNS||these-39/DT	prep_with||interfere-37/VB||pathways-40/NNS	herpesvirusinfections-12||herpesviruses-33||no||in this review, we summarize recent findings how macroautophagy restricts herpesvirusinfections directly, how macroautophagy and chaperone mediated autophagy contribute to herpesviral antigen presentation on mhc molecules, and which mechanisms herpesviruses have developed to interfere with these pathways.
amod||numbers-2/NNS||total-1/JJ	nsubjpass||reduced-11/VBN||numbers-2/NNS	nsubj||p-25/VBP||numbers-2/NNS	nn||groupbacteria-6/NN||c.-4/NN	nn||groupbacteria-6/NN||leptum-5/NN	prep_of||numbers-2/NNS||groupbacteria-6/NN	nn||prausnitzii-9/NNS||f.-8/NN	prep_of||numbers-2/NNS||prausnitzii-9/NNS	conj_and||groupbacteria-6/NN||prausnitzii-9/NNS	auxpass||reduced-11/VBN||were-10/VBD	root||ROOT-0/null||reduced-11/VBN	preconj||cd-14/NN||both-13/DT	prep_in||reduced-11/VBN||cd-14/NN	prep_in||reduced-11/VBN||uc-16/NN	conj_and||cd-14/NN||uc-16/NN	prepc_compared_to||cd-14/NN||to-18/TO	nn||p-21/NN||hc-19/NN	amod||p-21/NN||-lrb--20/JJ	pobj||cd-14/NN||p-21/NN	dep||0.0036-23/CD||=-22/SYM	dep||p-21/NN||0.0036-23/CD	conj_and||reduced-11/VBN||p-25/VBP	number||0.0001-27/CD||<-26/CD	dobj||p-25/VBP||0.0001-27/CD	advmod||p-25/VBP||respectively-28/RB	acomp||reduced-11/VBN||-rrb--29/JJ	cd-14||uc-16||no_rel||total numbers of c. leptum groupbacteria and f. prausnitzii were reduced in both cd and uc compared to hc -lrb- p = 0.0036 and p < 0.0001 respectively -rrb- .
nsubj||azole-5/NN||posaconazole-1/NN	cop||azole-5/NN||is-2/VBZ	det||azole-5/NN||the-3/DT	amod||azole-5/NN||only-4/JJ	root||ROOT-0/null||azole-5/NN	prep_with||azole-5/NN||activity-7/NN	prep_against||activity-7/NN||zygomycetes-9/NNS	amod||fungi-13/NNS||other-11/JJ	amod||fungi-13/NNS||difficult-to-treat-12/JJ	prep_against||activity-7/NN||fungi-13/NNS	conj_and||zygomycetes-9/NNS||fungi-13/NNS	vmod||azole-5/NN||representing-15/VBG	det||option-19/NN||a-16/DT	amod||option-19/NN||potential-17/JJ	nn||option-19/NN||treatment-18/NN	dobj||representing-15/VBG||option-19/NN	amod||mycosis-23/NNS||refractory-21/JJ	nn||mycosis-23/NNS||invasive-22/NN	prep_for||representing-15/VBG||mycosis-23/NNS	mycosis-23||posaconazole-1||yes||posaconazole is the only azole with activity against zygomycetes and other difficult-to-treat fungi, representing a potential treatment option for refractory invasive mycosis.
prep_in||resistant-7/JJ||contrast-2/NN	amod||mice-5/NNS||angptl4-null-4/JJ	nsubj||resistant-7/JJ||mice-5/NNS	cop||resistant-7/JJ||were-6/VBD	root||ROOT-0/null||resistant-7/JJ	amod||obesity-10/NN||diet-induced-9/JJ	prep_to||resistant-7/JJ||obesity-10/NN	xcomp||resistant-7/JJ||indicating-12/VBG	amod||effects-14/NNS||obesity-promoting-13/JJ	dobj||indicating-12/VBG||effects-14/NNS	prep_of||effects-14/NNS||angptl4-16/CD	det||condition-19/NN||the-18/DT	prep_under||indicating-12/VBG||condition-19/NN	amod||diet-22/NN||fat-enriched-21/JJ	prep_of||condition-19/NN||diet-22/NN	obesity-10||fat--1||no_rel||in contrast, angptl4-null mice were resistant to diet-induced obesity, indicating obesity-promoting effects of angptl4 under the condition of fat-enriched diet.
det||vaccine-7/NN||the-1/DT	amod||vaccine-7/NN||only-2/JJ	nn||vaccine-7/NN||tuberculosis-3/NNP	appos||vaccine-7/NN||tb-5/NN	nsubj||rin-14/NN||vaccine-7/NN	advmod||available-9/JJ||currently-8/RB	amod||vaccine-7/NN||available-9/JJ	cop||rin-14/NN||is-10/VBZ	amod||calmette-guã-12/JJ||bacillus-11/JJ	amod||rin-14/NN||calmette-guã-12/JJ	amod||rin-14/NN||©-13/JJ	root||ROOT-0/null||rin-14/NN	appos||rin-14/NN||bcg-16/NN	mark||has-21/VBZ||although-19/IN	nsubj||has-21/VBZ||it-20/PRP	advcl||rin-14/NN||has-21/VBZ	neg||efficacy-23/NN||no-22/DT	dobj||has-21/VBZ||efficacy-23/NN	prep_in||efficacy-23/NN||adults-25/NNS	tuberculosis-3||bcg-16||no||the only tuberculosis (tb) vaccine currently available is bacillus calmette-guã©rin (bcg), although it has no efficacy in adults.
nn||identification-2/NN||species-1/NN	nsubj||seems-13/VBZ||identification-2/NN	nsubj||important-16/JJ||identification-2/NN	prep_of||identification-2/NN||isolates-4/NNP	vmod||isolates-4/NNP||belonging-5/VBG	det||-rrb--12/NNS||the-7/DT	amod||complex-9/JJ||mycobacteriumtuberculosis-8/JJ	amod||-rrb--12/NNS||complex-9/JJ	amod||-rrb--12/NNS||-lrb--10/JJ	nn||-rrb--12/NNS||mtc-11/NN	prep_to||belonging-5/VBG||-rrb--12/NNS	root||ROOT-0/null||seems-13/VBZ	aux||important-16/JJ||to-14/TO	cop||important-16/JJ||be-15/VB	xcomp||seems-13/VBZ||important-16/JJ	det||treatment-20/NN||the-18/DT	amod||treatment-20/NN||appropriate-19/JJ	prep_for||important-16/JJ||treatment-20/NN	prep_of||treatment-20/NN||patients-22/NNS	mark||resistant-29/JJ||since-24/IN	nn||bovis-26/NNS||m.-25/NN	nsubj||resistant-29/JJ||bovis-26/NNS	cop||resistant-29/JJ||is-27/VBZ	advmod||resistant-29/JJ||naturally-28/RB	advcl||important-16/JJ||resistant-29/JJ	det||drug-38/NN||a-31/DT	amod||drug-38/NN||first-32/JJ	nn||drug-38/NN||line-33/NN	amod||drug-38/NN||anti-tuberculosis-34/JJ	nn||drug-38/NN||-lrb--35/NNP	nn||drug-38/NN||tb-36/NN	nn||drug-38/NN||-rrb--37/NN	prep_to||resistant-29/JJ||drug-38/NN	appos||drug-38/NN||pyrazinamide-40/NN	mark||susceptible-50/JJ||while-42/IN	nsubj||susceptible-50/JJ||most-43/JJS	det||members-48/NNS||the-45/DT	amod||members-48/NNS||other-46/JJ	nn||members-48/NNS||mtc-47/NN	prep_of||most-43/JJS||members-48/NNS	cop||susceptible-50/JJ||are-49/VBP	advcl||resistant-29/JJ||susceptible-50/JJ	det||agent-54/NN||this-52/DT	amod||agent-54/NN||antimicrobial-53/JJ	prep_to||susceptible-50/JJ||agent-54/NN	tb-36||pyrazinamide-40||yes||species identification of isolates belonging to the mycobacteriumtuberculosis complex -lrb- mtc -rrb- seems to be important for the appropriate treatment of patients , since m. bovis is naturally resistant to a first line anti-tuberculosis -lrb- tb -rrb- drug , pyrazinamide , while most of the other mtc members are susceptible to this antimicrobial agent .
det||group-4/NN||the-1/DT	amod||group-4/NN||ptz-induced-2/JJ	nn||group-4/NN||control-3/NN	nsubj||receive-8/VB||group-4/NN	nsubj||showed-11/VBD||group-4/NN	aux||receive-8/VB||did-6/VBD	neg||receive-8/VB||not-7/RB	rcmod||group-4/NN||receive-8/VB	det||sonication-10/NN||any-9/DT	dobj||receive-8/VB||sonication-10/NN	root||ROOT-0/null||showed-11/VBD	det||number-14/NN||a-12/DT	amod||number-14/NN||sustained-13/VBN	dobj||showed-11/VBD||number-14/NN	amod||bursts-19/NNS||epileptic-16/JJ	nn||bursts-19/NNS||eeg-17/NN	nn||bursts-19/NNS||signal-18/NN	prep_of||number-14/NN||bursts-19/NNS	epileptic-16||ptz--1||no||the ptz-induced control group that did not receive any sonication showed a sustained number of epileptic eeg signal bursts.
num||weeks-3/NNS||16-2/CD	prep_at||â-9/NN||weeks-3/NNS	nn||hbp-6/NN||morning-5/NN	nsubj||â-9/NN||hbp-6/NN	cop||â-9/NN||was-7/VBD	num||â-9/NN||135.0-8/CD	root||ROOT-0/null||â-9/NN	num||13.7-11/CD||±-10/CD	dep||â-9/NN||13.7-11/CD	punct||13.7-11/CD||/-12/:	number||â-14/CD||78.8-13/CD	num||hg-23/NN||â-14/CD	nn||hg-23/NN||±-15/NNP	num||hg-23/NN||9.9-16/CD	amod||hg-23/NN||â-17/JJ	prep||â-17/JJ||$-18/$	number||mmâ-20/CD||‰-19/CD	num||$-18/$||mmâ-20/CD	dep||$-18/$||$-21/$	num||$-21/$||‰-22/CD	nsubj||â-29/NN||hg-23/NN	amod||hbp-26/NN||bedtime-25/JJ	conj_and||hg-23/NN||hbp-26/NN	nsubj||â-29/NN||hbp-26/NN	cop||â-29/NN||was-27/VBD	num||â-29/NN||129.7-28/CD	dep||13.7-11/CD||â-29/NN	number||13.8-31/CD||±-30/CD	dep||â-29/NN||13.8-31/CD	punct||â-34/NN||/-32/:	num||â-34/NN||74.7-33/CD	dep||â-29/NN||â-34/NN	vmod||â-34/NN||±-35/VBN	num||â-37/NNS||10.1-36/CD	iobj||±-35/VBN||â-37/NNS	num||â-37/NNS||$-38/$	number||mmâ-40/CD||‰-39/CD	num||$-38/$||mmâ-40/CD	dobj||±-35/VBN||$-41/$	num||$-41/$||‰-42/CD	advmod||$-41/$||hg-43/RB	mark||±-50/NNP||whereas-45/IN	nsubj||±-50/NNP||cbp-46/NN	cop||±-50/NNP||was-47/VBD	number||â-49/CD||135.6-48/CD	num||±-50/NNP||â-49/CD	advcl||±-35/VBN||±-50/NNP	num||±-50/NNP||15.4-51/CD	punct||â-34/NN||/-52/:	number||â-54/CD||77.6-53/CD	num||â-57/NN||â-54/CD	nn||â-57/NN||±-55/NNP	num||â-57/NN||10.9-56/CD	dep||â-29/NN||â-57/NN	num||$-61/$||$-58/$	number||mmâ-60/CD||‰-59/CD	num||$-58/$||mmâ-60/CD	dep||â-57/NN||$-61/$	number||hg-63/CD||‰-62/CD	num||$-61/$||hg-63/CD	hg-63||hbp-26||no_rel||at 16 weeks, morning hbp was 135.0â±13.7/78.8â±9.9â€‰mmâ€‰hg and bedtime hbp was 129.7â±13.8/74.7â±10.1â€‰mmâ€‰hg, whereas cbp was 135.6â±15.4/77.6â±10.9â€‰mmâ€‰hg.
nsubj||weapon-13/NN||bacillusanthracis-1/NNS	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	appos||bacillusanthracis-1/NNS||agent-5/NN	prep_of||agent-5/NN||anthrax-7/NN	cop||weapon-13/NN||is-9/VBZ	det||weapon-13/NN||a-10/DT	amod||weapon-13/NN||proven-11/JJ	amod||weapon-13/NN||biological-12/JJ	root||ROOT-0/null||weapon-13/NN	anthrax-7||bacillusanthracis-1||no||bacillusanthracis , the causative agent of anthrax, is a proven biological weapon.
nn||evolution-2/NN||virus-1/NN	nsubj||facilitates-3/VBZ||evolution-2/NN	root||ROOT-0/null||facilitates-3/VBZ	det||emergence-5/NN||the-4/DT	dobj||facilitates-3/VBZ||emergence-5/NN	prep_of||emergence-5/NN||viruses-7/NNS	amod||impacts-10/NNS||unpredictable-9/JJ	prep_with||viruses-7/NNS||impacts-10/NNS	amod||health-13/NN||human-12/JJ	prep_on||impacts-10/NNS||health-13/NN	virus-1||viruses-7||no||virus evolution facilitates the emergence of viruses with unpredictable impacts on human health.
advmod||excluded-8/VBN||contrastingly-1/RB	nn||patients-4/NNS||hiv/aids-3/NNS	nsubjpass||excluded-8/VBN||patients-4/NNS	aux||excluded-8/VBN||have-5/VBP	auxpass||excluded-8/VBN||been-6/VBN	advmod||excluded-8/VBN||systematically-7/RB	root||ROOT-0/null||excluded-8/VBN	nn||studies-11/NNS||sepsis-10/NN	prep_from||excluded-8/VBN||studies-11/NNS	xcomp||excluded-8/VBN||limiting-13/VBG	det||understanding-15/NN||the-14/DT	dobj||limiting-13/VBG||understanding-15/NN	det||impact-18/NN||the-17/DT	prep_of||understanding-15/NN||impact-18/NN	prep_of||impact-18/NN||sepsis-20/NN	det||population-23/NN||this-22/DT	prep_in||limiting-13/VBG||population-23/NN	aids--1||hiv--1||no||contrastingly, hiv/aids patients have been systematically excluded from sepsis studies, limiting the understanding of the impact of sepsis in this population.
prep||excluded-20/VBN||given-1/VBN	det||insulin-4/NN||the-2/DT	amod||insulin-4/NN||low-3/JJ	pobj||given-1/VBN||insulin-4/NN	nn||levels-7/NNS||glucose-6/NN	pobj||given-1/VBN||levels-7/NNS	conj_and||insulin-4/NN||levels-7/NNS	amod||fasting-10/NN||prolonged-9/JJ	prep_after||insulin-4/NN||fasting-10/NN	nn||action-15/NN||hyperglycemia-12/NN	conj_and||hyperglycemia-12/NN||insulin-14/NN	nn||action-15/NN||insulin-14/NN	nsubjpass||excluded-20/VBN||action-15/NN	nsubj||intramuscular-31/VBP||action-15/NN	nn||se-17/FW||per-16/FW	advmod||excluded-20/VBN||se-17/FW	aux||excluded-20/VBN||can-18/MD	auxpass||excluded-20/VBN||be-19/VB	root||ROOT-0/null||excluded-20/VBN	amod||mechanisms-23/NNS||underlying-22/VBG	prep_as||excluded-20/VBN||mechanisms-23/NNS	vmod||mechanisms-23/NNS||pointing-25/VBG	amod||ffa-29/NN||elevated-27/JJ	nn||ffa-29/NN||plasma-28/NN	prep_toward||pointing-25/VBG||ffa-29/NN	conj_and/or||excluded-20/VBN||intramuscular-31/VBP	amod||accumulation-33/NN||fat-32/JJ	dobj||intramuscular-31/VBP||accumulation-33/NN	amod||causes-36/NNS||possible-35/JJ	prep_as||intramuscular-31/VBP||causes-36/NNS	det||reduction-40/NN||the-38/DT	amod||reduction-40/NN||observed-39/JJ	prep_for||causes-36/NNS||reduction-40/NN	amod||capacity-43/NN||mitochondrial-42/JJ	prep_in||reduction-40/NN||capacity-43/NN	hyperglycemia-12||glucose-6||no||given the low insulin and glucose levels after prolonged fasting, hyperglycemia and insulin action per se can be excluded as underlying mechanisms, pointing toward elevated plasma ffa and/or intramuscular fat accumulation as possible causes for the observed reduction in mitochondrial capacity.
amod||mycoplasmainfection-2/NN||recent-1/JJ	nsubjpass||determined-4/VBN||mycoplasmainfection-2/NN	auxpass||determined-4/VBN||was-3/VBD	root||ROOT-0/null||determined-4/VBN	xcomp||determined-4/VBN||utilizing-5/VBG	det||immunoassay-10/NN||the-6/DT	amod||immunoassay-10/NN||immunocard-7/JJ	nn||immunoassay-10/NN||mycoplasma-8/NN	nn||immunoassay-10/NN||enzyme-9/NN	dobj||utilizing-5/VBG||immunoassay-10/NN	appos||immunoassay-10/NN||eia-12/NN	prep_for||immunoassay-10/NN||detection-15/NN	nn||antibodies-19/NNS||mp-17/NN	nn||antibodies-19/NNS||igm-18/NN	prep_of||detection-15/NN||antibodies-19/NNS	nn||diagnostics-22/NNS||meredian-21/NN	appos||antibodies-19/NNS||diagnostics-22/NNS	nn||cincinnati-26/NNS||inc.-24/NNS	dep||diagnostics-22/NNS||cincinnati-26/NNS	dep||cincinnati-26/NNS||oh-28/FW	det||records-31/NNS||the-30/DT	nsubjpass||reviewed-36/VBN||records-31/NNS	num||patients-34/NNS||44-33/CD	prep_of||records-31/NNS||patients-34/NNS	auxpass||reviewed-36/VBN||were-35/VBD	rcmod||immunoassay-10/NN||reviewed-36/VBN	mycoplasmainfection-2||mycoplasma-8||no||recent mycoplasmainfection was determined utilizing the immunocard mycoplasma enzyme immunoassay (eia) for detection of mp igm antibodies (meredian diagnostics, inc., cincinnati, oh) the records of 44 patients were reviewed.
prepc_in||reported-15/VBN||england-2/VBN	prep_from||england-2/VBN||january-4/NNP	num||january-4/NNP||2004-5/CD	prep_through||england-2/VBN||march-7/NN	num||march-7/NN||2005-8/CD	num||cases-11/NNS||312-10/CD	nsubjpass||reported-15/VBN||cases-11/NNS	prep_of||cases-11/NNS||mumps-13/NNS	auxpass||reported-15/VBN||were-14/VBD	root||ROOT-0/null||reported-15/VBN	prep_in||reported-15/VBN||children-17/NNS	amod||children-17/NNS||eligible-18/JJ	aux||received-21/VBN||to-19/TO	aux||received-21/VBN||have-20/VB	xcomp||eligible-18/JJ||received-21/VBN	num||doses-23/NNS||2-22/CD	dobj||received-21/VBN||doses-23/NNS	prep_of||doses-23/NNS||mmrvaccine-25/NN	mumps-13||mmrvaccine-25||no_rel||in england from january 2004 through march 2005, 312 cases of mumps were reported in children eligible to have received 2 doses of mmrvaccine.
nsubj||show-2/VBP||results-1/NNS	root||ROOT-0/null||show-2/VBP	mark||induces-8/VBZ||that-3/IN	num||falciparum-7/NN||1-4/CD	amod||falciparum-7/NN||-rrb--5/JJ	nn||falciparum-7/NN||p.-6/NN	nsubj||induces-8/VBZ||falciparum-7/NN	ccomp||show-2/VBP||induces-8/VBZ	det||inflammation-11/NN||a-9/DT	amod||inflammation-11/NN||strong-10/JJ	dobj||induces-8/VBZ||inflammation-11/NN	vmod||inflammation-11/NN||characterized-12/VBN	det||increase-15/NN||an-14/DT	agent||characterized-12/VBN||increase-15/NN	prepc_in||characterized-12/VBN||circulating-17/VBG	dobj||circulating-17/VBG||leukocytes-18/NNS	det||release-21/NN||the-20/DT	dobj||induces-8/VBZ||release-21/NN	conj_and||inflammation-11/NN||release-21/NN	amod||cytokines-24/NNS||inflammatory-23/JJ	prep_of||release-21/NN||cytokines-24/NNS	num||-rrb--27/NNS||2-26/CD	nsubj||induces-37/VBZ||-rrb--27/NNS	prep_in||-rrb--27/NNS||contrast-29/NN	det||yoelii-35/NN||the-31/DT	amod||yoelii-35/NN||rodent-32/JJ	nn||yoelii-35/NN||parasite-33/NN	nn||yoelii-35/NN||p.-34/NN	appos||contrast-29/NN||yoelii-35/NN	conj_and||show-2/VBP||induces-37/VBZ	det||inflammation-42/NN||a-38/DT	advmod||moderate-41/JJ||far-39/RB	advmod||moderate-41/JJ||more-40/RBR	amod||inflammation-42/NN||moderate-41/JJ	dobj||induces-37/VBZ||inflammation-42/NN	number||-rrb--45/CD||3-44/CD	num||cells-49/NNS||-rrb--45/CD	amod||cells-49/NNS||human-46/JJ	amod||cells-49/NNS||red-47/JJ	nn||cells-49/NNS||blood-48/NN	nsubj||induce-54/VB||cells-49/NNS	det||anti-inflammatoryagents-52/NNS||the-51/DT	conj_and||cells-49/NNS||anti-inflammatoryagents-52/NNS	nsubj||induce-54/VB||anti-inflammatoryagents-52/NNS	vmod||anti-inflammatoryagents-52/NNS||employed-53/VBN	conj_and||show-2/VBP||induce-54/VB	amod||inflammation-56/NN||low-grade-55/JJ	dobj||induce-54/VB||inflammation-56/NN	num||macrophages-61/NNS||4-59/CD	amod||macrophages-61/NNS||-rrb--60/JJ	nsubj||seem-62/VBP||macrophages-61/NNS	nsubj||bear-64/VB||macrophages-61/NNS	conj_and||show-2/VBP||seem-62/VBP	aux||bear-64/VB||to-63/TO	xcomp||seem-62/VBP||bear-64/VB	det||function-68/NN||the-65/DT	advmod||critical-67/JJ||most-66/RBS	amod||function-68/NN||critical-67/JJ	dobj||bear-64/VB||function-68/NN	amod||survival-73/NN||controlling-70/JJ	nn||survival-73/NN||p.-71/NN	nn||survival-73/NN||falciparum-72/NN	prep_in||bear-64/VB||survival-73/NN	det||mice-76/NNS||those-75/DT	prep_in||survival-73/NN||mice-76/NNS	mark||have-83/VBP||whereas-78/IN	nn||cells-82/NNS||polymorphonuclear-79/NN	conj_and||polymorphonuclear-79/NN||nk-81/NN	nn||cells-82/NNS||nk-81/NN	nsubj||have-83/VBP||cells-82/NNS	advcl||bear-64/VB||have-83/VBP	advmod||role-87/NN||only-84/RB	det||role-87/NN||a-85/DT	amod||role-87/NN||minor-86/JJ	dobj||have-83/VBP||role-87/NN	anti-inflammatoryagents-52||inflammation-56||no_rel||results show that 1 -rrb- p. falciparum induces a strong inflammation characterized by an increase in circulating leukocytes and the release of inflammatory cytokines ; 2 -rrb- in contrast , the rodent parasite p. yoelii , induces a far more moderate inflammation ; 3 -rrb- human red blood cells and the anti-inflammatoryagents employed induce low-grade inflammation ; and 4 -rrb- macrophages seem to bear the most critical function in controlling p. falciparum survival in those mice , whereas polymorphonuclear and nk cells have only a minor role .
amod||prevalence-2/NN||increasing-1/VBG	nsubj||worsening-17/VBG||prevalence-2/NN	nn||resistance-5/NN||inh-4/NN	prep_of||prevalence-2/NN||resistance-5/NN	advmod||resistance-5/NN||especially-7/RB	amod||tb-12/NN||high-9/JJ	nn||tb-12/NN||tuberculosis-10/NNP	nn||tb-12/NN||-lrb--11/NNP	prep_in||especially-7/RB||tb-12/NN	advmod||prevalent-14/JJ||-rrb--13/RB	amod||countries-15/NNS||prevalent-14/JJ	dep||resistance-5/NN||countries-15/NNS	aux||worsening-17/VBG||is-16/VBZ	root||ROOT-0/null||worsening-17/VBG	det||burden-19/NN||the-18/DT	dobj||worsening-17/VBG||burden-19/NN	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||burden-19/NN||programs-23/NNS	mark||noted-30/VBN||since-25/IN	amod||rates-28/NNS||similar-26/JJ	nn||rates-28/NNS||transmission-27/NN	nsubjpass||noted-30/VBN||rates-28/NNS	auxpass||noted-30/VBN||are-29/VBP	advcl||worsening-17/VBG||noted-30/VBN	nn||strains-37/NNS||inh-32/NN	amod||strains-37/NNS||susceptible-33/JJ	conj_and||susceptible-33/JJ||resistant-35/JJ	amod||strains-37/NNS||resistant-35/JJ	nn||strains-37/NNS||m.tuberculosis-36/NN	prep_for||noted-30/VBN||strains-37/NNS	tb-21||inh-32||yes||increasing prevalence of inh resistance , especially in high tuberculosis -lrb- tb -rrb- prevalent countries is worsening the burden of tb control programs , since similar transmission rates are noted for inh susceptible and resistant m.tuberculosis strains .
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||the-3/DT	dobj||report-2/VBP||case-4/NN	det||man-9/NN||a-6/DT	amod||man-9/NN||35-year-old-7/JJ	amod||man-9/NN||indo-aryan-8/JJ	prep_of||case-4/NN||man-9/NN	amod||kidneydisease-14/NN||autosomal-11/JJ	amod||kidneydisease-14/NN||dominant-12/JJ	amod||kidneydisease-14/NN||polycystic-13/JJ	prep_with||report-2/VBP||kidneydisease-14/NN	vmod||kidneydisease-14/NN||associated-15/VBN	amod||syndrome-18/NN||nephrotic-17/JJ	prep_with||associated-15/VBN||syndrome-18/NN	det||decline-22/NN||a-20/DT	amod||decline-22/NN||concomitant-21/JJ	prep_with||associated-15/VBN||decline-22/NN	conj_and||syndrome-18/NN||decline-22/NN	poss||rate-27/NN||his-24/PRP$	nn||rate-27/NN||glomerular-25/NN	nn||rate-27/NN||filtration-26/NN	prep_in||associated-15/VBN||rate-27/NN	kidneydisease-14||indo--1||no||we report the case of a 35-year-old indo-aryan man with autosomal dominant polycystic kidneydisease associated with nephrotic syndrome and a concomitant decline in his glomerular filtration rate.
mark||activated-4/VBN||although-1/IN	nsubjpass||activated-4/VBN||it-2/PRP	nsubjpass||related-11/VBN||it-2/PRP	auxpass||activated-4/VBN||is-3/VBZ	advcl||same-19/JJ||activated-4/VBN	det||system-8/NN||the-6/DT	amod||system-8/NN||immune-7/JJ	agent||activated-4/VBN||system-8/NN	auxpass||related-11/VBN||is-10/VBZ	conj_and||activated-4/VBN||related-11/VBN	advcl||same-19/JJ||related-11/VBN	prep_to||related-11/VBN||allergicreactions-13/NNS	nsubj||same-19/JJ||it-15/PRP	cop||same-19/JJ||is-16/VBZ	neg||same-19/JJ||not-17/RB	det||same-19/JJ||the-18/DT	root||ROOT-0/null||same-19/JJ	amod||allergicreactions-22/NNS||other-21/JJ	prep_as||same-19/JJ||allergicreactions-22/NNS	allergicreactions-22||allergicreactions-22||no||although it is activated by the immune system and is related to allergicreactions, it is not the same as other allergicreactions.
det||understanding-2/NN||an-1/DT	nsubj||evolving-24/VBG||understanding-2/NN	nsubj||become-55/VBN||understanding-2/NN	det||risks-5/NNS||the-4/DT	prep_of||understanding-2/NN||risks-5/NNS	prep_of||understanding-2/NN||benefits-7/NNS	conj_and||risks-5/NNS||benefits-7/NNS	amod||value-11/NN||relative-10/JJ	prep_of||understanding-2/NN||value-11/NN	conj_and||risks-5/NNS||value-11/NN	prep_of||value-11/NN||glatirameracetate-13/NN	appos||glatirameracetate-13/NN||ga-15/NN	prep_in||glatirameracetate-13/NN||multiplesclerosis-18/NNS	appos||multiplesclerosis-18/NNS||ms-20/NN	aux||evolving-24/VBG||has-22/VBZ	aux||evolving-24/VBG||been-23/VBN	root||ROOT-0/null||evolving-24/VBG	prepc_based_on||evolving-24/VBG||on-26/IN	advmod||completed-28/VBN||recently-27/RB	amod||studies-30/NNS||completed-28/VBN	amod||studies-30/NNS||head-to-head-29/JJ	pobj||evolving-24/VBG||studies-30/NNS	dep||studies-30/NNS||regard-31/VBP	parataxis||regard-31/VBP||rebif-33/VB	nn||glatirameracetate-35/NN||vs-34/NN	dobj||rebif-33/VB||glatirameracetate-35/NN	prepc_in||rebif-33/VB||relapsing-37/VBG	nn||disease-39/NN||ms-38/NN	dobj||relapsing-37/VBG||disease-39/NN	prep||evolving-24/VBG||beyond-42/IN	amod||outcomes-47/NNS||betaseron-44/JJ	advmod||yielding-46/JJ||efficacy-45/RB	amod||outcomes-47/NNS||yielding-46/JJ	dep||evolving-24/VBG||outcomes-47/NNS	det||dose-51/NN||a-49/DT	amod||dose-51/NN||new-50/JJ	prep_of||outcomes-47/NNS||dose-51/NN	conj_and||evolving-24/VBG||become-55/VBN	nn||copaxone-59/NN||betaseron-57/NN	nn||copaxone-59/NN||vs-58/NN	dep||become-55/VBN||copaxone-59/NN	prep_in||copaxone-59/NN||multiplesclerosis-61/NNS	amod||gadolinium-64/NN||triple-dose-63/JJ	prep_with||multiplesclerosis-61/NNS||gadolinium-64/NN	amod||endpoints-68/NNS||3-tesla-66/JJ	nn||endpoints-68/NNS||mri-67/NN	prep_with||multiplesclerosis-61/NNS||endpoints-68/NNS	conj_and||gadolinium-64/NN||endpoints-68/NNS	glatirameracetate-35||multiplesclerosis-61||no_rel||an understanding of the risks, benefits, and relative value of glatirameracetate (ga) in multiplesclerosis (ms) has been evolving based on recently completed head-to-head studies regard (rebif vs glatirameracetate in relapsing ms disease); beyond (betaseron efficacy yielding outcomes of a new dose); and become (betaseron vs copaxone in multiplesclerosis with triple-dose gadolinium and 3-tesla mri endpoints).
det||mito-mice-3/NN||the-2/DT	prep_in||induced-10/VBN||mito-mice-3/NN	nsubj||induced-10/VBN||accumulation-5/NN	nn||mtdna-9/NN||î-7/NN	prep_of||accumulation-5/NN||mtdna-9/NN	root||ROOT-0/null||induced-10/VBN	amod||defects-13/NNS||mitochondrial-11/JJ	nn||defects-13/NNS||respiration-12/NN	dobj||induced-10/VBN||defects-13/NNS	amod||tissues-16/NNS||various-15/JJ	prep_in||defects-13/NNS||tissues-16/NNS	vmod||induced-10/VBN||resulting-18/VBG	amod||phenotypes-22/NNS||mitochondrial-20/JJ	nn||phenotypes-22/NNS||disease-21/NN	prep_in||resulting-18/VBG||phenotypes-22/NNS	amod||weight-28/NN||low-26/JJ	nn||weight-28/NN||body-27/NN	prep_such_as||phenotypes-22/NNS||weight-28/NN	amod||acidosis-31/NNS||lactic-30/JJ	prep_such_as||phenotypes-22/NNS||acidosis-31/NNS	conj_and||weight-28/NN||acidosis-31/NNS	prep_such_as||phenotypes-22/NNS||ischemia-33/NN	conj_and||weight-28/NN||ischemia-33/NN	prep_such_as||phenotypes-22/NNS||myopathy-35/NN	conj_and||weight-28/NN||myopathy-35/NN	prep_such_as||phenotypes-22/NNS||heartblock-37/NN	conj_and||weight-28/NN||heartblock-37/NN	prep_such_as||phenotypes-22/NNS||deafness-39/NNS	conj_and||weight-28/NN||deafness-39/NNS	amod||infertility-42/NN||male-41/JJ	prep_such_as||phenotypes-22/NNS||infertility-42/NN	conj_and||weight-28/NN||infertility-42/NN	prep_such_as||phenotypes-22/NNS||renalfailure-45/NN	conj_and||weight-28/NN||renalfailure-45/NN	heartblock-37||mito--1||no_rel||in the mito-mice, accumulation of î”mtdna induced mitochondrial respiration defects in various tissues, resulting in mitochondrial disease phenotypes, such as low body weight, lactic acidosis, ischemia, myopathy, heartblock, deafness, male infertility, and renalfailure.
nsubj||remains-5/VBZ||diagnosis-1/NN	amod||influenzapneumonia-4/NN||severe-3/JJ	prep_of||diagnosis-1/NN||influenzapneumonia-4/NN	root||ROOT-0/null||remains-5/VBZ	xcomp||remains-5/VBZ||challenging-6/VBG	det||lack-10/NN||a-9/DT	prep_because_of||challenging-6/VBG||lack-10/NN	prep_of||lack-10/NN||correlation-12/NN	det||presence-15/NN||the-14/DT	prep_between||correlation-12/NN||presence-15/NN	prep_of||presence-15/NN||influenzavirus-17/NNS	amod||status-20/NN||clinical-19/JJ	prep_of||presence-15/NN||status-20/NN	conj_and||influenzavirus-17/NNS||status-20/NN	influenzapneumonia-4||influenzavirus-17||no||diagnosis of severe influenzapneumonia remains challenging because of a lack of correlation between the presence of influenzavirus and clinical status.
dep||over-expressed-3/VBN||ets-1-1/JJ	auxpass||over-expressed-3/VBN||was-2/VBD	root||ROOT-0/null||over-expressed-3/VBN	xcomp||over-expressed-3/VBN||using-4/VBG	det||vector-9/NN||a-5/DT	amod||vector-9/NN||stably-incorporated-6/JJ	amod||vector-9/NN||tetracycline-inducible-7/JJ	nn||vector-9/NN||expression-8/NN	dobj||using-4/VBG||vector-9/NN	det||line-15/NN||the-11/DT	amod||line-15/NN||ovarian-12/JJ	nn||line-15/NN||cancer-13/NN	nn||line-15/NN||cell-14/NN	prep_in||vector-9/NN||line-15/NN	nsubjpass||over-expressed-3/VBN||2008-16/CD	nsubj||express-21/VB||2008-16/CD	aux||express-21/VB||does-19/VBZ	neg||express-21/VB||not-20/RB	rcmod||2008-16/CD||express-21/VB	amod||levels-24/NNS||detectable-22/JJ	amod||levels-24/NNS||basal-23/JJ	dobj||express-21/VB||levels-24/NNS	amod||protein-27/NN||ets-1-26/JJ	prep_of||levels-24/NNS||protein-27/NN	cancer-13||tetracycline--1||no_rel||ets-1 was over-expressed using a stably-incorporated tetracycline-inducible expression vector in the ovarian cancer cell line 2008, which does not express detectable basal levels of ets-1 protein.
det||probability-4/NN||the-1/DT	amod||probability-4/NN||adjusted-2/JJ	nn||probability-4/NN||survival-3/NN	nsubj||lower-6/JJR||probability-4/NN	cop||lower-6/JJR||was-5/VBD	root||ROOT-0/null||lower-6/JJR	amod||patients-10/NNS||hivpositive-8/JJ	nn||patients-10/NNS||tb-9/NN	prep_in||lower-6/JJR||patients-10/NNS	nsubj||â-13/VBP||<-12/NNP	dep||lower-6/JJR||â-13/VBP	num||%-17/NN||$-14/$	number||15-16/CD||‰-15/CD	num||$-14/$||15-16/CD	dobj||â-13/VBP||%-17/NN	mark||hiv-20/VBP||than-19/IN	ccomp||lower-6/JJR||hiv-20/VBP	amod||patients-23/NNS||negative-21/JJ	nn||patients-23/NNS||tb-22/NN	dobj||hiv-20/VBP||patients-23/NNS	nsubj||â-26/VBP||>-25/NNP	dep||patients-23/NNS||â-26/VBP	num||%-30/NN||$-27/$	number||85-29/CD||‰-28/CD	num||$-27/$||85-29/CD	dobj||â-26/VBP||%-30/NN	det||end-34/NN||the-33/DT	prep_at||patients-23/NNS||end-34/NN	det||period-38/NN||the-36/DT	amod||period-38/NN||dots-37/JJ	prep_of||end-34/NN||period-38/NN	amod||month-41/NN||8th-40/JJ	appos||period-38/NN||month-41/NN	hivpositive-8||hiv-20||no||the adjusted survival probability was lower in hivpositive tb patients (<â€‰15%) than hiv negative tb patients (>â€‰85%) at the end of the dots period (8th month).
nsubj||share-5/VBP||cr-1/NN	amod||exercise-4/NN||endurance-3/JJ	conj_and||cr-1/NN||exercise-4/NN	nsubj||share-5/VBP||exercise-4/NN	root||ROOT-0/null||share-5/VBP	det||function-9/NN||a-6/DT	amod||function-9/NN||potent-7/JJ	amod||function-9/NN||anti-inflammatory-8/JJ	dobj||share-5/VBP||function-9/NN	amod||tissues-12/NNS||adipose-11/JJ	prep_in||function-9/NN||tissues-12/NNS	prepc_in||share-5/VBP||ameliorating-14/VBG	amod||obesity-16/NN||diet-induced-15/JJ	dobj||ameliorating-14/VBG||obesity-16/NN	dobj||ameliorating-14/VBG||insulinresistance-18/NN	conj_and||obesity-16/NN||insulinresistance-18/NN	anti-inflammatory-8||insulinresistance-18||no_rel||cr and endurance exercise share a potent anti-inflammatory function in adipose tissues in ameliorating diet-induced obesity and insulinresistance.
amod||vaccines-9/NNS||immunization-1/JJ	amod||swine-6/NNS||1918-like-3/JJ	conj_and||1918-like-3/JJ||classical-5/JJ	amod||swine-6/NNS||classical-5/JJ	prep_with||immunization-1/JJ||swine-6/NNS	amod||vaccines-9/NNS||h1n1-7/JJ	nn||vaccines-9/NNS||virus-8/NN	nsubj||results-10/VBZ||vaccines-9/NNS	root||ROOT-0/null||results-10/VBZ	amod||antibodies-13/NNS||cross-protective-12/JJ	prep_in||results-10/VBZ||antibodies-13/NNS	det||influenza-19/NN||the-15/DT	num||h1n1-17/NNS||2009-16/CD	npadvmod||pandemic-18/JJ||h1n1-17/NNS	amod||influenza-19/NN||pandemic-18/JJ	prep_against||antibodies-13/NNS||influenza-19/NN	xcomp||results-10/VBZ||indicating-21/VBG	amod||similarities-23/NNS||antigenic-22/JJ	dobj||indicating-21/VBG||similarities-23/NNS	det||viruses-26/NNS||these-25/DT	prep_among||indicating-21/VBG||viruses-26/NNS	cross--1||antibodies-13||no_rel||immunization with 1918-like and classical swine h1n1 virus vaccines results in cross-protective antibodies against the 2009 h1n1 pandemic influenza, indicating antigenic similarities among these viruses.
nsubjpass||identified-3/VBN||m.tuberculosis-1/NNS	auxpass||identified-3/VBN||was-2/VBD	root||ROOT-0/null||identified-3/VBN	nn||culture-7/NN||reference-5/NN	amod||culture-7/NN||standard-6/JJ	agent||identified-3/VBN||culture-7/NN	num||suspects-15/NNS||34/98-9/CD	number||35-11/CD||-lrb--10/CD	dep||%-12/NN||35-11/CD	dep||suspects-15/NNS||%-12/NN	amod||suspects-15/NNS||-rrb--13/JJ	amod||suspects-15/NNS||mdr-tb-14/JJ	prep_among||culture-7/NN||suspects-15/NNS	tb--1||m.tuberculosis-1||no||m.tuberculosis was identified by reference standard culture among 34/98 -lrb- 35 % -rrb- mdr-tb suspects .
number||five-2/CD||ninety-1/CD	num||patients-3/NNS||five-2/CD	nsubjpass||diagnosed-5/VBN||patients-3/NNS	auxpass||diagnosed-5/VBN||were-4/VBD	root||ROOT-0/null||diagnosed-5/VBN	prep_of||diagnosed-5/VBN||cancer-7/NN	det||months-12/NNS||the-9/DT	amod||months-12/NNS||past-10/JJ	num||months-12/NNS||24-11/CD	prep_within||diagnosed-5/VBN||months-12/NNS	num||%-14/NN||,73.5-13/CD	nsubj||users-17/NNS||%-14/NN	cop||users-17/NNS||were-15/VBD	nn||users-17/NNS||cam-16/NN	rcmod||months-12/NNS||users-17/NNS	mark||follows-19/VBZ||as-18/IN	advcl||users-17/NNS||follows-19/VBZ	dep||months-12/NNS||massage-21/NN	num||%-24/NN||66.3-23/CD	appos||massage-21/NN||%-24/NN	dep||months-12/NNS||herbal-27/JJ	conj_and||massage-21/NN||herbal-27/JJ	num||%-30/NN||59.2-29/CD	appos||herbal-27/JJ||%-30/NN	amod||vitamins-34/NNS||mega-33/JJ	dep||months-12/NNS||vitamins-34/NNS	conj_and||massage-21/NN||vitamins-34/NNS	num||%-37/NN||55.1-36/CD	appos||vitamins-34/NNS||%-37/NN	amod||medicine-41/NN||chinese-40/JJ	dep||months-12/NNS||medicine-41/NN	conj_and||massage-21/NN||medicine-41/NN	number||%-44/NN||53.1-43/CD	dep||medicine-41/NN||%-44/NN	dep||months-12/NNS||prayer-48/NN	conj_and||massage-21/NN||prayer-48/NN	number||%-51/NN||42.9-50/CD	dep||prayer-48/NN||%-51/NN	vitamins-34||cancer-7||no_rel||ninety five patients were diagnosed of cancer within the past 24 months,73.5% were cam users as follows; massage(66.3%), herbal(59.2%), mega vitamins(55.1%), chinese medicine(53.1%),and prayer(42.9%).
nn||therapy-3/NN||combination-1/NN	amod||therapy-3/NN||antiretroviral-2/JJ	nsubj||mitigates-17/VBZ||therapy-3/NN	nsubj||lowers-22/VBZ||therapy-3/NN	poss||effect-8/NN||its-6/PRP$	amod||effect-8/NN||potent-7/JJ	prep_with||therapy-3/NN||effect-8/NN	amod||hivinfection-11/NN||cns-10/JJ	prep_on||effect-8/NN||hivinfection-11/NN	nn||rna-15/NN||csf-13/NN	nn||rna-15/NN||hiv-14/NN	prep_on||effect-8/NN||rna-15/NN	conj_and||hivinfection-11/NN||rna-15/NN	root||ROOT-0/null||mitigates-17/VBZ	det||immunoactivation-20/NN||both-18/DT	amod||immunoactivation-20/NN||intrathecal-19/JJ	dobj||mitigates-17/VBZ||immunoactivation-20/NN	conj_and||mitigates-17/VBZ||lowers-22/VBZ	nn||neopterin-24/NN||csf-23/NN	dobj||lowers-22/VBZ||neopterin-24/NN	hivinfection-11||hiv-14||no||combination antiretroviral therapy, with its potent effect on cns hivinfection and csf hiv rna, mitigates both intrathecal immunoactivation and lowers csf neopterin.
det||man-6/NN||an-1/DT	advmod||healthy-3/JJ||otherwise-2/RB	amod||man-6/NN||healthy-3/JJ	amod||man-6/NN||17-year-old-4/JJ	amod||man-6/NN||white-5/JJ	nsubjpass||treated-9/VBN||man-6/NN	nsubjpass||referred-17/VBN||man-6/NN	auxpass||treated-9/VBN||was-8/VBD	rcmod||man-6/NN||treated-9/VBN	amod||isotretinoin-12/NN||systemic-11/JJ	prep_with||treated-9/VBN||isotretinoin-12/NN	amod||acne-15/NN||recalcitrant-14/JJ	prep_for||isotretinoin-12/NN||acne-15/NN	auxpass||referred-17/VBN||was-16/VBD	root||ROOT-0/null||referred-17/VBN	amod||occlusion-22/NN||central-19/JJ	amod||occlusion-22/NN||retinal-20/JJ	nn||occlusion-22/NN||vein-21/NN	prep_with||referred-17/VBN||occlusion-22/NN	num||eye-25/NN||one-24/CD	prep_in||occlusion-22/NN||eye-25/NN	acne-15||isotretinoin-12||yes||an otherwise healthy 17-year-old white man who was treated with systemic isotretinoin for recalcitrant acne was referred with central retinal vein occlusion in one eye.
advmod||suggest-5/VBP||collectively-1/RB	det||results-4/NNS||these-3/DT	nsubj||suggest-5/VBP||results-4/NNS	root||ROOT-0/null||suggest-5/VBP	mark||acquired-16/VBN||that-6/IN	det||pml-10/NN||a-7/DT	advmod||virulent-9/JJ||more-8/RBR	amod||pml-10/NN||virulent-9/JJ	nsubjpass||acquired-16/VBN||pml-10/NN	vmod||pml-10/NN||causing-11/VBG	dobj||causing-11/VBG||phenotype-12/NN	prep_of||phenotype-12/NN||jcvirus-14/NNS	auxpass||acquired-16/VBN||is-15/VBZ	ccomp||suggest-5/VBP||acquired-16/VBN	amod||evolution-19/NN||adaptive-18/JJ	prep_via||acquired-16/VBN||evolution-19/NN	nsubj||changes-21/VBZ||evolution-19/NN	rcmod||evolution-19/NN||changes-21/VBZ	amod||specificity-23/NN||viral-22/JJ	dobj||changes-21/VBZ||specificity-23/NN	poss||receptor-27/NN||its-25/PRP$	amod||receptor-27/NN||cellular-26/JJ	prep_for||specificity-23/NN||receptor-27/NN	dep||receptor-27/NN||s-29/PRP	pml-10||jcvirus-14||no||collectively, these results suggest that a more virulent pml causing phenotype of jcvirus is acquired via adaptive evolution that changes viral specificity for its cellular receptor(s).
mark||negative-6/JJ||although-1/IN	nsubj||negative-6/JJ||pcr/hsv-2/NNP	prep_of||pcr/hsv-2/NNP||csf-4/NN	cop||negative-6/JJ||was-5/VBD	advcl||treated-12/VBN||negative-6/JJ	det||patient-9/NN||the-8/DT	nsubjpass||treated-12/VBN||patient-9/NN	nsubjpass||showed-17/VBD||patient-9/NN	nsubjpass||discharged-22/VBN||patient-9/NN	auxpass||treated-12/VBN||was-10/VBD	advmod||treated-12/VBN||empirically-11/RB	root||ROOT-0/null||treated-12/VBN	nn||acyclovir-15/NN||iv-14/NN	prep_with||treated-12/VBN||acyclovir-15/NN	conj_and||treated-12/VBN||showed-17/VBD	amod||improvement-19/NN||significant-18/JJ	dobj||showed-17/VBD||improvement-19/NN	auxpass||discharged-22/VBN||was-21/VBD	conj_and||treated-12/VBN||discharged-22/VBN	amod||condition-25/NN||good-24/JJ	prep_in||discharged-22/VBN||condition-25/NN	hsv--1||acyclovir-15||yes||although pcr/hsv of csf was negative, the patient was empirically treated with iv acyclovir and showed significant improvement and was discharged in good condition.
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	det||effectiveness-4/NN||the-3/DT	iobj||assessed-2/VBD||effectiveness-4/NN	prep_of||effectiveness-4/NN||cetuximab-6/NN	amod||irinotecan-9/NN||plus-7/IN	amod||irinotecan-9/NN||chronomodulated-8/JJ	dobj||assessed-2/VBD||irinotecan-9/NN	appos||irinotecan-9/NN||5-fluorouracil-11/NN	dep||5-fluorouracil-11/NN||5-fu-13/JJ	appos||irinotecan-9/NN||leucovorin-16/NN	conj_and||5-fluorouracil-11/NN||leucovorin-16/NN	appos||leucovorin-16/NN||fa-18/NN	appos||irinotecan-9/NN||oxaliplatin-21/NN	conj_and||5-fluorouracil-11/NN||oxaliplatin-21/NN	dep||oxaliplatin-21/NN||l-ohp-23/NN	amod||oxaliplatin-21/NN||chrono-iflo-26/JJ	vmod||5-fluorouracil-11/NN||administered-28/VBN	amod||chemotherapy-31/NN||neoadjuvant-30/JJ	prep_as||administered-28/VBN||chemotherapy-31/NN	aux||increase-33/VB||to-32/TO	xcomp||administered-28/VBN||increase-33/VB	det||resectability-35/NN||the-34/DT	dobj||increase-33/VB||resectability-35/NN	amod||metastases-39/NNS||colorectal-37/JJ	nn||metastases-39/NNS||liver-38/NN	prep_of||resectability-35/NN||metastases-39/NNS	metastases-39||irinotecan-9||yes||we assessed the effectiveness of cetuximab plus chronomodulated irinotecan, 5-fluorouracil (5-fu), leucovorin (fa) and oxaliplatin (l-ohp) (chrono-iflo) administered as neoadjuvant chemotherapy to increase the resectability of colorectal liver metastases.
nsubj||added-2/VBD||aliskiren-1/NN	nsubj||losartan-4/VB||aliskiren-1/NN	nsubj||tolerated-13/JJ||aliskiren-1/NN	root||ROOT-0/null||added-2/VBD	aux||losartan-4/VB||to-3/TO	xcomp||added-2/VBD||losartan-4/VB	amod||albuminuria-6/NN||reduced-5/VBN	dobj||losartan-4/VB||albuminuria-6/NN	amod||dysfunction-9/NN||renal-8/JJ	dobj||losartan-4/VB||dysfunction-9/NN	conj_and||albuminuria-6/NN||dysfunction-9/NN	cop||tolerated-13/JJ||was-11/VBD	advmod||tolerated-13/JJ||well-12/RB	conj_and||added-2/VBD||tolerated-13/JJ	prep_except_for||independent-23/JJ||hyperkalemia-17/NN	appos||hyperkalemia-17/NN||stage-19/NN	num||stage-19/NN||3-20/CD	dep||tolerated-13/JJ||independent-23/JJ	amod||stage-27/NN||baseline-25/JJ	nn||stage-27/NN||ckd-26/NN	prep_of||independent-23/JJ||stage-27/NN	prep_in||stage-27/NN||patients-29/NNS	prep_with||patients-29/NNS||type2diabetes-31/NNS	appos||type2diabetes-31/NNS||hypertension-33/NN	conj_and||added-2/VBD||nephropathy-36/JJ	conj_and||tolerated-13/JJ||nephropathy-36/JJ	type2diabetes-31||losartan-4||no_rel||aliskiren added to losartan reduced albuminuria and renal dysfunction and was well tolerated, except for hyperkalemia (stage 3), independent of baseline ckd stage in patients with type2diabetes, hypertension, and nephropathy.
nsubjpass||conducted-6/VBN||methods-1/NNS	nsubj||collect-8/VB||methods-1/NNS	det||review-4/NN||a-2/DT	nn||review-4/NN||desk-3/NN	dep||methods-1/NNS||review-4/NN	auxpass||conducted-6/VBN||was-5/VBD	root||ROOT-0/null||conducted-6/VBN	aux||collect-8/VB||to-7/TO	xcomp||conducted-6/VBN||collect-8/VB	amod||policies-11/NNS||chinese-9/JJ	nn||policies-11/NNS||government-10/NN	dobj||collect-8/VB||policies-11/NNS	nn||documents-14/NNS||project-13/NN	dobj||collect-8/VB||documents-14/NNS	conj_and||policies-11/NNS||documents-14/NNS	amod||articles-17/NNS||published-16/VBN	dobj||collect-8/VB||articles-17/NNS	conj_and||policies-11/NNS||articles-17/NNS	amod||participation-21/NN||civil-19/JJ	nn||participation-21/NN||society-20/NN	prep_on||articles-17/NNS||participation-21/NN	amod||programmes-24/NNS||hiv/aids-23/JJ	prep_of||participation-21/NN||programmes-24/NNS	prep_in||articles-17/NNS||china-26/NN	det||decades-31/NNS||the-28/DT	amod||decades-31/NNS||past-29/JJ	num||decades-31/NNS||two-30/CD	prep_over||articles-17/NNS||decades-31/NNS	aids--1||hiv--1||no||methods a desk review was conducted to collect chinese government policies, project documents and published articles on civil society participation of hiv/aids programmes in china over the past two decades.
nsubj||applied-2/VBD||we-1/PRP	nsubj||norovirus-28/VBZ||we-1/PRP	root||ROOT-0/null||applied-2/VBD	det||$-5/$||a-3/DT	amod||$-5/$||â-4/JJ	dobj||applied-2/VBD||$-5/$	num||$-5/$||œnext-generationâ-6/CD	nsubj||collected-19/VBN||$-7/$	num||$-7/$||parallel-8/CD	vmod||$-7/$||sequencing-9/VBG	dobj||sequencing-9/VBG||platform-10/NN	amod||detection-13/NN||viral-12/JJ	prep_for||sequencing-9/VBG||detection-13/NN	amod||samples-18/NNS||nasopharyngeal-15/JJ	conj_and||nasopharyngeal-15/JJ||fecal-17/JJ	amod||samples-18/NNS||fecal-17/JJ	prep_in||detection-13/NN||samples-18/NNS	dep||applied-2/VBD||collected-19/VBN	amod||influenzavirus-22/NNS||seasonal-21/JJ	prep_during||collected-19/VBN||influenzavirus-22/NNS	appos||infections-26/NNS||flu-24/NN	dobj||collected-19/VBN||infections-26/NNS	conj_and||applied-2/VBD||norovirus-28/VBZ	dobj||norovirus-28/VBZ||outbreaks-29/NNS	num||2007-33/CD||2005-31/CD	dep||2007-33/CD||to-32/TO	prep_from||norovirus-28/VBZ||2007-33/CD	prep_in||2007-33/CD||osaka-35/NN	appos||osaka-35/NN||japan-37/NN	flu-24||influenzavirus-22||no||we applied a â€œnext-generationâ€? parallel sequencing platform for viral detection in nasopharyngeal and fecal samples collected during seasonal influenzavirus (flu) infections and norovirus outbreaks from 2005 to 2007 in osaka, japan.
amod||subjects-2/NNS||adult-1/JJ	nsubj||eligible-37/JJ||subjects-2/NNS	vmod||subjects-2/NNS||diagnosed-3/VBN	amod||bronchitis-6/NNS||chronic-5/JJ	prep_with||diagnosed-3/VBN||bronchitis-6/NNS	amod||suggestive-10/NN||clinical-8/JJ	nn||suggestive-10/NN||symptoms-9/NNS	prep_with||diagnosed-3/VBN||suggestive-10/NN	det||type-14/NN||an-12/DT	nn||type-14/NN||anthonisen-13/NN	poss||exacerbation-17/NN||type-14/NN	amod||exacerbation-17/NN||acute-16/JJ	prep_of||suggestive-10/NN||exacerbation-17/NN	det||two-20/CD||any-19/DT	dep||exacerbation-17/NN||two-20/CD	det||criteria-24/NNS||the-22/DT	amod||criteria-24/NNS||following-23/JJ	prep_of||two-20/CD||criteria-24/NNS	advmod||increased-28/VBN||â-25/RB	pobj||â-25/RB||$-26/$	vmod||two-20/CD||increased-28/VBN	nn||purulence-34/NN||dyspnea-29/NN	dep||purulence-34/NN||cough-31/NN	dep||purulence-34/NN||sputum-33/NN	dobj||increased-28/VBN||purulence-34/NN	cop||eligible-37/JJ||were-36/VBD	root||ROOT-0/null||eligible-37/JJ	nsubj||fulfilling-40/VBG||those-39/DT	conj_and||eligible-37/JJ||fulfilling-40/VBG	det||subject-42/NN||the-41/DT	dobj||fulfilling-40/VBG||subject-42/NN	nn||criteria-44/NNS||selection-43/NN	nsubjpass||randomized-46/VBN||criteria-44/NNS	nsubj||receive-48/VB||criteria-44/NNS	auxpass||randomized-46/VBN||were-45/VBD	rcmod||subject-42/NN||randomized-46/VBN	aux||receive-48/VB||to-47/TO	xcomp||randomized-46/VBN||receive-48/VB	det||mg-52/NN||either-49/DT	nn||mg-52/NN||gemifloxacin-50/NN	num||mg-52/NN||320-51/CD	dobj||receive-48/VB||mg-52/NN	advmod||daily-54/JJ||once-53/RB	advmod||receive-48/VB||daily-54/JJ	advmod||receive-48/VB||cefpodoxime-56/JJ	conj_or||daily-54/JJ||cefpodoxime-56/JJ	dep||cefpodoxime-56/JJ||200-57/CD	advmod||cefpodoxime-56/JJ||mg-58/RB	advmod||cefpodoxime-56/JJ||twice-59/RB	advmod||cefpodoxime-56/JJ||daily-60/RB	advmod||cefpodoxime-56/JJ||orally-61/RB	num||days-64/NNS||7-63/CD	prep_for||receive-48/VB||days-64/NNS	bronchitis-6||gemifloxacin-50||yes||adult subjects diagnosed with chronic bronchitis with clinical symptoms suggestive of an anthonisen type ii acute exacerbation (any two of the following criteria â€“ increased dyspnea, cough, sputum purulence) were eligible and those fulfilling the subject selection criteria were randomized to receive either gemifloxacin 320 mg once daily or cefpodoxime 200 mg twice daily orally for 7 days.
nsubj||performed-3/VBD||we-1/PRP	advmod||performed-3/VBD||thus-2/RB	root||ROOT-0/null||performed-3/VBD	amod||analyses-6/NNS||full-4/JJ	nn||analyses-6/NNS||genome-5/NN	dobj||performed-3/VBD||analyses-6/NNS	num||listeriamonocytogenes-9/NNS||four-8/CD	prep_on||performed-3/VBD||listeriamonocytogenes-9/NNS	nn||isolates-15/NNS||human-12/NN	conj_and||human-12/NN||food-14/NN	nn||isolates-15/NNS||food-14/NN	prep_including||performed-3/VBD||isolates-15/NNS	preconj||case-20/NN||both-17/PDT	det||case-20/NN||a-18/DT	num||case-20/NN||1988-19/CD	prep_from||isolates-15/NNS||case-20/NN	amod||listeriosis-23/NNS||sporadic-22/JJ	prep_of||case-20/NN||listeriosis-23/NNS	det||outbreak-28/NN||a-25/DT	num||outbreak-28/NN||2000-26/CD	nn||outbreak-28/NN||listeriosis-27/NNS	prep_from||isolates-15/NNS||outbreak-28/NN	conj_and||case-20/NN||outbreak-28/NN	nsubjpass||linked-33/VBN||outbreak-28/NN	nsubj||contaminated-35/VB||outbreak-28/NN	aux||linked-33/VBN||had-31/VBD	auxpass||linked-33/VBN||been-32/VBN	rcmod||outbreak-28/NN||linked-33/VBN	aux||contaminated-35/VB||to-34/TO	xcomp||linked-33/VBN||contaminated-35/VB	dobj||contaminated-35/VB||food-36/NN	det||facility-41/NN||a-38/DT	amod||facility-41/NN||single-39/JJ	nn||facility-41/NN||processing-40/NN	prep_from||contaminated-35/VB||facility-41/NN	listeriosis-27||listeriamonocytogenes-9||no||we thus performed full genome analyses on four listeriamonocytogenes , including human and food isolates from both a 1988 case of sporadic listeriosis and a 2000 listeriosis outbreak, which had been linked to contaminated food from a single processing facility.
nsubj||allowed-5/VBD||analysis-1/NN	nn||constants-4/NNS||rate-3/NN	prep_of||analysis-1/NN||constants-4/NNS	root||ROOT-0/null||allowed-5/VBD	dobj||allowed-5/VBD||determination-6/NN	prep_of||determination-6/NN||kd-8/NN	det||complex-13/NN||each-10/DT	amod||complex-13/NN||non-covalent-11/JJ	amod||complex-13/NN||enzyme-dtnb-12/JJ	prep_for||allowed-5/VBD||complex-13/NN	det||rate-16/NN||the-15/DT	prep_for||allowed-5/VBD||rate-16/NN	conj_and||complex-13/NN||rate-16/NN	amod||rate-16/NN||constant-17/JJ	prep_for||constant-17/JJ||reaction-19/NN	aux||form-21/VB||to-20/TO	vmod||reaction-19/NN||form-21/VB	det||adduct-25/NN||the-22/DT	amod||adduct-25/NN||inactive-23/JJ	amod||adduct-25/NN||enzyme-thionitrobenzoate-24/JJ	dobj||form-21/VB||adduct-25/NN	enzyme--1||kd-8||no_rel||analysis of rate constants allowed determination of kd for each non-covalent enzyme-dtnb complex and the rate constant for reaction to form the inactive enzyme-thionitrobenzoate adduct.
aux||elucidate-2/VB||to-1/TO	advcl||analyzed-8/VBN||elucidate-2/VB	dobj||elucidate-2/VB||measles-3/NNS	advmod||elucidate-2/VB||immunopathology-4/RB	nsubj||analyzed-8/VBN||we-6/PRP	aux||analyzed-8/VBN||have-7/VBP	root||ROOT-0/null||analyzed-8/VBN	det||response-11/NN||the-9/DT	amod||response-11/NN||immune-10/JJ	dobj||analyzed-8/VBN||response-11/NN	prep_to||analyzed-8/VBN||measlesvirus-13/NNS	prep_in||measlesvirus-13/NNS||mice-15/NNS	amod||mice-15/NNS||transgenic-16/JJ	det||receptor-20/NN||the-18/DT	amod||receptor-20/NN||measlesvirus-19/JJ	prep_for||transgenic-16/JJ||receptor-20/NN	amod||cd150-23/NNS||human-22/JJ	appos||receptor-20/NN||cd150-23/NNS	measles-3||measlesvirus-19||no||to elucidate measles immunopathology, we have analyzed the immune response to measlesvirus in mice transgenic for the measlesvirus receptor, human cd150.
nsubj||disease-6/NN||bovinetuberculosis-1/NNS	cop||disease-6/NN||is-2/VBZ	det||disease-6/NN||an-3/DT	amod||disease-6/NN||important-4/JJ	amod||disease-6/NN||infectious-5/JJ	root||ROOT-0/null||disease-6/NN	vmod||disease-6/NN||caused-7/VBN	agent||caused-7/VBN||mycobacteriumbovis-9/NNS	nsubj||responsible-13/JJ||mycobacteriumbovis-9/NNS	cop||responsible-13/JJ||is-12/VBZ	rcmod||mycobacteriumbovis-9/NNS||responsible-13/JJ	amod||losses-17/NNS||considerable-15/JJ	amod||losses-17/NNS||economic-16/JJ	prep_for||responsible-13/JJ||losses-17/NNS	bovinetuberculosis-1||mycobacteriumbovis-9||no||bovinetuberculosis is an important infectious disease caused by mycobacteriumbovis , which is responsible for considerable economic losses.
poss||application-4/NN||their-2/PRP$	amod||application-4/NN||widespread-3/JJ	prep_despite||rare-10/JJ||application-4/NN	amod||hypersensitivityreactions-6/NNS||immune-mediated-5/JJ	nsubj||rare-10/JJ||hypersensitivityreactions-6/NNS	prep_to||hypersensitivityreactions-6/NNS||heparins-8/NNS	cop||rare-10/JJ||are-9/VBP	root||ROOT-0/null||rare-10/JJ	heparins-8||hypersensitivityreactions-6||no_rel||despite their widespread application immune-mediated hypersensitivityreactions to heparins are rare.
amod||vascular-2/NN||increased-1/VBN	nsubj||infection-14/NN||vascular-2/NN	advmod||infection-14/NN||permeability-3/RB	cop||infection-14/NN||is-4/VBZ	det||feature-7/NN||a-5/DT	nn||feature-7/NN||hallmark-6/NN	nn||infection-14/NN||feature-7/NN	amod||denguevirus-10/NNS||severe-9/JJ	prep_in||feature-7/NN||denguevirus-10/NNS	appos||denguevirus-10/NNS||dv-12/NN	root||ROOT-0/null||infection-14/NN	nsubjpass||speculated-23/VBN||dysfunction-17/NN	nsubj||contribute-25/VB||dysfunction-17/NN	amod||cells-20/NNS||endothelial-19/JJ	prep_of||dysfunction-17/NN||cells-20/NNS	aux||speculated-23/VBN||has-21/VBZ	auxpass||speculated-23/VBN||been-22/VBN	conj_and||infection-14/NN||speculated-23/VBN	aux||contribute-25/VB||to-24/TO	xcomp||speculated-23/VBN||contribute-25/VB	det||pathogenesis-28/NNS||the-27/DT	prep_in||contribute-25/VB||pathogenesis-28/NNS	prep_of||pathogenesis-28/NNS||denguehemorrhagicfever/dengueshocksyndrome-30/NN	appos||denguehemorrhagicfever/dengueshocksyndrome-30/NN||dhf/dss-32/NNS	denguehemorrhagicfever--1||denguevirus-10||no||increased vascular permeability is a hallmark feature in severe denguevirus (dv) infection, and dysfunction of endothelial cells has been speculated to contribute in the pathogenesis of denguehemorrhagicfever/dengueshocksyndrome (dhf/dss).
nsubj||describe-2/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	det||man-5/NN||a-3/DT	amod||man-5/NN||51-year-old-4/JJ	dobj||describe-2/VBP||man-5/NN	amod||b-celllymphoma-8/NN||jejunal-7/JJ	prep_with||describe-2/VBP||b-celllymphoma-8/NN	nsubj||developed-10/VBD||b-celllymphoma-8/NN	rcmod||b-celllymphoma-8/NN||developed-10/VBD	amod||episodes-12/NNS||recurrent-11/JJ	dobj||developed-10/VBD||episodes-12/NNS	amod||colitis-15/NNS||ischemic-14/JJ	prep_of||episodes-12/NNS||colitis-15/NNS	prep||developed-10/VBD||following-16/VBG	advmod||with-18/IN||chemotherapy-17/RB	pcomp||following-16/VBG||with-18/IN	amod||rituximab-27/NN||cyclophosphamide-19/JJ	conj_and||cyclophosphamide-19/JJ||vincristine-21/JJ	amod||rituximab-27/NN||vincristine-21/JJ	conj_and||cyclophosphamide-19/JJ||doxorubicine-23/JJ	amod||rituximab-27/NN||doxorubicine-23/JJ	conj_and||cyclophosphamide-19/JJ||prednisolone-25/JJ	amod||rituximab-27/NN||prednisolone-25/JJ	amod||rituximab-27/NN||plus-26/JJ	pobj||with-18/IN||rituximab-27/NN	appos||rituximab-27/NN||r-chop-29/NN	b-celllymphoma-8||rituximab-27||yes||we describe a 51-year-old man with jejunal b-celllymphoma who developed recurrent episodes of ischemic colitis following chemotherapy with cyclophosphamide, vincristine, doxorubicine and prednisolone plus rituximab (r-chop).
nsubj||argue-2/VBP||we-1/PRP	root||ROOT-0/null||argue-2/VBP	mark||requires-12/VBZ||that-3/IN	csubj||requires-12/VBZ||understanding-4/VBG	det||diseases-6/NNS||some-5/DT	dobj||understanding-4/VBG||diseases-6/NNS	prep_such_as||diseases-6/NNS||bacterialvaginosis-10/NNS	ccomp||argue-2/VBP||requires-12/VBZ	det||shift-14/NN||a-13/DT	dobj||requires-12/VBZ||shift-14/NN	prep_of||shift-14/NN||focus-16/NN	amod||bacteria-19/NNS||individual-18/JJ	prep_from||focus-16/NN||bacteria-19/NNS	dep||requires-12/VBZ||mathematical-22/NNP	prep_to||requires-12/VBZ||networks-24/NNS	amod||populations-27/NNS||interacting-26/VBG	prep_of||networks-24/NNS||populations-27/NNS	mark||provide-38/VB||that-30/IN	amod||properties-33/NNS||known-31/VBN	nn||properties-33/NNS||emergent-32/NN	nsubj||provide-38/VB||properties-33/NNS	det||networks-36/NNS||these-35/DT	prep_of||properties-33/NNS||networks-36/NNS	aux||provide-38/VB||will-37/MD	ccomp||argue-2/VBP||provide-38/VB	conj_and||requires-12/VBZ||provide-38/VB	dobj||provide-38/VB||insights-39/NNS	nsubj||elusive-44/JJ||insights-39/NNS	aux||elusive-44/JJ||would-41/MD	cop||elusive-44/JJ||be-42/VB	advmod||elusive-44/JJ||otherwise-43/RB	rcmod||insights-39/NNS||elusive-44/JJ	bacterialvaginosis-10||bacteria-19||no||we argue that understanding some diseases, such as bacterialvaginosis, requires a shift of focus from individual bacteria to (mathematical) networks of interacting populations, and that known emergent properties of these networks will provide insights that would be otherwise elusive.
nsubj||provides-2/VBZ||this-1/DT	root||ROOT-0/null||provides-2/VBZ	dobj||provides-2/VBZ||analogy-3/NN	amod||proteins-6/NNS||membrane-associated-5/JJ	prep_with||provides-2/VBZ||proteins-6/NNS	vmod||proteins-6/NNS||mediating-7/VBG	det||build-up-9/NN||the-8/DT	dobj||mediating-7/VBG||build-up-9/NN	prep_of||build-up-9/NN||â-11/NN	amod||build-up-9/NN||$-12/$	dep||$-12/$||œvirus-13/JJ	vmod||build-up-9/NN||factoriesâ-14/VBN	dobj||factoriesâ-14/VBN||$-15/$	quantmod||cells-17/CD||in-16/IN	num||$-15/$||cells-17/CD	vmod||$-15/$||infected-18/VBN	amod||viruses-23/NNS||diverse-20/JJ	amod||viruses-23/NNS||positive-strand-21/JJ	nn||viruses-23/NNS||rna-22/NN	prep_with||infected-18/VBN||viruses-23/NNS	amod||viruses-26/NNS||alpha-like-25/JJ	dep||viruses-23/NNS||viruses-26/NNS	amod||viruses-29/NNS||picorna-like-28/JJ	dep||viruses-23/NNS||viruses-29/NNS	conj_and||viruses-26/NNS||viruses-29/NNS	dep||viruses-23/NNS||flaviviruses-31/NNS	conj_and||viruses-26/NNS||flaviviruses-31/NNS	dep||viruses-23/NNS||nidoviruses-34/NNS	conj_and||viruses-26/NNS||nidoviruses-34/NNS	amod||viruses-39/NNS||negative-strand-37/JJ	nn||viruses-39/NNS||rna-38/NN	prep_with||infected-18/VBN||viruses-39/NNS	conj_and||viruses-23/NNS||viruses-39/NNS	appos||viruses-23/NNS||bunyaviruses-41/NNS	virus--1||viruses-39||no||this provides analogy with membrane-associated proteins mediating the build-up of â€œvirus factoriesâ€? in cells infected with diverse positive-strand rna viruses (alpha-like viruses, picorna-like viruses, flaviviruses, and nidoviruses) and negative-strand rna viruses (bunyaviruses).
poss||data-2/NNS||our-1/PRP$	nsubj||demonstrate-3/VBP||data-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	det||basis-6/NN||the-4/DT	amod||basis-6/NN||mechanistic-5/JJ	nsubj||hold-30/VB||basis-6/NN	amod||cd40â-13/NN||il-2-8/JJ	punct||±-11/NNP||/-9/:	nn||±-11/NNP||î-10/NNP	dep||cd40â-13/NN||±-11/NNP	prep_for||basis-6/NN||cd40â-13/NN	dep||cd40â-13/NN||$-14/$	amod||control-17/NN||mediated-16/JJ	npadvmod||that-22/IN||control-17/NN	prep_of||control-17/NN||metastases-19/NNS	prep_of||control-17/NN||suggest-21/NNS	conj_and||metastases-19/NNS||suggest-21/NNS	advmod||application-25/NN||that-22/IN	det||application-25/NN||the-23/DT	nn||application-25/NN||context-dependent-24/NN	npadvmod||of-26/IN||application-25/NN	dep||donors-28/CD||of-26/IN	neg||of-26/IN||no-27/RB	num||$-14/$||donors-28/CD	aux||hold-30/VB||may-29/MD	ccomp||demonstrate-3/VBP||hold-30/VB	dobj||hold-30/VB||promise-31/NN	prep_for||hold-30/VB||prevention-33/NN	prep_of||prevention-33/NN||metastaticdisease-35/NN	metastaticdisease-35||il-2-8||no_rel||our data demonstrate the mechanistic basis for il-2/î±-cd40â€“mediated control of metastases and suggest that the context-dependent application of no donors may hold promise for prevention of metastaticdisease.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||identify-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||identify-8/VB||to-7/TO	xcomp||was-6/VBD||identify-8/VB	det||presence-10/NN||the-9/DT	dobj||identify-8/VB||presence-10/NN	iobj||identify-8/VB||presence-10/NN	amod||inh-14/NN||isoniazid-12/JJ	prep_of||presence-10/NN||inh-14/NN	prep_of||presence-10/NN||rifampicin-17/NN	conj_and||inh-14/NN||rifampicin-17/NN	appos||presence-10/NN||rif-19/NN	nn||resistance-22/NN||drug-21/NN	dep||presence-10/NN||resistance-22/NN	amod||cases-32/NNS||new-24/JJ	advmod||treated-27/JJ||previously-26/RB	conj_and||new-24/JJ||treated-27/JJ	amod||cases-32/NNS||treated-27/JJ	nn||cases-32/NNS||tuberculosis-28/NNP	appos||cases-32/NNS||tb-30/NN	prep_in||resistance-22/NN||cases-32/NNS	vmod||cases-32/NNS||using-33/VBG	nn||sequencing-35/NN||dna-34/NN	dobj||using-33/VBG||sequencing-35/NN	tuberculosis-28||isoniazid-12||yes||the aim of this study was to identify the presence of isoniazid (inh) and rifampicin(rif) drug resistance in new and previously treated tuberculosis (tb) cases using dna sequencing.
det||prionprotein-2/NN||the-1/DT	nsubj||plays-6/VBZ||prionprotein-2/NN	appos||prionprotein-2/NN||prnp/prp-4/NN	root||ROOT-0/null||plays-6/VBZ	det||role-9/NN||a-7/DT	amod||role-9/NN||crucial-8/JJ	dobj||plays-6/VBZ||role-9/NN	prep_in||role-9/NN||transmissiblespongiformencephalopathies-11/NNS	appos||transmissiblespongiformencephalopathies-11/NNS||tses-13/NNS	amod||cjd-18/NN||creutzfeldt-jakobdisease-16/JJ	prep_like||plays-6/VBZ||cjd-18/NN	amod||cjd-18/NN||scrapie-21/JJ	amod||cjd-18/NN||madcowdisease-23/JJ	conj_and||scrapie-21/JJ||madcowdisease-23/JJ	prionprotein-2||transmissiblespongiformencephalopathies-11||no_rel||the prionprotein (prnp/prp) plays a crucial role in transmissiblespongiformencephalopathies (tses) like creutzfeldt-jakobdisease (cjd), scrapie and madcowdisease.
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||chloroquine-8||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
det||measures-4/NNS||the-1/DT	amod||measures-4/NNS||primary-2/JJ	nn||measures-4/NNS||outcome-3/NN	nsubj||difference-10/NN||measures-4/NNS	cop||difference-10/NN||were-5/VBD	dep||difference-10/NN||1-7/LS	det||difference-10/NN||the-9/DT	root||ROOT-0/null||difference-10/NN	det||score-13/NN||the-12/DT	prep_in||difference-10/NN||score-13/NN	amod||consumption-17/NN||weekly-15/JJ	nn||consumption-17/NN||alcohol-16/NN	prep_on||difference-10/NN||consumption-17/NN	dep||proportion-24/NN||2-21/LS	det||proportion-24/NN||the-23/DT	conj_and||difference-10/NN||proportion-24/NN	prep_of||proportion-24/NN||participants-26/NNS	vmod||participants-26/NNS||drinking-27/VBG	det||limit-31/NN||the-29/DT	amod||limit-31/NN||problemdrinking-30/VBG	prep_under||drinking-27/VBG||limit-31/NN	problemdrinking-30||alcohol-16||no||the primary outcome measures were (1) the difference in the score on weekly alcohol consumption, and (2) the proportion of participants drinking under the problemdrinking limit.
num||patients-5/NNS||42-3/CD	amod||patients-5/NNS||hiv/aids-4/JJ	prep_out_of||infected-13/VBN||patients-5/NNS	num||%-8/NN||59.5-7/CD	nsubjpass||infected-13/VBN||%-8/NN	appos||%-8/NN||25/42-10/CD	auxpass||infected-13/VBN||were-12/VBD	root||ROOT-0/null||infected-13/VBN	amod||parasites-16/NNS||intestinal-15/JJ	prep_with||infected-13/VBN||parasites-16/NNS	mark||infected-31/VBN||while-18/IN	advmod||%-21/NN||only-19/RB	num||%-21/NN||9.32-20/CD	nsubjpass||infected-31/VBN||%-21/NN	appos||%-21/NN||33/354-23/CD	det||patients-29/NNS||the-26/DT	amod||patients-29/NNS||hiv-27/JJ	amod||patients-29/NNS||negative-28/JJ	prep_of||%-21/NN||patients-29/NNS	auxpass||infected-31/VBN||were-30/VBD	advcl||infected-13/VBN||infected-31/VBN	amod||parasites-34/NNS||intestinal-33/JJ	prep_with||infected-31/VBN||parasites-34/NNS	aids--1||hiv-27||no||out of 42 hiv/aids patients, 59.5% (25/42) were infected with intestinal parasites, while only 9.32% (33/354) of the hiv negative patients were infected with intestinal parasites.
nsubj||pathogen-4/NN||salmonellatyphi-1/NNS	cop||pathogen-4/NN||is-2/VBZ	det||pathogen-4/NN||a-3/DT	root||ROOT-0/null||pathogen-4/NN	nsubj||causes-6/VBZ||pathogen-4/NN	rcmod||pathogen-4/NN||causes-6/VBZ	det||disease-9/NN||the-7/DT	amod||disease-9/NN||human-8/JJ	dobj||causes-6/VBZ||disease-9/NN	prep_of||disease-9/NN||typhoidfever-11/NN	typhoidfever-11||salmonellatyphi-1||no||salmonellatyphi is a pathogen that causes the human disease of typhoidfever.
det||study-4/NN||the-2/DT	amod||study-4/NN||cross-sectional-3/JJ	prep_in||investigated-7/VBD||study-4/NN	nsubj||investigated-7/VBD||we-6/PRP	root||ROOT-0/null||investigated-7/VBD	det||linkage-9/NN||the-8/DT	dobj||investigated-7/VBD||linkage-9/NN	det||snp-13/NN||the-11/DT	nn||snp-13/NN||candidate-12/NN	prep_between||linkage-9/NN||snp-13/NN	amod||snp-13/NN||rs1051295-14/JJ	amod||snp-13/NN||t2d-16/JJ	conj_and||rs1051295-14/JJ||t2d-16/JJ	prepc_by||investigated-7/VBD||comparing-18/VBG	prepc_by||investigated-7/VBD||comparing-18/VBG	conj_and||comparing-18/VBG||comparing-18/VBG	amod||function-20/NN||beta-cell-19/JJ	dobj||comparing-18/VBG||function-20/NN	nn||sensitivity-23/NN||insulin-22/NN	dobj||comparing-18/VBG||sensitivity-23/NN	conj_and||function-20/NN||sensitivity-23/NN	amod||genotypes-26/NNS||rs1051295-25/JJ	prep_among||function-20/NN||genotypes-26/NNS	det||population-30/NN||a-28/DT	amod||population-30/NN||general-29/JJ	prep_in||comparing-18/VBG||population-30/NN	num||subjects-33/NNS||1051-32/CD	prep_of||population-30/NN||subjects-33/NNS	prepc_at||comparing-18/VBG||fasting-35/VBG	nn||loading-39/NN||glucose-38/NN	prep_after||comparing-18/VBG||loading-39/NN	amod||tests-44/NNS||oral-41/JJ	nn||tests-44/NNS||glucose-42/NN	nn||tests-44/NNS||tolerance-43/NN	dep||loading-39/NN||tests-44/NNS	appos||tests-44/NNS||ogtt-46/NN	num||subjects-53/NNS||84-49/CD	amod||subjects-53/NNS||fasting-50/VBG	nn||subjects-53/NNS||glucose-51/NN	amod||subjects-53/NNS||impaired-52/VBN	prep_in||loading-39/NN||subjects-53/NNS	amod||traits-58/NNS||several-56/JJ	amod||traits-58/NNS||t2d-related-57/JJ	prep_in||loading-39/NN||traits-58/NNS	conj_and||subjects-53/NNS||traits-58/NNS	t2d-16||insulin-22||yes||in the cross-sectional study, we investigated the linkage between the candidate snp rs1051295 and t2d by comparing beta-cell function and insulin sensitivity among rs1051295 genotypes in a general population of 1051 subjects at fasting and after glucose loading (oral glucose tolerance tests, ogtt) in 84 fasting glucose impaired subjects, and several t2d-related traits.
det||review-3/NN||this-2/DT	prep_in||focus-6/VBP||review-3/NN	nsubj||focus-6/VBP||we-5/PRP	root||ROOT-0/null||focus-6/VBP	prep_on||focus-6/VBP||processes-8/NNS	prep_on||focus-6/VBP||organs-10/NNS	conj_and||processes-8/NNS||organs-10/NNS	prep_on||focus-6/VBP||systems-12/NNS	conj_and||processes-8/NNS||systems-12/NNS	vmod||processes-8/NNS||targeted-13/VBN	det||yessotoxin-18/NN||the-15/DT	amod||yessotoxin-18/NN||marine-16/JJ	nn||yessotoxin-18/NN||toxins-17/NNS	agent||targeted-13/VBN||yessotoxin-18/NN	appos||yessotoxin-18/NN||ytx-20/NN	agent||targeted-13/VBN||okadaicacid-23/NN	conj_and||yessotoxin-18/NN||okadaicacid-23/NN	appos||okadaicacid-23/NN||oa-25/NN	agent||targeted-13/VBN||palytoxin-28/NN	conj_and||yessotoxin-18/NN||palytoxin-28/NN	appos||palytoxin-28/NN||ptx-30/NN	oa-25||okadaicacid-23||no_rel||in this review, we focus on processes, organs and systems targeted by the marine toxins yessotoxin (ytx), okadaicacid (oa) and palytoxin (ptx).
aux||assess-2/VB||to-1/TO	advcl||obtained-84/VBN||assess-2/VB	dobj||assess-2/VB||gender-3/NN	dep||assess-2/VB||pubertal-6/NN	amod||differences-10/NNS||age-related-9/JJ	nsubjpass||obtained-84/VBN||differences-10/NNS	prep_in||differences-10/NNS||change-12/NN	amod||hsds-22/NNS||baseline-14/JJ	nn||hsds-22/NNS||height-15/NN	nn||hsds-22/NNS||standard-16/NN	nn||hsds-22/NNS||deviation-17/NN	nn||hsds-22/NNS||score-18/NN	nn||hsds-22/NNS||î-20/NN	prep_from||differences-10/NNS||hsds-22/NNS	conj_and||differences-10/NNS||data-25/NNS	nsubjpass||obtained-84/VBN||data-25/NNS	num||patients-36/NNS||5,797-27/CD	amod||patients-36/NNS||growthhormone-28/JJ	appos||patients-36/NNS||gh-30/NN	nn||patients-36/NNS||naã-32/NN	nn||patients-36/NNS||¯-33/NNP	nn||patients-36/NNS||ve-34/NNP	amod||patients-36/NNS||pediatric-35/JJ	prep_from||data-25/NNS||patients-36/NNS	number||18-39/CD||<-38/CD	num||years-40/NNS||18-39/CD	appos||patients-36/NNS||years-40/NNS	amod||deficiency-44/NN||growthhormone-43/JJ	prep_with||data-25/NNS||deficiency-44/NN	appos||data-25/NNS||ghd-46/NN	amod||deficiency-52/NN||multiple-49/JJ	amod||deficiency-52/NN||pituitary-50/JJ	nn||deficiency-52/NN||hormone-51/NN	conj_and||differences-10/NNS||deficiency-52/NN	nsubjpass||obtained-84/VBN||deficiency-52/NN	dep||deficiency-52/NN||mphd-54/JJ	nn||syndrome-58/NN||turner-57/NN	conj_and||differences-10/NNS||syndrome-58/NN	nsubjpass||obtained-84/VBN||syndrome-58/NN	appos||syndrome-58/NN||ts-60/NN	conj_and||differences-10/NNS||small-63/JJ	nsubjpass||obtained-84/VBN||small-63/JJ	amod||age-66/NN||gestational-65/JJ	prep_for||small-63/JJ||age-66/NN	appos||small-63/JJ||sga-68/NN	nn||syndrome-72/NN||noonan-71/NN	conj_and||differences-10/NNS||syndrome-72/NN	nsubjpass||obtained-84/VBN||syndrome-72/NN	appos||syndrome-72/NN||ns-74/NN	amod||shortstature-79/NN||idiopathic-78/JJ	conj_and||differences-10/NNS||shortstature-79/NN	nsubjpass||obtained-84/VBN||shortstature-79/NN	appos||differences-10/NNS||iss-81/NN	auxpass||obtained-84/VBN||were-83/VBD	root||ROOT-0/null||obtained-84/VBN	det||program-95/NN||the-86/DT	nn||program-95/NN||answer-87/NN	amod||studies-91/NNS||american-89/JJ	nn||studies-91/NNS||norditropin-90/NN	dep||program-95/NN||studies-91/NNS	amod||research-93/NN||web-enabled-92/JJ	dep||studies-91/NNS||research-93/NN	prep_from||obtained-84/VBN||program-95/NN	advmod||obtained-84/VBN||registry-96/RB	shortstature-79||growthhormone-43||yes||to assess gender-, pubertal-, age-related differences in change from baseline height standard deviation score (î”hsds), data from 5,797 growthhormone (gh) naã¯ve pediatric patients (<18 years) with growthhormone deficiency (ghd), multiple pituitary hormone deficiency (mphd), turner syndrome (ts), small for gestational age (sga), noonan syndrome (ns), and idiopathic shortstature (iss) were obtained from the answer (american norditropin studies web-enabled research) program registry.
nsubj||agent-5/NN||htlv-i-1/NNP	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causal-4/JJ	root||ROOT-0/null||agent-5/NN	amod||leukemia-10/NN||adult-7/JJ	nn||leukemia-10/NN||t-8/NN	nn||leukemia-10/NN||cell-9/NN	prep_of||agent-5/NN||leukemia-10/NN	dep||leukemia-10/NN||atll-12/JJ	amod||myelopathy/tropicalspasticparaparesis-16/NNS||htlv-i-associated-15/JJ	prep_of||agent-5/NN||myelopathy/tropicalspasticparaparesis-16/NNS	conj_and||leukemia-10/NN||myelopathy/tropicalspasticparaparesis-16/NNS	appos||leukemia-10/NN||ham/tsp-18/NN	tropicalspasticparaparesis--1||htlv-i-1||no||htlv-i is the causal agent of adult t cell leukemia (atll) and htlv-i-associated myelopathy/tropicalspasticparaparesis (ham/tsp).
amod||virus-7/NN||incurable-2/JJ	conj_but||incurable-2/JJ||treatable-4/JJ	amod||virus-7/NN||treatable-4/JJ	amod||virus-7/NN||herpes-5/JJ	amod||virus-7/NN||simplex-6/JJ	prep_including||halve-18/VB||virus-7/NN	appos||virus-7/NN||hsv-9/NN	num||ulcers-12/NNS||-2-11/CD	nsubj||halve-18/VB||ulcers-12/NNS	det||calculation-16/NN||the-14/DT	nn||calculation-16/NN||effectiveness-15/NN	prep_in||ulcers-12/NNS||calculation-16/NN	aux||halve-18/VB||would-17/MD	root||ROOT-0/null||halve-18/VB	det||proportion-20/NN||the-19/DT	dobj||halve-18/VB||proportion-20/NN	prep_of||proportion-20/NN||ulcers-22/NNS	dep||ulcers-22/NNS||cured-23/VBN	advmod||treated-26/VBN||correctly-25/RB	dep||ulcers-22/NNS||treated-26/VBN	conj_or||cured-23/VBN||treated-26/VBN	det||reduction-30/NN||this-29/DT	nsubjpass||countered-34/VBN||reduction-30/NN	aux||countered-34/VBN||could-31/MD	auxpass||countered-34/VBN||be-32/VB	advmod||countered-34/VBN||entirely-33/RB	conj_but||halve-18/VB||countered-34/VBN	agent||countered-34/VBN||including-36/VBG	amod||treatment-39/NN||episodic-37/JJ	amod||treatment-39/NN||antiviral-38/JJ	dobj||including-36/VBG||treatment-39/NN	det||guidelines-43/NNS||the-41/DT	amod||guidelines-43/NNS||national-42/JJ	prep_in||including-36/VBG||guidelines-43/NNS	antiviral-38||hsv-9||no_rel||including incurable but treatable herpes simplex virus (hsv)-2 ulcers in the effectiveness calculation would halve the proportion of ulcers cured or correctly treated, but this reduction could be entirely countered by including episodic antiviral treatment in the national guidelines.
det||range-4/NN||this-2/DT	nn||range-4/NN||dose-3/NN	prep_within||reduced-15/VBD||range-4/NN	det||population-9/NN||this-7/DT	nn||population-9/NN||patients-8/NNS	prep_in||reduced-15/VBD||population-9/NN	amod||dosage-13/NN||increasing-11/JJ	nn||dosage-13/NN||lidocaine-12/NN	nsubj||reduced-15/VBD||dosage-13/NN	nsubj||reduced-15/VBD||dosage-13/NN	advmod||reduced-15/VBD||significantly-14/RB	root||ROOT-0/null||reduced-15/VBD	conj_and||reduced-15/VBD||reduced-15/VBD	dobj||reduced-15/VBD||pain-16/NN	prep_during||reduced-15/VBD||injection-18/NN	nn||propofol-21/NN||microemulsion-20/NN	prep_of||injection-18/NN||propofol-21/NN	pain-16||propofol-21||yes||within this dose range and in this patients population, increasing lidocaine dosage significantly reduced pain during injection of microemulsion propofol.
amod||--3/NNS||compounds-1/JJ	amod||--3/NNS||1-deoxy-1-2/JJ	dep||--3/NNS||6-5/CD	amod||â-9/NN||-LSB--7/JJ	nn||â-9/NN||n-8/NN	dep||--3/NNS||â-9/NN	dep||â-9/NN||$-10/$	num||$-10/$||²-11/CD	dep||â-9/NN||furan-2-carbonyl-14/NN	nn||-RSB--18/NNS||hydrazino-17/NN	dep||furan-2-carbonyl-14/NN||-RSB--18/NNS	num||h-20/NN||-9-19/CD	dep||-RSB--18/NNS||h-20/NN	dep||furan-2-carbonyl-14/NN||purin-9-yl-22/JJ	amod||d-ribofuranuronamide-30/NN||n-ethyl-25/JJ	nn||²-28/NNP||î-27/NNP	dep||d-ribofuranuronamide-30/NN||²-28/NNP	dep||--3/NNS||d-ribofuranuronamide-30/NN	dep||d-ribofuranuronamide-30/NN||19-32/CD	amod||k-35/JJ||ha1-34/JJ	amod||iâ-71/NN||k-35/JJ	amod||iâ-71/NN||iâ-36/JJ	amod||iâ-71/NN||$-37/$	number||=-39/CD||‰-38/CD	num||$-37/$||=-39/CD	amod||iâ-71/NN||â-40/JJ	amod||iâ-71/NN||$-41/$	number||1050â-43/CD||‰-42/CD	num||$-41/$||1050â-43/CD	amod||iâ-71/NN||nm-44/JJ	amod||iâ-71/NN||ha2a-46/JJ	amod||iâ-71/NN||k-47/JJ	amod||iâ-71/NN||iâ-48/JJ	amod||iâ-71/NN||$-49/$	number||=-51/CD||‰-50/CD	num||$-49/$||=-51/CD	amod||iâ-71/NN||â-52/JJ	amod||iâ-71/NN||$-53/$	number||1550â-55/CD||‰-54/CD	num||$-53/$||1550â-55/CD	amod||iâ-71/NN||nm-56/JJ	amod||iâ-71/NN||ha2b-58/JJ	amod||iâ-71/NN||ec50â-59/JJ	amod||iâ-71/NN||$-60/$	number||=-62/CD||‰-61/CD	num||$-60/$||=-62/CD	amod||iâ-71/NN||â-63/JJ	amod||iâ-71/NN||$-64/$	number||82â-66/CD||‰-65/CD	num||$-64/$||82â-66/CD	amod||iâ-71/NN||nm-67/JJ	amod||iâ-71/NN||ha3-69/JJ	nn||iâ-71/NN||k-70/NN	appos||19-32/CD||iâ-71/NN	dep||iâ-71/NN||$-72/$	number||>-74/CD||‰-73/CD	num||$-72/$||>-74/CD	vmod||$-72/$||â-75/VBN	dep||m-81/NN||$-76/$	num||m-81/NN||‰-77/CD	num||m-81/NN||5â-78/CD	nn||m-81/NN||î-79/NN	num||m-81/NN||1/4-80/CD	dobj||â-75/VBN||m-81/NN	poss||analogue-86/NN||its-84/PRP$	amod||analogue-86/NN||2-chloro-85/JJ	dep||--3/NNS||analogue-86/NN	conj_and||d-ribofuranuronamide-30/NN||analogue-86/NN	nsubjpass||confirmed-139/VBN||23-87/CD	nsubj||agonists-146/NNS||23-87/CD	amod||iâ-91/NN||ha1-89/JJ	nn||iâ-91/NN||k-90/NN	dep||23-87/CD||iâ-91/NN	num||â-95/NN||$-92/$	number||=-94/CD||‰-93/CD	num||$-92/$||=-94/CD	prep||iâ-91/NN||â-95/NN	amod||î-134/NN||$-96/$	dep||$-96/$||‰-97/JJ	amod||î-134/NN||3500â-98/JJ	amod||î-134/NN||nm-99/JJ	amod||î-134/NN||ha2a-101/JJ	amod||î-134/NN||k-102/JJ	amod||î-134/NN||iâ-103/JJ	amod||î-134/NN||$-104/$	number||=-106/CD||‰-105/CD	num||$-104/$||=-106/CD	amod||î-134/NN||â-107/JJ	amod||î-134/NN||$-108/$	number||4950â-110/CD||‰-109/CD	num||$-108/$||4950â-110/CD	amod||î-134/NN||nm-111/JJ	amod||î-134/NN||ha2b-113/JJ	amod||î-134/NN||ec50â-114/JJ	amod||î-134/NN||$-115/$	number||=-117/CD||‰-116/CD	num||$-115/$||=-117/CD	amod||î-134/NN||â-118/JJ	amod||î-134/NN||$-119/$	number||210â-121/CD||‰-120/CD	num||$-119/$||210â-121/CD	amod||î-134/NN||nm-122/JJ	amod||î-134/NN||ha3-124/JJ	amod||î-134/NN||k-125/JJ	amod||î-134/NN||iâ-126/JJ	amod||î-134/NN||$-127/$	number||>-129/CD||‰-128/CD	num||$-127/$||>-129/CD	amod||î-134/NN||â-130/JJ	amod||î-134/NN||$-131/$	num||$-131/$||‰-132/CD	amod||î-134/NN||5â-133/JJ	dep||â-95/NN||î-134/NN	number||m-136/JJ||1/4-135/CD	amod||î-134/NN||m-136/JJ	auxpass||confirmed-139/VBN||were-138/VBD	rcmod||analogue-86/NN||confirmed-139/VBN	aux||agonists-146/NNS||to-140/TO	cop||agonists-146/NNS||be-141/VB	amod||agonists-146/NNS||potent-142/JJ	conj_and||potent-142/JJ||selective-144/JJ	amod||agonists-146/NNS||selective-144/JJ	amod||agonists-146/NNS||full-145/JJ	xcomp||confirmed-139/VBN||agonists-146/NNS	det||monophosphate-151/NN||a-148/DT	amod||monophosphate-151/NN||cyclic-149/JJ	nn||monophosphate-151/NN||adenosine-150/NN	prep_in||agonists-146/NNS||monophosphate-151/NN	appos||monophosphate-151/NN||camp-153/NN	amod||assay-156/JJ||functional-155/JJ	amod||monophosphate-151/NN||assay-156/JJ	amod||cells-164/NNS||chinese-158/JJ	nn||cells-164/NNS||hamster-159/NN	nn||cells-164/NNS||ovary-160/NN	appos||cells-164/NNS||cho-162/NN	prep_in||agonists-146/NNS||cells-164/NNS	vmod||cells-164/NNS||expressing-165/VBG	amod||ar-167/NN||ha2b-166/JJ	dobj||expressing-165/VBG||ar-167/NN	nm-122||ar-167||no_rel||compounds 1-deoxy-1-{6-[ n â€²-(furan-2-carbonyl)-hydrazino]-9 h -purin-9-yl}-n-ethyl- î² -d-ribofuranuronamide ( 19 , ha1 k iâ€‰=â€‰1050â nm, ha2a k iâ€‰=â€‰1550â nm, ha2b ec50â€‰=â€‰82â nm, ha3 k iâ€‰>â€‰5â î¼m) and its 2-chloro analogue 23 (ha1 k iâ€‰=â€‰3500â nm, ha2a k iâ€‰=â€‰4950â nm, ha2b ec50â€‰=â€‰210â nm, ha3 k iâ€‰>â€‰5â î¼m) were confirmed to be potent and selective full agonists in a cyclic adenosine monophosphate (camp) functional assay in chinese hamster ovary (cho) cells expressing ha2b ar.
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	det||safety-4/NN||the-3/DT	dobj||examined-2/VBD||safety-4/NN	dobj||examined-2/VBD||efficacy-6/NN	conj_and||safety-4/NN||efficacy-6/NN	det||combination-9/NN||the-8/DT	prep_of||safety-4/NN||combination-9/NN	amod||cancer-23/NN||s-1-11/JJ	advmod||docetaxel-14/JJ||biweekly-13/RB	conj_and||s-1-11/JJ||docetaxel-14/JJ	amod||cancer-23/NN||docetaxel-14/JJ	prep_in||docetaxel-14/JJ||patients-16/NNS	advmod||treated-19/JJ||previously-18/RB	amod||lung-22/NN||treated-19/JJ	amod||lung-22/NN||advanced-20/JJ	amod||lung-22/NN||non-small-cell-21/JJ	prep_with||patients-16/NNS||lung-22/NN	prep_of||combination-9/NN||cancer-23/NN	dep||cancer-23/NN||nsclc-25/JJ	nsclc-25||docetaxel-14||yes||we examined the safety and efficacy of the combination of s-1 and biweekly docetaxel in patients with previously treated advanced non-small-cell lung cancer (nsclc).
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	amod||hospitalization-4/NN||national-3/JJ	dobj||used-2/VBD||hospitalization-4/NN	nn||data-7/NNS||resistance-6/NN	dobj||used-2/VBD||data-7/NNS	conj_and||hospitalization-4/NN||data-7/NNS	aux||estimate-9/VB||to-8/TO	vmod||used-2/VBD||estimate-9/VB	det||number-12/NN||the-10/DT	amod||number-12/NN||annual-11/JJ	dobj||estimate-9/VB||number-12/NN	prep_of||number-12/NN||hospitalizations-14/NNS	prep_of||number-12/NN||deaths-16/NNS	conj_and||hospitalizations-14/NNS||deaths-16/NNS	vmod||hospitalizations-14/NNS||associated-17/VBN	prep_with||associated-17/VBN||s.aureus-19/NNS	prep_with||associated-17/VBN||mrsa-21/NN	conj_and||s.aureus-19/NNS||mrsa-21/NN	prep_from||associated-17/VBN||1999-23/CD	prep_through||associated-17/VBN||2005-25/CD	mrsa-21||s.aureus-19||no||we used national hospitalization and resistance data to estimate the annual number of hospitalizations and deaths associated with s.aureus and mrsa from 1999 through 2005 .
advmod||propose-4/VBP||thus-1/RB	nsubj||propose-4/VBP||we-3/PRP	root||ROOT-0/null||propose-4/VBP	mark||avenue-14/NN||that-5/IN	nsubj||avenue-14/NN||secretion-6/NN	prep_of||secretion-6/NN||ages-8/NNS	prep_by||ages-8/NNS||bacteria-10/NNS	cop||avenue-14/NN||is-11/VBZ	det||avenue-14/NN||a-12/DT	nn||avenue-14/NN||novel-13/NN	ccomp||propose-4/VBP||avenue-14/NN	nsubj||important-21/JJ||avenue-14/NN	amod||inflammation-17/NN||bacterial-induced-16/JJ	prep_of||avenue-14/NN||inflammation-17/NN	cop||important-21/JJ||is-19/VBZ	advmod||important-21/JJ||potentially-20/RB	rcmod||avenue-14/NN||important-21/JJ	det||pathophysiology-24/NN||the-23/DT	prep_in||important-21/JJ||pathophysiology-24/NN	prep_of||pathophysiology-24/NN||bacterialinfections-26/NNS	bacterialinfections-26||bacteria-10||no||thus, we propose that secretion of ages by bacteria is a novel avenue of bacterial-induced inflammation which is potentially important in the pathophysiology of bacterialinfections.
vmod||increased-23/VBN||using-1/VBG	nn||techniques-6/NNS||gas-2/NN	nn||techniques-6/NNS||chromatography-3/NN	nn||techniques-6/NNS||mass-4/NN	nn||techniques-6/NNS||spectrometry-5/NN	dobj||using-1/VBG||techniques-6/NNS	nsubjpass||increased-23/VBN||6-8/CD	num||oxysterols-12/NNS||7-11/CD	prep_out_of||6-8/CD||oxysterols-12/NNS	vmod||oxysterols-12/NNS||analysed-13/VBN	preconj||non-enzymatic-16/JJ||both-15/DT	amod||pathways-19/NNS||non-enzymatic-16/JJ	conj_and||non-enzymatic-16/JJ||enzymatic-18/JJ	amod||pathways-19/NNS||enzymatic-18/JJ	prep_from||analysed-13/VBN||pathways-19/NNS	auxpass||increased-23/VBN||were-20/VBD	advmod||increased-23/VBN||also-21/RB	advmod||increased-23/VBN||selectively-22/RB	root||ROOT-0/null||increased-23/VBN	det||parkinson-26/NN||the-25/DT	prep_in||increased-23/VBN||parkinson-26/NN	amod||cortex-30/NN||sdisease-28/JJ	amod||cortex-30/NN||visual-29/JJ	dep||parkinson-26/NN||cortex-30/NN	parkinson'sdisease--1||gas-2||no_rel||using gas chromatography mass spectrometry techniques, 6 out of 7 oxysterols analysed from both non-enzymatic and enzymatic pathways were also selectively increased in the parkinson'sdisease visual cortex.
vmod||has-26/VBZ||conclusionsâ-1/VBG	dobj||conclusionsâ-1/VBG||$-2/$	prep_in||$-2/$||contrast-5/NN	prep_to||conclusionsâ-1/VBG||animals-7/NNS	prep_in||conclusionsâ-1/VBG||humans-10/NNS	nsubj||has-26/VBZ||prevention-12/NN	amod||hypoglycemia-15/NN||portal-14/JJ	prep_of||prevention-12/NN||hypoglycemia-15/NN	amod||glucose-18/NN||oral-17/JJ	prep_with||hypoglycemia-15/NN||glucose-18/NN	det||beginning-21/NN||the-20/DT	prep_from||glucose-18/NN||beginning-21/NN	amod||hypoglycemia-25/NN||insulin-induced-23/JJ	amod||hypoglycemia-25/NN||slow-fall-24/JJ	prep_of||beginning-21/NN||hypoglycemia-25/NN	root||ROOT-0/null||has-26/VBZ	neg||effect-28/NN||no-27/DT	dobj||has-26/VBZ||effect-28/NN	amod||responses-33/NNS||sympathoadrenal-30/JJ	conj_and||sympathoadrenal-30/JJ||symptomatic-32/JJ	amod||responses-33/NNS||symptomatic-32/JJ	prep_on||effect-28/NN||responses-33/NNS	prep_to||has-26/VBZ||hypoglycemia-35/NN	hypoglycemia-35||glucose-18||yes||conclusionsâ€” in contrast to animals, in humans, prevention of portal hypoglycemia with oral glucose from the beginning of insulin-induced slow-fall hypoglycemia has no effect on sympathoadrenal and symptomatic responses to hypoglycemia.
det||findings-2/NNS||the-1/DT	nsubj||show-3/VBP||findings-2/NNS	root||ROOT-0/null||show-3/VBP	dep||exposed-13/VBN||1-4/LS	neg||facility-8/NN||no-6/DT	nn||facility-8/NN||health-7/NN	nsubjpass||exposed-13/VBN||facility-8/NN	nn||worker-11/NN||health-10/NN	conj_or||facility-8/NN||worker-11/NN	nsubjpass||exposed-13/VBN||worker-11/NN	auxpass||exposed-13/VBN||was-12/VBD	dep||show-3/VBP||exposed-13/VBN	det||components-16/NNS||all-15/DT	prep_to||exposed-13/VBN||components-16/NNS	det||intervention-19/NN||the-18/DT	prep_of||components-16/NNS||intervention-19/NN	dep||proportion-24/NN||2-21/LS	det||proportion-24/NN||the-23/DT	dep||intervention-19/NN||proportion-24/NN	nn||workers-27/NNS||health-26/NN	prep_of||proportion-24/NN||workers-27/NNS	nsubj||received-29/VBD||workers-27/NNS	rcmod||workers-27/NNS||received-29/VBD	det||training-33/NN||the-30/DT	amod||training-33/NN||enhanced-31/JJ	amod||training-33/NN||in-service-32/JJ	nsubj||%-36/NN||training-33/NN	cop||%-36/NN||was-34/VBD	num||%-36/NN||67-35/CD	ccomp||received-29/VBD||%-36/NN	dep||proportion-41/NN||3-38/LS	det||proportion-41/NN||the-40/DT	prep_of||proportion-24/NN||proportion-41/NN	conj_and||workers-27/NNS||proportion-41/NN	nsubj||received-29/VBD||proportion-41/NN	amod||children-44/NNS||febrile-43/JJ	prep_of||proportion-41/NN||children-44/NNS	amod||malaria-47/NN||uncomplicated-46/JJ	prep_with||children-44/NNS||malaria-47/NN	vmod||malaria-47/NN||treated-48/VBN	det||drug-53/NN||the-50/DT	amod||drug-53/NN||first-line-51/JJ	amod||drug-53/NN||anti-malarial-52/JJ	prep_with||treated-48/VBN||drug-53/NN	appos||drug-53/NN||artemether-lumefantrine-55/NN	appos||artemether-lumefantrine-55/NN||al-57/NNP	nn||facilities-62/NNS||health-61/NN	prep_at||treated-48/VBN||facilities-62/NNS	advmod||was-65/VBD||where-63/WRB	nsubj||was-65/VBD||al-64/NNP	advcl||treated-48/VBN||was-65/VBD	prep_in||was-65/VBD||stock-67/NN	vmod||stock-67/NN||increased-68/VBN	num||%-71/NN||76.9-70/CD	prep_from||increased-68/VBN||%-71/NN	num||%-74/NN||95-73/CD	dep||%-71/NN||%-74/NN	dep||%-74/NN||ci-75/NNP	num||ci-75/NNP||69.4-76/CD	num||ci-75/NNP||83.1-78/CD	num||%-82/NN||87.6-81/CD	prep_to||increased-68/VBN||%-82/NN	num||%-85/NN||95-84/CD	dep||%-82/NN||%-85/NN	number||82.5-87/CD||ci-86/CD	num||%-85/NN||82.5-87/CD	amod||%-85/NN||91.5-89/CD	dep||were-95/VBD||4-92/LS	expl||were-95/VBD||there-94/EX	parataxis||was-65/VBD||were-95/VBD	amod||improvements-99/NNS||modest-96/JJ	conj_but||modest-96/JJ||non-significant-98/JJ	amod||improvements-99/NNS||non-significant-98/JJ	nsubj||were-95/VBD||improvements-99/NNS	prepc_in||were-95/VBD||dispensing-101/VBG	prepc_in||were-95/VBD||counseling-103/VBG	conj_and||dispensing-101/VBG||counseling-103/VBG	dobj||dispensing-101/VBG||practices-104/NNS	prep_of||proportion-24/NN||5-107/CD	conj_and||workers-27/NNS||5-107/CD	nsubj||received-29/VBD||5-107/CD	advmod||restricted-113/VBN||when-109/WRB	det||analyses-111/NNS||the-110/DT	nsubjpass||restricted-113/VBN||analyses-111/NNS	auxpass||restricted-113/VBN||were-112/VBD	advcl||exposed-13/VBN||restricted-113/VBN	nn||workers-116/NNS||health-115/NN	prep_to||restricted-113/VBN||workers-116/NNS	nsubj||received-118/VBD||workers-116/NNS	nsubj||received-125/VBN||workers-116/NNS	rcmod||workers-116/NNS||received-118/VBD	det||training-122/NN||the-119/DT	amod||training-122/NN||enhanced-120/JJ	amod||training-122/NN||in-service-121/JJ	dobj||received-118/VBD||training-122/NN	aux||received-125/VBN||had-124/VBD	rcmod||workers-116/NNS||received-125/VBN	conj_and/or||received-118/VBD||received-125/VBN	amod||guidelines-127/NNS||new-126/JJ	dobj||received-125/VBN||guidelines-127/NNS	nn||aids-130/NNS||job-129/NN	nsubjpass||observed-140/VBN||aids-130/NNS	neg||improvements-134/NNS||no-132/DT	amod||improvements-134/NNS||significant-133/JJ	appos||aids-130/NNS||improvements-134/NNS	amod||tasks-138/NNS||reported-136/JJ	amod||tasks-138/NNS||case-management-137/JJ	prep_in||improvements-134/NNS||tasks-138/NNS	auxpass||observed-140/VBN||were-139/VBD	dep||show-3/VBP||observed-140/VBN	conj_and||exposed-13/VBN||observed-140/VBN	prepc_compared_to||observed-140/VBN||to-142/TO	pobj||observed-140/VBN||baseline-143/NN	malaria-47||artemether--1||yes||the findings show 1) no health facility or health worker was exposed to all components of the intervention; 2) the proportion of health workers who received the enhanced in-service training was 67%; 3) the proportion of febrile children with uncomplicated malaria treated with the first-line anti-malarial drug, artemether-lumefantrine (al), at health facilities where al was in stock increased from 76.9% (95%ci 69.4, 83.1) to 87.6% (95% ci 82.5, 91.5); 4) there were modest but non-significant improvements in dispensing and counseling practices; and 5) when the analyses were restricted to health workers who received the enhanced in-service training and/or had received new guidelines and job aids, no significant improvements in reported case-management tasks were observed compared to baseline.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||sequence-6/NN||the-3/DT	nn||sequence-6/NN||draft-4/NN	nn||sequence-6/NN||genome-5/NN	dobj||report-2/VBP||sequence-6/NN	det||strain-10/NN||a-8/DT	amod||strain-10/NN||methicillin-resistant-9/JJ	prep_of||sequence-6/NN||strain-10/NN	prep_of||strain-10/NN||staphylococcusaureus-12/NNS	vmod||staphylococcusaureus-12/NNS||designated-14/VBN	acomp||designated-14/VBN||mrsa-m2-15/JJ	mrsa--1||staphylococcusaureus-12||no||we report the draft genome sequence of a methicillin-resistant strain of staphylococcusaureus , designated mrsa-m2.
det||combination-3/NN||a-1/DT	amod||combination-3/NN||fixed-dose-2/JJ	nsubj||shown-13/VBN||combination-3/NN	prep_of||combination-3/NN||artemether-lumefantrine-5/NN	appos||combination-3/NN||al-7/NNP	nn||®-10/NNP||coartemâ-9/NNP	dep||al-7/NNP||®-10/NNP	aux||shown-13/VBN||has-12/VBZ	root||ROOT-0/null||shown-13/VBN	amod||efficacy-15/NN||high-14/JJ	dobj||shown-13/VBN||efficacy-15/NN	amod||tolerability-18/NN||good-17/JJ	dobj||shown-13/VBN||tolerability-18/NN	conj_and||efficacy-15/NN||tolerability-18/NN	dobj||shown-13/VBN||cost-effectiveness-20/NNS	conj_and||efficacy-15/NN||cost-effectiveness-20/NNS	prep_in||shown-13/VBN||adults-22/NNS	prep_in||shown-13/VBN||children-24/NNS	conj_and||adults-22/NNS||children-24/NNS	amod||malaria-27/NN||uncomplicated-26/JJ	prep_with||shown-13/VBN||malaria-27/NN	vmod||malaria-27/NN||caused-28/VBN	nn||falciparum-31/NN||plasmodium-30/NN	agent||caused-28/VBN||falciparum-31/NN	malaria-27||artemether--1||yes||a fixed-dose combination of artemether-lumefantrine (al, coartemâ®) has shown high efficacy, good tolerability and cost-effectiveness in adults and children with uncomplicated malaria caused by plasmodium falciparum .
nsubj||herpesvirus-17/NNS||varicella-zostervirus-1/NNS	nsubj||first-24/JJ||varicella-zostervirus-1/NNS	appos||varicella-zostervirus-1/NNS||vzv-3/NN	det||cause-7/NN||the-6/DT	appos||varicella-zostervirus-1/NNS||cause-7/NN	prep_of||cause-7/NN||chickenpox-9/NN	prep_of||cause-7/NN||zoster-11/NN	conj_and||chickenpox-9/NN||zoster-11/NN	cop||herpesvirus-17/NNS||was-13/VBD	det||herpesvirus-17/NNS||the-14/DT	amod||herpesvirus-17/NNS||first-15/JJ	amod||herpesvirus-17/NNS||human-16/JJ	root||ROOT-0/null||herpesvirus-17/NNS	aux||sequenced-20/VBN||to-18/TO	auxpass||sequenced-20/VBN||be-19/VB	vmod||herpesvirus-17/NNS||sequenced-20/VBN	advmod||sequenced-20/VBN||fully-21/RB	det||first-24/JJ||the-23/DT	conj_and||herpesvirus-17/NNS||first-24/JJ	prep_for||licensed-30/VBN||first-24/JJ	nsubjpass||licensed-30/VBN||vaccines-27/NNS	nsubjpass||used-33/VBN||vaccines-27/NNS	aux||licensed-30/VBN||have-28/VBP	auxpass||licensed-30/VBN||been-29/VBN	rcmod||first-24/JJ||licensed-30/VBN	advmod||used-33/VBN||widely-32/RB	rcmod||first-24/JJ||used-33/VBN	conj_and||licensed-30/VBN||used-33/VBN	chickenpox-9||vzv-3||yes||varicella-zostervirus (vzv), the cause of chickenpox and zoster, was the first human herpesvirus to be sequenced fully and the first for which vaccines have been licensed and widely used.
nsubj||identified-2/VBD||we-1/PRP	root||ROOT-0/null||identified-2/VBD	amod||analysis-5/NN||proteomic-4/JJ	prep_by||identified-2/VBD||analysis-5/NN	vmod||analysis-5/NN||using-6/VBG	amod||electrophoresis-8/NNS||2d-dige-7/JJ	dobj||using-6/VBG||electrophoresis-8/NNS	prep||using-6/VBG||combined-9/VBN	pcomp||combined-9/VBN||with-10/IN	amod||spectrometry-17/NN||maldi-tof-tof-11/JJ	conj_and||maldi-tof-tof-11/JJ||esi-linear-13/JJ	amod||spectrometry-17/NN||esi-linear-13/JJ	nn||spectrometry-17/NN||ion-14/NN	nn||spectrometry-17/NN||trap-15/NN	nn||spectrometry-17/NN||mass-16/NN	pobj||with-10/IN||spectrometry-17/NN	det||number-19/NN||a-18/DT	dobj||identified-2/VBD||number-19/NN	poss||expression-26/NN||number-19/NN	prep_of||number-19/NN||proteins-21/NNS	amod||functions-24/NNS||variable-23/JJ	prep_with||proteins-21/NNS||functions-24/NNS	nsubjpass||modulated-28/VBN||expression-26/NN	auxpass||modulated-28/VBN||is-27/VBZ	rcmod||number-19/NN||modulated-28/VBN	agent||modulated-28/VBN||snail1-30/NNS	amod||cells-36/NNS||sw480-adh-32/JJ	amod||cells-36/NNS||human-33/JJ	nn||cells-36/NNS||colon-34/NN	nn||cells-36/NNS||cancer-35/NN	prep_in||snail1-30/NNS||cells-36/NNS	tof--1||ion-14||no_rel||we identified by proteomic analysis using 2d-dige electrophoresis combined with maldi-tof-tof and esi-linear ion trap mass spectrometry a number of proteins with variable functions whose expression is modulated by snail1 in sw480-adh human colon cancer cells.
nsubj||sought-2/VBD||we-1/PRP	nsubj||determine-4/VB||we-1/PRP	root||ROOT-0/null||sought-2/VBD	aux||determine-4/VB||to-3/TO	xcomp||sought-2/VBD||determine-4/VB	mark||altered-36/VBN||if-5/IN	nsubjpass||altered-36/VBN||upa-6/NN	nn||inhibitor-9/NN||pa-8/NN	appos||upa-6/NN||inhibitor-9/NN	appos||inhibitor-9/NN||pai-11/NN	dep||inhibitor-9/NN||-1-13/CD	num||expression-20/NN||prostaglandin-15/CD	nn||expression-20/NN||pg-17/NN	amod||expression-20/NN||e2-19/JJ	appos||upa-6/NN||expression-20/NN	conj_and||inhibitor-9/NN||expression-20/NN	amod||fluid-24/NN||nipple-22/JJ	nn||fluid-24/NN||aspirate-23/NN	prep_in||expression-20/NN||fluid-24/NN	appos||fluid-24/NN||naf-26/NN	nn||expression-32/NN||upa-29/NN	conj_and||upa-29/NN||pge2-31/JJ	nn||expression-32/NN||pge2-31/JJ	prep_in||expression-20/NN||expression-32/NN	conj_and||fluid-24/NN||expression-32/NN	prep_in||expression-32/NN||plasma-34/NN	auxpass||altered-36/VBN||were-35/VBD	advcl||determine-4/VB||altered-36/VBN	nn||dose-39/NN||celecoxib-38/NN	agent||altered-36/VBN||dose-39/NN	agent||altered-36/VBN||concentration-41/NN	conj_and||dose-39/NN||concentration-41/NN	prep_in||altered-36/VBN||women-43/NNS	amod||risk-48/NN||increased-45/VBN	nn||risk-48/NN||breast-46/NN	nn||risk-48/NN||cancer-47/NN	prep_at||women-43/NNS||risk-48/NN	celecoxib-38||cancer-47||no_rel||we sought to determine if upa, pa inhibitor (pai)-1 and prostaglandin (pg)e2 expression in nipple aspirate fluid (naf) and upa and pge2 expression in plasma were altered by celecoxib dose and concentration in women at increased breast cancer risk.
det||effect-3/NN||the-1/DT	amod||effect-3/NN||inhibitory-2/JJ	nsubj||strong-13/JJ||effect-3/NN	nsubj||equivalent-17/JJ||effect-3/NN	det||ligands-6/NNS||these-5/DT	prep_of||effect-3/NN||ligands-6/NNS	amod||production-10/NN||cysteinyl-8/JJ	nn||production-10/NN||leukotriene-9/NN	prep_on||ligands-6/NNS||production-10/NN	cop||strong-13/JJ||is-11/VBZ	advmod||strong-13/JJ||quite-12/RB	root||ROOT-0/null||strong-13/JJ	cop||equivalent-17/JJ||is-15/VBZ	advmod||equivalent-17/JJ||almost-16/RB	conj_and||strong-13/JJ||equivalent-17/JJ	prep_to||equivalent-17/JJ||that-19/DT	det||zileuton-24/NN||the-21/DT	amod||zileuton-24/NN||anti-asthma-22/JJ	nn||zileuton-24/NN||compound-23/NN	prep_of||that-19/DT||zileuton-24/NN	asthma--1||zileuton-24||yes||the inhibitory effect of these ligands on cysteinyl leukotriene production is quite strong and is almost equivalent to that of the anti-asthma compound zileuton.
amod||studies-3/NNS||previous-2/JJ	prep_in||shown-7/VBN||studies-3/NNS	poss||group-5/NN||our-4/PRP$	nsubj||shown-7/VBN||group-5/NN	aux||shown-7/VBN||has-6/VBZ	root||ROOT-0/null||shown-7/VBN	mark||albicans-12/VBZ||that-8/IN	nsubj||albicans-12/VBZ||adhesion-9/NN	prep_of||adhesion-9/NN||c.-11/NN	ccomp||shown-7/VBN||albicans-12/VBZ	nn||tubes-14/NNS||germ-13/NN	nsubjpass||decreased-18/VBN||tubes-14/NNS	prep_to||tubes-14/NNS||polystyrene-16/NN	auxpass||decreased-18/VBN||is-17/VBZ	ccomp||albicans-12/VBZ||decreased-18/VBN	agent||decreased-18/VBN||saliva-20/NN	mark||enhanced-32/VBN||whereas-21/IN	amod||cells-25/NNS||c.-22/JJ	amod||cells-25/NNS||albicans-23/JJ	nn||cells-25/NNS||yeast-24/NN	nsubjpass||enhanced-32/VBN||cells-25/NNS	vmod||cells-25/NNS||adhesion-26/VBN	det||material-30/NN||the-28/DT	amod||material-30/NN||same-29/JJ	prep_to||adhesion-26/VBN||material-30/NN	auxpass||enhanced-32/VBN||is-31/VBZ	advcl||decreased-18/VBN||enhanced-32/VBN	adhesion-26||polystyrene-16||no_rel||in previous studies our group has shown that adhesion of c. albicans germ tubes to polystyrene is decreased by saliva whereas c. albicans yeast cells adhesion to the same material is enhanced .
nsubj||result-6/VBP||deficiencies-1/NNS	prep_in||deficiencies-1/NNS||gla-3/FW	prep_in||deficiencies-1/NNS||sda-5/FW	conj_and||gla-3/FW||sda-5/FW	root||ROOT-0/null||result-6/VBP	amod||susceptibility-9/NN||increased-8/VBN	prep_in||result-6/VBP||susceptibility-9/NN	prep_to||susceptibility-9/NN||bacterialinfection-11/NN	nsubjpass||associated-15/VBN||bacterialinfection-11/NN	auxpass||associated-15/VBN||is-14/VBZ	rcmod||bacterialinfection-11/NN||associated-15/VBN	amod||expression-19/NN||reduced-17/VBN	amod||expression-19/NN||basal-18/JJ	prep_with||associated-15/VBN||expression-19/NN	det||number-22/NN||a-21/DT	prep_of||expression-19/NN||number-22/NN	amod||$-26/NNS||immune-specific-24/JJ	amod||$-26/NNS||genesâ-25/JJ	prep_of||number-22/NN||$-26/NNS	dep||â-35/JJ||spp-1-29/JJ	conj_and||â-35/JJ||lys-7-31/JJ	amod||$-36/NNS||lys-7-31/JJ	conj_and||â-35/JJ||lys-2-34/JJ	amod||$-36/NNS||lys-2-34/JJ	amod||$-36/NNS||â-35/JJ	prep_including||$-26/NNS||$-36/NNS	nsubj||encode-39/VBP||$-36/NNS	rcmod||$-36/NNS||encode-39/VBP	amod||peptides-41/NNS||antimicrobial-40/JJ	dobj||encode-39/VBP||peptides-41/NNS	bacterialinfection-11||lys--1||no_rel||deficiencies in gla and sda result in increased susceptibility to bacterialinfection, which is associated with reduced basal expression of a number of immune-specific genesâ€”including spp-1 , lys-7 , and lys-2 â€”that encode antimicrobial peptides.
det||issues-2/NNS||these-1/DT	nsubj||are-3/VBP||issues-2/NNS	root||ROOT-0/null||are-3/VBP	dep||failure-9/NN||i-5/FW	amod||failure-9/NN||trastuzumab-7/JJ	nn||failure-9/NN||therapy-8/NN	dep||are-3/VBP||failure-9/NN	amod||development-14/NN||ii-12/JJ	appos||failure-9/NN||development-14/NN	amod||metastases-19/NNS||central-16/JJ	amod||metastases-19/NNS||nervous-17/JJ	nn||metastases-19/NNS||system-18/NN	prep_of||development-14/NN||metastases-19/NNS	appos||failure-9/NN||iii-22/NN	dep||failure-9/NN||minimizing-24/VBG	dobj||minimizing-24/VBG||toxicity-25/NN	parataxis||minimizing-24/VBG||iv-28/VB	parataxis||selecting-30/VBG||iv-28/VB	dep||failure-9/NN||selecting-30/VBG	conj_and||minimizing-24/VBG||selecting-30/VBG	det||partners-34/NNS||the-31/DT	advmod||appropriate-33/JJ||most-32/RBS	amod||partners-34/NNS||appropriate-33/JJ	dobj||selecting-30/VBG||partners-34/NNS	dep||partners-34/NNS||chemotherapy-36/JJ	dep||partners-34/NNS||non-chemotherapy-38/JJ	conj_and||chemotherapy-36/JJ||non-chemotherapy-38/JJ	nn||therapy-42/NN||combination-41/NN	prep_for||selecting-30/VBG||therapy-42/NN	prep_with||therapy-42/NN||lapatinib-44/NN	metastases-19||trastuzumab-7||no_rel||these issues are (i) trastuzumab therapy failure, (ii) development of central nervous system metastases, (iii) minimizing toxicity and (iv) selecting the most appropriate partners (chemotherapy and non-chemotherapy) for combination therapy with lapatinib.
det||changes-3/NNS||the-1/DT	amod||changes-3/NNS||multiple-2/JJ	nsubj||suggest-12/VBP||changes-3/NNS	nn||expression-8/NN||gene-5/NN	conj_and||gene-5/NN||protein-7/NN	nn||expression-8/NN||protein-7/NN	prep_in||changes-3/NNS||expression-8/NN	vmod||expression-8/NN||associated-9/VBN	prep_with||associated-9/VBN||cocaineaddiction-11/NN	root||ROOT-0/null||suggest-12/VBP	det||existence-14/NN||the-13/DT	dobj||suggest-12/VBP||existence-14/NN	det||mechanism-17/NN||a-16/DT	prep_of||existence-14/NN||mechanism-17/NN	nsubj||facilitates-19/VBZ||mechanism-17/NN	rcmod||mechanism-17/NN||facilitates-19/VBZ	det||response-23/NN||a-20/DT	amod||response-23/NN||coordinated-21/JJ	amod||response-23/NN||cellular-22/JJ	dobj||facilitates-19/VBZ||response-23/NN	prep_to||facilitates-19/VBZ||cocaine-25/NN	cocaineaddiction-11||cocaine-25||no||the multiple changes in gene and protein expression associated with cocaineaddiction suggest the existence of a mechanism that facilitates a coordinated cellular response to cocaine.
nsubj||alternative-7/NN||febuxostat-1/NN	cop||alternative-7/NN||is-2/VBZ	det||alternative-7/NN||the-3/DT	amod||alternative-7/NN||first-4/JJ	amod||alternative-7/NN||major-5/JJ	nn||alternative-7/NN||treatment-6/NN	root||ROOT-0/null||alternative-7/NN	prep_for||alternative-7/NN||gout-9/NN	mwe||than-12/IN||more-11/JJR	quantmod||40-13/CD||than-12/IN	num||years-14/NNS||40-13/CD	prep_in||gout-9/NN||years-14/NNS	cop||alternative-19/NN||is-16/VBZ	det||alternative-19/NN||a-17/DT	amod||alternative-19/NN||promising-18/JJ	conj_and||alternative-7/NN||alternative-19/NN	prep_to||alternative-19/NN||allopurinol-21/NN	mark||required-32/VBN||although-23/IN	amod||surveillance-26/NN||continued-24/VBN	amod||surveillance-26/NN||long-term-25/JJ	nsubjpass||required-32/VBN||surveillance-26/NN	prep_on||surveillance-26/NN||safety-28/NN	prep_on||surveillance-26/NN||efficacy-30/NN	conj_and||safety-28/NN||efficacy-30/NN	auxpass||required-32/VBN||is-31/VBZ	advcl||alternative-19/NN||required-32/VBN	gout-9||allopurinol-21||yes||febuxostat is the first major treatment alternative for gout in more than 40 years and is a promising alternative to allopurinol, although continued long-term surveillance on safety and efficacy is required.
nsubjpass||characterized-6/VBN||type2diabetesmellitus-1/NNS	nsubjpass||accompanied-23/VBN||type2diabetesmellitus-1/NNS	appos||type2diabetesmellitus-1/NNS||t2dm-3/NNP	auxpass||characterized-6/VBN||is-5/VBZ	root||ROOT-0/null||characterized-6/VBN	agent||characterized-6/VBN||defects-8/NNS	preconj||sensitivity-12/NN||both-10/DT	nn||sensitivity-12/NN||insulin-11/NN	prep_in||defects-8/NNS||sensitivity-12/NN	amod||secretion-16/NN||glucose-stimulated-14/JJ	nn||secretion-16/NN||insulin-15/NN	prep_in||defects-8/NNS||secretion-16/NN	conj_and||sensitivity-12/NN||secretion-16/NN	appos||sensitivity-12/NN||gsis-18/NNS	auxpass||accompanied-23/VBN||is-21/VBZ	advmod||accompanied-23/VBN||often-22/RB	conj_and||characterized-6/VBN||accompanied-23/VBN	agent||accompanied-23/VBN||obesity-25/NN	type2diabetesmellitus-1||insulin-15||yes||type2diabetesmellitus (t2dm) is characterized by defects in both insulin sensitivity and glucose-stimulated insulin secretion (gsis) and is often accompanied by obesity.
amod||years-3/NNS||recent-2/JJ	prep_in||been-10/VBN||years-3/NNS	nsubj||been-10/VBN||cases-5/NNS	nn||cancer-8/NN||breast-7/NN	prep_of||cases-5/NNS||cancer-8/NN	aux||been-10/VBN||have-9/VBP	root||ROOT-0/null||been-10/VBN	det||rise-13/NN||the-12/DT	prep_on||been-10/VBN||rise-13/NN	prep_in||been-10/VBN||vietnam-15/NN	cancer-8||rise-13||no_rel||in recent years, cases of breast cancer have been on the rise in vietnam.
amod||stenosis-2/NNS||mitral-1/JJ	nsubj||abnormality-9/NN||stenosis-2/NNS	appos||stenosis-2/NNS||ms-4/NN	cop||abnormality-9/NN||is-6/VBZ	det||abnormality-9/NN||a-7/DT	amod||abnormality-9/NN||structural-8/JJ	root||ROOT-0/null||abnormality-9/NN	det||apparatus-14/NN||the-11/DT	amod||apparatus-14/NN||mitral-12/JJ	nn||apparatus-14/NN||valve-13/NN	prep_of||abnormality-9/NN||apparatus-14/NN	nsubjpass||resulted-18/VBN||apparatus-14/NN	aux||resulted-18/VBN||can-16/MD	auxpass||resulted-18/VBN||be-17/VB	rcmod||apparatus-14/NN||resulted-18/VBN	amod||rheumaticfever-21/NN||previous-20/JJ	prep_from||resulted-18/VBN||rheumaticfever-21/NN	prep_from||resulted-18/VBN||non-rheumaticfever-23/NN	conj_or||rheumaticfever-21/NN||non-rheumaticfever-23/NN	amod||stenosis-28/NNS||congenital-26/JJ	amod||stenosis-28/NNS||mitral-27/JJ	prep_such_as||rheumaticfever-21/NN||stenosis-28/NNS	amod||etc.-33/NNS||malignant-30/JJ	amod||etc.-33/NNS||carcinoid-31/JJ	nn||etc.-33/NNS||disease-32/NN	appos||stenosis-28/NNS||etc.-33/NNS	rheumaticfever-21||rheumaticfever-21||no||mitral stenosis (ms) is a structural abnormality of the mitral valve apparatus that can be resulted from previous rheumaticfever or non-rheumaticfever such as congenital mitral stenosis, malignant carcinoid disease etc.
nsubj||reported-2/VBD||we-1/PRP	root||ROOT-0/null||reported-2/VBD	mark||suggesting-24/VBG||that-3/IN	nn||magnesium-5/NN||intracellular-4/NN	nsubj||suggesting-24/VBG||magnesium-5/NN	nn||platelets-9/NNS||cord-7/NN	nn||platelets-9/NNS||blood-8/NN	prep_of||magnesium-5/NN||platelets-9/NNS	cop||suggesting-24/VBG||is-10/VBZ	acomp||suggesting-24/VBG||lower-11/JJR	nn||groups-14/NNS||sga-13/NN	prep_in||lower-11/JJR||groups-14/NNS	prep_than||suggesting-24/VBG||that-16/DT	amod||groups-22/NNS||appropriate-18/JJ	amod||age-21/NN||gestational-20/JJ	prep_for||appropriate-18/JJ||age-21/NN	prep_in||that-16/DT||groups-22/NNS	ccomp||reported-2/VBD||suggesting-24/VBG	mark||result-29/VB||that-25/IN	amod||magnesiumdeficiency-27/NN||intrauterine-26/JJ	nsubj||result-29/VB||magnesiumdeficiency-27/NN	aux||result-29/VB||may-28/MD	ccomp||suggesting-24/VBG||result-29/VB	prep_in||result-29/VB||sga-31/NN	magnesiumdeficiency-27||magnesium-5||yes||we reported that intracellular magnesium of cord blood platelets is lower in sga groups than that in appropriate for gestational age groups, suggesting that intrauterine magnesiumdeficiency may result in sga.
nsubj||recorded-2/VBD||we-1/PRP	nsubj||examined-22/VBD||we-1/PRP	root||ROOT-0/null||recorded-2/VBD	amod||data-4/NNS||demographic-3/JJ	dobj||recorded-2/VBD||data-4/NNS	amod||prescription-7/NN||antenatal-6/JJ	appos||data-4/NNS||prescription-7/NN	amod||therapy-11/NN||intermittent-9/JJ	nn||therapy-11/NN||preventive-10/NN	prep_of||prescription-7/NN||therapy-11/NN	prep_during||recorded-2/VBD||pregnancy-13/NN	nn||use-19/NN||sulfadoxine-pyrimethamine-15/NN	conj_and||sulfadoxine-pyrimethamine-15/NN||bed-17/NN	nn||use-19/NN||bed-17/NN	amod||use-19/NN||net-18/JJ	prep_with||recorded-2/VBD||use-19/NN	conj_and||recorded-2/VBD||examined-22/VBD	amod||blood-24/NN||finger-prick-23/JJ	dobj||examined-22/VBD||blood-24/NN	nn||parasites-27/NNS||malaria-26/NN	prep_for||examined-22/VBD||parasites-27/NNS	nn||concentration-30/NN||hemoglobin-29/NN	prep_for||examined-22/VBD||concentration-30/NN	conj_and||parasites-27/NNS||concentration-30/NN	malaria-26||pyrimethamine--1||no||we recorded demographic data, antenatal prescription of intermittent preventive therapy during pregnancy with sulfadoxine-pyrimethamine and bed net use, and examined finger-prick blood for malaria parasites and hemoglobin concentration.
quantmod||two-thirds-3/NNS||fewer-1/JJR	quantmod||two-thirds-3/NNS||than-2/IN	nsubj||knew-4/VBD||two-thirds-3/NNS	root||ROOT-0/null||knew-4/VBD	mark||develop-27/VB||that-5/IN	quantmod||10-7/CD||about-6/RB	num||%-8/NN||10-7/CD	nsubj||develop-27/VB||%-8/NN	prep_of||%-8/NN||people-10/NNS	det||u.s.a.-13/NN||the-12/DT	prep_in||people-10/NNS||u.s.a.-13/NN	nsubj||have-15/VBP||u.s.a.-13/NN	rcmod||u.s.a.-13/NN||have-15/VBP	nn||-rrb--20/NNP||latent-16/NN	nn||-rrb--20/NNP||tuberculosisinfection-17/NN	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||ltbi-19/NNP	dobj||have-15/VBP||-rrb--20/NNP	det||system-25/NN||a-22/DT	amod||system-25/NN||normal-23/JJ	amod||system-25/NN||immune-24/JJ	dobj||have-15/VBP||system-25/NN	conj_and||-rrb--20/NNP||system-25/NN	aux||develop-27/VB||will-26/MD	ccomp||knew-4/VBD||develop-27/VB	nn||disease-29/NN||tb-28/NN	dobj||develop-27/VB||disease-29/NN	mark||part-36/NN||that-32/IN	nsubj||part-36/NN||bcg-33/NN	cop||part-36/NN||is-34/VBZ	neg||part-36/NN||not-35/RB	ccomp||knew-4/VBD||part-36/NN	conj_or||develop-27/VB||part-36/NN	det||program-41/NN||the-38/DT	amod||program-41/NN||routine-39/JJ	nn||program-41/NN||vaccination-40/NN	prep_of||part-36/NN||program-41/NN	det||u.s.a.-44/NN||the-43/DT	prep_in||program-41/NN||u.s.a.-44/NN	mark||complicates-47/VBZ||because-45/IN	nsubj||complicates-47/VBZ||it-46/PRP	advcl||part-36/NN||complicates-47/VBZ	dobj||complicates-47/VBZ||surveillance-48/NN	amod||infection-52/NN||new-50/JJ	nn||infection-52/NN||tb-51/NN	prep_for||surveillance-48/NN||infection-52/NN	tb-51||bcg-33||yes||fewer than two-thirds knew that about 10 % of people in the u.s.a. who have latent tuberculosisinfection -lrb- ltbi -rrb- and a normal immune system will develop tb disease , or that bcg is not part of the routine vaccination program in the u.s.a. because it complicates surveillance for new tb infection .
nsubj||cause-5/NN||diabeticnephropathy-1/NN	cop||cause-5/NN||is-2/VBZ	det||cause-5/NN||a-3/DT	amod||cause-5/NN||leading-4/VBG	root||ROOT-0/null||cause-5/NN	amod||renaldisease-8/NN||end-stage-7/JJ	prep_of||cause-5/NN||renaldisease-8/NN	nsubj||increasing-12/VBG||renaldisease-8/NN	aux||increasing-12/VBG||is-11/VBZ	rcmod||renaldisease-8/NN||increasing-12/VBG	prep_in||increasing-12/VBG||incidence-14/NN	advmod||increasing-12/VBG||worldwide-15/RB	amod||approaches-20/NNS||intensive-18/JJ	nn||approaches-20/NNS||treatment-19/NN	prep_despite||increasing-12/VBG||approaches-20/NNS	nn||control-27/NN||glycemic-23/NN	conj_and||glycemic-23/NN||blood-25/NN	nn||control-27/NN||blood-25/NN	nn||control-27/NN||pressure-26/NN	prep_such_as||approaches-20/NNS||control-27/NN	prep_in||control-27/NN||patients-29/NNS	prep_with||patients-29/NNS||diabetesmellitus-31/NNS	diabeticnephropathy-1||diabetesmellitus-31||no||diabeticnephropathy is a leading cause of end-stage renaldisease, which is increasing in incidence worldwide, despite intensive treatment approaches such as glycemic and blood pressure control in patients with diabetesmellitus.
nsubj||disease-5/NN||anthrax-1/NN	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||an-3/DT	amod||disease-5/NN||ancient-4/JJ	root||ROOT-0/null||disease-5/NN	vmod||disease-5/NN||caused-6/VBN	det||bacillusanthracis-10/NNS||the-8/DT	amod||bacillusanthracis-10/NNS||gram-positive-9/JJ	agent||caused-6/VBN||bacillusanthracis-10/NNS	advmod||gained-16/VBN||recently-12/RB	nsubj||gained-16/VBN||it-14/PRP	aux||gained-16/VBN||has-15/VBZ	parataxis||disease-5/NN||gained-16/VBN	amod||attention-18/NN||much-17/JJ	dobj||gained-16/VBN||attention-18/NN	poss||use-23/NN||its-21/PRP$	amod||use-23/NN||potential-22/JJ	prep_because_of||attention-18/NN||use-23/NN	amod||warfare-26/NN||biologic-25/JJ	prep_in||gained-16/VBN||warfare-26/NN	anthrax-1||bacillusanthracis-10||no||anthrax is an ancient disease caused by the gram-positive bacillusanthracis ; recently, it has gained much attention because of its potential use in biologic warfare.
nsubjpass||affected-5/VBN||cows-1/NNS	nsubjpass||hypothyroid-12/VBN||cows-1/NNS	auxpass||affected-5/VBN||were-4/VBD	rcmod||cows-1/NNS||affected-5/VBN	amod||liver-9/NN||severe-7/JJ	amod||liver-9/NN||fatty-8/JJ	prep_with||affected-5/VBN||liver-9/NN	auxpass||hypothyroid-12/VBN||were-11/VBD	root||ROOT-0/null||hypothyroid-12/VBN	prep_prior_to||hypothyroid-12/VBN||development-15/NN	det||condition-18/NN||the-17/DT	prep_of||development-15/NN||condition-18/NN	acomp||hypothyroid-12/VBN||due-19/JJ	amod||concentrations-23/NNS||lower-21/JJR	amod||concentrations-23/NNS||t4-22/JJ	prep_to||due-19/JJ||concentrations-23/NNS	acomp||hypothyroid-12/VBN||had-26/VBD	conj_and||due-19/JJ||had-26/VBD	advmod||lower-28/JJR||significantly-27/RB	amod||concentration-29/NN||lower-28/JJR	dobj||had-26/VBD||concentration-29/NN	prep_of||concentration-29/NN||t3-31/NNS	amod||ratios-35/NNS||higher-33/JJR	amod||ratios-35/NNS||t3/t4-34/JJ	prep_of||concentration-29/NN||ratios-35/NNS	conj_and||t3-31/NNS||ratios-35/NNS	prep_than||had-26/VBD||cows-37/NNS	amod||liver-43/NN||mild-39/JJ	conj_and||mild-39/JJ||moderate-41/JJ	amod||liver-43/NN||moderate-41/JJ	nn||liver-43/NN||fatty-42/NN	prep_with||cows-37/NNS||liver-43/NN	hypothyroid-12||t4-22||yes||cows, that were affected with severe fatty liver, were hypothyroid prior to development of the condition due to lower t4 concentrations, and had significantly lower concentration of t3 and higher t3/t4 ratios than cows with mild and moderate fatty liver.
nsubj||hypothesized-2/VBN||we-1/PRP	root||ROOT-0/null||hypothesized-2/VBN	mark||become-22/VBN||that-3/IN	mark||became-8/VBD||as-5/IN	nn||infections-7/NNS||mrsa-6/NN	nsubj||became-8/VBD||infections-7/NNS	advcl||become-22/VBN||became-8/VBD	advmod||common-10/JJ||more-9/RBR	acomp||became-8/VBD||common-10/JJ	amod||infections-13/NNS||s.aureus-12/JJ	prep_among||became-8/VBD||infections-13/NNS	det||community-16/NN||the-15/DT	prep_in||infections-13/NNS||community-16/NN	advmod||infections-20/NNS||perhaps-18/RB	nn||infections-20/NNS||mssa-19/NN	nsubj||become-22/VBN||infections-20/NNS	aux||become-22/VBN||had-21/VBD	ccomp||hypothesized-2/VBN||become-22/VBN	advmod||important-24/JJ||more-23/RBR	acomp||become-22/VBN||important-24/JJ	det||cause-27/NN||a-26/DT	prep_as||important-24/JJ||cause-27/NN	amod||infection-30/NN||healthcare-associated-29/JJ	prep_of||cause-27/NN||infection-30/NN	mrsa-6||s.aureus-12||no||we hypothesized that , as mrsa infections became more common among s.aureus infections in the community , perhaps mssa infections had become more important as a cause of healthcare-associated infection .
nn||acetylsalicylicacid-4/NN||background-1/NN	conj_and||background-1/NN||aim-3/NN	nn||acetylsalicylicacid-4/NN||aim-3/NN	nsubj||drug-16/NN||acetylsalicylicacid-4/NN	num||-RSB--9/NNS||asa-6/CD	nn||-RSB--9/NNS||-LSB--7/NNP	nn||-RSB--9/NNS||aspirin-8/NN	appos||acetylsalicylicacid-4/NN||-RSB--9/NNS	cop||drug-16/NN||is-11/VBZ	det||drug-16/NN||a-12/DT	advmod||used-14/VBN||commonly-13/RB	amod||drug-16/NN||used-14/VBN	amod||drug-16/NN||over-the-counter-15/JJ	root||ROOT-0/null||drug-16/NN	det||treatment-19/NN||the-18/DT	prep_for||drug-16/NN||treatment-19/NN	prep_of||treatment-19/NN||pain-21/NN	prep_of||treatment-19/NN||fever-23/NN	conj_or||pain-21/NN||fever-23/NN	prep_of||treatment-19/NN||colds-26/NNS	conj_or||pain-21/NN||colds-26/NNS	nsubj||limited-38/JJ||data-29/NNS	det||safety-32/NN||the-31/DT	prep_on||data-29/NNS||safety-32/NN	det||use-35/NN||this-34/DT	prep_of||safety-32/NN||use-35/NN	cop||limited-38/JJ||are-36/VBP	advmod||limited-38/JJ||very-37/RB	conj_but||drug-16/NN||limited-38/JJ	pain-21||asa-6||yes||background and aim acetylsalicylicacid (asa [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited.
nsubj||factor-6/NN||insulinresistance-1/NN	cop||factor-6/NN||is-2/VBZ	det||factor-6/NN||a-3/DT	amod||factor-6/NN||major-4/JJ	nn||factor-6/NN||risk-5/NN	root||ROOT-0/null||factor-6/NN	amod||type2diabetes-9/NNS||developing-8/VBG	prep_for||factor-6/NN||type2diabetes-9/NNS	dep||type2diabetes-9/NNS||caused-10/VBN	det||inability-13/NN||the-12/DT	prep_by||caused-10/VBN||inability-13/NN	amod||tissues-16/NNS||insulin-target-15/JJ	prep_of||inability-13/NN||tissues-16/NNS	aux||respond-18/VB||to-17/TO	xcomp||caused-10/VBN||respond-18/VB	advmod||respond-18/VB||properly-19/RB	prep_to||respond-18/VB||insulin-21/NN	dep||type2diabetes-9/NNS||contributes-24/VBZ	conj_and||caused-10/VBN||contributes-24/VBZ	det||morbidity-27/NN||the-26/DT	prep_to||contributes-24/VBZ||morbidity-27/NN	prep_of||morbidity-27/NN||obesity-29/NN	type2diabetes-9||insulin-21||yes||insulinresistance is a major risk factor for developing type2diabetes caused by the inability of insulin-target tissues to respond properly to insulin, and contributes to the morbidity of obesity.
det||advantages-3/NNS||the-1/DT	amod||advantages-3/NNS||pharmacological-2/JJ	nsubj||contributed-14/VBN||advantages-3/NNS	det||analog-7/NN||the-5/DT	amod||analog-7/NN||rapid-acting-6/JJ	prep_of||advantages-3/NNS||analog-7/NN	appos||analog-7/NN||insulinaspart-9/NN	prep_over||analog-7/NN||humaninsulin-12/NN	aux||contributed-14/VBN||have-13/VBP	root||ROOT-0/null||contributed-14/VBN	det||prescription-18/NN||the-16/DT	amod||prescription-18/NN||widespread-17/JJ	prep_to||contributed-14/VBN||prescription-18/NN	det||premix-21/NN||the-20/DT	prep_of||prescription-18/NN||premix-21/NN	amod||insulinaspart-24/NN||biphasic-23/JJ	appos||premix-21/NN||insulinaspart-24/NN	num||insulinaspart-24/NN||30/70-25/CD	appos||insulinaspart-24/NN||biasp-27/NN	num||biasp-27/NN||30-28/CD	prep_in||contributed-14/VBN||type-32/NN	num||type-32/NN||1-33/CD	appos||type-32/NN||t1dm-35/NNP	prep_in||contributed-14/VBN||type2diabetes-38/NNS	conj_and||type-32/NN||type2diabetes-38/NNS	appos||type-32/NN||t2dm-40/NNP	type2diabetes-38||humaninsulin-12||yes||the pharmacological advantages of the rapid-acting analog, insulinaspart, over humaninsulin have contributed to the widespread prescription of the premix, biphasic insulinaspart 30/70 (biasp 30), in type 1 (t1dm) and type2diabetes (t2dm).
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||differences-8/NNS||the-7/DT	dobj||investigated-6/VBD||differences-8/NNS	nn||sensitivity-11/NN||insulin-10/NN	prep_in||investigated-6/VBD||sensitivity-11/NN	prep_in||investigated-6/VBD||secretion-13/NN	conj_and||sensitivity-11/NN||secretion-13/NN	prep_between||sensitivity-11/NN||autoantibody-negative-15/NN	appos||autoantibody-negative-15/NN||abâˆ-17/NNP	amod||youth-27/NN||positive-22/JJ	nn||+-25/NNP||ab-24/NNP	appos||youth-27/NN||+-25/NNP	dep||investigated-6/VBD||youth-27/NN	advmod||diagnosed-30/JJ||clinically-29/RB	amod||type2diabetes-31/NNS||diagnosed-30/JJ	prep_with||youth-27/NN||type2diabetes-31/NNS	prep_in||investigated-6/VBD||comparison-33/NN	conj_and||sensitivity-11/NN||comparison-33/NN	nn||subjects-36/NNS||control-35/NN	prep_with||investigated-6/VBD||subjects-36/NNS	type2diabetes-31||insulin-10||yes||in this study, we investigated the differences in insulin sensitivity and secretion between autoantibody-negative (abâˆ’) and -positive (ab+) youth with clinically diagnosed type2diabetes in comparison with control subjects.
nsubj||equivalent-7/JJ||combination-1/NN	nsubj||leflunomide-9/VB||combination-1/NN	prep_of||combination-1/NN||methotrexate-3/NN	prep_of||combination-1/NN||hydroxychloroquine-5/NN	conj_and||methotrexate-3/NN||hydroxychloroquine-5/NN	cop||equivalent-7/JJ||is-6/VBZ	root||ROOT-0/null||equivalent-7/JJ	aux||leflunomide-9/VB||to-8/TO	xcomp||equivalent-7/JJ||leflunomide-9/VB	prep_in||leflunomide-9/VB||terms-11/NNS	prep_of||terms-11/NNS||efficacy-13/NN	prepc_in||leflunomide-9/VB||reducing-15/VBG	nn||activity-17/NN||disease-16/NN	dobj||reducing-15/VBG||activity-17/NN	det||treatment-21/NN||the-19/DT	amod||treatment-21/NN||initial-20/JJ	prep_in||reducing-15/VBG||treatment-21/NN	amod||rheumatoidarthritis-24/NNS||severe-23/JJ	prep_of||treatment-21/NN||rheumatoidarthritis-24/NNS	rheumatoidarthritis-24||methotrexate-3||yes||combination of methotrexate and hydroxychloroquine is equivalent to leflunomide in terms of efficacy in reducing disease activity in the initial treatment of severe rheumatoidarthritis.
det||initiative-7/NN||the-1/DT	amod||initiative-7/NN||womenâ-2/JJ	amod||initiative-7/NN||$-3/$	number||s-5/CD||™-4/CD	num||$-3/$||s-5/CD	nn||initiative-7/NN||health-6/NN	nsubj||found-8/VBD||initiative-7/NN	root||ROOT-0/null||found-8/VBD	mark||increases-17/VBZ||that-9/IN	nn||estrogen-11/NN||combination-10/NN	nsubj||increases-17/VBZ||estrogen-11/NN	amod||therapy-16/NN||progesterone-13/JJ	nn||therapy-16/NN||hormone-14/NN	nn||therapy-16/NN||replacement-15/NN	conj_and||estrogen-11/NN||therapy-16/NN	nsubj||increases-17/VBZ||therapy-16/NN	ccomp||found-8/VBD||increases-17/VBZ	nn||cancer-19/NN||breast-18/NN	dobj||increases-17/VBZ||cancer-19/NN	nsubj||compelled-25/VBN||cancer-19/NN	nn||risk-22/NN||cardiovasculardisease-21/NN	dobj||increases-17/VBZ||risk-22/NN	conj_and||cancer-19/NN||risk-22/NN	nsubj||compelled-25/VBN||risk-22/NN	rcmod||cancer-19/NN||compelled-25/VBN	amod||women-27/NNS||many-26/JJ	dobj||compelled-25/VBN||women-27/NNS	nsubj||seek-29/VB||women-27/NNS	aux||seek-29/VB||to-28/TO	xcomp||compelled-25/VBN||seek-29/VB	amod||alternatives-31/NNS||herbal-30/JJ	dobj||seek-29/VB||alternatives-31/NNS	prep_such_as||alternatives-31/NNS||blackcohoshextract-34/NN	appos||blackcohoshextract-34/NN||bce-36/NN	aux||relieve-39/VB||to-38/TO	vmod||blackcohoshextract-34/NN||relieve-39/VB	poss||symptoms-42/NNS||their-40/PRP$	amod||symptoms-42/NNS||menopausal-41/JJ	dobj||relieve-39/VB||symptoms-42/NNS	progesterone-13||cardiovasculardisease-21||no_rel||the womenâ€™s health initiative found that combination estrogen and progesterone hormone replacement therapy increases breast cancer and cardiovasculardisease risk, which compelled many women to seek herbal alternatives such as blackcohoshextract (bce) to relieve their menopausal symptoms.
det||administration-2/NN||the-1/DT	nsubj||result-9/VB||administration-2/NN	prep_of||administration-2/NN||hepatitisbimmunoglobulin-4/NN	vmod||hepatitisbimmunoglobulin-4/NN||followed-5/VBN	agent||followed-5/VBN||hepatitisbvaccine-7/NN	aux||result-9/VB||can-8/MD	root||ROOT-0/null||result-9/VB	det||efficacy-13/NN||a-11/DT	amod||efficacy-13/NN||protective-12/JJ	prep_in||result-9/VB||efficacy-13/NN	quantmod||90-16/CD||almost-15/RB	num||%-17/NN||90-16/CD	prep_of||efficacy-13/NN||%-17/NN	amod||transmission-20/NN||mother-to-child-19/JJ	prep_in||%-17/NN||transmission-20/NN	amod||virus-23/NN||hepatitisb-22/JJ	prep_of||transmission-20/NN||virus-23/NN	appos||virus-23/NN||hbv-25/NN	hbv-25||hepatitisbimmunoglobulin-4||yes||the administration of hepatitisbimmunoglobulin followed by hepatitisbvaccine can result in a protective efficacy of almost 90% in mother-to-child transmission of hepatitisb virus (hbv).
nn||cells-2/NNS||cancer-1/NN	nsubj||utilize-4/VB||cells-2/NNS	advmod||utilize-4/VB||predominantly-3/RB	root||ROOT-0/null||utilize-4/VB	dobj||utilize-4/VB||glycolysis-5/NNS	nn||production-8/NN||atp-7/NN	prep_for||glycolysis-5/NNS||production-8/NN	advmod||utilize-4/VB||even-9/RB	det||presence-12/NN||the-11/DT	prep_in||utilize-4/VB||presence-12/NN	amod||oxygen-15/NN||abundant-14/JJ	prep_of||presence-12/NN||oxygen-15/NN	det||environment-18/NN||an-17/DT	dobj||utilize-4/VB||environment-18/NN	nsubj||result-22/VB||environment-18/NN	aux||result-22/VB||would-20/MD	advmod||result-22/VB||normally-21/RB	rcmod||environment-18/NN||result-22/VB	nn||production-25/NN||energy-24/NN	prep_in||result-22/VB||production-25/NN	amod||phosphorylation-28/NN||oxidative-27/JJ	prep_through||result-22/VB||phosphorylation-28/NN	oxygen-15||cancer-1||no_rel||cancer cells predominantly utilize glycolysis for atp production even in the presence of abundant oxygen, an environment that would normally result in energy production through oxidative phosphorylation.
vmod||useful-15/JJ||understanding-1/VBG	det||cause-3/NN||the-2/DT	dobj||understanding-1/VBG||cause-3/NN	nn||p55-6/NNS||tnfr-5/NN	prep_of||cause-3/NN||p55-6/NNS	nn||³-9/NNP||ifn-î-8/NNP	nsubj||useful-15/JJ||³-9/NNP	nsubj||reduce-21/VB||³-9/NNP	nn||elevation-12/NN||crp-11/NN	conj_and||³-9/NNP||elevation-12/NN	nsubj||useful-15/JJ||elevation-12/NN	nsubj||reduce-21/VB||elevation-12/NN	aux||useful-15/JJ||may-13/MD	cop||useful-15/JJ||be-14/VB	root||ROOT-0/null||useful-15/JJ	prep_in||useful-15/JJ||development-17/NN	prep_of||development-17/NN||interventions-19/NNS	aux||reduce-21/VB||to-20/TO	xcomp||useful-15/JJ||reduce-21/VB	dobj||reduce-21/VB||mortality-22/NN	nn||patients-25/NNS||aids-24/NNS	prep_in||mortality-22/NN||patients-25/NNS	amod||diarrhoea-28/NN||chronic-27/JJ	prep_with||reduce-21/VB||diarrhoea-28/NN	prep_in||diarrhoea-28/NN||africa-30/NN	aids-24||ifn--1||no||understanding the cause of tnfr p55, ifn-î³ and crp elevation may be useful in development of interventions to reduce mortality in aids patients with chronic diarrhoea in africa.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||recommended-14/VBN||treatment-3/NN	prep_of||treatment-3/NN||malaria-5/NN	prep_in||malaria-5/NN||infants-7/NNS	vmod||infants-7/NNS||using-8/VBG	acomp||using-8/VBG||sulfadoxine-pyrimethamine-9/JJ	appos||treatment-3/NN||sp-ipti-11/NNP	auxpass||recommended-14/VBN||is-13/VBZ	root||ROOT-0/null||recommended-14/VBN	agent||recommended-14/VBN||who-16/WP	prep_for||recommended-14/VBN||implementation-18/NN	prep_in||implementation-18/NN||settings-20/NNS	advmod||high-27/JJ||where-21/WRB	nsubj||high-27/JJ||resistance-22/NN	prep_to||resistance-22/NN||sp-24/NN	cop||high-27/JJ||is-25/VBZ	neg||high-27/JJ||not-26/RB	rcmod||settings-20/NNS||high-27/JJ	malaria-5||pyrimethamine--1||no||intermittent preventive treatment of malaria in infants using sulfadoxine-pyrimethamine (sp-ipti) is recommended by who for implementation in settings where resistance to sp is not high.
amod||advances-3/NNS||recent-1/JJ	amod||advances-3/NNS||clinical-2/JJ	nsubj||include-9/VBP||advances-3/NNS	det||treatment-6/NN||the-5/DT	prep_in||advances-3/NNS||treatment-6/NN	prep_of||treatment-6/NN||aml-8/NN	root||ROOT-0/null||include-9/VBP	nsubj||demonstrating-11/VBG||studies-10/NNS	dep||include-9/VBP||demonstrating-11/VBG	det||benefit-13/NN||the-12/DT	dobj||demonstrating-11/VBG||benefit-13/NN	amod||therapy-17/NN||dose-intense-15/JJ	nn||therapy-17/NN||daunorubicin-16/NN	prep_of||benefit-13/NN||therapy-17/NN	nn||chemotherapy-20/NN||induction-19/NN	prep_in||therapy-17/NN||chemotherapy-20/NN	prep_for||demonstrating-11/VBG||patients-22/NNS	det||age-25/NN||any-24/DT	prep_of||patients-22/NNS||age-25/NN	aml-8||daunorubicin-16||yes||recent clinical advances in the treatment of aml include studies demonstrating the benefit of dose-intense daunorubicin therapy in induction chemotherapy for patients of any age.
det||mutation-4/NN||the-1/DT	amod||mutation-4/NN||dominant-negative-2/JJ	amod||mutation-4/NN||p467l-3/JJ	nsubjpass||identified-16/VBN||mutation-4/NN	amod||³-10/NNP||peroxisome-6/JJ	nn||³-10/NNP||proliferator-7/NN	nn||³-10/NNP||activated-8/NNP	nn||³-10/NNP||receptor-î-9/NNP	prep_in||mutation-4/NN||³-10/NNP	nn||³-13/NNP||pparî-12/NNP	appos||mutation-4/NN||³-13/NNP	auxpass||identified-16/VBN||was-15/VBD	root||ROOT-0/null||identified-16/VBN	amod||patients-19/NNS||insulin-resistant-18/JJ	prep_in||identified-16/VBN||patients-19/NNS	prep_with||identified-16/VBN||hyperglycemia-21/NN	prep_with||identified-16/VBN||lipodystrophy-23/NN	conj_and||hyperglycemia-21/NN||lipodystrophy-23/NN	hyperglycemia-21||insulin--1||yes||the dominant-negative p467l mutation in peroxisome proliferator activated receptor-î³ (pparî³) was identified in insulin-resistant patients with hyperglycemia and lipodystrophy.
aux||describe-2/VB||to-1/TO	csubj||associated-21/VBN||describe-2/VB	nn||persistence-4/NN||insulin-3/NN	dobj||describe-2/VB||persistence-4/NN	prep_among||describe-2/VB||patients-6/NNS	amod||therapy-11/NN||type2diabetes-8/JJ	amod||therapy-11/NN||initiating-9/JJ	nn||therapy-11/NN||insulin-10/NN	prep_with||patients-6/NNS||therapy-11/NN	amod||insulin-14/NN||basal-13/JJ	prep_with||therapy-11/NN||insulin-14/NN	nn||mixtures-17/NNS||insulin-16/NN	prep_with||therapy-11/NN||mixtures-17/NNS	conj_or||insulin-14/NN||mixtures-17/NNS	conj_and||describe-2/VB||determine-19/VB	csubj||associated-21/VBN||determine-19/VB	dobj||determine-19/VB||factors-20/NNS	root||ROOT-0/null||associated-21/VBN	prep_with||associated-21/VBN||nonpersistence-23/NN	type2diabetes-8||insulin-16||yes||to describe insulin persistence among patients with type2diabetes initiating insulin therapy with basal insulin or insulin mixtures and determine factors associated with nonpersistence.
nn||patients-2/NNS||gbs-1/NN	nsubjpass||treated-10/VBN||patients-2/NNS	cop||unable-4/JJ||being-3/VBG	vmod||patients-2/NNS||unable-4/JJ	aux||walk-6/VB||to-5/TO	xcomp||unable-4/JJ||walk-6/VB	acomp||walk-6/VB||unaided-7/JJ	auxpass||treated-10/VBN||are-8/VBP	advmod||treated-10/VBN||currently-9/RB	root||ROOT-0/null||treated-10/VBN	det||dose-16/NN||a-12/DT	amod||dose-16/NN||standard-13/JJ	amod||dose-16/NN||single-14/JJ	nn||dose-16/NN||ivig-15/NN	prep_with||treated-10/VBN||dose-16/NN	num||bodyweight-21/NN||0.4-18/CD	nn||bodyweight-21/NN||â-19/NN	nn||bodyweight-21/NN||g/kg-20/NN	dep||dose-16/NN||bodyweight-21/NN	amod||days-24/NNS||5â-23/JJ	prep_for||bodyweight-21/NN||days-24/NNS	gbs-1||ivig-15||yes||gbs patients being unable to walk unaided are currently treated with a standard single ivig dose (0.4â g/kg bodyweight for 5â days).
amod||studies-2/NNS||mechanistic-1/JJ	nsubj||reveal-3/VBP||studies-2/NNS	root||ROOT-0/null||reveal-3/VBP	mark||leads-10/VBZ||that-4/IN	nsubj||leads-10/VBZ||inhibition-5/NN	prep_of||inhibition-5/NN||hsp90-7/NNS	prep_during||hsp90-7/NNS||rsvinfection-9/NN	ccomp||reveal-3/VBP||leads-10/VBZ	det||degradation-13/NN||the-12/DT	prep_to||leads-10/VBZ||degradation-13/NN	det||protein-17/NN||a-15/DT	amod||protein-17/NN||viral-16/JJ	prep_of||degradation-13/NN||protein-17/NN	amod||protein-17/NN||similar-18/JJ	prep_in||similar-18/JJ||size-20/NN	det||protein-25/NN||the-22/DT	amod||protein-25/NN||rsv-23/JJ	dep||rsv-23/JJ||l-24/NN	nsubj||implicating-33/VBG||protein-25/NN	det||polymerase-31/NN||the-27/DT	amod||polymerase-31/NN||viral-28/JJ	amod||polymerase-31/NN||rna-dependent-29/JJ	nn||polymerase-31/NN||rna-30/NN	appos||protein-25/NN||polymerase-31/NN	prepc_to||similar-18/JJ||implicating-33/VBG	dobj||implicating-33/VBG||it-34/PRP	det||protein-39/NN||an-36/DT	amod||protein-39/NN||hsp90-37/JJ	nn||protein-39/NN||client-38/NN	prep_as||implicating-33/VBG||protein-39/NN	rsvinfection-9||rsv-23||no||mechanistic studies reveal that inhibition of hsp90 during rsvinfection leads to the degradation of a viral protein similar in size to the rsv l protein, the viral rna-dependent rna polymerase, implicating it as an hsp90 client protein.
nsubj||showed-5/VBD||typing-1/NNP	amod||isolates-4/NNS||leptospiral-3/JJ	prep_of||typing-1/NNP||isolates-4/NNS	root||ROOT-0/null||showed-5/VBD	mark||have-13/VBP||that-6/IN	amod||agents-8/NNS||causative-7/JJ	nsubj||have-13/VBP||agents-8/NNS	prep_of||agents-8/NNS||leptospirosis-10/NNS	prep_in||leptospirosis-10/NNS||mayotte-12/NN	ccomp||showed-5/VBD||have-13/VBP	amod||features-16/NNS||unique-14/JJ	amod||features-16/NNS||molecular-15/JJ	dobj||have-13/VBP||features-16/NNS	leptospirosis-10||leptospiral-3||no||typing of leptospiral isolates showed that causative agents of leptospirosis in mayotte have unique molecular features.
det||review-2/NN||this-1/DT	nsubj||considers-3/VBZ||review-2/NN	root||ROOT-0/null||considers-3/VBZ	amod||recommendations-5/NNS||current-4/JJ	dobj||considers-3/VBZ||recommendations-5/NNS	det||treatment-8/NN||the-7/DT	prep_for||recommendations-5/NNS||treatment-8/NN	prep_of||treatment-8/NN||oa-10/NN	det||evidence-15/NN||the-12/DT	advmod||evidence-15/NN||most-13/RBS	amod||evidence-15/NN||recent-14/JJ	dobj||considers-3/VBZ||evidence-15/NN	conj_and||recommendations-5/NNS||evidence-15/NN	det||risks-19/NNS||the-17/DT	amod||risks-19/NNS||cardiovascular-18/JJ	prep_on||evidence-15/NN||risks-19/NNS	vmod||risks-19/NNS||associated-20/VBN	amod||treatments-24/NNS||current-22/JJ	amod||treatments-24/NNS||nsaid-23/JJ	prep_with||associated-20/VBN||treatments-24/NNS	det||potential-28/NN||the-27/DT	dobj||considers-3/VBZ||potential-28/NN	conj_and||recommendations-5/NNS||potential-28/NN	amod||anti-inflammatoryagents-31/NNS||newer-30/JJR	prep_of||potential-28/NN||anti-inflammatoryagents-31/NNS	amod||profiles-35/NNS||improved-33/VBN	amod||profiles-35/NNS||benefit-risk-34/JJ	prep_with||anti-inflammatoryagents-31/NNS||profiles-35/NNS	anti-inflammatoryagents-31||oa-10||no_rel||this review considers current recommendations for the treatment of oa, the most recent evidence on the cardiovascular risks associated with current nsaid treatments, and the potential of newer anti-inflammatoryagents with improved benefit-risk profiles.
det||data-2/NNS||these-1/DT	nsubj||established-4/VBN||data-2/NNS	aux||established-4/VBN||have-3/VBP	root||ROOT-0/null||established-4/VBN	mark||prion-9/VBN||that-5/IN	amod||prions-7/NNS||kuru-6/JJ	nsubj||prion-9/VBN||prions-7/NNS	aux||prion-9/VBN||have-8/VBP	ccomp||established-4/VBN||prion-9/VBN	nn||properties-11/NNS||strain-10/NN	nsubj||equivalent-12/JJ||properties-11/NNS	xcomp||prion-9/VBN||equivalent-12/JJ	prep_to||equivalent-12/JJ||those-14/DT	amod||prions-29/NNS||classical-16/JJ	dep||prions-29/NNS||sporadic-18/JJ	conj_and||sporadic-18/JJ||iatrogenic-20/JJ	dep||prions-29/NNS||iatrogenic-20/JJ	amod||prions-29/NNS||cjd-22/JJ	nn||prions-29/NNS||prions-23/NNS	conj_but||prions-23/NNS||distinct-25/JJ	nn||prions-29/NNS||distinct-25/JJ	amod||cjd-28/NN||variant-27/JJ	prep_from||distinct-25/JJ||cjd-28/NN	prep_of||those-14/DT||prions-29/NNS	cjd-28||prions-29||no_rel||these data have established that kuru prions have prion strain properties equivalent to those of classical (sporadic and iatrogenic) cjd prions but distinct from variant cjd prions.
amod||levels-7/NNS||timp-1-1/JJ	conj_and||timp-1-1/JJ||timp-2-3/JJ	amod||levels-7/NNS||timp-2-3/JJ	conj_and||timp-1-1/JJ||timp-4-5/JJ	amod||levels-7/NNS||timp-4-5/JJ	nn||levels-7/NNS||serum-6/NN	nsubjpass||determined-9/VBN||levels-7/NNS	auxpass||determined-9/VBN||were-8/VBD	root||ROOT-0/null||determined-9/VBN	num||patients-12/NNS||53-11/CD	prep_in||determined-9/VBN||patients-12/NNS	prep_with||patients-12/NNS||ulcerativecolitis-14/NNS	appos||ulcerativecolitis-14/NNS||uc-16/NN	num||patients-20/NNS||52-19/CD	appos||ulcerativecolitis-14/NNS||patients-20/NNS	amod||cd-26/NNS||crohn-22/JJ	amod||cd-26/NNS||sdisease-24/JJ	prep_with||patients-20/NNS||cd-26/NNS	num||hc-30/NN||50-29/CD	prep_with||patients-20/NNS||hc-30/NN	conj_and||cd-26/NNS||hc-30/NN	advmod||available-36/JJ||commercially-35/RB	amod||assays-39/NNS||available-36/JJ	amod||assays-39/NNS||enzyme-linked-37/JJ	nn||assays-39/NNS||immunosorbent-38/NN	prep_by_means_of||determined-9/VBN||assays-39/NNS	ulcerativecolitis-14||hc-30||yes||timp-1, timp-2 and timp-4 serum levels were determined in 53 patients with ulcerativecolitis (uc), 52 patients with crohn'sdisease (cd) and 50 hc, by means of commercially available enzyme-linked immunosorbent assays.
nsubj||improved-2/VBD||statin-1/NN	root||ROOT-0/null||improved-2/VBD	amod||outcomes-4/NNS||clinical-3/JJ	dobj||improved-2/VBD||outcomes-4/NNS	advmod||improved-2/VBD||even-5/RB	nn||patients-8/NNS||ami-7/NN	prep_in||improved-2/VBD||patients-8/NNS	advmod||low-11/JJ||very-10/RB	amod||levels-13/NNS||low-11/JJ	amod||levels-13/NNS||ldl-c-12/JJ	prep_with||improved-2/VBD||levels-13/NNS	ami-7||statin-1||no_rel||statin improved clinical outcomes even in ami patients with very low ldl-c levels.
poss||laboratory-3/NN||our-2/PRP$	prep_in||address-6/VBP||laboratory-3/NN	nsubj||address-6/VBP||we-5/PRP	root||ROOT-0/null||address-6/VBP	advmod||unsettled-8/VBN||still-7/RB	amod||questions-9/NNS||unsettled-8/VBN	nsubj||ellipticine-47/VBP||questions-9/NNS	nsubj||mechanism-51/NN||questions-9/NNS	prep_of||ellipticine-47/VBP||mechanisms-13/NNS	prep_of||mechanisms-13/NNS||action-15/NN	amod||drugs-18/NNS||dna-damaging-17/JJ	prep_of||action-15/NN||drugs-18/NNS	nsubj||use-21/VBP||both-19/DT	advmod||use-21/VBP||currently-20/RB	rcmod||mechanisms-13/NNS||use-21/VBP	prep_for||use-21/VBP||treatment-23/NN	amod||neuroblastomas-26/NNS||human-25/JJ	prep_of||treatment-23/NN||neuroblastomas-26/NNS	dep||mechanisms-13/NNS||doxorubicin-28/NN	dep||mechanisms-13/NNS||cis-platin-30/NN	conj_and||doxorubicin-28/NN||cis-platin-30/NN	dep||mechanisms-13/NNS||cyclophosphamide-32/NN	conj_and||doxorubicin-28/NN||cyclophosphamide-32/NN	dep||mechanisms-13/NNS||etoposide-34/NN	conj_and||doxorubicin-28/NN||etoposide-34/NN	det||growth-41/NN||another-37/DT	amod||growth-41/NN||anticancer-38/JJ	nn||growth-41/NN||agent-39/NN	amod||growth-41/NN||decreasing-40/VBG	conj_and||mechanisms-13/NNS||growth-41/NN	prep_of||ellipticine-47/VBP||growth-41/NN	prep_of||growth-41/NN||neuroblastomas-43/NNS	prep_in||neuroblastomas-43/NNS||vitro-45/NNP	rcmod||questions-9/NNS||ellipticine-47/VBP	cop||mechanism-51/NN||are-49/VBP	amod||mechanism-51/NN||predominant-50/JJ	ccomp||address-6/VBP||mechanism-51/NN	dep||mechanism-51/NN||s-53/PRP	amod||mechanism-51/NN||responsible-55/JJ	poss||action-59/NN||their-57/PRP$	nn||action-59/NN||antitumor-58/NN	prep_for||responsible-55/JJ||action-59/NN	nn||lines-63/NNS||neuroblastoma-61/NN	nn||lines-63/NNS||cell-62/NN	prep_in||mechanism-51/NN||lines-63/NNS	prep_in||mechanism-51/NN||vitro-65/NN	neuroblastomas-43||etoposide-34||yes||in our laboratory, we address still unsettled questions, which of mechanisms of action of dna-damaging drugs both currently use for treatment of human neuroblastomas (doxorubicin, cis-platin, cyclophosphamide and etoposide) and another anticancer agent decreasing growth of neuroblastomas in vitro , ellipticine, are predominant mechanism(s) responsible for their antitumor action in neuroblastoma cell lines in vitro .
det||outcome-3/NN||the-1/DT	amod||outcome-3/NN||primary-2/JJ	nsubj||percentage-6/NN||outcome-3/NN	cop||percentage-6/NN||was-4/VBD	det||percentage-6/NN||the-5/DT	root||ROOT-0/null||percentage-6/NN	prep_of||percentage-6/NN||patients-8/NNS	prep_with||patients-8/NNS||vomiting-10/NN	amod||31â-17/NNS||0â-12/JJ	amod||31â-17/NNS||$-13/$	num||$-13/$||30-15/CD	prep_at||vomiting-10/NN||31â-17/NNS	dep||vomiting-10/NN||$-18/$	num||$-18/$||60-20/CD	dep||vomiting-10/NN||61â-23/NNS	conj_and||$-18/$||61â-23/NNS	num||minutes-27/NNS||$-24/$	num||$-24/$||120-26/CD	dep||61â-23/NNS||minutes-27/NNS	det||administration-30/NN||the-29/DT	prep_after||percentage-6/NN||administration-30/NN	prep_of||administration-30/NN||ondansetron-32/NN	prep_of||administration-30/NN||prochlorperazine-34/NN	conj_or||ondansetron-32/NN||prochlorperazine-34/NN	vomiting-10||prochlorperazine-34||yes||the primary outcome was the percentage of patients with vomiting at 0â€“30, 31â€“60, and 61â€“120 minutes after the administration of ondansetron or prochlorperazine.
det||analysis-2/NN||the-1/DT	nsubj||included-3/VBD||analysis-2/NN	root||ROOT-0/null||included-3/VBD	num||studies-8/NNS||three-4/CD	amod||studies-8/NNS||randomized-5/JJ	amod||studies-8/NNS||double-blind-7/JJ	dobj||included-3/VBD||studies-8/NNS	prep_in||studies-8/NNS||patients-10/NNS	prep_with||patients-10/NNS||schizophrenia-12/NN	amod||disorder-15/NN||schizoaffective-14/JJ	dobj||included-3/VBD||disorder-15/NN	conj_or||studies-8/NNS||disorder-15/NN	nn||disorder-19/NN||schizophreniform-18/NN	dobj||included-3/VBD||disorder-19/NN	conj_or||studies-8/NNS||disorder-19/NN	dep||disorder-19/NN||diagnosed-20/VBN	prepc_according_to||diagnosed-20/VBN||to-22/TO	det||manual-27/NN||the-23/DT	amod||manual-27/NN||diagnostic-24/JJ	conj_and||diagnostic-24/JJ||statistical-26/JJ	amod||manual-27/NN||statistical-26/JJ	pobj||diagnosed-20/VBN||manual-27/NN	amod||disorders-30/NNS||mental-29/JJ	npadvmod||4th-31/JJ||disorders-30/NNS	amod||edition-32/NN||4th-31/JJ	prep_of||manual-27/NN||edition-32/NN	advmod||assigned-35/VBN||randomly-34/RB	dep||disorder-19/NN||assigned-35/VBN	conj_and||diagnosed-20/VBN||assigned-35/VBN	prep_to||assigned-35/VBN||treatment-37/NN	poss||mg/day-44/NN||olanzapine-39/PRP$	amod||mg/day-44/NN||5â-40/JJ	amod||mg/day-44/NN||$-41/$	num||$-41/$||20-43/CD	prep_with||assigned-35/VBN||mg/day-44/NN	det||antipsychotic-47/NN||another-46/DT	prep_with||assigned-35/VBN||antipsychotic-47/NN	conj_or||mg/day-44/NN||antipsychotic-47/NN	amod||2â-50/NNS||haloperidol-49/JJ	dep||antipsychotic-47/NN||2â-50/NNS	num||mg/day-54/NN||$-51/$	num||$-51/$||20-53/CD	dep||2â-50/NNS||mg/day-54/NN	poss||mg/day-61/NN||risperidone-56/PRP$	amod||mg/day-61/NN||2â-57/JJ	amod||mg/day-61/NN||$-58/$	num||$-58/$||10-60/CD	dep||2â-50/NNS||mg/day-61/NN	conj_or||mg/day-54/NN||mg/day-61/NN	poss||mg/day-69/NN||ziprasidone-64/PRP$	amod||mg/day-69/NN||80â-65/JJ	amod||mg/day-69/NN||$-66/$	num||$-66/$||160-68/CD	dep||2â-50/NNS||mg/day-69/NN	conj_or||mg/day-54/NN||mg/day-69/NN	schizophrenia-12||haloperidol-49||yes||the analysis included three randomized, double-blind studies in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder diagnosed according to the diagnostic and statistical manual of mental disorders 4th edition and randomly assigned to treatment with olanzapine 5â€“20 mg/day or another antipsychotic (haloperidol 2â€“20 mg/day, risperidone 2â€“10 mg/day, or ziprasidone 80â€“160 mg/day).
nn||predictors-2/NNS||baseline-1/NN	nsubjpass||identified-56/VBN||predictors-2/NNS	prep_of||predictors-2/NNS||level-4/NN	amod||acuity-7/NN||visual-6/JJ	prep_of||level-4/NN||acuity-7/NN	dep||acuity-7/NN||age-9/NN	amod||amd-13/NN||age-relatedmaculardegeneration-11/JJ	dep||acuity-7/NN||amd-13/NN	conj_and||age-9/NN||amd-13/NN	dep||acuity-7/NN||cataract-16/NN	conj_and||age-9/NN||cataract-16/NN	dep||acuity-7/NN||living-18/NN	conj_and||age-9/NN||living-18/NN	advmod||living-18/NN||alone-19/RB	amod||health-23/NN||low-21/JJ	amod||health-23/NN||self-rated-22/JJ	dep||acuity-7/NN||health-23/NN	conj_and||age-9/NN||health-23/NN	amod||life-style-27/NN||sedentary-26/JJ	dep||acuity-7/NN||life-style-27/NN	conj_and||age-9/NN||life-style-27/NN	prep_of||predictors-2/NNS||speed-30/NN	conj_and||level-4/NN||speed-30/NN	amod||loss-34/NN||continued-32/VBN	amod||loss-34/NN||visual-33/JJ	prep_of||speed-30/NN||loss-34/NN	nn||dr-42/NN||age-36/NN	dep||dr-42/NN||amd-38/NN	dep||dr-42/NN||diabeticretinopathy-40/NN	dep||loss-34/NN||dr-42/NN	appos||dr-42/NN||cataract-45/NN	appos||dr-42/NN||living-47/NN	conj_and||cataract-45/NN||living-47/NN	advmod||living-47/NN||alone-48/RB	amod||triglycerides-53/NNPS||high-51/JJ	amod||triglycerides-53/NNPS||fasting-52/VBG	appos||dr-42/NN||triglycerides-53/NNPS	conj_and||cataract-45/NN||triglycerides-53/NNPS	auxpass||identified-56/VBN||were-55/VBD	root||ROOT-0/null||identified-56/VBN	speed-30||cataract-45||no_rel||baseline predictors of level of visual acuity (age, age-relatedmaculardegeneration (amd), cataract, living alone, low self-rated health, and sedentary life-style) and speed of continued visual loss (age, amd, diabeticretinopathy (dr), cataract, living alone, and high fasting triglycerides) were identified.
det||observations-2/NNS||these-1/DT	nsubj||call-3/VBP||observations-2/NNS	nsubj||assess-8/VB||observations-2/NNS	root||ROOT-0/null||call-3/VBP	amod||studies-6/NNS||further-5/JJ	prep_for||call-3/VBP||studies-6/NNS	aux||assess-8/VB||to-7/TO	xcomp||call-3/VBP||assess-8/VB	det||effectiveness-10/NN||the-9/DT	dobj||assess-8/VB||effectiveness-10/NN	prep_of||effectiveness-10/NN||fishoil-12/NN	det||supplement-16/NN||a-14/DT	amod||supplement-16/NN||dietary-15/JJ	prep_as||assess-8/VB||supplement-16/NN	det||prevention-19/NN||the-18/DT	prep_in||supplement-16/NN||prevention-19/NN	prep_in||supplement-16/NN||treatment-21/NN	conj_and||prevention-19/NN||treatment-21/NN	amod||cancer-25/NN||human-23/JJ	nn||cancer-25/NN||breast-24/NN	prep_of||prevention-19/NN||cancer-25/NN	fishoil-12||cancer-25||no_rel||these observations call for further studies to assess the effectiveness of fishoil as a dietary supplement in the prevention and treatment of human breast cancer.
amod||mice-4/NNS||db/db-2/JJ	amod||mice-4/NNS||diabetic-3/JJ	prep_in||aggravated-10/VBN||mice-4/NNS	det||lack-7/NN||the-6/DT	nsubj||aggravated-10/VBN||lack-7/NN	nsubj||diminished-19/VBN||lack-7/NN	prep_of||lack-7/NN||adiponectin-9/NN	root||ROOT-0/null||aggravated-10/VBN	det||decrease-13/NN||the-11/DT	amod||decrease-13/NN||hyperglycemia-induced-12/JJ	dobj||aggravated-10/VBN||decrease-13/NN	prepc_in||aggravated-10/VBN||circulating-15/VBG	dobj||circulating-15/VBG||epcs-16/NNS	advmod||diminished-19/VBN||also-18/RB	conj_and||aggravated-10/VBN||diminished-19/VBN	det||effects-22/NNS||the-20/DT	amod||effects-22/NNS||stimulatory-21/JJ	dobj||diminished-19/VBN||effects-22/NNS	det||rosiglitazone-28/NN||the-24/DT	amod||rosiglitazone-28/NN||pparî-25/JJ	amod||rosiglitazone-28/NN||³-26/JJ	nn||rosiglitazone-28/NN||agonist-27/NN	prep_of||effects-22/NNS||rosiglitazone-28/NN	nn||production-31/NN||epc-30/NN	prep_on||rosiglitazone-28/NN||production-31/NN	prep_on||rosiglitazone-28/NN||reendothelialization-33/NN	conj_and||production-31/NN||reendothelialization-33/NN	hyperglycemia--1||rosiglitazone-28||no_rel||in db/db diabetic mice, the lack of adiponectin aggravated the hyperglycemia-induced decrease in circulating epcs and also diminished the stimulatory effects of the pparî³ agonist rosiglitazone on epc production and reendothelialization.
amod||production-3/NN||diabetes-induced-1/JJ	nn||production-3/NN||superoxide-2/NN	nsubj||inhibited-9/JJ||production-3/NN	amod||fibrosis-6/NN||cardiac-5/JJ	conj_and||production-3/NN||fibrosis-6/NN	nsubj||inhibited-9/JJ||fibrosis-6/NN	cop||inhibited-9/JJ||were-7/VBD	advmod||inhibited-9/JJ||partially-8/RB	root||ROOT-0/null||inhibited-9/JJ	prep_by||inhibited-9/JJ||candesartan-11/NN	prep_by||inhibited-9/JJ||benazepril-13/NN	conj_and||candesartan-11/NN||benazepril-13/NN	mark||produced-17/VBD||whereas-15/IN	nsubj||produced-17/VBD||aliskiren-16/NN	advcl||inhibited-9/JJ||produced-17/VBD	amod||inhibition-19/NN||complete-18/JJ	dobj||produced-17/VBD||inhibition-19/NN	fibrosis-6||candesartan-11||no_rel||diabetes-induced superoxide production and cardiac fibrosis were partially inhibited by candesartan and benazepril, whereas aliskiren produced complete inhibition.
prep_in||introduced-10/VBD||2001-2/CD	det||service-6/NN||the-3/DT	amod||service-6/NN||national-4/JJ	nn||service-6/NN||health-5/NN	nsubj||introduced-10/VBD||service-6/NN	det||uk-9/NN||the-8/DT	prep_in||service-6/NN||uk-9/NN	root||ROOT-0/null||introduced-10/VBD	det||scheme-15/NN||a-11/DT	amod||scheme-15/NN||mandatory-12/JJ	nn||scheme-15/NN||bacteraemia-13/NN	nn||scheme-15/NN||surveillance-14/NN	dobj||introduced-10/VBD||scheme-15/NN	det||reporting-18/NN||the-17/DT	prep_for||introduced-10/VBD||reporting-18/NN	prep_of||reporting-18/NN||s.aureus-20/NNS	amod||s.aureus-23/NNS||methicillin-resistant-22/JJ	prep_for||introduced-10/VBD||s.aureus-23/NNS	conj_and||reporting-18/NN||s.aureus-23/NNS	nn||-rrb--26/NNP||-lrb--24/NNP	nn||-rrb--26/NNP||mrsa-25/NNP	dep||s.aureus-23/NNS||-rrb--26/NNP	mrsa-25||s.aureus-23||no||in 2001 the national health service in the uk introduced a mandatory bacteraemia surveillance scheme for the reporting of s.aureus and methicillin-resistant s.aureus -lrb- mrsa -rrb- .
expl||are-2/VBP||there-1/EX	root||ROOT-0/null||are-2/VBP	num||molâecules-7/NNS||two-3/CD	amod||molâecules-7/NNS||uncoordinated-4/JJ	amod||molâecules-7/NNS||acetonitrile-5/JJ	amod||molâecules-7/NNS||solvent-6/JJ	nsubj||are-2/VBP||molâecules-7/NNS	prep_per||molâecules-7/NNS||molâecule-9/NN	nn||compound-12/NN||title-11/NN	prep_of||molâecule-9/NN||compound-12/NN	det||structure-16/NN||the-14/DT	nn||structure-16/NN||crystal-15/NN	prep_in||compound-12/NN||structure-16/NN	crystal-15||uncoordinated-4||no_rel||there are two uncoordinated acetonitrile solvent molâ­ecules per molâ­ecule of title compound in the crystal structure.
amod||foods-2/NNS||whole-grain-1/JJ	nsubjpass||touted-4/VBN||foods-2/NNS	auxpass||touted-4/VBN||are-3/VBP	root||ROOT-0/null||touted-4/VBN	amod||benefits-8/NNS||multiple-6/JJ	nn||benefits-8/NNS||health-7/NN	prep_for||touted-4/VBN||benefits-8/NNS	prepc_including||touted-4/VBN||enhancing-11/VBG	nn||sensitivity-13/NN||insulin-12/NN	dobj||enhancing-11/VBG||sensitivity-13/NN	prepc_including||touted-4/VBN||reducing-15/VBG	conj_and||enhancing-11/VBG||reducing-15/VBG	amod||risk-17/NN||type2diabetes-16/JJ	dobj||reducing-15/VBG||risk-17/NN	type2diabetes-16||insulin-12||yes||whole-grain foods are touted for multiple health benefits, including enhancing insulin sensitivity and reducing type2diabetes risk.
advmod||were-6/VBD||however-1/RB	amod||titers-5/NNS||anti-env-3/JJ	nn||titers-5/NNS||antibody-4/NN	nsubj||were-6/VBD||titers-5/NNS	root||ROOT-0/null||were-6/VBD	amod||higher-9/JJR||4-fold-8/JJ	prep_over||were-6/VBD||higher-9/JJR	prep_in||higher-9/JJR||ham/tsp-11/NN	prepc_compared_to||were-6/VBD||to-13/TO	det||htlv-i-16/NN||both-14/DT	amod||htlv-i-16/NN||asymptomatic-15/JJ	pobj||were-6/VBD||htlv-i-16/NN	appos||htlv-i-16/NN||p-18/NNP	number||0.0001-20/CD||<-19/CD	num||p-18/NNP||0.0001-20/CD	amod||patients-24/NNS||atll-23/JJ	pobj||were-6/VBD||patients-24/NNS	conj_and||htlv-i-16/NN||patients-24/NNS	appos||htlv-i-16/NN||p-26/NNP	number||0.0005-28/CD||<-27/CD	num||p-26/NNP||0.0005-28/CD	antibody-4||ham--1||no_rel||however, anti-env antibody titers were over 4-fold higher in ham/tsp compared to both asymptomatic htlv-i ( p < 0.0001) and atll patients ( p < 0.0005).
det||aim-2/NN||the-1/DT	nsubj||is-6/VBZ||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||paper-5/NN||this-4/DT	prep_of||aim-2/NN||paper-5/NN	root||ROOT-0/null||is-6/VBZ	aux||evaluate-8/VB||to-7/TO	xcomp||is-6/VBZ||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	prep_of||effect-10/NN||antipsychotics-12/NNS	det||treatment-15/NN||the-14/DT	prep_for||antipsychotics-12/NNS||treatment-15/NN	prep_of||treatment-15/NN||schizophrenia-17/NN	det||community-20/NN||a-19/DT	prep_in||evaluate-8/VB||community-20/NN	vmod||community-20/NN||based-21/VBN	dobj||based-21/VBN||study-22/NN	amod||function-25/NN||sexual-24/JJ	prep_on||based-21/VBN||function-25/NN	nn||levels-28/NNS||prolactin-27/NN	prep_on||based-21/VBN||levels-28/NNS	conj_and||function-25/NN||levels-28/NNS	vmod||function-25/NN||comparing-29/VBG	det||use-31/NN||the-30/DT	dobj||comparing-29/VBG||use-31/NN	prep_of||use-31/NN||aripiprazole-33/NN	prep_of||use-31/NN||standard-35/NN	conj_and||aripiprazole-33/NN||standard-35/NN	prep_of||use-31/NN||care-37/NN	nsubj||choice-46/NN||care-37/NN	appos||care-37/NN||soc-39/NN	cop||choice-46/NN||was-43/VBD	det||choice-46/NN||a-44/DT	amod||choice-46/NN||limited-45/JJ	rcmod||care-37/NN||choice-46/NN	num||antipsychotics-53/NNS||three-48/CD	advmod||used-50/JJ||widely-49/RB	amod||antipsychotics-53/NNS||used-50/JJ	conj_and||used-50/JJ||available-52/JJ	amod||antipsychotics-53/NNS||available-52/JJ	prep_of||choice-46/NN||antipsychotics-53/NNS	dep||antipsychotics-53/NNS||olanzapine-55/NN	dep||olanzapine-55/NN||quetiapine-57/JJ	dep||olanzapine-55/NN||risperidone-59/JJ	conj_or||quetiapine-57/JJ||risperidone-59/JJ	det||trial-64/NN||the-62/DT	nn||trial-64/NN||schizophrenia-63/NN	dep||antipsychotics-53/NNS||trial-64/NN	amod||-RSB--73/NNS||aripiprazole-66/JJ	nn||-RSB--73/NNS||-LSB--67/NNP	nn||-RSB--73/NNS||star-68/NN	nn||-RSB--73/NNS||-RSB--69/NN	nn||-RSB--73/NNS||study-70/NN	nn||-RSB--73/NNS||-LSB--71/NN	amod||-RSB--73/NNS||nct00237913-72/JJ	prep_of||trial-64/NN||-RSB--73/NNS	schizophrenia-63||risperidone-59||yes||the aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (soc), which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone) (the schizophrenia trial of aripiprazole [star] study [nct00237913]).
nn||women-2/NNS||participants-1/NNS	nsubj||aged-3/VBN||women-2/NNS	root||ROOT-0/null||aged-3/VBN	num||years-5/NNS||15-44-4/CD	tmod||aged-3/VBN||years-5/NNS	amod||factors-9/NNS||major-7/JJ	nn||factors-9/NNS||risk-8/NN	prep_without||aged-3/VBN||factors-9/NNS	nsubj||started-14/VBD||factors-9/NNS	amod||thromboembolism-12/NN||venous-11/JJ	prep_for||factors-9/NNS||thromboembolism-12/NN	rcmod||factors-9/NNS||started-14/VBD	det||episode-17/NN||a-15/DT	amod||episode-17/NN||new-16/JJ	dobj||started-14/VBD||episode-17/NN	prep_of||episode-17/NN||use-19/NN	det||oralcontraceptive-22/NN||an-21/DT	prep_of||use-19/NN||oralcontraceptive-22/NN	vmod||oralcontraceptive-22/NN||containing-23/VBG	num||oestrogen-26/NN||30-24/CD	nn||oestrogen-26/NN||âµg-25/NN	dobj||containing-23/VBG||oestrogen-26/NN	prep_in||oestrogen-26/NN||combination-28/NN	preconj||drospirenone-31/NN||either-30/DT	prep_with||containing-23/VBG||drospirenone-31/NN	prep_with||containing-23/VBG||levonorgestrel-33/NN	conj_or||drospirenone-31/NN||levonorgestrel-33/NN	aux||2002-36/VB||may-35/MD	prep_between||drospirenone-31/NN||2002-36/VB	prep_between||drospirenone-31/NN||september-38/NNP	conj_and||2002-36/VB||september-38/NNP	num||september-38/NNP||2009-39/CD	thromboembolism-12||drospirenone-31||no||participants women aged 15-44 years without major risk factors for venous thromboembolism who started a new episode of use of an oralcontraceptive containing 30 âµg oestrogen in combination with either drospirenone or levonorgestrel between may 2002 and september 2009.
csubj||be-44/VB||based-1/VBN	det||study-4/NN||this-3/DT	prep_on||based-1/VBN||study-4/NN	prep_on||based-1/VBN||ceftriaxone-6/NN	conj_and||study-4/NN||ceftriaxone-6/NN	prep_on||based-1/VBN||cefixime-8/NN	conj_and||study-4/NN||cefixime-8/NN	prep_on||based-1/VBN||spectinomycin-11/NN	conj_and||study-4/NN||spectinomycin-11/NN	aux||used-14/VBN||can-12/MD	auxpass||used-14/VBN||be-13/VB	rcmod||study-4/NN||used-14/VBN	det||therapy-19/NN||an-16/DT	amod||therapy-19/NN||empirical-17/JJ	amod||therapy-19/NN||first-line-18/JJ	prep_as||used-14/VBN||therapy-19/NN	prep_for||therapy-19/NN||gonorrhoea-21/NN	prep_in||used-14/VBN||india-23/NN	prep_in||used-14/VBN||pakistan-25/NN	conj_and||india-23/NN||pakistan-25/NN	prep_in||used-14/VBN||bhutan-28/NN	conj_and||india-23/NN||bhutan-28/NN	amod||ciprofloxacin-31/NN||whereas-30/JJ	prep_in||used-14/VBN||ciprofloxacin-31/NN	conj_and||india-23/NN||ciprofloxacin-31/NN	nn||g-34/NN||penicillin-33/NN	prep_in||used-14/VBN||g-34/NN	conj_and||india-23/NN||g-34/NN	prep_in||used-14/VBN||tetracycline-36/NN	conj_and||india-23/NN||tetracycline-36/NN	prep_in||used-14/VBN||erythromycin-38/NN	conj_and||india-23/NN||erythromycin-38/NN	prep_in||used-14/VBN||azithromycin-41/NN	conj_and||india-23/NN||azithromycin-41/NN	aux||be-44/VB||should-42/MD	neg||be-44/VB||not-43/RB	root||ROOT-0/null||be-44/VB	gonorrhoea-21||cefixime-8||yes||based on this study, ceftriaxone, cefixime, and spectinomycin can be used as an empirical first-line therapy for gonorrhoea in india, pakistan, and bhutan, whereas ciprofloxacin, penicillin g, tetracycline, erythromycin, and azithromycin should not be.
nsubjpass||proven-4/VBN||sitagliptin-1/NN	nsubj||effective-7/JJ||sitagliptin-1/NN	nsubj||safe-9/JJ||sitagliptin-1/NN	aux||proven-4/VBN||has-2/VBZ	auxpass||proven-4/VBN||been-3/VBN	root||ROOT-0/null||proven-4/VBN	aux||effective-7/JJ||to-5/TO	cop||effective-7/JJ||be-6/VB	xcomp||proven-4/VBN||effective-7/JJ	xcomp||proven-4/VBN||safe-9/JJ	conj_and||effective-7/JJ||safe-9/JJ	prepc_as||effective-7/JJ||add-on-11/VBG	prep_to||add-on-11/VBG||insulin-13/NN	amod||patients-16/NNS||adult-15/JJ	prep_in||insulin-13/NN||patients-16/NNS	prep_with||add-on-11/VBG||type2diabetes-18/NNS	amod||deficiency-22/NN||absolute-20/JJ	nn||deficiency-22/NN||insulin-21/NN	prep_with||add-on-11/VBG||deficiency-22/NN	conj_and||type2diabetes-18/NNS||deficiency-22/NN	type2diabetes-18||sitagliptin-1||yes||sitagliptin has been proven to be effective and safe as add-on to insulin in adult patients with type2diabetes and absolute insulin deficiency.
num||injections-2/NNS||three-1/CD	root||ROOT-0/null||injections-2/NNS	det||vaccine-5/NN||the-4/DT	prep_of||injections-2/NNS||vaccine-5/NN	vmod||vaccine-5/NN||induced-6/VBN	amod||titers-8/NNS||high-7/JJ	dobj||induced-6/VBN||titers-8/NNS	amod||antibodies-11/NNS||virus-neutralizing-10/JJ	prep_of||titers-8/NNS||antibodies-11/NNS	advmod||protected-15/VBN||completely-14/RB	amod||mice-16/NNS||protected-15/VBN	prep_of||injections-2/NNS||mice-16/NNS	conj_and||vaccine-5/NN||mice-16/NNS	nn||infection-19/NN||wnv-18/NN	prep_from||mice-16/NNS||infection-19/NN	virus--1||antibodies-11||no_rel||three injections of the vaccine induced high titers of virus-neutralizing antibodies, and completely protected mice from wnv infection.
nsubj||compared-2/VBD||we-1/PRP	root||ROOT-0/null||compared-2/VBD	det||performances-4/NNS||the-3/DT	nsubj||assays-14/VBZ||performances-4/NNS	num||test-10/NN||3-6/CD	amod||test-10/NN||multiple-7/JJ	amod||test-10/NN||allergen-8/JJ	amod||test-10/NN||simultaneous-9/JJ	prep_of||performances-4/NNS||test-10/NN	appos||test-10/NN||mast-12/NN	ccomp||compared-2/VBD||assays-14/VBZ	nn||screen-17/NN||rida-15/NN	nn||screen-17/NN||allergy-16/NN	dobj||assays-14/VBZ||screen-17/NN	nn||germany-23/NN||r-biopharm-19/NN	dep||germany-23/NN||darmstadt-21/NN	appos||screen-17/NN||germany-23/NN	amod||system-29/NN||mast-26/JJ	nn||system-29/NN||optigen-27/NN	nn||system-29/NN||allergy-28/NN	appos||screen-17/NN||system-29/NN	amod||diagnostics-33/NNS||hitachi-31/JJ	nn||diagnostics-33/NNS||chemical-32/NN	nsubj||ca-38/MD||diagnostics-33/NNS	nn||view-36/NN||mountain-35/NN	appos||diagnostics-33/NNS||view-36/NN	dep||screen-17/NN||ca-38/MD	amod||allergy-43/NN||polycheck-42/VBG	dobj||assays-14/VBZ||allergy-43/NN	conj_and||screen-17/NN||allergy-43/NN	nn||gmbh-46/NN||biocheck-45/NN	appos||allergy-43/NN||gmbh-46/NN	dep||gmbh-46/NN||munster-48/NN	dep||gmbh-46/NN||germany-50/NN	allergy-43||allergy-43||no||we compared the performances of 3 multiple allergen simultaneous test (mast) assays rida allergy screen (r-biopharm, darmstadt, germany), mast optigen allergy system (hitachi chemical diagnostics, mountain view, ca), and polycheck allergy (biocheck gmbh, munster, germany).
nsubjpass||diagnosed-3/VBN||hiv-rols-1/NNS	auxpass||diagnosed-3/VBN||were-2/VBD	root||ROOT-0/null||diagnosed-3/VBN	dep||diagnosed-3/VBN||clinically-4/RB	det||clearinghouse-8/NN||the-6/DT	nn||clearinghouse-8/NN||eec-7/NN	prep_by||clinically-4/RB||clearinghouse-8/NN	amod||problems-11/NNS||oral-10/JJ	prep_on||clearinghouse-8/NN||problems-11/NNS	advmod||diagnosed-3/VBN||related-12/VBN	prep_to||related-12/VBN||hivinfection-14/NN	hivinfection-14||hiv--1||no||hiv-rols were diagnosed clinically by the eec clearinghouse on oral problems related to hivinfection.
prep_in||tolerated-11/VBN||patients-2/NNS	prep_with||patients-2/NNS||type2diabetes-4/CD	nsubjpass||tolerated-11/VBN||sitagliptin-6/NN	num||sitagliptin-6/NN||100-7/CD	advmod||tolerated-11/VBN||mg/day-8/RB	auxpass||tolerated-11/VBN||was-9/VBD	advmod||tolerated-11/VBN||well-10/RB	root||ROOT-0/null||tolerated-11/VBN	amod||trials-14/NNS||clinical-13/JJ	prep_in||tolerated-11/VBN||trials-14/NNS	quantmod||2-17/CD||up-15/IN	dep||2-17/CD||to-16/TO	num||years-18/NNS||2-17/CD	npadvmod||tolerated-11/VBN||years-18/NNS	prep_in||tolerated-11/VBN||duration-20/NN	type2diabetes-4||sitagliptin-6||yes||in patients with type2diabetes, sitagliptin 100 mg/day was well tolerated in clinical trials up to 2 years in duration.
advmod||healthy-3/JJ||eighty-1/RB	advmod||healthy-3/JJ||otherwise-2/RB	amod||women-4/NNS||healthy-3/JJ	nsubjpass||assigned-32/VBN||women-4/NNS	nsubj||receive-34/VB||women-4/NNS	vmod||women-4/NNS||aged-5/VBN	number||85-8/CD||18-6/CD	dep||85-8/CD||to-7/TO	num||years-9/NNS||85-8/CD	tmod||aged-5/VBN||years-9/NNS	conj_and||presenting-11/VBG||presenting-11/VBG	vmod||assigned-32/VBN||presenting-11/VBG	vmod||assigned-32/VBN||presenting-11/VBG	quantmod||one-15/CD||at-13/IN	mwe||at-13/IN||least-14/JJS	pobj||at-13/IN||least-14/JJS	prep_with||presenting-11/VBG||one-15/CD	det||dysuria-21/NN||the-17/DT	amod||dysuria-21/NN||main-18/JJ	nn||dysuria-21/NN||uti-19/NN	nn||dysuria-21/NN||symptoms-20/NNS	prep_of||one-15/CD||dysuria-21/NN	prep_of||one-15/CD||frequency-23/NN	conj_and||dysuria-21/NN||frequency-23/NN	det||factors-28/NNS||any-26/DT	amod||factors-28/NNS||complicating-27/VBG	prep_without||presenting-11/VBG||factors-28/NNS	auxpass||assigned-32/VBN||were-30/VBD	advmod||assigned-32/VBN||randomly-31/RB	root||ROOT-0/null||assigned-32/VBN	aux||receive-34/VB||to-33/TO	xcomp||assigned-32/VBN||receive-34/VB	det||ibuprofen-36/NN||either-35/DT	dobj||receive-34/VB||ibuprofen-36/NN	num||ã-38/NN||3-37/CD	dep||ibuprofen-36/NN||ã-38/NN	num||mg-41/NNS||400-40/CD	dep||ibuprofen-36/NN||mg-41/NNS	amod||mg-41/NNS||oral-42/JJ	nn||ã-46/NN||ciprofloxacin-44/NN	num||ã-46/NN||2-45/CD	dep||ibuprofen-36/NN||ã-46/NN	conj_or||mg-41/NNS||ã-46/NN	num||mg-49/NN||250-48/CD	dep||ibuprofen-36/NN||mg-49/NN	number||placebo-52/CD||+1-51/CD	dep||mg-49/NN||placebo-52/CD	dep||mg-49/NN||oral-54/JJ	appos||ibuprofen-36/NN||both-56/DT	num||days-59/NNS||three-58/CD	prep_for||both-56/DT||days-59/NNS	uti-19||ciprofloxacin-44||yes||eighty otherwise healthy women aged 18 to 85 years, presenting with at least one of the main uti symptoms dysuria and frequency and without any complicating factors, were randomly assigned to receive either ibuprofen 3 ã— 400 mg oral or ciprofloxacin 2 ã— 250 mg (+1 placebo) oral, both for three days.
det||therapies-3/NNS||the-1/DT	amod||therapies-3/NNS||incretin-based-2/JJ	nsubj||stimulate-4/VB||therapies-3/NNS	nsubj||inhibit-8/VB||therapies-3/NNS	nsubj||carry-16/VB||therapies-3/NNS	root||ROOT-0/null||stimulate-4/VB	nn||secretion-6/NN||insulin-5/NN	dobj||stimulate-4/VB||secretion-6/NN	conj_and||stimulate-4/VB||inhibit-8/VB	nn||secretion-10/NN||glucagon-9/NN	dobj||inhibit-8/VB||secretion-10/NN	det||manner-14/NN||a-12/DT	amod||manner-14/NN||glucose-dependent-13/JJ	prep_in||inhibit-8/VB||manner-14/NN	conj_and||stimulate-4/VB||carry-16/VB	neg||risk-19/NN||no-17/DT	amod||risk-19/NN||intrinsic-18/JJ	dobj||carry-16/VB||risk-19/NN	prep_of||risk-19/NN||hypoglycaemia-21/NN	hypoglycaemia-21||glucagon-9||yes||the incretin-based therapies stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner and carry no intrinsic risk of hypoglycaemia.
poss||study-2/NN||our-1/PRP$	nsubj||indicate-7/VBP||study-2/NN	nsubj||suggest-18/VBP||study-2/NN	amod||reports-6/NNS||recent-4/JJ	amod||reports-6/NNS||epidemiological-5/JJ	conj_and||study-2/NN||reports-6/NNS	nsubj||indicate-7/VBP||reports-6/NNS	root||ROOT-0/null||indicate-7/VBP	mark||threat-14/NN||that-8/IN	nsubj||threat-14/NN||hiv-1-9/JJ	cop||threat-14/NN||is-10/VBZ	advmod||threat-14/NN||still-11/RB	det||threat-14/NN||a-12/DT	amod||threat-14/NN||major-13/JJ	ccomp||indicate-7/VBP||threat-14/NN	prep_in||threat-14/NN||thailand-16/NN	conj_and||indicate-7/VBP||suggest-18/VBP	mark||strengthened-27/VBN||that-19/IN	nn||awareness-21/NN||hiv-20/NN	nsubjpass||strengthened-27/VBN||awareness-21/NN	nsubj||avoid-29/VB||awareness-21/NN	nn||needs-24/NNS||prevention-23/NN	conj_and||awareness-21/NN||needs-24/NNS	nsubjpass||strengthened-27/VBN||needs-24/NNS	nsubj||avoid-29/VB||needs-24/NNS	aux||strengthened-27/VBN||to-25/TO	auxpass||strengthened-27/VBN||be-26/VB	ccomp||suggest-18/VBP||strengthened-27/VBN	xcomp||suggest-18/VBP||strengthened-27/VBN	aux||avoid-29/VB||to-28/TO	xcomp||strengthened-27/VBN||avoid-29/VB	nn||resurgence-31/NN||aids-30/NNS	dobj||avoid-29/VB||resurgence-31/NN	aids-30||hiv-20||no||our study and recent epidemiological reports indicate that hiv-1 is still a major threat in thailand and suggest that hiv awareness and prevention needs to be strengthened to avoid aids resurgence.
csubj||be-44/VB||based-1/VBN	det||study-4/NN||this-3/DT	prep_on||based-1/VBN||study-4/NN	prep_on||based-1/VBN||ceftriaxone-6/NN	conj_and||study-4/NN||ceftriaxone-6/NN	prep_on||based-1/VBN||cefixime-8/NN	conj_and||study-4/NN||cefixime-8/NN	prep_on||based-1/VBN||spectinomycin-11/NN	conj_and||study-4/NN||spectinomycin-11/NN	aux||used-14/VBN||can-12/MD	auxpass||used-14/VBN||be-13/VB	rcmod||study-4/NN||used-14/VBN	det||therapy-19/NN||an-16/DT	amod||therapy-19/NN||empirical-17/JJ	amod||therapy-19/NN||first-line-18/JJ	prep_as||used-14/VBN||therapy-19/NN	prep_for||therapy-19/NN||gonorrhoea-21/NN	prep_in||used-14/VBN||india-23/NN	prep_in||used-14/VBN||pakistan-25/NN	conj_and||india-23/NN||pakistan-25/NN	prep_in||used-14/VBN||bhutan-28/NN	conj_and||india-23/NN||bhutan-28/NN	amod||ciprofloxacin-31/NN||whereas-30/JJ	prep_in||used-14/VBN||ciprofloxacin-31/NN	conj_and||india-23/NN||ciprofloxacin-31/NN	nn||g-34/NN||penicillin-33/NN	prep_in||used-14/VBN||g-34/NN	conj_and||india-23/NN||g-34/NN	prep_in||used-14/VBN||tetracycline-36/NN	conj_and||india-23/NN||tetracycline-36/NN	prep_in||used-14/VBN||erythromycin-38/NN	conj_and||india-23/NN||erythromycin-38/NN	prep_in||used-14/VBN||azithromycin-41/NN	conj_and||india-23/NN||azithromycin-41/NN	aux||be-44/VB||should-42/MD	neg||be-44/VB||not-43/RB	root||ROOT-0/null||be-44/VB	gonorrhoea-21||spectinomycin-11||yes||based on this study, ceftriaxone, cefixime, and spectinomycin can be used as an empirical first-line therapy for gonorrhoea in india, pakistan, and bhutan, whereas ciprofloxacin, penicillin g, tetracycline, erythromycin, and azithromycin should not be.
nn||guidelines-2/NNS||hypertension-1/NN	nsubj||recommend-3/VBP||guidelines-2/NNS	root||ROOT-0/null||recommend-3/VBP	det||use-5/NN||the-4/DT	dobj||recommend-3/VBP||use-5/NN	prep_of||use-5/NN||thiazidediuretics-7/NNS	amod||therapy-10/NN||first-line-9/JJ	prep_as||thiazidediuretics-7/NNS||therapy-10/NN	amod||hypertension-13/NN||uncomplicated-12/JJ	prep_for||therapy-10/NN||hypertension-13/NN	nsubj||under-prescribed-18/JJ||diuretics-16/NNS	cop||under-prescribed-18/JJ||are-17/VBP	conj_yet||recommend-3/VBP||under-prescribed-18/JJ	nsubj||treated-25/JJ||hypertension-21/NN	cop||treated-25/JJ||is-22/VBZ	advmod||treated-25/JJ||frequently-23/RB	advmod||treated-25/JJ||inadequately-24/RB	conj_yet||recommend-3/VBP||treated-25/JJ	conj_and||under-prescribed-18/JJ||treated-25/JJ	hypertension-21||diuretics-16||no_rel||hypertension guidelines recommend the use of thiazidediuretics as first-line therapy for uncomplicated hypertension, yet diuretics are under-prescribed, and hypertension is frequently inadequately treated.
det||avian-4/NN||the-1/DT	amod||avian-4/NN||recent-2/JJ	amod||avian-4/NN||h5n1-3/JJ	nsubj||influenzavirus-8/VBZ||avian-4/NN	amod||swine-origin-7/NN||h1n1-6/JJ	conj_and||avian-4/NN||swine-origin-7/NN	nsubj||influenzavirus-8/VBZ||swine-origin-7/NN	root||ROOT-0/null||influenzavirus-8/VBZ	nsubj||reaffirm-10/VB||outbreaks-9/NNS	ccomp||influenzavirus-8/VBZ||reaffirm-10/VB	mark||real-21/JJ||that-11/IN	det||threat-13/NN||the-12/DT	nsubj||real-21/JJ||threat-13/NN	nsubj||ever-present-23/JJ||threat-13/NN	det||pandemic-18/NN||a-15/DT	amod||pandemic-18/NN||world-wide-16/JJ	nn||pandemic-18/NN||influenza-17/NN	prep_of||threat-13/NN||pandemic-18/NN	cop||real-21/JJ||is-19/VBZ	preconj||real-21/JJ||both-20/DT	ccomp||reaffirm-10/VB||real-21/JJ	ccomp||reaffirm-10/VB||ever-present-23/JJ	conj_and||real-21/JJ||ever-present-23/JJ	h5n1-3||influenzavirus-8||no||the recent h5n1 avian and h1n1 swine-origin influenzavirus outbreaks reaffirm that the threat of a world-wide influenza pandemic is both real and ever-present.
nsubj||strategy-18/NN||chemoprophylaxis-1/NNS	amod||rifampicin-5/NN||single-3/JJ	nn||rifampicin-5/NN||dose-4/NN	prep_with||chemoprophylaxis-1/NNS||rifampicin-5/NN	prep||rifampicin-5/NN||given-6/VBN	pcomp||given-6/VBN||to-7/TO	pobj||to-7/TO||contacts-8/NNS	advmod||diagnosed-11/VBN||newly-10/RB	amod||patients-13/NNS||diagnosed-11/VBN	amod||patients-13/NNS||leprosy-12/JJ	prep_of||contacts-8/NNS||patients-13/NNS	cop||strategy-18/NN||is-14/VBZ	det||strategy-18/NN||a-15/DT	amod||strategy-18/NN||cost-effective-16/JJ	nn||strategy-18/NN||intervention-17/NN	root||ROOT-0/null||strategy-18/NN	leprosy-12||rifampicin-5||yes||chemoprophylaxis with single dose rifampicin given to contacts of newly diagnosed leprosy patients is a cost-effective intervention strategy.
det||studies-3/NNS||a-1/DT	amod||studies-3/NNS||few-2/JJ	nsubj||highlighted-5/VBN||studies-3/NNS	aux||highlighted-5/VBN||have-4/VBP	root||ROOT-0/null||highlighted-5/VBN	dobj||highlighted-5/VBN||differences-6/NNS	prep_in||highlighted-5/VBN||cryptococcosis-8/NNS	nn||gattii-11/NNS||c.-10/NN	prep_between||cryptococcosis-8/NNS||gattii-11/NNS	prep_between||cryptococcosis-8/NNS||c.neoformans-13/NNS	conj_and||gattii-11/NNS||c.neoformans-13/NNS	cryptococcosis-8||c.neoformans-13||no||a few studies have highlighted differences in cryptococcosis between c. gattii and c.neoformans .
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||previously-3/RB	root||ROOT-0/null||shown-4/VBN	mark||improves-10/VBZ||that-5/IN	amod||supplementation-8/NN||dietary-6/JJ	nn||supplementation-8/NN||leucine-7/NN	nsubj||improves-10/VBZ||supplementation-8/NN	advmod||improves-10/VBZ||significantly-9/RB	ccomp||shown-4/VBN||improves-10/VBZ	nn||metabolism-14/NN||glucose-11/NN	conj_and||glucose-11/NN||energy-13/NN	nn||metabolism-14/NN||energy-13/NN	dobj||improves-10/VBZ||metabolism-14/NN	amod||mice-18/NNS||diet-induced-16/JJ	nn||mice-18/NNS||obese-17/NN	prep_in||improves-10/VBZ||mice-18/NNS	vmod||improves-10/VBZ||suggesting-20/VBG	mark||therapy-30/NN||that-21/IN	amod||supplementation-23/NN||leucine-22/JJ	nsubj||therapy-30/NN||supplementation-23/NN	aux||therapy-30/NN||could-24/MD	advmod||therapy-30/NN||potentially-25/RB	cop||therapy-30/NN||be-26/VB	det||therapy-30/NN||a-27/DT	amod||adjuvant-29/JJ||useful-28/JJ	amod||therapy-30/NN||adjuvant-29/JJ	ccomp||suggesting-20/VBG||therapy-30/NN	prep_for||therapy-30/NN||obesity-32/NN	prep_for||therapy-30/NN||type2diabetes-34/NNS	conj_and||obesity-32/NN||type2diabetes-34/NNS	obese-17||adjuvant-29||no_rel||we have previously shown that dietary leucine supplementation significantly improves glucose and energy metabolism in diet-induced obese mice, suggesting that leucine supplementation could potentially be a useful adjuvant therapy for obesity and type2diabetes.
nsubjpass||induced-3/VBN||hypercholesterolemia-1/NN	auxpass||induced-3/VBN||was-2/VBD	root||ROOT-0/null||induced-3/VBN	det||diet-9/NN||a-5/DT	number||%-7/NN||2-6/CD	amod||diet-9/NN||%-7/NN	amod||diet-9/NN||cholesterol-containing-8/JJ	agent||induced-3/VBN||diet-9/NN	hypercholesterolemia-1||cholesterol--1||no||hypercholesterolemia was induced by a 2% cholesterol-containing diet.
advmod||considered-5/VBN||however-1/RB	nsubjpass||considered-5/VBN||nsaids-3/NNS	nsubj||effective-9/JJ||nsaids-3/NNS	auxpass||considered-5/VBN||are-4/VBP	root||ROOT-0/null||considered-5/VBN	aux||effective-9/JJ||to-6/TO	cop||effective-9/JJ||be-7/VB	advmod||effective-9/JJ||more-8/RBR	xcomp||considered-5/VBN||effective-9/JJ	prep_than||effective-9/JJ||acetaminophen-11/NN	prep_for||effective-9/JJ||relief-13/NN	prep_of||relief-13/NN||pain-15/NN	pain-15||nsaids-3||no_rel||however, nsaids are considered to be more effective than acetaminophen for relief of pain.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	nsubj||compare-10/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	xcomp||was-6/VBD||compare-10/VB	conj_and||evaluate-8/VB||compare-10/VB	det||effects-12/NNS||the-11/DT	dobj||evaluate-8/VB||effects-12/NNS	det||combination-18/NN||a-14/DT	amod||combination-18/NN||long-term-15/JJ	amod||combination-18/NN||fixed-dose-17/JJ	prep_of||effects-12/NNS||combination-18/NN	prep_of||combination-18/NN||sitagliptin-20/NN	prep_of||combination-18/NN||metformin-22/NN	conj_and||sitagliptin-20/NN||metformin-22/NN	prep_as||evaluate-8/VB||add-on-24/JJ	prep_to||add-on-24/JJ||insulin-26/NN	nn||index-30/NN||body-28/NN	nn||index-30/NN||mass-29/NN	prep_on||insulin-26/NN||index-30/NN	amod||glucose-34/NN||fasting-32/JJ	nn||glucose-34/NN||plasma-33/NN	prep_on||insulin-26/NN||glucose-34/NN	conj_and||index-30/NN||glucose-34/NN	prep_on||insulin-26/NN||fructosamine-36/NN	conj_and||index-30/NN||fructosamine-36/NN	prep_on||insulin-26/NN||hba1c-38/NNS	conj_and||index-30/NN||hba1c-38/NNS	prep_on||insulin-26/NN||lipids-40/NNS	conj_and||index-30/NN||lipids-40/NNS	amod||dose-44/NN||daily-43/JJ	prep_on||insulin-26/NN||dose-44/NN	conj_and||index-30/NN||dose-44/NN	prep_of||dose-44/NN||insulin-46/NN	det||type2diabetes-52/NNS||both-48/DT	amod||type2diabetes-52/NNS||type1diabetes-49/JJ	conj_and||type1diabetes-49/JJ||insulin-treated-51/JJ	amod||type2diabetes-52/NNS||insulin-treated-51/JJ	prep_in||insulin-46/NN||type2diabetes-52/NNS	type1diabetes-49||insulin-46||yes||the aim of this study was to evaluate and compare the effects of a long-term, fixed-dose combination of sitagliptin and metformin as add-on to insulin on body mass index, fasting plasma glucose, fructosamine, hba1c, lipids, and daily dose of insulin in both type1diabetes and insulin-treated type2diabetes.
mark||established-11/VBN||although-1/IN	amod||countries-5/NNS||western-4/JJ	prep_in||established-11/VBN||countries-5/NNS	amod||regimens-8/NNS||oxaliplatin-based-7/JJ	nsubjpass||established-11/VBN||regimens-8/NNS	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	advcl||accepted-40/VBN||established-11/VBN	det||treatment-16/NN||a-13/DT	amod||treatment-16/NN||gold-14/JJ	amod||treatment-16/NN||standard-15/JJ	prep_as||established-11/VBN||treatment-16/NN	prep_for||treatment-16/NN||patients-18/NNS	nn||iii-21/NN||stage-20/NN	prep_with||patients-18/NNS||iii-21/NN	amod||cancer-28/NN||high-23/JJ	nn||cancer-28/NN||risk-24/NN	nn||cancer-28/NN||stage-25/NN	nn||cancer-28/NN||ii-26/NN	nn||cancer-28/NN||colon-27/NN	prep_with||patients-18/NNS||cancer-28/NN	conj_or||iii-21/NN||cancer-28/NN	amod||resection-31/NN||curative-30/JJ	prep_after||established-11/VBN||resection-31/NN	prep_in||established-11/VBN||japan-34/NN	amod||regimens-36/NNS||fluorouracil-based-35/JJ	nsubjpass||accepted-40/VBN||regimens-36/NNS	nsubjpass||recommended-42/VBN||regimens-36/NNS	aux||accepted-40/VBN||have-37/VBP	auxpass||accepted-40/VBN||been-38/VBN	advmod||accepted-40/VBN||widely-39/RB	root||ROOT-0/null||accepted-40/VBN	conj_and||accepted-40/VBN||recommended-42/VBN	det||guidelines-45/NNS||the-44/DT	prep_in||accepted-40/VBN||guidelines-45/NNS	amod||settings-48/NNS||adjuvant-47/JJ	prep_for||guidelines-45/NNS||settings-48/NNS	prep_in||accepted-40/VBN||patients-50/NNS	nn||cancer-55/NN||stage-52/NN	nn||cancer-55/NN||iii-53/NN	nn||cancer-55/NN||colon-54/NN	prep_with||patients-50/NNS||cancer-55/NN	cancer-55||adjuvant-47||no_rel||although, in western countries, oxaliplatin-based regimens have been established as a gold standard treatment for patients with stage iii or high risk stage ii colon cancer after curative resection, in japan fluorouracil-based regimens have been widely accepted and recommended in the guidelines for adjuvant settings in patients with stage iii colon cancer.
aux||determine-2/VB||to-1/TO	advcl||studied-15/VBD||determine-2/VB	mark||reflect-7/VB||whether-3/IN	det||finding-5/NN||this-4/DT	nsubj||reflect-7/VB||finding-5/NN	aux||reflect-7/VB||could-6/MD	ccomp||determine-2/VB||reflect-7/VB	dobj||reflect-7/VB||emergence-8/NN	prep_of||emergence-8/NN||mycobacteriumtuberculosis-10/NNS	vmod||mycobacteriumtuberculosis-10/NNS||beijing-11/VBG	dobj||beijing-11/VBG||genotype-12/NN	nsubj||studied-15/VBD||we-14/PRP	root||ROOT-0/null||studied-15/VBD	det||sputum-18/NN||all-16/DT	amod||sputum-18/NN||new-17/JJ	nsubj||smearâ-19/VBD||sputum-18/NN	ccomp||studied-15/VBD||smearâ-19/VBD	amod||patients-24/NNS||$-20/JJ	amod||patients-24/NNS||positive-22/JJ	nn||patients-24/NNS||pulmonarytuberculosis-23/NNS	nsubj||registered-25/VBD||patients-24/NNS	ccomp||smearâ-19/VBD||registered-25/VBD	prep_for||registered-25/VBD||treatment-27/NN	num||districts-31/NNS||3-29/CD	amod||districts-31/NNS||rural-30/JJ	prep_in||treatment-27/NN||districts-31/NNS	prep_in||districts-31/NNS||vietnam-33/NN	amod||$-36/NNS||2003â-35/JJ	prep_during||registered-25/VBD||$-36/NNS	dep||$-36/NNS||2006-38/CD	pulmonarytuberculosis-23||mycobacteriumtuberculosis-10||no||to determine whether this finding could reflect emergence of mycobacteriumtuberculosis beijing genotype, we studied all new sputum smearâ€“positive pulmonarytuberculosis patients registered for treatment in 3 rural districts in vietnam during 2003â€“2006.
num||kinds-2/NNS||two-1/CD	nsubj||viruses-7/NNS||kinds-2/NNS	prep_of||kinds-2/NNS||them-4/PRP	cop||viruses-7/NNS||are-5/VBP	amod||viruses-7/NNS||mosquito-borne-6/JJ	root||ROOT-0/null||viruses-7/NNS	nsubj||lead-16/VB||viruses-7/NNS	nsubj||denguefever/dengue-21/VB||viruses-7/NNS	advmod||virus-11/NN||namely-9/RB	amod||virus-11/NN||japaneseencephalitis-10/JJ	appos||viruses-7/NNS||virus-11/NN	appos||viruses-7/NNS||denguevirus-13/NNS	conj_and||virus-11/NN||denguevirus-13/NNS	rcmod||viruses-7/NNS||lead-16/VB	prep_to||lead-16/VB||japaneseencephalitis-18/NNS	rcmod||viruses-7/NNS||denguefever/dengue-21/VB	conj_and||lead-16/VB||denguefever/dengue-21/VB	dobj||denguefever/dengue-21/VB||hemorrhagicfever-22/NN	advmod||denguefever/dengue-21/VB||respectively-23/RB	det||two-27/CD||the-25/DT	amod||two-27/CD||other-26/JJ	nsubj||viruses-30/NNS||two-27/CD	cop||viruses-30/NNS||are-28/VBP	amod||viruses-30/NNS||tick-borne-29/JJ	parataxis||viruses-7/NNS||viruses-30/NNS	nsubj||contribute-49/VBP||viruses-30/NNS	advmod||virus-34/NN||namely-32/RB	amod||virus-34/NN||tick-borneencephalitis-33/JJ	parataxis||viruses-7/NNS||virus-34/NN	conj_and||viruses-30/NNS||virus-34/NN	nsubj||contribute-49/VBP||virus-34/NN	amod||virus-38/NN||crimean-congo-36/JJ	nn||virus-38/NN||hemorrhagicfever-37/NN	parataxis||viruses-7/NNS||virus-38/NN	conj_and||viruses-30/NNS||virus-38/NN	nsubj||contribute-49/VBP||virus-38/NN	advmod||known-41/VBN||also-40/RB	dep||viruses-30/NNS||known-41/VBN	prepc_as||known-41/VBN||xinjiang-43/VBG	nn||virus-45/NN||hemorrhagicfever-44/NN	dobj||xinjiang-43/VBG||virus-45/NN	rcmod||viruses-30/NNS||contribute-49/VBP	prep_to||contribute-49/VBP||tick-borneencephalitis-51/NNS	nn||hemorrhagicfever-54/NN||xinjiang-53/NN	prep_to||contribute-49/VBP||hemorrhagicfever-54/NN	conj_and||tick-borneencephalitis-51/NNS||hemorrhagicfever-54/NN	advmod||contribute-49/VBP||respectively-55/RB	hemorrhagicfever-54||viruses-30||no||two kinds of them are mosquito-borne viruses, namely japaneseencephalitis virus and denguevirus, which lead to japaneseencephalitis, and denguefever/dengue hemorrhagicfever respectively; the other two are tick-borne viruses, namely tick-borneencephalitis virus and crimean-congo hemorrhagicfever virus (also known as xinjiang hemorrhagicfever virus), which contribute to tick-borneencephalitis and xinjiang hemorrhagicfever respectively.
amod||time-2/NN||median-1/JJ	nsubj||different-13/JJ||time-2/NN	nn||progression-5/NN||tumor-4/NN	prep_to||time-2/NN||progression-5/NN	amod||endpoint-8/NN||primary-7/JJ	appos||time-2/NN||endpoint-8/NN	cop||different-13/JJ||was-10/VBD	neg||different-13/JJ||not-11/RB	advmod||different-13/JJ||significantly-12/RB	root||ROOT-0/null||different-13/JJ	det||groups-17/NNS||the-15/DT	num||groups-17/NNS||two-16/CD	prep_between||different-13/JJ||groups-17/NNS	nn||months-22/NNS||placebo-19/NN	num||months-22/NNS||2.8-21/CD	dep||groups-17/NNS||months-22/NNS	dep||months-22/NNS||bosentan-24/NN	num||months-27/NNS||1.6-26/CD	appos||bosentan-24/NN||months-27/NNS	nn||ratio-31/NN||bosentan/placebo-29/NN	nn||ratio-31/NN||hazard-30/NN	dep||bosentan-24/NN||ratio-31/NN	amod||ratio-31/NN||1.144-33/CD	number||%-36/NN||95-35/CD	amod||ci-37/NN||%-36/NN	dep||bosentan-24/NN||ci-37/NN	num||.827-40/CD||0.717-1-39/CD	appos||ci-37/NN||.827-40/CD	dep||bosentan-24/NN||p-42/NN	dep||0.5683-44/CD||=-43/SYM	rcmod||p-42/NN||0.5683-44/CD	bosentan-24||tumor-4||no_rel||median time to tumor progression (primary endpoint) was not significantly different between the two groups (placebo, 2.8 months; bosentan, 1.6 months; bosentan/placebo hazard ratio, 1.144; 95% ci, 0.717-1.827; p = 0.5683).
det||factors-4/NNS||the-2/DT	nn||factors-4/NNS||risk-3/NN	prep_among||contributed-23/VBD||factors-4/NNS	vmod||factors-4/NNS||identified-5/VBN	amod||levels-8/NNS||low-7/JJ	nsubj||contributed-23/VBD||levels-8/NNS	prep_of||levels-8/NNS||vaccination-10/NN	amod||parity-13/NN||high-12/JJ	prep_of||levels-8/NNS||parity-13/NN	conj_and||vaccination-10/NN||parity-13/NN	amod||levels-17/NNS||low-16/JJ	prep_of||levels-8/NNS||levels-17/NNS	conj_and||vaccination-10/NN||levels-17/NNS	amod||awareness-20/NN||maternal-19/JJ	prep_of||levels-17/NNS||awareness-20/NN	prep_of||awareness-20/NN||vitamina-22/NN	root||ROOT-0/null||contributed-23/VBD	amod||risks-26/NNS||higher-25/JJR	prep_to||contributed-23/VBD||risks-26/NNS	advmod||contributed-23/VBD||ofvitaminadeficiency-27/RB	nn||children-30/NNS||muslim-29/NN	prep_among||contributed-23/VBD||children-30/NNS	ofvitaminadeficiency-27||vitamina-22||yes||among the risk factors identified, low levels of vaccination, high parity, and low levels of maternal awareness of vitamina contributed to higher risks ofvitaminadeficiency among muslim children.
det||pain-2/NN||the-1/DT	nsubjpass||refractory-4/VBN||pain-2/NN	auxpass||refractory-4/VBN||was-3/VBD	root||ROOT-0/null||refractory-4/VBN	amod||treatment-7/NN||medical-6/JJ	prep_to||refractory-4/VBN||treatment-7/NN	det||block-13/NN||a-10/DT	amod||block-13/NN||bilateral-11/JJ	amod||block-13/NN||sympathetic-12/JJ	nsubj||resulted-18/VBD||block-13/NN	prep_with||block-13/NN||lidocaine-15/NN	prep_with||block-13/NN||triamcinolone-17/NN	conj_and||lidocaine-15/NN||triamcinolone-17/NN	conj_but||refractory-4/VBN||resulted-18/VBD	prep_in||resulted-18/VBD||relief-20/NN	det||pain-23/NN||the-22/DT	prep_from||resulted-18/VBD||pain-23/NN	pain-23||lidocaine-15||yes||the pain was refractory to medical treatment, but a bilateral sympathetic block with lidocaine and triamcinolone resulted in relief from the pain.
amod||adjuvant-2/NN||current-1/JJ	nsubj||pharmacological-3/VBP||adjuvant-2/NN	root||ROOT-0/null||pharmacological-3/VBP	dobj||pharmacological-3/VBP||therapy-4/NN	amod||unfractionatedheparin-12/NN||ami-6/JJ	prep_with||ami-6/JJ||aspirin-8/NN	appos||aspirin-8/NN||clopidogrel-10/NN	prep_of||therapy-4/NN||unfractionatedheparin-12/NN	discourse||unfractionatedheparin-12/NN||uh-14/UH	amod||inhibitors-21/NNS||platelet-18/JJ	nn||inhibitors-21/NNS||gp-19/NN	nn||inhibitors-21/NNS||iib/iiia-20/NN	nsubj||provides-22/VBZ||inhibitors-21/NNS	conj_and||pharmacological-3/VBP||provides-22/VBZ	amod||benefits-25/NNS||useful-23/JJ	amod||benefits-25/NNS||therapeutic-24/JJ	dobj||provides-22/VBZ||benefits-25/NNS	ami-6||unfractionatedheparin-12||yes||current adjuvant pharmacological therapy of ami with aspirin, clopidogrel, unfractionatedheparin (uh), and platelet gp iib/iiia inhibitors provides useful therapeutic benefits.
mark||introduced-4/VBN||since-1/IN	nsubjpass||introduced-4/VBN||terbinafine-2/NN	auxpass||introduced-4/VBN||was-3/VBD	advcl||become-15/VBN||introduced-4/VBN	det||market-8/NN||the-6/DT	nn||market-8/NN||world-7/NN	prep_on||introduced-4/VBN||market-8/NN	num||years-10/NNS||17-9/CD	npadvmod||ago-11/RB||years-10/NNS	advmod||introduced-4/VBN||ago-11/RB	nsubj||become-15/VBN||it-13/PRP	aux||become-15/VBN||has-14/VBZ	root||ROOT-0/null||become-15/VBN	det||antifungal-18/NN||the-16/DT	amod||antifungal-18/NN||leading-17/VBG	xcomp||become-15/VBN||antifungal-18/NN	det||treatment-21/NN||the-20/DT	prep_for||antifungal-18/NN||treatment-21/NN	amod||fungalinfections-24/NNS||superficial-23/JJ	prep_of||treatment-21/NN||fungalinfections-24/NNS	vmod||treatment-21/NN||aided-26/VBN	amod||profiles-32/NNS||unique-28/JJ	amod||profiles-32/NNS||pharmacologic-29/JJ	conj_and||pharmacologic-29/JJ||microbiologic-31/JJ	amod||profiles-32/NNS||microbiologic-31/JJ	agent||aided-26/VBN||profiles-32/NNS	fungalinfections-24||terbinafine-2||yes||since terbinafine was introduced on the world market 17 years ago, it has become the leading antifungal for the treatment of superficial fungalinfections, aided by unique pharmacologic and microbiologic profiles.
nsubj||designed-2/VBD||we-1/PRP	nsubj||participate-50/VB||we-1/PRP	root||ROOT-0/null||designed-2/VBD	num||cascades-5/NNS||two-3/CD	amod||cascades-5/NNS||pmtct-4/JJ	dobj||designed-2/VBD||cascades-5/NNS	xcomp||designed-2/VBD||using-6/VBG	dobj||using-6/VBG||studies-7/NNS	prep_with||using-6/VBG||outcomes-9/NNS	nsubj||showed-16/VBD||outcomes-9/NNS	det||interventions-14/NNS||all-11/DT	amod||interventions-14/NNS||perinatal-12/JJ	amod||interventions-14/NNS||pmtct-13/JJ	prep_for||outcomes-9/NNS||interventions-14/NNS	rcmod||outcomes-9/NNS||showed-16/VBD	mark||notified-42/VBN||that-17/IN	det||%-21/NN||an-18/DT	amod||%-21/NN||estimated-19/VBN	num||%-21/NN||22-20/CD	nsubjpass||notified-42/VBN||%-21/NN	det||women-25/NNS||all-23/DT	amod||women-25/NNS||hivpositive-24/JJ	prep_of||%-21/NN||women-25/NNS	vmod||%-21/NN||attending-26/VBG	amod||care-28/NN||antenatal-27/JJ	dobj||attending-26/VBG||care-28/NN	num||%-31/NN||11-30/CD	dobj||attending-26/VBG||%-31/NN	conj_and||care-28/NN||%-31/NN	det||women-35/NNS||all-33/DT	amod||women-35/NNS||hivpositive-34/JJ	prep_of||%-31/NN||women-35/NNS	vmod||women-35/NNS||delivering-36/VBG	nn||ward-39/NN||labor-38/NN	prep_at||delivering-36/VBG||ward-39/NN	auxpass||notified-42/VBN||were-40/VBD	neg||notified-42/VBN||not-41/RB	ccomp||showed-16/VBD||notified-42/VBN	poss||status-46/NN||their-44/PRP$	nn||status-46/NN||hiv-45/NN	prep_about||notified-42/VBN||status-46/NN	aux||participate-50/VB||did-48/VBD	neg||participate-50/VB||not-49/RB	conj_and||designed-2/VBD||participate-50/VB	amod||program-53/NN||pmtct-52/JJ	prep_in||participate-50/VB||program-53/NN	hivpositive-34||hiv-45||no||we designed two pmtct cascades using studies with outcomes for all perinatal pmtct interventions which showed that an estimated 22% of all hivpositive women attending antenatal care and 11% of all hivpositive women delivering at labor ward were not notified about their hiv status and did not participate in pmtct program.
amod||vasculitis-4/NNS||anti-neutrophil-1/JJ	amod||vasculitis-4/NNS||cytoplasmic-2/JJ	amod||vasculitis-4/NNS||antibody-associated-3/JJ	nsubjpass||associated-7/VBN||vasculitis-4/NNS	aux||associated-7/VBN||has-5/VBZ	auxpass||associated-7/VBN||been-6/VBN	root||ROOT-0/null||associated-7/VBN	amod||drugs-10/NNS||many-9/JJ	prep_with||associated-7/VBN||drugs-10/NNS	nsubj||effect-18/NN||it-12/PRP	cop||effect-18/NN||is-13/VBZ	det||effect-18/NN||a-14/DT	advmod||rare-16/JJ||relatively-15/RB	amod||effect-18/NN||rare-16/JJ	nn||effect-18/NN||side-17/NN	conj_and||associated-7/VBN||effect-18/NN	det||hydralazine-22/NN||the-20/DT	amod||hydralazine-22/NN||antihypertensivedrug-21/VBG	prep_of||effect-18/NN||hydralazine-22/NN	vasculitis-4||antihypertensivedrug-21||no_rel||anti-neutrophil cytoplasmic antibody-associated vasculitis has been associated with many drugs and it is a relatively rare side effect of the antihypertensivedrug hydralazine.
det||analysis-3/NN||a-1/DT	amod||analysis-3/NN||pooled-2/JJ	nsubj||indicate-11/VB||analysis-3/NN	num||trials-8/NNS||25-5/CD	amod||trials-8/NNS||randomised-6/JJ	amod||trials-8/NNS||clinical-7/JJ	prep_of||analysis-3/NN||trials-8/NNS	aux||indicate-11/VB||does-9/VBZ	neg||indicate-11/VB||not-10/RB	root||ROOT-0/null||indicate-11/VB	mark||increases-16/VBZ||that-12/IN	nsubj||increases-16/VBZ||treatment-13/NN	prep_with||treatment-13/NN||sitagliptin-15/NN	ccomp||indicate-11/VB||increases-16/VBZ	amod||risk-18/NN||cardiovascular-17/JJ	dobj||increases-16/VBZ||risk-18/NN	prep_in||increases-16/VBZ||patients-20/NNS	prep_with||patients-20/NNS||type2diabetesmellitus-22/CD	type2diabetesmellitus-22||sitagliptin-15||yes||a pooled analysis of 25 randomised clinical trials does not indicate that treatment with sitagliptin increases cardiovascular risk in patients with type2diabetesmellitus.
nsubj||were-9/VBD||patients-1/NNS	vmod||patients-1/NNS||enrolled-2/VBN	det||trial-8/NN||the-4/DT	nn||trial-8/NN||asthma-5/NN	nn||trial-8/NN||intervention-6/NN	nn||trial-8/NN||research-7/NN	prep_in||enrolled-2/VBN||trial-8/NN	root||ROOT-0/null||were-9/VBD	amod||corticosteroids-12/NNS||inhaled-11/JJ	prep_on||were-9/VBD||corticosteroids-12/NNS	dep||corticosteroids-12/NNS||â-13/VBN	xcomp||â-13/VBN||‰-14/VBG	number||200-16/CD||¥-15/CD	num||+-23/NNS||200-16/CD	nn||+-23/NNS||î-17/NNP	num||+-23/NNS||1/4-18/CD	amod||+-23/NNS||g-19/JJ	amod||+-23/NNS||beclomethasone-20/JJ	conj_or||beclomethasone-20/JJ||equivalent-22/JJ	amod||+-23/NNS||equivalent-22/JJ	nsubj||long-acting-beta2-agonists-24/JJ||+-23/NNS	xcomp||‰-14/VBG||long-acting-beta2-agonists-24/JJ	dep||corticosteroids-12/NNS||demonstrated-26/VBN	conj_and||â-13/VBN||demonstrated-26/VBN	dobj||demonstrated-26/VBN||worsening-27/VBG	prep_of||worsening-27/VBG||asthma-29/NN	nn||withdrawal-34/NN||long-acting-î-31/NNP	nn||withdrawal-34/NN||²-32/NNP	amod||withdrawal-34/NN||2-agonist-33/JJ	prep_on||asthma-29/NN||withdrawal-34/NN	corticosteroids-12||asthma-29||no_rel||patients enrolled in the asthma intervention research trial were on inhaled corticosteroids â‰¥200 î¼g beclomethasone or equivalent + long-acting-beta2-agonists and demonstrated worsening of asthma on long-acting-î²2-agonist withdrawal.
amod||-rrb--9/NNS||inhaled-1/JJ	amod||-rrb--9/NNS||short-2/JJ	dep||short-2/JJ||acting-3/VBG	nn||²-5/NNS||î-4/NN	dobj||acting-3/VBG||²-5/NNS	amod||-rrb--9/NNS||2-agonists-6/JJ	amod||-rrb--9/NNS||-lrb--7/JJ	nn||-rrb--9/NNS||saba-8/NN	nsubjpass||used-15/VBN||-rrb--9/NNS	nn||albuterol-12/NNP||e.g.-11/NNP	appos||-rrb--9/NNS||albuterol-12/NNP	auxpass||used-15/VBN||are-14/VBP	root||ROOT-0/null||used-15/VBN	amod||reversal-18/NN||quick-17/JJ	prep_for||used-15/VBN||reversal-18/NN	prep_of||reversal-18/NN||bronchoconstriction-20/NN	prep_in||used-15/VBN||asthmatics-22/NNS	asthmatics-22||albuterol-12||yes||inhaled short acting î ² 2-agonists -lrb- saba -rrb- , e.g. albuterol , are used for quick reversal of bronchoconstriction in asthmatics .
nn||caregivers-2/NNS||volunteer-1/NN	nsubj||source-6/NN||caregivers-2/NNS	cop||source-6/NN||are-3/VBP	det||source-6/NN||a-4/DT	amod||source-6/NN||critical-5/JJ	root||ROOT-0/null||source-6/NN	prep_of||source-6/NN||support-8/NN	det||majority-11/NN||the-10/DT	prep_for||support-8/NN||majority-11/NN	prep_of||majority-11/NN||people-13/NNS	vmod||people-13/NNS||living-14/VBG	prep_with||living-14/VBG||hiv-16/NN	prep_with||living-14/VBG||aids-18/NNS	conj_and||hiv-16/NN||aids-18/NNS	amod||africa-21/NN||southern-20/JJ	prep_in||living-14/VBG||africa-21/NN	nsubj||has-24/VBZ||africa-21/NN	rcmod||africa-21/NN||has-24/VBZ	advmod||high-26/JJ||extremely-25/RB	amod||rates-29/NNS||high-26/JJ	amod||rates-29/NNS||hiv/aids-27/JJ	nn||rates-29/NNS||prevalence-28/NN	dobj||has-24/VBZ||rates-29/NNS	aids-18||hiv-16||no||volunteer caregivers are a critical source of support for the majority of people living with hiv and aids in southern africa, which has extremely high hiv/aids prevalence rates.
det||paper-3/NN||the-1/DT	amod||paper-3/NN||following-2/JJ	nsubj||presents-4/VBZ||paper-3/NN	root||ROOT-0/null||presents-4/VBZ	num||studies-8/NNS||three-5/CD	amod||studies-8/NNS||separate-6/JJ	nn||studies-8/NNS||case-7/NN	dobj||presents-4/VBZ||studies-8/NNS	amod||patients-11/NNS||female-10/JJ	prep_of||studies-8/NNS||patients-11/NNS	vmod||patients-11/NNS||suffering-12/VBG	amod||depression-17/NN||psychotic-14/JJ	nn||depression-17/NN||unipolar-15/NN	amod||depression-17/NN||major-16/JJ	prep_from||suffering-12/VBG||depression-17/NN	pobj||of-20/IN||depression-17/NN	dep||of-20/IN||all-19/DT	nsubjpass||admitted-23/VBN||of-20/IN	nsubjpass||treated-30/VBN||of-20/IN	auxpass||admitted-23/VBN||were-22/VBD	rcmod||depression-17/NN||admitted-23/VBN	det||ward-27/NN||a-25/DT	amod||ward-27/NN||psychiatric-26/JJ	prep_to||admitted-23/VBN||ward-27/NN	advmod||treated-30/VBN||successfully-29/RB	rcmod||depression-17/NN||treated-30/VBN	conj_and||admitted-23/VBN||treated-30/VBN	det||combination-33/NN||a-32/DT	prep_with||treated-30/VBN||combination-33/NN	prep_of||combination-33/NN||venlafaxine-35/NN	prep_of||combination-33/NN||olanzapine-37/NN	conj_and||venlafaxine-35/NN||olanzapine-37/NN	psychotic-14||olanzapine-37||yes||the following paper presents three separate case studies of female patients suffering from psychotic unipolar major depression, all of whom were admitted to a psychiatric ward and successfully treated with a combination of venlafaxine and olanzapine.
nn||glucose-2/NN||plasma-1/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	conj_and||glucose-2/NN||insulin-4/NN	nsubjpass||measured-12/VBN||insulin-4/NN	conj_and||glucose-2/NN||c-peptide-6/NN	nsubjpass||measured-12/VBN||c-peptide-6/NN	nn||concentrations-10/NNS||glucagon-9/NN	conj_and||glucose-2/NN||concentrations-10/NNS	nsubjpass||measured-12/VBN||concentrations-10/NNS	auxpass||measured-12/VBN||were-11/VBD	root||ROOT-0/null||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	det||min-15/NN||every-13/DT	num||min-15/NN||30-14/CD	dobj||measured-12/VBN||min-15/NN	amod||ingestion-42/NN||âˆ-17/JJ	dep||âˆ-17/JJ||’60-18/CD	num||min-21/NN||180-20/CD	prep_through||âˆ-17/JJ||min-21/NN	amod||administration-26/NN||random-sequence-23/JJ	amod||administration-26/NN||double-blind-25/JJ	prep_with||min-21/NN||administration-26/NN	prep_of||administration-26/NN||diazoxide-28/NN	num||mg/kg-31/NN||6.0-30/CD	appos||diazoxide-28/NN||mg/kg-31/NN	prep_of||administration-26/NN||placebo-34/NN	conj_or||diazoxide-28/NN||placebo-34/NN	amod||min-40/NN||âˆ-36/JJ	dep||âˆ-36/JJ||’30-37/CD	dep||âˆ-36/JJ||1-39/CD	conj_and||’30-37/CD||1-39/CD	prep_at||placebo-34/NN||min-40/NN	prep_from||measured-12/VBN||ingestion-42/NN	det||meal-47/NN||a-44/DT	nn||meal-47/NN||formula-45/NN	amod||meal-47/NN||mixed-46/JJ	prep_of||ingestion-42/NN||meal-47/NN	parataxis||measured-12/VBN||ensure-49/VB	advmod||ensure-49/VB||plus-50/CC	prep_at||measured-12/VBN||0-53/CD	vmod||0-53/CD||min-54/VBN	prep_after||min-54/VBN||diazoxide-56/NN	prep_after||min-54/VBN||placebo-59/NN	conj_and||diazoxide-56/NN||placebo-59/NN	cc||measured-12/VBN||and-60/CC	det||occasion-65/NN||a-63/DT	amod||occasion-65/NN||separate-64/JJ	prep_on||measured-12/VBN||occasion-65/NN	npadvmod||measured-12/VBN||ingestion-67/NN	prep_of||ingestion-67/NN||glimepiride-69/NN	number||mg-72/CD||4.0-71/CD	dep||glimepiride-69/NN||mg-72/CD	num||min-76/NN||0-75/CD	prep_at||glimepiride-69/NN||min-76/NN	prep_with||glimepiride-69/NN||glucose-79/NN	vmod||glucose-79/NN||infused-80/VBN	aux||prevent-82/VB||to-81/TO	xcomp||infused-80/VBN||prevent-82/VB	dobj||prevent-82/VB||hypoglycemia-83/NN	prep_after||measured-12/VBN||diazoxide-86/NN	prep_after||measured-12/VBN||placebo-89/NN	num||adults-94/NNS||11-91/CD	amod||adults-94/NNS||healthy-92/JJ	amod||adults-94/NNS||young-93/JJ	prep_in||placebo-89/NN||adults-94/NNS	hypoglycemia-83||diazoxide-86||no||plasma glucose, insulin, c-peptide, and glucagon concentrations were measured every 30 min from âˆ’60 through 180 min with random-sequence, double-blind administration of diazoxide (6.0 mg/kg) or placebo at âˆ’30 and 1 min, ingestion of a formula mixed meal (ensure plus) at 0 min after diazoxide and after placebo and, on a separate occasion, ingestion of glimepiride (4.0 mg) at 0 min (with glucose infused to prevent hypoglycemia) after diazoxide and after placebo in 11 healthy young adults.
det||reason-3/NN||the-1/DT	amod||reason-3/NN||main-2/JJ	nsubjpass||related-10/VBN||reason-3/NN	neg||exploring-7/VBG||not-5/RB	advmod||exploring-7/VBG||actively-6/RB	prepc_for||reason-3/NN||exploring-7/VBG	dep||exploring-7/VBG||ironoverload-8/VBN	auxpass||related-10/VBN||was-9/VBD	root||ROOT-0/null||related-10/VBN	amod||prognosis-14/NN||poor-12/JJ	nn||prognosis-14/NN||patient-13/NN	prep_to||related-10/VBN||prognosis-14/NN	mark||prognosis-29/NN||while-16/IN	det||reasons-19/NNS||the-17/DT	amod||reasons-19/NNS||main-18/JJ	nsubj||prognosis-29/NN||reasons-19/NNS	neg||initiating-22/VBG||not-21/RB	prepc_for||reasons-19/NNS||initiating-22/VBG	nn||therapy-25/NN||iron-23/NN	nn||therapy-25/NN||chelation-24/NN	dobj||initiating-22/VBG||therapy-25/NN	cop||prognosis-29/NN||were-26/VBD	amod||prognosis-29/NN||poor-27/JJ	nn||prognosis-29/NN||patient-28/NN	advcl||related-10/VBN||prognosis-29/NN	amod||age-33/NN||older-31/JJR	nn||age-33/NN||patient-32/NN	advcl||related-10/VBN||age-33/NN	conj_and||prognosis-29/NN||age-33/NN	ironoverload-8||iron-23||no||the main reason for not actively exploring ironoverload was related to poor patient prognosis, while the main reasons for not initiating iron chelation therapy were poor patient prognosis and older patient age.
det||rate-3/NN||the-1/DT	amod||rate-3/NN||relapse-2/JJ	nsubj||observed-4/VBD||rate-3/NN	root||ROOT-0/null||observed-4/VBD	num||months-7/NNS||12-6/CD	prep_after||observed-4/VBD||months-7/NNS	dobj||observed-4/VBD||treatment-8/NN	prep_with||treatment-8/NN||the-10/DT	nsubj||recommended-12/VBD||the-10/DT	rcmod||the-10/DT||recommended-12/VBD	nn||regimen-15/NN||mdr-13/NN	nn||regimen-15/NN||tb-14/NN	nsubj||equivalent-26/JJ||regimen-15/NN	dep||regimen-15/NN||amikacin-17/NN	appos||amikacin-17/NN||ethionamide-19/NN	appos||amikacin-17/NN||pyrazinamide-21/NN	conj_and||ethionamide-19/NN||pyrazinamide-21/NN	appos||amikacin-17/NN||moxifloxacin-23/NN	conj_and||ethionamide-19/NN||moxifloxacin-23/NN	cop||equivalent-26/JJ||was-25/VBD	ccomp||recommended-12/VBD||equivalent-26/JJ	det||treatment-35/NN||the-28/DT	dep||rate-30/NN||relapse-29/JJ	amod||treatment-35/NN||rate-30/NN	amod||treatment-35/NN||observed-31/JJ	num||months-34/NNS||6-33/CD	prep_after||observed-31/JJ||months-34/NNS	prep_to||equivalent-26/JJ||treatment-35/NN	det||regimen-42/NN||the-37/DT	amod||regimen-42/NN||recommended-38/VBN	nn||regimen-42/NN||drug-39/NN	amod||regimen-42/NN||susceptible-40/VBG	nn||regimen-42/NN||tb-41/NN	prep_with||treatment-35/NN||regimen-42/NN	dep||treatment-35/NN||rifampin-44/NN	dep||rifampin-44/NN||isoniazid-46/JJ	dep||rifampin-44/NN||pyrazinamide-48/JJ	conj_and||isoniazid-46/JJ||pyrazinamide-48/JJ	tb-41||pyrazinamide-48||yes||the relapse rate observed after 12 months treatment with the who recommended mdr tb regimen (amikacin, ethionamide, pyrazinamide and moxifloxacin) was equivalent to the relapse rate observed after 6 months treatment with the recommended drug susceptible tb regimen (rifampin, isoniazid and pyrazinamide).
nsubjpass||shown-3/VBN||fondaparinux-1/NN	nsubj||efficacious-6/JJ||fondaparinux-1/NN	auxpass||shown-3/VBN||was-2/VBD	root||ROOT-0/null||shown-3/VBN	aux||efficacious-6/JJ||to-4/TO	cop||efficacious-6/JJ||be-5/VB	xcomp||shown-3/VBN||efficacious-6/JJ	det||prevention-9/NN||the-8/DT	prep_in||efficacious-6/JJ||prevention-9/NN	amod||heparins-15/NNS||deep-11/JJ	nn||heparins-15/NNS||veinthrombosis-12/NN	nn||heparins-15/NNS||vs-13/NN	amod||heparins-15/NNS||low-molecular-weight-14/JJ	prep_of||prevention-9/NN||heparins-15/NNS	mark||shown-28/VBN||while-17/IN	det||setting-20/NN||the-19/DT	prep_in||shown-28/VBN||setting-20/NN	amod||disease-24/NN||venous-22/JJ	amod||disease-24/NN||thrombo-embolic-23/JJ	prep_of||setting-20/NN||disease-24/NN	nsubjpass||shown-28/VBN||it-26/PRP	nsubj||noninferior-31/JJ||it-26/PRP	auxpass||shown-28/VBN||was-27/VBD	advcl||efficacious-6/JJ||shown-28/VBN	aux||noninferior-31/JJ||to-29/TO	cop||noninferior-31/JJ||be-30/VB	xcomp||shown-28/VBN||noninferior-31/JJ	prep_to||noninferior-31/JJ||enoxaparin-33/NN	prep_to||noninferior-31/JJ||ufh-35/NN	conj_and||enoxaparin-33/NN||ufh-35/NN	fondaparinux-1||veinthrombosis-12||no_rel||fondaparinux was shown to be efficacious in the prevention of deep veinthrombosis vs low-molecular-weight heparins, while in the setting of venous thrombo-embolic disease, it was shown to be noninferior to enoxaparin and ufh.
advmod||focuses-5/VBZ||traditionally-1/RB	nn||prevention-4/NN||hiv-3/NN	nsubj||focuses-5/VBZ||prevention-4/NN	root||ROOT-0/null||focuses-5/VBZ	amod||behaviours-8/NNS||individual-7/JJ	prep_on||focuses-5/VBZ||behaviours-8/NNS	nsubj||place-10/VBP||behaviours-8/NNS	rcmod||behaviours-8/NNS||place-10/VBP	dobj||place-10/VBP||one-11/CD	prep_at||place-10/VBP||risk-13/NN	prep_for||risk-13/NN||hivinfection-15/NN	hivinfection-15||hiv-3||no||traditionally, hiv prevention focuses on individual behaviours that place one at risk for hivinfection.
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	amod||interviews-4/NNS||open-ended-3/JJ	dobj||conducted-2/VBD||interviews-4/NNS	num||individuals-7/NNS||41-6/CD	prep_with||conducted-2/VBD||individuals-7/NNS	dep||conducted-2/VBD||living-8/VBG	prep_with||living-8/VBG||hiv/aids-10/NNS	dep||conducted-2/VBD||attending-12/VBG	conj_and||living-8/VBG||attending-12/VBG	det||clinic-14/NN||a-13/DT	dobj||attending-12/VBG||clinic-14/NN	prep_in||attending-12/VBG||mbarara-16/NN	appos||mbarara-16/NN||uganda-18/NN	aux||understand-21/VB||to-20/TO	vmod||conducted-2/VBD||understand-21/VB	amod||barriers-23/NNS||structural-22/JJ	dobj||understand-21/VB||barriers-23/NNS	nn||adherence-26/NN||arv-25/NN	prep_to||understand-21/VB||adherence-26/NN	amod||care-29/NN||clinical-28/JJ	prep_to||understand-21/VB||care-29/NN	conj_and||adherence-26/NN||care-29/NN	aids--1||hiv--1||no||we conducted open-ended interviews with 41 individuals living with hiv/aids and attending a clinic in mbarara, uganda, to understand structural barriers to arv adherence and clinical care.
det||objective-2/NN||the-1/DT	nsubj||is-6/VBZ||objective-2/NN	nsubj||examine-8/VB||objective-2/NN	det||study-5/NN||this-4/DT	prep_of||objective-2/NN||study-5/NN	root||ROOT-0/null||is-6/VBZ	aux||examine-8/VB||to-7/TO	xcomp||is-6/VBZ||examine-8/VB	det||efficacy-10/NN||the-9/DT	dobj||examine-8/VB||efficacy-10/NN	dobj||examine-8/VB||tolerability-12/NN	conj_and||efficacy-10/NN||tolerability-12/NN	prep_of||efficacy-10/NN||miglitol-14/NN	prep_with||examine-8/VB||respect-16/NN	prepc_to||examine-8/VB||improving-18/VBG	amod||control-20/NN||glycemic-19/JJ	dobj||improving-18/VBG||control-20/NN	amod||patients-23/NNS||chinese-22/JJ	prep_in||control-20/NN||patients-23/NNS	prep_with||improving-18/VBG||type2diabetesmellitus-25/NNS	advmod||controlled-27/VBN||inadequately-26/RB	amod||type2diabetesmellitus-25/NNS||controlled-27/VBN	nn||treatment-32/NN||diet-29/NN	conj_and||diet-29/NN||sulfonylurea-31/NN	nn||treatment-32/NN||sulfonylurea-31/NN	prep_by||examine-8/VB||treatment-32/NN	type2diabetesmellitus-25||miglitol-14||yes||the objective of this study is to examine the efficacy and tolerability of miglitol with respect to improving glycemic control in chinese patients with type2diabetesmellitus inadequately controlled by diet and sulfonylurea treatment.
det||vaccine-7/NN||the-1/DT	amod||vaccine-7/NN||only-2/JJ	nn||vaccine-7/NN||tuberculosis-3/NNP	appos||vaccine-7/NN||tb-5/NN	nsubj||rin-14/NN||vaccine-7/NN	advmod||available-9/JJ||currently-8/RB	amod||vaccine-7/NN||available-9/JJ	cop||rin-14/NN||is-10/VBZ	amod||calmette-guã-12/JJ||bacillus-11/JJ	amod||rin-14/NN||calmette-guã-12/JJ	amod||rin-14/NN||©-13/JJ	root||ROOT-0/null||rin-14/NN	appos||rin-14/NN||bcg-16/NN	mark||has-21/VBZ||although-19/IN	nsubj||has-21/VBZ||it-20/PRP	advcl||rin-14/NN||has-21/VBZ	neg||efficacy-23/NN||no-22/DT	dobj||has-21/VBZ||efficacy-23/NN	prep_in||efficacy-23/NN||adults-25/NNS	tb-5||bcg-16||yes||the only tuberculosis (tb) vaccine currently available is bacillus calmette-guã©rin (bcg), although it has no efficacy in adults.
prep_in||showed-6/VBD||conclusion-2/NN	poss||data-5/NNS||our-4/PRP$	nsubj||showed-6/VBD||data-5/NNS	root||ROOT-0/null||showed-6/VBD	mark||affects-11/VBZ||that-7/IN	amod||hypercholesterolemia-9/NN||diet-induced-8/JJ	nsubj||affects-11/VBZ||hypercholesterolemia-9/NN	advmod||affects-11/VBZ||adversely-10/RB	ccomp||showed-6/VBD||affects-11/VBZ	nn||quality-13/NN||semen-12/NN	dobj||affects-11/VBZ||quality-13/NN	nn||motility-16/NN||sperm-15/NN	dobj||affects-11/VBZ||motility-16/NN	conj_and||quality-13/NN||motility-16/NN	dobj||affects-11/VBZ||capacitation-18/NN	conj_and||quality-13/NN||capacitation-18/NN	amod||reaction-21/NN||acrosomal-20/JJ	dobj||affects-11/VBZ||reaction-21/NN	conj_and||quality-13/NN||reaction-21/NN	prep_in||reaction-21/NN||rabbits-23/NNS	advmod||content-33/NN||probably-25/RB	det||increase-29/NN||an-28/DT	prep_due_to||content-33/NN||increase-29/NN	amod||cholesterol-32/NN||cellular-31/JJ	prep_in||increase-29/NN||cholesterol-32/NN	dep||reaction-21/NN||content-33/NN	nsubj||alters-35/VBZ||that-34/WDT	ccomp||content-33/NN||alters-35/VBZ	advmod||related-37/VBN||membrane-36/RB	amod||events-38/NNS||related-37/VBN	dobj||alters-35/VBZ||events-38/NNS	hypercholesterolemia-9||cholesterol-32||no||in conclusion, our data showed that diet-induced hypercholesterolemia adversely affects semen quality and sperm motility, capacitation and acrosomal reaction in rabbits; probably due to an increase in cellular cholesterol content that alters membrane related events.
nn||upregulation-2/NN||upa-1/NN	nsubj||have-13/VB||upregulation-2/NN	prep_in||upregulation-2/NN||concert-5/NN	amod||downregulation-10/NN||pai-1-7/JJ	conj_and||pai-1-7/JJ||pge2-9/JJ	amod||downregulation-10/NN||pge2-9/JJ	prep_with||concert-5/NN||downregulation-10/NN	aux||have-13/VB||may-12/MD	root||ROOT-0/null||have-13/VB	det||effect-17/NN||a-14/DT	nn||effect-17/NN||cancer-15/NN	nn||effect-17/NN||preventive-16/NN	dobj||have-13/VB||effect-17/NN	cancer-15||upa-1||no_rel||upa upregulation, in concert with pai-1 and pge2 downregulation, may have a cancer preventive effect.
amod||practice-3/NN||everyday-2/JJ	prep_in||experienced-16/VBD||practice-3/NN	nsubj||experienced-16/VBD||patients-5/NNS	prep_with||patients-5/NNS||type-7/NN	num||type-7/NN||1-8/CD	amod||insulins-15/NNS||type2diabetes-10/JJ	advmod||controlled-12/JJ||inadequately-11/RB	amod||insulins-15/NNS||controlled-12/JJ	prep_by||controlled-12/JJ||premix-14/NN	conj_or||patients-5/NNS||insulins-15/NNS	nsubj||experienced-16/VBD||insulins-15/NNS	root||ROOT-0/null||experienced-16/VBD	amod||improvement-18/NN||significant-17/JJ	dobj||experienced-16/VBD||improvement-18/NN	amod||control-21/NN||glycaemic-20/JJ	prep_in||experienced-16/VBD||control-21/NN	num||months-24/NNS||12-23/CD	prep_over||control-21/NN||months-24/NNS	prepc_after||experienced-16/VBD||switching-26/VBG	det||regimen-31/NN||a-28/DT	amod||regimen-31/NN||glargine-based-29/JJ	nn||regimen-31/NN||insulin-30/NN	prep_to||switching-26/VBG||regimen-31/NN	type2diabetes-10||glargine--1||yes||in everyday practice, patients with type 1 or type2diabetes inadequately controlled by premix insulins experienced significant improvement in glycaemic control over 12 months after switching to a glargine-based insulin regimen.
advmod||have-5/VBP||furthermore-1/RB	amod||patients-4/NNS||hemophiliac-3/JJ	nsubj||have-5/VBP||patients-4/NNS	root||ROOT-0/null||have-5/VBP	det||risk-8/NN||an-6/DT	amod||risk-8/NN||increased-7/VBN	dobj||have-5/VBP||risk-8/NN	amod||life-threatening-11/JJ||severe-10/JJ	amod||hemorrhage-12/NN||life-threatening-11/JJ	prep_of||risk-8/NN||hemorrhage-12/NN	nn||transfusions-15/NNS||blood-14/NN	appos||hemorrhage-12/NN||transfusions-15/NNS	advmod||transmission-20/NN||therefore-18/RB	nn||transmission-20/NN||hepatitis-19/NN	dobj||have-5/VBP||transmission-20/NN	conj_and||risk-8/NN||transmission-20/NN	advmod||hcv-25/NN||mainly-22/RB	amod||hcv-25/NN||hepatitisc-23/JJ	appos||transmission-20/NN||hcv-25/NN	hepatitisc-23||hcv-25||no||furthermore, hemophiliac patients have an increased risk of severe life-threatening hemorrhage, blood transfusions, and therefore hepatitis transmission, mainly hepatitisc (hcv).
det||findings-2/NNS||these-1/DT	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||modulate-8/VB||that-4/IN	nsubj||modulate-8/VB||pde5inhibitors-5/NNS	nsubj||enhance-13/VB||pde5inhibitors-5/NNS	aux||modulate-8/VB||may-6/MD	advmod||modulate-8/VB||effectively-7/RB	ccomp||suggest-3/VBP||modulate-8/VB	dobj||modulate-8/VB||btb-9/NN	advmod||modulate-8/VB||permeability-10/RB	ccomp||suggest-3/VBP||enhance-13/VB	conj_and||modulate-8/VB||enhance-13/VB	nn||efficacy-17/NN||delivery-14/NN	conj_and||delivery-14/NN||therapeutic-16/JJ	nn||efficacy-17/NN||therapeutic-16/JJ	dobj||enhance-13/VB||efficacy-17/NN	amod||antibodies-20/NNS||monoclonal-19/JJ	prep_of||efficacy-17/NN||antibodies-20/NNS	amod||metastases-24/NNS||hard-to-treat-22/JJ	nn||metastases-24/NNS||brain-23/NN	prep_in||antibodies-20/NNS||metastases-24/NNS	amod||tumors-28/NNS||different-26/JJ	amod||tumors-28/NNS||primary-27/JJ	prep_from||enhance-13/VB||tumors-28/NNS	nsubj||metastasized-31/VBN||tumors-28/NNS	aux||metastasized-31/VBN||had-30/VBD	rcmod||tumors-28/NNS||metastasized-31/VBN	det||brain-34/NN||the-33/DT	prep_to||metastasized-31/VBN||brain-34/NN	pde5inhibitors-5||metastasized-31||no_rel||these findings suggest that pde5inhibitors may effectively modulate btb permeability, and enhance delivery and therapeutic efficacy of monoclonal antibodies in hard-to-treat brain metastases from different primary tumors that had metastasized to the brain.
aux||study-2/VB||to-1/TO	csubj||refractory-14/VBD||study-2/VB	det||efficacy-4/NN||the-3/DT	dobj||study-2/VB||efficacy-4/NN	amod||patients-13/NNS||rituximab-6/JJ	amod||rheumatoidarthritis-9/NNS||active-8/JJ	prep_in||rituximab-6/JJ||rheumatoidarthritis-9/NNS	appos||patients-13/NNS||ra-11/NN	prep_of||efficacy-4/NN||patients-13/NNS	root||ROOT-0/null||refractory-14/VBD	prep_to||refractory-14/VBD||disease-16/NN	xcomp||refractory-14/VBD||modifying-17/VBG	amod||drugs-19/NNS||anti-rheumatic-18/JJ	dobj||modifying-17/VBG||drugs-19/NNS	appos||drugs-19/NNS||dmards-21/NNS	det||factor-27/NN||the-24/DT	nn||factor-27/NN||tumor-25/NN	nn||factor-27/NN||necrosis-26/NNS	prep_including||drugs-19/NNS||factor-27/NN	appos||factor-27/NN||tnf-29/NN	nn||antagonists-34/NNS||î-32/NN	nn||antagonists-34/NNS||±-33/NN	dep||factor-27/NN||antagonists-34/NNS	rheumatoidarthritis-9||rituximab-6||no_rel||to study the efficacy of rituximab in active rheumatoidarthritis (ra) patients refractory to disease modifying anti-rheumatic drugs (dmards) including the tumor necrosis factor (tnf)-î± antagonists.
nsubj||mtb-3/VBP||m.tuberculosis-1/NNS	advmod||mtb-3/VBP||-lrb--2/RB	root||ROOT-0/null||mtb-3/VBP	amod||components-7/NNS||-rrb--4/JJ	nn||components-7/NNS||cell-5/NN	nn||components-7/NNS||wall-6/NN	nsubjpass||implicated-10/VBN||components-7/NNS	aux||implicated-10/VBN||have-8/VBP	auxpass||implicated-10/VBN||been-9/VBN	ccomp||mtb-3/VBP||implicated-10/VBN	det||pathogenicity-13/NN||the-12/DT	prep_in||implicated-10/VBN||pathogenicity-13/NN	prep_of||pathogenicity-13/NN||tb-15/NN	advmod||target-22/NN||therefore-17/RB	aux||target-22/NN||have-18/VBP	cop||target-22/NN||been-19/VBN	det||target-22/NN||a-20/DT	amod||target-22/NN||prime-21/JJ	ccomp||mtb-3/VBP||target-22/NN	conj_and||implicated-10/VBN||target-22/NN	det||identification-25/NN||the-24/DT	prep_for||target-22/NN||identification-25/NN	prep_for||target-22/NN||characterization-27/NN	conj_and||identification-25/NN||characterization-27/NN	nn||proteins-31/NNS||cell-29/NN	nn||proteins-31/NNS||wall-30/NN	prep_of||identification-25/NN||proteins-31/NNS	amod||application-34/NN||potential-33/JJ	prep_with||target-22/NN||application-34/NN	nn||development-37/NN||vaccine-36/NN	prep_in||application-34/NN||development-37/NN	tb-15||m.tuberculosis-1||no||m.tuberculosis -lrb- mtb -rrb- cell wall components have been implicated in the pathogenicity of tb and therefore have been a prime target for the identification and characterization of cell wall proteins with potential application in vaccine development .
amod||evidence-2/NN||increasing-1/VBG	nsubj||suggest-3/VBP||evidence-2/NN	root||ROOT-0/null||suggest-3/VBP	mark||related-10/VBN||that-4/IN	det||factors-9/NNS||some-5/DT	amod||factors-9/NNS||crucial-6/JJ	amod||factors-9/NNS||nuclear-7/JJ	nn||factors-9/NNS||transcription-8/NN	nsubj||related-10/VBN||factors-9/NNS	ccomp||suggest-3/VBP||related-10/VBN	prep_to||related-10/VBN||hepatitiscvirus-12/NNS	amod||hepatosteatosis-15/NNS||associated-14/VBN	nsubj||hepatitiscvirus-25/VBZ||hepatosteatosis-15/NNS	conj_and||hepatosteatosis-15/NNS||hepatitiscvirusrna-17/NN	nsubj||hepatitiscvirus-25/VBZ||hepatitiscvirusrna-17/NN	nsubjpass||controlled-21/VBN||itself-18/PRP	aux||controlled-21/VBN||can-19/MD	auxpass||controlled-21/VBN||be-20/VB	rcmod||hepatosteatosis-15/NNS||controlled-21/VBN	amod||anti--24/NNS||specific-23/JJ	agent||controlled-21/VBN||anti--24/NNS	parataxis||suggest-3/VBP||hepatitiscvirus-25/VBZ	dobj||hepatitiscvirus-25/VBZ||nutrition-26/NN	hepatitiscvirusrna-17||hepatitiscvirus-25||no||increasing evidence suggest that some crucial nuclear transcription factors related to hepatitiscvirus -associated hepatosteatosis and hepatitiscvirusrna itself can be controlled by specific anti- hepatitiscvirus nutrition.
det||advantages-3/NNS||the-1/DT	amod||advantages-3/NNS||pharmacological-2/JJ	nsubj||contributed-14/VBN||advantages-3/NNS	det||analog-7/NN||the-5/DT	amod||analog-7/NN||rapid-acting-6/JJ	prep_of||advantages-3/NNS||analog-7/NN	appos||analog-7/NN||insulinaspart-9/NN	prep_over||analog-7/NN||humaninsulin-12/NN	aux||contributed-14/VBN||have-13/VBP	root||ROOT-0/null||contributed-14/VBN	det||prescription-18/NN||the-16/DT	amod||prescription-18/NN||widespread-17/JJ	prep_to||contributed-14/VBN||prescription-18/NN	det||premix-21/NN||the-20/DT	prep_of||prescription-18/NN||premix-21/NN	amod||insulinaspart-24/NN||biphasic-23/JJ	appos||premix-21/NN||insulinaspart-24/NN	num||insulinaspart-24/NN||30/70-25/CD	appos||insulinaspart-24/NN||biasp-27/NN	num||biasp-27/NN||30-28/CD	prep_in||contributed-14/VBN||type-32/NN	num||type-32/NN||1-33/CD	appos||type-32/NN||t1dm-35/NNP	prep_in||contributed-14/VBN||type2diabetes-38/NNS	conj_and||type-32/NN||type2diabetes-38/NNS	appos||type-32/NN||t2dm-40/NNP	type2diabetes-38||insulinaspart-24||yes||the pharmacological advantages of the rapid-acting analog, insulinaspart, over humaninsulin have contributed to the widespread prescription of the premix, biphasic insulinaspart 30/70 (biasp 30), in type 1 (t1dm) and type2diabetes (t2dm).
det||data-2/NNS||these-1/DT	nsubj||show-3/VBP||data-2/NNS	root||ROOT-0/null||show-3/VBP	mark||induces-7/VBZ||that-4/IN	nn||acutely-6/NN||ozone-5/NN	nsubj||induces-7/VBZ||acutely-6/NN	nsubj||insensitive-16/JJ||acutely-6/NN	ccomp||show-3/VBP||induces-7/VBZ	dobj||induces-7/VBZ||ahr-8/NN	aux||cch-10/VB||to-9/TO	vmod||induces-7/VBZ||cch-10/VB	dobj||cch-10/VB||independent-11/JJ	prep_of||independent-11/JJ||inflammation-13/NN	cop||insensitive-16/JJ||is-15/VBZ	ccomp||show-3/VBP||insensitive-16/JJ	conj_and||induces-7/VBZ||insensitive-16/JJ	amod||treatment-19/NN||steroid-18/JJ	prep_to||insensitive-16/JJ||treatment-19/NN	amod||inhibition-25/NN||cyclooxygenase-21/JJ	appos||inhibition-25/NN||cox-23/NN	prep_to||insensitive-16/JJ||inhibition-25/NN	conj_or||treatment-19/NN||inhibition-25/NN	inflammation-13||steroid-18||no_rel||these data show that ozone acutely induces ahr to cch independent of inflammation and is insensitive to steroid treatment or cyclooxygenase (cox) inhibition.
nsubj||represents-14/VBZ||development-1/NN	amod||-lrb--5/NNS||recombinant-3/JJ	nn||-lrb--5/NNS||bcg-4/NN	prep_of||development-1/NN||-lrb--5/NNS	vmod||-lrb--5/NNS||rbcg-6/VBG	amod||antigens-11/NNS||-rrb--7/JJ	amod||antigens-11/NNS||over-expressing-8/JJ	amod||antigens-11/NNS||promising-9/JJ	nn||antigens-11/NNS||immunodominant-10/NN	dobj||rbcg-6/VBG||antigens-11/NNS	prep_of||antigens-11/NNS||m.tuberculosis-13/NNS	root||ROOT-0/null||represents-14/VBZ	dobj||represents-14/VBZ||one-15/CD	det||approaches-19/NNS||the-17/DT	amod||approaches-19/NNS||potential-18/JJ	prep_of||one-15/CD||approaches-19/NNS	det||development-22/NN||the-21/DT	prep_for||approaches-19/NNS||development-22/NN	prep_of||development-22/NN||vaccines-24/NNS	prep_against||vaccines-24/NNS||tb-26/NN	tb-26||bcg-4||yes||development of recombinant bcg -lrb- rbcg -rrb- over-expressing promising immunodominant antigens of m.tuberculosis represents one of the potential approaches for the development of vaccines against tb .
det||study-2/NN||this-1/DT	nsubj||extension-5/NN||study-2/NN	cop||extension-5/NN||was-3/VBD	det||extension-5/NN||the-4/DT	root||ROOT-0/null||extension-5/NN	poss||study-9/NN||our-7/PRP$	nn||study-9/NN||switching-8/NN	prep_of||extension-5/NN||study-9/NN	amod||antipsychotics-12/NNS||other-11/JJ	prep_from||extension-5/NN||antipsychotics-12/NNS	aux||aripiprazole-14/VB||to-13/TO	vmod||extension-5/NN||aripiprazole-14/VB	advmod||stable-17/JJ||symptomatically-16/RB	amod||patients-18/NNS||stable-17/JJ	prep_in||aripiprazole-14/VB||patients-18/NNS	nn||disorder-23/NN||schizophrenia-20/NN	conj_or||schizophrenia-20/NN||schizoaffective-22/NN	nn||disorder-23/NN||schizoaffective-22/NN	prep_with||patients-18/NNS||disorder-23/NN	schizophrenia-20||aripiprazole-14||yes||this study was the extension of our switching study from other antipsychotics to aripiprazole in symptomatically stable patients with schizophrenia or schizoaffective disorder.
prep_in||found-9/VBN||contrast-2/NN	nsubjpass||found-9/VBN||mutations-4/NNS	prep_in||mutations-4/NNS||pfcyt-b-6/NN	auxpass||found-9/VBN||were-7/VBD	neg||found-9/VBN||not-8/RB	root||ROOT-0/null||found-9/VBN	num||patients-12/NNS||three-11/CD	prep_in||found-9/VBN||patients-12/NNS	vmod||patients-12/NNS||treated-13/VBN	prep_with||treated-13/VBN||atovaquone-proguanil-15/NN	nsubj||exhibited-17/VBD||atovaquone-proguanil-15/NN	rcmod||atovaquone-proguanil-15/NN||exhibited-17/VBD	amod||clearance-19/NN||delayed-18/JJ	dobj||exhibited-17/VBD||clearance-19/NN	det||infection-23/NN||the-21/DT	amod||infection-23/NN||primary-22/JJ	prep_of||clearance-19/NN||infection-23/NN	dobj||exhibited-17/VBD||in-26/IN	conj_nor||clearance-19/NN||in-26/IN	pobj||in-26/IN||two-27/CD	xcomp||exhibited-17/VBD||returning-28/VBG	dobj||returning-28/VBG||travellers-29/NNS	prep_with||returning-28/VBG||malaria-31/NN	nsubj||used-34/VBN||malaria-31/NN	aux||used-34/VBN||had-33/VBD	rcmod||malaria-31/NN||used-34/VBN	det||combination-36/NN||the-35/DT	dobj||used-34/VBN||combination-36/NN	prep_for||combination-36/NN||prophylaxis-38/NNS	malaria-31||atovaquone--1||yes||in contrast, mutations in pfcyt-b were not found in three patients treated with atovaquone-proguanil who exhibited delayed clearance of the primary infection, nor in two returning travellers with malaria who had used the combination for prophylaxis.
det||stoichiometries-3/NNS||the-2/DT	nsubj||produce-8/VBP||stoichiometries-3/NNS	nsubj||consume-10/VBP||stoichiometries-3/NNS	prep_from||support-31/VBP||stoichiometries-3/NNS	amod||pathways-6/NNS||metabolic-5/JJ	prep_of||stoichiometries-3/NNS||pathways-6/NNS	rcmod||stoichiometries-3/NNS||produce-8/VBP	rcmod||stoichiometries-3/NNS||consume-10/VBP	conj_or||produce-8/VBP||consume-10/VBP	number||+-12/CD||h-11/CD	dobj||produce-8/VBP||+-12/CD	det||availability-17/NN||the-15/DT	amod||availability-17/NN||greater-16/JJR	dobj||produce-8/VBP||availability-17/NN	conj_and||+-12/CD||availability-17/NN	prep_of||availability-17/NN||glucose-19/NN	prepc_compared_to||produce-8/VBP||to-21/TO	pobj||produce-8/VBP||oxygen-22/NN	amod||parts-25/NNS||most-24/JJS	prep_in||oxygen-22/NN||parts-25/NNS	det||tumor-28/NN||a-27/DT	prep_of||parts-25/NNS||tumor-28/NN	nsubj||support-31/VBP||we-30/PRP	root||ROOT-0/null||support-31/VBP	det||view-34/NN||the-32/DT	amod||view-34/NN||classic-33/JJ	dobj||support-31/VBP||view-34/NN	mark||originates-45/VBZ||that-35/IN	nsubj||originates-45/VBZ||most-36/JJS	nsubj||add-59/VBP||most-36/JJS	det||efflux-41/NN||the-38/DT	amod||efflux-41/NN||net-39/JJ	nn||efflux-41/NN||proton-40/NN	prep_of||most-36/JJS||efflux-41/NN	amod||gliomas-44/NNS||c6-43/JJ	prep_from||efflux-41/NN||gliomas-44/NNS	ccomp||support-31/VBP||originates-45/VBZ	amod||formation-48/NN||glycolytic-47/JJ	prep_in||originates-45/VBZ||formation-48/NN	nn||+-53/NNS||lactate-50/NN	conj_and||lactate-50/NN||h-52/NN	nn||+-53/NNS||h-52/NN	prep_of||formation-48/NN||+-53/NNS	det||tumor-56/NN||the-55/DT	prep_inside||originates-45/VBZ||tumor-56/NN	ccomp||support-31/VBP||add-59/VBP	conj_but||originates-45/VBZ||add-59/VBP	mark||taken-64/VBN||that-60/IN	det||lactate-62/NN||some-61/DT	nsubjpass||taken-64/VBN||lactate-62/NN	auxpass||taken-64/VBN||is-63/VBZ	ccomp||add-59/VBP||taken-64/VBN	prt||taken-64/VBN||up-65/RP	prep_into||taken-64/VBN||cells-67/NNS	det||rim-70/NN||the-69/DT	prep_in||cells-67/NNS||rim-70/NN	prep_on||rim-70/NN||mct1-72/CD	det||lactate-76/NN||some-75/DT	nsubj||diffuses-77/VBZ||lactate-76/NN	ccomp||add-59/VBP||diffuses-77/VBZ	conj_and||taken-64/VBN||diffuses-77/VBZ	prt||diffuses-77/VBZ||away-78/RP	xcomp||diffuses-77/VBZ||leaving-80/VBG	poss||protons-83/NNS||its-81/PRP$	amod||protons-83/NNS||associated-82/JJ	dobj||leaving-80/VBG||protons-83/NNS	acomp||originates-45/VBZ||available-84/JJ	aux||re-enter-86/VB||to-85/TO	xcomp||available-84/JJ||re-enter-86/VB	dobj||re-enter-86/VB||cells-87/NNS	prep_for||cells-87/NNS||extrusion-89/NN	prep_on||re-enter-86/VB||nhe1-91/CD	oxygen-22||tumor-56||no_rel||from the stoichiometries of metabolic pathways that produce or consume h+, and the greater availability of glucose compared to oxygen in most parts of a tumor, we support the classic view that most of the net proton efflux from c6 gliomas originates in glycolytic formation of lactate and h+ inside the tumor, but add that some lactate is taken up into cells in the rim on mct1, and some lactate diffuses away, leaving its associated protons available to re-enter cells for extrusion on nhe1.
aux||characterize-3/VB||to-1/TO	advmod||characterize-3/VB||better-2/RBR	dep||tested-14/VBD||characterize-3/VB	dobj||characterize-3/VB||mutations-4/NNS	amod||oncogenes-8/NNP||established-6/VBN	amod||oncogenes-8/NNP||known-7/VBN	prep_in||mutations-4/NNS||oncogenes-8/NNP	nn||genes-12/NNS||tumor-10/NN	nn||genes-12/NNS||suppressor-11/NN	prep_in||mutations-4/NNS||genes-12/NNS	conj_and||oncogenes-8/NNP||genes-12/NNS	nsubj||tested-14/VBD||we-13/PRP	root||ROOT-0/null||tested-14/VBD	det||spectrometric-17/NN||a-15/DT	amod||spectrometric-17/NN||mass-16/JJ	dobj||tested-14/VBD||spectrometric-17/NN	vmod||spectrometric-17/NN||based-18/VBN	dobj||based-18/VBN||platform-19/NN	aux||interrogate-21/VB||to-20/TO	vmod||based-18/VBN||interrogate-21/VB	amod||cancer-23/NN||common-22/JJ	dobj||interrogate-21/VB||cancer-23/NN	vmod||cancer-23/NN||associated-24/VBN	dobj||associated-24/VBN||mutations-25/NNS	det||panel-28/NN||a-27/DT	prep_across||associated-24/VBN||panel-28/NN	num||paraffin-33/NNS||77-30/CD	nn||paraffin-33/NNS||formalin-31/NN	amod||paraffin-33/NNS||fixed-32/VBN	prep_of||panel-28/NN||paraffin-33/NNS	vmod||paraffin-33/NNS||embedded-34/VBN	amod||cases-37/NNS||archived-35/JJ	nn||cases-37/NNS||btc-36/NN	dobj||embedded-34/VBN||cases-37/NNS	formalin-31||tumor-10||no_rel||to better characterize mutations in established known oncogenes and tumor suppressor genes we tested a mass spectrometric based platform to interrogate common cancer associated mutations across a panel of 77 formalin fixed paraffin embedded archived btc cases.
mark||contained-8/VBD||while-1/IN	det||diet-4/NN||the-2/DT	amod||diet-4/NN||high-fat-3/JJ	nsubj||contained-8/VBD||diet-4/NN	appos||diet-4/NN||hfd-6/NN	advcl||found-34/VBD||contained-8/VBD	nn||levels-10/NNS||equivalent-9/NN	nsubj||'s-24/VBZ||levels-10/NNS	amod||fattyacids-13/NNS||n-3-12/JJ	prep_of||levels-10/NNS||fattyacids-13/NNS	appos||fattyacids-13/NNS||fa-15/NN	possessive||fa-15/NN||'s-16/POS	amod||levels-20/NNS||higher-19/JJR	prep_of||levels-10/NNS||levels-20/NNS	conj_and||fattyacids-13/NNS||levels-20/NNS	amod||fa-23/NN||n-6-22/JJ	prep_of||levels-20/NNS||fa-23/NN	ccomp||contained-8/VBD||'s-24/VBZ	det||diet-28/NN||the-26/DT	nn||diet-28/NN||control-27/NN	prep_than||'s-24/VBZ||diet-28/NN	appos||diet-28/NN||ctr-30/NN	nsubj||found-34/VBD||we-33/PRP	root||ROOT-0/null||found-34/VBD	amod||decreases-36/NNS||significant-35/JJ	nsubj||'s-47/VBZ||decreases-36/NNS	amod||acid-39/NN||docosahexaenoic-38/JJ	prep_in||decreases-36/NNS||acid-39/NN	appos||acid-39/NN||dha-41/NN	amod||fa-46/NN||total-44/JJ	amod||fa-46/NN||n-3-45/JJ	prep_in||decreases-36/NNS||fa-46/NN	conj_and||acid-39/NN||fa-46/NN	ccomp||found-34/VBD||'s-47/VBZ	nn||maternal-50/NN||hfd-49/NN	prep_in||'s-47/VBZ||maternal-50/NN	amod||plasma-53/NN||fetal-52/JJ	prep_in||'s-47/VBZ||plasma-53/NN	conj_and||maternal-50/NN||plasma-53/NN	dha-41||fa-46||no_rel||while the high-fat diet (hfd) contained equivalent levels of n-3 fattyacids (fa's) and higher levels of n-6 fa's than the control diet (ctr), we found significant decreases in docosahexaenoic acid (dha) and total n-3 fa's in hfd maternal and fetal plasma.
amod||time-4/NN||sensory-1/JJ	nn||time-4/NN||block-2/NN	nn||time-4/NN||onset-3/NN	nsubjpass||defined-13/VBN||time-4/NN	nsubj||fentanyl-21/VB||time-4/NN	nsubjpass||recorded-35/VBN||time-4/NN	amod||time-9/NN||tourniquet-6/JJ	nn||time-9/NN||pain-7/NN	nn||time-9/NN||onset-8/NN	appos||time-4/NN||time-9/NN	auxpass||defined-13/VBN||was-12/VBD	rcmod||time-4/NN||defined-13/VBN	det||time-16/NN||the-15/DT	prep_as||defined-13/VBN||time-16/NN	amod||application-19/NN||tourniquet-18/JJ	prep_from||time-16/NN||application-19/NN	aux||fentanyl-21/VB||to-20/TO	xcomp||defined-13/VBN||fentanyl-21/VB	dobj||fentanyl-21/VB||administration-22/NN	prepc_for||fentanyl-21/VB||relieving-24/VBG	nn||pain-26/NN||tourniquet-25/NN	dobj||relieving-24/VBG||pain-26/NN	dobj||relieving-24/VBG||amount-28/NN	conj_and||pain-26/NN||amount-28/NN	amod||consumption-31/NN||analgesic-30/JJ	prep_of||pain-26/NN||consumption-31/NN	prep_during||relieving-24/VBG||surgery-33/NN	auxpass||recorded-35/VBN||were-34/VBD	root||ROOT-0/null||recorded-35/VBN	pain-26||fentanyl-21||yes||sensory block onset time, tourniquet pain onset time, which was defined as the time from tourniquet application to fentanyl administration for relieving tourniquet pain and amount of analgesic consumption during surgery were recorded.
vmod||detected-28/VBN||using-1/VBG	amod||chromatography-3/JJ||liquid-2/JJ	amod||techniques-7/NNS||chromatography-3/JJ	amod||techniques-7/NNS||mass-4/JJ	advmod||lipidomics-6/JJ||spectrometry-5/RB	amod||techniques-7/NNS||lipidomics-6/JJ	dobj||using-1/VBG||techniques-7/NNS	det||screen-11/NN||an-9/DT	amod||screen-11/NN||initial-10/JJ	prep_for||using-1/VBG||screen-11/NN	num||species-15/NNS||200-13/CD	nn||species-15/NNS||lipid-14/NN	prep_of||screen-11/NN||species-15/NNS	amod||changes-18/NNS||significant-17/JJ	nsubjpass||detected-28/VBN||changes-18/NNS	num||species-26/NNS||79-20/CD	amod||species-26/NNS||sphingolipid-21/JJ	conj_and||sphingolipid-21/JJ||glycerophospholipid-23/JJ	amod||species-26/NNS||glycerophospholipid-23/JJ	conj_and||sphingolipid-21/JJ||cholesterol-25/NN	amod||species-26/NNS||cholesterol-25/NN	prep_in||changes-18/NNS||species-26/NNS	auxpass||detected-28/VBN||were-27/VBD	root||ROOT-0/null||detected-28/VBN	det||cortex-32/NN||the-30/DT	amod||cortex-32/NN||visual-31/JJ	prep_in||detected-28/VBN||cortex-32/NN	amod||patients-37/NNS||parkinson-34/JJ	nn||patients-37/NNS||sdisease-36/NN	prep_of||cortex-32/NN||patients-37/NNS	parataxis||detected-28/VBN||nâ-39/VB	num||â-43/NN||$-40/$	number||=-42/CD||š-41/CD	num||$-40/$||=-42/CD	dobj||nâ-39/VB||â-43/NN	amod||â-43/NN||$-44/$	dep||$-44/$||š10-45/JJ	prepc_compared_to||detected-28/VBN||to-48/TO	pobj||detected-28/VBN||controls-49/NNS	dep||controls-49/NNS||nâ-51/NN	num||â-55/NN||$-52/$	number||=-54/CD||š-53/CD	num||$-52/$||=-54/CD	dep||nâ-51/NN||â-55/NN	dep||â-55/NN||$-56/$	num||$-56/$||š10-57/CD	dep||test-66/NN||assessed-60/NNP	amod||t-64/NN||two-sided-62/JJ	amod||t-64/NN||unpaired-63/JJ	prep_by||assessed-60/NNP||t-64/NN	prep_as||controls-49/NNS||test-66/NN	dep||test-66/NN||p-68/NN	nn||0.05-72/NNP||value-70/NN	nn||0.05-72/NNP||<-71/NNP	dep||p-68/NN||0.05-72/NNP	lipid-14||parkinson'sdisease--1||no_rel||using liquid chromatography mass spectrometry lipidomics techniques for an initial screen of 200 lipid species, significant changes in 79 sphingolipid, glycerophospholipid and cholesterol species were detected in the visual cortex of parkinson'sdisease patients (nâ€š=â€š10) compared to controls (nâ€š=â€š10) as assessed by two-sided unpaired t -test ( p- value <0.05).
root||ROOT-0/null||using-1/VBG	dobj||using-1/VBG||data-2/NNS	prep_on||using-1/VBG||mammals-4/NNS	dep||using-1/VBG||imported-5/VBD	prep_during||imported-5/VBD||2000â-7/CD	nsubj||using-1/VBG||$-8/$	npadvmod||host-17/RB||2005-10/NNS	dep||2005-10/NNS||we-12/PRP	poss||potential-15/NN||their-14/PRP$	prep_assessed||2005-10/NNS||potential-15/NN	vmod||potential-15/NN||to-16/TO	dep||27-18/CD||host-17/RB	num||$-8/$||27-18/CD	dep||$-8/$||selected-19/VBN	nn||zoonoses-21/NNS||risk-20/NN	dobj||selected-19/VBN||zoonoses-21/NNS	dep||$-8/$||created-23/VBN	conj_and||selected-19/VBN||created-23/VBN	det||assessment-26/NN||a-24/DT	nn||assessment-26/NN||risk-25/NN	dobj||created-23/VBN||assessment-26/NN	nsubj||inform-29/VB||assessment-26/NN	aux||inform-29/VB||could-28/MD	rcmod||assessment-26/NN||inform-29/VB	dobj||inform-29/VB||policy-30/NN	vmod||policy-30/NN||making-31/VBG	nn||importation-34/NN||wildlife-33/NN	prep_for||making-31/VBG||importation-34/NN	amod||surveillance-37/NN||zoonoticdisease-36/JJ	nsubj||using-1/VBG||surveillance-37/NN	conj_and||$-8/$||surveillance-37/NN	zoonoticdisease-36||inform-29||no_rel||using data on mammals imported during 2000â€“2005, we assessed their potential to host 27 selected risk zoonoses and created a risk assessment that could inform policy making for wildlife importation and zoonoticdisease surveillance.
aux||identify-2/VB||to-1/TO	advcl||performed-18/VBN||identify-2/VB	amod||locations-5/NNS||new-3/JJ	amod||locations-5/NNS||genomic-4/JJ	dobj||identify-2/VB||locations-5/NNS	vmod||locations-5/NNS||associated-6/VBN	prep_with||associated-6/VBN||irondeficiency-8/NN	det||study-13/NN||a-10/DT	amod||study-13/NN||genome-wide-11/JJ	nn||study-13/NN||association-12/NN	nsubjpass||performed-18/VBN||study-13/NN	appos||study-13/NN||gwas-15/NNS	auxpass||performed-18/VBN||was-17/VBD	root||ROOT-0/null||performed-18/VBN	xcomp||performed-18/VBN||using-19/VBG	dobj||using-19/VBG||dna-20/NN	vmod||dna-20/NN||collected-21/VBN	amod||men-24/NNS||white-23/JJ	prep_from||collected-21/VBN||men-24/NNS	vmod||men-24/NNS||aged-25/VBN	number||‰-27/CD||â-26/CD	num||y-30/NN||‰-27/CD	nn||y-30/NN||¥-28/NNP	num||y-30/NN||25-29/CD	dobj||aged-25/VBN||y-30/NN	nn||‰-34/NN||women-32/NNS	nn||‰-34/NN||â-33/NN	dobj||aged-25/VBN||‰-34/NN	conj_and||y-30/NN||‰-34/NN	vmod||y-30/NN||¥-35/VBG	num||y-37/NN||50-36/CD	dobj||¥-35/VBG||y-37/NN	det||study-47/NN||the-39/DT	amod||study-47/NN||hemochromatosis-40/JJ	conj_and||hemochromatosis-40/JJ||ironoverload-42/JJ	amod||study-47/NN||ironoverload-42/JJ	nn||study-47/NN||screening-43/NN	appos||study-47/NN||heirs-45/NNS	prep_in||y-37/NN||study-47/NN	amod||controls-67/NNS||serum-49/JJ	amod||controls-67/NNS||ferritin-50/JJ	appos||controls-67/NNS||sf-52/NN	nn||controls-67/NNS||â-54/NN	amod||controls-67/NNS||‰-55/JJ	amod||controls-67/NNS||$-56/$	number||$-56/$||12-57/CD	nn||controls-67/NNS||âµg-58/NN	punct||replete-66/JJ||/-59/:	amod||cases-62/NNS||l-60/JJ	dep||replete-66/JJ||cases-62/NNS	conj_and||cases-62/NNS||iron-65/NN	dep||replete-66/JJ||iron-65/NN	dep||controls-67/NNS||replete-66/JJ	prep_with||¥-35/VBG||controls-67/NNS	dep||controls-67/NNS||sf-69/VBN	number||100-71/CD||>-70/CD	num||âµg-72/NN||100-71/CD	iobj||sf-69/VBN||âµg-72/NN	punct||l-74/NN||/-73/:	dep||âµg-72/NN||l-74/NN	prep_in||l-74/NN||men-76/NNS	advmod||50-80/CD||sf-78/RB	number||50-80/CD||>-79/CD	appos||l-74/NN||50-80/CD	dep||50-80/CD||âµg-81/NN	punct||l-74/NN||/-82/:	dobj||sf-69/VBN||l-83/NN	prep_in||sf-69/VBN||women-85/NNS	hemochromatosis-40||iron-65||no||to identify new genomic locations associated with irondeficiency, a genome-wide association study (gwas) was performed using dna collected from white men aged â‰¥25 y and women â‰¥50 y in the hemochromatosis and ironoverload screening (heirs) study with serum ferritin (sf) â‰¤ 12 âµg/l (cases) and iron replete controls (sf>100 âµg/l in men, sf>50 âµg/l in women).
nsubj||rare-32/JJ||diseases-1/NNS	vmod||diseases-1/NNS||associated-2/VBN	amod||infections-8/NNS||epstein-barrvirus-4/JJ	appos||infections-8/NNS||ebv-6/NN	prep_with||associated-2/VBN||infections-8/NNS	prep_such_as||associated-2/VBN||infectiousmononucleosis-12/NNS	appos||infectiousmononucleosis-12/NNS||im-14/NN	amod||lymphohistiocytosis-19/NNS||ebv-associated-17/JJ	amod||lymphohistiocytosis-19/NNS||hemophagocytic-18/JJ	prep_such_as||associated-2/VBN||lymphohistiocytosis-19/NNS	conj_and||infectiousmononucleosis-12/NNS||lymphohistiocytosis-19/NNS	appos||lymphohistiocytosis-19/NNS||ebv-hlh-21/NN	amod||ebvinfection-26/NN||chronic-24/JJ	amod||ebvinfection-26/NN||active-25/JJ	prep_such_as||associated-2/VBN||ebvinfection-26/NN	conj_and||infectiousmononucleosis-12/NNS||ebvinfection-26/NN	appos||ebvinfection-26/NN||caebv-28/NNP	cop||rare-32/JJ||are-30/VBP	neg||rare-32/JJ||not-31/RB	root||ROOT-0/null||rare-32/JJ	amod||children-35/NNS||chinese-34/JJ	prep_in||rare-32/JJ||children-35/NNS	ebvinfection-26||ebv-6||no||diseases associated with epstein-barrvirus (ebv) infections, such as infectiousmononucleosis (im), ebv-associated hemophagocytic lymphohistiocytosis (ebv-hlh) and chronic active ebvinfection (caebv) are not rare in chinese children.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||roles-8/NNS||the-7/DT	dobj||investigated-6/VBD||roles-8/NNS	iobj||investigated-6/VBD||roles-8/NNS	nn||helper-12/NN||t-10/NN	nn||helper-12/NN||follicular-11/NN	prep_of||roles-8/NNS||helper-12/NN	appos||roles-8/NNS||tfh-14/NN	dep||roles-8/NNS||cells-16/NNS	amod||molecules-19/NNS||related-18/VBN	dep||roles-8/NNS||molecules-19/NNS	conj_and||cells-16/NNS||molecules-19/NNS	det||pathogenesis-22/NNS||the-21/DT	prep_in||investigated-6/VBD||pathogenesis-22/NNS	nn||infection-28/NN||chronichepatitisbvirus-24/NNP	appos||infection-28/NN||hbv-26/NN	prep_of||pathogenesis-22/NNS||infection-28/NN	hbv-26||hepatitisbvirus--1||no||in this study, we investigated the roles of t follicular helper (tfh) cells and related molecules in the pathogenesis of chronichepatitisbvirus (hbv) infection.
nsubj||inhibited-12/VBD||inhibition-1/NN	nsubj||prevented-23/VBD||inhibition-1/NN	nn||synthesis-4/NN||cholesterol-3/NN	prep_of||inhibition-1/NN||synthesis-4/NN	prep_of||inhibition-1/NN||accumulation-6/NN	conj_and||synthesis-4/NN||accumulation-6/NN	prep_of||synthesis-4/NN||lanosterol-8/NN	amod||treatment-11/NN||ketoconazole-10/JJ	prep_after||lanosterol-8/NN||treatment-11/NN	root||ROOT-0/null||inhibited-12/VBD	dobj||inhibited-12/VBD||uptake-13/NN	nn||integrin-20/NNS||collagen-15/NN	conj_and||collagen-15/NN||virus-17/NN	nn||integrin-20/NNS||virus-17/NN	conj_and||collagen-15/NN||clustered-19/NN	nn||integrin-20/NNS||clustered-19/NN	prep_of||uptake-13/NN||integrin-20/NNS	conj_and||inhibited-12/VBD||prevented-23/VBD	dobj||prevented-23/VBD||formation-24/NN	nn||bodies-27/NNS||multivesicular-26/NN	prep_of||formation-24/NN||bodies-27/NNS	prep_of||formation-24/NN||virusinfection-29/NNS	conj_and||bodies-27/NNS||virusinfection-29/NNS	collagen-15||virus-17||no_rel||inhibition of cholesterol synthesis and accumulation of lanosterol after ketoconazole treatment inhibited uptake of collagen, virus and clustered integrin, and prevented formation of multivesicular bodies and virusinfection.
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	num||patients-4/NNS||15-3/CD	nsubj||were-2/VBD||patients-4/NNS	det||group-7/NN||both-6/DT	prep_in||patients-4/NNS||group-7/NN	dep||group-7/NN||a-8/SYM	dep||group-7/NN||groupb-10/JJ	conj_and||a-8/SYM||groupb-10/JJ	rcmod||patients-4/NNS||mean-12/VBP	amod||values-19/NNS||a1c-13/JJ	num||values-19/NNS||-lrb--14/CD	number||%-16/NN||95-15/CD	amod||values-19/NNS||%-16/NN	nn||values-19/NNS||ci-17/NN	nn||values-19/NNS||-rrb--18/NN	nsubj||fell-20/VBD||values-19/NNS	ccomp||mean-12/VBP||fell-20/VBD	advmod||fell-20/VBD||in-21/RB	det||-lrb--24/NN||both-22/DT	nn||-lrb--24/NN||groups-23/NNS	iobj||fell-20/VBD||-lrb--24/NN	number||%-26/NN||7.40-25/CD	amod||-lrb--24/NN||%-26/NN	number||6.60-28/CD||-lsb--27/CD	num||â-29/NN||6.60-28/CD	iobj||fell-20/VBD||â-29/NN	iobj||fell-20/VBD||$-30/$	advmod||-rsb--33/RB||8.19-32/RB	dep||-lsb--37/CD||-rsb--33/RB	num||%-36/NN||6.96-35/CD	prep_to||-rsb--33/RB||%-36/NN	num||$-30/$||-lsb--37/CD	npadvmod||â-39/JJ||6.27-38/CD	amod||$-30/$||â-39/JJ	dep||fell-20/VBD||$-40/$	num||-rsb--43/NN||7.25-42/CD	npadvmod||6.03-66/RB||-rsb--43/NN	dep||<-46/NNP||p-45/RB	dep||-rsb--43/NN||<-46/NNP	num||<-46/NNP||0.01-47/CD	amod||iron-51/NN||intravenous-50/JJ	prep_with||<-46/NNP||iron-51/NN	num||%-54/NN||7.31-53/CD	prep_with||<-46/NNP||%-54/NN	conj_and||iron-51/NN||%-54/NN	number||6.42-56/CD||-lsb--55/CD	num||%-54/NN||6.42-56/CD	dep||$-58/$||â-57/RB	dep||-rsb--43/NN||$-58/$	advmod||-rsb--61/RB||8.54-60/RB	dep||-lsb--65/CD||-rsb--61/RB	num||%-64/NN||6.63-63/CD	prep_to||-rsb--61/RB||%-64/NN	num||$-58/$||-lsb--65/CD	dep||â-67/CD||6.03-66/RB	num||$-40/$||â-67/CD	dobj||fell-20/VBD||$-68/$	advmod||-rsb--71/JJ||7.36-70/RB	amod||p-73/NNS||-rsb--71/JJ	npadvmod||=-74/RB||p-73/NNS	dep||0.013-75/CD||=-74/RB	num||$-68/$||0.013-75/CD	nn||-rrb--78/NNS||esa-77/NN	dobj||fell-20/VBD||-rrb--78/NNS	groupb-10||iron-51||no_rel||there were 15 patients in both group a and groupb. mean a1c -lrb- 95 % ci -rrb- values fell in both groups -lrb- 7.40 % -lsb- 6.60 â $ `` 8.19 -rsb- to 6.96 % -lsb- 6.27 â $ `` 7.25 -rsb- , p < 0.01 , with intravenous iron and 7.31 % -lsb- 6.42 â $ `` 8.54 -rsb- to 6.63 % -lsb- 6.03 â $ `` 7.36 -rsb- , p = 0.013 , esa -rrb- .
det||results-2/NNS||these-1/DT	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||enhances-10/VBZ||that-4/IN	nsubj||enhances-10/VBZ||inhibition-5/NN	nsubj||indicates-18/VBZ||inhibition-5/NN	det||receptor-9/NN||the-7/DT	amod||receptor-9/NN||glucocorticoid-8/JJ	prep_of||inhibition-5/NN||receptor-9/NN	ccomp||suggest-3/VBP||enhances-10/VBZ	amod||integration-12/NN||retroviral-11/JJ	dobj||enhances-10/VBZ||integration-12/NN	det||genome-16/NN||the-14/DT	nn||genome-16/NN||host-15/NN	prep_into||enhances-10/VBZ||genome-16/NN	ccomp||suggest-3/VBP||indicates-18/VBZ	conj_and||enhances-10/VBZ||indicates-18/VBZ	mark||have-22/VB||that-19/IN	nsubj||have-22/VB||cells-20/NNS	aux||have-22/VB||may-21/MD	ccomp||indicates-18/VBZ||have-22/VB	det||protection-25/NN||a-23/DT	amod||protection-25/NN||natural-24/JJ	dobj||have-22/VB||protection-25/NN	nsubjpass||reduced-31/VBN||protection-25/NN	advmod||retroviralinfection-27/VBN||again-26/RB	vmod||protection-25/NN||retroviralinfection-27/VBN	aux||reduced-31/VBN||may-29/MD	auxpass||reduced-31/VBN||be-30/VB	rcmod||protection-25/NN||reduced-31/VBN	amod||antagonists-35/NNS||glucocorticoid-33/JJ	nn||antagonists-35/NNS||receptor-34/NN	agent||reduced-31/VBN||antagonists-35/NNS	retroviralinfection-27||retroviral-11||no||these results suggest that inhibition of the glucocorticoid receptor enhances retroviral integration into the host genome and indicates that cells may have a natural protection again retroviralinfection that may be reduced by glucocorticoid receptor antagonists.
advmod||assessed-17/VBN||here-1/RB	det||significance-5/NN||the-3/DT	amod||significance-5/NN||prognostic-4/JJ	nsubjpass||assessed-17/VBN||significance-5/NN	det||marker-9/NN||this-7/DT	amod||marker-9/NN||epigenetic-8/JJ	prep_of||significance-5/NN||marker-9/NN	amod||toxicity-15/NN||severe-13/JJ	amod||toxicity-15/NN||5-fu-14/JJ	prep_with_respect_to||marker-9/NN||toxicity-15/NN	auxpass||assessed-17/VBN||was-16/VBD	root||ROOT-0/null||assessed-17/VBN	num||patients-21/NNS||27-19/CD	nn||patients-21/NNS||cancer-20/NN	prep_in||assessed-17/VBN||patients-21/NNS	vmod||patients-21/NNS||receiving-22/VBG	dobj||receiving-22/VBG||5-fu-23/JJ	vmod||5-fu-23/JJ||based-24/VBN	advmod||based-24/VBN||chemotherapy-25/RB	num||patients-29/NNS||17-28/CD	prep_including||based-24/VBN||patients-29/NNS	vmod||patients-29/NNS||experiencing-30/VBG	amod||effects-34/NNS||severe-31/JJ	amod||effects-34/NNS||toxic-32/JJ	nn||effects-34/NNS||side-33/NN	dobj||experiencing-30/VBG||effects-34/NNS	nn||administration-37/NN||drug-36/NN	prep_following||effects-34/NNS||administration-37/NN	prep_of||none-39/NN||administration-37/NN	nsubj||carriers-43/NNS||none-39/NN	cop||carriers-43/NNS||were-42/VBD	rcmod||administration-37/NN||carriers-43/NNS	det||mutation-49/NN||a-45/DT	amod||mutation-49/NN||known-46/JJ	amod||mutation-49/NN||deleterious-47/JJ	amod||mutation-49/NN||dpyd-48/JJ	prep_of||carriers-43/NNS||mutation-49/NN	num||patients-54/NNS||ten-52/CD	nn||patients-54/NNS||control-53/NN	dobj||receiving-22/VBG||patients-54/NNS	conj_and||5-fu-23/JJ||patients-54/NNS	5-fu-23||ten-52||no_rel||here, the prognostic significance of this epigenetic marker with respect to severe 5-fu toxicity was assessed in 27 cancer patients receiving 5-fu based chemotherapy, including 17 patients experiencing severe toxic side effects following drug administration, none of which were carriers of a known deleterious dpyd mutation, and ten control patients.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	det||case-6/NN||the-3/DT	amod||case-6/NN||first-4/JJ	amod||case-6/NN||known-5/JJ	dobj||present-2/VBP||case-6/NN	det||patient-9/NN||a-8/DT	prep_of||case-6/NN||patient-9/NN	amod||squamouscellcarcinoma-12/NN||cervical-11/JJ	prep_with||present-2/VBP||squamouscellcarcinoma-12/NN	vmod||squamouscellcarcinoma-12/NN||complicated-13/VBN	amod||syndromes-16/NNS||paraneoplastic-15/JJ	agent||complicated-13/VBN||syndromes-16/NNS	det||secretion-22/NN||both-18/DT	amod||secretion-22/NN||dermatomyositis-19/JJ	conj_and||dermatomyositis-19/JJ||inappropriate-21/JJ	amod||secretion-22/NN||inappropriate-21/JJ	prep_of||syndromes-16/NNS||secretion-22/NN	amod||hormone-25/NN||antidiuretic-24/JJ	prep_of||secretion-22/NN||hormone-25/NN	appos||hormone-25/NN||siadh-27/NN	siadh-27||hormone-25||no_rel||we present the first known case of a patient with cervical squamouscellcarcinoma complicated by paraneoplastic syndromes of both dermatomyositis and inappropriate secretion of antidiuretic hormone (siadh).
nsubj||benefit-9/VB||clinicians-1/NNS	amod||countries-7/NNS||low-3/JJ	conj_and||low-3/JJ||middle-5/JJ	amod||countries-7/NNS||middle-5/JJ	nn||countries-7/NNS||income-6/NN	prep_in||clinicians-1/NNS||countries-7/NNS	aux||benefit-9/VB||could-8/MD	root||ROOT-0/null||benefit-9/VB	amod||training-12/NN||targeted-11/JJ	prep_from||benefit-9/VB||training-12/NN	amod||care-15/NN||chronic-14/JJ	prep_in||training-12/NN||care-15/NN	amod||adults-18/NNS||older-17/JJR	prep_for||benefit-9/VB||adults-18/NNS	prep_with||adults-18/NNS||hiv/aids-20/NNS	amod||complications-23/NNS||long-term-22/JJ	prep_for||benefit-9/VB||complications-23/NNS	conj_and||adults-18/NNS||complications-23/NNS	amod||treatment-26/NN||antiretroviral-25/JJ	prep_of||complications-23/NNS||treatment-26/NN	aids--1||hiv--1||no||clinicians in low and middle income countries could benefit from targeted training in chronic care for older adults with hiv/aids and long-term complications of antiretroviral treatment.
nsubj||tested-5/VBD||samples-1/NNS	amod||plants-4/NNS||symptomatic-3/JJ	prep_from||samples-1/NNS||plants-4/NNS	root||ROOT-0/null||tested-5/VBD	acomp||tested-5/VBD||negative-6/JJ	prep_for||negative-6/JJ||infection-8/NN	amod||virus-13/NN||tomato-10/JJ	amod||virus-13/NN||spotted-11/JJ	nn||virus-13/NN||wilt-12/NN	prep_by||tested-5/VBD||virus-13/NN	nn||virus-17/NN||tobacco-15/NN	nn||virus-17/NN||streak-16/NN	prep_by||tested-5/VBD||virus-17/NN	conj_and||virus-13/NN||virus-17/NN	nn||virus-21/NN||tobacco-19/NN	nn||virus-21/NN||etch-20/NN	prep_by||tested-5/VBD||virus-21/NN	conj_and||virus-13/NN||virus-21/NN	amod||viruses-26/NNS||other-23/JJ	amod||viruses-26/NNS||known-24/JJ	amod||viruses-26/NNS||tomato-infecting-25/JJ	prep_by||tested-5/VBD||viruses-26/NNS	conj_and||virus-13/NN||viruses-26/NNS	virus-21||viruses-26||no||samples from symptomatic plants tested negative for infection by tomato spotted wilt virus, tobacco streak virus, tobacco etch virus and other known tomato-infecting viruses.
amod||5-fluorouracil-2/NN||adjuvant-1/JJ	root||ROOT-0/null||5-fluorouracil-2/NN	appos||5-fluorouracil-2/NN||5fu-4/NNP	vmod||5-fluorouracil-2/NN||based-7/VBN	nsubjpass||considered-11/VBN||chemo-radiotherapy-8/NN	auxpass||considered-11/VBN||is-9/VBZ	advmod||considered-11/VBN||currently-10/RB	ccomp||based-7/VBN||considered-11/VBN	det||standard-13/NN||a-12/DT	dobj||considered-11/VBN||standard-13/NN	prep_of||standard-13/NN||care-15/NN	det||treatment-18/NN||the-17/DT	prep_for||5-fluorouracil-2/NN||treatment-18/NN	amod||cancer-21/NN||gastric-20/JJ	prep_of||treatment-18/NN||cancer-21/NN	cancer-21||5-fluorouracil-2||no_rel||adjuvant 5-fluorouracil (5fu)-based chemo-radiotherapy is currently considered a standard of care for the treatment of gastric cancer.
nsubj||improve-20/VB||addition-1/NN	nsubj||increased-25/VBD||addition-1/NN	amod||cancer-17/NN||oxaliplatin-3/JJ	prep_to||oxaliplatin-3/JJ||fluoropyrimidines-5/NNS	amod||chemoradiotherapy-8/NN||preoperative-7/JJ	prep_for||fluoropyrimidines-5/NNS||chemoradiotherapy-8/NN	prep_in||chemoradiotherapy-8/NN||patients-10/NNS	nn||ii-13/NN||stage-12/NN	prep_with||patients-10/NNS||ii-13/NN	prep_with||patients-10/NNS||iii-15/NN	conj_or||ii-13/NN||iii-15/NN	amod||cancer-17/NN||rectal-16/JJ	prep_of||addition-1/NN||cancer-17/NN	aux||improve-20/VB||did-18/VBD	neg||improve-20/VB||not-19/RB	root||ROOT-0/null||improve-20/VB	amod||response-23/NN||local-21/JJ	nn||response-23/NN||tumor-22/NN	dobj||improve-20/VB||response-23/NN	conj_but||improve-20/VB||increased-25/VBD	dobj||increased-25/VBD||toxicities-26/NNS	oxaliplatin-3||tumor-22||no_rel||addition of oxaliplatin to fluoropyrimidines for preoperative chemoradiotherapy in patients with stage ii or iii rectal cancer did not improve local tumor response but increased toxicities.
det||prevalence-3/NN||the-1/DT	amod||prevalence-3/NN||high-2/JJ	nsubj||resulted-10/VBN||prevalence-3/NN	prep_of||prevalence-3/NN||humanimmunodeficiencyvirus/acquiredimmunedeficiencysyndrome-5/NN	amod||africa-8/NN||sub-saharan-7/JJ	prep_in||humanimmunodeficiencyvirus/acquiredimmunedeficiencysyndrome-5/NN||africa-8/NN	aux||resulted-10/VBN||has-9/VBZ	root||ROOT-0/null||resulted-10/VBN	det||increase-14/NN||a-12/DT	amod||increase-14/NN||dramatic-13/JJ	prep_in||resulted-10/VBN||increase-14/NN	amod||children-19/NNS||orphans-16/JJ	conj_and||orphans-16/JJ||vulnerable-18/JJ	amod||children-19/NNS||vulnerable-18/JJ	prep_in||increase-14/NN||children-19/NNS	appos||children-19/NNS||ovc-21/NN	det||decade-26/NN||the-24/DT	amod||decade-26/NN||past-25/JJ	prep_over||resulted-10/VBN||decade-26/NN	acquiredimmunedeficiencysyndrome--1||humanimmunodeficiencyvirus--1||no||the high prevalence of humanimmunodeficiencyvirus/acquiredimmunedeficiencysyndrome in sub-saharan africa has resulted in a dramatic increase in orphans and vulnerable children (ovc) over the past decade.
nn||parameters-2/NNS||agitation-1/NN	nsubjpass||measured-16/VBN||parameters-2/NNS	nn||times-6/NNS||anesthesia-4/NN	nn||times-6/NNS||recovery-5/NN	conj_and||parameters-2/NNS||times-6/NNS	nsubjpass||measured-16/VBN||times-6/NNS	det||amounts-12/NNS||the-9/DT	amod||amounts-12/NNS||total-10/JJ	nn||amounts-12/NNS||administration-11/NN	conj_and||parameters-2/NNS||amounts-12/NNS	nsubjpass||measured-16/VBN||amounts-12/NNS	prep_of||amounts-12/NNS||midazolam-14/NN	auxpass||measured-16/VBN||were-15/VBD	root||ROOT-0/null||measured-16/VBN	agitation-1||midazolam-14||yes||agitation parameters, anesthesia recovery times, and the total administration amounts of midazolam were measured.
amod||budesonide-2/NN||inhaled-1/JJ	nsubj||suppressed-3/VBD||budesonide-2/NN	root||ROOT-0/null||suppressed-3/VBD	amod||defense-7/NN||pulmonary-4/JJ	amod||defense-7/NN||antibacterial-5/JJ	nn||defense-7/NN||host-6/NN	dobj||suppressed-3/VBD||defense-7/NN	det||model-12/NN||an-9/DT	amod||model-12/NN||asthmatic-10/JJ	nn||model-12/NN||mouse-11/NN	prep_in||suppressed-3/VBD||model-12/NN	nn||cells-17/NNS||lung-15/NN	nn||cells-17/NNS||epithelium-16/NN	prep_in||suppressed-3/VBD||cells-17/NNS	conj_and||model-12/NN||cells-17/NNS	prep_in||suppressed-3/VBD||vitro-19/NN	asthmatic-10||budesonide-2||no||inhaled budesonide suppressed pulmonary antibacterial host defense in an asthmatic mouse model and in lung epithelium cells in vitro .
nsubjpass||treated-4/VBN||diarrhea-1/NN	aux||treated-4/VBN||can-2/MD	auxpass||treated-4/VBN||be-3/VB	root||ROOT-0/null||treated-4/VBN	prep_with||treated-4/VBN||loperamide-6/NN	prep_with||treated-4/VBN||diphenoxylate-8/NN	conj_or||loperamide-6/NN||diphenoxylate-8/NN	diarrhea-1||diphenoxylate-8||yes||diarrhea can be treated with loperamide or diphenoxylate.
det||aim-2/NN||the-1/DT	nsubj||is-6/VBZ||aim-2/NN	det||study-5/NN||the-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||is-6/VBZ	aux||find-8/VB||to-7/TO	ccomp||is-6/VBZ||find-8/VB	prt||find-8/VB||out-9/RP	det||profile-12/NN||the-10/DT	amod||profile-12/NN||bacteriological-11/JJ	dobj||find-8/VB||profile-12/NN	det||ulcers-15/NNS||these-14/DT	prep_of||profile-12/NN||ulcers-15/NNS	aux||find-18/VB||to-17/TO	ccomp||is-6/VBZ||find-18/VB	conj_and||find-8/VB||find-18/VB	prt||find-18/VB||out-19/RP	det||susceptibility-22/NN||the-20/DT	amod||susceptibility-22/NN||antibiotic-21/JJ	dobj||find-18/VB||susceptibility-22/NN	det||isolates-25/NN||the-24/DT	prep_of||susceptibility-22/NN||isolates-25/NN	advmod||chosen-32/VBN||so-26/RB	mark||chosen-32/VBN||that-27/IN	amod||drugs-29/NNS||appropriate-28/JJ	nsubjpass||chosen-32/VBN||drugs-29/NNS	aux||chosen-32/VBN||may-30/MD	auxpass||chosen-32/VBN||be-31/VB	advcl||find-18/VB||chosen-32/VBN	prep_for||chosen-32/VBN||treatment-34/NN	prep_for||chosen-32/VBN||prevention-37/NN	conj_and||treatment-34/NN||prevention-37/NN	prep_of||prevention-37/NN||recurrence-39/NN	ulcers-15||antibiotic-21||no_rel||the aim of the study is to find out the bacteriological profile of these ulcers and to find out the antibiotic susceptibility of the isolates so that appropriate drugs may be chosen for treatment and for prevention of recurrence.
det||patient-2/NN||the-1/DT	nsubjpass||treated-4/VBN||patient-2/NN	auxpass||treated-4/VBN||was-3/VBD	ccomp||dipropionate-20/VBP||treated-4/VBN	amod||mg-9/NN||oral-6/JJ	amod||mg-9/NN||methylprednisolone-7/JJ	dep||methylprednisolone-7/JJ||48-8/CD	prep_with||treated-4/VBN||mg-9/NN	nn||®-12/NNP||prednolâ-11/NNP	dep||mg-9/NN||®-12/NNP	nn||nevzat-15/NN||mustafa-14/NN	dep||®-12/NNP||nevzat-15/NN	amod||clobetasol-19/NN||topical-18/JJ	nsubj||dipropionate-20/VBP||clobetasol-19/NN	root||ROOT-0/null||dipropionate-20/VBP	num||cream-23/NN||0.05-21/CD	nn||cream-23/NN||%-22/NN	dobj||dipropionate-20/VBP||cream-23/NN	nn||®-26/NNP||dermovateâ-25/NNP	dep||cream-23/NN||®-26/NNP	nn||smithkline-29/NN||glaxo-28/NN	dep||®-26/NNP||smithkline-29/NN	amod||urea-36/NN||topical-33/JJ	number||%-35/NN||4-34/CD	amod||urea-36/NN||%-35/NN	dobj||dipropionate-20/VBP||urea-36/NN	conj_and||cream-23/NN||urea-36/NN	dep||cream-23/NN||lotion-37/NN	amod||®-41/NNS||excipial-39/JJ	amod||®-41/NNS||lipoâ-40/JJ	dep||lotion-37/NN||®-41/NNS	dep||®-41/NNS||orva-43/NN	amod||bullouspemphigoid-47/NN||presumptive-46/JJ	prep_for||lotion-37/NN||bullouspemphigoid-47/NN	bullouspemphigoid-47||urea-36||no_rel||the patient was treated with oral methylprednisolone 48 mg (prednolâ®; mustafa nevzat), topical clobetasol dipropionate 0.05% cream (dermovateâ®; glaxo smithkline), and topical 4% urea lotion (excipial lipoâ®; orva) for presumptive bullouspemphigoid.
nsubj||lesions-12/NNS||progressivemultifocalleukoencephalopathy-1/NN	num||patients-4/NNS||12-3/CD	appos||progressivemultifocalleukoencephalopathy-1/NN||patients-4/NNS	cop||lesions-12/NNS||is-6/VBZ	det||lesions-12/NNS||the-7/DT	advmod||frequent-9/JJ||most-8/RBS	amod||lesions-12/NNS||frequent-9/JJ	amod||lesions-12/NNS||intracranial-10/JJ	amod||lesions-12/NNS||parenchymal-11/JJ	root||ROOT-0/null||lesions-12/NNS	vmod||lesions-12/NNS||followed-14/VBN	agent||followed-14/VBN||intracranialtuberculoma-16/NN	num||patients-19/NNS||7-18/CD	appos||intracranialtuberculoma-16/NN||patients-19/NNS	amod||lymphoma-26/NN||primary-22/JJ	amod||lymphoma-26/NN||central-23/JJ	amod||lymphoma-26/NN||nervous-24/JJ	nn||lymphoma-26/NN||system-25/NN	agent||followed-14/VBN||lymphoma-26/NN	conj_and||intracranialtuberculoma-16/NN||lymphoma-26/NN	num||patients-29/NNS||7-28/CD	appos||lymphoma-26/NN||patients-29/NNS	amod||cryptococcoma-33/NN||intracranial-32/JJ	agent||followed-14/VBN||cryptococcoma-33/NN	conj_and||intracranialtuberculoma-16/NN||cryptococcoma-33/NN	num||patients-36/NNS||4-35/CD	appos||cryptococcoma-33/NN||patients-36/NNS	nn||encephalitis-40/NN||toxoplasma-39/NN	agent||followed-14/VBN||encephalitis-40/NN	conj_and||intracranialtuberculoma-16/NN||encephalitis-40/NN	num||patients-43/NNS||4-42/CD	appos||encephalitis-40/NN||patients-43/NNS	amod||mycobacterialinfection-49/NN||disseminated-47/JJ	amod||mycobacterialinfection-49/NN||non-tuberculous-48/JJ	agent||followed-14/VBN||mycobacterialinfection-49/NN	conj_and||intracranialtuberculoma-16/NN||mycobacterialinfection-49/NN	num||patients-52/NNS||3-51/CD	appos||mycobacterialinfection-49/NN||patients-52/NNS	intracranialtuberculoma-16||tuberculous--1||no||progressivemultifocalleukoencephalopathy (12 patients) is the most frequent intracranial parenchymal lesions, followed by intracranialtuberculoma (7 patients), primary central nervous system lymphoma (7 patients), intracranial cryptococcoma (4 patients), toxoplasma encephalitis (4 patients), and disseminated non-tuberculous mycobacterialinfection (3 patients).
nn||²-2/NNP||tgf-î-1/NNP	nsubjpass||known-5/VBN||²-2/NNP	nsubj||play-7/VB||²-2/NNP	aux||known-5/VBN||has-3/VBZ	auxpass||known-5/VBN||been-4/VBN	root||ROOT-0/null||known-5/VBN	aux||play-7/VB||to-6/TO	xcomp||known-5/VBN||play-7/VB	det||role-10/NN||an-8/DT	amod||role-10/NN||important-9/JJ	dobj||play-7/VB||role-10/NN	amod||liverdiseases-13/NNS||various-12/JJ	prep_in||play-7/VB||liverdiseases-13/NNS	prep_including||liverdiseases-13/NNS||fibrosis-15/NN	amod||liver-19/NN||alcohol-induced-17/JJ	nn||liver-19/NN||fatty-18/NN	prep_including||liverdiseases-13/NNS||liver-19/NN	conj_and||fibrosis-15/NN||liver-19/NN	alcohol--1||liverdiseases-13||no_rel||tgf-î² has been known to play an important role in various liverdiseases including fibrosis and alcohol-induced fatty liver.
nsubjpass||caused-7/VBN||osteogenesisimperfecta-1/NN	appos||osteogenesisimperfecta-1/NN||oi-3/NN	auxpass||caused-7/VBN||is-5/VBZ	advmod||caused-7/VBN||generally-6/RB	root||ROOT-0/null||caused-7/VBN	det||mutation-11/NN||a-9/DT	amod||mutation-11/NN||dominant-10/JJ	agent||caused-7/VBN||mutation-11/NN	nn||i-14/FW||collagen-13/FW	prep_in||mutation-11/NN||i-14/FW	vmod||mutation-11/NN||encoded-16/VBN	det||genes-19/NNS||the-18/DT	agent||encoded-16/VBN||genes-19/NNS	amod||mutation-11/NN||col1a1-20/JJ	amod||mutation-11/NN||col1a2-22/JJ	conj_and||col1a1-20/JJ||col1a2-22/JJ	collagen-13||oi-3||no_rel||osteogenesisimperfecta (oi) is generally caused by a dominant mutation in collagen i, encoded by the genes col1a1 and col1a2 .
advmod||studies-3/NNS||only-1/RB	num||studies-3/NNS||two-2/CD	nsubjpass||reported-13/VBN||studies-3/NNS	nn||susceptibility-6/NN||pza-5/NN	prep_on||studies-3/NNS||susceptibility-6/NN	amod||strains-10/NNS||thai-8/JJ	nn||strains-10/NNS||m.tuberculosis-9/NNS	prep_among||susceptibility-6/NN||strains-10/NNS	aux||reported-13/VBN||have-11/VBP	auxpass||reported-13/VBN||been-12/VBN	root||ROOT-0/null||reported-13/VBN	nsubj||used-16/VBD||one-15/PRP	parataxis||reported-13/VBN||used-16/VBD	det||assay-19/NN||a-17/DT	amod||assay-19/NN||pyrazinamidase-18/JJ	dobj||used-16/VBD||assay-19/NN	det||other-23/JJ||the-22/DT	nsubj||used-24/VBD||other-23/JJ	parataxis||reported-13/VBN||used-24/VBD	conj_and||used-16/VBD||used-24/VBD	det||tb-28/NN||the-25/DT	amod||tb-28/NN||bactec-26/JJ	num||tb-28/NN||460-27/CD	dobj||used-24/VBD||tb-28/NN	nn||testing-32/NN||pza-30/NN	nn||testing-32/NN||susceptibility-31/NN	prep_for||used-24/VBD||testing-32/NN	tb-28||m.tuberculosis-9||no||only two studies on pza susceptibility among thai m.tuberculosis strains have been reported ; one used a pyrazinamidase assay , and the other used the bactec 460 tb for pza susceptibility testing .
advmod||available-17/JJ||however-1/RB	amod||evidence-4/NN||direct-3/JJ	nsubj||available-17/JJ||evidence-4/NN	det||presence-7/NN||the-6/DT	prep_of||evidence-4/NN||presence-7/NN	prep_of||presence-7/NN||viruses-9/NNS	poss||components-12/NNS||their-11/PRP$	prep_of||evidence-4/NN||components-12/NNS	conj_or||presence-7/NN||components-12/NNS	det||organ-15/NN||the-14/DT	prep_in||components-12/NNS||organ-15/NN	cop||available-17/JJ||are-16/VBP	root||ROOT-0/null||available-17/JJ	prep_for||available-17/JJ||retroviruses-19/NNS	appos||retroviruses-19/NNS||hfv-21/NN	prep_for||available-17/JJ||mumps-24/NNS	conj_and||retroviruses-19/NNS||mumps-24/NNS	amod||thyroiditis-27/NNS||subacute-26/JJ	prep_in||mumps-24/NNS||thyroiditis-27/NNS	prep_for||available-17/JJ||retroviruses-30/NNS	conj_and||retroviruses-19/NNS||retroviruses-30/NNS	dep||retroviruses-30/NNS||htlv-1-32/JJ	dep||retroviruses-30/NNS||hfv-34/NN	conj_and||htlv-1-32/JJ||hfv-34/NN	dep||retroviruses-30/NNS||hiv-36/NN	conj_and||htlv-1-32/JJ||hiv-36/NN	dep||retroviruses-30/NNS||sv40-38/NNS	conj_and||htlv-1-32/JJ||sv40-38/NNS	poss||disease-43/NN||graves-41/NNS	prep_in||retroviruses-30/NNS||disease-43/NN	prep_for||available-17/JJ||htlv-1-46/JJ	conj_and||retroviruses-19/NNS||htlv-1-46/JJ	conj_and||retroviruses-19/NNS||enterovirus-48/NNS	conj_and||htlv-1-46/JJ||enterovirus-48/NNS	conj_and||retroviruses-19/NNS||rubella-50/NN	conj_and||htlv-1-46/JJ||rubella-50/NN	conj_and||retroviruses-19/NNS||mumpsvirus-52/NNS	conj_and||htlv-1-46/JJ||mumpsvirus-52/NNS	conj_and||retroviruses-19/NNS||hsv-54/NN	conj_and||htlv-1-46/JJ||hsv-54/NN	conj_and||retroviruses-19/NNS||ebv-56/NN	conj_and||htlv-1-46/JJ||ebv-56/NN	conj_and||retroviruses-19/NNS||parvovirus-58/NNS	conj_and||htlv-1-46/JJ||parvovirus-58/NNS	poss||thyroiditis-62/NNS||hashimoto-60/NNP	prep_in||available-17/JJ||thyroiditis-62/NNS	mumps-24||mumpsvirus-52||no||however, direct evidence of the presence of viruses or their components in the organ are available for retroviruses (hfv) and mumps in subacute thyroiditis, for retroviruses (htlv-1, hfv, hiv and sv40) in graves's disease and for htlv-1, enterovirus, rubella, mumpsvirus, hsv, ebv and parvovirus in hashimoto's thyroiditis.
advmod||compared-4/VBD||here-1/RB	nsubj||compared-4/VBD||we-3/PRP	root||ROOT-0/null||compared-4/VBD	det||characteristics-9/NNS||the-5/DT	nn||characteristics-9/NNS||cell-6/NN	nn||characteristics-9/NNS||culture-7/NN	nn||characteristics-9/NNS||growth-8/NN	dobj||compared-4/VBD||characteristics-9/NNS	amod||viruses-13/NNS||haemorrhagic-11/JJ	nn||viruses-13/NNS||fever-12/NN	prep_of||characteristics-9/NNS||viruses-13/NNS	appos||viruses-13/NNS||hfv-15/NN	det||arenaviridae-20/NN||the-19/DT	prep_of||viruses-13/NNS||arenaviridae-20/NN	prep_of||viruses-13/NNS||filoviridae-22/NN	conj_and||arenaviridae-20/NN||filoviridae-22/NN	prep_of||viruses-13/NNS||bunyaviridae-24/NN	conj_and||arenaviridae-20/NN||bunyaviridae-24/NN	amod||families-29/NNS||flavivridae-27/JJ	nn||families-29/NNS||virus-28/NN	prep_of||viruses-13/NNS||families-29/NNS	conj_and||arenaviridae-20/NN||families-29/NNS	prepc_by||compared-4/VBD||performing-31/VBG	amod||analysis-33/NN||quantitative-32/JJ	dobj||performing-31/VBG||analysis-33/NN	nn||supernatants-37/NNS||cell-35/NN	nn||supernatants-37/NNS||culture-36/NN	prep_of||analysis-33/NN||supernatants-37/NNS	appos||microscopy-43/NN||i-40/NNP	amod||microscopy-43/NN||electron-42/JJ	prep_by||performing-31/VBG||microscopy-43/NN	det||quantification-46/NN||the-45/DT	prep_for||performing-31/VBG||quantification-46/NN	nn||particles-49/NNS||virus-48/NN	prep_of||quantification-46/NN||particles-49/NNS	appos||particles-49/NNS||ii-52/NN	amod||time-56/NN||quantitative-54/JJ	amod||time-56/NN||real-55/JJ	dep||particles-49/NNS||time-56/NN	vmod||time-56/NN||pcr-57/VBN	det||quantification-60/NN||the-59/DT	prep_for||pcr-57/VBN||quantification-60/NN	prep_of||quantification-60/NN||genomes-62/NNS	amod||determination-68/NN||iii-66/JJ	prep_of||quantification-46/NN||determination-68/NN	conj_and||particles-49/NNS||determination-68/NN	prep_of||determination-68/NN||focus-70/NN	vmod||determination-68/NN||forming-71/VBG	dobj||forming-71/VBG||units-72/NNS	agent||forming-71/VBG||coating-74/VBG	amod||antibodies-76/NNS||fluorescent-75/JJ	dobj||coating-74/VBG||antibodies-76/NNS	amod||monolayers-80/NNS||infected-78/JJ	nn||monolayers-80/NNS||cell-79/NN	prep_to||coating-74/VBG||monolayers-80/NNS	det||quantification-83/NN||the-82/DT	prep_for||determination-68/NN||quantification-83/NN	nn||infectivity-86/NN||virus-85/NN	prep_of||quantification-83/NN||infectivity-86/NN	virus-85||viruses-13||no||here, we compared the cell culture growth characteristics of haemorrhagic fever viruses (hfv), of the arenaviridae , filoviridae , bunyaviridae , and flavivridae virus families by performing quantitative analysis of cell culture supernatants by (i) electron microscopy for the quantification of virus particles, (ii) quantitative real time pcr for the quantification of genomes, and (iii) determination of focus forming units by coating fluorescent antibodies to infected cell monolayers for the quantification of virus infectivity.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||the-3/DT	dobj||report-2/VBP||case-4/NN	det||man-9/NN||a-6/DT	amod||man-9/NN||46-year-old-7/JJ	nn||man-9/NN||greek-8/NN	prep_of||case-4/NN||man-9/NN	nsubj||developed-11/VBD||man-9/NN	rcmod||man-9/NN||developed-11/VBD	amod||anemia-14/NN||severe-12/JJ	amod||anemia-14/NN||aplastic-13/JJ	dobj||developed-11/VBD||anemia-14/NN	prep_during||developed-11/VBD||treatment-16/NN	amod||alpha-20/NN||pegylated-18/JJ	amod||alpha-20/NN||interferon-19/JJ	amod||2a-21/NNS||alpha-20/NN	prep_with||developed-11/VBD||2a-21/NNS	amod||virusinfection-24/NN||chronichepatitisc-23/JJ	prep_for||2a-21/NNS||virusinfection-24/NN	chronichepatitisc-23||interferon-19||yes||we report the case of a 46-year-old greek man who developed severe aplastic anemia during treatment with pegylated interferon alpha 2a for chronichepatitisc virusinfection.
poss||study-2/NN||our-1/PRP$	nsubj||indicates-3/VBZ||study-2/NN	root||ROOT-0/null||indicates-3/VBZ	mark||important-18/JJ||that-4/IN	det||determinants-8/NNS||the-5/DT	amod||determinants-8/NNS||composite-6/JJ	amod||determinants-8/NNS||genetic-7/JJ	nsubj||important-18/JJ||determinants-8/NNS	vmod||determinants-8/NNS||related-9/VBN	det||conversion-16/NN||the-11/DT	amod||conversion-16/NN||androgenâ-12/JJ	amod||conversion-16/NN||$-13/JJ	nn||conversion-16/NN||estrogen-15/NN	prep_to||related-9/VBN||conversion-16/NN	cop||important-18/JJ||are-17/VBP	ccomp||indicates-3/VBZ||important-18/JJ	det||induction-21/NN||the-20/DT	prep_for||important-18/JJ||induction-21/NN	num||cancers-25/NNS||two-23/CD	amod||cancers-25/NNS||hormone-associated-24/JJ	prep_of||induction-21/NN||cancers-25/NNS	advmod||important-18/JJ||particularly-27/RB	det||subtypes-32/NNS||the-29/DT	amod||subtypes-32/NNS||hormone-driven-30/JJ	nn||subtypes-32/NNS||breasttumour-31/NN	prep_for||important-18/JJ||subtypes-32/NNS	breasttumour-31||estrogen-15||no||our study indicates that the composite genetic determinants related to the androgenâ€“estrogen conversion are important for the induction of two hormone-associated cancers, particularly for the hormone-driven breasttumour subtypes.
det||existence-2/NN||the-1/DT	nsubj||suggests-17/VBZ||existence-2/NN	amod||disorders-6/NNS||multiple-4/JJ	amod||disorders-6/NNS||inherited-5/VBN	prep_of||existence-2/NN||disorders-6/NNS	nn||metabolism-9/NN||iron-8/NN	prep_of||disorders-6/NNS||metabolism-9/NN	prep_in||metabolism-9/NN||man-11/NN	prep_in||metabolism-9/NN||rodents-13/NNS	conj_and||man-11/NN||rodents-13/NNS	amod||vertebrates-16/NNS||other-15/JJ	prep_in||metabolism-9/NN||vertebrates-16/NNS	conj_and||man-11/NN||vertebrates-16/NNS	root||ROOT-0/null||suggests-17/VBZ	amod||contributions-19/NNS||genetic-18/JJ	dobj||suggests-17/VBZ||contributions-19/NNS	prep_to||suggests-17/VBZ||irondeficiency-21/NN	irondeficiency-21||iron-8||yes||the existence of multiple inherited disorders of iron metabolism in man, rodents and other vertebrates suggests genetic contributions to irondeficiency.
prep_in||improve-4/VBP||sicklecelldisease-2/NN	nsubj||improve-4/VBP||transfusions-3/NNS	root||ROOT-0/null||improve-4/VBP	nn||flow-6/NN||blood-5/NN	dobj||improve-4/VBP||flow-6/NN	prepc_by||improve-4/VBP||reducing-8/VBG	det||proportion-10/NN||the-9/DT	nsubj||capable-14/JJ||proportion-10/NN	amod||cells-13/NNS||red-12/JJ	prep_of||proportion-10/NN||cells-13/NNS	xcomp||reducing-8/VBG||capable-14/JJ	prepc_of||capable-14/JJ||forming-16/VBG	nn||polymer-18/NNS||sicklehemoglobin-17/NN	dobj||forming-16/VBG||polymer-18/NNS	sicklecelldisease-2||sicklehemoglobin-17||no||in sicklecelldisease transfusions improve blood flow by reducing the proportion of red cells capable of forming sicklehemoglobin polymer.
nsubj||emerging-12/VBG||il2ra/cd25-1/NNS	det||gene-4/NN||the-3/DT	appos||il2ra/cd25-1/NNS||gene-4/NN	nn||±-9/NNS||interleukin-2-6/NN	nn||±-9/NNS||receptor-7/NN	nn||±-9/NNS||î-8/NN	prep_for||gene-4/NN||±-9/NNS	aux||emerging-12/VBG||is-11/VBZ	root||ROOT-0/null||emerging-12/VBG	det||gene-17/NN||a-14/DT	amod||gene-17/NN||general-15/JJ	nn||gene-17/NN||susceptibility-16/NN	prep_as||emerging-12/VBG||gene-17/NN	prep_for||gene-17/NN||autoimmunediseases-19/NNS	poss||role-23/NN||its-22/PRP$	prep_because_of||autoimmunediseases-19/NNS||role-23/NN	det||development-26/NN||the-25/DT	prep_in||emerging-12/VBG||development-26/NN	prep_in||emerging-12/VBG||function-28/NN	conj_and||development-26/NN||function-28/NN	amod||cells-32/NNS||regulatory-30/JJ	nn||cells-32/NNS||t-31/NN	prep_of||development-26/NN||cells-32/NNS	det||association-35/NN||the-34/DT	prep_in||emerging-12/VBG||association-35/NN	conj_and||development-26/NN||association-35/NN	amod||polymorphisms-38/NNS||single-nucleotide-37/JJ	prep_of||association-35/NN||polymorphisms-38/NNS	parataxis||emerging-12/VBG||snps-40/VBZ	det||gene-44/NN||this-43/DT	prep_within||emerging-12/VBG||gene-44/NN	prep_with||gene-44/NN||type1diabetesmellitus-46/NNS	appos||type1diabetesmellitus-46/NNS||dm-48/NN	prep_with||gene-44/NN||graves-51/NNS	conj_and||type1diabetesmellitus-46/NNS||graves-51/NNS	dep||graves-51/NNS||disease-53/NN	prep_with||gene-44/NN||rheumatoidarthritis-55/NNS	conj_and||type1diabetesmellitus-46/NNS||rheumatoidarthritis-55/NNS	appos||rheumatoidarthritis-55/NNS||ra-57/NN	prep_with||gene-44/NN||multiplesclerosis-61/NNS	conj_and||type1diabetesmellitus-46/NNS||multiplesclerosis-61/NNS	appos||multiplesclerosis-61/NNS||ms-63/NN	dm-48||autoimmunediseases-19||no_rel||il2ra/cd25 , the gene for interleukin-2 receptor î±, is emerging as a general susceptibility gene for autoimmunediseases because of its role in the development and function of regulatory t cells and the association of single-nucleotide polymorphisms (snps) within this gene with type1diabetesmellitus (dm), graves'disease, rheumatoidarthritis (ra), and multiplesclerosis (ms).
poss||method-2/NN||our-1/PRP$	nsubj||detected-3/VBD||method-2/NN	root||ROOT-0/null||detected-3/VBD	det||combination-5/NN||the-4/DT	dobj||detected-3/VBD||combination-5/NN	prep_of||combination-5/NN||metformin-7/NN	nsubj||avandamet-14/NN||metformin-7/NN	prep_of||combination-5/NN||rosiglitazone-9/NN	conj_and||metformin-7/NN||rosiglitazone-9/NN	nsubj||avandamet-14/NN||rosiglitazone-9/NN	cop||avandamet-14/NN||is-12/VBZ	advmod||avandamet-14/NN||actually-13/RB	rcmod||metformin-7/NN||avandamet-14/NN	det||drug-17/NN||a-16/DT	appos||avandamet-14/NN||drug-17/NN	nsubjpass||used-22/VBN||drug-17/NN	nsubj||treat-24/VB||drug-17/NN	aux||used-22/VBN||has-19/VBZ	auxpass||used-22/VBN||been-20/VBN	advmod||used-22/VBN||successfully-21/RB	rcmod||drug-17/NN||used-22/VBN	aux||treat-24/VB||to-23/TO	xcomp||used-22/VBN||treat-24/VB	dobj||treat-24/VB||type2diabetes-25/NNS	type2diabetes-25||rosiglitazone-9||yes||our method detected the combination of metformin and rosiglitazone, which is actually avandamet, a drug that has been successfully used to treat type2diabetes.
prep_in||associative-24/VBP||patients-2/NNS	amod||essential-5/JJ||benign-4/JJ	amod||blepharospasm-6/NN||essential-5/JJ	prep_with||patients-2/NNS||blepharospasm-6/NN	appos||blepharospasm-6/NN||beb-8/NN	det||dystonia-13/NN||a-11/DT	amod||dystonia-13/NN||focal-12/JJ	nsubj||associative-24/VBP||dystonia-13/NN	vmod||dystonia-13/NN||affecting-14/VBG	det||muscles-18/NNS||the-15/DT	amod||muscles-18/NNS||orbicularis-16/JJ	nn||muscles-18/NNS||oculi-17/NN	dobj||affecting-14/VBG||muscles-18/NNS	appos||muscles-18/NNS||hfsltp-20/NN	vmod||hfsltp-20/NN||induced-21/VBN	amod||ltp-like-23/NN||excessive-22/JJ	dobj||induced-21/VBN||ltp-like-23/NN	root||ROOT-0/null||associative-24/VBP	advmod||relative-26/JJ||plasticity-25/RB	acomp||associative-24/VBP||relative-26/JJ	amod||controls-29/NNS||healthy-28/JJ	prep_to||relative-26/JJ||controls-29/NNS	nsubjpass||normalized-33/VBN||controls-29/NNS	auxpass||normalized-33/VBN||was-32/VBD	rcmod||controls-29/NNS||normalized-33/VBN	amod||injections-39/NNS||botulinumtoxin-35/JJ	appos||injections-39/NNS||btx-37/NN	prep_after||normalized-33/VBN||injections-39/NNS	dep||normalized-33/VBN||quartarone-41/NNP	dep||normalized-33/VBN||al-43/NNP	conj_et||quartarone-41/NNP||al-43/NNP	dep||quartarone-41/NNP||2006-45/CD	blepharospasm-6||botulinumtoxin-35||no_rel||in patients with benign essential blepharospasm (beb), a focal dystonia affecting the orbicularis oculi muscles, hfsltp induced excessive ltp-like associative plasticity relative to healthy controls, which was normalized after botulinumtoxin (btx) injections (quartarone et al, 2006).
amod||lines-2/NNS||several-1/JJ	nsubj||support-5/VBP||lines-2/NNS	prep_of||lines-2/NNS||evidence-4/NN	root||ROOT-0/null||support-5/VBP	det||notion-7/NN||the-6/DT	dobj||support-5/VBP||notion-7/NN	mark||predispose-13/VB||that-8/IN	amod||viscosity-11/NN||elevated-9/JJ	nn||viscosity-11/NN||blood-10/NN	nsubj||predispose-13/VB||viscosity-11/NN	aux||predispose-13/VB||may-12/MD	ccomp||support-5/VBP||predispose-13/VB	prep_to||predispose-13/VB||insulinresistance-15/NN	prep_to||predispose-13/VB||type2diabetesmellitus-17/NNS	conj_and||insulinresistance-15/NN||type2diabetesmellitus-17/NNS	prepc_by||predispose-13/VB||limiting-19/VBG	dobj||limiting-19/VBG||delivery-20/NN	prep_of||delivery-20/NN||glucose-22/NN	prep_of||delivery-20/NN||insulin-24/NN	conj_and||glucose-22/NN||insulin-24/NN	prep_of||delivery-20/NN||oxygen-27/NN	conj_and||glucose-22/NN||oxygen-27/NN	advmod||active-30/JJ||metabolically-29/RB	amod||tissues-31/NNS||active-30/JJ	prep_to||glucose-22/NN||tissues-31/NNS	insulin-24||insulinresistance-15||no_rel||several lines of evidence support the notion that elevated blood viscosity may predispose to insulinresistance and type2diabetesmellitus by limiting delivery of glucose, insulin, and oxygen to metabolically active tissues.
amod||asthma-2/NN||aspirin-intolerant-1/JJ	nsubj||condition-9/NN||asthma-2/NN	appos||asthma-2/NN||aia-4/NN	cop||condition-9/NN||is-6/VBZ	det||condition-9/NN||a-7/DT	amod||condition-9/NN||rare-8/JJ	root||ROOT-0/null||condition-9/NN	nsubjpass||characterized-12/VBN||condition-9/NN	auxpass||characterized-12/VBN||is-11/VBZ	rcmod||condition-9/NN||characterized-12/VBN	det||development-15/NN||the-14/DT	agent||characterized-12/VBN||development-15/NN	prep_of||development-15/NN||bronchoconstriction-17/NN	amod||patients-20/NNS||asthmatic-19/JJ	prep_in||bronchoconstriction-17/NN||patients-20/NNS	prep_after||characterized-12/VBN||ingestion-22/NN	amod||anti-inflammatorydrugs-25/NNS||non-steroidal-24/JJ	prep_of||ingestion-22/NN||anti-inflammatorydrugs-25/NNS	prep_including||anti-inflammatorydrugs-25/NNS||aspirin-27/NN	asthmatic-19||aspirin-27||no||aspirin-intolerant asthma (aia) is a rare condition that is characterized by the development of bronchoconstriction in asthmatic patients after ingestion of non-steroidal anti-inflammatorydrugs including aspirin.
quantmod||half-2/PDT||over-1/IN	nsubj||positive-14/JJ||half-2/PDT	prep_of||half-2/PDT||persons-4/NNS	nsubjpass||tested-9/VBN||persons-4/NNS	prep_with||persons-4/NNS||hivinfection-6/NN	auxpass||tested-9/VBN||were-8/VBD	rcmod||persons-4/NNS||tested-9/VBN	prep_for||tested-9/VBN||hcv-11/NN	cop||positive-14/JJ||were-12/VBD	advmod||positive-14/JJ||anti-hcv-13/RB	root||ROOT-0/null||positive-14/JJ	nsubj||diagnosed-21/VBN||half-16/NN	prep_of||half-16/NN||these-18/DT	aux||diagnosed-21/VBN||had-19/VBD	advmod||diagnosed-21/VBN||hcv-20/RB	parataxis||positive-14/JJ||diagnosed-21/VBN	advmod||diagnosed-21/VBN||first-22/JJ	nn||identification-25/NN||hiv-24/NN	prep_with||first-22/JJ||identification-25/NN	det||years-29/NNS||a-26/DT	amod||years-29/NNS||median-27/JJ	num||years-29/NNS||3.5-28/CD	tmod||first-22/JJ||years-29/NNS	advmod||diagnosed-21/VBN||later-30/RB	hivinfection-6||hiv-24||no||over half of persons with hivinfection who were tested for hcv were anti-hcv positive; half of these had hcv diagnosed first with hiv identification a median 3.5 years later.
det||respondents-2/NNS||the-1/DT	nsubj||had-9/VBD||respondents-2/NNS	quantmod||than-5/IN||less-4/JJR	num||education-8/NN||than-5/IN	amod||school-7/NN||secondary-6/JJ	dep||than-5/IN||school-7/NN	prep_with||respondents-2/NNS||education-8/NN	root||ROOT-0/null||had-9/VBD	det||attitude-12/NN||a-10/DT	amod||attitude-12/NN||discriminatory-11/JJ	dobj||had-9/VBD||attitude-12/NN	amod||people-15/NNS||hivpositive-14/JJ	prep_toward||attitude-12/NN||people-15/NNS	nsubj||deserving-21/VBG||them-20/PRP	nsubj||suffer-23/VB||them-20/PRP	nsubj||dismissing-25/VBG||them-20/PRP	nsubj||hesitating-30/VBG||them-20/PRP	nsubj||sit-32/VB||them-20/PRP	nsubj||divorcing-42/VBG||them-20/PRP	nsubj||willingness-48/VBG||them-20/PRP	nsubjpass||tested-51/VBN||them-20/PRP	prepc_with_regard_to||had-9/VBD||deserving-21/VBG	aux||suffer-23/VB||to-22/TO	xcomp||deserving-21/VBG||suffer-23/VB	prepc_with_regard_to||had-9/VBD||dismissing-25/VBG	conj_and||deserving-21/VBG||dismissing-25/VBG	det||maid-28/NN||a-26/DT	amod||maid-28/NN||hivpositive-27/JJ	dobj||dismissing-25/VBG||maid-28/NN	prepc_with_regard_to||had-9/VBD||hesitating-30/VBG	conj_and||deserving-21/VBG||hesitating-30/VBG	aux||sit-32/VB||to-31/TO	xcomp||hesitating-30/VBG||sit-32/VB	det||person-37/NN||a-35/DT	amod||person-37/NN||hivpositive-36/JJ	prep_next_to||sit-32/VB||person-37/NN	det||bus-40/NN||the-39/DT	prep_in||sit-32/VB||bus-40/NN	prepc_with_regard_to||had-9/VBD||divorcing-42/VBG	conj_and||deserving-21/VBG||divorcing-42/VBG	det||spouse-45/NN||the-43/DT	amod||spouse-45/NN||infected-44/JJ	dobj||divorcing-42/VBG||spouse-45/NN	prepc_with_regard_to||had-9/VBD||willingness-48/VBG	conj_and||deserving-21/VBG||willingness-48/VBG	aux||tested-51/VBN||to-49/TO	auxpass||tested-51/VBN||get-50/VB	xcomp||willingness-48/VBG||tested-51/VBN	prep_for||tested-51/VBN||hiv-53/NN	nsubjpass||found-57/VBN||hiv-53/NN	nsubj||significant-61/JJ||hiv-53/NN	auxpass||found-57/VBN||was-56/VBD	rcmod||hiv-53/NN||found-57/VBN	aux||significant-61/JJ||to-58/TO	cop||significant-61/JJ||be-59/VB	advmod||significant-61/JJ||statistically-60/RB	xcomp||found-57/VBN||significant-61/JJ	hivpositive-36||hiv-53||no||the respondents with less than secondary school education had a discriminatory attitude toward hivpositive people, with regard to them deserving to suffer, dismissing a hivpositive maid, hesitating to sit next to a hivpositive person in the bus, divorcing the infected spouse, and willingness to get tested for hiv, which was found to be statistically significant.
vmod||assessed-10/VBN||using-1/VBG	num||samples-3/NNS||128-2/CD	dobj||using-1/VBG||samples-3/NNS	det||methods-8/NNS||the-5/DT	num||methods-8/NNS||five-6/CD	nn||methods-8/NNS||pcr-7/NN	nsubjpass||assessed-10/VBN||methods-8/NNS	auxpass||assessed-10/VBN||were-9/VBD	root||ROOT-0/null||assessed-10/VBN	det||protocol-16/NN||an-13/DT	amod||protocol-16/NN||in-house-14/JJ	nn||protocol-16/NN||pcr-15/NN	prep_including||assessed-10/VBN||protocol-16/NN	det||mtb-21/NN||the-18/DT	amod||mtb-21/NN||cobas-19/JJ	nn||mtb-21/NN||amplicor-20/NN	prep_including||assessed-10/VBN||mtb-21/NN	conj_and||protocol-16/NN||mtb-21/NN	det||mtb-26/NN||the-23/DT	amod||mtb-26/NN||cobas-24/JJ	nn||mtb-26/NN||taqman-25/NN	prep_including||assessed-10/VBN||mtb-26/NN	conj_and||protocol-16/NN||mtb-26/NN	det||pcr-32/NN||the-28/DT	amod||pcr-32/NN||advansure-29/JJ	amod||pcr-32/NN||tb/ntm-30/JJ	amod||pcr-32/NN||real-time-31/JJ	prep_including||assessed-10/VBN||pcr-32/NN	conj_and||protocol-16/NN||pcr-32/NN	det||kit-38/NN||the-35/DT	amod||kit-38/NN||real-q-36/JJ	nn||kit-38/NN||m.tuberculosis-37/NNS	prep_including||assessed-10/VBN||kit-38/NN	conj_and||protocol-16/NN||kit-38/NN	tb--1||mtb-26||no||using 128 samples , the five pcr methods were assessed , including an in-house pcr protocol , the cobas amplicor mtb , the cobas taqman mtb , the advansure tb/ntm real-time pcr , and the real-q m.tuberculosis kit .
det||study-3/NN||the-1/DT	amod||study-3/NN||current-2/JJ	nsubjpass||conducted-5/VBN||study-3/NN	nsubj||assess-7/VB||study-3/NN	auxpass||conducted-5/VBN||was-4/VBD	root||ROOT-0/null||conducted-5/VBN	aux||assess-7/VB||to-6/TO	xcomp||conducted-5/VBN||assess-7/VB	mark||protect-18/VB||whether-8/IN	nsubj||protect-18/VB||colostrum-9/NN	vmod||colostrum-9/NN||containing-10/VBG	amod||antibodies-12/NNS||rotavirus-specific-11/JJ	dobj||containing-10/VBG||antibodies-12/NNS	nn||®-15/NNP||gastrogard-râ-14/NNP	appos||antibodies-12/NNS||®-15/NNP	aux||protect-18/VB||could-17/MD	ccomp||assess-7/VB||protect-18/VB	prep_against||protect-18/VB||rotavirusinfection-20/NN	rotavirusinfection-20||rotavirus--1||yes||the current study was conducted to assess whether colostrum containing rotavirus-specific antibodies (gastrogard-râ®) could protect against rotavirusinfection.
nsubj||agent-8/NN||5-fluorouracil-1/NN	dep||5-fluorouracil-1/NN||5-fu-3/JJ	cop||agent-8/NN||is-5/VBZ	det||agent-8/NN||the-6/DT	amod||agent-8/NN||chemotherapeutic-7/JJ	root||ROOT-0/null||agent-8/NN	amod||choice-11/NN||first-10/JJ	prep_of||agent-8/NN||choice-11/NN	amod||cancer-14/NN||colorectal-13/JJ	prep_in||choice-11/NN||cancer-14/NN	amod||cases-19/NNS||most-18/JJS	prep_in||develops-24/VBZ||cases-19/NNS	nsubj||develops-24/VBZ||resistance-21/NN	prep_to||resistance-21/NN||5-fu-23/CD	conj_but||agent-8/NN||develops-24/VBZ	amod||mechanisms-27/NNS||various-26/JJ	prep_through||develops-24/VBZ||mechanisms-27/NNS	5-fu-23||cancer-14||no_rel||5-fluorouracil (5-fu) is the chemotherapeutic agent of first choice in colorectal cancer, but in most cases, resistance to 5-fu develops through various mechanisms.
nsubj||therapy-16/NN||treatment-1/NN	amod||sle-4/NN||severe-3/JJ	prep_in||treatment-1/NN||sle-4/NN	advmod||in-7/IN||especially-6/RB	rcmod||treatment-1/NN||in-7/IN	pobj||in-7/IN||lupusnephritis-8/NNS	aux||therapy-16/NN||has-10/VBZ	advmod||therapy-16/NN||traditionally-11/RB	cop||therapy-16/NN||been-12/VBN	det||therapy-16/NN||a-13/DT	amod||therapy-16/NN||standardized-14/JJ	amod||therapy-16/NN||schematic-15/JJ	root||ROOT-0/null||therapy-16/NN	prep_with||therapy-16/NN||cyclophosphamide-18/NN	prep_with||therapy-16/NN||prednisolone-20/NN	conj_and||cyclophosphamide-18/NN||prednisolone-20/NN	vmod||cyclophosphamide-18/NN||followed-21/VBN	agent||followed-21/VBN||azathioprine-23/NN	lupusnephritis-8||cyclophosphamide-18||yes||treatment in severe sle, especially in lupusnephritis, has traditionally been a standardized schematic therapy with cyclophosphamide and prednisolone followed by azathioprine.
det||emergence-4/NN||the-3/DT	prep_because_of||recommended-23/VBN||emergence-4/NN	amod||resistance-7/NN||chloroquine-6/JJ	prep_of||emergence-4/NN||resistance-7/NN	prep_in||resistance-7/NN||mali-9/NNS	nsubjpass||recommended-23/VBN||artemether-lumefantrine-11/NN	nsubj||available-35/JJ||artemether-lumefantrine-11/NN	appos||artemether-lumefantrine-11/NN||al-13/NNP	conj_or||artemether-lumefantrine-11/NN||artesunate-amodiaquine-16/NN	nsubjpass||recommended-23/VBN||artesunate-amodiaquine-16/NN	quantmod||aq-20/CD||as-18/RB	number||aq-20/CD||+-19/CD	dep||artesunate-amodiaquine-16/NN||aq-20/CD	auxpass||recommended-23/VBN||are-22/VBP	root||ROOT-0/null||recommended-23/VBN	amod||therapy-26/NN||first-line-25/JJ	prep_as||recommended-23/VBN||therapy-26/NN	amod||malaria-29/NN||uncomplicated-28/JJ	prep_for||therapy-26/NN||malaria-29/NN	aux||available-35/JJ||have-32/VBP	neg||available-35/JJ||not-33/RB	cop||available-35/JJ||been-34/VBN	conj_but||recommended-23/VBN||available-35/JJ	prep_in||available-35/JJ||mali-37/NNS	prep||available-35/JJ||until-38/IN	pobj||until-38/IN||recently-39/RB	amod||costs-43/NNS||high-42/JJ	prep_because_of||recently-39/RB||costs-43/NNS	malaria-29||artemether--1||yes||because of the emergence of chloroquine resistance in mali, artemether-lumefantrine (al) or artesunate-amodiaquine (as+aq) are recommended as first-line therapy for uncomplicated malaria, but have not been available in mali until recently because of high costs.
advmod||hbsag-24/VBG||furthermore-1/RB	mark||expressed-12/VBD||while-3/IN	nsubj||expressed-12/VBD||most-4/JJS	det||controls-7/NNS||the-6/DT	prep_of||most-4/JJS||controls-7/NNS	amod||infection-11/NN||ongoing-9/JJ	nn||infection-11/NN||hbv-10/NN	prep_with||controls-7/NNS||infection-11/NN	advcl||hbsag-24/VBG||expressed-12/VBD	xcomp||expressed-12/VBD||hbsag-13/VBG	det||majority-16/NN||the-15/DT	nsubj||hbsag-24/VBG||majority-16/NN	nn||patients-22/NNS||hcv-18/NN	conj_and||hcv-18/NN||hbv-20/JJ	nn||patients-22/NNS||hbv-20/JJ	amod||patients-22/NNS||positive-21/JJ	prep_of||majority-16/NN||patients-22/NNS	aux||hbsag-24/VBG||were-23/VBD	root||ROOT-0/null||hbsag-24/VBG	amod||positive-29/NN||negative-25/JJ	conj_and||negative-25/JJ||hbv-27/NN	amod||positive-29/NN||hbv-27/NN	nn||positive-29/NN||dna-28/NN	dobj||hbsag-24/VBG||positive-29/NN	hbv-27||hbsag-24||yes||furthermore, while most of the controls with ongoing hbv infection expressed hbsag, the majority of hcv and hbv positive patients were hbsag negative and hbv dna positive.
aux||elucidate-2/VB||to-1/TO	advcl||analyzed-15/VBD||elucidate-2/VB	mark||involved-6/VBN||whether-3/IN	nsubjpass||involved-6/VBN||micrornas-4/NNS	auxpass||involved-6/VBN||are-5/VBP	ccomp||elucidate-2/VB||involved-6/VBN	det||development-9/NN||the-8/DT	prep_in||involved-6/VBN||development-9/NN	amod||resistance-12/NN||fludarabine-11/JJ	prep_of||development-9/NN||resistance-12/NN	nsubj||analyzed-15/VBD||we-14/PRP	root||ROOT-0/null||analyzed-15/VBD	det||expression-17/NN||the-16/DT	dobj||analyzed-15/VBD||expression-17/NN	num||mirnas-21/NNS||723-19/CD	amod||mirnas-21/NNS||human-20/JJ	prep_of||expression-17/NN||mirnas-21/NNS	advmod||mirnas-21/NNS||before-22/RB	advmod||mirnas-21/NNS||5-days-24/JJ	conj_and||before-22/RB||5-days-24/JJ	amod||mono-therapy-27/NN||fludarabine-26/JJ	prep_after||5-days-24/JJ||mono-therapy-27/NN	num||patients-31/NNS||17-29/CD	nn||patients-31/NNS||cll-30/NN	prep_in||analyzed-15/VBD||patients-31/NNS	nsubjpass||classified-34/VBN||patients-31/NNS	nsubj||fludarabine-40/VB||patients-31/NNS	auxpass||classified-34/VBN||were-33/VBD	rcmod||patients-31/NNS||classified-34/VBN	prep_as||classified-34/VBN||responder-36/NN	prep_as||classified-34/VBN||refractory-38/NN	conj_or||responder-36/NN||refractory-38/NN	aux||fludarabine-40/VB||to-39/TO	xcomp||classified-34/VBN||fludarabine-40/VB	dobj||fludarabine-40/VB||treatment-41/NN	prepc_based_on||fludarabine-40/VB||on-43/IN	nn||criteria-45/NNS||nci-44/NN	pobj||fludarabine-40/VB||criteria-45/NNS	cll-30||fludarabine-40||yes||to elucidate whether micrornas are involved in the development of fludarabine resistance, we analyzed the expression of 723 human mirnas before and 5-days after fludarabine mono-therapy in 17 cll patients which were classified as responder or refractory to fludarabine treatment based on nci criteria.
aux||gather-2/VB||to-1/TO	advcl||collected-16/VBD||gather-2/VB	dobj||gather-2/VB||information-3/NN	amod||students-6/NNS||young-5/JJ	prep_about||gather-2/VB||students-6/NNS	poss||attitudes-9/NNS||their-8/PRP$	prep_about||gather-2/VB||attitudes-9/NNS	conj_and||students-6/NNS||attitudes-9/NNS	prep_about||gather-2/VB||knowledge-11/NN	conj_and||students-6/NNS||knowledge-11/NN	prep_about||knowledge-11/NN||hiv/aids-13/NNS	nsubj||collected-16/VBD||we-15/PRP	nsubj||made-21/VBD||we-15/PRP	root||ROOT-0/null||collected-16/VBD	num||questionnaires-19/NNS||600-17/CD	amod||questionnaires-19/NNS||structured-18/JJ	dobj||collected-16/VBD||questionnaires-19/NNS	conj_and||collected-16/VBD||made-21/VBD	num||interviews-24/NNS||23-22/CD	amod||interviews-24/NNS||semi-structured-23/JJ	dobj||made-21/VBD||interviews-24/NNS	num||groups-27/NNS||three-26/CD	prep_among||made-21/VBD||groups-27/NNS	prep_of||groups-27/NNS||students-29/NNS	aids--1||hiv--1||no||to gather information about young students and their attitudes and knowledge about hiv/aids, we collected 600 structured questionnaires and made 23 semi-structured interviews among three groups of students.
neg||differences-3/NNS||no-1/DT	amod||differences-3/NNS||significant-2/JJ	nsubjpass||found-5/VBN||differences-3/NNS	auxpass||found-5/VBN||were-4/VBD	root||ROOT-0/null||found-5/VBN	nn||subjects-10/NNS||smoking-7/NN	conj_and||smoking-7/NN||non-smoking-9/NN	nn||subjects-10/NNS||non-smoking-9/NN	prep_between||found-5/VBN||subjects-10/NNS	amod||asthma-13/NN||mild-12/JJ	prep_with||subjects-10/NNS||asthma-13/NN	prep_in||asthma-13/NN||regard-15/NN	amod||changes-18/NNS||clinical-17/JJ	prep_to||found-5/VBN||changes-18/NNS	nn||control-21/NN||asthma-20/NN	prep_in||changes-18/NNS||control-21/NN	amod||function-24/NN||pulmonary-23/JJ	appos||control-21/NN||function-24/NN	nn||inflammation-27/NN||airway-26/NN	appos||control-21/NN||inflammation-27/NN	conj_and||function-24/NN||inflammation-27/NN	det||period-32/NN||a-29/DT	amod||period-32/NN||2-month-30/JJ	nn||period-32/NN||treatment-31/NN	prep_following||function-24/NN||period-32/NN	prep_with||period-32/NN||budesonide-34/NN	det||association-37/NN||the-36/DT	prep_following||function-24/NN||association-37/NN	conj_or||period-32/NN||association-37/NN	prep_of||association-37/NN||budesonide-39/NN	prep_of||association-37/NN||formoterol-41/NN	conj_and||budesonide-39/NN||formoterol-41/NN	det||period-44/NN||a-43/DT	prep_for||association-37/NN||period-44/NN	num||months-47/NNS||2-46/CD	prep_of||period-44/NN||months-47/NNS	asthma-20||formoterol-41||no||no significant differences were found between smoking and non-smoking subjects with mild asthma in regard to clinical changes in asthma control, pulmonary function and airway inflammation following a 2-month treatment period with budesonide or the association of budesonide and formoterol for a period of 2 months.
amod||agents-3/NNS||multiple-2/JJ	prep_with||imperative-34/JJ||agents-3/NNS	advmod||available-5/JJ||now-4/RB	amod||agents-3/NNS||available-5/JJ	det||treatment-8/NN||the-7/DT	prep_for||agents-3/NNS||treatment-8/NN	amod||rcc-11/NN||advanced-10/JJ	prep_of||treatment-8/NN||rcc-11/NN	nsubj||imperative-34/JJ||identification-13/NN	amod||biomarkers-18/NNS||patient-15/JJ	conj_and||patient-15/JJ||tumor-specific-17/JJ	amod||biomarkers-18/NNS||tumor-specific-17/JJ	prep_of||identification-13/NN||biomarkers-18/NNS	aux||inform-20/VB||to-19/TO	vmod||biomarkers-18/NNS||inform-20/VB	poss||choice-22/NN||our-21/PRP$	dobj||inform-20/VB||choice-22/NN	amod||therapy-25/NN||first-line-24/JJ	prep_of||choice-22/NN||therapy-25/NN	det||sequence-29/NN||the-27/DT	amod||sequence-29/NN||proper-28/JJ	dobj||inform-20/VB||sequence-29/NN	conj_and||choice-22/NN||sequence-29/NN	amod||therapies-32/NNS||subsequent-31/JJ	prep_of||sequence-29/NN||therapies-32/NNS	cop||imperative-34/JJ||is-33/VBZ	root||ROOT-0/null||imperative-34/JJ	inform-20||rcc-11||no_rel||with multiple agents now available for the treatment of advanced rcc, identification of patient and tumor-specific biomarkers to inform our choice of first-line therapy and the proper sequence of subsequent therapies is imperative.
nn||²-6/NNS||epex-1/NN	conj_and||epex-1/NN||ep-icd-3/NN	nn||²-6/NNS||ep-icd-3/NN	conj_and||epex-1/NN||î-5/NN	nn||²-6/NNS||î-5/NN	nsubjpass||conducted-14/VBN||²-6/NNS	nsubjpass||correlated-29/VBN||²-6/NNS	dep||²-6/NNS||catenin-8/NN	advmod||using-10/VBG||immunohistochemistry-9/RB	vmod||catenin-8/NN||using-10/VBG	amod||antibodies-12/NNS||specific-11/JJ	dobj||using-10/VBG||antibodies-12/NNS	auxpass||conducted-14/VBN||was-13/VBD	root||ROOT-0/null||conducted-14/VBN	num||cancer-19/NN||58-16/CD	amod||cancer-19/NN||archived-17/JJ	nn||cancer-19/NN||thyroid-18/NN	prep_on||conducted-14/VBN||cancer-19/NN	appos||cancer-19/NN||tc-21/NN	num||blocks-24/NNS||tissue-23/CD	npadvmod||conducted-14/VBN||blocks-24/NNS	num||patients-27/NNS||34-26/CD	prep_from||conducted-14/VBN||patients-27/NNS	conj_and||conducted-14/VBN||correlated-29/VBN	nn||analysis-32/NN||survival-31/NN	prep_with||correlated-29/VBN||analysis-32/NN	det||patients-35/NNS||these-34/DT	prep_of||analysis-32/NN||patients-35/NNS	quantmod||17-39/CD||up-37/IN	dep||17-39/CD||to-38/TO	num||years-40/NNS||17-39/CD	prep_for||patients-35/NNS||years-40/NNS	cancer-19||antibodies-12||no_rel||epex, ep-icd and î²-catenin immunohistochemistry using specific antibodies was conducted on 58 archived thyroid cancer (tc) tissue blocks from 34 patients and correlated with survival analysis of these patients for up to 17 years.
nsubjpass||recruited-26/VBN||patients-1/NNS	amod||ulcerativecolitis-4/NNS||established-3/VBN	prep_with||patients-1/NNS||ulcerativecolitis-4/NNS	appos||ulcerativecolitis-4/NNS||uc-6/NN	amod||cd-13/NNS||crohn-9/JJ	amod||cd-13/NNS||sdisease-11/JJ	prep_with||patients-1/NNS||cd-13/NNS	conj_and||ulcerativecolitis-4/NNS||cd-13/NNS	nsubj||residents-19/NNS||cd-13/NNS	cop||residents-19/NNS||were-17/VBD	amod||residents-19/NNS||permanent-18/JJ	rcmod||cd-13/NNS||residents-19/NNS	det||districts-23/NNS||these-21/DT	amod||districts-23/NNS||adjoining-22/JJ	prep_of||residents-19/NNS||districts-23/NNS	auxpass||recruited-26/VBN||were-25/VBD	root||ROOT-0/null||recruited-26/VBN	nn||registries-29/NNS||hospital-28/NN	prep_from||recruited-26/VBN||registries-29/NNS	amod||clinics-32/NNS||out-patient-31/JJ	prep_from||recruited-26/VBN||clinics-32/NNS	conj_and||registries-29/NNS||clinics-32/NNS	uc-6||cd-13||no_rel||patients with established ulcerativecolitis (uc) and crohn'sdisease (cd), who were permanent residents of these adjoining districts, were recruited from hospital registries and out-patient clinics.
advmod||studied-4/VBD||here-1/RB	nsubj||studied-4/VBD||we-3/PRP	root||ROOT-0/null||studied-4/VBD	det||expression-6/NN||the-5/DT	dobj||studied-4/VBD||expression-6/NN	det||translocation-10/NN||the-8/DT	amod||translocation-10/NN||ten-eleven-9/JJ	prep_of||expression-6/NN||translocation-10/NN	appos||translocation-10/NN||tet-12/NN	nn||family-15/NN||gene-14/NN	dep||enzymes-21/NNS||family-15/NN	amod||deaminase/apolipoprotein-18/NN||activation-induced-17/JJ	conj_and||family-15/NN||deaminase/apolipoprotein-18/NN	dep||enzymes-21/NNS||deaminase/apolipoprotein-18/NN	dep||enzymes-21/NNS||b-19/SYM	amod||enzymes-21/NNS||mrna-editing-20/JJ	dep||expression-6/NN||enzymes-21/NNS	dep||enzymes-21/NNS||aid/apobec-23/JJ	det||lobule-29/NN||the-26/DT	amod||parietal-28/JJ||inferior-27/JJ	amod||lobule-29/NN||parietal-28/JJ	prep_in||enzymes-21/NNS||lobule-29/NN	appos||lobule-29/NN||ipl-31/NN	dep||lobule-29/NN||ba39-40-34/JJ	det||cerebellum-38/NN||the-37/DT	dep||expression-6/NN||cerebellum-38/NN	conj_and||enzymes-21/NNS||cerebellum-38/NN	amod||patients-50/NNS||psychotic-40/JJ	appos||patients-50/NNS||psy-42/NN	amod||patients-50/NNS||patients-44/JJ	amod||patients-50/NNS||depressed-46/JJ	appos||patients-50/NNS||dep-48/NN	prep_of||cerebellum-38/NN||patients-50/NNS	amod||subjects-56/NNS||nonpsychiatric-52/JJ	appos||subjects-56/NNS||ctr-54/NN	nsubj||obtained-57/VBD||subjects-56/NNS	conj_and||studied-4/VBD||obtained-57/VBD	det||institute-66/NN||the-59/DT	amod||institute-66/NN||stanley-60/JJ	nn||institute-66/NN||foundation-61/NN	nn||institute-66/NN||neuropathology-62/NN	nn||institute-66/NN||consortium-63/NN	amod||institute-66/NN||medical-64/JJ	nn||institute-66/NN||research-65/NN	prep_from||obtained-57/VBD||institute-66/NN	enzymes-21||ten--1||no_rel||here, we studied the expression of the ten-eleven translocation (tet) gene family and activation-induced deaminase/apolipoprotein b mrna-editing enzymes (aid/apobec) in the inferior parietal lobule (ipl) (ba39-40) and the cerebellum of psychotic (psy) patients, depressed (dep) patients and nonpsychiatric (ctr) subjects obtained from the stanley foundation neuropathology consortium medical research institute.
nn||viruses-2/NNS||dna-1/NN	nsubj||vulnerable-16/JJ||viruses-2/NNS	conj_and||viruses-2/NNS||retroviruses-4/NNS	nsubj||vulnerable-16/JJ||retroviruses-4/NNS	conj_and||viruses-2/NNS||hepadnaviruses-6/NNS	nsubj||vulnerable-16/JJ||hepadnaviruses-6/NNS	prep_such_as||viruses-2/NNS||hepatitisbvirus-10/NNS	appos||hepatitisbvirus-10/NNS||hbv-12/NN	cop||vulnerable-16/JJ||are-15/VBP	root||ROOT-0/null||vulnerable-16/JJ	amod||editing-19/NN||genetic-18/JJ	prep_to||vulnerable-16/JJ||editing-19/NN	amod||dna-23/NN||single-21/JJ	amod||dna-23/NN||stranded-22/JJ	prep_of||editing-19/NN||dna-23/NN	nn||apobec3-27/NNS||host-25/NN	nn||apobec3-27/NNS||cell-26/NN	prep_by||vulnerable-16/JJ||apobec3-27/NNS	appos||apobec3-27/NNS||a3-29/NNP	amod||deaminases-32/JJ||cytidine-31/JJ	amod||apobec3-27/NNS||deaminases-32/JJ	hbv-12||hepatitisbvirus-10||no||dna viruses, retroviruses and hepadnaviruses, such as hepatitisbvirus (hbv), are vulnerable to genetic editing of single stranded dna by host cell apobec3 (a3) cytidine deaminases.
det||patients-3/NNS||these-2/DT	nsubj||receiving-4/VBG||patients-3/NNS	prepc_in||dizziness-14/NN||receiving-4/VBG	nn||therapy-7/NN||combination-5/NN	nn||therapy-7/NN||anticonvulsant-6/NN	dobj||receiving-4/VBG||therapy-7/NN	det||aes-12/NN||the-9/DT	advmod||aes-12/NN||most-10/RBS	amod||aes-12/NN||common-11/JJ	nsubj||dizziness-14/NN||aes-12/NN	cop||dizziness-14/NN||were-13/VBD	root||ROOT-0/null||dizziness-14/NN	conj_and||dizziness-14/NN||nausea-16/NN	conj_and||dizziness-14/NN||vomiting-18/NN	conj_and||dizziness-14/NN||somnolence-20/NN	conj_and||dizziness-14/NN||diplopia-23/NN	anticonvulsant-6||vomiting-18||no_rel||in these patients receiving combination anticonvulsant therapy, the most common aes were dizziness, nausea and vomiting, somnolence, and diplopia.
advmod||administrated-20/VBN||furthermore-1/RB	nsubjpass||administrated-20/VBN||imiquimod-3/NN	det||ligand-6/NN||a-5/DT	dep||imiquimod-3/NN||ligand-6/NN	prep_of||ligand-6/NN||tlr7-8/CD	amod||rna-14/NN||tlr3-11/JJ	amod||rna-14/NN||specific-12/JJ	amod||rna-14/NN||short-hairpin-13/JJ	conj_and||imiquimod-3/NN||rna-14/NN	nsubjpass||administrated-20/VBN||rna-14/NN	vmod||rna-14/NN||plasmid-15/VBN	nn||interference-18/NN||rna-17/NN	prep_for||plasmid-15/VBN||interference-18/NN	auxpass||administrated-20/VBN||were-19/VBD	root||ROOT-0/null||administrated-20/VBN	advmod||administrated-20/VBN||respectively-22/RB	prep_in||administrated-20/VBN||vivo-25/NN	amod||rats-28/NNS||aipi-27/JJ	prep_to||vivo-25/NN||rats-28/NNS	aux||observe-30/VB||to-29/TO	vmod||vivo-25/NN||observe-30/VB	poss||effects-32/NNS||their-31/PRP$	dobj||observe-30/VB||effects-32/NNS	det||disease-35/NN||the-34/DT	prep_on||observe-30/VB||disease-35/NN	prepc_by||observe-30/VB||assessing-37/VBG	amod||parameters-40/NNS||various-38/JJ	amod||parameters-40/NNS||asthmatic-39/JJ	dobj||assessing-37/VBG||parameters-40/NNS	asthmatic-39||imiquimod-3||no_rel||furthermore, imiquimod (a ligand of tlr7) and tlr3 specific short-hairpin rna plasmid for rna interference were administrated, respectively, in vivo to aipi rats to observe their effects on the disease by assessing various asthmatic parameters.
det||risk-3/NN||an-1/DT	amod||risk-3/NN||individual-2/JJ	nsubj||decreased-7/VBD||risk-3/NN	nn||attack-6/NN||malaria-5/NN	prep_of||risk-3/NN||attack-6/NN	root||ROOT-0/null||decreased-7/VBD	quantmod||50-10/CD||about-9/RB	num||%-11/NN||50-10/CD	prep_by||decreased-7/VBD||%-11/NN	det||period-14/NN||the-13/DT	prep_during||%-11/NN||period-14/NN	mark||conducted-19/VBN||that-15/IN	amod||surveillance-17/NN||active-16/JJ	nsubjpass||conducted-19/VBN||surveillance-17/NN	auxpass||conducted-19/VBN||was-18/VBD	ccomp||decreased-7/VBD||conducted-19/VBN	det||reduction-28/NN||an-21/DT	amod||reduction-28/NN||additional-22/JJ	num||%-24/NN||15-23/CD	num||reduction-28/NN||%-24/NN	num||%-27/NN||25-26/CD	conj_and||%-24/NN||%-27/NN	num||reduction-28/NN||%-27/NN	nsubjpass||observed-40/VBN||reduction-28/NN	nn||falciparum-31/NN||plasmodium-30/NN	prep_of||reduction-28/NN||falciparum-31/NN	nn||incidence-35/NN||plasmodium-33/NN	nn||incidence-35/NN||vivax-34/NN	prep_of||reduction-28/NN||incidence-35/NN	conj_and||falciparum-31/NN||incidence-35/NN	advmod||falciparum-31/NN||respectively-37/RB	auxpass||observed-40/VBN||was-39/VBD	parataxis||decreased-7/VBD||observed-40/VBN	det||use-43/NN||the-42/DT	prep_after||observed-40/VBN||use-43/NN	amod||-rrb--50/NNS||artesunate-mefloquine-45/JJ	nn||-rrb--50/NNS||combination-46/NN	nn||-rrb--50/NNS||therapy-47/NN	nn||-rrb--50/NNS||-lrb--48/NN	nn||-rrb--50/NNS||act-49/NN	prep_of||use-43/NN||-rrb--50/NNS	prep_for||-rrb--50/NNS||treatment-52/NN	nn||falciparum-55/NN||p.-54/NN	prep_of||treatment-52/NN||falciparum-55/NN	malaria-5||mefloquine--1||yes||an individual risk of malaria attack decreased by about 50 % during the period that active surveillance was conducted ; an additional 15 % and 25 % reduction of plasmodium falciparum and plasmodium vivax incidence , respectively , was observed after the use of artesunate-mefloquine combination therapy -lrb- act -rrb- for treatment of p. falciparum .
nsubj||compared-2/VBD||we-1/PRP	nsubj||isolates-47/VBZ||we-1/PRP	root||ROOT-0/null||compared-2/VBD	det||performance-4/NN||the-3/DT	dobj||compared-2/VBD||performance-4/NN	det||mtbdr-9/NN||the-6/DT	nn||mtbdr-9/NN||genotypeâ-7/NNP	nn||mtbdr-9/NN||®-8/NNP	prep_of||performance-4/NN||mtbdr-9/NN	amod||specimens-45/NNS||assay-11/JJ	amod||tube-16/NN||mycobacterial-13/JJ	nn||tube-16/NN||growth-14/NN	nn||tube-16/NN||indicator-15/NN	prep_to||assay-11/JJ||tube-16/NN	amod||testing-20/NN||antimycobacterial-18/JJ	nn||testing-20/NN||susceptibility-19/NN	prep_for||tube-16/NN||testing-20/NN	amod||ast-23/NN||mgit-22/JJ	appos||testing-20/NN||ast-23/NN	nn||resistance-28/NN||detection-26/NN	nn||resistance-28/NN||inh-27/NN	prep_for||testing-20/NN||resistance-28/NN	nn||resistance-31/NN||rif-30/NN	appos||resistance-28/NN||resistance-31/NN	conj_and||assay-11/JJ||mdr-tb-34/JJ	amod||specimens-45/NNS||mdr-tb-34/JJ	amod||bacilli-38/NNS||stored-36/JJ	amod||bacilli-38/NNS||acid-fast-37/JJ	prep_in||mdr-tb-34/JJ||bacilli-38/NNS	appos||bacilli-38/NNS||afb-40/NN	amod||specimens-45/NNS||positive-43/JJ	nn||specimens-45/NNS||sputum-44/NN	dobj||compared-2/VBD||specimens-45/NNS	conj_plus||performance-4/NN||specimens-45/NNS	conj_and||compared-2/VBD||isolates-47/VBZ	det||laboratory-52/NN||a-49/DT	amod||laboratory-52/NN||public-50/JJ	nn||laboratory-52/NN||tb-51/NN	prep_at||isolates-47/VBZ||laboratory-52/NN	prep_in||laboratory-52/NN||bangkok-54/NN	dep||compared-2/VBD||thailand-56/VBD	tb-51||rif-30||yes||we compared the performance of the genotypeâ® mtbdr plus assay to mycobacterial growth indicator tube for antimycobacterial susceptibility testing (mgit ast) for detection inh resistance, rif resistance, and mdr-tb in stored acid-fast bacilli (afb)-positive sputum specimens and isolates at a public tb laboratory in bangkok, thailand.
nsubj||viruses-19/NNS||hepadnaviruses-1/NNS	prep_including||hepadnaviruses-1/NNS||hepatitisbvirus-4/NNS	appos||hepatitisbvirus-4/NNS||hbv-6/NN	det||pathogen-13/NN||a-9/DT	advmod||relevant-11/JJ||highly-10/RB	amod||pathogen-13/NN||relevant-11/JJ	amod||pathogen-13/NN||human-12/JJ	appos||hepatitisbvirus-4/NNS||pathogen-13/NN	cop||viruses-19/NNS||are-15/VBP	amod||viruses-19/NNS||small-16/JJ	amod||viruses-19/NNS||enveloped-17/JJ	nn||viruses-19/NNS||dna-18/NN	root||ROOT-0/null||viruses-19/NNS	nsubj||replicate-21/VBN||viruses-19/NNS	rcmod||viruses-19/NNS||replicate-21/VBN	amod||transcription-24/NN||reverse-23/JJ	prep_via||replicate-21/VBN||transcription-24/NN	hbv-6||hepatitisbvirus-4||no||hepadnaviruses, including hepatitisbvirus (hbv), a highly relevant human pathogen, are small enveloped dna viruses that replicate via reverse transcription.
nn||rates-2/NNS||success-1/NN	nsubj||%-9/NN||rates-2/NNS	prep_for||rates-2/NNS||daptomycin-4/NN	prep_versus||daptomycin-4/NN||vancomycin/gentamicin-6/NN	cop||%-9/NN||were-7/VBD	num||%-9/NN||45-8/CD	root||ROOT-0/null||%-9/NN	num||%-12/NN||27-11/CD	prep_versus||%-9/NN||%-12/NN	amod||bacteraemia-15/NN||complicated-14/JJ	prep_in||%-12/NN||bacteraemia-15/NN	num||%-18/NN||60-17/CD	prep_versus||%-9/NN||%-18/NN	conj_and||%-12/NN||%-18/NN	num||%-21/NN||45-20/CD	prep_versus||%-18/NN||%-21/NN	amod||bacteraemia-24/NN||uncomplicated-23/JJ	prep_in||%-21/NN||bacteraemia-24/NN	num||%-27/NN||50-26/CD	prep_versus||%-9/NN||%-27/NN	conj_and||%-12/NN||%-27/NN	num||%-30/NN||50-29/CD	prep_versus||%-27/NN||%-30/NN	amod||endocarditis-34/NNS||right-sided-32/JJ	nn||endocarditis-34/NNS||mrsa-33/NN	prep_in||%-30/NN||endocarditis-34/NNS	mrsa-33||daptomycin-4||no_rel||success rates for daptomycin versus vancomycin/gentamicin were 45% versus 27% in complicated bacteraemia, 60% versus 45% in uncomplicated bacteraemia and 50% versus 50% in right-sided mrsa endocarditis.
amod||therapy-3/NN||adjunctive-1/JJ	nn||therapy-3/NN||exenatide-2/NN	nsubj||reduces-4/VBZ||therapy-3/NN	root||ROOT-0/null||reduces-4/VBZ	amod||hyperglycemia-6/NN||postprandial-5/JJ	dobj||reduces-4/VBZ||hyperglycemia-6/NN	prep_in||reduces-4/VBZ||adolescents-8/NNS	prep_with||adolescents-8/NNS||type1diabetes-10/CD	type1diabetes-10||exenatide-2||no||adjunctive exenatide therapy reduces postprandial hyperglycemia in adolescents with type1diabetes.
root||ROOT-0/null||ustekinumabâ-1/VBG	dobj||ustekinumabâ-1/VBG||$-2/$	num||$-2/$||™-3/CD	cop||safety-5/NN||s-4/VBZ	aux||ustekinumabâ-1/VBG||safety-5/NN	cc||efficacy-7/RB||and-6/CC	dep||safety-5/NN||efficacy-7/RB	aux||evaluated-10/VBN||has-8/VBZ	auxpass||evaluated-10/VBN||been-9/VBN	ccomp||efficacy-7/RB||evaluated-10/VBN	det||treatment-13/NN||the-12/DT	prep_for||evaluated-10/VBN||treatment-13/NN	amod||plaquepsoriasis-16/NNS||moderate-to-severe-15/JJ	prep_of||treatment-13/NN||plaquepsoriasis-16/NNS	num||phase-19/NN||3-18/CD	prep_in||evaluated-10/VBN||phase-19/NN	vmod||phase-19/NN||iii-20/VBN	amod||trials-22/NNS||clinical-21/JJ	dobj||iii-20/VBN||trials-22/NNS	number||placebo-controlled-25/JJ||2-24/CD	aux||ustekinumabâ-1/VBG||placebo-controlled-25/JJ	conj_and||safety-5/NN||placebo-controlled-25/JJ	dep||safety-5/NN||phoenix-27/VB	dobj||phoenix-27/VB||1-28/CD	dobj||phoenix-27/VB||2-30/CD	conj_and||1-28/CD||2-30/CD	number||comparator-controlled-35/JJ||1-34/CD	aux||ustekinumabâ-1/VBG||comparator-controlled-35/JJ	conj_and||safety-5/NN||comparator-controlled-35/JJ	dep||safety-5/NN||accept-37/VB	nsubj||ustekinumabâ-1/VBG||study-39/NN	nsubj||proved-41/VBD||which-40/WDT	nsubj||failed-50/VBD||which-40/WDT	nsubj||unresponsive-60/JJ||which-40/WDT	nsubj||phototherapy-62/VB||which-40/WDT	nsubj||unable-66/JJ||which-40/WDT	nsubj||use-68/VB||which-40/WDT	ccomp||study-39/NN||proved-41/VBD	acomp||proved-41/VBD||advantageous-42/JJ	prep_in||advantageous-42/JJ||patients-44/NNS	nsubj||treatment-naive-47/JJ||patients-44/NNS	cop||treatment-naive-47/JJ||were-46/VBD	rcmod||patients-44/NNS||treatment-naive-47/JJ	advmod||failed-50/VBD||previously-49/RB	ccomp||study-39/NN||failed-50/VBD	conj_or||proved-41/VBD||failed-50/VBD	amod||medications-53/NNS||other-51/JJ	nn||medications-53/NNS||immunosuppressive-52/NN	dobj||failed-50/VBD||medications-53/NNS	prep_including||medications-53/NNS||cyclosporine-55/NN	prep_including||medications-53/NNS||methotrexate-57/NN	conj_or||cyclosporine-55/NN||methotrexate-57/NN	cop||unresponsive-60/JJ||were-59/VBD	ccomp||study-39/NN||unresponsive-60/JJ	conj_or||proved-41/VBD||unresponsive-60/JJ	aux||phototherapy-62/VB||to-61/TO	xcomp||unresponsive-60/JJ||phototherapy-62/VB	cop||unable-66/JJ||were-65/VBD	ccomp||study-39/NN||unable-66/JJ	conj_or||proved-41/VBD||unable-66/JJ	aux||use-68/VB||to-67/TO	xcomp||unable-66/JJ||use-68/VB	xcomp||unable-66/JJ||tolerate-70/VB	conj_or||use-68/VB||tolerate-70/VB	amod||therapies-72/NNS||other-71/JJ	dobj||use-68/VB||therapies-72/NNS	plaquepsoriasis-16||immunosuppressive-52||no_rel||ustekinumabâ€™s safety and efficacy has been evaluated for the treatment of moderate-to-severe plaquepsoriasis in 3 phase iii clinical trials, 2 placebo-controlled (phoenix 1 and 2), and 1 comparator-controlled (accept) study which proved advantageous in patients who were treatment-naive, previously failed other immunosuppressive medications including cyclosporine or methotrexate, were unresponsive to phototherapy, or were unable to use or tolerate other therapies.
nsubj||medication-6/NN||ranolazine-1/NN	nsubjpass||considered-17/VBN||ranolazine-1/NN	cop||medication-6/NN||is-2/VBZ	det||medication-6/NN||a-3/DT	amod||medication-6/NN||proven-4/JJ	amod||medication-6/NN||antianginal-5/JJ	root||ROOT-0/null||medication-6/NN	prep_in||medication-6/NN||patients-8/NNS	amod||heartdisease-12/NN||symptomatic-10/JJ	amod||heartdisease-12/NN||coronary-11/JJ	prep_with||patients-8/NNS||heartdisease-12/NN	aux||considered-17/VBN||should-15/MD	auxpass||considered-17/VBN||be-16/VB	conj_and||medication-6/NN||considered-17/VBN	det||agent-22/NN||an-19/DT	amod||agent-22/NN||initial-20/JJ	amod||agent-22/NN||antianginal-21/JJ	prep_as||considered-17/VBN||agent-22/NN	prep_for||agent-22/NN||those-24/DT	prep_with||those-24/DT||hypotension-26/NN	prep_with||those-24/DT||bradycardia-28/NN	conj_or||hypotension-26/NN||bradycardia-28/NN	bradycardia-28||antianginal-21||no_rel||ranolazine is a proven antianginal medication in patients with symptomatic coronary heartdisease, and should be considered as an initial antianginal agent for those with hypotension or bradycardia.
nsubj||are-11/VBP||studies-1/NNS	aux||explore-3/VB||to-2/TO	vmod||studies-1/NNS||explore-3/VB	det||effect-5/NN||the-4/DT	dobj||explore-3/VB||effect-5/NN	prep_of||effect-5/NN||anticoagulants-7/NNS	nn||survival-10/NN||cancer-9/NN	prep_on||anticoagulants-7/NNS||survival-10/NN	root||ROOT-0/null||are-11/VBP	advmod||are-11/VBP||underway-12/RB	amod||malignancies-15/NNS||other-14/JJ	prep_in||are-11/VBP||malignancies-15/NNS	nn||breast-24/NN||lung-18/NN	dep||breast-24/NN||pancreas-20/NN	dep||breast-24/NN||ovary-22/NN	prep_such_as||malignancies-15/NNS||breast-24/NN	nn||cancer-28/NN||stomach-27/NN	prep_such_as||malignancies-15/NNS||cancer-28/NN	conj_and||breast-24/NN||cancer-28/NN	malignancies-15||anticoagulants-7||no_rel||studies to explore the effect of anticoagulants on cancer survival are underway in other malignancies such as lung, pancreas, ovary, breast, and stomach cancer.
nn||treatment-3/NN||gancyclovir-2/NN	prep_following||went-11/VBD||treatment-3/NN	amod||viremia-7/NN||subsequent-5/JJ	nn||viremia-7/NN||cytomegalovirus-6/NNS	prep_of||treatment-3/NN||viremia-7/NN	det||patient-10/NN||the-9/DT	nsubj||went-11/VBD||patient-10/NN	nsubj||receive-14/VB||patient-10/NN	root||ROOT-0/null||went-11/VBD	prt||went-11/VBD||on-12/RP	aux||receive-14/VB||to-13/TO	xcomp||went-11/VBD||receive-14/VB	det||course-16/NN||a-15/DT	dobj||receive-14/VB||course-16/NN	prep_of||course-16/NN||epoch-18/NN	advmod||mg/m2/day-52/NN||etoposide-20/RB	num||mg/m2/day-22/NNS||50-21/CD	pobj||etoposide-20/RB||mg/m2/day-22/NNS	prep_on||etoposide-20/RB||days-24/NNS	amod||mg/m2/day-52/NN||1â-25/JJ	amod||mg/m2/day-52/NN||$-26/$	num||$-26/$||4-28/CD	amod||mg/m2/day-52/NN||vincristine-30/JJ	num||mg/m2/day-32/NNS||0.4-31/CD	dep||vincristine-30/JJ||mg/m2/day-32/NNS	prep_on||mg/m2/day-32/NNS||days-34/NNS	amod||mg/m2/day-52/NN||1â-35/JJ	amod||mg/m2/day-52/NN||$-36/$	num||$-36/$||4-38/CD	amod||mg/m2/day-52/NN||doxorubicin-40/JJ	num||mg/m2/day-42/NNS||10-41/CD	dep||doxorubicin-40/JJ||mg/m2/day-42/NNS	prep_on||mg/m2/day-42/NNS||days-44/NNS	amod||mg/m2/day-52/NN||1â-45/JJ	amod||mg/m2/day-52/NN||$-46/$	num||$-46/$||4-48/CD	amod||mg/m2/day-52/NN||cyclophosphamide-50/JJ	number||cyclophosphamide-50/JJ||750-51/CD	dep||epoch-18/NN||mg/m2/day-52/NN	prep_on||mg/m2/day-52/NN||day-54/NN	num||day-54/NN||6-55/CD	advmod||1â-63/JJ||prednisolone-58/RB	num||mg/m2/day-60/NNS||60-59/CD	pobj||prednisolone-58/RB||mg/m2/day-60/NNS	prep_on||prednisolone-58/RB||days-62/NNS	prep_on||mg/m2/day-52/NN||1â-63/JJ	conj_and||day-54/NN||1â-63/JJ	dep||1â-63/JJ||$-64/$	num||$-64/$||6-66/CD	viremia-7||prednisolone-58||no_rel||following gancyclovir treatment of subsequent cytomegalovirus viremia, the patient went on to receive a course of epoch (etoposide 50 mg/m2/day on days 1â€“4, vincristine 0.4 mg/m2/day on days 1â€“4, doxorubicin 10 mg/m2/day on days 1â€“4, cyclophosphamide 750 mg/m2/day on day 6, and prednisolone 60 mg/m2/day on days 1â€“6).
nsubj||been-3/VBN||families-1/NNS	aux||been-3/VBN||have-2/VBP	root||ROOT-0/null||been-3/VBN	det||forefront-6/NN||the-5/DT	prep_at||been-3/VBN||forefront-6/NN	det||response-9/NN||the-8/DT	prep_of||forefront-6/NN||response-9/NN	det||epidemic-13/NN||the-11/DT	amod||epidemic-13/NN||hiv/aids-12/JJ	prep_to||been-3/VBN||epidemic-13/NN	amod||countries-16/NNS||high-prevalence-15/JJ	prep_in||epidemic-13/NN||countries-16/NNS	aids--1||hiv--1||no||families have been at the forefront of the response to the hiv/aids epidemic in high-prevalence countries.
mark||clear-4/JJ||although-1/IN	nsubj||clear-4/JJ||it-2/PRP	cop||clear-4/JJ||is-3/VBZ	advcl||cause-47/VB||clear-4/JJ	mark||have-16/VBP||that-5/IN	det||patients-7/NNS||some-6/DT	nsubj||have-16/VBP||patients-7/NNS	prep_with||patients-7/NNS||acetylsalicylicacid-9/NN	appos||acetylsalicylicacid-9/NN||asa-11/NN	amod||asthma-15/NN||sensitive-14/JJ	dep||acetylsalicylicacid-9/NN||asthma-15/NN	ccomp||clear-4/JJ||have-16/VBP	poss||onset-19/NN||their-17/PRP$	amod||onset-19/NN||clinical-18/JJ	dobj||have-16/VBP||onset-19/NN	prep_of||onset-19/NN||disease-21/NN	prep_in||disease-21/NN||childhood-23/NN	prep_in||disease-21/NN||bronchoconstriction-25/NN	conj_and||childhood-23/NN||bronchoconstriction-25/NN	mark||seen-30/VBN||after-26/IN	nn||challenge-28/NN||asa-27/NN	nsubjpass||seen-30/VBN||challenge-28/NN	auxpass||seen-30/VBN||is-29/VBZ	advcl||have-16/VBP||seen-30/VBN	prep_in||seen-30/VBN||0-32/CD	num||%-35/NN||22-34/CD	prep_to||seen-30/VBN||%-35/NN	amod||children-38/NNS||asthmatic-37/JJ	prep_of||%-35/NN||children-38/NNS	advmod||challenged-40/VBN||so-39/RB	vmod||children-38/NNS||challenged-40/VBN	nsubj||cause-47/VB||ibuprofen-42/NN	amod||doses-45/NNS||antipyretic-44/JJ	prep_at||ibuprofen-42/NN||doses-45/NNS	aux||cause-47/VB||may-46/MD	root||ROOT-0/null||cause-47/VB	amod||problems-50/NNS||acute-48/JJ	nn||problems-50/NNS||respiratory-49/NN	dobj||cause-47/VB||problems-50/NNS	advmod||cause-47/VB||only-51/RB	det||number-56/NN||a-53/DT	advmod||small-55/JJ||very-54/RB	amod||number-56/NN||small-55/JJ	prep_in||cause-47/VB||number-56/NN	amod||moderate-60/JJ||mild-58/JJ	dep||moderate-60/JJ||to-59/TO	amod||asthmatics-61/NNS||moderate-60/JJ	prep_of||number-56/NN||asthmatics-61/NNS	asthma-15||acetylsalicylicacid-9||no||although it is clear that some patients with acetylsalicylicacid (asa)-sensitive asthma have their clinical onset of disease in childhood and bronchoconstriction after asa challenge is seen in 0 to 22% of asthmatic children so challenged, ibuprofen at antipyretic doses may cause acute respiratory problems only in a very small number of mild to moderate asthmatics.
nsubj||-lsb--7/VBZ||aims-1/NNS	aux||compare-3/VB||to-2/TO	vmod||aims-1/NNS||compare-3/VB	num||approaches-6/NNS||two-4/CD	amod||approaches-6/NNS||progressive-5/JJ	dobj||compare-3/VB||approaches-6/NNS	root||ROOT-0/null||-lsb--7/VBZ	amod||insulinglargine-9/NN||once-daily-8/JJ	dobj||-lsb--7/VBZ||insulinglargine-9/NN	prep||insulinglargine-9/NN||plus-10/CC	nn||+-19/NNS||â-11/NNP	nn||+-19/NNS||‰-12/NNP	amod||+-19/NNS||$-13/$	number||$-13/$||3-14/CD	dep||$-13/$||mealtime-15/JJ	amod||+-19/NNS||lispro-16/JJ	amod||+-19/NNS||-lrb--17/JJ	nn||+-19/NNS||g-18/NN	pobj||plus-10/CC||+-19/NNS	advmod||-rrb--21/JJ||l-20/RB	amod||+-19/NNS||-rrb--21/JJ	nn||-rrb--29/NN||insulin-23/NN	nn||-rrb--29/NN||lispro-24/NN	nn||-rrb--29/NN||mix-25/NN	num||-rrb--29/NN||50/50-26/CD	num||-rrb--29/NN||-lrb--27/CD	amod||-rrb--29/NN||lm50/50-28/JJ	prep_vs.||+-19/NNS||-rrb--29/NN	vmod||-rrb--29/NN||progression-30/VBN	advmod||up-32/RB||once-31/RB	advmod||progression-30/VBN||up-32/RB	aux||thrice-34/VB||to-33/TO	xcomp||progression-30/VBN||thrice-34/VB	amod||progression-38/NN||daily-35/JJ	amod||progression-38/NN||-lrb--36/JJ	nn||progression-38/NN||premix-37/NN	dobj||thrice-34/VB||progression-38/NN	nn||-rsb--42/NNP||pp-40/NNP	nn||-rsb--42/NNP||-rrb--41/NNP	appos||progression-38/NN||-rsb--42/NNP	prepc_of||-rsb--42/NNP||beginning-44/VBG	prepc_of||-rsb--42/NNP||advancing-46/VBG	conj_and||beginning-44/VBG||advancing-46/VBG	dobj||beginning-44/VBG||insulin-47/NN	prep_in||+-19/NNS||patients-49/NNS	prep_with||patients-49/NNS||type2diabetes-51/CD	vmod||+-19/NNS||-lrb--52/VBG	num||control-58/NN||t2d-53/CD	amod||control-58/NN||-rrb--54/JJ	conj_and||-rrb--54/JJ||inadequate-56/JJ	amod||control-58/NN||inadequate-56/JJ	amod||control-58/NN||glycaemic-57/JJ	dobj||-lrb--52/VBG||control-58/NN	amod||therapy-61/NN||oral-60/JJ	prep_on||control-58/NN||therapy-61/NN	det||aim-65/NN||the-64/DT	prep_with||-lrb--52/VBG||aim-65/NN	prepc_of||aim-65/NN||showing-67/VBG	dobj||showing-67/VBG||non-inferiority-68/NN	prep_of||non-inferiority-68/NN||pp-70/NN	aux||g-72/VB||to-71/TO	vmod||showing-67/VBG||g-72/VB	amod||l-74/NN||+-73/JJ	dobj||g-72/VB||l-74/NN	type2diabetes-51||insulinglargine-9||yes||aims to compare two progressive approaches -lsb- once-daily insulinglargine plus â ‰ $ 3 mealtime lispro -lrb- g+l -rrb- vs. insulin lispro mix 50/50 -lrb- lm50/50 -rrb- progression once up to thrice daily -lrb- premix progression , pp -rrb- -rsb- of beginning and advancing insulin in patients with type2diabetes -lrb- t2d -rrb- and inadequate glycaemic control on oral therapy , with the aim of showing non-inferiority of pp to g+l .
det||mutations-2/NNS||the-1/DT	nsubjpass||detected-14/VBN||mutations-2/NNS	vmod||mutations-2/NNS||known-3/VBN	prepc_as||known-3/VBN||causing-5/VBG	nn||resistance-7/NN||adefovir-6/NN	dobj||causing-5/VBG||resistance-7/NN	amod||resistance-7/NN||rtn236t-9/JJ	amod||resistance-7/NN||rta181v/t-11/JJ	conj_and||rtn236t-9/JJ||rta181v/t-11/JJ	auxpass||detected-14/VBN||are-13/VBP	root||ROOT-0/null||detected-14/VBN	det||domain-21/NN||the-16/DT	dep||functional-20/JJ||d-17/SYM	conj_and||d-17/SYM||b-19/SYM	dep||functional-20/JJ||b-19/SYM	amod||domain-21/NN||functional-20/JJ	prep_within||detected-14/VBN||domain-21/NN	det||polymerase-25/NN||the-23/DT	nn||polymerase-25/NN||hbv-24/NN	prep_of||domain-21/NN||polymerase-25/NN	advmod||detected-14/VBN||respectively-27/RB	hbv-24||adefovir-6||yes||the mutations known as causing adefovir resistance, rtn236t and rta181v/t, are detected within the d and b functional domain of the hbv polymerase, respectively.
amod||minimus-3/NNS||purified-1/JJ	nn||minimus-3/NNS||a.-2/NN	nsubj||cypor-4/VBP||minimus-3/NNS	root||ROOT-0/null||cypor-4/VBP	amod||-rrb--8/NNS||enzyme-5/JJ	amod||-rrb--8/NNS||-lrb--6/JJ	nn||-rrb--8/NNS||ancypor-7/NN	nsubj||partner-14/NN||-rrb--8/NNS	nsubj||loses-19/VBZ||-rrb--8/NNS	cop||partner-14/NN||is-11/VBZ	det||partner-14/NN||the-12/DT	nn||partner-14/NN||redox-13/NN	rcmod||-rrb--8/NNS||partner-14/NN	amod||p450s-17/NNS||cytochrome-16/JJ	prep_of||partner-14/NN||p450s-17/NNS	ccomp||cypor-4/VBP||loses-19/VBZ	amod||-rrb--24/NNS||flavin-adenosine-20/JJ	amod||-rrb--24/NNS||di-nucleotide-21/JJ	amod||-rrb--24/NNS||-lrb--22/JJ	nn||-rrb--24/NNS||fad-23/NN	dobj||loses-19/VBZ||-rrb--24/NNS	amod||cofactors-31/NNS||flavin-26/JJ	amod||cofactors-31/NNS||mono-nucleotide-27/JJ	amod||cofactors-31/NNS||-lrb--28/JJ	nn||cofactors-31/NNS||fmn-29/NN	nn||cofactors-31/NNS||-rrb--30/NN	dobj||loses-19/VBZ||cofactors-31/NNS	conj_and||-rrb--24/NNS||cofactors-31/NNS	nsubj||affect-33/VBP||cofactors-31/NNS	rcmod||cofactors-31/NNS||affect-33/VBP	poss||activity-36/NN||its-34/PRP$	amod||activity-36/NN||enzyme-35/JJ	dobj||affect-33/VBP||activity-36/NN	fmn-29||di--1||no_rel||purified a. minimus cypor enzyme -lrb- ancypor -rrb- , which is the redox partner of cytochrome p450s , loses flavin-adenosine di-nucleotide -lrb- fad -rrb- and flavin mono-nucleotide -lrb- fmn -rrb- cofactors that affect its enzyme activity .
mark||higher-6/JJR||although-1/IN	amod||prevalence-3/NN||hbsag-2/VBG	nsubj||higher-6/JJR||prevalence-3/NN	cop||higher-6/JJR||is-4/VBZ	advmod||higher-6/JJR||much-5/RB	advcl||high-29/JJ||higher-6/JJR	prep_among||higher-6/JJR||subjects-8/NNS	nsubj||hivpositive-11/JJ||subjects-8/NNS	cop||hivpositive-11/JJ||are-10/VBP	rcmod||subjects-8/NNS||hivpositive-11/JJ	num||%-14/NN||14.0-13/CD	dep||subjects-8/NNS||%-14/NN	num||%-17/NN||4.3-16/CD	dep||subjects-8/NNS||%-17/NN	conj_versus||%-14/NN||%-17/NN	det||prevalence-21/NN||the-20/DT	nsubj||high-29/JJ||prevalence-21/NN	nsubj||warrant-32/VB||prevalence-21/NN	prepc_of||prevalence-21/NN||hbsag-23/VBG	amod||subjects-27/NNS||hiv-25/JJ	amod||subjects-27/NNS||negative-26/JJ	prep_in||hbsag-23/VBG||subjects-27/NNS	cop||high-29/JJ||is-28/VBZ	root||ROOT-0/null||high-29/JJ	advmod||high-29/JJ||enough-30/RB	aux||warrant-32/VB||to-31/TO	xcomp||high-29/JJ||warrant-32/VB	det||recommendation-34/NN||a-33/DT	dobj||warrant-32/VB||recommendation-34/NN	aux||screen-36/VB||to-35/TO	vmod||recommendation-34/NN||screen-36/VB	det||clients-38/NNS||all-37/DT	dobj||screen-36/VB||clients-38/NNS	nn||centers-41/NNS||vct-40/NN	prep_at||screen-36/VB||centers-41/NNS	nn||status-45/NN||hiv-44/NN	prep_irrespective_of||screen-36/VB||status-45/NN	hbsag-23||hivpositive-11||no_rel||although hbsag prevalence is much higher among subjects who are hivpositive (14.0% versus 4.3%), the prevalence of hbsag in hiv negative subjects is high enough to warrant a recommendation to screen all clients at vct centers irrespective of hiv status.
aux||characterize-2/VB||to-1/TO	csubj||randomized-37/VBD||characterize-2/VB	det||amount-4/NN||the-3/DT	dobj||characterize-2/VB||amount-4/NN	amod||hypoglycemia-7/NN||nocturnal-6/JJ	prep_of||amount-4/NN||hypoglycemia-7/NN	conj_and||characterize-2/VB||evaluate-9/VB	csubj||randomized-37/VBD||evaluate-9/VB	dobj||evaluate-9/VB||factors-10/NNS	vmod||factors-10/NNS||associated-11/VBN	amod||hypoglycemia-14/NN||nocturnal-13/JJ	prep_with||associated-11/VBN||hypoglycemia-14/NN	vmod||hypoglycemia-14/NN||assessed-15/VBN	amod||monitoring-19/NN||continuous-17/JJ	nn||monitoring-19/NN||glucose-18/NN	prep_with||assessed-15/VBN||monitoring-19/NN	appos||monitoring-19/NN||cgm-21/NN	prep_in||monitoring-19/NN||adults-24/NNS	prep_in||monitoring-19/NN||children-26/NNS	conj_and||adults-24/NNS||children-26/NNS	prep_with||assessed-15/VBN||type1diabetes-28/NNS	nsubj||participated-30/VBD||type1diabetes-28/NNS	rcmod||type1diabetes-28/NNS||participated-30/VBD	det||cgm-36/NN||the-32/DT	amod||cgm-36/NN||juvenilediabetes-33/JJ	nn||cgm-36/NN||research-34/NN	nn||cgm-36/NN||foundation-35/NN	prep_in||participated-30/VBD||cgm-36/NN	root||ROOT-0/null||randomized-37/VBD	amod||trial-39/NN||clinical-38/JJ	dobj||randomized-37/VBD||trial-39/NN	glucose-18||juvenilediabetes-33||no_rel||to characterize the amount of nocturnal hypoglycemia and evaluate factors associated with nocturnal hypoglycemia assessed with continuous glucose monitoring (cgm) in adults and children with type1diabetes who participated in the juvenilediabetes research foundation cgm randomized clinical trial.
det||activity-2/NN||the-1/DT	nsubjpass||thought-18/VBN||activity-2/NN	nsubj||determinant-23/NN||activity-2/NN	amod||dehydrogenase-5/NN||dihydropyrimidine-4/JJ	prep_of||activity-2/NN||dehydrogenase-5/NN	appos||dehydrogenase-5/NN||dpd-7/NN	det||enzyme-12/NN||the-10/DT	amod||enzyme-12/NN||key-11/JJ	appos||activity-2/NN||enzyme-12/NN	amod||catabolism-15/NN||pyrimidine-14/JJ	prep_of||enzyme-12/NN||catabolism-15/NN	auxpass||thought-18/VBN||is-17/VBZ	root||ROOT-0/null||thought-18/VBN	aux||determinant-23/NN||to-19/TO	cop||determinant-23/NN||be-20/VB	det||determinant-23/NN||an-21/DT	amod||determinant-23/NN||important-22/JJ	xcomp||thought-18/VBN||determinant-23/NN	det||occurrence-26/NN||the-25/DT	prep_for||determinant-23/NN||occurrence-26/NN	amod||reactions-30/NNS||severe-28/JJ	amod||reactions-30/NNS||toxic-29/JJ	prep_of||occurrence-26/NN||reactions-30/NNS	prep_to||reactions-30/NNS||5-fluorouracil-32/NN	nsubj||one-39/CD||5-fluorouracil-32/NN	dep||5-fluorouracil-32/NN||5-fu-34/JJ	cop||one-39/CD||is-38/VBZ	rcmod||5-fluorouracil-32/NN||one-39/CD	det||most-42/JJS||the-41/DT	prep_of||one-39/CD||most-42/JJS	advmod||prescribed-44/VBN||commonly-43/RB	vmod||most-42/JJS||prescribed-44/VBN	amod||agents-46/NNS||chemotherapeutic-45/JJ	dobj||prescribed-44/VBN||agents-46/NNS	det||treatment-49/NN||the-48/DT	prep_for||agents-46/NNS||treatment-49/NN	amod||cancers-52/NNS||solid-51/JJ	prep_of||treatment-49/NN||cancers-52/NNS	cancers-52||enzyme-12||no_rel||the activity of dihydropyrimidine dehydrogenase (dpd), the key enzyme of pyrimidine catabolism, is thought to be an important determinant for the occurrence of severe toxic reactions to 5-fluorouracil (5-fu), which is one of the most commonly prescribed chemotherapeutic agents for the treatment of solid cancers.
amod||survival-2/NN||clonogenic-1/JJ	nsubj||reveal-16/VBP||survival-2/NN	nn||viability-assays-5/NNS||live/dead-4/NN	conj_and||survival-2/NN||viability-assays-5/NNS	nsubj||reveal-16/VBP||viability-assays-5/NNS	advmod||with-8/IN||together-7/RB	rcmod||survival-2/NN||with-8/IN	amod||activity-10/NN||enzymatic-9/JJ	pobj||with-8/IN||activity-10/NN	nn||assays-14/NNS||cell-12/NN	nn||assays-14/NNS||proliferation-13/NN	pobj||with-8/IN||assays-14/NNS	conj_and||activity-10/NN||assays-14/NNS	root||ROOT-0/null||reveal-16/VBP	mark||correlate-28/VBP||that-17/IN	det||levels-19/NNS||the-18/DT	nsubj||correlate-28/VBP||levels-19/NNS	amod||activity-24/NN||paclitaxel-induced-21/JJ	amod||activity-24/NN||caspase-3-22/JJ	amod||activity-24/NN||enzymatic-23/JJ	prep_of||levels-19/NNS||activity-24/NN	nn||cells-27/NNS||tumor-26/NN	prep_in||activity-24/NN||cells-27/NNS	ccomp||reveal-16/VBP||correlate-28/VBP	advmod||correlate-28/VBP||directly-29/RB	nn||sensitivity-32/NN||tumor-31/NN	prep_with||correlate-28/VBP||sensitivity-32/NN	det||drug.we-35/NN||the-34/DT	prep_to||correlate-28/VBP||drug.we-35/NN	rcmod||drug.we-35/NN||observed-36/VBD	det||increase-39/NN||a-37/DT	amod||increase-39/NN||2-fold-38/JJ	dobj||observed-36/VBD||increase-39/NN	amod||activity-42/NN||caspase-3-41/JJ	prep_in||increase-39/NN||activity-42/NN	amod||cells-46/NNS||4t1-luc-44/JJ	nn||cells-46/NNS||breasttumor-45/NN	prep_in||activity-42/NN||cells-46/NNS	det||decrease-53/NN||a-49/DT	amod||decrease-53/NN||3-fold-50/JJ	conj_and||3-fold-50/JJ||4-fold-52/JJ	amod||decrease-53/NN||4-fold-52/JJ	dobj||observed-36/VBD||decrease-53/NN	conj_but||increase-39/NN||decrease-53/NN	prep_in||decrease-53/NN||a549-55/NNS	amod||lines-61/NNS||a427-57/JJ	nn||lines-61/NNS||lung-58/NN	nn||lines-61/NNS||tumor-59/NN	nn||lines-61/NNS||cell-60/NN	prep_in||decrease-53/NN||lines-61/NNS	conj_and||a549-55/NNS||lines-61/NNS	advmod||observed-36/VBD||respectively-63/RB	breasttumor-45||paclitaxel--1||yes||clonogenic survival and live/dead viability-assays, together with enzymatic activity and cell proliferation assays, reveal that the levels of paclitaxel-induced caspase-3 enzymatic activity in tumor cells correlate directly with tumor sensitivity to the drug.we observed a 2-fold increase in caspase-3 activity in 4t1-luc breasttumor cells, but a 3-fold and 4-fold decrease in a549 and a427 lung tumor cell lines, respectively.
nsubj||protein-6/NN||adiponectin-1/NN	cop||protein-6/NN||is-2/VBZ	det||protein-6/NN||an-3/DT	advmod||related-5/VBN||obesity-4/RB	amod||protein-6/NN||related-5/VBN	root||ROOT-0/null||protein-6/NN	nsubj||mediates-8/VBZ||that-7/WDT	ccomp||protein-6/NN||mediates-8/VBZ	det||risk-10/NN||the-9/DT	dobj||mediates-8/VBZ||risk-10/NN	prep_of||risk-10/NN||type2diabetes-12/NNS	amod||individuals-15/NNS||obese-14/JJ	prep_in||type2diabetes-12/NNS||individuals-15/NNS	poss||anti-inflammatory-18/NN||its-17/PRP$	prep_with||mediates-8/VBZ||anti-inflammatory-18/NN	nn||properties-21/NNS||insulin-sensitizing-20/NN	prep_with||mediates-8/VBZ||properties-21/NNS	conj_and||anti-inflammatory-18/NN||properties-21/NNS	anti-inflammatory-18||type2diabetes-12||no_rel||adiponectin is an obesity related protein that mediates the risk of type2diabetes in obese individuals with its anti-inflammatory and insulin-sensitizing properties.
mark||suggested-6/VBN||although-1/IN	det||studies-4/NNS||some-2/DT	amod||studies-4/NNS||previous-3/JJ	nsubj||suggested-6/VBN||studies-4/NNS	aux||suggested-6/VBN||have-5/VBP	advcl||examined-24/VBN||suggested-6/VBN	mark||comprised-14/VBN||that-7/IN	amod||growth-9/NN||posttraumatic-8/JJ	nsubjpass||comprised-14/VBN||growth-9/NN	appos||growth-9/NN||ptg-11/NN	auxpass||comprised-14/VBN||is-13/VBZ	ccomp||suggested-6/VBN||comprised-14/VBN	amod||factors-17/NNS||several-16/JJ	prep_of||comprised-14/VBN||factors-17/NNS	amod||properties-20/NNS||different-19/JJ	prep_with||comprised-14/VBN||properties-20/NNS	nsubj||examined-24/VBN||few-22/JJ	aux||examined-24/VBN||have-23/VBP	root||ROOT-0/null||examined-24/VBN	predet||association-27/NN||both-25/PDT	det||association-27/NN||the-26/DT	dobj||examined-24/VBN||association-27/NN	prep_between||examined-24/VBN||ptg-29/NN	prep_between||examined-24/VBN||posttraumaticstressdisorder-31/NN	conj_and||ptg-29/NN||posttraumaticstressdisorder-31/NN	dep||examined-24/VBN||ptsd-33/VBN	prep_between||examined-24/VBN||ptg-37/NN	conj_and||ptg-29/NN||ptg-37/NN	conj_and||ptg-29/NN||resilience-39/NN	conj_and||ptg-37/NN||resilience-39/NN	vmod||ptg-37/NN||focusing-41/VBG	prep_on||focusing-41/VBG||each-43/DT	det||factors-46/NNS||the-45/DT	prep_of||each-43/DT||factors-46/NNS	prep_of||factors-46/NNS||ptg-48/NN	ptsd-33||ptg-48||no_rel||although some previous studies have suggested that posttraumatic growth (ptg) is comprised of several factors with different properties, few have examined both the association between ptg and posttraumaticstressdisorder (ptsd) and between ptg and resilience, focusing on each of the factors of ptg.
amod||studies-2/NNS||clinical-1/JJ	nsubj||shown-4/VBN||studies-2/NNS	aux||shown-4/VBN||have-3/VBP	root||ROOT-0/null||shown-4/VBN	mark||effective-12/JJ||that-5/IN	nsubj||effective-12/JJ||naproxen-6/NN	conj_and||naproxen-6/NN||ibuprofen-8/NN	nsubj||effective-12/JJ||ibuprofen-8/NN	cop||effective-12/JJ||are-9/VBP	advmod||effective-12/JJ||significantly-10/RB	advmod||effective-12/JJ||more-11/RBR	ccomp||shown-4/VBN||effective-12/JJ	prepc_at||effective-12/JJ||reducing-14/VBG	nn||pain-16/NN||oa-15/NN	dobj||reducing-14/VBG||pain-16/NN	mark||acetaminophen-19/NN||than-17/IN	cop||acetaminophen-19/NN||is-18/VBZ	ccomp||effective-12/JJ||acetaminophen-19/NN	nsubj||has-27/VBZ||acetaminophen-19/NN	det||therapy-24/NN||the-21/DT	amod||therapy-24/NN||traditional-22/JJ	amod||therapy-24/NN||first-line-23/JJ	appos||acetaminophen-19/NN||therapy-24/NN	rcmod||acetaminophen-19/NN||has-27/VBZ	neg||activity-31/NN||no-28/DT	amod||activity-31/NN||apparent-29/JJ	amod||activity-31/NN||anti-inflammatory-30/JJ	dobj||has-27/VBZ||activity-31/NN	det||joints-34/NNS||the-33/DT	prep_in||activity-31/NN||joints-34/NNS	pain-16||ibuprofen-8||yes||clinical studies have shown that naproxen and ibuprofen are significantly more effective at reducing oa pain than is acetaminophen, the traditional first-line therapy, which has no apparent anti-inflammatory activity in the joints.
quantmod||two-thirds-3/NNS||fewer-1/JJR	quantmod||two-thirds-3/NNS||than-2/IN	nsubj||knew-4/VBD||two-thirds-3/NNS	root||ROOT-0/null||knew-4/VBD	mark||develop-27/VB||that-5/IN	quantmod||10-7/CD||about-6/RB	num||%-8/NN||10-7/CD	nsubj||develop-27/VB||%-8/NN	prep_of||%-8/NN||people-10/NNS	det||u.s.a.-13/NN||the-12/DT	prep_in||people-10/NNS||u.s.a.-13/NN	nsubj||have-15/VBP||u.s.a.-13/NN	rcmod||u.s.a.-13/NN||have-15/VBP	nn||-rrb--20/NNP||latent-16/NN	nn||-rrb--20/NNP||tuberculosisinfection-17/NN	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||ltbi-19/NNP	dobj||have-15/VBP||-rrb--20/NNP	det||system-25/NN||a-22/DT	amod||system-25/NN||normal-23/JJ	amod||system-25/NN||immune-24/JJ	dobj||have-15/VBP||system-25/NN	conj_and||-rrb--20/NNP||system-25/NN	aux||develop-27/VB||will-26/MD	ccomp||knew-4/VBD||develop-27/VB	nn||disease-29/NN||tb-28/NN	dobj||develop-27/VB||disease-29/NN	mark||part-36/NN||that-32/IN	nsubj||part-36/NN||bcg-33/NN	cop||part-36/NN||is-34/VBZ	neg||part-36/NN||not-35/RB	ccomp||knew-4/VBD||part-36/NN	conj_or||develop-27/VB||part-36/NN	det||program-41/NN||the-38/DT	amod||program-41/NN||routine-39/JJ	nn||program-41/NN||vaccination-40/NN	prep_of||part-36/NN||program-41/NN	det||u.s.a.-44/NN||the-43/DT	prep_in||program-41/NN||u.s.a.-44/NN	mark||complicates-47/VBZ||because-45/IN	nsubj||complicates-47/VBZ||it-46/PRP	advcl||part-36/NN||complicates-47/VBZ	dobj||complicates-47/VBZ||surveillance-48/NN	amod||infection-52/NN||new-50/JJ	nn||infection-52/NN||tb-51/NN	prep_for||surveillance-48/NN||infection-52/NN	tb-51||bcg-33||no||fewer than two-thirds knew that about 10 % of people in the u.s.a. who have latent tuberculosisinfection -lrb- ltbi -rrb- and a normal immune system will develop tb disease , or that bcg is not part of the routine vaccination program in the u.s.a. because it complicates surveillance for new tb infection .
amod||examples-2/NNS||several-1/JJ	nsubjpass||challenged-12/VBN||examples-2/NNS	nn||viruses-5/NNS||rna-4/NN	prep_for||examples-2/NNS||viruses-5/NNS	amod||congruence-9/NN||host-virus-7/JJ	nn||congruence-9/NN||tree-8/NN	prep_of||viruses-5/NNS||congruence-9/NN	aux||challenged-12/VBN||are-10/VBP	auxpass||challenged-12/VBN||being-11/VBG	root||ROOT-0/null||challenged-12/VBN	virus--1||viruses-5||no||several examples for rna viruses of host-virus tree congruence are being challenged.
aux||address-2/VB||to-1/TO	advcl||developed-8/VBN||address-2/VB	det||question-4/NN||this-3/DT	dobj||address-2/VB||question-4/NN	nsubj||developed-8/VBN||we-6/PRP	aux||developed-8/VBN||have-7/VBP	root||ROOT-0/null||developed-8/VBN	det||method-10/NN||a-9/DT	dobj||developed-8/VBN||method-10/NN	aux||identify-12/VB||to-11/TO	vmod||method-10/NN||identify-12/VB	amod||proteins-15/NNS||cellular-13/JJ	nn||proteins-15/NNS||surface-14/NN	dobj||identify-12/VB||proteins-15/NNS	nsubj||permit-17/VBP||proteins-15/NNS	rcmod||proteins-15/NNS||permit-17/VBP	vmod||method-10/NN||mediate-19/VB	conj_or||identify-12/VB||mediate-19/VB	vmod||method-10/NN||enhance-21/VB	conj_or||identify-12/VB||enhance-21/VB	dobj||enhance-21/VB||hivinfection-22/NN	amod||types-26/NNS||different-24/JJ	nn||types-26/NNS||cell/tissue-25/NN	prep_in||enhance-21/VB||types-26/NNS	amod||individuals-29/NNS||hiv-infected-28/JJ	prep_in||types-26/NNS||individuals-29/NNS	hivinfection-22||hiv--1||no||to address this question, we have developed a method to identify cellular surface proteins that permit, mediate or enhance hivinfection in different cell/tissue types in hiv-infected individuals.
aux||investigate-2/VB||to-1/TO	advcl||tested-43/VBD||investigate-2/VB	det||occurrence-5/NN||the-3/DT	amod||occurrence-5/NN||possible-4/JJ	dobj||investigate-2/VB||occurrence-5/NN	iobj||investigate-2/VB||occurrence-5/NN	prep_of||occurrence-5/NN||humanimmunodeficiencyvirus-7/NNS	appos||humanimmunodeficiencyvirus-7/NNS||hiv-9/NN	amod||virus-15/NN||human-12/JJ	amod||virus-15/NN||t-cell-13/JJ	amod||virus-15/NN||lymphotropic-14/JJ	prep_of||occurrence-5/NN||virus-15/NN	conj_or||humanimmunodeficiencyvirus-7/NNS||virus-15/NN	nn||i-18/NNS||type-17/NN	appos||virus-15/NN||i-18/NNS	appos||occurrence-5/NN||htlv-i-20/NNP	dep||occurrence-5/NN||infections-22/NNS	det||states-26/NNS||the-24/DT	amod||states-26/NNS||united-25/VBN	prep_in||infections-22/NNS||states-26/NNS	prep_prior_to||investigate-2/VB||1979-1981-29/CD	advmod||recognized-40/VBN||when-31/WRB	amod||syndrome-34/NN||acquired-32/VBN	amod||syndrome-34/NN||immunedeficiency-33/JJ	nsubjpass||recognized-40/VBN||syndrome-34/NN	appos||syndrome-34/NN||aids-36/NNS	auxpass||recognized-40/VBN||was-38/VBD	advmod||recognized-40/VBN||first-39/RB	advcl||investigate-2/VB||recognized-40/VBN	nsubj||tested-43/VBD||we-42/PRP	root||ROOT-0/null||tested-43/VBD	dobj||tested-43/VBD||sera-44/NN	amod||women-48/NNS||310-46/JJ	amod||women-48/NNS||pregnant-47/JJ	prep_from||tested-43/VBD||women-48/NNS	nsubj||participated-50/VBD||women-48/NNS	rcmod||women-48/NNS||participated-50/VBD	det||project-55/NN||the-52/DT	amod||project-55/NN||collaborative-53/JJ	amod||project-55/NN||perinatal-54/JJ	prep_in||participated-50/VBD||project-55/NN	det||1959-1964-59/NN||the-57/DT	nn||1959-1964-59/NN||period-58/NN	prep_during||participated-50/VBD||1959-1964-59/NN	nn||antibody-64/NN||hiv-61/NN	conj_and||hiv-61/NN||htlv-i-63/NN	nn||antibody-64/NN||htlv-i-63/NN	prep_for||1959-1964-59/NN||antibody-64/NN	aids-36||hiv-61||no||to investigate the possible occurrence of humanimmunodeficiencyvirus (hiv) or human t-cell lymphotropic virus, type i (htlv-i) infections in the united states prior to 1979-1981, when acquired immunedeficiency syndrome (aids) was first recognized, we tested sera from 310 pregnant women who participated in the collaborative perinatal project during the period 1959-1964 for hiv and htlv-i antibody.
det||treatment-3/NN||the-1/DT	amod||treatment-3/NN||lidocaine-2/JJ	nsubj||decreased-7/VBD||treatment-3/NN	vmod||treatment-3/NN||resulted-4/VBN	prep||resulted-4/VBN||in-5/IN	pcomp||in-5/IN||significantly-6/RB	root||ROOT-0/null||decreased-7/VBD	nn||activity-9/NN||brain-8/NN	dobj||decreased-7/VBD||activity-9/NN	det||groups-13/NNS||both-11/DT	amod||groups-13/NNS||patient-12/JJ	prep_in||decreased-7/VBD||groups-13/NNS	amod||regions-17/NNS||distinct-15/JJ	nn||regions-17/NNS||brain-16/NN	prep_with||decreased-7/VBD||regions-17/NNS	vmod||regions-17/NNS||responding-18/VBG	det||group-21/NN||each-20/DT	prep_in||responding-18/VBG||group-21/NN	nsubjpass||correlated-29/VBN||sub-regions-24/NNS	det||areas-27/NNS||these-26/DT	prep_within||sub-regions-24/NNS||areas-27/NNS	auxpass||correlated-29/VBN||were-28/VBD	conj_and||decreased-7/VBD||correlated-29/VBN	nn||ratings-32/NNS||pain-31/NN	prep_with||correlated-29/VBN||ratings-32/NNS	advmod||correlated-29/VBN||specifically-33/RB	det||group-36/NN||each-35/DT	prep_for||correlated-29/VBN||group-36/NN	amod||cortex-40/NN||medial-38/JJ	amod||cortex-40/NN||prefrontal-39/JJ	dep||group-36/NN||cortex-40/NN	prep_in||cortex-40/NN||cbp-42/NN	prep_in||cortex-40/NN||thalamus-44/NNS	conj_and||cbp-42/NN||thalamus-44/NNS	prep_in||cortex-40/NN||oa-46/NN	lidocaine-2||pain-31||no_rel||the lidocaine treatment resulted in significantly decreased brain activity in both patient groups with distinct brain regions responding in each group, and sub-regions within these areas were correlated with pain ratings specifically for each group (medial prefrontal cortex in cbp and thalamus in oa).
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||previously-3/RB	root||ROOT-0/null||shown-4/VBN	mark||improves-10/VBZ||that-5/IN	amod||supplementation-8/NN||dietary-6/JJ	nn||supplementation-8/NN||leucine-7/NN	nsubj||improves-10/VBZ||supplementation-8/NN	advmod||improves-10/VBZ||significantly-9/RB	ccomp||shown-4/VBN||improves-10/VBZ	nn||metabolism-14/NN||glucose-11/NN	conj_and||glucose-11/NN||energy-13/NN	nn||metabolism-14/NN||energy-13/NN	dobj||improves-10/VBZ||metabolism-14/NN	amod||mice-18/NNS||diet-induced-16/JJ	nn||mice-18/NNS||obese-17/NN	prep_in||improves-10/VBZ||mice-18/NNS	vmod||improves-10/VBZ||suggesting-20/VBG	mark||therapy-30/NN||that-21/IN	amod||supplementation-23/NN||leucine-22/JJ	nsubj||therapy-30/NN||supplementation-23/NN	aux||therapy-30/NN||could-24/MD	advmod||therapy-30/NN||potentially-25/RB	cop||therapy-30/NN||be-26/VB	det||therapy-30/NN||a-27/DT	amod||adjuvant-29/JJ||useful-28/JJ	amod||therapy-30/NN||adjuvant-29/JJ	ccomp||suggesting-20/VBG||therapy-30/NN	prep_for||therapy-30/NN||obesity-32/NN	prep_for||therapy-30/NN||type2diabetes-34/NNS	conj_and||obesity-32/NN||type2diabetes-34/NNS	obese-17||leucine-22||no_rel||we have previously shown that dietary leucine supplementation significantly improves glucose and energy metabolism in diet-induced obese mice, suggesting that leucine supplementation could potentially be a useful adjuvant therapy for obesity and type2diabetes.
nsubj||phosphatase-7/NN||yoph-1/NN	cop||phosphatase-7/NN||is-2/VBZ	det||phosphatase-7/NN||an-3/DT	advmod||active-5/JJ||exceptionally-4/RB	amod||phosphatase-7/NN||active-5/JJ	nn||phosphatase-7/NN||tyrosine-6/NN	root||ROOT-0/null||phosphatase-7/NN	nsubj||essential-10/JJ||phosphatase-7/NN	cop||essential-10/JJ||is-9/VBZ	rcmod||phosphatase-7/NN||essential-10/JJ	prep_for||essential-10/JJ||virulence-12/NN	prep_of||virulence-12/NN||yersiniapestis-14/NNS	det||bacterium-17/NN||the-16/DT	appos||yersiniapestis-14/NNS||bacterium-17/NN	vmod||bacterium-17/NN||causing-18/VBG	ccomp||causing-18/VBG||plague-19/VB	plague-19||yersiniapestis-14||no||yoph is an exceptionally active tyrosine phosphatase that is essential for virulence of yersiniapestis , the bacterium causing plague.
amod||idus-4/NNS||current-1/JJ	conj_and||current-1/JJ||former-3/JJ	amod||idus-4/NNS||former-3/JJ	nsubjpass||recruited-6/VBN||idus-4/NNS	auxpass||recruited-6/VBN||were-5/VBD	root||ROOT-0/null||recruited-6/VBN	agent||recruited-6/VBN||respondent-8/NN	dep||respondent-8/NN||driven-9/VBN	xcomp||driven-9/VBN||sampling-10/VBG	det||setting-14/NN||an-12/DT	amod||setting-14/NN||urban-13/JJ	prep_in||sampling-10/VBG||setting-14/NN	prep_in||setting-14/NN||java-16/NN	dep||respondent-8/NN||interviewed-19/VBN	conj_and||driven-9/VBN||interviewed-19/VBN	nn||use-22/NN||drug-21/NN	prep_regarding||interviewed-19/VBN||use-22/NN	nn||behavior-26/NN||hiv-24/NN	nn||behavior-26/NN||risk-25/NN	prep_regarding||interviewed-19/VBN||behavior-26/NN	conj_and||use-22/NN||behavior-26/NN	vmod||use-22/NN||using-27/VBG	det||index-32/NN||the-28/DT	amod||index-32/NN||european-29/JJ	nn||index-32/NN||addiction-30/NN	nn||index-32/NN||severity-31/NN	dobj||using-27/VBG||index-32/NN	det||questionnaire-39/NN||the-34/DT	nn||questionnaire-39/NN||blood-35/NN	num||questionnaire-39/NN||borne-36/CD	nn||questionnaire-39/NN||virus-37/NN	nn||questionnaire-39/NN||transmission-38/NN	dobj||using-27/VBG||questionnaire-39/NN	conj_and||index-32/NN||questionnaire-39/NN	virus-37||idus-4||yes||current and former idus were recruited by respondent driven sampling in an urban setting in java, and interviewed regarding drug use and hiv risk behavior using the european addiction severity index and the blood borne virus transmission questionnaire.
amod||therapy-2/NN||oxymetholone-1/JJ	nsubj||failed-15/VBD||therapy-2/NN	nsubj||obtain-17/VB||therapy-2/NN	vmod||therapy-2/NN||failed-3/VBN	aux||improve-5/VB||to-4/TO	xcomp||failed-3/VBN||improve-5/VB	det||anemia-8/NN||the-6/DT	amod||anemia-8/NN||transfusion-dependent-7/JJ	dobj||improve-5/VB||anemia-8/NN	det||rechallenge-11/NN||a-10/DT	dobj||improve-5/VB||rechallenge-11/NN	conj_and||anemia-8/NN||rechallenge-11/NN	prep_with||improve-5/VB||esas-13/NNS	advmod||failed-15/VBD||continuously-14/RB	root||ROOT-0/null||failed-15/VBD	aux||obtain-17/VB||to-16/TO	xcomp||failed-15/VBD||obtain-17/VB	det||response-20/NN||a-18/DT	amod||response-20/NN||sustained-19/JJ	dobj||obtain-17/VB||response-20/NN	anemia-8||oxymetholone-1||yes||oxymetholone therapy failed to improve the transfusion-dependent anemia and a rechallenge with esas continuously failed to obtain a sustained response.
amod||models-3/NNS||logistic-1/JJ	nn||models-3/NNS||regression-2/NN	nsubjpass||fitted-5/VBN||models-3/NNS	nsubj||assess-7/VB||models-3/NNS	auxpass||fitted-5/VBN||were-4/VBD	root||ROOT-0/null||fitted-5/VBN	aux||assess-7/VB||to-6/TO	xcomp||fitted-5/VBN||assess-7/VB	det||association-9/NN||the-8/DT	dobj||assess-7/VB||association-9/NN	amod||geometric-12/JJ||stavudine-11/JJ	amod||ratio-14/NN||geometric-12/JJ	amod||ratio-14/NN||mean-13/JJ	prep_between||association-9/NN||ratio-14/NN	number||1-16/CD||>-15/CD	num||ratio-14/NN||1-16/CD	amod||glucose-20/NN||impaired-18/VBN	amod||glucose-20/NN||fasting-19/JJ	dobj||assess-7/VB||glucose-20/NN	conj_and||association-9/NN||glucose-20/NN	appos||glucose-20/NN||impairedglucosetolerance-22/NN	appos||glucose-20/NN||hyperlactataemia-24/NN	conj_and||impairedglucosetolerance-22/NN||hyperlactataemia-24/NN	appos||glucose-20/NN||hypertriglyceridaemia-26/NN	conj_and||impairedglucosetolerance-22/NN||hypertriglyceridaemia-26/NN	appos||glucose-20/NN||lipoatrophy-29/NN	conj_and||impairedglucosetolerance-22/NN||lipoatrophy-29/NN	fitted-5||stavudine-11||no_rel||logistic regression models were fitted to assess the association between stavudine geometric mean ratio > 1 and impaired fasting glucose, impairedglucosetolerance, hyperlactataemia, hypertriglyceridaemia, and lipoatrophy.
amod||investigations-3/NNS||basic-1/JJ	nn||investigations-3/NNS||science-2/NN	nsubj||spawned-5/VBN||investigations-3/NNS	aux||spawned-5/VBN||have-4/VBP	root||ROOT-0/null||spawned-5/VBN	amod||questions-8/NNS||clinical-7/JJ	prep_from||spawned-5/VBN||questions-8/NNS	det||biology-13/NN||the-11/DT	amod||biology-13/NN||molecular-12/JJ	prep_such_as||questions-8/NNS||biology-13/NN	amod||cancer-16/NN||colorectal-15/JJ	prep_of||biology-13/NN||cancer-16/NN	prep_such_as||questions-8/NNS||use-18/NN	conj_and||biology-13/NN||use-18/NN	amod||inhibitors-21/NNS||cyclooxygenase-20/JJ	prep_of||use-18/NN||inhibitors-21/NNS	nn||regression-24/NN||polyp-23/NN	prep_of||use-18/NN||regression-24/NN	conj_and||inhibitors-21/NNS||regression-24/NN	nn||antagonists-29/NNS||novel-27/NN	nn||antagonists-29/NNS||cytokine-28/NN	prep_such_as||questions-8/NNS||antagonists-29/NNS	conj_and||biology-13/NN||antagonists-29/NNS	prep_in||antagonists-29/NNS||inflammatoryboweldisease-31/NN	inflammatoryboweldisease-31||basic-1||no_rel||basic science investigations have spawned from clinical questions such as the molecular biology of colorectal cancer, use of cyclooxygenase inhibitors and polyp regression, and novel cytokine antagonists in inflammatoryboweldisease.
nn||bovis-2/NNS||m.-1/NN	nsubj||bacille-3/VBP||bovis-2/NNS	root||ROOT-0/null||bacille-3/VBP	nn||-rrb--9/NNP||calmette-guã-4/NNP	nn||-rrb--9/NNP||©-5/NNP	nn||-rrb--9/NNP||rin-6/NNP	nn||-rrb--9/NNP||-lrb--7/NNP	nn||-rrb--9/NNP||bcg-8/NNP	nsubj||fails-22/VBZ||-rrb--9/NNP	nsubj||protect-25/VB||-rrb--9/NNP	advmod||vaccine-15/NN||currently-11/RB	det||vaccine-15/NN||the-12/DT	advmod||available-14/JJ||only-13/RB	amod||vaccine-15/NN||available-14/JJ	appos||-rrb--9/NNP||vaccine-15/NN	nn||-rrb--20/NNP||tuberculosis-17/NNP	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||tb-19/NNP	prep_against||vaccine-15/NN||-rrb--20/NNP	ccomp||bacille-3/VBP||fails-22/VBZ	aux||protect-25/VB||to-23/TO	advmod||protect-25/VB||adequately-24/RB	xcomp||fails-22/VBZ||protect-25/VB	dobj||protect-25/VB||individuals-26/NNS	amod||infection-32/NN||active-28/JJ	conj_and||active-28/JJ||latent-30/JJ	amod||infection-32/NN||latent-30/JJ	nn||infection-32/NN||tb-31/NN	prep_from||protect-25/VB||infection-32/NN	tb-31||bcg-8||yes||m. bovis bacille calmette-guã © rin -lrb- bcg -rrb- , currently the only available vaccine against tuberculosis -lrb- tb -rrb- , fails to adequately protect individuals from active and latent tb infection .
nsubjpass||derived-3/VBN||insulinresistance-1/NN	auxpass||derived-3/VBN||was-2/VBD	root||ROOT-0/null||derived-3/VBN	nn||measures-7/NNS||blood-5/NN	nn||measures-7/NNS||chemistry-6/NN	prep_from||derived-3/VBN||measures-7/NNS	prepc_of||measures-7/NNS||fasting-9/VBG	dobj||fasting-9/VBG||insulin-10/NN	dobj||fasting-9/VBG||glucose-12/NN	conj_and||insulin-10/NN||glucose-12/NN	vmod||fasting-9/VBG||using-13/VBG	det||method-18/NN||the-14/DT	amod||method-18/NN||homeostasis-15/JJ	nn||method-18/NN||model-16/NN	nn||method-18/NN||assessment-17/NN	dobj||using-13/VBG||method-18/NN	insulinresistance-1||glucose-12||no_rel||insulinresistance was derived from blood chemistry measures of fasting insulin and glucose using the homeostasis model assessment method.
nsubj||increases-2/VBZ||iugr-1/NN	root||ROOT-0/null||increases-2/VBZ	det||risk-4/NN||the-3/DT	dobj||increases-2/VBZ||risk-4/NN	amod||sensitivity-18/NN||type2diabetesmellitus-6/JJ	appos||sensitivity-18/NN||t2dm-8/NNP	amod||life-12/NN||later-11/JJ	prep_in||sensitivity-18/NN||life-12/NN	amod||insulin-17/NN||reduced-16/VBN	prep_due_to||sensitivity-18/NN||insulin-17/NN	prep_of||risk-4/NN||sensitivity-18/NN	amod||adaptation-21/NN||impaired-20/VBN	prep_of||risk-4/NN||adaptation-21/NN	conj_and||sensitivity-18/NN||adaptation-21/NN	nn||secretion-24/NN||insulin-23/NN	prep_of||adaptation-21/NN||secretion-24/NN	type2diabetesmellitus-6||insulin-23||yes||iugr increases the risk of type2diabetesmellitus (t2dm) in later life, due to reduced insulin sensitivity and impaired adaptation of insulin secretion.
nsubj||tested-5/VBD||samples-1/NNS	amod||plants-4/NNS||symptomatic-3/JJ	prep_from||samples-1/NNS||plants-4/NNS	root||ROOT-0/null||tested-5/VBD	acomp||tested-5/VBD||negative-6/JJ	prep_for||negative-6/JJ||infection-8/NN	amod||virus-13/NN||tomato-10/JJ	amod||virus-13/NN||spotted-11/JJ	nn||virus-13/NN||wilt-12/NN	prep_by||tested-5/VBD||virus-13/NN	nn||virus-17/NN||tobacco-15/NN	nn||virus-17/NN||streak-16/NN	prep_by||tested-5/VBD||virus-17/NN	conj_and||virus-13/NN||virus-17/NN	nn||virus-21/NN||tobacco-19/NN	nn||virus-21/NN||etch-20/NN	prep_by||tested-5/VBD||virus-21/NN	conj_and||virus-13/NN||virus-21/NN	amod||viruses-26/NNS||other-23/JJ	amod||viruses-26/NNS||known-24/JJ	amod||viruses-26/NNS||tomato-infecting-25/JJ	prep_by||tested-5/VBD||viruses-26/NNS	conj_and||virus-13/NN||viruses-26/NNS	virus-21||viruses-26||no||samples from symptomatic plants tested negative for infection by tomato spotted wilt virus, tobacco streak virus, tobacco etch virus and other known tomato-infecting viruses.
amod||conditions-3/NNS||basal-2/JJ	prep_under||induced-20/VBN||conditions-3/NNS	nn||diet-6/NN||control-5/NN	appos||conditions-3/NNS||diet-6/NN	amod||treatment-13/NN||chronic-9/JJ	nn||treatment-13/NN||cb-10/NN	nn||treatment-13/NN||receptor-11/NN	nn||treatment-13/NN||agonist-12/NN	nsubj||induced-20/VBN||treatment-13/NN	appos||treatment-13/NN||i.e.-15/NNP	num||weeks-18/NNS||6-17/CD	dep||i.e.-15/NNP||weeks-18/NNS	root||ROOT-0/null||induced-20/VBN	dobj||induced-20/VBN||glucoseintolerance-21/NN	vmod||glucoseintolerance-21/NN||stimulated-23/VBN	amod||endotoxaemia-25/NN||metabolic-24/JJ	dobj||stimulated-23/VBN||endotoxaemia-25/NN	amod||infiltration-30/NN||increased-28/VBN	amod||infiltration-30/NN||macrophage-29/JJ	dobj||induced-20/VBN||infiltration-30/NN	conj_and||glucoseintolerance-21/NN||infiltration-30/NN	dep||infiltration-30/NN||cd11c-32/NNS	amod||expression-35/NN||f4/80-34/JJ	dep||infiltration-30/NN||expression-35/NN	conj_and||cd11c-32/NNS||expression-35/NN	det||muscles-39/NNS||the-38/DT	prep_in||infiltration-30/NN||muscles-39/NNS	det||phenomenon-42/NN||this-41/DT	nsubjpass||associated-44/VBN||phenomenon-42/NN	auxpass||associated-44/VBN||was-43/VBD	parataxis||induced-20/VBN||associated-44/VBN	det||metabolism-49/NN||an-46/DT	amod||metabolism-49/NN||altered-47/VBN	nn||metabolism-49/NN||lipid-48/NN	prep_with||associated-44/VBN||metabolism-49/NN	dep||metabolism-49/NN||increased-51/VBN	amod||expression-54/NN||pgc-1î-52/JJ	amod||expression-54/NN||±-53/JJ	dobj||increased-51/VBN||expression-54/NN	amod||expression-58/NN||decreased-56/VBN	amod||expression-58/NN||cpt-1b-57/JJ	dobj||increased-51/VBN||expression-58/NN	conj_and||expression-54/NN||expression-58/NN	det||tissue-62/NN||this-61/DT	prep_in||metabolism-49/NN||tissue-62/NN	lipid-48||glucoseintolerance-21||no_rel||under basal conditions (control diet), chronic cb receptor agonist treatment (i.e., 6 weeks) induced glucoseintolerance, stimulated metabolic endotoxaemia, and increased macrophage infiltration ( cd11c and f4/80 expression) in the muscles; this phenomenon was associated with an altered lipid metabolism (increased pgc-1î± expression and decreased cpt-1b expression) in this tissue.
mark||closed-9/VBD||conclusion-1/NN	nsubj||improve-15/VB||conclusion-1/NN	nsubj||reduce-22/VB||conclusion-1/NN	det||trials-6/NNS||these-2/DT	num||trials-6/NNS||two-3/CD	amod||trials-6/NNS||small-4/JJ	nn||trials-6/NNS||crossover-5/NN	nsubj||suggest-7/VBP||trials-6/NNS	rcmod||conclusion-1/NN||suggest-7/VBP	ccomp||suggest-7/VBP||closed-9/VBD	nn||delivery-11/NN||loop-10/NN	dobj||closed-9/VBD||delivery-11/NN	prep_of||delivery-11/NN||insulin-13/NN	aux||improve-15/VB||may-14/MD	root||ROOT-0/null||improve-15/VB	amod||control-17/NN||overnight-16/JJ	dobj||improve-15/VB||control-17/NN	nn||levels-20/NNS||glucose-19/NN	prep_of||control-17/NN||levels-20/NNS	conj_and||improve-15/VB||reduce-22/VB	det||risk-24/NN||the-23/DT	dobj||reduce-22/VB||risk-24/NN	amod||hypoglycaemia-27/NN||nocturnal-26/JJ	prep_of||risk-24/NN||hypoglycaemia-27/NN	prep_in||reduce-22/VB||adults-29/NNS	prep_with||adults-29/NNS||type1diabetes-31/CD	hypoglycaemia-27||glucose-19||yes||conclusion these two small crossover trials suggest that closed loop delivery of insulin may improve overnight control of glucose levels and reduce the risk of nocturnal hypoglycaemia in adults with type1diabetes.
nsubj||result-6/VBP||deficiencies-1/NNS	prep_in||deficiencies-1/NNS||gla-3/FW	prep_in||deficiencies-1/NNS||sda-5/FW	conj_and||gla-3/FW||sda-5/FW	root||ROOT-0/null||result-6/VBP	amod||susceptibility-9/NN||increased-8/VBN	prep_in||result-6/VBP||susceptibility-9/NN	prep_to||susceptibility-9/NN||bacterialinfection-11/NN	nsubjpass||associated-15/VBN||bacterialinfection-11/NN	auxpass||associated-15/VBN||is-14/VBZ	rcmod||bacterialinfection-11/NN||associated-15/VBN	amod||expression-19/NN||reduced-17/VBN	amod||expression-19/NN||basal-18/JJ	prep_with||associated-15/VBN||expression-19/NN	det||number-22/NN||a-21/DT	prep_of||expression-19/NN||number-22/NN	amod||$-26/NNS||immune-specific-24/JJ	amod||$-26/NNS||genesâ-25/JJ	prep_of||number-22/NN||$-26/NNS	dep||â-35/JJ||spp-1-29/JJ	conj_and||â-35/JJ||lys-7-31/JJ	amod||$-36/NNS||lys-7-31/JJ	conj_and||â-35/JJ||lys-2-34/JJ	amod||$-36/NNS||lys-2-34/JJ	amod||$-36/NNS||â-35/JJ	prep_including||$-26/NNS||$-36/NNS	nsubj||encode-39/VBP||$-36/NNS	rcmod||$-36/NNS||encode-39/VBP	amod||peptides-41/NNS||antimicrobial-40/JJ	dobj||encode-39/VBP||peptides-41/NNS	lys--1||sda-5||no_rel||deficiencies in gla and sda result in increased susceptibility to bacterialinfection, which is associated with reduced basal expression of a number of immune-specific genesâ€”including spp-1 , lys-7 , and lys-2 â€”that encode antimicrobial peptides.
amod||options-2/NNS||several-1/JJ	nsubjpass||licensed-10/VBN||options-2/NNS	det||treatment-5/NN||the-4/DT	prep_for||options-2/NNS||treatment-5/NN	prep_of||treatment-5/NN||hepatitisb-7/NN	aux||licensed-10/VBN||have-8/VBP	auxpass||licensed-10/VBN||been-9/VBN	root||ROOT-0/null||licensed-10/VBN	det||interferon-15/NN||the-12/DT	amod||interferon-15/NN||last-13/JJ	nn||interferon-15/NN||years-14/NNS	prep_in||licensed-10/VBN||interferon-15/NN	amod||interferon-18/NN||pegylated-17/JJ	prep_in||licensed-10/VBN||interferon-18/NN	conj_and||interferon-15/NN||interferon-18/NN	prep_in||licensed-10/VBN||lamivudine-20/NN	conj_and||interferon-15/NN||lamivudine-20/NN	prep_in||licensed-10/VBN||adefovir-22/NN	conj_and||interferon-15/NN||adefovir-22/NN	prep_in||licensed-10/VBN||entecavir-24/NN	conj_and||interferon-15/NN||entecavir-24/NN	prep_in||licensed-10/VBN||telbivudine-27/NN	conj_and||interferon-15/NN||telbivudine-27/NN	hepatitisb-7||entecavir-24||yes||several options for the treatment of hepatitisb have been licensed in the last years interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine.
nn||design-2/NN||research-1/NN	nsubj||gain-8/VB||design-2/NN	nn||$-5/NNP||methodsâ-4/NNP	conj_and||design-2/NN||$-5/NNP	nsubj||gain-8/VB||$-5/NNP	aux||gain-8/VB||to-7/TO	advcl||measured-24/VBD||gain-8/VB	dobj||gain-8/VB||insight-9/NN	det||role-12/NN||the-11/DT	prep_into||gain-8/VB||role-12/NN	prep_of||role-12/NN||pref-1-14/JJ	det||onset-17/NN||the-16/DT	prep_on||pref-1-14/JJ||onset-17/NN	prep_of||onset-17/NN||insulinresistance-19/NN	prep_of||onset-17/NN||type2diabetes-21/NNS	conj_and||insulinresistance-19/NN||type2diabetes-21/NNS	nsubj||measured-24/VBD||we-23/PRP	root||ROOT-0/null||measured-24/VBD	nn||composition-26/NN||body-25/NN	dobj||measured-24/VBD||composition-26/NN	amod||metabolism-31/NN||whole-body-28/JJ	amod||metabolism-31/NN||insulin-stimulated-29/JJ	nn||metabolism-31/NN||glucose-30/NN	dobj||measured-24/VBD||metabolism-31/NN	conj_and||composition-26/NN||metabolism-31/NN	det||clamp-35/NN||a-33/DT	amod||clamp-35/NN||hyperinsulinemic-euglycemic-34/JJ	prep_during||measured-24/VBD||clamp-35/NN	amod||transgenic-38/JJ||pref-1-37/JJ	prep_in||clamp-35/NN||transgenic-38/JJ	amod||mice-42/NNS||wild-type-40/JJ	nn||mice-42/NNS||control-41/NN	prep_in||clamp-35/NN||mice-42/NNS	conj_and||transgenic-38/JJ||mice-42/NNS	vmod||clamp-35/NN||fed-43/VBN	det||diet-46/NN||a-44/DT	amod||diet-46/NN||high-fat-45/JJ	dobj||fed-43/VBN||diet-46/NN	insulin--1||insulinresistance-19||no_rel||research design and methodsâ€” to gain insight into the role of pref-1 on the onset of insulinresistance and type2diabetes, we measured body composition and whole-body insulin-stimulated glucose metabolism during a hyperinsulinemic-euglycemic clamp in pref-1 transgenic and wild-type control mice fed a high-fat diet.
nn||patients-4/NNS||uc-1/NN	conj_and||uc-1/NN||cd-3/NN	nn||patients-4/NNS||cd-3/NN	nsubj||had-5/VBD||patients-4/NNS	root||ROOT-0/null||had-5/VBD	advmod||lower-7/JJR||significantly-6/RB	amod||levels-10/NNS||lower-7/JJR	amod||levels-10/NNS||serum-8/JJ	amod||levels-10/NNS||timp-4-9/JJ	dobj||had-5/VBD||levels-10/NNS	advmod||compared-12/VBN||when-11/WRB	rcmod||levels-10/NNS||compared-12/VBN	prep_to||compared-12/VBN||hc-14/NN	dep||levels-10/NNS||p-16/VBN	dep||0.008-18/CD||=-17/SYM	ccomp||p-16/VBN||0.008-18/CD	dep||levels-10/NNS||p-20/VBN	conj_and||p-16/VBN||p-20/VBN	dep||0.02-22/CD||=-21/SYM	ccomp||p-20/VBN||0.02-22/CD	advmod||p-20/VBN||respectively-23/RB	uc-1||hc-14||yes||uc and cd patients had significantly lower serum timp-4 levels when compared to hc (p = 0.008 and p = 0.02 respectively).
det||study-2/NN||this-1/DT	nsubj||demonstrated-3/VBD||study-2/NN	root||ROOT-0/null||demonstrated-3/VBD	mark||higher-18/JJR||that-4/IN	csubj||higher-18/JJR||circulating-5/VBG	nn||plasmablasts-8/NNS||igg-6/NN	nn||plasmablasts-8/NNS||+-7/NN	dobj||circulating-5/VBG||plasmablasts-8/NNS	amod||secretion-11/NN||spontaneous-10/JJ	dobj||circulating-5/VBG||secretion-11/NN	conj_and||plasmablasts-8/NNS||secretion-11/NN	amod||antibodies-15/NNS||bcg-specific-13/JJ	nn||antibodies-15/NNS||igg-14/NN	prep_of||secretion-11/NN||antibodies-15/NNS	cop||higher-18/JJR||were-16/VBD	advmod||higher-18/JJR||significantly-17/RB	ccomp||demonstrated-3/VBD||higher-18/JJR	prep_in||higher-18/JJR||patients-20/NNS	amod||tb-23/NN||active-22/JJ	prep_with||patients-20/NNS||tb-23/NN	prepc_compared_with||higher-18/JJR||with-25/IN	nn||cases-28/NNS||latent-26/NN	nn||cases-28/NNS||tb-27/NN	pobj||higher-18/JJR||cases-28/NNS	amod||controls-31/NNS||non-tb-30/JJ	pobj||higher-18/JJR||controls-31/NNS	conj_and||cases-28/NNS||controls-31/NNS	tb-27||bcg--1||no||this study demonstrated that circulating igg+ plasmablasts and spontaneous secretion of bcg-specific igg antibodies were significantly higher in patients with active tb compared with latent tb cases and non-tb controls.
nsubj||remained-19/VBD||hepatitisbinfection-1/NN	amod||status-4/NN||positive-3/JJ	dep||hepatitisbinfection-1/NN||status-4/NN	prep_for||status-4/NN||hbsag-6/NN	prep_for||status-4/NN||hbcab-8/NN	conj_and||hbsag-6/NN||hbcab-8/NN	nn||levels-13/NNS||serum-11/NN	nn||levels-13/NNS||triglyceride-12/NN	conj_and||hepatitisbinfection-1/NN||levels-13/NNS	nsubj||remained-19/VBD||levels-13/NNS	amod||levels-18/NNS||high-15/JJ	nn||levels-18/NNS||density-16/NN	nn||levels-18/NNS||lipoprotein-17/NN	conj_and||hepatitisbinfection-1/NN||levels-18/NNS	nsubj||remained-19/VBD||levels-18/NNS	root||ROOT-0/null||remained-19/VBD	amod||factors-23/NNS||significant-21/JJ	nn||factors-23/NNS||risk-22/NN	prep_as||remained-19/VBD||factors-23/NNS	prep_after||remained-19/VBD||age-adjustment-25/NN	hepatitisbinfection-1||hbsag-6||yes||hepatitisbinfection (positive status for hbsag and hbcab), serum triglyceride levels and high density lipoprotein levels remained as significant risk factors after age-adjustment.
nn||patients-2/NNS||patients-1/NNS	nsubj||carvedilol-naive-4/JJ||patients-2/NNS	nsubj||had-6/VBD||patients-2/NNS	cop||carvedilol-naive-4/JJ||were-3/VBD	root||ROOT-0/null||carvedilol-naive-4/JJ	conj_and||carvedilol-naive-4/JJ||had-6/VBD	amod||hypertension-8/NN||essential-7/JJ	dobj||had-6/VBD||hypertension-8/NN	amod||hypertension-12/NN||renal-10/JJ	amod||hypertension-12/NN||parenchymal-11/JJ	dobj||had-6/VBD||hypertension-12/NN	conj_or||hypertension-8/NN||hypertension-12/NN	hypertension-12||carvedilol--1||yes||patients patients were carvedilol-naive and had essential hypertension or renal parenchymal hypertension.
nsubj||member-8/NN||missing-in-metastasis-1/NNS	appos||missing-in-metastasis-1/NNS||mim-3/NN	cop||member-8/NN||is-5/VBZ	det||member-8/NN||a-6/DT	amod||member-8/NN||defining-7/VBG	root||ROOT-0/null||member-8/NN	det||subfamily-17/NN||the-10/DT	amod||subfamily-17/NN||inverse-11/JJ	nn||subfamily-17/NN||bin/amphiphysin/rvs-12/NNS	nn||subfamily-17/NN||domain-13/NN	appos||subfamily-17/NN||i-bar-15/NN	prep_of||member-8/NN||subfamily-17/NN	num||regulators-23/NNS||lipid-19/CD	amod||regulators-23/NNS||binding-20/JJ	amod||regulators-23/NNS||cytoskeletal-22/JJ	prep_of||member-8/NN||regulators-23/NNS	dep||altered-27/VBN||whose-24/WP$	nsubjpass||altered-27/VBN||levels-25/NNS	auxpass||altered-27/VBN||are-26/VBP	dep||regulators-23/NNS||altered-27/VBN	det||number-30/NN||a-29/DT	prep_in||altered-27/VBN||number-30/NN	prep_of||number-30/NN||cancers-32/NNS	lipid-19||metastasis--1||no_rel||missing-in-metastasis (mim) is a defining member of the inverse bin/amphiphysin/rvs domain (i-bar) subfamily of lipid binding, cytoskeletal regulators whose levels are altered in a number of cancers.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-5/NN||a-3/DT	amod||case-5/NN||rare-4/JJ	dobj||report-2/VBP||case-5/NN	amod||vasculitis-11/NNS||hydralazine-induced-7/JJ	amod||vasculitis-11/NNS||anti-neutrophil-8/JJ	amod||vasculitis-11/NNS||cytoplasmic-9/JJ	amod||vasculitis-11/NNS||antibody-associated-10/JJ	prep_of||case-5/NN||vasculitis-11/NNS	det||woman-16/NN||a-13/DT	amod||woman-16/NN||62-year-old-14/JJ	amod||woman-16/NN||caucasian-15/JJ	prep_in||vasculitis-11/NNS||woman-16/NN	nsubj||presented-18/VBN||woman-16/NN	rcmod||woman-16/NN||presented-18/VBN	det||syndrome-22/NN||a-20/DT	amod||syndrome-22/NN||vasculitic-21/JJ	prep_with||presented-18/VBN||syndrome-22/NN	det||throat-26/NN||a-24/DT	amod||throat-26/NN||sore-25/JJ	prep_with||presented-18/VBN||throat-26/NN	prep_with||presented-18/VBN||mouthulcers-28/NNS	conj_and||throat-26/NN||mouthulcers-28/NNS	prep_with||presented-18/VBN||otalgia-30/NN	conj_and||throat-26/NN||otalgia-30/NN	amod||months-33/NNS||several-32/JJ	prep_after||presented-18/VBN||months-33/NNS	amod||symptoms-36/NNS||constitutional-35/JJ	prep_of||months-33/NNS||symptoms-36/NNS	vasculitis-11||hydralazine--1||no_rel||we report a rare case of hydralazine-induced anti-neutrophil cytoplasmic antibody-associated vasculitis in a 62-year-old caucasian woman who presented with a vasculitic syndrome with a sore throat, mouthulcers and otalgia after several months of constitutional symptoms.
aux||investigate-2/VB||to-1/TO	csubj||synthase-12/VBD||investigate-2/VB	csubj||synthase-12/VBD||investigate-2/VB	det||expression-4/NN||the-3/DT	dobj||investigate-2/VB||expression-4/NN	amod||prostaglandin-7/NN||microsomal-6/JJ	prep_of||expression-4/NN||prostaglandin-7/NN	dep||expression-4/NN||e-8/SYM	appos||expression-4/NN||pge-10/NN	root||ROOT-0/null||synthase-12/VBD	conj_and||synthase-12/VBD||synthase-12/VBD	dobj||synthase-12/VBD||1-13/CD	dep||1-13/CD||mpges-1-15/JJ	dobj||synthase-12/VBD||cyclooxygenase-18/NN	conj_and||1-13/CD||cyclooxygenase-18/NN	appos||cyclooxygenase-18/NN||cox-20/NN	nn||biopsies-24/NNS||muscle-23/NN	prep_in||cyclooxygenase-18/NN||biopsies-24/NNS	prep_from||synthase-12/VBD||patients-26/NNS	prep_with||patients-26/NNS||polymyositis-28/NNS	prep_with||patients-26/NNS||dermatomyositis-30/NNS	conj_or||polymyositis-28/NNS||dermatomyositis-30/NNS	amod||treatment-36/NN||conventional-34/JJ	nn||treatment-36/NN||immunosuppressive-35/NN	prep_after||synthase-12/VBD||treatment-36/NN	prep_before||synthase-12/VBD||treatment-36/NN	dermatomyositis-30||immunosuppressive-35||no_rel||to investigate the expression of microsomal prostaglandin e (pge) synthase 1 (mpges-1) and cyclooxygenase (cox) in muscle biopsies from patients with polymyositis or dermatomyositis before and after conventional immunosuppressive treatment.
det||understanding-3/NN||a-1/DT	amod||understanding-3/NN||better-2/JJR	nsubj||help-12/VB||understanding-3/NN	nsubj||develop-14/VB||understanding-3/NN	det||anorexia-10/NN||the-5/DT	amod||anorexia-10/NN||neurobiological-6/JJ	nn||anorexia-10/NN||mechanisms-7/NNP	amod||anorexia-10/NN||underlying-8/JJ	amod||anorexia-10/NN||inflammation-associated-9/JJ	prep_of||understanding-3/NN||anorexia-10/NN	aux||help-12/VB||will-11/MD	root||ROOT-0/null||help-12/VB	aux||develop-14/VB||to-13/TO	xcomp||help-12/VB||develop-14/VB	nn||stimulants-16/NNS||appetite-15/NN	dobj||develop-14/VB||stimulants-16/NNS	nn||patients-21/NNS||cancer-18/NN	conj_and||cancer-18/NN||aids-20/NNS	nn||patients-21/NNS||aids-20/NNS	prep_for||develop-14/VB||patients-21/NNS	stimulants-16||cancer-18||no_rel||a better understanding of the neurobiological mechanisms underlying inflammation-associated anorexia will help to develop appetite stimulants for cancer and aids patients.
aux||determine-2/VB||to-1/TO	advcl||conducted-21/VBD||determine-2/VB	det||epidemiology-4/NN||the-3/DT	dobj||determine-2/VB||epidemiology-4/NN	prep_of||epidemiology-4/NN||outbreaks-6/NNS	prep_of||outbreaks-6/NNS||avianinfluenzaavirus-8/NNS	amod||h5n1-11/NNS||subtypes-10/JJ	dep||avianinfluenzaavirus-8/NNS||h5n1-11/NNS	appos||h5n1-11/NNS||h9n2-13/NNS	prep_in||determine-2/VB||chickens-16/NNS	prep_in||chickens-16/NNS||bangladesh-18/NN	nsubj||conducted-21/VBD||we-20/PRP	nsubj||examined-24/VBD||we-20/PRP	root||ROOT-0/null||conducted-21/VBD	dobj||conducted-21/VBD||surveys-22/NNS	conj_and||conducted-21/VBD||examined-24/VBD	nsubj||isolates-26/VBZ||virus-25/NN	ccomp||examined-24/VBD||isolates-26/VBZ	h5n1-11||avianinfluenzaavirus-8||no||to determine the epidemiology of outbreaks of avianinfluenzaavirus (subtypes h5n1, h9n2) in chickens in bangladesh, we conducted surveys and examined virus isolates.
amod||variants-3/NNS||postnatally-t/f-1/JJ	nn||variants-3/NNS||env-2/NN	nsubj||appear-6/VB||variants-3/NNS	nsubj||possess-8/VB||variants-3/NNS	aux||appear-6/VB||do-4/VBP	neg||appear-6/VB||not-5/RB	root||ROOT-0/null||appear-6/VB	aux||possess-8/VB||to-7/TO	xcomp||appear-6/VB||possess-8/VB	det||ability-11/NN||a-9/DT	amod||ability-11/NN||superior-10/JJ	dobj||possess-8/VB||ability-11/NN	aux||interact-13/VB||to-12/TO	vmod||possess-8/VB||interact-13/VB	prep||interact-13/VB||with-14/IN	vmod||possess-8/VB||cross-16/VB	conj_and||interact-13/VB||cross-16/VB	det||barrier-19/NN||a-17/DT	amod||barrier-19/NN||mucosal-18/JJ	dobj||cross-16/VB||barrier-19/NN	det||resistance-23/NN||an-21/DT	amod||resistance-23/NN||exceptional-22/JJ	dobj||cross-16/VB||resistance-23/NN	conj_or||barrier-19/NN||resistance-23/NN	prep_to||cross-16/VB||neutralization-25/NN	nsubj||define-27/VB||neutralization-25/NN	rcmod||neutralization-25/NN||define-27/VB	poss||capability-29/NN||their-28/PRP$	dobj||define-27/VB||capability-29/NN	aux||initiate-31/VB||to-30/TO	vmod||capability-29/NN||initiate-31/VB	dobj||initiate-31/VB||infection-32/NN	det||tract-37/NN||the-34/DT	amod||tract-37/NN||infant-35/JJ	amod||tract-37/NN||gastrointestinal-36/JJ	prep_across||initiate-31/VB||tract-37/NN	det||setting-40/NN||the-39/DT	prep_in||tract-37/NN||setting-40/NN	prepc_of||setting-40/NN||preexisting-42/VBG	amod||antibodies-44/NNS||maternal-43/JJ	dobj||preexisting-42/VBG||antibodies-44/NNS	cross-16||antibodies-44||no_rel||postnatally-t/f env variants do not appear to possess a superior ability to interact with and cross a mucosal barrier or an exceptional resistance to neutralization that define their capability to initiate infection across the infant gastrointestinal tract in the setting of preexisting maternal antibodies.
nsubj||impairs-2/VBZ||hivinfection-1/NN	root||ROOT-0/null||impairs-2/VBZ	amod||immunity-5/NN||systemic-3/JJ	amod||immunity-5/NN||acquired-4/VBN	dobj||impairs-2/VBZ||immunity-5/NN	expl||is-9/VBZ||there-8/EX	conj_but||impairs-2/VBZ||is-9/VBZ	amod||information-11/NN||limited-10/VBN	nsubj||is-9/VBZ||information-11/NN	prep_in||information-11/NN||humans-13/NNS	amod||defects-18/NNS||hiv-related-15/JJ	amod||defects-18/NNS||cell-mediated-16/JJ	amod||defects-18/NNS||immune-17/JJ	prep_on||humans-13/NNS||defects-18/NNS	det||lung-21/NN||the-20/DT	prep_in||defects-18/NNS||lung-21/NN	hivinfection-1||hiv--1||no||hivinfection impairs systemic acquired immunity, but there is limited information in humans on hiv-related cell-mediated immune defects in the lung.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||identified-6/VBD||study-4/NN	nsubj||identified-6/VBD||we-5/PRP	root||ROOT-0/null||identified-6/VBD	dobj||identified-6/VBD||genes-7/NNS	nsubj||predict-12/VB||genes-7/NNS	dobj||identified-6/VBD||mirnas-9/NNS	conj_and||genes-7/NNS||mirnas-9/NNS	nsubj||predict-12/VB||mirnas-9/NNS	aux||predict-12/VB||may-11/MD	rcmod||genes-7/NNS||predict-12/VB	amod||resistance-14/NN||clinical-13/JJ	dobj||predict-12/VB||resistance-14/NN	prep_of||resistance-14/NN||cll-16/NN	aux||fludarabine-18/VB||to-17/TO	vmod||predict-12/VB||fludarabine-18/VB	vmod||predict-12/VB||describe-21/VB	conj_and||fludarabine-18/VB||describe-21/VB	det||mechanism-25/NN||an-22/DT	amod||mechanism-25/NN||interesting-23/JJ	amod||mechanism-25/NN||oncogenic-24/JJ	dobj||fludarabine-18/VB||mechanism-25/NN	nn||patients-28/NNS||cll-27/NN	prep_in||fludarabine-18/VB||patients-28/NNS	amod||patients-28/NNS||resistant-29/JJ	aux||fludarabine-31/VB||to-30/TO	xcomp||resistant-29/JJ||fludarabine-31/VB	dobj||altered-42/VBN||which-33/WDT	det||myc-36/NN||the-34/DT	amod||myc-36/NN||complete-35/JJ	nsubjpass||altered-42/VBN||myc-36/NN	amod||network-40/NN||specific-38/JJ	amod||network-40/NN||regulatory-39/JJ	dep||myc-36/NN||network-40/NN	auxpass||altered-42/VBN||was-41/VBD	prepc_by||fludarabine-31/VB||altered-42/VBN	dep||fludarabine-18/VB||dna-44/NN	dep||fludarabine-18/VB||rna-46/NN	conj_and||dna-44/NN||rna-46/NN	dep||dna-44/NN||levels-47/NNS	amod||targets-51/NNS||transcriptional-50/JJ	dep||fludarabine-18/VB||targets-51/NNS	conj_and||dna-44/NN||targets-51/NNS	cll-27||fludarabine-31||yes||in the present study we identified genes and mirnas that may predict clinical resistance of cll to fludarabine, and describe an interesting oncogenic mechanism in cll patients resistant to fludarabine by which the complete myc -specific regulatory network was altered (dna and rna levels, and transcriptional targets).
advmod||15â-2/JJ||approximately-1/RB	nsubjpass||associated-10/VBN||15â-2/JJ	dep||%-5/NN||$-3/$	num||$-3/$||š-4/CD	amod||15â-2/JJ||%-5/NN	amod||priondisease-8/NN||human-7/JJ	prep_of||15â-2/JJ||priondisease-8/NN	auxpass||associated-10/VBN||is-9/VBZ	root||ROOT-0/null||associated-10/VBN	amod||mutations-14/NNS||autosomal-dominant-12/JJ	amod||mutations-14/NNS||pathogenic-13/JJ	prep_with||associated-10/VBN||mutations-14/NNS	det||gene-21/NN||the-16/DT	amod||gene-21/NN||prionprotein-17/JJ	appos||gene-21/NN||prp-19/NN	prep_in||mutations-14/NNS||gene-21/NN	priondisease-8||prionprotein-17||no||approximately 15â€š% of human priondisease is associated with autosomal-dominant pathogenic mutations in the prionprotein (prp) gene.
nsubj||applied-2/VBD||we-1/PRP	root||ROOT-0/null||applied-2/VBD	amod||principles-5/NNS||fuzzy-3/JJ	nn||principles-5/NNS||logic-4/NN	dobj||applied-2/VBD||principles-5/NNS	aux||modify-7/VB||to-6/TO	vmod||applied-2/VBD||modify-7/VB	amod||rates-14/NNS||intravenous-8/JJ	amod||rates-14/NNS||norepinephrine-9/JJ	appos||rates-14/NNS||noradrenaline-11/NN	nn||rates-14/NNS||infusion-13/NN	dobj||modify-7/VB||rates-14/NNS	amod||infusion-17/NN||norepinephrine-16/JJ	prep_during||rates-14/NNS||infusion-17/NN	amod||patients-20/NNS||septic-19/JJ	prep_in||modify-7/VB||patients-20/NNS	mark||reduce-24/VB||in-21/IN	dep||reduce-24/VB||order-22/NN	aux||reduce-24/VB||to-23/TO	advcl||modify-7/VB||reduce-24/VB	det||duration-26/NN||the-25/DT	dobj||reduce-24/VB||duration-26/NN	prep_of||duration-26/NN||shock-28/NN	shock-28||norepinephrine-16||yes||we applied fuzzy logic principles to modify intravenous norepinephrine (noradrenaline) infusion rates during norepinephrine infusion in septic patients in order to reduce the duration of shock.
poss||patients-5/NNS||results-1/NNS	amod||patients-5/NNS||$-3/JJ	nsubj||had-15/VBD||patients-5/NNS	nsubj||had-62/VBD||patients-5/NNS	prep_with||patients-5/NNS||type1diabetes-7/CD	det||history-12/NN||a-9/DT	amod||history-12/NN||positive-10/JJ	amod||history-12/NN||parental-11/JJ	conj_and||patients-5/NNS||history-12/NN	nsubj||had-15/VBD||history-12/NN	prep_of||history-12/NN||type2diabetes-14/CD	root||ROOT-0/null||had-15/VBD	det||prevalence-18/NN||a-16/DT	amod||prevalence-18/NN||higher-17/JJR	dobj||had-15/VBD||prevalence-18/NN	det||syndrome-22/NN||the-20/DT	amod||syndrome-22/NN||metabolic-21/JJ	prep_of||prevalence-18/NN||syndrome-22/NN	amod||syndrome-22/NN||-lrb--23/NN	number||-lrb--23/NN||44-24/CD	num||%-27/NN||38-26/CD	prep_vs.||syndrome-22/NN||%-27/NN	dep||prevalence-18/NN||p-29/NN	dep||-rrb--32/NNS||=-30/SYM	num||-rrb--32/NNS||0.013-31/CD	rcmod||p-29/NN||-rrb--32/NNS	det||profile-36/NN||a-34/DT	amod||profile-36/NN||metabolic-35/JJ	dobj||had-15/VBD||profile-36/NN	conj_and||prevalence-18/NN||profile-36/NN	vmod||profile-36/NN||related-37/VBN	aux||insulinresistance-39/VB||to-38/TO	xcomp||related-37/VBN||insulinresistance-39/VB	amod||bmi-42/NN||-lrb--40/NN	dep||-lrb--40/NN||higher-41/JJR	dobj||insulinresistance-39/VB||bmi-42/NN	amod||circumference-46/NN||larger-44/JJR	nn||circumference-46/NN||waist-45/NN	conj_and||prevalence-18/NN||circumference-46/NN	conj_and||profile-36/NN||circumference-46/NN	amod||triglycerides-50/NNS||higher-49/JJR	conj_and||prevalence-18/NN||triglycerides-50/NNS	conj_and||profile-36/NN||triglycerides-50/NNS	conj_and||profile-36/NN||a1c-52/NNS	conj_and||triglycerides-50/NNS||a1c-52/NNS	conj_and||profile-36/NN||insulin-55/NN	conj_and||triglycerides-50/NNS||insulin-55/NN	nn||insulin-55/NN||dose-56/FW	nn||insulin-55/NN||per-57/FW	nn||insulin-55/NN||kilogram-58/FW	dep||insulin-55/NN||-rrb--59/FW	advmod||had-62/VBD||also-61/RB	conj_and||had-15/VBD||had-62/VBD	det||onset-65/NN||a-63/DT	amod||onset-65/NN||later-64/JJ	dobj||had-62/VBD||onset-65/NN	nsubjpass||confirmed-88/VBN||onset-65/NN	prep_of||onset-65/NN||type1diabetes-67/NN	nn||type1diabetes-67/NN||-lrb--68/FW	nn||type1diabetes-67/NN||17.2-69/FW	nn||type1diabetes-67/NN||â-70/FW	nn||type1diabetes-67/NN||±-71/FW	nn||type1diabetes-67/NN||9.2-72/FW	nn||type1diabetes-67/NN||vs.-73/FW	nn||type1diabetes-67/NN||16.1-74/FW	dep||type1diabetes-67/NN||â-75/FW	punct||type1diabetes-67/NN||±-76/``	num||years-78/NNS||8.9-77/CD	dep||type1diabetes-67/NN||years-78/NNS	vmod||onset-65/NN||p-80/VBN	dep||-rrb--83/NNS||=-81/SYM	num||-rrb--83/NNS||0.008-82/CD	ccomp||p-80/VBN||-rrb--83/NNS	auxpass||confirmed-88/VBN||was-86/VBD	advmod||confirmed-88/VBN||also-87/RB	rcmod||onset-65/NN||confirmed-88/VBN	det||control-94/NN||the-90/DT	advmod||available-92/JJ||publicly-91/RB	amod||control-94/NN||available-92/JJ	nn||control-94/NN||diabetes-93/NN	prep_in||confirmed-88/VBN||control-94/NN	nn||data-98/NN||complications-96/NNS	nn||data-98/NN||trial-97/NN	prep_in||confirmed-88/VBN||data-98/NN	conj_and||control-94/NN||data-98/NN	vmod||control-94/NN||set-99/VBN	type2diabetes-14||insulin-55||yes||results â $ '' patients with type1diabetes and a positive parental history of type2diabetes had a higher prevalence of the metabolic syndrome -lrb- 44 vs. 38 % ; p = 0.013 -rrb- and a metabolic profile related to insulinresistance -lrb- higher bmi , larger waist circumference , and higher triglycerides , a1c , and insulin dose per kilogram -rrb- and also had a later onset of type1diabetes -lrb- 17.2 â ± 9.2 vs. 16.1 â ± 8.9 years ; p = 0.008 -rrb- , which was also confirmed in the publicly available diabetes control and complications trial data set .
det||form-4/NN||the-1/DT	amod||form-4/NN||primary-2/JJ	amod||form-4/NN||circulating-3/JJ	nsubj||-RSB--15/VBZ||form-4/NN	prep_of||form-4/NN||vitamind-6/NN	amod||-LSB--9/NN||25-hydroxy-vitamind-8/JJ	appos||vitamind-6/NN||-LSB--9/NN	num||-LSB--9/NN||25-10/CD	discourse||vitamind-6/NN||oh-12/UH	dep||vitamind-6/NN||d-14/SYM	root||ROOT-0/null||-RSB--15/VBZ	auxpass||associated-18/VBN||is-17/VBZ	dep||-RSB--15/VBZ||associated-18/VBN	amod||outcomes-22/NNS||multiple-20/JJ	amod||outcomes-22/NNS||medical-21/JJ	prep_with||associated-18/VBN||outcomes-22/NNS	prep_including||-RSB--15/VBZ||rickets-25/NNS	prep_including||-RSB--15/VBZ||osteoporosis-27/NNS	conj_and||rickets-25/NNS||osteoporosis-27/NNS	prep_including||-RSB--15/VBZ||multiplesclerosis-29/NNS	conj_and||rickets-25/NNS||multiplesclerosis-29/NNS	prep_including||-RSB--15/VBZ||cancer-31/NN	conj_and||rickets-25/NNS||cancer-31/NN	osteoporosis-27||vitamind-6||yes||the primary circulating form of vitamind, 25-hydroxy-vitamind [25(oh)d], is associated with multiple medical outcomes, including rickets, osteoporosis, multiplesclerosis and cancer.
nn||depletion-2/NN||iron-1/NN	nsubjpass||evaluated-15/VBN||depletion-2/NN	appos||depletion-2/NN||lack-4/NN	nn||stores-7/NNS||iron-6/NN	prep_of||lack-4/NN||stores-7/NNS	advmod||evaluated-15/VBN||irondeficiency-9/RB	nsubjpass||evaluated-15/VBN||irondeficiencyanemia-11/NN	conj_and||irondeficiencyanemia-11/NN||anemia-13/NN	nsubjpass||evaluated-15/VBN||anemia-13/NN	auxpass||evaluated-15/VBN||were-14/VBD	root||ROOT-0/null||evaluated-15/VBN	prep_among||evaluated-15/VBN||them-17/PRP	irondeficiencyanemia-11||iron-6||yes||iron depletion, lack of iron stores, irondeficiency, irondeficiencyanemia and anemia were evaluated among them.
nsubj||analyzed-2/VBD||we-1/PRP	root||ROOT-0/null||analyzed-2/VBD	nn||flora-4/NNS||gut-3/NN	dobj||analyzed-2/VBD||flora-4/NNS	prep_in||analyzed-2/VBD||patients-6/NNS	amod||sirs-10/NNS||systemicinflammatoryresponsesyndrome-8/JJ	prep_with||patients-6/NNS||sirs-10/NNS	amod||bacteria-15/NNS||evaluated-13/JJ	amod||bacteria-15/NNS||key-14/JJ	prep_with||patients-6/NNS||bacteria-15/NNS	conj_and||sirs-10/NNS||bacteria-15/NNS	poss||values-19/NNS||their-17/PRP$	nn||values-19/NNS||cutoff-18/NN	prep_in||analyzed-2/VBD||values-19/NNS	conj_and||patients-6/NNS||values-19/NNS	amod||complications-22/NNS||infectious-21/JJ	prep_for||values-19/NNS||complications-22/NNS	prep_for||values-19/NNS||mortality-24/NN	conj_and||complications-22/NNS||mortality-24/NN	prepc_by||analyzed-2/VBD||using-26/VBG	nn||trees-30/NNS||classification-27/NN	conj_and||classification-27/NN||regression-29/NN	nn||trees-30/NNS||regression-29/NN	dobj||using-26/VBG||trees-30/NNS	appos||trees-30/NNS||cart-32/NN	systemicinflammatoryresponsesyndrome-8||bacteria-15||no||we analyzed gut flora in patients with systemicinflammatoryresponsesyndrome (sirs) and evaluated key bacteria and their cutoff values for infectious complications and mortality by using classification and regression trees (cart).
amod||changes-2/NNS||possible-1/JJ	nsubjpass||compared-11/VBN||changes-2/NNS	nsubjpass||compared-11/VBN||changes-2/NNS	nn||patterns-5/NNS||protein-4/NN	prep_of||changes-2/NNS||patterns-5/NNS	amod||tb-8/NN||active-7/JJ	prep_in||patterns-5/NNS||tb-8/NN	auxpass||compared-11/VBN||were-9/VBD	advmod||compared-11/VBN||also-10/RB	root||ROOT-0/null||compared-11/VBN	conj_and||compared-11/VBN||compared-11/VBN	amod||vivo-13/NN||ex-12/JJ	dobj||compared-11/VBN||vivo-13/NN	amod||samples-17/NNS||whole-15/JJ	nn||samples-17/NNS||blood-16/NN	prep_between||compared-11/VBN||samples-17/NNS	vmod||samples-17/NNS||incubated-18/VBN	prep_with||incubated-18/VBN||mycobacteriumtuberculosis-20/NNS	appos||samples-17/NNS||mtb-22/NN	amod||antigens-26/NNS||specific-25/JJ	dep||samples-17/NNS||antigens-26/NNS	dep||antigens-26/NNS||stimulated-28/VBN	dobj||stimulated-28/VBN||condition-29/NN	amod||conditions-34/NNS||unstimulated-33/JJ	prep_under||compared-11/VBN||conditions-34/NNS	tb-8||mycobacteriumtuberculosis-20||no||possible changes of protein patterns in active tb were also compared ex vivo between whole blood samples incubated with mycobacteriumtuberculosis ( mtb )-specific antigens (stimulated condition) and under unstimulated conditions.
mark||noticed-8/VBN||although-1/IN	amod||non-adherence-3/NN||high-2/JJ	nsubjpass||noticed-8/VBN||non-adherence-3/NN	prep_to||non-adherence-3/NN||medication-5/NN	aux||noticed-8/VBN||has-6/VBZ	auxpass||noticed-8/VBN||been-7/VBN	advcl||known-17/VBN||noticed-8/VBN	prep_for||noticed-8/VBN||ulcerativecolitis-10/NNS	appos||ulcerativecolitis-10/NNS||uc-12/NN	nsubjpass||known-17/VBN||little-15/RB	nsubj||mesalamine-21/VB||little-15/RB	auxpass||known-17/VBN||is-16/VBZ	root||ROOT-0/null||known-17/VBN	prep_about||known-17/VBN||adherence-19/NN	aux||mesalamine-21/VB||to-20/TO	xcomp||known-17/VBN||mesalamine-21/VB	dobj||mesalamine-21/VB||treatments-22/NNS	nsubj||predict-27/VB||treatments-22/NNS	dobj||mesalamine-21/VB||determinants-24/NNS	conj_and||treatments-22/NNS||determinants-24/NNS	nsubj||predict-27/VB||determinants-24/NNS	aux||predict-27/VB||can-26/MD	rcmod||treatments-22/NNS||predict-27/VB	dobj||predict-27/VB||adherence-28/NN	ulcerativecolitis-10||mesalamine-21||yes||although high non-adherence to medication has been noticed for ulcerativecolitis (uc), little is known about adherence to mesalamine treatments and determinants that can predict adherence.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||determine-8/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||was-6/VBD||determine-8/VB	det||reproducibility-11/NN||the-9/DT	amod||reproducibility-11/NN||inter-study-10/JJ	dobj||determine-8/VB||reproducibility-11/NN	amod||cmr-15/NN||adenosine-13/JJ	nn||cmr-15/NN||stress-14/NN	prep_of||reproducibility-11/NN||cmr-15/NN	prep_in||cmr-15/NN||patients-17/NNS	amod||cad-21/NN||symptomatic-19/JJ	amod||cad-21/NN||multi-vessel-20/JJ	prep_with||determine-8/VB||cad-21/NN	prep_with||determine-8/VB||those-23/DT	conj_and||cad-21/NN||those-23/DT	amod||risk-26/NN||low-25/JJ	prep_at||determine-8/VB||risk-26/NN	prep_for||risk-26/NN||cad-28/NN	adenosine-13||cad-28||no_rel||the purpose of this study was to determine the inter-study reproducibility of adenosine stress cmr in patients with symptomatic multi-vessel cad and those at low risk for cad.
det||decrease-3/NN||these-1/DT	nn||decrease-3/NN||agents-2/NNS	nsubj||myocardial-4/VBP||decrease-3/NN	root||ROOT-0/null||myocardial-4/VBP	nn||demand-6/NN||oxygen-5/NN	dobj||myocardial-4/VBP||demand-6/NN	dobj||myocardial-4/VBP||ischemia-8/NN	conj_and||demand-6/NN||ischemia-8/NN	prepc_by||myocardial-4/VBP||reducing-10/VBG	nn||rate-12/NN||heart-11/NN	dobj||reducing-10/VBG||rate-12/NN	dep||myocardial-4/VBP||lowering-14/VBG	nn||pressure-16/NN||blood-15/NN	dobj||lowering-14/VBG||pressure-16/NN	dep||myocardial-4/VBP||optimizing-19/VBG	conj_and/or||lowering-14/VBG||optimizing-19/VBG	nn||characteristics-22/NNS||ventricular-20/NN	nn||characteristics-22/NNS||loading-21/NN	dobj||optimizing-19/VBG||characteristics-22/NNS	oxygen-5||ischemia-8||no_rel||these agents decrease myocardial oxygen demand and ischemia by reducing heart rate, lowering blood pressure, and/or optimizing ventricular loading characteristics.
nsubj||had-6/VBD||one-1/CD	det||women-5/NNS||every-3/DT	num||women-5/NNS||three-4/CD	prep_in||one-1/CD||women-5/NNS	root||ROOT-0/null||had-6/VBD	dobj||had-6/VBD||anaemia-7/NN	dobj||had-6/VBD||deficiency-9/NN	conj_and||anaemia-7/NN||deficiency-9/NN	prep_of||anaemia-7/NN||folicacid-11/NN	mark||had-17/VBD||while-12/IN	nsubj||had-17/VBD||one-13/CD	det||two-16/CD||every-15/DT	prep_in||one-13/CD||two-16/CD	advcl||had-6/VBD||had-17/VBD	dobj||had-17/VBD||irondeficiency-18/NN	vmod||had-17/VBD||suggesting-20/VBG	mark||constitute-28/VBP||that-21/IN	nsubj||constitute-28/VBP||deficiencies-22/NNS	preconj||folicacid-25/NN||both-24/DT	prep_of||deficiencies-22/NNS||folicacid-25/NN	prep_of||deficiencies-22/NNS||iron-27/NN	conj_and||folicacid-25/NN||iron-27/NN	ccomp||suggesting-20/VBG||constitute-28/VBP	det||deficiencies-32/NNS||the-29/DT	amod||deficiencies-32/NNS||major-30/JJ	nn||deficiencies-32/NNS||micronutrient-31/NN	dobj||constitute-28/VBP||deficiencies-32/NNS	nn||women-35/NNS||ethiopian-34/NN	prep_in||deficiencies-32/NNS||women-35/NNS	irondeficiency-18||iron-27||yes||one in every three women had anaemia and deficiency of folicacid while one in every two had irondeficiency, suggesting that deficiencies of both folicacid and iron constitute the major micronutrient deficiencies in ethiopian women.
nsubj||included-2/VBD||these-1/DT	root||ROOT-0/null||included-2/VBD	det||role-4/NN||the-3/DT	dobj||included-2/VBD||role-4/NN	prep_of||role-4/NN||statins-6/NNS	det||agent-10/NN||an-8/DT	amod||agent-10/NN||anti-lipid-9/JJ	appos||statins-6/NNS||agent-10/NN	prepc_in||included-2/VBD||reducing-13/VBG	amod||morbidity-15/NN||post-stroke-14/JJ	dobj||reducing-13/VBG||morbidity-15/NN	dobj||reducing-13/VBG||mortality-17/NN	conj_and||morbidity-15/NN||mortality-17/NN	prepc_in||included-2/VBD||decreasing-20/VBG	conj_and||reducing-13/VBG||decreasing-20/VBG	det||plaque-24/NN||the-21/DT	amod||plaque-24/NN||carotid-22/JJ	amod||plaque-24/NN||atherosclerotic-23/JJ	dobj||decreasing-20/VBG||plaque-24/NN	prep_in||plaque-24/NN||middle-26/NN	vmod||middle-26/NN||aged-27/VBN	dobj||aged-27/VBN||patients-28/NNS	amod||risk-31/NN||increased-30/VBN	prep_at||aged-27/VBN||risk-31/NN	prep_of||risk-31/NN||cardiovasculardisease-33/NN	amod||infusion-36/NN||glucose-potassium-insulin-35/JJ	dobj||decreasing-20/VBG||infusion-36/NN	conj_and||plaque-24/NN||infusion-36/NN	amod||acute-39/JJ||hyperglyceamic-38/JJ	amod||patients-41/NNS||acute-39/JJ	nn||patients-41/NNS||stroke-40/NN	prep_in||infusion-36/NN||patients-41/NNS	dep||infusion-36/NN||pioglitazone-43/VB	det||medication-47/NN||an-45/DT	amod||medication-47/NN||anti-diabetic-46/JJ	dobj||pioglitazone-43/VB||medication-47/NN	nsubj||reduce-50/VB||medication-47/NN	aux||reduce-50/VB||to-49/TO	xcomp||pioglitazone-43/VB||reduce-50/VB	dobj||reduce-50/VB||recurrence-51/NN	prep_of||recurrence-51/NN||stroke-53/NN	nn||patients-58/NNS||type-55/NN	num||patients-58/NNS||2-56/CD	nn||patients-58/NNS||diabetic-57/NN	prep_in||reduce-50/VB||patients-58/NNS	parataxis||pioglitazone-43/VB||administration-60/NN	amod||urokinase-63/NN||intra-arterial-62/JJ	prep_of||administration-60/NN||urokinase-63/NN	det||agent-67/NN||a-65/DT	amod||agent-67/NN||thrombolytic-66/JJ	appos||urokinase-63/NN||agent-67/NN	det||role-71/NN||the-70/DT	prep_of||administration-60/NN||role-71/NN	conj_and||urokinase-63/NN||role-71/NN	nn||therapy-74/NN||laser-73/NN	prep_of||role-71/NN||therapy-74/NN	amod||dissolution-77/NN||clot-76/JJ	prep_in||therapy-74/NN||dissolution-77/NN	dep||administration-60/NN||given-78/VBN	mark||is-83/VBZ||that-79/IN	prep_at||is-83/VBZ||present-81/JJ	expl||is-83/VBZ||there-82/EX	pcomp||given-78/VBN||is-83/VBZ	advmod||fda-86/NN||only-84/RB	num||fda-86/NN||one-85/CD	nsubj||is-83/VBZ||fda-86/NN	vmod||fda-86/NN||approved-87/VBN	amod||agent-89/NN||thrombolytic-88/JJ	dobj||approved-87/VBN||agent-89/NN	nn||tpa-92/NN||r-91/NN	dep||administration-60/NN||tpa-92/NN	parataxis||pioglitazone-43/VB||benefit-95/VB	prep_of||benefit-95/VB||warfarin-97/NN	det||anticoagulant-100/NN||an-99/DT	appos||warfarin-97/NN||anticoagulant-100/NN	amod||patients-104/NNS||elderly-103/JJ	prep_in||warfarin-97/NN||patients-104/NNS	prep_with||benefit-95/VB||atrialfibrillation-106/NN	det||community-109/NN||the-108/DT	prep_in||atrialfibrillation-106/NN||community-109/NN	parataxis||pioglitazone-43/VB||nxy-111/VB	det||agent-117/NN||a-113/DT	amod||radical-115/JJ||free-114/JJ	amod||agent-117/NN||radical-115/JJ	amod||agent-117/NN||trapping-116/JJ	dep||nxy-111/VB||agent-117/NN	parataxis||pioglitazone-43/VB||minocycline-120/VB	conj_and||nxy-111/VB||minocycline-120/VB	det||tested-122/NN||both-121/DT	dobj||nxy-111/VB||tested-122/NN	prep_as||nxy-111/VB||neuroprotectants-124/NNS	dobj||decreasing-20/VBG||zoledronate-127/NN	conj_and||plaque-24/NN||zoledronate-127/NN	det||bisphosphonate-131/NN||an-129/DT	amod||bisphosphonate-131/NN||intravenous-130/JJ	appos||zoledronate-127/NN||bisphosphonate-131/NN	aux||prevent-134/VB||to-133/TO	vmod||zoledronate-127/NN||prevent-134/VB	dobj||prevent-134/VB||loss-135/NN	nn||density-139/NN||bone-137/NN	nn||density-139/NN||mineral-138/NN	prep_of||loss-135/NN||density-139/NN	det||extremity-143/NN||the-141/DT	amod||extremity-143/NN||affected-142/VBN	prep_of||density-139/NN||extremity-143/NN	advmod||role-148/NN||finally-146/RB	det||role-148/NN||the-147/DT	prep_of||density-139/NN||role-148/NN	conj_and||extremity-143/NN||role-148/NN	prep_of||role-148/NN||nicardipine-150/NN	det||blocker-155/NN||a-152/DT	nn||blocker-155/NN||calcium-153/NN	nn||blocker-155/NN||channel-154/NN	dep||nicardipine-150/NN||blocker-155/NN	det||prevention-159/NN||the-158/DT	prep_in||nicardipine-150/NN||prevention-159/NN	prep_of||prevention-159/NN||vasospasm-161/NN	vmod||zoledronate-127/NN||hydrocortisone-164/VB	conj_and||prevent-134/VB||hydrocortisone-164/VB	aux||prevent-166/VB||to-165/TO	xcomp||hydrocortisone-164/VB||prevent-166/VB	dobj||prevent-166/VB||hyponatraemia-167/NN	amod||hemorrhage-170/NN||sub-arachnoid-169/JJ	prep_after||prevent-166/VB||hemorrhage-170/NN	hemorrhage-170||urokinase-63||no||these included the role of statins (an anti-lipid agent) in reducing post-stroke morbidity and mortality, and decreasing the carotid atherosclerotic plaque in middle aged patients at increased risk of cardiovasculardisease; glucose-potassium-insulin infusion in hyperglyceamic acute stroke patients; pioglitazone (an anti-diabetic medication) to reduce recurrence of stroke in type 2 diabetic patients; administration of intra-arterial urokinase (a thrombolytic agent) and the role of laser therapy in clot dissolution given that at present there is only one fda approved thrombolytic agent (r tpa); benefit of warfarin (an anticoagulant) in elderly patients with atrialfibrillation in the community; nxy (a free radical trapping agent) and minocycline both tested as neuroprotectants; and zoledronate (an intravenous bisphosphonate) to prevent loss of bone mineral density of the affected extremity, and finally the role of nicardipine (a calcium channel blocker) in the prevention of vasospasm, and hydrocortisone to prevent hyponatraemia after sub-arachnoid hemorrhage.
root||ROOT-0/null||we-1/PRP	vmod||we-1/PRP||evaluated-2/VBN	acomp||evaluated-2/VBN||v.cholerae-3/JJ	amod||responses-7/NNS||specific-5/JJ	amod||responses-7/NNS||immune-6/JJ	dep||we-1/PRP||responses-7/NNS	det||cohort-10/NN||a-9/DT	prep_in||responses-7/NNS||cohort-10/NN	prep_of||cohort-10/NN||patients-12/NNS	amod||cholera-15/NN||severe-14/JJ	prep_with||patients-12/NNS||cholera-15/NN	cholera-15||v.cholerae-3||no||we evaluated v.cholerae - specific immune responses in a cohort of patients with severe cholera .
mark||factor-5/NN||as-1/IN	nsubj||factor-5/NN||nicotineaddiction-2/NN	cop||factor-5/NN||is-3/VBZ	det||factor-5/NN||the-4/DT	advcl||suggested-23/VBN||factor-5/NN	vmod||factor-5/NN||preventing-6/VBG	amod||women-8/NNS||many-7/JJ	dobj||preventing-6/VBG||women-8/NNS	nn||cessation-11/NN||smoking-10/NN	prep_from||preventing-6/VBG||cessation-11/NN	prep_during||preventing-6/VBG||pregnancy-13/NN	nn||therapy-17/NN||nicotine-15/NN	nn||therapy-17/NN||replacement-16/NN	nsubjpass||suggested-23/VBN||therapy-17/NN	appos||therapy-17/NN||nrt-19/NN	aux||suggested-23/VBN||has-21/VBZ	auxpass||suggested-23/VBN||been-22/VBN	root||ROOT-0/null||suggested-23/VBN	det||alternative-27/NN||a-25/DT	amod||alternative-27/NN||better-26/JJR	prep_as||suggested-23/VBN||alternative-27/NN	det||fetus-30/NN||the-29/DT	prep_for||alternative-27/NN||fetus-30/NN	nicotineaddiction-2||nicotine-15||no||as nicotineaddiction is the factor preventing many women from smoking cessation during pregnancy, nicotine replacement therapy (nrt) has been suggested as a better alternative for the fetus.
det||study-2/NN||this-1/DT	nsubj||gives-3/VBZ||study-2/NN	root||ROOT-0/null||gives-3/VBZ	iobj||gives-3/VBZ||us-4/PRP	det||knowledge-9/NN||an-5/DT	amod||knowledge-9/NN||overview-6/JJ	prep_about||overview-6/JJ||hiv/aids-8/NNS	dobj||gives-3/VBZ||knowledge-9/NN	prep_in||knowledge-9/NN||detention-11/NN	nn||province-14/NN||hunan-13/NN	prep_in||detention-11/NN||province-14/NN	det||sites-19/NNS||all-17/DT	nn||sites-19/NNS||detention-18/NN	nsubj||provided-23/VBD||sites-19/NNS	det||study-22/NN||the-21/DT	prep_in||sites-19/NNS||study-22/NN	conj_and||gives-3/VBZ||provided-23/VBD	amod||services-26/NNS||hiv/aids-24/JJ	nn||services-26/NNS||intervention-25/NN	dobj||provided-23/VBD||services-26/NNS	prep_among||provided-23/VBD||detainees-28/NNS	nsubj||focused-30/VBN||detainees-28/NNS	rcmod||detainees-28/NNS||focused-30/VBN	amod||attitude-35/NN||hiv/aids-32/JJ	nn||attitude-35/NN||knowledge-33/NN	prep_on||focused-30/VBN||attitude-35/NN	nn||behaviors-39/NNS||health-38/NN	prep_on||focused-30/VBN||behaviors-39/NNS	conj_and||attitude-35/NN||behaviors-39/NNS	aids--1||hiv--1||no||this study gives us an overview about hiv/aids knowledge in detention in hunan province, and all detention sites in the study provided hiv/aids intervention services among detainees that focused on hiv/aids knowledge, attitude, and health behaviors.
nsubj||characterize-5/VBP||perturbations-1/NNS	nn||metabolism-4/NN||lipid-3/NN	prep_in||perturbations-1/NNS||metabolism-4/NN	root||ROOT-0/null||characterize-5/VBP	dobj||characterize-5/VBP||many-6/JJ	det||chronicdiseases-9/NNS||the-8/DT	prep_of||many-6/JJ||chronicdiseases-9/NNS	advmod||plaguing-11/VBG||currently-10/RB	vmod||chronicdiseases-9/NNS||plaguing-11/VBG	poss||society-13/NN||our-12/PRP$	dobj||plaguing-11/VBG||society-13/NN	prep_such_as||many-6/JJ||obesity-17/NN	prep_such_as||many-6/JJ||diabetes-19/NN	conj_and||obesity-17/NN||diabetes-19/NN	prep_such_as||many-6/JJ||cardiovasculardisease-22/NN	conj_and||obesity-17/NN||cardiovasculardisease-22/NN	lipid-3||chronicdiseases-9||no_rel||perturbations in lipid metabolism characterize many of the chronicdiseases currently plaguing our society, such as obesity, diabetes, and cardiovasculardisease.
det||findings-2/NNS||these-1/DT	nsubj||demonstrate-3/VBP||findings-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	det||possibility-5/NN||the-4/DT	dobj||demonstrate-3/VBP||possibility-5/NN	nsubj||enhance-7/VB||possibility-5/NN	nsubj||suggest-25/VB||possibility-5/NN	aux||enhance-7/VB||to-6/TO	xcomp||demonstrate-3/VBP||enhance-7/VB	det||immunogenicity-9/NN||the-8/DT	dobj||enhance-7/VB||immunogenicity-9/NN	det||vector-15/NN||the-11/DT	advmod||attenuated-13/JJ||highly-12/RB	amod||vector-15/NN||attenuated-13/JJ	amod||vector-15/NN||nyvac-14/JJ	prep_of||immunogenicity-9/NN||vector-15/NN	det||insertion-18/NN||the-17/DT	prep_by||enhance-7/VB||insertion-18/NN	det||c7l-23/NNS||the-20/DT	amod||c7l-23/NNS||host-range-21/JJ	nn||c7l-23/NNS||gene-22/NN	prep_of||insertion-18/NN||c7l-23/NNS	xcomp||demonstrate-3/VBP||suggest-25/VB	conj_and||enhance-7/VB||suggest-25/VB	det||use-27/NN||the-26/DT	dobj||suggest-25/VB||use-27/NN	det||vector-31/NN||this-29/DT	amod||vector-31/NN||modified-30/VBN	prep_of||use-27/NN||vector-31/NN	det||candidate-36/NN||an-33/DT	amod||candidate-36/NN||improved-34/VBN	nn||candidate-36/NN||vaccine-35/NN	prep_as||vector-31/NN||candidate-36/NN	prep_against||candidate-36/NN||hiv/aids-38/NNS	aids--1||hiv--1||no||these findings demonstrate the possibility to enhance the immunogenicity of the highly attenuated nyvac vector by the insertion of the host-range gene c7l and suggest the use of this modified vector as an improved vaccine candidate against hiv/aids.
amod||cases-2/NNS||human-1/JJ	nsubj||originate-9/VBD||cases-2/NNS	nn||infection-8/NN||plague-4/NNP	appos||infection-8/NN||yersiniapestis-6/NNS	prep_of||cases-2/NNS||infection-8/NN	root||ROOT-0/null||originate-9/VBD	advmod||originate-9/VBD||ultimately-11/RB	det||bacterium-15/NN||the-14/DT	poss||populations-19/NNS||bacterium-15/NN	nn||populations-19/NNS||wildlife-17/NN	nn||populations-19/NNS||host-18/NN	prep_in||originate-9/VBD||populations-19/NNS	plague-4||yersiniapestis-6||no||human cases of plague ( yersiniapestis ) infection originate, ultimately, in the bacterium's wildlife host populations.
det||objective-2/NN||the-1/DT	nsubj||was-6/VBD||objective-2/NN	nsubj||evaluate-8/VB||objective-2/NN	det||study-5/NN||this-4/DT	prep_of||objective-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||efficacy-10/NN||the-9/DT	dobj||evaluate-8/VB||efficacy-10/NN	dobj||evaluate-8/VB||safety-12/NN	conj_and||efficacy-10/NN||safety-12/NN	amod||extended-release-16/NN||methylphenidatehcl-14/JJ	nn||extended-release-16/NN||oros-15/NNS	prep_of||efficacy-10/NN||extended-release-16/NN	appos||extended-release-16/NN||oros-mph-18/NN	prep_among||extended-release-16/NN||children-21/NNS	nn||hyperactivitydisorder-25/NN||attention-23/NN	nn||hyperactivitydisorder-25/NN||deficit-24/NN	prep_with||children-21/NNS||hyperactivitydisorder-25/NN	nsubjpass||treated-33/VBN||hyperactivitydisorder-25/NN	dep||hyperactivitydisorder-25/NN||adhd-27/VBN	aux||treated-33/VBN||had-30/VBD	auxpass||treated-33/VBN||been-31/VBN	advmod||treated-33/VBN||previously-32/RB	rcmod||hyperactivitydisorder-25/NN||treated-33/VBN	amod||immediate-release-36/NN||methylphenidatehcl-35/JJ	prep_with||treated-33/VBN||immediate-release-36/NN	appos||extended-release-16/NN||mph-ir-38/NN	adhd-27||methylphenidatehcl-35||yes||the objective of this study was to evaluate the efficacy and safety of methylphenidatehcl oros extended-release (oros-mph) among children with attention deficit hyperactivitydisorder (adhd) who had been previously treated with methylphenidatehcl immediate-release (mph-ir).
amod||creutzfeldt-jakobdisease-2/NN||sporadic-1/JJ	nsubj||disorder-10/NN||creutzfeldt-jakobdisease-2/NN	dep||creutzfeldt-jakobdisease-2/NN||scjd-4/VBN	cop||disorder-10/NN||is-6/VBZ	det||disorder-10/NN||a-7/DT	amod||disorder-10/NN||rare-8/JJ	nn||disorder-10/NN||neurodegenerative-9/NN	root||ROOT-0/null||disorder-10/NN	prep_in||induces-23/VBZ||disorder-10/NN	nsubj||induces-23/VBZ||accumulation-13/NN	det||isoform-17/NN||a-15/DT	amod||isoform-17/NN||pathogenic-16/JJ	prep_of||accumulation-13/NN||isoform-17/NN	prep_of||isoform-17/NN||prionprotein-19/NN	dep||prionprotein-19/NN||prpsc-21/JJ	rcmod||disorder-10/NN||induces-23/VBZ	amod||damage-25/NN||neuronal-24/JJ	dobj||induces-23/VBZ||damage-25/NN	amod||features-29/NNS||distinct-27/JJ	amod||features-29/NNS||pathologic-28/JJ	prep_with||induces-23/VBZ||features-29/NNS	prionprotein-19||creutzfeldt-jakobdisease-2||no_rel||sporadic creutzfeldt-jakobdisease (scjd) is a rare neurodegenerative disorder in which accumulation of a pathogenic isoform of prionprotein (prpsc) induces neuronal damage with distinct pathologic features.
amod||microscopic-3/NNS||subsequent-1/JJ	nn||microscopic-3/NNS||electron-2/NN	nsubj||aminoacid-22/VBD||microscopic-3/NNS	conj_and||microscopic-3/NNS||biochemical-5/NN	nsubj||aminoacid-22/VBD||biochemical-5/NN	amod||studies-9/NNS||genetic-8/JJ	conj_and||microscopic-3/NNS||studies-9/NNS	nsubj||aminoacid-22/VBD||studies-9/NNS	vmod||studies-9/NNS||identified-10/VBN	det||orthomyxovirus-12/NNS||an-11/DT	dobj||identified-10/VBN||orthomyxovirus-12/NNS	num||segments-16/NNS||seven-14/CD	nn||segments-16/NNS||rna-15/NN	prep_with||identified-10/VBN||segments-16/NNS	vmod||segments-16/NNS||exhibiting-17/VBG	quantmod||50-19/CD||approximately-18/RB	num||%-20/NN||50-19/CD	dobj||exhibiting-17/VBG||%-20/NN	advmod||aminoacid-22/VBD||overall-21/RB	root||ROOT-0/null||aminoacid-22/VBD	dobj||aminoacid-22/VBD||identity-23/NN	nn||virus-27/NN||humaninfluenza-25/NN	nn||virus-27/NN||c-26/NN	prep_to||aminoacid-22/VBD||virus-27/NN	humaninfluenza-25||orthomyxovirus-12||no||subsequent electron microscopic, biochemical, and genetic studies identified an orthomyxovirus with seven rna segments exhibiting approximately 50% overall aminoacid identity to humaninfluenza c virus.
amod||diagnosis-3/NN||accurate-1/JJ	amod||diagnosis-3/NN||molecular-2/JJ	nsubj||critical-13/JJ||diagnosis-3/NN	amod||diabetesmellitus-8/NNS||monogenic-5/JJ	amod||diabetesmellitus-8/NNS||non-autoimmune-6/JJ	amod||diabetesmellitus-8/NNS||neonatal-7/JJ	prep_of||diagnosis-3/NN||diabetesmellitus-8/NNS	appos||diabetesmellitus-8/NNS||ndm-10/NN	cop||critical-13/JJ||is-12/VBZ	root||ROOT-0/null||critical-13/JJ	amod||care-16/NN||patient-15/JJ	prep_for||critical-13/JJ||care-16/NN	mark||treated-29/VBN||as-18/IN	nsubjpass||treated-29/VBN||patients-19/NNS	vmod||patients-19/NNS||carrying-20/VBG	det||mutation-22/NN||a-21/DT	dobj||carrying-20/VBG||mutation-22/NN	prep_in||mutation-22/NN||kcnj11-24/NNS	prep_in||mutation-22/NN||abcc8-26/NNS	conj_or||kcnj11-24/NNS||abcc8-26/NNS	aux||treated-29/VBN||can-27/MD	auxpass||treated-29/VBN||be-28/VB	advcl||critical-13/JJ||treated-29/VBN	amod||drugs-33/NNS||oral-31/JJ	nn||drugs-33/NNS||sulfonylurea-32/NN	agent||treated-29/VBN||drugs-33/NNS	nn||therapy-37/NN||insulin-36/NN	prep_instead_of||drugs-33/NNS||therapy-37/NN	sulfonylurea-32||diabetesmellitus-8||no_rel||accurate molecular diagnosis of monogenic non-autoimmune neonatal diabetesmellitus (ndm) is critical for patient care, as patients carrying a mutation in kcnj11 or abcc8 can be treated by oral sulfonylurea drugs instead of insulin therapy.
amod||--3/NNS||compounds-1/JJ	amod||--3/NNS||1-deoxy-1-2/JJ	dep||--3/NNS||6-5/CD	amod||â-9/NN||-LSB--7/JJ	nn||â-9/NN||n-8/NN	dep||--3/NNS||â-9/NN	dep||â-9/NN||$-10/$	num||$-10/$||²-11/CD	dep||â-9/NN||furan-2-carbonyl-14/NN	nn||-RSB--18/NNS||hydrazino-17/NN	dep||furan-2-carbonyl-14/NN||-RSB--18/NNS	num||h-20/NN||-9-19/CD	dep||-RSB--18/NNS||h-20/NN	dep||furan-2-carbonyl-14/NN||purin-9-yl-22/JJ	amod||d-ribofuranuronamide-30/NN||n-ethyl-25/JJ	nn||²-28/NNP||î-27/NNP	dep||d-ribofuranuronamide-30/NN||²-28/NNP	dep||--3/NNS||d-ribofuranuronamide-30/NN	dep||d-ribofuranuronamide-30/NN||19-32/CD	amod||k-35/JJ||ha1-34/JJ	amod||iâ-71/NN||k-35/JJ	amod||iâ-71/NN||iâ-36/JJ	amod||iâ-71/NN||$-37/$	number||=-39/CD||‰-38/CD	num||$-37/$||=-39/CD	amod||iâ-71/NN||â-40/JJ	amod||iâ-71/NN||$-41/$	number||1050â-43/CD||‰-42/CD	num||$-41/$||1050â-43/CD	amod||iâ-71/NN||nm-44/JJ	amod||iâ-71/NN||ha2a-46/JJ	amod||iâ-71/NN||k-47/JJ	amod||iâ-71/NN||iâ-48/JJ	amod||iâ-71/NN||$-49/$	number||=-51/CD||‰-50/CD	num||$-49/$||=-51/CD	amod||iâ-71/NN||â-52/JJ	amod||iâ-71/NN||$-53/$	number||1550â-55/CD||‰-54/CD	num||$-53/$||1550â-55/CD	amod||iâ-71/NN||nm-56/JJ	amod||iâ-71/NN||ha2b-58/JJ	amod||iâ-71/NN||ec50â-59/JJ	amod||iâ-71/NN||$-60/$	number||=-62/CD||‰-61/CD	num||$-60/$||=-62/CD	amod||iâ-71/NN||â-63/JJ	amod||iâ-71/NN||$-64/$	number||82â-66/CD||‰-65/CD	num||$-64/$||82â-66/CD	amod||iâ-71/NN||nm-67/JJ	amod||iâ-71/NN||ha3-69/JJ	nn||iâ-71/NN||k-70/NN	appos||19-32/CD||iâ-71/NN	dep||iâ-71/NN||$-72/$	number||>-74/CD||‰-73/CD	num||$-72/$||>-74/CD	vmod||$-72/$||â-75/VBN	dep||m-81/NN||$-76/$	num||m-81/NN||‰-77/CD	num||m-81/NN||5â-78/CD	nn||m-81/NN||î-79/NN	num||m-81/NN||1/4-80/CD	dobj||â-75/VBN||m-81/NN	poss||analogue-86/NN||its-84/PRP$	amod||analogue-86/NN||2-chloro-85/JJ	dep||--3/NNS||analogue-86/NN	conj_and||d-ribofuranuronamide-30/NN||analogue-86/NN	nsubjpass||confirmed-139/VBN||23-87/CD	nsubj||agonists-146/NNS||23-87/CD	amod||iâ-91/NN||ha1-89/JJ	nn||iâ-91/NN||k-90/NN	dep||23-87/CD||iâ-91/NN	num||â-95/NN||$-92/$	number||=-94/CD||‰-93/CD	num||$-92/$||=-94/CD	prep||iâ-91/NN||â-95/NN	amod||î-134/NN||$-96/$	dep||$-96/$||‰-97/JJ	amod||î-134/NN||3500â-98/JJ	amod||î-134/NN||nm-99/JJ	amod||î-134/NN||ha2a-101/JJ	amod||î-134/NN||k-102/JJ	amod||î-134/NN||iâ-103/JJ	amod||î-134/NN||$-104/$	number||=-106/CD||‰-105/CD	num||$-104/$||=-106/CD	amod||î-134/NN||â-107/JJ	amod||î-134/NN||$-108/$	number||4950â-110/CD||‰-109/CD	num||$-108/$||4950â-110/CD	amod||î-134/NN||nm-111/JJ	amod||î-134/NN||ha2b-113/JJ	amod||î-134/NN||ec50â-114/JJ	amod||î-134/NN||$-115/$	number||=-117/CD||‰-116/CD	num||$-115/$||=-117/CD	amod||î-134/NN||â-118/JJ	amod||î-134/NN||$-119/$	number||210â-121/CD||‰-120/CD	num||$-119/$||210â-121/CD	amod||î-134/NN||nm-122/JJ	amod||î-134/NN||ha3-124/JJ	amod||î-134/NN||k-125/JJ	amod||î-134/NN||iâ-126/JJ	amod||î-134/NN||$-127/$	number||>-129/CD||‰-128/CD	num||$-127/$||>-129/CD	amod||î-134/NN||â-130/JJ	amod||î-134/NN||$-131/$	num||$-131/$||‰-132/CD	amod||î-134/NN||5â-133/JJ	dep||â-95/NN||î-134/NN	number||m-136/JJ||1/4-135/CD	amod||î-134/NN||m-136/JJ	auxpass||confirmed-139/VBN||were-138/VBD	rcmod||analogue-86/NN||confirmed-139/VBN	aux||agonists-146/NNS||to-140/TO	cop||agonists-146/NNS||be-141/VB	amod||agonists-146/NNS||potent-142/JJ	conj_and||potent-142/JJ||selective-144/JJ	amod||agonists-146/NNS||selective-144/JJ	amod||agonists-146/NNS||full-145/JJ	xcomp||confirmed-139/VBN||agonists-146/NNS	det||monophosphate-151/NN||a-148/DT	amod||monophosphate-151/NN||cyclic-149/JJ	nn||monophosphate-151/NN||adenosine-150/NN	prep_in||agonists-146/NNS||monophosphate-151/NN	appos||monophosphate-151/NN||camp-153/NN	amod||assay-156/JJ||functional-155/JJ	amod||monophosphate-151/NN||assay-156/JJ	amod||cells-164/NNS||chinese-158/JJ	nn||cells-164/NNS||hamster-159/NN	nn||cells-164/NNS||ovary-160/NN	appos||cells-164/NNS||cho-162/NN	prep_in||agonists-146/NNS||cells-164/NNS	vmod||cells-164/NNS||expressing-165/VBG	amod||ar-167/NN||ha2b-166/JJ	dobj||expressing-165/VBG||ar-167/NN	nm-122||ar-167||no_rel||compounds 1-deoxy-1-{6-[ n â€²-(furan-2-carbonyl)-hydrazino]-9 h -purin-9-yl}-n-ethyl- î² -d-ribofuranuronamide ( 19 , ha1 k iâ€‰=â€‰1050â nm, ha2a k iâ€‰=â€‰1550â nm, ha2b ec50â€‰=â€‰82â nm, ha3 k iâ€‰>â€‰5â î¼m) and its 2-chloro analogue 23 (ha1 k iâ€‰=â€‰3500â nm, ha2a k iâ€‰=â€‰4950â nm, ha2b ec50â€‰=â€‰210â nm, ha3 k iâ€‰>â€‰5â î¼m) were confirmed to be potent and selective full agonists in a cyclic adenosine monophosphate (camp) functional assay in chinese hamster ovary (cho) cells expressing ha2b ar.
nn||cells-2/NNS||cancer-1/NN	nsubjpass||known-5/VBN||cells-2/NNS	nsubj||display-7/VB||cells-2/NNS	auxpass||known-5/VBN||are-3/VBP	advmod||known-5/VBN||well-4/RB	root||ROOT-0/null||known-5/VBN	aux||display-7/VB||to-6/TO	xcomp||known-5/VBN||display-7/VB	det||uptake-11/NN||an-8/DT	amod||uptake-11/NN||enhanced-9/JJ	nn||uptake-11/NN||sugar-10/NN	dobj||display-7/VB||uptake-11/NN	dobj||display-7/VB||consumption-13/NN	conj_and||uptake-11/NN||consumption-13/NN	cancer-1||sugar-10||no_rel||cancer cells are well known to display an enhanced sugar uptake and consumption.
prep_in||rare-13/JJ||contrast-2/NN	advmod||life-threatening-5/JJ||potentially-4/RB	amod||anaphylacticreactions-8/NNS||life-threatening-5/JJ	amod||anaphylacticreactions-8/NNS||systemic-6/JJ	amod||anaphylacticreactions-8/NNS||immediate-type-7/JJ	nsubj||rare-13/JJ||anaphylacticreactions-8/NNS	prep_to||anaphylacticreactions-8/NNS||heparins-10/NNS	cop||rare-13/JJ||are-11/VBP	advmod||rare-13/JJ||extremely-12/RB	root||ROOT-0/null||rare-13/JJ	heparins-10||anaphylacticreactions-8||no_rel||in contrast, potentially life-threatening systemic immediate-type anaphylacticreactions to heparins are extremely rare.
amod||cause-2/NN||primary-1/JJ	nsubjpass||coded-6/VBN||cause-2/NN	prep_of||cause-2/NN||death-4/NN	auxpass||coded-6/VBN||was-5/VBD	root||ROOT-0/null||coded-6/VBN	prep_as||coded-6/VBN||hiv/aids-8/NNS	prep_as||coded-6/VBN||cardiovasculardisease-10/NN	conj_or||hiv/aids-8/NNS||cardiovasculardisease-10/NN	amod||heartdisease-13/NN||coronary-12/JJ	prep_as||coded-6/VBN||heartdisease-13/NN	conj_or||hiv/aids-8/NNS||heartdisease-13/NN	amod||myocardialinfarction-16/NN||acute-15/JJ	prep_as||coded-6/VBN||myocardialinfarction-16/NN	conj_or||hiv/aids-8/NNS||myocardialinfarction-16/NN	prep_as||coded-6/VBN||stroke-18/NN	conj_or||hiv/aids-8/NNS||stroke-18/NN	prep_as||coded-6/VBN||diabetes-20/NN	conj_or||hiv/aids-8/NNS||diabetes-20/NN	prep_as||coded-6/VBN||cancer-23/NN	conj_or||hiv/aids-8/NNS||cancer-23/NN	aids--1||hiv--1||no||primary cause of death was coded as hiv/aids, cardiovasculardisease, coronary heartdisease, acute myocardialinfarction, stroke, diabetes, or cancer.
det||hearts-4/NNS||the-2/DT	num||hearts-4/NNS||five-3/CD	prep_in||infused-11/VBN||hearts-4/NNS	prep_without||hearts-4/NNS||vf-6/NN	nsubjpass||infused-11/VBN||flecainide-8/NN	auxpass||infused-11/VBN||was-9/VBD	advmod||infused-11/VBN||subsequently-10/RB	root||ROOT-0/null||infused-11/VBN	det||domain-15/NN||the-13/DT	amod||domain-15/NN||sotalol-14/JJ	prep_in||infused-11/VBN||domain-15/NN	vf-6||sotalol-14||yes||in the five hearts without vf, flecainide was subsequently infused in the sotalol domain.
det||groups-3/NNS||the-1/DT	num||groups-3/NNS||two-2/CD	nsubj||comparable-11/JJ||groups-3/NNS	dep||groups-3/NNS||dexamethasone-6/JJ	dep||groups-3/NNS||ondansetron-8/JJ	conj_and||dexamethasone-6/JJ||ondansetron-8/JJ	cop||comparable-11/JJ||were-10/VBD	root||ROOT-0/null||comparable-11/JJ	prep_in||comparable-11/JJ||outcome-13/NN	prep_in||comparable-11/JJ||terms-16/NNS	amod||nausea-19/NN||post-operative-18/JJ	prep_of||terms-16/NNS||nausea-19/NN	prep_of||terms-16/NNS||vomiting-21/NN	conj_and||nausea-19/NN||vomiting-21/NN	prep_in||terms-16/NNS||patients-24/NNS	vmod||patients-24/NNS||undergoing-25/VBG	amod||cholecystectomy-27/NN||laparoscopic-26/JJ	dobj||undergoing-25/VBG||cholecystectomy-27/NN	vomiting-21||dexamethasone-6||yes||the two groups, (dexamethasone and ondansetron) were comparable in outcome, in terms of post-operative nausea and vomiting, in patients undergoing laparoscopic cholecystectomy.
aux||investigate-2/VB||to-1/TO	csubj||argentipes-10/VBZ||investigate-2/VB	det||susceptibility-7/NN||the-3/DT	nn||susceptibility-7/NN||ddt-4/NN	conj_and||ddt-4/NN||deltamethrin-6/NN	nn||susceptibility-7/NN||deltamethrin-6/NN	dobj||investigate-2/VB||susceptibility-7/NN	prep_of||susceptibility-7/NN||phlebotomus-9/NNS	root||ROOT-0/null||argentipes-10/VBZ	det||vector-13/NN||the-12/DT	dep||countries-27/NNS||vector-13/NN	nn||donovani-16/NNS||leishmania-15/NN	prep_of||vector-13/NN||donovani-16/NNS	amod||countries-27/NNS||responsible-18/JJ	prep_for||responsible-18/JJ||visceralleishmaniasis-20/NNS	appos||visceralleishmaniasis-20/NNS||vl-22/NN	prep_in||visceralleishmaniasis-20/NNS||two-26/CD	dobj||argentipes-10/VBZ||countries-27/NNS	dep||countries-27/NNS||india-29/JJ	dep||countries-27/NNS||nepal-31/JJ	conj_and||india-29/JJ||nepal-31/JJ	amod||histories-35/NNS||different-34/JJ	prep_with||argentipes-10/VBZ||histories-35/NNS	amod||exposure-38/NN||insecticide-37/JJ	prep_of||histories-35/NNS||exposure-38/NN	insecticide-37||visceralleishmaniasis-20||no_rel||to investigate the ddt and deltamethrin susceptibility of phlebotomus argentipes , the vector of leishmania donovani , responsible for visceralleishmaniasis (vl), in two countries (india and nepal) with different histories of insecticide exposure.
poss||finding-2/NN||our-1/PRP$	nsubj||offers-3/VBZ||finding-2/NN	nsubj||brings-22/VBZ||finding-2/NN	root||ROOT-0/null||offers-3/VBZ	det||understanding-6/NN||a-4/DT	amod||understanding-6/NN||better-5/JJR	nsubj||virus-20/NN||understanding-6/NN	det||transmission-9/NN||the-8/DT	prep_of||understanding-6/NN||transmission-9/NN	prep_of||understanding-6/NN||evolution-11/NN	conj_and||transmission-9/NN||evolution-11/NN	det||pandemic-15/NN||the-13/DT	num||pandemic-15/NN||2009-14/CD	prep_of||transmission-9/NN||pandemic-15/NN	det||virus-20/NN||a-16/DT	nn||virus-20/NN||h1n1-18/NN	xcomp||offers-3/VBZ||virus-20/NN	conj_and||offers-3/VBZ||brings-22/VBZ	dobj||brings-22/VBZ||attention-23/NN	aux||further-25/VB||to-24/TO	vmod||brings-22/VBZ||further-25/VB	advmod||severe-27/JJ||potentially-26/RB	amod||pandemic-29/NN||severe-27/JJ	nn||pandemic-29/NN||influenza-28/NN	dobj||further-25/VB||pandemic-29/NN	nsubj||result-32/VB||pandemic-29/NN	aux||result-32/VB||may-31/MD	rcmod||pandemic-29/NN||result-32/VB	amod||evolution-35/NN||cross-host-34/JJ	prep_from||result-32/VB||evolution-35/NN	det||influenzaviruses-38/NNS||the-37/DT	prep_of||evolution-35/NN||influenzaviruses-38/NNS	influenza-28||influenzaviruses-38||no||our finding offers a better understanding of the transmission and evolution of the 2009 pandemic a (h1n1) virus and brings attention to further potentially severe influenza pandemic that may result from cross-host evolution of the influenzaviruses.
det||patients-4/NNS||the-1/DT	amod||patients-4/NNS||479-2/JJ	amod||patients-4/NNS||evaluable-3/JJ	nsubj||had-11/VBD||patients-4/NNS	prep_with||patients-4/NNS||metastaticcancer-6/NN	amod||sites-10/NNS||other-8/JJ	nn||sites-10/NNS||primarycancer-9/NN	prep_from||metastaticcancer-6/NN||sites-10/NNS	root||ROOT-0/null||had-11/VBD	dobj||had-11/VBD||cr-12/NN	dobj||had-11/VBD||pr-14/NN	conj_and||cr-12/NN||pr-14/NN	amod||rates-20/NNS||cr-17/JJ	amod||rates-20/NNS||+-18/JJ	nn||rates-20/NNS||pr-19/NN	dobj||had-11/VBD||rates-20/NNS	conj_and||cr-12/NN||rates-20/NNS	num||%-23/NN||25-22/CD	prep_of||rates-20/NNS||%-23/NN	num||%-26/NN||27-25/CD	prep_of||rates-20/NNS||%-26/NN	conj_and||%-23/NN||%-26/NN	num||%-30/NN||51-29/CD	prep_of||rates-20/NNS||%-30/NN	conj_and||%-23/NN||%-30/NN	num||weeks-33/NNS||4-32/CD	prep_at||%-30/NN||weeks-33/NNS	num||%-36/NN||26-35/CD	prep_of||rates-20/NNS||%-36/NN	conj_and||%-23/NN||%-36/NN	num||%-39/NN||22-38/CD	prep_of||rates-20/NNS||%-39/NN	conj_and||%-23/NN||%-39/NN	num||%-43/NN||48-42/CD	prep_of||rates-20/NNS||%-43/NN	conj_and||%-23/NN||%-43/NN	num||weeks-46/NNS||8-45/CD	prep_at||%-43/NN||weeks-46/NNS	num||%-50/NN||22-49/CD	prep_of||rates-20/NNS||%-50/NN	conj_and||%-23/NN||%-50/NN	num||%-53/NN||29-52/CD	prep_of||rates-20/NNS||%-53/NN	conj_and||%-23/NN||%-53/NN	num||%-57/NN||51-56/CD	prep_of||rates-20/NNS||%-57/NN	conj_and||%-23/NN||%-57/NN	num||weeks-60/NNS||12-59/CD	prep_at||had-11/VBD||weeks-60/NNS	cr-17||metastaticcancer-6||no_rel||the 479 evaluable patients with metastaticcancer from other primarycancer sites had cr , pr , and cr + pr rates of 25%, 27%, and 51% at 4 weeks; 26%, 22%, and 48% at 8 weeks; and 22%, 29%, and 51% at 12 weeks.
amod||proctitis-5/NNS||lymphogranulomavenereum-1/JJ	appos||proctitis-5/NNS||lgv-3/NN	nsubjpass||caused-7/VBN||proctitis-5/NNS	nsubj||endemic-17/JJ||proctitis-5/NNS	auxpass||caused-7/VBN||is-6/VBZ	root||ROOT-0/null||caused-7/VBN	agent||caused-7/VBN||chlamydiatrachomatis-9/NNS	appos||chlamydiatrachomatis-9/NNS||ct-11/NN	amod||l-14/NN||genotype-13/JJ	dobj||caused-7/VBN||l-14/NN	cop||endemic-17/JJ||is-16/VBZ	conj_and||caused-7/VBN||endemic-17/JJ	prep_among||endemic-17/JJ||men-19/NNS	nsubj||have-21/VBP||men-19/NNS	rcmod||men-19/NNS||have-21/VBP	dobj||have-21/VBP||sex-22/NN	prep_with||have-21/VBP||men-24/NNS	appos||men-24/NNS||msm-26/NN	amod||society-30/NN||western-29/JJ	prep_in||men-24/NNS||society-30/NN	lymphogranulomavenereum-1||chlamydiatrachomatis-9||no||lymphogranulomavenereum (lgv) proctitis is caused by chlamydiatrachomatis (ct) genotype l and is endemic among men who have sex with men (msm) in western society.
amod||patients-3/NNS||sixty-one-1/JJ	nn||patients-3/NNS||adult-2/NN	nsubjpass||assigned-11/VBN||patients-3/NNS	prep_with||patients-3/NNS||type1diabetes-5/NNS	vmod||type1diabetes-5/NNS||treated-6/VBN	prep_with||treated-6/VBN||csii-8/NNS	auxpass||assigned-11/VBN||were-9/VBD	advmod||assigned-11/VBN||randomly-10/RB	root||ROOT-0/null||assigned-11/VBN	preconj||learning-14/VBG||either-13/CC	prepc_to||assigned-11/VBN||learning-14/VBG	amod||counting-16/NN||carbohydrate-15/JJ	dobj||learning-14/VBG||counting-16/NN	appos||counting-16/NN||intervention-18/NN	prepc_to||assigned-11/VBN||estimating-21/VBG	conj_or||learning-14/VBG||estimating-21/VBG	amod||dose-24/NN||pre-meal-22/JJ	nn||dose-24/NN||insulin-23/NN	dobj||estimating-21/VBG||dose-24/NN	det||way-29/NN||the-26/DT	amod||way-29/NN||usual-27/JJ	amod||way-29/NN||empirical-28/JJ	prep_in||dose-24/NN||way-29/NN	appos||way-29/NN||control-31/NN	type1diabetes-5||insulin-23||yes||sixty-one adult patients with type1diabetes treated with csii were randomly assigned to either learning carbohydrate counting (intervention) or estimating pre-meal insulin dose in the usual empirical way (control).
amod||replication-2/NN||successful-1/JJ	nsubj||depends-19/VBZ||replication-2/NN	conj_and||replication-2/NN||transmission-4/NN	nsubj||depends-19/VBZ||transmission-4/NN	amod||viruses-8/NNS||large-6/JJ	nn||viruses-8/NNS||dna-7/NN	prep_of||replication-2/NN||viruses-8/NNS	det||family-16/NN||the-11/DT	amod||family-16/NN||cytomegaloviruses-12/JJ	appos||family-16/NN||cmv-14/NN	prep_such_as||viruses-8/NNS||family-16/NN	prep_of||family-16/NN||viruses-18/NNS	root||ROOT-0/null||depends-19/VBZ	det||ability-22/NN||the-21/DT	prep_on||depends-19/VBZ||ability-22/NN	aux||interfere-24/VB||to-23/TO	vmod||ability-22/NN||interfere-24/VB	amod||aspects-27/NNS||multiple-26/JJ	prep_with||interfere-24/VB||aspects-27/NNS	det||response-32/NN||the-29/DT	nn||response-32/NN||host-30/NN	amod||response-32/NN||immune-31/JJ	prep_of||aspects-27/NNS||response-32/NN	cmv-14||cytomegaloviruses-12||no||successful replication and transmission of large dna viruses such as the cytomegaloviruses (cmv) family of viruses depends on the ability to interfere with multiple aspects of the host immune response.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||possibility-10/NN||the-9/DT	dobj||investigate-8/VB||possibility-10/NN	mark||causes-17/VBZ||that-11/IN	det||synthesis-16/NN||a-12/DT	amod||synthesis-16/NN||decreased-13/VBN	amod||synthesis-16/NN||mitochondrial-14/JJ	nn||synthesis-16/NN||atp-15/NN	nsubj||causes-17/VBZ||synthesis-16/NN	nsubj||plays-23/VBZ||synthesis-16/NN	ccomp||investigate-8/VB||causes-17/VBZ	amod||fatigue-21/NN||muscular-18/JJ	conj_and||muscular-18/JJ||mental-20/JJ	amod||fatigue-21/NN||mental-20/JJ	dobj||causes-17/VBZ||fatigue-21/NN	ccomp||investigate-8/VB||plays-23/VBZ	conj_and||causes-17/VBZ||plays-23/VBZ	det||role-25/NN||a-24/DT	dobj||plays-23/VBZ||role-25/NN	det||pathophysiology-28/NN||the-27/DT	prep_in||plays-23/VBZ||pathophysiology-28/NN	det||chronicfatiguesyndrome-31/NN||the-30/DT	prep_of||pathophysiology-28/NN||chronicfatiguesyndrome-31/NN	appos||chronicfatiguesyndrome-31/NN||cfs/me-33/NN	atp-15||chronicfatiguesyndrome-31||no_rel||the aim of this study was to investigate the possibility that a decreased mitochondrial atp synthesis causes muscular and mental fatigue and plays a role in the pathophysiology of the chronicfatiguesyndrome (cfs/me).
nsubj||contained-2/VBD||orf1-1/NNS	nsubj||showed-12/VBD||orf1-1/NNS	root||ROOT-0/null||contained-2/VBD	dobj||contained-2/VBD||motifs-3/NNS	amod||polymerases-7/NNS||rna-dependent-5/JJ	nn||polymerases-7/NNS||rna-6/NN	prep_of||motifs-3/NNS||polymerases-7/NNS	appos||polymerases-7/NNS||rdrp-9/NN	conj_and||contained-2/VBD||showed-12/VBD	dobj||showed-12/VBD||similarities-13/NNS	prep_to||showed-12/VBD||rdrp-15/NN	nn||virus-19/NN||scleropthora-17/NN	nn||virus-19/NN||macrospora-18/NN	prep_of||rdrp-15/NN||virus-19/NN	amod||virus-19/NN||a-20/DT	nn||a-23/NNP||smv-22/NNP	dep||a-20/DT||a-23/NNP	prep_to||showed-12/VBD||viruses-26/NNS	conj_and||rdrp-15/NN||viruses-26/NNS	det||family-30/NN||the-28/DT	amod||family-30/NN||nodaviridae-29/JJ	prep_within||viruses-26/NNS||family-30/NN	virus-19||viruses-26||no||orf1 contained motifs of rna-dependent rna polymerases (rdrp) and showed similarities to rdrp of scleropthora macrospora virus a (smv a) and viruses within the nodaviridae family.
nsubj||included-9/VBD||factors-1/NNS	vmod||factors-1/NNS||related-2/VBN	prep_to||related-2/VBN||participation-4/NN	nn||programs-8/NNS||hiv-6/NN	nn||programs-8/NNS||prevention-7/NN	prep_in||participation-4/NN||programs-8/NNS	root||ROOT-0/null||included-9/VBD	nn||perception-18/NN||age-10/NN	dep||perception-18/NN||ethnicity-12/NN	dep||perception-18/NN||income-14/NN	amod||perception-18/NN||hiv-16/JJ	nn||perception-18/NN||risk-17/NN	dobj||included-9/VBD||perception-18/NN	dep||included-9/VBD||living-20/VBG	prep_with||living-20/VBG||boyfriend-22/NN	dep||included-9/VBD||living-24/VBG	conj_and||living-20/VBG||living-24/VBG	amod||area-27/NN||urban-26/JJ	nsubj||talked-36/VBN||area-27/NN	appos||area-27/NN||size-29/NN	amod||network-33/NN||msm-31/JJ	amod||network-33/NN||social-32/JJ	prep_of||size-29/NN||network-33/NN	aux||talked-36/VBN||having-35/VBG	prepc_in||living-24/VBG||talked-36/VBN	nn||status-39/NN||hiv-38/NN	prep_about||talked-36/VBN||status-39/NN	prep_with||talked-36/VBN||partners-41/NNS	dep||included-9/VBD||knowing-44/VBG	conj_and||living-20/VBG||knowing-44/VBG	dobj||knowing-44/VBG||someone-45/NN	nsubj||hivpositive-48/JJ||someone-45/NN	cop||hivpositive-48/JJ||is-47/VBZ	rcmod||someone-45/NN||hivpositive-48/JJ	hivpositive-48||hiv-38||no||factors related to participation in hiv prevention programs included age, ethnicity, income, hiv risk perception, living with boyfriend, living in urban area, size of msm social network, having talked about hiv status with partners, and knowing someone who is hivpositive.
nn||tissue-2/NN||lymphoreticular-1/NN	nsubj||showed-3/VBD||tissue-2/NN	root||ROOT-0/null||showed-3/VBD	neg||evidence-5/NN||no-4/DT	dobj||showed-3/VBD||evidence-5/NN	nn||colonization-8/NN||prion-7/NN	prep_of||evidence-5/NN||colonization-8/NN	vmod||showed-3/VBD||suggesting-10/VBG	mark||similar-18/JJ||that-11/IN	det||pathogenesis-14/NNS||the-12/DT	amod||pathogenesis-14/NNS||peripheral-13/JJ	nsubj||similar-18/JJ||pathogenesis-14/NNS	prep_of||pathogenesis-14/NNS||kuru-16/NN	cop||similar-18/JJ||is-17/VBZ	ccomp||suggesting-10/VBG||similar-18/JJ	prep_to||similar-18/JJ||that-20/DT	vmod||that-20/DT||seen-21/VBN	amod||cjd-24/NN||classical-23/JJ	prep_in||seen-21/VBN||cjd-24/NN	prep_in||seen-21/VBN||vcjd-27/NN	conj_negcc||cjd-24/NN||vcjd-27/NN	vcjd-27||prion-7||no_rel||lymphoreticular tissue showed no evidence of prion colonization, suggesting that the peripheral pathogenesis of kuru is similar to that seen in classical cjd rather than vcjd.
amod||analyses-5/NNS||case-control-2/JJ	conj_and||case-control-2/JJ||case-series-4/JJ	amod||analyses-5/NNS||case-series-4/JJ	prep_in||examined-8/VBD||analyses-5/NNS	nsubj||examined-8/VBD||we-7/PRP	root||ROOT-0/null||examined-8/VBD	nn||concentrations-10/NNS||serum-9/NN	dobj||examined-8/VBD||concentrations-10/NNS	amod||25ohd-14/NNS||25-hydroxyvitamind-12/JJ	prep_of||concentrations-10/NNS||25ohd-14/NNS	prep_in||25ohd-14/NNS||relation-17/NN	nn||characteristics-22/NNS||breast-19/NN	nn||characteristics-22/NNS||cancer-20/NN	amod||characteristics-22/NNS||prognostic-21/JJ	prep_to||examined-8/VBD||characteristics-22/NNS	amod||grade-26/NN||histologic-25/JJ	prep_including||examined-8/VBD||grade-26/NN	nn||receptor-29/NN||estrogen-28/NN	appos||grade-26/NN||receptor-29/NN	appos||receptor-29/NN||er-31/NN	amod||subtypes-36/NNS||molecular-35/JJ	nsubj||enrolled-67/VBD||subtypes-36/NNS	vmod||subtypes-36/NNS||defined-37/VBN	agent||defined-37/VBN||er-39/NN	amod||pr-44/NN||progesterone-41/JJ	nn||pr-44/NN||receptor-42/NN	agent||defined-37/VBN||pr-44/NN	conj_and||er-39/NN||pr-44/NN	agent||defined-37/VBN||her2-47/NNS	conj_and||er-39/NN||her2-47/NNS	num||women-51/NNS||579-50/CD	prep_among||defined-37/VBN||women-51/NNS	nn||cancer-55/NN||incident-53/NN	nn||cancer-55/NN||breast-54/NN	prep_with||women-51/NNS||cancer-55/NN	num||controls-58/NNS||574-57/CD	prep_among||defined-37/VBN||controls-58/NNS	conj_and||women-51/NNS||controls-58/NNS	vmod||controls-58/NNS||matched-59/VBN	prep_on||matched-59/VBN||age-61/NN	prep_on||matched-59/VBN||time-63/NN	conj_and||age-61/NN||time-63/NN	nn||draw-66/NN||blood-65/NN	prep_of||age-61/NN||draw-66/NN	conj_and||examined-8/VBD||enrolled-67/VBD	det||institute-73/NN||the-69/DT	amod||institute-73/NN||roswell-70/JJ	nn||institute-73/NN||park-71/NN	nn||institute-73/NN||cancer-72/NN	prep_in||enrolled-67/VBD||institute-73/NN	num||2008-77/CD||2003-75/CD	dep||2008-77/CD||to-76/TO	prep_from||enrolled-67/VBD||2008-77/CD	cancer-72||progesterone-41||no_rel||in case-control and case-series analyses, we examined serum concentrations of 25-hydroxyvitamind (25ohd) in relation to breast cancer prognostic characteristics, including histologic grade, estrogen receptor (er), and molecular subtypes defined by er, progesterone receptor (pr) and her2, among 579 women with incident breast cancer and 574 controls matched on age and time of blood draw enrolled in the roswell park cancer institute from 2003 to 2008.
nsubjpass||considered-4/VBN||phentermine-1/NN	aux||considered-4/VBN||has-2/VBZ	auxpass||considered-4/VBN||been-3/VBN	root||ROOT-0/null||considered-4/VBN	det||drug-8/NN||a-5/DT	advmod||safe-7/JJ||relatively-6/RB	amod||drug-8/NN||safe-7/JJ	dobj||considered-4/VBN||drug-8/NN	aux||treat-10/VB||to-9/TO	vmod||considered-4/VBN||treat-10/VB	advmod||treat-10/VB||obesity-11/RB	amod||investigation-15/NN||further-14/JJ	nsubjpass||needed-17/VBN||investigation-15/NN	nsubj||decide-19/VB||investigation-15/NN	auxpass||needed-17/VBN||is-16/VBZ	conj_and||considered-4/VBN||needed-17/VBN	aux||decide-19/VB||to-18/TO	xcomp||needed-17/VBN||decide-19/VB	det||safety-21/NN||the-20/DT	dobj||decide-19/VB||safety-21/NN	dobj||decide-19/VB||dosage-23/NN	conj_and||safety-21/NN||dosage-23/NN	prep_of||safety-21/NN||phentermine-25/NN	obesity-11||phentermine-25||yes||phentermine has been considered a relatively safe drug to treat obesity, and further investigation is needed to decide the safety and dosage of phentermine.
amod||cmr-3/NN||adenosine-1/JJ	nn||cmr-3/NN||stress-2/NN	nsubj||techniques-14/NNS||cmr-3/NN	amod||analyses-11/NNS||qualitative-6/JJ	conj_and||qualitative-6/JJ||semi-quantitative-8/JJ	amod||analyses-11/NNS||semi-quantitative-8/JJ	amod||analyses-11/NNS||normalized-9/JJ	nn||analyses-11/NNS||upslope-10/NN	prep_by||cmr-3/NN||analyses-11/NNS	cop||techniques-14/NNS||are-12/VBP	amod||techniques-14/NNS||reproducible-13/JJ	root||ROOT-0/null||techniques-14/NNS	det||patients-17/NNS||both-16/DT	prep_in||techniques-14/NNS||patients-17/NNS	amod||cad-20/NN||multi-vessel-19/JJ	prep_with||techniques-14/NNS||cad-20/NN	prep_with||techniques-14/NNS||those-22/DT	conj_and||cad-20/NN||those-22/DT	amod||cad-25/NN||known-24/VBN	prep_without||techniques-14/NNS||cad-25/NN	adenosine-1||cad-25||no_rel||adenosine stress cmr, by qualitative and semi-quantitative normalized upslope analyses are reproducible techniques in both patients with multi-vessel cad and those without known cad.
advmod||provided-8/VBN||moreover-1/RB	amod||information-4/NN||little-3/JJ	nsubjpass||provided-8/VBN||information-4/NN	prep_on||information-4/NN||hiv/aids-6/NNS	auxpass||provided-8/VBN||was-7/VBD	root||ROOT-0/null||provided-8/VBN	det||communities-11/NNS||the-10/DT	prep_to||provided-8/VBN||communities-11/NNS	advmod||have-15/VBP||so-12/RB	mark||have-15/VBP||that-13/IN	nsubj||have-15/VBP||we-14/PRP	advcl||provided-8/VBN||have-15/VBP	dobj||have-15/VBP||disadvantage-16/NN	amod||epidemic-20/NN||controlling-18/VBG	amod||epidemic-20/NN||hiv/aids-19/JJ	prep_of||disadvantage-16/NN||epidemic-20/NN	det||region-23/NN||the-22/DT	prep_in||epidemic-20/NN||region-23/NN	aids--1||hiv--1||no||moreover, little information on hiv/aids was provided to the communities so that we have disadvantage of controlling hiv/aids epidemic in the region.
prep_in||fused-14/VBN||acutepromyelocyticleukemia-2/NN	appos||acutepromyelocyticleukemia-2/NN||apl-4/NN	det||protein-12/NN||the-7/DT	amod||protein-12/NN||promyelocyticleukemia-8/JJ	nn||protein-12/NN||pml-10/NN	nsubjpass||fused-14/VBN||protein-12/NN	auxpass||fused-14/VBN||is-13/VBZ	root||ROOT-0/null||fused-14/VBN	det||alpha-19/NN||the-16/DT	amod||alpha-19/NN||retinoicacid-17/JJ	nn||alpha-19/NN||receptor-18/NN	prep_to||fused-14/VBN||alpha-19/NN	appos||alpha-19/NN||rar-21/NN	apl-4||retinoicacid-17||yes||in acutepromyelocyticleukemia (apl), the promyelocyticleukemia (pml) protein is fused to the retinoicacid receptor alpha (rar).
nsubjpass||obtained-16/VBN||data-1/NNS	amod||characteristics-4/NNS||socio-demographic-3/JJ	prep_on||data-1/NNS||characteristics-4/NNS	appos||characteristics-4/NNS||patterns-6/NNS	amod||behavior-11/NN||migration-8/JJ	amod||behavior-11/NN||sexual-10/JJ	prep_of||patterns-6/NNS||behavior-11/NN	nn||status-14/NN||hivinfection-13/NN	prep_of||patterns-6/NNS||status-14/NN	conj_and||behavior-11/NN||status-14/NN	auxpass||obtained-16/VBN||were-15/VBD	root||ROOT-0/null||obtained-16/VBN	det||population-19/NN||a-18/DT	prep_for||obtained-16/VBN||population-19/NN	num||women-22/NNS||11,677-21/CD	prep_of||population-19/NN||women-22/NNS	vmod||women-22/NNS||aged-23/VBN	amod||$-25/$||15â-24/VBD	dobj||aged-23/VBN||$-25/$	num||$-25/$||49-27/CD	prep_of||population-19/NN||men-29/NNS	conj_and||women-22/NNS||men-29/NNS	vmod||men-29/NNS||aged-30/VBN	amod||$-32/$||15â-31/VBD	dobj||aged-30/VBN||$-32/$	num||$-32/$||54-34/CD	amod||members-37/NNS||resident-36/JJ	prep_of||population-19/NN||members-37/NNS	conj_and||women-22/NNS||members-37/NNS	prep_of||members-37/NNS||households-39/NNS	det||area-44/NN||a-41/DT	amod||area-44/NN||demographic-42/JJ	nn||area-44/NN||surveillance-43/NN	prep_within||households-39/NNS||area-44/NN	vmod||area-44/NN||participating-45/VBG	nn||surveillance-48/NN||hiv-47/NN	prep_in||participating-45/VBG||surveillance-48/NN	prep_in||surveillance-48/NN||2003â-50/NNS	num||2003â-50/NNS||$-51/$	num||$-51/$||04-53/CD	hivinfection-13||hiv-47||no||data on socio-demographic characteristics, patterns of migration, sexual behavior and hivinfection status were obtained for a population of 11,677 women aged 15â€“49 and men aged 15â€“54, resident members of households within a demographic surveillance area participating in hiv surveillance in 2003â€“04.
nsubj||analysed-2/VBD||we-1/PRP	nsubj||analysed-2/VBD||we-1/PRP	root||ROOT-0/null||analysed-2/VBD	conj_and||analysed-2/VBD||analysed-2/VBD	dobj||analysed-2/VBD||data-3/NNS	det||prevalence-6/NN||the-5/DT	prep_on||analysed-2/VBD||prevalence-6/NN	nn||infection-9/NN||ocular-8/NN	prep_of||prevalence-6/NN||infection-9/NN	prep_with||analysed-2/VBD||chlamydiatrachomatis-11/NNS	nn||disease-15/NN||activetrachoma-14/NN	prep_of||analysed-2/VBD||disease-15/NN	num||individuals-18/NNS||4,436-17/CD	prep_among||disease-15/NN||individuals-18/NNS	num||communities-21/NNS||two-20/CD	prep_from||individuals-18/NNS||communities-21/NNS	det||gambia-24/NN||the-23/DT	prep_in||communities-21/NNS||gambia-24/NN	amod||africa-27/NN||west-26/JJ	appos||gambia-24/NN||africa-27/NN	num||communities-31/NNS||two-30/CD	prep_from||individuals-18/NNS||communities-31/NNS	conj_and||communities-21/NNS||communities-31/NNS	prep_in||communities-31/NNS||tanzania-33/NN	amod||africa-36/NN||east-35/JJ	appos||tanzania-33/NN||africa-36/NN	activetrachoma-14||chlamydiatrachomatis-11||no||we analysed data on the prevalence of ocular infection with chlamydiatrachomatis and of activetrachoma disease among 4,436 individuals from two communities in the gambia (west africa) and two communities in tanzania (east africa).
prep_in||determined-23/VBN||adulthood-2/NN	nsubjpass||determined-23/VBN||effects-4/NNS	amod||response-8/NN||acoustic-6/JJ	nn||response-8/NN||startle-7/NN	prep_on||effects-4/NNS||response-8/NN	prep_on||effects-4/NNS||habituation-10/NN	conj_and||response-8/NN||habituation-10/NN	amod||ppi-15/NN||prepulse-12/JJ	nn||ppi-15/NN||inhibition-13/NN	prep_on||effects-4/NNS||ppi-15/NN	conj_and||response-8/NN||ppi-15/NN	nn||sensitization-21/NN||foot-19/NN	nn||sensitization-21/NN||shock-20/NN	prep_on||effects-4/NNS||sensitization-21/NN	conj_and||response-8/NN||sensitization-21/NN	auxpass||determined-23/VBN||were-22/VBD	root||ROOT-0/null||determined-23/VBN	ppi-15||shock-20||no_rel||in adulthood, effects on acoustic startle response, habituation, prepulse inhibition (ppi), and foot shock sensitization were determined.
det||study-4/NN||a-1/DT	amod||study-4/NN||detailed-2/JJ	amod||study-4/NN||cross-sectional-3/JJ	nsubjpass||performed-6/VBN||study-4/NN	nsubj||assess-8/VB||study-4/NN	auxpass||performed-6/VBN||was-5/VBD	root||ROOT-0/null||performed-6/VBN	aux||assess-8/VB||to-7/TO	xcomp||performed-6/VBN||assess-8/VB	det||relationship-10/NN||the-9/DT	dobj||assess-8/VB||relationship-10/NN	nn||products-14/NNS||lipid-12/NN	nn||products-14/NNS||oxidation-13/NN	prep_between||relationship-10/NN||products-14/NNS	nn||³-17/NNS||î-16/NN	dobj||assess-8/VB||³-17/NNS	conj_and||relationship-10/NN||³-17/NNS	dobj||assess-8/VB||glutamyltransferase-19/NN	conj_and||relationship-10/NN||glutamyltransferase-19/NN	amod||protein-23/NN||high-sensitivity-21/JJ	amod||protein-23/NN||c-reactive-22/JJ	appos||glutamyltransferase-19/NN||protein-23/NN	appos||protein-23/NN||hs-crp-25/NN	amod||activities-30/NNS||phospholipase-29/JJ	dobj||assess-8/VB||activities-30/NNS	conj_and||relationship-10/NN||activities-30/NNS	prep_with||activities-30/NNS||respect-32/NN	det||status-36/NN||the-34/DT	amod||status-36/NN||metabolic-35/JJ	prep_to||assess-8/VB||status-36/NN	det||cohort-39/NN||a-38/DT	prep_in||status-36/NN||cohort-39/NN	advmod||healthy-42/JJ||otherwise-41/RB	amod||individuals-43/NNS||healthy-42/JJ	prep_of||cohort-39/NN||individuals-43/NNS	cross--1||lipid-12||no_rel||a detailed cross-sectional study was performed to assess the relationship between lipid oxidation products, î³-glutamyltransferase, high-sensitivity c-reactive protein (hs-crp), and phospholipase activities with respect to the metabolic status in a cohort of otherwise healthy individuals.
nsubj||likely-9/JJ||enterovirus-1/NNS	nsubj||induce-11/VB||enterovirus-1/NNS	num||infection-6/NN||71-2/CD	nn||infection-6/NN||ev71-4/NN	dep||enterovirus-1/NNS||infection-6/NN	cop||likely-9/JJ||is-7/VBZ	advmod||likely-9/JJ||more-8/RBR	root||ROOT-0/null||likely-9/JJ	aux||induce-11/VB||to-10/TO	xcomp||likely-9/JJ||induce-11/VB	amod||complications-13/NNS||severe-12/JJ	dobj||induce-11/VB||complications-13/NNS	dobj||induce-11/VB||mortality-15/NN	conj_and||complications-13/NNS||mortality-15/NN	amod||enteroviruses-18/NNS||other-17/JJ	prep_than||induce-11/VB||enteroviruses-18/NNS	enterovirus-1||enteroviruses-18||no||enterovirus 71 (ev71) infection is more likely to induce severe complications and mortality than other enteroviruses.
nsubj||lower-3/VB||exercise-1/NN	aux||lower-3/VB||can-2/MD	root||ROOT-0/null||lower-3/VB	xcomp||lower-3/VB||circulating-4/VBG	nsubj||responsible-12/JJ||levels-5/NNS	prep_of||levels-5/NNS||estrogen-7/NN	det||hormone-11/NN||the-9/DT	amod||hormone-11/NN||female-10/JJ	appos||estrogen-7/NN||hormone-11/NN	xcomp||circulating-4/VBG||responsible-12/JJ	nn||proliferation-15/NN||tumor-14/NN	prep_for||responsible-12/JJ||proliferation-15/NN	det||form-19/NN||the-17/DT	amod||form-19/NN||estrogen-sensitive-18/JJ	prep_in||proliferation-15/NN||form-19/NN	det||disease-22/NN||the-21/DT	prep_of||form-19/NN||disease-22/NN	estrogen-7||tumor-14||no_rel||exercise can lower circulating levels of estrogen, the female hormone responsible for tumor proliferation in the estrogen-sensitive form of the disease.
det||purpose-2/NN||the-1/DT	nsubj||was-7/VBD||purpose-2/NN	nsubj||determine-9/VB||purpose-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||purpose-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||determine-9/VB||to-8/TO	xcomp||was-7/VBD||determine-9/VB	dobj||determine-9/VB||relationship-10/NN	nn||activity-13/NN||disease-12/NN	prep_between||relationship-10/NN||activity-13/NN	amod||markers-16/NNS||systemic-15/JJ	dobj||determine-9/VB||markers-16/NNS	conj_and||relationship-10/NN||markers-16/NNS	nn||degradation-19/NN||cartilage-18/NN	prep_of||markers-16/NNS||degradation-19/NN	amod||telopeptides-24/NNS||urinary-21/JJ	amod||telopeptides-24/NNS||c-terminal-22/JJ	amod||telopeptides-24/NNS||cross-linking-23/JJ	dobj||determine-9/VB||telopeptides-24/NNS	conj_and||relationship-10/NN||telopeptides-24/NNS	nn||collagen-28/NN||type-26/NN	nn||collagen-28/NN||ii-27/NN	prep_of||telopeptides-24/NNS||collagen-28/NN	appos||collagen-28/NN||uctx-ii-30/NNP	nn||degradation-35/NN||bone-34/NN	dobj||determine-9/VB||degradation-35/NN	conj_and||relationship-10/NN||degradation-35/NN	advmod||telopeptides-40/NNS||urinary-37/RB	amod||telopeptides-40/NNS||c-terminal-38/JJ	amod||telopeptides-40/NNS||cross-linking-39/JJ	dobj||determine-9/VB||telopeptides-40/NNS	conj_and||relationship-10/NN||telopeptides-40/NNS	nn||collagen-44/NN||type-42/FW	nn||collagen-44/NN||i-43/FW	prep_of||telopeptides-40/NNS||collagen-44/NN	appos||collagen-44/NN||uctx-i-46/NNP	amod||progression-50/NN||structural-49/JJ	dobj||determine-9/VB||progression-50/NN	conj_and||relationship-10/NN||progression-50/NN	prep_of||progression-50/NN||osteoarthritis-52/NNS	appos||osteoarthritis-52/NNS||oa-54/NN	amod||efficacy-59/NN||potential-57/JJ	amod||efficacy-59/NN||therapeutic-58/JJ	dobj||determine-9/VB||efficacy-59/NN	conj_and||relationship-10/NN||efficacy-59/NN	nn||collagen-63/NN||type-61/NN	nn||collagen-63/NN||ii-62/NN	prep_of||efficacy-59/NN||collagen-63/NN	appos||collagen-63/NN||collii-65/NNP	prep_in||determine-9/VB||combination-68/NN	prep_with||determine-9/VB||glucosamine-70/NN	prep_with||determine-9/VB||chondroitinsulfate-72/NN	conj_and||glucosamine-70/NN||chondroitinsulfate-72/NN	appos||glucosamine-70/NN||gc-74/NN	osteoarthritis-52||chondroitinsulfate-72||yes||the purpose of the present study was to determine relationship between disease activity, systemic markers of cartilage degradation, urinary c-terminal cross-linking telopeptides of type ii collagen (uctx-ii), and bone degradation, urinary c-terminal cross-linking telopeptides of type i collagen (uctx-i), structural progression of osteoarthritis (oa) and potential therapeutic efficacy of type ii collagen (collii) in combination with glucosamine and chondroitinsulfate (gc).
num||patient-2/NN||one-1/CD	nsubj||developed-3/VBD||patient-2/NN	root||ROOT-0/null||developed-3/VBD	nn||reactivation-5/NN||hbv-4/NN	dobj||developed-3/VBD||reactivation-5/NN	amod||withdrawal-8/NN||lamivudine-7/JJ	prep_after||developed-3/VBD||withdrawal-8/NN	num||patients-12/NNS||4-11/CD	nsubj||developed-13/VBD||patients-12/NNS	conj_and||developed-3/VBD||developed-13/VBD	det||mutation-19/NN||the-14/DT	amod||mutation-19/NN||ymdd-15/JJ	dep||ymdd-15/JJ||tyrosine-methionine-aspartate-aspartate-17/JJ	dobj||developed-13/VBD||mutation-19/NN	amod||therapy-22/NN||lamivudine-21/JJ	prep_during||developed-13/VBD||therapy-22/NN	hbv-4||lamivudine-21||yes||one patient developed hbv reactivation after lamivudine withdrawal, and 4 patients developed the ymdd (tyrosine-methionine-aspartate-aspartate) mutation during lamivudine therapy.
det||burkholderiapseudomallei-5/NNS||the-1/DT	amod||burkholderiapseudomallei-5/NNS||soil-dwelling-2/JJ	amod||burkholderiapseudomallei-5/NNS||saprophyte-3/JJ	nn||burkholderiapseudomallei-5/NNS||bacterium-4/NN	nsubj||cause-8/NN||burkholderiapseudomallei-5/NNS	cop||cause-8/NN||is-6/VBZ	det||cause-8/NN||the-7/DT	root||ROOT-0/null||cause-8/NN	prep_of||cause-8/NN||melioidosis-10/NNS	det||disease-14/NN||a-12/DT	amod||disease-14/NN||severe-13/JJ	prep_of||cause-8/NN||disease-14/NN	conj_and||melioidosis-10/NNS||disease-14/NN	prep_of||disease-14/NN||humans-16/NNS	prep_of||disease-14/NN||animals-18/NNS	conj_and||humans-16/NNS||animals-18/NNS	nn||asia-21/NN||southeast-20/NN	prep_in||humans-16/NNS||asia-21/NN	amod||australia-24/NN||northern-23/JJ	prep_of||cause-8/NN||australia-24/NN	conj_and||melioidosis-10/NNS||australia-24/NN	melioidosis-10||burkholderiapseudomallei-5||no||the soil-dwelling saprophyte bacterium burkholderiapseudomallei is the cause of melioidosis, a severe disease of humans and animals in southeast asia and northern australia.
nsubj||observed-2/VBD||we-1/PRP	nsubj||formed-34/VBD||we-1/PRP	nsubj||expressed-41/VBD||we-1/PRP	root||ROOT-0/null||observed-2/VBD	nn||expression-5/NN||differential-3/NN	nn||expression-5/NN||hkmt-4/NN	dobj||observed-2/VBD||expression-5/NN	prep_in||immortal-32/JJ||expression-5/NN	det||model-10/NN||a-7/DT	nn||model-10/NN||lung-8/NN	nn||model-10/NN||cancer-9/NN	prep_in||expression-5/NN||model-10/NN	amod||cells-20/NNS||normal-13/JJ	amod||cells-20/NNS||human-14/JJ	nn||cells-20/NNS||bronchial-15/NN	nn||cells-20/NNS||epithelial-16/NN	appos||cells-20/NNS||nhbe-18/NN	nsubj||immortal-32/JJ||cells-20/NNS	vmod||cells-20/NNS||expressing-21/VBG	dobj||expressing-21/VBG||telomerase-22/NN	amod||antigen-27/NN||sv40-24/JJ	amod||antigen-27/NN||large-25/JJ	nn||antigen-27/NN||t-26/NN	dobj||expressing-21/VBG||antigen-27/NN	conj_and||telomerase-22/NN||antigen-27/NN	dobj||expressing-21/VBG||ras-30/NN	conj_and||telomerase-22/NN||ras-30/NN	cop||immortal-32/JJ||were-31/VBD	rcmod||expression-5/NN||immortal-32/JJ	conj_and||observed-2/VBD||formed-34/VBD	dobj||formed-34/VBD||colonies-35/NNS	amod||agar-38/NN||soft-37/JJ	prep_in||formed-34/VBD||agar-38/NN	conj_and||observed-2/VBD||expressed-41/VBD	amod||hkmts-43/NNS||specific-42/JJ	dobj||expressed-41/VBD||hkmts-43/NNS	amod||residues-50/NNS||h3-45/JJ	amod||residues-50/NNS||lysine-46/JJ	dep||lysine-46/JJ||9-47/CD	dep||lysine-46/JJ||27-49/CD	conj_and||9-47/CD||27-49/CD	prep_for||expressed-41/VBD||residues-50/NNS	amod||residue-57/NN||h3-54/JJ	nn||residue-57/NN||lysine-55/NN	num||residue-57/NN||4-56/CD	prep_for||expressed-41/VBD||residue-57/NN	conj_negcc||residues-50/NNS||residue-57/NN	cancer-9||lysine-55||no_rel||we observed differential hkmt expression in a lung cancer model in which normal human bronchial epithelial (nhbe) cells expressing telomerase, sv40 large t antigen, and ras were immortal, formed colonies in soft agar, and expressed specific hkmts for h3 lysine 9 and 27 residues but not for h3 lysine 4 residue.
nn||priondiseases-4/NNS||human-1/NN	conj_and||human-1/NN||animal-3/NN	nn||priondiseases-4/NNS||animal-3/NN	nsubj||are-5/VBP||priondiseases-4/NNS	ccomp||understand-24/VBP||are-5/VBP	prep||are-5/VBP||under-6/IN	amod||control-8/NN||genetic-7/JJ	pobj||under-6/IN||control-8/NN	prep||are-5/VBP||apart-11/RB	conj_but||under-6/IN||apart-11/RB	dep||under-6/IN||from-12/IN	pobj||from-12/IN||prnp-13/NN	det||gene-16/NN||the-15/DT	dep||prnp-13/NN||gene-16/NN	nsubj||encodes-18/VBZ||gene-16/NN	rcmod||gene-16/NN||encodes-18/VBZ	det||prionprotein-20/NN||the-19/DT	dobj||encodes-18/VBZ||prionprotein-20/NN	nsubj||understand-24/VBP||we-23/PRP	root||ROOT-0/null||understand-24/VBP	advmod||human-27/JJ||little-25/RB	advmod||human-27/JJ||about-26/RB	dobj||understand-24/VBP||human-27/JJ	amod||bovine-30/JJ||susceptibility-28/JJ	dep||bovine-30/JJ||to-29/TO	amod||prions-36/NNS||bovine-30/JJ	nn||prions-36/NNS||spongiform-31/NN	nn||prions-36/NNS||encephalopathy-32/NN	discourse||prions-36/NNS||bse-34/UH	dep||human-27/JJ||prions-36/NNS	det||agent-40/NN||the-38/DT	amod||agent-40/NN||causal-39/JJ	appos||human-27/JJ||agent-40/NN	nn||disease-47/NN||variant-42/NN	amod||disease-47/NN||creutzfeldtâ-43/JJ	amod||disease-47/NN||$-44/JJ	nn||disease-47/NN||jakob-46/NN	prep_of||agent-40/NN||disease-47/NN	dep||human-27/JJ||vcjd-49/VBN	priondiseases-4||prions-36||no||human and animal priondiseases are under genetic control, but apart from prnp (the gene that encodes the prionprotein), we understand little about human susceptibility to bovine spongiform encephalopathy (bse) prions, the causal agent of variant creutzfeldtâ€“jakob disease (vcjd).
nsubj||drug-5/NN||dronedarone-1/NN	cop||drug-5/NN||is-2/VBZ	det||drug-5/NN||a-3/DT	amod||drug-5/NN||unique-4/JJ	root||ROOT-0/null||drug-5/NN	nsubj||serve-8/VB||drug-5/NN	aux||serve-8/VB||may-7/MD	rcmod||drug-5/NN||serve-8/VB	det||role-11/NN||a-9/DT	amod||role-11/NN||key-10/JJ	dobj||serve-8/VB||role-11/NN	aux||treat-13/VB||to-12/TO	vmod||serve-8/VB||treat-13/VB	dobj||treat-13/VB||patients-14/NNS	prep_with||treat-13/VB||atrialfibrillation-16/NN	dronedarone-1||atrialfibrillation-16||no_rel||dronedarone is a unique drug that may serve a key role to treat patients with atrialfibrillation.
det||significance-2/NN||the-1/DT	nsubj||deserves-15/VBZ||significance-2/NN	prepc_of||significance-2/NN||circulating-4/VBG	amod||dsrna-8/NN||rotavirusantigen-5/JJ	conj_and||rotavirusantigen-5/JJ||genomic-7/JJ	amod||dsrna-8/NN||genomic-7/JJ	dobj||circulating-4/VBG||dsrna-8/NN	prep_in||circulating-4/VBG||serum-10/NN	prep_of||serum-10/NN||patients-12/NNS	prep_with||patients-12/NNS||diarrhea-14/NN	root||ROOT-0/null||deserves-15/VBZ	amod||study-17/NN||further-16/JJ	dobj||deserves-15/VBZ||study-17/NN	rotavirusantigen-5||diarrhea-14||no_rel||the significance of circulating rotavirusantigen and genomic dsrna in serum of patients with diarrhea deserves further study.
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	amod||decreases-4/NNS||significant-3/JJ	nsubj||were-2/VBD||decreases-4/NNS	prep_in||decreases-4/NNS||survival-6/NN	nn||output-9/NN||urine-8/NN	prep_in||decreases-4/NNS||output-9/NN	conj_and||survival-6/NN||output-9/NN	amod||output-12/NN||cardiac-11/JJ	prep_in||decreases-4/NNS||output-12/NN	conj_and||survival-6/NN||output-12/NN	nn||delivery-15/NN||oxygen-14/NN	conj_and||survival-6/NN||delivery-15/NN	conj_and||output-12/NN||delivery-15/NN	amod||min-18/NN||60â-17/JJ	prep_at||output-12/NN||min-18/NN	amod||consumption-21/NN||o2-20/JJ	prep_in||decreases-4/NNS||consumption-21/NN	conj_and||survival-6/NN||consumption-21/NN	amod||min-24/NN||120â-23/JJ	prep_at||consumption-21/NN||min-24/NN	det||group-28/NN||the-26/DT	nn||group-28/NN||pneumonia-27/NN	prep_in||min-24/NN||group-28/NN	prepc_compared_to||group-28/NN||to-30/TO	det||group-35/NN||the-31/DT	amod||group-35/NN||nonâ-32/JJ	amod||group-35/NN||$-33/$	number||$-33/$||pneumonia-34/CD	pobj||group-28/NN||group-35/NN	pneumonia-34||oxygen-14||yes||there were significant decreases in survival, urine output, cardiac output and oxygen delivery at 60â min and o2 consumption at 120â min in the pneumonia group compared to the nonâ€?pneumonia group.
amod||nanotube-4/NN||single-1/JJ	nn||nanotube-4/NN||wall-2/NN	nn||nanotube-4/NN||carbon-3/NN	nn||constructs-8/NNS||nanotube-4/NN	appos||constructs-8/NNS||swcnt-6/NN	nsubjpass||appended-11/VBN||constructs-8/NNS	auxpass||appended-11/VBN||were-9/VBD	advmod||appended-11/VBN||covalently-10/RB	root||ROOT-0/null||appended-11/VBN	amod||chelates-14/NNS||radiometal-ion-13/JJ	prep_with||appended-11/VBN||chelates-14/NNS	amod||,4,7,10-17/CD||1,4,7,10-tetraazacyclododecane-1-16/JJ	dep||chelates-14/NNS||,4,7,10-17/CD	amod||-RSB--23/NNP||tetraacetic-19/JJ	amod||-RSB--23/NNP||acid-20/JJ	nn||-RSB--23/NNP||-LSB--21/NNP	nn||-RSB--23/NNP||dota-22/NNP	dep||,4,7,10-17/CD||-RSB--23/NNP	amod||-RSB--29/NNS||desferrioxamine-25/JJ	amod||-RSB--29/NNS||b-26/JJ	amod||-RSB--29/NNS||-LSB--27/JJ	nn||-RSB--29/NNS||dfo-28/NN	dep||,4,7,10-17/CD||-RSB--29/NNS	conj_or||-RSB--23/NNP||-RSB--29/NNS	det||tumor-33/NN||the-32/DT	prep_with||appended-11/VBN||tumor-33/NN	conj_and||chelates-14/NNS||tumor-33/NN	amod||e4g10-36/NNS||neovascular-targeting-34/JJ	nn||e4g10-36/NNS||antibody-35/NN	dep||tumor-33/NN||e4g10-36/NNS	ion--1||tumor-33||no_rel||single wall carbon nanotube (swcnt) constructs were covalently appended with radiometal-ion chelates (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [dota] or desferrioxamine b [dfo]) and the tumor neovascular-targeting antibody e4g10.
prep||led-9/VBD||beginning-1/VBG	pcomp||beginning-1/VBG||in-2/IN	pobj||in-2/IN||1955-3/CD	det||creation-6/NN||the-5/DT	nsubj||led-9/VBD||creation-6/NN	prep_of||creation-6/NN||poliovirusvaccines-8/NNS	root||ROOT-0/null||led-9/VBD	det||reduction-13/NN||a-11/DT	amod||reduction-13/NN||stepwise-12/JJ	prep_to||led-9/VBD||reduction-13/NN	prep_in||led-9/VBD||poliomyelitis-15/NNP	xcomp||led-9/VBD||culminating-17/VBG	det||elimination-21/NN||the-19/DT	amod||elimination-21/NN||unpredicted-20/JJ	prep_in||culminating-17/VBG||elimination-21/NN	amod||polioviruses-24/NNS||wild-23/JJ	prep_of||elimination-21/NN||polioviruses-24/NNS	det||states-28/NNS||the-26/DT	amod||states-28/NNS||united-27/VBN	prep_in||culminating-17/VBG||states-28/NNS	prep_by||states-28/NNS||1972-30/CD	poliomyelitis-15||poliovirusvaccines-8||yes||beginning in 1955, the creation of poliovirusvaccines led to a stepwise reduction in poliomyelitis, culminating in the unpredicted elimination of wild polioviruses in the united states by 1972.
amod||yields-12/NNS||interferon-1/JJ	amod||therapy-4/NN||ribavirin-3/JJ	conj_and||interferon-1/JJ||therapy-4/NN	amod||yields-12/NNS||therapy-4/NN	amod||virus-7/NN||chronichepatitisc-6/JJ	prep_for||therapy-4/NN||virus-7/NN	discourse||virus-7/NN||hcv-9/UH	nn||yields-12/NNS||infection-11/NN	nsubj||sustained-13/VBD||yields-12/NNS	root||ROOT-0/null||sustained-13/VBD	amod||rates-19/NNS||virological-14/JJ	nn||rates-19/NNS||response-15/NN	discourse||rates-19/NNS||svr-17/UH	dobj||sustained-13/VBD||rates-19/NNS	prep_of||rates-19/NNS||50â-21/NNS	dep||%-25/NN||$-22/$	num||$-22/$||80-24/CD	amod||50â-21/NNS||%-25/NN	chronichepatitisc-6||ribavirin-3||yes||interferon and ribavirin therapy for chronichepatitisc virus (hcv) infection yields sustained virological response (svr) rates of 50â€“80%.
nsubj||medication-6/NN||ranolazine-1/NN	nsubjpass||considered-16/VBN||ranolazine-1/NN	cop||medication-6/NN||is-2/VBZ	det||medication-6/NN||a-3/DT	amod||medication-6/NN||proven-4/JJ	amod||medication-6/NN||antianginal-5/JJ	root||ROOT-0/null||medication-6/NN	prep_in||medication-6/NN||patients-8/NNS	amod||coronaryheartdisease-11/NN||symptomatic-10/JJ	prep_with||patients-8/NNS||coronaryheartdisease-11/NN	aux||considered-16/VBN||should-14/MD	auxpass||considered-16/VBN||be-15/VB	conj_and||medication-6/NN||considered-16/VBN	det||agent-21/NN||an-18/DT	amod||agent-21/NN||initial-19/JJ	amod||agent-21/NN||antianginal-20/JJ	prep_as||considered-16/VBN||agent-21/NN	prep_for||agent-21/NN||those-23/DT	prep_with||those-23/DT||hypotension-25/NN	prep_with||those-23/DT||bradycardia-27/NN	conj_or||hypotension-25/NN||bradycardia-27/NN	coronaryheartdisease-11||ranolazine-1||no_rel||ranolazine is a proven antianginal medication in patients with symptomatic coronaryheartdisease, and should be considered as an initial antianginal agent for those with hypotension or bradycardia.
num||percent-2/NN||seventeen-1/CD	nsubj||resistant-8/JJ||percent-2/NN	det||cultures-6/NNS||all-4/DT	amod||cultures-6/NNS||positive-5/JJ	prep_of||percent-2/NN||cultures-6/NNS	cop||resistant-8/JJ||were-7/VBD	root||ROOT-0/null||resistant-8/JJ	preconj||isoniazid-11/NN||both-10/DT	prep_to||resistant-8/JJ||isoniazid-11/NN	prep_to||resistant-8/JJ||rifampin-13/NN	conj_and||isoniazid-11/NN||rifampin-13/NN	dep||resistant-18/NN||i.e.-15/FW	dep||resistant-18/NN||multidrug-17/JJ	dep||isoniazid-11/NN||resistant-18/NN	num||%-22/NN||16-21/CD	nsubjpass||infected-39/VBN||%-22/NN	prep_of||%-22/NN||patients-24/NNS	vmod||patients-24/NNS||dying-25/VBG	det||phase-29/NN||the-27/DT	nn||phase-29/NN||initiation-28/NN	prep_during||dying-25/VBG||phase-29/NN	poss||course-34/NN||their-31/PRP$	amod||course-34/NN||first-32/JJ	advmod||first-32/JJ||ever-33/RB	prep_of||phase-29/NN||course-34/NN	nn||treatment-37/NN||tuberculosis-36/NNP	prep_of||course-34/NN||treatment-37/NN	auxpass||infected-39/VBN||were-38/VBD	parataxis||resistant-8/JJ||infected-39/VBN	amod||bacilli-42/NNS||multidrug-resistant-41/JJ	prep_with||infected-39/VBN||bacilli-42/NNS	tuberculosis-36||rifampin-13||yes||seventeen percent of all positive cultures were resistant to both isoniazid and rifampin (i.e., multidrug resistant); 16% of patients dying during the initiation phase of their first ever course of tuberculosis treatment were infected with multidrug-resistant bacilli.
prep_such_as||is-5/VBZ||such-2/JJ	expl||is-5/VBZ||there-4/EX	root||ROOT-0/null||is-5/VBZ	det||need-7/NN||a-6/DT	nsubj||is-5/VBZ||need-7/NN	aux||prioritize-9/VB||to-8/TO	vmod||need-7/NN||prioritize-9/VB	amod||programmes-11/NNS||hiv/aids-10/JJ	dobj||prioritize-9/VB||programmes-11/NNS	aids--1||hiv--1||no||as such, there is a need to prioritize hiv/aids programmes.
vmod||apoptosis-22/VBZ||switching-1/VBG	nn||females-3/NNS||hfd-2/NN	dobj||switching-1/VBG||females-3/NNS	det||diet-7/NN||a-5/DT	nn||diet-7/NN||ctr-6/NN	prep_to||switching-1/VBG||diet-7/NN	det||pregnancy-11/NN||a-9/DT	amod||pregnancy-11/NN||subsequent-10/JJ	prep_during||switching-1/VBG||pregnancy-11/NN	vmod||pregnancy-11/NN||normalized-12/VBN	amod||dha-14/NN||fetal-13/JJ	dobj||normalized-12/VBN||dha-14/NN	amod||fa-17/NN||n-3-16/JJ	nsubj||apoptosis-22/VBZ||fa-17/NN	nsubj||ctr-24/VB||fa-17/NN	possessive||fa-17/NN||'s-18/POS	amod||hepatic-21/NN||fetal-20/JJ	conj_and||fa-17/NN||hepatic-21/NN	nsubj||apoptosis-22/VBZ||hepatic-21/NN	nsubj||ctr-24/VB||hepatic-21/NN	root||ROOT-0/null||apoptosis-22/VBZ	aux||ctr-24/VB||to-23/TO	xcomp||apoptosis-22/VBZ||ctr-24/VB	dobj||ctr-24/VB||levels-25/NNS	dha-14||fa-17||no_rel||switching hfd females to a ctr diet during a subsequent pregnancy normalized fetal dha, n-3 fa's and fetal hepatic apoptosis to ctr levels.
det||association-3/NN||a-1/DT	amod||association-3/NN||significant-2/JJ	nsubjpass||observed-5/VBN||association-3/NN	auxpass||observed-5/VBN||was-4/VBD	root||ROOT-0/null||observed-5/VBN	det||sle-10/NN||the-7/DT	amod||sle-10/NN||lupus-8/JJ	nn||sle-10/NN||cohort-9/NN	prep_in||observed-5/VBN||sle-10/NN	amod||health-13/NN||gullah-12/JJ	prep_in||sle-10/NN||health-13/NN	appos||health-13/NN||sleigh-15/NN	det||allele-22/NN||the-18/DT	amod||allele-22/NN||ga26-19/JJ	nn||allele-22/NN||base-20/NN	nn||allele-22/NN||pair-21/NN	prep_between||health-13/NN||allele-22/NN	prep_in||sle-10/NN||absence-24/NN	conj_and||health-13/NN||absence-24/NN	prep_of||absence-24/NN||nephritis-26/NNS	base-20||nephritis-26||no_rel||a significant association was observed in the lupus cohort sle in gullah health (sleigh) between the ga26 base pair allele and absence of nephritis.
nsubj||demonstrated-3/VBN||experiments-1/NNS	aux||demonstrated-3/VBN||have-2/VBP	root||ROOT-0/null||demonstrated-3/VBN	mark||plays-6/VBZ||that-4/IN	nsubj||plays-6/VBZ||no-5/RB	nsubj||mediates-16/VBZ||no-5/RB	nsubj||proteoglycans-37/VBZ||no-5/RB	nsubj||helps-40/VBZ||no-5/RB	nsubj||mediate-42/VB||no-5/RB	ccomp||demonstrated-3/VBN||plays-6/VBZ	det||role-9/NN||a-7/DT	amod||role-9/NN||catabolic-8/JJ	dobj||plays-6/VBZ||role-9/NN	det||development-12/NN||the-11/DT	prep_in||plays-6/VBZ||development-12/NN	prep_of||development-12/NN||oa-14/NN	ccomp||demonstrated-3/VBN||mediates-16/VBZ	conj_and||plays-6/VBZ||mediates-16/VBZ	det||response-19/NN||the-17/DT	amod||response-19/NN||inflammatory-18/JJ	dobj||mediates-16/VBZ||response-19/NN	auxpass||involved-22/VBN||is-21/VBZ	dep||plays-6/VBZ||involved-22/VBN	det||degradation-25/NN||the-24/DT	prep_in||involved-22/VBN||degradation-25/NN	nn||metalloproteinases-28/NNS||matrix-27/NN	prep_of||degradation-25/NN||metalloproteinases-28/NNS	dep||plays-6/VBZ||inhibits-30/VBZ	det||synthesis-32/NN||the-31/DT	dobj||inhibits-30/VBZ||synthesis-32/NN	det||collagen-35/NN||both-34/DT	prep_of||synthesis-32/NN||collagen-35/NN	ccomp||demonstrated-3/VBN||proteoglycans-37/VBZ	conj_and||plays-6/VBZ||proteoglycans-37/VBZ	ccomp||demonstrated-3/VBN||helps-40/VBZ	conj_and||plays-6/VBZ||helps-40/VBZ	aux||mediate-42/VB||to-41/TO	xcomp||helps-40/VBZ||mediate-42/VB	dobj||mediate-42/VB||apoptosis-43/NNS	oa-14||collagen-35||no_rel||experiments have demonstrated that no plays a catabolic role in the development of oa and mediates the inflammatory response, is involved in the degradation of matrix metalloproteinases, inhibits the synthesis of both collagen and proteoglycans, and helps to mediate apoptosis.
advmod||show-3/VBP||here-1/RB	nsubj||show-3/VBP||we-2/PRP	nsubj||ecsod-12/VBD||we-2/PRP	nsubj||increases-21/VBZ||we-2/PRP	nsubj||promotes-31/VBZ||we-2/PRP	root||ROOT-0/null||show-3/VBP	det||transfer-6/NN||that-4/DT	nn||transfer-6/NN||gene-5/NN	dobj||show-3/VBP||transfer-6/NN	prep_of||transfer-6/NN||ecsod-8/NN	conj_negcc||show-3/VBP||ecsod-12/VBD	xcomp||ecsod-12/VBD||lacking-13/VBG	dobj||lacking-13/VBG||hbd-14/NN	dep||hbd-14/NN||ecsod-î-16/VBG	dobj||ecsod-î-16/VBG||hbd-18/NN	conj_negcc||show-3/VBP||increases-21/VBZ	amod||levels-23/NNS||h2o2-22/JJ	dobj||increases-21/VBZ||levels-23/NNS	nn||muscle-26/NN||adductor-25/NN	prep_in||increases-21/VBZ||muscle-26/NN	prep_of||muscle-26/NN||mice-28/NNS	conj_and||show-3/VBP||promotes-31/VBZ	dobj||promotes-31/VBZ||angiogenesis-32/NNS	amod||ischemia-35/NN||hindlimb-34/JJ	prep_after||promotes-31/VBZ||ischemia-35/NN	h2o2-22||ischemia-35||no_rel||here we show that gene transfer of ecsod, but not ecsod lacking hbd (ecsod-î”hbd), increases h2o2 levels in adductor muscle of mice, and promotes angiogenesis after hindlimb ischemia.
nsubj||bioequivalent-3/JJ||fosaprepitant-1/NN	nsubj||aprepitant-5/VB||fosaprepitant-1/NN	nsubj||offer-9/VB||fosaprepitant-1/NN	cop||bioequivalent-3/JJ||is-2/VBZ	root||ROOT-0/null||bioequivalent-3/JJ	aux||aprepitant-5/VB||to-4/TO	xcomp||bioequivalent-3/JJ||aprepitant-5/VB	aux||offer-9/VB||could-8/MD	conj_and||bioequivalent-3/JJ||offer-9/VB	amod||benefits-11/NNS||potential-10/JJ	dobj||offer-9/VB||benefits-11/NNS	prep_for||offer-9/VB||patients-13/NNS	nsubj||unable-17/JJ||patients-13/NNS	nsubj||tolerate-19/VB||patients-13/NNS	aux||unable-17/JJ||may-15/MD	cop||unable-17/JJ||be-16/VB	rcmod||patients-13/NNS||unable-17/JJ	aux||tolerate-19/VB||to-18/TO	xcomp||unable-17/JJ||tolerate-19/VB	amod||administration-21/NN||oral-20/JJ	dobj||tolerate-19/VB||administration-21/NN	prep_of||administration-21/NN||antiemetics-23/NNS	det||episode-26/NN||an-25/DT	prep_during||tolerate-19/VB||episode-26/NN	prep_of||episode-26/NN||nausea-28/NN	prep_of||episode-26/NN||vomiting-30/NN	conj_or||nausea-28/NN||vomiting-30/NN	aprepitant-5||vomiting-30||no_rel||fosaprepitant is bioequivalent to aprepitant, and could offer potential benefits for patients who may be unable to tolerate oral administration of antiemetics during an episode of nausea or vomiting.
det||association-2/NN||the-1/DT	nsubj||suggests-18/VBZ||association-2/NN	amod||chronicity-6/NN||greater-4/JJR	nn||chronicity-6/NN||smoking-5/NN	prep_of||association-2/NN||chronicity-6/NN	amod||performance-9/NN||poorer-8/JJR	prep_of||association-2/NN||performance-9/NN	conj_and||chronicity-6/NN||performance-9/NN	amod||measures-12/NNS||multiple-11/JJ	prep_on||performance-9/NN||measures-12/NNS	prep_after||measures-12/NNS||control-14/NN	nn||consumption-17/NN||alcohol-16/NN	prep_for||control-14/NN||consumption-17/NN	root||ROOT-0/null||suggests-18/VBZ	mark||adds-22/VBZ||that-19/IN	amod||smoking-21/NN||chronic-20/JJ	nsubj||adds-22/VBZ||smoking-21/NN	ccomp||suggests-18/VBZ||adds-22/VBZ	det||burden-25/NN||an-23/DT	amod||burden-25/NN||additional-24/JJ	dobj||adds-22/VBZ||burden-25/NN	aux||neurocognitive-27/VB||to-26/TO	vmod||burden-25/NN||neurocognitive-27/VB	dobj||neurocognitive-27/VB||function-28/NN	prep_in||neurocognitive-27/VB||those-30/DT	prep_with||those-30/DT||alcoholdependence-32/NN	alcoholdependence-32||alcohol-16||no||the association of greater smoking chronicity and poorer performance on multiple measures after control for alcohol consumption suggests that chronic smoking adds an additional burden to neurocognitive function in those with alcoholdependence.
det||structures-3/NNS||the-1/DT	amod||structures-3/NNS||three-dimensional-2/JJ	nsubj||determined-8/VBD||structures-3/NNS	amod||gpgs-6/NNS||m.tuberculosis-5/JJ	prep_of||structures-3/NNS||gpgs-6/NNS	advmod||determined-8/VBD||now-7/RB	root||ROOT-0/null||determined-8/VBD	xcomp||determined-8/VBD||provide-9/VB	amod||data-11/NNS||such-10/JJ	dobj||provide-9/VB||data-11/NNS	det||family-16/NN||a-13/DT	amod||enzyme-15/JJ||novel-14/JJ	amod||family-16/NN||enzyme-15/JJ	prep_for||provide-9/VB||family-16/NN	nsubj||lay-44/VBD||family-16/NN	advmod||establishing-19/VBG||clearly-18/RB	vmod||family-16/NN||establishing-19/VBG	det||determinants-22/NNS||the-20/DT	amod||determinants-22/NNS||molecular-21/JJ	dobj||establishing-19/VBG||determinants-22/NNS	amod||recognition-25/NN||substrate-24/JJ	prep_for||establishing-19/VBG||recognition-25/NN	prep_for||establishing-19/VBG||catalysis-27/NNS	conj_and||recognition-25/NN||catalysis-27/NNS	mark||providing-30/VBG||while-29/IN	advcl||establishing-19/VBG||providing-30/VBG	det||scaffold-33/NN||an-31/DT	amod||scaffold-33/NN||experimental-32/JJ	dobj||providing-30/VBG||scaffold-33/NN	det||design-38/NN||the-35/DT	amod||design-38/NN||structure-based-36/JJ	amod||design-38/NN||rational-37/JJ	prep_for||providing-30/VBG||design-38/NN	amod||inhibitors-41/NNS||specific-40/JJ	prep_of||design-38/NN||inhibitors-41/NNS	rcmod||family-16/NN||lay-44/VBD	det||foundation-46/NN||the-45/DT	dobj||lay-44/VBD||foundation-46/NN	det||development-49/NN||the-48/DT	prep_for||lay-44/VBD||development-49/NN	amod||therapies-53/NNS||novel-51/JJ	amod||therapies-53/NNS||anti-tuberculosis-52/JJ	prep_of||development-49/NN||therapies-53/NNS	enzyme-15||tuberculosis--1||no_rel||the three-dimensional structures of m.tuberculosis gpgs now determined provide such data for a novel enzyme family , clearly establishing the molecular determinants for substrate recognition and catalysis , while providing an experimental scaffold for the structure-based rational design of specific inhibitors , which lay the foundation for the development of novel anti-tuberculosis therapies .
amod||studies-2/NNS||further-1/JJ	nsubjpass||required-4/VBN||studies-2/NNS	nsubj||define-6/VB||studies-2/NNS	auxpass||required-4/VBN||are-3/VBP	root||ROOT-0/null||required-4/VBN	aux||define-6/VB||to-5/TO	xcomp||required-4/VBN||define-6/VB	amod||strategies-8/NNS||setting-specific-7/JJ	dobj||define-6/VB||strategies-8/NNS	aux||reduce-10/VB||to-9/TO	dep||define-6/VB||reduce-10/VB	dobj||reduce-10/VB||mortality-11/NN	amod||bacteraemia-14/NN||s.aureus-13/JJ	prep_from||reduce-10/VB||bacteraemia-14/NN	dep||reduce-10/VB||prevent-16/VB	nn||transmission-18/NN||mrsa-17/NN	dobj||prevent-16/VB||transmission-18/NN	aux||define-22/VB||to-21/TO	dep||define-6/VB||define-22/VB	conj_and||reduce-10/VB||define-22/VB	det||burden-24/NN||the-23/DT	dobj||define-22/VB||burden-24/NN	nn||disease-27/NN||s.aureus-26/NNS	prep_of||burden-24/NN||disease-27/NN	prep_of||burden-24/NN||emergence-29/NN	conj_and||disease-27/NN||emergence-29/NN	nn||resistance-32/NN||drug-31/NN	prep_of||disease-27/NN||resistance-32/NN	det||world-36/NN||the-34/DT	amod||world-36/NN||developing-35/VBG	prep_throughout||define-22/VB||world-36/NN	mrsa-17||s.aureus-26||no||further studies are required to define setting-specific strategies to reduce mortality from s.aureus bacteraemia , prevent mrsa transmission , and to define the burden of s.aureus disease and emergence of drug resistance throughout the developing world .
advmod||absent-19/JJ||however-1/RB	det||effects-6/NNS||the-3/DT	amod||effects-6/NNS||expected-4/JJ	amod||effects-6/NNS||beneficial-5/JJ	nsubj||absent-19/JJ||effects-6/NNS	amod||fgf21-9/NNS||endogenous-8/JJ	prep_of||effects-6/NNS||fgf21-9/NNS	aux||increase-11/VB||to-10/TO	vmod||effects-6/NNS||increase-11/VB	nn||tolerance-13/NN||glucose-12/NN	dobj||increase-11/VB||tolerance-13/NN	vmod||effects-6/NNS||reduce-15/VB	conj_and||increase-11/VB||reduce-15/VB	xcomp||reduce-15/VB||circulating-16/VBG	dobj||circulating-16/VBG||triglycerides-17/NNPS	cop||absent-19/JJ||are-18/VBP	root||ROOT-0/null||absent-19/JJ	prep_in||absent-19/JJ||obesity-21/NN	obesity-21||glucose-12||no_rel||however, the expected beneficial effects of endogenous fgf21 to increase glucose tolerance and reduce circulating triglycerides are absent in obesity.
det||sites-3/NNS||the-1/DT	amod||sites-3/NNS||functional-2/JJ	nsubjpass||predicted-5/VBN||sites-3/NNS	auxpass||predicted-5/VBN||were-4/VBD	root||ROOT-0/null||predicted-5/VBN	nn||enzymes-8/NNS||nudix-7/NN	prep_for||predicted-5/VBN||enzymes-8/NNS	amod||microorganisms-11/NNS||pathogenic-10/JJ	prep_from||predicted-5/VBN||microorganisms-11/NNS	amod||pneumonia-15/NN||streprococcus-14/JJ	prep_such_as||microorganisms-11/NNS||pneumonia-15/NN	appos||pneumonia-15/NN||2b06-17/NNP	amod||faecalis-21/NNS||enterococcus-20/JJ	prep_such_as||microorganisms-11/NNS||faecalis-21/NNS	conj_and||pneumonia-15/NN||faecalis-21/NNS	appos||pneumonia-15/NN||2azw-23/NNP	pneumonia-15||enzymes-8||no_rel||the functional sites were predicted for nudix enzymes from pathogenic microorganisms such as streprococcus pneumonia (2b06) and enterococcus faecalis (2azw).
amod||analyses-2/NNS||secondary-1/JJ	nsubj||compare-4/VB||analyses-2/NNS	aux||compare-4/VB||will-3/MD	ccomp||hiv-15/VBP||compare-4/VB	det||rates-6/NNS||the-5/DT	dobj||compare-4/VB||rates-6/NNS	prep_of||rates-6/NNS||change-8/NN	amod||count-11/NN||cd4-10/JJ	prep_in||compare-4/VB||count-11/NN	amod||log10-14/NNS||median-13/JJ	nsubj||hiv-15/VBP||log10-14/NNS	root||ROOT-0/null||hiv-15/VBP	amod||load-17/NN||viral-16/JJ	dobj||hiv-15/VBP||load-17/NN	amod||events-21/NNS||drug-related-19/JJ	amod||events-21/NNS||adverse-20/JJ	appos||load-17/NN||events-21/NNS	dobj||hiv-15/VBP||frequency-23/NN	conj_and||load-17/NN||frequency-23/NN	nn||reactivations-26/NNS||hsv-25/NN	prep_of||frequency-23/NN||reactivations-26/NNS	dobj||hiv-15/VBP||rate-28/NN	conj_and||load-17/NN||rate-28/NN	amod||hsv-31/NN||acyclovir-resistant-30/JJ	prep_of||rate-28/NN||hsv-31/NN	dobj||hiv-15/VBP||quality-34/NN	conj_and||load-17/NN||quality-34/NN	prep_of||quality-34/NN||life-36/NN	nn||arms-39/NNS||study-38/NN	prep_between||life-36/NN||arms-39/NNS	hsv-31||acyclovir--1||yes||secondary analyses will compare the rates of change in cd4 count, median log10 hiv viral load, drug-related adverse events, frequency of hsv reactivations, rate of acyclovir-resistant hsv, and quality of life between study arms.
nsubj||common-10/JJ||co-infection-1/NN	amod||hcv-5/NN||hepatitisc-3/JJ	prep_with||co-infection-1/NN||hcv-5/NN	prep_with||co-infection-1/NN||hiv-8/NN	conj_and||hcv-5/NN||hiv-8/NN	cop||common-10/JJ||is-9/VBZ	root||ROOT-0/null||common-10/JJ	nsubj||accelerates-13/VBZ||hiv-12/NN	conj_and||common-10/JJ||accelerates-13/VBZ	amod||progression-16/NN||hepatic-14/JJ	nn||progression-16/NN||disease-15/NN	nsubj||due-17/JJ||progression-16/NN	xcomp||accelerates-13/VBZ||due-17/JJ	prep_to||due-17/JJ||hcv-19/NN	hepatitisc-3||hcv-19||no||co-infection with hepatitisc (hcv) and hiv is common and hiv accelerates hepatic disease progression due to hcv.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||propofol-18||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
prep||remains-33/VBZ||given-1/VBN	det||efficacy-3/NN||the-2/DT	pobj||given-1/VBN||efficacy-3/NN	pobj||given-1/VBN||safety-5/NN	conj_and||efficacy-3/NN||safety-5/NN	amod||issues-9/NNS||tolerability-8/JJ	pobj||given-1/VBN||issues-9/NNS	conj_and||efficacy-3/NN||issues-9/NNS	vmod||issues-9/NNS||associated-10/VBN	prep_with||associated-10/VBN||nsaids-12/NNS	nsubj||remains-33/VBZ||development-14/NN	amod||agents-17/NNS||new-16/JJ	prep_of||development-14/NN||agents-17/NNS	aux||manage-19/VB||to-18/TO	vmod||development-14/NN||manage-19/VB	det||pain-21/NN||the-20/DT	dobj||manage-19/VB||pain-21/NN	vmod||pain-21/NN||associated-22/VBN	vmod||pain-21/NN||associated-22/VBN	conj_but||associated-22/VBN||associated-22/VBN	prep_with||associated-22/VBN||arthritis-24/NN	det||cardiovascular-28/JJ||the-27/DT	prep_without||associated-22/VBN||cardiovascular-28/JJ	amod||events-32/NNS||gastrointestinal-30/JJ	amod||events-32/NNS||adverse-31/JJ	prep_without||associated-22/VBN||events-32/NNS	conj_and||cardiovascular-28/JJ||events-32/NNS	root||ROOT-0/null||remains-33/VBZ	det||priority-35/NN||a-34/DT	xcomp||remains-33/VBZ||priority-35/NN	pain-21||nsaids-12||no_rel||given the efficacy, safety, and tolerability issues associated with nsaids, development of new agents to manage the pain associated with arthritis but without the cardiovascular and gastrointestinal adverse events remains a priority.
amod||pruritus-2/NNS||chloroquine-induced-1/JJ	nsubj||remains-3/VBZ||pruritus-2/NNS	root||ROOT-0/null||remains-3/VBZ	xcomp||remains-3/VBZ||one-4/CD	det||side-effects-9/NNS||the-6/DT	advmod||side-effects-9/NNS||most-7/RBS	amod||side-effects-9/NNS||common-8/JJ	prep_of||one-4/CD||side-effects-9/NNS	det||use-12/NN||the-11/DT	prep_in||side-effects-9/NNS||use-12/NN	prep_of||use-12/NN||chloroquine-14/NN	det||prophylaxis-17/NN||the-16/DT	prep_in||chloroquine-14/NN||prophylaxis-17/NN	prep_in||chloroquine-14/NN||treatment-19/NN	conj_and||prophylaxis-17/NN||treatment-19/NN	amod||malaria-22/NN||uncomplicated-21/JJ	prep_of||prophylaxis-17/NN||malaria-22/NN	det||advent-25/NN||the-24/DT	prep_before||remains-3/VBZ||advent-25/NN	amod||therapies-29/NNS||artemisinin-based-27/JJ	nn||therapies-29/NNS||combination-28/NN	prep_of||advent-25/NN||therapies-29/NNS	malaria-22||chloroquine-14||yes||chloroquine-induced pruritus remains one of the most common side-effects in the use of chloroquine in the prophylaxis and treatment of uncomplicated malaria before the advent of artemisinin-based combination therapies.
aux||gain-2/VB||to-1/TO	advcl||undertook-20/VBD||gain-2/VB	dobj||gain-2/VB||insight-3/NN	nn||signatures-7/NNS||gene-5/NN	nn||signatures-7/NNS||expression-6/NN	prep_into||gain-2/VB||signatures-7/NNS	nsubj||distinguish-10/VB||signatures-7/NNS	aux||distinguish-10/VB||can-9/MD	rcmod||signatures-7/NNS||distinguish-10/VB	dobj||distinguish-10/VB||atopicdermatitis-11/NNS	amod||controls-14/NNS||non-atopic-13/JJ	prep_from||distinguish-10/VB||controls-14/NNS	nn||biopsies-17/NNS||skin-16/NN	prep_without||distinguish-10/VB||biopsies-17/NNS	nsubj||undertook-20/VBD||we-19/PRP	root||ROOT-0/null||undertook-20/VBD	det||study-23/NN||a-21/DT	amod||study-23/NN||comparative-22/JJ	dobj||undertook-20/VBD||study-23/NN	nn||expression-26/NN||gene-25/NN	prep_of||study-23/NN||expression-26/NN	prep_in||undertook-20/VBD||fdks-28/NNS	amod||donors-31/NNS||adult-30/JJ	prep_from||fdks-28/NNS||donors-31/NNS	prep_with||undertook-20/VBD||atopicdermatitis-33/NNS	amod||donors-36/NNS||non-atopic-35/JJ	prep_with||undertook-20/VBD||donors-36/NNS	conj_and||atopicdermatitis-33/NNS||donors-36/NNS	atopicdermatitis-33||atopic--1||no||to gain insight into gene expression signatures that can distinguish atopicdermatitis from non-atopic controls without skin biopsies, we undertook a comparative study of gene expression in fdks from adult donors with atopicdermatitis and non-atopic donors.
det||activity-5/NN||the-1/DT	dep||vitro-3/NN||in-2/IN	amod||activity-5/NN||vitro-3/NN	amod||activity-5/NN||anticandidal-4/JJ	nsubj||racemosus-8/VBZ||activity-5/NN	prep_of||activity-5/NN||asparagus-7/NNS	dep||investigated-14/VBN||racemosus-8/VBZ	nsubj||extract-12/VB||roots-9/NNS	conj_and||roots-9/NNS||tubers-11/NNS	nsubj||extract-12/VB||tubers-11/NNS	ccomp||racemosus-8/VBZ||extract-12/VB	auxpass||investigated-14/VBN||was-13/VBD	root||ROOT-0/null||investigated-14/VBN	nn||albicans-17/NNS||candida-16/NN	prep_against||investigated-14/VBN||albicans-17/NNS	nn||tropicalis-20/NNS||candida-19/NN	prep_against||investigated-14/VBN||tropicalis-20/NNS	conj_and||albicans-17/NNS||tropicalis-20/NNS	nn||krusei-23/NNS||candida-22/NN	prep_against||investigated-14/VBN||krusei-23/NNS	conj_and||albicans-17/NNS||krusei-23/NNS	nn||guillermondii-26/NNS||candida-25/NN	prep_against||investigated-14/VBN||guillermondii-26/NNS	conj_and||albicans-17/NNS||guillermondii-26/NNS	nn||parapsilosis-29/NNS||candida-28/NN	prep_against||investigated-14/VBN||parapsilosis-29/NNS	conj_and||albicans-17/NNS||parapsilosis-29/NNS	prep_against||investigated-14/VBN||candida-31/NN	conj_and||albicans-17/NNS||candida-31/NN	nsubjpass||investigated-14/VBN||stellatoida-32/NN	nsubjpass||isolated-36/VBN||stellatoida-32/NN	auxpass||isolated-36/VBN||are-35/VBP	rcmod||stellatoida-32/NN||isolated-36/VBN	amod||patients-39/NNS||vaginalthrush-38/JJ	prep_from||isolated-36/VBN||patients-39/NNS	vaginalthrush-38||candida-31||no||the in vitro anticandidal activity of asparagus racemosus roots and tubers extract was investigated against candida albicans, candida tropicalis, candida krusei, candida guillermondii, candida parapsilosis and candida stellatoida, which are isolated from vaginalthrush patients.
nsubj||±-9/VBZ||mice-1/NNS	det||deletion-5/NN||a-3/DT	amod||deletion-5/NN||whole-body-4/JJ	prep_with||mice-1/NNS||deletion-5/NN	det||î-8/NN||the-7/DT	prep_of||deletion-5/NN||î-8/NN	root||ROOT-0/null||±-9/VBZ	num||subunit-12/NN||2-10/CD	amod||subunit-12/NN||catalytic-11/JJ	dobj||±-9/VBZ||subunit-12/NN	prep_of||subunit-12/NN||ampk-14/NN	dep||±-9/VBZ||ampkî-16/VBG	nn||2âˆ-18/NNP||±-17/NNP	poss||âˆ-21/NNP||2âˆ-18/NNP	nn||âˆ-21/NNP||/-20/NNP	dobj||ampkî-16/VBG||âˆ-21/NNP	poss||littermates-27/NNS||their-25/PRP$	amod||littermates-27/NNS||wild-type-26/JJ	nsubjpass||fed-29/VBN||littermates-27/NNS	auxpass||fed-29/VBN||were-28/VBD	conj_and||±-9/VBZ||fed-29/VBN	advmod||chow-34/NN||either-31/RB	det||chow-34/NN||a-32/DT	amod||chow-34/NN||low-fat-33/JJ	prep_on||fed-29/VBN||chow-34/NN	det||corn-38/NN||a-37/DT	prep_on||fed-29/VBN||corn-38/NN	conj_or||chow-34/NN||corn-38/NN	amod||diet-41/NN||oil-based-39/JJ	amod||diet-41/NN||high-fat-40/JJ	dep||corn-38/NN||diet-41/NN	appos||diet-41/NN||chf-43/NN	det||diet-49/NN||a-47/DT	nn||diet-49/NN||chf-48/NN	prep_on||fed-29/VBN||diet-49/NN	conj_or||chow-34/NN||diet-49/NN	number||%-52/NN||15-51/CD	amod||lipids-53/NNS||%-52/NN	prep_with||diet-49/NN||lipids-53/NNS	vmod||lipids-53/NNS||replaced-54/VBN	amod||concentrate-58/NN||n-3-56/JJ	amod||concentrate-58/NN||lc-pufa-57/JJ	agent||replaced-54/VBN||concentrate-58/NN	nn||f-62/NNP||chf-60/NNP	nn||f-62/NNP||+-61/NNP	appos||concentrate-58/NN||f-62/NNP	chf-60||lipids-53||no_rel||mice with a whole-body deletion of the î±2 catalytic subunit of ampk (ampkî±2âˆ’/âˆ’) and their wild-type littermates were fed on either a low-fat chow, or a corn oil-based high-fat diet (chf), or a chf diet with 15% lipids replaced by n-3 lc-pufa concentrate (chf+f).
nn||mutants-2/NNS||femab-1/NN	nsubj||show-3/VBP||mutants-2/NNS	nsubj||hypersusceptible-10/JJ||mutants-2/NNS	root||ROOT-0/null||show-3/VBP	det||rate-7/NN||a-4/DT	amod||rate-7/NN||reduced-5/JJ	nn||rate-7/NN||growth-6/NN	dobj||show-3/VBP||rate-7/NN	cop||hypersusceptible-10/JJ||are-9/VBP	conj_and||show-3/VBP||hypersusceptible-10/JJ	advmod||antibiotics-14/NNS||virtually-12/RB	det||antibiotics-14/NNS||all-13/DT	nsubj||making-19/VBG||antibiotics-14/NNS	prep_including||making-19/VBG||methicillin-17/NN	prepc_to||hypersusceptible-10/JJ||making-19/VBG	amod||target-23/NN||femab-20/JJ	det||target-23/NN||a-21/DT	amod||target-23/NN||potential-22/JJ	dobj||making-19/VBG||target-23/NN	aux||restore-25/VB||to-24/TO	vmod||making-19/VBG||restore-25/VB	nn||²-27/NNS||î-26/NN	dobj||restore-25/VB||²-27/NNS	nn||susceptibility-30/NN||lactam-29/NN	nsubj||-lrb--34/VBZ||susceptibility-30/NN	amod||s.aureus-33/NNS||methicillin-resistant-32/JJ	prep_in||susceptibility-30/NN||s.aureus-33/NNS	parataxis||show-3/VBP||-lrb--34/VBZ	nn||-rrb--36/NNS||mrsa-35/NN	dobj||-lrb--34/VBZ||-rrb--36/NNS	mrsa-35||s.aureus-33||no||femab mutants show a reduced growth rate and are hypersusceptible to virtually all antibiotics , including methicillin , making femab a potential target to restore î ² - lactam susceptibility in methicillin-resistant s.aureus -lrb- mrsa -rrb- .
det||vaccine-4/NN||the-1/DT	amod||vaccine-4/NN||mtb72f-2/JJ	nn||vaccine-4/NN||subunit-3/NN	nsubjpass||hoped-14/VBN||vaccine-4/NN	nsubj||provide-16/VB||vaccine-4/NN	prep_for||vaccine-4/NN||tuberculosis-6/NNP	advmod||in-9/IN||currently-8/RB	rcmod||vaccine-4/NN||in-9/IN	amod||trials-11/NNS||clinical-10/JJ	pobj||in-9/IN||trials-11/NNS	auxpass||hoped-14/VBN||is-13/VBZ	root||ROOT-0/null||hoped-14/VBN	aux||provide-16/VB||to-15/TO	xcomp||hoped-14/VBN||provide-16/VB	amod||protection-18/NN||improved-17/VBN	dobj||provide-16/VB||protection-18/NN	prepc_compared_to||provide-16/VB||to-20/TO	det||bcgvaccine-23/NN||the-21/DT	amod||bcgvaccine-23/NN||current-22/JJ	pobj||provide-16/VB||bcgvaccine-23/NN	tuberculosis-6||bcgvaccine-23||yes||the mtb72f subunit vaccine for tuberculosis, currently in clinical trials, is hoped to provide improved protection compared to the current bcgvaccine.
amod||combinations-4/NNS||docetaxel-1/JJ	conj_and||docetaxel-1/JJ||gemcitabine-3/JJ	amod||combinations-4/NNS||gemcitabine-3/JJ	nsubj||proven-6/VBN||combinations-4/NNS	aux||proven-6/VBN||have-5/VBP	root||ROOT-0/null||proven-6/VBN	acomp||proven-6/VBN||active-7/JJ	det||treatment-10/NN||the-9/DT	prep_for||proven-6/VBN||treatment-10/NN	prep_of||treatment-10/NN||non-smallcelllungcancer-12/NN	dep||non-smallcelllungcancer-12/NN||nsclc-14/JJ	docetaxel-1||nsclc-14||no_rel||docetaxel and gemcitabine combinations have proven active for the treatment of non-smallcelllungcancer (nsclc).
advmod||demonstrated-12/VBD||recently-1/RB	det||nateglinide-4/NN||the-3/DT	nsubj||demonstrated-12/VBD||nateglinide-4/NN	conj_and||nateglinide-4/NN||valsartan-6/NN	nsubj||demonstrated-12/VBD||valsartan-6/NN	nn||trial-11/NN||impairedglucosetolerance-8/NN	num||trial-11/NN||outcomes-9/CD	nn||trial-11/NN||research-10/NN	prep_in||nateglinide-4/NN||trial-11/NN	root||ROOT-0/null||demonstrated-12/VBD	mark||resulted-27/VBD||that-13/IN	nsubj||resulted-27/VBD||treatment-14/NN	det||blocker-19/NN||the-16/DT	nn||blocker-19/NN||angiotensin-17/NN	nn||blocker-19/NN||receptor-18/NN	prep_with||treatment-14/NN||blocker-19/NN	appos||blocker-19/NN||arb-21/NN	vmod||blocker-19/NN||valsartan-23/VBN	num||years-26/NNS||5-25/CD	prep_for||valsartan-23/VBN||years-26/NNS	ccomp||demonstrated-12/VBD||resulted-27/VBD	det||reduction-31/NN||a-29/DT	amod||reduction-31/NN||relative-30/JJ	prep_in||resulted-27/VBD||reduction-31/NN	num||%-34/NN||14-33/CD	prep_of||reduction-31/NN||%-34/NN	det||incidence-37/NN||the-36/DT	prep_in||resulted-27/VBD||incidence-37/NN	prep_of||incidence-37/NN||type2diabetes-39/CD	prep_in||resulted-27/VBD||subjects-41/NNS	amod||metabolism-45/NN||impaired-43/VBN	nn||metabolism-45/NN||glucose-44/NN	prep_with||subjects-41/NNS||metabolism-45/NN	appos||metabolism-45/NN||igm-47/NN	type2diabetes-39||nateglinide-4||yes||recently, the nateglinide and valsartan in impairedglucosetolerance outcomes research trial demonstrated that treatment with the angiotensin receptor blocker (arb) valsartan for 5 years resulted in a relative reduction of 14% in the incidence of type2diabetes in subjects with impaired glucose metabolism (igm).
vmod||performed-10/VBD||using-1/VBG	det||line-7/NN||the-2/DT	amod||line-7/NN||hl60-3/JJ	nn||line-7/NN||multipotent-4/NN	nn||line-7/NN||promyelocyticleukemia-5/NN	nn||line-7/NN||cell-6/NN	dobj||using-1/VBG||line-7/NN	nsubj||performed-10/VBD||we-9/PRP	root||ROOT-0/null||performed-10/VBD	dobj||performed-10/VBD||experiments-11/NNS	nsubj||led-14/VBN||experiments-11/NNS	advmod||led-14/VBN||ultimately-13/RB	rcmod||experiments-11/NNS||led-14/VBN	num||attractors-20/NNS||two-16/CD	amod||attractors-20/NNS||different-17/JJ	nn||attractors-20/NNS||cell-18/NN	nn||attractors-20/NNS||fate-19/NN	prep_to||led-14/VBN||attractors-20/NNS	num||treatments-23/NNS||two-22/CD	prep_by||led-14/VBN||treatments-23/NNS	amod||dosage-26/NN||varying-25/VBG	prep_of||treatments-23/NNS||dosage-26/NN	prep_of||treatments-23/NNS||duration-28/NN	conj_and||dosage-26/NN||duration-28/NN	det||all-trans-retinoicacid-33/NN||the-30/DT	amod||all-trans-retinoicacid-33/NN||differentiation-31/JJ	nn||all-trans-retinoicacid-33/NN||agent-32/NN	prep_of||duration-28/NN||all-trans-retinoicacid-33/NN	appos||all-trans-retinoicacid-33/NN||atra-35/NNP	promyelocyticleukemia-5||all-trans-retinoicacid-33||yes||using the hl60 multipotent promyelocyticleukemia cell line, we performed experiments that ultimately led to two different cell fate attractors by two treatments of varying dosage and duration of the differentiation agent all-trans-retinoicacid (atra).
amod||years-3/NNS||recent-2/JJ	prep_in||discussed-21/VBN||years-3/NNS	det||ways-6/NNS||the-5/DT	prep_in||interact-11/VBP||ways-6/NNS	nsubjpass||discussed-21/VBN||ways-6/NNS	amod||programs-10/NNS||hiv/aids-focused-9/JJ	nsubj||interact-11/VBP||programs-10/NNS	rcmod||ways-6/NNS||interact-11/VBP	det||delivery-14/NN||the-13/DT	prep_with||interact-11/VBP||delivery-14/NN	amod||services-18/NNS||other-16/JJ	nn||services-18/NNS||health-17/NN	prep_of||delivery-14/NN||services-18/NNS	auxpass||discussed-21/VBN||is-19/VBZ	advmod||discussed-21/VBN||often-20/RB	root||ROOT-0/null||discussed-21/VBN	det||evidence-25/NN||the-24/DT	nsubj||limited-38/JJ||evidence-25/NN	mark||strengthen-31/VBP||whether-28/IN	nn||programs-30/NNS||hiv/aids-29/NNS	nsubj||strengthen-31/VBP||programs-30/NNS	nsubj||distort-33/VBP||programs-30/NNS	prepc_as_to||evidence-25/NN||strengthen-31/VBP	prepc_as_to||evidence-25/NN||distort-33/VBP	conj_or||strengthen-31/VBP||distort-33/VBP	amod||services-36/NNS||overall-34/JJ	nn||services-36/NNS||health-35/NN	dobj||strengthen-31/VBP||services-36/NNS	cop||limited-38/JJ||is-37/VBZ	conj_but||discussed-21/VBN||limited-38/JJ	aids--1||hiv--1||no||in recent years, the ways in which hiv/aids-focused programs interact with the delivery of other health services is often discussed, but the evidence as to whether hiv/aids programs strengthen or distort overall health services is limited.
poss||study-2/NN||our-1/PRP$	nsubj||indicated-3/VBD||study-2/NN	root||ROOT-0/null||indicated-3/VBD	mark||played-11/VBD||that-4/IN	amod||activation-6/NN||tlr2-5/JJ	nsubj||played-11/VBD||activation-6/NN	nsubj||illustrated-21/VBD||activation-6/NN	amod||pgn-10/NN||infectious-8/JJ	amod||pgn-10/NN||bacterial-9/JJ	prep_by||activation-6/NN||pgn-10/NN	ccomp||indicated-3/VBD||played-11/VBD	det||role-14/NN||an-12/DT	amod||role-14/NN||important-13/JJ	dobj||played-11/VBD||role-14/NN	nn||invasiveness-19/NNS||breast-16/NN	nn||invasiveness-19/NNS||cancer-17/NN	nn||invasiveness-19/NNS||cell-18/NN	prep_in||played-11/VBD||invasiveness-19/NNS	ccomp||indicated-3/VBD||illustrated-21/VBD	conj_and||played-11/VBD||illustrated-21/VBD	det||link-24/NN||a-22/DT	amod||link-24/NN||new-23/JJ	dobj||illustrated-21/VBD||link-24/NN	amod||bacteria-27/NNS||infectious-26/JJ	prep_between||link-24/NN||bacteria-27/NNS	det||cells-31/NNS||the-29/DT	nn||cells-31/NNS||cancer-30/NN	prep_between||link-24/NN||cells-31/NNS	conj_and||bacteria-27/NNS||cells-31/NNS	xcomp||indicated-3/VBD||suggesting-33/VBG	det||importance-35/NN||the-34/DT	dobj||suggesting-33/VBG||importance-35/NN	amod||therapy-38/NN||antibiotic-37/JJ	prep_of||importance-35/NN||therapy-38/NN	aux||treat-40/VB||to-39/TO	vmod||suggesting-33/VBG||treat-40/VB	dobj||treat-40/VB||cancer-41/NN	prep_with||treat-40/VB||bacterialinfection-43/NN	bacterialinfection-43||bacteria-27||no||our study indicated that tlr2 activation by infectious bacterial pgn played an important role in breast cancer cell invasiveness and illustrated a new link between infectious bacteria and the cancer cells, suggesting the importance of antibiotic therapy to treat cancer with bacterialinfection.
amod||countries-4/NNS||many-2/JJ	amod||countries-4/NNS||malaria-endemic-3/JJ	prep_in||compromise-10/VB||countries-4/NNS	amod||resistance-7/NN||increasing-6/VBG	nsubj||compromise-10/VB||resistance-7/NN	aux||compromise-10/VB||may-8/MD	advmod||compromise-10/VB||soon-9/RB	root||ROOT-0/null||compromise-10/VB	det||efficacy-12/NN||the-11/DT	dobj||compromise-10/VB||efficacy-12/NN	amod||sp-16/NN||sulphadoxine-pyrimethamine-14/JJ	prep_of||efficacy-12/NN||sp-16/NN	amod||treatment-21/NN||intermittent-19/JJ	amod||treatment-21/NN||preventative-20/JJ	prep_for||sp-16/NN||treatment-21/NN	appos||treatment-21/NN||ipt-23/NN	prep_of||treatment-21/NN||malaria-26/NN	prep_in||compromise-10/VB||pregnancy-28/NN	malaria-26||pyrimethamine--1||no||in many malaria-endemic countries, increasing resistance may soon compromise the efficacy of sulphadoxine-pyrimethamine (sp) for intermittent preventative treatment (ipt) of malaria in pregnancy.
aux||compare-2/VB||to-1/TO	advcl||calculated-66/VBN||compare-2/VB	det||ability-5/NN||the-3/DT	amod||ability-5/NN||discriminatory-4/JJ	dobj||compare-2/VB||ability-5/NN	num||indices-9/NNS||5-7/CD	amod||indices-9/NNS||prognostic-8/JJ	prep_of||ability-5/NN||indices-9/NNS	appos||indices-9/NNS||i.e.-11/NNP	nn||analysis-15/NN||recursive-13/NN	amod||analysis-15/NN||partitioning-14/VBG	dobj||compare-2/VB||analysis-15/NN	conj_and||ability-5/NN||analysis-15/NN	appos||analysis-15/NN||rpa-17/NN	amod||score-21/NN||basic-20/JJ	dobj||compare-2/VB||score-21/NN	conj_and||ability-5/NN||score-21/NN	prep_for||score-21/NN||bms-23/NN	dep||ability-5/NN||bsbm-25/VB	nn||index-29/NN||score-28/NN	dobj||compare-2/VB||index-29/NN	conj_and||ability-5/NN||index-29/NN	amod||sir-33/NN||radiosurgery-31/JJ	prep_for||index-29/NN||sir-33/NN	amod||assessment-38/NN||graded-36/JJ	amod||assessment-38/NN||prognostic-37/JJ	appos||sir-33/NN||assessment-38/NN	dep||ability-5/NN||gpa-40/VBN	amod||gpa-45/NN||modified-44/VBN	dobj||compare-2/VB||gpa-45/NN	conj_and||ability-5/NN||gpa-45/NN	det||tumor-50/NN||the-47/DT	amod||tumor-50/NN||combined-48/JJ	amod||tumor-50/NN||primary-49/JJ	prep_including||gpa-45/NN||tumor-50/NN	nn||status-53/NN||ecm-52/NN	prep_including||gpa-45/NN||status-53/NN	conj_and||tumor-50/NN||status-53/NN	appos||tumor-50/NN||mgpa-55/NNP	det||criteria-61/NNS||the-58/DT	amod||criteria-61/NNS||akaike-59/JJ	nn||criteria-61/NNS||information-60/NN	nsubjpass||calculated-66/VBN||criteria-61/NNS	appos||criteria-61/NNS||aic-63/NN	auxpass||calculated-66/VBN||were-65/VBD	root||ROOT-0/null||calculated-66/VBN	tumor-50||basic-20||no_rel||to compare the discriminatory ability of 5 prognostic indices, i.e., recursive partitioning analysis (rpa), basic score for bms (bsbm), score index for radiosurgery (sir), graded prognostic assessment (gpa), and modified gpa including the combined primary tumor and ecm status (mgpa), the akaike information criteria (aic) were calculated.
advmod||comprehend-3/JJ||fully-2/RB	amod||chytridiomycosis-4/NNS||comprehend-3/JJ	prep_to||essential-22/JJ||chytridiomycosis-4/NNS	det||disease-8/NN||the-6/DT	nn||disease-8/NN||amphibian-7/NN	appos||chytridiomycosis-4/NNS||disease-8/NN	vmod||disease-8/NN||caused-9/VBN	det||dendrobatidis-15/NNS||the-11/DT	amod||dendrobatidis-15/NNS||chytrid-12/JJ	nn||dendrobatidis-15/NNS||fungus-13/NN	nn||dendrobatidis-15/NNS||batrachochytrium-14/NN	agent||caused-9/VBN||dendrobatidis-15/NNS	appos||dendrobatidis-15/NNS||bd-17/NN	nsubj||essential-22/JJ||it-20/PRP	nsubj||understand-24/VB||it-20/PRP	cop||essential-22/JJ||is-21/VBZ	root||ROOT-0/null||essential-22/JJ	aux||understand-24/VB||to-23/TO	xcomp||essential-22/JJ||understand-24/VB	advmod||affects-27/VBZ||how-25/WRB	nsubj||affects-27/VBZ||bd-26/NN	ccomp||understand-24/VB||affects-27/VBZ	dobj||affects-27/VBZ||amphibians-28/NNS	poss||range-32/NN||their-30/PRP$	amod||range-32/NN||remarkable-31/JJ	prep_throughout||affects-27/VBZ||range-32/NN	nn||histories-35/NNS||life-34/NN	prep_of||range-32/NN||histories-35/NNS	chytridiomycosis-4||fungus-13||no||to fully comprehend chytridiomycosis, the amphibian disease caused by the chytrid fungus batrachochytrium dendrobatidis (bd), it is essential to understand how bd affects amphibians throughout their remarkable range of life histories.
nn||treatment-3/NN||gancyclovir-2/NN	prep_following||went-11/VBD||treatment-3/NN	amod||viremia-7/NN||subsequent-5/JJ	nn||viremia-7/NN||cytomegalovirus-6/NNS	prep_of||treatment-3/NN||viremia-7/NN	det||patient-10/NN||the-9/DT	nsubj||went-11/VBD||patient-10/NN	nsubj||receive-14/VB||patient-10/NN	root||ROOT-0/null||went-11/VBD	prt||went-11/VBD||on-12/RP	aux||receive-14/VB||to-13/TO	xcomp||went-11/VBD||receive-14/VB	det||course-16/NN||a-15/DT	dobj||receive-14/VB||course-16/NN	prep_of||course-16/NN||epoch-18/NN	advmod||mg/m2/day-52/NN||etoposide-20/RB	num||mg/m2/day-22/NNS||50-21/CD	pobj||etoposide-20/RB||mg/m2/day-22/NNS	prep_on||etoposide-20/RB||days-24/NNS	amod||mg/m2/day-52/NN||1â-25/JJ	amod||mg/m2/day-52/NN||$-26/$	num||$-26/$||4-28/CD	amod||mg/m2/day-52/NN||vincristine-30/JJ	num||mg/m2/day-32/NNS||0.4-31/CD	dep||vincristine-30/JJ||mg/m2/day-32/NNS	prep_on||mg/m2/day-32/NNS||days-34/NNS	amod||mg/m2/day-52/NN||1â-35/JJ	amod||mg/m2/day-52/NN||$-36/$	num||$-36/$||4-38/CD	amod||mg/m2/day-52/NN||doxorubicin-40/JJ	num||mg/m2/day-42/NNS||10-41/CD	dep||doxorubicin-40/JJ||mg/m2/day-42/NNS	prep_on||mg/m2/day-42/NNS||days-44/NNS	amod||mg/m2/day-52/NN||1â-45/JJ	amod||mg/m2/day-52/NN||$-46/$	num||$-46/$||4-48/CD	amod||mg/m2/day-52/NN||cyclophosphamide-50/JJ	number||cyclophosphamide-50/JJ||750-51/CD	dep||epoch-18/NN||mg/m2/day-52/NN	prep_on||mg/m2/day-52/NN||day-54/NN	num||day-54/NN||6-55/CD	advmod||1â-63/JJ||prednisolone-58/RB	num||mg/m2/day-60/NNS||60-59/CD	pobj||prednisolone-58/RB||mg/m2/day-60/NNS	prep_on||prednisolone-58/RB||days-62/NNS	prep_on||mg/m2/day-52/NN||1â-63/JJ	conj_and||day-54/NN||1â-63/JJ	dep||1â-63/JJ||$-64/$	num||$-64/$||6-66/CD	cytomegalovirus-6||gancyclovir-2||yes||following gancyclovir treatment of subsequent cytomegalovirus viremia, the patient went on to receive a course of epoch (etoposide 50 mg/m2/day on days 1â€“4, vincristine 0.4 mg/m2/day on days 1â€“4, doxorubicin 10 mg/m2/day on days 1â€“4, cyclophosphamide 750 mg/m2/day on day 6, and prednisolone 60 mg/m2/day on days 1â€“6).
det||signature-3/NN||the-1/DT	nn||signature-3/NN||dm-2/NN	nsubj||has-4/VBZ||signature-3/NN	nsubj||predictive-14/JJ||signature-3/NN	root||ROOT-0/null||has-4/VBZ	amod||overlap-6/NNS||minimal-5/JJ	dobj||has-4/VBZ||overlap-6/NNS	det||signatures-10/NNS||the-8/DT	amod||signatures-10/NNS||extant-9/JJ	prep_with||overlap-6/NNS||signatures-10/NNS	cop||predictive-14/JJ||is-12/VBZ	advmod||predictive-14/JJ||highly-13/RB	conj_and||has-4/VBZ||predictive-14/JJ	prep_of||predictive-14/JJ||survival-16/NN	num||datasets-22/NNS||5-18/CD	amod||datasets-22/NNS||large-19/JJ	nn||datasets-22/NNS||breast-20/NN	nn||datasets-22/NNS||cancer-21/NN	prep_in||survival-16/NN||datasets-22/NNS	cancer-21||dm-2||no_rel||the dm signature has minimal overlap with the extant signatures and is highly predictive of survival in 5 large breast cancer datasets.
poss||data-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||endogenous-9/VBZ||that-4/IN	nn||tissues-6/NNS||cancer-5/NN	nsubj||endogenous-9/VBZ||tissues-6/NNS	advmod||secrete-8/JJ||directly-7/RB	amod||tissues-6/NNS||secrete-8/JJ	ccomp||suggest-3/VBP||endogenous-9/VBZ	dobj||endogenous-9/VBZ||formaldehyde-10/NN	det||formaldehyde-14/NN||this-13/DT	nsubj||induces-18/VBZ||formaldehyde-14/NN	amod||concentration-17/NN||low-16/JJ	prep_at||formaldehyde-14/NN||concentration-17/NN	conj_and||suggest-3/VBP||induces-18/VBZ	amod||pain-22/NN||metastatic-19/JJ	nn||pain-22/NN||bone-20/NN	nn||pain-22/NN||cancer-21/NN	dobj||induces-18/VBZ||pain-22/NN	amod||activation-25/NN||trpv1-24/JJ	prep_through||induces-18/VBZ||activation-25/NN	advmod||induces-18/VBZ||especially-26/RB	nn||environment-30/NN||tumor-28/NN	amod||environment-30/NN||acidic-29/JJ	prep_under||induces-18/VBZ||environment-30/NN	cancer-21||formaldehyde-14||no_rel||our data suggest that cancer tissues directly secrete endogenous formaldehyde, and this formaldehyde at low concentration induces metastatic bone cancer pain through trpv1 activation especially under tumor acidic environment.
advmod||active-2/JJ||highly-1/RB	amod||therapy-4/NN||active-2/JJ	amod||therapy-4/NN||antiretroviral-3/JJ	nsubj||changed-9/VBN||therapy-4/NN	appos||therapy-4/NN||haart-6/NN	aux||changed-9/VBN||has-8/VBZ	root||ROOT-0/null||changed-9/VBN	det||face-11/NN||the-10/DT	dobj||changed-9/VBN||face-11/NN	amod||acquiredimmunedeficiencysyndrome-17/NN||humanimmunodeficiencyvirus-13/JJ	appos||acquiredimmunedeficiencysyndrome-17/NN||hiv-15/NN	prep_of||face-11/NN||acquiredimmunedeficiencysyndrome-17/NN	appos||acquiredimmunedeficiencysyndrome-17/NN||aids-19/NNS	prepc_by||changed-9/VBN||leading-22/VBG	amod||decreases-25/NNS||dramatic-24/JJ	prep_to||leading-22/VBG||decreases-25/NNS	amod||morbidity-28/NN||hiv-related-27/JJ	prep_in||decreases-25/NNS||morbidity-28/NN	prep_in||decreases-25/NNS||mortality-30/NN	conj_and||morbidity-28/NN||mortality-30/NN	det||developed-33/JJ||the-32/DT	prep_in||leading-22/VBG||developed-33/JJ	prepc_by||changed-9/VBN||developing-37/VBG	conj_and||leading-22/VBG||developing-37/VBG	dobj||developing-37/VBG||world-38/NN	acquiredimmunedeficiencysyndrome-17||humanimmunodeficiencyvirus-13||no||highly active antiretroviral therapy (haart) has changed the face of humanimmunodeficiencyvirus (hiv) acquiredimmunedeficiencysyndrome (aids) by leading to dramatic decreases in hiv-related morbidity and mortality in the developed as well as developing world.
det||line-3/NN||an-1/DT	amod||line-3/NN||independent-2/JJ	nsubjpass||provided-7/VBN||line-3/NN	prep_of||line-3/NN||evidence-5/NN	auxpass||provided-7/VBN||was-6/VBD	root||ROOT-0/null||provided-7/VBN	det||efficacy-10/NN||the-9/DT	prep_for||provided-7/VBN||efficacy-10/NN	amod||therapy-13/NN||antiviral-12/JJ	prep_of||efficacy-10/NN||therapy-13/NN	prepc_in||provided-7/VBN||preventing-15/VBG	dobj||preventing-15/VBG||phn-16/NN	prepc_in||provided-7/VBN||reducing-18/VBG	conj_and||preventing-15/VBG||reducing-18/VBG	amod||burden-21/NN||total-19/JJ	nn||burden-21/NN||pain-20/NN	dobj||reducing-18/VBG||burden-21/NN	antiviral-12||phn-16||no_rel||an independent line of evidence was provided for the efficacy of antiviral therapy in preventing phn and reducing total pain burden.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||cost-effectiveness-4/NNS||the-3/DT	dobj||evaluate-2/VB||cost-effectiveness-4/NNS	prep_of||cost-effectiveness-4/NNS||aripiprazole-6/NN	prep_of||cost-effectiveness-4/NNS||olanzapine-8/NN	conj_and||aripiprazole-6/NN||olanzapine-8/NN	prep_in||evaluate-2/VB||patients-10/NNS	prep_with||patients-10/NNS||schizophrenia-12/NN	schizophrenia-12||olanzapine-8||yes||to evaluate the cost-effectiveness of aripiprazole and olanzapine in patients with schizophrenia.
det||hospital-2/NN||the-1/DT	nsubj||has-4/VBZ||hospital-2/NN	advmod||has-4/VBZ||now-3/RB	root||ROOT-0/null||has-4/VBZ	amod||water-6/NN||constant-5/JJ	dobj||has-4/VBZ||water-6/NN	dobj||has-4/VBZ||electricity-8/NN	conj_and||water-6/NN||electricity-8/NN	det||theatre-13/NN||a-10/DT	amod||theatre-13/NN||functioning-11/VBG	nn||theatre-13/NN||operating-12/NN	dobj||has-4/VBZ||theatre-13/NN	conj_and||water-6/NN||theatre-13/NN	nn||room-16/NN||emergency-15/NN	dobj||has-4/VBZ||room-16/NN	conj_and||water-6/NN||room-16/NN	det||unit-20/NN||the-18/DT	amod||unit-20/NN||maternity-19/JJ	nsubj||have-25/VBP||unit-20/NN	poss||wards-24/NNS||children-22/NNS	conj_and||unit-20/NN||wards-24/NNS	nsubj||have-25/VBP||wards-24/NNS	parataxis||has-4/VBZ||have-25/VBP	amod||equipment-28/NN||better-26/JJR	nn||equipment-28/NN||emergency-27/NN	dobj||have-25/VBP||equipment-28/NN	expl||is-31/VBZ||there-30/EX	parataxis||has-4/VBZ||is-31/VBZ	conj_and||have-25/VBP||is-31/VBZ	det||supply-35/NN||a-32/DT	advmod||reliable-34/JJ||more-33/RBR	amod||supply-35/NN||reliable-34/JJ	nsubj||is-31/VBZ||supply-35/NN	nn||drugs-40/NNS||oxygen-37/NN	conj_and||oxygen-37/NN||emergency-39/NN	nn||drugs-40/NNS||emergency-39/NN	prep_of||supply-35/NN||drugs-40/NNS	prep_including||supply-35/NN||misoprostol-43/NN	amod||haemorrhage-49/NN||treating-46/JJ	nn||haemorrhage-49/NN||post-47/NN	nn||haemorrhage-49/NN||partum-48/NN	prep_for||misoprostol-43/NN||haemorrhage-49/NN	prep_including||supply-35/NN||magnesiumsulphate-52/NN	conj_and||misoprostol-43/NN||magnesiumsulphate-52/NN	amod||pre-eclampsia-56/NN||severe-55/JJ	prep_for||misoprostol-43/NN||pre-eclampsia-56/NN	pre-eclampsia-56||magnesiumsulphate-52||yes||the hospital now has constant water and electricity, a functioning operating theatre and emergency room; the maternity unit and children's wards have better emergency equipment and there is a more reliable supply of oxygen and emergency drugs, including misoprostol (for treating post partum haemorrhage) and magnesiumsulphate (for severe pre-eclampsia).
amod||carriers-2/NNS||inactive-1/JJ	nsubj||have-8/VBP||carriers-2/NNS	amod||levels-7/NNS||lower-4/JJR	nn||levels-7/NNS||baseline-5/NN	nn||levels-7/NNS||hbsag-6/NN	prep_with||carriers-2/NNS||levels-7/NNS	root||ROOT-0/null||have-8/VBP	det||decline-14/NN||a-9/DT	amod||decline-14/NN||greater-10/JJR	advmod||hbsag-13/JJ||accelerating-12/RB	conj_and||greater-10/JJR||hbsag-13/JJ	amod||decline-14/NN||hbsag-13/JJ	dobj||have-8/VBP||decline-14/NN	prep_over||decline-14/NN||time-16/NN	nn||genotypes-21/NNS||hbv-20/NN	prep_regardless_of||have-8/VBP||genotypes-21/NNS	hbv-20||hbsag-13||yes||inactive carriers with lower baseline hbsag levels have a greater and accelerating hbsag decline over time, regardless of hbv genotypes.
det||model-2/NN||a-1/DT	nsubjpass||designed-29/VBN||model-2/NN	nsubj||simulate-31/VB||model-2/NN	vmod||model-2/NN||incorporating-3/VBG	advmod||incorporating-3/VBG||heterogeneity-4/RB	prep_in||incorporating-3/VBG||age-6/NN	appos||model-2/NN||gender-8/NN	amod||activity-11/NN||sexual-10/JJ	appos||model-2/NN||activity-11/NN	conj_and||gender-8/NN||activity-11/NN	nn||status-14/NN||hivinfection-13/NN	appos||model-2/NN||status-14/NN	conj_and||gender-8/NN||status-14/NN	appos||model-2/NN||stage-16/NN	conj_and||gender-8/NN||stage-16/NN	prep_of||stage-16/NN||disease-18/NN	nn||coverage/discontinuation-21/NN||prep-20/NN	appos||disease-18/NN||coverage/discontinuation-21/NN	nn||susceptibility-26/NN||hiv-24/NN	nn||susceptibility-26/NN||drug-25/NN	appos||model-2/NN||susceptibility-26/NN	conj_and||gender-8/NN||susceptibility-26/NN	auxpass||designed-29/VBN||was-28/VBD	root||ROOT-0/null||designed-29/VBN	aux||simulate-31/VB||to-30/TO	xcomp||designed-29/VBN||simulate-31/VB	det||impact-33/NN||the-32/DT	dobj||simulate-31/VB||impact-33/NN	prep_of||impact-33/NN||prep-35/NN	nn||prevention-38/NN||hiv-37/NN	prep_on||simulate-31/VB||prevention-38/NN	nn||resistance-41/NN||drug-40/NN	prep_on||simulate-31/VB||resistance-41/NN	conj_and||prevention-38/NN||resistance-41/NN	det||epidemic-45/NN||a-43/DT	amod||epidemic-45/NN||sub-saharan-44/JJ	prep_in||prevention-38/NN||epidemic-45/NN	hivinfection-13||hiv-37||no||a model incorporating heterogeneity in age, gender, sexual activity, hivinfection status, stage of disease, prep coverage/discontinuation, and hiv drug susceptibility, was designed to simulate the impact of prep on hiv prevention and drug resistance in a sub-saharan epidemic.
amod||patients-2/NNS||many-1/JJ	nsubj||take-5/VBP||patients-2/NNS	prep_with||patients-2/NNS||osteoarthritis-4/NNS	root||ROOT-0/null||take-5/VBP	amod||term-11/NN||nonsteroidalanti-inflammatorydrugs-6/JJ	nn||term-11/NN||nsaids-8/NN	amod||term-11/NN||long-10/JJ	dobj||take-5/VBP||term-11/NN	nn||control-14/NN||pain-13/NN	prep_for||term-11/NN||control-14/NN	nonsteroidalanti-inflammatorydrugs-6||osteoarthritis-4||no_rel||many patients with osteoarthritis take nonsteroidalanti-inflammatorydrugs (nsaids) long term for pain control.
det||inducer-6/NN||the-2/DT	advmod||used-4/VBN||clinically-3/RB	amod||inducer-6/NN||used-4/VBN	nn||inducer-6/NN||differentiation-5/NN	prep_unlike||target-44/VB||inducer-6/NN	advmod||inducer-6/NN||all-7/DT	dep||inducer-6/NN||trans-9/NNS	vmod||trans-9/NNS||retinoicacid-10/VBN	amod||shows-13/NNS||tenovin-6-12/JJ	nsubj||target-44/VB||shows-13/NNS	vmod||shows-13/NNS||limited-14/VBN	dobj||limited-14/VBN||effects-15/NNS	prepc_on||limited-14/VBN||promyelocyticleukemiaâ-17/VBG	dobj||promyelocyticleukemiaâ-17/VBG||$-18/$	amod||±-23/NNS||retinoicacid-20/JJ	nn||±-23/NNS||receptor-21/NN	nn||±-23/NNS||î-22/NN	npadvmod||that-39/RB||±-23/NNS	number||±-26/CD||pml-rar-î-25/CD	dep||±-23/NNS||±-26/CD	nn||formation-33/NN||stability-28/NN	conj_and||stability-28/NN||promyelocyticleukemia-30/NN	nn||formation-33/NN||promyelocyticleukemia-30/NN	amod||formation-33/NN||nuclear-31/JJ	nn||formation-33/NN||body-32/NN	dep||±-26/CD||formation-33/NN	amod||cells-36/NNS||nb4-35/JJ	prep_in||±-26/CD||cells-36/NNS	appos||cells-36/NNS||suggesting-38/NNP	dep||tenovin-6-40/CD||that-39/RB	num||$-18/$||tenovin-6-40/CD	aux||target-44/VB||does-41/VBZ	neg||target-44/VB||not-42/RB	advmod||target-44/VB||directly-43/RB	root||ROOT-0/null||target-44/VB	amod||activity-47/NN||pml-rar-î-45/JJ	amod||activity-47/NN||±-46/JJ	dobj||target-44/VB||activity-47/NN	promyelocyticleukemia-30||retinoicacid-20||yes||unlike the clinically used differentiation inducer all- trans retinoicacid, tenovin-6 shows limited effects on promyelocyticleukemiaâ€“retinoicacid receptor î± (pml-rar-î±) stability and promyelocyticleukemia nuclear body formation in nb4 cells, suggesting that tenovin-6 does not directly target pml-rar-î± activity.
nn||cancer-2/NN||prostate-1/NN	nsubj||cancer-8/NN||cancer-2/NN	cop||cancer-8/NN||is-3/VBZ	det||cancer-8/NN||the-4/DT	amod||cancer-8/NN||single-5/JJ	advmod||prevalent-7/JJ||most-6/RBS	amod||cancer-8/NN||prevalent-7/JJ	root||ROOT-0/null||cancer-8/NN	dep||men-11/NNS||us-10/PRP	prep_in||cancer-8/NN||men-11/NNS	poss||standard-14/NN||men-11/NNS	amod||standard-14/NN||gold-13/JJ	nsubj||assessment-19/NN||standard-14/NN	prep_of||standard-14/NN||diagnosis-16/NN	cop||assessment-19/NN||is-17/VBZ	amod||assessment-19/NN||histologic-18/JJ	rcmod||men-11/NNS||assessment-19/NN	prep_of||assessment-19/NN||biopsies-21/NNS	cancer-8||gold-13||no_rel||prostate cancer is the single most prevalent cancer in us men whose gold standard of diagnosis is histologic assessment of biopsies.
nsubjpass||documented-34/VBN||viruses-1/NNS	nsubj||develop-36/VB||viruses-1/NNS	dep||viruses-1/NNS||other-2/JJ	det||viruses-6/NNS||the-4/DT	nn||viruses-6/NNS||hepatitis-5/NN	prep_than||viruses-1/NNS||viruses-6/NNS	amod||virus-15/NN||parvovirusb19-9/JJ	amod||epstein-13/JJ||cytomegalovirus-11/JJ	amod||virus-15/NN||epstein-13/JJ	nn||virus-15/NN||bar-14/NN	prep_such_as||viruses-6/NNS||virus-15/NN	nn||virus-19/NN||transfusion-17/NN	amod||virus-19/NN||transmitted-18/JJ	prep_such_as||viruses-6/NNS||virus-19/NN	conj_and||virus-15/NN||virus-19/NN	appos||virus-19/NN||ttv-21/NN	amod||virus-26/NN||non-a-e-24/JJ	nn||virus-26/NN||hepatitis-25/NN	prep_such_as||viruses-6/NNS||virus-26/NN	conj_and||virus-15/NN||virus-26/NN	amod||viruses-29/NNS||unknown-28/JJ	appos||virus-26/NN||viruses-29/NNS	aux||documented-34/VBN||has-31/VBZ	advmod||documented-34/VBN||also-32/RB	auxpass||documented-34/VBN||been-33/VBN	root||ROOT-0/null||documented-34/VBN	aux||develop-36/VB||to-35/TO	xcomp||documented-34/VBN||develop-36/VB	det||syndrome-38/NN||the-37/DT	dobj||develop-36/VB||syndrome-38/NN	virus-26||viruses-29||no||viruses other than the hepatitis viruses such as parvovirusb19, cytomegalovirus, epstein bar virus, transfusion transmitted virus (ttv) and non-a-e hepatitis virus (unknown viruses) has also been documented to develop the syndrome.
poss||patients-5/NNS||results-1/NNS	amod||patients-5/NNS||$-3/JJ	nsubj||had-15/VBD||patients-5/NNS	nsubj||had-62/VBD||patients-5/NNS	prep_with||patients-5/NNS||type1diabetes-7/CD	det||history-12/NN||a-9/DT	amod||history-12/NN||positive-10/JJ	amod||history-12/NN||parental-11/JJ	conj_and||patients-5/NNS||history-12/NN	nsubj||had-15/VBD||history-12/NN	prep_of||history-12/NN||type2diabetes-14/CD	root||ROOT-0/null||had-15/VBD	det||prevalence-18/NN||a-16/DT	amod||prevalence-18/NN||higher-17/JJR	dobj||had-15/VBD||prevalence-18/NN	det||syndrome-22/NN||the-20/DT	amod||syndrome-22/NN||metabolic-21/JJ	prep_of||prevalence-18/NN||syndrome-22/NN	amod||syndrome-22/NN||-lrb--23/NN	number||-lrb--23/NN||44-24/CD	num||%-27/NN||38-26/CD	prep_vs.||syndrome-22/NN||%-27/NN	dep||prevalence-18/NN||p-29/NN	dep||-rrb--32/NNS||=-30/SYM	num||-rrb--32/NNS||0.013-31/CD	rcmod||p-29/NN||-rrb--32/NNS	det||profile-36/NN||a-34/DT	amod||profile-36/NN||metabolic-35/JJ	dobj||had-15/VBD||profile-36/NN	conj_and||prevalence-18/NN||profile-36/NN	vmod||profile-36/NN||related-37/VBN	aux||insulinresistance-39/VB||to-38/TO	xcomp||related-37/VBN||insulinresistance-39/VB	amod||bmi-42/NN||-lrb--40/NN	dep||-lrb--40/NN||higher-41/JJR	dobj||insulinresistance-39/VB||bmi-42/NN	amod||circumference-46/NN||larger-44/JJR	nn||circumference-46/NN||waist-45/NN	conj_and||prevalence-18/NN||circumference-46/NN	conj_and||profile-36/NN||circumference-46/NN	amod||triglycerides-50/NNS||higher-49/JJR	conj_and||prevalence-18/NN||triglycerides-50/NNS	conj_and||profile-36/NN||triglycerides-50/NNS	conj_and||profile-36/NN||a1c-52/NNS	conj_and||triglycerides-50/NNS||a1c-52/NNS	conj_and||profile-36/NN||insulin-55/NN	conj_and||triglycerides-50/NNS||insulin-55/NN	nn||insulin-55/NN||dose-56/FW	nn||insulin-55/NN||per-57/FW	nn||insulin-55/NN||kilogram-58/FW	dep||insulin-55/NN||-rrb--59/FW	advmod||had-62/VBD||also-61/RB	conj_and||had-15/VBD||had-62/VBD	det||onset-65/NN||a-63/DT	amod||onset-65/NN||later-64/JJ	dobj||had-62/VBD||onset-65/NN	nsubjpass||confirmed-88/VBN||onset-65/NN	prep_of||onset-65/NN||type1diabetes-67/NN	nn||type1diabetes-67/NN||-lrb--68/FW	nn||type1diabetes-67/NN||17.2-69/FW	nn||type1diabetes-67/NN||â-70/FW	nn||type1diabetes-67/NN||±-71/FW	nn||type1diabetes-67/NN||9.2-72/FW	nn||type1diabetes-67/NN||vs.-73/FW	nn||type1diabetes-67/NN||16.1-74/FW	dep||type1diabetes-67/NN||â-75/FW	punct||type1diabetes-67/NN||±-76/``	num||years-78/NNS||8.9-77/CD	dep||type1diabetes-67/NN||years-78/NNS	vmod||onset-65/NN||p-80/VBN	dep||-rrb--83/NNS||=-81/SYM	num||-rrb--83/NNS||0.008-82/CD	ccomp||p-80/VBN||-rrb--83/NNS	auxpass||confirmed-88/VBN||was-86/VBD	advmod||confirmed-88/VBN||also-87/RB	rcmod||onset-65/NN||confirmed-88/VBN	det||control-94/NN||the-90/DT	advmod||available-92/JJ||publicly-91/RB	amod||control-94/NN||available-92/JJ	nn||control-94/NN||diabetes-93/NN	prep_in||confirmed-88/VBN||control-94/NN	nn||data-98/NN||complications-96/NNS	nn||data-98/NN||trial-97/NN	prep_in||confirmed-88/VBN||data-98/NN	conj_and||control-94/NN||data-98/NN	vmod||control-94/NN||set-99/VBN	type1diabetes-67||insulin-55||yes||results â $ '' patients with type1diabetes and a positive parental history of type2diabetes had a higher prevalence of the metabolic syndrome -lrb- 44 vs. 38 % ; p = 0.013 -rrb- and a metabolic profile related to insulinresistance -lrb- higher bmi , larger waist circumference , and higher triglycerides , a1c , and insulin dose per kilogram -rrb- and also had a later onset of type1diabetes -lrb- 17.2 â ± 9.2 vs. 16.1 â ± 8.9 years ; p = 0.008 -rrb- , which was also confirmed in the publicly available diabetes control and complications trial data set .
det||production-6/NN||the-1/DT	amod||production-6/NN||current-2/JJ	amod||production-6/NN||diagnostic-3/JJ	nn||production-6/NN||kits-4/NNS	nn||production-6/NN||utilising-5/NN	nsubj||detect-16/VB||production-6/NN	nsubj||unable-21/JJ||production-6/NN	nsubj||distinguish-23/VB||production-6/NN	nn||³-9/NNP||ifn-î-8/NNP	prep_of||production-6/NN||³-9/NNP	prep_in||³-9/NNP||response-11/NN	nn||antigens-14/NNS||tb-13/NN	prep_to||response-11/NN||antigens-14/NNS	aux||detect-16/VB||can-15/MD	root||ROOT-0/null||detect-16/VB	nn||infection-18/NN||mtb-17/NN	dobj||detect-16/VB||infection-18/NN	cop||unable-21/JJ||are-20/VBP	conj_but||detect-16/VB||unable-21/JJ	aux||distinguish-23/VB||to-22/TO	xcomp||unable-21/JJ||distinguish-23/VB	prep_between||distinguish-23/VB||infection-25/NN	prep_between||distinguish-23/VB||disease-27/NN	conj_and||infection-25/NN||disease-27/NN	tb-13||mtb-17||no||the current diagnostic kits utilising production of ifn-î³ in response to tb antigens can detect mtb infection but are unable to distinguish between infection and disease.
nsubj||effective-61/JJ||analysis-1/NN	amod||terbinafine-58/NN||total-3/JJ	num||trials-5/NNS||eight-4/CD	nsubj||state-9/NN||trials-5/NNS	num||patients-8/NNS||1181-7/CD	prep_including||trials-5/NNS||patients-8/NNS	ccomp||total-3/JJ||state-9/NN	mark||likely-17/JJ||that-10/IN	nsubj||likely-17/JJ||treatment-11/NN	nsubj||produce-19/VB||treatment-11/NN	amod||terbinafine-14/NN||continuous-13/JJ	prep_with||treatment-11/NN||terbinafine-14/NN	cop||likely-17/JJ||is-15/VBZ	advmod||likely-17/JJ||more-16/RBR	ccomp||state-9/NN||likely-17/JJ	aux||produce-19/VB||to-18/TO	xcomp||likely-17/JJ||produce-19/VB	amod||cure-23/NN||mycological-20/JJ	conj_and||mycological-20/JJ||clinical-22/JJ	amod||cure-23/NN||clinical-22/JJ	dobj||produce-19/VB||cure-23/NN	prepc_compared_to||produce-19/VB||to-25/TO	amod||itraconazole-27/NN||intermittent-26/JJ	pobj||produce-19/VB||itraconazole-27/NN	nn||2.3-31/NNS||odds-29/NNS	nn||2.3-31/NNS||ratio-30/NN	prep_with||itraconazole-27/NN||2.3-31/NNS	number||%-34/NN||95-33/CD	amod||ci-35/NN||%-34/NN	dep||likely-17/JJ||ci-35/NN	amod||ci-35/NN||1.7-37/CD	num||p-40/NNS||3.0-39/CD	prep_to||ci-35/NN||p-40/NNS	number||0.0001-42/CD||<-41/CD	num||p-40/NNS||0.0001-42/CD	mark||tolerated-51/JJ||though-44/IN	preconj||itraconazole-46/NN||both-45/DT	nsubj||tolerated-51/JJ||itraconazole-46/NN	conj_and||itraconazole-46/NN||terbinafine-48/NN	nsubj||tolerated-51/JJ||terbinafine-48/NN	cop||tolerated-51/JJ||are-49/VBP	advmod||tolerated-51/JJ||well-50/RB	ccomp||likely-17/JJ||tolerated-51/JJ	advmod||effective-54/JJ||highly-53/RB	conj_and||total-3/JJ||effective-54/JJ	amod||terbinafine-58/NN||effective-54/JJ	nn||terbinafine-58/NN||drugs-55/NNS	amod||terbinafine-58/NN||continuous-57/JJ	prep_of||analysis-1/NN||terbinafine-58/NN	cop||effective-61/JJ||is-59/VBZ	advmod||effective-61/JJ||more-60/RBR	root||ROOT-0/null||effective-61/JJ	amod||itraconazole-64/NN||intermittent-63/JJ	prep_than||effective-61/JJ||itraconazole-64/NN	prepc_at||effective-61/JJ||achieving-66/VBG	amod||cure-68/NN||mycological-67/JJ	dobj||achieving-66/VBG||cure-68/NN	amod||onychomycosis-71/NNS||toenail-70/JJ	prep_of||cure-68/NN||onychomycosis-71/NNS	onychomycosis-71||itraconazole-64||yes||analysis of total eight trials including 1181 patients state that treatment with continuous terbinafine is more likely to produce mycological and clinical cure compared to intermittent itraconazole with odds ratio 2.3(95% ci, 1.7 to 3.0 p <0.0001) though both itraconazole and terbinafine are well tolerated and highly effective drugs, continuous terbinafine is more effective than intermittent itraconazole at achieving mycological cure of toenail onychomycosis
nsubj||treatment-4/NN||warfarin-1/NN	cop||treatment-4/NN||is-2/VBZ	det||treatment-4/NN||the-3/DT	root||ROOT-0/null||treatment-4/NN	prep_of||treatment-4/NN||choice-6/NN	amod||patients-9/NNS||high-risk-8/JJ	prep_in||choice-6/NN||patients-9/NNS	prep_with||patients-9/NNS||af-11/NN	poss||efficacy-16/NN||its-14/PRP$	amod||efficacy-16/NN||superior-15/JJ	nsubjpass||recognized-27/VBN||efficacy-16/NN	prep_over||efficacy-16/NN||aspirin-18/NN	prepc_for||aspirin-18/NN||preventing-20/VBG	dobj||preventing-20/VBG||stroke-21/NN	det||patients-24/NNS||these-23/DT	prep_in||preventing-20/VBG||patients-24/NNS	auxpass||recognized-27/VBN||is-25/VBZ	advmod||recognized-27/VBN||widely-26/RB	conj_and||treatment-4/NN||recognized-27/VBN	stroke-21||warfarin-1||yes||warfarin is the treatment of choice in high-risk patients with af, and its superior efficacy over aspirin for preventing stroke in these patients is widely recognized.
det||appearance-3/NN||the-1/DT	amod||appearance-3/NN||simultaneous-2/JJ	nsubj||common-10/JJ||appearance-3/NN	prep_of||appearance-3/NN||tuberculosis-5/NNP	prep_of||appearance-3/NN||bacterialinfection-7/NNP	conj_and||tuberculosis-5/NNP||bacterialinfection-7/NNP	cop||common-10/JJ||is-8/VBZ	neg||common-10/JJ||not-9/RB	root||ROOT-0/null||common-10/JJ	dep||common-10/JJ||to-14/TO	poss||knowledge-16/NN||our-15/PRP$	pobj||to-14/TO||knowledge-16/NN	det||association-19/NN||the-18/DT	nsubjpass||reported-30/VBN||association-19/NN	prep_of||association-19/NN||infection-21/NN	amod||anginosus-24/NNS||streptococcus-23/JJ	prep_by||infection-21/NN||anginosus-24/NNS	prep_by||infection-21/NN||mycobacteriumtuberculosis-26/NNS	conj_and||anginosus-24/NNS||mycobacteriumtuberculosis-26/NNS	aux||reported-30/VBN||has-27/VBZ	neg||reported-30/VBN||not-28/RB	auxpass||reported-30/VBN||been-29/VBN	ccomp||common-10/JJ||reported-30/VBN	conj_and||common-10/JJ||reported-30/VBN	advmod||reported-30/VBN||previously-31/RB	det||literature-34/NN||the-33/DT	prep_in||reported-30/VBN||literature-34/NN	tuberculosis-5||mycobacteriumtuberculosis-26||no||the simultaneous appearance of tuberculosis and bacterialinfection is not common, and, to our knowledge, the association of infection by streptococcus anginosus and mycobacteriumtuberculosis has not been reported previously in the literature.
nsubj||reduced-8/VBD||knockdown-1/NN	amod||lipin2-4/NNS||hepatic-3/JJ	prep_of||knockdown-1/NN||lipin2-4/NNS	nn||mice-7/NNS||dio-6/NN	prep_in||lipin2-4/NNS||mice-7/NNS	root||ROOT-0/null||reduced-8/VBD	amod||hyperglycemia-10/NN||fasting-9/VBG	dobj||reduced-8/VBD||hyperglycemia-10/NN	amod||signaling-15/NN||improved-12/VBN	amod||signaling-15/NN||hepatic-13/JJ	nn||signaling-15/NN||insulin-14/NN	dobj||reduced-8/VBD||signaling-15/NN	conj_and||hyperglycemia-10/NN||signaling-15/NN	hyperglycemia-10||insulin-14||yes||knockdown of hepatic lipin2 in dio mice reduced fasting hyperglycemia and improved hepatic insulin signaling.
det||findings-2/NNS||these-1/DT	nsubj||highlight-3/VB||findings-2/NNS	root||ROOT-0/null||highlight-3/VB	det||possibility-5/NN||the-4/DT	dobj||highlight-3/VB||possibility-5/NN	prepc_of||possibility-5/NN||boosting-7/VBG	npadvmod||cellular-9/JJ||cross-type-8/NN	dobj||boosting-7/VBG||cellular-9/JJ	amod||immunity-12/NN||humoral-11/JJ	dobj||boosting-7/VBG||immunity-12/NN	conj_and||cellular-9/JJ||immunity-12/NN	advmod||pathogenic-15/JJ||highly-14/RB	amod||h5n1-18/NNS||pathogenic-15/JJ	amod||h5n1-18/NNS||avianinfluenzaavirus-16/JJ	nn||h5n1-18/NNS||subtype-17/NN	prep_against||cellular-9/JJ||h5n1-18/NNS	amod||vaccination-22/NN||seasonal-20/JJ	nn||vaccination-22/NN||influenza-21/NN	prep_by||boosting-7/VBG||vaccination-22/NN	h5n1-18||avianinfluenzaavirus-16||no||these findings highlight the possibility of boosting cross-type cellular and humoral immunity against highly pathogenic avianinfluenzaavirus subtype h5n1 by seasonal influenza vaccination.
det||study-2/NN||the-1/DT	nsubj||included-3/VBD||study-2/NN	root||ROOT-0/null||included-3/VBD	num||patients-7/NNS||one-4/CD	num||patients-7/NNS||hundred-5/CD	amod||patients-7/NNS||eighty-6/JJ	dobj||included-3/VBD||patients-7/NNS	dep||patients-7/NNS||divided-8/VBN	det||diabetic-13/NN||the-10/DT	amod||diabetic-13/NN||following-11/JJ	nn||diabetic-13/NN||groups-12/NNS	prep_in||divided-8/VBN||diabetic-13/NN	amod||disorders-17/NNS||ischemic-15/JJ	amod||disorders-17/NNS||cardiopathy-related-16/JJ	prep_without||diabetic-13/NN||disorders-17/NNS	appos||diabetic-13/NN||dm-19/NN	amod||disorders-35/NNS||diabetic-22/JJ	prep_with||diabetic-22/JJ||clinical-24/JJ	prep_with||diabetic-22/JJ||off-clinical-26/JJ	conj_or||clinical-24/JJ||off-clinical-26/JJ	dep||diabetic-22/JJ||electrocardiogram-28/NN	amod||ultrasound-31/NN||cardiac-30/JJ	appos||electrocardiogram-28/NN||ultrasound-31/NN	amod||disorders-35/NNS||ischemic-33/JJ	amod||disorders-35/NNS||cardiopathy-related-34/JJ	appos||diabetic-13/NN||disorders-35/NNS	amod||ic-39/NN||dm-37/JJ	amod||ic-39/NN||+-38/JJ	appos||disorders-35/NNS||ic-39/NN	dep||patients-7/NNS||nondiabetic-43/JJ	conj_and||divided-8/VBN||nondiabetic-43/JJ	amod||disorders-47/NNS||ischemic-45/JJ	amod||disorders-47/NNS||cardiopathy-related-46/JJ	prep_with||nondiabetic-43/JJ||disorders-47/NNS	appos||disorders-47/NNS||ic-49/NN	cardiopathy--1||dm-37||no_rel||the study included one hundred eighty patients divided in the following groups diabetic without ischemic cardiopathy-related disorders (dm), diabetic with clinical or off-clinical (electrocardiogram, cardiac ultrasound) ischemic cardiopathy-related disorders (dm + ic), and nondiabetic with ischemic cardiopathy-related disorders (ic).
advmod||reported-26/VBN||besides-1/RB	amod||hemangioma-4/NN||unilateral-3/JJ	nsubjpass||reported-26/VBN||hemangioma-4/NN	det||case-9/NN||a-6/DT	amod||case-9/NN||unique-7/JJ	amod||case-9/NN||concurrent-8/JJ	appos||hemangioma-4/NN||case-9/NN	prep_of||case-9/NN||tetracycline-11/NN	vmod||tetracycline-11/NN||induced-12/VBN	amod||toxicity-14/NN||gastric-13/JJ	dobj||induced-12/VBN||toxicity-14/NN	det||dog-17/NN||a-16/DT	prep_in||induced-12/VBN||dog-17/NN	vmod||dog-17/NN||characterized-19/VBN	agent||characterized-19/VBN||gastritis-21/NNS	agent||characterized-19/VBN||ulceration-23/NN	conj_and||gastritis-21/NNS||ulceration-23/NN	aux||reported-26/VBN||is-24/VBZ	auxpass||reported-26/VBN||being-25/VBG	root||ROOT-0/null||reported-26/VBN	advmod||reported-26/VBN||here-27/RB	tetracycline-11||ulceration-23||no_rel||besides, unilateral hemangioma, a unique concurrent case of tetracycline induced gastric toxicity in a dog, characterized by gastritis and ulceration is being reported here.
nsubj||shows-2/VBZ||it-1/PRP	root||ROOT-0/null||shows-2/VBZ	mark||likely-17/JJ||that-3/IN	prep||likely-17/JJ||given-5/VBN	det||epidemiology-8/NN||the-6/DT	amod||epidemiology-8/NN||local-7/JJ	pobj||given-5/VBN||epidemiology-8/NN	det||viruses-12/NNS||the-10/DT	num||viruses-12/NNS||two-11/CD	prep_of||epidemiology-8/NN||viruses-12/NNS	amod||patients-15/NNS||co-infected-14/JJ	nsubj||likely-17/JJ||patients-15/NNS	nsubj||have-19/VB||patients-15/NNS	cop||likely-17/JJ||are-16/VBP	ccomp||shows-2/VBZ||likely-17/JJ	aux||have-19/VB||to-18/TO	xcomp||likely-17/JJ||have-19/VB	amod||levels-22/NNS||low-20/JJ	nn||levels-22/NNS||replication-21/NN	dobj||have-19/VB||levels-22/NNS	prep_of||levels-22/NNS||hbv-24/NN	vmod||hbv-24/NN||suggesting-25/VBG	det||effect-28/NN||a-26/DT	amod||effect-28/NN||suppressive-27/JJ	dobj||suggesting-25/VBG||effect-28/NN	prep_of||effect-28/NN||hcv-30/NN	prep_on||suggesting-25/VBG||hbv-32/NN	hbv-32||viruses-12||no||it shows that, given the local epidemiology of the two viruses, co-infected patients are likely to have low replication levels of hbv suggesting a suppressive effect of hcv on hbv.
nsubj||agent-5/NN||bartonellahenselae-1/NN	nsubj||causes-9/VBZ||bartonellahenselae-1/NN	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||zoonotic-4/JJ	root||ROOT-0/null||agent-5/NN	prep_of||agent-5/NN||catscratchdisease-7/NN	conj_and||agent-5/NN||causes-9/VBZ	advmod||fatal-11/JJ||potentially-10/RB	amod||infections-12/NNS||fatal-11/JJ	dobj||causes-9/VBZ||infections-12/NNS	amod||patients-15/NNS||immunocompromised-14/JJ	prep_in||causes-9/VBZ||patients-15/NNS	catscratchdisease-7||bartonellahenselae-1||no||bartonellahenselae is the zoonotic agent of catscratchdisease and causes potentially fatal infections in immunocompromised patients.
nn||²-2/NNP||tgf-î-1/NNP	nsubjpass||known-5/VBN||²-2/NNP	nsubj||play-7/VB||²-2/NNP	aux||known-5/VBN||has-3/VBZ	auxpass||known-5/VBN||been-4/VBN	root||ROOT-0/null||known-5/VBN	aux||play-7/VB||to-6/TO	xcomp||known-5/VBN||play-7/VB	det||role-10/NN||an-8/DT	amod||role-10/NN||important-9/JJ	dobj||play-7/VB||role-10/NN	amod||liverdiseases-13/NNS||various-12/JJ	prep_in||play-7/VB||liverdiseases-13/NNS	prep_including||liverdiseases-13/NNS||fibrosis-15/NN	amod||liver-19/NN||alcohol-induced-17/JJ	nn||liver-19/NN||fatty-18/NN	prep_including||liverdiseases-13/NNS||liver-19/NN	conj_and||fibrosis-15/NN||liver-19/NN	alcohol--1||fibrosis-15||no_rel||tgf-î² has been known to play an important role in various liverdiseases including fibrosis and alcohol-induced fatty liver.
nsubjpass||injected-4/VBN||animals-1/NNS	nsubj||showed-20/VBD||animals-1/NNS	auxpass||injected-4/VBN||were-3/VBD	rcmod||animals-1/NNS||injected-4/VBN	det||dose-8/NN||a-6/DT	amod||dose-8/NN||low-7/JJ	prep_with||injected-4/VBN||dose-8/NN	num||î-11/NN||10-10/CD	dep||dose-8/NN||î-11/NN	num||g-13/NN||1/4-12/CD	dep||î-11/NN||g-13/NN	nn||transposon-18/NN||statin-16/NN	nn||transposon-18/NN||ae-17/NN	prep_of||dose-8/NN||transposon-18/NN	vmod||transposon-18/NN||plasmid-19/VBN	root||ROOT-0/null||showed-20/VBD	det||decrease-23/NN||a-21/DT	amod||decrease-23/NN||significant-22/JJ	dobj||showed-20/VBD||decrease-23/NN	nn||formation-26/NN||tumor-25/NN	prep_in||showed-20/VBD||formation-26/NN	advmod||plasmid-33/VBD||only-27/RB	advmod||plasmid-33/VBD||when-28/WRB	nsubj||plasmid-33/VBD||co-injected-29/JJ	nn||transposase-encoding-32/NN||sb-31/NN	prep_with||co-injected-29/JJ||transposase-encoding-32/NN	advcl||showed-20/VBD||plasmid-33/VBD	mark||affect-62/VB||while-35/IN	prep_for||affect-62/VB||animals-37/NNS	vmod||animals-37/NNS||injected-38/VBN	det||dose-42/NN||a-40/DT	amod||dose-42/NN||higher-41/JJR	prep_with||injected-38/VBN||dose-42/NN	num||î-45/NN||25-44/CD	dep||dose-42/NN||î-45/NN	num||g-47/NN||1/4-46/CD	dep||î-45/NN||g-47/NN	amod||transposon-52/NN||statin-50/JJ	nn||transposon-52/NN||ae-51/NN	prep_of||dose-42/NN||transposon-52/NN	nsubj||affect-62/VB||co-injection-54/NN	amod||plasmid-58/NN||sb-56/JJ	amod||plasmid-58/NN||transposase-encoding-57/JJ	prep_of||co-injection-54/NN||plasmid-58/NN	aux||affect-62/VB||did-59/VBD	neg||affect-62/VB||not-60/RB	advmod||affect-62/VB||significantly-61/RB	dep||plasmid-33/VBD||affect-62/VB	nn||load-64/NN||tumor-63/NN	dobj||affect-62/VB||load-64/NN	tumor-63||sb-56||no_rel||animals that were injected with a low dose (10 î¼g) of statin ae transposon plasmid showed a significant decrease in tumor formation only when co-injected with sb transposase-encoding plasmid, while for animals injected with a higher dose (25 î¼g) of statin ae transposon, co-injection of sb transposase-encoding plasmid did not significantly affect tumor load.
nsubj||cause-13/NN||staphylococcusaureus-1/NNS	advmod||s.aureus-5/NNS||particularly-3/RB	amod||s.aureus-5/NNS||methicillin-resistant-4/JJ	appos||staphylococcusaureus-1/NNS||s.aureus-5/NNS	nn||-rrb--8/NNP||-lrb--6/NNP	nn||-rrb--8/NNP||mrsa-7/NNP	dep||s.aureus-5/NNS||-rrb--8/NNP	cop||cause-13/NN||is-10/VBZ	det||cause-13/NN||an-11/DT	amod||cause-13/NN||important-12/JJ	root||ROOT-0/null||cause-13/NN	amod||skin-16/NN||pyogenic-15/JJ	prep_of||cause-13/NN||skin-16/NN	nn||-rrb--21/NNS||softtissueinfections-18/NNS	nn||-rrb--21/NNS||-lrb--19/NN	nn||-rrb--21/NNS||sstis-20/NN	prep_of||cause-13/NN||-rrb--21/NNS	conj_and||skin-16/NN||-rrb--21/NNS	mrsa-7||staphylococcusaureus-1||no||staphylococcusaureus , particularly methicillin-resistant s.aureus -lrb- mrsa -rrb- , is an important cause of pyogenic skin and softtissueinfections -lrb- sstis -rrb- .
advmod||humanrabies-2/JJ||most-1/RBS	amod||deaths-3/NNS||humanrabies-2/JJ	nsubjpass||attributed-10/VBN||deaths-3/NNS	det||states-7/NNS||the-5/DT	amod||states-7/NNS||united-6/VBN	prep_in||deaths-3/NNS||states-7/NNS	aux||attributed-10/VBN||can-8/MD	auxpass||attributed-10/VBN||be-9/VB	root||ROOT-0/null||attributed-10/VBN	amod||exposures-13/NNS||unrecognized-12/JJ	prep_to||attributed-10/VBN||exposures-13/NNS	prep_to||attributed-10/VBN||rabiesviruses-15/NNS	vmod||rabiesviruses-15/NNS||associated-16/VBN	prep_with||associated-16/VBN||bats-18/NNS	advmod||rabiesviruses-15/NNS||particularly-20/RB	dep||rabiesviruses-15/NNS||those-21/DT	vmod||those-21/DT||associated-22/VBN	num||species-28/NNS||two-24/CD	amod||species-28/NNS||infrequently-25/JJ	amod||species-28/NNS||encountered-26/JJ	nn||species-28/NNS||bat-27/NN	prep_with||associated-22/VBN||species-28/NNS	nsubj||noctivagans-31/VBZ||lasionycteris-30/NNS	nsubj||pipistrellus-33/VBZ||lasionycteris-30/NNS	dep||those-21/DT||noctivagans-31/VBZ	dep||those-21/DT||pipistrellus-33/VBZ	conj_and||noctivagans-31/VBZ||pipistrellus-33/VBZ	dobj||noctivagans-31/VBZ||subflavus-34/NNS	humanrabies-2||rabiesviruses-15||no||most humanrabies deaths in the united states can be attributed to unrecognized exposures to rabiesviruses associated with bats, particularly those associated with two infrequently encountered bat species ( lasionycteris noctivagans and pipistrellus subflavus ).
nsubjpass||introduced-6/VBN||artesunate-amodiaquine-1/NN	appos||artesunate-amodiaquine-1/NN||as-aq-3/NNP	auxpass||introduced-6/VBN||was-5/VBD	root||ROOT-0/null||introduced-6/VBN	prep_in||introduced-6/VBN||ghana-8/NN	det||drug-13/NN||the-10/DT	amod||drug-13/NN||first-11/JJ	nn||drug-13/NN||line-12/NN	prep_as||introduced-6/VBN||drug-13/NN	prep_for||drug-13/NN||treatment-15/NN	amod||malaria-18/NN||uncomplicated-17/JJ	prep_of||treatment-15/NN||malaria-18/NN	prep_in||malaria-18/NN||2004-20/CD	amodiaquine--1||malaria-18||no_rel||artesunate-amodiaquine (as-aq) was introduced in ghana as the first line drug for treatment of uncomplicated malaria in 2004.
det||woman-3/NN||a-1/DT	amod||woman-3/NN||32-year-old-2/JJ	nsubj||presented-10/VBD||woman-3/NN	det||history-6/NN||a-5/DT	prep_with||woman-3/NN||history-6/NN	amod||use-9/NN||oralcontraceptive-8/JJ	prep_of||history-6/NN||use-9/NN	root||ROOT-0/null||presented-10/VBD	nn||abdominalpain-15/NN||nausea-12/NN	conj_and||nausea-12/NN||severe-14/JJ	nn||abdominalpain-15/NN||severe-14/JJ	prep_with||presented-10/VBD||abdominalpain-15/NN	prep||abdominalpain-15/NN||but-16/CC	neg||ascites-18/NN||no-17/DT	pobj||but-16/CC||ascites-18/NN	pobj||but-16/CC||stigmata-20/NN	conj_or||ascites-18/NN||stigmata-20/NN	prep_of||ascites-18/NN||cirrhosis-22/NNS	cirrhosis-22||oralcontraceptive-8||no_rel||a 32-year-old woman with a history of oralcontraceptive use presented with nausea and severe abdominalpain but no ascites or stigmata of cirrhosis.
amod||inhibitor-3/NN||urinary-1/JJ	nn||inhibitor-3/NN||trypsin-2/NN	nsubjpass||used-16/VBN||inhibitor-3/NN	appos||inhibitor-3/NN||uti-5/NN	det||inhibitor-11/NN||a-8/DT	amod||inhibitor-11/NN||serine-9/JJ	nn||inhibitor-11/NN||protease-10/NN	appos||inhibitor-3/NN||inhibitor-11/NN	aux||used-16/VBN||has-13/VBZ	auxpass||used-16/VBN||been-14/VBN	advmod||used-16/VBN||widely-15/RB	root||ROOT-0/null||used-16/VBN	prep_in||used-16/VBN||japan-18/NN	det||drug-21/NN||a-20/DT	prep_as||used-16/VBN||drug-21/NN	prep_for||drug-21/NN||patients-23/NNS	amod||inflammatory-26/JJ||acute-25/JJ	amod||disorders-27/NNS||inflammatory-26/JJ	prep_with||patients-23/NNS||disorders-27/NNS	amod||coagulation-32/NN||disseminated-30/JJ	nn||coagulation-32/NN||intravascular-31/NN	prep_such_as||disorders-27/NNS||coagulation-32/NN	appos||coagulation-32/NN||dic-34/NN	prep_such_as||disorders-27/NNS||shock-37/NN	conj_and||coagulation-32/NN||shock-37/NN	prep_such_as||disorders-27/NNS||pancreatitis-40/NNS	conj_and||coagulation-32/NN||pancreatitis-40/NNS	shock-37||dic-34||no_rel||urinary trypsin inhibitor (uti), a serine protease inhibitor, has been widely used in japan as a drug for patients with acute inflammatory disorders such as disseminated intravascular coagulation (dic), shock, and pancreatitis.
mark||prevalent-5/JJ||while-1/IN	nsubj||prevalent-5/JJ||jcvirus-2/NNS	cop||prevalent-5/JJ||is-3/VBZ	advmod||prevalent-5/JJ||highly-4/RB	advcl||disease-15/NN||prevalent-5/JJ	det||population-9/NN||the-7/DT	amod||population-9/NN||human-8/JJ	prep_in||prevalent-5/JJ||population-9/NN	nsubj||disease-15/NN||pml-11/NN	cop||disease-15/NN||is-12/VBZ	det||disease-15/NN||a-13/DT	amod||disease-15/NN||rare-14/JJ	root||ROOT-0/null||disease-15/NN	nsubj||afflicts-18/VBZ||disease-15/NN	advmod||afflicts-18/VBZ||exclusively-17/RB	rcmod||disease-15/NN||afflicts-18/VBZ	advmod||percentage-22/NN||only-19/RB	det||percentage-22/NN||a-20/DT	amod||percentage-22/NN||small-21/JJ	dobj||afflicts-18/VBZ||percentage-22/NN	amod||individuals-25/NNS||immunocompromised-24/JJ	prep_of||percentage-22/NN||individuals-25/NNS	prep_including||individuals-25/NNS||those-27/DT	vmod||those-27/DT||affected-28/VBN	amod||aids-32/NNS||hiv-30/JJ	agent||affected-28/VBN||aids-32/NNS	amod||drugs-36/NNS||immunosuppressive-35/JJ	agent||affected-28/VBN||drugs-36/NNS	conj_or||aids-32/NNS||drugs-36/NNS	pml-11||jcvirus-2||no||while jcvirus is highly prevalent in the human population, pml is a rare disease that exclusively afflicts only a small percentage of immunocompromised individuals including those affected by hiv (aids) or immunosuppressive drugs.
nsubj||vitamin-5/NN||niacin-1/NN	cop||vitamin-5/NN||is-2/VBZ	det||vitamin-5/NN||a-3/DT	amod||vitamin-5/NN||b-complex-4/JJ	root||ROOT-0/null||vitamin-5/NN	nsubjpass||used-9/VBN||vitamin-5/NN	aux||used-9/VBN||has-7/VBZ	auxpass||used-9/VBN||been-8/VBN	rcmod||vitamin-5/NN||used-9/VBN	prep_for||used-9/VBN||decades-11/NNS	det||management-14/NN||the-13/DT	prep_for||decades-11/NNS||management-14/NN	amod||dyslipidemias-17/NNS||mixed-16/JJ	prep_of||management-14/NN||dyslipidemias-17/NNS	amod||hypercholesterolemia-20/NN||primary-19/JJ	prep_of||management-14/NN||hypercholesterolemia-20/NN	conj_and||dyslipidemias-17/NNS||hypercholesterolemia-20/NN	vitamin-5||hypercholesterolemia-20||no_rel||niacin is a b-complex vitamin which has been used for decades for the management of mixed dyslipidemias and primary hypercholesterolemia.
dep||alpha-2/NN||human-1/JJ	amod||isoforms-4/NNS||alpha-2/NN	nn||isoforms-4/NNS||importin-3/NN	nsubj||viruses-48/VBZ||isoforms-4/NNS	dep||isoforms-4/NNS||associated-5/VBN	advmod||associated-5/VBN||efficiently-6/RB	amod||protein-9/NN||pb2-8/JJ	prep_to||efficiently-6/RB||protein-9/NN	det||virus-14/NN||an-11/DT	amod||virus-14/NN||h3n2-12/JJ	amod||virus-14/NN||human-13/JJ	prep_of||protein-9/NN||virus-14/NN	dep||isoforms-4/NNS||bound-16/VBN	conj_but||associated-5/VBN||bound-16/VBN	amod||extents-21/NNS||diminished-18/JJ	conj_and||diminished-18/JJ||variable-20/JJ	amod||extents-21/NNS||variable-20/JJ	prep_to||bound-16/VBN||extents-21/NNS	prep_to||bound-16/VBN||pb2-23/NNS	amod||avian-26/NN||h5n1-25/JJ	prep_from||pb2-23/NNS||avian-26/NN	amod||strains-29/NNS||human-28/JJ	prep_from||pb2-23/NNS||strains-29/NNS	conj_or||avian-26/NN||strains-29/NNS	xcomp||bound-16/VBN||suggesting-31/VBG	mark||important-42/JJ||that-32/IN	det||function-34/NN||the-33/DT	nsubj||important-42/JJ||function-34/NN	amod||importin-37/NN||alpha-36/JJ	prep_of||function-34/NN||importin-37/NN	nn||replication-40/NN||rna-39/NN	prep_during||importin-37/NN||replication-40/NN	cop||important-42/JJ||is-41/VBZ	ccomp||suggesting-31/VBG||important-42/JJ	det||adaptation-45/NN||the-44/DT	prep_for||important-42/JJ||adaptation-45/NN	prep_of||adaptation-45/NN||avian-47/NN	root||ROOT-0/null||viruses-48/VBZ	det||host-52/NN||the-50/DT	amod||host-52/NN||human-51/JJ	prep_to||viruses-48/VBZ||host-52/NN	virus-14||viruses-48||no||human alpha importin isoforms associated efficiently to pb2 protein of an h3n2 human virus but bound to diminished and variable extents to pb2 from h5n1 avian or human strains, suggesting that the function of alpha importin during rna replication is important for the adaptation of avian viruses to the human host.
amod||monotherapy-2/NN||thalidomide-1/JJ	nsubj||has-9/VBZ||monotherapy-2/NN	amod||multiplemyeloma-5/NN||relapsed/refractory-4/JJ	prep_in||monotherapy-2/NN||multiplemyeloma-5/NN	appos||monotherapy-2/NN||mm-7/NN	root||ROOT-0/null||has-9/VBZ	det||rate-12/NN||a-10/DT	nn||rate-12/NN||response-11/NN	dobj||has-9/VBZ||rate-12/NN	num||%-15/NN||30-14/CD	prep_of||rate-12/NN||%-15/NN	multiplemyeloma-5||thalidomide-1||yes||thalidomide monotherapy in relapsed/refractory multiplemyeloma (mm) has a response rate of 30%.
nsubj||inhibitor-9/NN||valproicacid-1/NN	appos||valproicacid-1/NN||vpa-3/NN	cop||inhibitor-9/NN||is-5/VBZ	det||inhibitor-9/NN||a-6/DT	amod||inhibitor-9/NN||histone-7/JJ	nn||inhibitor-9/NN||deacetylase-8/NN	root||ROOT-0/null||inhibitor-9/NN	nsubj||holds-11/VBZ||inhibitor-9/NN	rcmod||inhibitor-9/NN||holds-11/VBZ	dobj||holds-11/VBZ||promise-12/NN	nn||therapy-15/NN||cancer-14/NN	prep_for||promise-12/NN||therapy-15/NN	cancer-14||valproicacid-1||no_rel||valproicacid (vpa) is a histone deacetylase inhibitor that holds promise for cancer therapy.
amod||gene-deficient-2/NN||il-10-1/JJ	nn||mice-9/NNS||gene-deficient-2/NN	dep||mice-9/NNS||il10-4/JJ	punct||il10-4/JJ||/-6/:	nsubj||develop-10/VBP||mice-9/NNS	nsubjpass||used-36/VBN||mice-9/NNS	root||ROOT-0/null||develop-10/VBP	amod||colitis-12/NNS||cd-like-11/JJ	dobj||develop-10/VBP||colitis-12/NNS	advmod||develop-10/VBP||mainly-13/RB	det||colon-16/NN||the-15/DT	prep_in||develop-10/VBP||colon-16/NN	prep_in||develop-10/VBP||part-19/NN	amod||responses-23/NNS||inappropriate-22/JJ	prep_due_to||part-19/NN||responses-23/NNS	amod||bacteria-27/NNS||normal-25/JJ	amod||bacteria-27/NNS||intestinal-26/JJ	prep_to||responses-23/NNS||bacteria-27/NNS	amod||strains-30/NNS||enterococcus-29/JJ	prep_including||bacteria-27/NNS||strains-30/NNS	aux||used-36/VBN||have-33/VBP	advmod||used-36/VBN||therefore-34/RB	auxpass||used-36/VBN||been-35/VBN	conj_and||develop-10/VBP||used-36/VBN	det||model-40/NN||an-38/DT	nn||model-40/NN||animal-39/NN	prep_as||used-36/VBN||model-40/NN	prep_of||model-40/NN||cd-42/NN	cd-42||colitis-12||no_rel||il-10 gene-deficient ( il10 -/- ) mice develop cd-like colitis mainly in the colon, in part due to inappropriate responses to normal intestinal bacteria including enterococcus strains, and have therefore been used as an animal model of cd.
det||database-8/NN||the-1/DT	nn||network-4/NN||health-2/NN	nn||network-4/NN||improvement-3/NN	nn||database-8/NN||network-4/NN	dep||network-4/NN||thin-6/JJ	nsubjpass||used-10/VBN||database-8/NN	nsubj||identify-12/VB||database-8/NN	auxpass||used-10/VBN||was-9/VBD	root||ROOT-0/null||used-10/VBN	aux||identify-12/VB||to-11/TO	xcomp||used-10/VBN||identify-12/VB	dobj||identify-12/VB||patients-13/NNS	prep_with||identify-12/VB||adhd-15/NN	nsubj||received-17/VBD||adhd-15/NN	rcmod||adhd-15/NN||received-17/VBD	poss||prescription-20/NN||their-18/PRP$	amod||prescription-20/NN||first-19/JJ	dobj||received-17/VBD||prescription-20/NN	prepc_for||received-17/VBD||methylphenidate-22/NN	punct||dexamfetamine/atomoxetine-24/NN||/-23/:	dep||methylphenidate-22/NN||dexamfetamine/atomoxetine-24/NN	amod||6â-27/NNS||aged-26/JJ	appos||dexamfetamine/atomoxetine-24/NN||6â-27/NNS	num||years-31/NNS||$-28/$	num||$-28/$||17-30/CD	tmod||methylphenidate-22/NN||years-31/NNS	adhd-15||dexamfetamine--1||yes||the health improvement network (thin) database was used to identify patients with adhd who received their first prescription for methylphenidate/ dexamfetamine/atomoxetine, aged 6â€“17 years.
nn||upregulation-2/NN||upa-1/NN	nsubj||have-13/VB||upregulation-2/NN	prep_in||upregulation-2/NN||concert-5/NN	amod||downregulation-10/NN||pai-1-7/JJ	conj_and||pai-1-7/JJ||pge2-9/JJ	amod||downregulation-10/NN||pge2-9/JJ	prep_with||concert-5/NN||downregulation-10/NN	aux||have-13/VB||may-12/MD	root||ROOT-0/null||have-13/VB	det||effect-17/NN||a-14/DT	nn||effect-17/NN||cancer-15/NN	nn||effect-17/NN||preventive-16/NN	dobj||have-13/VB||effect-17/NN	cancer-15||pge2-9||no_rel||upa upregulation, in concert with pai-1 and pge2 downregulation, may have a cancer preventive effect.
amod||data-2/NNS||compelling-1/JJ	nsubj||demonstrate-3/VBP||data-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||results-8/VBZ||that-4/IN	amod||anorexia-6/NN||inflammation-associated-5/JJ	nsubj||results-8/VBZ||anorexia-6/NN	advmod||results-8/VBZ||directly-7/RB	ccomp||demonstrate-3/VBP||results-8/VBZ	det||action-11/NN||the-10/DT	prep_from||results-8/VBZ||action-11/NN	amod||factors-14/NNS||pro-inflammatory-13/JJ	prep_of||action-11/NN||factors-14/NNS	advmod||e2-20/NNS||primarily-16/RB	amod||e2-20/NNS||cytokines-17/JJ	conj_and||cytokines-17/JJ||prostaglandins-19/JJ	amod||e2-20/NNS||prostaglandins-19/JJ	appos||factors-14/NNS||e2-20/NNS	det||system-25/NN||the-23/DT	amod||system-25/NN||nervous-24/JJ	prep_on||results-8/VBZ||system-25/NN	anorexia-6||prostaglandins-19||no_rel||compelling data demonstrate that inflammation-associated anorexia directly results from the action of pro-inflammatory factors, primarily cytokines and prostaglandins e2, on the nervous system.
nsubj||suggest-2/VBP||we-1/PRP	root||ROOT-0/null||suggest-2/VBP	mark||site-8/NN||that-3/IN	det||stomata-5/NN||these-4/DT	nsubj||site-8/NN||stomata-5/NN	cop||site-8/NN||are-6/VBP	det||site-8/NN||the-7/DT	ccomp||suggest-2/VBP||site-8/NN	nsubj||negotiate-17/VB||site-8/NN	prep_of||site-8/NN||retention-10/NN	amod||fibres-13/NNS||long-12/JJ	prep_of||retention-10/NN||fibres-13/NNS	aux||negotiate-17/VB||can-15/MD	neg||negotiate-17/VB||not-16/RB	rcmod||site-8/NN||negotiate-17/VB	nsubj||leading-19/JJ||them-18/PRP	xcomp||negotiate-17/VB||leading-19/JJ	nn||pathology-24/NN||inflammation-21/NN	conj_and||inflammation-21/NN||pleural-23/NN	nn||pathology-24/NN||pleural-23/NN	prep_to||leading-19/JJ||pathology-24/NN	prep_including||pathology-24/NN||mesothelioma-26/NN	mesothelioma-26||fibres-13||no_rel||we suggest that these stomata are the site of retention of long fibres which cannot negotiate them leading to inflammation and pleural pathology including mesothelioma.
amod||patients-2/NNS||sixty-1/JJ	nsubjpass||divided-12/VBN||patients-2/NNS	prep_with||patients-2/NNS||psychoticdisorder-4/NN	nsubjpass||assigned-7/VBN||psychoticdisorder-4/NN	auxpass||assigned-7/VBN||were-6/VBD	rcmod||psychoticdisorder-4/NN||assigned-7/VBN	amod||treatment-10/NN||6-month-9/JJ	prep_to||assigned-7/VBN||treatment-10/NN	auxpass||divided-12/VBN||were-11/VBD	root||ROOT-0/null||divided-12/VBN	num||groups-15/NNS||two-14/CD	prep_in||divided-12/VBN||groups-15/NNS	num||haloperidol-18/NN||30-16/CD	amod||haloperidol-18/NN||received-17/VBN	dobj||divided-12/VBN||haloperidol-18/NN	amod||antipsychotic-22/NN||first-20/JJ	nn||antipsychotic-22/NN||generation-21/NN	appos||haloperidol-18/NN||antipsychotic-22/NN	num||olanzapine-27/NN||30-25/CD	amod||olanzapine-27/NN||received-26/VBN	dobj||divided-12/VBN||olanzapine-27/NN	conj_and||haloperidol-18/NN||olanzapine-27/NN	amod||antipsychotic-31/NN||second-29/JJ	nn||antipsychotic-31/NN||generation-30/NN	appos||olanzapine-27/NN||antipsychotic-31/NN	psychoticdisorder-4||haloperidol-18||yes||sixty patients with psychoticdisorder who were assigned to 6-month treatment were divided in two groups 30 received haloperidol (first generation antipsychotic) and 30 received olanzapine (second generation antipsychotic).
det||increase-3/NN||the-1/DT	amod||increase-3/NN||observed-2/JJ	nsubj||indicates-10/VBZ||increase-3/NN	amod||ratio-9/NN||serum-5/JJ	amod||ratio-9/NN||igf-1-6/JJ	conj_and||igf-1-6/JJ||insulin-to-glucose-8/JJ	amod||ratio-9/NN||insulin-to-glucose-8/JJ	prep_of||increase-3/NN||ratio-9/NN	root||ROOT-0/null||indicates-10/VBZ	mark||result-15/VB||that-11/IN	nn||restriction-13/NN||sleep-12/NN	nsubj||result-15/VB||restriction-13/NN	aux||result-15/VB||may-14/MD	ccomp||indicates-10/VBZ||result-15/VB	det||risk-19/NN||an-17/DT	amod||risk-19/NN||increased-18/VBN	prep_in||result-15/VB||risk-19/NN	aux||develop-21/VB||to-20/TO	vmod||risk-19/NN||develop-21/VB	dobj||develop-21/VB||type2diabetes-22/NNS	insulin--1||type2diabetes-22||no_rel||the observed increase of serum igf-1 and insulin-to-glucose ratio indicates that sleep restriction may result in an increased risk to develop type2diabetes.
det||mouse-7/NN||the-1/DT	amod||mouse-7/NN||nonobese-2/JJ	nn||mouse-7/NN||diabetic-3/NN	appos||mouse-7/NN||nod-5/NN	nsubj||model-12/NN||mouse-7/NN	cop||model-12/NN||is-8/VBZ	det||model-12/NN||a-9/DT	amod||model-12/NN||well-established-10/JJ	nn||model-12/NN||mouse-11/NN	root||ROOT-0/null||model-12/NN	amod||type1diabetes-15/NNS||spontaneous-14/JJ	prep_of||model-12/NN||type1diabetes-15/NNS	nsubjpass||characterized-19/VBN||type1diabetes-15/NNS	auxpass||characterized-19/VBN||is-18/VBZ	rcmod||type1diabetes-15/NNS||characterized-19/VBN	det||destruction-23/NN||an-21/DT	amod||destruction-23/NN||autoimmune-22/JJ	agent||characterized-19/VBN||destruction-23/NN	det||²-29/NN||the-25/DT	amod||²-29/NN||insulin-secreting-26/JJ	amod||²-29/NN||pancreatic-27/JJ	nn||²-29/NN||î-28/NN	prep_of||destruction-23/NN||²-29/NN	dep||²-29/NN||cells-31/NNS	type1diabetes-15||insulin--1||yes||the nonobese diabetic (nod) mouse is a well-established mouse model of spontaneous type1diabetes, which is characterized by an autoimmune destruction of the insulin-secreting pancreatic î²-cells.
det||study-2/NN||this-1/DT	nsubjpass||designed-4/VBN||study-2/NN	nsubj||evaluate-6/VB||study-2/NN	auxpass||designed-4/VBN||was-3/VBD	root||ROOT-0/null||designed-4/VBN	aux||evaluate-6/VB||to-5/TO	xcomp||designed-4/VBN||evaluate-6/VB	det||efficacy-8/NN||the-7/DT	dobj||evaluate-6/VB||efficacy-8/NN	dobj||evaluate-6/VB||safety-10/NN	conj_and||efficacy-8/NN||safety-10/NN	amod||mmc-14/NN||mitomycin-c-12/JJ	prep_of||efficacy-8/NN||mmc-14/NN	vmod||mmc-14/NN||augmented-16/VBN	xcomp||augmented-16/VBN||needling-17/VBG	dobj||needling-17/VBG||procedure-18/NN	det||management-21/NN||the-20/DT	prep_in||needling-17/VBG||management-21/NN	amod||bleb-24/NN||failed-23/VBN	prep_of||management-21/NN||bleb-24/NN	prep_after||evaluate-6/VB||trabeculectomy-26/NN	amod||glaucoma-29/NN||congenital-28/JJ	prep_in||evaluate-6/VB||glaucoma-29/NN	glaucoma-29||mitomycin-c-12||yes||this study was designed to evaluate the efficacy and safety of mitomycin-c (mmc) augmented needling procedure in the management of failed bleb after trabeculectomy in congenital glaucoma.
det||contribution-2/NN||the-1/DT	nsubjpass||considered-15/VBN||contribution-2/NN	nn||use-5/NN||alcohol-4/NN	prep_of||contribution-2/NN||use-5/NN	det||vulnerability-9/NN||the-7/DT	nn||vulnerability-9/NN||hiv-8/NN	prep_to||use-5/NN||vulnerability-9/NN	prep_of||vulnerability-9/NN||women-11/NNS	auxpass||considered-15/VBN||is-12/VBZ	neg||considered-15/VBN||not-13/RB	advmod||considered-15/VBN||currently-14/RB	root||ROOT-0/null||considered-15/VBN	advmod||designed-22/VBN||when-16/WRB	nn||programs-19/NNS||hiv-17/NN	nn||programs-19/NNS||prevention-18/NN	nsubjpass||designed-22/VBN||programs-19/NNS	nsubjpass||implemented-24/VBN||programs-19/NNS	aux||designed-22/VBN||are-20/VBP	auxpass||designed-22/VBN||being-21/VBG	advcl||considered-15/VBN||designed-22/VBN	advcl||considered-15/VBN||implemented-24/VBN	conj_and||designed-22/VBN||implemented-24/VBN	xcomp||designed-22/VBN||leaving-25/VBG	det||group-27/NN||a-26/DT	dobj||leaving-25/VBG||group-27/NN	amod||women-30/NNS||high-risk-29/JJ	prep_of||group-27/NN||women-30/NNS	vmod||women-30/NNS||uncovered-31/VBN	advmod||needed-34/VBN||much-33/RB	amod||services-35/NNS||needed-34/VBN	agent||uncovered-31/VBN||services-35/NNS	prep_such_as||services-35/NNS||treatment-38/NN	det||range-41/NN||a-40/DT	prep_for||treatment-38/NN||range-41/NN	nn||problems-44/NNS||health-43/NN	prep_of||range-41/NN||problems-44/NNS	prep_including||problems-44/NNS||alcoholdependence-46/NN	alcohol-4||alcoholdependence-46||no_rel||the contribution of alcohol use to the hiv vulnerability of women is not currently considered when hiv prevention programs are being designed and implemented leaving a group of high-risk women uncovered by much needed services such as treatment for a range of health problems including alcoholdependence.
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||safety-4/NN||the-3/DT	dobj||compare-2/VB||safety-4/NN	dobj||compare-2/VB||efficacy-6/NN	conj_and||safety-4/NN||efficacy-6/NN	amod||ointment-10/NN||loteprednoletabonate-8/JJ	amod||ointment-10/NN||ophthalmic-9/JJ	prep_of||safety-4/NN||ointment-10/NN	number||%-12/NN||0.5-11/CD	amod||ointment-10/NN||%-12/NN	amod||ointment-15/NN||le-14/JJ	appos||ointment-10/NN||ointment-15/NN	det||formulation-22/NN||a-18/DT	amod||formulation-22/NN||new-19/JJ	amod||formulation-22/NN||topical-20/JJ	nn||formulation-22/NN||ointment-21/NN	appos||ointment-10/NN||formulation-22/NN	prep_with||compare-2/VB||vehicle-25/NN	det||treatment-28/NN||the-27/DT	prep_for||vehicle-25/NN||treatment-28/NN	prep_of||treatment-28/NN||inflammation-30/NN	prep_of||treatment-28/NN||pain-32/NN	conj_and||inflammation-30/NN||pain-32/NN	nn||surgery-35/NN||cataract-34/NN	prep_following||vehicle-25/NN||surgery-35/NN	loteprednoletabonate-8||inflammation-30||no_rel||to compare the safety and efficacy of loteprednoletabonate ophthalmic ointment 0.5% (le ointment), a new topical ointment formulation, with vehicle for the treatment of inflammation and pain following cataract surgery.
advmod||promoted-12/VBD||overall-1/RB	num||%-4/NN||30-3/CD	nsubj||promoted-12/VBD||%-4/NN	prep_of||%-4/NN||bowenoidpapulosis-6/NNS	amod||hpv-10/NN||high-8/JJ	nn||hpv-10/NN||risk-9/NN	prep_with||bowenoidpapulosis-6/NNS||hpv-10/NN	advmod||promoted-12/VBD||strongly-11/RB	root||ROOT-0/null||promoted-12/VBD	dobj||promoted-12/VBD||iaps-13/NNS	amod||iaps-13/NNS||family-14/NN	amod||iaps-13/NNS||c-myc-16/JJ	conj_and||family-14/NN||c-myc-16/JJ	nsubj||activate-22/VB||condylomaacuminatum-18/NN	aux||activate-22/VB||did-19/VBD	neg||activate-22/VB||not-20/RB	advmod||activate-22/VB||significantly-21/RB	conj_but||promoted-12/VBD||activate-22/VB	det||genes-24/NNS||those-23/DT	dobj||activate-22/VB||genes-24/NNS	bowenoidpapulosis-6||hpv-10||no||overall, 30% of bowenoidpapulosis with high risk hpv strongly promoted iaps family and c-myc but condylomaacuminatum did not significantly activate those genes.
aux||explore-2/VB||to-1/TO	csubj||randomized-25/VBD||explore-2/VB	dobj||explore-2/VB||patients-3/NNS	nn||professionals-7/NNS||health-6/NN	poss||experiences-9/NNS||professionals-7/NNS	dobj||explore-2/VB||experiences-9/NNS	conj_and||patients-3/NNS||experiences-9/NNS	prepc_of||experiences-9/NNS||initiating-11/VBG	dobj||initiating-11/VBG||insulin-12/NN	prep_as||initiating-11/VBG||part-14/NN	det||treating-17/NN||the-16/DT	prep_of||part-14/NN||treating-17/NN	aux||target-19/VB||to-18/TO	vmod||treating-17/NN||target-19/VB	prep_in||target-19/VB||type2diabetes-21/CD	dep||experiences-9/NNS||4-t-23/JJ	root||ROOT-0/null||randomized-25/VBD	amod||trial-27/NN||controlled-26/JJ	dobj||randomized-25/VBD||trial-27/NN	type2diabetes-21||insulin-12||yes||to explore patients' and health professionals' experiences of initiating insulin as part of the treating to target in type2diabetes (4-t) randomized controlled trial.
poss||approach-2/NN||our-1/PRP$	nsubjpass||based-4/VBN||approach-2/NN	auxpass||based-4/VBN||was-3/VBD	root||ROOT-0/null||based-4/VBN	prep_on||based-4/VBN||pre-fractionation-6/NN	nn||exchange-9/NN||ion-8/NN	prep_with||based-4/VBN||exchange-9/NN	advmod||coupled-11/VBN||chromatography-10/RB	vmod||exchange-9/NN||coupled-11/VBN	prep_with||coupled-11/VBN||matrix-13/NN	vmod||matrix-13/NN||assisted-14/VBN	nn||desorption-time-16/NN||laser-15/NN	dobj||assisted-14/VBN||desorption-time-16/NN	nn||analysis-21/NN||flight-18/NN	nn||analysis-21/NN||mass-19/NN	nn||analysis-21/NN||spectrometry-20/NN	prep_of||desorption-time-16/NN||analysis-21/NN	vmod||analysis-21/NN||assisted-22/VBN	det||chromatography-26/NN||a-24/DT	amod||chromatography-26/NN||liquid-25/JJ	agent||assisted-22/VBN||chromatography-26/NN	dep||chromatography-26/NN||lc-maldi-tof/tof-28/JJ	tof--1||ion-8||no_rel||our approach was based on pre-fractionation with ion exchange chromatography coupled with matrix assisted laser desorption-time of flight mass spectrometry analysis assisted by a liquid chromatography (lc-maldi-tof/tof).
nsubjpass||defined-3/VBN||type1diabetes-1/NNS	auxpass||defined-3/VBN||was-2/VBD	root||ROOT-0/null||defined-3/VBN	prep_as||defined-3/VBN||age-5/NN	nn||years-12/NNS||onset-7/NNP	nn||years-12/NNS||â-8/NNP	nn||years-12/NNS||‰-9/NNP	amod||years-12/NNS||$-10/$	number||$-10/$||40-11/CD	prep_at||defined-3/VBN||years-12/NNS	nn||treatment-15/NN||insulin-14/NN	appos||years-12/NNS||treatment-15/NN	vmod||treatment-15/NN||initiated-16/VBN	num||year-19/NN||1-18/CD	prep_within||initiated-16/VBN||year-19/NN	amod||â-23/NN||c-peptide-22/JJ	nsubj||‰-24/VBZ||â-23/NN	conj_and||defined-3/VBN||‰-24/VBZ	amod||nmol/l-27/NN||$-25/$	number||$-25/$||0.3-26/CD	dobj||‰-24/VBZ||nmol/l-27/NN	type1diabetes-1||insulin-14||yes||type1diabetes was defined as age at onset â‰¤40 years, insulin treatment initiated within 1 year, and c-peptide â‰¤0.3 nmol/l.
neg||difference-4/NN||no-1/DT	advmod||significant-3/JJ||statistically-2/RB	amod||difference-4/NN||significant-3/JJ	nsubjpass||found-6/VBN||difference-4/NN	auxpass||found-6/VBN||was-5/VBD	root||ROOT-0/null||found-6/VBN	det||groups-12/NNS||the-8/DT	nn||groups-12/NNS||dexamethasone-9/NN	conj_and||dexamethasone-9/NN||placebo-11/NN	nn||groups-12/NNS||placebo-11/NN	prep_between||found-6/VBN||groups-12/NNS	nn||score-15/NN||pain-14/NN	prep_in||found-6/VBN||score-15/NN	prep_in||found-6/VBN||nausea-17/NN	conj_or||score-15/NN||nausea-17/NN	prep_in||found-6/VBN||vomiting-19/NN	conj_or||score-15/NN||vomiting-19/NN	prep_in||found-6/VBN||irritability-21/NN	conj_or||score-15/NN||irritability-21/NN	amod||postoperatively-26/NN||analgesic-24/JJ	nn||postoperatively-26/NN||requirement-25/NN	prep_in||found-6/VBN||postoperatively-26/NN	conj_or||score-15/NN||postoperatively-26/NN	nausea-17||dexamethasone-9||yes||no statistically significant difference was found between the dexamethasone and placebo groups in pain score, nausea, vomiting, irritability, or analgesic requirement postoperatively.
amod||scores-4/NNS||verbal-1/JJ	amod||scores-4/NNS||analogue-2/JJ	nn||scores-4/NNS||pain-3/NN	nsubj||need-11/VBP||scores-4/NNS	appos||scores-4/NNS||incidence-6/NN	amod||pain-9/NN||distressing-8/JJ	prep_of||incidence-6/NN||pain-9/NN	ccomp||recorded-28/VBN||need-11/VBP	amod||boluses-14/NNS||supplementary/rescue-13/JJ	prep_of||need-11/VBP||boluses-14/NNS	appos||boluses-14/NNS||dose-16/NN	prep_of||dose-16/NN||bupivacaine-18/NN	vmod||bupivacaine-18/NN||consumed-19/VBN	amod||satisfaction-22/NN||maternal-21/JJ	nsubjpass||recorded-28/VBN||satisfaction-22/NN	amod||scores-26/NNS||neonatal-24/JJ	nn||scores-26/NNS||apgar-25/NN	conj_and||satisfaction-22/NN||scores-26/NNS	nsubjpass||recorded-28/VBN||scores-26/NNS	auxpass||recorded-28/VBN||were-27/VBD	root||ROOT-0/null||recorded-28/VBN	pain-9||bupivacaine-18||yes||verbal analogue pain scores, incidence of distressing pain, need of supplementary/rescue boluses, dose of bupivacaine consumed, maternal satisfaction and neonatal apgar scores were recorded.
mark||cause-5/NN||since-1/IN	nsubj||cause-5/NN||legionella-2/NN	cop||cause-5/NN||is-3/VBZ	det||cause-5/NN||a-4/DT	nsubj||require-17/VBP||cause-5/NN	advcl||taken-23/VBN||cause-5/NN	number||%-11/NN||2-7/CD	dep||%-11/NN||%-8/NN	dep||%-11/NN||to-9/TO	number||%-11/NN||15-10/CD	prep_of||cause-5/NN||%-11/NN	det||pneumonias-15/NNS||all-13/DT	amod||pneumonias-15/NNS||community-acquired-14/JJ	prep_of||%-11/NN||pneumonias-15/NNS	rcmod||cause-5/NN||require-17/VBP	dobj||require-17/VBP||hospitalization-18/NN	nsubjpass||taken-23/VBN||legionellosis-20/NNS	nsubjpass||forgotten-34/VBN||legionellosis-20/NNS	aux||taken-23/VBN||should-21/MD	auxpass||taken-23/VBN||be-22/VB	root||ROOT-0/null||taken-23/VBN	prep_into||taken-23/VBN||account-25/NN	det||infection-30/NN||an-27/DT	amod||infection-30/NN||atypical-28/JJ	amod||infection-30/NN||pulmonary-29/JJ	prep_in||account-25/NN||infection-30/NN	neg||forgotten-34/VBN||not-32/RB	auxpass||forgotten-34/VBN||be-33/VB	conj_and||taken-23/VBN||forgotten-34/VBN	legionellosis-20||legionella-2||no||since legionella is a cause of 2% to 15% of all community-acquired pneumonias that require hospitalization, legionellosis should be taken into account in an atypical pulmonary infection and not be forgotten.
det||factors-2/NNS||some-1/DT	nsubjpass||correlated-7/VBN||factors-2/NNS	prep_of||factors-2/NNS||ptg-4/NN	auxpass||correlated-7/VBN||were-5/VBD	advmod||correlated-7/VBN||positively-6/RB	root||ROOT-0/null||correlated-7/VBN	prep_with||correlated-7/VBN||resilience-9/NN	nsubjpass||regarded-14/VBN||resilience-9/NN	aux||regarded-14/VBN||can-12/MD	auxpass||regarded-14/VBN||be-13/VB	rcmod||resilience-9/NN||regarded-14/VBN	det||outcome-17/NN||an-16/DT	prep_as||regarded-14/VBN||outcome-17/NN	prepc_of||outcome-17/NN||coping-19/VBG	dobj||coping-19/VBG||success-20/NN	mark||correlated-29/VBN||whereas-22/IN	amod||factors-24/NNS||other-23/JJ	nsubjpass||correlated-29/VBN||factors-24/NNS	prep_of||factors-24/NNS||ptg-26/NN	auxpass||correlated-29/VBN||were-27/VBD	advmod||correlated-29/VBN||positively-28/RB	advcl||correlated-7/VBN||correlated-29/VBN	amod||symptoms-32/NNS||ptsd-31/JJ	prep_with||correlated-29/VBN||symptoms-32/NNS	nsubjpass||regarded-37/VBN||symptoms-32/NNS	aux||regarded-37/VBN||can-35/MD	auxpass||regarded-37/VBN||be-36/VB	rcmod||symptoms-32/NNS||regarded-37/VBN	prepc_as||regarded-37/VBN||signifying-39/VBG	vmod||signifying-39/VBG||coping-40/VBG	dobj||coping-40/VBG||effort-41/NN	det||face-44/NN||the-43/DT	prep_in||coping-40/VBG||face-44/NN	amod||distress-47/NN||enduring-46/VBG	prep_of||face-44/NN||distress-47/NN	ptsd-31||ptg-26||no_rel||some factors of ptg were positively correlated with resilience, which can be regarded as an outcome of coping success, whereas other factors of ptg were positively correlated with ptsd symptoms, which can be regarded as signifying coping effort in the face of enduring distress.
det||sample-3/NN||a-1/DT	amod||sample-3/NN||representative-2/JJ	nsubj||-lrb--8/VBZ||sample-3/NN	det||population-7/NN||the-5/DT	nn||population-7/NN||u.s.-6/NN	prep_of||sample-3/NN||population-7/NN	root||ROOT-0/null||-lrb--8/VBZ	det||health-11/NN||the-9/DT	amod||health-11/NN||national-10/JJ	iobj||-lrb--8/VBZ||health-11/NN	nn||survey-15/NN||nutrition-13/NN	nn||survey-15/NN||examination-14/NN	iobj||-lrb--8/VBZ||survey-15/NN	conj_and||health-11/NN||survey-15/NN	amod||nhanes-17/NNS||-lsb--16/JJ	dobj||-lrb--8/VBZ||nhanes-17/NNS	dep||-rrb--19/NN||-rsb--18/NN	amod||nhanes-17/NNS||-rrb--19/NN	amod||$-22/NNS||2005â-21/JJ	prep_from||nhanes-17/NNS||$-22/NNS	nsubjpass||assessed-42/VBN||2006-24/CD	nsubj||determine-44/VB||2006-24/CD	num||adults-28/NNS||1,547-26/CD	amod||adults-28/NNS||nondiabetic-27/JJ	prep_including||2006-24/CD||adults-28/NNS	vmod||adults-28/NNS||-lrb--29/VBN	dep||years-32/NNS||>-30/SYM	num||years-32/NNS||18-31/CD	dep||-lrb--29/VBN||years-32/NNS	nn||-rrb--35/NNS||age-34/NN	prep_of||years-32/NNS||-rrb--35/NNS	det||history-38/NN||a-37/DT	prep_without||-lrb--29/VBN||history-38/NN	prep_of||history-38/NN||myocardialinfarction-40/NN	auxpass||assessed-42/VBN||was-41/VBD	dep||nhanes-17/NNS||assessed-42/VBN	aux||determine-44/VB||to-43/TO	xcomp||assessed-42/VBN||determine-44/VB	det||proportion-46/NN||the-45/DT	dobj||determine-44/VB||proportion-46/NN	prep_of||proportion-46/NN||adults-48/NNS	nsubj||met-50/VBD||adults-48/NNS	rcmod||adults-48/NNS||met-50/VBD	det||criteria-52/NNS||the-51/DT	dobj||met-50/VBD||criteria-52/NNS	prep_for||met-50/VBD||ifg/igt-54/NN	det||proportion-58/NN||the-57/DT	prep_of||proportion-46/NN||proportion-58/NN	conj_and||adults-48/NNS||proportion-58/NN	dobj||reported-65/VBD||proportion-58/NN	amod||subjects-61/NNS||ifg/igt-60/JJ	prep_of||proportion-58/NN||subjects-61/NNS	num||-rrb--64/NNS||1-63/CD	nsubj||reported-65/VBD||-rrb--64/NNS	rcmod||proportion-58/NN||reported-65/VBD	xcomp||reported-65/VBD||receiving-66/VBG	det||diagnosis-68/NN||a-67/DT	dobj||receiving-66/VBG||diagnosis-68/NN	poss||physicians-71/NNS||their-70/PRP$	prep_from||receiving-66/VBG||physicians-71/NNS	num||-rrb--74/NNS||2-73/CD	nsubjpass||prescribed-76/VBN||-rrb--74/NNS	auxpass||prescribed-76/VBN||were-75/VBD	dep||nhanes-17/NNS||prescribed-76/VBN	conj_and||assessed-42/VBN||prescribed-76/VBN	nn||modification-78/NN||lifestyle-77/NN	dobj||prescribed-76/VBN||modification-78/NN	det||agent-82/NN||an-80/DT	amod||agent-82/NN||antihyperglycemic-81/JJ	dobj||prescribed-76/VBN||agent-82/NN	conj_or||modification-78/NN||agent-82/NN	num||-rrb--86/NNS||3-85/CD	nsubj||were-87/VBD||-rrb--86/NNS	dep||nhanes-17/NNS||were-87/VBD	conj_and||assessed-42/VBN||were-87/VBD	advmod||were-87/VBD||currently-88/RB	prep_on||were-87/VBD||therapy-90/NN	myocardialinfarction-40||antihyperglycemic-81||no_rel||a representative sample of the u.s. population -lrb- the national health and nutrition examination survey -lsb- nhanes -rsb- -rrb- from 2005â $ `` 2006 including 1,547 nondiabetic adults -lrb- > 18 years of age -rrb- without a history of myocardialinfarction was assessed to determine the proportion of adults who met the criteria for ifg/igt , and the proportion of ifg/igt subjects who 1 -rrb- reported receiving a diagnosis from their physicians ; 2 -rrb- were prescribed lifestyle modification or an antihyperglycemic agent ; and 3 -rrb- were currently on therapy .
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||identify-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||identify-8/VB||to-7/TO	xcomp||was-6/VBD||identify-8/VB	det||presence-10/NN||the-9/DT	dobj||identify-8/VB||presence-10/NN	iobj||identify-8/VB||presence-10/NN	amod||inh-14/NN||isoniazid-12/JJ	prep_of||presence-10/NN||inh-14/NN	prep_of||presence-10/NN||rifampicin-17/NN	conj_and||inh-14/NN||rifampicin-17/NN	appos||presence-10/NN||rif-19/NN	nn||resistance-22/NN||drug-21/NN	dep||presence-10/NN||resistance-22/NN	amod||cases-32/NNS||new-24/JJ	advmod||treated-27/JJ||previously-26/RB	conj_and||new-24/JJ||treated-27/JJ	amod||cases-32/NNS||treated-27/JJ	nn||cases-32/NNS||tuberculosis-28/NNP	appos||cases-32/NNS||tb-30/NN	prep_in||resistance-22/NN||cases-32/NNS	vmod||cases-32/NNS||using-33/VBG	nn||sequencing-35/NN||dna-34/NN	dobj||using-33/VBG||sequencing-35/NN	tuberculosis-28||isoniazid-12||yes||the aim of this study was to identify the presence of isoniazid (inh) and rifampicin(rif) drug resistance in new and previously treated tuberculosis (tb) cases using dna sequencing.
amod||men-2/NNS||fifty-nine-1/JJ	nsubjpass||studied-14/VBN||men-2/NNS	advmod||controlled-5/VBN||well-4/RB	amod||type2diabetes-6/NNS||controlled-5/VBN	prep_with||men-2/NNS||type2diabetes-6/NNS	num||men-12/NNS||18-8/CD	amod||men-12/NNS||age-matched-9/JJ	amod||men-12/NNS||healthy-10/JJ	amod||men-12/NNS||normoglycemic-11/JJ	prep_with||men-2/NNS||men-12/NNS	conj_and||type2diabetes-6/NNS||men-12/NNS	auxpass||studied-14/VBN||were-13/VBD	root||ROOT-0/null||studied-14/VBN	xcomp||studied-14/VBN||using-15/VBG	amod||tomography-18/NN||positron-16/JJ	nn||tomography-18/NN||emission-17/NN	dobj||using-15/VBG||tomography-18/NN	aux||assess-20/VB||to-19/TO	vmod||using-15/VBG||assess-20/VB	amod||perfusion-23/NN||hepatic-21/JJ	nn||perfusion-23/NN||tissue-22/NN	dobj||assess-20/VB||perfusion-23/NN	amod||glucose-26/NN||insulin-stimulated-25/JJ	dobj||assess-20/VB||glucose-26/NN	amod||metabolism-31/NN||fasting-29/JJ	amod||metabolism-31/NN||fattyacid-30/JJ	dobj||assess-20/VB||metabolism-31/NN	conj_and||glucose-26/NN||metabolism-31/NN	dobj||assess-20/VB||respectively-33/RB	advmod||glucose-26/NN||respectively-33/RB	conj_and||glucose-26/NN||respectively-33/RB	prep_in||assess-20/VB||relation-36/NN	amod||content-40/NN||hepatic-38/JJ	nn||content-40/NN||triglyceride-39/NN	prep_to||relation-36/NN||content-40/NN	vmod||content-40/NN||quantified-42/VBN	amod||spectroscopy-47/NN||proton-44/JJ	amod||spectroscopy-47/NN||magnetic-45/JJ	nn||spectroscopy-47/NN||resonance-46/NN	agent||quantified-42/VBN||spectroscopy-47/NN	glucose-26||type2diabetes-6||no_rel||fifty-nine men with well controlled type2diabetes and 18 age-matched healthy normoglycemic men were studied using positron emission tomography to assess hepatic tissue perfusion, insulin-stimulated glucose, and fasting fattyacid metabolism, respectively, in relation to hepatic triglyceride content, quantified by proton magnetic resonance spectroscopy.
amod||cmv-3/NN||human-2/JJ	prep_unlike||profile-39/VB||cmv-3/NN	appos||cmv-3/NN||hcmv-5/NNP	dep||reduced-12/VBN||whose-8/WP$	nsubjpass||reduced-12/VBN||growth-9/NN	auxpass||reduced-12/VBN||was-10/VBD	advmod||reduced-12/VBN||significantly-11/RB	dep||cmv-3/NN||reduced-12/VBN	advmod||tagged-25/VBN||when-13/WRB	nsubjpass||tagged-25/VBN||ie2-14/NNS	det||homologue-18/NN||the-16/DT	amod||homologue-18/NN||hcmv-17/JJ	dep||ie2-14/NNS||homologue-18/NN	prep_of||homologue-18/NN||ie3-20/NNS	prep_in||ie3-20/NNS||mcmv-22/NNP	auxpass||tagged-25/VBN||was-24/VBD	advcl||reduced-12/VBN||tagged-25/VBN	prep_with||tagged-25/VBN||egfp-27/NN	nsubj||profile-39/VB||mcmvs-29/NNS	prepc_with||mcmvs-29/NNS||ie3â-31/VBG	dobj||ie3â-31/VBG||$-32/$	npadvmod||unchanged-37/RB||egfp-34/NN	num||egfp-34/NN||presented-35/CD	advmod||egfp-34/NN||an-36/DT	dep||replication-38/CD||unchanged-37/RB	num||$-32/$||replication-38/CD	root||ROOT-0/null||profile-39/VB	cmv-3||hcmv-17||no||unlike human cmv (hcmv), whose growth was significantly reduced when ie2 (the hcmv homologue of ie3 in mcmv) was tagged with egfp, mcmvs with ie3â€“egfp presented an unchanged replication profile.
det||probability-3/NN||the-1/DT	amod||probability-3/NN||cumulative-2/JJ	nsubj||%-23/NN||probability-3/NN	prep_of||probability-3/NN||hivinfection-5/NN	nsubjpass||tested-15/VBN||hivinfection-5/NN	prep_among||hivinfection-5/NN||babies-7/NNS	amod||regimen-12/NN||single-9/JJ	nn||regimen-12/NN||dose-10/NN	nn||regimen-12/NN||nevirapine-11/NN	prep_on||babies-7/NNS||regimen-12/NN	auxpass||tested-15/VBN||were-14/VBD	rcmod||hivinfection-5/NN||tested-15/VBN	prepc_at||tested-15/VBN||>-17/VBG	dep||months-20/NNS||=-18/SYM	num||months-20/NNS||18-19/CD	ccomp||>-17/VBG||months-20/NNS	cop||%-23/NN||was-21/VBD	num||%-23/NN||15.0-22/CD	root||ROOT-0/null||%-23/NN	num||%-26/NN||95-25/CD	dep||%-23/NN||%-26/NN	vmod||%-26/NN||ci-27/VBN	num||.1-29/CD||9.8-22-28/CD	dobj||ci-27/VBN||.1-29/CD	prep_in||%-23/NN||2007-32/CD	mark||%-38/NN||whereas-34/IN	nsubj||%-38/NN||it-35/PRP	cop||%-38/NN||was-36/VBD	num||%-38/NN||8.2-37/CD	advcl||%-23/NN||%-38/NN	num||%-41/NN||95-40/CD	dep||%-38/NN||%-41/NN	vmod||%-41/NN||ci-42/VBN	num||.97-44/CD||5.55-11-43/CD	dobj||ci-42/VBN||.97-44/CD	prep_among||%-38/NN||babies-47/NNS	nsubjpass||tested-53/VBN||babies-47/NNS	amod||regimen-50/NN||zidovudine-49/JJ	prep_on||babies-47/NNS||regimen-50/NN	auxpass||tested-53/VBN||were-52/VBD	rcmod||babies-47/NNS||tested-53/VBN	prepc_at||tested-53/VBN||>-55/VBG	dep||days-58/NNS||=-56/SYM	num||days-58/NNS||45-57/CD	ccomp||>-55/VBG||days-58/NNS	prep_in||>-55/VBG||2009-60/CD	hivinfection-5||nevirapine-11||yes||the cumulative probability of hivinfection among babies on single dose nevirapine regimen who were tested at >=18 months was 15.0% (95% ci 9.8-22.1) in 2007, whereas it was 8.2% (95% ci 5.55-11.97) among babies on zidovudine regimen who were tested at >=45 days in 2009.
det||challenge-4/NN||a-2/DT	amod||challenge-4/NN||controlled-3/JJ	prep_in||found-12/VBN||challenge-4/NN	prep_with||challenge-4/NN||glucose-6/NN	nn||factor-10/NN||tumor-8/NN	nn||factor-10/NN||necrosis-9/NNS	nsubjpass||found-12/VBN||factor-10/NN	nsubjpass||elevated-15/VBN||factor-10/NN	auxpass||found-12/VBN||was-11/VBD	root||ROOT-0/null||found-12/VBN	aux||elevated-15/VBN||to-13/TO	auxpass||elevated-15/VBN||be-14/VB	xcomp||found-12/VBN||elevated-15/VBN	poss||serum-18/NN||his-17/PRP$	prep_in||elevated-15/VBN||serum-18/NN	tumor-8||glucose-6||no_rel||in a controlled challenge with glucose, tumor necrosis factor was found to be elevated in his serum.
amod||imaging-3/NN||computed-1/JJ	nn||imaging-3/NN||tomography-2/NN	nsubj||revealed-7/VBD||imaging-3/NN	det||abdomen-6/NN||the-5/DT	prep_of||imaging-3/NN||abdomen-6/NN	root||ROOT-0/null||revealed-7/VBD	det||appearance-9/NN||the-8/DT	dobj||revealed-7/VBD||appearance-9/NN	amod||pyelonephritis-12/NNS||bilateral-11/JJ	prep_of||appearance-9/NN||pyelonephritis-12/NNS	advmod||failed-16/VBD||however-14/RB	nsubj||failed-16/VBD||he-15/PRP	nsubj||improve-18/VB||he-15/PRP	nsubj||developed-25/VBD||he-15/PRP	parataxis||revealed-7/VBD||failed-16/VBD	aux||improve-18/VB||to-17/TO	xcomp||failed-16/VBD||improve-18/VB	amod||antibiotics-21/NNS||broad-spectrum-20/JJ	prep_with||improve-18/VB||antibiotics-21/NNS	advmod||developed-25/VBD||subsequently-24/RB	parataxis||revealed-7/VBD||developed-25/VBD	conj_and||failed-16/VBD||developed-25/VBD	amod||neuropathies-28/NNS||multiple-26/JJ	amod||neuropathies-28/NNS||cranial-27/JJ	dobj||developed-25/VBD||neuropathies-28/NNS	amod||obtundation-31/NN||increasing-30/VBG	dobj||developed-25/VBD||obtundation-31/NN	conj_and||neuropathies-28/NNS||obtundation-31/NN	vmod||developed-25/VBD||necessitating-33/VBG	dobj||necessitating-33/VBG||intubation-34/NN	dobj||necessitating-33/VBG||ventilation-36/NN	conj_and||intubation-34/NN||ventilation-36/NN	pyelonephritis-12||antibiotics-21||no_rel||computed tomography imaging of the abdomen revealed the appearance of bilateral pyelonephritis, however he failed to improve with broad-spectrum antibiotics, and subsequently developed multiple cranial neuropathies and increasing obtundation, necessitating intubation and ventilation.
amod||trials-3/NNS||published-1/VBN	amod||trials-3/NNS||double-blind-2/JJ	nsubj||show-4/VBP||trials-3/NNS	root||ROOT-0/null||show-4/VBP	mark||achieves-12/VBZ||that-5/IN	amod||therapy-7/NN||budesonide/formoterol-6/JJ	nsubj||achieves-12/VBZ||therapy-7/NN	vmod||therapy-7/NN||delivered-8/VBN	amod||fashion-11/NN||smart-10/JJ	prep_in||delivered-8/VBN||fashion-11/NN	ccomp||show-4/VBP||achieves-12/VBZ	amod||outcomes-15/NNS||better-13/JJR	nn||outcomes-15/NNS||asthma-14/NN	dobj||achieves-12/VBZ||outcomes-15/NNS	amod||monotherapy-18/NN||budesonide-17/JJ	prep_than||achieves-12/VBZ||monotherapy-18/NN	amod||doses-21/NNS||lower-20/JJR	prep_than||achieves-12/VBZ||doses-21/NNS	conj_or||monotherapy-18/NN||doses-21/NNS	amod||therapy-24/NN||budesonide/formoterol-23/JJ	prep_of||doses-21/NNS||therapy-24/NN	vmod||therapy-24/NN||delivered-25/VBN	amod||dosage-28/NN||constant-27/JJ	prep_in||delivered-25/VBN||dosage-28/NN	asthma-14||formoterol--1||yes||published double-blind trials show that budesonide/formoterol therapy delivered in smart fashion achieves better asthma outcomes than budesonide monotherapy or lower doses of budesonide/formoterol therapy delivered in constant dosage.
nsubj||inhibited-12/VBD||inhibition-1/NN	nsubj||prevented-23/VBD||inhibition-1/NN	nn||synthesis-4/NN||cholesterol-3/NN	prep_of||inhibition-1/NN||synthesis-4/NN	prep_of||inhibition-1/NN||accumulation-6/NN	conj_and||synthesis-4/NN||accumulation-6/NN	prep_of||synthesis-4/NN||lanosterol-8/NN	amod||treatment-11/NN||ketoconazole-10/JJ	prep_after||lanosterol-8/NN||treatment-11/NN	root||ROOT-0/null||inhibited-12/VBD	dobj||inhibited-12/VBD||uptake-13/NN	nn||integrin-20/NNS||collagen-15/NN	conj_and||collagen-15/NN||virus-17/NN	nn||integrin-20/NNS||virus-17/NN	conj_and||collagen-15/NN||clustered-19/NN	nn||integrin-20/NNS||clustered-19/NN	prep_of||uptake-13/NN||integrin-20/NNS	conj_and||inhibited-12/VBD||prevented-23/VBD	dobj||prevented-23/VBD||formation-24/NN	nn||bodies-27/NNS||multivesicular-26/NN	prep_of||formation-24/NN||bodies-27/NNS	prep_of||formation-24/NN||virusinfection-29/NNS	conj_and||bodies-27/NNS||virusinfection-29/NNS	virus-17||ketoconazole-10||no_rel||inhibition of cholesterol synthesis and accumulation of lanosterol after ketoconazole treatment inhibited uptake of collagen, virus and clustered integrin, and prevented formation of multivesicular bodies and virusinfection.
det||cohort-3/NN||the-1/DT	amod||cohort-3/NN||medalist-2/JJ	nsubj||has-29/VBZ||cohort-3/NN	det||±-9/NN||a-6/DT	amod||±-9/NN||mean-7/JJ	nn||±-9/NN||â-8/NN	prep_with||cohort-3/NN||±-9/NN	vmod||±-9/NN||sd-10/VBN	nn||duration-12/NN||disease-11/NN	nn||â-22/NN||duration-12/NN	conj_and||duration-12/NN||age-14/NN	nn||â-22/NN||age-14/NN	num||â-17/NN||56.2-16/CD	prep_of||duration-12/NN||â-17/NN	amod||â-22/NN||±-18/JJ	dep||±-18/JJ||5.8-19/CD	dep||±-18/JJ||67.2-21/CD	conj_and||5.8-19/CD||67.2-21/CD	dobj||sd-10/VBN||â-22/NN	number||7.5-24/CD||±-23/CD	num||years-25/NNS||7.5-24/CD	tmod||sd-10/VBN||years-25/NNS	advmod||sd-10/VBN||respectively-27/RB	dep||mean-39/VBP||has-29/VBZ	det||phenotype-32/NN||a-30/DT	amod||phenotype-32/NN||clinical-31/JJ	dobj||has-29/VBZ||phenotype-32/NN	amod||type1diabetes-35/JJ||similar-33/JJ	dep||type1diabetes-35/JJ||to-34/TO	amod||phenotype-32/NN||type1diabetes-35/JJ	appos||phenotype-32/NN||type1diabetes-37/NNP	root||ROOT-0/null||mean-39/VBP	nn||onset-43/NN||â-40/NN	num||onset-43/NN||±-41/CD	nn||onset-43/NN||sd-42/NN	dobj||mean-39/VBP||onset-43/NN	num||±-47/NNS||11.0-45/CD	nn||±-47/NNS||â-46/NN	prep_at||onset-43/NN||±-47/NNS	num||years-49/NNS||6.4-48/CD	nsubj||mean-39/VBP||years-49/NNS	appos||years-49/NNS||bmi-51/NN	num||â-54/NN||26.0-53/CD	prep_at||bmi-51/NN||â-54/NN	number||5.1-56/CD||±-55/CD	num||kg/m2-57/NNS||5.1-56/CD	dep||â-54/NN||kg/m2-57/NNS	nn||dose-60/NN||insulin-59/NN	prep_at||bmi-51/NN||dose-60/NN	conj_and||â-54/NN||dose-60/NN	num||±-64/NNS||0.46-62/CD	nn||±-64/NNS||â-63/NN	prep_of||dose-60/NN||±-64/NNS	number||u/kg-66/JJ||0.2-65/CD	amod||±-64/NNS||u/kg-66/JJ	number||1/4-69/CD||âˆ-68/CD	prep_at||bmi-51/NN||1/4-69/CD	conj_and||â-54/NN||1/4-69/CD	num||%-71/NN||94-70/CD	npadvmod||positive-72/JJ||%-71/NN	amod||1/4-69/CD||positive-72/JJ	amod||dr4-76/NNS||dr3-74/JJ	amod||dr4-76/NNS||and/or-75/JJ	prep_for||1/4-69/CD||dr4-76/NNS	num||%-80/NN||29.5-79/CD	prep_at||bmi-51/NN||%-80/NN	conj_and||â-54/NN||%-80/NN	amod||autoantibodies-91/NNS||positive-81/JJ	det||decarboxylase-87/NN||either-83/DT	amod||decarboxylase-87/NN||ia2-84/JJ	conj_or||ia2-84/JJ||glutamicacid-86/JJ	amod||decarboxylase-87/NN||glutamicacid-86/JJ	prep_for||positive-81/JJ||decarboxylase-87/NN	appos||decarboxylase-87/NN||gad-89/NN	dep||%-80/NN||autoantibodies-91/NNS	type1diabetes-37||glutamicacid-86||no_rel||the medalist cohort, with a mean â± sd disease duration and age of 56.2 â± 5.8 and 67.2 â± 7.5 years, respectively, has a clinical phenotype similar to type1diabetes (type1diabetes) mean â± sd onset at 11.0 â± 6.4 years, bmi at 26.0 â± 5.1 kg/m2, insulin dose of 0.46 â± 0.2 u/kg, âˆ¼94% positive for dr3 and/or dr4, and 29.5% positive for either ia2 or glutamicacid decarboxylase (gad) autoantibodies.
advmod||investigated-4/VBD||specifically-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	dep||changes-9/NNS||a-7/DT	dobj||investigated-4/VBD||changes-9/NNS	nn||flux-12/NN||glucose-11/NN	prep_in||changes-9/NNS||flux-12/NN	amod||ar-15/NN||cardiac-14/JJ	prep_via||flux-12/NN||ar-15/NN	dobj||investigated-4/VBD||sdh-17/NN	conj_and||changes-9/NNS||sdh-17/NN	det||function-20/NN||a-19/DT	prep_as||sdh-17/NN||function-20/NN	nn||duration-23/NN||diabetes-22/NN	prep_of||function-20/NN||duration-23/NN	dep||injury-29/NN||b-26/NN	amod||injury-29/NN||ischemic-28/JJ	dobj||investigated-4/VBD||injury-29/NN	conj_and||changes-9/NNS||injury-29/NN	conj_and||changes-9/NNS||function-31/NN	conj_and||injury-29/NN||function-31/NN	prep_after||injury-29/NN||ir-33/NN	dep||effect-39/NN||c-36/NN	det||effect-39/NN||the-38/DT	dobj||investigated-4/VBD||effect-39/NN	conj_and||changes-9/NNS||effect-39/NN	prep_of||effect-39/NN||inhibition-41/NN	prep_of||inhibition-41/NN||ar-43/NN	dobj||investigated-4/VBD||sdh-45/NN	conj_or||changes-9/NNS||sdh-45/NN	amod||injury-48/NN||ischemic-47/JJ	prep_on||sdh-45/NN||injury-48/NN	prep_on||sdh-45/NN||function-50/NN	conj_and||injury-48/NN||function-50/NN	glucose-11||ar-43||no_rel||specifically, we investigated, (a) changes in glucose flux via cardiac ar and sdh as a function of diabetes duration, (b) ischemic injury and function after ir, (c) the effect of inhibition of ar or sdh on ischemic injury and function.
nsubj||likely-14/JJ||women-1/NNS	nsubj||have-16/VB||women-1/NNS	det||malaria-11/NN||either-3/DT	dep||acute-7/JJ||acute-4/JJ	amod||malaria-11/NN||acute-7/JJ	conj_and||acute-7/JJ||chronic-9/JJ	amod||malaria-11/NN||chronic-9/JJ	amod||malaria-11/NN||placental-10/JJ	prep_with||women-1/NNS||malaria-11/NN	cop||likely-14/JJ||were-12/VBD	advmod||likely-14/JJ||less-13/RBR	dep||is-25/VBZ||likely-14/JJ	aux||have-16/VB||to-15/TO	xcomp||likely-14/JJ||have-16/VB	dobj||have-16/VB||irondeficiency-17/NN	prep_than||irondeficiency-17/NN||women-19/NNS	amod||infection-23/NN||placental-21/JJ	nn||infection-23/NN||malaria-22/NN	prep_without||have-16/VB||infection-23/NN	expl||is-25/VBZ||there-24/EX	root||ROOT-0/null||is-25/VBZ	det||priority-27/NN||a-26/DT	nsubj||is-25/VBZ||priority-27/NN	aux||establish-29/VB||to-28/TO	vmod||priority-27/NN||establish-29/VB	mark||enhances-43/VBZ||if-30/IN	csubj||enhances-43/VBZ||reversing-31/VBG	advmod||reversing-31/VBG||irondeficiency-32/RB	nn||programs-36/NNS||iron-34/NN	nn||programs-36/NNS||supplementation-35/NN	prep_through||reversing-31/VBG||programs-36/NNS	dep||programs-36/NNS||either-37/DT	dep||either-37/DT||prior-38/RB	prep||prior-38/RB||to-39/TO	dep||programs-36/NNS||during-41/IN	conj_or||either-37/DT||during-41/IN	pobj||during-41/IN||pregnancy-42/NN	advcl||establish-29/VB||enhances-43/VBZ	nn||risk-45/NN||malaria-44/NN	dobj||enhances-43/VBZ||risk-45/NN	irondeficiency-32||iron-34||yes||women with either acute, or acute and chronic placental malaria were less likely to have irondeficiency than women without placental malaria infection there is a priority to establish if reversing irondeficiency through iron supplementation programs either prior to or during pregnancy enhances malaria risk.
nsubj||increased-8/VBD||animals-1/NNS	vmod||animals-1/NNS||primed-2/VBN	prep||primed-2/VBN||with-3/IN	nsubj||showed-5/VBD||afro-1-4/JJ	parataxis||primed-2/VBN||showed-5/VBD	dobj||showed-5/VBD||i-6/FW	root||ROOT-0/null||increased-8/VBD	amod||production-11/NN||ag85b-specific-9/JJ	amod||production-11/NN||ifn-gamma-10/JJ	dobj||increased-8/VBD||production-11/NN	det||assay-15/NN||the-13/DT	nn||assay-15/NN||wba-14/NN	prep_in||production-11/NN||assay-15/NN	amod||pg/ml-20/NN||median-17/JJ	amod||pg/ml-20/NN||>-18/JJ	num||pg/ml-20/NN||400-19/CD	dep||assay-15/NN||pg/ml-20/NN	num||animals-23/NNS||6-22/CD	prep_for||pg/ml-20/NN||animals-23/NNS	num||week-26/NN||one-25/CD	dep||assay-15/NN||week-26/NN	det||boost-30/NN||the-28/DT	amod||boost-30/NN||first-29/JJ	prep_after||increased-8/VBD||boost-30/NN	amod||tb-antigens-33/NNS||adenoviral-delivered-32/JJ	prep_with||boost-30/NN||tb-antigens-33/NNS	prep||increased-8/VBD||as-34/IN	prep||increased-8/VBD||compared-35/VBN	pcomp||compared-35/VBN||to-36/TO	pobj||to-36/TO||animals-37/NNS	vmod||animals-37/NNS||primed-38/VBN	prep_with||primed-38/VBN||bcg-40/NN	number||200-43/CD||<-42/CD	num||pg/ml-44/NNS||200-43/CD	appos||bcg-40/NN||pg/ml-44/NNS	dobj||primed-38/VBN||ii-47/NN	amod||proliferation-52/NN||stronger-49/JJR	nn||proliferation-52/NN||t-50/NN	nn||proliferation-52/NN||cell-51/NN	npadvmod||primed-38/VBN||proliferation-52/NN	det||subset-59/NN||the-54/DT	amod||subset-59/NN||cd8alpha/alpha-55/JJ	amod||subset-59/NN||+-56/JJ	nn||subset-59/NN||t-57/NN	nn||subset-59/NN||cell-58/NN	prep_in||primed-38/VBN||subset-59/NN	amod||index-62/NN||proliferative-61/JJ	dep||subset-59/NN||index-62/NN	num||%-64/NN||17-63/CD	dep||index-62/NN||%-64/NN	prepc_as||subset-59/NN||compared-67/VBN	pcomp||compared-67/VBN||to-68/TO	amod||animals-70/NNS||bcg-primed-69/JJ	pobj||to-68/TO||animals-70/NNS	amod||index-73/NN||proliferative-72/JJ	dep||subset-59/NN||index-73/NN	number||%-75/NN||5-74/CD	amod||index-73/NN||%-75/NN	amod||cells-80/NNS||cd8alpha/alpha-77/JJ	amod||cells-80/NNS||+-78/JJ	nn||cells-80/NNS||t-79/NN	prep_in||index-73/NN||cells-80/NNS	ifn--1||tb--1||no_rel||animals primed with afro-1 showed i) increased ag85b-specific ifn-gamma production in the wba assay (median >400 pg/ml for 6 animals) one week after the first boost with adenoviral-delivered tb-antigens as compared to animals primed with bcg (<200 pg/ml), ii) stronger t cell proliferation in the cd8alpha/alpha+ t cell subset (proliferative index 17%) as compared to bcg-primed animals (proliferative index 5% in cd8alpha/alpha+ t cells).
det||group-5/NN||the-2/DT	amod||group-5/NN||prophylactic-3/JJ	nn||group-5/NN||lamivudine-4/NN	prep_in||was-8/VBD||group-5/NN	expl||was-8/VBD||there-7/EX	root||ROOT-0/null||was-8/VBD	advmod||less-10/JJR||significantly-9/RB	amod||hbv-11/NN||less-10/JJR	nsubj||was-8/VBD||hbv-11/NN	dep||hbv-11/NN||reactivation-12/NN	num||patient-15/NN||1-14/CD	nsubj||vs-20/VBP||patient-15/NN	num||%-18/NN||2-17/CD	appos||patient-15/NN||%-18/NN	dep||hbv-11/NN||vs-20/VBP	num||patients-22/NNS||20-21/CD	dobj||vs-20/VBP||patients-22/NNS	num||%-25/NN||16-24/CD	appos||patients-22/NNS||%-25/NN	dep||patients-22/NNS||p-28/NN	dep||0.002-30/CD||=-29/SYM	rcmod||p-28/NN||0.002-30/CD	amod||disruption-34/NN||less-33/JJR	nsubj||was-8/VBD||disruption-34/NN	conj_and||hbv-11/NN||disruption-34/NN	prep_of||disruption-34/NN||chemotherapy-36/NN	num||vs-39/NN||7-38/CD	nsubj||p-42/VBP||vs-39/NN	number||%-41/NN||14-40/CD	amod||vs-39/NN||%-41/NN	dep||hbv-11/NN||p-42/VBP	dep||0.04-44/CD||=-43/SYM	ccomp||p-42/VBP||0.04-44/CD	amod||hepatitis-50/NN||less-48/JJR	amod||hepatitis-50/NN||severe-49/JJ	nsubj||was-8/VBD||hepatitis-50/NN	conj_and||hbv-11/NN||hepatitis-50/NN	num||vs-53/NN||0-52/CD	dep||hepatitis-50/NN||vs-53/NN	num||%-55/NN||17-54/CD	nsubj||0.002-58/CD||%-55/NN	vmod||%-55/NN||p-56/VBN	dep||0.002-58/CD||=-57/SYM	rcmod||vs-53/NN||0.002-58/CD	hbv-11||lamivudine-4||yes||in the prophylactic lamivudine group, there was significantly less hbv reactivation (1 patient (2%) vs 20 patients (16%); p =0.002), less disruption of chemotherapy (7 vs 14% p =0.04), and less severe hepatitis (0 vs 17% p =0.002).
det||study-2/NN||the-1/DT	nsubj||suggested-3/VBD||study-2/NN	root||ROOT-0/null||suggested-3/VBD	det||exposure-6/NN||that-4/DT	amod||exposure-6/NN||short-term-5/JJ	dobj||suggested-3/VBD||exposure-6/NN	nn||±-9/NNS||î-8/NN	prep_to||suggested-3/VBD||±-9/NNS	dep||±-9/NNS||cp-11/NN	nn||mice-14/NNS||albino-13/NN	prep_in||cp-11/NN||mice-14/NNS	vmod||mice-14/NNS||induced-15/VBN	amod||lesions-17/NNS||toxicopathological-16/JJ	dobj||induced-15/VBN||lesions-17/NNS	nn||tissue-20/NN||testicular-19/NN	prep_in||induced-15/VBN||tissue-20/NN	vmod||tissue-20/NN||leading-21/VBG	amod||levels-26/NNS||decreased-23/VBN	nn||levels-26/NNS||plasma-24/NN	nn||levels-26/NNS||testosterone-25/NN	prep_to||leading-21/VBG||levels-26/NNS	testosterone-25||cp-11||no_rel||the study suggested that short-term exposure to î±-cp in albino mice induced toxicopathological lesions in testicular tissue leading to decreased plasma testosterone levels.
num||polymorphisms-4/NNS||four-1/CD	amod||polymorphisms-4/NNS||single-2/JJ	nn||polymorphisms-4/NNS||nucleotide-3/NN	nsubjpass||reported-21/VBN||polymorphisms-4/NNS	nsubjpass||associated-24/VBN||polymorphisms-4/NNS	appos||polymorphisms-4/NNS||snps-6/NNS	dep||polymorphisms-4/NNS||rs2237892-9/NNS	appos||rs2237892-9/NNS||rs2237895-11/CD	num||rs2237895-11/CD||rs2237897-13/CD	appos||rs2237892-9/NNS||rs2283228-16/CD	conj_and||rs2237895-11/CD||rs2283228-16/CD	prep_in||polymorphisms-4/NNS||kcnq1-19/CD	auxpass||reported-21/VBN||are-20/VBP	root||ROOT-0/null||reported-21/VBN	aux||associated-24/VBN||to-22/TO	auxpass||associated-24/VBN||be-23/VB	xcomp||reported-21/VBN||associated-24/VBN	amod||t2dm-28/NNS||type2diabetesmellitus-26/JJ	prep_with||associated-24/VBN||t2dm-28/NNS	advmod||caused-32/VBN||possibly-31/RB	vmod||t2dm-28/NNS||caused-32/VBN	det||reduction-35/NN||a-34/DT	agent||caused-32/VBN||reduction-35/NN	nn||secretion-38/NN||insulin-37/NN	prep_in||reduction-35/NN||secretion-38/NN	amod||glucose-42/NN||higher-40/JJR	nn||glucose-42/NN||fasting-41/NN	prep_in||reduction-35/NN||glucose-42/NN	conj_and||secretion-38/NN||glucose-42/NN	det||results-46/NNS||the-45/DT	nsubj||inconsistent-48/JJ||results-46/NNS	cop||inconsistent-48/JJ||are-47/VBP	conj_but||reported-21/VBN||inconsistent-48/JJ	type2diabetesmellitus-26||insulin-37||yes||four single nucleotide polymorphisms (snps) (rs2237892, rs2237895, rs2237897, and rs2283228) in kcnq1 are reported to be associated with type2diabetesmellitus (t2dm), possibly caused by a reduction in insulin secretion and higher fasting glucose, but the results are inconsistent.
amod||therapy-3/NN||expanded-1/VBN	amod||therapy-3/NN||antiretroviral-2/JJ	nsubj||use-7/VBP||therapy-3/NN	appos||therapy-3/NN||art-5/NN	root||ROOT-0/null||use-7/VBP	aux||reduce-9/VB||may-8/MD	ccomp||use-7/VBP||reduce-9/VB	dobj||reduce-9/VB||aids-10/NNS	vmod||aids-10/NNS||orphanhood-11/VBN	amod||mortality-15/NN||decreasing-13/VBG	nn||mortality-15/NN||adult-14/NN	agent||orphanhood-11/VBN||mortality-15/NN	amod||transmission-19/NN||population-level-17/JJ	nn||transmission-19/NN||hiv-18/NN	agent||orphanhood-11/VBN||transmission-19/NN	conj_and||mortality-15/NN||transmission-19/NN	aids-10||hiv-18||no||expanded antiretroviral therapy (art) use may reduce aids orphanhood by decreasing adult mortality and population-level hiv transmission.
prep_in||able-7/JJ||addition-2/NN	det||kit-5/NN||the-4/DT	nsubj||able-7/JJ||kit-5/NN	nsubj||detect-9/VB||kit-5/NN	cop||able-7/JJ||was-6/VBD	root||ROOT-0/null||able-7/JJ	aux||detect-9/VB||to-8/TO	xcomp||able-7/JJ||detect-9/VB	num||strains-11/NNS||two-10/CD	dobj||detect-9/VB||strains-11/NNS	nn||influenzaviruses-14/NNS||novel-13/NN	prep_of||strains-11/NNS||influenzaviruses-14/NNS	nn||a/california/12-17/NNS||influenza-16/NN	appos||influenzaviruses-14/NNS||a/california/12-17/NNS	pobj||of-32/IN||a/california/12-17/NNS	punct||a/h1n1-29/NNS||/-18/:	dep||a/h1n1-29/NNS||2009-19/CD	appos||2009-19/CD||h1n1-21/NNP	advmod||isolated-25/JJ||clinically-24/RB	amod||novel-27/NN||isolated-25/JJ	amod||novel-27/NN||wild-type-26/JJ	conj_and||2009-19/CD||novel-27/NN	dep||a/h1n1-29/NNS||novel-27/NN	nn||a/h1n1-29/NNS||influenza-28/NN	dep||a/california/12-17/NNS||a/h1n1-29/NNS	dep||of-32/IN||both-31/DT	nsubj||spreading-35/VBG||of-32/IN	aux||spreading-35/VBG||are-34/VBP	rcmod||a/california/12-17/NNS||spreading-35/VBG	advmod||spreading-35/VBG||epidemically-36/RB	det||world-39/NN||the-38/DT	prep_throughout||spreading-35/VBG||world-39/NN	influenza-28||influenzaviruses-14||no||in addition, the kit was able to detect two strains of novel influenzaviruses, influenza a/california/12/2009(h1n1) and clinically isolated wild-type novel influenza a/h1n1, both of which are spreading epidemically throughout the world.
amod||war-2/NN||intensity-modulated-1/JJ	nsubj||provides-3/VBZ||war-2/NN	root||ROOT-0/null||provides-3/VBZ	det||option-7/NN||a-4/DT	amod||option-7/NN||new-5/JJ	amod||option-7/NN||promising-6/JJ	dobj||provides-3/VBZ||option-7/NN	det||treatment-11/NN||the-9/DT	nn||treatment-11/NN||consolidation-10/NN	prep_in||option-7/NN||treatment-11/NN	nn||carcinoma-14/NN||ovarian-13/NN	prep_of||treatment-11/NN||carcinoma-14/NN	prep_in||carcinoma-14/NN||patients-16/NNS	det||remission-21/NN||a-18/DT	amod||remission-21/NN||complete-19/JJ	amod||remission-21/NN||pathologic-20/JJ	prep_with||patients-16/NNS||remission-21/NN	amod||chemotherapy-24/NN||adjuvant-23/JJ	prep_after||provides-3/VBZ||chemotherapy-24/NN	carcinoma-14||adjuvant-23||no_rel||intensity-modulated war provides a new promising option in the consolidation treatment of ovarian carcinoma in patients with a complete pathologic remission after adjuvant chemotherapy.
nsubj||anticoagulant-7/NN||warfarin-1/NN	cop||anticoagulant-7/NN||is-2/VBZ	det||anticoagulant-7/NN||a-3/DT	advmod||prescribed-5/JJ||commonly-4/RB	amod||anticoagulant-7/NN||prescribed-5/JJ	amod||anticoagulant-7/NN||oral-6/JJ	root||ROOT-0/null||anticoagulant-7/NN	prep_in||anticoagulant-7/NN||patients-9/NNS	amod||thromboembolism-16/NN||prosthetic-11/JJ	nn||thromboembolism-16/NN||valve-12/NN	nn||thromboembolism-16/NN||disease-13/NN	prep_with||patients-9/NNS||venous-15/NNS	conj_and||thromboembolism-16/NN||venous-15/NNS	prep_with||patients-9/NNS||thromboembolism-16/NN	prep_with||patients-9/NNS||stroke-18/NN	conj_and||thromboembolism-16/NN||stroke-18/NN	thromboembolism-16||warfarin-1||yes||warfarin is a commonly prescribed oral anticoagulant in patients with prosthetic valve disease, venous thromboembolism and stroke.
aux||test-2/VB||to-1/TO	dep||studied-6/VBD||test-2/VB	det||hypothesis-4/NNS||this-3/DT	dobj||test-2/VB||hypothesis-4/NNS	nsubj||studied-6/VBD||we-5/PRP	root||ROOT-0/null||studied-6/VBD	det||effect-8/NN||the-7/DT	dobj||studied-6/VBD||effect-8/NN	amod||stereoisomers-13/NNS||long-term-10/JJ	amod||stereoisomers-13/NNS||inhaled-11/JJ	amod||stereoisomers-13/NNS||albuterol-12/JJ	prep_of||effect-8/NN||stereoisomers-13/NNS	amod||response-17/NN||immediate-15/JJ	amod||response-17/NN||allergic-16/JJ	prep_on||stereoisomers-13/NNS||response-17/NN	appos||response-17/NN||iar-19/NN	amod||hyperresponsiveness-23/NNS||airway-22/JJ	prep_on||stereoisomers-13/NNS||hyperresponsiveness-23/NNS	conj_and||response-17/NN||hyperresponsiveness-23/NNS	appos||response-17/NN||ahr-25/NN	nn||models-29/NNS||mouse-28/NN	prep_in||studied-6/VBD||models-29/NNS	prep_of||models-29/NNS||asthma-31/NN	asthma-31||albuterol-12||yes||to test this hypothesis we studied the effect of long-term inhaled albuterol stereoisomers on immediate allergic response (iar) and airway hyperresponsiveness (ahr) in mouse models of asthma.
amod||i-6/NNS||human-1/JJ	amod||i-6/NNS||t-cell-2/JJ	nn||i-6/NNS||leukemia-3/NN	nn||i-6/NNS||virus-4/NN	nn||i-6/NNS||type-5/NN	nsubj||cause-11/VB||i-6/NNS	dep||i-6/NNS||htlv-1-8/JJ	aux||cause-11/VB||can-10/MD	root||ROOT-0/null||cause-11/VB	det||malignancy-14/NN||an-12/DT	amod||malignancy-14/NN||aggressive-13/JJ	dobj||cause-11/VB||malignancy-14/NN	vmod||malignancy-14/NN||known-15/VBN	amod||leukemia/lymphoma-19/NN||adult-17/JJ	amod||leukemia/lymphoma-19/NN||t-cell-18/JJ	prep_as||known-15/VBN||leukemia/lymphoma-19/NN	appos||leukemia/lymphoma-19/NN||atl-21/NN	amod||diseases-27/NNS||inflammatory-26/JJ	dobj||cause-11/VB||diseases-27/NNS	conj_and||malignancy-14/NN||diseases-27/NNS	amod||tropicalspasticparaparesis-32/NNS||htlv-1-associatedmyelopathy-30/JJ	amod||tropicalspasticparaparesis-32/NNS||/-31/JJ	prep_such_as||diseases-27/NNS||tropicalspasticparaparesis-32/NNS	appos||tropicalspasticparaparesis-32/NNS||ham/tsp-34/NN	ham--1||htlv-1-8||no||human t-cell leukemia virus type i (htlv-1) can cause an aggressive malignancy known as adult t-cell leukemia/lymphoma (atl) as well as inflammatory diseases such as htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp).
det||porphyrins-3/NNS||the-1/DT	num||porphyrins-3/NNS||two-2/CD	nsubj||conjugated-4/VBD||porphyrins-3/NNS	root||ROOT-0/null||conjugated-4/VBD	advmod||conjugated-4/VBD||efficiently-5/RB	num||antibodies-9/NNS||three-7/CD	amod||antibodies-9/NNS||monoclonal-8/JJ	prep_to||efficiently-5/RB||antibodies-9/NNS	nsubj||recognize-19/VBP||antibodies-9/NNS	dep||antibodies-9/NNS||anti-cd104-11/JJ	dep||anti-cd104-11/JJ||anti-cd146-13/JJ	dep||anti-cd104-11/JJ||anti-cd326-15/JJ	conj_and||anti-cd146-13/JJ||anti-cd326-15/JJ	rcmod||antibodies-9/NNS||recognize-19/VBP	nsubj||over-expressed-22/JJ||antigens-20/NNS	advmod||over-expressed-22/JJ||commonly-21/RB	xcomp||recognize-19/VBP||over-expressed-22/JJ	det||range-25/NN||a-24/DT	prep_on||over-expressed-22/JJ||range-25/NN	nn||cells-28/NNS||tumour-27/NN	prep_of||range-25/NN||cells-28/NNS	tumour-27||antibodies-9||no_rel||the two porphyrins conjugated efficiently to three monoclonal antibodies (anti-cd104, anti-cd146 and anti-cd326), which recognize antigens commonly over-expressed on a range of tumour cells.
det||group-4/NN||the-1/DT	amod||group-4/NN||elevated-2/JJ	nn||group-4/NN||crp-3/NN	nsubj||had-5/VBD||group-4/NN	root||ROOT-0/null||had-5/VBD	nn||cell-10/NN||iron-6/NN	conj_and||iron-6/NN||red-8/JJ	nn||cell-10/NN||red-8/JJ	nn||cell-10/NN||blood-9/NN	dobj||had-5/VBD||cell-10/NN	appos||cell-10/NN||rbc-12/NN	advmod||characteristic-15/JJ||profiles-14/RB	amod||cell-10/NN||characteristic-15/JJ	amod||stimulation-19/NN||chronic-17/JJ	amod||stimulation-19/NN||immune-18/JJ	prep_of||had-5/VBD||stimulation-19/NN	appos||stimulation-19/NN||cis-21/NN	det||group-28/NN||the-25/DT	amod||group-28/NN||normal-26/JJ	nn||group-28/NN||crp-27/NN	prep_of||had-5/VBD||group-28/NN	conj_and||stimulation-19/NN||group-28/NN	appos||group-28/NN||profiles-30/NNS	amod||irondeficiency-33/NN||true-32/JJ	prep_of||profiles-30/NNS||irondeficiency-33/NN	irondeficiency-33||iron-6||yes||the elevated crp group had iron and red blood cell (rbc) profiles characteristic of chronic immune stimulation (cis), and the normal crp group, profiles of true irondeficiency.
nn||guidelines-2/NNS||hypertension-1/NN	nsubj||recommend-3/VBP||guidelines-2/NNS	root||ROOT-0/null||recommend-3/VBP	det||use-5/NN||the-4/DT	dobj||recommend-3/VBP||use-5/NN	prep_of||use-5/NN||thiazidediuretics-7/NNS	amod||therapy-10/NN||first-line-9/JJ	prep_as||thiazidediuretics-7/NNS||therapy-10/NN	amod||hypertension-13/NN||uncomplicated-12/JJ	prep_for||therapy-10/NN||hypertension-13/NN	nsubj||under-prescribed-18/JJ||diuretics-16/NNS	cop||under-prescribed-18/JJ||are-17/VBP	conj_yet||recommend-3/VBP||under-prescribed-18/JJ	nsubj||treated-25/JJ||hypertension-21/NN	cop||treated-25/JJ||is-22/VBZ	advmod||treated-25/JJ||frequently-23/RB	advmod||treated-25/JJ||inadequately-24/RB	conj_yet||recommend-3/VBP||treated-25/JJ	conj_and||under-prescribed-18/JJ||treated-25/JJ	hypertension-21||thiazidediuretics-7||no_rel||hypertension guidelines recommend the use of thiazidediuretics as first-line therapy for uncomplicated hypertension, yet diuretics are under-prescribed, and hypertension is frequently inadequately treated.
amod||mutations-2/NNS||loss-of-function-1/JJ	nsubjpass||associated-8/VBN||mutations-2/NNS	det||gene-6/NN||the-4/DT	nn||gene-6/NN||filaggrin-5/NN	prep_within||mutations-2/NNS||gene-6/NN	auxpass||associated-8/VBN||are-7/VBP	root||ROOT-0/null||associated-8/VBN	prep_with||associated-8/VBN||atopicdermatitis-10/NNS	amod||diseases-14/NNS||other-12/JJ	amod||diseases-14/NNS||atopic-13/JJ	prep_with||associated-8/VBN||diseases-14/NNS	conj_and||atopicdermatitis-10/NNS||diseases-14/NNS	advmod||gene-22/NN||therefore-16/RB	nsubj||gene-22/NN||filaggrin-18/NN	cop||gene-22/NN||is-19/VBZ	det||gene-22/NN||a-20/DT	nn||gene-22/NN||candidate-21/NN	parataxis||associated-8/VBN||gene-22/NN	det||etiology-25/NN||the-24/DT	prep_in||gene-22/NN||etiology-25/NN	prep_of||etiology-25/NN||peanutallergy-27/NN	atopicdermatitis-10||atopic-13||no||loss-of-function mutations within the filaggrin gene are associated with atopicdermatitis and other atopic diseases; therefore, filaggrin is a candidate gene in the etiology of peanutallergy.
csubjpass||undertaken-30/VBN||considering-1/VBG	det||number-4/NN||a-2/DT	amod||number-4/NN||large-3/JJ	dobj||considering-1/VBG||number-4/NN	amod||cases-7/NNS||clinical-6/JJ	prep_of||number-4/NN||cases-7/NNS	nn||genome-11/NN||infection-9/NN	amod||genome-11/NN||complete-10/JJ	prep_of||cases-7/NNS||genome-11/NN	vmod||genome-11/NN||based-12/VBN	nn||characterization-14/NN||sequence-13/NN	dobj||based-12/VBN||characterization-14/NN	amod||virus-18/NN||indian-16/JJ	amod||virus-18/NN||h1n1pdm-17/JJ	prep_of||characterization-14/NN||virus-18/NN	poss||analysis-22/NN||their-20/PRP$	amod||analysis-22/NN||phylogenetic-21/JJ	prep_of||characterization-14/NN||analysis-22/NN	conj_and||virus-18/NN||analysis-22/NN	prep_with||based-12/VBN||respect-24/NN	prepc_to||based-12/VBN||circulating-26/VBG	amod||viruses-28/NNS||global-27/JJ	dobj||circulating-26/VBG||viruses-28/NNS	auxpass||undertaken-30/VBN||was-29/VBD	root||ROOT-0/null||undertaken-30/VBN	aux||reveal-33/VB||to-32/TO	xcomp||undertaken-30/VBN||reveal-33/VB	det||pattern-36/NN||the-34/DT	amod||pattern-36/NN||phylodynamic-35/JJ	dobj||reveal-33/VB||pattern-36/NN	amod||virus-39/NN||h1n1pdm-38/JJ	prep_of||pattern-36/NN||virus-39/NN	prep_in||reveal-33/VB||india-41/NN	amod||$-44/NNS||2009â-43/JJ	prep_from||reveal-33/VB||$-44/NNS	dep||$-44/NNS||2011-46/CD	virus-39||viruses-28||no||considering a large number of clinical cases of infection complete genome based sequence characterization of indian h1n1pdm virus and their phylogenetic analysis with respect to circulating global viruses was undertaken, to reveal the phylodynamic pattern of h1n1pdm virus in india from 2009â€“2011.
nsubj||observed-3/VBD||we-1/PRP	advmod||observed-3/VBD||also-2/RB	root||ROOT-0/null||observed-3/VBD	mark||genotypes-11/NNS||that-4/IN	det||ag-7/NN||the-5/DT	amod||ag-7/NN||mcp-1-6/JJ	nsubj||genotypes-11/NNS||ag-7/NN	conj_and||ag-7/NN||gg-9/NN	nsubj||genotypes-11/NNS||gg-9/NN	ccomp||observed-3/VBD||genotypes-11/NNS	rcmod||genotypes-11/NNS||contribute-12/VBP	det||occurrence-15/NN||the-14/DT	prep_to||contribute-12/VBP||occurrence-15/NN	prep_of||occurrence-15/NN||thrombocytopenia-17/NN	nn||patients-20/NNS||sle-19/NN	prep_in||contribute-12/VBP||patients-20/NNS	dep||2.618-23/CD||=-22/SYM	ccomp||observed-3/VBD||2.618-23/CD	conj_or||genotypes-11/NNS||2.618-23/CD	num||â-26/NN||1.280-25/CD	dep||genotypes-11/NNS||â-26/NN	dep||â-26/NN||$-27/$	num||$-27/$||5.352-29/CD	advmod||â-26/NN||p-31/RB	num||0.0089-33/CD||=-32/CD	pobj||p-31/RB||0.0089-33/CD	mcp--1||sle-19||no_rel||we also observed that the mcp-1 ag and gg -genotypes contribute to the occurrence of thrombocytopenia in sle patients or = 2.618 (1.280â€“5.352, p = 0.0089).
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-7/VBD||aim-3/NN	nsubj||assess-9/VB||aim-3/NN	det||analysis-6/NN||this-5/DT	prep_of||aim-3/NN||analysis-6/NN	root||ROOT-0/null||was-7/VBD	aux||assess-9/VB||to-8/TO	xcomp||was-7/VBD||assess-9/VB	det||effect-11/NN||the-10/DT	dobj||assess-9/VB||effect-11/NN	amod||pressurized-14/JJ||budesonide/formoterol-13/JJ	amod||inhaler-16/NN||pressurized-14/JJ	amod||inhaler-16/NN||metered-dose-15/JJ	prep_of||effect-11/NN||inhaler-16/NN	nn||pmdi-19/NNS||bud/fm-18/NN	appos||inhaler-16/NN||pmdi-19/NNS	dobj||assess-9/VB||bud-22/NN	conj_and||effect-11/NN||bud-22/NN	amod||criteria-25/NNS||predefined-24/JJ	prep_on||bud-22/NN||criteria-25/NNS	prep_for||criteria-25/NNS||asthma-27/NN	amod||asthma-27/NN||worsening-28/VBG	det||metric-33/NN||an-30/DT	nn||metric-33/NN||asthma-31/NN	nn||metric-33/NN||control-32/NN	appos||bud-22/NN||metric-33/NN	advmod||aligned-35/VBN||generally-34/RB	vmod||metric-33/NN||aligned-35/VBN	prep_with||aligned-35/VBN||definitions-37/NNS	amod||exacerbations-41/NNS||moderate-39/JJ	nn||exacerbations-41/NNS||asthma-40/NN	prep_of||definitions-37/NNS||exacerbations-41/NNS	num||populations-46/NNS||four-44/CD	amod||populations-46/NNS||different-45/JJ	prep_across||bud-22/NN||populations-46/NNS	asthma-40||budesonide--1||yes||objective the aim of this analysis was to assess the effect of budesonide/formoterol pressurized metered-dose inhaler (bud/fm pmdi) and bud on predefined criteria for asthma worsening, an asthma control metric generally aligned with definitions of moderate asthma exacerbations, across four different populations.
nsubjpass||collected-3/VBN||strains-1/NNS	nsubjpass||tested-19/VBN||strains-1/NNS	auxpass||collected-3/VBN||were-2/VBD	root||ROOT-0/null||collected-3/VBN	num||patients-11/NNS||1824-5/CD	amod||patients-11/NNS||diagnosed-6/JJ	nn||patients-11/NNS||sputum-7/NN	amod||patients-11/NNS||smear-8/JJ	amod||patients-11/NNS||positive-9/JJ	nn||patients-11/NNS||pulmonarytb-10/NN	prep_from||collected-3/VBN||patients-11/NNS	amod||province-14/NN||jiangsu-13/JJ	prep_in||patients-11/NNS||province-14/NN	prep_of||province-14/NN||china-16/NN	advmod||tested-19/VBN||then-18/RB	conj_and||collected-3/VBN||tested-19/VBN	nn||susceptibility-22/NN||drug-21/NN	prep_for||tested-19/VBN||susceptibility-22/NN	prep_against||susceptibility-22/NN||rifampicin-24/NN	prep_against||susceptibility-22/NN||isoniazid-26/NN	conj_and||rifampicin-24/NN||isoniazid-26/NN	prep_against||susceptibility-22/NN||ethambutol-28/NN	conj_and||rifampicin-24/NN||ethambutol-28/NN	prep_against||susceptibility-22/NN||streptomycin-30/NN	conj_and||rifampicin-24/NN||streptomycin-30/NN	pulmonarytb-10||rifampicin-24||no_rel||strains were collected from 1824 diagnosed sputum smear positive pulmonarytb patients in jiangsu province of china and then tested for drug susceptibility against rifampicin, isoniazid, ethambutol and streptomycin.
det||cohort-6/NN||a-1/DT	amod||cohort-6/NN||12-matched-2/JJ	amod||cohort-6/NN||new-3/JJ	nn||cohort-6/NN||insulin-4/NN	nn||cohort-6/NN||user-5/NN	nsubjpass||selected-31/VBN||cohort-6/NN	prep_on||cohort-6/NN||age-8/NN	nn||±-11/NNS||â-10/NN	dep||age-8/NN||±-11/NNS	num||years-13/NNS||3-12/CD	dep||±-11/NNS||years-13/NNS	amod||status-17/NN||smoking-16/VBG	prep_on||cohort-6/NN||status-17/NN	conj_and||age-8/NN||status-17/NN	prep_on||cohort-6/NN||likelihood-20/NN	conj_and||age-8/NN||likelihood-20/NN	prepc_of||likelihood-20/NN||initiating-22/VBG	nn||therapy-24/NN||insulin-23/NN	dobj||initiating-22/VBG||therapy-24/NN	dep||selected-31/VBN||â-26/VB	num||0.05-28/CD||±-27/CD	dobj||â-26/VB||0.05-28/CD	auxpass||selected-31/VBN||was-30/VBD	root||ROOT-0/null||selected-31/VBN	det||cohort-34/NN||a-33/DT	prep_from||selected-31/VBN||cohort-34/NN	num||patients-38/NNS||4,623-36/CD	amod||patients-38/NNS||chinese-37/JJ	prep_of||cohort-34/NN||patients-38/NNS	prep_with||selected-31/VBN||type2diabetes-40/JJ	prep_with||selected-31/VBN||free-42/JJ	conj_and||type2diabetes-40/JJ||free-42/JJ	prep_of||free-42/JJ||cancer-44/NN	prep_with||selected-31/VBN||naive-47/JJ	conj_and||type2diabetes-40/JJ||naive-47/JJ	prep_to||naive-47/JJ||insulin-49/NN	prep_at||insulin-49/NN||enrollment-51/NN	type2diabetes-40||insulin-49||yes||a 12-matched new insulin user cohort on age (â±3 years), smoking status, and likelihood of initiating insulin therapy (â±0.05) was selected from a cohort of 4,623 chinese patients with type2diabetes, free of cancer, and naive to insulin at enrollment.
nsubjpass||characterized-3/VBN||it-1/PRP	auxpass||characterized-3/VBN||is-2/VBZ	root||ROOT-0/null||characterized-3/VBN	agent||characterized-3/VBN||seizures-5/NNS	amod||retardation-8/NN||mental-7/JJ	appos||seizures-5/NNS||retardation-8/NN	nn||lesions-11/NNS||hamartomatous-10/NN	appos||seizures-5/NNS||lesions-11/NNS	conj_and||retardation-8/NN||lesions-11/NNS	prep_including||seizures-5/NNS||facialangiofibroma-14/NN	amod||astrocytoma-19/NN||subependymal-16/JJ	amod||astrocytoma-19/NN||giant-17/JJ	nn||astrocytoma-19/NN||cell-18/NN	prep_including||seizures-5/NNS||astrocytoma-19/NN	conj_and||facialangiofibroma-14/NN||astrocytoma-19/NN	amod||rhabdomyoma-22/NN||cardiac-21/JJ	prep_including||seizures-5/NNS||rhabdomyoma-22/NN	conj_and||facialangiofibroma-14/NN||rhabdomyoma-22/NN	amod||angiomyolipoma-25/NN||renal-24/JJ	prep_including||seizures-5/NNS||angiomyolipoma-25/NN	conj_and||facialangiofibroma-14/NN||angiomyolipoma-25/NN	appos||seizures-5/NNS||aml-27/NN	facialangiofibroma-14||hamartomatous-10||no||it is characterized by seizures, mental retardation and hamartomatous lesions, including facialangiofibroma, subependymal giant cell astrocytoma, cardiac rhabdomyoma and renal angiomyolipoma (aml).
nn||factors-2/NNS||risk-1/NN	nsubj||significant-42/JJ||factors-2/NNS	prep_such_as||factors-2/NNS||age-5/NN	nn||status-8/NN||smoking-7/NN	prep_such_as||factors-2/NNS||status-8/NN	conj_and||age-5/NN||status-8/NN	amod||cholesterol-11/NN||total-10/JJ	prep_such_as||factors-2/NNS||cholesterol-11/NN	conj_and||age-5/NN||cholesterol-11/NN	amod||levels-17/NNS||high-13/JJ	nn||levels-17/NNS||density-14/NN	nn||levels-17/NNS||lipoprotein-15/NN	nn||levels-17/NNS||cholesterol-16/NN	prep_such_as||factors-2/NNS||levels-17/NNS	conj_and||age-5/NN||levels-17/NNS	vmod||significant-42/JJ||qualifying-19/VBG	dobj||qualifying-19/VBG||event-20/NN	det||syndrome-25/NN||the-22/DT	amod||syndrome-25/NN||acute-23/JJ	amod||syndrome-25/NN||coronary-24/JJ	prep_for||qualifying-19/VBG||syndrome-25/NN	appos||syndrome-25/NN||revascularization-27/NN	appos||revascularization-27/NN||history-29/NN	prep_of||history-29/NN||stroke-31/NN	prep_of||history-29/NN||diabetes-33/NN	conj_or||stroke-31/NN||diabetes-33/NN	nn||grade-36/NN||angina-35/NN	nsubj||significant-42/JJ||grade-36/NN	conj_and||grade-36/NN||treatment-38/NN	nsubj||significant-42/JJ||treatment-38/NN	prep_with||grade-36/NN||pravastatin-40/NN	cop||significant-42/JJ||were-41/VBD	root||ROOT-0/null||significant-42/JJ	prep_for||significant-42/JJ||development-44/NN	preconj||first-47/JJ||both-46/DT	prep_of||development-44/NN||first-47/JJ	amod||events-51/NNS||subsequent-49/JJ	nn||events-51/NNS||mi-50/NN	prep_of||development-44/NN||events-51/NNS	conj_and||first-47/JJ||events-51/NNS	cholesterol-16||stroke-31||no_rel||risk factors such as age, smoking status, total cholesterol and high density lipoprotein cholesterol levels, qualifying event for the acute coronary syndrome, revascularization, history of stroke or diabetes, angina grade and treatment with pravastatin were significant for development of both first and subsequent mi events.
nsubj||conclude-2/VBP||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	mark||precedes-15/VBZ||that-3/IN	amod||activation-6/NN||altered-4/JJ	nn||activation-6/NN||insulin-5/NN	nsubj||precedes-15/VBZ||activation-6/NN	nsubj||contribute-18/VB||activation-6/NN	det||pi3k/akt-9/NN||the-8/DT	prep_of||activation-6/NN||pi3k/akt-9/NN	det||pathway-14/NN||the-12/DT	nn||pathway-14/NN||mapk-13/NN	prep_of||activation-6/NN||pathway-14/NN	conj_negcc||pi3k/akt-9/NN||pathway-14/NN	ccomp||conclude-2/VBP||precedes-15/VBZ	aux||contribute-18/VB||may-17/MD	ccomp||conclude-2/VBP||contribute-18/VB	conj_and||precedes-15/VBZ||contribute-18/VB	prep_to||contribute-18/VB||development-20/NN	amod||insulinresistance-23/NN||whole-body-22/JJ	prep_of||development-20/NN||insulinresistance-23/NN	prep_of||development-20/NN||type2diabetes-25/NNS	conj_and||insulinresistance-23/NN||type2diabetes-25/NNS	prep_in||contribute-18/VB||men-27/NNS	prep_with||men-27/NNS||lbw-29/NN	type2diabetes-25||insulin-5||yes||we conclude that altered insulin activation of the pi3k/akt but not the mapk pathway precedes and may contribute to development of whole-body insulinresistance and type2diabetes in men with lbw.
nsubjpass||collected-3/VBN||sera-1/NN	auxpass||collected-3/VBN||were-2/VBD	root||ROOT-0/null||collected-3/VBN	prep_at||collected-3/VBN||weeks-5/NNS	num||weeks-5/NNS||0-6/CD	prep_at||collected-3/VBN||4-8/CD	conj_and||weeks-5/NNS||4-8/CD	det||total-11/NN||a-10/DT	prep_from||collected-3/VBN||total-11/NN	num||patients-14/NNS||336-13/CD	prep_of||total-11/NN||patients-14/NNS	nn||dataset-17/NN||training-16/NN	dep||patients-14/NNS||dataset-17/NN	appos||dataset-17/NN||n-19/NN	dep||100-21/CD||=-20/SYM	rcmod||n-19/NN||100-21/CD	nn||dataset-24/NN||test-23/NN	dep||n-19/NN||dataset-24/NN	vmod||dataset-24/NN||n-26/VBN	dep||236-28/CD||=-27/SYM	ccomp||n-26/VBN||236-28/CD	det||study-33/NN||the-31/DT	amod||study-33/NN||go-forward-32/JJ	prep_from||collected-3/VBN||study-33/NN	prep_of||study-33/NN||patients-35/NNS	amod||rheumatoidarthritis-38/NNS||active-37/JJ	prep_with||collected-3/VBN||rheumatoidarthritis-38/NNS	prep_despite||collected-3/VBN||mtx-40/NN	mtx-40||rheumatoidarthritis-38||no_rel||sera were collected at weeks 0 and 4 from a total of 336 patients (training dataset, n = 100; test dataset, n = 236) from the go-forward study of patients with active rheumatoidarthritis despite mtx.
det||population-2/NN||the-1/DT	nsubj||comprised-3/VBN||population-2/NN	nsubj||receiving-13/VBG||population-2/NN	root||ROOT-0/null||comprised-3/VBN	dobj||comprised-3/VBN||patients-4/NNS	det||diagnosis-8/NN||a-6/DT	amod||diagnosis-8/NN||first-7/JJ	prep_with||comprised-3/VBN||diagnosis-8/NN	amod||depressivedisorder-11/NN||major-10/JJ	prep_of||diagnosis-8/NN||depressivedisorder-11/NN	conj_and||comprised-3/VBN||receiving-13/VBG	det||one-18/NN||the-15/DT	amod||one-18/NN||first-16/JJ	nn||one-18/NN||time-17/NN	prep_for||receiving-13/VBG||one-18/NN	det||escitalopram-23/NN||the-20/DT	amod||escitalopram-23/NN||following-21/JJ	nn||escitalopram-23/NN||ssris-22/NNS	prep_of||one-18/NN||escitalopram-23/NN	appos||escitalopram-23/NN||sertraline-25/NN	appos||escitalopram-23/NN||paroxetine-27/NN	conj_and||sertraline-25/NN||paroxetine-27/NN	appos||escitalopram-23/NN||citalopram-30/NN	conj_and||sertraline-25/NN||citalopram-30/NN	depressivedisorder-11||paroxetine-27||yes||the population comprised patients with a first diagnosis of major depressivedisorder and receiving for the first time one of the following ssris escitalopram, sertraline, paroxetine, and citalopram.
aux||illustrate-2/VB||to-1/TO	advcl||focused-8/VBN||illustrate-2/VB	det||approach-4/NN||this-3/DT	dobj||illustrate-2/VB||approach-4/NN	nsubj||focused-8/VBN||we-6/PRP	aux||focused-8/VBN||have-7/VBP	root||ROOT-0/null||focused-8/VBN	det||detection-11/NN||the-10/DT	prep_on||focused-8/VBN||detection-11/NN	prep_of||detection-11/NN||viruses-13/NNS	nsubj||cause-15/VBP||viruses-13/NNS	rcmod||viruses-13/NNS||cause-15/VBP	nsubj||using-20/VBG||hemorrhagicfever-16/NN	appos||hemorrhagicfever-16/NN||hf-18/NN	dep||cause-15/VBP||using-20/VBG	det||hf-virus-23/NNS||a-21/DT	nn||hf-virus-23/NNS||custom-22/NN	dobj||using-20/VBG||hf-virus-23/NNS	advmod||using-20/VBG||microarray-24/RB	hemorrhagicfever-16||viruses-13||no||to illustrate this approach, we have focused on the detection of viruses that cause hemorrhagicfever (hf) using a custom hf-virus microarray.
det||study-5/NN||this-2/DT	nn||study-5/NN||retrospective-3/NN	amod||study-5/NN||cross-sectional-4/JJ	prep_in||evaluated-26/VBN||study-5/NN	det||value-8/NN||the-6/DT	amod||value-8/NN||prognostic-7/JJ	nsubjpass||evaluated-26/VBN||value-8/NN	amod||parameters-16/NNS||basic-10/JJ	amod||parameters-16/NNS||cerebrospinal-11/JJ	nn||parameters-16/NNS||fluid-12/NN	appos||parameters-16/NNS||csf-14/NN	prep_of||value-8/NN||parameters-16/NNS	prep_in||parameters-16/NNS||patients-18/NNS	prep_with||patients-18/NNS||bacterialmeningitis-20/NNS	prep_with||patients-18/NNS||viralmeningoencephalitis-22/NNS	conj_and||bacterialmeningitis-20/NNS||viralmeningoencephalitis-22/NNS	prep_with||patients-18/NNS||leptomeningealmetastases-24/NNS	conj_and||bacterialmeningitis-20/NNS||leptomeningealmetastases-24/NNS	auxpass||evaluated-26/VBN||were-25/VBD	root||ROOT-0/null||evaluated-26/VBN	basic-10||bacterialmeningitis-20||no_rel||in this retrospective cross-sectional study the prognostic value of basic cerebrospinal fluid (csf) parameters in patients with bacterialmeningitis, viralmeningoencephalitis and leptomeningealmetastases were evaluated.
prep_in||studied-15/VBN||total-2/NN	num||subjects-5/NNS||2,011-4/CD	nsubjpass||studied-15/VBN||subjects-5/NNS	dep||subjects-5/NNS||aged-7/VBN	dobj||aged-7/VBN||30â-8/NNS	num||years-12/NNS||$-9/$	num||$-9/$||70-11/CD	dep||30â-8/NNS||years-12/NNS	auxpass||studied-15/VBN||were-14/VBD	root||ROOT-0/null||studied-15/VBN	num||patients-19/NNS||1,247-18/CD	prep_including||studied-15/VBN||patients-19/NNS	amod||type2diabetes-22/NNS||recent-onset-21/JJ	prep_with||patients-19/NNS||type2diabetes-22/NNS	amod||autoantibodies-26/NNS||glutamicacid-24/VBN	nn||autoantibodies-26/NNS||decarboxylase-25/NN	prep_without||type2diabetes-22/NNS||autoantibodies-26/NNS	dep||autoantibodies-26/NNS||gadas-28/NNS	number||nonâ-32/CD||117-31/CD	num||patients-36/NNS||nonâ-32/CD	amod||patients-36/NNS||$-33/$	dep||$-33/$||insulin-requiring-35/NN	appos||autoantibodies-26/NNS||patients-36/NNS	prep_with||patients-36/NNS||gadas-38/NNS	nsubj||received-42/VBN||gadas-38/NNS	aux||received-42/VBN||had-40/VBD	neg||received-42/VBN||not-41/RB	rcmod||gadas-38/NNS||received-42/VBN	nn||therapy-44/NN||insulin-43/NN	dobj||received-42/VBN||therapy-44/NN	quantmod||6-48/CD||at-46/IN	mwe||at-46/IN||least-47/JJS	pobj||at-46/IN||least-47/JJS	num||months-49/NNS||6-48/CD	prep_for||therapy-44/NN||months-49/NNS	prep_after||received-42/VBN||diagnosis-51/NN	dep||patients-36/NNS||designated-53/VBN	nn||diabetes-56/NN||latent-54/NN	amod||diabetes-56/NN||autoimmune-55/JJ	dobj||designated-53/VBN||diabetes-56/NN	prep_of||diabetes-56/NN||adults-58/NNS	vmod||adults-58/NNS||-LSB--59/VBN	prep||-LSB--59/VBN||lada-60/NN	dep||lada-60/NN||-RSB--61/NN	num||type-65/NN||288-64/CD	prep_with||patients-19/NNS||type-65/NN	conj_and||type2diabetes-22/NNS||type-65/NN	num||patients-68/NNS||1-66/CD	amod||patients-68/NNS||diabetic-67/JJ	dep||type-65/NN||patients-68/NNS	num||subjects-73/NNS||359-71/CD	amod||subjects-73/NNS||normal-72/JJ	prep_with||patients-19/NNS||subjects-73/NNS	conj_and||type2diabetes-22/NNS||subjects-73/NNS	type2diabetes-22||insulin-43||yes||in total, 2,011 subjects (aged 30â€“70 years) were studied, including 1,247 patients with recent-onset type2diabetes without glutamicacid decarboxylase autoantibodies (gadas), 117 nonâ€“insulin-requiring patients with gadas who had not received insulin therapy for at least 6 months after diagnosis (designated latent autoimmune diabetes of adults [lada]), 288 type 1 diabetic patients, and 359 normal subjects.
det||origin-4/NN||the-2/DT	amod||origin-4/NN||geographical-3/JJ	prep_concerning||showed-13/VBD||origin-4/NN	det||samples-7/NNS||the-6/DT	prep_of||origin-4/NN||samples-7/NNS	det||markers-12/NNS||the-9/DT	num||markers-12/NNS||three-10/CD	nn||markers-12/NNS||hbv-11/NN	nsubj||showed-13/VBD||markers-12/NNS	root||ROOT-0/null||showed-13/VBD	det||hbsag-18/NN||a-14/DT	advmod||significant-16/JJ||statistically-15/RB	amod||hbsag-18/NN||significant-16/JJ	nn||hbsag-18/NN||difference-17/NN	nsubj||frequent-38/JJ||hbsag-18/NN	dep||hbsag-18/NN||pâ-20/NN	num||â-24/NN||$-21/$	number||=-23/CD||š-22/CD	num||$-21/$||=-23/CD	dep||pâ-20/NN||â-24/NN	dep||â-24/NN||$-25/$	num||$-25/$||š0-26/CD	num||$-25/$||.033-27/CD	conj_and||hbsag-18/NN||anti-hbc-30/JJ	nsubj||frequent-38/JJ||anti-hbc-30/JJ	appos||anti-hbc-30/JJ||p-32/NNP	number||0.001-34/CD||<-33/CD	num||p-32/NNP||0.001-34/CD	cop||frequent-38/JJ||were-36/VBD	advmod||frequent-38/JJ||more-37/RBR	ccomp||showed-13/VBD||frequent-38/JJ	prep_in||frequent-38/JJ||amazonas-40/NNS	nn||departments-43/NNS||magdalena-42/NN	prep_in||frequent-38/JJ||departments-43/NNS	conj_and||amazonas-40/NNS||departments-43/NNS	hbv-11||hbsag-18||yes||concerning the geographical origin of the samples, the three hbv markers showed a statistically significant difference hbsag (pâ€š=â€š0.033) and anti-hbc (p<0.001) were more frequent in amazonas and magdalena departments.
amod||disposal-4/NN||impaired-1/VBN	amod||disposal-4/NN||insulin-dependent-2/JJ	nn||disposal-4/NN||glucose-3/NN	nsubj||harbinger-11/NN||disposal-4/NN	prep_in||disposal-4/NN||muscle-6/NN	prep_in||disposal-4/NN||fat-8/NN	conj_and||muscle-6/NN||fat-8/NN	cop||harbinger-11/NN||is-9/VBZ	det||harbinger-11/NN||a-10/DT	root||ROOT-0/null||harbinger-11/NN	prep_of||harbinger-11/NN||type2diabetes-13/CD	amod||models-17/NNS||murine-16/JJ	nsubj||conspicuous-26/JJ||models-17/NNS	amod||insulinresistance-20/NN||selective-19/JJ	prep_of||models-17/NNS||insulinresistance-20/NN	det||sites-24/NNS||these-22/DT	num||sites-24/NNS||two-23/CD	prep_at||insulinresistance-20/NN||sites-24/NNS	cop||conspicuous-26/JJ||are-25/VBP	conj_but||harbinger-11/NN||conspicuous-26/JJ	poss||failure-29/NN||their-28/PRP$	prep_by||conspicuous-26/JJ||failure-29/NN	aux||cause-31/VB||to-30/TO	vmod||failure-29/NN||cause-31/VB	dobj||cause-31/VB||hyperglycemia-32/NN	type2diabetes-13||insulin--1||yes||impaired insulin-dependent glucose disposal in muscle and fat is a harbinger of type2diabetes, but murine models of selective insulinresistance at these two sites are conspicuous by their failure to cause hyperglycemia.
nsubj||improves-2/VBZ||vildagliptin-1/NN	root||ROOT-0/null||improves-2/VBZ	amod||control-4/NN||glycemic-3/JJ	dobj||improves-2/VBZ||control-4/NN	advmod||if-7/IN||little-6/RB	amod||patients-15/NNS||if-7/IN	det||gain-10/NN||any-8/DT	nn||gain-10/NN||weight-9/NN	dep||if-7/IN||gain-10/NN	dep||if-7/IN||hypoglycemia-12/NN	conj_or||gain-10/NN||hypoglycemia-12/NN	prep_in||gain-10/NN||adult-14/NN	prep_with||improves-2/VBZ||patients-15/NNS	prep_with||patients-15/NNS||type2diabetes-17/CD	advmod||given-19/VBN||when-18/WRB	advcl||improves-2/VBZ||given-19/VBN	advmod||given-19/VBN||alone-20/RB	advcl||improves-2/VBZ||in-22/IN	conj_or||given-19/VBN||in-22/IN	pobj||in-22/IN||combination-23/NN	prep_with||in-22/IN||metformin-25/NNS	prep_with||in-22/IN||thiazolidinediones-27/NNS	conj_or||metformin-25/NNS||thiazolidinediones-27/NNS	prep_with||in-22/IN||sulfonylureas-30/NNS	conj_or||metformin-25/NNS||sulfonylureas-30/NNS	type2diabetes-17||metformin-25||yes||vildagliptin improves glycemic control with little if any weight gain or hypoglycemia in adult patients with type2diabetes when given alone or in combination with metformin, thiazolidinediones, or sulfonylureas.
nsubj||compared-2/VBD||we-1/PRP	root||ROOT-0/null||compared-2/VBD	det||incidence-4/NN||the-3/DT	dobj||compared-2/VBD||incidence-4/NN	amod||vomiting-7/NN||postoperative-6/JJ	prep_of||incidence-4/NN||vomiting-7/NN	appos||vomiting-7/NN||pov-9/NN	prep_in||compared-2/VBD||children-12/NNS	vmod||children-12/NNS||undergoing-13/VBG	det||adenotonsillectomy-15/NN||an-14/DT	dobj||undergoing-13/VBG||adenotonsillectomy-15/NN	nsubjpass||induced-22/VBN||anesthesia-17/NN	nsubjpass||maintained-26/VBN||anesthesia-17/NN	num||group-20/NN||one-19/CD	prep_in||anesthesia-17/NN||group-20/NN	auxpass||induced-22/VBN||was-21/VBD	parataxis||compared-2/VBD||induced-22/VBN	prep_with||induced-22/VBN||propofol-24/NN	parataxis||compared-2/VBD||maintained-26/VBN	conj_and||induced-22/VBN||maintained-26/VBN	prep_with||maintained-26/VBN||sevoflurane-28/NN	prep_with||maintained-26/VBN||nitrousoxide-30/NN	conj_and||sevoflurane-28/NN||nitrousoxide-30/NN	det||group-35/NN||the-33/DT	amod||group-35/NN||other-34/JJ	nsubj||received-36/VBD||group-35/NN	parataxis||compared-2/VBD||received-36/VBD	conj_and||induced-22/VBN||received-36/VBD	amod||anesthesia-39/NN||total-37/JJ	amod||anesthesia-39/NN||intravenous-38/JJ	dobj||received-36/VBD||anesthesia-39/NN	appos||anesthesia-39/NN||tiva-41/NNP	prep_with||received-36/VBD||propofol-remifentanil-44/NN	vomiting-7||nitrousoxide-30||no||we compared the incidence of postoperative vomiting (pov) in children undergoing an adenotonsillectomy; anesthesia in one group was induced with propofol and maintained with sevoflurane and nitrousoxide, and the other group received total intravenous anesthesia (tiva) with propofol-remifentanil.
amod||trials-4/NNS||twenty-five-1/JJ	amod||trials-4/NNS||completed-2/VBN	amod||trials-4/NNS||randomized-3/JJ	nsubjpass||included-12/VBN||trials-4/NNS	nsubj||cilostazol-37/VBP||trials-4/NNS	num||patients-7/NNS||17,383-6/CD	dep||trials-4/NNS||patients-7/NNS	prep_with||patients-7/NNS||ihd-9/NN	auxpass||included-12/VBN||were-11/VBD	root||ROOT-0/null||included-12/VBN	nsubj||involving-14/VBG||which-13/WDT	ccomp||included-12/VBN||involving-14/VBG	det||use-16/NN||the-15/DT	nsubj||clopidogrel-35/JJ||use-16/NN	amod||inhibitors-24/NNS||intravenous-18/JJ	appos||inhibitors-24/NNS||iv-20/NN	amod||inhibitors-24/NNS||gp-22/JJ	nn||inhibitors-24/NNS||iib/iiia-23/NNP	prep_of||use-16/NN||inhibitors-24/NNS	nn||tirofiban-30/NN||abciximab-26/NN	dep||tirofiban-30/NN||eptifibatide-28/NN	appos||use-16/NN||tirofiban-30/NN	appos||use-16/NN||aspirin-33/NN	xcomp||involving-14/VBG||clopidogrel-35/JJ	conj_and/or||included-12/VBN||cilostazol-37/VBP	ihd-9||abciximab-26||yes||twenty-five completed randomized trials (17,383 patients with ihd) were included which involving the use of intravenous (iv) gp iib/iiia inhibitors (abciximab, eptifibatide, tirofiban), aspirin, clopidogrel and/or cilostazol.
amod||trials-6/NNS||several-1/JJ	amod||controlled-5/JJ||large-2/JJ	advmod||controlled-5/JJ||randomized-4/RB	amod||trials-6/NNS||controlled-5/JJ	nsubj||show-7/VBP||trials-6/NNS	root||ROOT-0/null||show-7/VBP	det||syndrome-24/NN||that-8/DT	amod||syndrome-24/NN||eptifibatide-9/JJ	amod||therapy-12/NN||adjunctive-11/JJ	prep_as||eptifibatide-9/JJ||therapy-12/NN	amod||care-15/NN||standard-14/JJ	prep_to||eptifibatide-9/JJ||care-15/NN	prep_in||care-15/NN||patients-17/NNS	amod||elevation-21/NN||non-st-19/JJ	nn||elevation-21/NN||segment-20/NN	prep_with||patients-17/NNS||elevation-21/NN	amod||syndrome-24/NN||acute-22/JJ	amod||syndrome-24/NN||coronary-23/JJ	nsubjpass||associated-26/VBN||syndrome-24/NN	auxpass||associated-26/VBN||is-25/VBZ	ccomp||show-7/VBP||associated-26/VBN	det||reduction-30/NN||a-28/DT	amod||reduction-30/NN||significant-29/JJ	prep_with||associated-26/VBN||reduction-30/NN	det||incidence-33/NN||the-32/DT	prep_in||reduction-30/NN||incidence-33/NN	prep_of||incidence-33/NN||death-35/NN	prep_of||incidence-33/NN||myocardialinfarction-37/NN	conj_or||death-35/NN||myocardialinfarction-37/NN	myocardialinfarction-37||eptifibatide-9||yes||several large, randomized controlled trials show that eptifibatide as adjunctive therapy to standard care in patients with non-st segment elevation acute coronary syndrome is associated with a significant reduction in the incidence of death or myocardialinfarction.
nsubj||food-5/NN||montelukast-1/NN	nsubj||has-14/VBZ||montelukast-1/NN	cop||food-5/NN||is-2/VBZ	dep||food-5/NN||a-3/DT	dep||food-5/NN||us-4/PRP	root||ROOT-0/null||food-5/NN	nn||asthma-9/NN||drug-7/NN	nn||asthma-9/NN||administration-approved-8/NN	conj_and||food-5/NN||asthma-9/NN	nn||controller-12/NN||eib-11/NN	conj_and||food-5/NN||controller-12/NN	conj_and||asthma-9/NN||controller-12/NN	conj_and||food-5/NN||has-14/VBZ	det||number-16/NN||a-15/DT	dobj||has-14/VBZ||number-16/NN	amod||advantages-19/NNS||potential-18/JJ	prep_of||number-16/NN||advantages-19/NNS	amod||medications-23/NNS||other-21/JJ	nn||medications-23/NNS||asthma-22/NN	prep_to||advantages-19/NNS||medications-23/NNS	amod||onset-26/NN||short-25/JJ	prep_including||medications-23/NNS||onset-26/NN	prep_of||onset-26/NN||action-28/NN	prep_including||medications-23/NNS||ease-30/NN	conj_and||onset-26/NN||ease-30/NN	prep_of||ease-30/NN||use-32/NN	prep_including||medications-23/NNS||lack-35/NN	conj_and||onset-26/NN||lack-35/NN	prep_of||lack-35/NN||tolerance-37/NN	asthma-22||montelukast-1||yes||montelukast is a us food and drug administration-approved asthma and eib controller and has a number of potential advantages to other asthma medications including short onset of action, ease of use, and lack of tolerance.
nn||data-2/NNS||facility-1/NN	nsubj||confirm-3/VBP||data-2/NNS	root||ROOT-0/null||confirm-3/VBP	amod||scale-up-5/NN||significant-4/JJ	dobj||confirm-3/VBP||scale-up-5/NN	amod||delivery-9/NN||hiv/aids-7/JJ	nn||delivery-9/NN||service-8/NN	prep_in||confirm-3/VBP||delivery-9/NN	det||countries-12/NNS||both-11/DT	prep_in||delivery-9/NN||countries-12/NNS	aids--1||hiv--1||no||facility data confirm significant scale-up in hiv/aids service delivery in both countries.
nsubj||result-3/VB||this-1/DT	aux||result-3/VB||may-2/MD	root||ROOT-0/null||result-3/VB	amod||transmission-6/NN||enhanced-5/JJ	prep_in||result-3/VB||transmission-6/NN	amod||parasites-10/NNS||mutant-8/JJ	nn||parasites-10/NNS||malaria-9/NN	prep_of||transmission-6/NN||parasites-10/NNS	mark||shown-14/VBN||as-12/IN	advmod||shown-14/VBN||previously-13/RB	advcl||result-3/VB||shown-14/VBN	amod||resistant-17/JJ||chloroquine-16/JJ	amod||parasites-18/NNS||resistant-17/JJ	prep_for||shown-14/VBN||parasites-18/NNS	malaria-9||chloroquine-16||yes||this may result in enhanced transmission of mutant malaria parasites, as previously shown for chloroquine resistant parasites.
amod||status-2/NN||hiv/aids-1/JJ	nsubjpass||known-4/VBN||status-2/NN	auxpass||known-4/VBN||was-3/VBD	ccomp||reported-19/VBD||known-4/VBN	amod||children-11/NNS||68-6/CD	num||%-9/NN||17.4-8/CD	appos||children-11/NNS||%-9/NN	agent||known-4/VBN||children-11/NNS	nn||caretakers-18/NNS||93-13/CD	num||%-16/NN||29-15/CD	appos||caretakers-18/NNS||%-16/NN	nsubj||reported-19/VBD||caretakers-18/NNS	root||ROOT-0/null||reported-19/VBD	xcomp||reported-19/VBD||knowing-20/VBG	det||child-22/NN||the-21/DT	poss||status-48/NN||child-22/NN	amod||status-48/NN||serostatus-24/JJ	num||years-26/NNS||two-25/CD	npadvmod||serostatus-24/JJ||years-26/NNS	poss||survey-30/NN||our-29/PRP$	prep_prior_to||serostatus-24/JJ||survey-30/NN	appos||survey-30/NN||180-32/CD	mark||told-44/VBN||180-32/CD	num||%-35/NN||46.2-34/CD	appos||180-32/CD||%-35/NN	nsubj||said-38/VBD||respondents-37/NNS	rcmod||180-32/CD||said-38/VBD	det||child-41/NN||the-40/DT	nsubjpass||told-44/VBN||child-41/NN	aux||told-44/VBN||should-42/MD	auxpass||told-44/VBN||be-43/VB	ccomp||said-38/VBD||told-44/VBN	nn||hiv/aids-47/NNS||his/her-46/NN	prep_about||told-44/VBN||hiv/aids-47/NNS	dobj||knowing-20/VBG||status-48/NN	advmod||older-52/JJR||when-49/WRB	nsubj||older-52/JJR||he/she-50/NN	cop||older-52/JJR||is-51/VBZ	rcmod||child-22/NN||older-52/JJR	ccomp||status-48/NN||older-52/JJR	num||years-55/NNS||14-54/CD	prep_than||older-52/JJR||years-55/NNS	prep_of||years-55/NNS||age-57/NN	aids--1||hiv--1||no||hiv/aids status was known by 68 (17.4%) children, 93 (29%) caretakers reported knowing the child's serostatus two years prior to our survey, 180 (46.2%) respondents said that the child should be told about his/her hiv/aids status when he/she is older than 14 years of age.
aux||review-2/VB||to-1/TO	root||ROOT-0/null||review-2/VB	det||literature-4/NN||the-3/DT	dobj||review-2/VB||literature-4/NN	det||treatment-7/NN||the-6/DT	prep_on||literature-4/NN||treatment-7/NN	amod||disease-11/NN||gastroesophageal-9/JJ	nn||disease-11/NN||reflux-10/NN	prep_of||treatment-7/NN||disease-11/NN	dep||treatment-7/NN||gerd-13/VBN	prep_with||review-2/VB||emphasis-16/NN	prep_on||emphasis-16/NN||protonpumpinhibitors-18/NNS	appos||protonpumpinhibitors-18/NNS||ppis-20/NNS	advmod||review-2/VB||particularly-23/RB	amod||esomeprazole-26/NN||delayed-release-25/JJ	prep_on||review-2/VB||esomeprazole-26/NN	aux||identify-30/VB||to-29/TO	conj_and||review-2/VB||identify-30/VB	dobj||identify-30/VB||properties-31/NNS	amod||effects-34/NNS||adverse-33/JJ	nsubj||observed-37/VBD||effects-34/NNS	prep_of||effects-34/NNS||ppis-36/NNS	conj_and||review-2/VB||observed-37/VBD	det||treatment-40/NN||the-39/DT	prep_in||observed-37/VBD||treatment-40/NN	prep_of||treatment-40/NN||gerd-42/NN	prep_in||observed-37/VBD||children-44/NNS	prep_in||observed-37/VBD||adolescents-46/NNS	conj_and||children-44/NNS||adolescents-46/NNS	gerd-42||esomeprazole-26||yes||to review the literature on the treatment of gastroesophageal reflux disease (gerd) with emphasis on protonpumpinhibitors (ppis), particularly on delayed-release esomeprazole, and to identify properties and adverse effects of ppis observed in the treatment of gerd in children and adolescents.
nn||rates-2/NNS||success-1/NN	nsubj||%-9/NN||rates-2/NNS	prep_for||rates-2/NNS||daptomycin-4/NN	prep_versus||daptomycin-4/NN||vancomycin/gentamicin-6/NN	cop||%-9/NN||were-7/VBD	num||%-9/NN||45-8/CD	root||ROOT-0/null||%-9/NN	num||%-12/NN||27-11/CD	prep_versus||%-9/NN||%-12/NN	amod||bacteraemia-15/NN||complicated-14/JJ	prep_in||%-12/NN||bacteraemia-15/NN	num||%-18/NN||60-17/CD	prep_versus||%-9/NN||%-18/NN	conj_and||%-12/NN||%-18/NN	num||%-21/NN||45-20/CD	prep_versus||%-18/NN||%-21/NN	amod||bacteraemia-24/NN||uncomplicated-23/JJ	prep_in||%-21/NN||bacteraemia-24/NN	num||%-27/NN||50-26/CD	prep_versus||%-9/NN||%-27/NN	conj_and||%-12/NN||%-27/NN	num||%-30/NN||50-29/CD	prep_versus||%-27/NN||%-30/NN	amod||endocarditis-34/NNS||right-sided-32/JJ	nn||endocarditis-34/NNS||mrsa-33/NN	prep_in||%-30/NN||endocarditis-34/NNS	endocarditis-34||daptomycin-4||no_rel||success rates for daptomycin versus vancomycin/gentamicin were 45% versus 27% in complicated bacteraemia, 60% versus 45% in uncomplicated bacteraemia and 50% versus 50% in right-sided mrsa endocarditis.
advmod||used-5/VBN||until-1/IN	advmod||until-1/IN||now-2/RB	nsubjpass||used-5/VBN||adenosine-3/NN	auxpass||used-5/VBN||was-4/VBD	root||ROOT-0/null||used-5/VBN	amod||conditions-8/NNS||certain-7/JJ	prep_for||used-5/VBN||conditions-8/NNS	amod||tachycardia-12/NN||paroxysmal-10/JJ	amod||tachycardia-12/NN||supraventricular-11/JJ	prep_like||conditions-8/NNS||tachycardia-12/NN	appos||tachycardia-12/NN||psvt-14/NN	nn||parkinson-18/NN||wolff-17/NN	prep_for||used-5/VBN||parkinson-18/NN	conj_and||conditions-8/NNS||parkinson-18/NN	amod||syndrome-23/NN||white-19/JJ	appos||syndrome-23/NN||wpw-21/NN	dep||parkinson-18/NN||syndrome-23/NN	wpw-21||adenosine-3||yes||until now adenosine was used for certain conditions like paroxysmal supraventricular tachycardia (psvt) and wolff parkinson white (wpw) syndrome.
det||model-2/NN||a-1/DT	nsubjpass||designed-29/VBN||model-2/NN	nsubj||simulate-31/VB||model-2/NN	vmod||model-2/NN||incorporating-3/VBG	advmod||incorporating-3/VBG||heterogeneity-4/RB	prep_in||incorporating-3/VBG||age-6/NN	appos||model-2/NN||gender-8/NN	amod||activity-11/NN||sexual-10/JJ	appos||model-2/NN||activity-11/NN	conj_and||gender-8/NN||activity-11/NN	nn||status-14/NN||hivinfection-13/NN	appos||model-2/NN||status-14/NN	conj_and||gender-8/NN||status-14/NN	appos||model-2/NN||stage-16/NN	conj_and||gender-8/NN||stage-16/NN	prep_of||stage-16/NN||disease-18/NN	nn||coverage/discontinuation-21/NN||prep-20/NN	appos||disease-18/NN||coverage/discontinuation-21/NN	nn||susceptibility-26/NN||hiv-24/NN	nn||susceptibility-26/NN||drug-25/NN	appos||model-2/NN||susceptibility-26/NN	conj_and||gender-8/NN||susceptibility-26/NN	auxpass||designed-29/VBN||was-28/VBD	root||ROOT-0/null||designed-29/VBN	aux||simulate-31/VB||to-30/TO	xcomp||designed-29/VBN||simulate-31/VB	det||impact-33/NN||the-32/DT	dobj||simulate-31/VB||impact-33/NN	prep_of||impact-33/NN||prep-35/NN	nn||prevention-38/NN||hiv-37/NN	prep_on||simulate-31/VB||prevention-38/NN	nn||resistance-41/NN||drug-40/NN	prep_on||simulate-31/VB||resistance-41/NN	conj_and||prevention-38/NN||resistance-41/NN	det||epidemic-45/NN||a-43/DT	amod||epidemic-45/NN||sub-saharan-44/JJ	prep_in||prevention-38/NN||epidemic-45/NN	hivinfection-13||hiv-37||no||a model incorporating heterogeneity in age, gender, sexual activity, hivinfection status, stage of disease, prep coverage/discontinuation, and hiv drug susceptibility, was designed to simulate the impact of prep on hiv prevention and drug resistance in a sub-saharan epidemic.
advmod||hbsag-24/VBG||furthermore-1/RB	mark||expressed-12/VBD||while-3/IN	nsubj||expressed-12/VBD||most-4/JJS	det||controls-7/NNS||the-6/DT	prep_of||most-4/JJS||controls-7/NNS	amod||infection-11/NN||ongoing-9/JJ	nn||infection-11/NN||hbv-10/NN	prep_with||controls-7/NNS||infection-11/NN	advcl||hbsag-24/VBG||expressed-12/VBD	xcomp||expressed-12/VBD||hbsag-13/VBG	det||majority-16/NN||the-15/DT	nsubj||hbsag-24/VBG||majority-16/NN	nn||patients-22/NNS||hcv-18/NN	conj_and||hcv-18/NN||hbv-20/JJ	nn||patients-22/NNS||hbv-20/JJ	amod||patients-22/NNS||positive-21/JJ	prep_of||majority-16/NN||patients-22/NNS	aux||hbsag-24/VBG||were-23/VBD	root||ROOT-0/null||hbsag-24/VBG	amod||positive-29/NN||negative-25/JJ	conj_and||negative-25/JJ||hbv-27/NN	amod||positive-29/NN||hbv-27/NN	nn||positive-29/NN||dna-28/NN	dobj||hbsag-24/VBG||positive-29/NN	hbv-27||hbsag-24||yes||furthermore, while most of the controls with ongoing hbv infection expressed hbsag, the majority of hcv and hbv positive patients were hbsag negative and hbv dna positive.
amod||children-3/NNS||hiv-infected-2/JJ	prep_in||accompanied-13/VBN||children-3/NNS	amod||tb-8/NN||definite-5/JJ	conj_or||definite-5/JJ||probable-7/JJ	amod||tb-8/NN||probable-7/JJ	prep_with||children-3/NNS||tb-8/NN	amod||treatment-11/NN||anti-tuberculosis-10/JJ	nsubjpass||accompanied-13/VBN||treatment-11/NN	auxpass||accompanied-13/VBN||is-12/VBZ	root||ROOT-0/null||accompanied-13/VBN	det||reduction-16/NN||a-15/DT	agent||accompanied-13/VBN||reduction-16/NN	det||magnitude-19/NN||the-18/DT	prep_in||reduction-16/NN||magnitude-19/NN	det||response-25/NN||the-21/DT	amod||response-25/NN||ifn-î-22/JJ	amod||response-25/NN||³-23/JJ	nn||response-25/NN||elispot-24/NN	prep_of||magnitude-19/NN||response-25/NN	prep_to||accompanied-13/VBN||mtb-antigens-27/NNS	tb-8||mtb--1||no||in hiv-infected children with definite or probable tb, anti-tuberculosis treatment is accompanied by a reduction in the magnitude of the ifn-î³ elispot response to mtb-antigens.
nn||management-2/NN||symptom-1/NN	nsubj||part-16/NN||management-2/NN	prep_for||management-2/NN||persons-4/NNS	vmod||persons-4/NNS||living-5/VBG	prep_with||living-5/VBG||hiv-7/NN	appos||hiv-7/NN||plhiv-9/NNP	prep_with||living-5/VBG||aids-12/NNS	conj_or||hiv-7/NN||aids-12/NNS	cop||part-16/NN||is-13/VBZ	det||part-16/NN||an-14/DT	amod||part-16/NN||important-15/JJ	root||ROOT-0/null||part-16/NN	nn||management-19/NN||care-18/NN	prep_of||part-16/NN||management-19/NN	aids-12||hiv-7||no||symptom management for persons living with hiv (plhiv) or aids is an important part of care management.
det||conversion-3/NN||the-1/DT	amod||conversion-3/NN||conformational-2/JJ	nsubj||responsible-21/JJ||conversion-3/NN	det||prionprotein-8/NN||the-5/DT	amod||prionprotein-8/NN||host-derived-6/JJ	amod||prionprotein-8/NN||cellular-7/JJ	prep_of||conversion-3/NN||prionprotein-8/NN	dep||prionprotein-8/NN||prpc-10/JJ	det||isoform-16/NN||the-13/DT	amod||isoform-16/NN||disease-associated-14/JJ	nn||isoform-16/NN||scrapie-15/NN	prep_into||prionprotein-8/NN||isoform-16/NN	dep||isoform-16/NN||prpsc-18/JJ	cop||responsible-21/JJ||is-20/VBZ	root||ROOT-0/null||responsible-21/JJ	det||pathogenesis-24/NNS||the-23/DT	prep_for||responsible-21/JJ||pathogenesis-24/NNS	prep_of||pathogenesis-24/NNS||transmissiblespongiformencephalopathies-26/NNS	appos||transmissiblespongiformencephalopathies-26/NNS||tses-28/NNS	transmissiblespongiformencephalopathies-26||prionprotein-8||no||the conformational conversion of the host-derived cellular prionprotein (prpc) into the disease-associated scrapie isoform (prpsc) is responsible for the pathogenesis of transmissiblespongiformencephalopathies (tses).
amod||quotient-14/NN||white-1/JJ	nn||quotient-14/NN||blood-2/NN	nn||quotient-14/NN||cell-3/NN	nn||quotient-14/NN||count-4/NN	dep||quotient-14/NN||csf/serum-6/NN	nn||quotient-14/NN||glucose-7/NN	nn||quotient-14/NN||ratio-8/NN	dep||quotient-14/NN||protein-10/NN	dep||quotient-14/NN||csf/serum-12/NN	nn||quotient-14/NN||albumin-13/NN	nsubjpass||analyzed-25/VBN||quotient-14/NN	nn||indices-17/NNS||immunoglobulin-16/NN	conj_and||quotient-14/NN||indices-17/NNS	nsubjpass||analyzed-25/VBN||indices-17/NNS	prep_for||quotient-14/NN||igg-19/NN	prep_for||quotient-14/NN||iga-21/NN	conj_and||igg-19/NN||iga-21/NN	prep_for||quotient-14/NN||igm-23/NN	conj_and||igg-19/NN||igm-23/NN	auxpass||analyzed-25/VBN||were-24/VBD	root||ROOT-0/null||analyzed-25/VBN	num||patients-28/NNS||90-27/CD	prep_in||analyzed-25/VBN||patients-28/NNS	prep_with||patients-28/NNS||bacterialmeningitis-30/NNS	num||patients-33/NNS||117-32/CD	prep_in||analyzed-25/VBN||patients-33/NNS	conj_and||patients-28/NNS||patients-33/NNS	prep_with||patients-33/NNS||viralmeningoencephalitis-35/NNS	num||patients-38/NNS||36-37/CD	prep_in||analyzed-25/VBN||patients-38/NNS	conj_and||patients-28/NNS||patients-38/NNS	prep_with||patients-38/NNS||leptomeningealmetastases-40/NNS	det||total-43/NN||a-42/DT	prep_in||leptomeningealmetastases-40/NNS||total-43/NN	num||samples-47/NNS||480-45/CD	nn||samples-47/NNS||csf-46/NN	prep_of||total-43/NN||samples-47/NNS	viralmeningoencephalitis-35||albumin-13||no_rel||white blood cell count, csf/serum glucose ratio, protein, csf/serum albumin quotient and immunoglobulin indices for igg, iga and igm were analyzed in 90 patients with bacterialmeningitis, 117 patients with viralmeningoencephalitis and 36 patients with leptomeningealmetastases in a total of 480 csf samples.
det||administration-2/NN||the-1/DT	nsubj||stay-34/VBP||administration-2/NN	prep_of||administration-2/NN||cr-4/NN	prep_to||cr-4/NN||children-6/NNS	prep_to||cr-4/NN||adolescents-8/NNS	conj_and||children-6/NNS||adolescents-8/NNS	amod||results-12/NNS||tbi-10/JJ	amod||results-12/NNS||improved-11/JJ	prep_with||children-6/NNS||results-12/NNS	amod||parameters-15/NNS||several-14/JJ	prep_in||results-12/NNS||parameters-15/NNS	prep_including||stay-34/VBP||duration-18/NN	nn||amnesia-22/NN||post-20/NN	amod||amnesia-22/NN||traumatic-21/JJ	prep_of||duration-18/NN||amnesia-22/NN	appos||amnesia-22/NN||pta-24/NN	nsubj||stay-34/VBP||duration-27/NN	amod||unit-33/NN||intubation-29/JJ	amod||unit-33/NN||intensive-31/JJ	nn||unit-33/NN||care-32/NN	prep_of||duration-27/NN||unit-33/NN	root||ROOT-0/null||stay-34/VBP	pta-24||amnesia-22||no_rel||the administration of cr to children and adolescents with tbi improved results in several parameters, including duration of post traumatic amnesia (pta), duration of intubation, intensive care unit stay.
amod||levels-2/NNS||low-1/JJ	nsubjpass||reported-11/VBN||levels-2/NNS	nn||arginine-5/NN||serum-4/NN	prep_of||levels-2/NNS||arginine-5/NN	nn||dysfunction-8/NNS||endothelium-7/NN	prep_of||levels-2/NNS||dysfunction-8/NNS	conj_and||arginine-5/NN||dysfunction-8/NNS	aux||reported-11/VBN||have-9/VBP	auxpass||reported-11/VBN||been-10/VBN	root||ROOT-0/null||reported-11/VBN	prep_in||reported-11/VBN||melas-13/NNS	det||treatment-16/NN||this-15/DT	nsubj||increase-18/VB||treatment-16/NN	nsubj||promote-24/VB||treatment-16/NN	aux||increase-18/VB||may-17/MD	conj_and||reported-11/VBN||increase-18/VB	advmod||increase-18/VB||no-19/RB	amod||cells-22/NNS||endothelial-21/JJ	prep_in||no-19/RB||cells-22/NNS	conj_and||reported-11/VBN||promote-24/VB	conj_and||increase-18/VB||promote-24/VB	dobj||promote-24/VB||vasodilation-25/NN	amod||cerebralischemia-28/NN||decreasing-27/VBG	dobj||promote-24/VB||cerebralischemia-28/NN	conj_and||vasodilation-25/NN||cerebralischemia-28/NN	dobj||promote-24/VB||strokes-30/NNS	conj_and||vasodilation-25/NN||strokes-30/NNS	cerebralischemia-28||arginine-5||no_rel||low levels of serum arginine and endothelium dysfunction have been reported in melas and this treatment may increase no in endothelial cells and promote vasodilation, decreasing cerebralischemia and strokes.
prep_for||plasmid-28/VBN||animals-2/NNS	vmod||animals-2/NNS||injected-3/VBN	num||transposon-11/NNS||10-5/CD	number||1/4-7/CD||î-6/CD	num||transposon-11/NNS||1/4-7/CD	amod||transposon-11/NNS||g-8/JJ	amod||transposon-11/NNS||statin-9/JJ	nn||transposon-11/NNS||ae-10/NN	prep_with||injected-3/VBN||transposon-11/NNS	vmod||transposon-11/NNS||plasmid-12/VBN	det||number-15/NN||the-14/DT	nsubjpass||plasmid-28/VBN||number-15/NN	nn||nodules-18/NNS||tumor-17/NN	prep_of||number-15/NN||nodules-18/NNS	auxpass||plasmid-28/VBN||was-19/VBD	advmod||plasmid-28/VBN||inversely-20/RB	pobj||inversely-20/RB||proportional-21/CD	det||amount-24/NN||the-23/DT	prep_to||inversely-20/RB||amount-24/NN	amod||sb-27/NN||co-injected-26/JJ	prep_of||amount-24/NN||sb-27/NN	root||ROOT-0/null||plasmid-28/VBN	tumor-17||sb-27||no_rel||for animals injected with 10 î¼g statin ae transposon plasmid, the number of tumor nodules was inversely proportional to the amount of co-injected sb plasmid.
nsubjpass||reported-4/VBN||it-1/PRP	aux||reported-4/VBN||has-2/VBZ	auxpass||reported-4/VBN||been-3/VBN	root||ROOT-0/null||reported-4/VBN	mark||inhibit-16/VB||that-5/IN	amod||protein-11/NN||hepatitisbvirus-6/JJ	nn||protein-11/NN||hbv-8/NN	amod||protein-11/NN||core-10/JJ	nsubj||inhibit-16/VB||protein-11/NN	appos||protein-11/NN||hbc-13/NN	aux||inhibit-16/VB||can-15/MD	ccomp||reported-4/VBN||inhibit-16/VB	det||transcription-18/NN||the-17/DT	dobj||inhibit-16/VB||transcription-18/NN	amod||gene-23/NN||human-20/JJ	amod||gene-23/NN||interferon-induced-21/JJ	nn||gene-23/NN||mxa-22/NN	prep_of||transcription-18/NN||gene-23/NN	hbv-8||hepatitisbvirus-6||no||it has been reported that hepatitisbvirus (hbv) core protein (hbc) can inhibit the transcription of human interferon-induced mxa gene.
nsubj||have-4/VB||acarbose-1/NN	aux||have-4/VB||may-2/MD	advmod||have-4/VB||thus-3/RB	root||ROOT-0/null||have-4/VB	advmod||beneficial-6/JJ||more-5/RBR	amod||effects-7/NNS||beneficial-6/JJ	dobj||have-4/VB||effects-7/NNS	amod||function-11/NN||postprandial-9/JJ	amod||function-11/NN||endothelial-10/JJ	prep_on||have-4/VB||function-11/NN	prep_in||function-11/NN||patients-13/NNS	prep_with||patients-13/NNS||type2diabetes-15/CD	prep_than||have-4/VB||nateglinide-17/NN	type2diabetes-15||acarbose-1||yes||acarbose may thus have more beneficial effects on postprandial endothelial function in patients with type2diabetes than nateglinide.
det||earliest-3/JJS||the-2/DT	prep_among||imposition-16/NN||earliest-3/JJS	det||responses-8/NNS||the-5/DT	amod||responses-8/NNS||most-6/JJS	amod||responses-8/NNS||enduring-7/VBG	conj_and||earliest-3/JJS||responses-8/NNS	prep_among||imposition-16/NN||responses-8/NNS	det||hiv/aids-11/NNS||the-10/DT	prep_to||responses-8/NNS||hiv/aids-11/NNS	nsubj||imposition-16/NN||epidemic-12/NN	aux||imposition-16/NN||has-13/VBZ	cop||imposition-16/NN||been-14/VBN	det||imposition-16/NN||the-15/DT	root||ROOT-0/null||imposition-16/NN	prep_by||imposition-16/NN||governments-18/NNS	nn||stay-22/NN||entry-20/NN	prep_of||governments-18/NNS||stay-22/NN	nn||restrictions-26/NNS||residence-25/NN	prep_of||governments-18/NNS||restrictions-26/NNS	conj_and||stay-22/NN||restrictions-26/NNS	prep_for||imposition-16/NN||non-nationals-28/NNS	vmod||non-nationals-28/NNS||living-29/VBG	prep_with||living-29/VBG||hiv-31/NN	prep_with||living-29/VBG||aids-33/NNS	conj_and||hiv-31/NN||aids-33/NNS	aids-33||hiv-31||no||among the earliest and the most enduring responses to the hiv/aids epidemic has been the imposition by governments of entry, stay, and residence restrictions for non-nationals living with hiv and aids.
amod||variants-2/NNS||genetic-1/JJ	conj_or||variants-2/NNS||variants-2/NNS	nsubjpass||analyzed-8/VBN||variants-2/NNS	nsubjpass||analyzed-8/VBN||variants-2/NNS	nsubj||assess-10/VB||variants-2/NNS	nsubj||assess-10/VB||variants-2/NNS	prep_in||variants-2/NNS||ask1-6/CD	prep_near||variants-2/NNS||ask1-6/CD	auxpass||analyzed-8/VBN||were-7/VBD	root||ROOT-0/null||analyzed-8/VBN	aux||assess-10/VB||to-9/TO	xcomp||analyzed-8/VBN||assess-10/VB	det||role-12/NN||the-11/DT	dobj||assess-10/VB||role-12/NN	det||gene-15/NN||this-14/DT	prep_of||role-12/NN||gene-15/NN	nn||action-18/NN||insulin-17/NN	prep_in||gene-15/NN||action-18/NN	prep_in||gene-15/NN||type2diabetes-20/NN	conj_and||action-18/NN||type2diabetes-20/NN	insulin-17||type2diabetes-20||no_rel||genetic variants in or near ask1 were analyzed to assess the role of this gene in insulin action and type2diabetes.
aux||compare-2/VB||to-1/TO	csubj||ahmed-15/VBD||compare-2/VB	amod||outcomes-4/NNS||surgical-3/JJ	dobj||compare-2/VB||outcomes-4/NNS	nn||patients-8/NNS||neovascular-6/NN	nn||patients-8/NNS||glaucoma-7/NN	prep_in||compare-2/VB||patients-8/NNS	nsubj||underwent-10/VBD||patients-8/NNS	rcmod||patients-8/NNS||underwent-10/VBD	advmod||underwent-10/VBD||trabeculectomy-11/RB	amod||versus-14/NNS||mitomycinc-13/JJ	prep_with||underwent-10/VBD||versus-14/NNS	root||ROOT-0/null||ahmed-15/VBD	amod||implantation-18/NN||glaucoma-16/JJ	nn||implantation-18/NN||valve-17/NN	dobj||ahmed-15/VBD||implantation-18/NN	glaucoma-16||mitomycinc-13||yes||to compare surgical outcomes in neovascular glaucoma patients who underwent trabeculectomy with mitomycinc versus ahmed glaucoma valve implantation.
nsubj||endocrinedisease-6/NN||endogenous-1/NNS	vmod||endogenous-1/NNS||cushing-2/VBG	dobj||cushing-2/VBG||syndrome-3/NN	cop||endocrinedisease-6/NN||is-4/VBZ	det||endocrinedisease-6/NN||an-5/DT	root||ROOT-0/null||endocrinedisease-6/NN	vmod||endocrinedisease-6/NN||caused-7/VBN	amod||secretion-10/NN||excessive-9/JJ	agent||caused-7/VBN||secretion-10/NN	nn||hormone-13/NN||adrenocorticotropin-12/NN	prep_of||secretion-10/NN||hormone-13/NN	quantmod||80-16/CD||approximately-15/RB	num||%-17/NN||80-16/CD	prep_in||caused-7/VBN||%-17/NN	prep_of||%-17/NN||cases-19/NNS	advmod||caused-7/VBN||usually-21/RB	det||adenoma-26/NN||a-23/DT	advmod||corticotroph-25/JJ||pituitary-24/RB	amod||adenoma-26/NN||corticotroph-25/JJ	agent||caused-7/VBN||adenoma-26/NN	amod||-RSB--31/NNP||cushingdisease-28/JJ	nn||-RSB--31/NNP||-LSB--29/NNP	nn||-RSB--31/NNP||cd-30/NN	appos||adenoma-26/NN||-RSB--31/NNP	adrenocorticotropin-12||adenoma-26||no_rel||endogenous cushing syndrome is an endocrinedisease caused by excessive secretion of adrenocorticotropin hormone in approximately 80% of cases, usually by a pituitary corticotroph adenoma (cushingdisease [cd]).
nsubj||drug-7/NN||lansoprazole-1/NN	cop||drug-7/NN||is-2/VBZ	det||drug-7/NN||an-3/DT	amod||drug-7/NN||acid-4/JJ	amod||drug-7/NN||proton-pump-5/JJ	nn||drug-7/NN||inhibiting-6/NN	root||ROOT-0/null||drug-7/NN	nsubjpass||used-10/VBN||drug-7/NN	auxpass||used-10/VBN||is-9/VBZ	rcmod||drug-7/NN||used-10/VBN	det||treatment-13/NN||the-12/DT	prep_for||used-10/VBN||treatment-13/NN	amod||ulcers-18/NNS||duodenal-15/JJ	conj_or||duodenal-15/JJ||gastric-17/JJ	amod||ulcers-18/NNS||gastric-17/JJ	prep_of||treatment-13/NN||ulcers-18/NNS	nn||infection-22/NN||h.-20/NN	nn||infection-22/NN||pylori-21/NN	prep_of||treatment-13/NN||infection-22/NN	conj_or||ulcers-18/NNS||infection-22/NN	amod||disease-26/NN||gastroesophageal-24/JJ	nn||disease-26/NN||reflux-25/NN	prep_of||treatment-13/NN||disease-26/NN	conj_or||ulcers-18/NNS||disease-26/NN	prep_of||treatment-13/NN||zollinger-ellisonsyndrome-28/NN	conj_or||ulcers-18/NNS||zollinger-ellisonsyndrome-28/NN	zollinger-ellisonsyndrome-28||lansoprazole-1||yes||lansoprazole is an acid proton-pump inhibiting drug that is used for the treatment of duodenal or gastric ulcers , h. pylori infection , gastroesophageal reflux disease or zollinger-ellisonsyndrome .
nn||design-2/NN||research-1/NN	dep||infused-8/VBZ||design-2/NN	nn||$-5/NNP||methodsâ-4/NNP	conj_and||design-2/NN||$-5/NNP	dep||infused-8/VBZ||$-5/NNP	nsubj||infused-8/VBZ||we-7/PRP	nsubj||infused-8/VBZ||we-7/PRP	nsubj||infused-8/VBZ||we-7/PRP	root||ROOT-0/null||infused-8/VBZ	conj_and||infused-8/VBZ||infused-8/VBZ	conj_and||infused-8/VBZ||infused-8/VBZ	amod||anp-10/NN||human-9/JJ	dobj||infused-8/VBZ||anp-10/NN	dep||infused-8/VBZ||25-12/CD	nn||â-14/FW||ng-13/FW	dep||25-12/CD||â-14/FW	punct||25-12/CD||·-15/:	poss||minâˆ-21/NN||kgâˆ-16/NNP	number||â-19/NN||1-18/CD	amod||minâˆ-21/NN||â-19/NN	punct||minâˆ-21/NN||·-20/``	dep||25-12/CD||minâˆ-21/NN	dep||minâˆ-21/NN||1-23/CD	num||men-27/NNS||12-26/CD	prep_during||infused-8/VBZ||men-27/NNS	prep_in||infused-8/VBZ||men-27/NNS	nsubj||â-31/VBP||age-29/NN	num||age-29/NN||32-30/CD	dep||men-27/NNS||â-31/VBP	punct||years-34/NNS||±-32/``	num||years-34/NNS||0.8-33/CD	dobj||â-31/VBP||years-34/NNS	nn||â-38/FW||bmi-36/FW	nn||â-38/FW||23.3-37/FW	appos||years-34/NNS||â-38/FW	punct||years-34/NNS||±-39/''	number||kg/m2-41/JJ||0.4-40/CD	amod||years-34/NNS||kg/m2-41/JJ	advmod||men-27/NNS||before-43/IN	npadvmod||h-49/RB||2-48/CD	conj||infused-8/VBZ||h-49/RB	prep_after||infused-8/VBZ||ingestion-51/NN	det||meal-57/NN||a-53/DT	amod||meal-57/NN||standardized-54/JJ	amod||meal-57/NN||high-fat-55/JJ	nn||meal-57/NN||test-56/NN	prep_of||ingestion-51/NN||meal-57/NN	det||fashion-65/NN||a-59/DT	amod||fashion-65/NN||randomized-60/JJ	amod||fashion-65/NN||double-blind-62/JJ	amod||fashion-65/NN||cross-over-64/JJ	prep_in||meal-57/NN||fashion-65/NN	cross--1||fat--1||no_rel||research design and methodsâ€” we infused human anp (25 ng â· kgâˆ’1 â· minâˆ’1) in 12 men (age 32 â± 0.8 years, bmi 23.3 â± 0.4 kg/m2) before, during, and 2 h after ingestion of a standardized high-fat test meal in a randomized, double-blind, cross-over fashion.
amod||immunomodulators-2/NNS||concomitant-1/JJ	nsubj||reduced-10/VBD||immunomodulators-2/NNS	det||form-5/NN||the-4/DT	prep_in||immunomodulators-2/NNS||form-5/NN	prep_of||form-5/NN||methotrexate-7/NN	prep_of||form-5/NN||azathioprine-9/NN	conj_or||methotrexate-7/NN||azathioprine-9/NN	root||ROOT-0/null||reduced-10/VBD	det||immunogenicity-12/NN||the-11/DT	dobj||reduced-10/VBD||immunogenicity-12/NN	amod||antibodies-15/NNS||therapeutic-14/JJ	prep_of||immunogenicity-12/NN||antibodies-15/NNS	prep_in||reduced-10/VBD||rheumatoidarthritis-17/NNS	nn||disease-20/NN||crohn-19/NN	prep_in||reduced-10/VBD||disease-20/NN	conj_and||rheumatoidarthritis-17/NNS||disease-20/NN	prep_in||reduced-10/VBD||juvenileidiopathicarthritis-23/NNS	conj_and||rheumatoidarthritis-17/NNS||juvenileidiopathicarthritis-23/NNS	rheumatoidarthritis-17||azathioprine-9||yes||concomitant immunomodulators in the form of methotrexate or azathioprine reduced the immunogenicity of therapeutic antibodies in rheumatoidarthritis, crohn disease, and juvenileidiopathicarthritis.
csubj||enhance-5/VB||answering-1/VBG	det||question-3/NN||this-2/DT	dobj||answering-1/VBG||question-3/NN	aux||enhance-5/VB||may-4/MD	root||ROOT-0/null||enhance-5/VB	poss||understanding-8/NN||our-6/PRP$	amod||understanding-8/NN||basic-7/JJ	dobj||enhance-5/VB||understanding-8/NN	nn||evolution-11/NN||virus-10/NN	prep_of||understanding-8/NN||evolution-11/NN	nn||applications-14/NNS||advance-13/NN	prep_of||understanding-8/NN||applications-14/NNS	conj_and||evolution-11/NN||applications-14/NNS	prep_of||understanding-8/NN||viruses-16/NNS	amod||vaccines-20/NNS||live-18/JJ	amod||vaccines-20/NNS||attenuated-19/JJ	prep_as||enhance-5/VB||vaccines-20/NNS	amod||vectors-23/NNS||gene-therapy-22/JJ	prep_as||enhance-5/VB||vectors-23/NNS	conj_or||vaccines-20/NNS||vectors-23/NNS	amod||therapeutics-27/NNS||anti-tumor-26/JJ	prep_as||enhance-5/VB||therapeutics-27/NNS	conj_or||vaccines-20/NNS||therapeutics-27/NNS	virus-10||viruses-16||no||answering this question may enhance our basic understanding of virus evolution and advance applications of viruses as live attenuated vaccines, gene-therapy vectors, or anti-tumor therapeutics.
det||ulcer-2/NN||the-1/DT	nsubj||improved-3/VBD||ulcer-2/NN	root||ROOT-0/null||improved-3/VBD	advmod||slightly-5/RB||only-4/RB	dobj||improved-3/VBD||slightly-5/RB	num||months-8/NNS||2-7/CD	prep_after||improved-3/VBD||months-8/NNS	amod||ointment-12/NN||povidone-iodine-10/JJ	nn||ointment-12/NN||sugar-11/NN	prep_with||improved-3/VBD||ointment-12/NN	amod||nausea-16/NN||severe-15/JJ	prep_because_of||ointment-12/NN||nausea-16/NN	prep_because_of||ointment-12/NN||anorexia-18/NN	conj_and||nausea-16/NN||anorexia-18/NN	nausea-16||povidone-iodine-10||no_rel||the ulcer improved only slightly after 2 months with povidone-iodine sugar ointment because of severe nausea and anorexia.
advmod||remain-11/VBP||however-1/RB	det||manifestations-5/NNS||the-3/DT	amod||manifestations-5/NNS||pulmonary-4/JJ	nsubj||remain-11/VBP||manifestations-5/NNS	prep_of||manifestations-5/NNS||hiv/acquiredimmunodeficiencysyndrome-7/NN	appos||hiv/acquiredimmunodeficiencysyndrome-7/NN||aids-9/NNS	root||ROOT-0/null||remain-11/VBP	det||cause-14/NN||a-12/DT	amod||cause-14/NN||major-13/JJ	xcomp||remain-11/VBP||cause-14/NN	prep_of||cause-14/NN||morbidity-16/NN	prep_of||cause-14/NN||mortality-18/NN	conj_and||morbidity-16/NN||mortality-18/NN	aids-9||hiv--1||no||however, the pulmonary manifestations of hiv/acquiredimmunodeficiencysyndrome (aids) remain a major cause of morbidity and mortality.
det||injection-3/NN||an-1/DT	amod||injection-3/NN||intravenous-2/JJ	nsubj||resolved-7/VBD||injection-3/NN	nsubj||normalized-15/VBD||injection-3/NN	amod||antibiotics-6/NNS||anti-staphylococcal-5/JJ	prep_of||injection-3/NN||antibiotics-6/NNS	root||ROOT-0/null||resolved-7/VBD	det||pain-10/NN||the-8/DT	amod||pain-10/NN||back-9/JJ	dobj||resolved-7/VBD||pain-10/NN	nn||pain-13/NN||radicular-12/NN	dobj||resolved-7/VBD||pain-13/NN	conj_and||pain-10/NN||pain-13/NN	conj_and||resolved-7/VBD||normalized-15/VBD	det||findings-18/NNS||the-16/DT	nn||findings-18/NNS||laboratory-17/NN	dobj||normalized-15/VBD||findings-18/NNS	pain-13||antibiotics-6||no_rel||an intravenous injection of anti-staphylococcal antibiotics resolved the back pain and radicular pain and normalized the laboratory findings.
amod||evidence-2/NN||recent-1/JJ	nsubj||demonstrated-4/VBN||evidence-2/NN	aux||demonstrated-4/VBN||has-3/VBZ	root||ROOT-0/null||demonstrated-4/VBN	mark||becoming-9/VBG||that-5/IN	nn||mites-7/NNS||scabies-6/NNS	nsubj||becoming-9/VBG||mites-7/NNS	aux||becoming-9/VBG||are-8/VBP	ccomp||demonstrated-4/VBN||becoming-9/VBG	advmod||tolerant-11/JJ||increasingly-10/RB	acomp||becoming-9/VBG||tolerant-11/JJ	amod||permethrin-14/NN||topical-13/JJ	prep_to||tolerant-11/JJ||permethrin-14/NN	amod||ivermectin-17/NN||oral-16/JJ	prep_to||tolerant-11/JJ||ivermectin-17/NN	conj_and||permethrin-14/NN||ivermectin-17/NN	scabies-6||permethrin-14||yes||recent evidence has demonstrated that scabies mites are becoming increasingly tolerant to topical permethrin and oral ivermectin.
prep_objectiveâ||examined-5/VBD||$-2/$	nsubj||examined-5/VBD||we-4/PRP	root||ROOT-0/null||examined-5/VBD	amod||rats-14/NNS||20-week-old-7/JJ	dep||20-week-old-7/JJ||zucker-8/JJR	amod||rats-14/NNS||diabetic-9/JJ	amod||rats-14/NNS||fatty-10/JJ	discourse||rats-14/NNS||zdf-12/UH	prep_in||examined-5/VBD||rats-14/NNS	mark||alter-25/VB||whether-15/IN	nsubj||alter-25/VB||restoration-16/NN	nsubj||improve-30/VB||restoration-16/NN	amod||expression-23/NN||hepatic-18/JJ	nn||expression-23/NN||glucokinase-19/NN	discourse||expression-23/NN||gk-21/UH	prep_of||restoration-16/NN||expression-23/NN	aux||alter-25/VB||would-24/MD	ccomp||examined-5/VBD||alter-25/VB	amod||flux-28/NN||hepatic-26/JJ	nn||flux-28/NN||glucose-27/NN	dobj||alter-25/VB||flux-28/NN	ccomp||examined-5/VBD||improve-30/VB	conj_and||alter-25/VB||improve-30/VB	dobj||improve-30/VB||hyperglycemia-31/NN	hyperglycemia-31||glucose-27||no||objectiveâ€” we examined in 20-week-old zucker diabetic fatty (zdf) rats whether restoration of hepatic glucokinase (gk) expression would alter hepatic glucose flux and improve hyperglycemia.
nsubjpass||associated-3/VBN||priondiseases-1/NNS	auxpass||associated-3/VBN||are-2/VBP	root||ROOT-0/null||associated-3/VBN	det||accumulation-6/NN||the-5/DT	prep_with||associated-3/VBN||accumulation-6/NN	det||form-10/NN||an-8/DT	amod||form-10/NN||abnormal-9/JJ	prep_of||accumulation-6/NN||form-10/NN	det||prionprotein-14/NN||the-12/DT	amod||prionprotein-14/NN||host-coded-13/JJ	prep_of||form-10/NN||prionprotein-14/NN	appos||prionprotein-14/NN||prp-16/NN	priondiseases-1||prionprotein-14||no||priondiseases are associated with the accumulation of an abnormal form of the host-coded prionprotein (prp).
nsubj||review-3/VBP||we-1/PRP	advmod||review-3/VBP||also-2/RB	root||ROOT-0/null||review-3/VBP	det||literature-6/NN||the-4/DT	amod||literature-6/NN||current-5/JJ	dobj||review-3/VBP||literature-6/NN	amod||diseases-13/NNS||hivan-8/JJ	conj_and||hivan-8/JJ||hiv-associated-10/JJ	amod||diseases-13/NNS||hiv-associated-10/JJ	amod||diseases-13/NNS||immune-11/JJ	amod||diseases-13/NNS||complex-12/JJ	prep_on||literature-6/NN||diseases-13/NNS	appos||diseases-13/NNS||hivicds-15/NNS	hivan-8||hiv--1||no||we also review the current literature on hivan and hiv-associated immune complex diseases (hivicds).
det||prevention-3/NN||the-1/DT	nn||prevention-3/NN||stroke-2/NN	nsubj||reduced-33/VBD||prevention-3/NN	amod||reduction-6/NN||aggressive-5/JJ	prep_by||prevention-3/NN||reduction-6/NN	nn||levels-9/NNS||cholesterol-8/NN	prep_of||reduction-6/NN||levels-9/NNS	dep||levels-9/NNS||sparcl-11/JJ	nsubj||showed-14/VBD||trial-13/NN	rcmod||levels-9/NNS||showed-14/VBD	amod||treatment-16/NN||daily-15/JJ	dobj||showed-14/VBD||treatment-16/NN	num||mg-19/NN||80-18/CD	prep_with||showed-14/VBD||mg-19/NN	prep_of||mg-19/NN||atorvastatin-21/NN	prep_in||showed-14/VBD||patients-23/NNS	det||stroke-27/NN||a-25/DT	amod||stroke-27/NN||recent-26/JJ	prep_with||patients-23/NNS||stroke-27/NN	prep_with||patients-23/NNS||transientischemicattack-29/NN	conj_or||stroke-27/NN||transientischemicattack-29/NN	appos||stroke-27/NN||tia-31/NN	root||ROOT-0/null||reduced-33/VBD	det||incidence-35/NN||the-34/DT	dobj||reduced-33/VBD||incidence-35/NN	amod||stroke-40/NN||fatal-37/JJ	conj_or||fatal-37/JJ||nonfatal-39/JJ	amod||stroke-40/NN||nonfatal-39/JJ	prep_of||incidence-35/NN||stroke-40/NN	num||%-43/NN||16-42/CD	prep_by||reduced-33/VBD||%-43/NN	cholesterol-8||stroke-40||no_rel||the stroke prevention by aggressive reduction of cholesterol levels (sparcl) trial showed daily treatment with 80 mg of atorvastatin in patients with a recent stroke or transientischemicattack (tia) reduced the incidence of fatal or nonfatal stroke by 16%.
nsubjpass||classified-3/VBN||breasttumors-1/NNS	auxpass||classified-3/VBN||are-2/VBP	root||ROOT-0/null||classified-3/VBN	prepc_based_on||classified-3/VBN||on-5/IN	det||status-15/NN||the-6/DT	amod||status-15/NN||estrogen-7/JJ	dep||alpha-9/NN||receptor-8/JJ	amod||status-15/NN||alpha-9/NN	number||±-12/CD||erî-11/CD	dep||alpha-9/NN||±-12/CD	nn||status-15/NN||expression-14/NN	pobj||classified-3/VBN||status-15/NN	advmod||negative-18/JJ||er-17/RB	amod||tumors-22/NNS||negative-18/JJ	advmod||positive-21/JJ||er-20/RB	conj_and||negative-18/JJ||positive-21/JJ	amod||tumors-22/NNS||positive-21/JJ	prep_into||status-15/NN||tumors-22/NNS	breasttumors-1||estrogen-7||yes||breasttumors are classified based on the estrogen receptor alpha (erî±) expression status into er negative and er positive tumors.
amod||trials-4/NNS||several-1/JJ	amod||trials-4/NNS||randomized-2/JJ	amod||trials-4/NNS||controlled-3/JJ	nsubjpass||initiated-6/VBN||trials-4/NNS	nsubj||assess-8/VB||trials-4/NNS	nsubj||assess-8/VB||trials-4/NNS	auxpass||initiated-6/VBN||were-5/VBD	root||ROOT-0/null||initiated-6/VBN	aux||assess-8/VB||to-7/TO	xcomp||initiated-6/VBN||assess-8/VB	xcomp||initiated-6/VBN||assess-8/VB	conj_and||assess-8/VB||assess-8/VB	det||impact-10/NN||the-9/DT	dobj||assess-8/VB||impact-10/NN	amod||therapy-14/NN||hsv-2-12/JJ	nn||therapy-14/NN||suppressive-13/NN	prep_of||impact-10/NN||therapy-14/NN	det||acquisition-17/NN||the-16/DT	prep_on||therapy-14/NN||acquisition-17/NN	prep_of||acquisition-17/NN||hivinfection-19/NN	amod||men-23/NNS||hsv-2-21/JJ	amod||men-23/NNS||infected-22/JJ	prep_by||assess-8/VB||men-23/NNS	prep_by||assess-8/VB||women-25/NNS	conj_and||men-23/NNS||women-25/NNS	det||transmission-31/NN||the-29/DT	amod||transmission-31/NN||onward-30/JJ	prep_on||assess-8/VB||transmission-31/NN	prep_of||transmission-31/NN||hiv-33/NN	amod||men-39/NNS||hsv-2-35/JJ	punct||hiv-37/NN||/-36/:	dep||men-39/NNS||hiv-37/NN	prep_by||assess-8/VB||co-infected-38/JJ	amod||men-39/NNS||co-infected-38/JJ	conj_and||men-39/NNS||co-infected-38/JJ	prep_by||assess-8/VB||men-39/NNS	prep_by||assess-8/VB||women-41/NNS	conj_and||men-39/NNS||women-41/NNS	hivinfection-19||hiv-37||no||several randomized controlled trials were initiated to assess the impact of hsv-2 suppressive therapy on the acquisition of hivinfection by hsv-2 infected men and women, and on the onward transmission of hiv by hsv-2/hiv co-infected men and women.
mark||retard-6/VB||although-1/IN	amod||insulin-3/NN||nasal-2/JJ	nsubj||retard-6/VB||insulin-3/NN	aux||retard-6/VB||did-4/VBD	neg||retard-6/VB||not-5/RB	advcl||provides-29/VBZ||retard-6/VB	dobj||retard-6/VB||loss-7/NN	amod||²-11/NNS||residual-9/JJ	nn||²-11/NNS||î-10/NN	prep_of||loss-7/NN||²-11/NNS	nn||function-14/NN||cell-13/NN	dep||loss-7/NN||function-14/NN	prep_in||function-14/NN||adults-16/NNS	amod||type1diabetes-19/NNS||established-18/VBN	prep_with||adults-16/NNS||type1diabetes-19/NNS	nsubj||provides-29/VBZ||evidence-21/NN	mark||induced-24/VBN||that-22/IN	nsubj||induced-24/VBN||it-23/PRP	dep||evidence-21/NN||induced-24/VBN	amod||tolerance-26/NN||immune-25/JJ	dobj||induced-24/VBN||tolerance-26/NN	prep_to||induced-24/VBN||insulin-28/NN	root||ROOT-0/null||provides-29/VBZ	det||rationale-31/NN||a-30/DT	dobj||provides-29/VBZ||rationale-31/NN	poss||application-34/NN||its-33/PRP$	prep_for||rationale-31/NN||application-34/NN	aux||prevent-36/VB||to-35/TO	vmod||application-34/NN||prevent-36/VB	dobj||prevent-36/VB||diabetes-37/NN	amod||individuals-40/NNS||at-risk-39/JJ	prep_in||prevent-36/VB||individuals-40/NNS	type1diabetes-19||insulin-28||yes||although nasal insulin did not retard loss of residual î²-cell function in adults with established type1diabetes, evidence that it induced immune tolerance to insulin provides a rationale for its application to prevent diabetes in at-risk individuals.
amod||variants-2/NNS||ask1-1/JJ	nsubj||increase-4/VB||variants-2/NNS	aux||increase-4/VB||may-3/MD	root||ROOT-0/null||increase-4/VB	advmod||increase-4/VB||susceptibility-5/RB	prep_to||increase-4/VB||type2diabetes-7/CD	amod||sensitivity-11/NN||decreasing-9/VBG	nn||sensitivity-11/NN||insulin-10/NN	prep_by||increase-4/VB||sensitivity-11/NN	amod||expression-15/NN||reduced-13/JJ	amod||expression-15/NN||ask1-14/JJ	prep_via||sensitivity-11/NN||expression-15/NN	insulin-10||type2diabetes-7||no_rel||ask1 variants may increase susceptibility to type2diabetes by decreasing insulin sensitivity via reduced ask1 expression.
nn||variables-2/NNS||outcome-1/NN	nsubj||pain-7/NN||variables-2/NNS	det||study-5/NN||the-4/DT	prep_in||variables-2/NNS||study-5/NN	cop||pain-7/NN||were-6/VBD	root||ROOT-0/null||pain-7/NN	conj_and||pain-7/NN||requirement-9/NN	prep_of||requirement-9/NN||analgesics-11/NNS	amod||score-15/NN||global-13/JJ	nn||score-15/NN||satisfaction-14/NN	conj_and||pain-7/NN||score-15/NN	amod||stay-18/NN||length-of-hospital-17/JJ	conj_and||pain-7/NN||stay-18/NN	pain-7||analgesics-11||no_rel||outcome variables in the study were pain, requirement of analgesics, global satisfaction score and length-of-hospital stay.
advmod||thereafter-2/RB||soon-1/RB	advmod||reported-17/VBN||thereafter-2/RB	prep_in||reported-17/VBN||1983-5/CD	det||retrovirus-9/NNS||another-7/DT	amod||retrovirus-9/NNS||human-8/JJ	nsubjpass||reported-17/VBN||retrovirus-9/NNS	nsubjpass||implicated-19/VBN||retrovirus-9/NNS	appos||retrovirus-9/NNS||humanimmunodeficiencyvirus-11/NNS	appos||humanimmunodeficiencyvirus-11/NNS||hiv-13/NN	auxpass||reported-17/VBN||was-16/VBD	root||ROOT-0/null||reported-17/VBN	conj_and||reported-17/VBN||implicated-19/VBN	det||agent-23/NN||the-21/DT	amod||agent-23/NN||etiologic-22/JJ	prep_as||reported-17/VBN||agent-23/NN	prep_of||agent-23/NN||aids-25/NNS	aids-25||humanimmunodeficiencyvirus-11||no||soon thereafter, in 1983, another human retrovirus, humanimmunodeficiencyvirus (hiv), was reported and implicated as the etiologic agent of aids.
det||study-2/NN||the-1/DT	nsubj||investigated-3/VBD||study-2/NN	root||ROOT-0/null||investigated-3/VBD	det||possibility-5/NN||the-4/DT	dobj||investigated-3/VBD||possibility-5/NN	prepc_of||possibility-5/NN||identifying-7/VBG	det||speed-9/NN||the-8/DT	dobj||identifying-7/VBG||speed-9/NN	det||movement-13/NN||an-11/DT	amod||movement-13/NN||imagined-12/JJ	prep_of||speed-9/NN||movement-13/NN	nn||recordings-16/NNS||eeg-15/NN	prep_from||identifying-7/VBG||recordings-16/NNS	amod||patients-22/NNS||amyotrophiclateralsclerosis-18/JJ	appos||patients-22/NNS||als-20/NN	prep_in||recordings-16/NNS||patients-22/NNS	amyotrophiclateralsclerosis-18||speed-9||no_rel||the study investigated the possibility of identifying the speed of an imagined movement from eeg recordings in amyotrophiclateralsclerosis (als) patients.
aux||update-2/VB||to-1/TO	root||ROOT-0/null||update-2/VB	det||programme-7/NN||the-3/DT	amod||programme-7/NN||national-4/JJ	nn||programme-7/NN||malaria-5/NN	nn||programme-7/NN||control-6/NN	dobj||update-2/VB||programme-7/NN	prep_of||programme-7/NN||mali-9/NNS	det||efficacy-12/NN||the-11/DT	prep_on||mali-9/NNS||efficacy-12/NN	prep_of||efficacy-12/NN||chloroquine-14/NN	prep_of||efficacy-12/NN||amodiaquine-16/NN	conj_and||chloroquine-14/NN||amodiaquine-16/NN	prep_of||efficacy-12/NN||sulphadoxine-pyrimethamine-18/NN	conj_and||chloroquine-14/NN||sulphadoxine-pyrimethamine-18/NN	det||treatment-21/NN||the-20/DT	prep_in||update-2/VB||treatment-21/NN	amod||falciparummalaria-24/NN||uncomplicated-23/JJ	prep_of||treatment-21/NN||falciparummalaria-24/NN	malaria-5||pyrimethamine--1||no||to update the national malaria control programme of mali on the efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine in the treatment of uncomplicated falciparummalaria.
dep||vitro-2/NN||in-1/IN	amod||exposure-3/NN||vitro-2/NN	nsubj||revealed-15/VBD||exposure-3/NN	amod||samples-6/NNS||patient-5/JJ	prep_of||exposure-3/NN||samples-6/NNS	aux||etoposide-8/VB||to-7/TO	vmod||exposure-3/NN||etoposide-8/VB	det||agent-13/NN||a-10/DT	advmod||damaging-12/VBG||dna-11/RB	amod||agent-13/NN||damaging-12/VBG	appos||exposure-3/NN||agent-13/NN	root||ROOT-0/null||revealed-15/VBD	num||â-18/NN||three-16/CD	amod||â-18/NN||distinct-17/JJ	dobj||revealed-15/VBD||â-18/NN	amod||response-22/NN||$-19/$	dep||$-19/$||œdna-20/JJ	nn||response-22/NN||damage-21/NN	prep||â-18/NN||response-22/NN	appos||response-22/NN||ddr-24/NN	punct||$-28/$||/-26/:	dep||$-28/$||apoptosisâ-27/RB	dep||response-22/NN||$-28/$	number||1-30/CD||profiles-29/CD	num||$-28/$||1-30/CD	nn||blasts-33/NNS||aml-32/NN	dep||response-22/NN||blasts-33/NNS	det||ddr-37/NN||a-35/DT	amod||ddr-37/NN||defective-36/JJ	prep_with||blasts-33/NNS||ddr-37/NN	prep_with||blasts-33/NNS||failure-39/NN	conj_and||ddr-37/NN||failure-39/NN	aux||undergo-41/VB||to-40/TO	vmod||blasts-33/NNS||undergo-41/VB	dobj||undergo-41/VB||apoptosis-42/NNS	dep||blasts-47/NNS||2-44/LS	nn||blasts-47/NNS||aml-46/NN	dep||response-22/NN||blasts-47/NNS	conj_and||blasts-33/NNS||blasts-47/NNS	amod||ddr-50/NN||proficient-49/JJ	prep_with||blasts-47/NNS||ddr-50/NN	prep_with||blasts-47/NNS||failure-52/NN	conj_and||ddr-50/NN||failure-52/NN	aux||undergo-54/VB||to-53/TO	vmod||failure-52/NN||undergo-54/VB	dobj||undergo-54/VB||apoptosis-55/NNS	dep||blasts-60/NNS||3-57/LS	nn||blasts-60/NNS||aml-59/NN	dep||response-22/NN||blasts-60/NNS	conj_and||blasts-33/NNS||blasts-60/NNS	prep_with||blasts-60/NNS||proficiency-62/NN	det||ddr-65/NN||both-64/DT	prep_in||proficiency-62/NN||ddr-65/NN	amod||pathways-68/NNS||apoptosis-67/JJ	dep||response-22/NN||pathways-68/NNS	conj_and||blasts-33/NNS||pathways-68/NNS	aml-59||etoposide-8||yes||in vitro exposure of patient samples to etoposide, a dna damaging agent, revealed three distinct â€œdna damage response (ddr)/apoptosisâ€? profiles 1) aml blasts with a defective ddr and failure to undergo apoptosis; 2) aml blasts with proficient ddr and failure to undergo apoptosis; 3) aml blasts with proficiency in both ddr and apoptosis pathways.
det||family-2/NN||a-1/DT	nsubjpass||based-11/VBN||family-2/NN	nsubjpass||established-22/VBN||family-2/NN	amod||herpesviruses-5/NNS||mollusc-4/JJ	prep_of||family-2/NN||herpesviruses-5/NNS	appos||family-2/NN||malacoherpesviridae-7/NN	auxpass||based-11/VBN||was-10/VBD	rcmod||family-2/NN||based-11/VBN	det||oyster-17/NN||a-13/DT	amod||oyster-17/NN||single-14/JJ	nn||oyster-17/NN||virus-15/NN	nn||oyster-17/NN||infecting-16/NN	prep_on||based-11/VBN||oyster-17/NN	aux||established-22/VBN||can-18/MD	advmod||established-22/VBN||now-19/RB	auxpass||established-22/VBN||be-20/VB	advmod||established-22/VBN||further-21/RBR	root||ROOT-0/null||established-22/VBN	agent||established-22/VBN||including-24/VBG	det||abalone-30/NN||a-25/DT	advmod||related-27/VBN||distantly-26/RB	amod||abalone-30/NN||related-27/VBN	nn||abalone-30/NN||herpesvirus-28/NN	amod||abalone-30/NN||infecting-29/VBG	dobj||including-24/VBG||abalone-30/NN	nsubj||neurotropic-39/JJ||abalone-30/NN	amod||viruses-37/NNS||many-35/JJ	nn||viruses-37/NNS||vertebrate-36/NN	prep_like||neurotropic-39/JJ||viruses-37/NNS	cop||neurotropic-39/JJ||is-38/VBZ	rcmod||abalone-30/NN||neurotropic-39/JJ	virus-15||viruses-37||no||a family of mollusc herpesviruses, malacoherpesviridae , that was based on a single virus infecting oyster can now be further established by including a distantly related herpesvirus infecting abalone, which, like many vertebrate viruses is neurotropic.
mark||knew-4/VBD||although-1/IN	num||%-3/NN||91.4-2/CD	nsubj||knew-4/VBD||%-3/NN	advcl||know-15/VB||knew-4/VBD	nsubjpass||transmitted-7/VBN||tb-5/NN	auxpass||transmitted-7/VBN||was-6/VBD	ccomp||knew-4/VBD||transmitted-7/VBN	prep_via||transmitted-7/VBN||aerosols-9/NNS	quantmod||one-third-12/NN||about-11/RB	nsubj||know-15/VB||one-third-12/NN	aux||know-15/VB||did-13/VBD	neg||know-15/VB||not-14/RB	root||ROOT-0/null||know-15/VB	det||method-17/NN||the-16/DT	dobj||know-15/VB||method-17/NN	prepc_for||know-15/VB||administering-19/VBG	dobj||administering-19/VBG||tuberculin-20/NN	det||vaccine-28/NN||that-23/DT	amod||vaccine-28/NN||bacilluscalmette-guerin-24/JJ	nn||vaccine-28/NN||bcg-26/NN	nsubj||contraindication-32/NN||vaccine-28/NN	cop||contraindication-32/NN||was-29/VBD	neg||contraindication-32/NN||not-30/RB	det||contraindication-32/NN||a-31/DT	conj_or||know-15/VB||contraindication-32/NN	aux||tb-34/VB||to-33/TO	vmod||contraindication-32/NN||tb-34/VB	nn||testing-36/NN||skin-35/NN	dobj||tb-34/VB||testing-36/NN	tb-34||bcg-26||yes||although 91.4% knew tb was transmitted via aerosols, about one-third did not know the method for administering tuberculin, or that bacilluscalmette-guerin (bcg) vaccine was not a contraindication to tb skin testing.
aux||investigate-2/VB||to-1/TO	root||ROOT-0/null||investigate-2/VB	mark||produce-18/VB||whether-3/IN	ccomp||investigate-2/VB||not-5/RB	conj_or||produce-18/VB||not-5/RB	nsubj||produce-18/VB||coadministration-6/NN	prep_of||coadministration-6/NN||tacrolimus-8/NNS	appos||tacrolimus-8/NNS||tac-10/NN	prep_with||tacrolimus-8/NNS||prednisolone-13/NN	appos||prednisolone-13/NN||psl-15/NN	aux||produce-18/VB||can-17/MD	ccomp||investigate-2/VB||produce-18/VB	det||effect-21/NN||a-19/DT	amod||effect-21/NN||beneficial-20/JJ	dobj||produce-18/VB||effect-21/NN	det||treatment-24/NN||the-23/DT	prep_in||produce-18/VB||treatment-24/NN	amod||dermatomyositis-28/NNS||polymyositis-26/JJ	amod||dermatomyositis-28/NNS||/-27/JJ	prep_of||treatment-24/NN||dermatomyositis-28/NNS	appos||dermatomyositis-28/NNS||pm/dm-30/NNP	polymyositis-26||dm--1||no_rel||to investigate whether or not coadministration of tacrolimus (tac) with prednisolone (psl) can produce a beneficial effect in the treatment of polymyositis/ dermatomyositis (pm/dm).
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||characterize-8/VB||aim-2/NN	det||work-5/NN||this-4/DT	prep_of||aim-2/NN||work-5/NN	root||ROOT-0/null||was-6/VBD	aux||characterize-8/VB||to-7/TO	xcomp||was-6/VBD||characterize-8/VB	xcomp||characterize-8/VB||using-10/VBG	prep_in||using-10/VBG||vitro-12/NN	prep_in||using-10/VBG||in-14/IN	conj_and||vitro-12/NN||in-14/IN	nn||strategies-16/NNS||vivo-15/NN	pobj||in-14/IN||strategies-16/NNS	det||anti-inflammatory-19/NN||the-18/DT	pobj||in-14/IN||anti-inflammatory-19/NN	conj_and||strategies-16/NNS||anti-inflammatory-19/NN	amod||anti-angiogenic-23/JJ||anti-coagulant-21/JJ	pobj||in-14/IN||anti-angiogenic-23/JJ	amod||strategies-16/NNS||anti-angiogenic-23/JJ	conj_and||strategies-16/NNS||anti-angiogenic-23/JJ	amod||activities-27/NNS||anti-tumor-26/JJ	pobj||in-14/IN||activities-27/NNS	conj_and||strategies-16/NNS||activities-27/NNS	num||fractions-33/NNS||two-29/CD	amod||fractions-33/NNS||main-30/JJ	amod||fractions-33/NNS||sulfated-31/JJ	nn||fractions-33/NNS||polysaccharide-32/NN	prep_of||activities-27/NNS||fractions-33/NNS	vmod||fractions-33/NNS||obtained-34/VBN	nn||saccharina-37/NN||l.-36/NN	prep_from||obtained-34/VBN||saccharina-37/NN	det||fraction-42/NN||a-38/DT	amod||fraction-42/NN||-rrb--39/JJ	amod||fraction-42/NN||l.s.-1-40/JJ	dep||l.s.-1-40/JJ||.0-41/CD	dobj||using-10/VBG||fraction-42/NN	advmod||consisting-44/VBG||mainly-43/RB	vmod||fraction-42/NN||consisting-44/VBG	amod||mannoglucuronofucans-47/NNS||o-sulfated-46/JJ	prep_of||consisting-44/VBG||mannoglucuronofucans-47/NNS	prep_of||consisting-44/VBG||b-49/SYM	conj_and||mannoglucuronofucans-47/NNS||b-49/SYM	amod||fraction-53/NN||-rrb--50/JJ	amod||fraction-53/NN||l.s.-1-51/JJ	num||fraction-53/NN||.25-52/CD	dobj||consisting-44/VBG||fraction-53/NN	advmod||composed-55/VBN||mainly-54/RB	vmod||fraction-53/NN||composed-55/VBN	amod||fucans-58/NNS||sulfated-57/JJ	prep_of||composed-55/VBN||fucans-58/NNS	anti-inflammatory-19||tumor--1||no_rel||the aim of this work was to characterize , using in vitro and in vivo strategies , the anti-inflammatory , anti-coagulant , anti-angiogenic , and anti-tumor activities of two main sulfated polysaccharide fractions obtained from l. saccharina a -rrb- l.s.-1 .0 fraction mainly consisting of o-sulfated mannoglucuronofucans and b -rrb- l.s.-1 .25 fraction mainly composed of sulfated fucans .
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||safety-4/NN||the-3/DT	dobj||compare-2/VB||safety-4/NN	dobj||compare-2/VB||efficacy-6/NN	conj_and||safety-4/NN||efficacy-6/NN	amod||ointment-10/NN||loteprednoletabonate-8/JJ	amod||ointment-10/NN||ophthalmic-9/JJ	prep_of||safety-4/NN||ointment-10/NN	number||%-12/NN||0.5-11/CD	amod||ointment-10/NN||%-12/NN	amod||ointment-15/NN||le-14/JJ	appos||ointment-10/NN||ointment-15/NN	det||formulation-22/NN||a-18/DT	amod||formulation-22/NN||new-19/JJ	amod||formulation-22/NN||topical-20/JJ	nn||formulation-22/NN||ointment-21/NN	appos||ointment-10/NN||formulation-22/NN	prep_with||compare-2/VB||vehicle-25/NN	det||treatment-28/NN||the-27/DT	prep_for||vehicle-25/NN||treatment-28/NN	prep_of||treatment-28/NN||inflammation-30/NN	prep_of||treatment-28/NN||pain-32/NN	conj_and||inflammation-30/NN||pain-32/NN	nn||surgery-35/NN||cataract-34/NN	prep_following||vehicle-25/NN||surgery-35/NN	vehicle-25||pain-32||no_rel||to compare the safety and efficacy of loteprednoletabonate ophthalmic ointment 0.5% (le ointment), a new topical ointment formulation, with vehicle for the treatment of inflammation and pain following cataract surgery.
amod||concentrations-3/NNS||serial-1/JJ	nn||concentrations-3/NNS||mtx-2/NN	nsubjpass||measured-5/VBN||concentrations-3/NNS	auxpass||measured-5/VBN||were-4/VBD	root||ROOT-0/null||measured-5/VBN	prep_in||measured-5/VBN||plasma-7/NN	prep_in||measured-5/VBN||intracellular-9/NN	conj_and||plasma-7/NN||intracellular-9/NN	xcomp||measured-5/VBN||mtxpg-10/VBG	nsubjpass||measured-13/VBN||concentrations-11/NNS	auxpass||measured-13/VBN||were-12/VBD	ccomp||mtxpg-10/VBG||measured-13/VBN	prepc_in||measured-13/VBN||circulating-15/VBG	nn||cells-17/NNS||leukemia-16/NN	dobj||circulating-15/VBG||cells-17/NNS	leukemia-16||mtx-2||yes||serial mtx concentrations were measured in plasma and intracellular mtxpg concentrations were measured in circulating leukemia cells.
prep_in||establishes-9/VBZ||conclusion-2/NN	det||cart-7/NN||the-4/DT	amod||cart-7/NN||nac-5-htr4-5/JJ	nn||cart-7/NN||/-6/NN	nsubj||establishes-9/VBZ||cart-7/NN	advmod||establishes-9/VBZ||pathway-8/RB	root||ROOT-0/null||establishes-9/VBZ	det||â-11/NN||a-10/DT	nsubj||suggesting-22/VBG||â-11/NN	amod||â-11/NN||$-12/$	dep||$-12/$||˜tight-13/JJ	dep||â-11/NN||junction-15/NN	prep_between||â-11/NN||anorexia-18/NN	prep_between||â-11/NN||hyperactivity-20/NN	conj_and||anorexia-18/NN||hyperactivity-20/NN	dep||establishes-9/VBZ||suggesting-22/VBG	det||existence-24/NN||the-23/DT	dobj||suggesting-22/VBG||existence-24/NN	det||unit-29/NN||a-26/DT	amod||functional-28/JJ||primary-27/JJ	amod||unit-29/NN||functional-28/JJ	prep_of||existence-24/NN||unit-29/NN	amod||unit-29/NN||susceptible-30/JJ	nn||overeating-33/NN||limit-32/NN	prep_to||susceptible-30/JJ||overeating-33/NN	vmod||unit-29/NN||associated-34/VBN	amod||rules-39/NNS||resting-36/JJ	amod||rules-39/NNS||following-37/JJ	nn||rules-39/NNS||homeostasis-38/NNS	prep_with||associated-34/VBN||rules-39/NNS	nac--1||overeating-33||no_rel||in conclusion, the nac-5-htr4/cart pathway establishes a â€˜tight-junction' between anorexia and hyperactivity, suggesting the existence of a primary functional unit susceptible to limit overeating associated with resting following homeostasis rules.
det||study-3/NN||this-2/DT	prep_in||shown-7/VBN||study-3/NN	nsubj||shown-7/VBN||we-5/PRP	aux||shown-7/VBN||have-6/VBP	root||ROOT-0/null||shown-7/VBN	det||vaccination-11/NN||that-8/DT	amod||vaccination-11/NN||heterologous-9/JJ	amod||vaccination-11/NN||prime-boost-10/JJ	dobj||shown-7/VBN||vaccination-11/NN	nn||tb-15/NN||tuberculosis-13/NNP	prep_against||shown-7/VBN||tb-15/NN	vmod||tb-15/NN||using-17/VBG	amod||priming/dna-hsp-20/NN||intranasal-18/JJ	nn||priming/dna-hsp-20/NN||bcg-19/NN	dobj||using-17/VBG||priming/dna-hsp-20/NN	prep_than||provided-26/VBD||priming/dna-hsp-20/NN	num||boosting-22/NNS||65-21/CD	nsubj||provided-26/VBD||boosting-22/NNS	appos||boosting-22/NNS||bcgin/dna-24/NNP	rcmod||priming/dna-hsp-20/NN||provided-26/VBD	advmod||greater-28/JJR||significantly-27/RB	amod||protection-29/NN||greater-28/JJR	dobj||provided-26/VBD||protection-29/NN	vmod||that-31/DT||afforded-32/VBN	det||subcutaneous-36/NNS||a-34/DT	amod||subcutaneous-36/NNS||single-35/JJ	agent||afforded-32/VBN||subcutaneous-36/NNS	nn||dose-39/NN||intranasal-38/NN	agent||afforded-32/VBN||dose-39/NN	conj_or||subcutaneous-36/NNS||dose-39/NN	prep_of||subcutaneous-36/NNS||bcg-41/NN	tuberculosis-13||bcg-41||no||in this study, we have shown that heterologous prime-boost vaccination against tuberculosis (tb) using intranasal bcg priming/dna-hsp65 boosting (bcgin/dna) provided significantly greater protection than that afforded by a single subcutaneous or intranasal dose of bcg.
amod||treatment-3/NN||bosentan-2/JJ	prep_following||decreased-16/VBN||treatment-3/NN	aux||reduce-5/VB||to-4/TO	vmod||treatment-3/NN||reduce-5/VB	dobj||reduce-5/VB||pulmonaryhypertension-6/NN	det||levels-10/NNS||the-8/DT	nn||levels-10/NNS||expression-9/NN	nsubjpass||decreased-16/VBN||levels-10/NNS	amod||gene-13/NN||mmp-2-12/JJ	prep_of||levels-10/NNS||gene-13/NN	auxpass||decreased-16/VBN||were-14/VBD	advmod||decreased-16/VBN||significantly-15/RB	root||ROOT-0/null||decreased-16/VBN	prep_on||decreased-16/VBN||day-18/NN	num||day-18/NN||7-19/CD	prep_on||decreased-16/VBN||28-21/CD	conj_and||day-18/NN||28-21/CD	pulmonaryhypertension-6||bosentan-2||yes||following bosentan treatment to reduce pulmonaryhypertension, the expression levels of mmp-2 gene were significantly decreased on day 7 and 28.
nsubj||390-2/VBD||participants-1/NNS	root||ROOT-0/null||390-2/VBD	dobj||390-2/VBD||patients-3/NNS	amod||treatment-7/NN||type2diabetes-5/JJ	nn||treatment-7/NN||receiving-6/NN	prep_with||390-2/VBD||treatment-7/NN	prep_with||390-2/VBD||insulin-9/NN	type2diabetes-5||insulin-9||yes||participants 390 patients with type2diabetes receiving treatment with insulin.
nsubj||compared-2/VBD||we-1/PRP	nsubj||isolates-47/VBZ||we-1/PRP	root||ROOT-0/null||compared-2/VBD	det||performance-4/NN||the-3/DT	dobj||compared-2/VBD||performance-4/NN	det||mtbdr-9/NN||the-6/DT	nn||mtbdr-9/NN||genotypeâ-7/NNP	nn||mtbdr-9/NN||®-8/NNP	prep_of||performance-4/NN||mtbdr-9/NN	amod||specimens-45/NNS||assay-11/JJ	amod||tube-16/NN||mycobacterial-13/JJ	nn||tube-16/NN||growth-14/NN	nn||tube-16/NN||indicator-15/NN	prep_to||assay-11/JJ||tube-16/NN	amod||testing-20/NN||antimycobacterial-18/JJ	nn||testing-20/NN||susceptibility-19/NN	prep_for||tube-16/NN||testing-20/NN	amod||ast-23/NN||mgit-22/JJ	appos||testing-20/NN||ast-23/NN	nn||resistance-28/NN||detection-26/NN	nn||resistance-28/NN||inh-27/NN	prep_for||testing-20/NN||resistance-28/NN	nn||resistance-31/NN||rif-30/NN	appos||resistance-28/NN||resistance-31/NN	conj_and||assay-11/JJ||mdr-tb-34/JJ	amod||specimens-45/NNS||mdr-tb-34/JJ	amod||bacilli-38/NNS||stored-36/JJ	amod||bacilli-38/NNS||acid-fast-37/JJ	prep_in||mdr-tb-34/JJ||bacilli-38/NNS	appos||bacilli-38/NNS||afb-40/NN	amod||specimens-45/NNS||positive-43/JJ	nn||specimens-45/NNS||sputum-44/NN	dobj||compared-2/VBD||specimens-45/NNS	conj_plus||performance-4/NN||specimens-45/NNS	conj_and||compared-2/VBD||isolates-47/VBZ	det||laboratory-52/NN||a-49/DT	amod||laboratory-52/NN||public-50/JJ	nn||laboratory-52/NN||tb-51/NN	prep_at||isolates-47/VBZ||laboratory-52/NN	prep_in||laboratory-52/NN||bangkok-54/NN	dep||compared-2/VBD||thailand-56/VBD	tb-51||rif-30||yes||we compared the performance of the genotypeâ® mtbdr plus assay to mycobacterial growth indicator tube for antimycobacterial susceptibility testing (mgit ast) for detection inh resistance, rif resistance, and mdr-tb in stored acid-fast bacilli (afb)-positive sputum specimens and isolates at a public tb laboratory in bangkok, thailand.
amod||confirmation-3/NN||further-2/JJ	prep_with||warrant-12/VB||confirmation-3/NN	amod||studies-7/NNS||large-5/JJ	amod||studies-7/NNS||prospective-6/JJ	prep_in||confirmation-3/NN||studies-7/NNS	det||findings-10/NNS||these-9/DT	nsubj||warrant-12/VB||findings-10/NNS	aux||warrant-12/VB||could-11/MD	root||ROOT-0/null||warrant-12/VB	amod||supplementation-14/NN||vitamind-13/JJ	dobj||warrant-12/VB||supplementation-14/NN	prepc_for||warrant-12/VB||reducing-16/VBG	nn||risk-19/NN||breast-17/NN	nn||risk-19/NN||cancer-18/NN	dobj||reducing-16/VBG||risk-19/NN	advmod||risk-19/NN||particularly-21/RB	dep||risk-19/NN||those-22/DT	amod||characteristics-26/NNS||poor-24/JJ	amod||characteristics-26/NNS||prognostic-25/JJ	prep_with||reducing-16/VBG||characteristics-26/NNS	amod||women-29/NNS||premenopausal-28/JJ	prep_among||characteristics-26/NNS||women-29/NNS	vitamind-13||cancer-18||no_rel||with further confirmation in large prospective studies, these findings could warrant vitamind supplementation for reducing breast cancer risk, particularly those with poor prognostic characteristics among premenopausal women.
amod||viruses-2/NNS||several-1/JJ	nsubjpass||associated-5/VBN||viruses-2/NNS	aux||associated-5/VBN||have-3/VBP	auxpass||associated-5/VBN||been-4/VBN	root||ROOT-0/null||associated-5/VBN	det||development-8/NN||the-7/DT	prep_with||associated-5/VBN||development-8/NN	amod||arthritis-11/NN||inflammatory-10/JJ	prep_of||development-8/NN||arthritis-11/NN	det||viruses-16/NNS||the-14/DT	nn||viruses-16/NNS||hepatitis-15/NN	prep_including||development-8/NN||viruses-16/NNS	amod||virus-19/NN||hepatitisb-18/JJ	dep||viruses-16/NNS||virus-19/NN	nn||virus-22/NN||hepatitisc-21/NN	dep||viruses-16/NNS||virus-22/NN	conj_and||virus-19/NN||virus-22/NN	prep_including||development-8/NN||hiv-25/NN	conj_and||viruses-16/NNS||hiv-25/NN	det||parvovirusb19-28/NN||the-27/DT	prep_including||development-8/NN||parvovirusb19-28/NN	conj_and||viruses-16/NNS||parvovirusb19-28/NN	det||virus-i-34/NN||the-30/DT	amod||virus-i-34/NN||human-31/JJ	amod||virus-i-34/NN||t-cell-32/JJ	amod||virus-i-34/NN||lymphotropic-33/JJ	prep_including||development-8/NN||virus-i-34/NN	conj_and||viruses-16/NNS||virus-i-34/NN	det||alphaviruses-38/NNS||the-37/DT	prep_including||development-8/NN||alphaviruses-38/NNS	conj_and||viruses-16/NNS||alphaviruses-38/NNS	virus-22||viruses-16||no||several viruses have been associated with the development of inflammatory arthritis, including the hepatitis viruses (hepatitisb virus and hepatitisc virus), hiv, the parvovirusb19, the human t-cell lymphotropic virus-i, and the alphaviruses.
det||study-2/NN||this-1/DT	nsubj||established-4/VBN||study-2/NN	aux||established-4/VBN||has-3/VBZ	root||ROOT-0/null||established-4/VBN	amod||correlation-6/NN||inverse-5/JJ	dobj||established-4/VBN||correlation-6/NN	det||increase-9/NN||the-8/DT	prep_of||correlation-6/NN||increase-9/NN	amod||immunity-12/NN||th1/th2-11/JJ	prep_of||increase-9/NN||immunity-12/NN	det||decline-15/NN||the-14/DT	prep_of||correlation-6/NN||decline-15/NN	conj_and||increase-9/NN||decline-15/NN	nn||load-19/NN||hbv-17/NN	nn||load-19/NN||dna-18/NN	prep_of||decline-15/NN||load-19/NN	amod||patients-23/NNS||chronic-21/JJ	nn||patients-23/NNS||hbv-22/NN	prep_in||load-19/NN||patients-23/NNS	amod||treatment-26/NN||adefovirdipivoxil-25/JJ	prep_during||established-4/VBN||treatment-26/NN	hbv-22||adefovirdipivoxil-25||yes||this study has established inverse correlation of the increase of th1/th2 immunity and the decline of hbv dna load in chronic hbv patients during adefovirdipivoxil treatment.
nn||triglyceride-3/NN||plasma-1/NN	amod||triglyceride-3/NN||total-2/JJ	nsubj||level-7/VBP||triglyceride-3/NN	appos||triglyceride-3/NN||tg-5/NN	root||ROOT-0/null||level-7/VBP	nsubjpass||studied-11/VBN||variations-8/NNS	aux||studied-11/VBN||have-9/VBP	auxpass||studied-11/VBN||been-10/VBN	ccomp||level-7/VBP||studied-11/VBN	prep_in||studied-11/VBN||patients-13/NNS	amod||virus-16/NN||hepatitisc-15/JJ	prep_with||patients-13/NNS||virus-16/NN	appos||virus-16/NN||hcv-18/NN	amod||chronichepatitis-22/NNS||related-21/VBN	dep||patients-13/NNS||chronichepatitis-22/NNS	dep||chronichepatitis-22/NNS||ch-c-24/JJ	chronichepatitis-22||tg-5||no_rel||plasma total triglyceride (tg) level variations have been studied in patients with hepatitisc virus (hcv)-related chronichepatitis (ch-c).
nsubj||examines-2/VBZ||it-1/PRP	nsubj||provides-43/VBZ||it-1/PRP	root||ROOT-0/null||examines-2/VBZ	det||data-4/NNS||the-3/DT	dobj||examines-2/VBZ||data-4/NNS	vmod||data-4/NNS||accumulated-6/VBN	num||years-9/NNS||15-8/CD	prep_over||accumulated-6/VBN||years-9/NNS	det||efficacy-14/NN||the-12/DT	amod||efficacy-14/NN||comparative-13/JJ	prep_on||data-4/NNS||efficacy-14/NN	prep_of||efficacy-14/NN||terbinafine-16/NN	amod||itraconazole-21/NN||vs-18/JJ	nn||itraconazole-21/NN||griseofulvin-19/NN	appos||terbinafine-16/NN||itraconazole-21/NN	dep||itraconazole-21/NN||fluconazole-23/NN	det||management-27/NN||the-26/DT	prep_in||terbinafine-16/NN||management-27/NN	det||infections-30/NNS||the-29/DT	prep_of||management-27/NN||infections-30/NNS	prep_for||indicated-36/VBN||infections-30/NNS	nsubjpass||indicated-36/VBN||it-33/PRP	auxpass||indicated-36/VBN||is-34/VBZ	advmod||indicated-36/VBN||primarily-35/RB	rcmod||infections-30/NNS||indicated-36/VBN	dep||terbinafine-16/NN||eg-38/NN	appos||eg-38/NN||dermatophytoses-40/NNS	conj_and||examines-2/VBZ||provides-43/VBZ	det||discussion-46/NN||a-44/DT	amod||discussion-46/NN||brief-45/JJ	dobj||provides-43/VBZ||discussion-46/NN	poss||use-49/NN||its-48/PRP$	prep_on||provides-43/VBZ||use-49/NN	det||treatment-52/NN||the-51/DT	prep_for||use-49/NN||treatment-52/NN	amod||infections-55/NNS||non-dermatophyte-54/JJ	prep_of||treatment-52/NN||infections-55/NNS	dermatophytoses-40||dermatophyte--1||no||it examines the data, accumulated over 15 years, on the comparative efficacy of terbinafine (vs griseofulvin, itraconazole, fluconazole) in the management of the infections for which it is primarily indicated (eg, dermatophytoses) and provides a brief discussion on its use for the treatment of non-dermatophyte infections.
advmod||noted-24/VBN||moreover-1/RB	det||increase-4/NN||the-3/DT	nsubjpass||noted-24/VBN||increase-4/NN	nsubj||pronounced-28/JJ||increase-4/NN	det||contents-7/NNS||the-6/DT	prep_in||increase-4/NN||contents-7/NNS	det||compounds-11/NNS||these-9/DT	amod||compounds-11/NNS||antioxidant-10/JJ	prep_of||contents-7/NNS||compounds-11/NNS	nn||activity-15/NN||oil-13/NN	nn||activity-15/NN||antioxidant-14/NN	prep_of||contents-7/NNS||activity-15/NN	conj_and||compounds-11/NNS||activity-15/NN	det||application-20/NN||the-18/DT	nn||application-20/NN||foliar-19/NN	prep_due_to||compounds-11/NNS||application-20/NN	prep_of||application-20/NN||proline-22/NN	auxpass||noted-24/VBN||was-23/VBD	root||ROOT-0/null||noted-24/VBN	aux||pronounced-28/JJ||to-25/TO	cop||pronounced-28/JJ||be-26/VB	advmod||pronounced-28/JJ||more-27/RBR	xcomp||noted-24/VBN||pronounced-28/JJ	nn||conditions-32/NNS||water-30/NN	nn||conditions-32/NNS||deficit-31/NN	prep_under||pronounced-28/JJ||conditions-32/NNS	deficit-31||oil-13||no_rel||moreover, the increase in the contents of these antioxidant compounds and oil antioxidant activity due to the foliar application of proline was noted to be more pronounced under water deficit conditions.
det||man-4/NN||a-1/DT	amod||man-4/NN||41-year-old-2/JJ	nn||man-4/NN||japanese-3/NN	nsubj||received-6/VBN||man-4/NN	aux||received-6/VBN||had-5/VBD	root||ROOT-0/null||received-6/VBN	amod||therapy-12/NN||successful-7/JJ	nn||therapy-12/NN||interferon-8/NN	nn||therapy-12/NN||ifn-10/NN	dobj||received-6/VBN||therapy-12/NN	prep_against||therapy-12/NN||chronichepatitisc-14/NN	prep_in||received-6/VBN||1994-16/CD	chronichepatitisc-14||ifn-10||yes||a 41-year-old japanese man had received successful interferon (ifn) therapy against chronichepatitisc in 1994.
mark||drug-7/NN||since-1/IN	nsubj||drug-7/NN||pyrazinamide-2/NN	cop||drug-7/NN||is-3/VBZ	det||drug-7/NN||a-4/DT	advmod||used-6/VBN||commonly-5/RB	amod||drug-7/NN||used-6/VBN	advcl||predict-28/VB||drug-7/NN	prep_in||drug-7/NN||tuberculosis-9/NNP	nsubj||disease-16/NN||which-11/WDT	cop||disease-16/NN||is-12/VBZ	det||disease-16/NN||a-13/DT	amod||disease-16/NN||common-14/JJ	amod||disease-16/NN||infectious-15/JJ	conj_and||drug-7/NN||disease-16/NN	advcl||predict-28/VB||disease-16/NN	amod||countries-19/NNS||developing-18/VBG	prep_in||disease-16/NN||countries-19/NNS	det||reports-24/NNS||the-22/DT	amod||reports-24/NNS||similar-23/JJ	prep_with||predict-28/VB||reports-24/NNS	nsubj||predict-28/VB||we-26/PRP	nsubj||prevent-34/VB||we-26/PRP	aux||predict-28/VB||can-27/MD	root||ROOT-0/null||predict-28/VB	amod||detection-31/NN||early-29/JJ	nn||detection-31/NN||case-30/NN	dobj||predict-28/VB||detection-31/NN	aux||prevent-34/VB||can-33/MD	conj_and||predict-28/VB||prevent-34/VB	det||occurrence-36/NN||the-35/DT	dobj||prevent-34/VB||occurrence-36/NN	amod||reactions-39/NNS||similar-38/JJ	prep_of||occurrence-36/NN||reactions-39/NNS	prep_in||prevent-34/VB||future-41/NN	tuberculosis-9||pyrazinamide-2||yes||since pyrazinamide is a commonly used drug in tuberculosis and which is a common infectious disease in developing countries, with the similar reports, we can predict early case detection and can prevent the occurrence of similar reactions in future.
nsubjpass||offered-3/VBN||olc-1/NN	auxpass||offered-3/VBN||was-2/VBD	root||ROOT-0/null||offered-3/VBN	prep_to||offered-3/VBN||patients-5/NNS	amod||cholelithiasis-8/NNS||symptomatic-7/JJ	prep_with||offered-3/VBN||cholelithiasis-8/NNS	nsubj||met-10/VBD||cholelithiasis-8/NNS	rcmod||cholelithiasis-8/NNS||met-10/VBD	det||asa-16/NN||the-11/DT	amod||asa-16/NN||following-12/JJ	amod||asa-16/NN||established-13/JJ	nn||asa-16/NN||inclusion-14/NN	nn||asa-16/NN||criteria-15/NNS	dobj||met-10/VBD||asa-16/NN	iobj||met-10/VBD||asa-16/NN	nn||society-19/NN||american-18/NN	dep||asa-16/NN||society-19/NN	prep_of||society-19/NN||anesthesiology-21/NN	amod||i-27/NNS||physical-23/JJ	nn||i-27/NNS||status-24/NN	nn||i-27/NNS||classification-25/NN	nn||i-27/NNS||class-26/NN	dep||asa-16/NN||i-27/NNS	dep||asa-16/NN||ii-29/NN	conj_and||i-27/NNS||ii-29/NN	dep||i-27/NNS||age-31/NN	num||age-31/NN||18-32/CD	num||years-35/NNS||70-34/CD	dep||age-31/NN||years-35/NNS	nn||index-39/NN||body-37/NN	nn||index-39/NN||mass-38/NN	dep||i-27/NNS||index-39/NN	appos||index-39/NN||bmi-41/NN	amod||index-39/NN||<-43/JJ	num||kg/m2-45/NNS||30-44/CD	dep||<-43/JJ||kg/m2-45/NNS	nn||acceptance-48/NN||patient-47/NN	dep||i-27/NNS||acceptance-48/NN	dep||i-27/NNS||cooperation-50/NN	conj_and||acceptance-48/NN||cooperation-50/NN	amod||consent-53/NN||informed-52/JJ	appos||acceptance-48/NN||consent-53/NN	dep||i-27/NNS||presence-56/NN	det||adult-60/NN||a-58/DT	amod||adult-60/NN||responsible-59/JJ	prep_of||presence-56/NN||adult-60/NN	aux||accompany-62/VB||to-61/TO	vmod||met-10/VBD||accompany-62/VB	det||patient-64/NN||the-63/DT	dobj||accompany-62/VB||patient-64/NN	poss||residency-70/NN||his-66/PRP$	amod||residency-70/NN||residency-67/JJ	nn||residency-70/NN||patient-69/NN	prep_to||accompany-62/VB||residency-70/NN	prep_in||met-10/VBD||athens-72/NNS	cholelithiasis-8||asa-16||no_rel||olc was offered to patients with symptomatic cholelithiasis who met the following established inclusion criteria asa (american society of anesthesiology) physical status classification class i and ii; age 18 - 70 years; body mass index (bmi) < 30 kg/m2; patient acceptance and cooperation (informed consent); presence of a responsible adult to accompany the patient to his residency; patient residency in athens.
nsubjpass||assessed-3/VBN||pain-1/NN	auxpass||assessed-3/VBN||was-2/VBD	root||ROOT-0/null||assessed-3/VBN	det||scale-7/NN||a-5/DT	amod||scale-7/NN||four-point-6/JJ	prep_on||assessed-3/VBN||scale-7/NN	amod||injection-11/NN||microemulsion-9/JJ	amod||injection-11/NN||propofol-10/JJ	prep_during||assessed-3/VBN||injection-11/NN	pain-1||propofol-10||yes||pain was assessed on a four-point scale during microemulsion propofol injection.
amod||africa-3/NN||sub-saharan-2/JJ	prep_in||is-6/VBZ||africa-3/NN	nsubj||is-6/VBZ||kenya-5/NN	root||ROOT-0/null||is-6/VBZ	prep_among||is-6/VBZ||countries-8/NNS	vmod||countries-8/NNS||affected-9/VBN	det||pandemic-15/NN||the-11/DT	nn||pandemic-15/NN||hiv-12/NN	conj_and||hiv-12/NN||aids-14/NNS	nn||pandemic-15/NN||aids-14/NNS	agent||affected-9/VBN||pandemic-15/NN	nsubj||led-17/VBD||pandemic-15/NN	rcmod||pandemic-15/NN||led-17/VBD	det||declaration-20/NN||the-19/DT	prep_to||led-17/VBD||declaration-20/NN	prep_of||declaration-20/NN||aids-22/NNS	det||disaster-26/NN||a-24/DT	amod||disaster-26/NN||national-25/JJ	prep_as||led-17/VBD||disaster-26/NN	prep_in||disaster-26/NN||1999-28/CD	aids-22||hiv-12||no||in sub-saharan africa, kenya is among countries affected by the hiv and aids pandemic which led to the declaration of aids as a national disaster in 1999.
nn||sodium-2/NN||enoxaparin-1/NN	nsubj||heparin-8/NN||sodium-2/NN	cop||heparin-8/NN||is-3/VBZ	det||heparin-8/NN||a-4/DT	amod||heparin-8/NN||low-5/JJ	amod||heparin-8/NN||molecular-6/JJ	nn||heparin-8/NN||weight-7/NN	root||ROOT-0/null||heparin-8/NN	appos||heparin-8/NN||lmwh-10/NN	prep_for||heparin-8/NN||use-13/NN	prepc_in||use-13/NN||preventing-15/VBG	amod||venousthrombosis-17/NNS||deep-16/JJ	dobj||preventing-15/VBG||venousthrombosis-17/NNS	prep_in||preventing-15/VBG||patients-19/NNS	vmod||patients-19/NNS||undergoing-20/VBG	amod||arthroplasty-23/NN||total-21/JJ	nn||arthroplasty-23/NN||hip-22/NN	dobj||undergoing-20/VBG||arthroplasty-23/NN	amod||arthroplasty-27/NN||total-25/JJ	nn||arthroplasty-27/NN||knee-26/NN	dobj||undergoing-20/VBG||arthroplasty-27/NN	conj_and||arthroplasty-23/NN||arthroplasty-27/NN	venousthrombosis-17||enoxaparin-1||yes||enoxaparin sodium is a low molecular weight heparin (lmwh) for use in preventing deep venousthrombosis in patients undergoing total hip arthroplasty and total knee arthroplasty.
det||china-2/NN||each-1/DT	nsubj||cares-3/VBZ||china-2/NN	root||ROOT-0/null||cares-3/VBZ	nsubjpass||required-6/VBN||site-4/NN	nsubj||carry-8/VB||site-4/NN	auxpass||required-6/VBN||was-5/VBD	ccomp||cares-3/VBZ||required-6/VBN	aux||carry-8/VB||to-7/TO	xcomp||required-6/VBN||carry-8/VB	prt||carry-8/VB||out-9/RP	dobj||carry-8/VB||surveillance-10/NN	dobj||carry-8/VB||surveys-12/NNS	conj_and||surveillance-10/NN||surveys-12/NNS	aux||understand-14/VB||to-13/TO	vmod||carry-8/VB||understand-14/VB	det||epidemic-18/NN||the-15/DT	amod||epidemic-18/NN||local-16/JJ	nn||epidemic-18/NN||hiv/aids-17/NN	dobj||understand-14/VB||epidemic-18/NN	aux||deliver-21/VB||to-20/TO	vmod||carry-8/VB||deliver-21/VB	amod||interventions-23/NNS||primary-22/JJ	dobj||deliver-21/VB||interventions-23/NNS	aux||reduce-25/VB||to-24/TO	vmod||deliver-21/VB||reduce-25/VB	vmod||deliver-21/VB||reduce-25/VB	conj_and||reduce-25/VB||reduce-25/VB	amod||hivinfections-27/NNS||new-26/JJ	dobj||reduce-25/VB||hivinfections-27/NNS	amod||groups-32/NNS||high-risk-31/JJ	prep_among||reduce-25/VB||groups-32/NNS	prep_from||reduce-25/VB||groups-32/NNS	aux||prevent-35/VB||to-34/TO	dep||reduce-25/VB||prevent-35/VB	amod||transmission-37/NN||mother-to-child-36/JJ	dobj||prevent-35/VB||transmission-37/NN	aux||treat-40/VB||to-39/TO	dep||reduce-25/VB||treat-40/VB	conj_and||prevent-35/VB||treat-40/VB	nn||patients-42/NNS||aids-41/NNS	dobj||treat-40/VB||patients-42/NNS	amod||medicines-45/NNS||antiretroviral-44/JJ	prep_with||treat-40/VB||medicines-45/NNS	aux||provide-48/VB||to-47/TO	dep||reduce-25/VB||provide-48/VB	conj_and||prevent-35/VB||provide-48/VB	nn||services-50/NNS||support-49/NN	dobj||provide-48/VB||services-50/NNS	prep_to||provide-48/VB||families-52/NNS	vmod||families-52/NNS||affected-53/VBN	agent||affected-53/VBN||hiv/aids-55/NNS	aids-41||hiv--1||no||each china cares site was required to carry out surveillance and surveys to understand the local hiv/aids epidemic, to deliver primary interventions to reduce new hivinfections among and from high-risk groups, to prevent mother-to-child transmission, to treat aids patients with antiretroviral medicines and to provide support services to families affected by hiv/aids.
det||challenge-2/NN||a-1/DT	nsubj||is-9/VBZ||challenge-2/NN	nsubj||develop-11/VB||challenge-2/NN	nn||research-8/NN||tuberculosis-4/NNP	appos||research-8/NN||tb-6/NN	prep_in||challenge-2/NN||research-8/NN	root||ROOT-0/null||is-9/VBZ	aux||develop-11/VB||to-10/TO	xcomp||is-9/VBZ||develop-11/VB	det||test-15/NN||a-12/DT	amod||test-15/NN||new-13/JJ	amod||test-15/NN||immunological-14/JJ	dobj||develop-11/VB||test-15/NN	nsubj||help-18/VB||test-15/NN	aux||help-18/VB||can-17/MD	rcmod||test-15/NN||help-18/VB	ccomp||help-18/VB||distinguish-19/VB	prep_among||distinguish-19/VB||subjects-22/NNS	amod||subjects-22/NNS||responsive-23/JJ	nn||gold-27/NN||quantiferon-25/NN	nn||gold-27/NN||tb-26/NN	prep_to||responsive-23/JJ||gold-27/NN	prep_in||gold-27/NN||tube-29/NN	appos||subjects-22/NNS||qft-it-31/NN	dobj||distinguish-19/VB||those-34/DT	nsubj||able-37/JJ||those-34/DT	nsubj||control-39/VB||those-34/DT	cop||able-37/JJ||are-36/VBP	rcmod||those-34/DT||able-37/JJ	aux||control-39/VB||to-38/TO	xcomp||able-37/JJ||control-39/VB	nn||replication-41/NN||mtb-40/NN	dobj||control-39/VB||replication-41/NN	amod||ltbi-44/NNS||remote-43/JJ	dep||replication-41/NN||ltbi-44/NNS	amod||infection-47/NN||recent-46/JJ	dep||replication-41/NN||infection-47/NN	conj_and||ltbi-44/NNS||infection-47/NN	amod||tb-50/NN||past-49/JJ	dep||replication-41/NN||tb-50/NN	conj_and||ltbi-44/NNS||tb-50/NN	prep_from||control-39/VB||those-53/DT	nsubj||can-55/MD||those-53/DT	rcmod||those-53/DT||can-55/MD	neg||can-55/MD||not-56/RB	amod||disease-60/NN||active-58/JJ	nn||disease-60/NN||tb-59/NN	appos||those-53/DT||disease-60/NN	tb-59||mtb-40||no||a challenge in tuberculosis (tb) research is to develop a new immunological test that can help distinguish, among subjects responsive to quantiferon tb gold in tube (qft-it), those who are able to control mtb replication (remote ltbi, recent infection and past tb) from those who cannot (active tb disease).
det||gene-2/NN||each-1/DT	root||ROOT-0/null||gene-2/NN	prep_of||gene-2/NN||mal/hok/24-4/CD	punct||gene-2/NN||/-5/:	nsubjpass||related-13/VBN||09-6/CD	appos||09-6/CD||h5n1-8/NNP	auxpass||related-13/VBN||is-10/VBZ	advmod||related-13/VBN||phylogenetically-11/RB	advmod||related-13/VBN||closely-12/RB	dep||gene-2/NN||related-13/VBN	prep_to||related-13/VBN||that-15/DT	prep_of||that-15/DT||influenzaviruses-17/NNS	vmod||influenzaviruses-17/NNS||isolated-18/VBN	amod||birds-22/NNS||migratory-20/JJ	nn||birds-22/NNS||water-21/NN	prep_from||isolated-18/VBN||birds-22/NNS	nsubj||flew-24/VBD||birds-22/NNS	rcmod||birds-22/NNS||flew-24/VBD	poss||lakes-28/NNS||their-26/PRP$	amod||lakes-28/NNS||nesting-27/JJ	prep_from||flew-24/VBD||lakes-28/NNS	prep_in||flew-24/VBD||autumn-30/NN	h5n1-8||influenzaviruses-17||no||each gene of mal/hok/24/09 (h5n1) is phylogenetically closely related to that of influenzaviruses isolated from migratory water birds that flew from their nesting lakes in autumn.
amod||concentrations-3/NNS||increased-1/VBN	nn||concentrations-3/NNS||hepcidin-2/NN	nsubj||lead-4/VBP||concentrations-3/NNS	nsubj||iron-6/VB||concentrations-3/NNS	root||ROOT-0/null||lead-4/VBP	aux||iron-6/VB||to-5/TO	xcomp||lead-4/VBP||iron-6/VB	dobj||iron-6/VB||sequestration-7/NN	prep_in||sequestration-7/NN||macrophages-9/NNS	vmod||sequestration-7/NN||contributing-11/VBG	det||pathogenesis-14/NNS||the-13/DT	prep_to||contributing-11/VBG||pathogenesis-14/NNS	prep_of||pathogenesis-14/NNS||anaemia-16/NN	amod||disease-19/NN||chronic-18/JJ	prep_of||anaemia-16/NN||disease-19/NN	mark||observed-24/VBN||whereas-20/IN	amod||hepcidin-22/NN||decreased-21/VBN	nsubjpass||observed-24/VBN||hepcidin-22/NN	auxpass||observed-24/VBN||is-23/VBZ	advcl||contributing-11/VBG||observed-24/VBN	amod||diseases-30/NNS||irondeficiency-26/JJ	conj_and||irondeficiency-26/JJ||primary-28/JJ	amod||diseases-30/NNS||primary-28/JJ	nn||diseases-30/NNS||ironoverload-29/NN	prep_in||observed-24/VBN||diseases-30/NNS	prep_such_as||diseases-30/NNS||hereditaryhemochromatosis-33/NNS	ironoverload-29||iron-6||no||increased hepcidin concentrations lead to iron sequestration in macrophages, contributing to the pathogenesis of anaemia of chronic disease whereas decreased hepcidin is observed in irondeficiency and primary ironoverload diseases such as hereditaryhemochromatosis.
det||mito-mice-3/NN||the-2/DT	prep_in||induced-10/VBN||mito-mice-3/NN	nsubj||induced-10/VBN||accumulation-5/NN	nn||mtdna-9/NN||î-7/NN	prep_of||accumulation-5/NN||mtdna-9/NN	root||ROOT-0/null||induced-10/VBN	amod||defects-13/NNS||mitochondrial-11/JJ	nn||defects-13/NNS||respiration-12/NN	dobj||induced-10/VBN||defects-13/NNS	amod||tissues-16/NNS||various-15/JJ	prep_in||defects-13/NNS||tissues-16/NNS	vmod||induced-10/VBN||resulting-18/VBG	amod||phenotypes-22/NNS||mitochondrial-20/JJ	nn||phenotypes-22/NNS||disease-21/NN	prep_in||resulting-18/VBG||phenotypes-22/NNS	amod||weight-28/NN||low-26/JJ	nn||weight-28/NN||body-27/NN	prep_such_as||phenotypes-22/NNS||weight-28/NN	amod||acidosis-31/NNS||lactic-30/JJ	prep_such_as||phenotypes-22/NNS||acidosis-31/NNS	conj_and||weight-28/NN||acidosis-31/NNS	prep_such_as||phenotypes-22/NNS||ischemia-33/NN	conj_and||weight-28/NN||ischemia-33/NN	prep_such_as||phenotypes-22/NNS||myopathy-35/NN	conj_and||weight-28/NN||myopathy-35/NN	prep_such_as||phenotypes-22/NNS||heartblock-37/NN	conj_and||weight-28/NN||heartblock-37/NN	prep_such_as||phenotypes-22/NNS||deafness-39/NNS	conj_and||weight-28/NN||deafness-39/NNS	amod||infertility-42/NN||male-41/JJ	prep_such_as||phenotypes-22/NNS||infertility-42/NN	conj_and||weight-28/NN||infertility-42/NN	prep_such_as||phenotypes-22/NNS||renalfailure-45/NN	conj_and||weight-28/NN||renalfailure-45/NN	renalfailure-45||mito--1||no||in the mito-mice, accumulation of î”mtdna induced mitochondrial respiration defects in various tissues, resulting in mitochondrial disease phenotypes, such as low body weight, lactic acidosis, ischemia, myopathy, heartblock, deafness, male infertility, and renalfailure.
nn||physicians-2/NNS||family-1/NN	nsubj||received-3/VBD||physicians-2/NNS	root||ROOT-0/null||received-3/VBD	nn||education-6/NN||insulin-4/NN	nn||education-6/NN||initiation/titration-5/NN	nsubj||cardâ-13/VBD||education-6/NN	det||â-10/NN||a-8/DT	amod||â-10/NN||physician-specific-9/JJ	appos||education-6/NN||â-10/NN	amod||â-10/NN||$-11/$	dep||$-11/$||˜report-12/JJ	ccomp||received-3/VBD||cardâ-13/VBD	dobj||cardâ-13/VBD||$-14/$	num||$-14/$||™-15/CD	det||characteristics-18/NNS||the-17/DT	prep_on||cardâ-13/VBD||characteristics-18/NNS	poss||population-25/NN||their-20/PRP$	amod||population-25/NN||type2diabetes-21/JJ	appos||population-25/NN||t2dm-23/NNP	prep_of||characteristics-18/NNS||population-25/NN	det||registry-29/NN||a-28/DT	prep_on||cardâ-13/VBD||registry-29/NN	conj_and||characteristics-18/NNS||registry-29/NN	amod||patients-32/NNS||insulin-eligible-31/JJ	prep_of||registry-29/NN||patients-32/NNS	det||workshop-35/NN||a-34/DT	prep_at||cardâ-13/VBD||workshop-35/NN	type2diabetes-21||insulin-4||yes||family physicians received insulin initiation/titration education, a physician-specific â€˜report cardâ€™ on the characteristics of their type2diabetes (t2dm) population, and a registry of insulin-eligible patients at a workshop.
det||microenvironment-3/NN||the-1/DT	nn||microenvironment-3/NN||tumor-2/NN	nsubj||caused-4/VBD||microenvironment-3/NN	root||ROOT-0/null||caused-4/VBD	amod||up-regulation-8/NN||rapid-5/JJ	conj_and||rapid-5/JJ||dramatic-7/JJ	amod||up-regulation-8/NN||dramatic-7/JJ	dobj||caused-4/VBD||up-regulation-8/NN	amod||i-11/FW||arginase-10/JJ	prep_of||up-regulation-8/NN||i-11/FW	amod||synthase-15/NN||inducible-13/JJ	nn||synthase-15/NN||nitricoxide-14/NN	dobj||caused-4/VBD||synthase-15/NN	conj_and||up-regulation-8/NN||synthase-15/NN	prep_in||synthase-15/NN||mdsc-17/NN	nsubjpass||accompanied-21/VBN||mdsc-17/NN	auxpass||accompanied-21/VBN||was-20/VBD	rcmod||mdsc-17/NN||accompanied-21/VBN	agent||accompanied-21/VBN||down-regulation-23/NN	amod||dinucleotide-27/NN||nicotinamide-25/JJ	nn||dinucleotide-27/NN||adenine-26/NN	prep_of||down-regulation-23/NN||dinucleotide-27/NN	vmod||dinucleotide-27/NN||phosphateâ-28/VBG	dobj||phosphateâ-28/VBG||$-29/$	nn||and-32/NNP||oxidase-31/NNP	npadvmod||oxygen-34/RB||and-32/NNP	advmod||and-32/NNP||reactive-33/RB	dep||species-35/CD||oxygen-34/RB	num||$-29/$||species-35/CD	det||cells-38/NNS||these-37/DT	prep_in||$-29/$||cells-38/NNS	nitricoxide-14||tumor-2||no_rel||the tumor microenvironment caused rapid and dramatic up-regulation of arginase i and inducible nitricoxide synthase in mdsc, which was accompanied by down-regulation of nicotinamide adenine dinucleotide phosphateâ€“oxidase and reactive oxygen species in these cells.
nsubj||reported-3/VBD||we-1/PRP	advmod||reported-3/VBD||earlier-2/RB	root||ROOT-0/null||reported-3/VBD	mark||resulted-20/VBD||that-4/IN	nsubj||resulted-20/VBD||treatment-5/NN	amod||cultures-8/NNS||astrocyte-7/JJ	prep_of||treatment-5/NN||cultures-8/NNS	det||concentration-12/NN||a-10/DT	amod||concentration-12/NN||pathophysiological-11/JJ	prep_with||cultures-8/NNS||concentration-12/NN	prep_of||concentration-12/NN||ammonia-14/NN	num||nh4cl-18/NNS||5-16/CD	nn||nh4cl-18/NNS||mm-17/NNP	appos||ammonia-14/NN||nh4cl-18/NNS	ccomp||reported-3/VBD||resulted-20/VBD	det||activation-23/NN||the-22/DT	prep_in||resulted-20/VBD||activation-23/NN	amod||factor-kappab-26/NN||nuclear-25/JJ	prep_of||activation-23/NN||factor-kappab-26/NN	appos||factor-kappab-26/NN||nf-îºb-28/NNP	mark||diminished-36/VBN||that-31/IN	nsubj||diminished-36/VBN||inhibition-32/NN	amod||activation-35/NN||such-34/JJ	prep_of||inhibition-32/NN||activation-35/NN	ccomp||reported-3/VBD||diminished-36/VBN	conj_and||resulted-20/VBD||diminished-36/VBN	dobj||diminished-36/VBN||astrocyte-37/NN	amod||astrocyte-37/NN||swelling-38/VBG	vmod||diminished-36/VBN||suggesting-40/VBG	det||role-43/NN||a-41/DT	amod||role-43/NN||key-42/JJ	dobj||suggesting-40/VBG||role-43/NN	prep_of||role-43/NN||nf-îºb-45/NN	det||mechanism-48/NN||the-47/DT	prep_in||suggesting-40/VBG||mechanism-48/NN	amod||astrocyte-51/NN||ammonia-induced-50/JJ	prep_of||mechanism-48/NN||astrocyte-51/NN	amod||astrocyte-51/NN||swelling-52/VBG	ammonia-14||swelling-52||no_rel||we earlier reported that treatment of astrocyte cultures with a pathophysiological concentration of ammonia (5 mm nh4cl) resulted in the activation of nuclear factor-kappab (nf-îºb) and that inhibition of such activation diminished astrocyte swelling, suggesting a key role of nf-îºb in the mechanism of ammonia-induced astrocyte swelling.
det||epidemic-6/NN||the-1/DT	amod||epidemic-6/NN||humanimmunodeficiencyvirus/acquiredimmunodeficiencysyndrome-2/JJ	nn||epidemic-6/NN||hiv/aids-4/NN	nsubj||is-7/VBZ||epidemic-6/NN	nsubj||reached-14/VBN||epidemic-6/NN	root||ROOT-0/null||is-7/VBZ	poss||decade-11/NN||its-9/PRP$	amod||decade-11/NN||third-10/JJ	prep_in||is-7/VBZ||decade-11/NN	aux||reached-14/VBN||has-13/VBZ	conj_and||is-7/VBZ||reached-14/VBN	amod||proportions-17/NNS||alarming-16/JJ	prep_to||reached-14/VBN||proportions-17/NNS	advmod||reached-14/VBN||worldwide-18/RB	aids--1||hiv--1||no||the humanimmunodeficiencyvirus/acquiredimmunodeficiencysyndrome (hiv/aids) epidemic is in its third decade and has reached to alarming proportions worldwide.
advmod||inhibit-25/VB||however-1/RB	amod||cells-5/NNS||huh7-4/JJ	nsubj||expressing-7/VBG||cells-5/NNS	advmod||expressing-7/VBG||stably-6/RB	prepc_in||inhibit-25/VB||expressing-7/VBG	dobj||expressing-7/VBG||wt-8/NN	det||proteins-13/NNS||the-10/DT	amod||proteins-13/NNS||mutated-11/JJ	nn||proteins-13/NNS||hbc-12/NN	dobj||expressing-7/VBG||proteins-13/NNS	conj_or||wt-8/NN||proteins-13/NNS	dep||proteins-13/NNS||l60v-15/NNP	dep||l60v-15/NNP||s87g-17/JJ	dep||l60v-15/NNP||i97l-19/JJ	conj_or||s87g-17/JJ||i97l-19/JJ	nn||±-23/NNP||ifn-î-22/NNP	nsubj||inhibit-25/VB||±-23/NNP	aux||inhibit-25/VB||could-24/MD	root||ROOT-0/null||inhibit-25/VB	det||level-33/NN||the-26/DT	amod||level-33/NN||extra-27/JJ	conj_and||extra-27/JJ||intracellular-30/JJ	amod||level-33/NN||intracellular-30/JJ	amod||level-33/NN||hbv-31/JJ	nn||level-33/NN||dna-32/NN	dobj||inhibit-25/VB||level-33/NN	nn||secretion-36/NN||hbsag-35/NN	dobj||inhibit-25/VB||secretion-36/NN	conj_and||level-33/NN||secretion-36/NN	det||level-40/NN||a-38/DT	amod||level-40/NN||similar-39/JJ	prep_to||level-33/NN||level-40/NN	prepc_compared_to||inhibit-25/VB||to-42/TO	pobj||inhibit-25/VB||that-43/DT	prep_in||that-43/DT||cells-45/NNS	vmod||cells-45/NNS||transfected-46/VBN	nn||plasmids-49/NNS||control-48/NN	prep_with||transfected-46/VBN||plasmids-49/NNS	hbv-31||hbsag-35||yes||however, in huh7 cells stably expressing wt or the mutated hbc proteins (l60v, s87g or i97l), ifn-î± could inhibit the extra- and intracellular hbv dna level and hbsag secretion to a similar level compared to that in cells transfected with control plasmids.
det||intervention-5/NN||the-1/DT	amod||intervention-5/NN||spinal-2/JJ	nn||intervention-5/NN||osteoporosis-3/NN	amod||intervention-5/NN||therapeutic-4/JJ	nsubj||trial-18/NN||intervention-5/NN	appos||intervention-5/NN||soti-7/NNP	cop||trial-18/NN||was-9/VBD	det||trial-18/NN||an-10/DT	amod||trial-18/NN||international-11/JJ	amod||trial-18/NN||double-13/JJ	amod||trial-18/NN||blind-14/JJ	amod||trial-18/NN||placebo-16/JJ	amod||trial-18/NN||controlled-17/JJ	root||ROOT-0/null||trial-18/NN	vmod||trial-18/NN||supporting-20/VBG	det||efficacy-22/NN||the-21/DT	dobj||supporting-20/VBG||efficacy-22/NN	amod||2-25/CD||strontiumranelate-24/JJ	prep_of||efficacy-22/NN||2-25/CD	advmod||supporting-20/VBG||g/day-26/RB	prepc_in||supporting-20/VBG||reducing-28/VBG	det||risk-30/NN||the-29/DT	dobj||reducing-28/VBG||risk-30/NN	amod||fractures-33/NNS||vertebral-32/JJ	prep_of||risk-30/NN||fractures-33/NNS	amod||women-36/NNS||postmenopausal-35/JJ	prep_in||fractures-33/NNS||women-36/NNS	prep_with||reducing-28/VBG||osteoporosis-38/NNS	det||fracture-43/NN||a-40/DT	amod||vertebral-42/JJ||prevalent-41/JJ	amod||fracture-43/NN||vertebral-42/JJ	prep_with||reducing-28/VBG||fracture-43/NN	conj_and||osteoporosis-38/NNS||fracture-43/NN	osteoporosis-38||strontiumranelate-24||no_rel||the spinal osteoporosis therapeutic intervention (soti) was an international, double blind, placebo controlled trial, supporting the efficacy of strontiumranelate 2 g/day in reducing the risk of vertebral fractures in postmenopausal women with osteoporosis and a prevalent vertebral fracture.
det||time-4/NN||the-2/DT	amod||time-4/NN||first-3/JJ	prep_for||brings-16/VBZ||time-4/NN	det||supplement-7/NN||this-6/DT	nsubj||brings-16/VBZ||supplement-7/NN	det||journal-10/NN||the-9/DT	prep_to||supplement-7/NN||journal-10/NN	det||society-15/NN||the-12/DT	amod||society-15/NN||international-13/JJ	nn||society-15/NN||aids-14/NNS	prep_of||journal-10/NN||society-15/NN	root||ROOT-0/null||brings-16/VBZ	prt||brings-16/VBZ||together-17/RP	num||place-20/NN||one-19/CD	prep_in||brings-16/VBZ||place-20/NN	det||rationale-22/NN||the-21/DT	dobj||brings-16/VBZ||rationale-22/NN	amod||services-25/NNS||family-centred-24/JJ	prep_for||rationale-22/NN||services-25/NNS	prep_for||services-25/NNS||children-27/NNS	vmod||children-27/NNS||affected-28/VBN	agent||affected-28/VBN||hiv-30/NN	agent||affected-28/VBN||aids-32/NNS	conj_and||hiv-30/NN||aids-32/NNS	prep_for||rationale-22/NN||some-34/DT	conj_and||services-25/NNS||some-34/DT	det||evidence-38/NN||the-36/DT	amod||evidence-38/NN||available-37/JJ	prep_of||some-34/DT||evidence-38/NN	det||effectiveness-41/NN||the-40/DT	prep_for||evidence-38/NN||effectiveness-41/NN	prepc_of||effectiveness-41/NN||doing-43/VBG	advmod||doing-43/VBG||so-44/RB	aids-32||hiv-30||no||for the first time, this supplement to the journal of the international aids society brings together in one place the rationale for family-centred services for children affected by hiv and aids and some of the available evidence for the effectiveness of doing so.
det||study-2/NN||this-1/DT	nsubj||analysis-6/NN||study-2/NN	cop||analysis-6/NN||is-3/VBZ	det||analysis-6/NN||a-4/DT	amod||analysis-6/NN||secondary-5/JJ	root||ROOT-0/null||analysis-6/NN	det||trial-11/NN||the-8/DT	amod||trial-11/NN||nichd-9/JJ	amod||trial-11/NN||mfmu-10/JJ	prep_of||analysis-6/NN||trial-11/NN	prep_of||trial-11/NN||aspirin-13/NN	aux||prevent-15/VB||to-14/TO	vmod||analysis-6/NN||prevent-15/VB	dobj||prevent-15/VB||preeclampsia-16/NN	amod||pregnancies-19/NNS||high-risk-18/JJ	prep_in||prevent-15/VB||pregnancies-19/NNS	preeclampsia-16||aspirin-13||yes||this study is a secondary analysis of the nichd mfmu trial of aspirin to prevent preeclampsia in high-risk pregnancies.
det||results-2/NNS||the-1/DT	nsubj||revealed-8/VBN||results-2/NNS	vmod||results-2/NNS||achieved-3/VBN	poss||study-6/NN||our-5/PRP$	prep_in||achieved-3/VBN||study-6/NN	aux||revealed-8/VBN||have-7/VBP	root||ROOT-0/null||revealed-8/VBN	det||risk-12/NN||the-9/DT	amod||risk-12/NN||highest-10/JJS	amod||risk-12/NN||thrombotic-11/JJ	dobj||revealed-8/VBN||risk-12/NN	det||groups-15/NNS||the-14/DT	prep_among||risk-12/NN||groups-15/NNS	amod||patients-18/NNS||diabetic-17/JJ	prep_of||groups-15/NNS||patients-18/NNS	nsubj||is-21/VBZ||patients-18/NNS	rcmod||patients-18/NNS||is-21/VBZ	amod||correlation-24/NN||direct-23/JJ	prep_in||is-21/VBZ||correlation-24/NN	det||values-28/NNS||the-26/DT	amod||values-28/NNS||high-27/JJ	prep_with||is-21/VBZ||values-28/NNS	nsubj||explain-68/VB||values-28/NNS	prep_of||values-28/NNS||interleukin-1-beta-30/JJ	det||modifications-33/NNS||the-32/DT	prep_of||values-28/NNS||modifications-33/NNS	conj_and||interleukin-1-beta-30/JJ||modifications-33/NNS	nn||parameters-36/NNS||lipid-35/NN	prep_of||values-28/NNS||parameters-36/NNS	vmod||values-28/NNS||acknowledging-38/VBG	det||data-40/NNS||the-39/DT	dobj||acknowledging-38/VBG||data-40/NNS	det||literature-43/NN||the-42/DT	prep_in||data-40/NNS||literature-43/NN	prepc_according_to||acknowledging-38/VBG||to-46/TO	dobj||alters-49/VBZ||which-47/WDT	nsubj||alters-49/VBZ||hyperglycemia-48/NN	nsubj||generates-63/VBZ||hyperglycemia-48/NN	pcomp||acknowledging-38/VBG||alters-49/VBZ	amod||functions-51/NNS||endothelial-50/JJ	dobj||alters-49/VBZ||functions-51/NNS	advmod||alters-49/VBZ||directly-52/RB	advmod||alters-49/VBZ||indirectly-54/RB	conj_and||directly-52/RB||indirectly-54/RB	prep_by||alters-49/VBZ||synthesis-56/NN	nn||factors-59/NNS||growth-58/NN	prep_of||synthesis-56/NN||factors-59/NNS	prep_of||synthesis-56/NN||cytokines-61/NNS	conj_and||factors-59/NNS||cytokines-61/NNS	pcomp||acknowledging-38/VBG||generates-63/VBZ	conj_and||alters-49/VBZ||generates-63/VBZ	amod||disorders-65/NNS||metabolic-64/JJ	dobj||generates-63/VBZ||disorders-65/NNS	aux||explain-68/VB||would-67/MD	rcmod||values-28/NNS||explain-68/VB	det||risk-71/NN||the-69/DT	amod||risk-71/NN||high-70/JJ	dobj||explain-68/VB||risk-71/NN	amod||events-74/NNS||thrombotic-73/JJ	prep_for||risk-71/NN||events-74/NNS	lipid-35||hyperglycemia-48||no_rel||the results achieved in our study have revealed the highest thrombotic risk among the groups of diabetic patients, which is in direct correlation with the high values of interleukin-1-beta and the modifications of lipid parameters, acknowledging the data in the literature, according to which hyperglycemia alters endothelial functions directly and indirectly by synthesis of growth factors and cytokines and generates metabolic disorders which would explain the high risk for thrombotic events.
prepc_after||3.077-57/CD||adjusting-2/VBG	prep_for||adjusting-2/VBG||covariates-4/NNS	nn||type-16/NN||gender-7/NN	dep||type-16/NN||age-9/NN	dep||type-16/NN||hypertension-11/NN	dep||type-16/NN||diabetes-13/NN	amod||type-16/NN||va-15/JJ	prep_such_as||covariates-4/NNS||type-16/NN	nn||levels-19/NNS||hemoglobin-18/NN	prep_such_as||covariates-4/NNS||levels-19/NNS	conj_and||type-16/NN||levels-19/NNS	nn||index-23/NN||body-21/NN	nn||index-23/NN||mass-22/NN	prep_such_as||covariates-4/NNS||index-23/NN	conj_and||type-16/NN||index-23/NN	amod||hormone-26/NN||parathyroid-25/JJ	prep_such_as||covariates-4/NNS||hormone-26/NN	conj_and||type-16/NN||hormone-26/NN	amod||levels-31/NNS||calcium-phosphorus-29/JJ	nn||levels-31/NNS||product-30/NN	prep_such_as||covariates-4/NNS||levels-31/NNS	conj_and||type-16/NN||levels-31/NNS	det||ratio-35/NN||the-33/DT	nn||ratio-35/NN||hazard-34/NN	nsubj||3.077-57/CD||ratio-35/NN	prep_of||ratio-35/NN||vabf-37/NN	dep||ratio-35/NN||defined-39/VBN	prepc_as||defined-39/VBN||<-41/VBG	num||ml/min-43/NN||853-42/CD	dobj||<-41/VBG||ml/min-43/NN	prep_in||ml/min-43/NN||avf-45/NN	prepc_as||defined-39/VBN||<-47/VBG	conj_or||<-41/VBG||<-47/VBG	num||ml/min-49/NN||830-48/CD	dobj||<-47/VBG||ml/min-49/NN	prep_in||ml/min-49/NN||avg-51/NN	nn||va-55/NN||incident-54/NN	prep_to||ratio-35/NN||va-55/NN	cop||3.077-57/CD||was-56/VBD	root||ROOT-0/null||3.077-57/CD	num||%-60/NN||95-59/CD	dep||3.077-57/CD||%-60/NN	nn||interval-62/NN||confidence-61/NN	dep||%-60/NN||interval-62/NN	num||.395-65/CD||1.127-8-64/CD	appos||interval-62/NN||.395-65/CD	dep||interval-62/NN||p-67/NN	dep||0.028-69/CD||=-68/SYM	rcmod||p-67/NN||0.028-69/CD	phosphorus--1||hypertension-11||no_rel||after adjusting for covariates such as gender, age, hypertension, diabetes, va type, hemoglobin levels, body mass index, parathyroid hormone, and calcium-phosphorus product levels, the hazard ratio of vabf (defined as <853 ml/min in avf or <830 ml/min in avg) to incident va was 3.077 (95% confidence interval, 1.127-8.395; p =0.028).
advmod||had-5/VBD||moreover-1/RB	neg||patient-4/NN||no-3/DT	nsubj||had-5/VBD||patient-4/NN	root||ROOT-0/null||had-5/VBD	det||titre-8/NN||an-6/DT	amod||titre-8/NN||anti-hbsab-7/JJ	dobj||had-5/VBD||titre-8/NN	num||reactivation-14/NN||10-10/CD	amod||reactivation-14/NN||iu/l-11/JJ	conj_or||iu/l-11/JJ||hbv-13/JJ	amod||reactivation-14/NN||hbv-13/JJ	prep_below||titre-8/NN||reactivation-14/NN	amod||seroreversion-17/NN||hbsag-16/JJ	dep||reactivation-14/NN||seroreversion-17/NN	amod||detection-22/NN||positive-19/JJ	nn||detection-22/NN||hbv-20/NN	nn||detection-22/NN||dna-21/NN	dep||reactivation-14/NN||detection-22/NN	conj_or||seroreversion-17/NN||detection-22/NN	hbv-20||hbsag-16||yes||moreover, no patient had an anti-hbsab titre below 10 iu/l or hbv reactivation (hbsag seroreversion or positive hbv dna detection).
num||kinds-2/NNS||two-1/CD	nsubj||viruses-7/NNS||kinds-2/NNS	prep_of||kinds-2/NNS||them-4/PRP	cop||viruses-7/NNS||are-5/VBP	amod||viruses-7/NNS||mosquito-borne-6/JJ	root||ROOT-0/null||viruses-7/NNS	nsubj||lead-16/VBP||viruses-7/NNS	nsubj||denguefever/denguehemorrhagicfever-21/VBP||viruses-7/NNS	advmod||virus-11/NN||namely-9/RB	amod||virus-11/NN||japaneseencephalitis-10/JJ	appos||viruses-7/NNS||virus-11/NN	appos||viruses-7/NNS||denguevirus-13/NNS	conj_and||virus-11/NN||denguevirus-13/NNS	rcmod||viruses-7/NNS||lead-16/VBP	prep_to||lead-16/VBP||japaneseencephalitis-18/NNS	rcmod||viruses-7/NNS||denguefever/denguehemorrhagicfever-21/VBP	conj_and||lead-16/VBP||denguefever/denguehemorrhagicfever-21/VBP	advmod||denguefever/denguehemorrhagicfever-21/VBP||respectively-22/RB	det||two-26/CD||the-24/DT	amod||two-26/CD||other-25/JJ	nsubj||viruses-29/NNS||two-26/CD	cop||viruses-29/NNS||are-27/VBP	amod||viruses-29/NNS||tick-borne-28/JJ	parataxis||viruses-7/NNS||viruses-29/NNS	nsubj||contribute-47/VBP||viruses-29/NNS	advmod||virus-33/NN||namely-31/RB	amod||virus-33/NN||tick-borneencephalitis-32/JJ	parataxis||viruses-7/NNS||virus-33/NN	conj_and||viruses-29/NNS||virus-33/NN	nsubj||contribute-47/VBP||virus-33/NN	amod||virus-36/NN||crimean-congohemorrhagicfever-35/JJ	parataxis||viruses-7/NNS||virus-36/NN	conj_and||viruses-29/NNS||virus-36/NN	nsubj||contribute-47/VBP||virus-36/NN	advmod||known-39/VBN||also-38/RB	dep||viruses-29/NNS||known-39/VBN	prepc_as||known-39/VBN||xinjiang-41/VBG	nn||virus-43/NN||hemorrhagicfever-42/NN	dobj||xinjiang-41/VBG||virus-43/NN	rcmod||viruses-29/NNS||contribute-47/VBP	prep_to||contribute-47/VBP||tick-borneencephalitis-49/NNS	nn||hemorrhagicfever-52/NN||xinjiang-51/NN	prep_to||contribute-47/VBP||hemorrhagicfever-52/NN	conj_and||tick-borneencephalitis-49/NNS||hemorrhagicfever-52/NN	advmod||contribute-47/VBP||respectively-53/RB	tick-borneencephalitis-49||viruses-29||no||two kinds of them are mosquito-borne viruses, namely japaneseencephalitis virus and denguevirus, which lead to japaneseencephalitis, and denguefever/denguehemorrhagicfever respectively; the other two are tick-borne viruses, namely tick-borneencephalitis virus and crimean-congohemorrhagicfever virus (also known as xinjiang hemorrhagicfever virus), which contribute to tick-borneencephalitis and xinjiang hemorrhagicfever respectively.
dep||help-60/VB||the-2/NN	dep||the-2/NN||gloom-5/NN	amod||results-11/NNS||disappointing-9/JJ	nn||results-11/NNS||research-10/NN	prep_over||help-60/VB||results-11/NNS	prep_on||help-60/VB||vaccine-13/NN	nsubj||threatens-19/VBZ||development-14/NN	nsubj||overshadow-21/VB||development-14/NN	conj_and||development-14/NN||virucides-16/NNS	nsubj||threatens-19/VBZ||virucides-16/NNS	nsubj||overshadow-21/VB||virucides-16/NNS	rcmod||vaccine-13/NN||threatens-19/VBZ	aux||overshadow-21/VB||to-20/TO	xcomp||threatens-19/VBZ||overshadow-21/VB	advmod||positive-23/JJ||more-22/RBR	acomp||overshadow-21/VB||positive-23/JJ	amod||vaccine-13/NN||hiv/aids-related-26/JJ	dep||hiv/aids-related-26/JJ||news-27/NN	prep_such_as||news-27/NN||findings-31/NNS	det||circumcision-34/NN||that-32/DT	amod||circumcision-34/NN||male-33/JJ	nsubj||reduce-36/VB||circumcision-34/NN	aux||reduce-36/VB||might-35/MD	parataxis||help-60/VB||reduce-36/VB	det||likelihood-38/NN||the-37/DT	dobj||reduce-36/VB||likelihood-38/NN	nn||transmission-41/NN||hiv-40/NN	prep_of||likelihood-38/NN||transmission-41/NN	nsubj||giving-44/VBG||that-43/WDT	dobj||reduce-36/VB||giving-44/VBG	conj_and||likelihood-38/NN||giving-44/VBG	amod||drugs-46/NNS||antiretroviral-45/JJ	dobj||giving-44/VBG||drugs-46/NNS	prep||reduce-36/VB||to-47/TO	nsubj||help-60/VB||high-risk-50/JJ	amod||people-54/NNS||hiv-negative-53/JJ	nsubj||help-60/VB||people-54/NNS	amod||prophylaxis-57/NNS||pre-exposure-56/JJ	appos||people-54/NNS||prophylaxis-57/NNS	aux||help-60/VB||could-59/MD	root||ROOT-0/null||help-60/VB	xcomp||help-60/VB||protect-61/VB	dobj||protect-61/VB||them-62/PRP	prep_from||protect-61/VB||infection-64/NN	aids--1||hiv-40||no||" the ""gloom"" over disappointing research results on vaccine development and virucides ""threatens to overshadow more positive"" hiv/aids-related news, such as findings that male circumcision might reduce the likelihood of hiv transmission and that giving antiretroviral drugs to ""high-risk"" hiv-negative people (pre-exposure prophylaxis) could help protect them from infection."
amod||ratings-2/NNS||highest-1/JJS	nsubjpass||obtained-4/VBN||ratings-2/NNS	auxpass||obtained-4/VBN||were-3/VBD	root||ROOT-0/null||obtained-4/VBN	prep_for||obtained-4/VBN||knowledge-6/NN	det||role-9/NN||the-8/DT	prep_of||knowledge-6/NN||role-9/NN	nn||consumption-12/NN||sugar-11/NN	prep_of||role-9/NN||consumption-12/NN	nn||±-15/NNP||meanâ-14/NNP	nsubj||sd-16/VBP||±-15/NNP	dep||knowledge-6/NN||sd-16/VBP	number||â-18/CD||3.73-17/CD	num||±-19/NNP||â-18/CD	dobj||sd-16/VBP||±-19/NNP	num||±-19/NNP||0.60-20/CD	prep_for||obtained-4/VBN||sealants-23/NNS	conj_and||knowledge-6/NN||sealants-23/NNS	num||â-26/NN||3.58-25/CD	dep||sealants-23/NNS||â-26/NN	dep||â-26/NN||±-27/NNP	num||±-27/NNP||0.68-28/CD	nn||fluoridation-33/NN||water-32/NN	prep_for||obtained-4/VBN||fluoridation-33/NN	conj_and||knowledge-6/NN||fluoridation-33/NN	num||â-36/NN||3.35-35/CD	dep||fluoridation-33/NN||â-36/NN	dep||â-36/NN||±-37/NNP	num||±-37/NNP||0.81-38/CD	amod||prevention-42/NN||caries-41/JJ	prep_in||fluoridation-33/NN||prevention-42/NN	det||lowest-45/JJS||the-44/DT	dep||knowledge-6/NN||lowest-45/JJS	poss||knowledge-48/NN||their-47/PRP$	prep_for||lowest-45/JJS||knowledge-48/NN	det||superiority-51/NN||the-50/DT	prep_of||knowledge-48/NN||superiority-51/NN	det||use-54/NN||the-53/DT	prep_of||superiority-51/NN||use-54/NN	nn||toothpaste-57/NN||fluoride-56/NN	prep_of||use-54/NN||toothpaste-57/NN	prep_over||toothpaste-57/NN||technique-59/NN	prep_of||technique-59/NN||brushing-61/NNP	num||1.09-66/NNS||1.11-63/CD	nn||1.09-66/NNS||â-64/NNP	nn||1.09-66/NNS||±-65/NN	appos||brushing-61/NNP||1.09-66/NNS	caries-41||fluoride-56||yes||highest ratings were obtained for knowledge of the role of sugar consumption (meanâ±sd 3.73â±0.60), sealants (3.58â±0.68), and water fluoridation (3.35â±0.81) in caries prevention; the lowest for their knowledge of the superiority of the use of fluoride toothpaste over technique of brushing (1.11â±1.09).
amod||benzodiazepines-2/NNS||gaba-acting-1/JJ	nsubj||exert-3/VBD||benzodiazepines-2/NNS	ccomp||neurons-22/VBZ||exert-3/VBD	det||patients-6/NNS||some-5/DT	prep_in||exert-3/VBD||patients-6/NNS	nn||effects-10/NNS||autism-8/NN	nn||effects-10/NNS||paradoxical-9/NN	prep_with||exert-3/VBD||effects-10/NNS	xcomp||exert-3/VBD||raising-12/VBG	det||possibility-14/NN||the-13/DT	dobj||raising-12/VBG||possibility-14/NN	nsubj||like-16/VBP||possibility-14/NN	rcmod||possibility-14/NN||like-16/VBP	prep_in||like-16/VBP||epilepsies-18/NNS	nn||excites-21/NNS||gaba-20/NN	nsubj||neurons-22/VBZ||excites-21/NNS	root||ROOT-0/null||neurons-22/VBZ	amod||concentrations-27/NNS||elevated-25/JJ	nn||concentrations-27/NNS||intracellular-26/NN	prep_because_of||neurons-22/VBZ||concentrations-27/NNS	prep_of||concentrations-27/NNS||chloride-29/NN	autism-8||benzodiazepines-2||no_rel||gaba-acting benzodiazepines exert in some patients with autism paradoxical effects, raising the possibility that like in epilepsies, gaba excites neurons because of elevated intracellular concentrations of chloride.
det||study-3/NN||this-1/DT	amod||study-3/NN||prospective-2/JJ	nsubj||assessed-4/VBD||study-3/NN	root||ROOT-0/null||assessed-4/VBD	det||effects-6/NNS||the-5/DT	dobj||assessed-4/VBD||effects-6/NNS	amod||function-9/NN||auditory-8/JJ	prep_on||assessed-4/VBD||function-9/NN	det||dose-15/NN||a-11/DT	amod||dose-15/NN||standard-12/JJ	amod||dose-15/NN||3-day-13/JJ	amod||dose-15/NN||oral-14/JJ	prep_of||function-9/NN||dose-15/NN	prep_of||dose-15/NN||artesunate-17/NN	num||mg/kg/day-20/NN||4-19/CD	appos||artesunate-17/NN||mg/kg/day-20/NN	prep||assessed-4/VBD||combined-22/VBN	pcomp||combined-22/VBN||with-23/IN	pobj||with-23/IN||mefloquine-24/NN	num||mg/kg-27/NN||25-26/CD	appos||mefloquine-24/NN||mg/kg-27/NN	prep_in||mefloquine-24/NN||patients-30/NNS	amod||falciparummalaria-34/NN||acute-32/JJ	amod||falciparummalaria-34/NN||uncomplicated-33/JJ	prep_with||patients-30/NNS||falciparummalaria-34/NN	vmod||falciparummalaria-34/NN||treated-35/VBN	det||unit-41/NN||the-37/DT	amod||unit-41/NN||shoklo-38/JJ	nn||unit-41/NN||malaria-39/NN	nn||unit-41/NN||research-40/NN	prep_at||treated-35/VBN||unit-41/NN	det||border-46/NN||the-44/DT	amod||border-46/NN||thai-burmese-45/JJ	prep_on||treated-35/VBN||border-46/NN	malaria-39||mefloquine-24||yes||this prospective study assessed the effects on auditory function of a standard 3-day oral dose of artesunate (4 mg/kg/day) combined with mefloquine (25 mg/kg) in patients with acute uncomplicated falciparummalaria treated at the shoklo malaria research unit, on the thai-burmese border.
nsubjpass||hampered-20/VBN||elucidation-1/NN	det||transmission-4/NN||the-3/DT	prep_of||elucidation-1/NN||transmission-4/NN	prep_of||elucidation-1/NN||epidemiology-6/NN	conj_and||transmission-4/NN||epidemiology-6/NN	prep_of||elucidation-1/NN||evolution-9/NN	conj_and||transmission-4/NN||evolution-9/NN	prep_of||transmission-4/NN||mycobacteriumulcerans-11/NNS	det||agent-15/NN||the-13/DT	amod||agent-15/NN||causative-14/JJ	appos||elucidation-1/NN||agent-15/NN	prep_of||agent-15/NN||buruliulcer-17/NN	auxpass||hampered-20/VBN||is-19/VBZ	root||ROOT-0/null||hampered-20/VBN	det||lack-24/NN||the-22/DT	amod||lack-24/NN||striking-23/JJ	agent||hampered-20/VBN||lack-24/NN	amod||diversity-27/NN||genetic-26/JJ	prep_of||lack-24/NN||diversity-27/NN	det||pathogen-31/NN||this-29/DT	amod||pathogen-31/NN||emerging-30/VBG	prep_of||diversity-27/NN||pathogen-31/NN	buruliulcer-17||mycobacteriumulcerans-11||no||elucidation of the transmission, epidemiology, and evolution of mycobacteriumulcerans , the causative agent of buruliulcer, is hampered by the striking lack of genetic diversity of this emerging pathogen.
nn||administration-2/NN||metformin-1/NN	nsubj||exerts-7/VBZ||administration-2/NN	prep_in||administration-2/NN||patients-4/NNS	prep_with||patients-4/NNS||pcos-6/NNS	root||ROOT-0/null||exerts-7/VBZ	det||action-10/NN||a-8/DT	nn||action-10/NN||differential-9/NN	dobj||exerts-7/VBZ||action-10/NN	det||levels-15/NNS||the-12/DT	amod||levels-15/NNS||ovarian-13/JJ	nn||levels-15/NNS||amh-14/NN	prep_on||exerts-7/VBZ||levels-15/NNS	det||basis-18/NN||the-17/DT	prep_on||levels-15/NNS||basis-18/NN	amod||response-21/NN||ovulatory-20/JJ	prep_of||basis-18/NN||response-21/NN	pcos-6||metformin-1||no_rel||metformin administration in patients with pcos exerts a differential action on the ovarian amh levels on the basis of ovulatory response.
aux||understand-2/VB||to-1/TO	advcl||used-10/VBD||understand-2/VB	det||regulation-4/NN||the-3/DT	dobj||understand-2/VB||regulation-4/NN	amod||adcc-7/NN||macrophage-mediated-6/JJ	prep_of||regulation-4/NN||adcc-7/NN	nsubj||used-10/VBD||we-9/PRP	root||ROOT-0/null||used-10/VBD	amod||bcelllymphoma-12/NN||human-11/JJ	dobj||used-10/VBD||bcelllymphoma-12/NN	vmod||bcelllymphoma-12/NN||coated-13/VBN	prep_with||coated-13/VBN||rituximab-15/NN	det||target-19/NN||the-17/DT	nn||target-19/NN||tumor-18/NN	prep_as||coated-13/VBN||target-19/NN	amod||macrophages-22/NNS||murine-21/JJ	dobj||used-10/VBD||macrophages-22/NNS	conj_and||bcelllymphoma-12/NN||macrophages-22/NNS	vmod||macrophages-22/NNS||primed-23/VBN	nn||³-26/NNP||ifnî-25/NNP	prep_with||primed-23/VBN||³-26/NNP	det||effectors-29/NNS||the-28/DT	prep_as||³-26/NNP||effectors-29/NNS	bcelllymphoma-12||rituximab-15||yes||to understand the regulation of macrophage-mediated adcc, we used human bcelllymphoma coated with rituximab as the tumor target and murine macrophages primed with ifnî³ as the effectors.
mwe||than-2/IN||more-1/JJR	quantmod||74.2-3/CD||than-2/IN	num||%-4/NN||74.2-3/CD	nsubj||knew-8/VBD||%-4/NN	det||adults-7/NNS||the-6/DT	prep_of||%-4/NN||adults-7/NNS	root||ROOT-0/null||knew-8/VBD	dobj||knew-8/VBD||someone-9/NN	prep_with||knew-8/VBD||hiv/aids-11/NNS	mwe||than-15/IN||more-14/JJR	quantmod||90-16/CD||than-15/IN	num||%-17/NN||90-16/CD	nsubj||identified-19/VBD||%-17/NN	advmod||identified-19/VBD||correctly-18/RB	conj_and||knew-8/VBD||identified-19/VBD	nn||modes-21/NNS||transmission-20/NN	dobj||identified-19/VBD||modes-21/NNS	nn||methods-24/NNS||prevention-23/NN	dobj||identified-19/VBD||methods-24/NNS	conj_and||modes-21/NNS||methods-24/NNS	prep_of||modes-21/NNS||hiv-26/NN	aids--1||hiv-26||no||more than 74.2% of the adults knew someone with hiv/aids, and more than 90% correctly identified transmission modes and prevention methods of hiv.
amod||hips-2/NNS||painful-1/JJ	nsubjpass||caused-8/VBN||hips-2/NNS	amod||masses-5/NNS||periprosthetic-4/JJ	prep_with||hips-2/NNS||masses-5/NNS	aux||caused-8/VBN||may-6/MD	auxpass||caused-8/VBN||be-7/VB	root||ROOT-0/null||caused-8/VBN	amod||wear-11/NN||high-10/JJ	agent||caused-8/VBN||wear-11/NN	mark||ruled-18/VBN||if-14/IN	nsubjpass||ruled-18/VBN||this-15/DT	aux||ruled-18/VBN||can-16/MD	auxpass||ruled-18/VBN||be-17/VB	advcl||considered-25/VBN||ruled-18/VBN	prt||ruled-18/VBN||out-19/RP	nn||hypersensitivity-22/NN||metal-21/NN	nsubjpass||considered-25/VBN||hypersensitivity-22/NN	aux||considered-25/VBN||should-23/MD	auxpass||considered-25/VBN||be-24/VB	conj_but||caused-8/VBN||considered-25/VBN	metal-21||hypersensitivity-22||no_rel||painful hips with periprosthetic masses may be caused by high wear, but if this can be ruled out, metal hypersensitivity should be considered.
root||ROOT-0/null||mal/hok/24-1/CD	punct||mal/hok/24-1/CD||/-2/:	nsubj||avianinfluenzavirus-10/NNS||09-3/CD	nsubj||quails-18/VBZ||09-3/CD	nsubj||antigenically-22/JJ||09-3/CD	appos||09-3/CD||h5n1-5/NNP	cop||avianinfluenzavirus-10/NNS||is-7/VBZ	det||avianinfluenzavirus-10/NNS||a-8/DT	amod||avianinfluenzavirus-10/NNS||non-pathogenic-9/JJ	dep||mal/hok/24-1/CD||avianinfluenzavirus-10/NNS	prep_for||avianinfluenzavirus-10/NNS||chickens-12/NNS	amod||ducks-15/NNS||domestic-14/JJ	appos||chickens-12/NNS||ducks-15/NNS	dep||mal/hok/24-1/CD||quails-18/VBZ	conj_and||avianinfluenzavirus-10/NNS||quails-18/VBZ	cop||antigenically-22/JJ||is-21/VBZ	dep||mal/hok/24-1/CD||antigenically-22/JJ	conj_and||avianinfluenzavirus-10/NNS||antigenically-22/JJ	advmod||distinct-25/JJ||genetically-24/RB	conj_and||avianinfluenzavirus-10/NNS||distinct-25/JJ	conj_and||antigenically-22/JJ||distinct-25/JJ	det||hpaivs-29/NNS||the-27/DT	amod||hpaivs-29/NNS||h5n1-28/JJ	prep_from||distinct-25/JJ||hpaivs-29/NNS	vmod||hpaivs-29/NNS||prevailing-30/VBG	prep_in||prevailing-30/VBG||birds-32/NNS	prep_in||birds-32/NNS||eurasia-34/NN	prep_in||birds-32/NNS||africa-36/NN	conj_and||eurasia-34/NN||africa-36/NN	h5n1-28||avianinfluenzavirus-10||no||mal/hok/24/09 (h5n1) is a non-pathogenic avianinfluenzavirus for chickens, domestic ducks, and quails, and is antigenically and genetically distinct from the h5n1 hpaivs prevailing in birds in eurasia and africa.
root||ROOT-0/null||primary-1/JJ	aux||measure-4/VB||to-3/TO	vmod||primary-1/JJ||measure-4/VB	det||prevalence-6/NN||the-5/DT	dobj||measure-4/VB||prevalence-6/NN	prep_of||prevalence-6/NN||pain-8/NN	prep_in||measure-4/VB||hiv/aids-10/NNS	prep_with||hiv/aids-10/NNS||patients-12/NNS	aids--1||hiv--1||no||primary - to measure the prevalence of pain in hiv/aids with patients.
aux||evaluate-2/VB||to-1/TO	csubj||maleate-22/VBP||evaluate-2/VB	det||efficacy-5/NN||the-3/DT	amod||efficacy-5/NN||long-term-4/JJ	dobj||evaluate-2/VB||efficacy-5/NN	dobj||evaluate-2/VB||safety-7/NN	conj_and||efficacy-5/NN||safety-7/NN	num||combinations-13/NNS||3-9/CD	advmod||available-11/JJ||commercially-10/RB	amod||combinations-13/NNS||available-11/JJ	amod||combinations-13/NNS||fixed-12/VBN	prep_of||efficacy-5/NN||combinations-13/NNS	nn||analogs-16/NNS||prostaglandin-15/NN	prep_of||evaluate-2/VB||analogs-16/NNS	det||prostamide-19/NN||a-18/DT	prep_of||evaluate-2/VB||prostamide-19/NN	conj_or||analogs-16/NNS||prostamide-19/NN	prep_with||evaluate-2/VB||timolol-21/NN	root||ROOT-0/null||maleate-22/VBP	prep_in||maleate-22/VBP||patients-24/NNS	amod||openangleglaucoma-27/NN||primary-26/JJ	prep_with||patients-24/NNS||openangleglaucoma-27/NN	nn||hypertension-30/NN||ocular-29/NN	prep_with||patients-24/NNS||hypertension-30/NN	conj_or||openangleglaucoma-27/NN||hypertension-30/NN	openangleglaucoma-27||prostaglandin-15||no_rel||to evaluate the long-term efficacy and safety of 3 commercially available fixed combinations of prostaglandin analogs or a prostamide with timolol maleate in patients with primary openangleglaucoma or ocular hypertension.
det||design-6/NN||a-2/DT	amod||design-6/NN||double-blinded-3/JJ	amod||design-6/NN||randomized-4/JJ	nn||design-6/NN||crossover-5/NN	prep_in||examined-12/VBN||design-6/NN	amod||function-10/NN||postprandial-8/JJ	amod||function-10/NN||endothelial-9/JJ	nsubjpass||examined-12/VBN||function-10/NN	auxpass||examined-12/VBN||was-11/VBD	root||ROOT-0/null||examined-12/VBN	num||individuals-15/NNS||28-14/CD	prep_in||examined-12/VBN||individuals-15/NNS	amod||type2diabetes-20/NNS||impairedglucosetolerance-17/JJ	conj_or||impairedglucosetolerance-17/JJ||recent-onset-19/JJ	amod||type2diabetes-20/NNS||recent-onset-19/JJ	prep_with||individuals-15/NNS||type2diabetes-20/NNS	det||injection-24/NN||a-22/DT	amod||injection-24/NN||single-23/JJ	prep_after||examined-12/VBN||injection-24/NN	prep_of||injection-24/NN||exenatide-26/NN	prep_of||injection-24/NN||placebo-28/NN	conj_or||exenatide-26/NN||placebo-28/NN	vmod||injection-24/NN||given-29/VBN	advmod||given-29/VBN||just-30/RB	det||meal-34/NN||a-32/DT	amod||meal-34/NN||high-fat-33/JJ	prep_before||given-29/VBN||meal-34/NN	type2diabetes-20||exenatide-26||yes||in a double-blinded randomized crossover design, postprandial endothelial function was examined in 28 individuals with impairedglucosetolerance or recent-onset type2diabetes after a single injection of exenatide or placebo given just before a high-fat meal.
prep_following||reaches-6/VBZ||injection-2/NN	nsubj||reaches-6/VBZ||biasp-4/NN	num||biasp-4/NN||30-5/CD	root||ROOT-0/null||reaches-6/VBZ	amod||levels-10/NNS||higher-7/JJR	amod||levels-10/NNS||plasma-8/JJ	nn||levels-10/NNS||insulin-9/NN	dobj||reaches-6/VBZ||levels-10/NNS	advmod||quickly-12/RB||more-11/RBR	advmod||reaches-6/VBZ||quickly-12/RB	amod||premix-15/NN||human-14/JJ	prep_than||reaches-6/VBZ||premix-15/NN	nn||insulin-18/NN||basal-17/NN	prep_than||reaches-6/VBZ||insulin-18/NN	conj_or||premix-15/NN||insulin-18/NN	vmod||reaches-6/VBZ||giving-20/VBG	amod||reduction-22/NN||effective-21/JJ	dobj||giving-20/VBG||reduction-22/NN	amod||hyperglycemia-25/NN||postprandial-24/JJ	prep_of||reduction-22/NN||hyperglycemia-25/NN	hyperglycemia-25||insulin-18||yes||following injection, biasp 30 reaches higher plasma insulin levels more quickly than human premix or basal insulin, giving effective reduction of postprandial hyperglycemia.
det||results-2/NNS||these-1/DT	nsubj||prove-4/VB||results-2/NNS	aux||prove-4/VB||should-3/MD	root||ROOT-0/null||prove-4/VB	acomp||prove-4/VB||useful-5/JJ	prepc_for||prove-4/VB||understanding-7/VBG	prepc_for||prove-4/VB||overcoming-9/VBG	conj_and||understanding-7/VBG||overcoming-9/VBG	dobj||understanding-7/VBG||refractoriness-10/NNS	aux||fludarabine-12/VB||to-11/TO	vmod||refractoriness-10/NNS||fludarabine-12/VB	advmod||prove-4/VB||also-14/RB	prepc_for||prove-4/VB||predicting-16/VBG	conj_and||understanding-7/VBG||predicting-16/VBG	det||outcome-19/NN||the-17/DT	amod||outcome-19/NN||clinical-18/JJ	dobj||predicting-16/VBG||outcome-19/NN	nn||patients-22/NNS||cll-21/NN	prep_of||outcome-19/NN||patients-22/NNS	advmod||predicting-16/VBG||before-23/RB	advmod||predicting-16/VBG||early-25/RB	conj_or||before-23/RB||early-25/RB	poss||treatment-28/NN||their-27/PRP$	prep_during||predicting-16/VBG||treatment-28/NN	cll-21||fludarabine-12||yes||these results should prove useful for understanding and overcoming refractoriness to fludarabine and also for predicting the clinical outcome of cll patients before or early during their treatment.
nsubjpass||reported-7/VBN||cases-1/NNS	amod||pancreatitis-4/NNS||acute-3/JJ	prep_of||cases-1/NNS||pancreatitis-4/NNS	aux||reported-7/VBN||have-5/VBP	auxpass||reported-7/VBN||been-6/VBN	root||ROOT-0/null||reported-7/VBN	prep_in||reported-7/VBN||association-9/NN	prep_with||reported-7/VBN||exenatide-11/NN	prep_with||reported-7/VBN||sitagliptin-13/NN	conj_and||exenatide-11/NN||sitagliptin-13/NN	prep_with||reported-7/VBN||type2diabetes-16/NNS	conj_and||exenatide-11/NN||type2diabetes-16/NNS	prep_without||reported-7/VBN||use-18/NN	det||medications-21/NNS||these-20/DT	prep_of||use-18/NN||medications-21/NNS	exenatide-11||pancreatitis-4||no_rel||cases of acute pancreatitis have been reported in association with exenatide, sitagliptin, and type2diabetes without use of these medications.
det||investigation-3/NN||this-2/DT	prep_in||evaluated-5/VBD||investigation-3/NN	nsubj||evaluated-5/VBD||we-4/PRP	root||ROOT-0/null||evaluated-5/VBD	num||indexes-8/NNS||nine-6/CD	amod||indexes-8/NNS||metabolic-7/JJ	dobj||evaluated-5/VBD||indexes-8/NNS	amod||tests-13/NNS||intravenous-10/JJ	nn||tests-13/NNS||glucose-11/NN	nn||tests-13/NNS||tolerance-12/NN	prep_from||evaluated-5/VBD||tests-13/NNS	appos||tests-13/NNS||ivgtts-15/NNS	amod||tests-21/NNS||oral-18/JJ	nn||tests-21/NNS||glucose-19/NN	nn||tests-21/NNS||tolerance-20/NN	prep_from||evaluated-5/VBD||tests-21/NNS	conj_and||tests-13/NNS||tests-21/NNS	appos||tests-13/NNS||ogtts-23/NNS	det||effort-27/NN||an-26/DT	prep_in||evaluated-5/VBD||effort-27/NN	aux||determine-29/VB||to-28/TO	vmod||evaluated-5/VBD||determine-29/VB	poss||performance-32/NN||their-30/PRP$	amod||performance-32/NN||prognostic-31/JJ	dobj||determine-29/VB||performance-32/NN	prepc_in||determine-29/VB||predicting-34/VBG	det||development-36/NN||the-35/DT	dobj||predicting-34/VBG||development-36/NN	prep_of||development-36/NN||type1diabetes-38/CD	prep_in||predicting-34/VBG||those-40/DT	amod||risk-43/NN||moderate-42/JJ	prep_with||those-40/DT||risk-43/NN	mark||defined-46/VBN||as-45/IN	advcl||evaluated-5/VBD||defined-46/VBN	amod||relation-49/NN||familial-48/JJ	prep_by||defined-46/VBN||relation-49/NN	det||individual-55/NN||a-51/DT	nn||individual-55/NN||type-52/NN	num||individual-55/NN||1-53/CD	amod||individual-55/NN||diabetic-54/JJ	prep_to||defined-46/VBN||individual-55/NN	det||test-59/NN||a-57/DT	amod||test-59/NN||positive-58/JJ	appos||individual-55/NN||test-59/NN	amod||antibodies-63/NNS||islet-61/JJ	nn||antibodies-63/NNS||cell-62/NN	prep_for||test-59/NN||antibodies-63/NNS	nn||autoantibody-66/NN||insulin-65/NN	prep_for||test-59/NN||autoantibody-66/NN	conj_and||antibodies-63/NNS||autoantibody-66/NN	prep||defined-46/VBN||but-68/CC	amod||tolerance-71/NN||normal-69/JJ	nn||tolerance-71/NN||glucose-70/NN	pobj||but-68/CC||tolerance-71/NN	type1diabetes-38||insulin-65||yes||in this investigation we evaluated nine metabolic indexes from intravenous glucose tolerance tests (ivgtts) and oral glucose tolerance tests (ogtts) in an effort to determine their prognostic performance in predicting the development of type1diabetes in those with moderate risk, as defined by familial relation to a type 1 diabetic individual, a positive test for islet cell antibodies and insulin autoantibody, but normal glucose tolerance.
nsubj||er-13/NN||two-1/CD	det||pathways-7/NNS||the-3/DT	advmod||common-5/JJ||most-4/RBS	amod||pathways-7/NNS||common-5/JJ	nn||pathways-7/NNS||signalling-6/NN	prep_of||two-1/CD||pathways-7/NNS	nn||cancer-10/NN||breast-9/NN	prep_in||pathways-7/NNS||cancer-10/NN	cop||er-13/NN||are-11/VBP	det||er-13/NN||the-12/DT	root||ROOT-0/null||er-13/NN	nn||receptor-16/NN||oestrogen-15/NN	appos||er-13/NN||receptor-16/NN	amod||pathway-20/NN||ligand-18/JJ	nn||pathway-20/NN||activation-19/NN	dep||er-13/NN||pathway-20/NN	det||emt-26/NN||the-22/DT	amod||emt-26/NN||e-cadherin-23/JJ	amod||emt-26/NN||snai1-24/JJ	nn||emt-26/NN||slug-25/NN	conj_and||er-13/NN||emt-26/NN	quantmod||$-29/$||epithelialâ-28/RB	num||transition-32/NN||$-29/$	nn||transition-32/NN||mesenchymal-31/NN	appos||emt-26/NN||transition-32/NN	advmod||er-13/NN||pathway-34/RB	cancer-10||oestrogen-15||no_rel||two of the most common signalling pathways in breast cancer are the er (oestrogen receptor) ligand activation pathway and the e-cadherin snai1 slug emt (epithelialâ€“mesenchymal transition) pathway.
det||drugs-3/NNS||the-1/DT	amod||drugs-3/NNS||adjuvant-2/JJ	nsubj||effective-16/JJ||drugs-3/NNS	dep||drugs-3/NNS||ketamine-5/JJ	dep||drugs-3/NNS||ntg-7/JJ	conj_or||ketamine-5/JJ||ntg-7/JJ	advmod||added-10/VBD||when-9/WRB	rcmod||drugs-3/NNS||added-10/VBD	aux||lidocaine-12/VB||to-11/TO	xcomp||added-10/VBD||lidocaine-12/VB	prep_in||lidocaine-12/VB||ivra-14/NN	cop||effective-16/JJ||were-15/VBD	root||ROOT-0/null||effective-16/JJ	prepc_in||effective-16/JJ||improving-18/VBG	det||quality-21/NN||the-19/DT	amod||quality-21/NN||overall-20/JJ	dobj||improving-18/VBG||quality-21/NN	prep_of||quality-21/NN||anesthesia-23/NN	prepc_in||effective-16/JJ||reducing-25/VBG	conj_and||improving-18/VBG||reducing-25/VBG	amod||pain-27/NN||tourniquet-26/JJ	dobj||reducing-25/VBG||pain-27/NN	prepc_in||effective-16/JJ||increasing-29/VBG	conj_and||improving-18/VBG||increasing-29/VBG	amod||tolerance-31/NN||tourniquet-30/JJ	dobj||increasing-29/VBG||tolerance-31/NN	prepc_in||effective-16/JJ||improving-33/VBG	conj_and||improving-18/VBG||improving-33/VBG	det||analgesia-36/NN||the-34/DT	amod||analgesia-36/NN||postoperative-35/JJ	dobj||improving-33/VBG||analgesia-36/NN	prep_in||analgesia-36/NN||comparison-38/NN	det||group-42/NN||the-40/DT	nn||group-42/NN||control-41/NN	prep_to||improving-33/VBG||group-42/NN	pain-27||ketamine-5||yes||the adjuvant drugs (ketamine or ntg) when added to lidocaine in ivra were effective in improving the overall quality of anesthesia, reducing tourniquet pain, increasing tourniquet tolerance and improving the postoperative analgesia in comparison to the control group.
nsubj||help-3/VB||this-1/DT	aux||help-3/VB||should-2/MD	root||ROOT-0/null||help-3/VB	xcomp||help-3/VB||reduce-4/VB	det||prevalence-7/NN||the-5/DT	amod||prevalence-7/NN||national-6/JJ	dobj||reduce-4/VB||prevalence-7/NN	prep_of||prevalence-7/NN||hiv/aids-9/NNS	aids--1||hiv--1||no||this should help reduce the national prevalence of hiv/aids
det||increase-2/NN||an-1/DT	nsubjpass||associated-12/VBN||increase-2/NN	nsubjpass||associated-12/VBN||increase-2/NN	amod||adiposity-9/NN||total-4/JJ	conj_and||total-4/JJ||visceral-8/JJ	amod||adiposity-9/NN||visceral-8/JJ	prep_in||increase-2/NN||adiposity-9/NN	auxpass||associated-12/VBN||is-10/VBZ	advmod||associated-12/VBN||probably-11/RB	root||ROOT-0/null||associated-12/VBN	conj_negcc||associated-12/VBN||associated-12/VBN	det||decrease-15/NN||a-14/DT	prep_with||associated-12/VBN||decrease-15/NN	nn||distensibility-18/NN||vascular-17/NN	prep_in||decrease-15/NN||distensibility-18/NN	det||boys-24/NNS||the-20/DT	nn||boys-24/NNS||gujarati-21/NN	nn||boys-24/NNS||indian-22/NN	amod||boys-24/NNS||adolescent-23/JJ	prep_in||distensibility-18/NN||boys-24/NNS	prep_in||associated-12/VBN||girls-28/NNS	advmod||indicating-31/VBG||thus-30/RB	xcomp||associated-12/VBN||indicating-31/VBG	det||role-34/NN||a-32/DT	amod||role-34/NN||protective-33/JJ	dobj||indicating-31/VBG||role-34/NN	amod||estrogen-38/NN||female-36/JJ	nn||estrogen-38/NN||sexhormone-37/NN	prep_of||role-34/NN||estrogen-38/NN	nsubjpass||shown-42/VBN||estrogen-38/NN	nsubj||protect-45/VB||estrogen-38/NN	aux||shown-42/VBN||has-40/VBZ	auxpass||shown-42/VBN||been-41/VBN	rcmod||estrogen-38/NN||shown-42/VBN	advmod||shown-42/VBN||earlier-43/RBR	aux||protect-45/VB||to-44/TO	xcomp||shown-42/VBN||protect-45/VB	det||vasculature-47/NN||the-46/DT	dobj||protect-45/VB||vasculature-47/NN	prep_from||protect-45/VB||atherosclerosis-49/NNS	amod||dysfunction-52/NN||endothelial-51/JJ	appos||atherosclerosis-49/NNS||dysfunction-52/NN	nsubj||occurs-54/VBZ||dysfunction-52/NN	rcmod||dysfunction-52/NN||occurs-54/VBZ	prep_with||occurs-54/VBZ||increase-56/NN	prep_in||increase-56/NN||adiposity-58/NN	sexhormone-37||adiposity-58||no_rel||an increase in total as well as visceral adiposity is probably associated with a decrease in vascular distensibility in the gujarati indian adolescent boys but not in girls, thus indicating a protective role of female sexhormone estrogen which has been shown earlier to protect the vasculature from atherosclerosis, endothelial dysfunction which occurs with increase in adiposity.
det||risk-2/NN||the-1/DT	nsubjpass||characterized-11/VBN||risk-2/NN	amod||exposure-5/NN||occupational-4/JJ	prep_for||risk-2/NN||exposure-5/NN	prep_to||exposure-5/NN||hiv-7/NN	aux||characterized-11/VBN||has-8/VBZ	auxpass||characterized-11/VBN||been-9/VBN	advmod||characterized-11/VBN||well-10/RB	root||ROOT-0/null||characterized-11/VBN	det||world-15/NN||the-13/DT	amod||world-15/NN||developed-14/VBN	prep_in||characterized-11/VBN||world-15/NN	amod||information-19/NN||limited-18/JJ	nsubj||available-21/JJ||information-19/NN	cop||available-21/JJ||is-20/VBZ	conj_but||characterized-11/VBN||available-21/JJ	det||risk-25/NN||this-23/DT	nn||risk-25/NN||transmission-24/NN	prep_about||available-21/JJ||risk-25/NN	amod||settings-28/NNS||resource-constrained-27/JJ	prep_in||risk-25/NN||settings-28/NNS	xcomp||available-21/JJ||facing-29/VBG	det||burden-32/NN||the-30/DT	amod||burden-32/NN||largest-31/JJS	dobj||facing-29/VBG||burden-32/NN	prep_of||burden-32/NN||hivinfection-34/NN	hivinfection-34||hiv-7||no||the risk for occupational exposure to hiv has been well characterized in the developed world, but limited information is available about this transmission risk in resource-constrained settings facing the largest burden of hivinfection.
vmod||amyloid-8/VBD||circulating-1/VBG	dobj||circulating-1/VBG||levels-2/NNS	amod||protein-5/NN||c-reactive-4/JJ	prep_of||levels-2/NNS||protein-5/NN	nsubj||amyloid-8/VBD||serum-7/NN	root||ROOT-0/null||amyloid-8/VBD	det||±-14/NNS||a-9/DT	nn||necrosis-12/NNS||tumor-11/NN	nn||±-14/NNS||necrosis-12/NNS	amod||±-14/NNS||factor-î-13/JJ	nsubjpass||measured-39/VBN||±-14/NNS	amod||-1-20/NN||interleukin-16/JJ	appos||-1-20/NN||il-18/NN	conj_and||±-14/NNS||-1-20/NN	nsubjpass||measured-39/VBN||-1-20/NN	amod||monocyte-26/JJ||il-6-22/JJ	amod||monocyte-26/JJ||il-8-24/JJ	amod||protein-1-28/NN||monocyte-26/JJ	amod||protein-1-28/NN||chemotactic-27/JJ	conj_and||±-14/NNS||protein-1-28/NN	nsubjpass||measured-39/VBN||protein-1-28/NN	nn||protein-33/NN||heat-31/NN	nn||protein-33/NN||shock-32/NN	conj_and||±-14/NNS||protein-33/NN	nsubjpass||measured-39/VBN||protein-33/NN	appos||protein-33/NN||hsp-35/NN	dep||protein-33/NN||70-37/CD	auxpass||measured-39/VBN||were-38/VBD	ccomp||amyloid-8/VBD||measured-39/VBN	amod||assays-43/NNS||enzyme-linked-41/JJ	nn||assays-43/NNS||immunosorbent-42/NN	prep_with||measured-39/VBN||assays-43/NNS	enzyme--1||shock-32||no_rel||circulating levels of c-reactive protein, serum amyloid a, tumor necrosis factor-î±, interleukin (il)-1, il-6, il-8, monocyte chemotactic protein-1, and heat shock protein (hsp)70 were measured with enzyme-linked immunosorbent assays.
nsubj||drug-6/NN||atovaquone-proguanil-1/NN	cop||drug-6/NN||is-2/VBZ	num||drug-6/NN||one-3/CD	amod||drug-6/NN||such-4/JJ	nn||drug-6/NN||combination-5/NN	root||ROOT-0/null||drug-6/NN	vmod||drug-6/NN||used-7/VBN	dep||used-7/VBN||both-8/DT	prep_for||used-7/VBN||prophylaxis-10/NNS	prep_for||used-7/VBN||prophylaxis-10/NNS	conj_and||prophylaxis-10/NNS||prophylaxis-10/NNS	prep_in||prophylaxis-10/NNS||travellers-12/NNS	prep_for||prophylaxis-10/NNS||treatment-16/NN	amod||cases-20/NNS||acute-18/JJ	nn||cases-20/NNS||malaria-19/NN	prep_of||treatment-16/NN||cases-20/NNS	nn||hospitals-23/NNS||european-22/NN	prep_in||used-7/VBN||hospitals-23/NNS	prep_in||used-7/VBN||clinics-25/NNS	conj_and||hospitals-23/NNS||clinics-25/NNS	malaria-19||proguanil--1||yes||atovaquone-proguanil is one such combination drug used both for prophylaxis in travellers, and for treatment of acute malaria cases in european hospitals and clinics.
num||genes-2/NNS||ten-1/CD	nsubjpass||up-regulated-15/VBN||genes-2/NNS	vmod||genes-2/NNS||related-3/VBN	nn||metabolism-6/NN||carbon-5/NN	prep_with||related-3/VBN||metabolism-6/NN	dep||genes-2/NNS||pcka-8/NN	dep||genes-2/NNS||fumb-10/NN	conj_and||pcka-8/NN||fumb-10/NN	prep_among||pcka-8/NN||others-12/NNS	auxpass||up-regulated-15/VBN||were-14/VBD	root||ROOT-0/null||up-regulated-15/VBN	det||mutant-19/NN||the-17/DT	nn||mutant-19/NN||bvrr-18/NN	prep_in||up-regulated-15/VBN||mutant-19/NN	nn||genes-23/NNS||denitrification-22/NN	nsubjpass||regulated-33/VBN||genes-23/NNS	dep||genes-23/NNS||nirk-25/NN	dep||nirk-25/NN||norc-27/JJ	dep||nirk-25/NN||nosz-29/JJ	conj_and||norc-27/JJ||nosz-29/JJ	auxpass||regulated-33/VBN||were-31/VBD	advmod||regulated-33/VBN||also-32/RB	conj_and||up-regulated-15/VBN||regulated-33/VBN	carbon-5||ten-1||no_rel||ten genes related with carbon metabolism ( pcka and fumb among others) were up-regulated in the bvrr mutant, and denitrification genes ( nirk, norc and nosz ) were also regulated.
det||study-2/NN||this-1/DT	nsubjpass||carried-4/VBN||study-2/NN	nsubj||assess-7/VB||study-2/NN	auxpass||carried-4/VBN||was-3/VBD	root||ROOT-0/null||carried-4/VBN	prt||carried-4/VBN||out-5/RP	aux||assess-7/VB||to-6/TO	xcomp||carried-4/VBN||assess-7/VB	det||magnitude-9/NN||the-8/DT	dobj||assess-7/VB||magnitude-9/NN	dobj||assess-7/VB||factors-11/NNS	conj_and||magnitude-9/NN||factors-11/NNS	vmod||magnitude-9/NN||associated-12/VBN	amod||disclosure-16/NN||hivseropositive-14/JJ	nn||disclosure-16/NN||status-15/NN	prep_of||associated-12/VBN||disclosure-16/NN	amod||partners-19/NNS||sexual-18/JJ	prep_to||disclosure-16/NN||partners-19/NNS	prep_among||associated-12/VBN||peoples-21/NNS	vmod||peoples-21/NNS||living-22/VBG	prep_with||living-22/VBG||hiv/aids-24/NNS	aids--1||hiv--1||no||this study was carried out to assess the magnitude and factors associated of hivseropositive status disclosure to sexual partners among peoples living with hiv/aids.
nsubj||disease-9/NN||severeacuterespiratorysyndrome-1/NN	appos||severeacuterespiratorysyndrome-1/NN||sars-3/NNS	cop||disease-9/NN||is-5/VBZ	det||disease-9/NN||an-6/DT	amod||disease-9/NN||emerging-7/VBG	amod||disease-9/NN||infectious-8/JJ	root||ROOT-0/null||disease-9/NN	vmod||disease-9/NN||caused-10/VBN	det||coronavirussars-cov-14/NN||the-12/DT	nn||coronavirussars-cov-14/NN||novel-13/NN	agent||caused-10/VBN||coronavirussars-cov-14/NN	sars-3||sars-cov--1||no||severeacuterespiratorysyndrome (sars) is an emerging infectious disease caused by the novel coronavirussars-cov.
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	amod||methods-6/NNS||standardized-3/JJ	amod||methods-6/NNS||kaplan-meier-4/JJ	nn||methods-6/NNS||survival-5/NN	dobj||used-2/VBD||methods-6/NNS	aux||determine-8/VB||to-7/TO	vmod||used-2/VBD||determine-8/VB	dobj||determine-8/VB||differences-9/NNS	prep_in||differences-9/NNS||time-11/NN	prep_of||time-11/NN||progression-13/NN	prep_from||determine-8/VB||hiv-15/NN	prep_to||determine-8/VB||aids-17/NNS	prep_to||determine-8/VB||death-19/NN	conj_and||aids-17/NNS||death-19/NN	prep_by||determine-8/VB||race/ethnicity-22/NN	prep_by||determine-8/VB||sex-24/NN	conj_and||race/ethnicity-22/NN||sex-24/NN	nn||group-27/NN||age-26/NN	prep_by||determine-8/VB||group-27/NN	conj_and||race/ethnicity-22/NN||group-27/NN	amod||count-32/NN||cd4-29/JJ	amod||count-32/NN||+-30/JJ	amod||count-32/NN||t-cell-31/JJ	prep_by||determine-8/VB||count-32/NN	conj_and||race/ethnicity-22/NN||count-32/NN	amod||residence-35/NN||metropolitan-34/JJ	prep_by||determine-8/VB||residence-35/NN	conj_and||race/ethnicity-22/NN||residence-35/NN	nn||year-39/NN||diagnosis-38/NN	prep_by||determine-8/VB||year-39/NN	conj_and||race/ethnicity-22/NN||year-39/NN	aids-17||hiv-15||no||we used standardized kaplan-meier survival methods to determine differences in time of progression from hiv to aids and death, by race/ethnicity, sex, age group, cd4+ t-cell count, metropolitan residence, and diagnosis year.
nn||design-2/NN||research-1/NN	nsubj||pumpâ-10/VBD||design-2/NN	poss||insulin-9/NN||methods-4/NNS	nn||insulin-9/NN||$-6/NNP	num||insulin-9/NN||seventeen-8/CD	conj_and||design-2/NN||insulin-9/NN	nsubj||pumpâ-10/VBD||insulin-9/NN	root||ROOT-0/null||pumpâ-10/VBD	num||adolescents-14/NNS||$-11/$	num||$-11/$||treated-13/CD	nsubj||underwent-17/VBD||adolescents-14/NNS	prep_with||adolescents-14/NNS||type1diabetes-16/CD	ccomp||pumpâ-10/VBD||underwent-17/VBD	num||procedures-21/NNS||two-18/CD	amod||procedures-21/NNS||euglycemic-19/JJ	nn||procedures-21/NNS||clamp-20/NN	dobj||underwent-17/VBD||procedures-21/NNS	det||bolus-26/NNS||a-23/DT	num||bolus-26/NNS||0.2-24/CD	amod||bolus-26/NNS||unit/kg-25/VBG	prep_after||underwent-17/VBD||bolus-26/NNS	preconj||insulinaspart-29/NN||either-28/DT	prep_of||bolus-26/NNS||insulinaspart-29/NN	prep_of||bolus-26/NNS||lispro-31/NN	conj_or||insulinaspart-29/NN||lispro-31/NN	prep_on||insulinaspart-29/NN||day-33/NN	num||day-33/NN||1-34/CD	prep_of||bolus-26/NNS||day-36/NN	conj_and||insulinaspart-29/NN||day-36/NN	num||day-36/NN||4-37/CD	nn||insertion-42/NN||insulin-39/NN	nn||insertion-42/NN||pump-40/NN	nn||insertion-42/NN||site-41/NN	prep_of||day-36/NN||insertion-42/NN	type1diabetes-16||insulinaspart-29||yes||research design and methods â€”seventeen insulin pumpâ€“treated adolescents with type1diabetes underwent two euglycemic clamp procedures after a 0.2 unit/kg bolus of either insulinaspart or lispro on day 1 and day 4 of insulin pump site insertion.
amod||o1-2/NNS||v.cholerae-1/JJ	nsubj||pathogen-7/NN||o1-2/NNS	cop||pathogen-7/NN||is-3/VBZ	det||pathogen-7/NN||the-4/DT	amod||pathogen-7/NN||major-5/JJ	amod||pathogen-7/NN||bacterial-6/JJ	root||ROOT-0/null||pathogen-7/NN	det||cause-10/NN||a-9/DT	conj_and||pathogen-7/NN||cause-10/NN	amod||disease-14/NN||severe-12/JJ	nn||disease-14/NN||cholera-13/NN	prep_of||cause-10/NN||disease-14/NN	num||%-17/NN||23-16/CD	prep_in||disease-14/NN||%-17/NN	prep_of||%-17/NN||patients-19/NNS	prep_from||patients-19/NNS||mirpur-21/NN	cholera-13||v.cholerae-1||no||v.cholerae o1 is the major bacterial pathogen and a cause of severe cholera disease in 23 % of patients from mirpur .
advmod||report-4/VBP||here-1/RB	nsubj||report-4/VBP||we-3/PRP	root||ROOT-0/null||report-4/VBP	det||ã-7/NN||a-5/DT	num||ã-7/NN||3.0-6/CD	dobj||report-4/VBP||ã-7/NN	nn||structure-10/NN||crystal-9/NN	dep||ã-7/NN||structure-10/NN	det||ferritin-13/NN||a-12/DT	prep_of||structure-10/NN||ferritin-13/NN	appos||ã-7/NN||annotated-15/JJ	prep_as||annotated-15/JJ||bacterioferritin-17/NN	dep||annotated-15/JJ||b-18/SYM	appos||annotated-15/JJ||bfrb-20/NN	prep_from||annotated-15/JJ||mycobacteriumtuberculosis-24/NNS	dep||ã-7/NN||mtb-26/VBN	det||agent-31/NN||the-29/DT	amod||agent-31/NN||causative-30/JJ	appos||ã-7/NN||agent-31/NN	nsubj||continues-35/VBZ||agent-31/NN	nsubj||one-38/CD||agent-31/NN	prep_of||agent-31/NN||tuberculosis-33/NNP	rcmod||agent-31/NN||continues-35/VBZ	aux||one-38/CD||to-36/TO	cop||one-38/CD||be-37/VB	xcomp||continues-35/VBZ||one-38/CD	det||world-41/NN||the-40/DT	poss||diseases-44/NNS||world-41/NN	amod||diseases-44/NNS||deadliest-43/JJS	prep_of||one-38/CD||diseases-44/NNS	tuberculosis-33||mtb-26||no||here, we report a 3.0 ã… crystal structure of a ferritin, annotated as bacterioferritin b (bfrb), from mycobacteriumtuberculosis (mtb), the causative agent of tuberculosis that continues to be one of the world's deadliest diseases.
prep_in||shown-24/VBN||patients-2/NNS	amod||asthma-5/NN||persistent-4/JJ	prep_with||patients-2/NNS||asthma-5/NN	advmod||treated-7/VBN||previously-6/RB	vmod||asthma-5/NN||treated-7/VBN	preconj||treated-7/VBN||either-8/CC	amod||beta-agonists-11/NNS||short-acting-10/JJ	prep_with||treated-7/VBN||beta-agonists-11/NNS	advmod||treated-7/VBN||alone-12/RB	amod||therapy-16/NN||twice-daily-14/JJ	nn||therapy-16/NN||maintenance-15/NN	npadvmod||treated-7/VBN||therapy-16/NN	prep_with||treated-7/VBN||ics-18/NN	conj_or||beta-agonists-11/NNS||ics-18/NN	amod||mf-21/NN||once-daily-20/JJ	nsubjpass||shown-24/VBN||mf-21/NN	nsubj||superior-27/JJ||mf-21/NN	nsubj||placebo-29/VB||mf-21/NN	nsubjpass||shown-45/VBN||mf-21/NN	aux||shown-24/VBN||has-22/VBZ	auxpass||shown-24/VBN||been-23/VBN	root||ROOT-0/null||shown-24/VBN	aux||superior-27/JJ||to-25/TO	cop||superior-27/JJ||be-26/VB	xcomp||shown-24/VBN||superior-27/JJ	aux||placebo-29/VB||to-28/TO	xcomp||superior-27/JJ||placebo-29/VB	prepc_in||placebo-29/VB||improving-31/VBG	nn||function-33/NN||lung-32/NN	dobj||improving-31/VBG||function-33/NN	nn||control-36/NN||symptom-35/NN	dobj||improving-31/VBG||control-36/NN	conj_and||function-33/NN||control-36/NN	dobj||improving-31/VBG||quality-39/NN	conj_and||function-33/NN||quality-39/NN	prep_of||quality-39/NN||life-41/NN	aux||shown-45/VBN||has-44/VBZ	conj_and||shown-24/VBN||shown-45/VBN	amod||efficacy-47/NN||comparable-46/JJ	dobj||shown-45/VBN||efficacy-47/NN	prepc_compared_with||shown-45/VBN||with-49/IN	pobj||shown-45/VBN||budesonide-50/JJ	pobj||shown-45/VBN||beclomethasone-52/JJ	conj_and||budesonide-50/JJ||beclomethasone-52/JJ	pobj||shown-45/VBN||fluticasone-55/JJ	conj_and||budesonide-50/JJ||fluticasone-55/JJ	asthma-5||budesonide-50||yes||in patients with persistent asthma previously treated either with short-acting beta-agonists alone or twice-daily maintenance therapy with ics, once-daily mf has been shown to be superior to placebo in improving lung function, symptom control, and quality of life; and has shown comparable efficacy compared with budesonide, beclomethasone, and fluticasone.
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-7/VBD||aim-3/NN	nsubj||present-9/VB||aim-3/NN	det||study-6/NN||this-5/DT	prep_of||aim-3/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||present-9/VB||to-8/TO	xcomp||was-7/VBD||present-9/VB	det||results-11/NNS||the-10/DT	dobj||present-9/VB||results-11/NNS	det||analysis-15/NN||a-13/DT	amod||analysis-15/NN||prespecified-14/JJ	prep_of||results-11/NNS||analysis-15/NN	amod||endpoints-19/NNS||key-17/JJ	amod||endpoints-19/NNS||secondary-18/JJ	prep_of||analysis-15/NN||endpoints-19/NNS	det||study-27/NN||a-21/DT	amod||study-27/NN||12-week-22/JJ	amod||study-27/NN||open-label-24/JJ	amod||study-27/NN||single-arm-26/JJ	prep_from||present-9/VB||study-27/NN	vmod||study-27/NN||evaluating-28/VBG	det||efficacy-30/NN||the-29/DT	dobj||evaluating-28/VBG||efficacy-30/NN	dobj||evaluating-28/VBG||safety-32/NN	conj_and||efficacy-30/NN||safety-32/NN	amod||hydrochlorothiazide-36/NN||olmesartanmedoxomil-34/JJ	nn||hydrochlorothiazide-36/NN||plus-35/NN	prep_of||efficacy-30/NN||hydrochlorothiazide-36/NN	appos||hydrochlorothiazide-36/NN||hctz-38/NNP	prep_in||evaluating-28/VBG||patients-41/NNS	prep_with||patients-41/NNS||hypertension-43/NN	prep_with||patients-41/NNS||type2diabetes-45/NNS	conj_and||hypertension-43/NN||type2diabetes-45/NNS	hypertension-43||olmesartanmedoxomil-34||yes||objective the aim of this study was to present the results of a prespecified analysis of key secondary endpoints from a 12-week, open-label, single-arm study evaluating the efficacy and safety of olmesartanmedoxomil plus hydrochlorothiazide (hctz) in patients with hypertension and type2diabetes.
det||patterns-2/NNS||the-1/DT	nsubjpass||monitored-13/VBN||patterns-2/NNS	amod||symptoms-5/NNS||clinical-4/JJ	prep_of||patterns-2/NNS||symptoms-5/NNS	amod||virus-8/NN||faecal-7/JJ	prep_of||patterns-2/NNS||virus-8/NN	conj_and||symptoms-5/NNS||virus-8/NN	amod||virus-8/NN||shedding-9/VBG	prep_of||patterns-2/NNS||seroconversion-11/NN	conj_and||symptoms-5/NNS||seroconversion-11/NN	auxpass||monitored-13/VBN||were-12/VBD	root||ROOT-0/null||monitored-13/VBN	advmod||revealing-19/VBG||up-15/RB	num||weeks-18/NNS||10-17/CD	prep_to||up-15/RB||weeks-18/NNS	prepc_for||monitored-13/VBN||revealing-19/VBG	amod||differences-23/NNS||subtle-20/JJ	conj_but||subtle-20/JJ||reproducible-22/JJ	amod||differences-23/NNS||reproducible-22/JJ	dobj||revealing-19/VBG||differences-23/NNS	det||viruses-27/NNS||the-25/DT	num||viruses-27/NNS||two-26/CD	prep_between||differences-23/NNS||viruses-27/NNS	virus-8||viruses-27||no||the patterns of clinical symptoms, faecal virus shedding and seroconversion were monitored for up to 10 weeks revealing subtle but reproducible differences between the two viruses.
nn||risk-2/NN||cvd-1/NN	nsubj||higher-4/JJR||risk-2/NN	cop||higher-4/JJR||was-3/VBD	root||ROOT-0/null||higher-4/JJR	prep_in||higher-4/JJR||caucasians-6/NNS	amod||ethnicities-9/NNS||other-8/JJ	prep_than||caucasians-6/NNS||ethnicities-9/NNS	det||factor-13/NN||the-11/DT	nn||factor-13/NN||risk-12/NN	nsubjpass||raised-17/VBN||factor-13/NN	vmod||factor-13/NN||contributing-14/VBG	advmod||contributing-14/VBG||most-15/RBS	auxpass||raised-17/VBN||was-16/VBD	parataxis||higher-4/JJR||raised-17/VBN	dobj||raised-17/VBN||cholesterol-18/NN	cholesterol-18||cvd-1||no_rel||cvd risk was higher in caucasians than other ethnicities; the risk factor contributing most was raised cholesterol.
advmod||lowest-111/JJS||nationally-1/RB	num||%-4/NN||32.0-3/CD	nsubj||lowest-111/JJS||%-4/NN	num||-RSB--12/NNS||95-6/CD	nn||-RSB--12/NNS||%-7/NN	nn||-RSB--12/NNS||confidence-8/NN	amod||-RSB--12/NNS||interval-9/JJ	amod||-RSB--12/NNS||-LSB--10/JJ	nn||-RSB--12/NNS||ci-11/NN	dep||%-4/NN||-RSB--12/NNS	amod||-RSB--12/NNS||=-13/VBN	number||%-18/NN||30.3-14/CD	dep||%-18/NN||%-15/NN	dep||%-18/NN||to-16/TO	number||%-18/NN||33.6-17/CD	dep||=-13/VBN||%-18/NN	prep_of||%-4/NN||girls-21/NNS	vmod||girls-21/NNS||aged-22/VBN	number||17-25/CD||13-23/CD	dep||17-25/CD||to-24/TO	num||years-26/NNS||17-25/CD	nsubj||received-30/VBN||years-26/NNS	prep_in||years-26/NNS||2010-28/CD	aux||received-30/VBN||had-29/VBD	dep||aged-22/VBN||received-30/VBN	num||doses-32/NNS||three-31/CD	dobj||received-30/VBN||doses-32/NNS	det||hpvvaccine-35/NN||the-34/DT	prep_of||doses-32/NNS||hpvvaccine-35/NN	nsubj||lower-42/JJR||coverage-38/NN	nsubj||lower-42/JJR||coverage-38/NN	cop||lower-42/JJR||was-39/VBD	advmod||lower-42/JJR||statistically-40/RB	advmod||lower-42/JJR||significantly-41/RB	dep||aged-22/VBN||lower-42/JJR	conj_and||received-30/VBN||lower-42/JJR	conj_and||received-30/VBN||lower-42/JJR	conj_and||lower-42/JJR||lower-42/JJR	det||uninsured-45/JJ||the-44/DT	prep_among||lower-42/JJR||uninsured-45/JJ	num||%-48/NN||14.1-47/CD	dep||uninsured-45/JJ||%-48/NN	num||%-51/NN||95-50/CD	appos||%-48/NN||%-51/NN	vmod||%-51/NN||ci-52/VBN	dep||%-55/NN||=-53/SYM	num||%-55/NN||9.4-54/CD	ccomp||ci-52/VBN||%-55/NN	num||%-58/NN||20.6-57/CD	prep_to||ci-52/VBN||%-58/NN	det||states-64/NNS||some-62/DT	amod||states-64/NNS||southern-63/JJ	prep_in||lower-42/JJR||states-64/NNS	dep||states-64/NNS||eg-66/NN	num||%-69/NN||20.0-68/CD	appos||eg-66/NN||%-69/NN	nn||-RSB--82/NNS||alabama-71/NNP	nn||-RSB--82/NNS||-LSB--72/NNP	number||%-74/NN||95-73/CD	amod||-RSB--82/NNS||%-74/NN	amod||-RSB--82/NNS||ci-75/JJ	amod||-RSB--82/NNS||=-76/VBN	number||%-81/NN||13.9-77/CD	dep||%-81/NN||%-78/NN	dep||%-81/NN||to-79/TO	number||%-81/NN||27.9-80/CD	num||-RSB--82/NNS||%-81/NN	prep_in||%-69/NN||-RSB--82/NNS	nn||-RSB--95/NNS||mississippi-84/NNP	nn||-RSB--95/NNS||-LSB--85/NNP	number||%-87/NN||95-86/CD	amod||-RSB--95/NNS||%-87/NN	amod||-RSB--95/NNS||ci-88/JJ	amod||-RSB--95/NNS||=-89/VBN	number||%-94/NN||13.8-90/CD	dep||%-94/NN||%-91/NN	dep||%-94/NN||to-92/TO	number||%-94/NN||28.2-93/CD	num||-RSB--95/NNS||%-94/NN	prep_in||%-69/NN||-RSB--95/NNS	conj_and||-RSB--82/NNS||-RSB--95/NNS	advmod||highest-103/JJS||where-98/WRB	amod||rates-101/NNS||cervical-99/JJ	nn||rates-101/NNS||cancer-100/NN	nsubj||highest-103/JJS||rates-101/NNS	cop||highest-103/JJS||were-102/VBD	advcl||lower-42/JJR||highest-103/JJS	amod||prevalence-108/NN||recent-105/JJ	nn||prevalence-108/NN||pap-106/NN	amod||prevalence-108/NN||testing-107/VBG	advcl||lower-42/JJR||prevalence-108/NN	conj_and||highest-103/JJS||prevalence-108/NN	cop||lowest-111/JJS||was-109/VBD	det||lowest-111/JJS||the-110/DT	root||ROOT-0/null||lowest-111/JJS	cancer-100||hpvvaccine-35||no_rel||nationally, 32.0% (95% confidence interval [ci] = 30.3% to 33.6%) of girls aged 13 to 17 years in 2010 had received three doses of the hpvvaccine, and coverage was statistically significantly lower among the uninsured (14.1%, 95% ci = 9.4% to 20.6%) and in some southern states (eg, 20.0% in alabama [95% ci = 13.9% to 27.9%] and mississippi [95% ci = 13.8% to 28.2%]), where cervical cancer rates were highest and recent pap testing prevalence was the lowest.
nn||treatment-3/NN||gancyclovir-2/NN	prep_following||went-11/VBD||treatment-3/NN	amod||viremia-7/NN||subsequent-5/JJ	nn||viremia-7/NN||cytomegalovirus-6/NNS	prep_of||treatment-3/NN||viremia-7/NN	det||patient-10/NN||the-9/DT	nsubj||went-11/VBD||patient-10/NN	nsubj||receive-14/VB||patient-10/NN	root||ROOT-0/null||went-11/VBD	prt||went-11/VBD||on-12/RP	aux||receive-14/VB||to-13/TO	xcomp||went-11/VBD||receive-14/VB	det||course-16/NN||a-15/DT	dobj||receive-14/VB||course-16/NN	prep_of||course-16/NN||epoch-18/NN	advmod||mg/m2/day-52/NN||etoposide-20/RB	num||mg/m2/day-22/NNS||50-21/CD	pobj||etoposide-20/RB||mg/m2/day-22/NNS	prep_on||etoposide-20/RB||days-24/NNS	amod||mg/m2/day-52/NN||1â-25/JJ	amod||mg/m2/day-52/NN||$-26/$	num||$-26/$||4-28/CD	amod||mg/m2/day-52/NN||vincristine-30/JJ	num||mg/m2/day-32/NNS||0.4-31/CD	dep||vincristine-30/JJ||mg/m2/day-32/NNS	prep_on||mg/m2/day-32/NNS||days-34/NNS	amod||mg/m2/day-52/NN||1â-35/JJ	amod||mg/m2/day-52/NN||$-36/$	num||$-36/$||4-38/CD	amod||mg/m2/day-52/NN||doxorubicin-40/JJ	num||mg/m2/day-42/NNS||10-41/CD	dep||doxorubicin-40/JJ||mg/m2/day-42/NNS	prep_on||mg/m2/day-42/NNS||days-44/NNS	amod||mg/m2/day-52/NN||1â-45/JJ	amod||mg/m2/day-52/NN||$-46/$	num||$-46/$||4-48/CD	amod||mg/m2/day-52/NN||cyclophosphamide-50/JJ	number||cyclophosphamide-50/JJ||750-51/CD	dep||epoch-18/NN||mg/m2/day-52/NN	prep_on||mg/m2/day-52/NN||day-54/NN	num||day-54/NN||6-55/CD	advmod||1â-63/JJ||prednisolone-58/RB	num||mg/m2/day-60/NNS||60-59/CD	pobj||prednisolone-58/RB||mg/m2/day-60/NNS	prep_on||prednisolone-58/RB||days-62/NNS	prep_on||mg/m2/day-52/NN||1â-63/JJ	conj_and||day-54/NN||1â-63/JJ	dep||1â-63/JJ||$-64/$	num||$-64/$||6-66/CD	cytomegalovirus-6||gancyclovir-2||yes||following gancyclovir treatment of subsequent cytomegalovirus viremia, the patient went on to receive a course of epoch (etoposide 50 mg/m2/day on days 1â€“4, vincristine 0.4 mg/m2/day on days 1â€“4, doxorubicin 10 mg/m2/day on days 1â€“4, cyclophosphamide 750 mg/m2/day on day 6, and prednisolone 60 mg/m2/day on days 1â€“6).
mwe||than-2/IN||more-1/JJR	quantmod||50-3/CD||than-2/IN	num||%-4/NN||50-3/CD	nsubj||ribavirin-25/VBZ||%-4/NN	amod||viruses-7/NNS||hepatitisc-6/JJ	prep_of||%-4/NN||viruses-7/NNS	appos||viruses-7/NNS||hcv-9/NN	amod||patients-13/NNS||infected-12/JJ	nsubj||respond-16/VB||patients-13/NNS	aux||respond-16/VB||do-14/VBP	neg||respond-16/VB||not-15/RB	parataxis||ribavirin-25/VBZ||respond-16/VB	det||interferon-20/NN||the-18/DT	amod||interferon-20/NN||classical-19/JJ	prep_to||respond-16/VB||interferon-20/NN	appos||interferon-20/NN||ifn-22/NN	punct||respond-16/VB||/-24/:	root||ROOT-0/null||ribavirin-25/VBZ	dep||ribavirin-25/VBZ||rbv-27/NN	nn||therapy-30/NN||combination-29/NN	dobj||ribavirin-25/VBZ||therapy-30/NN	hepatitisc-6||ifn-22||no_rel||more than 50% of hepatitisc viruses (hcv)-infected patients do not respond to the classical interferon (ifn)/ribavirin (rbv) combination therapy.
advmod||seen-15/VBN||irondeficiency-1/RB	nn||depletion-8/NN||anemia-3/NN	conj_and||depletion-8/NN||irondeficiencyanemia-5/NN	nsubjpass||seen-15/VBN||irondeficiencyanemia-5/NN	conj_and||depletion-8/NN||iron-7/NN	nsubjpass||seen-15/VBN||iron-7/NN	nsubjpass||seen-15/VBN||depletion-8/NN	conj_and||depletion-8/NN||lack-10/NN	nsubjpass||seen-15/VBN||lack-10/NN	nn||resources-13/NNS||iron-12/NN	prep_of||depletion-8/NN||resources-13/NNS	auxpass||seen-15/VBN||were-14/VBD	root||ROOT-0/null||seen-15/VBN	prep_in||seen-15/VBN||2.3-17/CD	prep_in||seen-15/VBN||4.08-19/CD	conj_and||2.3-17/CD||4.08-19/CD	prep_in||seen-15/VBN||2.14-21/CD	conj_and||2.3-17/CD||2.14-21/CD	prep_in||seen-15/VBN||22.76-23/NNP	conj_and||2.3-17/CD||22.76-23/NNP	amod||percent-26/NN||4.66-25/JJ	prep_in||seen-15/VBN||percent-26/NN	conj_and||2.3-17/CD||percent-26/NN	advmod||seen-15/VBN||respectively-27/RB	irondeficiencyanemia-5||iron-12||yes||irondeficiency, anemia, irondeficiencyanemia, iron depletion and lack of iron resources were seen in 2.3, 4.08, 2.14, 22.76 and 4.66 percent respectively.
nsubj||suggests-2/VBZ||this-1/DT	nsubj||oxidative-9/VBD||this-1/DT	root||ROOT-0/null||suggests-2/VBZ	det||normalization-4/NN||that-3/DT	dobj||suggests-2/VBZ||normalization-4/NN	nn||metabolism-7/NN||lipid-6/NN	prep_of||normalization-4/NN||metabolism-7/NN	conj_and/or||suggests-2/VBZ||oxidative-9/VBD	nn||status-11/NN||stress-10/NN	nsubj||represent-17/VB||status-11/NN	det||cortex-15/NN||the-13/DT	amod||cortex-15/NN||visual-14/JJ	prep_in||status-11/NN||cortex-15/NN	aux||represent-17/VB||may-16/MD	ccomp||oxidative-9/VBD||represent-17/VB	det||route-20/NN||a-18/DT	nn||route-20/NN||novel-19/NN	dobj||represent-17/VB||route-20/NN	prep_for||represent-17/VB||treatment-22/NN	amod||symptoms-25/NNS||non-motor-24/JJ	prep_of||treatment-22/NN||symptoms-25/NNS	amod||hallucinations-30/NNS||visual-29/JJ	prep_such_as||treatment-22/NN||hallucinations-30/NNS	nsubjpass||experienced-34/VBN||hallucinations-30/NNS	auxpass||experienced-34/VBN||are-33/VBP	rcmod||hallucinations-30/NNS||experienced-34/VBN	det||majority-37/NN||a-36/DT	agent||experienced-34/VBN||majority-37/NN	amod||patients-42/NNS||parkinson-39/JJ	nn||patients-42/NNS||sdisease-41/NN	prep_of||majority-37/NN||patients-42/NNS	lipid-6||parkinson'sdisease--1||no_rel||this suggests that normalization of lipid metabolism and/or oxidative stress status in the visual cortex may represent a novel route for treatment of non-motor symptoms, such as visual hallucinations, that are experienced by a majority of parkinson'sdisease patients.
nsubj||were-2/VBD||results-1/NNS	root||ROOT-0/null||were-2/VBD	prepc_compared_to||were-2/VBD||to-4/TO	num||principles-7/NNS||three-5/CD	nn||principles-7/NNS||programming-6/NN	pobj||were-2/VBD||principles-7/NNS	vmod||principles-7/NNS||drawn-8/VBN	prep_from||drawn-8/VBN||research-10/NN	amod||countries-14/NNS||high-12/JJ	nn||countries-14/NNS||prevalence-13/NN	prep_in||research-10/NN||countries-14/NNS	amod||efforts-17/NNS||family-centered-15/JJ	nn||efforts-17/NNS||preventive-16/NN	dobj||drawn-8/VBN||efforts-17/NNS	dobj||drawn-8/VBN||treatment-19/NN	conj_and||efforts-17/NNS||treatment-19/NN	dobj||drawn-8/VBN||care-22/VB	conj_and||efforts-17/NNS||care-22/VB	amod||support-25/NN||family-focused-24/JJ	dobj||drawn-8/VBN||support-25/NN	conj_and||efforts-17/NNS||support-25/NN	aux||ensure-27/VB||to-26/TO	vmod||support-25/NN||ensure-27/VB	dobj||ensure-27/VB||capacity-28/NN	aux||care-30/VB||to-29/TO	vmod||ensure-27/VB||care-30/VB	prep||care-30/VB||for-31/IN	vmod||ensure-27/VB||protect-33/VB	conj_and||care-30/VB||protect-33/VB	det||children-35/NNS||these-34/DT	dobj||protect-33/VB||children-35/NNS	amod||livelihood-40/NN||sustaining-38/VBN	amod||livelihood-40/NN||economic-39/JJ	dobj||drawn-8/VBN||livelihood-40/NN	conj_and||efforts-17/NNS||livelihood-40/NN	nn||households-45/NNS||hiv-42/NN	conj_and||hiv-42/NN||aids-affected-44/JJ	nn||households-45/NNS||aids-affected-44/JJ	prep_of||livelihood-40/NN||households-45/NNS	aids--1||hiv-42||no||results were compared to three programming principles drawn from research in high prevalence countries family-centered preventive efforts, treatment, and care; family-focused support to ensure capacity to care for and protect these children; and sustaining economic livelihood of hiv and aids-affected households.
poss||results-2/NNS||our-1/PRP$	nsubjpass||used-5/VBN||results-2/NNS	nsubj||help-11/VB||results-2/NNS	aux||used-5/VBN||can-3/MD	auxpass||used-5/VBN||be-4/VB	root||ROOT-0/null||used-5/VBN	agent||used-5/VBN||researchers-7/NNS	agent||used-5/VBN||policy-makers-9/NNS	conj_and||researchers-7/NNS||policy-makers-9/NNS	aux||help-11/VB||to-10/TO	xcomp||used-5/VBN||help-11/VB	xcomp||help-11/VB||inform-12/VB	dobj||inform-12/VB||them-13/PRP	det||efficacy-16/NN||the-15/DT	prep_of||inform-12/VB||efficacy-16/NN	amod||text-20/NN||mobile-18/JJ	nn||text-20/NN||phone-19/NN	prep_of||efficacy-16/NN||text-20/NN	vmod||text-20/NN||messaging-21/VBG	dobj||messaging-21/VBG||interventions-22/NNS	aux||promote-24/VB||to-23/TO	vmod||messaging-21/VBG||promote-24/VB	amod||adherence-26/NN||patient-25/JJ	dobj||promote-24/VB||adherence-26/NN	nn||treatment-29/NN||tb-28/NN	prep_to||promote-24/VB||treatment-29/NN	inform-12||tb-28||no_rel||our results can be used by researchers and policy-makers to help inform them of the efficacy of mobile phone text messaging interventions to promote patient adherence to tb treatment.
advmod||provided-8/VBN||moreover-1/RB	amod||information-4/NN||little-3/JJ	nsubjpass||provided-8/VBN||information-4/NN	prep_on||information-4/NN||hiv/aids-6/NNS	auxpass||provided-8/VBN||was-7/VBD	root||ROOT-0/null||provided-8/VBN	det||communities-11/NNS||the-10/DT	prep_to||provided-8/VBN||communities-11/NNS	advmod||have-15/VBP||so-12/RB	mark||have-15/VBP||that-13/IN	nsubj||have-15/VBP||we-14/PRP	advcl||provided-8/VBN||have-15/VBP	dobj||have-15/VBP||disadvantage-16/NN	amod||epidemic-20/NN||controlling-18/VBG	amod||epidemic-20/NN||hiv/aids-19/JJ	prep_of||disadvantage-16/NN||epidemic-20/NN	det||region-23/NN||the-22/DT	prep_in||epidemic-20/NN||region-23/NN	aids--1||hiv--1||no||moreover, little information on hiv/aids was provided to the communities so that we have disadvantage of controlling hiv/aids epidemic in the region.
nn||deficiency-2/NN||insulin-1/NN	nsubjpass||induced-6/VBN||deficiency-2/NN	conj_and||deficiency-2/NN||hyperglycemia-4/NN	nsubjpass||induced-6/VBN||hyperglycemia-4/NN	auxpass||induced-6/VBN||were-5/VBD	root||ROOT-0/null||induced-6/VBN	prep_with||induced-6/VBN||streptozotocin-8/NN	appos||streptozotocin-8/NN||stz-10/NN	amod||mice-16/NNS||c57bl/6-13/JJ	nn||mice-16/NNS||fxr-14/NN	nn||mice-16/NNS||ko-15/NN	prep_in||streptozotocin-8/NN||mice-16/NNS	hyperglycemia-4||streptozotocin-8||no_rel||insulin deficiency and hyperglycemia were induced with streptozotocin (stz) in c57bl/6 fxr ko mice.
det||extent-3/NN||the-2/DT	prep_to||suggests-26/VBZ||extent-3/NN	mark||mimics-11/VBZ||that-4/IN	det||nicotine-7/NN||the-5/DT	amod||nicotine-7/NN||combined-6/VBN	nsubj||mimics-11/VBZ||nicotine-7/NN	nn||sensitization-10/NN||pcp-9/NN	conj_and||nicotine-7/NN||sensitization-10/NN	nsubj||mimics-11/VBZ||sensitization-10/NN	dep||extent-3/NN||mimics-11/VBZ	amod||nicotineaddiction-13/NN||comorbid-12/JJ	dobj||mimics-11/VBZ||nicotineaddiction-13/NN	prep_in||nicotineaddiction-13/NN||schizophrenia-15/NN	det||effect-20/NN||the-17/DT	amod||effect-20/NN||preferential-18/JJ	nn||effect-20/NN||inhibitory-19/NN	nsubj||suggests-26/VBZ||effect-20/NN	prep_of||effect-20/NN||iptakalim-22/NN	amod||hyperlocomotion-25/NN||nicotine-induced-24/JJ	prep_on||iptakalim-22/NN||hyperlocomotion-25/NN	root||ROOT-0/null||suggests-26/VBZ	mark||drug-34/NN||that-27/IN	nsubj||drug-34/NN||iptakalim-28/NN	aux||drug-34/NN||may-29/MD	cop||drug-34/NN||be-30/VB	det||drug-34/NN||a-31/DT	amod||drug-34/NN||potential-32/JJ	amod||drug-34/NN||useful-33/JJ	ccomp||suggests-26/VBZ||drug-34/NN	det||abuse-39/NN||the-36/DT	nn||abuse-39/NN||treatment-37/NN	nn||abuse-39/NN||nicotine-38/NN	prep_for||drug-34/NN||abuse-39/NN	prep_in||abuse-39/NN||schizophrenia-41/NN	nicotineaddiction-13||nicotine-38||no||to the extent that the combined nicotine and pcp sensitization mimics comorbid nicotineaddiction in schizophrenia, the preferential inhibitory effect of iptakalim on nicotine-induced hyperlocomotion suggests that iptakalim may be a potential useful drug for the treatment nicotine abuse in schizophrenia.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	det||improvement-4/NN||the-3/DT	dobj||assess-2/VB||improvement-4/NN	prep_in||improvement-4/NN||psychopathology-6/NN	amod||schizophrenia-9/NN||treatment-resistant-8/JJ	prep_of||psychopathology-6/NN||schizophrenia-9/NN	amod||therapy-12/NN||clozapine-11/JJ	prep_with||assess-2/VB||therapy-12/NN	aux||study-15/VB||to-14/TO	conj_and||assess-2/VB||study-15/VB	det||relationship-17/NN||the-16/DT	dobj||study-15/VB||relationship-17/NN	amod||variables-23/NNS||sociodemographic-19/JJ	conj_and||sociodemographic-19/JJ||various-21/JJ	amod||variables-23/NNS||various-21/JJ	nn||variables-23/NNS||psychopathology-22/NN	prep_between||relationship-17/NN||variables-23/NNS	prep_among||study-15/VB||patients-25/NNS	amod||schizophrenia-28/NN||treatment-resistant-27/JJ	prep_with||patients-25/NNS||schizophrenia-28/NN	schizophrenia-28||clozapine-11||yes||to assess the improvement in psychopathology of treatment-resistant schizophrenia with clozapine therapy and to study the relationship between sociodemographic and various psychopathology variables among patients with treatment-resistant schizophrenia.
advmod||caused-24/VBD||indonesiaâ-1/RB	nsubj||decision-5/NN||$-2/$	num||$-2/$||™-3/CD	cop||decision-5/NN||s-4/VBZ	parataxis||caused-24/VBD||decision-5/NN	aux||withhold-7/VB||to-6/TO	vmod||decision-5/NN||withhold-7/VB	dobj||withhold-7/VB||samples-8/NNS	prep_of||samples-8/NNS||avianinfluenzavirus-10/NNS	det||h5n1-13/NNS||a-11/DT	nsubj||caused-24/VBD||h5n1-13/NNS	det||organization-19/NN||the-16/DT	nn||organization-19/NN||world-17/NN	nn||organization-19/NN||health-18/NN	prep_from||h5n1-13/NNS||organization-19/NN	prep||organization-19/NN||for-20/IN	pobj||for-20/IN||much-21/RB	prep_of||much-21/RB||2007-23/CD	root||ROOT-0/null||caused-24/VBD	det||crisis-26/NN||a-25/DT	dobj||caused-24/VBD||crisis-26/NN	amod||health-29/NN||global-28/JJ	prep_in||caused-24/VBD||health-29/NN	h5n1-13||avianinfluenzavirus-10||no||indonesiaâ€™s decision to withhold samples of avianinfluenzavirus a (h5n1) from the world health organization for much of 2007 caused a crisis in global health.
nsubj||agent-6/NN||francisellatularensis-1/NNS	nsubj||responsible-9/JJ||francisellatularensis-1/NNS	cop||agent-6/NN||is-2/VBZ	det||agent-6/NN||a-3/DT	amod||agent-6/NN||category-a-4/JJ	amod||agent-6/NN||select-5/JJ	root||ROOT-0/null||agent-6/NN	cop||responsible-9/JJ||is-8/VBZ	conj_and||agent-6/NN||responsible-9/JJ	prep_for||responsible-9/JJ||tularemia-11/NN	prep_in||responsible-9/JJ||humans-13/NNS	prep_in||responsible-9/JJ||animals-15/NNS	conj_and||humans-13/NNS||animals-15/NNS	tularemia-11||francisellatularensis-1||no||francisellatularensis is a category-a select agent and is responsible for tularemia in humans and animals.
nsubj||conclude-2/VBP||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	mark||reduces-5/VBZ||that-3/IN	nsubj||reduces-5/VBZ||dha-4/NN	ccomp||conclude-2/VBP||reduces-5/VBZ	det||ability-7/NN||the-6/DT	dobj||reduces-5/VBZ||ability-7/NN	nsubj||control-13/VB||ability-7/NN	num||cells-11/NNS||j774a-9/CD	num||cells-11/NNS||.1-10/CD	prep_of||ability-7/NN||cells-11/NNS	aux||control-13/VB||to-12/TO	xcomp||reduces-5/VBZ||control-13/VB	dobj||control-13/VB||m.tuberculosis-14/NNS	prep_in||m.tuberculosis-14/NNS||response-16/NN	prep_to||control-13/VB||activation-18/NN	nn||³-21/NNP||ifnî-20/NNP	prep_by||control-13/VB||³-21/NNP	prep_by||control-13/VB||modulation-24/NN	amod||signaling-29/NNS||ifnî-26/JJ	amod||signaling-29/NNS||³-27/JJ	nn||signaling-29/NNS||receptor-28/NN	prep_of||modulation-24/NN||signaling-29/NNS	prep_of||modulation-24/NN||function-31/NN	conj_and||signaling-29/NNS||function-31/NN	vmod||control-13/VB||suggesting-33/VBG	mark||have-38/VB||that-34/IN	amod||diets-36/NNS||n-3pufa-enriched-35/JJ	nsubj||have-38/VB||diets-36/NNS	aux||have-38/VB||may-37/MD	ccomp||suggesting-33/VBG||have-38/VB	det||effect-41/NN||a-39/DT	amod||effect-41/NN||detrimental-40/JJ	dobj||have-38/VB||effect-41/NN	nn||immunity-44/NN||host-43/NN	prep_on||effect-41/NN||immunity-44/NN	prep_to||have-38/VB||tuberculosis-46/NNP	tuberculosis-46||m.tuberculosis-14||no||we conclude that dha reduces the ability of j774a .1 cells to control m.tuberculosis in response to activation by ifnî ³ , by modulation of ifnî ³ receptor signaling and function , suggesting that n-3pufa-enriched diets may have a detrimental effect on host immunity to tuberculosis .
det||treatment-3/NN||the-1/DT	amod||treatment-3/NN||lidocaine-2/JJ	nsubj||decreased-7/VBD||treatment-3/NN	vmod||treatment-3/NN||resulted-4/VBN	prep||resulted-4/VBN||in-5/IN	pcomp||in-5/IN||significantly-6/RB	root||ROOT-0/null||decreased-7/VBD	nn||activity-9/NN||brain-8/NN	dobj||decreased-7/VBD||activity-9/NN	det||groups-13/NNS||both-11/DT	amod||groups-13/NNS||patient-12/JJ	prep_in||decreased-7/VBD||groups-13/NNS	amod||regions-17/NNS||distinct-15/JJ	nn||regions-17/NNS||brain-16/NN	prep_with||decreased-7/VBD||regions-17/NNS	vmod||regions-17/NNS||responding-18/VBG	det||group-21/NN||each-20/DT	prep_in||responding-18/VBG||group-21/NN	nsubjpass||correlated-29/VBN||sub-regions-24/NNS	det||areas-27/NNS||these-26/DT	prep_within||sub-regions-24/NNS||areas-27/NNS	auxpass||correlated-29/VBN||were-28/VBD	conj_and||decreased-7/VBD||correlated-29/VBN	nn||ratings-32/NNS||pain-31/NN	prep_with||correlated-29/VBN||ratings-32/NNS	advmod||correlated-29/VBN||specifically-33/RB	det||group-36/NN||each-35/DT	prep_for||correlated-29/VBN||group-36/NN	amod||cortex-40/NN||medial-38/JJ	amod||cortex-40/NN||prefrontal-39/JJ	dep||group-36/NN||cortex-40/NN	prep_in||cortex-40/NN||cbp-42/NN	prep_in||cortex-40/NN||thalamus-44/NNS	conj_and||cbp-42/NN||thalamus-44/NNS	prep_in||cortex-40/NN||oa-46/NN	pain-31||lidocaine-2||yes||the lidocaine treatment resulted in significantly decreased brain activity in both patient groups with distinct brain regions responding in each group, and sub-regions within these areas were correlated with pain ratings specifically for each group (medial prefrontal cortex in cbp and thalamus in oa).
aux||understand-3/VB||to-1/TO	advmod||understand-3/VB||better-2/RBR	dep||examined-12/VBD||understand-3/VB	det||role-5/NN||the-4/DT	dobj||understand-3/VB||role-5/NN	prep_of||role-5/NN||pd-1-7/JJ	amod||immunity-10/NN||antiviral-9/JJ	prep_in||pd-1-7/JJ||immunity-10/NN	nsubj||examined-12/VBD||we-11/PRP	root||ROOT-0/null||examined-12/VBD	det||expression-14/NN||the-13/DT	dobj||examined-12/VBD||expression-14/NN	amod||cells-26/NNS||pd-1-16/JJ	amod||+-24/NNS||epstein-barrvirus-18/JJ	appos||+-24/NNS||ebv-20/NN	amod||+-24/NNS||epitope-specific-22/JJ	num||+-24/NNS||cd8-23/CD	prep_on||pd-1-16/JJ||+-24/NNS	nn||cells-26/NNS||t-25/NN	prep_of||expression-14/NN||cells-26/NNS	amod||infectiousmononucleosis-29/NNS||acute-28/JJ	prep_during||examined-12/VBD||infectiousmononucleosis-29/NNS	appos||infectiousmononucleosis-29/NNS||aim-31/NN	prep_during||examined-12/VBD||convalescence-34/NN	conj_and||infectiousmononucleosis-29/NNS||convalescence-34/NN	infectiousmononucleosis-29||epstein-barrvirus-18||no||to better understand the role of pd-1 in antiviral immunity we examined the expression of pd-1 on epstein-barrvirus (ebv) epitope-specific cd8+ t cells during acute infectiousmononucleosis (aim) and convalescence.
mark||analyze-4/VB||in-1/IN	dep||analyze-4/VB||order-2/NN	aux||analyze-4/VB||to-3/TO	advcl||studied-19/VBD||analyze-4/VB	amod||cells-6/NNS||dendritic-5/JJ	dobj||analyze-4/VB||cells-6/NNS	appos||cells-6/NNS||dcs-8/NN	vmod||cells-6/NNS||activation-10/VBN	prep_following||activation-10/VBN||infection-12/NN	amod||strains-16/NNS||different-14/JJ	amod||strains-16/NNS||mycobacterial-15/JJ	prep_with||infection-12/NN||strains-16/NNS	nsubj||studied-19/VBD||we-18/PRP	ccomp||mycobacteriumtuberculosis-36/VBZ||studied-19/VBD	det||profiles-22/NNS||the-20/DT	nn||profiles-22/NNS||expression-21/NN	dobj||studied-19/VBD||profiles-22/NNS	num||genes-25/NNS||165-24/CD	prep_of||profiles-22/NNS||genes-25/NNS	amod||dcs-29/NN||human-27/JJ	amod||dcs-29/NN||monocyte-derived-28/JJ	prep_of||genes-25/NNS||dcs-29/NN	vmod||dcs-29/NN||infected-30/VBN	prep_with||infected-30/VBN||h37rv-32/CD	det||virulent-35/NN||a-34/DT	nsubj||mycobacteriumtuberculosis-36/VBZ||virulent-35/NN	root||ROOT-0/null||mycobacteriumtuberculosis-36/VBZ	dep||mycobacteriumtuberculosis-36/VBZ||mtb-38/NN	nn||strain-41/NN||laboratory-40/NN	dobj||mycobacteriumtuberculosis-36/VBZ||strain-41/NN	dobj||mycobacteriumtuberculosis-36/VBZ||cmt97-43/NNS	conj_and||strain-41/NN||cmt97-43/NNS	det||isolate-48/NN||a-45/DT	amod||isolate-48/NN||clinical-46/JJ	nn||isolate-48/NN||mtb-47/NN	dobj||mycobacteriumtuberculosis-36/VBZ||isolate-48/NN	conj_and||strain-41/NN||isolate-48/NN	amod||bacillus-51/NNS||mycobacteriumbovis-50/JJ	dobj||mycobacteriumtuberculosis-36/VBZ||bacillus-51/NNS	conj_and||strain-41/NN||bacillus-51/NNS	nn||rin-54/NNP||calmette-guã-52/NNP	nn||rin-54/NNP||©-53/NNP	dep||bacillus-51/NNS||rin-54/NNP	appos||rin-54/NNP||bcg-56/NN	amod||pasteur-60/NN||aventis-59/JJ	dobj||mycobacteriumtuberculosis-36/VBZ||pasteur-60/NN	conj_and||strain-41/NN||pasteur-60/NN	nn||japan-64/NN||bcg-63/NN	dobj||mycobacteriumtuberculosis-36/VBZ||japan-64/NN	conj_and||strain-41/NN||japan-64/NN	nsubj||employed-67/VBN||both-66/DT	rcmod||japan-64/NN||employed-67/VBN	prep_as||employed-67/VBN||vaccine-69/NN	prep_against||vaccine-69/NN||tuberculosis-71/NNP	tuberculosis-71||mtb-47||no||in order to analyze dendritic cells (dcs) activation following infection with different mycobacterial strains, we studied the expression profiles of 165 genes of human monocyte-derived dcs infected with h37rv, a virulent mycobacteriumtuberculosis (mtb) laboratory strain, cmt97, a clinical mtb isolate, mycobacteriumbovis bacillus calmette-guã©rin (bcg), aventis pasteur, and bcg japan, both employed as vaccine against tuberculosis.
det||physician-traveler-3/NN||an-1/DT	nn||physician-traveler-3/NN||american-2/NN	nsubj||presented-7/VBD||physician-traveler-3/NN	nsubjpass||treated-15/VBN||physician-traveler-3/NN	amod||africa-6/NN||east-5/JJ	prep_to||physician-traveler-3/NN||africa-6/NN	root||ROOT-0/null||presented-7/VBD	prep_with||presented-7/VBD||manifestations-9/NNS	amod||malaria-12/NN||cerebral-11/JJ	prep_of||manifestations-9/NNS||malaria-12/NN	auxpass||treated-15/VBN||was-14/VBD	conj_and||presented-7/VBD||treated-15/VBN	amod||quinidine-18/NN||intravenous-17/JJ	prep_with||treated-15/VBN||quinidine-18/NN	amod||falciparummalaria-21/NN||chloroquine-resistant-20/JJ	prep_for||quinidine-18/NN||falciparummalaria-21/NN	falciparummalaria-21||quinidine-18||yes||an american physician-traveler to east africa presented with manifestations of cerebral malaria and was treated with intravenous quinidine for chloroquine-resistant falciparummalaria.
nsubj||reported-6/VBD||none-1/NN	det||other-4/JJ||the-3/DT	prep_of||none-1/NN||other-4/JJ	advmod||reported-6/VBD||previously-5/RB	root||ROOT-0/null||reported-6/VBD	nsubjpass||associated-9/VBN||snps-7/NNS	auxpass||associated-9/VBN||were-8/VBD	ccomp||reported-6/VBD||associated-9/VBN	prep_with||associated-9/VBN||type2diabetes-11/CD	advmod||found-17/VBN||however-13/RB	nsubjpass||found-17/VBN||associations-15/NNS	auxpass||found-17/VBN||were-16/VBD	parataxis||reported-6/VBD||found-17/VBN	amod||variants-22/NNS||cdkal1-19/JJ	conj_and||cdkal1-19/JJ||hhex-21/JJ	amod||variants-22/NNS||hhex-21/JJ	prep_between||found-17/VBN||variants-22/NNS	amod||response-26/NN||acute-24/JJ	nn||response-26/NN||insulin-25/NN	prep_between||found-17/VBN||response-26/NN	conj_and||variants-22/NNS||response-26/NN	appos||response-26/NN||air-28/NN	advmod||associated-39/VBN||where-31/WRB	det||alleles-35/NNS||the-32/DT	amod||alleles-35/NNS||caucasian-33/JJ	nn||alleles-35/NNS||risk-34/NN	nsubjpass||associated-39/VBN||alleles-35/NNS	prep_for||alleles-35/NNS||type2diabetes-37/CD	auxpass||associated-39/VBN||were-38/VBD	rcmod||response-26/NN||associated-39/VBN	amod||secretion-43/NN||reduced-41/VBN	nn||secretion-43/NN||insulin-42/NN	prep_with||associated-39/VBN||secretion-43/NN	amod||indians-47/NNS||normoglycemic-45/JJ	nn||indians-47/NNS||pima-46/NN	prep_in||secretion-43/NN||indians-47/NNS	type2diabetes-37||insulin-42||yes||none of the other previously reported snps were associated with type2diabetes; however, associations were found between cdkal1 and hhex variants and acute insulin response (air), where the caucasian risk alleles for type2diabetes were associated with reduced insulin secretion in normoglycemic pima indians.
det||woman-3/NN||a-1/DT	amod||woman-3/NN||73-year-old-2/JJ	nsubjpass||given-7/VBN||woman-3/NN	prep_with||woman-3/NN||dementia-5/NN	auxpass||given-7/VBN||was-6/VBD	root||ROOT-0/null||given-7/VBN	acomp||given-7/VBN||clozapine-8/JJ	amod||symptoms-12/NNS||treatment-resistant-10/JJ	amod||symptoms-12/NNS||psychotic-11/JJ	prep_for||given-7/VBN||symptoms-12/NNS	psychotic-11||clozapine-8||yes||a 73-year-old woman with dementia was given clozapine for treatment-resistant psychotic symptoms.
advmod||essential-10/JJ||therefore-1/RB	amod||identification-6/NN||rapid-3/JJ	conj_and||rapid-3/JJ||accurate-5/JJ	amod||identification-6/NN||accurate-5/JJ	nsubj||essential-10/JJ||identification-6/NN	prep_of||identification-6/NN||salmonella-8/NN	cop||essential-10/JJ||is-9/VBZ	root||ROOT-0/null||essential-10/JJ	amod||diagnosis-15/NN||timely-12/JJ	conj_and||timely-12/JJ||correct-14/JJ	amod||diagnosis-15/NN||correct-14/JJ	prep_for||essential-10/JJ||diagnosis-15/NN	prep_of||diagnosis-15/NN||salmonellainfections-17/NNS	salmonellainfections-17||salmonella-8||no||therefore, rapid and accurate identification of salmonella is essential for timely and correct diagnosis of salmonellainfections.
poss||study-4/NN||our-2/PRP$	amod||study-4/NN||recent-3/JJ	prep_in||determined-7/VBD||study-4/NN	nsubj||determined-7/VBD||we-6/PRP	root||ROOT-0/null||determined-7/VBD	det||value-10/NN||the-8/DT	amod||value-10/NN||cut-off-9/JJ	dobj||determined-7/VBD||value-10/NN	amod||expression-13/NN||cd20-12/JJ	prep_of||value-10/NN||expression-13/NN	det||level-16/NN||the-15/DT	prep_at||determined-7/VBD||level-16/NN	number||000-19/CD||25-18/CD	num||molecules-20/NNS||000-19/CD	prep_of||level-16/NN||molecules-20/NNS	amod||soluble-23/JJ||equivalent-22/JJ	amod||fluorochrome-24/NN||soluble-23/JJ	prep_of||molecules-20/NNS||fluorochrome-24/NN	appos||fluorochrome-24/NN||mesf-26/NN	aux||predictor-31/NN||to-28/TO	cop||predictor-31/NN||be-29/VB	det||predictor-31/NN||the-30/DT	vmod||determined-7/VBD||predictor-31/NN	prep_of||predictor-31/NN||response-33/NN	aux||rituximab-35/VB||to-34/TO	vmod||predictor-31/NN||rituximab-35/VB	xcomp||rituximab-35/VB||containing-36/VBG	dobj||containing-36/VBG||treatment-37/NN	prep_in||containing-36/VBG||patients-39/NNS	prep_with||patients-39/NNS||b-celllymphomas-41/NNS	b-celllymphomas-41||rituximab-35||yes||in our recent study, we determined the cut-off value of cd20 expression at the level of 25 000 molecules of equivalent soluble fluorochrome (mesf) to be the predictor of response to rituximab containing treatment in patients with b-celllymphomas.
mark||developed-6/VBN||although-1/IN	amod||tools-3/NNS||many-2/JJ	nsubjpass||developed-6/VBN||tools-3/NNS	aux||developed-6/VBN||have-4/VBP	auxpass||developed-6/VBN||been-5/VBN	advcl||occur-19/VB||developed-6/VBN	det||diagnosis-9/NN||the-8/DT	prep_for||developed-6/VBN||diagnosis-9/NN	prep_of||diagnosis-9/NN||sars-11/NNS	amod||reactions-14/NNS||false-positive-13/JJ	nsubj||occur-19/VB||reactions-14/NNS	amod||sera-17/NN||negative-16/JJ	prep_in||reactions-14/NNS||sera-17/NN	aux||occur-19/VB||may-18/MD	root||ROOT-0/null||occur-19/VB	prep_because_of||occur-19/VB||cross-reactivity-22/NN	amod||coronaviruses-25/NNS||other-24/JJ	prep_with||cross-reactivity-22/NN||coronaviruses-25/NNS	sars-11||coronaviruses-25||no||although many tools have been developed for the diagnosis of sars, false-positive reactions in negative sera may occur because of cross-reactivity with other coronaviruses.
preconj||loss-3/NN||both-1/DT	nn||loss-3/NN||weight-2/NN	nsubj||vldlâ-31/VBD||loss-3/NN	conj_and||loss-3/NN||ezetimibe-5/NN	nsubj||vldlâ-31/VBD||ezetimibe-5/NN	nn||loss-8/NN||weight-7/NN	conj_plus||loss-3/NN||loss-8/NN	nsubj||vldlâ-31/VBD||loss-8/NN	advmod||loss-3/NN||significantly-9/RB	det||p-12/NN||all-11/DT	nsubj||<-13/VBZ||p-12/NN	parataxis||vldlâ-31/VBD||<-13/VBZ	dobj||<-13/VBZ||0.05-14/CD	amod||tissues-24/NNS||reduced-16/JJ	nn||tissues-24/NNS||body-17/NN	nn||visceral-20/NN||weight-18/NN	nn||tissues-24/NNS||visceral-20/NN	conj_and||visceral-20/NN||subcutaneous-22/JJ	nn||tissues-24/NNS||subcutaneous-22/JJ	nn||tissues-24/NNS||adipose-23/NN	nsubj||vldlâ-31/VBD||tissues-24/NNS	nn||triglycerides-29/NNS||insulinresistance-26/NN	conj_and||insulinresistance-26/NN||plasma-28/NN	nn||triglycerides-29/NNS||plasma-28/NN	appos||tissues-24/NNS||triglycerides-29/NNS	root||ROOT-0/null||vldlâ-31/VBD	dobj||vldlâ-31/VBD||$-32/$	nn||fetuin-a-38/NN||apob-100-34/NNP	appos||fetuin-a-38/NN||apoc-iii-36/NNP	npadvmod||plasma-45/RB||fetuin-a-38/NN	dep||protein-4-42/JJ||retinol-binding-41/RB	dep||fetuin-a-38/NN||protein-4-42/JJ	dep||fetuin-a-38/NN||increased-44/JJ	conj_and||protein-4-42/JJ||increased-44/JJ	dep||adiponectin-46/CD||plasma-45/RB	num||$-32/$||adiponectin-46/CD	advmod||vldlâ-31/VBD||concentrations-47/RB	ezetimibe-5||insulinresistance-26||no_rel||both weight loss and ezetimibe plus weight loss significantly (all p < 0.05) reduced body weight, visceral and subcutaneous adipose tissues, insulinresistance and plasma triglycerides, vldlâ€“apob-100, apoc-iii, fetuin-a, and retinol-binding protein-4 and increased plasma adiponectin concentrations.
nsubj||observed-27/VBD||dyspnoea-1/NN	vmod||dyspnoea-1/NN||developed-2/VBN	mark||progressed-6/VBD||as-3/IN	nn||injury-5/NN||liver-4/NN	nsubj||progressed-6/VBD||injury-5/NN	advcl||developed-2/VBN||progressed-6/VBD	det||resistance-12/NN||the-8/DT	amod||resistance-12/NN||increased-9/VBN	amod||resistance-12/NN||pulmonary-10/JJ	nn||resistance-12/NN||vascular-11/NN	conj_and||dyspnoea-1/NN||resistance-12/NN	nsubj||observed-27/VBD||resistance-12/NN	npadvmod||+-15/JJ||636-14/CD	dep||resistance-12/NN||+-15/JJ	punct||+-15/JJ||/-16/:	num||vs-19/NN||95-18/CD	dep||+-15/JJ||vs-19/NN	num||/-22/NNS||301-20/CD	amod||/-22/NNS||+-21/JJ	dep||vs-19/NN||/-22/NNS	amod||mpa/s/m3-25/NNS||26.9-24/JJ	dep||/-22/NNS||mpa/s/m3-25/NNS	root||ROOT-0/null||observed-27/VBD	aux||reflect-29/VB||may-28/MD	ccomp||observed-27/VBD||reflect-29/VB	det||development-31/NN||the-30/DT	dobj||reflect-29/VB||development-31/NN	prep_of||development-31/NN||respiratorydistresssyndrome-33/NN	mpa--1||respiratorydistresssyndrome-33||no_rel||dyspnoea developed as liver injury progressed and the increased pulmonary vascular resistance (636 +/- 95 vs 301 +/- 26.9 mpa/s/m3) observed may reflect the development of respiratorydistresssyndrome.
nsubj||displayed-6/VBD||replacement-1/NN	prep_of||replacement-1/NN||lamivudine-3/NN	prep_by||lamivudine-3/NN||adefovir-5/NN	root||ROOT-0/null||displayed-6/VBD	neg||advantage-8/NN||no-7/DT	dobj||displayed-6/VBD||advantage-8/NN	det||lack-11/NN||the-10/DT	prep_despite||displayed-6/VBD||lack-11/NN	nn||mutations-14/NNS||resistance-13/NN	prep_of||lack-11/NN||mutations-14/NNS	advmod||displayed-6/VBD||thus-16/RB	neg||decrease-18/NN||no-17/DT	nsubjpass||observed-22/VBN||decrease-18/NN	prep_in||decrease-18/NN||viremia-20/NN	auxpass||observed-22/VBN||was-21/VBD	parataxis||displayed-6/VBD||observed-22/VBN	nn||treatment-25/NN||adefovir-24/NN	prep_under||observed-22/VBN||treatment-25/NN	viremia-20||adefovir-24||no_rel||replacement of lamivudine by adefovir displayed no advantage despite the lack of resistance mutations, thus no decrease in viremia was observed under adefovir treatment.
nsubj||bacterialinfection-5/NN||scrubtyphus-1/NNS	cop||bacterialinfection-5/NN||is-2/VBZ	det||bacterialinfection-5/NN||a-3/DT	amod||bacterialinfection-5/NN||mite-borne-4/JJ	root||ROOT-0/null||bacterialinfection-5/NN	prep_of||bacterialinfection-5/NN||humans-7/NNS	vmod||humans-7/NNS||caused-8/VBN	agent||caused-8/VBN||orientiatsutsugamushi-10/NNS	nsubj||causes-12/VBZ||orientiatsutsugamushi-10/NNS	rcmod||orientiatsutsugamushi-10/NNS||causes-12/VBZ	det||vasculitis-15/NNS||a-13/DT	amod||vasculitis-15/NNS||generalized-14/JJ	dobj||causes-12/VBZ||vasculitis-15/NNS	nsubj||involve-18/VB||vasculitis-15/NNS	aux||involve-18/VB||may-17/MD	rcmod||vasculitis-15/NNS||involve-18/VB	det||tissues-20/NNS||the-19/DT	dobj||involve-18/VB||tissues-20/NNS	det||system-24/NN||any-22/DT	nn||system-24/NN||organ-23/NN	prep_of||tissues-20/NNS||system-24/NN	scrubtyphus-1||orientiatsutsugamushi-10||no||scrubtyphus is a mite-borne bacterialinfection of humans caused by orientiatsutsugamushi that causes a generalized vasculitis that may involve the tissues of any organ system.
det||model-2/NN||the-1/DT	nsubj||predicts-3/VBZ||model-2/NN	root||ROOT-0/null||predicts-3/VBZ	mark||cost-effective-7/JJ||that-4/IN	nsubj||cost-effective-7/JJ||it-5/PRP	nsubj||keep-9/VB||it-5/PRP	cop||cost-effective-7/JJ||is-6/VBZ	ccomp||predicts-3/VBZ||cost-effective-7/JJ	aux||keep-9/VB||to-8/TO	xcomp||cost-effective-7/JJ||keep-9/VB	det||patient-11/NN||a-10/DT	dobj||keep-9/VB||patient-11/NN	prep_with||keep-9/VB||schizophrenia-13/NN	prep_in||schizophrenia-13/NN||germany-15/NN	amod||risperidone-18/NN||branded-17/JJ	prep_on||keep-9/VB||risperidone-18/NN	prepc_instead_of||risperidone-18/NN||switching-21/VBG	dobj||switching-21/VBG||him/her-22/NN	amod||risperidone-25/NN||generic-24/JJ	prep_to||switching-21/VBG||risperidone-25/NN	dep||risperidone-25/NN||assuming-27/VBG	det||reduction-31/NN||a-28/DT	number||%-30/NN||40-29/CD	amod||reduction-31/NN||%-30/NN	dobj||assuming-27/VBG||reduction-31/NN	nn||costs-34/NNS||medication-33/NN	prep_in||reduction-31/NN||costs-34/NNS	mark||exceeds-47/VBZ||if-37/IN	det||probability-40/NN||the-38/DT	amod||probability-40/NN||incremental-39/JJ	nsubj||exceeds-47/VBZ||probability-40/NN	prepc_of||probability-40/NN||becoming-42/VBG	xcomp||becoming-42/VBG||non-compliant-43/NN	amod||substitution-46/NN||generic-45/JJ	prep_after||becoming-42/VBG||substitution-46/NN	advcl||cost-effective-7/JJ||exceeds-47/VBZ	num||%-49/NN||5.2-48/CD	dobj||exceeds-47/VBZ||%-49/NN	schizophrenia-13||risperidone-25||yes||the model predicts that it is cost-effective to keep a patient with schizophrenia in germany on branded risperidone instead of switching him/her to generic risperidone (assuming a 40% reduction in medication costs), if the incremental probability of becoming non-compliant after generic substitution exceeds 5.2%.
nsubjpass||treated-6/VBN||he-1/PRP	aux||treated-6/VBN||was-2/VBD	advmod||treated-6/VBN||also-3/RB	advmod||treated-6/VBN||concomitantly-4/RB	auxpass||treated-6/VBN||being-5/VBG	root||ROOT-0/null||treated-6/VBN	amod||infections-10/NNS||other-8/JJ	amod||infections-10/NNS||opportunistic-9/JJ	prep_for||treated-6/VBN||infections-10/NNS	amod||retinitis-16/NNS||cytomegalovirus-12/JJ	nn||retinitis-16/NNS||-lrb--13/NN	nn||retinitis-16/NNS||cmv-14/NN	nn||retinitis-16/NNS||-rrb--15/NN	prep_including||infections-10/NNS||retinitis-16/NNS	nn||foscarnet-19/NN||i.v.-18/NN	prep_with||retinitis-16/NNS||foscarnet-19/NN	quantmod||2-22/CD||almost-21/RB	num||months-23/NNS||2-22/CD	prep_for||foscarnet-19/NN||months-23/NNS	det||presentation-28/NN||the-26/DT	nn||presentation-28/NN||index-27/NN	prep_prior_to||months-23/NNS||presentation-28/NN	cmv-14||foscarnet-19||yes||he was also concomitantly being treated for other opportunistic infections including cytomegalovirus -lrb- cmv -rrb- retinitis with i.v. foscarnet for almost 2 months prior to the index presentation .
aux||compare-2/VB||to-1/TO	csubj||doublet-12/VBP||compare-2/VB	det||activity-4/NN||the-3/DT	dobj||compare-2/VB||activity-4/NN	dobj||compare-2/VB||toxicity-6/NN	conj_and||activity-4/NN||toxicity-6/NN	prep_of||activity-4/NN||docetaxel/carboplatin-8/NN	appos||docetaxel/carboplatin-8/NN||dc-10/NN	root||ROOT-0/null||doublet-12/VBP	amod||agent-15/NN||vs-13/JJ	amod||agent-15/NN||single-14/JJ	nsubj||docetaxel-16/VB||agent-15/NN	ccomp||doublet-12/VBP||docetaxel-16/VB	dep||treatment-22/NN||d-18/LS	amod||treatment-22/NN||as-20/IN	amod||treatment-22/NN||second-line-21/JJ	dobj||docetaxel-16/VB||treatment-22/NN	prep_in||treatment-22/NN||patients-24/NNS	amod||non-smallcelllungcancer-27/NN||advanced-26/VBN	prep_with||patients-24/NNS||non-smallcelllungcancer-27/NN	dep||treatment-22/NN||nsclc-29/JJ	non-smallcelllungcancer-27||docetaxel-16||yes||to compare the activity and toxicity of docetaxel/carboplatin (dc) doublet vs single agent docetaxel (d) as second-line treatment in patients with advanced non-smallcelllungcancer (nsclc).
prep_in||establishes-9/VBZ||conclusion-2/NN	det||cart-7/NN||the-4/DT	amod||cart-7/NN||nac-5-htr4-5/JJ	nn||cart-7/NN||/-6/NN	nsubj||establishes-9/VBZ||cart-7/NN	advmod||establishes-9/VBZ||pathway-8/RB	root||ROOT-0/null||establishes-9/VBZ	det||â-11/NN||a-10/DT	nsubj||suggesting-22/VBG||â-11/NN	amod||â-11/NN||$-12/$	dep||$-12/$||˜tight-13/JJ	dep||â-11/NN||junction-15/NN	prep_between||â-11/NN||anorexia-18/NN	prep_between||â-11/NN||hyperactivity-20/NN	conj_and||anorexia-18/NN||hyperactivity-20/NN	dep||establishes-9/VBZ||suggesting-22/VBG	det||existence-24/NN||the-23/DT	dobj||suggesting-22/VBG||existence-24/NN	det||unit-29/NN||a-26/DT	amod||functional-28/JJ||primary-27/JJ	amod||unit-29/NN||functional-28/JJ	prep_of||existence-24/NN||unit-29/NN	amod||unit-29/NN||susceptible-30/JJ	nn||overeating-33/NN||limit-32/NN	prep_to||susceptible-30/JJ||overeating-33/NN	vmod||unit-29/NN||associated-34/VBN	amod||rules-39/NNS||resting-36/JJ	amod||rules-39/NNS||following-37/JJ	nn||rules-39/NNS||homeostasis-38/NNS	prep_with||associated-34/VBN||rules-39/NNS	nac--1||anorexia-18||no_rel||in conclusion, the nac-5-htr4/cart pathway establishes a â€˜tight-junction' between anorexia and hyperactivity, suggesting the existence of a primary functional unit susceptible to limit overeating associated with resting following homeostasis rules.
nsubj||searched-2/VBD||we-1/PRP	root||ROOT-0/null||searched-2/VBD	ccomp||searched-2/VBD||medline-3/VB	ccomp||searched-2/VBD||pubmed-5/VB	conj_and||medline-3/VB||pubmed-5/VB	dobj||medline-3/VB||terms-6/NNS	nn||stage-9/NN||labour-8/NN	dep||terms-6/NNS||stage-9/NN	dep||stage-9/NN||third-11/JJ	dep||ergonovine-17/NN||ergonovine-15/JJ	dep||medline-3/VB||ergonovine-17/NN	amod||ergonovine-17/NN||tartrate-18/JJ	amod||ergonovine-17/NN||methylergonovine-20/JJ	conj_or||tartrate-18/JJ||methylergonovine-20/JJ	amod||ergonovine-17/NN||oxytocin-22/JJ	conj_or||tartrate-18/JJ||oxytocin-22/JJ	amod||ergonovine-17/NN||oxytocics-24/JJ	conj_or||tartrate-18/JJ||oxytocics-24/JJ	amod||ergonovine-17/NN||misoprostol-26/JJ	conj_or||tartrate-18/JJ||misoprostol-26/JJ	ccomp||searched-2/VBD||and-28/VB	conj_and||medline-3/VB||and-28/VB	parataxis||and-28/VB||postpartumhaemorrhage-30/VB	parataxis||and-28/VB||haemorrhage-32/VB	conj_or||postpartumhaemorrhage-30/VB||haemorrhage-32/VB	conj_and||medline-3/VB||cochrane-35/VB	conj_and||and-28/VB||cochrane-35/VB	dobj||and-28/VB||reviews-36/NNS	det||restriction-40/NN||any-38/DT	nn||restriction-40/NN||language-39/NN	prep_without||and-28/VB||restriction-40/NN	postpartumhaemorrhage-30||ergonovine-17||yes||we searched medline and pubmed terms (labour stage, third) and (ergonovine, ergonovine tartrate, methylergonovine, oxytocin, oxytocics or misoprostol) and (postpartumhaemorrhage or haemorrhage) and cochrane reviews without any language restriction.
nsubj||increased-8/VBD||offspring-1/NN	conj_negcc||offspring-1/NN||controls-5/NNS	nsubj||increased-8/VBD||controls-5/NNS	advmod||increased-8/VBD||significantly-7/RB	root||ROOT-0/null||increased-8/VBD	dobj||increased-8/VBD||isi-9/NN	prep_in||increased-8/VBD||response-11/NN	det||intervention-15/NN||an-13/DT	nn||intervention-15/NN||exercise-14/NN	prep_to||increased-8/VBD||intervention-15/NN	vmod||increased-8/VBD||indicating-17/VBG	mark||modulated-24/JJ||that-18/IN	nn||sensitivity-20/NN||insulin-19/NN	nsubj||modulated-24/JJ||sensitivity-20/NN	cop||modulated-24/JJ||is-21/VBZ	advmod||modulated-24/JJ||more-22/RBR	advmod||modulated-24/JJ||highly-23/RB	ccomp||indicating-17/VBG||modulated-24/JJ	amod||activity-27/NN||physical-26/JJ	prep_by||modulated-24/JJ||activity-27/NN	prep_in||activity-27/NN||daughters-29/NNS	prep_of||daughters-29/NNS||patients-31/NNS	prep_with||patients-31/NNS||type2diabetes-33/CD	dep||modulated-24/JJ||than-34/IN	prep_in||modulated-24/JJ||women-36/NNS	neg||history-40/NN||no-38/DT	nn||history-40/NN||family-39/NN	prep_with||women-36/NNS||history-40/NN	det||disease-43/NN||the-42/DT	prep_of||history-40/NN||disease-43/NN	type2diabetes-33||insulin-19||yes||offspring, but not controls, significantly increased isi in response to an exercise intervention, indicating that insulin sensitivity is more highly modulated by physical activity in daughters of patients with type2diabetes than in women with no family history of the disease.
det||study-4/NN||a-1/DT	amod||study-4/NN||cross-2/JJ	amod||study-4/NN||sectional-3/JJ	root||ROOT-0/null||study-4/NN	amod||women-7/NNS||hivpositive-6/JJ	prep_of||study-4/NN||women-7/NNS	vmod||study-4/NN||attending-8/VBG	det||centre-13/NN||a-9/DT	amod||centre-13/NN||large-10/JJ	nn||centre-13/NN||hiv-11/NN	nn||centre-13/NN||treatment-12/NN	dobj||attending-8/VBG||centre-13/NN	prep_in||centre-13/NN||lagos-15/NNS	appos||lagos-15/NNS||nigeria-17/NN	hivpositive-6||hiv-11||no||a cross sectional study of hivpositive women attending a large hiv treatment centre in lagos, nigeria.
amod||measures-3/NNS||secondary-1/JJ	nn||measures-3/NNS||outcome-2/NN	nsubj||included-4/VBD||measures-3/NNS	root||ROOT-0/null||included-4/VBD	dobj||included-4/VBD||opioids-5/NNS	nn||use-8/NN||alcohol-7/NN	dobj||included-4/VBD||use-8/NN	conj_and||opioids-5/NNS||use-8/NN	prepc_according_to||included-4/VBD||to-10/TO	pobj||included-4/VBD||urinalysis-11/NNS	amod||ratings-14/NNS||self-report-13/JJ	nsubj||measured-30/VBN||ratings-14/NNS	appos||ratings-14/NNS||intensity-16/NN	amod||craving-19/NN||opioid-18/JJ	prep_of||intensity-16/NN||craving-19/NN	vmod||craving-19/NN||assessed-20/VBN	det||scale-25/NN||a-22/DT	amod||scale-25/NN||visual-23/JJ	amod||scale-25/NN||analogue-24/JJ	prep_with||assessed-20/VBN||scale-25/NN	amod||symptoms-28/NNS||opioidwithdrawal-27/JJ	npadvmod||as-29/RB||symptoms-28/NNS	advmod||measured-30/VBN||as-29/RB	conj_and||included-4/VBD||measured-30/VBN	det||scale-36/NN||the-32/DT	amod||scale-36/NN||short-33/JJ	amod||scale-36/NN||opiate-34/JJ	nn||scale-36/NN||withdrawal-35/NN	prep_by||measured-30/VBN||scale-36/NN	nn||scores-39/NNS||depression-38/NN	prep_by||measured-30/VBN||scores-39/NNS	conj_and||scale-36/NN||scores-39/NNS	det||inventory-43/NN||the-41/DT	nn||inventory-43/NN||hamilton-42/NN	prep_on||measured-30/VBN||inventory-43/NN	opioidwithdrawal-27||opioids-5||no||secondary outcome measures included opioids and alcohol use according to urinalysis and self-report ratings, intensity of opioid craving assessed with a visual analogue scale, opioidwithdrawal symptoms as measured by the short opiate withdrawal scale and depression scores on the hamilton inventory.
nn||pain-2/NN||chest-1/NN	nsubj||symptom-7/NN||pain-2/NN	cop||symptom-7/NN||is-3/VBZ	det||symptom-7/NN||a-4/DT	amod||symptom-7/NN||common-5/JJ	amod||symptom-7/NN||presenting-6/JJ	root||ROOT-0/null||symptom-7/NN	nsubj||requires-16/VBZ||symptom-7/NN	nn||users-10/NNS||cocaine-9/NN	prep_of||symptom-7/NN||users-10/NNS	det||department-14/NN||the-12/DT	nn||department-14/NN||emergency-13/NN	prep_to||users-10/NNS||department-14/NN	rcmod||symptom-7/NN||requires-16/VBZ	det||work-19/NN||a-17/DT	amod||work-19/NN||thorough-18/JJ	dobj||requires-16/VBZ||work-19/NN	prt||requires-16/VBZ||up-20/RP	pain-2||cocaine-9||yes||chest pain is a common presenting symptom of cocaine users to the emergency department that requires a thorough work up.
det||study-2/NN||this-1/DT	nsubj||suggested-3/VBD||study-2/NN	root||ROOT-0/null||suggested-3/VBD	mark||maintain-11/VBP||that-4/IN	advmod||stable-7/JJ||most-5/RBS	advmod||stable-7/JJ||clinically-6/RB	amod||outpatients-8/NNS||stable-7/JJ	nsubj||maintain-11/VBP||outpatients-8/NNS	prep_with||outpatients-8/NNS||schizophrenia-10/NN	ccomp||suggested-3/VBD||maintain-11/VBP	poss||states-14/NNS||their-12/PRP$	nn||states-14/NNS||remission-13/NN	dobj||maintain-11/VBP||states-14/NNS	auxpass||switched-17/VBN||being-16/VBG	prepc_after||maintain-11/VBP||switched-17/VBN	aux||aripiprazole-19/VB||to-18/TO	xcomp||switched-17/VBN||aripiprazole-19/VB	amod||aggravation-24/NN||serious-22/JJ	nn||aggravation-24/NN||symptom-23/NN	prep_without||aripiprazole-19/VB||aggravation-24/NN	amod||events-27/NNS||adverse-26/JJ	prep_without||aripiprazole-19/VB||events-27/NNS	conj_and||aggravation-24/NN||events-27/NNS	det||course-30/NN||a-29/DT	prep_over||aripiprazole-19/VB||course-30/NN	num||weeks-33/NNS||26-32/CD	prep_of||course-30/NN||weeks-33/NNS	schizophrenia-10||aripiprazole-19||yes||this study suggested that most clinically stable outpatients with schizophrenia maintain their remission states after being switched to aripiprazole, without serious symptom aggravation and adverse events over a course of 26 weeks.
det||activities-3/NNS||the-1/DT	nn||activities-3/NNS||plasma-2/NN	nsubjpass||studied-37/VBN||activities-3/NNS	conj_and||activities-3/NNS||antigens-5/NNS	nsubjpass||studied-37/VBN||antigens-5/NNS	prep_of||activities-3/NNS||pai-1-7/NN	prep_of||activities-3/NNS||tpa-9/NN	conj_and||pai-1-7/NN||tpa-9/NN	det||levels-12/NNS||the-11/DT	conj_and||activities-3/NNS||levels-12/NNS	nsubjpass||studied-37/VBN||levels-12/NNS	det||complex-17/NN||the-14/DT	amod||complex-17/NN||tpa/pai-15/JJ	amod||complex-17/NN||-1-16/JJ	prep_of||levels-12/NNS||complex-17/NN	nn||insulin-22/NN||serum-21/NN	prep_of||levels-12/NNS||insulin-22/NN	conj_and||complex-17/NN||insulin-22/NN	prep_of||levels-12/NNS||parameter-24/NN	conj_and||complex-17/NN||parameter-24/NN	det||panel-29/NN||the-26/DT	amod||panel-29/NN||coronary-27/JJ	nn||panel-29/NN||risk-28/NN	prep_of||parameter-24/NN||panel-29/NN	nn||glucose-32/NN||plasma-31/NN	prep_of||levels-12/NNS||glucose-32/NN	conj_and||complex-17/NN||glucose-32/NN	amod||state-35/NN||fasting-34/JJ	prep_at||glucose-32/NN||state-35/NN	auxpass||studied-37/VBN||were-36/VBD	ccomp||subjects-61/VBZ||studied-37/VBN	number||t2d-40/CD||303-39/CD	num||subjects-41/NNS||t2d-40/CD	prep_in||studied-37/VBN||subjects-41/NNS	dep||subjects-41/NNS||227-43/VBN	prep_with||227-43/VBN||mets-45/NNS	prep_with||227-43/VBN||76-47/CD	conj_and||mets-45/NNS||76-47/CD	prep_without||227-43/VBN||mets-49/NNS	num||subjects-56/NNS||131-52/CD	amod||subjects-56/NNS||normal-53/JJ	amod||subjects-56/NNS||non-diabetic-54/JJ	amod||subjects-56/NNS||non-metabolic-55/JJ	nsubj||subjects-61/VBZ||subjects-56/NNS	num||mets-60/NNS||101-58/CD	amod||mets-60/NNS||non-diabetic-59/JJ	conj_and||subjects-56/NNS||mets-60/NNS	nsubj||subjects-61/VBZ||mets-60/NNS	root||ROOT-0/null||subjects-61/VBZ	t2d-40||insulin-22||yes||the plasma activities and antigens of pai-1 and tpa and the levels of the tpa/pai-1 complex as well as serum insulin, parameter of the coronary risk panel and plasma glucose at fasting state were studied in 303 t2d subjects (227 with mets and 76 without mets), 131 normal non-diabetic non-metabolic subjects and 101 non-diabetic mets subjects.
nsubj||implanted-2/VBD||we-1/PRP	root||ROOT-0/null||implanted-2/VBD	num||implants-5/NNS||four-3/CD	amod||implants-5/NNS||xaracoll-4/JJ	nsubj||containing-7/VBG||implants-5/NNS	dep||containing-7/VBG||each-6/DT	dep||implanted-2/VBD||containing-7/VBG	num||mg-9/NN||50-8/CD	dobj||containing-7/VBG||mg-9/NN	prep_of||mg-9/NN||bupivacainehydrochloride-11/NN	number||mg-14/CD||200-13/CD	num||dose-16/NN||mg-14/CD	nn||dose-16/NN||total-15/NN	appos||bupivacainehydrochloride-11/NN||dose-16/NN	num||men-20/NNS||ten-19/CD	prep_in||containing-7/VBG||men-20/NNS	vmod||men-20/NNS||undergoing-21/VBG	amod||hernioplasty-26/NN||laparoscopic-22/JJ	amod||hernioplasty-26/NN||inguinal-23/JJ	conj_or||inguinal-23/JJ||umbilical-25/JJ	amod||hernioplasty-26/NN||umbilical-25/JJ	dobj||undergoing-21/VBG||hernioplasty-26/NN	bupivacainehydrochloride-11||ten-19||no_rel||we implanted four xaracoll implants each containing 50 mg of bupivacainehydrochloride (200 mg total dose) in ten men undergoing laparoscopic inguinal or umbilical hernioplasty.
nsubj||explored-2/VBD||we-1/PRP	root||ROOT-0/null||explored-2/VBD	advmod||different-4/JJ||how-3/WRB	advmod||fare-14/VB||different-4/JJ	amod||groups-8/NNS||socioeconomic-5/JJ	conj_and||socioeconomic-5/JJ||racial/ethnic-7/JJ	amod||groups-8/NNS||racial/ethnic-7/JJ	nsubj||fare-14/VB||groups-8/NNS	det||states-12/NNS||the-10/DT	amod||states-12/NNS||united-11/VBN	prep_in||groups-8/NNS||states-12/NNS	aux||fare-14/VB||might-13/MD	ccomp||explored-2/VBD||fare-14/VB	det||pandemic-18/NN||an-16/DT	nn||pandemic-18/NN||influenza-17/NN	prep_in||fare-14/VB||pandemic-18/NN	det||basis-21/NN||the-20/DT	prep_on||fare-14/VB||basis-21/NN	amod||factors-24/NNS||social-23/JJ	prep_of||basis-21/NN||factors-24/NNS	det||exposure-27/NN||that-25/DT	nn||exposure-27/NN||shape-26/NN	dep||factors-24/NNS||exposure-27/NN	prep_of||basis-21/NN||vulnerability-29/NN	conj_and||factors-24/NNS||vulnerability-29/NN	prep_to||vulnerability-29/NN||influenzavirus-31/NNS	prep_of||basis-21/NN||timeliness-34/NNS	conj_and||factors-24/NNS||timeliness-34/NNS	conj_and||factors-24/NNS||adequacy-36/NN	conj_and||timeliness-34/NNS||adequacy-36/NN	prep_of||timeliness-34/NNS||treatment-38/NN	influenza-17||influenzavirus-31||no||we explored how different socioeconomic and racial/ethnic groups in the united states might fare in an influenza pandemic on the basis of social factors that shape exposure, vulnerability to influenzavirus, and timeliness and adequacy of treatment.
advmod||research-3/NN||more-1/RBR	amod||research-3/NN||empirical-2/JJ	nsubjpass||needed-5/VBN||research-3/NN	auxpass||needed-5/VBN||is-4/VBZ	root||ROOT-0/null||needed-5/VBN	amod||aspects-9/NNS||various-7/JJ	amod||aspects-9/NNS||methodological-8/JJ	prep_on||needed-5/VBN||aspects-9/NNS	mark||obtain-13/VB||in-10/IN	dep||obtain-13/VB||order-11/NN	aux||obtain-13/VB||to-12/TO	advcl||needed-5/VBN||obtain-13/VB	amod||weights-18/NNS||valid-14/JJ	conj_and||valid-14/JJ||reliable-16/JJ	amod||weights-18/NNS||reliable-16/JJ	amod||weights-18/NNS||hrql-17/JJ	dobj||obtain-13/VB||weights-18/NNS	amod||evaluations-21/NNS||economic-20/JJ	prep_in||obtain-13/VB||evaluations-21/NNS	amod||prevention-24/NN||hiv/aids-23/JJ	prep_of||evaluations-21/NNS||prevention-24/NN	nn||interventions-27/NNS||treatment-26/NN	prep_of||evaluations-21/NNS||interventions-27/NNS	conj_and||prevention-24/NN||interventions-27/NNS	aids--1||hiv--1||no||more empirical research is needed on various methodological aspects in order to obtain valid and reliable hrql weights in economic evaluations of hiv/aids prevention and treatment interventions.
nn||fibre-2/NN||conclusion-1/NN	nsubj||effective-11/JJ||fibre-2/NN	conj_and||fibre-2/NN||antispasmodics-4/NNS	nsubj||effective-11/JJ||antispasmodics-4/NNS	conj_and||fibre-2/NN||peppermintoil-7/NN	nsubj||effective-11/JJ||peppermintoil-7/NN	cop||effective-11/JJ||were-8/VBD	det||effective-11/JJ||all-9/DT	advmod||effective-11/JJ||more-10/RBR	root||ROOT-0/null||effective-11/JJ	prep_than||effective-11/JJ||placebo-13/NN	det||treatment-16/NN||the-15/DT	prep_in||effective-11/JJ||treatment-16/NN	prep_of||treatment-16/NN||irritablebowelsyndrome-18/NN	irritablebowelsyndrome-18||peppermintoil-7||no_rel||conclusion fibre, antispasmodics, and peppermintoil were all more effective than placebo in the treatment of irritablebowelsyndrome.
amod||formulations-3/NNS||commercial-1/JJ	nn||formulations-3/NNS||methotrexate-2/NN	nsubj||have-7/VBP||formulations-3/NNS	appos||formulations-3/NNS||mtx-5/NN	root||ROOT-0/null||have-7/VBP	amod||action-10/NN||poor-8/JJ	amod||action-10/NN||anti-inflammatory-9/JJ	dobj||have-7/VBP||action-10/NN	amod||treatment-13/NN||intra-articular-12/JJ	prep_for||action-10/NN||treatment-13/NN	prep_of||treatment-13/NN||rheumatoidarthritis-15/NNS	rheumatoidarthritis-15||methotrexate-2||yes||commercial methotrexate formulations (mtx) have poor anti-inflammatory action for intra-articular treatment of rheumatoidarthritis.
det||study-3/NN||the-1/DT	nn||study-3/NN||simulation-2/NN	nsubj||shows-4/VBZ||study-3/NN	root||ROOT-0/null||shows-4/VBZ	mark||predicted-51/VBN||that-5/IN	det||used-11/VBN||the-8/DT	advmod||used-11/VBN||most-9/RBS	advmod||used-11/VBN||commonly-10/RB	prep_under||predicted-51/VBN||used-11/VBN	advmod||approaches-16/NNS||generally-13/RB	amod||approaches-16/NNS||accepted-14/VBN	nn||approaches-16/NNS||therapy-15/NN	conj_and||used-11/VBN||approaches-16/NNS	prep_under||predicted-51/VBN||approaches-16/NNS	nn||infection-19/NN||hdv-18/NN	prep_for||approaches-16/NNS||infection-19/NN	prep_such_as||approaches-16/NNS||lamivudine-23/NN	appos||lamivudine-23/NN||lmv-25/NN	amod||alpha-interferon-31/NN||ribavirine-28/JJ	amod||alpha-interferon-31/NN||peggylated-30/JJ	prep_such_as||approaches-16/NNS||alpha-interferon-31/NN	conj_or||lamivudine-23/NN||alpha-interferon-31/NN	appos||lamivudine-23/NN||ifn-33/NN	det||combination-37/NN||a-36/DT	conj_or||used-11/VBN||combination-37/NN	prep_under||predicted-51/VBN||combination-37/NN	prep_of||combination-37/NN||both-39/DT	nn||monotherapy-42/NN||lmv-41/NN	nsubjpass||predicted-51/VBN||monotherapy-42/NN	nsubj||reduce-55/VB||monotherapy-42/NN	nsubj||hdv-59/VB||monotherapy-42/NN	nn||therapy-45/NN||combination-44/NN	conj_and||monotherapy-42/NN||therapy-45/NN	nsubjpass||predicted-51/VBN||therapy-45/NN	nsubj||reduce-55/VB||therapy-45/NN	prep_of||monotherapy-42/NN||lmv-47/NN	prep_of||monotherapy-42/NN||ifn-49/NN	conj_and||lmv-47/NN||ifn-49/NN	auxpass||predicted-51/VBN||were-50/VBD	ccomp||shows-4/VBZ||predicted-51/VBN	aux||reduce-55/VB||to-52/TO	advmod||effectively-54/RB||more-53/RBR	advmod||reduce-55/VB||effectively-54/RB	xcomp||predicted-51/VBN||reduce-55/VB	det||hbv-57/NN||the-56/DT	dobj||reduce-55/VB||hbv-57/NN	xcomp||predicted-51/VBN||hdv-59/VB	conj_and||reduce-55/VB||hdv-59/VB	amod||loads-61/NNS||viral-60/JJ	dobj||hdv-59/VB||loads-61/NNS	det||case-64/NN||the-63/DT	prep_in||hdv-59/VB||case-64/NN	amod||scenarios-67/NNS||super-infection-66/JJ	prep_of||case-64/NN||scenarios-67/NNS	advmod||compared-69/VBN||when-68/WRB	advcl||hdv-59/VB||compared-69/VBN	det||co-infection-72/NN||the-71/DT	prep_with||compared-69/VBN||co-infection-72/NN	hbv-57||lamivudine-23||yes||the simulation study shows that, under the most commonly used and generally accepted therapy approaches for hdv infection, such as lamivudine (lmv) or ribavirine, peggylated alpha-interferon (ifn) or a combination of both, lmv monotherapy and combination therapy of lmv and ifn were predicted to more effectively reduce the hbv and hdv viral loads in the case of super-infection scenarios when compared with the co-infection.
nsubjpass||prescribed-3/VBN||she-1/PRP	nsubjpass||began-10/VBD||she-1/PRP	auxpass||prescribed-3/VBN||was-2/VBD	root||ROOT-0/null||prescribed-3/VBN	dobj||prescribed-3/VBN||trifluoperazine-4/NN	num||mg/day-7/NN||5-6/CD	appos||trifluoperazine-4/NN||mg/day-7/NN	conj_and||prescribed-3/VBN||began-10/VBD	amod||therapy-12/NN||cognitive-behavioral-11/JJ	dobj||began-10/VBD||therapy-12/NN	prep_for||began-10/VBD||psychosis-14/NNS	psychosis-14||trifluoperazine-4||yes||she was prescribed trifluoperazine (5 mg/day) and began cognitive-behavioral therapy for psychosis.
nsubj||antispasmodics-9/VBZ||objective-1/NN	nsubj||peppermintoil-12/JJ||objective-1/NN	aux||determine-3/VB||to-2/TO	vmod||objective-1/NN||determine-3/VB	det||effect-5/NN||the-4/DT	dobj||determine-3/VB||effect-5/NN	prep_of||effect-5/NN||fibre-7/NN	root||ROOT-0/null||antispasmodics-9/VBZ	conj_and||antispasmodics-9/VBZ||peppermintoil-12/JJ	det||treatment-15/NN||the-14/DT	prep_in||peppermintoil-12/JJ||treatment-15/NN	prep_of||treatment-15/NN||irritablebowelsyndrome-17/NN	peppermintoil-12||irritablebowelsyndrome-17||no_rel||objective to determine the effect of fibre, antispasmodics, and peppermintoil in the treatment of irritablebowelsyndrome.
nsubjpass||prescribed-3/VBN||antibiotics-1/NNS	auxpass||prescribed-3/VBN||were-2/VBD	root||ROOT-0/null||prescribed-3/VBN	advmod||prescribed-3/VBN||acutely-4/RB	num||%-7/NN||66-6/CD	prep_in||prescribed-3/VBN||%-7/NN	appos||%-7/NN||359/543-9/CD	prep_of||%-7/NN||children-12/NNS	prep_with||children-12/NNS||urinarytractinfection-14/NN	num||%-17/NN||69-16/CD	prep_in||prescribed-3/VBN||%-17/NN	conj_and||%-7/NN||%-17/NN	appos||%-17/NN||366/533-19/CD	prep_with||%-17/NN||pneumonia-22/NN	num||%-26/NN||81-25/CD	prep_in||prescribed-3/VBN||%-26/NN	conj_and||%-7/NN||%-26/NN	appos||%-26/NN||52/64-28/CD	prep_with||%-26/NN||bacteraemia-31/NN	urinarytractinfection-14||antibiotics-1||no_rel||antibiotics were prescribed acutely in 66% (359/543) of children with urinarytractinfection, 69% (366/533) with pneumonia, and 81% (52/64) with bacteraemia.
amod||areas-4/NNS||second-1/JJ	amod||areas-4/NNS||hypoxic-3/JJ	nsubjpass||decreased-7/VBN||areas-4/NNS	auxpass||decreased-7/VBN||are-5/VBP	advmod||decreased-7/VBN||also-6/RB	root||ROOT-0/null||decreased-7/VBN	amod||treatment-11/NN||metronomic-9/JJ	amod||treatment-11/NN||cpt11-10/JJ	agent||decreased-7/VBN||treatment-11/NN	agent||decreased-7/VBN||temozolomide-15/NN	conj_and||treatment-11/NN||temozolomide-15/NN	hypoxic-3||temozolomide-15||no_rel||second, hypoxic areas are also decreased by metronomic cpt11 treatment as well as temozolomide.
amod||acid-2/NN||tauroursodeoxycholic-1/JJ	nsubjpass||used-16/VBN||acid-2/NN	nsubj||study-18/VB||acid-2/NN	appos||acid-2/NN||tudca-4/NNP	det||chaperone-9/NN||a-7/DT	amod||chaperone-9/NN||chemical-8/JJ	appos||acid-2/NN||chaperone-9/NN	nsubj||alleviates-11/VBZ||chaperone-9/NN	rcmod||chaperone-9/NN||alleviates-11/VBZ	nn||stress-13/NN||er-12/NN	dobj||alleviates-11/VBZ||stress-13/NN	auxpass||used-16/VBN||was-15/VBD	root||ROOT-0/null||used-16/VBN	aux||study-18/VB||to-17/TO	xcomp||used-16/VBN||study-18/VB	det||mechanism-20/NN||the-19/DT	dobj||study-18/VB||mechanism-20/NN	vmod||mechanism-20/NN||underlying-21/VBG	amod||downregulation-24/NN||obesity-induced-22/JJ	nn||downregulation-24/NN||adiponectin-23/NN	dobj||underlying-21/VBG||downregulation-24/NN	amod||mice-27/NNS||db/db-26/JJ	prep_in||underlying-21/VBG||mice-27/NNS	amod||mice-32/NNS||high-fat-29/JJ	amod||mice-32/NNS||diet-induced-30/JJ	nn||mice-32/NNS||obese-31/NN	appos||mice-27/NNS||mice-32/NNS	amod||adipocytes-38/NNS||er-stressed-36/JJ	amod||adipocytes-38/NNS||3t3-l1-37/JJ	prep_in||underlying-21/VBG||adipocytes-38/NNS	conj_and||mice-27/NNS||adipocytes-38/NNS	obesity--1||chemical-8||no_rel||tauroursodeoxycholic acid (tudca), a chemical chaperone that alleviates er stress, was used to study the mechanism underlying obesity-induced adiponectin downregulation in db/db mice, high-fat diet-induced obese mice, and in er-stressed 3t3-l1 adipocytes.
det||data-2/NNS||these-1/DT	nsubj||suggest-4/VBP||data-2/NNS	advmod||suggest-4/VBP||also-3/RB	root||ROOT-0/null||suggest-4/VBP	mark||useful-12/JJ||that-5/IN	det||use-7/NN||the-6/DT	nsubj||useful-12/JJ||use-7/NN	prep_of||use-7/NN||fluoxetine-9/NN	aux||useful-12/JJ||may-10/MD	cop||useful-12/JJ||be-11/VB	ccomp||suggest-4/VBP||useful-12/JJ	prepc_in||useful-12/JJ||increasing-14/VBG	amod||responses-16/NNS||epinephrine-15/JJ	dobj||increasing-14/VBG||responses-16/NNS	prep_during||increasing-14/VBG||hypoglycemia-18/NN	amod||practice-21/NN||clinical-20/JJ	prep_in||hypoglycemia-18/NN||practice-21/NN	hypoglycemia-18||fluoxetine-9||no_rel||these data also suggest that the use of fluoxetine may be useful in increasing epinephrine responses during hypoglycemia in clinical practice.
det||isolation-2/NN||the-1/DT	nsubj||led-29/VBN||isolation-2/NN	det||coronavirus-5/NNS||the-4/DT	prep_of||isolation-2/NN||coronavirus-5/NNS	appos||coronavirus-5/NNS||cov-7/NN	vmod||coronavirus-5/NNS||identified-9/VBN	det||cause-12/NN||the-11/DT	prep_as||identified-9/VBN||cause-12/NN	prep_of||cause-12/NN||severeacuterespiratorysyndrome-14/NN	det||detection-17/NN||the-16/DT	prep_as||identified-9/VBN||detection-17/NN	conj_and||cause-12/NN||detection-17/NN	num||covs-22/NNS||2-19/CD	amod||covs-22/NNS||new-20/JJ	amod||covs-22/NNS||human-21/JJ	prep_of||detection-17/NN||covs-22/NNS	dep||covs-22/NNS||hcov-nl63-24/JJ	dep||covs-22/NNS||hcov-hku1-26/JJ	conj_and||hcov-nl63-24/JJ||hcov-hku1-26/JJ	aux||led-29/VBN||have-28/VBP	root||ROOT-0/null||led-29/VBN	prep_to||led-29/VBN||studies-31/NNS	det||epidemiology-34/NN||the-33/DT	prep_of||studies-31/NNS||epidemiology-34/NN	amod||effects-39/NNS||clinical-36/JJ	conj_and||clinical-36/JJ||socioeconomic-38/JJ	amod||effects-39/NNS||socioeconomic-38/JJ	prep_to||led-29/VBN||effects-39/NNS	conj_and||studies-31/NNS||effects-39/NNS	prep_of||effects-39/NNS||infections-41/NNS	vmod||infections-41/NNS||caused-42/VBN	det||hcovs-45/NNS||all-44/DT	agent||caused-42/VBN||hcovs-45/NNS	prep_including||caused-42/VBN||those-48/DT	vmod||those-48/DT||known-49/VBN	det||1960s-53/NNS||the-51/DT	amod||1960s-53/NNS||late-52/JJ	prep_since||known-49/VBN||1960s-53/NNS	dep||1960s-53/NNS||hcov-229e-55/JJ	dep||1960s-53/NNS||hcov-oc43-57/JJ	conj_and||hcov-229e-55/JJ||hcov-oc43-57/JJ	severeacuterespiratorysyndrome-14||coronavirus-5||no||the isolation of the coronavirus (cov) identified as the cause of severeacuterespiratorysyndrome and the detection of 2 new human covs (hcov-nl63 and hcov-hku1) have led to studies of the epidemiology and clinical and socioeconomic effects of infections caused by all hcovs, including those known since the late 1960s (hcov-229e and hcov-oc43).
nsubj||response-37/NN||methods-1/NNS	nsubj||conducted-3/VBD||we-2/PRP	rcmod||methods-1/NNS||conducted-3/VBD	det||review-6/NN||a-4/DT	nn||review-6/NN||desk-5/NN	dobj||conducted-3/VBD||review-6/NN	nsubj||had-13/VBN||review-6/NN	amod||policies-10/NNS||key-8/JJ	amod||policies-10/NNS||national-level-9/JJ	prep_of||review-6/NN||policies-10/NNS	aux||had-13/VBN||have-12/VBP	rcmod||review-6/NN||had-13/VBN	det||impact-16/NN||a-14/DT	amod||impact-16/NN||major-15/JJ	dobj||had-13/VBN||impact-16/NN	prepc_on||had-13/VBN||chinaâ-18/VBG	dobj||chinaâ-18/VBG||$-19/$	num||$-19/$||™-20/CD	nsubj||hiv/aids-22/VBZ||s-21/PRP	nsubj||examined-26/VBD||s-21/PRP	rcmod||$-19/$||hiv/aids-22/VBZ	dobj||hiv/aids-22/VBZ||epidemic-23/NN	rcmod||$-19/$||examined-26/VBD	conj_and||hiv/aids-22/VBZ||examined-26/VBD	amod||data-29/NNS||recent-27/JJ	amod||data-29/NNS||epidemiological-28/JJ	nsubj||relevant-30/JJ||data-29/NNS	nsubj||chinaâ-32/VB||data-29/NNS	xcomp||examined-26/VBD||relevant-30/JJ	aux||chinaâ-32/VB||to-31/TO	xcomp||relevant-30/JJ||chinaâ-32/VB	dobj||chinaâ-32/VB||$-33/$	num||$-33/$||™-34/CD	cop||response-37/NN||s-35/VBZ	nn||response-37/NN||hiv-36/NN	root||ROOT-0/null||response-37/NN	aids--1||hiv-36||no||methods we conducted a desk review of key national-level policies that have had a major impact on chinaâ€™s hiv/aids epidemic, and examined recent epidemiological data relevant to chinaâ€™s hiv response.
aux||identify-2/VB||to-1/TO	advcl||performed-18/VBN||identify-2/VB	amod||locations-5/NNS||new-3/JJ	amod||locations-5/NNS||genomic-4/JJ	dobj||identify-2/VB||locations-5/NNS	vmod||locations-5/NNS||associated-6/VBN	prep_with||associated-6/VBN||irondeficiency-8/NN	det||study-13/NN||a-10/DT	amod||study-13/NN||genome-wide-11/JJ	nn||study-13/NN||association-12/NN	nsubjpass||performed-18/VBN||study-13/NN	appos||study-13/NN||gwas-15/NNS	auxpass||performed-18/VBN||was-17/VBD	root||ROOT-0/null||performed-18/VBN	xcomp||performed-18/VBN||using-19/VBG	dobj||using-19/VBG||dna-20/NN	vmod||dna-20/NN||collected-21/VBN	amod||men-24/NNS||white-23/JJ	prep_from||collected-21/VBN||men-24/NNS	vmod||men-24/NNS||aged-25/VBN	number||‰-27/CD||â-26/CD	num||y-30/NN||‰-27/CD	nn||y-30/NN||¥-28/NNP	num||y-30/NN||25-29/CD	dobj||aged-25/VBN||y-30/NN	nn||‰-34/NN||women-32/NNS	nn||‰-34/NN||â-33/NN	dobj||aged-25/VBN||‰-34/NN	conj_and||y-30/NN||‰-34/NN	vmod||y-30/NN||¥-35/VBG	num||y-37/NN||50-36/CD	dobj||¥-35/VBG||y-37/NN	det||study-47/NN||the-39/DT	amod||study-47/NN||hemochromatosis-40/JJ	conj_and||hemochromatosis-40/JJ||ironoverload-42/JJ	amod||study-47/NN||ironoverload-42/JJ	nn||study-47/NN||screening-43/NN	appos||study-47/NN||heirs-45/NNS	prep_in||y-37/NN||study-47/NN	amod||controls-67/NNS||serum-49/JJ	amod||controls-67/NNS||ferritin-50/JJ	appos||controls-67/NNS||sf-52/NN	nn||controls-67/NNS||â-54/NN	amod||controls-67/NNS||‰-55/JJ	amod||controls-67/NNS||$-56/$	number||$-56/$||12-57/CD	nn||controls-67/NNS||âµg-58/NN	punct||replete-66/JJ||/-59/:	amod||cases-62/NNS||l-60/JJ	dep||replete-66/JJ||cases-62/NNS	conj_and||cases-62/NNS||iron-65/NN	dep||replete-66/JJ||iron-65/NN	dep||controls-67/NNS||replete-66/JJ	prep_with||¥-35/VBG||controls-67/NNS	dep||controls-67/NNS||sf-69/VBN	number||100-71/CD||>-70/CD	num||âµg-72/NN||100-71/CD	iobj||sf-69/VBN||âµg-72/NN	punct||l-74/NN||/-73/:	dep||âµg-72/NN||l-74/NN	prep_in||l-74/NN||men-76/NNS	advmod||50-80/CD||sf-78/RB	number||50-80/CD||>-79/CD	appos||l-74/NN||50-80/CD	dep||50-80/CD||âµg-81/NN	punct||l-74/NN||/-82/:	dobj||sf-69/VBN||l-83/NN	prep_in||sf-69/VBN||women-85/NNS	irondeficiency-8||iron-65||yes||to identify new genomic locations associated with irondeficiency, a genome-wide association study (gwas) was performed using dna collected from white men aged â‰¥25 y and women â‰¥50 y in the hemochromatosis and ironoverload screening (heirs) study with serum ferritin (sf) â‰¤ 12 âµg/l (cases) and iron replete controls (sf>100 âµg/l in men, sf>50 âµg/l in women).
amod||inhibitor-3/NN||urinary-1/JJ	nn||inhibitor-3/NN||trypsin-2/NN	nsubjpass||used-16/VBN||inhibitor-3/NN	appos||inhibitor-3/NN||uti-5/NN	det||inhibitor-11/NN||a-8/DT	amod||inhibitor-11/NN||serine-9/JJ	nn||inhibitor-11/NN||protease-10/NN	appos||inhibitor-3/NN||inhibitor-11/NN	aux||used-16/VBN||has-13/VBZ	auxpass||used-16/VBN||been-14/VBN	advmod||used-16/VBN||widely-15/RB	root||ROOT-0/null||used-16/VBN	prep_in||used-16/VBN||japan-18/NN	det||drug-21/NN||a-20/DT	prep_as||used-16/VBN||drug-21/NN	prep_for||drug-21/NN||patients-23/NNS	amod||inflammatory-26/JJ||acute-25/JJ	amod||disorders-27/NNS||inflammatory-26/JJ	prep_with||patients-23/NNS||disorders-27/NNS	amod||coagulation-32/NN||disseminated-30/JJ	nn||coagulation-32/NN||intravascular-31/NN	prep_such_as||disorders-27/NNS||coagulation-32/NN	appos||coagulation-32/NN||dic-34/NN	prep_such_as||disorders-27/NNS||shock-37/NN	conj_and||coagulation-32/NN||shock-37/NN	prep_such_as||disorders-27/NNS||pancreatitis-40/NNS	conj_and||coagulation-32/NN||pancreatitis-40/NNS	trypsin-2||uti-5||no_rel||urinary trypsin inhibitor (uti), a serine protease inhibitor, has been widely used in japan as a drug for patients with acute inflammatory disorders such as disseminated intravascular coagulation (dic), shock, and pancreatitis.
det||case-2/NN||the-1/DT	nsubjpass||presented-26/VBN||case-2/NN	det||suffering-7/NN||an-4/DT	amod||suffering-7/NN||18-year-old-5/JJ	amod||suffering-7/NN||female-6/JJ	prep_of||case-2/NN||suffering-7/NN	prep_from||suffering-7/NN||bipolaraffectivedisorder-9/NN	nsubjpass||treated-16/VBN||bipolaraffectivedisorder-9/NN	appos||bipolaraffectivedisorder-9/NN||mania-11/NN	aux||treated-16/VBN||was-14/VBD	auxpass||treated-16/VBN||being-15/VBG	rcmod||bipolaraffectivedisorder-9/NN||treated-16/VBN	prep_with||treated-16/VBN||carbamazepine-18/NN	prep_with||treated-16/VBN||lithium-20/NN	conj_and||carbamazepine-18/NN||lithium-20/NN	prep_with||treated-16/VBN||chlorpromazine-22/NN	conj_and||carbamazepine-18/NN||chlorpromazine-22/NN	prep_with||treated-16/VBN||benzhexol-24/NN	conj_and||carbamazepine-18/NN||benzhexol-24/NN	auxpass||presented-26/VBN||is-25/VBZ	root||ROOT-0/null||presented-26/VBN	bipolaraffectivedisorder-9||lithium-20||yes||the case of an 18-year-old female suffering from bipolaraffectivedisorder (mania) who was being treated with carbamazepine, lithium, chlorpromazine and benzhexol is presented.
det||end-3/NN||the-2/DT	prep_at||lower-25/JJR||end-3/NN	det||period-7/NN||the-5/DT	amod||period-7/NN||24-week-6/JJ	prep_of||end-3/NN||period-7/NN	nn||prevalence-14/NN||bp-9/NN	dep||prevalence-14/NN||lvmi-11/NN	dep||prevalence-14/NN||lvh-13/NN	nsubj||lower-25/JJR||prevalence-14/NN	nn||levels-18/NNS||plasma-16/NN	nn||levels-18/NNS||adma-17/NN	conj_and||prevalence-14/NN||levels-18/NNS	nsubj||lower-25/JJR||levels-18/NNS	det||group-22/NN||the-20/DT	amod||group-22/NN||nitrate-21/JJ	prep_in||prevalence-14/NN||group-22/NN	cop||lower-25/JJR||were-23/VBD	advmod||lower-25/JJR||significantly-24/RB	root||ROOT-0/null||lower-25/JJR	prep_than||lower-25/JJR||those-27/DT	det||group-31/NN||the-29/DT	amod||group-31/NN||non-nitrate-30/JJ	prep_in||those-27/DT||group-31/NN	lvh-13||nitrate-21||no_rel||at the end of the 24-week period, bp, lvmi, lvh prevalence and plasma adma levels in the nitrate group were significantly lower than those in the non-nitrate group.
nsubjpass||enrolled-3/VBN||participants-1/NNS	auxpass||enrolled-3/VBN||were-2/VBD	root||ROOT-0/null||enrolled-3/VBN	det||study-7/NN||a-5/DT	amod||study-7/NN||cross-sectional-6/JJ	prep_in||enrolled-3/VBN||study-7/NN	amod||assessment-10/NN||lipoatrophy-9/JJ	prep_with||enrolled-3/VBN||assessment-10/NN	amod||test-15/NN||oral-12/JJ	nn||test-15/NN||glucose-13/NN	nn||test-15/NN||tolerance-14/NN	prep_with||enrolled-3/VBN||test-15/NN	conj_and||assessment-10/NN||test-15/NN	amod||triglycerides-18/NNPS||fasting-17/JJ	prep_with||enrolled-3/VBN||triglycerides-18/NNPS	conj_and||assessment-10/NN||triglycerides-18/NNPS	nn||lactate-22/NN||finger-20/NN	nn||lactate-22/NN||prick-21/NN	prep_with||enrolled-3/VBN||lactate-22/NN	conj_and||assessment-10/NN||lactate-22/NN	amod||concentrations-26/NNS||stavudine-25/JJ	prep_with||enrolled-3/VBN||concentrations-26/NNS	conj_and||assessment-10/NN||concentrations-26/NNS	cross--1||stavudine-25||no_rel||participants were enrolled in a cross-sectional study with lipoatrophy assessment, oral glucose tolerance test, fasting triglycerides, finger prick lactate, and stavudine concentrations.
nsubj||used-6/VBD||methods-1/NNS	det||analysis-5/NN||this-2/DT	nn||analysis-5/NN||post-3/NN	nn||analysis-5/NN||hoc-4/NN	dep||methods-1/NNS||analysis-5/NN	root||ROOT-0/null||used-6/VBD	dobj||used-6/VBD||data-7/NNS	det||study-15/NN||a-9/DT	amod||study-15/NN||1-year-10/JJ	amod||study-15/NN||randomized-12/JJ	amod||study-15/NN||open-label-14/JJ	prep_from||used-6/VBD||study-15/NN	prep_of||study-15/NN||olanzapine-17/NN	prep_of||study-15/NN||risperidone-19/NN	conj_and||olanzapine-17/NN||risperidone-19/NN	prep_of||study-15/NN||typicalantipsychotics-22/NNS	conj_and||olanzapine-17/NN||typicalantipsychotics-22/NNS	det||treatment-25/NN||the-24/DT	prep_in||used-6/VBD||treatment-25/NN	prep_of||treatment-25/NN||schizophrenia-27/NN	schizophrenia-27||risperidone-19||yes||methods this post hoc analysis used data from a 1-year, randomized, open-label study of olanzapine, risperidone, and typicalantipsychotics in the treatment of schizophrenia.
det||therapies-3/NNS||the-1/DT	amod||therapies-3/NNS||incretin-based-2/JJ	nsubj||stimulate-4/VB||therapies-3/NNS	nsubj||inhibit-8/VB||therapies-3/NNS	nsubj||carry-16/VB||therapies-3/NNS	root||ROOT-0/null||stimulate-4/VB	nn||secretion-6/NN||insulin-5/NN	dobj||stimulate-4/VB||secretion-6/NN	conj_and||stimulate-4/VB||inhibit-8/VB	nn||secretion-10/NN||glucagon-9/NN	dobj||inhibit-8/VB||secretion-10/NN	det||manner-14/NN||a-12/DT	amod||manner-14/NN||glucose-dependent-13/JJ	prep_in||inhibit-8/VB||manner-14/NN	conj_and||stimulate-4/VB||carry-16/VB	neg||risk-19/NN||no-17/DT	amod||risk-19/NN||intrinsic-18/JJ	dobj||carry-16/VB||risk-19/NN	prep_of||risk-19/NN||hypoglycaemia-21/NN	hypoglycaemia-21||glucose--1||yes||the incretin-based therapies stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner and carry no intrinsic risk of hypoglycaemia.
mark||overshadowed-10/VBN||although-1/IN	det||mortality-3/NN||the-2/DT	nsubjpass||overshadowed-10/VBN||mortality-3/NN	amod||mortality-3/NN||attributable-4/JJ	prep_to||attributable-4/JJ||cancer-6/NN	prep_in||cancer-6/NN||type2diabetes-8/CD	auxpass||overshadowed-10/VBN||is-9/VBZ	advcl||suggest-22/VBP||overshadowed-10/VBN	agent||overshadowed-10/VBN||that-12/DT	amod||cardiovasculardisease-15/JJ||due-13/JJ	dep||cardiovasculardisease-15/JJ||to-14/TO	amod||that-12/DT||cardiovasculardisease-15/JJ	amod||data-18/NNS||emerging-17/VBG	nsubj||suggest-22/VBP||data-18/NNS	amod||studies-21/NNS||epidemiologic-20/JJ	prep_from||data-18/NNS||studies-21/NNS	root||ROOT-0/null||suggest-22/VBP	mark||confer-27/VB||that-23/IN	nn||therapy-25/NN||insulin-24/NN	nsubj||confer-27/VB||therapy-25/NN	aux||confer-27/VB||may-26/MD	ccomp||suggest-22/VBP||confer-27/VB	amod||risk-29/NN||added-28/VBN	dobj||confer-27/VB||risk-29/NN	prep_for||risk-29/NN||cancer-31/NN	advmod||mediated-34/VBN||perhaps-33/RB	vmod||cancer-31/NN||mediated-34/VBN	agent||mediated-34/VBN||signaling-36/VBG	det||receptor-45/NN||the-38/DT	amod||receptor-45/NN||igf-1-39/JJ	amod||factor-1-43/NN||insulin-like-41/JJ	nn||factor-1-43/NN||growth-42/NN	appos||receptor-45/NN||factor-1-43/NN	prep_through||signaling-36/VBG||receptor-45/NN	type2diabetes-8||insulin-24||yes||although the mortality attributable to cancer in type2diabetes is overshadowed by that due to cardiovasculardisease, emerging data from epidemiologic studies suggest that insulin therapy may confer added risk for cancer, perhaps mediated by signaling through the igf-1 (insulin-like growth factor-1) receptor.
nsubj||problem-8/NN||viralhepatitis-1/NNS	cop||problem-8/NN||is-2/VBZ	det||problem-8/NN||a-3/DT	amod||problem-8/NN||serious-4/JJ	amod||problem-8/NN||global-5/JJ	amod||problem-8/NN||public-6/JJ	nn||problem-8/NN||health-7/NN	root||ROOT-0/null||problem-8/NN	vmod||problem-8/NN||affecting-9/VBG	dobj||affecting-9/VBG||billions-10/NNS	prep_of||billions-10/NNS||people-12/NNS	advmod||affecting-9/VBG||globally-13/RB	det||virus-18/NN||both-16/DT	amod||virus-18/NN||hepatitisb-17/JJ	nsubj||spreading-31/VBG||virus-18/NN	appos||virus-18/NN||hbv-20/NN	amod||infections-28/NNS||hepatitisc-23/JJ	nn||infections-28/NNS||virus-24/NN	appos||infections-28/NNS||hcv-26/NN	conj_and||virus-18/NN||infections-28/NNS	nsubj||spreading-31/VBG||infections-28/NNS	aux||spreading-31/VBG||are-29/VBP	advmod||spreading-31/VBG||rapidly-30/RB	conj_and||problem-8/NN||spreading-31/VBG	det||countries-35/NNS||the-33/DT	amod||countries-35/NNS||developing-34/VBG	prep_in||spreading-31/VBG||countries-35/NNS	amod||education-44/NN||bangladesh-37/JJ	det||lack-41/NN||the-40/DT	prep_due_to||education-44/NN||lack-41/NN	prep_of||lack-41/NN||health-43/NN	prep_including||countries-35/NNS||education-44/NN	appos||education-44/NN||poverty-46/NN	appos||education-44/NN||illiteracy-48/NN	conj_and||poverty-46/NN||illiteracy-48/NN	appos||education-44/NN||lack-50/NN	conj_and||poverty-46/NN||lack-50/NN	amod||vaccination-53/NN||hepatitisb-52/JJ	prep_of||poverty-46/NN||vaccination-53/NN	hepatitisb-52||hepatitisbvirus--1||no||viralhepatitis is a serious global public health problem affecting billions of people globally, and both hepatitisb virus (hbv) and hepatitisc virus (hcv) infections are rapidly spreading in the developing countries including bangladesh due to the lack of health education, poverty, illiteracy and lack of hepatitisb vaccination.
nsubjpass||reduced-5/VBN||inhibition-1/NN	prep_by||inhibition-1/NN||insulin-3/NN	auxpass||reduced-5/VBN||was-4/VBD	root||ROOT-0/null||reduced-5/VBN	amod||platelets-8/NNS||type2diabetes-7/JJ	prep_in||reduced-5/VBN||platelets-8/NNS	vmod||platelets-8/NNS||resulting-9/VBG	det||tf-16/NN||an-11/DT	nn||tf-16/NN||âˆ-12/NN	num||tf-16/NN||1/4-13/CD	amod||tf-16/NN||1.6-fold-14/JJ	amod||tf-16/NN||higher-15/JJR	prep_in||resulting-9/VBG||tf-16/NN	vmod||tf-16/NN||synthesis-17/VBN	dep||synthesis-17/VBN||than-18/IN	amod||subjects-22/NNS||matched-20/VBN	nn||subjects-22/NNS||control-21/NN	prep_in||synthesis-17/VBN||subjects-22/NNS	type2diabetes-7||insulin-3||yes||inhibition by insulin was reduced in type2diabetes platelets resulting in an âˆ¼1.6-fold higher tf synthesis than in matched control subjects.
nn||exposure-2/NN||asbestos-1/NN	nsubj||leads-16/VBZ||exposure-2/NN	advmod||when-5/WRB||especially-4/RB	advmod||present-14/JJ||when-5/WRB	amod||evidence-7/NN||radiographic-6/JJ	nsubj||present-14/JJ||evidence-7/NN	amod||fibrosis-10/NN||interstitial-9/JJ	prep_of||evidence-7/NN||fibrosis-10/NN	prep_from||fibrosis-10/NN||asbestosis-12/NNS	cop||present-14/JJ||is-13/VBZ	rcmod||exposure-2/NN||present-14/JJ	root||ROOT-0/null||leads-16/VBZ	amod||decreases-19/NNS||significant-18/JJ	prep_to||leads-16/VBZ||decreases-19/NNS	prep_in||decreases-19/NNS||fvc-21/NN	prep_in||decreases-19/NNS||fev1-23/NNS	conj_and||fvc-21/NN||fev1-23/NNS	det||dlco-26/NN||the-25/DT	prep_in||decreases-19/NNS||dlco-26/NN	conj_and||fvc-21/NN||dlco-26/NN	asbestosis-12||asbestos-1||no||asbestos exposure, especially when radiographic evidence of interstitial fibrosis from asbestosis is present, leads to significant decreases in fvc, fev1 and the dlco.
nsubj||drug-9/NN||levetiracetam-1/NN	appos||levetiracetam-1/NN||lev-3/NN	cop||drug-9/NN||is-5/VBZ	det||drug-9/NN||a-6/DT	amod||drug-9/NN||novel-7/JJ	amod||drug-9/NN||antiepileptic-8/JJ	root||ROOT-0/null||drug-9/NN	nsubjpass||approved-17/VBN||drug-9/NN	appos||drug-9/NN||aed-11/NN	aux||approved-17/VBN||has-14/VBZ	advmod||approved-17/VBN||recently-15/RB	auxpass||approved-17/VBN||been-16/VBN	rcmod||drug-9/NN||approved-17/VBN	amod||treatment-20/NN||add-on-19/JJ	prep_as||approved-17/VBN||treatment-20/NN	amod||types-24/NNS||various-22/JJ	nn||types-24/NNS||seizure-23/NN	prep_for||treatment-20/NN||types-24/NNS	nn||populations-27/NNS||epilepsy-26/NN	prep_in||approved-17/VBN||populations-27/NNS	nsubj||include-29/VBP||populations-27/NNS	rcmod||populations-27/NNS||include-29/VBP	dobj||include-29/VBP||children-30/NNS	amod||seizures-34/NNS||refractory-32/JJ	amod||seizures-34/NNS||partial-33/JJ	prep_for||children-30/NNS||seizures-34/NNS	nn||¥-40/NNP||epilepsy-36/NN	nn||¥-40/NNP||patients-37/NNS	nn||¥-40/NNP||â-38/NN	nn||¥-40/NNP||‰-39/NNP	prep_in||include-29/VBP||¥-40/NNP	num||years-42/NNS||4-41/CD	npadvmod||old-43/JJ||years-42/NNS	amod||¥-40/NNP||old-43/JJ	amod||seizures-47/NNS||myoclonic-46/JJ	prep_for||¥-40/NNP||seizures-47/NNS	amod||myoclonic-50/JJ||juvenile-49/JJ	amod||patients-70/NNS||myoclonic-50/JJ	nn||patients-70/NNS||epilepsy-51/NN	nn||patients-70/NNS||patients-52/NNS	nn||patients-70/NNS||â-53/NN	amod||patients-70/NNS||‰-54/JJ	number||12-56/CD||¥-55/CD	num||years-57/NNS||12-56/CD	npadvmod||old-58/JJ||years-57/NNS	amod||patients-70/NNS||old-58/JJ	conj_and||old-58/JJ||for-61/IN	amod||patients-70/NNS||for-61/IN	amod||seizures-65/NNS||primary-62/JJ	amod||seizures-65/NNS||generalized-63/JJ	amod||seizures-65/NNS||tonic-clonic-64/JJ	pobj||for-61/IN||seizures-65/NNS	prep_in||seizures-65/NNS||idiopathic-67/NN	amod||patients-70/NNS||generalized-68/JJ	nn||patients-70/NNS||epilepsy-69/NN	prep_in||seizures-47/NNS||patients-70/NNS	dep||patients-70/NNS||â-72/VBN	nn||¥-74/NNP||‰-73/NNP	dobj||â-72/VBN||¥-74/NNP	num||years-76/NNS||6-75/CD	npadvmod||old-77/JJ||years-76/NNS	amod||¥-74/NNP||old-77/JJ	nn||approval-80/NN||fda-79/NN	prep_with||â-72/VBN||approval-80/NN	nn||¥-84/NNP||â-82/NNP	nn||¥-84/NNP||‰-83/NNP	dep||approval-80/NN||¥-84/NNP	num||years-86/NNS||12-85/CD	npadvmod||old-87/JJ||years-86/NNS	amod||¥-84/NNP||old-87/JJ	nn||approval-90/NN||emea-89/NN	prep_with||â-72/VBN||approval-90/NN	epilepsy-69||levetiracetam-1||yes||levetiracetam (lev) is a novel antiepileptic drug (aed) that has recently been approved as add-on treatment for various seizure types in epilepsy populations that include children for refractory partial seizures in epilepsy patients â‰¥4 years old, for myoclonic seizures in juvenile myoclonic epilepsy patients â‰¥12 years old, and for primary generalized tonic-clonic seizures in idiopathic generalized epilepsy patients (â‰¥6 years old with fda approval; â‰¥12 years old with emea approval).
nsubj||causes-2/VBZ||varicella-zostervirus-1/NNS	nsubj||shingles-8/VBZ||varicella-zostervirus-1/NNS	root||ROOT-0/null||causes-2/VBZ	dobj||causes-2/VBZ||chickenpox-3/NN	amod||infection-6/NN||primary-5/JJ	prep_upon||causes-2/VBZ||infection-6/NN	conj_and||causes-2/VBZ||shingles-8/VBZ	prep_after||shingles-8/VBZ||reactivation-10/NN	chickenpox-3||varicella-zostervirus-1||yes||varicella-zostervirus causes chickenpox upon primary infection and shingles after reactivation.
nsubj||remains-2/VBZ||it-1/PRP	root||ROOT-0/null||remains-2/VBZ	acomp||remains-2/VBZ||unknown-3/JJ	mark||increase-8/VB||whether-4/IN	nsubj||increase-8/VB||exenatide-5/NN	conj_or||exenatide-5/NN||sitagliptin-7/NN	nsubj||increase-8/VB||sitagliptin-7/NN	ccomp||remains-2/VBZ||increase-8/VB	det||risk-10/NN||the-9/DT	dobj||increase-8/VB||risk-10/NN	amod||pancreatitis-13/NNS||acute-12/JJ	prep_of||risk-10/NN||pancreatitis-13/NNS	exenatide-5||pancreatitis-13||no_rel||it remains unknown whether exenatide or sitagliptin increase the risk of acute pancreatitis.
nsubj||show-2/VBP||we-1/PRP	root||ROOT-0/null||show-2/VBP	det||time-7/NN||the-5/DT	amod||time-7/NN||first-6/JJ	prep_for||show-2/VBP||time-7/NN	mark||depolarized-23/JJ||that-9/IN	nn||²-11/NNS||î-10/NN	nsubj||depolarized-23/JJ||²-11/NNS	dep||²-11/NNS||cells-13/NNS	vmod||cells-13/NNS||isolated-14/VBN	det||patient-20/NN||a-16/DT	amod||patient-20/NN||non-insulinoma-17/JJ	amod||patient-20/NN||pancreatogenous-18/JJ	nn||patient-20/NN||hypoglycemicsyndrome-19/NN	prep_from||isolated-14/VBN||patient-20/NN	cop||depolarized-23/JJ||are-21/VBP	advmod||depolarized-23/JJ||constantly-22/RB	ccomp||show-2/VBP||depolarized-23/JJ	advmod||at-26/IN||even-25/RB	prep||depolarized-23/JJ||at-26/IN	amod||levels-29/NNS||low-27/JJ	nn||levels-29/NNS||glucose-28/NN	pobj||at-26/IN||levels-29/NNS	nn||physiology-36/NN||display-32/NN	amod||physiology-36/NN||normal-33/JJ	amod||physiology-36/NN||k-atp-34/JJ	nn||physiology-36/NN||channel-35/NN	prep||depolarized-23/JJ||physiology-36/NN	conj_but||at-26/IN||physiology-36/NN	hypoglycemicsyndrome-19||glucose-28||yes||we show, for the first time, that î²-cells isolated from a non-insulinoma pancreatogenous hypoglycemicsyndrome patient are constantly depolarized, even at low glucose levels, but display normal k-atp channel physiology.
det||guideline-3/NN||the-1/DT	amod||guideline-3/NN||national-2/JJ	nsubj||recommends-4/VBZ||guideline-3/NN	root||ROOT-0/null||recommends-4/VBZ	num||diagnosis-7/NN||three-5/CD	amod||diagnosis-7/NN||different-6/JJ	dep||recommends-4/VBZ||diagnosis-7/NN	nn||strategies-10/NNS||treatment-9/NN	dep||recommends-4/VBZ||strategies-10/NNS	conj_and||diagnosis-7/NN||strategies-10/NNS	nn||i-15/NNS||health-12/NN	nn||i-15/NNS||post-13/NN	nn||i-15/NNS||level-14/NN	prep_at||diagnosis-7/NN||i-15/NNS	det||use-18/NN||the-17/DT	dobj||recommends-4/VBZ||use-18/NN	det||p.falciparum-21/NN||a-20/DT	prep_of||use-18/NN||p.falciparum-21/NN	punct||rdt-25/NN||/-22/:	amod||rdt-25/NN||vivax-23/JJ	amod||rdt-25/NN||specific-24/JJ	dep||use-18/NN||rdt-25/NN	nn||tool-28/NN||diagnosis-27/NN	prep_as||rdt-25/NN||tool-28/NN	aux||treat-31/VB||to-30/TO	prep_as||rdt-25/NN||treat-31/VB	conj_and||tool-28/NN||treat-31/VB	vmod||tool-28/NN||treat-31/VB	prep_with||treat-31/VB||artemether-lumefantrine-33/NN	appos||artemether-lumefantrine-33/NN||al-35/NNP	amod||cq-40/NN||chloroquine-38/JJ	prep_with||treat-31/VB||cq-40/NN	conj_or||artemether-lumefantrine-33/NN||cq-40/NN	prep_with||treat-31/VB||referral-43/NN	conj_or||artemether-lumefantrine-33/NN||referral-43/NN	mark||diagnosed-48/VBN||if-44/IN	det||patient-46/NN||the-45/DT	nsubjpass||diagnosed-48/VBN||patient-46/NN	auxpass||diagnosed-48/VBN||was-47/VBD	advcl||treat-31/VB||diagnosed-48/VBN	prep_with||diagnosed-48/VBN||p.falciparum-50/NN	prep_with||diagnosed-48/VBN||p.vivax-52/NN	conj_or||p.falciparum-50/NN||p.vivax-52/NN	neg||malaria-55/NN||no-54/DT	prep_with||diagnosed-48/VBN||malaria-55/NN	conj_or||p.falciparum-50/NN||malaria-55/NN	dep||rdt-25/NN||respectively-57/RB	nn||pan/pf-60/NN||parascreen-59/NN	dep||use-18/NN||pan/pf-60/NN	vmod||pan/pf-60/NN||based-61/VBN	dobj||based-61/VBN||strategy-62/NN	csubj||diagnosed-101/VBD||ii-65/VB	det||use-68/NN||the-67/DT	dobj||ii-65/VB||use-68/NN	det||rdt-73/NN||a-70/DT	amod||rdt-73/NN||p.falciparum-71/JJ	amod||rdt-73/NN||specific-72/JJ	prep_of||ii-65/VB||rdt-73/NN	prep_of||ii-65/VB||al-75/NNP	conj_and||rdt-73/NN||al-75/NNP	nn||cases-78/NNS||p.falciparum-77/NN	prep_for||al-75/NNP||cases-78/NNS	prep_for||al-75/NNP||cq-80/NN	conj_and||cases-78/NNS||cq-80/NN	det||rest-83/NN||the-82/DT	prep_for||cases-78/NNS||rest-83/NN	nn||pf-86/NN||paracheck-85/NN	dep||cases-78/NNS||pf-86/NN	vmod||pf-86/NN||based-87/VBN	dobj||based-87/VBN||strategy-88/NN	conj_and||ii-65/VB||iii-92/VB	csubj||diagnosed-101/VBD||iii-92/VB	det||use-95/NN||the-94/DT	dobj||iii-92/VB||use-95/NN	prep_of||iii-92/VB||al-97/NNP	det||cases-100/NNS||all-99/DT	prep_for||al-97/NNP||cases-100/NNS	parataxis||recommends-4/VBZ||diagnosed-101/VBD	advmod||diagnosed-101/VBD||presumptively-102/RB	prep_as||diagnosed-101/VBD||malaria-104/NN	dep||malaria-104/NN||presumptive-106/NN	vmod||presumptive-106/NN||based-107/VBN	dobj||based-107/VBN||strategy-108/NN	chloroquine-38||malaria-104||no_rel||the national guideline recommends three different diagnosis and treatment strategies at health post level i) the use of a p.falciparum / vivax specific rdt as diagnosis tool and to treat with artemether-lumefantrine (al), chloroquine (cq) or referral if the patient was diagnosed with p.falciparum , p.vivax or no malaria, respectively (parascreen pan/pf based strategy); ii) the use of a p.falciparum specific rdt and al for p.falciparum cases and cq for the rest (paracheck pf based strategy); and iii) the use of al for all cases diagnosed presumptively as malaria (presumptive based strategy).
det||response-4/NN||the-1/DT	amod||response-4/NN||innate-2/JJ	amod||response-4/NN||immune-3/JJ	nsubj||essential-6/JJ||response-4/NN	cop||essential-6/JJ||is-5/VBZ	root||ROOT-0/null||essential-6/JJ	det||defense-10/NN||the-8/DT	nn||defense-10/NN||host-9/NN	prep_to||essential-6/JJ||defense-10/NN	prep_against||defense-10/NN||viruses-12/NNS	prep_through||essential-6/JJ||restriction-15/NN	nn||replication-18/NN||virus-17/NN	prep_of||restriction-15/NN||replication-18/NN	prep_of||restriction-15/NN||coordination-20/NN	conj_and||replication-18/NN||coordination-20/NN	det||response-25/NN||the-22/DT	amod||response-25/NN||adaptive-23/JJ	amod||response-25/NN||immune-24/JJ	prep_of||restriction-15/NN||response-25/NN	virus-17||viruses-12||no||the innate immune response is essential to the host defense against viruses, through restriction of virus replication and coordination of the adaptive immune response.
root||ROOT-0/null||hereditary-1/VBD	amod||k-dependent-4/NN||combined-2/VBN	nn||k-dependent-4/NN||vitamin-3/NN	nsubj||clottingfactors-5/VBZ||k-dependent-4/NN	ccomp||hereditary-1/VBD||clottingfactors-5/VBZ	nsubj||bleedingdisorder-14/NN||deficiency-6/NN	dep||deficiency-6/NN||vkcfd-8/VBN	cop||bleedingdisorder-14/NN||is-10/VBZ	det||bleedingdisorder-14/NN||a-11/DT	amod||bleedingdisorder-14/NN||rare-12/JJ	amod||bleedingdisorder-14/NN||congenital-13/JJ	ccomp||clottingfactors-5/VBZ||bleedingdisorder-14/NN	vmod||bleedingdisorder-14/NN||resulting-15/VBG	amod||levels-19/NNS||variably-17/JJ	amod||levels-19/NNS||decreased-18/VBN	prep_from||resulting-15/VBG||levels-19/NNS	amod||ii-23/NN||coagulation-21/JJ	nn||ii-23/NN||factors-22/NNS	prep_of||levels-19/NNS||ii-23/NN	prep_of||levels-19/NNS||vii-25/NN	conj_and||ii-23/NN||vii-25/NN	prep_of||levels-19/NNS||ix-27/NN	conj_and||ii-23/NN||ix-27/NN	prep_of||levels-19/NNS||x-29/SYM	conj_and||ii-23/NN||x-29/SYM	amod||anticoagulants-34/NNS||natural-33/JJ	ccomp||clottingfactors-5/VBZ||anticoagulants-34/NNS	conj_and||bleedingdisorder-14/NN||anticoagulants-34/NNS	dep||anticoagulants-34/NNS||protein-35/NN	nsubj||hereditary-1/VBD||c-36/SYM	nn||s-39/NNS||protein-38/NN	appos||c-36/SYM||s-39/NNS	nn||z.-42/NN||protein-41/NN	appos||c-36/SYM||z.-42/NN	conj_and||s-39/NNS||z.-42/NN	ix-27||bleedingdisorder-14||no_rel||hereditary combined vitamin k-dependent clottingfactors deficiency (vkcfd) is a rare congenital bleedingdisorder resulting from variably decreased levels of coagulation factors ii, vii, ix and x as well as natural anticoagulants protein c, protein s and protein z.
nsubjpass||included-30/VBN||patients-1/NNS	advmod||hypertension-5/NN||previously-3/RB	amod||hypertension-5/NN||uncontrolled-4/JJ	prep_with||patients-1/NNS||hypertension-5/NN	quantmod||one-9/CD||at-7/IN	mwe||at-7/IN||least-8/JJS	pobj||at-7/IN||least-8/JJS	num||factor-12/NN||one-9/CD	amod||factor-12/NN||further-10/JJ	nn||factor-12/NN||risk-11/NN	prep_with||hypertension-5/NN||factor-12/NN	prep_in||deemed-16/VBD||factor-12/NN	nsubj||deemed-16/VBD||physicians-15/NNS	rcmod||factor-12/NN||deemed-16/VBD	det||treatment-18/NN||a-17/DT	dobj||deemed-16/VBD||treatment-18/NN	num||hctz-25/NNS||16-20/CD	amod||hctz-25/NNS||mg-21/JJ	amod||hctz-25/NNS||candesartan/12-22/JJ	num||hctz-25/NNS||.5-23/CD	nn||hctz-25/NNS||mg-24/NN	prep_with||deemed-16/VBD||hctz-25/NNS	aux||necessary-28/JJ||to-26/TO	cop||necessary-28/JJ||be-27/VB	vmod||deemed-16/VBD||necessary-28/JJ	auxpass||included-30/VBN||were-29/VBD	root||ROOT-0/null||included-30/VBN	hypertension-5||hctz-25||yes||patients with previously uncontrolled hypertension with at least one further risk factor in which physicians deemed a treatment with 16 mg candesartan/12.5 mg hctz to be necessary were included.
amod||standard-2/NN||gold-1/JJ	nsubj||number-8/NN||standard-2/NN	amod||fever-5/NN||malaria-attributable-4/JJ	prep_for||standard-2/NN||fever-5/NN	cop||number-8/NN||was-6/VBD	det||number-8/NN||the-7/DT	root||ROOT-0/null||number-8/NN	prep_of||number-8/NN||fevers-10/NNS	amod||fevers-10/NNS||attributable-11/JJ	prep_to||attributable-11/JJ||malaria-13/NN	vmod||fevers-10/NNS||estimated-15/VBN	agent||estimated-15/VBN||comparing-17/VBG	nn||densities-19/NNS||parasite-18/NN	dobj||comparing-17/VBG||densities-19/NNS	prep_of||densities-19/NNS||febrile-21/NN	amod||subjects-24/NNS||non-febrile-23/JJ	prep_versus||febrile-21/NN||subjects-24/NNS	malaria-13||gold-1||no_rel||gold standard for malaria-attributable fever was the number of fevers attributable to malaria, estimated by comparing parasite densities of febrile versus non-febrile subjects.
nsubj||included-9/VBD||factors-1/NNS	vmod||factors-1/NNS||related-2/VBN	prep_to||related-2/VBN||participation-4/NN	nn||programs-8/NNS||hiv-6/NN	nn||programs-8/NNS||prevention-7/NN	prep_in||participation-4/NN||programs-8/NNS	root||ROOT-0/null||included-9/VBD	nn||perception-18/NN||age-10/NN	dep||perception-18/NN||ethnicity-12/NN	dep||perception-18/NN||income-14/NN	amod||perception-18/NN||hiv-16/JJ	nn||perception-18/NN||risk-17/NN	dobj||included-9/VBD||perception-18/NN	dep||included-9/VBD||living-20/VBG	prep_with||living-20/VBG||boyfriend-22/NN	dep||included-9/VBD||living-24/VBG	conj_and||living-20/VBG||living-24/VBG	amod||area-27/NN||urban-26/JJ	nsubj||talked-36/VBN||area-27/NN	appos||area-27/NN||size-29/NN	amod||network-33/NN||msm-31/JJ	amod||network-33/NN||social-32/JJ	prep_of||size-29/NN||network-33/NN	aux||talked-36/VBN||having-35/VBG	prepc_in||living-24/VBG||talked-36/VBN	nn||status-39/NN||hiv-38/NN	prep_about||talked-36/VBN||status-39/NN	prep_with||talked-36/VBN||partners-41/NNS	dep||included-9/VBD||knowing-44/VBG	conj_and||living-20/VBG||knowing-44/VBG	dobj||knowing-44/VBG||someone-45/NN	nsubj||hivpositive-48/JJ||someone-45/NN	cop||hivpositive-48/JJ||is-47/VBZ	rcmod||someone-45/NN||hivpositive-48/JJ	hivpositive-48||hiv-38||no||factors related to participation in hiv prevention programs included age, ethnicity, income, hiv risk perception, living with boyfriend, living in urban area, size of msm social network, having talked about hiv status with partners, and knowing someone who is hivpositive.
mark||recommended-5/VBN||although-1/IN	nsubjpass||recommended-5/VBN||walking-2/NN	auxpass||recommended-5/VBN||is-3/VBZ	advmod||recommended-5/VBN||commonly-4/RB	advcl||used-23/VBN||recommended-5/VBN	prepc_for||recommended-5/VBN||reducing-7/VBG	dobj||reducing-7/VBG||pain-8/NN	prepc_for||recommended-5/VBN||increasing-10/VBG	conj_and||reducing-7/VBG||increasing-10/VBG	amod||function-12/NN||physical-11/JJ	dobj||increasing-10/VBG||function-12/NN	prep_in||increasing-10/VBG||people-14/NNS	prep_with||people-14/NNS||oa-16/NN	amod||sulphate-19/NN||glucosamine-18/JJ	nsubjpass||used-23/VBN||sulphate-19/NN	nsubj||alleviate-25/VB||sulphate-19/NN	nsubj||slow-28/VB||sulphate-19/NN	aux||used-23/VBN||has-20/VBZ	advmod||used-23/VBN||also-21/RB	auxpass||used-23/VBN||been-22/VBN	root||ROOT-0/null||used-23/VBN	aux||alleviate-25/VB||to-24/TO	xcomp||used-23/VBN||alleviate-25/VB	dobj||alleviate-25/VB||pain-26/NN	xcomp||used-23/VBN||slow-28/VB	conj_and||alleviate-25/VB||slow-28/VB	det||progression-30/NN||the-29/DT	dobj||slow-28/VB||progression-30/NN	prep_of||progression-30/NN||oa-32/NN	oa-32||glucosamine-18||yes||although walking is commonly recommended for reducing pain and increasing physical function in people with oa, glucosamine sulphate has also been used to alleviate pain and slow the progression of oa.
nsubjpass||cured-9/VBN||patients-1/NNS	amod||tumors-6/NNS||advanced-3/JJ	nn||tumors-6/NNS||germ-4/NN	nn||tumors-6/NNS||cell-5/NN	prep_with||patients-1/NNS||tumors-6/NNS	aux||cured-9/VBN||can-7/MD	auxpass||cured-9/VBN||be-8/VB	root||ROOT-0/null||cured-9/VBN	amod||chemotherapy-12/NN||cisplatin-based-11/JJ	prep_with||cured-9/VBN||chemotherapy-12/NN	det||outcome-16/NN||the-15/DT	nsubj||remains-17/VBZ||outcome-16/NN	conj_but||cured-9/VBN||remains-17/VBZ	advmod||remains-17/VBZ||unsatisfactory-18/RB	prep_for||remains-17/VBZ||patients-20/NNS	prep_with||patients-20/NNS||relapseddisease-22/NN	det||patients-26/NNS||those-25/DT	prep_including||patients-20/NNS||patients-26/NNS	amod||disease-29/NN||refractory-28/JJ	prep_with||patients-26/NNS||disease-29/NN	nn||transplantation-33/NN||bone-31/NN	nn||transplantation-33/NN||marrow-32/NN	prep_after||disease-29/NN||transplantation-33/NN	relapseddisease-22||cisplatin--1||no_rel||patients with advanced germ cell tumors can be cured with cisplatin-based chemotherapy, but the outcome remains unsatisfactory for patients with relapseddisease, including those patients with refractory disease after bone marrow transplantation.
det||stress-3/NN||the-1/DT	amod||stress-3/NN||oxidative-2/JJ	nsubj||accompanies-5/VBZ||stress-3/NN	nsubj||attributed-30/VBD||stress-3/NN	nsubj||obesity-32/VB||stress-3/NN	rcmod||stress-3/NN||accompanies-5/VBZ	nsubj||contribute-27/VB||feeding-6/NN	advmod||when-9/WRB||particularly-8/RB	advmod||is-11/VBZ||when-9/WRB	expl||is-11/VBZ||there-10/EX	rcmod||feeding-6/NN||is-11/VBZ	amod||ingestion-13/NN||excessive-12/JJ	nsubj||is-11/VBZ||ingestion-13/NN	amod||macronutrients-18/NNS||fat-15/JJ	amod||macronutrients-18/NNS||and/or-16/JJ	amod||macronutrients-18/NNS||other-17/JJ	prep_of||ingestion-13/NN||macronutrients-18/NNS	amod||ingestion-21/NN||concomitant-20/JJ	prep_without||macronutrients-18/NNS||ingestion-21/NN	amod||foods/beverages-24/NNS||antioxidant-rich-23/JJ	prep_of||ingestion-21/NN||foods/beverages-24/NNS	aux||contribute-27/VB||may-26/MD	ccomp||accompanies-5/VBZ||contribute-27/VB	prep_to||contribute-27/VB||inflammation-29/NN	root||ROOT-0/null||attributed-30/VBD	aux||obesity-32/VB||to-31/TO	xcomp||attributed-30/VBD||obesity-32/VB	inflammation-29||fat-15||no_rel||the oxidative stress which accompanies feeding, particularly when there is excessive ingestion of fat and/or other macronutrients without concomitant ingestion of antioxidant-rich foods/beverages, may contribute to inflammation attributed to obesity.
csubj||influences-11/VBZ||encapsulating-1/VBG	amod||influenzavirus-4/NNS||inactivated-2/JJ	amod||influenzavirus-4/NNS||h5n1-3/JJ	dobj||encapsulating-1/VBG||influenzavirus-4/NNS	dobj||encapsulating-1/VBG||cpg-6/NN	conj_and||influenzavirus-4/NNS||cpg-6/NN	advmod||nanoparticles-9/JJ||emulsified-8/RB	prep_into||encapsulating-1/VBG||nanoparticles-9/JJ	advmod||nanoparticles-9/JJ||critically-10/RB	root||ROOT-0/null||influences-11/VBZ	det||responses-14/NNS||the-12/DT	amod||responses-14/NNS||humoral-13/JJ	dobj||influences-11/VBZ||responses-14/NNS	amod||influenza-17/NN||pandemic-16/JJ	prep_against||responses-14/NNS||influenza-17/NN	h5n1-3||influenzavirus-4||no||encapsulating inactivated h5n1 influenzavirus and cpg into emulsified nanoparticles critically influences the humoral responses against pandemic influenza.
poss||study-2/NN||our-1/PRP$	nsubj||demonstrated-3/VBD||study-2/NN	nsubj||suggest-21/VBP||study-2/NN	root||ROOT-0/null||demonstrated-3/VBD	mark||increased-11/VBN||that-4/IN	det||a2ars-6/NN||the-5/DT	nsubjpass||increased-11/VBN||a2ars-6/NN	det||putamen-9/NN||the-8/DT	prep_in||a2ars-6/NN||putamen-9/NN	auxpass||increased-11/VBN||were-10/VBD	ccomp||demonstrated-3/VBD||increased-11/VBN	det||patients-15/NNS||the-13/DT	nn||patients-15/NNS||pd-14/NN	prep_in||increased-11/VBN||patients-15/NNS	prep_with||increased-11/VBN||dyskinesia-17/NN	advmod||suggest-21/VBP||also-20/RB	conj_and||demonstrated-3/VBD||suggest-21/VBP	mark||compensate-28/VB||that-22/IN	det||a2ars-24/NN||the-23/DT	nsubj||compensate-28/VB||a2ars-24/NN	det||putamen-27/NN||the-26/DT	prep_in||a2ars-24/NN||putamen-27/NN	ccomp||suggest-21/VBP||compensate-28/VB	det||decrease-32/NN||the-30/DT	amod||decrease-32/NN||asymmetrical-31/JJ	prep_for||compensate-28/VB||decrease-32/NN	prep_of||decrease-32/NN||dopamine-34/NN	amod||patients-40/NNS||drug-naã-36/JJ	nn||patients-40/NNS||¯-37/NNP	nn||patients-40/NNS||ve-38/NN	nn||patients-40/NNS||pd-39/NN	prep_in||compensate-28/VB||patients-40/NNS	mark||increases-45/VBZ||that-42/IN	nn||therapy-44/NN||antiparkinsonian-43/NN	nsubj||increases-45/VBZ||therapy-44/NN	ccomp||suggest-21/VBP||increases-45/VBZ	conj_and||compensate-28/VB||increases-45/VBZ	det||a2ars-47/NN||the-46/DT	dobj||increases-45/VBZ||a2ars-47/NN	det||putamen-50/NN||the-49/DT	prep_in||a2ars-47/NN||putamen-50/NN	dyskinesia-17||antiparkinsonian-43||no_rel||our study demonstrated that the a2ars in the putamen were increased in the pd patients with dyskinesia, and also suggest that the a2ars in the putamen compensate for the asymmetrical decrease of dopamine in drug-naã¯ve pd patients and that antiparkinsonian therapy increases the a2ars in the putamen.
det||female-3/NN||a-1/DT	amod||female-3/NN||72-year-old-2/JJ	nsubj||treated-11/VBN||female-3/NN	det||male-7/NN||a-5/DT	amod||male-7/NN||57-year-old-6/JJ	conj_and||female-3/NN||male-7/NN	nsubj||treated-11/VBN||male-7/NN	prep_with||male-7/NN||chronichepatitisc-9/NN	aux||treated-11/VBN||were-10/VBD	root||ROOT-0/null||treated-11/VBN	det||therapy-15/NN||a-13/DT	nn||therapy-15/NN||combination-14/NN	prep_with||treated-11/VBN||therapy-15/NN	amod||-rrb--21/NNS||pegylated-17/JJ	nn||-rrb--21/NNS||interferon-18/NN	nn||-rrb--21/NNS||-lrb--19/NN	amod||-rrb--21/NNS||peg-ifn-20/JJ	prep_of||therapy-15/NN||-rrb--21/NNS	dep||treated-11/VBN||î-23/VBN	amod||s.c.-31/NN||±-24/JJ	amod||s.c.-31/NN||2a-25/JJ	number||180-27/CD||-lrb--26/CD	num||s.c.-31/NN||180-27/CD	nn||s.c.-31/NN||î-28/NN	num||s.c.-31/NN||1/4-29/CD	nn||s.c.-31/NN||g-30/NN	dobj||î-23/VBN||s.c.-31/NN	advmod||week-34/NN||once-32/RB	det||week-34/NN||a-33/DT	tmod||î-23/VBN||week-34/NN	nn||-rrb--43/NNS||-rrb--35/NNP	conj_and||-rrb--35/NNP||ribavirin-37/NNP	nn||-rrb--43/NNS||ribavirin-37/NNP	nn||-rrb--43/NNS||-lrb--38/NNP	num||-rrb--43/NNS||1,000-39/CD	amod||-rrb--43/NNS||mg-40/JJ	nn||-rrb--43/NNS||orally-41/NN	amod||-rrb--43/NNS||daily-42/JJ	dobj||treated-11/VBN||-rrb--43/NNS	chronichepatitisc-9||ribavirin-37||yes||a 72-year-old female and a 57-year-old male with chronichepatitisc were treated with a combination therapy of pegylated interferon -lrb- peg-ifn -rrb- - î ± 2a -lrb- 180 î 1/4 g s.c. once a week -rrb- and ribavirin -lrb- 1,000 mg orally daily -rrb- .
quantmod||99-2/CD||almost-1/RB	num||%-3/NN||99-2/CD	nsubj||heard-8/VBN||%-3/NN	det||respondents-6/NNS||the-5/DT	prep_of||%-3/NN||respondents-6/NNS	aux||heard-8/VBN||had-7/VBD	root||ROOT-0/null||heard-8/VBN	prep_of||heard-8/VBN||hiv/aids-10/NNS	num||%-14/NN||89-13/CD	nsubj||identify-16/VB||%-14/NN	aux||identify-16/VB||could-15/MD	conj_and||heard-8/VBN||identify-16/VB	dobj||identify-16/VB||ways-17/NNS	nsubj||protect-19/VB||ways-17/NNS	aux||protect-19/VB||to-18/TO	xcomp||identify-16/VB||protect-19/VB	dobj||protect-19/VB||oneself-20/PRP	advmod||hiv/aids-24/NNS||sexually-22/RB	amod||hiv/aids-24/NNS||transmitted-23/JJ	prep_against||protect-19/VB||hiv/aids-24/NNS	aids--1||hiv--1||no||almost 99% of the respondents had heard of hiv/aids, and 89% could identify ways to protect oneself against sexually transmitted hiv/aids.
amod||imaging-2/NN||bioluminescence-1/JJ	nsubj||exhibited-16/VBD||imaging-2/NN	nn||xenografts-5/NNS||tumor-4/NN	prep_of||imaging-2/NN||xenografts-5/NNS	advmod||expressing-7/VBG||stably-6/RB	vmod||xenografts-5/NNS||expressing-7/VBG	det||sensor-10/NN||the-8/DT	amod||sensor-10/NN||pik3ca-9/JJ	dobj||expressing-7/VBG||sensor-10/NN	amod||cells-15/NNS||pa1-12/JJ	conj_and||pa1-12/JJ||a2780-14/JJ	amod||cells-15/NNS||a2780-14/JJ	prep_in||sensor-10/NN||cells-15/NNS	root||ROOT-0/null||exhibited-16/VBD	amod||activity-18/NN||attenuating-17/JJ	dobj||exhibited-16/VBD||activity-18/NN	det||change-21/NN||any-20/DT	prep_without||exhibited-16/VBD||change-21/NN	amod||tumors-24/NNS||skov3-23/JJ	prep_in||change-21/NN||tumors-24/NNS	xcomp||exhibited-16/VBD||expressing-25/VBG	det||sensor-28/NN||the-26/DT	amod||sensor-28/NN||pik3ca-27/JJ	dobj||expressing-25/VBG||sensor-28/NN	nn||treatment-31/NN||cisplatin-30/NN	prep_after||expressing-25/VBG||treatment-31/NN	tumors-24||cisplatin-30||no_rel||bioluminescence imaging of tumor xenografts stably expressing the pik3ca sensor in pa1 and a2780 cells exhibited attenuating activity without any change in skov3 tumors expressing the pik3ca sensor after cisplatin treatment.
nsubj||component-8/NN||rifampicin-1/NN	appos||rifampicin-1/NN||rif-3/NN	cop||component-8/NN||is-5/VBZ	det||component-8/NN||a-6/DT	amod||component-8/NN||major-7/JJ	root||ROOT-0/null||component-8/NN	amod||therapy-13/NN||fixed-10/VBN	nn||therapy-13/NN||dose-11/NN	nn||therapy-13/NN||combination-12/NN	prep_in||component-8/NN||therapy-13/NN	det||treatment-16/NN||the-15/DT	prep_for||therapy-13/NN||treatment-16/NN	prep_of||treatment-16/NN||tuberculosis-18/NNP	tuberculosis-18||rif-3||yes||rifampicin (rif) is a major component in fixed dose combination therapy for the treatment of tuberculosis.
mark||intractable-5/JJ||while-1/IN	nsubj||intractable-5/JJ||seizures-2/NNS	cop||intractable-5/JJ||are-3/VBP	advmod||intractable-5/JJ||usually-4/RB	advcl||appears-24/VBZ||intractable-5/JJ	prep_to||intractable-5/JJ||medication-7/NN	amod||complex-11/NN||tuberous-9/JJ	nn||complex-11/NN||sclerosis-10/NN	prep_in||intractable-5/JJ||complex-11/NN	appos||complex-11/NN||tsc-13/NN	det||cause-19/NN||a-16/DT	amod||cause-19/NN||common-17/JJ	amod||cause-19/NN||genetic-18/JJ	dep||intractable-5/JJ||cause-19/NN	prep_of||cause-19/NN||epilepsy-21/NN	nsubj||appears-24/VBZ||vigabatrin-23/NN	nsubj||have-26/VB||vigabatrin-23/NN	root||ROOT-0/null||appears-24/VBZ	aux||have-26/VB||to-25/TO	xcomp||appears-24/VBZ||have-26/VB	amod||efficacy-28/NN||unique-27/JJ	dobj||have-26/VB||efficacy-28/NN	prep_for||efficacy-28/NN||epilepsy-30/NN	prep_in||epilepsy-30/NN||tsc-32/NN	epilepsy-30||vigabatrin-23||yes||while seizures are usually intractable to medication in tuberous sclerosis complex (tsc), a common genetic cause of epilepsy, vigabatrin appears to have unique efficacy for epilepsy in tsc.
amod||m.tb-2/NN||rifampin-resistant-1/JJ	nsubjpass||found-37/VBN||m.tb-2/NN	dep||m.tb-2/NN||nâ-4/NN	num||â-8/NN||$-5/$	number||=-7/CD||š-6/CD	num||$-5/$||=-7/CD	dep||nâ-4/NN||â-8/NN	dep||â-8/NN||$-9/$	num||$-9/$||š41-10/CD	conj_and||m.tb-2/NN||tb-iris-13/NNS	nsubjpass||found-37/VBN||tb-iris-13/NNS	dep||tb-iris-13/NNS||nâ-15/NN	num||â-19/NN||$-16/$	number||=-18/CD||š-17/CD	num||$-16/$||=-18/CD	dep||nâ-15/NN||â-19/NN	dep||â-19/NN||$-20/$	num||$-20/$||š51-21/CD	npadvmod||resistant-25/JJ||drug-24/NN	amod||bacterialinfections-26/NNS||resistant-25/JJ	conj_and||m.tb-2/NN||bacterialinfections-26/NNS	nsubjpass||found-37/VBN||bacterialinfections-26/NNS	dep||m.tb-2/NN||nâ-28/NN	num||â-32/NN||$-29/$	number||=-31/CD||š-30/CD	num||$-29/$||=-31/CD	dep||nâ-28/NN||â-32/NN	dep||â-32/NN||$-33/$	num||$-33/$||š12-34/CD	auxpass||found-37/VBN||were-36/VBD	root||ROOT-0/null||found-37/VBN	num||%-40/NN||12-39/CD	prep_in||found-37/VBN||%-40/NN	num||%-43/NN||14-42/CD	prep_in||found-37/VBN||%-43/NN	conj_and||%-40/NN||%-43/NN	num||%-46/NN||3.4-45/CD	prep_in||found-37/VBN||%-46/NN	conj_and||%-40/NN||%-46/NN	det||cases-50/NNS||the-48/DT	amod||cases-50/NNS||352-49/JJ	prep_of||%-46/NN||cases-50/NNS	advmod||found-37/VBN||respectively-52/RB	tb--1||rifampin--1||yes||rifampin-resistant m.tb (nâ€š=â€š41), tb-iris (nâ€š=â€š51) and drug resistant bacterialinfections (nâ€š=â€š12) were found in 12%, 14% and 3.4% of the 352 cases, respectively.
det||study-2/NN||this-1/DT	nsubjpass||based-4/VBN||study-2/NN	auxpass||based-4/VBN||is-3/VBZ	root||ROOT-0/null||based-4/VBN	nn||samples-9/NNS||tumor-6/NN	conj_and||tumor-6/NN||serum-8/NN	nn||samples-9/NNS||serum-8/NN	prep_on||based-4/VBN||samples-9/NNS	num||patients-14/NNS||93-11/CD	amod||patients-14/NNS||adult-12/JJ	nn||patients-14/NNS||sts-13/NN	prep_from||based-4/VBN||patients-14/NNS	sts-13||tumor-6||no_rel||this study is based on tumor and serum samples from 93 adult sts patients.
advmod||represent-8/VB||overall-1/RB	det||line-6/NN||the-3/DT	nn||line-6/NN||hab-4/NN	nn||line-6/NN||mouse-5/NN	nsubj||represent-8/VB||line-6/NN	aux||represent-8/VB||may-7/MD	root||ROOT-0/null||represent-8/VB	det||model-11/NN||an-9/DT	amod||model-11/NN||interesting-10/JJ	dobj||represent-8/VB||model-11/NN	dep||represent-8/VB||i-13/VB	prepc_for||represent-8/VB||identifying-16/VBG	amod||factors-18/NNS||biological-17/JJ	dobj||identifying-16/VBG||factors-18/NNS	vmod||factors-18/NNS||underlying-19/VBG	amod||responses-23/NNS||misguided-20/JJ	amod||responses-23/NNS||conditioned-21/JJ	nn||responses-23/NNS||fear-22/NN	dobj||underlying-19/VBG||responses-23/NNS	dobj||underlying-19/VBG||ii-26/NN	conj_and||responses-23/NNS||ii-26/NN	prepc_for||underlying-19/VBG||studying-29/VBG	amod||pharmacotherapies-32/NNS||novel-30/JJ	amod||pharmacotherapies-32/NNS||anxiolytic-31/JJ	dobj||studying-29/VBG||pharmacotherapies-32/NNS	prep_for||pharmacotherapies-32/NNS||patients-34/NNS	amod||disorders-37/NNS||fear-associated-36/JJ	prep_with||patients-34/NNS||disorders-37/NNS	prep_including||pharmacotherapies-32/NNS||post-traumaticstressdisorder-40/NN	prep_including||pharmacotherapies-32/NNS||phobias-42/NN	conj_and||post-traumaticstressdisorder-40/NN||phobias-42/NN	post-traumaticstressdisorder-40||anxiolytic-31||no_rel||overall, the hab mouse line may represent an interesting model (i) for identifying biological factors underlying misguided conditioned fear responses and (ii) for studying novel anxiolytic pharmacotherapies for patients with fear-associated disorders, including post-traumaticstressdisorder and phobias.
nsubj||treated-2/VBD||we-1/PRP	root||ROOT-0/null||treated-2/VBD	det||level-5/NN||a-3/DT	amod||level-5/NN||long-4/JJ	dobj||treated-2/VBD||level-5/NN	iobj||treated-2/VBD||level-5/NN	nsubj||had-16/VBD||level-5/NN	nsubj||undergo-18/VB||level-5/NN	nsubj||drainage-24/VB||level-5/NN	dep||level-5/NN||t4-l1-7/JJ	amod||abscess-10/NNS||epidural-9/JJ	dep||level-5/NN||abscess-10/NNS	det||patient-14/NN||a-12/DT	amod||patient-14/NN||diabetic-13/JJ	prep_in||abscess-10/NNS||patient-14/NN	rcmod||level-5/NN||had-16/VBD	aux||undergo-18/VB||to-17/TO	xcomp||had-16/VBD||undergo-18/VB	amod||decompression-22/NNS||emergent-19/JJ	amod||decompression-22/NNS||long-20/JJ	nn||decompression-22/NNS||level-21/NN	dobj||undergo-18/VB||decompression-22/NNS	xcomp||had-16/VBD||drainage-24/VB	conj_and||undergo-18/VB||drainage-24/VB	acomp||drainage-24/VB||due-25/JJ	aux||complete-27/VB||to-26/TO	xcomp||due-25/JJ||complete-27/VB	dobj||complete-27/VB||paralysis-28/NN	det||extremities-32/NNS||the-30/DT	amod||extremities-32/NNS||lower-31/JJR	prep_of||paralysis-28/NN||extremities-32/NNS	dobj||complete-27/VB||progression-34/NN	conj_and||paralysis-28/NN||progression-34/NN	amod||deficit-37/NN||neurologic-36/JJ	prep_of||progression-34/NN||deficit-37/NN	det||level-42/NN||the-39/DT	amod||level-42/NN||upper-40/JJ	amod||level-42/NN||thoracic-41/JJ	prep_toward||complete-27/VB||level-42/NN	t4--1||deficit-37||no_rel||we treated a long level (t4-l1) epidural abscess in a diabetic patient who had to undergo emergent long level decompression and drainage due to complete paralysis of the lower extremities and progression of neurologic deficit toward the upper thoracic level.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||studied-8/VBN||study-4/NN	nsubj||studied-8/VBN||we-6/PRP	aux||studied-8/VBN||have-7/VBP	root||ROOT-0/null||studied-8/VBN	ccomp||studied-8/VBN||total-9/VB	num||patients-12/NNS||177-10/CD	amod||patients-12/NNS||eligible-11/JJ	dobj||total-9/VB||patients-12/NNS	dobj||total-9/VB||subjects-14/NNS	conj_and||patients-12/NNS||subjects-14/NNS	num||epstein-barr-virus-19/NNS||128-16/CD	amod||epstein-barr-virus-19/NNS||healthy-17/JJ	nn||epstein-barr-virus-19/NNS||latent-18/NN	prep_including||patients-12/NNS||epstein-barr-virus-19/NNS	appos||epstein-barr-virus-19/NNS||ebv-21/NN	amod||subjects-25/NNS||infected-24/JJ	dep||epstein-barr-virus-19/NNS||subjects-25/NNS	num||patients-31/NNS||17-27/CD	amod||patients-31/NNS||newly-onset-28/JJ	amod||patients-31/NNS||acute-29/JJ	nn||patients-31/NNS||infectiousmononucleosis-30/NN	dep||epstein-barr-virus-19/NNS||patients-31/NNS	conj_and||subjects-25/NNS||patients-31/NNS	num||patients-37/NNS||16-33/CD	amod||patients-37/NNS||newly-diagnosed-34/JJ	amod||patients-37/NNS||ebv-associated-35/JJ	nn||patients-37/NNS||hodgkinlymphoma-36/NN	dep||epstein-barr-virus-19/NNS||patients-37/NNS	conj_and||subjects-25/NNS||patients-37/NNS	num||subjects-44/NNS||16-40/CD	amod||subjects-44/NNS||ebv-negative-41/JJ	amod||subjects-44/NNS||normal-42/JJ	nn||subjects-44/NNS||control-43/NN	dep||epstein-barr-virus-19/NNS||subjects-44/NNS	conj_and||subjects-25/NNS||subjects-44/NNS	infectiousmononucleosis-30||ebv-21||no||in the present study, we have studied total 177 eligible patients and subjects including 128 healthy latent epstein-barr-virus(ebv)-infected subjects, 17 newly-onset acute infectiousmononucleosis patients, 16 newly-diagnosed ebv-associated hodgkinlymphoma patients, and 16 ebv-negative normal control subjects.
aux||examine-2/VB||to-1/TO	root||ROOT-0/null||examine-2/VB	det||significance-4/NN||the-3/DT	dobj||examine-2/VB||significance-4/NN	amod||immunoassay-11/NN||vzv-igg-6/JJ	nn||immunoassay-11/NN||igg-8/NN	amod||immunoassay-11/NN||enzyme-10/JJ	prep_of||significance-4/NN||immunoassay-11/NN	appos||immunoassay-11/NN||eia-13/NN	det||determination-17/NN||the-16/DT	nsubj||counts-22/VBZ||determination-17/NN	amod||lymphocyte-21/NN||peripheral-19/JJ	nn||lymphocyte-21/NN||blood-20/NN	prep_of||determination-17/NN||lymphocyte-21/NN	conj_and||examine-2/VB||counts-22/VBZ	det||diagnosis-25/NN||the-24/DT	prep_in||counts-22/VBZ||diagnosis-25/NN	amod||zostersineherpete-28/NN||ophthalmic-27/JJ	prep_of||diagnosis-25/NN||zostersineherpete-28/NN	amod||zsh-31/NN||ophthalmic-30/JJ	appos||zostersineherpete-28/NN||zsh-31/NN	zostersineherpete-28||vzv--1||no||to examine the significance of vzv-igg (igg) enzyme immunoassay (eia) and the determination of peripheral blood lymphocyte counts in the diagnosis of ophthalmic zostersineherpete (ophthalmic zsh).
nsubj||pathogen-5/NN||legionellapneumophila-1/NN	cop||pathogen-5/NN||is-2/VBZ	det||pathogen-5/NN||an-3/DT	amod||pathogen-5/NN||opportunistic-4/JJ	root||ROOT-0/null||pathogen-5/NN	nsubj||cause-8/VB||pathogen-5/NN	aux||cause-8/VB||can-7/MD	rcmod||pathogen-5/NN||cause-8/VB	det||pneumonia-11/NN||a-9/DT	amod||pneumonia-11/NN||severe-10/JJ	dobj||cause-8/VB||pneumonia-11/NN	vmod||pneumonia-11/NN||called-12/VBN	dobj||called-12/VBN||legionnaires-13/NNS	dobj||called-12/VBN||disease-15/NN	legionnaires'disease--1||legionellapneumophila-1||no||legionellapneumophila is an opportunistic pathogen that can cause a severe pneumonia called legionnaires'disease.
nn||nervosa-3/NN||bulimia-2/NN	prep_in||found-13/VBN||nervosa-3/NN	det||therapy-10/NN||both-5/DT	amod||therapy-10/NN||fluoxetine-6/JJ	conj_and||fluoxetine-6/JJ||cognitive-8/JJ	amod||therapy-10/NN||cognitive-8/JJ	nn||therapy-10/NN||behavior-9/NN	nsubjpass||found-13/VBN||therapy-10/NN	nsubj||effective-16/JJ||therapy-10/NN	aux||found-13/VBN||have-11/VBP	auxpass||found-13/VBN||been-12/VBN	root||ROOT-0/null||found-13/VBN	aux||effective-16/JJ||to-14/TO	cop||effective-16/JJ||be-15/VB	xcomp||found-13/VBN||effective-16/JJ	bulimia-2||fluoxetine-6||yes||in bulimia nervosa, both fluoxetine and cognitive behavior therapy have been found to be effective.
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	det||survey-5/NN||a-3/DT	amod||survey-5/NN||cross-sectional-4/JJ	dobj||conducted-2/VBD||survey-5/NN	aux||estimate-7/VB||to-6/TO	vmod||conducted-2/VBD||estimate-7/VB	det||prevalence-9/NN||the-8/DT	dobj||estimate-7/VB||prevalence-9/NN	prep_of||prevalence-9/NN||hyperglycemia-11/NN	amod||adults-14/NNS||chinese-13/JJ	prep_among||estimate-7/VB||adults-14/NNS	advmod||diagnosed-17/JJ||newly-16/RB	amod||hiv/aids-18/NNS||diagnosed-17/JJ	prep_with||estimate-7/VB||hiv/aids-18/NNS	aids--1||hiv--1||no||we conducted a cross-sectional survey to estimate the prevalence of hyperglycemia among chinese adults with newly diagnosed hiv/aids.
amod||nanotube-4/NN||single-1/JJ	nn||nanotube-4/NN||wall-2/NN	nn||nanotube-4/NN||carbon-3/NN	nn||constructs-8/NNS||nanotube-4/NN	appos||constructs-8/NNS||swcnt-6/NN	nsubjpass||appended-11/VBN||constructs-8/NNS	auxpass||appended-11/VBN||were-9/VBD	advmod||appended-11/VBN||covalently-10/RB	root||ROOT-0/null||appended-11/VBN	amod||chelates-14/NNS||radiometal-ion-13/JJ	prep_with||appended-11/VBN||chelates-14/NNS	amod||,4,7,10-17/CD||1,4,7,10-tetraazacyclododecane-1-16/JJ	dep||chelates-14/NNS||,4,7,10-17/CD	amod||-RSB--23/NNP||tetraacetic-19/JJ	amod||-RSB--23/NNP||acid-20/JJ	nn||-RSB--23/NNP||-LSB--21/NNP	nn||-RSB--23/NNP||dota-22/NNP	dep||,4,7,10-17/CD||-RSB--23/NNP	amod||-RSB--29/NNS||desferrioxamine-25/JJ	amod||-RSB--29/NNS||b-26/JJ	amod||-RSB--29/NNS||-LSB--27/JJ	nn||-RSB--29/NNS||dfo-28/NN	dep||,4,7,10-17/CD||-RSB--29/NNS	conj_or||-RSB--23/NNP||-RSB--29/NNS	det||tumor-33/NN||the-32/DT	prep_with||appended-11/VBN||tumor-33/NN	conj_and||chelates-14/NNS||tumor-33/NN	amod||e4g10-36/NNS||neovascular-targeting-34/JJ	nn||e4g10-36/NNS||antibody-35/NN	dep||tumor-33/NN||e4g10-36/NNS	chelates-14||tumor-33||no_rel||single wall carbon nanotube (swcnt) constructs were covalently appended with radiometal-ion chelates (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [dota] or desferrioxamine b [dfo]) and the tumor neovascular-targeting antibody e4g10.
nsubj||effect-11/NN||pain-1/NN	det||injection-4/NN||the-3/DT	prep_upon||pain-1/NN||injection-4/NN	prep_of||injection-4/NN||propofol-6/NN	cop||effect-11/NN||is-7/VBZ	det||effect-11/NN||a-8/DT	amod||effect-11/NN||common-9/JJ	amod||effect-11/NN||adverse-10/JJ	root||ROOT-0/null||effect-11/NN	pain-1||propofol-6||yes||pain upon the injection of propofol is a common adverse effect.
det||analysis-3/NN||a-1/DT	amod||analysis-3/NN||secondary-2/JJ	nsubjpass||carried-17/VBN||analysis-3/NN	nsubj||assess-20/VB||analysis-3/NN	det||survey-10/NN||the-5/DT	num||survey-10/NN||2000-6/CD	amod||survey-10/NN||multiple-7/JJ	nn||survey-10/NN||cluster-8/NN	nn||survey-10/NN||indicator-9/NN	prep_of||analysis-3/NN||survey-10/NN	appos||analysis-3/NN||mics-12/NNS	prep_for||analysis-3/NN||iraq-15/NNP	auxpass||carried-17/VBN||was-16/VBD	root||ROOT-0/null||carried-17/VBN	prt||carried-17/VBN||out-18/RP	aux||assess-20/VB||to-19/TO	xcomp||carried-17/VBN||assess-20/VB	det||extent-22/NN||the-21/DT	dobj||assess-20/VB||extent-22/NN	amod||knowledge-25/NN||hiv/aids-related-24/JJ	prep_of||extent-22/NN||knowledge-25/NN	amod||women-28/NNS||iraqi-27/JJ	prep_among||assess-20/VB||women-28/NNS	aids--1||hiv--1||no||a secondary analysis of the 2000 multiple cluster indicator survey (mics) for iraq was carried out to assess the extent of hiv/aids-related knowledge among iraqi women.
nsubj||effective-4/JJ||bcg-1/NN	cop||effective-4/JJ||is-2/VBZ	advmod||effective-4/JJ||also-3/RB	root||ROOT-0/null||effective-4/JJ	det||treatment-7/NN||the-6/DT	prep_in||effective-4/JJ||treatment-7/NN	prep_of||treatment-7/NN||condylomataacuminata-9/NN	vmod||condylomataacuminata-9/NN||caused-10/VBN	amod||humanpapillomavirus-13/NNS||low-risk-12/JJ	agent||caused-10/VBN||humanpapillomavirus-13/NNS	appos||humanpapillomavirus-13/NNS||hpv-15/NN	condylomataacuminata-9||hpv-15||no||bcg is also effective in the treatment of condylomataacuminata caused by low-risk humanpapillomavirus (hpv).
det||risk-2/NN||this-1/DT	nsubj||appears-3/VBZ||risk-2/NN	nsubj||dependent-7/JJ||risk-2/NN	root||ROOT-0/null||appears-3/VBZ	aux||dependent-7/JJ||to-4/TO	cop||dependent-7/JJ||be-5/VB	advmod||dependent-7/JJ||dose-6/RB	xcomp||appears-3/VBZ||dependent-7/JJ	nsubj||have-11/VB||which-9/WDT	aux||have-11/VB||may-10/MD	ccomp||dependent-7/JJ||have-11/VB	amod||ramifications-13/NNS||important-12/JJ	dobj||have-11/VB||ramifications-13/NNS	nsubj||require-18/VBP||ramifications-13/NNS	nn||patients-16/NNS||arthritis-15/NN	prep_for||ramifications-13/NNS||patients-16/NNS	rcmod||ramifications-13/NNS||require-18/VBP	amod||treatment-20/NN||long-term-19/JJ	dobj||require-18/VBP||treatment-20/NN	amod||doses-23/NNS||high-22/JJ	prep_with||require-18/VBP||doses-23/NNS	prep_of||doses-23/NNS||anti-inflammatorydrugs-25/NNS	arthritis-15||anti-inflammatorydrugs-25||no_rel||this risk appears to be dose dependent, which may have important ramifications for arthritis patients who require long-term treatment with high doses of anti-inflammatorydrugs.
det||timing-2/NN||the-1/DT	nsubjpass||calculated-14/VBN||timing-2/NN	nsubjpass||calculated-14/VBN||timing-2/NN	nsubj||determine-20/VB||timing-2/NN	prep_of||timing-2/NN||onset-4/NN	vmod||onset-4/NN||offset-6/VBN	prep_of||timing-2/NN||duration-9/NN	conj_and||onset-4/NN||duration-9/NN	nn||secretion-12/NN||melatonin-11/NN	prep_of||duration-9/NN||secretion-12/NN	auxpass||calculated-14/VBN||were-13/VBD	root||ROOT-0/null||calculated-14/VBN	conj_and||calculated-14/VBN||calculated-14/VBN	prep_after||calculated-14/VBN||stroke-18/NN	prep_before||calculated-14/VBN||stroke-18/NN	aux||determine-20/VB||to-19/TO	xcomp||calculated-14/VBN||determine-20/VB	dobj||determine-20/VB||changes-21/NNS	nn||rhythms-24/NNS||circadian-23/NN	prep_in||determine-20/VB||rhythms-24/NNS	nn||secretion-27/NN||melatonin-26/NN	prep_of||rhythms-24/NNS||secretion-27/NN	melatonin-26||stroke-18||no_rel||the timing of onset, offset, and duration of melatonin secretion were calculated before and after stroke to determine changes in circadian rhythms of melatonin secretion.
mark||use-14/VBP||although-1/IN	amod||groups-4/NNS||different-3/JJ	prep_in||use-14/VBP||groups-4/NNS	det||severeacuterespiratorysyndrome-coronavirus-8/NNS||the-6/DT	amod||severeacuterespiratorysyndrome-coronavirus-8/NNS||coronaviruses-7/JJ	nsubj||use-14/VBP||severeacuterespiratorysyndrome-coronavirus-8/NNS	appos||severeacuterespiratorysyndrome-coronavirus-8/NNS||sars-cov-10/NNP	conj_and||severeacuterespiratorysyndrome-coronavirus-8/NNS||nl63-13/NNS	nsubj||use-14/VBP||nl63-13/NNS	advcl||enzyme-21/VBP||use-14/VBP	det||receptor-17/NN||the-15/DT	amod||receptor-17/NN||same-16/JJ	dobj||use-14/VBP||receptor-17/NN	nn||converting-20/NNP||angiotensin-19/NNP	nsubj||enzyme-21/VBP||converting-20/NNP	root||ROOT-0/null||enzyme-21/VBP	dep||enzyme-21/VBP||ace-23/VB	dobj||enzyme-21/VBP||-2-25/CD	prep_for||enzyme-21/VBP||entry-28/NN	det||cell-32/NN||the-30/DT	nn||cell-32/NN||host-31/NN	prep_into||entry-28/NN||cell-32/NN	severeacuterespiratorysyndrome--1||sars-cov-10||no||although in different groups, the coronaviruses severeacuterespiratorysyndrome-coronavirus (sars-cov) and nl63 use the same receptor, angiotensin converting enzyme (ace)-2, for entry into the host cell.
det||database-8/NN||the-1/DT	nn||network-4/NN||health-2/NN	nn||network-4/NN||improvement-3/NN	nn||database-8/NN||network-4/NN	dep||network-4/NN||thin-6/JJ	nsubjpass||used-10/VBN||database-8/NN	nsubj||identify-12/VB||database-8/NN	auxpass||used-10/VBN||was-9/VBD	root||ROOT-0/null||used-10/VBN	aux||identify-12/VB||to-11/TO	xcomp||used-10/VBN||identify-12/VB	dobj||identify-12/VB||patients-13/NNS	prep_with||identify-12/VB||adhd-15/NN	nsubj||received-17/VBD||adhd-15/NN	rcmod||adhd-15/NN||received-17/VBD	poss||prescription-20/NN||their-18/PRP$	amod||prescription-20/NN||first-19/JJ	dobj||received-17/VBD||prescription-20/NN	prepc_for||received-17/VBD||methylphenidate-22/NN	punct||dexamfetamine/atomoxetine-24/NN||/-23/:	dep||methylphenidate-22/NN||dexamfetamine/atomoxetine-24/NN	amod||6â-27/NNS||aged-26/JJ	appos||dexamfetamine/atomoxetine-24/NN||6â-27/NNS	num||years-31/NNS||$-28/$	num||$-28/$||17-30/CD	tmod||methylphenidate-22/NN||years-31/NNS	adhd-15||atomoxetine--1||yes||the health improvement network (thin) database was used to identify patients with adhd who received their first prescription for methylphenidate/ dexamfetamine/atomoxetine, aged 6â€“17 years.
advmod||compared-4/VBD||here-1/RB	nsubj||compared-4/VBD||we-3/PRP	root||ROOT-0/null||compared-4/VBD	det||characteristics-9/NNS||the-5/DT	nn||characteristics-9/NNS||cell-6/NN	nn||characteristics-9/NNS||culture-7/NN	nn||characteristics-9/NNS||growth-8/NN	dobj||compared-4/VBD||characteristics-9/NNS	amod||viruses-13/NNS||haemorrhagic-11/JJ	nn||viruses-13/NNS||fever-12/NN	prep_of||characteristics-9/NNS||viruses-13/NNS	appos||viruses-13/NNS||hfv-15/NN	det||arenaviridae-20/NN||the-19/DT	prep_of||viruses-13/NNS||arenaviridae-20/NN	prep_of||viruses-13/NNS||filoviridae-22/NN	conj_and||arenaviridae-20/NN||filoviridae-22/NN	prep_of||viruses-13/NNS||bunyaviridae-24/NN	conj_and||arenaviridae-20/NN||bunyaviridae-24/NN	amod||families-29/NNS||flavivridae-27/JJ	nn||families-29/NNS||virus-28/NN	prep_of||viruses-13/NNS||families-29/NNS	conj_and||arenaviridae-20/NN||families-29/NNS	prepc_by||compared-4/VBD||performing-31/VBG	amod||analysis-33/NN||quantitative-32/JJ	dobj||performing-31/VBG||analysis-33/NN	nn||supernatants-37/NNS||cell-35/NN	nn||supernatants-37/NNS||culture-36/NN	prep_of||analysis-33/NN||supernatants-37/NNS	appos||microscopy-43/NN||i-40/NNP	amod||microscopy-43/NN||electron-42/JJ	prep_by||performing-31/VBG||microscopy-43/NN	det||quantification-46/NN||the-45/DT	prep_for||performing-31/VBG||quantification-46/NN	nn||particles-49/NNS||virus-48/NN	prep_of||quantification-46/NN||particles-49/NNS	appos||particles-49/NNS||ii-52/NN	amod||time-56/NN||quantitative-54/JJ	amod||time-56/NN||real-55/JJ	dep||particles-49/NNS||time-56/NN	vmod||time-56/NN||pcr-57/VBN	det||quantification-60/NN||the-59/DT	prep_for||pcr-57/VBN||quantification-60/NN	prep_of||quantification-60/NN||genomes-62/NNS	amod||determination-68/NN||iii-66/JJ	prep_of||quantification-46/NN||determination-68/NN	conj_and||particles-49/NNS||determination-68/NN	prep_of||determination-68/NN||focus-70/NN	vmod||determination-68/NN||forming-71/VBG	dobj||forming-71/VBG||units-72/NNS	agent||forming-71/VBG||coating-74/VBG	amod||antibodies-76/NNS||fluorescent-75/JJ	dobj||coating-74/VBG||antibodies-76/NNS	amod||monolayers-80/NNS||infected-78/JJ	nn||monolayers-80/NNS||cell-79/NN	prep_to||coating-74/VBG||monolayers-80/NNS	det||quantification-83/NN||the-82/DT	prep_for||determination-68/NN||quantification-83/NN	nn||infectivity-86/NN||virus-85/NN	prep_of||quantification-83/NN||infectivity-86/NN	virus-85||viruses-13||no||here, we compared the cell culture growth characteristics of haemorrhagic fever viruses (hfv), of the arenaviridae , filoviridae , bunyaviridae , and flavivridae virus families by performing quantitative analysis of cell culture supernatants by (i) electron microscopy for the quantification of virus particles, (ii) quantitative real time pcr for the quantification of genomes, and (iii) determination of focus forming units by coating fluorescent antibodies to infected cell monolayers for the quantification of virus infectivity.
det||wake-3/NN||the-2/DT	prep_in||classified-20/VBD||wake-3/NN	det||revolution-7/NN||the-5/DT	amod||revolution-7/NN||bacterial-6/JJ	prep_of||wake-3/NN||revolution-7/NN	amod||koch-10/NN||robert-9/JJ	prep_after||revolution-7/NN||koch-10/NN	vmod||koch-10/NN||identified-11/VBN	det||tuberculosisbacillus-13/NNS||the-12/DT	dobj||identified-11/VBN||tuberculosisbacillus-13/NNS	amod||professionals-19/NNS||medical-15/JJ	conj_and||medical-15/JJ||public-17/JJ	amod||professionals-19/NNS||public-17/JJ	nn||professionals-19/NNS||health-18/NN	nsubj||classified-20/VBD||professionals-19/NNS	root||ROOT-0/null||classified-20/VBD	det||forms-23/NNS||the-21/DT	amod||forms-23/NNS||various-22/JJ	dobj||classified-20/VBD||forms-23/NNS	prep_of||forms-23/NNS||consumption-25/NN	prep_of||forms-23/NNS||phthisis-27/NNS	conj_and||consumption-25/NN||phthisis-27/NNS	det||disease-31/NN||a-29/DT	amod||disease-31/NN||single-30/JJ	prep_as||classified-20/VBD||disease-31/NN	dep||disease-31/NN||tuberculosis-33/NNP	phthisis-27||tuberculosisbacillus-13||no||in the wake of the bacterial revolution after robert koch identified the tuberculosisbacillus, medical and public health professionals classified the various forms of consumption and phthisis as a single disease--tuberculosis.
nn||levels-2/NNS||plasma-1/NN	nsubjpass||raised-23/VBN||levels-2/NNS	amod||peptide-6/NN||atrial-4/JJ	amod||peptide-6/NN||natriuretic-5/JJ	prep_of||levels-2/NNS||peptide-6/NN	appos||peptide-6/NN||anp-8/NN	prep_of||levels-2/NNS||brainnatriureticpeptide-11/NN	conj_and||peptide-6/NN||brainnatriureticpeptide-11/NN	appos||brainnatriureticpeptide-11/NN||bnp-13/NN	amod||peptide-18/NN||c-type-16/JJ	amod||peptide-18/NN||natriuretic-17/JJ	prep_of||levels-2/NNS||peptide-18/NN	conj_and||peptide-6/NN||peptide-18/NN	appos||peptide-18/NN||cnp-20/NN	auxpass||raised-23/VBN||are-22/VBP	root||ROOT-0/null||raised-23/VBN	nn||models-26/NNS||animal-25/NN	prep_in||raised-23/VBN||models-26/NNS	prep_in||raised-23/VBN||humans-28/NNS	conj_and||models-26/NNS||humans-28/NNS	prep_with||raised-23/VBN||endotoxicshock-30/NN	prep_with||raised-23/VBN||correlate-32/NN	conj_and||endotoxicshock-30/NN||correlate-32/NN	det||dysfunction-37/NN||the-34/DT	amod||dysfunction-37/NN||associated-35/JJ	amod||dysfunction-37/NN||cardiovascular-36/JJ	prep_with||raised-23/VBN||dysfunction-37/NN	brainnatriureticpeptide-11||endotoxicshock-30||no_rel||plasma levels of atrial natriuretic peptide (anp), brainnatriureticpeptide (bnp) and c-type natriuretic peptide (cnp) are raised in animal models and humans with endotoxicshock and correlate with the associated cardiovascular dysfunction.
neg||method-3/NN||no-1/DT	num||method-3/NN||one-2/CD	nsubj||superior-5/JJ||method-3/NN	cop||superior-5/JJ||is-4/VBZ	root||ROOT-0/null||superior-5/JJ	prep_to||superior-5/JJ||another-7/DT	det||gamut-10/NN||some-9/DT	nsubjpass||practiced-14/VBN||gamut-10/NN	prep_of||gamut-10/NN||techniques-12/NNS	auxpass||practiced-14/VBN||are-13/VBP	conj_and||superior-5/JJ||practiced-14/VBN	amod||counselors-17/NNS||hiv/aids-16/JJ	agent||practiced-14/VBN||counselors-17/NNS	aids--1||hiv--1||no||no one method is superior to another and some gamut of techniques are practiced by hiv/aids counselors.
det||prionprotein-2/NN||the-1/DT	nsubj||plays-6/VBZ||prionprotein-2/NN	appos||prionprotein-2/NN||prnp/prp-4/NN	root||ROOT-0/null||plays-6/VBZ	det||role-9/NN||a-7/DT	amod||role-9/NN||crucial-8/JJ	dobj||plays-6/VBZ||role-9/NN	prep_in||role-9/NN||transmissiblespongiformencephalopathies-11/NNS	appos||transmissiblespongiformencephalopathies-11/NNS||tses-13/NNS	amod||cjd-18/NN||creutzfeldt-jakobdisease-16/JJ	prep_like||plays-6/VBZ||cjd-18/NN	amod||cjd-18/NN||scrapie-21/JJ	amod||cjd-18/NN||madcowdisease-23/JJ	conj_and||scrapie-21/JJ||madcowdisease-23/JJ	prionprotein-2||creutzfeldt-jakobdisease-16||no_rel||the prionprotein (prnp/prp) plays a crucial role in transmissiblespongiformencephalopathies (tses) like creutzfeldt-jakobdisease (cjd), scrapie and madcowdisease.
amod||deficits-3/NNS||declarative-1/JJ	nn||deficits-3/NNS||memory-2/NN	nsubj||common-5/JJ||deficits-3/NNS	cop||common-5/JJ||are-4/VBP	root||ROOT-0/null||common-5/JJ	amod||adults-8/NNS||untreated-7/JJ	prep_in||common-5/JJ||adults-8/NNS	amod||hyperactivitydisorder-11/NN||attention-deficit-10/JJ	prep_with||adults-8/NNS||hyperactivitydisorder-11/NN	dep||adults-8/NNS||adhd-13/VBN	amod||evidence-18/NN||limited-17/JJ	nsubj||exists-19/VBZ||evidence-18/NN	nsubj||support-21/VB||evidence-18/NN	conj_but||common-5/JJ||exists-19/VBZ	aux||support-21/VB||to-20/TO	xcomp||exists-19/VBZ||support-21/VB	dobj||support-21/VB||improvement-22/NN	prep_after||support-21/VB||treatment-24/NN	prep_with||treatment-24/NN||methylphenidate-26/NN	adhd-13||methylphenidate-26||yes||declarative memory deficits are common in untreated adults with attention-deficit hyperactivitydisorder (adhd), but limited evidence exists to support improvement after treatment with methylphenidate.
amod||inhibitors-3/NNS||serine-1/JJ	nn||inhibitors-3/NNS||protease-2/NN	nsubjpass||involved-22/VBN||inhibitors-3/NNS	appos||inhibitors-3/NNS||serpins-5/NNS	nn||c-inhibitor-17/NN||antithrombin-8/NN	dep||c-inhibitor-17/NN||antitrypsin-10/NN	dep||c-inhibitor-17/NN||neuroserpin-12/NN	dep||c-inhibitor-17/NN||antichymotrypsin-14/NN	dep||c-inhibitor-17/NN||protein-16/NN	prep_like||inhibitors-3/NNS||c-inhibitor-17/NN	nn||inhibitor-20/NNS||plasminogenactivator-19/NN	prep_like||inhibitors-3/NNS||inhibitor-20/NNS	conj_and||c-inhibitor-17/NN||inhibitor-20/NNS	auxpass||involved-22/VBN||is-21/VBZ	root||ROOT-0/null||involved-22/VBN	amod||functions-26/NNS||important-24/JJ	amod||functions-26/NNS||biological-25/JJ	prep_in||involved-22/VBN||functions-26/NNS	nn||coagulation-29/NN||blood-28/NN	prep_like||functions-26/NNS||coagulation-29/NN	prep_like||functions-26/NNS||fibrinolysis-31/NNS	conj_and||coagulation-29/NN||fibrinolysis-31/NNS	prep_like||functions-26/NNS||inflammation-33/NN	conj_and||coagulation-29/NN||inflammation-33/NN	nn||migration-36/NN||cell-35/NN	prep_like||functions-26/NNS||migration-36/NN	conj_and||coagulation-29/NN||migration-36/NN	amod||activation-39/NN||complement-38/JJ	prep_like||functions-26/NNS||activation-39/NN	conj_and||coagulation-29/NN||activation-39/NN	plasminogenactivator-19||inflammation-33||no_rel||serine protease inhibitors (serpins) like antithrombin, antitrypsin, neuroserpin, antichymotrypsin, protein c-inhibitor and plasminogenactivator inhibitor is involved in important biological functions like blood coagulation, fibrinolysis, inflammation, cell migration and complement activation.
det||analysis-2/NN||this-1/DT	nsubjpass||carried-4/VBN||analysis-2/NN	auxpass||carried-4/VBN||was-3/VBD	root||ROOT-0/null||carried-4/VBN	prt||carried-4/VBN||out-5/RP	det||context-8/NN||the-7/DT	prep_in||carried-4/VBN||context-8/NN	det||trial-11/NN||a-10/DT	prep_of||context-8/NN||trial-11/NN	amod||treatment-16/NN||malaria-13/JJ	amod||treatment-16/NN||intermittent-14/JJ	nn||treatment-16/NN||preventive-15/NN	prep_of||trial-11/NN||treatment-16/NN	prep_in||treatment-16/NN||pregnancy-18/NN	amod||iptp-sp-22/NN||sulphadoxine-pyrimethamine-20/JJ	prep_with||carried-4/VBN||iptp-sp-22/NN	advmod||received-29/VBD||where-25/WRB	det||groups-28/NNS||both-26/DT	nn||groups-28/NNS||intervention-27/NN	nsubj||received-29/VBD||groups-28/NNS	rcmod||iptp-sp-22/NN||received-29/VBD	det||insecticide-31/NN||an-30/DT	nsubj||treated-32/VBD||insecticide-31/NN	ccomp||received-29/VBD||treated-32/VBD	dobj||treated-32/VBD||net-33/NN	det||clinic-37/NN||the-35/DT	amod||clinic-37/NN||antenatal-36/JJ	prep_through||treated-32/VBD||clinic-37/NN	appos||clinic-37/NN||anc-39/NN	prep_in||treated-32/VBD||mozambique-42/NN	malaria-13||pyrimethamine--1||yes||this analysis was carried out in the context of a trial of malaria intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine (iptp-sp), where both intervention groups received an insecticide treated net through the antenatal clinic (anc) in mozambique.
advmod||niacin-induced-10/JJ||however-1/RB	det||limitation-5/NN||a-3/DT	amod||limitation-5/NN||major-4/JJ	nsubj||niacin-induced-10/JJ||limitation-5/NN	poss||use-8/NN||its-7/PRP$	prep_to||limitation-5/NN||use-8/NN	cop||niacin-induced-10/JJ||is-9/VBZ	root||ROOT-0/null||niacin-induced-10/JJ	xcomp||niacin-induced-10/JJ||flushing-11/VBG	vmod||flushing-11/VBG||occurring-12/VBG	advmod||occurring-12/VBG||even-13/RB	det||formulations-17/NNS||the-15/DT	amod||formulations-17/NNS||extended-release-16/JJ	prep_with||occurring-12/VBG||formulations-17/NNS	flushing-11||niacin--1||no||however, a major limitation to its use is niacin-induced flushing occurring even with the extended-release formulations.
nsubj||mitigate-3/VB||treatments-1/NNS	nsubj||cancer-27/NN||treatments-1/NNS	rcmod||treatments-1/NNS||mitigate-3/VB	det||risk-5/NN||the-4/DT	dobj||mitigate-3/VB||risk-5/NN	amod||metastases-9/NNS||early-7/JJ	amod||metastases-9/NNS||distant-8/JJ	prep_of||risk-5/NN||metastases-9/NNS	appos||treatments-1/NNS||dm-11/NN	cop||cancer-27/NN||are-13/VBP	advmod||cancer-27/NN||therefore-15/RB	amod||cancer-27/NN||likely-17/JJ	aux||improve-19/VB||to-18/TO	xcomp||likely-17/JJ||improve-19/VB	amod||survival-21/NN||overall-20/JJ	dobj||improve-19/VB||survival-21/NN	prep_in||improve-19/VB||women-23/NNS	amod||breast-26/NN||early-25/JJ	prep_with||women-23/NNS||breast-26/NN	root||ROOT-0/null||cancer-27/NN	appos||cancer-27/NN||ebc-29/NN	metastases-9||dm-11||no_rel||treatments that mitigate the risk of early distant metastases (dm) are, therefore, likely to improve overall survival in women with early breast cancer (ebc).
nsubjpass||trained-8/VBN||volunteers-1/NNS	dep||volunteers-1/NNS||one-3/CD	prep_per||one-3/CD||village-5/NN	auxpass||trained-8/VBN||were-7/VBD	root||ROOT-0/null||trained-8/VBN	prepc_on||trained-8/VBN||using-10/VBG	dobj||using-10/VBG||rdts-11/NNS	prep_for||rdts-11/NNS||diagnosis-13/NN	prep_for||rdts-11/NNS||artesunate-15/NN	conj_and||diagnosis-13/NN||artesunate-15/NN	dobj||using-10/VBG||sulphadoxine-pyrimethamine-17/NN	conj_plus||rdts-11/NNS||sulphadoxine-pyrimethamine-17/NN	prepc_for||sulphadoxine-pyrimethamine-17/NN||treating-19/VBG	nn||patients-21/NNS||malaria-20/NN	dobj||treating-19/VBG||patients-21/NNS	dobj||using-10/VBG||referral-26/NN	conj_and||rdts-11/NNS||referral-26/NN	amod||cases-31/NNS||severe-28/JJ	conj_and||severe-28/JJ||non-malaria-30/JJ	amod||cases-31/NNS||non-malaria-30/JJ	prep_of||referral-26/NN||cases-31/NNS	malaria-20||pyrimethamine--1||no||volunteers (one per village) were trained on using rdts for diagnosis and artesunate plus sulphadoxine-pyrimethamine for treating malaria patients, as well as referral of severe and non-malaria cases.
det||viruses-2/NNS||these-1/DT	nsubj||showed-3/VBD||viruses-2/NNS	root||ROOT-0/null||showed-3/VBD	amod||replication-5/NN||low-level-4/JJ	dobj||showed-3/VBD||replication-5/NN	nsubj||supported-10/VBD||replication-5/NN	amod||dna-8/NN||viral-7/JJ	prep_of||replication-5/NN||dna-8/NN	rcmod||replication-5/NN||supported-10/VBD	amod||expression-12/NN||greater-11/JJR	dobj||supported-10/VBD||expression-12/NN	det||genes-16/NNS||the-14/DT	amod||genes-16/NNS||induced-15/JJ	prep_of||expression-12/NN||genes-16/NNS	prep_than||supported-10/VBD||that-18/DT	amod||methods-21/NNS||other-20/JJ	prep_of||that-18/DT||methods-21/NNS	nsubj||insufficient-25/JJ||that-23/WDT	nsubj||support-27/VB||that-23/WDT	cop||insufficient-25/JJ||was-24/VBD	rcmod||replication-5/NN||insufficient-25/JJ	conj_but||supported-10/VBD||insufficient-25/JJ	aux||support-27/VB||to-26/TO	xcomp||insufficient-25/JJ||support-27/VB	det||production-29/NN||the-28/DT	dobj||support-27/VB||production-29/NN	amod||virus-32/NN||replication-competent-31/JJ	prep_of||production-29/NN||virus-32/NN	virus-32||viruses-2||no||these viruses showed low-level replication of viral dna that supported greater expression of the induced genes than that of other methods but that was insufficient to support the production of replication-competent virus.
poss||elimination-5/NN||cocaine-1/NN	advmod||rapid-4/JJ||very-3/RB	amod||elimination-5/NN||rapid-4/JJ	nsubjpass||considered-11/VBN||elimination-5/NN	det||body-8/NN||the-7/DT	prep_from||elimination-5/NN||body-8/NN	aux||considered-11/VBN||should-9/MD	auxpass||considered-11/VBN||be-10/VB	root||ROOT-0/null||considered-11/VBN	prepc_in||considered-11/VBN||attempting-13/VBG	aux||understand-15/VB||to-14/TO	xcomp||attempting-13/VBG||understand-15/VB	dobj||understand-15/VB||patterns-16/NNS	prep_of||patterns-16/NNS||cocaineabuse-18/NN	amod||phenomena-22/NNS||such-21/JJ	dobj||understand-15/VB||phenomena-22/NNS	conj_and||patterns-16/NNS||phenomena-22/NNS	amod||tolerance-27/NN||bingeing-24/JJ	conj_and||bingeing-24/JJ||acute-26/JJ	amod||tolerance-27/NN||acute-26/JJ	prep_as||phenomena-22/NNS||tolerance-27/NN	cocaineabuse-18||cocaine-1||no||cocaine's very rapid elimination from the body should be considered in attempting to understand patterns of cocaineabuse, and such phenomena as bingeing and acute tolerance.
amod||offspring-2/NN||sedentary-1/JJ	nsubj||insulin-resistant-10/JJ||offspring-2/NN	prep_of||offspring-2/NN||patients-4/NNS	prep_with||patients-4/NNS||type2diabetes-6/CD	cop||insulin-resistant-10/JJ||are-7/VBP	advmod||insulin-resistant-10/JJ||often-8/RB	advmod||insulin-resistant-10/JJ||more-9/RBR	root||ROOT-0/null||insulin-resistant-10/JJ	prep_than||insulin-resistant-10/JJ||persons-12/NNS	neg||history-16/NN||no-14/DT	nn||history-16/NN||family-15/NN	prep_with||persons-12/NNS||history-16/NN	prep_of||history-16/NN||diabetes-18/NN	advmod||are-31/VBP||when-21/WRB	amod||offspring-25/NN||active-22/JJ	conj_or||active-22/JJ||fit-24/JJ	amod||offspring-25/NN||fit-24/JJ	nsubj||are-31/VBP||offspring-25/NN	amod||patients-30/NNS||type-27/NN	number||type-27/NN||2-28/CD	amod||patients-30/NNS||diabetic-29/JJ	prep_of||offspring-25/NN||patients-30/NNS	advcl||evident-42/JJ||are-31/VBP	prepc_compared_with||are-31/VBP||with-33/IN	amod||persons-35/NNS||non-diabetic-34/JJ	pobj||are-31/VBP||persons-35/NNS	nsubj||evident-42/JJ||differences-37/NNS	prep_in||differences-37/NNS||insulinresistance-39/NN	cop||evident-42/JJ||are-40/VBP	advmod||evident-42/JJ||less-41/RBR	conj_but||insulin-resistant-10/JJ||evident-42/JJ	fit-24||insulin--1||no_rel||sedentary offspring of patients with type2diabetes are often more insulin-resistant than persons with no family history of diabetes, but when active or fit offspring of type 2 diabetic patients are compared with non-diabetic persons, differences in insulinresistance are less evident.
nsubj||performed-2/VBD||we-1/PRP	root||ROOT-0/null||performed-2/VBD	det||analysis-4/NN||an-3/DT	dobj||performed-2/VBD||analysis-4/NN	amod||aberrations-7/NNS||genomic-6/JJ	prep_of||analysis-4/NN||aberrations-7/NNS	nn||profiles-11/NNS||gene-9/NN	nn||profiles-11/NNS||expression-10/NN	prep_of||analysis-4/NN||profiles-11/NNS	conj_and||aberrations-7/NNS||profiles-11/NNS	amod||expression-15/NN||micrornas-14/JJ	prep_of||analysis-4/NN||expression-15/NN	conj_and||aberrations-7/NNS||expression-15/NN	nn||blood-18/NN||cll-17/NN	prep_in||expression-15/NN||blood-18/NN	dep||analysis-4/NN||b-19/SYM	amod||isolated-21/JJ||lymphocytes-20/JJ	amod||analysis-4/NN||isolated-21/JJ	det||course-24/NN||the-23/DT	prep_during||performed-2/VBD||course-24/NN	poss||treatment-28/NN||patients-26/NNS	prep_of||course-24/NN||treatment-28/NN	prep_with||performed-2/VBD||fludarabine-30/NN	cll-17||fludarabine-30||yes||we performed an analysis of genomic aberrations, gene expression profiles, and micrornas expression in cll blood b lymphocytes isolated during the course of patients' treatment with fludarabine.
det||toxicity-4/NN||the-3/DT	prep_due_to||started-23/VBN||toxicity-4/NN	prep_of||toxicity-4/NN||cyclophosphamide-6/NN	poss||disease-11/NN||her-8/PRP$	advmod||mild-10/JJ||relatively-9/RB	amod||disease-11/NN||mild-10/JJ	appos||cyclophosphamide-6/NN||disease-11/NN	vmod||toxicity-4/NN||sparing-12/VBG	det||kidneys-14/NNS||the-13/DT	dobj||sparing-12/VBG||kidneys-14/NNS	det||rheumatoidarthritis-18/NNS||the-16/DT	amod||rheumatoidarthritis-18/NNS||underlying-17/VBG	dobj||sparing-12/VBG||rheumatoidarthritis-18/NNS	conj_and||kidneys-14/NNS||rheumatoidarthritis-18/NNS	amod||methotrexate-21/NN||weekly-20/JJ	nsubjpass||started-23/VBN||methotrexate-21/NN	auxpass||started-23/VBN||was-22/VBD	root||ROOT-0/null||started-23/VBN	amod||prednisone-27/NN||low-25/JJ	nn||prednisone-27/NN||dose-26/NN	nsubjpass||continued-29/VBN||prednisone-27/NN	auxpass||continued-29/VBN||was-28/VBD	conj_and||started-23/VBN||continued-29/VBN	rheumatoidarthritis-18||methotrexate-21||yes||due to the toxicity of cyclophosphamide, her relatively mild disease sparing the kidneys and the underlying rheumatoidarthritis, weekly methotrexate was started and low dose prednisone was continued.
det||objective-2/NN||the-1/DT	nsubj||was-6/VBD||objective-2/NN	nsubj||examine-8/VB||objective-2/NN	det||study-5/NN||this-4/DT	prep_of||objective-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||examine-8/VB||to-7/TO	xcomp||was-6/VBD||examine-8/VB	det||effects-10/NNS||the-9/DT	dobj||examine-8/VB||effects-10/NNS	prep_of||effects-10/NNS||methylphenidate-12/NN	nn||functioning-15/NN||memory-14/NN	prep_on||examine-8/VB||functioning-15/NN	prep_of||functioning-15/NN||adults-17/NNS	prep_with||adults-17/NNS||adhd-19/NN	adhd-19||methylphenidate-12||yes||the objective of this study was to examine the effects of methylphenidate on memory functioning of adults with adhd.
det||receptor-3/NN||the-1/DT	nn||receptor-3/NN||androgen-2/NN	nsubj||member-9/NN||receptor-3/NN	appos||receptor-3/NN||ar-5/NN	cop||member-9/NN||is-7/VBZ	det||member-9/NN||a-8/DT	root||ROOT-0/null||member-9/NN	nsubj||plays-20/VBZ||member-9/NN	det||family-15/NN||the-11/DT	amod||family-15/NN||nuclear-12/JJ	nn||family-15/NN||hormone-13/NN	nn||family-15/NN||receptor-14/NN	prep_of||member-9/NN||family-15/NN	nn||factors-18/NNS||transcription-17/NN	prep_of||family-15/NN||factors-18/NNS	rcmod||member-9/NN||plays-20/VBZ	det||role-23/NN||a-21/DT	amod||role-23/NN||critical-22/JJ	dobj||plays-20/VBZ||role-23/NN	prepc_in||plays-20/VBZ||regulating-25/VBG	dobj||regulating-25/VBG||expression-26/NN	prep_of||expression-26/NN||genes-28/NNS	vmod||genes-28/NNS||involved-29/VBN	nn||development-32/NN||prostate-31/NN	prep_in||involved-29/VBN||development-32/NN	prep_in||involved-29/VBN||transformation-34/NN	conj_and||development-32/NN||transformation-34/NN	ar-5||hormone-13||no_rel||the androgen receptor (ar) is a member of the nuclear hormone receptor family of transcription factors that plays a critical role in regulating expression of genes involved in prostate development and transformation.
nsubj||tested-2/VBD||we-1/PRP	root||ROOT-0/null||tested-2/VBD	det||system-5/NN||this-3/DT	amod||system-5/NN||genotyping-4/VBG	nsubj||isolates-13/VBZ||system-5/NN	amod||analysis-9/NN||molecular-7/JJ	amod||analysis-9/NN||epidemiological-8/JJ	prep_for||system-5/NN||analysis-9/NN	num||m.tuberculosis-12/NNS||369-11/CD	prep_of||analysis-9/NN||m.tuberculosis-12/NNS	ccomp||tested-2/VBD||isolates-13/VBZ	num||regions-16/NNS||3-15/CD	prep_from||isolates-13/VBZ||regions-16/NNS	prep_of||regions-16/NNS||brazil-18/NN	det||country-23/NN||a-20/DT	amod||country-23/NN||high-21/JJ	amod||country-23/NN||tb-burden-22/JJ	appos||brazil-18/NN||country-23/NN	tb--1||m.tuberculosis-12||no||we tested this genotyping system for molecular epidemiological analysis of 369 m.tuberculosis isolates from 3 regions of brazil , a high tb-burden country .
amod||seroprevalence-2/NN||overall-1/JJ	nsubjpass||found-29/VBN||seroprevalence-2/NN	nsubj||%-33/NN||seroprevalence-2/NN	vmod||seroprevalence-2/NN||evaluated-3/VBN	agent||evaluated-3/VBN||immunofluorescence-5/NN	vmod||immunofluorescence-5/NN||using-6/VBG	num||antigens-9/NNS||six-7/CD	amod||antigens-9/NNS||rickettsial-8/JJ	dobj||using-6/VBG||antigens-9/NNS	nn||group-14/NN||spottedfever-11/NN	conj_and||spottedfever-11/NN||typhus-13/NN	nn||group-14/NN||typhus-13/NN	appos||antigens-9/NNS||group-14/NN	amod||populations-18/NNS||rural-17/JJ	prep_in||antigens-9/NNS||populations-18/NNS	num||villages-21/NNS||two-20/CD	prep_of||populations-18/NNS||villages-21/NNS	det||region-25/NN||the-23/DT	amod||region-25/NN||sine-saloum-24/JJ	prep_of||villages-21/NNS||region-25/NN	prep_of||region-25/NN||senegal-27/NN	auxpass||found-29/VBN||was-28/VBD	root||ROOT-0/null||found-29/VBN	aux||%-33/NN||to-30/TO	cop||%-33/NN||be-31/VB	num||%-33/NN||21.4-32/CD	xcomp||found-29/VBN||%-33/NN	num||%-36/NN||51-35/CD	xcomp||found-29/VBN||%-36/NN	conj_and||%-33/NN||%-36/NN	nn||rickettsiae-40/NN||spottedfever-38/NN	nn||rickettsiae-40/NN||group-39/NN	prep_for||%-33/NN||rickettsiae-40/NN	nn||villages-45/NNS||dielmo-42/NN	conj_and||dielmo-42/NN||ndiop-44/NN	nn||villages-45/NNS||ndiop-44/NN	prep_for||rickettsiae-40/NN||villages-45/NNS	advmod||%-33/NN||respectively-47/RB	spottedfever-38||rickettsiae-40||no||overall seroprevalence evaluated by immunofluorescence using six rickettsial antigens (spottedfever and typhus group) in rural populations of two villages of the sine-saloum region of senegal was found to be 21.4% and 51% for spottedfever group rickettsiae for dielmo and ndiop villages, respectively.
advmod||caused-3/VBN||entericfever-1/RB	auxpass||caused-3/VBN||is-2/VBZ	root||ROOT-0/null||caused-3/VBN	det||salmonellatyphi-7/NN||the-5/DT	amod||salmonellatyphi-7/NN||serotypes-6/JJ	agent||caused-3/VBN||salmonellatyphi-7/NN	nn||paratyphi-10/NNS||salmonella-9/NN	appos||salmonellatyphi-7/NN||paratyphi-10/NNS	nsubjpass||caused-3/VBN||a-11/SYM	nn||paratyphi-14/NNS||salmonella-13/NN	appos||a-11/SYM||paratyphi-14/NNS	dep||paratyphi-14/NNS||b-15/SYM	nn||c.-19/NN||salmonella-17/NN	nn||c.-19/NN||paratyphi-18/NN	dep||paratyphi-14/NNS||c.-19/NN	conj_and||b-15/SYM||c.-19/NN	entericfever-1||salmonellatyphi-7||no||entericfever is caused by the serotypes salmonellatyphi, salmonella paratyphi a, salmonella paratyphi b and salmonella paratyphi c.
nsubj||collected-2/VBD||we-1/PRP	root||ROOT-0/null||collected-2/VBD	amod||records-4/NNS||medical-3/JJ	dobj||collected-2/VBD||records-4/NNS	num||men-8/NNS||170-6/CD	amod||men-8/NNS||adult-7/JJ	prep_of||records-4/NNS||men-8/NNS	dep||men-8/NNS||diagnosed-9/VBN	prep_with||diagnosed-9/VBN||chronichepatitisc-11/NN	nsubj||started-13/VBD||chronichepatitisc-11/NN	rcmod||chronichepatitisc-11/NN||started-13/VBD	dobj||started-13/VBD||treatment-14/NN	det||combination-17/NN||a-16/DT	prep_with||started-13/VBD||combination-17/NN	amod||interferon-alpha-20/NN||pegylated-19/JJ	prep_of||combination-17/NN||interferon-alpha-20/NN	prep_with||started-13/VBD||ribavirin-22/NNP	conj_and||combination-17/NN||ribavirin-22/NNP	prep_between||ribavirin-22/NNP||january-24/NNP	num||january-24/NNP||2003-25/CD	dep||men-8/NNS||june-27/NNP	conj_and||diagnosed-9/VBN||june-27/NNP	num||june-27/NNP||2009-28/CD	det||centre-33/NN||the-30/DT	amod||centre-33/NN||croatian-31/JJ	nn||centre-33/NN||reference-32/NN	prep_at||june-27/NNP||centre-33/NN	prep_for||centre-33/NN||viralhepatitis-35/NNS	ribavirin-22||chronichepatitisc-11||no_rel||we collected medical records of 170 adult men diagnosed with chronichepatitisc who started treatment with a combination of pegylated interferon-alpha and ribavirin between january 2003 and june 2009 at the croatian reference centre for viralhepatitis.
det||system-5/NN||a-1/DT	amod||system-5/NN||continuous-2/JJ	nn||system-5/NN||glucose-3/NN	nn||system-5/NN||monitoring-4/NN	nsubj||have-7/VB||system-5/NN	aux||have-7/VB||may-6/MD	root||ROOT-0/null||have-7/VB	dobj||have-7/VB||utility-8/NN	amod||women-11/NNS||pregnant-10/JJ	prep_in||utility-8/NN||women-11/NNS	amod||diabetes-14/NN||insulin-treated-13/JJ	prep_with||have-7/VB||diabetes-14/NN	advmod||for-17/IN||especially-16/RB	dep||have-7/VB||for-17/IN	det||women-19/NNS||those-18/DT	pobj||for-17/IN||women-19/NNS	nsubj||difficult-25/JJ||women-19/NNS	nsubj||control-27/VB||women-19/NNS	nn||sugars-22/NNS||blood-21/NN	prep_with||women-19/NNS||sugars-22/NNS	cop||difficult-25/JJ||are-24/VBP	rcmod||women-19/NNS||difficult-25/JJ	aux||control-27/VB||to-26/TO	xcomp||difficult-25/JJ||control-27/VB	nsubj||experience-30/VBP||who-29/WP	dep||have-7/VB||experience-30/VBP	conj_or||for-17/IN||experience-30/VBP	amod||hypoglycemia-32/NN||nocturnal-31/JJ	dobj||experience-30/VBP||hypoglycemia-32/NN	advmod||need-40/VBP||however-34/RB	amod||systems-39/NNS||continuous-36/JJ	nn||systems-39/NNS||glucose-37/NN	nn||systems-39/NNS||monitoring-38/NN	nsubj||need-40/VBP||systems-39/NNS	parataxis||have-7/VB||need-40/VBP	amod||study-42/NN||additional-41/JJ	dobj||need-40/VBP||study-42/NN	prep_as||need-40/VBP||part-44/NN	amod||trials-49/NNS||larger-46/JJR	amod||trials-49/NNS||randomized-48/JJ	prep_of||part-44/NN||trials-49/NNS	hypoglycemia-32||glucose-37||yes||a continuous glucose monitoring system may have utility in pregnant women with insulin-treated diabetes, especially for those women with blood sugars that are difficult to control or who experience nocturnal hypoglycemia; however, continuous glucose monitoring systems need additional study as part of larger, randomized trials.
